PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DAJ	Candan, S; Arslan, G				Candan, S; Arslan, G			The site of action of epidural fentanyl	ANESTHESIA AND ANALGESIA			English	Letter							VOLUNTEERS; ANALGESIA; INFUSION; HUMANS		Baskent Univ, Sch Med, Dept Anesthesiol & Reanimatol, TR-06490 Ankara, Turkey	Candan, S (reprint author), Baskent Univ, Sch Med, Dept Anesthesiol & Reanimatol, TR-06490 Ankara, Turkey.	selimcandantr@yahoo.co.uk					BROMAGE PR, 1969, J CLIN PHARMACOL N D, V9, P30; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; INAGAKI Y, 1992, ANESTH ANALG, V74, P856; Liu SS, 1996, ANESTH ANALG, V82, P98, DOI 10.1097/00000539-199601000-00017; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010	6	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2004	99	4					1261	1262		10.1213/01.ANE.0000132710.79703.CA			2	Anesthesiology	Anesthesiology	856IW	WOS:000224039900058	15385388				2020-06-30	J	Lindow, SW; Dhillon, AR; Husaini, SW; Russell, IF				Lindow, SW; Dhillon, AR; Husaini, SW; Russell, IF			A randomised double-blind comparison of epidural fentanyl versus fentanyl and bupivicaine for pain relief in the second stage of labour	BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY			English	Article							2ND STAGE; CONTROLLED TRIAL; ANALGESIA; DELIVERY; WOMEN; MODE	Objectives To compare the effectiveness of two different methods for epidural analgesia in the second stage of labour-fentanyl alone versus the usual mixture of bupivicaine and fentanyl. Design A double-blind, randomised, controlled trial. Setting An English maternity hospital. Sample Eighty nulliparous women in the second stage of labour. Methods After successful institution of epidural analgesia with a continuous infusion of bupivicaine/fentanyl mixture in the first stage of labour, the patients were randomised at full dilatation to receive either continuation of the same solution or a change to a fentanyl-only solution given at the same rate. Main outcome measures Mode of delivery, duration of the second stage and quality of analgesia. Results There was no difference in the number of instrumental deliveries (30%vs 27.5%) or the duration of the second stage (141 vs 147 minutes) between the bupivicaine/fentanyl and fentanyl groups, respectively. The bupivicaine/fentanyl group demonstrated a lower need for rescue epidural analgesia (1 vs 6, RR 0.2, 95% CI 0.02-1.3) and significantly fewer high pain scores (11 vs 20, RR 0.6, 95% CI 0.3-1.0). Conclusion Second stage epidural analgesia with fentanyl did not alter delivery outcomes or labour duration but resulted in poorer analgesia.	Univ Hull, Hull Royal Infirm, Womens & Childrens Hosp, Dept Obstet & Gynaecol, Kingston Upon Hull, Yorks, England; Castlehill Hosp, Dept Anaesthet, Cottingham, East Yorkshire, England	Lindow, SW (reprint author), Univ Hull, Hull Royal Infirm, Womens & Childrens Hosp, Dept Obstet & Gynaecol, Anlaby Rd, Kingston Upon Hull, Yorks, England.						CHAMBERLAIN G, 1995, CONT REV OBSTET GYNA, V7, P69; CHESTNUT DH, 1987, ANESTHESIOLOGY, V66, P774, DOI 10.1097/00000542-198706000-00011; CHESTNUT DH, 1991, ANESTHESIOLOGY, V74, P805, DOI 10.1097/00000542-199105000-00001; FERGUSON J. K. W., 1941, SURG GYNECOL AND OBSTET, V73, P359; FUCHS AR, 1991, AM J OBSTET GYNECOL, V165, P1515; GOODFELLOW CF, 1983, BRIT J OBSTET GYNAEC, V90, P214, DOI 10.1111/j.1471-0528.1983.tb08611.x; MacArthur C, 2001, LANCET, V358, P19; Olofsson C, 1998, ACTA ANAESTH SCAND, V42, P284, DOI 10.1111/j.1399-6576.1998.tb04918.x; PHILLIPS KC, 1983, ANAESTHESIA, V38, P972, DOI 10.1111/j.1365-2044.1983.tb12028.x; SAUNDERS NJS, 1989, BRIT MED J, V299, P1423, DOI 10.1136/bmj.299.6713.1423; STODDART AP, 1994, ANAESTHESIA, V49, P1087, DOI 10.1111/j.1365-2044.1994.tb04362.x; STUDD JWW, 1980, BRIT J OBSTET GYNAEC, V87, P1015, DOI 10.1111/j.1471-0528.1980.tb04466.x	12	3	4	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1470-0328			BJOG-INT J OBSTET GY	BJOG	OCT	2004	111	10					1075	1080		10.1111/j.1471-0528.2004.00267.x			6	Obstetrics & Gynecology	Obstetrics & Gynecology	855SZ	WOS:000223995700008	15383109				2020-06-30	J	Arcand, G; Girard, FO; McCormack, M; Chouinard, P; Boudreault, D; Williams, S				Arcand, G; Girard, FO; McCormack, M; Chouinard, P; Boudreault, D; Williams, S			Bilateral sixth cranial nerve palsy after unintentional dural puncture	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							EPIDURAL BLOOD PATCH; HEADACHE	Purpose: Bilateral sixth nerve palsy is a known though uncommon complication following dural puncture. The recommended treatment consists of hydration and alternate monocular occlusion. The value and the timing of an epidural blood patch (EBP) for sixth nerve palsy remains controversial as some authors have demonstrated benefits in performing an EBP early in course of the nerve palsy whereas others have not found any advantage when an EBP was performed later. Clinical features: A 40-yr-old woman developed bilateral sixth nerve palsy ten days after an unintentional dural puncture. An EBP was done within 24 hr after the onset of the symptoms and immediate improvement of the diplopia was noted by the patient and confirmed by an ophthalmologist. Complete resolution of the diplopia occurred 36 days after the dural puncture. Conclusion: Blood patching within 24 hr of the onset of diplopia may be a reasonable treatment for ocular nerve palsy as it relieved the postdural puncture headache and produced partial improvement of the diplopia.	CHUM, Hop Notre Dame, Dept Anesthesiol, Montreal, PQ H2L 4M1, Canada; CHUM, Hop Notre Dame, Dept Surg, Montreal, PQ, Canada	Arcand, G (reprint author), CHUM, Hop Notre Dame, Dept Anesthesiol, 1560 Sherbrooke E, Montreal, PQ H2L 4M1, Canada.	francois.girard.chum@ssss.gouv.qc.ca					Barsoum WK, 1999, SPINE, V24, P585, DOI 10.1097/00007632-199903150-00019; De Veuster I, 1994, Bull Soc Belge Ophtalmol, V252, P45; Duffy PJ, 1999, CAN J ANAESTH, V46, P878, DOI 10.1007/BF03012979; DUNBAR SA, 1994, ANESTH ANALG, V79, P806; Follens I, 2001, Bull Soc Belge Ophtalmol, P29; GREENE NM, 1961, ANESTHESIOLOGY, V22, P682, DOI 10.1097/00000542-196109000-00004; HEYMAN HJ, 1982, ANESTH ANALG, V61, P948; PANNULLO SC, 1993, NEUROLOGY, V43, P919, DOI 10.1212/WNL.43.5.919; Szokol JW, 1999, REGION ANESTH PAIN M, V24, P470; Thomke F, 2000, NEUROLOGY, V54, P768, DOI 10.1212/WNL.54.3.768; Thorsen G., 1947, ACTA CHIR SCAND SUPPL, V121, P1; VANDAM LD, 1956, JAMA-J AM MED ASSOC, V161, P586, DOI 10.1001/jama.1956.02970070018005; VIAL F, 2000, ANN FR ANESTH, V20, P32	13	35	35	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	OCT	2004	51	8					821	823		10.1007/BF03018456			3	Anesthesiology	Anesthesiology	865HJ	WOS:000224693000011	15470172	Bronze			2020-06-30	J	Mi, WD; Sakai, T; Kudo, T; Kudo, M; Matsuki, A				Mi, WD; Sakai, T; Kudo, T; Kudo, M; Matsuki, A			Performance of bispectral index and auditory evoked potential monitors in detecting loss of consciousness during anaesthetic induction with propofol with and without fentanyl	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia; induction; anaesthetics; intravenous; propofol; analgesics; narcotic; fentanyl; monitoring; bispectral index; auditory evoked potentials	REPEATED TRANSITIONS; BLOOD-CONCENTRATION; ALFENTANIL; DEPTH; UNCONSCIOUSNESS; VOLUNTEERS; MIDAZOLAM; EMERGENCE	Background and objective: To investigate and compare the performance of bispectral Index (BIS) and auditory evoked response index (AAI) in detecting the transition from consciousness to unconsciousness during anaesthesia induction by propofol, alone and in combination with fentanyl. Methods: Anaesthesia was induced with either an intravenous infusion of 30 mg kg(-1) h(-1) of propofol plus 2 mug kg(-1) of fentanyl (Group PF, n = 20) or an intravenous infusion of 30 mg kg(-1) h(-1) of propofol plus normal saline (Group P, n = 20). BIS, AAI and the doses of propofol administered were recorded at the end-point of unresponsiveness to verbal commands. The propofol plasma concentration was also measured. Results: The propofol dose and plasma propofol concentration required to achieve loss of consciousness were significantly lower in patients pretreated with fentanyl (P < 0.001). The mean BIS value at loss of consciousness was significantly different between the two groups (74.10 in Group PF vs. 60.80 in Group P) (P < 0.001). However, no difference in the AAI was seen between the two groups at loss of consciousness (32.90 in Group PF vs. 31.80 in Group P) (P > 0.05). In both groups, the regression analysis values (r-values) between BIS and plasma propofol concentrations at the onset of unconsciousness were higher than those between AAI and propofol concentrations (0.553 vs. 0.180 in Group P; 0.432 vs. 0.308 in Group PF). Conclusions: These results show that a fentanyl bolus is effective in augmenting the hypnotic effect of propofol during anaesthesia induction. AAI appears to be able to measure the transition from consciousness to unconsciousness at similar values, regardless of whether or not fentanyl pretreatment is used whereas the BIS values were not independent of fentanyl pretreatment. This suggests that AAI may be a better indicator of conscious status during propofol/fentanyl anaesthesia, where it appears to be independent of the anaesthesia regimen.	Hirosaki Univ, Sch Med, Dept Anaesthesiol, Hirosaki, Aomori 036, Japan	Mi, WD (reprint author), Chinese Peoples Liberat Army Gen Hosp, Dept Anesthesiol, 28 Fu Xing Rd, Beijing 100853, Peoples R China.	wwdd1962@yahoo.com.cn					Absalom AR, 2001, BRIT J ANAESTH, V87, P778, DOI 10.1093/bja/87.5.778; Bailey P.L., 2000, ANESTHESIA, P273; Davies FW, 1996, ANAESTHESIA, V51, P107, DOI 10.1111/j.1365-2044.1996.tb07694.x; Doi M, 1997, BRIT J ANAESTH, V78, P180; Gajraj RJ, 1999, BRIT J ANAESTH, V82, P672; Gajraj RJ, 1998, BRIT J ANAESTH, V80, P46; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Heier T, 1996, ACTA ANAESTH SCAND, V40, P1087, DOI 10.1111/j.1399-6576.1996.tb05570.x; Iselin-Chaves IA, 2000, ANESTHESIOLOGY, V92, P1300, DOI 10.1097/00000542-200005000-00018; Jensen EW, 1998, MED ENG PHYS, V20, P722; LESLIE K, 1995, ANESTH ANALG, V81, P1269, DOI 10.1097/00000539-199512000-00025; Litvan H, 2002, ACTA ANAESTH SCAND, V46, P245, DOI 10.1034/j.1399-6576.2002.t01-1-460304.x; Mantzaridis H, 1997, ANAESTHESIA, V52, P1030, DOI 10.1111/j.1365-2044.1997.185-az0327.x; Mi W. D., 1999, European Journal of Anaesthesiology, V16, P47, DOI 10.1046/j.1365-2346.1999.00421.x; Mi WD, 1998, CAN J ANAESTH, V45, P19, DOI 10.1007/BF03011986; MOFFAT AC, 1989, ANAESTHESIA, V44, P644, DOI 10.1111/j.1365-2044.1989.tb13584.x; SHORT TG, 1992, BRIT J ANAESTH, V69, P162, DOI 10.1093/bja/69.2.162; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Struys MMRF, 2002, ANESTHESIOLOGY, V96, P803, DOI 10.1097/00000542-200204000-00006	20	14	18	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	OCT	2004	21	10					807	811		10.1017/S0265021504000092			5	Anesthesiology	Anesthesiology	885ZI	WOS:000226195500009	15678736				2020-06-30	J	Guay, J; Lortie, L				Guay, J; Lortie, L			Activation of the renin-angiotensin system contributes significantly to the pathophysiology of oliguria in patients undergoing posterior spinal fusion	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						surgery; scoliosis; spinal fusion; oliguria; intraoperative; postoperative; pituitary hormones posterior; vasopressin; atrial natriuretic factor; aldosterone; renin-angiotensin system	ATRIAL-NATRIURETIC-FACTOR; ANTIDIURETIC-HORMONE; INAPPROPRIATE SECRETION; IDIOPATHIC SCOLIOSIS; RENAL-FUNCTION; SURGERY; HYPONATREMIA; HYPOTENSION; ANESTHESIA; PRESSURE	Background and objective: This study was undertaken to investigate the role played by antidiuretic hormone (ADH), the renin-angiotensin system and atrial natriuretic factor (ANF) in the oliguria in patients undergoing spinal fusion. Methods: Sixteen patients undergoing posterior spinal fusion using isoflurane and fentanyl (n = 8) or sufentanil (n = 8) had renin, aldosterone, ADH and ANF measurements. Results: Compared to the non-oliguric patients, the oliguric patients had a higher number of fused vertebrae 10.5 +/- 1.3 vs. 9.0 +/- 0.5 (P = 0.01) and higher renin values at 12 h (3.3 +/- 3.2 vs. 0.7 +/- 0.6 ngL(-1) s(-1), P = 0.04). Hormonal values that had a significant correlation with intraoperative diuresis were: renin at 0.5 h (r(2) = 0.26, P = 0.04), aldosterone at 0.5 h (r(2) = 0.30, P = 0.03) and ANF at 0.5 h (r(2) = 0.32, P = 0.02). Those that had a significant correlation with the mean postoperative diuresis were: renin at 6 h (r(2) = 0.29, P = 0.03), 8 h ((r)2 = 0.26, P = 0.04) and 12h (r(2) = 0.31, P = 0.03), aldosterone at 6h (r(2) = 0.54, P = 0.001), 8 h (r(2) = 0.40, P = 0.01) and 12 h (r(2) = 0.32, P = 0.03), ADH at 24h (r(2) = 0.38, P = 0.01) and ANF at 6h (r(2) = 0.26, P = 0.045). Using stepwise regression, excluding hormonal values, only two continuous variables had a significant correlation with the mean postoperative diuresis: the number of fused vertebrae (P = 0.02) and the length of surgery (P = 0.02). Conclusion: Activation of the renin-angiotensin system is the major cause of the early intraoperative oliguria. ADH and the renin-angiotensin system are both involved in the pathophysiology of postoperative oliguria in patients undergoing spinal fusion.	Univ Montreal, Dept Anaesthesiol, Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada; Hop St Justine, Res Ctr, Montreal, PQ H3T 1C5, Canada	Guay, J (reprint author), Univ Montreal, Dept Anaesthesiol, Hop Maison Neuve Rosemont, 5415 Assompot Blvd, Montreal, PQ H1T 2M4, Canada.	joanne.guay@umontreal.ca					ADAMS HA, 1990, ANAESTHESIST, V39, P269; BELL GR, 1986, J BONE JOINT SURG AM, V68A, P720, DOI 10.2106/00004623-198668050-00012; BURROWS FA, 1983, CRIT CARE MED, V11, P527, DOI 10.1097/00003246-198307000-00009; Clark MA, 1998, METHOD FIND EXP CLIN, V20, P115, DOI 10.1358/mf.1998.20.2.485643; Cregg N, 1999, PAEDIATR ANAESTH, V9, P505, DOI 10.1046/j.1460-9592.1999.00043.x; Davis KL, 2003, CLIN THER, V25, P2647, DOI 10.1016/S0149-2918(03)80326-0; DeGasperi A, 1994, Transpl Int, V7 Suppl 1, pS134; EDWARDS BS, 1988, CIRC RES, V62, P191, DOI 10.1161/01.RES.62.2.191; ELSTER AD, 1985, CLIN ORTHOP RELAT R, P136; GUAY J, 1992, ANESTH ANALG, V75, P405; GUTKOWSKA J, 1986, CLIN INVEST MED, V9, P222; Hering R, 2001, ANESTH ANALG, V92, P1226, DOI 10.1097/00000539-200105000-00027; HOPF HB, 1994, ANESTHESIOLOGY, V80, P992, DOI 10.1097/00000542-199405000-00007; KANO T, 1986, J JAP SURG SOC, V87, P1398; Kudoh A, 1999, J CLIN ANESTH, V11, P101, DOI 10.1016/S0952-8180(99)00012-4; Langenbach MR, 2002, J CARDIOVASC SURG, V43, P595; Levine JP, 2001, PLAST RECONSTR SURG, V108, P1501, DOI 10.1097/00006534-200111000-00009; LIEHLAI MW, 2000, CRIT CARE MED, V28, P3126; Lobo DN, 2002, LANCET, V359, P1812, DOI 10.1016/S0140-6736(02)08711-1; MAYER N, 1990, CIRC SHOCK, V30, P165; MIRENDA JV, 1991, ANESTH ANALG, V72, P667; MONK TG, 1992, ANESTHESIOLOGY, V76, P39, DOI 10.1097/00000542-199201000-00006; PATHAK KS, 1985, ANESTH ANALG, V64, P509; ROSSAINT R, 1993, J APPL PHYSIOL, V75, P2484; RYLANCE PB, 1988, J BONE JOINT SURG BR, V70, P127; Tambe AA, 2003, INJURY, V34, P253, DOI 10.1016/S0020-1383(02)00256-5; Tsubo Toshihito, 1993, Japanese Journal of Anesthesiology, V42, P66; ZAYAS VM, 1993, AM J PHYSIOL, V265, pF686	28	4	4	0	0	GREENWICH MEDICAL MEDIA LTD	LONDON	137 EUSTON RD, 4TH FLOOR, LONDON NW1 2AA, ENGLAND	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	OCT	2004	21	10					812	818		10.1017/S0265021504000109			7	Anesthesiology	Anesthesiology	885ZI	WOS:000226195500010	15678737				2020-06-30	J	Jain, K; Grover, VK; Mahajan, R; Batra, YK				Jain, K; Grover, VK; Mahajan, R; Batra, YK			Effect of varying doses of fentanyl with low dose spinal bupivacaine for caesarean delivery in patients with pregnancy-induced hypertension	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article						pregnancy induced hypertension; preeclampsia; bupivacaine; fentanyl; spinal anaesthesia; intrathecal opioids	INTRATHECAL FENTANYL; LABOR ANALGESIA; ANESTHESIA; SECTION; PREECLAMPSIA; REPAIR	The purpose of this study was to evaluate haemodynamic stability, perioperative analgesia and neonatal outcome following intrathecal 0.5% bupivacaine 7.5 mg with varying doses of fentanyl, in parturients with pregnancy-induced hypertension. Forty-five parturients with pregnancy-induced hypertension scheduled for caesarean section were randomly allocated to receive 7.5 mg bupivacaine with saline I mL (group B), fentanyl 10 mug (group Bf(10)) or fentanyl 20 mug (group Bf(20)) intrathecally. Heart rate, blood pressure, and sensory block were recorded at regular intervals. Pain, nausea, vomiting, pruritus or any other side effects were sought. Neonatal outcome was assessed using Apgar score and umbilical artery blood gas analysis. Adequate surgical anaesthesia was established in all three Groups. There was a statistically significant fall in mean arterial pressure in all three groups within 4-6 min of subarachnoid block (P < 0.05), but the decrease in MAP was <20% of baseline in all three groups. Pain and discomfort during surgery were experienced more frequently in group B than in groups Bf(10) and Bf(20) (P < 0.05). Duration of postoperative analgesia was significantly longer in group Bf20 (5.55 +/- 1.18 h) than in group Bf10 (3.97 +/- 2.12 h) and group B (3.27 +/- 1.8 h) (P < 0.05). Neonatal outcome was similar in the three groups. Intrathecal fentanyl with low dose bupivacaine provides good surgical anaesthesia and prolongs the duration of analgesia without haemodynamic or neonatal compromise in patients with pregnancy-induced hypertension undergoing caesarean delivery. (C) 2004 Elsevier Ltd. All rights reserved.	Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India	Grover, VK (reprint author), Postgrad Inst Med Educ & Res, Dept Anaesthesia & Intens Care, Chandigarh 160012, India.	suman_vinod@yahoo.co.in					ABBOUD T, 1982, AM J OBSTET GYNECOL, V144, P915, DOI 10.1016/0002-9378(82)90184-3; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BROMAGE PR, 1964, BRIT J ANAESTH, V36, P342, DOI 10.1093/bja/36.6.342; Cascio M, 1997, CAN J ANAESTH, V44, P605, DOI 10.1007/BF03015443; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Hood DD, 1999, ANESTHESIOLOGY, V90, P1276, DOI 10.1097/00000542-199905000-00009; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Karinen J, 1996, BRIT J ANAESTH, V76, P616; Manullang TR, 2000, ANESTH ANALG, V90, P1162, DOI 10.1097/00000539-200005000-00030; Martyr JW, 2001, ANAESTH INTENS CARE, V29, P501, DOI 10.1177/0310057X0102900509; Nesbitt IDE, 1999, ANAESTHESIA, V54, P887; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; PEDERSEN H, 1989, ANESTH ANALG, V69, P46; RAMANATHAN J, 2000, REG ANESTH PAIN MED, V25, P170; SANTOS A, 1984, ANESTH ANALG, V63, P1009; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014; WALLACE DH, 1995, OBSTET GYNECOL, V86, P193, DOI 10.1016/0029-7844(95)00139-I; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019	22	17	19	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	OCT	2004	13	4					215	220		10.1016/j.ijoa.2004.04.006			6	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	868RL	WOS:000224930600003	15477049				2020-06-30	J	Corcoran, TB; Engel, A; Sakamoto, H; O'Callaghan-Enright, S; O'Donnell, A; Heffron, JA; Shorten, G				Corcoran, TB; Engel, A; Sakamoto, H; O'Callaghan-Enright, S; O'Donnell, A; Heffron, JA; Shorten, G			The effects of propofol on lipid peroxidation and inflammatory response in elective coronary artery bypass grafting	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						cytokines; cardiopulmonary bypass; oxygenderived free radicals; inflammation; myocardial ischemia reperfusion injury	ISCHEMIA-REPERFUSION INJURY; ISOLATED RAT-HEART; K-ATP CHANNELS; CARDIOPULMONARY BYPASS; MYOCARDIAL-ISCHEMIA; PROINFLAMMATORY CYTOKINES; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; DYSFUNCTION; OXYGEN	Objective: To determine whether the antioxidant and anti-inflammatory properties of propofol confer benefit in adult patients undergoing elective coronary artery bypass grafting. Design: Prospective, blinded, randomized, controlled clinical investigation. Setting: Single-center, university teaching hospital and academic research laboratory. Participants: Twenty-one adult patients (11 control, 10 intervention) with chronic stable angina and normal ventricular function scheduled to undergo elective coronary artery bypass grafting. Interventions: All patients received a standardized fentanyl-isoflurane anesthetic. Fifteen minutes before reperfusion, patients in the intervention group received a target-controlled infusion of propofol, continued for 4 hours after cross-clamp release. Patients in the control group received saline administered in a similar fashion. Measurements: Serum concentration of malondialdehyde (MDA) (from systemic and coronary sinus blood); systemic concentrations of interleukins 4, 6, 8, and 10; and systemic leukocyte functions ( respiratory burst, phagocytosis, and 132 integrin expression) were measured up to 36 hours after reperfusion. Results: A high serum malondialdehyde concentration was detected in the coronary sinus in control patients, 10 minutes after reperfusion; serum malondialdehyde was not detected in the coronary sinus at this time in patients who received propofol (41.4 [15.6-1,150] mumol/L v 0, p = 0.004). Interleukin-8 concentrations increased 2 and 4 hours after reperfusion in the control group. Interleukin-6 concentrations were greater in the control group than the propofol group 4 hours after clamp release (289.1 [165.2-561] rhog/mL v 153.2 (58.2-280.3) rhog/mL, respectively, p = 0.003). Mean dose of propofol was 31.7 mg/kg during the study period. Conclusion: Clinically relevant concentrations of propofol may attenuate free radical-mediated and inflammatory components of myocardial reperfusion injury in patients undergoing elective coronary artery bypass graft surgery. (C) 2004 Elsevier Inc. All rights reserved.	Univ Coll Cork, Dept Anaesthesia, Cork, Ireland	Corcoran, TB (reprint author), Royal Perth Hosp, Dept Intens Care Med, Wellington St, Perth, WA 6000, Australia.	mascor@gofree.indigo.ie					Bao YP, 1998, BRIT J ANAESTH, V81, P584, DOI 10.1093/bja/81.4.584; BOLLI R, 1989, CIRC RES, V65, P607, DOI 10.1161/01.RES.65.3.607; BOLLI R, 1990, FREE RADICAL RES COM, V9, P169, DOI 10.3109/10715769009145674; BREISBLATT WM, 1990, J AM COLL CARDIOL, V15, P1261, DOI 10.1016/S0735-1097(10)80011-7; BULL AW, 1985, ANAL BIOCHEM, V149, P284, DOI 10.1016/0003-2697(85)90506-8; BURNS SA, 1995, CIRCULATION, V92, P315, DOI 10.1161/01.CIR.92.9.315; CECONI C, 1991, AM J PHYSIOL, V260, pH1057; Chandrasekar B, 1999, CIRCULATION, V99, P427, DOI 10.1161/01.CIR.99.3.427; Cheng YJ, 2002, ANESTH ANALG, V94, P1617, DOI 10.1097/00000539-200206000-00047; De Hert SG, 2002, ANESTHESIOLOGY, V97, P42, DOI 10.1097/00000542-200207000-00007; De la Cruz JP, 1998, ANESTH ANALG, V87, P1141, DOI 10.1097/00000539-199811000-00031; Ebel D, 1999, BRIT J ANAESTH, V83, P903, DOI 10.1093/bja/83.6.903; Elwatidy AMF, 1999, ANN THORAC SURG, V68, P447, DOI 10.1016/S0003-4975(99)00359-8; Galinanes M, 1996, CIRCULATION, V94, P364; Hall RI, 1997, ANESTH ANALG, V85, P766, DOI 10.1097/00000539-199710000-00011; HENNEIN HA, 1994, J THORAC CARDIOV SUR, V108, P626; HESS ML, 1984, J MOL CELL CARDIOL, V16, P969, DOI 10.1016/S0022-2828(84)80011-5; Javadov SA, 2000, CARDIOVASC RES, V45, P360, DOI 10.1016/S0008-6363(99)00365-X; Jordan JE, 1999, CARDIOVASC RES, V43, P860, DOI 10.1016/S0008-6363(99)00187-X; Kersten JR, 1996, ANESTHESIOLOGY, V85, P794, DOI 10.1097/00000542-199610000-00015; Kirklin JK, 1989, CARDIOPULMONARY BYPA, P131; Kokita N, 1998, ANESTH ANALG, V86, P252, DOI 10.1097/00000539-199802000-00006; Kokita N, 1996, ANESTHESIOLOGY, V84, P117, DOI 10.1097/00000542-199601000-00014; KUKIELKA GL, 1995, CIRCULATION, V92, P1866, DOI 10.1161/01.CIR.92.7.1866; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; Mathur S, 1999, ANESTHESIOLOGY, V91, P1349, DOI 10.1097/00000542-199911000-00027; Mathy-Hartert M, 1998, MEDIAT INFLAMM, V7, P327, DOI 10.1080/09629359890848; Mathy-Hartert M, 2000, ANAESTHESIA, V55, P1066, DOI 10.1046/j.1365-2044.2000.01606.x; Meissner A, 2000, ANESTH ANALG, V91, P1333; Mikawa K, 1998, ANESTH ANALG, V87, P695, DOI 10.1097/00000539-199809000-00039; Mouithys-Mickalad A, 1998, BIOCHEM BIOPH RES CO, V249, P833, DOI 10.1006/bbrc.1998.9235; MURPHY PG, 1992, BRIT J ANAESTH, V68, P613, DOI 10.1093/bja/68.6.613; MUSACCHIO E, 1991, PHARMACOL TOXICOL, V69, P75, DOI 10.1111/j.1600-0773.1991.tb00414.x; Park JL, 1999, ANN THORAC SURG, V68, P1905, DOI 10.1016/S0003-4975(99)01073-5; PETROS AJ, 1993, BRIT J PHARMACOL, V109, P6, DOI 10.1111/j.1476-5381.1993.tb13523.x; Sawa Y, 1996, J THORAC CARDIOV SUR, V111, P29, DOI 10.1016/S0022-5223(96)70398-7; Wan S, 1996, J THORAC CARDIOV SUR, V112, P806, DOI 10.1016/S0022-5223(96)70068-5; Weman SM, 2000, ANN THORAC SURG, V70, P807, DOI 10.1016/S0003-4975(00)01638-6; Whitworth B, 1998, PROF ENG, V11, P28; Yoo KY, 1999, BRIT J ANAESTH, V82, P90; Zahler S, 1999, CARDIOVASC RES, V41, P722, DOI 10.1016/S0008-6363(98)00229-6	42	29	31	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	OCT	2004	18	5					592	604		10.1053/j.jvca.2004.07.018			13	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	867KD	WOS:000224840600009	15578470				2020-06-30	J	Neema, PK; Sinha, PK; Varma, PK; Rathod, RC				Neema, PK; Sinha, PK; Varma, PK; Rathod, RC			Simultaneous repair of bilateral multiple emphysematous bullae with a secundum atrial septal defect	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						bullous disease; atrial septal defect; cardiopulmonary bypass; anesthesia; emphysema; pulmonary bullae; combined cardiac and pulmonary surgery	LUNG-VOLUME REDUCTION; EPIDURAL-ANESTHESIA; DISEASE; SURGERY		Sree Chitra Tirunal Inst Med Sci & Technol, Dept Anaesthesiol, Trivandrum 695011, Kerala, India; Sree Chitra Tirunal Inst Med Sci & Technol, Dept Cardiothorac & Vasc Surg, Trivandrum 695011, Kerala, India	Neema, PK (reprint author), Sree Chitra Tirunal Inst Med Sci & Technol, Dept Anaesthesiol, Trivandrum 695011, Kerala, India.	neema@sctimst.ac.in	Varma, Praveen/AAQ-1774-2020	Varma, Praveen/0000-0003-3978-2874			BENUMOF JL, 1985, ANESTH ANALG, V64, P821; Brochu MC, 2002, CIRCULATION, V106, P1821, DOI 10.1161/01.CIR.0000029924.90823.E0; Cohen E, 1990, J Cardiothorac Anesth, V4, P119, DOI 10.1016/0888-6296(90)90458-R; Connery LE, 1999, BRIT J ANAESTH, V83, P493; DOMINO KB, 1998, ANESTHESIOL CLIN N A, V16, P295; FROST EAM, 1990, ANESTHESIOL CLIN N A, V8, P657; Gelb AF, 1999, CHEST, V116, P1608, DOI 10.1378/chest.116.6.1608; GRATZ I, 1999, ANES CLIN N AM, V17, P693; Hasnain J U, 1992, J Cardiothorac Vasc Anesth, V6, P624, DOI 10.1016/1053-0770(92)90109-K; HORLOCKER TT, 1999, ANESTHESIOL CLIN N A, V17, P861; Liem T H, 1992, J Cardiothorac Vasc Anesth, V6, P156; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Lowdermilk GA, 2000, ANN THORAC SURG, V69, P1670, DOI 10.1016/S0003-4975(00)01295-9; MESTRES CA, 2001, ASIAN CARDIOVASC THO, V9, P155; *NAT EMPH TREATM T, 2001, NEW ENGL J MED, V34, P1075; Naunheim KS, 1999, ANN THORAC SURG, V68, P2026, DOI 10.1016/S0003-4975(99)01153-4; Rao V, 1996, ANN THORAC SURG, V62, P342, DOI 10.1016/0003-4975(96)00206-8; ROSSI A, 1995, INTENS CARE MED, V21, P522, DOI 10.1007/BF01706208; Stirling GR, 2001, ANN THORAC SURG, V72, P641, DOI 10.1016/S0003-4975(01)02421-3; VANDERMEULEN EP, 1994, ANESTH ANALG, V79, P1165; VANSTRUM GS, 1988, ANESTH ANALG, V67, P261; WEST JB, 1996, BEST ARID TAYLORS PH, P529; WEST JB, 1996, BEST TAYLORS PHYSL B, P560; Wilkinson JL, 1998, CARDIOL YOUNG, V8, P295, DOI 10.1017/S104795110000679X; WONG DH, 1995, ANESTH ANALG, V80, P276, DOI 10.1097/00000539-199502000-00013	25	2	2	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	OCT	2004	18	5					632	636		10.1053/j.jvca.2004.07.012			5	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	867KD	WOS:000224840600017	15578478				2020-06-30	J	Butelman, ER; Harris, TJ; Kreek, MJ				Butelman, ER; Harris, TJ; Kreek, MJ			Antiallodynic effects of loperamide and fentanyl against topical capsaicin-induced allodynia in unanesthetized primates	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							DELTA-OPIOID AGONISTS; RHESUS-MONKEYS; VANILLOID RECEPTOR; MECHANICAL HYPERALGESIA; P-GLYCOPROTEIN; NERVE INJURY; PAIN; MU; MORPHINE; NEURONS	Capsaicin produces thermal allodynia in animals and humans by acting as an agonist at vanilloid receptor subtype 1 [VR1; also known as transient receptor potential vanilloid type 1 (TRPV1)]. VR1 receptors are widely distributed in the periphery (e.g., on primary afferent neurons). These studies examined the ability of loperamide (0.1-1 mg/kg s.c.; a mu-opioid agonist that is peripherally selective after systemic administration), in preventing and reversing thermal allodynia caused by topical capsaicin (0.004 M) in rhesus monkeys, within a tail withdrawal assay (n=4; 38degreesC and 42degreesC; normally non-noxious thermal stimuli). The effects of loperamide were compared with those of the centrally penetrating mu-agonist, fentanyl (0.0032-0.032 mg/kg s.c.). We also characterized the allodynic effects of the endogenous VR1 agonist ("endovanilloid"), N-oleoyldopamine (OLDA; 0.0013-0.004 M). In this model, loperamide and fentanyl produced dose-dependent prevention of capsaicin-induced allodynia, whereas only fentanyl produced robust reversal of ongoing allodynia. Antagonism experiments with naltrexone (0.1 mg/kg s.c.) or its analog, methylnaltrexone (0.32 mg/kg s.c.), which does not readily cross the blood-brain barrier, suggest that the antiallodynic effects of loperamide and fentanyl were predominantly mediated by peripherally and centrally located mu-receptors, respectively. Loperamide and fentanyl (1 mg/kg and 0.032 mg/kg, respectively) also prevented OLDA (0.004 M)-induced allodynia. Up to the largest dose studied, loperamide was devoid of thermal antinociceptive effects at 48 C (a noxious thermal stimulus, in the absence of capsaicin). By contrast, fentanyl (0.01-0.032 mg/kg) caused dose-dependent antinociception in this sensitive thermal antinociceptive assay (a presumed centrally mediated effect). These studies show that loperamide, acting as a peripherally selective mu-agonist after systemic administration, can prevent capsaicin-induced thermal allodynia in primates in vivo, in the absence of thermal antinociceptive effects.	Rockefeller Univ, New York, NY 10021 USA	Butelman, ER (reprint author), Rockefeller Univ, Box 171,1230 York Ave, New York, NY 10021 USA.	butelme@mail.rockefeller.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA05130, DA00049, DA11113]		Anderson WS, 2002, PAIN, V99, P207, DOI 10.1016/S0304-3959(02)00103-3; ANDREEV N, 1994, NEUROSCIENCE, V58, P793, DOI 10.1016/0306-4522(94)90456-1; Brandt MR, 2001, J PHARMACOL EXP THER, V296, P939; Butelman ER, 2004, PSYCHONEUROENDOCRINO, V29, P307, DOI 10.1016/S0306-4530(03)00030-1; Butelman ER, 2003, J PHARMACOL EXP THER, V306, P1106, DOI 10.1124/jpet.103.052381; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Chu CJ, 2003, J BIOL CHEM, V278, P13633, DOI 10.1074/jbc.M211231200; CHURCH J, 1994, MOL PHARMACOL, V45, P747; CULP WJ, 1989, BRAIN, V112, P1317, DOI 10.1093/brain/112.5.1317; DeHaven-Hudkins DL, 2002, LIFE SCI, V71, P2787, DOI 10.1016/S0024-3205(02)02102-1; Dehaven-Hudkins DL, 1999, J PHARMACOL EXP THER, V289, P494; FRANCE CP, 1990, J PHARMACOL EXP THER, V252, P600; Houghton AK, 1998, ANESTHESIOLOGY, V89, P190, DOI 10.1097/00000542-199807000-00026; Hudson LJ, 2001, EUR J NEUROSCI, V13, P2105, DOI 10.1046/j.0953-816x.2001.01591.x; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Junger H, 2002, BURNS, V28, P772, DOI 10.1016/S0305-4179(02)00199-7; KENAKIN TP, 1993, PHARM ANAL DRUG RECE; Ko MC, 1998, J PHARMACOL EXP THER, V285, P518; Ko MC, 1998, J PHARMACOL EXP THER, V286, P150; Ko MC, 2002, J PHARMACOL EXP THER, V301, P698, DOI 10.1124/jpet.301.2.698; KO MC, IN PRESS J PHARM EXP; Kupers RC, 1997, PAIN, V72, P269, DOI 10.1016/S0304-3959(97)00052-3; LAMOTTE RH, 1992, J PHYSIOL-LONDON, V448, P749, DOI 10.1113/jphysiol.1992.sp019068; Menendez L, 2003, NEUROREPORT, V14, P867, DOI 10.1097/01.wnr.0000069963.11849.af; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Negus SS, 1999, J PHARMACOL EXP THER, V290, P1132; Nozaki-Taguchi N, 1999, ANESTHESIOLOGY, V90, P225, DOI 10.1097/00000542-199901000-00029; O'Mahony S, 2001, ONCOLOGY-NY, V15, P61; Reichert JA, 2001, PAIN, V89, P221, DOI 10.1016/S0304-3959(00)00365-1; REYNOLDS IJ, 1986, J PHARMACOL EXP THER, V237, P731; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; Southall MD, 2003, J PHARMACOL EXP THER, V304, P217, DOI 10.1124/jpet.102.040675; Szabo T, 2002, MOL BRAIN RES, V98, P51, DOI 10.1016/S0169-328X(01)00313-8; SZALLASI A, 1993, N-S ARCH PHARMACOL, V347, P84; TAKASUNA M, 1994, BEHAV PHARMACOL, V5, P189, DOI 10.1097/00008877-199404000-00010; Toll L, 1998, NIDA Res Monogr, V178, P440; Truong W, 2003, ANN NEUROL, V53, P366, DOI 10.1002/ana.10465; Twillman RK, 1999, J PAIN SYMPTOM MANAG, V17, P288, DOI 10.1016/S0885-3924(98)00140-7; Walker KM, 2003, J PHARMACOL EXP THER, V304, P56, DOI 10.1124/jpet.102.042010; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; Yanagita T, 1979, NIDA Res Monogr, V27, P106; Yuan CS, 1999, NEUROPHARMACOLOGY, V38, P425, DOI 10.1016/S0028-3908(98)00192-0; Yuan CS, 2002, J PHARMACOL EXP THER, V300, P118, DOI 10.1124/jpet.300.1.118; Zollner C, 2003, MOL PHARMACOL, V64, P202, DOI 10.1124/mol.64.2.202	44	30	30	0	1	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	OCT	2004	311	1					155	163		10.1124/jpet.104.068411			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	854IK	WOS:000223896100019	15152028				2020-06-30	J	Bell, G; Dickson, U; Arana, A; Robinson, D; Marshall, C; Morton, N				Bell, G; Dickson, U; Arana, A; Robinson, D; Marshall, C; Morton, N			Remifentanil vs fentanyl/morphine for pain and stress control during pediatric cardiac surgery	PEDIATRIC ANESTHESIA			English	Article						congenital heart disease; remifentanil; stress response	PHARMACOKINETICS; PHARMACODYNAMICS; ALFENTANIL; GI87084B; CHILDREN	Background: Remifentanil is a short acting, potent synthetic opioid that does not accumulate after infusion or repeated bolus doses. It may be rapidly titrated to the requirements of individual patients. Titrated infusion of remifentanil may be able to provide potent analgesia required for pediatric cardiac surgery and obtund the stress response in theater whilst not having the persistent respiratory depression and sedation seen with longer acting opioids. Methods: Twenty patients were randomized to receive a titrated infusion of remifentanil (0-1 mug.kg(-1).min(-1)) or a standard dose of fentanyl (30 mug.kg(-1)) prebypass plus morphine (1 mg.kg(-1)) on rewarming. Blood samples for glucose and cortisol were taken at regular intervals from induction through bypass and into the first 24 h of postoperative intensive care. In addition to biochemical indicators of the stress response we recorded baseline hemodynamic parameters and any acute physiological events. Results: Ten patients received morphine, seven received remifentanil. There were no statistically significant differences between the two treatment groups in cortisol measurements, mean arterial pressure or heart rate recordings. In the last time period the remifentanil group had a larger rise in blood glucose concentration (baseline 3.9, rise 3 mmol.l(-1)) than the fentanyl/morphine group (baseline 4.2 rise 1.9 mmol.l(-1)), CI -4.3 to -0.2. Conclusions: The only significant difference was in glucose in the postbypass time periods. Although statistically significant, this difference is insufficient evidence of increased stress in the remifentanil group. The results show that in the patients studied there was no clinically important difference between the two techniques.	Royal Hosp Sick Children, Dept Anaesthet, Glasgow G3 8SJ, Lanark, Scotland; Childrens Hosp, Dept Anaesthet, Birmingham B16 8ET, W Midlands, England; Leeds Gen Infirm, Dept Anaesthet, Leeds, W Yorkshire, England; Dept Anaesthet, Auckland, New Zealand	Bell, G (reprint author), Royal Hosp Sick Children, Dept Anaesthet, Yorkhill, Glasgow G3 8SJ, Lanark, Scotland.	graham.bell@yorkhill.scot.nhs.uk	Morton, Neil/AAE-6594-2020	Morton, Neil/0000-0001-8848-7914; Marshall, Caroline/0000-0001-5901-2004			Davis PJ, 1997, ANESTH ANALG, V84, P982, DOI 10.1097/00000539-199705000-00007; Davis PJ, 1999, ANESTH ANALG, V89, P904, DOI 10.1097/00000539-199910000-00016; EGAN TD, 1994, ANESTHESIOLOGY, V81, pA374, DOI 10.1097/00000542-199409001-00373; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Prys-Roberts C, 2000, ANAESTHESIA, V55, P870, DOI 10.1046/j.1365-2044.2000.01607.x; Wee LH, 1999, PAEDIATR ANAESTH, V9, P415, DOI 10.1046/j.1460-9592.1999.00419.x; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005	7	11	12	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	OCT	2004	14	10					856	860		10.1111/j.1460-9592.2004.01326.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	856JW	WOS:000224042500009	15385015				2020-06-30	J	Delogu, G; Antonelli, A; Signore, M; Marcucci, L; Petrinelli, P; Tellan, G; Antonucci, A; Elli, R				Delogu, G; Antonelli, A; Signore, M; Marcucci, L; Petrinelli, P; Tellan, G; Antonucci, A; Elli, R			Chromosome instability in T-cells cultured in the presence of pancuronium or fentanyl	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						apoptosis; fentanyl; genomic instability; pancuronium; telomeric association; chromosome instability	TELOMERIC ASSOCIATIONS; APOPTOSIS; DEATH	Background: Genomic instability is recognized as a cause of cellular apoptosis and certain drugs that exhibit a proapoptotic effect are also able to induce chromosome damage. Since we found in recent experiments that drugs such as pancuronium and fentanyl exerted an apoptogenic effect on T cells, we studied the capacity of those agents to promote chromosome instability, i.e. chromosome aberrations (CA) and telomeric associations (tas) in peripheral blood lymphocytes. Methods: Lymphocytes from healthy donors were cultured with pancuronium or fentanyl, using two different concentrations for each drug: 20 and 200 ng/ml for pancuronium and 10 and 30 ng/ml for fentanyl, respectively. Cells were exposed to each concentration of these drugs either for 24 or 48 h. The higher concentration chosen was the same at which we detected the proapoptotic effect in our previous works. Cytogenetic analysis was performed by means of a standard technique and chromosome aberrations or telomeric associations were blindly evaluated by two independent observers. Results: The chromosome aberrations we observed in treated cells were not significantly different from control lymphocytes. However, an unusual rate of telomeric associations (P < 0.001) was detected in cells exposed to both pancuronium and fentanyl, at each concentration tested and at each exposure time of the study. Conclusions: Fentanyl and pancuronium do not have a direct clastogenic effect on T cultures, but at the same concentrations at which we demonstrated their apoptogenic power, these drugs are able to increase genomic instability through inducing an elevated rate of telomeric associations. Such a capacity could exploit in peripheral T cells the same mitochondrion-mediated signal pathway of apoptosis death.	Univ Roma La Sapienza, Dept Anesthesia & Intens Care, Rome, Italy; Univ Roma La Sapienza, Dept Cellular Biotechnol & Hematol, Rome, Italy; Ist Super Sanita, Dept Hematol Oncol & Mol Med, Rome, Italy	Delogu, G (reprint author), Policlin Umberto 1, Dept Anesthesia & Intens Care, I-00161 Rome, Italy.	giovanna.delogu@uniroma1.it	Signore, Michele/J-8563-2016	Signore, Michele/0000-0002-0262-842X; TELLAN, GUGLIELMO/0000-0002-4129-3300			ALLEN JS, 2003, TERATOG CARCINOG S1, V1, pS37; Blasco MA, 2002, NAT REV CANCER, V2, P627, DOI 10.1038/nrc862; BLISHCHENKO EY, 1994, IMMUNOL LETT, V42, P13, DOI 10.1016/0165-2478(94)90028-0; Chan CF, 2001, NEUROCHEM INT, V38, P135, DOI 10.1016/S0197-0186(00)00070-X; D'Agnano I, 1998, ENVIRON MOL MUTAGEN, V32, P56, DOI 10.1002/(SICI)1098-2280(1998)32:1<56::AID-EM7>3.0.CO;2-9; Delogu G, 2004, J TRAUMA, V57, P75, DOI 10.1097/01.TA.0000075349.66640.3E; Delogu G, 2003, ACTA ANAESTH SCAND, V47, P1138, DOI 10.1034/j.1399-6576.2003.00209.x; Espejel S, 2002, EMBO J, V21, P2207, DOI 10.1093/emboj/21.9.2207; IPCS (International Program on Chemical Safety), 1985, GUID STUD GEN EFF HU, V46, P45; Liu HP, 2001, J MOL CELL CARDIOL, V33, P2007, DOI 10.1006/jmcc.2001.1464; Liu L, 2003, J BIOL CHEM, V278, P31998, DOI 10.1074/jbc.M303553200; MOORHEAD PS, 1960, EXP CELL RES, V20, P613, DOI 10.1016/0014-4827(60)90138-5; MORGAN R, 1986, HUM GENET, V73, P260, DOI 10.1007/BF00401240; Pandita TK, 2002, ONCOGENE, V21, P611, DOI 10.1038/sj.onc.1205060; Pathak S, 1998, ONCOL REP, V5, P373; Petrinelli P, 2001, CANCER GENET CYTOGEN, V125, P46, DOI 10.1016/S0165-4608(00)00358-7; Ramirez R, 2003, J BIOL CHEM, V278, P836, DOI 10.1074/jbc.M206818200; Saldanha SN, 2003, EUR J BIOCHEM, V270, P389, DOI 10.1046/j.1432-1033.2003.03410.x; Samper E, 2003, AGING CELL, V2, P277, DOI 10.1046/j.1474-9728.2003.00062.x; Snyder RD, 2001, MUTAT RES-REV MUTAT, V488, P151, DOI 10.1016/S1383-5742(01)00055-2; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Zagon IS, 2003, NEUROPEPTIDES, V37, P79, DOI 10.1016/S0143-4179(03)00007-6; Zhang TC, 2003, CARCINOGENESIS, V24, P1811, DOI 10.1093/carcin/bgg141	23	3	3	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2004	48	8					968	972		10.1111/j.0001-5172.2004.00453.x			5	Anesthesiology	Anesthesiology	847FT	WOS:000223378800006	15315613				2020-06-30	J	Soysal, S; Karcioglu, O; Demircan, A; Topacoglu, H; Serinken, M; Ozucelik, N; Tirpan, K; Gunerli, A				Soysal, S; Karcioglu, O; Demircan, A; Topacoglu, H; Serinken, M; Ozucelik, N; Tirpan, K; Gunerli, A			Comparison of meperidine plus midazolam and fentanyl plus midazolam in procedural sedation: A double-blind, randomized controlled trial	ADVANCES IN THERAPY			English	Article						procedural sedation; orthopedic reductions; fentanyl; meperidine; midazolam; emergency department	EMERGENCY-DEPARTMENT; PRESCHOOL-CHILDREN; LACERATION REPAIR; RECTAL MIDAZOLAM; EFFICACY; REDUCTION; FRACTURES; TRAUMA; PAIN	This double-blind, randomized, prospective study was conducted to compare the analgesic and sedative efficacy of fentanyl and meperidine in orthopedic closed reduction of fractures and dislocations undertaken in the emergency department. Seventy consecutive adult patients with fractures or dislocations suitable for reduction were randomized to receive fentanyl (1 mcg/kg; n=36) or meperidine (0.5 mg/kg; n=34) in combination with midazolam (0.02 mg/kg). Vital signs and alertness scale scores of the patients were monitored. The Visual Analog Scale (VAS) was used to determine the degree of pain. There was no statistically significant difference between the VAS mean scores of the fentanyl and meperidine groups (t test, P=.772). The need for additional analgesic drugs was significantly more frequent in patients receiving meperidine (P=.018). No adverse events, such as hypotension or respiratory depression, were noted. Euphoria occurred in one patient in the fentanyl group. Although dose requirements differ, fentanyl and meperidine provide effective and reliable analgesia in closed reduction of fractures and dislocations.	Dokuz Eylul Univ, Sch Med, Dept Emergency Med, TR-35340 Izmir, Turkey; Dokuz Eylul Univ, Sch Med, Dept Publ Hlth, TR-35340 Izmir, Turkey; Dokuz Eylul Univ, Sch Med, Dept Anesthesiol, TR-35340 Izmir, Turkey	Soysal, S (reprint author), Dokuz Eylul Univ, Sch Med, Emergency Dept, TR-35340 Izmir, Turkey.						BILLMIRE DA, 1985, J TRAUMA, V25, P1079; Burton JH, 2002, ANN EMERG MED, V40, P496, DOI 10.1067/mem.2002.126607; Chudnofsky CR, 2000, ACAD EMERG MED, V7, P228, DOI 10.1111/j.1553-2712.2000.tb01064.x; CHUDNOFSKY CR, 1998, EMERGENCY MED CONCEP, P301; FRIEDLAND LR, 1994, ANN EMERG MED, V23, P203, DOI 10.1016/S0196-0644(94)70031-1; Furia JP, 1997, ORTHOPEDICS, V20, P423; GRANT A, 1993, INJURY, V24, P461, DOI 10.1016/0020-1383(93)90150-5; Jantos TJ, 1996, ANN EMERG MED, V28, P145, DOI 10.1016/S0196-0644(96)70054-9; Kanegaye JT, 2003, PEDIATR EMERG CARE, V19, P329, DOI 10.1097/01.pec.0000092578.40174.85; LERMAN B, 1996, AM J EMERG MED, V14, P440; Melzack R, 1994, TXB PAIN, P337; MICHAEL F, 1996, ANN EMERG MED, V27, P461; NICOLAOU DD, 2000, EMERGEN MED, P269; SCHUTZMAN SA, 1994, ANN EMERG MED, V24, P1059, DOI 10.1016/S0196-0644(94)70234-9; SHANE SA, 1994, ANN EMERG MED, V24, P1065, DOI 10.1016/S0196-0644(94)70235-7; Singer AJ, 1999, ANN EMERG MED, V33, P652, DOI 10.1016/S0196-0644(99)70194-0; TERNDRUP TE, 1993, ANN EMERG MED, V22, P206, DOI 10.1016/S0196-0644(05)80204-5; THEROUX MC, 1993, PEDIATRICS, V91, P624; WRIGHT SW, 1993, ANN EMERG MED, V22, P201, DOI 10.1016/S0196-0644(05)80203-3	19	4	4	0	2	HEALTH COMMUNICATIONS INC	EDISON	292 FERNWOOD AVE, EDISON, NJ 08837 USA	0741-238X			ADV THER	Adv. Ther.	SEP-OCT	2004	21	5					312	321		10.1007/BF02850035			10	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	889DJ	WOS:000226423400004	15727400				2020-06-30	J	Moreno, JD				Moreno, JD			Medical ethics and non-lethal weapons	AMERICAN JOURNAL OF BIOETHICS			English	Article									Univ Virginia, Ctr Biomed Eth, Charlottesville, VA 22903 USA	Moreno, JD (reprint author), Univ Virginia, Ctr Biomed Eth, Charlottesville, VA 22903 USA.						Coupland RM, 2003, LANCET, V362, P1346, DOI 10.1016/S0140-6736(03)14684-3; Moreno JD, 2004, AM J BIOETHICS, V4, pW20; WHITE J, 2004, WASH POST       0723, pA1	3	2	2	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1526-5161			AM J BIOETHICS	Am. J. Bioeth.	FAL	2004	4	4					W1	W2		10.1080/15265160490908077			2	Ethics; Medical Ethics; Social Issues; Social Sciences, Biomedical	Social Sciences - Other Topics; Medical Ethics; Social Issues; Biomedical Social Sciences	893BF	WOS:000226693600039	16192174				2020-06-30	J	MuraliKrishna, G				MuraliKrishna, G			A response to 'The sterility of fentanyl vials', Bayshev FK, Anaesthesia 2004; 59 : 627	ANAESTHESIA			English	Letter											gmuralikrishna@kgh.nhs.uk						0	0	0	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	SEP	2004	59	9					929	929		10.1111/j.1365-2044.2004.03937.x			1	Anesthesiology	Anesthesiology	845ZI	WOS:000223283800043	15310383				2020-06-30	J	Meissner, W; Hartmann, M; Kahler, G; Brauer, M				Meissner, W; Hartmann, M; Kahler, G; Brauer, M			Effect of enteral naloxone on the incidence of gastritis and esophagitis in mechanically ventilated patients	ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE			German	Article						naloxone; gastrointestinal motility; gastritis; esophagitis; intensive care	CRITICALLY-ILL PATIENTS; INTENSIVE-CARE PATIENTS; NEOSTIGMINE; ENDOSCOPY; REFLUX; CONSTIPATION; INHIBITION; FREQUENCY; MORPHINE	Background: Gastrtis and esophagitis are frequent and severe complications in intensive care patients, mainly caused by increased duodenogastral reflux. Opioids, commonly used in intensive care, are known to impair gastrointestinal (GI) motility which increases retrograd flow of gastric content. In a previous study, we showed that enteral administered naloxone reduces gastric reflux by selectively blocking GI opioid receptors. Therefore, in a subpopulation of these patients we studied the effect of enteral naloxone on the incidence of mucosal injury in opioid-treated, mechanically ventilated patients. Methods: After IRB approval, mechanically ventilated, fentanyl-treated patients without gastrointestinal surgery or diseases were assigned to receive 8 mg naloxone or placebo four times daily via a gastric tube. Additional inclusion criteria were opioid treatment for at least three days and endoscopy of the upper GI tract. Frequency of gastritis and esophagitis was quantified according to the Savary-Miller Score, and further parameter of GI motility (frequency of propulsive medication, amount of enteral feeding) were measured. Results: In four of seventeen patients of the naloxone group (24%) and 14 of 22 patients of the placebo group (64%; p = 0.02), esophageal or gastral mucosal injuries were detected. In the naloxone group, gastral reflux as well as need for propulsive medication were significantly lower. Volume of enteral feeding showed an increasing trend in the second half of the study. Conclusion: Reduction of esophagogastral mucosal injury and reduced need for procinetic medication suggests an improvement of GI motility by enteral naloxone in fentanyl-treated, mechanically ventilated patients.	Klinikum FSU Jena, Klin Anasthesiol & Intensivtherapie, D-07740 Jena, Germany; Univ Jena, Apotheke Univ Klinikum, Jena, Germany; Univ Klinikum, Sekt Endoskopie & Sonograph, Chirurg Klin, Mannheim, Germany	Meissner, W (reprint author), Klinikum FSU Jena, Klin Anasthesiol & Intensivtherapie, Bachstr 18, D-07740 Jena, Germany.	Winfried.Meissner@med.uni-jena.de					Berger MM, 2000, CRIT CARE MED, V28, P2217, DOI 10.1097/00003246-200007000-00006; Booth CM, 2002, CRIT CARE MED, V30, P1429, DOI 10.1097/00003246-200207000-00005; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; Doherty WL, 2003, CRIT CARE, V7, P206, DOI 10.1186/cc1849; FISHMAN J, 1973, J PHARMACOL EXP THER, V187, P575; Herbert MK, 2001, ANASTH INTENSIV NOTF, V36, P337, DOI 10.1055/s-2001-14805; Heyland DK, 1996, INTENS CARE MED, V22, P1339, DOI 10.1007/s001340050261; MANARA L, 1985, ANNU REV PHARMACOL, V25, P249, DOI 10.1146/annurev.pa.25.040185.001341; MANARA L, 1986, J PHARMACOL EXP THER, V237, P945; Meissner W, 2003, CRIT CARE MED, V31, P776, DOI 10.1097/01.CCM.0000053652.80849.9F; Meissner W, 2000, PAIN, V84, P105, DOI 10.1016/S0304-3959(99)00185-2; MITTAL RK, 1986, DIGEST DIS SCI, V31, P936, DOI 10.1007/BF01303214; Murphy DB, 1997, ANESTHESIOLOGY, V87, P765, DOI 10.1097/00000542-199710000-00008; NIEDERAU C, 1994, Z GASTROENTEROL, V32, P465; Plaisier PW, 1997, EUR J SURG, V163, P903; Plaisier PW, 1998, EUR J GASTROEN HEPAT, V10, P997, DOI 10.1097/00042737-199812000-00003; Ponec RJ, 1999, NEW ENGL J MED, V341, P137, DOI 10.1056/NEJM199907153410301; REYNOLDS JC, 1984, AM J PHYSIOL, V246, pG130; SAVARY M, 1978, HDB ATLAS ENDOSCOPY, P119; Taguchi A, 2001, NEW ENGL J MED, V345, P935, DOI 10.1056/NEJMoa010564; Thomas MC, 2003, AM J HEALTH-SYST PH, V60, P1264, DOI 10.1093/ajhp/60.12.1264; van der Spoel JI, 2001, INTENS CARE MED, V27, P822, DOI 10.1007/s001340100926; Wilmer A, 1999, GASTROENTEROLOGY, V116, P1293, DOI 10.1016/S0016-5085(99)70492-0	23	6	6	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-2661	1439-1074		ANASTH INTENSIV NOTF	Anasthesiol. Intensivmed. NotfMed. Schmerzther.	SEP	2004	39	9					538	541		10.1055/s-2004-825738			4	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	854KJ	WOS:000223901200004	15334330				2020-06-30	J	Shibutani, K; Inchiosa, MA; Sawada, K; Bairamian, M				Shibutani, K; Inchiosa, MA; Sawada, K; Bairamian, M			Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients - Derivation of dosing weight ("pharmacokinetic mass")	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 11-15, 2003	SAN FRANCISCO, CA	Amer Soc Anesthesiologists			BODY-COMPOSITION; BLOOD FLOWS; ALFENTANIL; INFUSION; SUFENTANIL; DRUGS	Background: The currently available pharmacokinetic models for fentanyl were derived from normal weight patients and were not scaled to body weight. Their application to obese patients may cause overprediction of the plasma concentration of fentanyl. This study examined the influence of body weight on the predictive accuracy of two models (ANESTHESIOLOGY 1990; 73:1091-102 and J Pharmacol Exp Ther 1987; 240:159-66). Further, we attempted to derive suggested dosing mass weights for fentanyl that improved predicted accuracy. Method: Seventy patients undergoing major elective surgery with total body weight (TBW)<85 kg and body mass index <30 (Group L) and 39 patients with TBW greater than or equal to 85 kg and body mass index > 30 (Group O) were studied. In Group L and Group O, the mean TBW was 69 kg, and 125 kg, respectively and the mean body mass index in Group L and Group O was 24 and 44, respectively. Fentanyl infusion was used during surgery and postoperatively for analgesia. Plasma fentanyl concentrations were measured and predicted concentrations were obtained by computer simulation; 465 pairs of measured and predicted values were obtained. Results: The influence of TBW on the performance errors of the original two models was examined with nonlinear regression analysis. Shafer error versus TBW showed a highly significant negative relationship (R squared = 0.689, P < 0.001); i.e., the Shafer model systematically overestimated fentanyl concentration as weight increased. The Scott and Stanski model showed greater variation (R squared = 0.303). We used the exponential equation for Shafer performance error versus TBW to derive suggested dosing weights ("pharmacokinetic mass") for obese patients. The pharmacokinetic mass versus TBW curve was essentially linear below 100 kg (with slope of 0.65) and approached a plateau above 140 kg. For patients weighing 140 to 200 kg, dosing weights of 100-108 kg are projected. Total body clearance (mil/min) showed a strong linear correlation with pharmacokinetic mass (r = 0.793; P < 0.001), whereas the relationship with TBW was nonlinear.	New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA; New York Med Coll, Dept Anesthesiol, Valhalla, NY 10595 USA; Nagoya Univ, Dept Anesthesia & Crit Care, Nagoya, Aichi, Japan	Inchiosa, MA (reprint author), New York Med Coll, Dept Pharmacol, Valhalla, NY 10595 USA.	mario_inchiosa@mymc.edu					AGARWAL N, 1982, SURGERY, V92, P226; Bjorkman S, 1998, ANESTHESIOLOGY, V88, P657, DOI 10.1097/00000542-199803000-00016; Bouillon T, 1998, ANESTHESIOLOGY, V89, P557, DOI 10.1097/00000542-199809000-00002; Egan TD, 1998, ANESTHESIOLOGY, V89, P562, DOI 10.1097/00000542-199809000-00004; GLASS PSA, 1995, ANESTH ANALG, V81, P665, DOI 10.1097/00000539-199510000-00001; GLASS PSA, 1990, ANESTHESIOLOGY, V73, P1082, DOI 10.1097/00000542-199012000-00004; HENTHORN TK, 1992, CLIN PHARMACOL THER, V52, P190, DOI 10.1038/clpt.1992.129; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; MAITRE PO, 1987, ANESTHESIOLOGY, V66, P3, DOI 10.1097/00000542-198701000-00002; MORGAN DJ, 1994, CLIN PHARMACOKINET, V26, P292, DOI 10.2165/00003088-199426040-00005; SCHWARTZ AE, 1991, ANESTH ANALG, V73, P790; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Slepchenko G, 2003, ANESTHESIOLOGY, V98, P65, DOI 10.1097/00000542-200301000-00014; Wada DR, 1997, ANESTHESIOLOGY, V87, P884, DOI 10.1097/00000542-199710000-00024	16	54	58	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	SEP	2004	101	3					603	613		10.1097/00000542-200409000-00008			11	Anesthesiology	Anesthesiology	850IS	WOS:000223605100006	15329584				2020-06-30	J	Kharasch, ED; Whittington, D; Hoffer, C				Kharasch, ED; Whittington, D; Hoffer, C			Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 11-15, 2003	SAN FRANCISCO, CA	Amer Soc Anesthesiologists			BREAKTHROUGH CANCER PAIN; BLOOD-BRAIN-BARRIER; P-GLYCOPROTEIN; DRUG-INTERACTIONS; GRAPEFRUIT JUICE; INTERINDIVIDUAL VARIABILITY; HEALTHY-VOLUNTEERS; NONINVASIVE PROBE; DOSE-TITRATION; PHARMACOKINETICS	Background: Oral transmucosal fentanyl citrate (OTF) was developed to provide rapid analgesia and is specifically approved for treating breakthrough cancer pain. Fentanyl in OTF is absorbed across the oral mucosa, but a considerable portion is swallowed and absorbed enterally. Fentanyl metabolism is catalyzed by cytochrome P4503A4 (CYP3A). The role of intestinal or hepatic first-pass metabolism and CYP3A activity in OTF disposition is unknown. This investigation examined the influence of hepatic and intestinal CYP3A activity on the disposition and clinical effects of OTF. Methods: Healthy volunteers (n = 12) were studied in an Institutional Review Board-approved, randomized, balanced, four-way crossover. They received OTF (10 mug/kg) after hepatic/intestinal CYP3A induction by rifampin, hepatic/intestinal CYP3A inhibition by troleandomycin, selective intestinal CYP3A inhibition by grapefruit juice, or nothing (control). Plasma fentanyl and norfentanyl concentrations were determined by mass spectrometry. Fentanyl effects were measured by dark-adapted pupil diameter and subjective self-assessments using visual analog scales' Results: Peak plasma fentanyl concentrations, time to peak, and maximum pupil diameter change from baseline were unchanged after rifampin, troleandomycin, and grapefruit juice. Fentanyl elimination, however, was significantly affected by CYP3A alterations. After control, rifampin, troleandomycin and grapefruit juice, respectively, area under the curve of plasma fentanyl versus time was 5.9 +/- 3.7, 2.2 +/- 0.8,* 10.4 +/- 8.9,* and 5.8 +/- 3.3 h(.)ng/ml; norfentanyl/fentanyl plasma area under the curve ratios were 0.92 +/- 0.63, 3.2 +/- 1.8,* 0.08 +/- 0.14,* and 0.67 +/- 0.33 (*P < 0.05 versus control). Discussion: Peak fentanyl concentrations and clinical effects after OTF were minimally affected by altering both intestinal and hepatic CYP3A activity, whereas fentanyl metabolism, elimination, and duration of effects were significantly affected; selective intestinal CYP3A inhibition had minimal effects. This suggests that first-pass metabolism minimally influences OTF bioavailability. When treating breakthrough pain, with careful attention to maximal mucosal absorption and minimal swallowing, CYP3A variability and drug interactions are unlikely to affect the onset or magnitude of OTF analgesia; however, duration may be affected.	Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	Kharasch, ED (reprint author), Univ Washington, Dept Anesthesiol, Box 356540,1959 NE Pacific St,RR-442, Seattle, WA 98195 USA.	kharasch@u.washington.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR00037]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K24-DA00417]		*AM PAIN SOC, 2003, [No title captured]; Ameer B, 1997, CLIN PHARMACOKINET, V33, P103, DOI 10.2165/00003088-199733020-00003; Berger A, 2003, J PAIN SYMPTOM MANAG, V26, P723, DOI 10.1016/S0885-3924(03)00255-0; Bruera E, 2003, JAMA-J AM MED ASSOC, V290, P2476, DOI 10.1001/jama.290.18.2476; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; CIRELLA VN, 1987, ANESTH ANALG, V66, P703; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Dale O, 2002, CLIN PHARMACOL THER, V72, P536, DOI 10.1067/mcp.2002.128386; de Boer AG, 2003, ANNU REV PHARMACOL, V43, P629, DOI 10.1146/annurev.pharmtox.43.100901.140204; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; FUSEAU E, 1984, CLIN PHARMACOL THER, V35, P733, DOI 10.1038/clpt.1984.104; Graff CL, 2003, PHARM RES-DORDR, V20, P1225, DOI 10.1023/A:1025053115583; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; Kharasch ED, 2004, J CLIN PHARMACOL, V44, P224, DOI 10.1177/0091270003262075; Kharasch ED, 2004, BRIT J CLIN PHARMACO, V57, P600, DOI 10.1111/j.1365-2125.2003.02053.x; Kharasch ED, 2003, CLIN PHARMACOL THER, V74, P543, DOI 10.1016/j.clpt.2003.08.011; Kharasch ED, 2003, ANESTHESIOLOGY, V99, P752, DOI 10.1097/00000542-200309000-00036; Kharasch ED, 2003, CLIN PHARMACOL THER, V73, P199, DOI 10.1067/mcp.2003.30; Kharasch ED, 1997, ANESTHESIOLOGY, V87, P36, DOI 10.1097/00000542-199707000-00006; Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Lown KS, 1997, J CLIN INVEST, V99, P2545, DOI 10.1172/JCI119439; Lundahl J, 1997, EUR J CLIN PHARMACOL, V52, P139, DOI 10.1007/s002280050263; Marshall KA, 1996, MAYO CLIN PROC, V71, P472, DOI 10.4065/71.5.472; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; McNicol E, 2003, J PAIN, V4, P231, DOI 10.1016/S1526-5900(03)00556-X; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mercadante S, 1999, ONCOLOGY-NY, V13, P215; Niemi M, 2003, CLIN PHARMACOKINET, V42, P819, DOI 10.2165/00003088-200342090-00003; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Phimmasone S, 2001, CLIN PHARMACOL THER, V70, P505, DOI 10.1067/mcp.2001.119994; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Robert R, 2003, J BURN CARE REHABIL, V24, P351, DOI 10.1097/01.BCR.0000095504.69283.F2; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; STANLEY TH, 1989, ANESTH ANALG, V69, P21; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Tateishi T, 1996, ANESTH ANALG, V82, P167; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; Wrighton SA, 2000, DRUG METAB REV, V32, P339, DOI 10.1081/DMR-100102338; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; Zeppetella G, 2001, PALLIATIVE MED, V15, P243, DOI 10.1191/026921601678576220; Zong J, 2003, J PHARMACOL EXP THER, V306, P556, DOI 10.1124/jpet.103.049452	52	47	50	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	SEP	2004	101	3					729	737		10.1097/00000542-200409000-00022			9	Anesthesiology	Anesthesiology	850IS	WOS:000223605100020	15329598				2020-06-30	J	Kharasch, ED; Hoffer, C; Whittington, D				Kharasch, ED; Hoffer, C; Whittington, D			Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate	ANESTHESIOLOGY			English	Article							BREAKTHROUGH CANCER PAIN; NITROUS-OXIDE ANESTHESIA; HEALTHY-VOLUNTEERS; DOSE-TITRATION; ALFENTANIL; MANAGEMENT; SUPPLEMENT; OPIOIDS; SURGERY; HUMANS	Background: Cancer pain is primarily a problem of older persons. Oral transmucosal fentanyl citrate (OTF) was developed to provide rapid analgesia and is die first drug specifically approved for treating breakthrough cancer pain. Fentanyl in OTF is absorbed across the oral mucosa but a considerable portion is swallowed and absorbed enterally. The effects of age on OTF pharmacokinetics and pharmacodynamics are unknown. This investigation evaluated OTF disposition and clinical effects in older (60-75 yr) compared with younger (18-40 yr) volunteers. Methods: Healthy young (26 +/- 6 yr) and older (67 +/- 6 yr) volunteers (n = 12 each) were studied in an Institutional Review Board approved protocol. They received OTF (10 mug/kg). Plasma femanyl. and norfentanyl concentrations were determined by mass spectrometry. Fentanyl effects were measured by dark-adapted pupil diameter and by subjective self-assessments using visual analog scales. Results: Plasma fentanyl and norfentanyl concentrations and pharmacokinetic parameters did not differ between younger and older subjects. Maximum pupil diameter change from baseline was significantly less in older (3.1 +/- 0.7 mm) compared with younger (4.5 +/- 1.1 mm) subjects (P < 0.05). OTF-dependent subjective assessments of alertness/sedation, energy level, confusion, clumsiness, anxiety, and nausea did not differ in the older subjects. Discussion: The pharmacokinetics of OTF were not altered in older volunteers. In contrast, there was a somewhat diminished response to the miotic effects of fentanyl in older subjects. No change in OTF dosing in the elderly would appear necessary because of altered pharmacokinetics. If the response to OTF in older patients is similar to that in older volunteers and miosis is representative of analgesia and respiratory depression, then changes in OTF dosing with age alone do not appear indicated.	Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	Kharasch, ED (reprint author), Univ Washington, Dept Anesthesiol, Box 356540,1959 NE Pacific St,RR-442, Seattle, WA 98195 USA.	kharasch@u.washington.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR00037]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K24-DA00417]		Ariano RE, 2001, J CLIN PHARMACOL, V41, P757, DOI 10.1177/00912700122010663; AUSEMS ME, 1986, ANESTHESIOLOGY, V65, P362, DOI 10.1097/00000542-198610000-00004; Balducci L, 2001, CRIT REV ONCOL HEMAT, V37, P137, DOI 10.1016/S1040-8428(00)00109-8; BENTLEY JB, 1982, ANESTH ANALG, V61, P968; Birren JE, 1955, J GERONTOL, V5, P216; Bitsios P, 1996, AGE AGEING, V25, P432, DOI 10.1093/ageing/25.6.432; Bjorkman S, 1998, ANESTHESIOLOGY, V88, P657, DOI 10.1097/00000542-199803000-00016; Bruera E, 2003, JAMA-J AM MED ASSOC, V290, P2476, DOI 10.1001/jama.290.18.2476; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Davis MP, 2003, DRUG AGING, V20, P23, DOI 10.2165/00002512-200320010-00003; DAVIS PB, 1988, J APPL PHYSIOL, V65, P200; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; FUSEAU E, 1984, CLIN PHARMACOL THER, V35, P733, DOI 10.1038/clpt.1984.104; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; Ibrahim AE, 2003, ANESTHESIOLOGY, V98, P853, DOI 10.1097/00000542-200304000-00011; Kharasch ED, 2004, ANESTHESIOLOGY, V101, P729, DOI 10.1097/00000542-200409000-00022; Lawlor PG, 2002, CANCER-AM CANCER SOC, V94, P1836, DOI 10.1002/cncr.10389; Lee M, 2003, J PAIN SYMPTOM MANAG, V26, P743, DOI 10.1016/S0885-3924(03)00241-0; LEMMENS HJM, 1988, BRIT J ANAESTH, V61, P173, DOI 10.1093/bja/61.2.173; LEMMENS HJM, 1988, ANESTH ANALG, V67, P956; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Mercadante S, 2002, CANCER, V94, P832, DOI 10.1002/cncr.10249; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Minto CF, 1997, ANESTHESIOLOGY, V86, P10, DOI 10.1097/00000542-199701000-00004; MURRAY RB, 1983, LIFE SCI, V33, P495, DOI 10.1016/0024-3205(83)90123-6; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Phimmasone S, 2001, CLIN PHARMACOL THER, V70, P505, DOI 10.1067/mcp.2001.119994; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SINGLETON MA, 1988, BRIT J ANAESTH, V60, P619, DOI 10.1093/bja/60.6.619; STANLEY TH, 1989, ANESTH ANALG, V69, P21; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; WINN B, 1994, INVEST OPHTH VIS SCI, V35, P1132; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	44	29	31	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	SEP	2004	101	3					738	743		10.1097/00000542-200409000-00023			6	Anesthesiology	Anesthesiology	850IS	WOS:000223605100021	15329599				2020-06-30	J	Portas, T				Portas, T			A review of drugs and techniques used for sedation and anaesthesia in a captive rhineceros species	AUSTRALIAN VETERINARY JOURNAL			English	Review							RHINOCEROS DICEROS-BICORNIS; CHEMICAL IMMOBILIZATION; ETORPHINE M99; COMBINATIONS; MANAGEMENT; FENTANYL; CAPTURE; SIMUM	Captive rhinoceros species are most frequently sedated and/or anaesthetised with the potent opioid, etorphine hydrochloride in combination with an alpha-2 adrenoreceptor agonist or the butyrophenone, azaperone. Carfentanil citrate based combinations have also been used to a lesser extent. In recent years butorphanol tartrate based combinations have been used with good success to induce neuroleptanalgesia. Sedation and anaesthesia are complicated by the large size of all rhinoceros species and their sensitivity to potent opioids. Potential complications include respiratory depression, hypoxaemia, hypertension, pulmonary shunting and ventilation/perfusion mismatch. The pharmacology of the principal drugs used for sedating/anaesthetising rhinoceros is reviewed. Techniques for sedating/anaesthetising the various species and potential complications associated with chemical restraint are discussed.	Western Plains Zoo, Dubbo, NSW 2830, Australia	Portas, T (reprint author), Western Plains Zoo, POB 831, Dubbo, NSW 2830, Australia.						ALLEN JL, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P343; Allen JL, 1996, J ZOO WILDLIFE MED, V27, P496; Atkinson MW, 2002, J ZOO WILDLIFE MED, V33, P157, DOI 10.1638/1042-7260(2002)033[0157:RCIOAC]2.0.CO;2; BAIER J, 1997, P AM ASS ZOO VET, P172; Ball Ray L., 2001, P176; BLUMER E, 1996, AZA RHINOCEROS HUSBA, P47; CORNICKSEAHORN JL, 1995, J AM VET MED ASSOC, V206, P508; DINERSTEIN E, 1990, WILDLIFE SOC B, V18, P36; DUTOIT JG, 1998, RHINO RANCHING, P31; Gandolf AR, 2000, J ZOO WILDLIFE MED, V31, P112, DOI 10.1638/1042-7260(2000)031[0112:MCUMIA]2.0.CO;2; HEARD DJ, 1992, J ZOO WILDLIFE MED, V23, P197; Jones D.M., 1979, International Zoo Yearbook, V19, P239, DOI 10.1111/j.1748-1090.1979.tb00572.x; Klein LV, 1997, P AM ASS ZOO VET, P127; Kock MD, 1995, J ZOO WILDLIFE MED, V26, P207; KOCK MD, 1992, J ZOO WILDLIFE MED, V23, P181; KOCK MD, 1990, J ZOO WILDLIFE MED, V21, P155; Langan J, 2001, J ZOO WILDLIFE MED, V32, P118, DOI 10.1638/1042-7260(2001)032[0118:DAMOAP]2.0.CO;2; LEBLANC PH, 1987, J ZOO WILDLIFE MED, V18, P141, DOI 10.2307/20094825; LEES P, 1976, BRIT J PHARMACOL, V56, P263, DOI 10.1111/j.1476-5381.1976.tb07637.x; Miller C, 1998, NAT GENET, V20, P228; Miller RE, 1998, P AM ASS ZOO VET AM, P213; Moresco A, 2001, J ZOO WILDLIFE MED, V32, P81, DOI 10.1638/1042-7260(2001)032[0081:UONTRC]2.0.CO;2; NANCE MD, 1998, P AM ASS ZOO VET, P208; RAATH JP, 1999, ZOO WILDLIFE MED CUR, V4, P556; Radcliffe RW, 2000, J ZOO WILDLIFE MED, V31, P196, DOI 10.1638/1042-7260(2000)031[0196:BAAAAS]2.0.CO;2; Radcliffe RW, 2000, J ZOO WILDLIFE MED, V31, P71, DOI 10.1638/1042-7260(2000)031[0071:ALLIAJ]2.0.CO;2; Reuter H, 1998, P AM ASS ZOO VET, P410; Rogers P.S., 1993, P512; Swan GE, 1993, CAPTURE CARE MANUAL, P17; WALZER C, 2000, P AM ASS ZOO VET INT, P98	30	24	27	0	22	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0005-0423	1751-0813		AUST VET J	Aust. Vet. J.	SEP	2004	82	9					542	549		10.1111/j.1751-0813.2004.tb11196.x			8	Veterinary Sciences	Veterinary Sciences	855FM	WOS:000223958600016	15478725				2020-06-30	J	Sullivan, SR; Friedrich, JB; Engrav, LH; Round, KA; Heimbach, DM; Heckbert, SR; Carrougher, GJ; Lezotte, DC; Wiechman, SA; Honari, S; Klein, MB; Gibran, NS				Sullivan, SR; Friedrich, JB; Engrav, LH; Round, KA; Heimbach, DM; Heckbert, SR; Carrougher, GJ; Lezotte, DC; Wiechman, SA; Honari, S; Klein, MB; Gibran, NS			"Opioid creep" is real and may be the cause of "fluid creep"	BURNS			English	Article						burn; opioid; analgesics; pain	ABDOMINAL COMPARTMENT SYNDROME; BURN PATIENTS; THERMAL BURNS; PAIN; RESUSCITATION; MANAGEMENT; MORPHINE; INJURY; PHARMACOKINETICS; METABOLITES	Recent studies have shown that burn patients receive larger volumes of fluids than predicted by the Baxter formula and the reason for this is unclear. One potential reason is that increased analgesics are used which could blunt the response to fluid resuscitation. The purpose of this study was to compare the administration of opioid agonists in patients treated at a single burn center in the 1970s and in the year 2000. We performed a retrospective chart review comparing two matched cohorts. Group I consisted of II patients admitted between 1975 and 1978. Group II consisted of II patients admitted in 2000 matched for age, sex and %TBSA. Patients in Group II received a significantly higher mean opioid equivalent than those in Group I (26.5 +/- 12.3 versus 3.9 +/- 2.2 in the first 24 h, P < 0.001). In addition, in Group II, a larger variety and combination of opioid agonists were used. This review demonstrates a significant increase from the 1970s to 2000 in the type, dose prescribed and dose delivered of opioid agonists. Along with "fluid creep", we have also increased our use of opioid agonists or "opioid creep". Higher doses of opioid agonists may have hemodynamic consequences, which may contribute to the increased fluid volumes. (C) 2004 Elsevier Ltd and ISBI. All rights reserved.	Univ Washington, Harborview Med Ctr, Div Plast Surg, Harborview Med Ctr, Seattle, WA USA; Univ Washington, Dept Pharm, Harborview Med Ctr, Seattle, WA USA; Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Colorado, Hlth Sci Ctr, Sect Med Informat, Dept Prevent Med & Biostat, Denver, CO USA; Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA USA; Harborview Med Ctr, Seattle, WA USA	Engrav, LH (reprint author), Univ Washington, Harborview Med Ctr, Div Plast Surg, Harborview Med Ctr, Box 359796,325 9th Ave, Seattle, WA USA.	engrav@u.washington.edu	Sullivan, Stephen/C-6389-2013				Ashburn Michael A., 1995, Journal of Burn Care and Rehabilitation, V16, P365, DOI 10.1097/00004630-199505001-00006; ATCHISON NE, 1991, PAIN, V47, P41, DOI 10.1016/0304-3959(91)90009-M; Baxter C, 1979, J Trauma, V19, P864; Baxter C R, 1974, Clin Plast Surg, V1, P693; BAXTER CR, 1968, ANN NY ACAD SCI, V150, P874, DOI 10.1111/j.1749-6632.1968.tb14738.x; BAXTER CR, 1981, J TRAUMA, V21, P687, DOI 10.1097/00005373-198108001-00016; BAXTER CR, 1974, POSTGRAD MED, V55, P131, DOI 10.1080/00325481.1974.11713664; BAXTER CR, 1978, SURG CLIN N AM, V58, P1313; BAXTER CR, 1970, ADV SURG, V4, P308; BAXTER CR, 1973, S TREATM BURNS SAINT, P42; BAXTER CR, 1971, CONT BURN MANAGEMENT, P7; Biffl WL, 2001, AM J SURG, V182, P645, DOI 10.1016/S0002-9610(01)00814-5; Byers JF, 2001, J BURN CARE REHABIL, V22, P144, DOI 10.1097/00004630-200103000-00011; CHOINIERE M, 1990, PAIN, V40, P143, DOI 10.1016/0304-3959(90)90065-L; Engrav LH, 2000, J BURN CARE REHABIL, V21, P91, DOI 10.1097/00004630-200021020-00002; Faura CC, 1998, PAIN, V74, P43, DOI 10.1016/S0304-3959(97)00142-5; FRIEDRICH JB, IN PRESS BURNS; FURMAN W R, 1990, Journal of Burn Care and Rehabilitation, V11, P391, DOI 10.1097/00004630-199009000-00003; Gibbons J, 1998, J BURN CARE REHABIL, V19, P225, DOI 10.1097/00004630-199805000-00008; Gueugniaud PY, 2000, INTENS CARE MED, V26, P848, DOI 10.1007/s001340051273; Hedderich R, 1999, CRIT CARE CLIN, V15, P167, DOI 10.1016/S0749-0704(05)70046-4; Heidrich G, 1981, J BURN CARE REHABIL, V2, P259, DOI 10.1097/00004630-198109000-00005; Herman R. A., 1994, Journal of Burn Care and Rehabilitation, V15, P95, DOI 10.1097/00004630-199403000-00002; Hobson KG, 2002, J TRAUMA, V53, P1129, DOI 10.1097/00005373-200212000-00016; Honari Shari, 1997, Journal of Burn Care and Rehabilitation, V18, P500, DOI 10.1097/00004630-199711000-00006; Iafrati N S, 1986, J Burn Care Rehabil, V7, P413, DOI 10.1097/00004630-198609000-00008; Ivy ME, 2000, J TRAUMA, V49, P387, DOI 10.1097/00005373-200009000-00001; JAEHDE L, 1995, CLIN PHARMACOKINET, V29, P15, DOI 10.2165/00003088-199529010-00003; Jonsson CE, 1998, BURNS, V24, P448, DOI 10.1016/S0305-4179(98)00050-3; Kealey G. P., 1995, Journal of Burn Care and Rehabilitation, V16, P363, DOI 10.1097/00004630-199505001-00005; Kreimeier U, 2000, CRIT CARE, V4, pS3, DOI 10.1186/cc968; LATARJET J, 1995, BURNS, V21, P344, DOI 10.1016/0305-4179(95)00003-8; LUTERMAN A, 1980, DRUG THERAPY     DEC, P15; MacLennan N, 1998, ANESTHESIOLOGY, V89, P749, DOI 10.1097/00000542-199809000-00027; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MARTYN J, 1986, ANESTHESIOLOGY, V65, P67, DOI 10.1097/00000542-198607000-00011; MARTYN JAJ, 1984, CLIN PHARMACOL THER, V35, P535, DOI 10.1038/clpt.1984.73; Marvin J A, 1985, Crit Care Clin, V1, P147; MAX MB, 1992, PRINCIPLES ANALGESIC; MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27; MILLER JG, 1994, BURNS, V20, P542, DOI 10.1016/0305-4179(94)90018-3; Patterson David R., 1995, Journal of Burn Care and Rehabilitation, V16, P372, DOI 10.1097/00004630-199505001-00007; Perreault S, 2001, ANN PHARMACOTHER, V35, P1588; PERRY S, 1983, J BURN CARE REHABIL, V4, P276; PERRY S, 1981, J BURN CARE REHABIL, V2, P322; Pruitt BA, 2000, J TRAUMA, V49, P567, DOI 10.1097/00005373-200009000-00030; Rae CP, 2000, EUR J ANAESTH, V17, P43, DOI 10.1046/j.1365-2346.2000.00600.x; REISINE T, 1996, [No title captured], P521; ROUBY JJ, 1981, CIRCULATION, V64, P53, DOI 10.1161/01.CIR.64.1.53; SHERIDAN RL, 1994, J TRAUMA, V36, P301, DOI 10.1097/00005373-199403000-00003; Ulmer JF, 1998, J BURN CARE REHABIL, V19, P151, DOI 10.1097/00004630-199803000-00014; Walkenstein M. D., 1982, J BURN CARE REHABIL, V3, P233	52	58	59	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179	1879-1409		BURNS	Burns	SEP	2004	30	6					583	590		10.1016/j.burns.2004.03.002			8	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	850ZB	WOS:000223651800013	15302427				2020-06-30	J	Clark, AJ; Ahmedzai, SH; Allan, LG; Camacho, F; Horbay, GLA; Richarz, U; Simpson, K				Clark, AJ; Ahmedzai, SH; Allan, LG; Camacho, F; Horbay, GLA; Richarz, U; Simpson, K			Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						adverse effects; age groups; body mass index; body weight; fentanyl; morphine; pain	LONG-TERM TREATMENT; TTS-FENTANYL; OPIOIDS; TRIAL; MILD	Purpose: To evaluate effectiveness and safety information of transdermal fentanyl (TDF) (Duragesic/Durogesic*) and sustained-release oral morphine (SRM) in cancer pain (CP) and chronic non-cancer pain (NCR), a pooled analysis was conducted on datasets of published, open label, uncontrolled (no comparator group) and randomised controlled (with SRM as comparator) studies of TDF Patients and methods: Eight trials with treatment durations of at least 28 days met the inclusion criteria. The effectiveness analysis assessed changes in average pain and pain 'right now' scores between baseline and Day 28. The safety analysis evaluated the incidence of adverse events (AEs) reported within the first 28 days of treatment with TDF or SRM. Subgroup analyses included pain type, gender, age, weight, and body mass index. Results: Pooled efficacy data were available from 1220 patients; these showed that both TDF and SRM were effective in improving pain 'right now' scores (0-100 scale) from baseline to Day 28. The improvement was significantly more pronounced in the TDF treatment group (-26.7 +/- 31.3 for TDF, -18.7 +/- 30.9 for SRM, p = 0.002). This favourable effect of TDF was most apparent amongst patients with NCR Data concerning AEs were available from over 2500 patients with CP (3 out of 10 patients) or chronic NCR (7 out of 10 patients). Significantly fewer patients in the TDF than in the SRM group reported any AE (72% vs. 87% respectively; p < 0.001), or an AE leading to the study drug being permanently discontinued (16% vs. 23% respectively; p < 0.001). Constipation and somnolence occurred considerably less frequently in the TDF than in the SRM treatment group. This difference was statistically significant in both the CP and NCR subgroups. Conclusion: This pooled data analysis provides expanded insight into the safety and effectiveness profile of transdermal fentanyl in patients with chronic pain. It shows significantly improved pain relief with transdermal fentanyl compared with sustained-release oral morphine, and supports current evidence of favourable tolerability of transdermal fentanyl, particularly with regard to reduced constipation and somnolence.	Dalhousie Univ, Pain Management Unit, QEIIHSC, Halifax, NS B3H 1V8, Canada; Univ Sheffield, Royal Hallamshire Hosp, Acad Palliat Med Unit, Sheffield S10 2JF, S Yorkshire, England; Damos, Don Mills, ON, Canada; Janssen Ortho Inc, Toronto, ON, Canada; Janssen Cilag AG, Baar, Switzerland; Univ Leeds, St James Hosp, Pain Management Serv, Leeds LS9 7TF, W Yorkshire, England	Clark, AJ (reprint author), Dalhousie Univ, Pain Management Unit, QEIIHSC, Room 4090,Dickson Bldg,5820 Univ Ave, Halifax, NS B3H 1V8, Canada.	john.clark@cdha.nshealth.ca		Ahmedzai, Sam/0000-0002-2028-8510			Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Allan L., 2003, PAIN EUROPE, VIV, P260; BJORNEBOE O, 2003, PAIN EUROPE, V4, P249; Cherny N I, 1994, J Palliat Care, V10, P57; CHOU R, 2000, J PAIN SYMTPOM MANAG, V26, P1026; DIZDAR Y, 2003, PAIN EUROPE, V4, P300; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; DONNER B, 1995, ANTI-CANCER DRUG, V6, P39, DOI 10.1097/00001813-199504003-00007; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; HERREROBEAUMONT G, 2003, PAIN EUROPE, V4, P250; JOHNSON M, STUDY COMPARE SUBJEC; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; LORUSSO P, 2001, P 9 WORLD PAIN SEATT; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; Menten J, 2002, CURR MED RES OPIN, V18, P488, DOI 10.1185/030079902125001272; Mercadante S, 1999, ONCOLOGY-NY, V13, P215; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Mystakidou K, 2003, J PAIN, V4, P298, DOI 10.1016/S1526-5900(03)00632-1; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Mystakidou K, 2001, ANTICANCER RES, V21, P2225; Nugent M, 2001, J PAIN SYMPTOM MANAG, V21, P385, DOI 10.1016/S0885-3924(01)00257-3; PORTENOY RK, 1994, PROGR PAIN RES MANAG; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Sabatowski R, 2003, J PAIN SYMPTOM MANAG, V25, P38, DOI 10.1016/S0885-3924(02)00539-0; SCHUG SA, 1991, DRUGS, V42, P228, DOI 10.2165/00003495-199142020-00005; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; Tawfik MO, 2004, CURR MED RES OPIN, V20, P259, DOI 10.1185/030079903125003026; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Watson C P N, 2004, Pain Res Manag, V9, P19; Weiss SC, 2001, LANCET, V357, P1311, DOI 10.1016/S0140-6736(00)04515-3; WIFFEN P, 2004, COCHRANE LIB; World Health Organization (WHO), 1996, WHO TECHN REP SER, V866; Yeo W, 1997, PALLIATIVE MED, V11, P233, DOI 10.1177/026921639701100308; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9	35	73	83	1	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.	SEP	2004	20	9					1419	1428		10.1185/030079904X2114			10	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	860KS	WOS:000224343100011	15383190				2020-06-30	J	Robertson, EN; Driessen, JJ; Booij, LHDJ				Robertson, EN; Driessen, JJ; Booij, LHDJ			Suxamethonium administration prolongs the duration of action of subsequent rocuronium	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						neuromuscular agents, rocuronium, suxamethonium, onset, recovery; intraocular pressure; drug interactions; cardiovascular physiology, heart rate, blood pressure	INTUBATING CONDITIONS; SUCCINYLCHOLINE; ORG-9426	Background and aim: Rocuronium may be given to patients for intubation and also after they have received suxamethonium for intubation. The neuromuscular profile of rocuronium given after recovery from suxamethonium may not be identical to that when rocuronium has been given alone. The neuromuscular effects of suxamethonium and rocuronium, and their effects on intraocular pressure (TOP), heart rate (HR) and arterial pressure were also recorded. Methods: Thirty patients were randomly allocated to receive either 0.6 mg kg(-1) rocuronium (n = 15) or 1 mg kg(-1) suxamethonium (n = 15) for intubation. Anaesthesia was first induced using propofol 2.5 mg kg(-1) and fentanyl 2 mug kg(-1) and maintained with propofol 6-12 mg kg(-1) h(-1). The response of the thumb to supra-maximal train-of-four (TOF) ulnar nerve stimulation at the wrist was measured using a mechanomyograph. In the suxamethonium group, when the first twitch of the TOF had recovered to 90%, rocuronium 0.6 mg kg(-1) was administered. Before administration of relaxant, baseline readings of HR, arterial pressure and TOP were measured until stable, then the appropriate relaxant administered. Thereafter, all readings were repeated at 30, 90, 150, 210 and 270 s. Tracheal intubation was performed 300 s after the intubating dose and all recordings repeated 30 s later. Mechanomyographic monitoring was continued until 70% TOF recovery. Results: Suxamethonium had a more rapid onset than rocuronium (49 s vs. 74 s, P < 0.0001). The onset time of rocuronium after suxamethonium was significantly reduced (56 s) and the time to recover to a TOF of 70% following rocuronium was increased by previous suxamethonium administration (47 vs. 58 min, P < 0.05). Suxamethonium caused a marked rise in TOP (>30%) and HR (>10%) while rocuronium had little effect on either. Conclusion: Previous suxamethonium administration decreases the onset time and increases the duration of action of rocuronium. Unlike suxamethonium, rocuronium has few cardiovascular effects and causes little change in TOP.	Univ Med Ctr, Dept Anesthesiol, NL-6500 HB Nijmegen, Netherlands	Robertson, EN (reprint author), Univ Med Ctr, Dept Anesthesiol, Postbus 9101, NL-6500 HB Nijmegen, Netherlands.	e.robertson@anes.umcn.nl	Driessen, J.J./L-4284-2015				Cadamy AJ, 1999, BRIT J ANAESTH, V83, P824; Caldwell JE, 1997, ANESTH ANALG, V85, P473; COOPER R, 1992, BRIT J ANAESTH, V69, P269, DOI 10.1093/bja/69.3.269; DUBOIS MY, 1991, ANESTH ANALG, V72, P364; DUBOIS MY, 1995, J CLIN ANESTH, V7, P44, DOI 10.1016/0952-8180(94)00002-L; HUIZINGA ACT, 1992, ACTA ANAESTH SCAND, V36, P463, DOI 10.1111/j.1399-6576.1992.tb03498.x; LIBONATI MM, 1985, ANESTHESIOLOGY, V62, P637, DOI 10.1097/00000542-198505000-00017; McCourt KC, 1998, ANAESTHESIA, V53, P867, DOI 10.1046/j.1365-2044.1998.00342.x; Mitra S, 2001, EUR J ANAESTH, V18, P836; PUHRINGER FK, 1992, ANESTH ANALG, V75, P37; ROBERTSON EN, 1994, EUROPEAN J ANAEST S9, V11, P116; Sparr HJ, 2001, EUR J ANAESTH, V18, P71; YASPUDA I, 1982, ANESTHESIOLOGY, V57, P289	13	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	SEP	2004	21	9					734	737		10.1017/S0265021504009111			4	Anesthesiology	Anesthesiology	876SJ	WOS:000225517500011	15595587				2020-06-30	J	Landy, SH				Landy, SH			Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: A case series	HEADACHE			English	Article						migraine headache pain; oral transmucosal fentanyl citrate; oral transmucosal fentanyl citrate; opioid; outpatient	BREAKTHROUGH PAIN; CANCER-PATIENTS; MORPHINE; SULFATE; TRIAL	Background.-Migraine headache pain that does not respond to traditional antimigraine medications frequently requires treatment in the emergency department(ED) with parenteral opioids. Rapid onset of pain relief in an outpatient setting for migraine headache is the primary objective of patients and clinicians. Oral transmucosal fentanyl citrate (OTFC(R); ACTIQ(R)) is a novel opioid product designed to deliver rapid analgesia to patients who experience breakthrough pain (BTP). Objective.-To evaluate the effectiveness, tolerability, and patient satisfaction with OTFC for the outpatient treatment of acute, refractory migraine headache pain. Patients and Methods.-Twenty patients with recurrent acute, refractory migraine headaches who had been referred to this headache clinic are reported in this case series. All patients had a history of tolerating parenteral opioids in the ED when experiencing refractory migraine pain and had been treated with outpatient opioid therapies in attempts to manage their migraine pain. Patients were prescribed OTFC( 400 mug) as rescue treatment for moderate or severe migraine headache pain as outpatients. Patients were instructed to self-administer OTFC at home and complete a diary recording: pain intensity (11-point scale; 10 = worst pain imaginable to 0 = no pain) before and 15, 30, 60, and 120 minutes after OTFC; satisfaction with the effectiveness of OTFC (selecting 1 of 7 categories ranging from "very dissatisfied" through "very satisfied") rated at 120 minutes; and adverse events. Results.-Eighteen patients (13 female) experienced a migraine and self-administered OTFC. OTFC successfully treated migraine episodes in all 18 outpatients; no patient went to an ED. OTFC rapidly reduced pain intensity, with significant improvement at 15 minutes that was sustained and provided progressively more pain relief at 30, 60, and 120 minutes (all P <.01). Mean (SEM) pain intensity significantly declined from 8.83 (0.35) pretreatment to 2.28 (0.67) at 120 minutes, an average reduction of 75% (P <.01). Patients' satisfaction ratings with OTFC were overwhelmingly positive, with 94% being satisfied and more than half (56%) being "very satisfied." Three (17%) patients experienced nausea, two (11%) somnolence, and one (6%) each itching, vomiting, and dry mouth. All adverse events were mild or moderate in severity. Conclusions.-OTFC rapidly and significantly relieved acute, refractory migraine pain in outpatients, prevented the need for an ED visit, and was associated with high patient satisfaction ratings. The rapid onset of migraine headache pain relief in this case series is consistent with the analgesic effect reported with the use of OTFC in patients with BTP. OTFC was well tolerated in these patients who had a history of tolerating parenteral opioids in the ED when experiencing refractory migraine pain and had been treated with outpatient opioid therapies in attempts to manage their migraine pain. OTFC may be effective for outpatient treatment of acute, refractory migraine headache pain. Further controlled studies are warranted.	Wesley Headache Clin, Memphis, TN 38018 USA	Landy, SH (reprint author), Wesley Headache Clin, 8000 Centerview Pkwy,Suite 101, Memphis, TN 38018 USA.						BECKETT BE, 1999, PHARMACOTHERAPY PATH, P1027; BURNS TA, 2001, AM J ANESTHESIOL, V28, P35; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; CLOYD JC, 2001, EMERGENCY DEP TREATM, P3; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Demirkaya S, 2001, HEADACHE, V41, P171, DOI 10.1046/j.1526-4610.2001.111006171.x; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; GERWELS JW, 1994, J DERMATOL SURG ONC, V20, P823, DOI 10.1111/j.1524-4725.1994.tb03712.x; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; LIND GH, 1991, ANN EMERG MED, V20, P1117, DOI 10.1016/S0196-0644(05)81387-3; Lipton RB, 2002, HEADACHE, V42, pS3, DOI 10.1046/j.1526-4610.2002.0420s1003.x; *MED EC CO, 2002, PRESCR INF ACTIQ OR, P1184; Morgenstern LB, 2001, HEADACHE, V41, P537, DOI 10.1046/j.1526-4610.2001.041006537.x; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; STANG PE, 1994, NEUROLOGY, V44, P47; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006	17	12	14	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	SEP	2004	44	8					762	766		10.1111/j.1526-4610.2004.04142.x			5	Clinical Neurology	Neurosciences & Neurology	849JF	WOS:000223534000003	15330821				2020-06-30	J	Poklis, A				Poklis, A			Urine concentrations of fentanyl and norfentanyl during application of Duragesic (R) transdermal patches	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							PHARMACOKINETICS		Virginia Commonwealth Univ, Sch Med, Dept Pathol, Richmond, VA 23298 USA; Ameritox Lab, Midland, TX 79706 USA	Poklis, A (reprint author), Alphonse Poklis, Box 98-0165,Med Coll Virginia Stn, Richmond, VA 23298 USA.	apoklis@vcu.edu					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; BASELT RC, 2003, DISPOSITION TOXIC DR, P319; CALIS KA, 1992, CLIN PHARMACY, V11, P22; HESS R, 1972, EUR J CLIN PHARMACOL, V4, P137, DOI 10.1007/BF00561135; MARSHALL BE, 1985, GOODMAN GILMANS PHAR, P517; MARUYAMA Y, 1979, KEIO J MED, V18, P50; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; *MED EC CO, 1994, PHYS DESK REF, P1092; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; RAFII A, 1990, AM PAIN SOC ANN M ST; SCHWARTZ JG, 1994, AM J FOREN MED PATH, V15, P236, DOI 10.1097/00000433-199409000-00011; STOECKEL H, 1979, BRIT J ANAESTH, V51, P741, DOI 10.1093/bja/51.8.741	12	33	33	0	5	PRESTON PUBLICATIONS INC	NILES	7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648 USA	0146-4760			J ANAL TOXICOL	J. Anal. Toxicol.	SEP	2004	28	6					422	425		10.1093/jat/28.6.422			4	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	850RQ	WOS:000223630500007	15516290	Bronze			2020-06-30	J	Kudoh, A; Takase, H; Takazawa, T				Kudoh, A; Takase, H; Takazawa, T			A comparison of anesthetic quality in propofol-spinal anesthesia and propofol-fentanyl anesthesia for total knee arthroplasty in elderly patients	JOURNAL OF CLINICAL ANESTHESIA			English	Article						elderly; spinal anesthesia; fentanyl; propofol; total knee arthroplasty	MINI-MENTAL-STATE; GENERAL-ANESTHESIA; POSTOPERATIVE PAIN; COGNITIVE FUNCTION; RECOVERY SCORE; DESFLURANE; SEVOFLURANE; DELIRIUM; SURGERY	Study Objective: To compare propofol plus spinal anesthesia during spontaneous ventilation using the Laryngeal Mask Airway and propofol plus fentanyl anesthesia during mechanical ventilation with an endotracheal tube on qualify of recovery after anesthesia. Design: Prospective, randomized, study. Setting: Hirosaki National Hospital. Patients: 150 patients (aged > 70 years) undergoing total knee arthroplasty. Interventions: Patients were divided randomly into two groups, to receive spontaneous ventilation with a Laryngeal Mask Airway during propofol-spinal anesthesia, or to receive Propofol-fentanyl anesthesia with mechanical ventilation via endotracheal tube. Measurements: Quality of anesthesia recovery such as nausea. vomiting headache. Pain throat, hoarse voice, back pain, dizziness, feeling, comfortable, dreaming recovery times in recovery of anesthesia, recovery times. postoperative pain, confusion, was assessed. Main Results: The frequency of postoperative pain throat, hoarse voice. and nausea was signficantly lower in the propofol-spinal anesthesia group than the propol-fentanyl anesthesia group. The time to extubation, emergence, response to commands. and orientation were significantly faster (p < 0.001) in the propofol-spinal anesthesia group than the propofol-fentanyl anesthesia group. The frequency of postoperative confusion occurring in the propofol-spinal anesthesia group during the first 24 hours was significantly lower than. that of the propofol-fentanyl anesthesia group (p = 0.03). Conclusions: Propofol-spinal anesthesia provided better and faster recovery than did propofol-fentanyl anesthesia for elderly patients undergoing total knee arthroplasty. (C) 2004, by Elsevier Inc.	Hirosaki Natl Hosp, Dept Anesthesiol, Hirosaki, Aomori 0368545, Japan	Kudoh, A (reprint author), Hirosaki Natl Hosp, Dept Anesthesiol, 1 Tominocho, Hirosaki, Aomori 0368545, Japan.	masuika@cc.hirosaki-u.ac.jp					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Apfelbaum JL, 1996, ANESTH ANALG, V83, P721, DOI 10.1097/00000539-199610000-00010; Chen XG, 2001, ANESTH ANALG, V93, P1489, DOI 10.1097/00000539-200112000-00029; CORK RC, 1994, ANESTH ANALG, V79, P719; Eger EI, 2000, PHARMACOECONOMICS, V17, P245, DOI 10.2165/00019053-200017030-00003; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HARRIS TJB, 1971, BRIT J ANAESTH, V43, P172, DOI 10.1093/bja/43.2.172; HEATH PJ, 1990, ANAESTHESIA, V45, P911, DOI 10.1111/j.1365-2044.1990.tb14617.x; HOLE A, 1980, ACTA ANAESTH SCAND, V24, P279, DOI 10.1111/j.1399-6576.1980.tb01549.x; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; Joo HS, 2000, ANESTH ANALG, V91, P213, DOI 10.1097/00000539-200007000-00040; Juvin P, 1997, ANESTH ANALG, V85, P647, DOI 10.1097/00000539-199709000-00029; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; Larsen B, 2000, ANESTH ANALG, V90, P168, DOI 10.1097/00000539-200001000-00035; MacKenzie DM, 1996, PSYCHOL MED, V26, P427, DOI 10.1017/S0033291700034826; MURRAY AM, 1993, J GERONTOL, V48, pM181, DOI 10.1093/geronj/48.5.M181; Myles PS, 2000, BRIT J ANAESTH, V84, P11; Niskanen MM, 2002, ANAESTHESIA, V57, P1052, DOI 10.1046/j.1365-2044.2002.02789.x; Tarazi EM, 1998, J CLIN ANESTH, V10, P272, DOI 10.1016/S0952-8180(98)00027-0; THORBURN J, 1980, BRIT J ANAESTH, V52, P1117, DOI 10.1093/bja/52.11.1117; Vaida SJ, 2000, J CLIN ANESTH, V12, P374, DOI 10.1016/S0952-8180(00)00174-4; Yamakage M, 1999, J CLIN ANESTH, V11, P375, DOI 10.1016/S0952-8180(99)00064-1; ZACNY JP, 1993, ANESTH ANALG, V77, P544	23	16	18	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	SEP	2004	16	6					405	410		10.1016/j.jclinane.2003.10.003			6	Anesthesiology	Anesthesiology	879XK	WOS:000225752400002	15567642				2020-06-30	J	Mouledous, L; Diaz, MF; Gutstein, HB				Mouledous, L; Diaz, MF; Gutstein, HB			Modulation of extracellular signal-regulated kinase (ERK) activity by acute and chronic opioid treatment in neuronal and glial cell lines	JOURNAL OF NEUROCHEMISTRY			English	Article						C6; fentanyl; mitogen-activated protein kinase; mu opioid receptor; neuro2A; SH-SY5Y	ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; HAMSTER OVARY CELLS; ADENYLYL-CYCLASE; CHRONIC EXPOSURE; LOCUS-COERULEUS; SH-SY5Y CELLS; MAP KINASE; RECEPTOR; MU	Acute mu opioid application has been shown to activate extracellular signal-related kinases (ERKs) in various non-neural cell lines. However, ERK activation in neuronal cells following acute morphine treatment is more questionable. Moreover, the ERK activation phenomenon observed in vivo after withdrawal of chronic opioids has never been demonstrated in vitro. The goal of this study was to determine if mu agonist treatment induced ERK activation acutely or after withdrawal of chronic opioids in one glial and three neuronal cell lines. We found that acute application of opioids was not able to activate ERK in neuronal cell lines but was able to activate ERK in a glial cell line. In another set of experiments, cells were chronically treated with escalating doses of a mu opioid agonist. After 8 days, the agonist was removed from the media and naloxone applied. Acute ERK activation was not seen in any tested cell line after agonist removal. These findings suggest that opioids may acutely activate ERK in non-neuronal cells, and that the acute ERK activation observed in some brain regions during opioid withdrawal in vivo might be mediated by indirect effects on neuronal cells.	Univ Texas, MD Anderson Canc Ctr, Dept Anesthesiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	Gutstein, HB (reprint author), Univ Texas, MD Anderson Canc Ctr, Dept Anesthesiol, Box 110,1515 Holcombe Blvd, Houston, TX 77030 USA.	hgutstein@mdanderson.org		Mouledous, Lionel/0000-0002-7675-3493	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 15146, DA 11500]		Belcheva MM, 2001, J BIOL CHEM, V276, P33847, DOI 10.1074/jbc.M101535200; Belcheva MM, 2002, NEUROSIGNALS, V11, P34, DOI 10.1159/000057320; Belcheva MM, 1998, J NEUROCHEM, V70, P635; Berhow MT, 1996, J NEUROSCI, V16, P4707; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chuang LF, 1997, J BIOL CHEM, V272, P26815, DOI 10.1074/jbc.272.43.26815; DaMotta ACR, 1997, ARQ NEURO-PSIQUIAT, V55, P444, DOI 10.1590/S0004-282X1997000300016; Eitan S, 2003, J NEUROSCI, V23, P8360; FIELDS A, 1995, BRAIN RES, V687, P94, DOI 10.1016/0006-8993(95)00475-6; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Gutstein HB, 1997, ANESTHESIOLOGY, V87, P1118, DOI 10.1097/00000542-199711000-00016; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; KAZMI SMI, 1987, MOL PHARMACOL, V32, P109; KENNEDY C, 1991, MOL PHARMACOL, V40, P1000; Kramer HK, 2000, NEUROPHARMACOLOGY, V39, P1707, DOI 10.1016/S0028-3908(99)00243-9; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Li LY, 1996, MOL PHARMACOL, V50, P599; Liu JG, 2001, BRAIN RES REV, V38, P1, DOI 10.1016/S0165-0173(01)00057-1; Mazzucchelli C, 2000, CELL MOL LIFE SCI, V57, P604, DOI 10.1007/PL00000722; OLASMAA M, 1988, BRAIN RES, V475, P291, DOI 10.1016/0006-8993(88)90617-8; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Schulz S, 1998, EUR J NEUROSCI, V10, P1196, DOI 10.1046/j.1460-9568.1998.00103.x; Singewald N, 1998, PROG NEUROBIOL, V56, P237, DOI 10.1016/S0301-0082(98)00039-2; Smart D, 1997, BRIT J PHARMACOL, V120, P1165, DOI 10.1038/sj.bjp.0701012; Song P, 2001, NEUROSCI RES, V39, P281, DOI 10.1016/S0168-0102(00)00226-1; Taylor DA, 2001, J PHARMACOL EXP THER, V297, P11; THOMPSON RC, 1993, NEURON, V11, P903, DOI 10.1016/0896-6273(93)90120-G; Trapaidze N, 2000, MOL BRAIN RES, V76, P220, DOI 10.1016/S0169-328X(00)00002-4; Tso PH, 2001, NEUROSCI LETT, V316, P13, DOI 10.1016/S0304-3940(01)02340-0	31	10	11	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2004	90	6					1371	1377		10.1111/j.1471-4159.2004.02610.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	850VN	WOS:000223642600010	15341521				2020-06-30	J	Ozyuvaci, E; Alnigenis, NY; Altan, A				Ozyuvaci, E; Alnigenis, NY; Altan, A			The effect of transdermal fentanyl treatment on serum cortisol concentrations in patients with non-cancer pain	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article; Proceedings Paper	Conference on Pain in Europea IV	SEP 02-06, 2003	Prague, CZECH REPUBLIC	European Federat Int Assoc Study Pain Chapters		transdermal fentanyl; chronic pain; serum cortisol concentration	LOW-BACK-PAIN; EFFICACY; OPIOIDS	We treated 50 patients with chronic nonmalignant pain using transdermal fentanyl (TDF) 25 mug/hr and concurrently measured pain using a visual analog scale (VAS) and serum cortisol concentration. Vile determined these outcomes at baseline and on days 30, 60, and 90 of the therapy. The patients also were asked to document any adverse effects. We found that mean cortisol concentrations on days 30, 60, and 90 of therapy were significantly (P < 0.0001) lower than the basal mean cortisol level, and mean VAS scores at days 30, 60, and 90 of therapy were also significantly better than the initial mean value (P < 0.0001). Fourteen patients experienced severe adverse events. These observations suggest that serum cortisol concentrations may be elevated. in chronic non-cancer Pain states and that TDF therapy can reduce cortisol levels, in parallel with reduction in pain. J Pain Symptom Manage 2004;28:277-281. (C) 2004 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	SSK Okmeydani Educ Hosp, Dept Anesthesiol & Intens Care, Istanbul, Turkey; SSK Okmeydani Educ Hosp, Dept Internal Med, Div Rheumatol, Istanbul, Turkey	Ozyuvaci, E (reprint author), Yesil Belgrad Evleri,B-21,Gokturk Beldesi, TR-34077 Istanbul, Turkey.						Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; AXELROD J, 1984, SCIENCE, V224, P452, DOI 10.1126/science.6143403; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Dellemijn PLI, 2001, EUR J PAIN-LONDON, V5, P333, DOI 10.1053/eujp.2001.0240; FERRACCIOLI G, 1990, J RHEUMATOL, V17, P869; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; MCQUAY HJ, 1989, BRIT J ANAESTH, V63, P213, DOI 10.1093/bja/63.2.213; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; Pacheco MJB, 2003, SEMIN ARTHRITIS RHEU, V32, P266, DOI 10.1053/sarh.2003.49993; PORTENOY R, 1990, J PAIN SYMPTOM MA S1, V5, P546; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; Tennant F, 2002, PAIN MED, V3, P132, DOI 10.1046/j.1526-4637.2002.02019.x; THEORELL T, 1984, ANN CLIN RES, V19, P53; World Health Organization (WHO), 1996, WHO TECHN REP SER, V866	14	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	SEP	2004	28	3					277	281		10.1016/j.jpainsymman.2003.11.004			5	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	856UY	WOS:000224071900017	15336341	Bronze			2020-06-30	J	Menahem, S; Shvartzman, P				Menahem, S; Shvartzman, P			High-dose fentanyl patch for cancer pain	JOURNAL OF THE AMERICAN BOARD OF FAMILY PRACTICE			English	Article							TRANSDERMAL FENTANYL; MANAGEMENT; PATIENT	Objective: To describe a successful experience with a high dose ( 1000 mug/hr) of transdermal fentanyl for cancer pain relief. Case Report: A 62-year-old man suffering from rectal carcinoma was treated by our home care hospice unit during his last 3.5 months of life. At admission to our home care unit, he suffered mostly from severe anal pain ( verbal pain scale of 10/10) due to advanced disease. He was then on 150 mug/hr transdermal fentanyl. Adjuvant therapy with amitriptyline 50 mg/day and dexamethasone 4 mg/day was added, but it did not relieve his pain. The dose of transdermal fentanyl was increased gradually to 1000 mug/hr with good pain control ( verbal pain scale of 1 to 4/10 most of the time). Before his death, he was mentally alert with good pain control. Conclusions: High doses of transdermal fentanyl ( 1000 mug/hr; 10 patches) should be considered for pain relief in cancer patients.	Ben Gurion Univ Negev, Fac Hlth Sci, Dept Family Med,Pain & Palliat Unit, Sial Res Ctr Family Med & Primary Care, IL-84105 Beer Sheva, Israel; Clalit Hlth Serv, Beer Sheva, Israel	Menahem, S (reprint author), Ben Gurion Univ Negev, Fac Hlth Sci, Dept Family Med,Pain & Palliat Unit, Sial Res Ctr Family Med & Primary Care, POB 653, IL-84105 Beer Sheva, Israel.	sassonm@bezeqint.net	SHVARTZMAN, PESACH/F-2134-2012				Ahmedzai S, 1997, EUR J CANCER, V33, pS8, DOI 10.1016/S0959-8049(97)00205-0; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Billings JA, 2000, BMJ-BRIT MED J, V321, P555, DOI 10.1136/bmj.321.7260.555; Bleeker CP, 2001, EUR J PAIN-LONDON, V5, P325, DOI 10.1053/eujp.2000.0220; BONICA JJ, 1985, ADV PAIN RES THER, V9, P589; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Cherny N, 2000, J Oncol Manag, V9, P8; Cleary J F, 2000, Cancer Control, V7, P120; *JANSS PHARM, 2001, DUR FENT TRANSD SYST; LEHR VT, 1993, ANN PHARMACOTHER, V27, P575, DOI 10.1177/106002809302700508; Moynihan TJ, 2003, MAYO CLIN PROC, V78, P1397, DOI 10.4065/78.11.1397; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; SIMMONDS MA, 1992, J PAIN SYMPTOM MANAG, V7, pS36, DOI 10.1016/0885-3924(92)90051-I; SKAER TL, 1993, CLIN THER, V15, P638; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Vielhaber A, 2002, HEMATOL ONCOL CLIN N, V16, P527, DOI 10.1016/S0889-8588(02)00016-3	17	9	9	0	3	AMER BOARD FAMILY MEDICINE	LEXINGTON	2228 YOUNG DR, LEXINGTON, KY 40505 USA	0893-8652			J AM BOARD FAM PRACT	J. Am. Board Fam. Pract.	SEP-OCT	2004	17	5					388	390		10.3122/jabfm.17.5.388			3	Medicine, General & Internal	General & Internal Medicine	852MV	WOS:000223760300012	15355954	Bronze			2020-06-30	J	Howard, LL; Kearns, KS; Clippinger, TL; Larsen, RS; Morris, PJ				Howard, LL; Kearns, KS; Clippinger, TL; Larsen, RS; Morris, PJ			Chemical immobilization of rhebok (Pelea capreolus) with carfentanil-xylazine or etorphine-xylazine	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						rhebok; Pelea capreolus; carfentanil; etorphine; xylazine; anesthesia; yohimbine; naltrexone	PULSE OXIMETRY	Twelve adult rhebok (Pelea capreolus) were immobilized using a combination of 0.4 mg/kg xylazine and either 0.01 mg/kg of carfentanil (n = 6) or 0.01 mg/kg etorphine (n = 6), delivered i.m. using a remote injection system. Induction and recovery times, heart rate, respiratory rate, rectal temperature, oxygen saturation, end-tidal CO. (ETCO2). anesthetic depth, indirect blood pressure, and arterial blood gases were recorded. Rhebok were not intubated but nasal oxygen was administered. Forty minutes after induction, anesthesia was antagonized with naltrexone and yohimbine. Mean initial heart rate was significantly higher in the carfentanil group than in the etorphine group. Mean initial oxygen saturation was consistent with hypoxia in both the carfentanil group and the etorphine group. In both groups, arterial pH decreased and partial pressure of carbon dioxide increased during the first 15 min of anesthesia. and values were similar in both groups. These findings were consistent with respiratory acidosis and decreased ventilation. Values for respiratory rate, temperature, oxygen saturation, ETCO2, and blood pressure were similar for both groups at all time periods. During the first 5 min of anesthesia. rhebok in the carfentanil group were more responsive to stimuli than rhebok in the etorphine group. After administration of antagonists, time to first arousal was significantly shorter in the etorphine group than in the carfentanil group. Although cardiopulmonary values were similar for the two groups, rhebok in the carfentanil group were at a comparatively lighter plane of anesthesia, and some individuals in this group required additional manual and chemical restraint for medical procedures to be performed. In conclusion, for captive adult rhebok, 0.01 mg/kg of etorphine and 0.4 mg/kg of xylazine are recommended over 0.01 mg/kg carfentanil and 0.4 mg/kg xylazine because of qualitatively better anesthetic episodes and shorter recovery times.	Zool Soc San Diego, San Diego, CA 92112 USA; Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA	Howard, LL (reprint author), Zool Soc San Diego, POB 120551, San Diego, CA 92112 USA.						ALFORD BT, 1974, J AM VET MED ASSOC, V164, P702; Allen Jack L., 1999, P2; ALLEN JL, 1989, J ZOO WILDLIFE MED, V20, P423; ALLEN JL, 1991, P AM ASS ZOO VET ANN, P336; Burroughs R.E.J., 1993, P348; GROSKY W, 1995, IEEE MULTIMEDIA, V2, P7; Hackett TB, 2002, VET CLIN N AM-SMALL, V32, P1021, DOI 10.1016/S0195-5616(02)00042-6; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; HASKINS SC, 1996, 1996 LUMB JONES VET, P409; Heard DJ, 1996, AM J VET RES, V57, P87; HORAK IG, 1982, ONDERSTEPOORT J VET, V49, P147; KOCK RA, 1985, J ASS VET ANAESTH, V13, P58; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; NEILSEN L, 1996, 1996 LUMB JONES VET, P736; NOWAK RM, 1997, [No title captured]; Schumacher J, 1997, J ZOO WILDLIFE MED, V28, P166; SNYDER SH, 1977, SCI AM, V236, P44, DOI 10.1038/scientificamerican0377-44; Thurmon JC, 1996, LUMB JONES VET ANEST, P183; Wright B, 1996, COMP CONT EDUC PRACT, V18, P1083	19	17	18	1	8	AMER ASSOC ZOO VETERINARIANS	MEDIA	6 NORTH PENNELL ROAD, MEDIA, PA 19063 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	SEP	2004	35	3					312	319		10.1638/03-090			8	Veterinary Sciences	Veterinary Sciences	857UH	WOS:000224143400005	15526885				2020-06-30	J	Baudelet, C; Gallez, B				Baudelet, C; Gallez, B			Effect of anesthesia on the signal intensity in tumors using BOLD-MRI: Comparison with flow measurements by laser Doppler flowmetry and oxygen measurements by luminescence-based probes	MAGNETIC RESONANCE IMAGING			English	Article						BOLD MRI; anesthesia; tumor; blood flow; oxygen	SODIUM PENTOBARBITAL-ANESTHESIA; BLOOD-FLOW; RADIATION RESPONSE; PARTIAL-PRESSURE; CARDIAC-OUTPUT; NORMAL TISSUE; SOLID TUMORS; MOUSE-TUMORS; TENSION; OXYLITE	BOLD-contrast functional magnetic resonance imaging (MRI) was used to assess the evolution of tumor oxygenation and blood flow after administration of four different anesthetics: pentobarbital (60 mg/kg), ketamine/xylazine (80/8 mg/kg), fentanyl/droperidol (0.078/3.9 mg/kg), and isoflurane (1.5%). Gradient echo sequences were carried out at 4.7 Tesla in a TLT tumor model implanted in the muscle of NMRI mice. In parallel experiments, tumor blood flow and tumor pO(2) were measured using the OxyLite/OxyFlo probe system. A comparison was made with the changes occurring in the skeletal muscle (host tissue). The signal intensity was dramatically decreased in tumors after administration of anesthetics, except isoflurane. These results correlated well with measurements of oxygenation and blood perfusion. Isoflurane produced constant muscle pO(2) and blood perfusion although large transient fluctuations in pO(2) and blood flow were reported in some tumors. Our results emphasize the need for careful monitoring of the effects of anesthesia when trying to identify new therapeutic approaches that are aimed at modulating tumor hemodynamics. (C) 2004 Elsevier Inc. All rights reserved.	Catholic Univ Louvain, Lab Biomed Magnet Resonance, Lab Med Chem & Radiopharm, B-1200 Brussels, Belgium	Gallez, B (reprint author), Catholic Univ Louvain, Lab Biomed Magnet Resonance, Lab Med Chem & Radiopharm, B-1200 Brussels, Belgium.	gallez@cmfa.ucl.ac.be					Baudelet C, 2002, MAGN RESON MED, V48, P980, DOI 10.1002/mrm.10318; Baudelet C, 2003, MAGNET RESON MED, V49, P985, DOI 10.1002/mrm.10468; Braun RD, 1999, AM J PHYSIOL-HEART C, V277, pH551; Braun RD, 2001, AM J PHYSIOL-HEART C, V280, pH2533; CHAPLIN DJ, 1995, BRIT J CANCER, V71, P1210, DOI 10.1038/bjc.1995.235; CULLEN BM, 1985, INT J RADIAT BIOL, V48, P761, DOI 10.1080/09553008514551861; Demeure RJ, 2002, PHYS MED BIOL, V47, P1819, DOI 10.1088/0031-9155/47/10/315; DENEKAMP J, 1979, INT J RADIAT BIOL, V35, P277, DOI 10.1080/09553007914550321; Dewhirst MW, 1996, BRIT J CANCER, V74, pS247; EGER EI, 1984, BRIT J ANAESTH, V56, pS71; FLECKNELL P, 1996, [No title captured]; Gallez B, 1999, MAGNET RESON MED, V42, P627, DOI 10.1002/(SICI)1522-2594(199910)42:4<627::AID-MRM2>3.0.CO;2-M; GOLDFINE ID, 1979, ENDOCRINOLOGY, V105, P920, DOI 10.1210/endo-105-4-920; Griffiths JR, 1999, BRIT J RADIOL, V72, P627, DOI 10.1259/bjr.72.859.10624317; Howe FA, 2001, NMR BIOMED, V14, P497, DOI 10.1002/nbm.716; JOHNSON R, 1976, RADIOLOGY, V118, P697, DOI 10.1148/118.3.697; Jordan BF, 2003, INT J RADIAT ONCOL, V55, P1066, DOI 10.1016/S0360-3016(02)04505-4; Jordan BF, 2002, CANCER RES, V62, P3555; Jordan BF, 2000, INT J RADIAT ONCOL, V48, P565, DOI 10.1016/S0360-3016(00)00694-5; KARCZMAR GS, 1994, NMR BIOMED, V7, P3, DOI 10.1002/nbm.1940070103; Kerger H, 1997, ANESTHESIOLOGY, V86, P372, DOI 10.1097/00000542-199702000-00012; Kimura H, 1996, CANCER RES, V56, P5522; MANDERS WT, 1976, CIRC RES, V39, P512, DOI 10.1161/01.RES.39.4.512; MENKE H, 1988, RADIAT RES, V114, P64, DOI 10.2307/3577144; MILROSS CG, 1996, RADIAT ONCOL INVEST, V4, P108; MOULDER JE, 1984, INT J RADIAT ONCOL, V10, P695, DOI 10.1016/0360-3016(84)90301-8; PALLAVICINI MG, 1983, INT J RADIAT ONCOL, V9, P1321, DOI 10.1016/0360-3016(83)90263-8; Pavlovic M, 1996, BRIT J CANCER, V74, pS222; Robinson SP, 1997, BRIT J CANCER, V75, P1000, DOI 10.1038/bjc.1997.172; Sancho AR, 1997, CANCER CHEMOTH PHARM, V40, P521, DOI 10.1007/s002800050696; SHELDON PW, 1977, INT J RADIAT BIOL, V32, P571, DOI 10.1080/09553007714551351; SKOLLEBORG KC, 1990, LAB ANIM, V24, P221, DOI 10.1258/002367790780866100; SKORNIK WA, 1990, J APPL PHYSIOL, V68, P2536; Snyder SA, 2001, INT J RADIAT ONCOL, V51, P494, DOI 10.1016/S0360-3016(01)01654-6; Sonveaux P, 2002, FASEB J, V16, P1979, DOI 10.1096/fj.02-0487fje; Steen R G, 1989, NMR Biomed, V2, P87, DOI 10.1002/nbm.1940020302; SUIT HD, 1985, RADIAT RES, V104, P47, DOI 10.2307/3576776; TAPER HS, 1966, CANCER RES, V26, P143; TUMA RF, 1985, AM J PHYSIOL, V249, pH485; Urano M, 2002, RADIAT RES, V158, P167, DOI 10.1667/0033-7587(2002)158[0167:MOTTOT]2.0.CO;2; Wojtczak L, 1996, ACTA BIOCHIM POL, V43, P361; Yang XP, 1999, AM J PHYSIOL-HEART C, V277, pH1967; ZANELLI GD, 1975, BRIT J CANCER, V32, P380, DOI 10.1038/bjc.1975.238; ZHAO M, 1995, MAGN RESON MED, V33, P610, DOI 10.1002/mrm.1910330505	44	59	60	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X	1873-5894		MAGN RESON IMAGING	Magn. Reson. Imaging	SEP	2004	22	7					905	912		10.1016/j.mri.2004.02.005			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	843WY	WOS:000223118900001	15288130				2020-06-30	J	Binstock, W; Rubin, R; Bachman, C; Kahana, M; McDade, W; Lynch, JP				Binstock, W; Rubin, R; Bachman, C; Kahana, M; McDade, W; Lynch, JP			The effect of premedication with OTFC, with or without ondansetron, on postoperative agitation, and nausea and vomiting in pediatric ambulatory patients	PEDIATRIC ANESTHESIA			English	Article						anesthesia; emergence; excitation; sevoflurane; ondansetron; OTFC; PONV	TRANSMUCOSAL FENTANYL CITRATE; PREANESTHETIC MEDICATION; PRESCHOOL-CHILDREN; PARENTAL PRESENCE; SURGERY PATIENTS; ORAL CLONIDINE; SEVOFLURANE; MIDAZOLAM; ANESTHESIA; HALOTHANE	Background: The purpose of this study was to evaluate, in the pediatric ambulatory surgical population, the efficacy of: (i) oral transmucosal fentanyl citrate (OTFC), when given preoperatively, to reduce postoperative excitement associated with sevoflurane, and (ii) intravenous ondansetron to reduce postoperative nausea and vomiting (PONV) associated with OTFC. Methods: This randomized, double-blinded, placebo controlled study evaluated the efficacy of OTFC [normal dose (ND) = 10-15 mug.kg(-1) or low dose = 100 mug] compared with placebo in the prevention of postoperative agitation; and the efficacy of ondansetron (0.1 mg.kg(-1) to 4 mg) compared with placebo to reduce PONV associated with OTFC. Results: There were 125 patients evaluated (2-10 years old, ASA class I or II and weight 10-40 kg). Preoperatively OTFC was associated with an increased likelihood of cooperation at baseline (P = 0.018). Postoperatively there was a higher incidence of vomiting in children that received OTFC. The anxiety/agitation of patients entering the PACU was significantly less in children who received OTFC ND (P < 0.001). This effect decreased over time. Patients with respiratory adverse events related to the study drug were significantly higher in groups who received OTFC, however, they were not of clinical significance. OTFC was associated with delays in time for eligibility to PACU discharge (P = 0.003). Conclusions: Even though OTFC reduced early postoperative agitation the increase in side effects, namely PONV and prolonged recovery times, limits its clinical usefulness. The study demonstrates the tradeoffs between anxiety and agitation vs vomiting, respiratory events and prolonged recovery times. Ambulatory pediatric patients undergoing procedures in which opioids would be routinely used might benefit the most from OTFC combined with ondansetron as part of the anesthetic technique.	Univ Chicago, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA	Binstock, W (reprint author), Univ Chicago, Dept Anesthesia & Crit Care, 5847 Maryland Ave,MC 4028, Chicago, IL 60637 USA.	wbb1@uchicago.edu		McDade, William/0000-0003-1068-8702			Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; ASHBURN MA, 1990, CAN J ANAESTH, V37, P857, DOI 10.1007/BF03006621; BRZUSTOWICZ RM, 1984, ANESTHESIOLOGY, V60, P475, DOI 10.1097/00000542-198405000-00014; COHEN MM, 1990, ANESTH ANALG, V70, P160; ECKENHOFF J, 1961, ANESTHESIOLOGY, V22, P667, DOI 10.1097/00000542-196109000-00002; Fazi L, 2001, ANESTH ANALG, V92, P56; FRIESEN RH, 1995, PAEDIATR ANAESTH, V5, P29, DOI 10.1111/j.1460-9592.1995.tb00236.x; FRIESEN RH, 1992, ANESTHESIOLOGY, V76, P46, DOI 10.1097/00000542-199201000-00007; FRINK EJ, 1992, ANESTH ANALG, V74, P241, DOI 10.1213/00000539-199202000-00012; Kain ZN, 2000, ANESTHESIOLOGY, V92, P939, DOI 10.1097/00000542-200004000-00010; Kain ZN, 1998, ANESTHESIOLOGY, V89, P1147, DOI 10.1097/00000542-199811000-00015; Lerman J, 1996, ANESTHESIOLOGY, V84, P1332, DOI 10.1097/00000542-199606000-00009; LYONS B, 1995, CAN J ANAESTH, V42, P473, DOI 10.1007/BF03011683; MALVIYA S, 1990, ANESTHESIOLOGY, V72, P793, DOI 10.1097/00000542-199005000-00003; MCGRAW T, 1994, CAN J ANAESTH, V41, P1094, DOI 10.1007/BF03015661; Patel RI, 1997, ANESTH ANALG, V85, P538, DOI 10.1097/00000539-199709000-00011; Shiga M, 2000, ANESTHESIOLOGY, V93, P954, DOI 10.1097/00000542-200010000-00013; STREISAND JB, 1989, ANESTH ANALG, V69, P28; Tanaka M, 2000, ANESTHESIOLOGY, V93, P1217, DOI 10.1097/00000542-200011000-00014; Uezono S, 2000, ANESTH ANALG, V91, P563, DOI 10.1213/00000539-200009000-00012; UMMENHOFER W, 1994, ANESTHESIOLOGY, V81, P804, DOI 10.1097/00000542-199410000-00006; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005; WILTON NCT, 1988, ANESTHESIOLOGY, V69, P972, DOI 10.1097/00000542-198812000-00032; YASTER M, 1997, PEDIAT PAIN MANAGEME, P7	24	14	17	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	SEP	2004	14	9					759	767		10.1111/j.1460-9592.2004.01296.x			9	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	849KL	WOS:000223537400009	15330959				2020-06-30	J	Celiker, V; Basgul, E; Karagoz, AH				Celiker, V; Basgul, E; Karagoz, AH			Anesthesia in Beckwith-Wiedemann syndrome	PEDIATRIC ANESTHESIA			English	Article						Beckwith-Weidemann syndrome; tracheomalacia; anesthia : general		Anesthetic management of a 3-month-old boy with Beckwith-Wiedemann syndrome for bronchoscopy is reported. Management may be complicated by a difficult airway, congenital heart disease, and hypoglycemia. We did not have difficulty in airway management either with tracheal intubation or rigid bronchoscopy, but we could not extubate the baby because of tracheomalacia.	Hacettepe Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-06100 Ankara, Turkey	Karagoz, AH (reprint author), Bestekar Sok 28-9, TR-06680 Ankara, Turkey.	heves@ada.net.tr					GERVER WJM, 1991, EUR J PEDIATR, V150, P634, DOI 10.1007/BF02072623; Li M, 1998, AM J MED GENET, V79, P253; MARTINEZ RMY, 1985, EUR J PEDIATR, V143, P233, DOI 10.1007/BF00442150; Martinez RMY, 1996, CLIN GENET, V50, P272; WENG EY, 1995, CLIN PEDIATR, V34, P317, DOI 10.1177/000992289503400605	5	3	4	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	SEP	2004	14	9					778	780		10.1111/j.1460-9592.2004.01283.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	849KL	WOS:000223537400012	15330962				2020-06-30	J	Subramaniam, K; Myers, LB				Subramaniam, K; Myers, LB			Combined general and epidural anesthesia for a child with Alagille syndrome: a case report	PEDIATRIC ANESTHESIA			English	Article						disease; Alagille syndrome; anesthesia; epidural; surgery; laparotomy	RANDOMIZED-TRIAL; LIVER-FUNCTION; SURGERY; ANALGESIA; PROPOFOL; PATIENT	Alagille syndrome (syndromic paucity of interlobular bile ducts) is the most common form of familial intrahepatic cholestasis. We describe the perioperative management of a pediatric patient with Alagille syndrome undergoing ileal exclusion and the specific issues associated with epidural anesthesia with this syndrome.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Anesthesiol & Crit Care Med, Boston, MA USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Anesthesia Perioperat & Crit Care Med, Boston, MA USA	Myers, LB (reprint author), Childrens Hosp, Dept Anesthesia, Bader 3,300 Longwood Ave, Boston, MA 02115 USA.	laura.myers@tch.harvard.edu					Adachi T, 1999, BRIT J ANAESTH, V83, P488; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Carli F, 2001, DIS COLON RECTUM, V44, P1083, DOI 10.1007/BF02234626; Choudhry DK, 1998, PAEDIATR ANAESTH, V8, P79, DOI 10.1046/j.1460-9592.1998.00668.x; CLARKE RSJ, 1976, BRIT J ANAESTH, V48, P119, DOI 10.1093/bja/48.2.119; Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331; Goyagi T, 1995, Masui, V44, P338; HARPER MH, 1982, ANESTH ANALG, V61, P79; Kouraklis G, 2000, INT SURG, V85, P353; Lykavieris P, 2003, PEDIATRICS, V111, P167, DOI 10.1542/peds.111.1.167; Muller C, 1996, Z GASTROENTEROL, V34, P809; MURRAY JM, 1992, BRIT J ANAESTH, V69, P643, DOI 10.1093/bja/69.6.643; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Quiros-Tejeira RE, 1999, J PEDIATR GASTR NUTR, V29, P431, DOI 10.1097/00005176-199910000-00011; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; ROBINSON FP, 1985, POSTGRAD MED J, V61, P160; VIEGAS O, 1979, ANESTHESIOLOGY, V51, P556, DOI 10.1097/00000542-197912000-00017	17	2	2	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	SEP	2004	14	9					787	791		10.1111/j.1460-9592.2004.01285.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	849KL	WOS:000223537400014	15330964				2020-06-30	J	Gallantine, EL; Meert, TF				Gallantine, EL; Meert, TF			Attenuation of the gerbil writhing response by mu-, kappa- and delta-opioids, and NK-1, -2 and -3 receptor antagonists	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						opioid; tachykinin; writhing; visceral; gerbil; NK-1; NK-2; NK-3; calcium channel antagonist	SUBSTANCE-P; VISCERAL PAIN; NONPEPTIDE ANTAGONISTS; CHANNEL BLOCKERS; PRIMARY AFFERENT; SPINAL-CORD; RAT; MICE; MORPHINE; NK1	mu-, kappa- and delta-opioid receptor agonists are reported to attenuate the acetic-acid-induced abdominal constriction response in mice. NK-1, -2 and -3 receptor antagonists also display activity in several visceral pain models. As the gerbil NK-1 receptor is comparable to the human receptor, we evaluated the efficacy of NK-1, -2 and -3 receptor antagonists and opioids (both alone and in combination) in the writhing test in this species. The effects of a selective L-type calcium (Ca2+) channel antagonist on the writhing response were also assessed to determine the contribution of Ca2+ channel antagonism to the antinociceptive effects of the NK-1 antagonists. Gerbils received subcutaneous injections of either the mu-opioids morphine or fentanyl, the K-opioid U50,488-H, the delta-opioid SNC80, NK-1 antagonists R116301, CP-96,345 or GR203040, the NK-2 antagonist SR-48968, the NK-3 antagonist SR-142801 or the Ca2+ channel antagonist nimodipine. Writhing was evoked 1 h after treatment by intraperitoneal injection of 0.2 ml 1% acetic acid solution and the frequency was recorded. Morphine, fentanyl and U50,488-H attenuated the writhing response dose dependently with complete inhibition occurring at the highest doses. SNC80 did not significantly attenuate the writhing response even at a dose of 40 mg/kg. The tachykinin NK-1 antagonists CP-96,345 and GR203040, the NK-2 antagonist SR-48968 and the NK-3 antagonist SR-142801 reduced the writhing frequency although without complete inhibition. The NK-1 antagonist 8116301 displayed limited activity at doses up to 40 mg/kg. Nimodipine did not exhibit any antinociceptive efficacy in this assay. Adding the NK-1, -2 or -3 antagonists to the opioids did not improve the efficacy of the opioids. Selective NK antagonists may therefore be effective in a visceral nociception assay in gerbils but do not modulate opioid action. (C) 2004 Elsevier Inc. All rights reserved.	PRD Johnson & Johnson, R&D, B-2340 Beerse, Belgium; Univ Newcastle Upon Tyne, Sch Med, Fac Med Sci, Sch Clin & Lab Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Meert, TF (reprint author), PRD Johnson & Johnson, R&D, Turnhoutseweg 30, B-2340 Beerse, Belgium.	tmeert@prdbe.jnj.com					Aicher SA, 2000, J NEUROSCI, V20, P4345; AIMONE LD, 1989, PEPTIDES, V10, P1127, DOI 10.1016/0196-9781(89)90003-X; Beattie DT, 1995, BRIT J PHARMACOL, V116, P3149, DOI 10.1111/j.1476-5381.1995.tb15117.x; BENTLEY GA, 1981, BRIT J PHARMACOL, V73, P325, DOI 10.1111/j.1476-5381.1981.tb10425.x; BERESFORD IJM, 1991, BRIT J PHARMACOL, V104, P292, DOI 10.1111/j.1476-5381.1991.tb12423.x; Betancur C, 1997, TRENDS PHARMACOL SCI, V18, P372, DOI 10.1016/S0165-6147(97)90666-0; BILSKY EJ, 1995, J PHARMACOL EXP THER, V273, P359; Bueno L, 2002, GUT, V51, pI19, DOI 10.1136/gut.51.suppl_1.i19; Bueno L, 1997, GASTROENTEROLOGY, V112, P1714, DOI 10.1016/S0016-5085(97)70056-8; Challet E, 2001, NEUROPHARMACOLOGY, V40, P408, DOI 10.1016/S0028-3908(00)00165-9; Chen Y, 2000, NEUROSCIENCE, V95, P787; COLLIER HOJ, 1968, BRIT J PHARMACOL, V32, P295, DOI 10.1111/j.1476-5381.1968.tb00973.x; Friese N, 1997, LIFE SCI, V60, P625, DOI 10.1016/S0024-3205(96)00647-9; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; GITTER BD, 1991, EUR J PHARMACOL, V197, P237, DOI 10.1016/0014-2999(91)90532-U; Holzer P, 2001, EUR J PHARMACOL, V429, P177, DOI 10.1016/S0014-2999(01)01319-X; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; Julia V, 1997, AM J PHYSIOL-GASTR L, V272, pG141; Julia V, 1999, GASTROENTEROLOGY, V116, P1124, DOI 10.1016/S0016-5085(99)70015-6; Laird JMA, 2000, NEUROSCIENCE, V98, P345, DOI 10.1016/S0306-4522(00)00148-2; LEMBECK F, 1985, EUR J PHARMACOL, V114, P241, DOI 10.1016/0014-2999(85)90365-6; Liu XH, 1998, BRAIN RES, V804, P95, DOI 10.1016/S0006-8993(98)00671-4; Liu ZH, 2003, LIFE SCI, V73, P233, DOI 10.1016/S0024-3205(03)00263-7; McLean PG, 1998, EUR J PHARMACOL, V345, P247, DOI 10.1016/S0014-2999(98)00040-5; Meert TF, 2003, PHARMACOL BIOCHEM BE, V76, P17, DOI 10.1016/S0091-3057(03)00187-4; Megens AAHP, 2002, J PHARMACOL EXP THER, V302, P696, DOI 10.1124/jpet.102.034348; MILLAN MJ, 1990, TRENDS PHARMACOL SCI, V11, P70, DOI 10.1016/0165-6147(90)90321-X; MINAMI M, 1995, MOL BRAIN RES, V30, P203, DOI 10.1016/0169-328X(94)00290-U; MIRANDA HF, 1992, EUR J PHARMACOL, V217, P137, DOI 10.1016/0014-2999(92)90833-P; MIRANDA HF, 1993, GEN PHARMACOL-VASC S, V24, P201, DOI 10.1016/0306-3623(93)90035-V; NAGAHISA A, 1992, EUR J PHARMACOL, V217, P191, DOI 10.1016/0014-2999(92)90847-W; Ozaki N, 2000, J NEUROPHYSIOL, V83, P2209; Reichert JA, 2001, PAIN, V89, P221, DOI 10.1016/S0304-3959(00)00365-1; Ribeiro-da-Silva A, 2000, NEUROPEPTIDES, V34, P256, DOI 10.1054/npep.2000.0834; Romerio SC, 1999, CLIN PHARMACOL THER, V66, P522, DOI 10.1016/S0009-9236(99)70016-0; RUPNIAK NMJ, 1993, BRIT J PHARMACOL, V110, P1607, DOI 10.1111/j.1476-5381.1993.tb14008.x; SACKS L, 1982, APPL STAT, P36; Satoh M, 1995, PHARMACOL THERAPEUT, V68, P343, DOI 10.1016/0163-7258(95)02011-X; SCHMAUSS C, 1983, LIFE SCI, V33, P653, DOI 10.1016/0024-3205(83)90587-8; SCHMIDT AW, 1992, EUR J PHARMACOL, V219, P491, DOI 10.1016/0014-2999(92)90498-S; SEGUIN L, 1995, PAIN, V61, P325, DOI 10.1016/0304-3959(94)00194-J; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Sora I, 1999, EUR J PHARMACOL, V366, pR3, DOI 10.1016/S0014-2999(98)00933-9; Stout SC, 2001, ANNU REV PHARMACOL, V41, P877, DOI 10.1146/annurev.pharmtox.41.1.877; Zharkovsky A, 1999, PAIN, V79, P217, DOI 10.1016/S0304-3959(98)00176-6; Zhou L, 1998, J PHARMACOL EXP THER, V286, P1000; Zimmer A, 1998, P NATL ACAD SCI USA, V95, P2630, DOI 10.1073/pnas.95.5.2630; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	48	6	6	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	SEP	2004	79	1					125	135		10.1016/j.pbb.2004.06.010			11	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	860IU	WOS:000224336700016	15388292				2020-06-30	J	Basu, S; Krishnamurthy, B; Walsh, TH				Basu, S; Krishnamurthy, B; Walsh, TH			Value of fentanyl in flexible sigmoidoscopy	WORLD JOURNAL OF SURGERY			English	Article							NITROUS-OXIDE; COLORECTAL-CANCER; FIBEROPTIC SIGMOIDOSCOPY; CONTROLLED TRIAL; COLONOSCOPY; SEDATION; INHALATION; ANALGESIA; ROUTINE; GASTROSCOPY	Studies have recorded significant patient discomfort during flexible sigmoidoscopy when it is performed without sedation/analgesia. This study observed whether a single dose of 50 mcg intravenous fentanyl reduces pain, improving compliance, acceptability, and completion rates. In a prospective study, 109 consecutive patients were offered the option of 50 mcg intravenous fentanyl or no analgesia. Patient's pre-procedure expectations, objective pain scores, and willingness to undergo a subsequent procedure using the same technique were recorded. Endoscopist recorded the success, complications, and objective pain scores for each patient. Of the 46 patients (42%) choosing fentanyl, 9 (20%) experienced moderate/severe pain as against 26(41%) of the 63 patients (58%) opting for no analgesia (p < 0.05). Further, 52% receiving fentanyl had a significantly better experience compared to their pre-procedure expectations as against 33% who received no analgesia (p < 0.05). No patient receiving fentanyl expressed unwillingness to undergo the procedure again using the same technique, whereas 16 (25%) of those receiving no analgesia indicated they would not (p < 0.01). Endoscopists recorded moderate/severe pain in 13 patients (12%), whereas 35 patients (32%) recorded moderate/severe pain (p < 0.001). Analgesia for endoscopy should involve patient choice. However, a single dose of 50 mcg fentanyl reduced patient discomfort and improved satisfaction. It appeared safe and likely to improve patient compliance and acceptability for flexible sigmoidoscopy.	St Marys Hosp, Endoscopy Unit, Newport PO30 5TG, Isle Of Wight, England	Basu, S (reprint author), Royal Bournemouth Hosp, Castle Lane E, Bournemouth BH7 7DW, Dorset, England.	sanjoy000@aol.com					ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; Briggs M, 1999, J PAIN SYMPTOM MANAG, V18, P438, DOI 10.1016/S0885-3924(99)00092-5; CALVEY TN, 1997, PRINCIPLES PRACTICE; Cockburn J, 1995, J Med Screen, V2, P79; Detsky AS, 2001, NEW ENGL J MED, V345, P607, DOI 10.1056/NEJM200108233450809; Drossman DA, 1996, AM J GASTROENTEROL, V91, P287; DUBOW RA, 1985, GASTROINTEST ENDOSC, V31, P305, DOI 10.1016/S0016-5107(85)72211-0; FOX E, 1987, STRESS MEDICINE, V3, P563; Frazier AL, 2000, JAMA-J AM MED ASSOC, V284, P1954, DOI 10.1001/jama.284.15.1954; GROBE JL, 1983, AM J GASTROENTEROL, V78, P569; Harding TA, 2000, ENDOSCOPY, V32, P457, DOI 10.1055/s-2000-652; JENSEN MP, 1992, [No title captured], P135; JOHNSON RA, 1982, J FAM PRACTICE, V14, P757; LANIUS M, 1990, Z GASTROENTEROL, V28, P651; LEVY N, 1989, ENDOSCOPY, V21, P263, DOI 10.1055/s-2007-1012965; LINDBLOM A, 1994, ENDOSCOPY, V26, P283, DOI 10.1055/s-2007-1008968; MCCARTHY BD, 1993, J GEN INTERN MED, V8, P120, DOI 10.1007/BF02599753; NotiniGudmarsson AK, 1996, ENDOSCOPY, V28, P283, DOI 10.1055/s-2007-1005454; Rex DK, 2000, AM J GASTROENTEROL, V95, P868, DOI 10.1111/j.1572-0241.2000.02059.x; ROWLAND AS, 1995, AM J EPIDEMIOL, V141, P531, DOI 10.1093/oxfordjournals.aje.a117468; SARLES HE, 1986, AM J GASTROENTEROL, V81, P369; SAUNDERS BP, 1994, GASTROINTEST ENDOSC, V40, P418, DOI 10.1016/S0016-5107(94)70203-9; SAUNDERS BP, 1995, GASTROINTEST ENDOSC, V42, P123, DOI 10.1016/S0016-5107(95)70067-6; SCHUTZ SM, 1994, GASTROINTEST ENDOSC, V40, P119, DOI 10.1016/S0016-5107(94)70038-9; Terruzzi V, 2001, GASTROINTEST ENDOSC, V54, P169, DOI 10.1067/mge.2001.113923; TORIBARA NW, 1995, NEW ENGL J MED, V332, P861, DOI 10.1056/NEJM199503303321306; TRAUL DG, 1983, DIS COLON RECTUM, V26, P161, DOI 10.1007/BF02560161; Trojan J, 1997, ENDOSCOPY, V29, P17, DOI 10.1055/s-2007-1004055; VANDAM J, 2000, NEW ENGL J MED, V342, P1219; WHERRY DC, 1994, SURG ENDOSC-ULTRAS, V8, P393, DOI 10.1007/BF00642439; WILKINS CJ, 1989, BRIT J ANAESTH, V63, P346, DOI 10.1093/bja/63.3.346; WINNAN G, 1980, NEW ENGL J MED, V302, P1011, DOI 10.1056/NEJM198005013021806; Woolf SH, 2000, NEW ENGL J MED, V343, P1641, DOI 10.1056/NEJM200011303432211; Zuccaro G Jr, 2000, Gastrointest Endosc Clin N Am, V10, P1	34	8	8	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	SEP	2004	28	9					930	934		10.1007/s00268-004-7374-8			5	Surgery	Surgery	859XL	WOS:000224301600016	15593470				2020-06-30	J	Kim, TW; Harbott, M				Kim, TW; Harbott, M			The use of caudal morphine for pediatric liver transplantation	ANESTHESIA AND ANALGESIA			English	Article							ANALGESIC REQUIREMENTS	A 3-yr-old female with cryptogenic cirrhosis presented for a liver transplant. After the induction and intubation, we performed a supplemental caudal block with a 22-gauge B-bevel needle in the usual sterile fashion, and 0.6 mg of Duramorph was injected without complications. Initially, the 14.9-kg child received a total of 110 mug of fentanyl in the first 2 h of the 6-h operation and was maintained on air-oxygen-isoflurane. The child was easily tracheally extubated and remained hemodynamically stable. In the pediatric intensive care unit, she was weaned off oxygen, out of bed, and required minimal pain control in the first 18 h.	Texas Childrens Hosp, Baylor Coll Med, Dept Anesthesiol, Houston, TX 77030 USA	Kim, TW (reprint author), Texas Childrens Hosp, Baylor Coll Med, Dept Anesthesiol, 6621 Fannin St,Ste B310,MC 2-1495, Houston, TX 77030 USA.	twkim@bcm.tmc.edu					BARASH PG, 2001, ANESTHESIA VASCULAR, P929; Donovan KL, 1997, TRANSPLANTATION, V63, P1423, DOI 10.1097/00007890-199705270-00010; EISENACH JC, 1989, MAYO CLIN PROC, V64, P356, DOI 10.1016/S0025-6196(12)65257-4; Moretti EW, 2002, J CLIN ANESTH, V14, P416, DOI 10.1016/S0952-8180(02)00390-2; Sanner MA, 2003, CLIN TRANSPLANT, V17, P391, DOI 10.1034/j.1399-0012.2003.00065.x; SHARPE MD, 1999, INTENSIVE CARE UNIT, P297	6	12	12	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2004	99	2					373	374		10.1213/01.ANE.0000122822.58156.48			2	Anesthesiology	Anesthesiology	840YS	WOS:000222897100012	15271708				2020-06-30	J	Prakash, S; Fatima, T; Pawar, M				Prakash, S; Fatima, T; Pawar, M			Patient-controlled analgesia with fentanyl for burn dressing changes	ANESTHESIA AND ANALGESIA			English	Article							INTRAVENOUS FENTANYL; DEMAND; ALFENTANIL; INFUSION; MORPHINE	In this randomized, double-blinded study in 60 ASA I or II adults with >20% body-surface area thermal burns, we investigated the feasibility of patient-controlled analgesia (PCA) with fentanyl for pain management during dressing changes and determined the optimal PCA-fentanyl demand dose. An initial loading dose of IV fentanyl 1 mug/kg was administered. Patients received on-demand analgesia with fentanyl (10, 20,30, and 40 mug) whenever their visual analog scale (VAS) score was >2. Mean VAS scores in the 10 and 20 mug groups (7.73 +/- 1.33 and 7.20 +/- 1.21, respectively) were significantly higher than those in the 30 and 40 mug groups (4.47 +/- 0.83 and 3.90 +/- 0.63, respectively) (all P = 0.000). Demand/delivery ratios were significantly larger in the 10 and 20 mug groups (3.03 +/- 1.06 and 2.54 +/- 0.49, respectively) than those in the 30 and 40 mug groups (1.36 +/- 0.34 and 1.37 +/- 0.36, respectively) (all P = 0.000). VAS scores and demand/delivery ratios were comparable in the 30 and 40 mug groups (P = 0.260 and P = 0.977, respectively), which suggests comparable analgesic efficacy. There was no hemodynamic instability or respiratory depression. The optimal demand dose of PCA-fentanyl was 30 mug (5-min lockout interval) after an initial loading dose of IV 1 fentanyl 1 mug/kg.	Vardhman Mahavir Med Coll, Dept Anaesthesia & Intens Care, New Delhi, India; Safdarjang Hosp, Dept Anaesthesia & Intens Care, New Delhi, India	Prakash, S (reprint author), 155-3 Basant Lane,Railway Colony, New Delhi 110055, India.	prakashsunil70@hotmail.com					Ashburn Michael A., 1995, Journal of Burn Care and Rehabilitation, V16, P365, DOI 10.1097/00004630-199505001-00006; BADETTI C, 1994, ANN FR ANESTH, V13, P789, DOI 10.1016/S0750-7658(05)80915-3; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; CHOINIERE M, 1992, ANAESTHESIA, V47, P467, DOI 10.1111/j.1365-2044.1992.tb02266.x; Gallagher G, 2000, ANAESTHESIA, V55, P1159, DOI 10.1046/j.1365-2044.2000.01712.x; GLASS PSA, 1992, ANESTH ANALG, V74, P345; KINSELLA J, 1988, BURNS, V14, P500, DOI 10.1016/S0305-4179(88)80011-1; KLUGER MT, 1990, ANAESTHESIA, V45, P1072, DOI 10.1111/j.1365-2044.1990.tb14893.x; LAHMANN KA, 1986, SCHMERZ PAIN DOULEUR, V7, P146; LAITINEN J, 1992, ANESTHESIOLOGY, V76, P194, DOI 10.1097/00000542-199202000-00006; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; MacLennan N, 1998, ANESTHESIOLOGY, V89, P749, DOI 10.1097/00000542-199809000-00027; MCCOY EP, 1993, ANAESTHESIA, V48, P256, DOI 10.1111/j.1365-2044.1993.tb06914.x; OWEN H, 1996, INT PRACTICE ANAESTH, V2, P1; Pal SK, 1997, BURNS, V23, P404, DOI 10.1016/S0305-4179(97)00029-6; Sim KM, 1996, BURNS, V22, P238, DOI 10.1016/0305-4179(95)00121-2; STOELTING RK, 1999, OPIOID AGONISTS ANTA, P93; WELCHEW EA, 1983, ANAESTHESIA, V38, P19, DOI 10.1111/j.1365-2044.1983.tb10367.x; WERMELING DP, 1986, CLIN PHARMACY, V5, P832	19	32	36	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2004	99	2					552	555		10.1213/01.ANE.0000125110.56886.90			4	Anesthesiology	Anesthesiology	840YS	WOS:000222897100041	15271737				2020-06-30	J	Marcus, MAE; Van Kleef, M; Joosten, EAJ				Marcus, MAE; Van Kleef, M; Joosten, EAJ			The quest for new devices to improve postoperative pain control	ANESTHESIA AND ANALGESIA			English	Letter									Univ Hosp Maastricht, Dept Anesthesiol, Maastricht, Netherlands	Marcus, MAE (reprint author), Univ Hosp Maastricht, Dept Anesthesiol, Maastricht, Netherlands.						Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E	1	1	1	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2004	99	2					623	623		10.1213/01.ANE.0000130905.16148.FD			1	Anesthesiology	Anesthesiology	840YS	WOS:000222897100062	15271757				2020-06-30	J	Kotwal, RS; O'Connor, KC; Johnson, TR; Mosely, DS; Meyer, DE; Holcomb, JB				Kotwal, RS; O'Connor, KC; Johnson, TR; Mosely, DS; Meyer, DE; Holcomb, JB			A novel pain management strategy for combat casualty care	ANNALS OF EMERGENCY MEDICINE			English	Article							ORAL TRANSMUCOSAL FENTANYL; CITRATE PREMEDICATION; CHILDREN; SEDATION; RESUSCITATION; ANALGESIA; TRIAL; OTFC	Study objective: Pain control in trauma patients should be an integral part of the continuum of care, beginning at the scene with out-of-hospital trauma management, sustained through the evacuation process and optimized during hospitalization. This, study evaluates the effectiveness of a novel application of a pain control medication, currently indicated for the management of chronic and breakthrough cancer pain, in the reduction of acute pain for wounded Special Operations soldiers in an austere combat environment. Methods: Doses (1,600 mug) of oral transmucosal fentanyl citrate were administered by medical personnel during missions executed in support of Operation Iraqi Freedom from March 3, 2003, to May 3, 2003. Hemodynamically stable casualties presenting with isolated, uncomplicated orthopedic injuries or extremity wounds who would not have otherwise required an intravenous catheter were eligible for treatment and evaluation. Pretreatment, 15-minute posttreatment, and 5-hour posttreatment pain intensities were quantified by the verbal 0-to-10 numeric rating scale. Results: A total of 22 patients, aged 21 to 37 years, met the study criterion. The mean difference in verbal pain scores (5.77; 95% confidence interval [CI] 5.18 to 6.37) was found to be statistically significant between the mean pain rating at 0 minutes and the rating at 15 minutes. However, the mean difference (0.39; 95% CI -0.18 to 0.96) was not statistically significant between 15 minutes and 5 hours, indicating the sustained action of the intervention without the need for redosing. One patient experienced an episode of hypoventilation that resolved readily with administration of naloxone. Other documented adverse effects were minor and included pruritus (22.7%), nausea (13.6%), emesis (9.1%), and lightheadedness (9.1%). Conclusion: Oral transmucosal fentanyl citrate can provide an alternative means of delivering effective, rapid-onset, and noninvasive pain management in an out-of-hospital, combat, or austere environment.	Univ Texas, Med Branch, Dept Prevent Med, Galveston, TX 77555 USA; Command & Gen Staff Coll, Ft Leavenworth, KS USA; Uniformed Serv Univ Hlth Sci, Dept Mil & Emergency Med, Bethesda, MD 20814 USA; Walter Reed Army Med Ctr, Emergency & Operat Med Serv, Washington, DC 20307 USA; USA, Inst Surg Res, Trauma Div, Ft Sam Houston, TX 78234 USA	Kotwal, RS (reprint author), Univ Texas, Med Branch, Dept Prevent Med, 301 Univ Blvd, Galveston, TX 77555 USA.	rskotwal@utmb.edu					*AC PAIN MAN GUID, 1992, [No title captured]; American Pain Society, 2000, Case Manager, V11, P50; ASHBURN MA, 1993, ANESTH ANALG, V76, P377; ASHBURN MA, 1990, CAN J ANAESTH, V37, P857, DOI 10.1007/BF03006621; Berthier F, 1998, AM J EMERG MED, V16, P132, DOI 10.1016/S0735-6757(98)90029-8; Bowen TE, 1988, EMERGENCY WAR SURG 2; Butler F, 2003, MIL MED, V168, P911; Butler FK, 2000, MIL MED, V165, P1; Butler FK, 1996, MIL MED, V161, P3; Carver AC, 2001, NEUROL CLIN, V19, P921, DOI 10.1016/S0733-8619(05)70054-2; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P736; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; DACHS R, 2001, EMERGEN MED, V33, P19; Ducharme J, 2000, ANN EMERG MED, V35, P592, DOI 10.1016/S0196-0644(00)70033-3; FELD LH, 1989, ANESTHESIOLOGY, V71, P374, DOI 10.1097/00000542-198909000-00010; FINE PG, 1991, PAIN, V45, P149, DOI 10.1016/0304-3959(91)90181-V; GERWELS JW, 1994, J DERMATOL SURG ONC, V20, P823, DOI 10.1111/j.1524-4725.1994.tb03712.x; Holcomb JB, 2003, J TRAUMA, V54, pS46, DOI 10.1097/01.TA.0000051936.91915.A2; Klein EJ, 2002, PEDIATRICS, V109, P894, DOI 10.1542/peds.109.5.894; LEAWOOD KS, 2003, [No title captured]; Li JMW, 2002, MED CLIN N AM, V86, P771, DOI 10.1016/S0025-7125(02)00025-1; LIND GH, 1991, ANN EMERG MED, V20, P1117, DOI 10.1016/S0196-0644(05)81387-3; Macaluso AD, 1996, ANESTH ANALG, V82, P158, DOI 10.1097/00000539-199601000-00029; *NAT ASS EMS PHYS, 2003, PREHOSPITAL EMERG CA, V7, P482; *NDA, 1997, 20747 NDA US FOOD DR; O'Mahony S, 2000, SURG CLIN N AM, V80, P729, DOI 10.1016/S0039-6109(05)70209-7; OWENS TM, 1995, J TRAUMA, V39, P200, DOI 10.1097/00005373-199508000-00004; Proudfoot Jeffrey, 1995, Emergency Medicine Clinics of North America, V13, P357; SACCHETTI A, 1994, ANN EMERG MED, V23, P237, DOI 10.1016/S0196-0644(94)70037-0; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; SCHUTZMAN SA, 1994, ANN EMERG MED, V24, P1059, DOI 10.1016/S0196-0644(94)70234-9; Schutzman SA, 1996, ANN EMERG MED, V28, P385, DOI 10.1016/S0196-0644(96)70001-X; Schwartz RB, 2001, MIL MED, V166, P982; STANLEY TH, 1989, ANESTH ANALG, V69, P21; STREISAND JB, 1989, ANESTH ANALG, V69, P28; Weiss EA, 1999, MED CLIN N AM, V83, P885; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x; WILSON JE, 1989, AM J EMERG MED, V7, P620, DOI 10.1016/0735-6757(89)90286-6	38	48	52	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	AUG	2004	44	2					121	127		10.1016/j.annemergmed.2004.03.025			7	Emergency Medicine	Emergency Medicine	842AY	WOS:000222975900005	15278083				2020-06-30	J	De Lorenzo, RA				De Lorenzo, RA			Emergency medicine research on the front lines	ANNALS OF EMERGENCY MEDICINE			English	Editorial Material							INFORMED-CONSENT		Brooke Army Med Ctr, Dept Emergency Med, MCHE EM, Ft Sam Houston, TX 78234 USA	De Lorenzo, RA (reprint author), Brooke Army Med Ctr, Dept Emergency Med, MCHE EM, 3851 Roger Brooke Dr, Ft Sam Houston, TX 78234 USA.	RADeLorenzo@satx.rr.com		De Lorenzo, Robert/0000-0003-4364-9590			BELLAMY RF, 1984, MIL MED, V149, P55; Biros MH, 2003, ANN EMERG MED, V42, P550, DOI 10.1067/S0196-0644(03)00490-6; BURKLE FM, 1994, ANN EMERG MED, V23, P755, DOI 10.1016/S0196-0644(94)70311-6; DeLorenzo RA, 1997, AVIAT SPACE ENVIR MD, V68, P56; Fish SS, 2004, ANN EMERG MED, V43, P449, DOI 10.1016/j.annemergmed.2003.11.004; Kotwal RS, 2004, ANN EMERG MED, V44, P121, DOI 10.1016/j.annemergmed.2004.03.025; MANINGAS PA, 1989, MIL MED, V154, P71; Schofer JM, 1999, JAMA-J AM MED ASSOC, V281, P1657, DOI 10.1001/jama.281.17.1657; TRUNKEY DD, 1999, TRAUMA; VANDERHAMM DG, OVERVIEW ARMY MED RE; ZAJTCHUK R, 1990, TXB MILITARY MED CON	11	2	2	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	AUG	2004	44	2					128	130		10.1016/j.annemergmed.2004.05.018			3	Emergency Medicine	Emergency Medicine	842AY	WOS:000222975900006	15278084				2020-06-30	J	Litman, RS				Litman, RS			Propofol and pediatric sedation	ANNALS OF EMERGENCY MEDICINE			English	Letter									Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA	Litman, RS (reprint author), Univ Penn, Childrens Hosp Philadelphia, Sch Med, Philadelphia, PA 19104 USA.		Litman, Ron/AAK-6146-2020				Bassett KE, 2003, ANN EMERG MED, V42, P773, DOI 10.1016/S0196-0644(03)00619-X; Green SM, 2003, ANN EMERG MED, V42, P792, DOI 10.1016/S0196-0644(03)00746-7; Guenther E, 2003, ANN EMERG MED, V42, P783, DOI 10.1016/S0196-0644(03)00634-6; Litman Ronald S., 1998, Pediatric Dentistry, V20, P318; Litman RS, 1996, ANESTHESIOLOGY, V85, P1217, DOI 10.1097/00000542-199611000-00049; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007	6	1	1	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	AUG	2004	44	2					184	184		10.1016/j.annemergmed.2004.01.037			1	Emergency Medicine	Emergency Medicine	842AY	WOS:000222975900021	15278995				2020-06-30	J	Meyer, TN; da Silva, AL				Meyer, TN; da Silva, AL			Ketamine reduces mortality of severely burnt rats, when compared to midazolam plus fentanyl	BURNS			English	Article						heat-shock response; burns; protection; ketamine; midazolam; fentanyl	HEAT-SHOCK RESPONSE; ACUTE LUNG INJURY; HUMAN WHOLE-BLOOD; THERMAL-INJURY; INFLAMMATORY RESPONSE; STRESS PROTEINS; FLAP SURVIVAL; IN-VITRO; INDUCTION; MODEL	Ketamine can provide protective effects, through its anti-inflammatory properties, as shown in animal models of septic shock and endotoxemia. and has elicited the heat-shock response (HSR) in experimental studies. The HSR has reduced the mortality after severe burns in rats. This Study has tested the hypothesis that ketamine could be protective in experimental burns and that it could generate the FISR. One hundred and twenty adult male Fischer rats were randomly divided into five groups. Rats in the first group (n = 20) were sham-anesthetized. In the second group (n = 20), rats were anesthetized with ketamine and shaved. In the third group (n = 20) rats were anesthetized with midazolam plus fentanyl and shaved. In the fourth group (n = 30), rats were anesthetized with ketamine, shaved and submitted to 29% body Surface third-degree burns using a brass bar. In the fifth group (n = 30), rats were anesthetized with midazolam plus fentanyl. shaved and Submitted to 29% body surface third-degree burns using a brass bar. Mortality rates were measured at 1, 2, 3 5, 7, 10, 15 and 25 days. Liver and lung samples were collected from all groups for heat-shock protein 70 (HSP70) detection. No animals died in the first. second or third group. Animals anesthetized with ketamine showed significantly decreased mortality, as compared to those anesthetized with midazolam plus fentanyl, from day 2 to day 10 (P < 0.01, Fischer's exact test) and from day 10 to day 25 (P < 0.05). HSP70 was positive in the lungs of animals from all groups, without any differences among them, and was found in none of the liver samples. In conclusion, the mortality was significantly lesser in ketamine-anesthetized burnt rats than in burnt animals anesthetized with midazolam plus fentanyl. Ketamine has not elicited the HSR in this model of experimental burns and, therefore, its protective effects were not shown to be mediated through this mechanism. (C) 2004 Elsevier Ltd and ISBI. All rights reserved.	Vale do Rio Verde Univ, Hlth Sci Inst, INCIS, UNINCOR, BR-37410000 Tres Coracoes, MG, Brazil; Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, Brazil	Meyer, TN (reprint author), Vale do Rio Verde Univ, Hlth Sci Inst, INCIS, UNINCOR, Rua Desembargador Alberto Luz 129, BR-37410000 Tres Coracoes, MG, Brazil.	tufi@unincor.br					BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; BODAI BI, 1983, ANESTH ANALG, V62, P398; CARR VM, 1993, NEUROREPORT, V5, P197, DOI 10.1097/00001756-199312000-00002; Cone JB, 1997, J TRAUMA, V43, P41, DOI 10.1097/00005373-199707000-00011; CURRIE RW, 1993, CIRCULATION, V87, P963, DOI 10.1161/01.CIR.87.3.963; DROST AC, 1993, ANN SURG, V218, P74, DOI 10.1097/00000658-199307000-00012; ELLIS J, 1987, NATURE, V328, P378, DOI 10.1038/328378a0; Fujimori S, 1997, DIGEST DIS SCI, V42, P1987, DOI 10.1023/A:1018892000606; GARRAMONE RR, 1994, PLAST RECONSTR SURG, V93, P1242, DOI 10.1097/00006534-199405000-00021; Hahm KB, 1997, FREE RADICAL BIO MED, V22, P711, DOI 10.1016/S0891-5849(96)00406-6; Hansbrough JF, 1996, J SURG RES, V61, P17, DOI 10.1006/jsre.1996.0074; Hernandez M R, 1993, J Glaucoma, V2, P50; HERNDON DN, 1989, ANN SURG, V209, P547, DOI 10.1097/00000658-198905000-00006; Hill GE, 1998, ANESTH ANALG, V87, P1015, DOI 10.1097/00000539-199811000-00006; Horton JW, 1996, J SURG RES, V61, P97, DOI 10.1006/jsre.1996.0087; HORTON JW, 1993, J TRAUMA, V34, P429, DOI 10.1097/00005373-199303000-00021; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; JAATTELA M, 1992, ANN MED, V24, P249, DOI 10.3109/07853899209149952; Kawasaki T, 1999, ANESTH ANALG, V89, P665; Klosterhalfen B, 1997, SHOCK, V7, P254, DOI 10.1097/00024382-199704000-00003; Klosterhalfen B, 1997, SHOCK, V7, P358, DOI 10.1097/00024382-199705000-00008; KOENIG WJ, 1992, PLAST RECONSTR SURG, V90, P659, DOI 10.1097/00006534-199210000-00016; Larsen B, 1998, ANESTHESIOLOGY, V89, P1218, DOI 10.1097/00000542-199811000-00023; Li CY, 1997, CAN J ANAESTH, V44, P989, DOI 10.1007/BF03011971; MA L, 1989, J TRAUMA, V29, P1245, DOI 10.1097/00005373-198909000-00010; Meyer T N, 1999, Rev Assoc Med Bras (1992), V45, P181, DOI 10.1590/S0104-42301999000200016; Meyer T. N, 1998, ACTA CIR BRAS, V13, P217; Meyer TN, 2000, BURNS, V26, P233, DOI 10.1016/S0305-4179(99)00139-4; MEYER TN, 1999, ACTA CIR BRAS, V14, P199; MEYER TN, 1998, CIRURGIA GERIATRICA, P187; MULLIGAN MS, 1994, AM J PATHOL, V144, P1008; Nayeem MA, 1997, AM J PHYSIOL-HEART C, V273, pH861; ORIORDAIN MG, 1992, ARCH SURG-CHICAGO, V127, P152; OTAKA M, 1994, INT J BIOCHEM, V26, P805; PANNEN BHJ, 1995, ANESTHESIOLOGY, V83, P850, DOI 10.1097/00000542-199510000-00026; Pfenninger E, 1997, ANAESTHESIST, V46, pS47, DOI 10.1007/PL00002465; RAPAPORT FT, 1982, ANN SURG, V195, P294, DOI 10.1097/00000658-198203000-00009; RENIS M, 1994, BIOCHEM MOL BIOL INT, V33, P345; RIBEIRO SP, 1994, CRIT CARE MED, V22, P922, DOI 10.1097/00003246-199406000-00008; RITOSSA F, 1962, EXPERIENTIA, V18, P571, DOI 10.1007/BF02172188; Rucker M, 2001, SURGERY, V129, P292, DOI 10.1067/msy.2001.111079; Sakai T, 2000, CAN J ANAESTH, V47, P1019, DOI 10.1007/BF03024876; SCHMIDT H, 1995, CRIT CARE MED, V23, P2008, DOI 10.1097/00003246-199512000-00009; Shimaoka M, 1996, BRIT J ANAESTH, V77, P238, DOI 10.1093/bja/77.2.238; SOLOMKIN JS, 1990, J TRAUMA, V30, P80; Stojadinovic A, 1997, CRIT CARE MED, V25, P309, DOI 10.1097/00003246-199702000-00020; TAKENAKA I, 1994, ANESTHESIOLOGY, V80, P402, DOI 10.1097/00000542-199402000-00020; Tarnow P, 1996, J SURG RES, V62, P1, DOI 10.1006/jsre.1996.0163; TILL GO, 1983, J TRAUMA, V23, P269, DOI 10.1097/00005373-198304000-00001; TILL GO, 1985, AM J PATHOL, V119, P376; Tons C, 1997, LANGENBECK ARCH CHIR, V382, P43; Udelsman R, 1994, Curr Probl Surg, V31, P658; VANDERLINDEN P, 1990, ANESTH ANALG, V70, P608; VILLAR J, 1994, CRIT CARE MED, V22, P914; VILLAR J, 1993, AM REV RESPIR DIS, V147, P177, DOI 10.1164/ajrccm/147.1.177; WALKER HL, 1968, J TRAUM, V8, P1049, DOI 10.1097/00005373-196811000-00006; Wang BH, 1998, PLAST RECONSTR SURG, V101, P776, DOI 10.1097/00006534-199803000-00029; Weigand MA, 2000, ANESTH ANALG, V90, P206, DOI 10.1097/00000539-200001000-00041; WELCH WJ, 1992, PHYSIOL REV, V72, P1063; WINCHURCH RA, 1987, SURGERY, V102, P808	60	18	21	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179	1879-1409		BURNS	Burns	AUG	2004	30	5					425	430		10.1016/j.burns.2004.01.006			6	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	840AZ	WOS:000222830700004	15225906				2020-06-30	J	Lin, CS; Sun, WZ; Chan, WH; Lin, CJ; Yeh, HM; Mok, MS				Lin, CS; Sun, WZ; Chan, WH; Lin, CJ; Yeh, HM; Mok, MS			Intravenous lidocaine and ephedrine, but not propofol, suppress fentanyl-induced cough	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							ANESTHESIA; BOLUS; BRONCHOCONSTRICTION; RECEPTORS	Purpose: The aim of this study was to evaluate the effectiveness of lidocaine, propofol and ephedrine in suppressing fentanyl-induced cough. Methods: One hundred and eighteen patients were randomly assigned into four groups and the following medications were given intravenously: patients in Group I (n = 31) received normal saline 2 mL, Group II (n = 29) received lidocaine 2 mg(.)kg(-1), Group III (n = 30) received propofol 0.6 mg(.)kg(-1) and Group IV (n = 28) received ephedrine 5 mg. At one minute after the study medication, fentanyl 2.5 mug(.)kg(-1) was given intravenously within two seconds. The occurrence of cough and vital sign profiles were recorded within two minutes after fentanyl bolus by an anesthesiologist blinded to study design. Results: Sixty-five percent of patients in the placebo group had cough, whereas the frequency was significantly decreased in Groups II (14%) and IV (21%). Although a numerically lower frequency of cough was noted in Group III (37%), it was not statistically different from that of the placebo group. SpO(2) decreased significantly in patients of Group III compared to placebo; one patient experienced hypoxemia necessitating mask ventilation. Patients in Group III showed a decrease in heart rate and systolic blood pressure (2 beats(.)min(-1) and 8 mmHg vs baseline). Patients in Group IV showed an increase in both measurements (5 beats(.)min(-1) and 8 mmHg vs baseline). No truncal rigidity was observed throughout the study. Conclusions: Intravenous lidocaine 2 mg(.)kg(-1) or ephedrine 5 mg, but not propofol 0.6 mg(.)kg(-1), was effective in preventing fentanyl-induced cough. The results provide a convenient method to decrease fentanyl-induced cough.	Natl Taiwan Univ Hosp, Dept Anesthesiol, Taipei 100, Taiwan; Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; Taipei Med Univ Hosp, Taipei, Taiwan	Chan, WH (reprint author), Natl Taiwan Univ Hosp, Dept Anesthesiol, 7 Chung Shan S Rd, Taipei 100, Taiwan.	andrchan@ms34.hinet.net		Yeh, Huei-Ming/0000-0003-0077-3284; SUN, WEI-ZEN/0000-0001-8543-2600			Agarwal A, 2003, CAN J ANAESTH, V50, P297, DOI 10.1007/BF03017801; BENTHUYSEN JL, 1986, ANESTHESIOLOGY, V64, P440, DOI 10.1097/00000542-198604000-00005; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; CIGARINI I, 1990, ACTA ANAESTH SCAND, V34, P253, DOI 10.1111/j.1399-6576.1990.tb03080.x; Hirota K, 1999, BRIT J ANAESTH, V82, P87; INOUE K, 1980, N-S ARCH PHARMACOL, V312, P57, DOI 10.1007/BF00502575; KARLSSON JA, 1988, J APPL PHYSIOL, V65, P1007; LOU YP, 1993, ACTA PHYSIOL SCAND, V149, P1; Lui PW, 1996, CAN J ANAESTH, V43, P1216; PAINTAL AS, 1969, J PHYSIOL-LONDON, V203, P511, DOI 10.1113/jphysiol.1969.sp008877; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; PIZOV R, 1995, ANESTHESIOLOGY, V82, P1111, DOI 10.1097/00000542-199505000-00004; POULTON TJ, 1979, ANESTHESIOLOGY, V50, P470, DOI 10.1097/00000542-197905000-00018; REITAN JA, 1978, ANESTH ANALG, V57, P31; Tsou Chih-Hsiang, 2002, Acta Anaesthesiol Sin, V40, P165; Tweed WA, 2001, ANESTH ANALG, V92, P1442; VIDRUK EH, 1977, J APPL PHYSIOL, V43, P397; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012; YUKIOK H, 1993, ANESTH ANALG, V77, P309, DOI 10.1213/00000539-199377020-00016; YUKIOKA H, 1985, ANESTH ANALG, V64, P1189	20	54	98	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	AUG-SEP	2004	51	7					654	659		10.1007/BF03018421			6	Anesthesiology	Anesthesiology	856KR	WOS:000224044600003	15310631	Bronze			2020-06-30	J	Yang, H; Choi, PTL; McChesney, J; Buckley, N				Yang, H; Choi, PTL; McChesney, J; Buckley, N			Induction with sevoflurane-remifentanil is comparable to propofol-fentanyl-rocuronium in PONV after laparoscopic surgery	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							OMITTING NITROUS-OXIDE; POSTOPERATIVE NAUSEA; TRACHEAL INTUBATION; MUSCLE-RELAXANTS; GYNECOLOGICAL SURGERY; GENERAL-ANESTHESIA; METAANALYSIS; CHOLECYSTECTOMY; PREVENTION; SATISFACTION	Purpose: To compare sevoflurane-remifentanil induction and propofol-fentanyl-rocuronium induction with regards to the frequency of moderate to severe postoperative nausea and vomiting (PONV) in the first 24 hr after laparoscopic day surgery. Methods: After informed consent, 156 ASA physical status class I to III patients undergoing laparoscopic cholecystectomy or tubal ligation were randomized to either induction with sevoflurane 8%, N2O 67% and iv remifentanil 1 to 1.5 mug(.)kg(-1) or induction with iv fentanyl 2 to 3 mug(.)kg(-1), propofol 2 mg(.)kg(-1), and rocuronium 0.3 to 0.5 mg(.)kg(-1). All patients received iv ketorolac 0.5 mg(.)kg(-1) at induction and sevoflurane-N2O maintenance anesthesia with rocuronium as needed. PONV was treated with iv ondansetron, droperidol, or dimenhydrinate; postoperative pain was treated with opioid analgesics. Patients were followed for 24 hr with regards to PONV and pain. Intubating conditions, induction and emergence times, time to achieve fast-track discharge criteria, and drug costs were measured. Results: No differences were seen between the two groups in their frequencies of 24-hr moderate to severe PONV and postoperative pain, or in their intubating conditions, induction and emergence times, and time to achieve fast-track discharge criteria. Patients undergoing sevoflurane-remifentanil induction received more morphine (11 mg vs 8 mg; P < 0.001) in the postanesthetic care unit. Sevoflurane-remifentanil induction resulted in similar anesthetic and total drug costs for both procedures. Conclusion: We did not demonstrate any difference in PONV, pain, or anesthetic/recovery times or costs between the sevoflurane and propofol groups. Sevoflurane-remifentanil induction is a feasible technique for anesthetic induction.	McMaster Univ, Dept Anaesthesia, Hamilton Hlth Sci, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, St Josephs Healthcare, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada	Buckley, N (reprint author), McMaster Univ, Dept Anaesthesia, Hamilton Hlth Sci, 1200 Main St W,Room HSC2UI, Hamilton, ON L8N 3Z5, Canada.	buckleyn@mcmaster.ca					Alexander R, 1999, ANAESTHESIA, V54, P1037, DOI 10.1046/j.1365-2044.1999.00904.x; Alexander R, 1999, ANAESTHESIA, V54, P1032, DOI 10.1046/j.1365-2044.1999.01070.x; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Chung F, 1999, CAN J ANAESTH, V46, pR18, DOI 10.1007/BF03013179; Divatia JV, 1996, ANESTHESIOLOGY, V85, P1055, DOI 10.1097/00000542-199611000-00014; Fleischmann E, 1999, ANESTH ANALG, V88, P930, DOI 10.1097/00000539-199904000-00046; Grant S, 1998, BRIT J ANAESTH, V81, P540, DOI 10.1093/bja/81.4.540; HAIGH CG, 1993, BRIT J ANAESTH, V71, P517, DOI 10.1093/bja/71.4.517; Hartung J, 1996, ANESTH ANALG, V83, P114, DOI 10.1097/00000539-199607000-00020; Hedayati B, 1999, BRIT J ANAESTH, V83, P776; Jokela R, 1999, ACTA ANAESTH SCAND, V43, P645, DOI 10.1034/j.1399-6576.1999.430609.x; Joo HS, 2000, ANESTH ANALG, V91, P213, DOI 10.1097/00000539-200007000-00040; Joo HS, 2001, CAN J ANAESTH, V48, P646, DOI 10.1007/BF03016197; Juckenhofel S, 1999, ANAESTHESIST, V48, P807, DOI 10.1007/s001010050789; Klemola UM, 2000, ACTA ANAESTH SCAND, V44, P465, DOI 10.1034/j.1399-6576.2000.440419.x; Naguib M, 1996, CAN J ANAESTH, V43, P226, DOI 10.1007/BF03011739; PETERSON RG, 2002, CARDIOVASCULAR TOXIC; Sneyd JR, 1998, EUR J ANAESTH, V15, P433, DOI 10.1097/00003643-199807000-00009; Stevens JB, 1998, ANESTH ANALG, V86, P45, DOI 10.1097/00000539-199801000-00009; Swiatkowski J, 1999, EUR J ANAESTH, V16, P766; Tang J, 1999, ANESTHESIOLOGY, V91, P253, DOI 10.1097/00000542-199907000-00034; Thompson JP, 1998, BRIT J ANAESTH, V80, P467, DOI 10.1093/bja/80.4.467; Tong D, 1997, ANESTHESIOLOGY, V87, P856, DOI 10.1097/00000542-199710000-00020; Tramer M, 1997, BRIT J ANAESTH, V78, P256; Tramer M, 1997, BRIT J ANAESTH, V78, P247; Tramer M, 1996, BRIT J ANAESTH, V76, P186; Tramer MR, 1999, BRIT J ANAESTH, V82, P379, DOI 10.1093/bja/82.3.379; Tramer MR, 2000, EVIDENCE BASED RESOURCE IN ANAESTHESIA AND ANALGESIA, P157; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; White PF, 1999, ANESTH ANALG, V88, P1069, DOI 10.1097/00000539-199905000-00018; Woods AW, 1998, EUR J ANAESTH, V15, P714, DOI 10.1097/00003643-199811000-00014	32	18	20	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	AUG-SEP	2004	51	7					660	667		10.1007/BF03018422			8	Anesthesiology	Anesthesiology	856KR	WOS:000224044600004	15310632	Bronze			2020-06-30	J	Karabinis, A; Mandragos, K; Stergiopoulos, S; Komnos, A; Soukup, J; Speelberg, B; Kirkham, AJT				Karabinis, A; Mandragos, K; Stergiopoulos, S; Komnos, A; Soukup, J; Speelberg, B; Kirkham, AJT			Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial [ISRCTN50308308]	CRITICAL CARE			English	Article						analgesia-based sedation; fentanyl; intensive care; morphine; remifentanil	INTRACRANIAL-PRESSURE; BLOOD-FLOW; FENTANYL; SUFENTANIL; PROPOFOL; ISOFLURANE; CRANIOTOMY; ALFENTANIL; INFUSION	Introduction This randomised, open-label, observational, multicentre, parallel group study assessed the safety and efficacy of analgesia-based sedation using remifentanil in the neuro-intensive care unit. Methods Patients aged 18-80 years admitted to the intensive care unit within the previous 24 hours, with acute brain injury or after neurosurgery, intubated, expected to require mechanical ventilation for 1-5 days and requiring daily downward titration of sedation for assessment of neurological function were studied. Patients received one of two treatment regimens. Regimen one consisted of analgesia-based sedation, in which remifentanil (initial rate 9 mug kg(-1) h(-1)) was titrated before the addition of a hypnotic agent (propofol [0.5 mg kg(-1) h(-1)] during days 1-3, midazolam [0.03 mg kg(-1) h(-1)] during days 4 and 5) (n = 84). Regimen two consisted of hypnotic-based sedation: hypnotic agent (propofol days 1 - 3; midazolam days 4 and 5) and fentanyl (n = 37) or morphine (n = 40) according to routine clinical practice. For each regimen, agents were titrated to achieve optimal sedation (Sedation - Agitation Scale score 1 - 3) and analgesia (Pain Intensity score 1 - 2). Results Overall, between-patient variability around the time of neurological assessment was statistically significantly smaller when using remifentanil (remifentanil 0.44 versus fentanyl 0.86 [P = 0.024] versus morphine 0.98 [P = 0.006]. Overall, mean neurological assessment times were significantly shorter when using remifentanil (remifentanil 0.41 hour versus fentanyl 0.71 hour [P = 0.001] versus morphine 0.82 hour [P < 0.001])). Patients receiving the remifentanil-based regimen were extubated significantly faster than those treated with morphine (1.0 hour versus 1.93 hour, P = 0.001) but there was no difference between remifentanil and fentanyl. Remifentanil was effective, well tolerated and provided comparable haemodynamic stability to that of the hypnotic-based regimen. Over three times as many users rated analgesia-based sedation with remifentanil as very good or excellent in facilitating assessment of neurological function compared with the hypnotic-based regimen. Conclusions Analgesia-based sedation with remifentanil permitted significantly faster and more predictable awakening for neurological assessment. Analgesia-based sedation with remifentanil was very effective, well tolerated and had a similar adverse event and haemodynamic profile to those of hypnotic-based regimens when used in critically ill neuro-intensive care unit patients for up to 5 days.	Genimatas Gen Hosp, Intens Care Unit, Athens, Greece; Red Cross Gen Hosp Athens, Intens Care Unit, Athens, Greece; Athens Hlth Sci Univ, SICU, Dept Surg 4, Athens, Greece; Athens Hlth Sci Univ, Trauma Unit, Dept Surg 4, Athens, Greece; Gen Hosp Larissa, Dept Intens Care, Larisa, Greece; Univ Halle Wittenberg, Dept Anesthesiol & Intens Care Med, D-06097 Halle An Der Saale, Germany; St Elisabeth Hosp Ziekenhuis, Tilburg, Netherlands; GlaxoSmithKline, Greenford, Middx, England	Karabinis, A (reprint author), Genimatas Gen Hosp, Intens Care Unit, Athens, Greece.	akarab@ath.forthnet.gr					ALBANESE J, 1993, ANESTHESIOLOGY, V79, P493, DOI 10.1097/00000542-199309000-00012; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; Breen D, 2004, CRIT CARE, V8, pR21, DOI 10.1186/cc2399; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Carrasco G, 1998, CRIT CARE MED, V26, P844, DOI 10.1097/00003246-199805000-00015; Coles JP, 2000, J NEUROSURG ANESTH, V12, P15, DOI 10.1097/00008506-200001000-00004; Fragen R. J., 1994, Anesthesiology (Hagerstown), V81, pA376; Gesztesi Z, 1999, ANESTH ANALG, V89, P1282, DOI 10.1213/00000539-199911000-00038; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; Hans P, 2000, ANAESTHESIA, V55, P255, DOI 10.1046/j.1365-2044.2000.01277.x; HOFFMAN WE, 1993, ANESTHESIOLOGY, V79, P107, DOI 10.1097/00000542-199307000-00016; JAMES MK, 1991, J PHARMACOL EXP THER, V259, P712; Johnson KB, 1998, J NEUROSURG ANESTH, V10, P25, DOI 10.1097/00008506-199801000-00006; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Kessler P, 2001, INTENS CARE MED, V27, pS239; Kirkham AJ, 2001, INTENS CARE MED, V27, pS238; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; Muellejans B, 2004, CRIT CARE, V8, pR1, DOI 10.1186/cc2398; Rhoney DH, 2001, NEUROL RES, V23, P237, DOI 10.1179/016164101101198398; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Servin Frederique S, 2003, Curr Opin Anaesthesiol, V16, P367, DOI 10.1097/00001503-200308000-00001; SPERRY RJ, 1992, ANESTHESIOLOGY, V77, P416, DOI 10.1097/00000542-199209000-00002; TRINDLE MR, 1993, ANESTHESIOLOGY, V78, P454, DOI 10.1097/00000542-199303000-00008; Warner DS, 1999, ANESTH ANALG, V89, pS33; Warner DS, 1996, ANESTH ANALG, V83, P348, DOI 10.1097/00000539-199608000-00025; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005	26	107	117	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	AUG	2004	8	4					R268	R280		10.1186/cc2896			13	Critical Care Medicine	General & Internal Medicine	846GU	WOS:000223304600016	15312228	DOAJ Gold, Green Published			2020-06-30	J	Larson, MD; Berry, PD; May, J; Bjorksten, A; Sessler, DI				Larson, MD; Berry, PD; May, J; Bjorksten, A; Sessler, DI			Latency of pupillary reflex dilation during general anesthesia	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						nociception; windup; pupil; opioids; sensory block	NOXIOUS-STIMULATION; NERVOUS-SYSTEM; LIGHT REFLEX; HUMAN-SKIN; WIND-UP; ISOFLURANE; PAIN; ALFENTANIL; FENTANYL; FIBERS	Areas of insensibility produced by neuraxial anesthesia or peripheral nerve blocks can be detected during general anesthesia by failure of noxious stimulation to trigger pupillary reflex dilation. We examined the latency of pupillary reflex dilation and the effect of fentanyl on the latency of reflex dilation during anesthesia in nine volunteers. We hypothesized that the reflex was generated by slowly conducting C nociceptive fibers and would be significantly delayed if a distal dermatome (L-4) was stimulated compared with a proximal dermatome (C-5). We also hypothesized that fentanyl would prolong the latency and alter the shape of the reflex. After induction of general anesthesia, pupillary reflex dilation was measured with an infrared pupillometer every 5 min after stimulations of the L-4 and C-5 dermatomes. Fentanyl (3 mug/kg) was then given intravenously. Pupillary reflex dilation latencies were calculated by examining each individual measurement. After 3 h, naloxone (400 mug) was given intravenously; anesthesia was then discontinued. Pupillary reflex dilation had a long latency and consisted of distinct early and late phases. No differences were found between latencies of reflex dilation after simulation of L-4 and C-5 dermatomes either before or after fentanyl administration. Fentanyl at high concentrations essentially eliminated pupillary reflex dilation; but over the 180-min observation period, first early and then late dilation returned. Fentanyl produced a small increase in the latency of the initial early dilation. We conclude that pupillary reflex dilation during anesthesia is not initiated by slowly conducting C fibers and that fentanyl depresses the reflex in a stereotypical manner.	Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; Univ Melbourne, Royal Melbourne Hosp, Dept Anesthesia, Parkville, Vic 3052, Australia; Univ Louisville, Outcomes Res Inst, Louisville, KY 40202 USA; Univ Louisville, Dept Anesthesiol & Pharmacol, Louisville, KY 40202 USA	Larson, MD (reprint author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA.	larsonm@anesthesia.ucsf.edu	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-061655]		ADRIAENSEN H, 1983, J NEUROPHYSIOL, V49, P111; ASHE JH, 1978, EXP NEUROL, V59, P413, DOI 10.1016/0014-4886(78)90233-9; Barvais L, 2003, BRIT J ANAESTH, V91, P347, DOI 10.1093/bja/aeg178; Bender MB, 1940, AM J PHYSIOL, V130, P0268; BJORKMAN S, 1988, J CHROMATOGR-BIOMED, V433, P95, DOI 10.1016/S0378-4347(00)80588-5; BROMM B, 1984, HUM NEUROBIOL, V3, P33; CULLEN DJ, 1972, ANESTHESIOLOGY, V36, P21, DOI 10.1097/00000542-197201000-00005; EVANS MH, 1961, J PHYSIOL-LONDON, V158, P560, DOI 10.1113/jphysiol.1961.sp006785; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; Kakigi R, 2003, NEUROSCI RES, V45, P255, DOI 10.1016/S0168-0102(02)00230-4; KOSS MC, 1986, J PHARMACOL METHOD, V15, P1, DOI 10.1016/0160-5402(86)90002-1; LARSON MD, 1991, ANESTHESIOLOGY, V75, P62, DOI 10.1097/00000542-199107000-00011; Larson MD, 1997, ANESTHESIOLOGY, V87, P849, DOI 10.1097/00000542-199710000-00019; Larson MD, 1996, ANESTHESIOLOGY, V85, P748, DOI 10.1097/00000542-199610000-00009; Larson MD, 2003, ANESTH ANALG, V97, P1652, DOI 10.1213/01.ANE.0000090011.19809.93; Larson MD, 1997, REGION ANESTH, V22, P461, DOI 10.1016/S1098-7339(97)80034-X; Larson MD, 2001, BRIT J CLIN PHARMACO, V51, P27, DOI 10.1046/j.1365-2125.2001.01311.x; LARSON MD, 1993, ANESTHESIOLOGY, V79, P42, DOI 10.1097/00000542-199307000-00009; LARSON MD, 1993, ANESTH ANALG, V76, P1072; Larson MD, 2000, REGION ANESTH PAIN M, V25, P60, DOI 10.1016/S1098-7339(00)80012-7; Leslie K, 1996, ANESTHESIOLOGY, V84, P52, DOI 10.1097/00000542-199601000-00006; Lewis T, 1937, CLIN SCI, V3, P67; LOEWENFELD I, 1993, PUPIL ANATOMY PHYSL; LOEWENFELD IE, 1958, DOC OPTHALMOL, V12, P184; PRICE DD, 1985, PAIN, V22, P261, DOI 10.1016/0304-3959(85)90026-0; PRICE DD, 1977, PAIN, V3, P57, DOI 10.1016/0304-3959(77)90035-5; STRICHARTZ GR, 1998, [No title captured], P35; Szabadi E, 1996, J PSYCHOPHARMACOL, V10, P6; You HJ, 2003, BRAIN RES, V960, P235, DOI 10.1016/S0006-8993(02)03895-7; ZBINDEN AM, 1994, ANESTHESIOLOGY, V80, P253, DOI 10.1097/00000542-199402000-00004	30	12	12	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587	1522-1601		J APPL PHYSIOL	J. Appl. Physiol.	AUG	2004	97	2					725	730		10.1152/japplphysiol.00098.2004			6	Physiology; Sport Sciences	Physiology; Sport Sciences	841NF	WOS:000222936500038	15247200				2020-06-30	J	Karakaya, D; Baris, S; Ozkan, F; Demircan, S; Gok, U; Ustun, E; Tur, A				Karakaya, D; Baris, S; Ozkan, F; Demircan, S; Gok, U; Ustun, E; Tur, A			Analgesic effects of interpleural bupivacaine with fentanyl for post-thoracotomy pain	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						posterolateral thoracotomy; interpleural analgesia; bupivacaine; fentanyl; intravenous analgesia	INTRAPLEURAL BUPIVACAINE; THORACOTOMY; MORPHINE; CHOLECYSTECTOMY; INFUSION	Objective: The analgesic effect of bupivacaine/fentanyl with epinephrine given interpleurally after thoracotomy was investigated in a randomized placebo and intravenous controlled study. Design: Prospective clinical study. Setting: University teaching hospital. Participants: Sixty American Society of Anesthesiologists physical status II and III patients scheduled for posterolateral thoracotomy with general anesthesia. Interventions: Patients were randomly divided into 4 groups to receive either 0.5% bupivacaine/1.5 mug/kg of fentanyl with 5 mug/mL of epinephrine (n = 15, group IPBF), 0.5% bupivacaine with 5 mug/mL of epinephrine (n = 15, group IPB), or saline (n = 15, group IPS) in a total volume of 15 to 20 mL in 60 seconds by an interpleural catheter placed at the end of surgery by direct vision. The same volume of bupivacaine 0.25% and 1.5 mug/kg of fentanyl with 5 mug/mL of epinephrine to group IPBF, bupivacaine 0.25% with 5 mug/mL of epinephrine to group IPB or saline to group IPS was injected through the interpleural catheter every 6 hours for 48 hours postoperatively. Intravenous fentanyl (n = 15, group IVF) and interpleural saline groups received 1.5 mug/kg of fentanyl intravenously at the first complaint of pain. All patients also received patient-controlled analgesia (PCA) with fentanyl for 48 hours postoperatively. Metamizol sodium was used as a rescue analgesic. Measurements and Main Results: Adequacy of pain relief was evaluated with the "Prince Henry Pain Scale" and visual analog pain scale. Fentanyl consumption via PCA and complications were evaluated for 48 hours. Visual analog scale scores were significantly higher in the interpleural saline group at 4 and 12 hours (6.6 +/- 1.2 and 5.0 +/- 2.1, respectively) postoperatively. Significantly more patients in the IPBF group had lower pain scores during coughing and deep breathing. Fentanyl consumption via PCA device was significantly higher in the intravenous fentanyl group (1,069 +/- 96.9 mug) than the interpleural groups (577.3 +/- 72.2 mug, 651.1 +/- 61.9 mug, and 601.0 +/- 22.6 mug in IPBF, IPB, and IPS groups, respectively). Conclusion: It is concluded that total fentanyl consumption via PCA decreased in all interpleural groups, but pain during coughing and deep breathing was significantly reduced in only the interpleural bupivacaine/fentanyl with epinephrine group. mu 2004 Elsevier Inc. All rights reserved.	Ondokuz Mayis Univ, Tip Fak, Dept Anesthesiol, TR-55139 Kurupelit, Turkey; Ondokuz Mayis Univ, Dept Thorac Surg, Kurupelit, Turkey	Karakaya, D (reprint author), Ondokuz Mayis Univ, Tip Fak, Dept Anesthesiol, TR-55139 Kurupelit, Turkey.	denizk@omu.edu.tr					AYKAC B, 1995, J CARDIOTHOR VASC AN, V9, P538, DOI 10.1016/S1053-0770(05)80137-5; COVINO BG, 1988, ANESTH ANALG, V67, P427; FERRANTE FM, 1991, ANESTH ANALG, V72, P105; INDERBITZI R, 1992, THORAC CARDIOV SURG, V40, P87, DOI 10.1055/s-2007-1020119; Karakaya D, 2001, REGION ANESTH PAIN M, V26, P434, DOI 10.1053/rapm.2001.24675; LAURITO CE, 1991, ANESTH ANALG, V72, P516; MANN LJ, 1992, ANN THORAC SURG, V53, P449, DOI 10.1016/0003-4975(92)90267-8; Ohlmer A, 1997, Anaesthesiol Reanim, V22, P159; ROSENBERG PH, 1987, ANESTHESIOLOGY, V67, P811, DOI 10.1097/00000542-198711000-00034; Savage Clare, 2002, Chest Surg Clin N Am, V12, P251, DOI 10.1016/S1052-3359(02)00011-X; SCHNEIDER RF, 1993, CHEST, V103, P414, DOI 10.1378/chest.103.2.414; Silomon M, 2000, ANESTH ANALG, V91, P44, DOI 10.1097/00000539-200007000-00009; STEIN C, 1993, ANESTH ANALG, V76, P182; STROMSKAG KE, 1988, ANESTH ANALG, V67, P430; TORDA TA, 1984, BRIT J ANAESTH, V56, P141, DOI 10.1093/bja/56.2.141; Vade Boncouer TR, 1993, POSTOPERATIVE PAIN M, P383; WELTE M, 1992, BRIT J ANAESTH, V69, P637, DOI 10.1093/bja/69.6.637	17	11	12	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	AUG	2004	18	4					461	465		10.1053/j.jvca.2004.05.026			5	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	858WQ	WOS:000224223500013	15365929				2020-06-30	J	Pang, MP; Wilkens, LR; On, SJ; McMullin, B				Pang, MP; Wilkens, LR; On, SJ; McMullin, B			Oral sedation for cataract surgery	JOURNAL OF CATARACT AND REFRACTIVE SURGERY			English	Letter																CLARKE RSJ, 1981, DRUGS, V22, P26, DOI 10.2165/00003495-198122010-00002; JACOX A, 1994, AHCPR PUBLICATION, pCH2; Kain ZN, 2000, ANESTHESIOLOGY, V93, P676, DOI 10.1097/00000542-200009000-00016; MCGOLDRICK KE, 1996, COMPLICATIONS ANESTH, pCH28; STOELTING RK, 1991, PHARM PHYSL ANESTHES, pCH5; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009	6	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0886-3350			J CATARACT REFR SURG	J. Cataract. Refract. Surg.	AUG	2004	30	8					1810	1812		10.1016/j.jcrs.2004.06.001			3	Ophthalmology; Surgery	Ophthalmology; Surgery	850XE	WOS:000223646900042	15313316				2020-06-30	J	Ozmen, I; Ciftci, M; Kufrevioglu, OI; Curuk, MA				Ozmen, I; Ciftci, M; Kufrevioglu, OI; Curuk, MA			Investigation of the mutation points and effects of some drugs on glucose-6-phosphate dehydrogenase-deficient people in the Erzurum region	JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY			English	Article						glucose-6-phosphate dehydrogenase; deficiency; mutation; SSCP; drugs	SINGLE-STRAND CONFORMATION; ERYTHROCYTE GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; AFRICAN CHILDREN; G6PD DEFICIENCY; ENZYME-ACTIVITY; GENE; DNA; HETEROGENEITY; CHROMOSOME; SEQUENCE	We have carried out a systematic study of the molecular basis of glucose-6-phosphate dehydrogenase (G6PD) deficiency on three samples of 1,183 children aged 0.5-6 years from Erzurum, in eastern Anatolia. Total genomic DNAs were isolated from the blood samples of a healthy person and the three persons determined with G6PD deficiency by examining the enzyme activity and hemoglobin ratio. Then PCR amplification of the entire coding region in eight fragments was carried out followed by Agarose gel electrophoresis. The 540-bp PCR fragment containing exons VI-VII and the 550 bp PCR fragment containing exons XI-XIII were digested with EcoRI and with NIaIII, respectively. SSCP techniques for eight fragments (exons II, III-IV, V, VI-VII, VIII, IX, X, and XI-XIII) were employed to determine the mutations on the exons of the G6PD gene. A mutation occurred on the region of the exons 6 and 7 of one person (person-1) and exon 5 of two G6PD-deficient persons (person 2 and 3) examined. The sequential approach described is fast and efficient and could be applied to other populations. Effects of analgesic drugs on G6PD were studied on the purified enzyme (ammonium fractionation, dialysis and 2',5' ADP-Sepharose 4B affinity chromatography) for the healthy person and G6PD-deficient persons 1, 2 and 3. The effects of remifentanil hydrochloride, fentanyl citrate, alfentanil hydrochloride and pethidine hydrochloride, as analgesic drugs, on G6PD activity were tested. Although remifentanil hydrochloride, fentanyl citrate (I-50 values; 1.45 mM and 6.1 mM, respectively) inhibited the activity of the enzyme belonging to the healthy person, they did not alter enzyme activity on two of the three persons with G6PD deficiency. Other drugs (alfentanil hydrochloride and pethidine hydrochloride) did not effect the enzyme activity of the healthy or G6PD-deficient children.	Ataturk Univ, Arts & Sci Fac, Dept Chem, TR-25240 Erzurum, Turkey; Biotechnol Applicat & Res Ctr, TR-25240 Erzurum, Turkey; Cukurova Univ, Sch Med, Dept Biochem, Adana, Turkey	Kufrevioglu, OI (reprint author), Ataturk Univ, Arts & Sci Fac, Dept Chem, TR-25240 Erzurum, Turkey.	okufrevi@atauni.edu.tr	Curuk, Mehmet/J-3894-2018				AKSOY K, 1990, C U TIP FAK DER, V2, P186; AKSOY M, 1980, HUM HERED, V30, P3, DOI 10.1159/000153079; AKSU TA, 1990, AM J EPIDEMIOL, V131, P1094, DOI 10.1093/oxfordjournals.aje.a115602; ALLISON AC, 1961, BRIT MED J, V1, P1346, DOI 10.1136/bmj.1.5236.1346; BERKOW R, 1987, MANUEL DIAGNOSIS THE; BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613; BEUTLER E, 1977, BRIT J HAEMATOL, V35, P331, DOI 10.1111/j.1365-2141.1977.tb00589.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALABRO V, 1993, AM J HUM GENET, V52, P527; CHAN TK, 1974, T ROY SOC TROP MED H, V68, P61, DOI 10.1016/0035-9203(74)90253-3; CHEN EY, 1991, GENOMICS, V10, P792, DOI 10.1016/0888-7543(91)90465-Q; Ciftci M, 2000, PHARMACOL RES, V41, P109; Ciftci M, 2001, CLIN BIOCHEM, V34, P297, DOI 10.1016/S0009-9120(01)00207-7; CORCORAN CM, 1992, HUM GENET, V88, P688, DOI 10.1007/BF02265298; GILLES HM, 1967, LANCET, V1, P138; HEINTZ B, 1989, KLIN WOCHENSCHR, V67, P1068, DOI 10.1007/BF01727011; Kayaalp SO, 1998, RASYONEL TEDAVI YONU; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laurence DR, 1997, CLIN PHARM; MARKOWITZ N, 1987, REV INFECT DIS, V9, pS218; Mason PJ, 1996, BRIT J HAEMATOL, V94, P585, DOI 10.1111/j.1365-2141.1996.tb00001.x; Mehta A, 2000, BEST PRACT RES CL HA, V13, P21, DOI 10.1053/beha.1999.0055; MELONI T, 1991, J PEDIATR-US, V118, P909, DOI 10.1016/S0022-3476(05)82206-1; MORELLI A, 1978, P NATL ACAD SCI USA, V75, P1979, DOI 10.1073/pnas.75.4.1979; NINFALI P, 1990, PREP BIOCHEM, V20, P297, DOI 10.1080/00327489008050202; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Ozmen I, 2004, J ENZYM INHIB MED CH, V19, P45, DOI 10.1080/1475636032000141917; PERSICO MG, 1986, NUCLEIC ACIDS RES, V14, P2511, DOI 10.1093/nar/14.6.2511; POGGI V, 1990, BIOCHEM J, V271, P157, DOI 10.1042/bj2710157; PONCZ M, 1982, HEMOGLOBIN, V6, P27, DOI 10.3109/03630268208996930; SAY B, 1965, ACTA PAEDIATR SCAND, V54, P319, DOI 10.1111/j.1651-2227.1965.tb06378.x; SHREVE DS, 1977, BIOCHEM BIOPH RES CO, V78, P1369, DOI 10.1016/0006-291X(77)91443-7; SIPAHIOGLU H, 1979, KAYSERI U GEVHER NES, V1, P101; TAKIZAWA T, 1986, P NATL ACAD SCI USA, V83, P4157, DOI 10.1073/pnas.83.12.4157; TONIOLO D, 1991, GENE, V102, P197, DOI 10.1016/0378-1119(91)90078-P; Toniolo D, 1984, Mol Biol Med, V2, P89; TONIOLO D, 1988, EMBO J, V7, P401, DOI 10.1002/j.1460-2075.1988.tb02827.x; Weksler B.B., 1990, CECIL ESSENTIALS MED, P341; *WHO, 1981, GLUC 6 PHOSPH DEH DE	39	3	3	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1475-6366	1475-6374		J ENZYM INHIB MED CH	J. Enzym. Inhib. Med. Chem.	AUG	2004	19	4					355	360		10.1080/14756360410001667328			6	Biochemistry & Molecular Biology; Chemistry, Medicinal	Biochemistry & Molecular Biology; Pharmacology & Pharmacy	847DC	WOS:000223371900010	15558953				2020-06-30	J	Taha, J; Favre, J; Janszen, M; Galarza, M; Taha, A				Taha, J; Favre, J; Janszen, M; Galarza, M; Taha, A			Correlation between withdrawal symptoms and medication pump residual volume in patients with implantable synchromed pumps	NEUROSURGERY			English	Article						failed back syndrome; intrathecally administered drug therapy; morphine; pain modulation; pump		OBJECTIVE: To investigate whether patients with implantable SynchroMed pumps (Medtronic, Inc., Minneapolis, MN) develop symptoms of drug withdrawal at residual medication volumes that exceed 2 ml (the alarm residual volume recommended by the manufacturer). METHODS: The data sheets of 88 patients with implantable SynchroMed pumps were retrospectively reviewed. The following parameters were analyzed: development of symptoms of drug withdrawal; drugs used in the pump; disease state; drug residual volume in the pump; intake of orally administered medications; time of development of withdrawal symptoms; drug flow volume through the pump; daily intrathecally administered drug dose; and drug concentration. in the pump. RESULTS: Of 88 patients, 21 (24%) consistently developed symptoms of drug withdrawal I to 7 days before the drug residual volume reached a mean of 2.7 ml (range, 2.1-3.8 ml; median, 2.6 ml). Symptoms first developed I to 18 months after surgery. In all patients, symptoms of drug withdrawal subsided after pump refill and did not recur after the alarm volume was increased to 4 ml. Symptom development did not correlate with intake of orally administered medication, drug flow volume through the pump, intrathecally administered drug dose, drug concentration in the pump, drugs used in the pump, or disease state. CONCLUSION: Some patients develop symptoms of drug withdrawal at residual volumes that exceed 2 ml. We could not identify factors that predict this occurrence. Withdrawal symptoms did not recur when the alarm volume was increased to 4 ml.	Kettering Med, Div Neurosurg, Dayton, OH USA; Montreux Hosp, Div Neurosurg, Montreux, Switzerland; Vet Adm Med Ctr, Cincinnati, OH 45220 USA; Univ Beirut, Med Ctr, Div Orthoped, Beirut, Lebanon	Taha, J (reprint author), Taha Neurosurg Clin, 3533 So Blvd,Suite 3000, Kettering, OH 45429 USA.	jamal.taha@kmcnetwork.org					Green LB, 1999, ARCH PHYS MED REHAB, V80, P1600, DOI 10.1016/S0003-9993(99)90337-4; IMPLANTATION SYNCHRO	2	12	12	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	AUG	2004	55	2					390	393		10.1227/01.NEU.0000129698.73730.E4			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	844WJ	WOS:000223191500028	15271246				2020-06-30	J	Katz, J; Schmid, R; Snijdelaar, DG; Coderre, TJ; McCartney, CJL; Wowk, A				Katz, J; Schmid, R; Snijdelaar, DG; Coderre, TJ; McCartney, CJL; Wowk, A			Pre-emptive analgesia using intravenous fentanyl plus low-dose ketamine for radical prostatectomy under general anesthesia does not produce short-term or long-term reductions in pain or analgesic use	PAIN			English	Article; Proceedings Paper	Annual Conference of the Canadian-Pain-Society	MAY 10, 2001	MONTREAL, CANADA	Canadian Pain Soc		analgesia; fentanyl; ketamine	POSTOPERATIVE PAIN; ABDOMINAL HYSTERECTOMY; EPIDURAL MORPHINE; HYPERALGESIA; PHARMACOLOGY; CONSUMPTION; ANTAGONISTS; TOLERANCE	The aim of the study was to evaluate post-operative pain and analgesic use after pre-operative or post-incisional i.v. fentanyl plus low dose i.v. ketamine vs. a standard treatment receiving i.v. fentanyl but not ketamine. Men undergoing radical prostatectomy under general anesthesia were randomly assigned in a double-blinded manner to one of three groups. Patients received i.v. fentanyl before incision followed by an i.v. bolus dose (0.2 ml kg(-1)) and an i.v. infusion (0.0025 ml kg(-1) min(-1)) of 1 mg ml(-1) ketamine (group 1) or normal saline (groups 2 and 3). Seventy minutes after incision, patients received i.v. fentanyl followed by an i.v. bolus dose (0.2 ml kg- 1) and an i.v. infusion (0.0025 ml kg(-1) min(-1)) of saline (groups 1 and 3) or ketamine (group 2). Pain, von Frey pain thresholds, and cumulative morphine consumption using patient-controlled analgesia (PCA) were assessed up to 72 h after surgery. 143 patients completed the study (group 1, n = 47; group 2, n = 50; group 3, n = 46). Cumulative PCA morphine (mean +/- SD) did not differ significantly among groups (group 1, 92.3 +/- 45.9 mg; group 2, 107.2 +/- 58.4 mg; group 3, 103.6 +/- 50.4 mg; P = 0.08 for groups 1 vs. 2, and groups 1 vs. 3). On day 3, the hourly rate (mean +/- SEM) of morphine consumption was significantly lower (P < 0.0009) in group 1 (0.61 +/- 0.013 mg h(-1)) than group 2 (0.86 +/- 0.011 mg h(-1)) and group 3 (0.89 +/- 0.008 mg h(-1)). Pain scores and von Frey pain thresholds did not differ significantly among groups. Two-week and 6-month follow-ups did not reveal significant group differences in pain incidence, intensity, disability or mental health. Pre-operative, low-dose administration of i.v. ketamine did not result in a clinically meaningful reduction in pain or morphine consumption when compared with post-incisional administration of ketamine or a saline control condition. (C) 2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	York Univ, Dept Psychol, Toronto, ON M3J 2R7, Canada; York Univ, Sch Kinesiol & Hlth Sci, Toronto, ON M3J 2R7, Canada; Univ Hlth Network, Dept Anesthesia & Pain Management, Toronto, ON, Canada; Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; Univ Nijmegen, Med Ctr, Pain Ctr, Dept Anesthesiol, Nijmegen, Netherlands; McGill Univ, Dept Anesthesia, Ctr Hlth, Inst Res, Montreal, PQ, Canada; McGill Univ, Dept Neurol & Neurosurg, Ctr Hlth, Inst Res, Montreal, PQ, Canada; McGill Univ, Dept Psychol, Ctr Hlth, Inst Res, Montreal, PQ, Canada; Mcgill Ctr Res Pain, Montreal, PQ, Canada	Katz, J (reprint author), Toronto Gen Hosp, Dept Anesthesia & Pain Management, EN-3-440,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	jkatz@uhnres.utoronto.ca	Coderre, Terence/B-4825-2012; Katz, Joel/J-7015-2014	Katz, Joel/0000-0002-8686-447X			Adam F, 1999, ANESTH ANALG, V89, P444, DOI 10.1097/00000539-199908000-00036; Aida S, 2000, ANESTHESIOLOGY, V92, P1624, DOI 10.1097/00000542-200006000-00020; BROWN BW, 1993, [No title captured]; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; CHAPMAN V, 1992, BRAIN RES, V573, P321, DOI 10.1016/0006-8993(92)90780-D; CLEMENTS JA, 1982, J PHARM SCI, V71, P539, DOI 10.1002/jps.2600710516; Crain SM, 2000, PAIN, V84, P121, DOI 10.1016/S0304-3959(99)00223-7; Dahl V, 2000, ANESTH ANALG, V90, P1419, DOI 10.1097/00000539-200006000-00031; DAJCZMAN E, 1991, CHEST, V99, P270, DOI 10.1378/chest.99.2.270; Dallal GE, 1988, DESIGN SUPPLEMENTARY; Dickenson AH, 1997, ACTA ANAESTH SCAND, V41, P112, DOI 10.1111/j.1399-6576.1997.tb04624.x; Fu ES, 1997, ANESTH ANALG, V84, P1086, DOI 10.1097/00000539-199705000-00024; Glantz S., 1997, PRIMER BIOSTATISTICS, P459; HAMMERSLEY JM, 1964, MONTE CARLO METHODS; HIRATA S, 1995, ANESTH ANALG, V81, P1111, DOI 10.1097/00000539-199511000-00044; Hoffmann VLH, 2003, EUR J PAIN, V7, P121, DOI 10.1016/S1090-3801(02)00074-5; Katz J, 2003, ANESTHESIOLOGY, V98, P1449, DOI 10.1097/00000542-200306000-00023; KATZ J, 1994, PAIN, V59, P395, DOI 10.1016/0304-3959(94)90026-4; Katz J, 1999, SURG CLIN N AM, V79, P231, DOI 10.1016/S0039-6109(05)70381-9; Katz J., 2003, CLIN PAIN MANAGEMENT, P113; Kee WDN, 1997, ANESTH ANALG, V85, P1294, DOI 10.1097/00000539-199712000-00021; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Kissin I, 2000, ANESTH ANALG, V91, P1483, DOI 10.1097/00000539-200012000-00035; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; MARIETTA MP, 1977, J PHARMACOL EXP THER, V202, P157; MATHISEN LC, 1995, PAIN, V61, P215, DOI 10.1016/0304-3959(94)00170-J; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Menigaux C, 2000, ANESTH ANALG, V90, P129, DOI 10.1097/00000539-200001000-00029; ROYTBLAT L, 1993, ANESTH ANALG, V77, P1161; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Sethna NF, 1998, ANESTH ANALG, V86, P1250, DOI 10.1097/00000539-199806000-00022; Snijdelaar DG, 2004, ANAESTHESIA, V59, P222, DOI 10.1111/j.1365-2044.2003.03620.x; Spielberger CD, 1970, STAI MANUAL STATE TR; TVERSKOY M, 1994, ANESTH ANALG, V78, P205, DOI 10.1213/00000539-199402000-00002; WARE JEJ, 1979, [No title captured], V3; WEINSTEIN MC, 1989, MED CARE, V27, P593, DOI 10.1097/00005650-198906000-00003; WHITE PF, 1985, BRIT J ANAESTH, V57, P197, DOI 10.1093/bja/57.2.197; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; WILCOX GL, 1991, P 6 WORLD C PAIN, P91; Wilder-Smith OHG, 1998, ANESTH ANALG, V86, P95, DOI 10.1097/00000539-199801000-00019; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	44	43	49	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	AUG	2004	110	3					707	718		10.1016/j.pain.2004.05.011			12	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	848AH	WOS:000223438800025	15288412				2020-06-30	J	Brunner, T; Johr, M				Brunner, T; Johr, M			Anesthetic management of a child with xeroderma pigmentosum	PEDIATRIC ANESTHESIA			English	Letter							ABNORMALITIES		Kantonsspital, Dept Anaesthesia, CH-60000 Luzern 16, Switzerland	Brunner, T (reprint author), Kantonsspital, Dept Anaesthesia, CH-60000 Luzern 16, Switzerland.	joehrmartin@bluewin.ch		Johr, Martin/0000-0002-7573-0302			BAUM VC, 1999, ANESTHESIA GENETICA, P327; KRAEMER KH, 1987, ARCH DERMATOL, V123, P241, DOI 10.1001/archderm.123.2.241; Masuku ES, 2002, CIRP ANN-MANUF TECHN, V51, P169, DOI 10.1016/S0007-8506(07)61492-9; MEYER RJ, 1982, ANAESTH INTENS CARE, V10, P64, DOI 10.1177/0310057X8201000115; MORIWAKI S, 1993, BRIT J DERMATOL, V128, P91, DOI 10.1111/j.1365-2133.1993.tb00154.x; Norgauer J, 2003, EUR J DERMATOL, V13, P4; REITZ M, 1993, ARZNEIMITTEL-FORSCH, V43-1, P418	7	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	AUG	2004	14	8					697	698		10.1111/j.1460-9592.2004.01367.x			2	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	845GI	WOS:000223228500018	15283834				2020-06-30	J	Mekis, D; Kamenik, M				Mekis, D; Kamenik, M			A randomised controlled trial comparing remifentanil and fentanyl for induction of anaesthesia in CABG surgery	WIENER KLINISCHE WOCHENSCHRIFT			English	Article						CABG surgery; anaesthesia; intravenous; fentanyl; remifentanil; haemodynamics	BYPASS GRAFT-SURGERY; EARLY EXTUBATION; CARDIAC-SURGERY; PROPOFOL; PHARMACOKINETICS; SUFENTANIL	Introduction: In a prospective randomised trial we studied haemodynamic stability during induction of anaesthesia for CABG surgery in patients receiving remifentanil-propofol or fentanyl-propofol anaesthesia. Methods: Fifty-four patients scheduled for elective CABG surgery were studied. Anaesthesia was induced with propofol and pancuronium. The patients were randomly assigned to two groups according to the opioid used during the induction. The remifentanil group received 0.5 mug kg(-1) min(-1) of the drug and the fentanyl group received 5 mug kg(-1). We measured blood pressure, central venous pressure and heart rate continuously for 15 min before and 30 min after orotracheal intubation. We also recorded use of rescue medication for maintaining the mean arterial pressure between 65 and 85 mmHg. Results: After induction of anaesthesia the mean arterial pressure and heart rate decreased significantly in both groups (P < 0.05). After orotracheal intubation the mean arterial pressure and heart rate increased significantly in the fentanyl group but not in the remifentanil group (P < 0.05). The incidence of hypertonic events necessitating the use of rescue medication was significantly higher in the fentanyl group (P < 0.05). Conclusions: Our results show more stable haemodynamics after induction of anaesthesia in CABG surgery in patients receiving remifentanil-propofol than in patients receiving fentanyl-propofol.	Maribor Teaching Hosp, Dept Anaesthesiol Intens Care & Pain Management, Maribor, Slovenia	Kamenik, M (reprint author), Maribor Teaching Hosp, Dept Anaesthesiol Intens Care & Pain Management, Maribor, Slovenia.	mirt.kamenik@mf.uni-lj.si					BEVAN DR, 1996, CLIN ANESTH, P835; DESOUZA G, 1997, ANESTHESIOLOGY, V87, P119; Elliott P, 2000, ANESTH ANALG, V91, P58, DOI 10.1097/00000539-200007000-00011; Engoren M, 2001, ANESTH ANALG, V93, P859, DOI 10.1097/00000539-200110000-00011; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Howie MB, 2001, ANESTH ANALG, V92, P1084; Lehmann A, 2000, J CARDIOTHOR VASC AN, V14, P416, DOI 10.1053/jcan.2000.7945; Mollhoff T, 2001, BRIT J ANAESTH, V87, P718, DOI 10.1093/bja/87.5.718; MUZI M, 1992, ANESTH ANALG, V74, P877; Myles PS, 2002, ANESTH ANALG, V95, P805, DOI 10.1097/00000539-200210000-00004; Olivier P, 2000, J CARDIOTHOR VASC AN, V14, P29, DOI 10.1016/S1053-0770(00)90052-1; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Rauch H, 2001, ANAESTHESIST, V50, P87, DOI 10.1007/s001010050969; Wang JYY, 1999, ANAESTH INTENS CARE, V27, P363, DOI 10.1177/0310057X9902700405; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005	15	5	5	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0043-5325	1613-7671		WIEN KLIN WOCHENSCHR	Wien. Klin. Wochen.	JUL 31	2004	116	14					484	488		10.1007/BF03040944			5	Medicine, General & Internal	General & Internal Medicine	848KI	WOS:000223465900009	15379144				2020-06-30	J	Ambados, F; Brealey, J				Ambados, F; Brealey, J			Compatibility of ketamine hydrochloride and fentanyl citrate in polypropylene syringes	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Letter							POSTOPERATIVE ANALGESIA; MORPHINE		Queen Elizabeth Hosp, Dept Pharm, Woodville, SA 5011, Australia; Queen Elizabeth Hosp, Electron Microscopy Unit, Woodville, SA 5011, Australia	Ambados, F (reprint author), Queen Elizabeth Hosp, Dept Pharm, 28 Woodville Rd, Woodville, SA 5011, Australia.	fotios.ambados@nwahs.sa.gov.au					Adriaenssens G, 1999, BRIT J ANAESTH, V83, P393; Eilers H, 2001, ANESTH ANALG, V93, P213, DOI 10.1097/00000539-200107000-00042; Javery KB, 1996, CAN J ANAESTH, V43, P212, DOI 10.1007/BF03011736	3	5	6	0	0	AMER SOC HEALTH-SYSTEM PHARMACISTS	BETHESDA	7272 WISCONSIN AVE, BETHESDA, MD 20814 USA	1079-2082			AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	JUL 15	2004	61	14					1438	+		10.1093/ajhp/61.14.1438			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	838FT	WOS:000222699600008	15332689				2020-06-30	J	Cohen, SP; Larkin, T				Cohen, SP; Larkin, T			Sedation with ketamine during intradiscal electrothermal therapy	SPINE			English	Article						analgesia; back pain; intradiscal electrothermal therapy; ketamine; N-methyl-D-aspartate; sedation	BACK-PAIN; HIPPOCAMPAL-NEURONS; FOLLOW-UP; ANESTHESIA	Study Design. A technical report. Objectives. To present a new and improved method to sedate patients during intradiscal electrothermal therapy (IDET). Summary of Background Data. The current standard of practice is to sedate patients with short-acting benzodiazepines and opioids during the coagulation phase of intradiscal electrothermal therapy. There are few data on the subject, but it is estimated that between 5% and 20% of IDET procedures are either aborted early or switched to a lower heating temperature because patients cannot tolerate the optimal, recommended heating protocol. A priori, one must assume these patients are more likely to fail their treatment than those who are able to tolerate complete heating. Methods. The authors treated 9 patients receiving intradiscal electrothermal therapy who were unable to tolerate the latter portion of their heating protocol secondary to axial low back pain despite high doses of opioids, with low dose ketamine. This paper outlines our experience with "rescue" doses of ketamine, along with the rationale and guidelines for its use. Results. After receiving ketamine, all patients were able to complete the full intradiscal electrothermal therapy heating protocol. The rescue dosages of ketamine ranged from 15 to 55 mg. The dosages of midazolam used to prevent the psychomimetic effects of ketamine ranged from 3 to 7 mg. Oxygen saturation and hemodynamic parameters did not change significantly after ketamine was administered, and all patients remained responsive throughout the procedure. There were no adverse effects or complications reported. Conclusions. When used judiciously to treat axial back pain during intradiscal electrothermal therapy heating, ketamine is a safe and effective rescue medication.	Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, Pain Management Ctr, Baltimore, MD 21287 USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; Landstuhl Reg Army Med Ctr, Landstuhl, Germany	Cohen, SP (reprint author), Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, Pain Management Ctr, Blalock 1415,600 N Wolfe St, Baltimore, MD 21287 USA.	spc5_2000@yahoo.com					Cohen SP, 2003, SPINE, V28, P1142, DOI 10.1097/00007632-200306010-00011; Cohen SP, 2002, J SPINAL DISORD TECH, V15, P537, DOI 10.1097/00024720-200212000-00020; Derby R, 2000, NEUROMODULATION, V3, P82, DOI 10.1046/j.1525-1403.2000.00082.x; Himmelseher S, 1996, ANESTH ANALG, V83, P505, DOI 10.1097/00000539-199609000-00011; Himmelseher S, 1996, ANESTHESIOLOGY, V85, pA711; Karasek M, 2000, SPINE, V25, P2601, DOI 10.1097/00007632-200010150-00010; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; LENZ G, 1984, ACTA ANAESTH SCAND, V28, P351, DOI 10.1111/j.1399-6576.1984.tb02075.x; Nadeson R, 2002, BRIT J ANAESTH, V88, P685, DOI 10.1093/bja/88.5.685; PEDERSON L, 1993, ANAESTHESIA, V48, P67; Saal JA, 2000, SPINE, V25, P2622, DOI 10.1097/00007632-200010150-00013; Taittonen MT, 1998, ANESTH ANALG, V87, P161, DOI 10.1097/00000539-199807000-00034	12	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	JUL 15	2004	29	14					1590	1592		10.1097/01.BRS.0000131216.28800.71			3	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	838HK	WOS:000222703900017	15247585				2020-06-30	J	Olofsson, K; Alling, C; Lundberg, D; Malmros, C				Olofsson, K; Alling, C; Lundberg, D; Malmros, C			Abolished circadian rhythm of melatonin secretion in sedated and artificially ventilated intensive care patients	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						circadian rhythm; critical illness; ICU syndrome; intensive care; melatonin; sleep	URINARY MELATONIN; UNIT; SLEEP; ANESTHESIA; SURGERY	Background: Sleep disturbance is common in intensive care patients. Aside from its unpleasantness, there is a correlation with intensive care unit (ICU) syndrome/delirium. Reasons for sleep deprivation appear to be multifactorial, including the underlying illness, an acute superimposed disturbance, medications, and the ICU environment itself. There are reasons to believe that alterations of the 'biological clock' might contribute. Melatonin secretion is one reflection of this internal sleep/wake mechanism. Melatonin levels are normally high during the night and low during daytime, being suppressed by bright light. Methods: Melatonin levels in blood and urine were studied over 3 consecutive days in eight critically ill patients during deep sedation and mechanical ventilation. Sedation was assessed with the sedation-agitation (SAS) scale and bispectral index (BIS) monitor. Results: The circadian rhythm of melatonin release was abolished in all but one patient, who recovered much more quickly than the others. There was no correlation between melatonin levels and levels of sedation. Conclusions: This study indicates that dyssynchronization of the melatonin secretion rhythm is common in critically ill and mechanically ventilated patients. It could be hypothesized that an impairment of the melatonin rhythm may play a role in the development of sleep disturbances and delirium in intensive care patients, and that melatonin supply could reduce the incidence of these phenomena.	Helsingborg Hosp, Dept Anesthesiol & Intens Care, S-25187 Helsingborg, Sweden; Univ Lund Hosp, Dept Med Neurochem, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Anesthesiol & Intens Care, S-22185 Lund, Sweden	Olofsson, K (reprint author), Helsingborg Hosp, Dept Anesthesiol & Intens Care, S-25187 Helsingborg, Sweden.	karin.olofsson@helsingborgslasarett.se					AURELL J, 1985, BRIT MED J, V290, P1029, DOI 10.1136/bmj.290.6474.1029; De Deyne C, 1998, INTENS CARE MED, V24, P1294, DOI 10.1007/s001340050765; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; ESPOSTI D, 1988, J PINEAL RES, V5, P35, DOI 10.1111/j.1600-079X.1988.tb00766.x; Granberg A, 1999, Intensive Crit Care Nurs, V15, P19, DOI 10.1016/S0964-3397(99)80062-7; Granberg A, 1996, Intensive Crit Care Nurs, V12, P173, DOI 10.1016/S0964-3397(96)80537-4; Guo XY, 2002, ANESTH ANALG, V94, P1085, DOI 10.1097/00000539-200205000-00006; Karkela J, 2002, ACTA ANAESTH SCAND, V46, P30, DOI 10.1034/j.1399-6576.2002.460106.x; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KRACHMAN SL, 1995, CHEST, V107, P1713, DOI 10.1378/chest.107.6.1713; LANG U, 1981, J CLIN ENDOCR METAB, V53, P645, DOI 10.1210/jcem-53-3-645; Miyazaki T, 2003, SURGERY, V133, P662, DOI 10.1067/msy.2003.149; Mundigler G, 2002, CRIT CARE MED, V30, P536, DOI 10.1097/00003246-200203000-00007; Nishimura S, 1998, J PINEAL RES, V25, P73, DOI 10.1111/j.1600-079X.1998.tb00542.x; Reber A, 1998, ACTA ANAESTH SCAND, V42, P1050, DOI 10.1111/j.1399-6576.1998.tb05375.x; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Shilo L, 1999, AM J MED SCI, V317, P278, DOI 10.1097/00000441-199905000-00002; Simmons LE, 1999, CRIT CARE MED, V27, P1499, DOI 10.1097/00003246-199908000-00016; WEBER RJ, 1985, DRUG INTEL CLIN PHAR, V19, P13; WEITZMAN ED, 1978, [No title captured], V13, P325; Wetterberg L, 1999, EUR ARCH PSY CLIN N, V249, P256, DOI 10.1007/s004060050095; YUWILER A, 1989, J NEUROCHEM, V52, P46, DOI 10.1111/j.1471-4159.1989.tb10896.x; Zisapel N, 1999, BIOL SIGNAL RECEPT, V8, P84	23	149	156	2	16	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2004	48	6					679	684		10.1111/j.0001-5172.2004.00401.x			6	Anesthesiology	Anesthesiology	828IR	WOS:000221967500002	15196098				2020-06-30	J	Varpula, T; Valta, P; Niemi, R; Takkunen, O; Hynynen, M; Pettila, V				Varpula, T; Valta, P; Niemi, R; Takkunen, O; Hynynen, M; Pettila, V			Airway pressure release ventilation as a primary ventilatory mode in acute respiratory distress syndrome	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						acute respiratory distress syndrome; airway pressure release ventilation; mechanical ventilation	ACUTE LUNG INJURY; MECHANICAL VENTILATION; PERFUSION DISTRIBUTIONS; CONSENSUS CONFERENCE; CLINICAL-COURSE; FAILURE; SUPPORT; OXYGENATION; PULMONARY; SYSTEM	Background: Airway pressure release ventilation (APRV) is a ventilatory mode, which allows unsupported spontaneous breathing at any phase of the ventilatory cycle. Airway pressure release ventilation as compared with pressure support (PS), another partial ventilatory mode, has been shown to improve gas exchange and cardiac output. We hypothesized whether the use of APRV with maintained unsupported spontaneous breathing as an initial mode of ventilatory support promotes faster recovery from respiratory failure in patients with acute respiratory distress syndrome (ARDS) than PS combined with synchronized intermittent ventilation (SIMV-group). Methods: In a randomized trial 58 patients were randomized to receive either APRV or SIMV after a predefined stabilization period. Both groups shared common physiological targets, and uniform principles of general care were followed. Results: Inspiratory pressure was significantly lower in the APRV-group (25.9 +/- 0.6 vs. 28.6 +/- 0.7 cmH(2)O) within the first week of the study (P = 0.007). PEEP-levels and physiological variables (PaO2/FiO(2)-ratio, PaCO2 , pH, minute ventilation, mean arterial pressure, cardiac output) were comparable between the groups. At day 28, the number of ventilator-free days was similar (13.4 +/- 1.7 in the APRV-group and 12.2 +/- 1.5 in the SIMV-group), as was the mortality (17% and 18%, respectively). Conclusion: We conclude that when used as a primary ventilatory mode in patients with ARDS, APRV did not differ from SIMV with PS in clinically relevant outcome.	Univ Helsinki Hosp, Jorvi Hosp, Dept Anesthesiol & Intens Care Med, Intens Care Unit, Espoo 02740, Finland; Univ Helsinki Hosp, Dept Anesthesiol & Intens Care Med, Intens Care Unit, Helsinki, Finland; Kuopio Univ Hosp, Dept Anesthesiol & Intens Care Med, SF-70210 Kuopio, Finland	Varpula, T (reprint author), Univ Helsinki Hosp, Jorvi Hosp, Dept Anesthesiol & Intens Care Med, Intens Care Unit, Turuntie 150, Espoo 02740, Finland.	tero.varpula@hus.fi					BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; BROCHARD L, 1987, AM REV RESPIR DIS, V136, P411, DOI 10.1164/ajrccm/136.2.411; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; CANE RD, 1991, CHEST, V100, P460, DOI 10.1378/chest.100.2.460; DOUGLAS WW, 1977, AM REV RESPIR DIS, V115, P559; DOWNS JB, 1977, ANESTH ANALG, V56, P88; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1510, DOI 10.1164/rccm.200208-956OC; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Estenssoro E, 2002, CRIT CARE MED, V30, P2450, DOI 10.1097/00003246-200211000-00008; FROESE AB, 1974, ANESTHESIOLOGY, V41, P242, DOI 10.1097/00000542-197409000-00006; HEDENSTIERNA G, 1994, ANESTHESIOLOGY, V80, P751, DOI 10.1097/00000542-199404000-00006; Hering R, 2002, INTENS CARE MED, V28, P1426, DOI 10.1007/s00134-002-1442-z; Hormann C, 1997, ACTA ANAESTH SCAND, V41, P152; Karason S, 2002, ACTA ANAESTH SCAND, V46, P1053, DOI 10.1034/j.1399-6576.2002.460901.x; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kuhlen R, 1999, INTENS CARE MED, V25, P1203, DOI 10.1007/s001340051045; Lim CM, 2003, CRIT CARE MED, V31, P411, DOI 10.1097/01.CCM.0000048631.88155.39; Lu Q, 1999, AM J RESP CRIT CARE, V159, P275, DOI 10.1164/ajrccm.159.1.9802082; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; Meduri GU, 1998, JAMA-J AM MED ASSOC, V280, P159, DOI 10.1001/jama.280.2.159; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Negri EM, 2002, PATHOL RES PRACT, V198, P355, DOI 10.1078/0344-0338-00266; Pelosi P, 2001, INTENS CARE MED, V27, P457, DOI 10.1007/s001340100879; PELOSI P, 2000, ANESTESIOLOGICA, V66, P779; PELOSI P, 2000, ANESTESIOLOGICA, V66, P785; PUTENSEN C, 1995, AM J RESP CRIT CARE, V151, P993; PUTENSEN C, 1994, AM J RESP CRIT CARE, V150, P101, DOI 10.1164/ajrccm.150.1.8025733; Putensen C, 2001, AM J RESP CRIT CARE, V164, P43, DOI 10.1164/ajrccm.164.1.2001078; PUTENSEN C, 1994, CRIT CARE MED, V22, P1976; Putensen C, 1999, AM J RESP CRIT CARE, V159, P1241, DOI 10.1164/ajrccm.159.4.9806077; RASANEN J, 1991, CRIT CARE MED, V19, P1234; Rathgeber J, 1997, EUR J ANAESTH, V14, P576, DOI 10.1046/j.1365-2346.1994.00178.x; ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304; SANTAK B, 1991, INTENS CARE MED, V17, P136, DOI 10.1007/BF01704716; SLUTSKY AS, 1994, INTENS CARE MED, V20, P150, DOI 10.1007/BF01707673; STOCK MC, 1987, CRIT CARE MED, V15, P462, DOI 10.1097/00003246-198705000-00002; SYDOW M, 1994, AM J RESP CRIT CARE, V149, P1550, DOI 10.1164/ajrccm.149.6.8004312; Valta P, 1999, CRIT CARE MED, V27, P2367, DOI 10.1097/00003246-199911000-00008; Varpula T, 2001, ACTA ANAESTH SCAND, V45, P340, DOI 10.1034/j.1399-6576.2001.045003340.x; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156; Wrigge H, 2003, ANESTHESIOLOGY, V99, P376, DOI 10.1097/00000542-200308000-00019	41	81	87	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2004	48	6					722	731		10.1111/j.0001-5172.2004.00411.x			10	Anesthesiology	Anesthesiology	828IR	WOS:000221967500009	15196105				2020-06-30	J	Halonen, P; Sarvela, J; Saisto, T; Soikkeli, A; Halmesmaki, E; Korttila, K				Halonen, P; Sarvela, J; Saisto, T; Soikkeli, A; Halmesmaki, E; Korttila, K			Patient-controlled epidural technique improves analgesia for labor but increases cesarean delivery rate compared with the intermittent bolus technique	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						bupivacaine; fentanyl; mode of delivery; patient-controlled epidural analgesia	MIDWIFE TOP-UPS; CONTINUOUS-INFUSION; NULLIPAROUS WOMEN; 0.125-PERCENT	Background: We tested the hypothesis that patient-controlled epidural analgesia for labor (PCEA) provides better analgesia and satisfaction than the intermittent bolus technique (bolus) without affecting the mode of delivery. Methods: We randomized 187 parturients to receive labor analgesia using either the PCEA or bolus technique. The PCEA group received a starting bolus of 14 mg of bupivacaine and 60 mug of fentanyl in a 15-ml volume, followed by a background infusion (bupivacaine 0.08% and fentanyl 2 mug ml(-1)) 5 ml h(-1) with a 5-ml bolus and 15-min lock-out interval. The bolus group received boluses of 20 mg of bupivacaine and 75 mug of fentanyl in a 15-ml volume. Results: Parturients in the PCEA group had significantly (P < 0.05-0.01) less pain during the first and second stages of labor. There was no difference in the spontaneous delivery rate between the groups, but the cesarean delivery rate was significantly (P < 0.05) higher (16.3% vs. 6.7%) in the PCEA group than in the bolus group. Bupivacaine consumption was significantly (P < 0.01) higher (11.2 mg h(-1) vs. 9.6 mg h(-1)) and the second stage of labor was significantly (P < 0.01) longer (70 min vs. 54 min) in the PCEA group than in the bolus group. Patient satisfaction was equally good in both groups. Conclusion: The PCEA technique provided better pain relief. This was associated with higher bupivacaine consumption, prolongation of the second stage of labor, and an increased rate of cesarean section.	Univ Helsinki, Cent Hosp, Dept Anesthesia & Intens Care, Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland	Halonen, P (reprint author), Univ Helsinki, Cent Hosp, Womens Hosp, PB 140, Helsinki 00029, Finland.	pekka.halonen@hus.fi					Boutros A, 1999, INT J OBSTET ANESTH, V8, P236, DOI 10.1016/S0959-289X(99)80103-4; BROMAGE PR, 1978, EPIDURAL ANALGESIA, P119; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1201, DOI 10.1097/00000542-199406000-00006; CHESTNUT DH, 1994, ANESTHESIOLOGY, V80, P1193, DOI 10.1097/00000542-199406000-00005; CHESTNUT DH, 1988, ANESTHESIOLOGY, V68, P754, DOI 10.1097/00000542-198805000-00013; Cohen SE, 2000, ANESTHESIOLOGY, V92, P387, DOI 10.1097/00000542-200002000-00019; Collis RE, 1999, BRIT J ANAESTH, V82, P233, DOI 10.1093/bja/82.2.233; GAMBLING DR, 1990, ANESTH ANALG, V70, P256; Olofsson C, 1998, ACTA ANAESTH SCAND, V42, P284, DOI 10.1111/j.1399-6576.1998.tb04918.x; Paech M, 1998, BAILLIERE CLIN OB GY, V12, P377, DOI 10.1016/S0950-3552(98)80073-4; PAECH MJ, 1995, ANAESTH INTENS CARE, V23, P459, DOI 10.1177/0310057X9502300408; PURDIE J, 1992, BRIT J ANAESTH, V68, P580, DOI 10.1093/bja/68.6.580; Ranta P, 1994, Int J Obstet Anesth, V3, P193, DOI 10.1016/0959-289X(94)90067-1; Ross A, 1998, BAILLIERE CLIN OB GY, V12, P499, DOI 10.1016/S0950-3552(98)80081-3; VYVER M, 2002, BRIT J ANAESTH, V89, P459	15	11	12	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2004	48	6					732	737		10.1111/j.0001-5172.2004.00413.x			6	Anesthesiology	Anesthesiology	828IR	WOS:000221967500010	15196106				2020-06-30	J	Vuori, A; Salo, M; Viljanto, J; Pajulo, O; Pulkki, K; Nevalainen, T				Vuori, A; Salo, M; Viljanto, J; Pajulo, O; Pulkki, K; Nevalainen, T			Effects of post-operative pain treatment using non-steroidal anti-inflammatory analgesics, opioids or epidural blockade on systemic and local immune responses in children	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						analgesia; anesthesia; child immune response; wound	KILLER-CELL CYTOTOXICITY; GENERAL-ANESTHESIA; DICLOFENAC SODIUM; BALANCED ANESTHESIA; LYMPHOCYTE FUNCTION; ORTHOPEDIC-SURGERY; CYTOKINE RESPONSE; SURGICAL PATIENTS; OXYGEN-TENSION; MAJOR SURGERY	Background: Many studies have been carried out on the effects of anaesthetic drugs and methods on the immune response, but pain and its relief also affect the immune response. We measured systemic immune responses in the blood circulation and local responses in the surgical wound when non-steroidal anti-inflammatory analgesics (NSAIDs), opioids or epidural blockade was used in the peri-operative treatment of pain. Methods: Responses were measured in 51 children, aged from 2 to 12 years and undergoing major surgery under balanced anaesthesia. Bolus doses of diclofenac intravenously (i.v.) and rectally (NSAID group), continuous i.v. infusion of oxycodone (opioid group) or continuous epidural infusion of bupivacaine + fentanyl (epidural group) were used peri-operatively for pain relief. Results: The only difference related to the analgesic method was shorter duration of post-operative leucocytosis and lower phytohaemagglutinin (PHA)-induced lymphocyte proliferative responses in peripheral blood in the opioid group than in the NSAID or epidural groups. By contrast, time-related alterations were seen overall in leucocyte and differential counts, lymphocyte and their subset counts, lymphocyte proliferative responses, and in serum cortisol, C-reactive protein, plasma interleukin-6 and group II phospholipase A(2) concentrations and in the appearance of different cell types in the wound. Conclusions: Post-operative pain treatments using diclofenac (NSAID), oxycodone (opioid) and epidural blockade have basically similar effects on systemic and local immune responses with only slight, probably clinically unimportant differences in children undergoing surgery under general anaesthesia.	Loimaa Reg Hosp, Dept Anesthesia, Loimaa, Finland; Univ Turku, Dept Anesthesia & Intens Care, Turku, Finland; Univ Turku, Medicity Res Lab, Turku, Finland; Univ Turku, Dept Paediat Surg, Turku, Finland; Univ Turku, Dept Cent Lab & Pathol, Turku, Finland	Vuori, A (reprint author), Turku Univ, Cent Hosp, Dept Anaesthesia & Intens Care, POB 52, FIN-20521 Turku, Finland.	matti.salo@luukku.com					Allen DB, 1997, ARCH SURG-CHICAGO, V132, P991; Avall A, 1997, ANESTHESIOLOGY, V87, P511, DOI 10.1097/00000542-199709000-00009; BARBUL A, 1989, ANN SURG, V209, P479, DOI 10.1097/00000658-198904000-00015; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Berde CB, 2002, NEW ENGL J MED, V347, P1094, DOI 10.1056/NEJMra012626; BEYER JE, 1989, PEDIATR CLIN N AM, V36, P837; Bordin JO, 1999, TRANSFUSION, V39, P718, DOI 10.1046/j.1537-2995.1999.39070718.x; Buggy DJ, 2002, ANESTHESIOLOGY, V97, P952, DOI 10.1097/00000542-200210000-00030; Carli F, 2002, ANESTHESIOLOGY, V97, P540, DOI 10.1097/00000542-200209000-00005; Cohen J, 1988, STAT POWER ANAL BEHA; EFRON JE, 1990, J SURG RES, V48, P460, DOI 10.1016/0022-4804(90)90013-R; ESKOLA J, 1975, IMMUNOL COMMUN, V4, P297, DOI 10.3109/08820137509055781; Farrar Mark W, 2002, Anesthesiol Clin North Am, V20, P59, DOI 10.1016/S0889-8537(03)00055-5; Gilliland HE, 1997, ANESTH ANALG, V85, P1394, DOI 10.1097/00000539-199712000-00039; GOODWIN JS, 1983, SEMIN ARTHRITIS RHEU, V13, P134, DOI 10.1016/0049-0172(83)90033-1; Greisen J, 1999, BRIT J ANAESTH, V83, P235, DOI 10.1093/bja/83.2.235; Hamra JG, 1996, ANESTHESIOLOGY, V85, P355, DOI 10.1097/00000542-199608000-00018; Hansen TG, 1998, EUR J ANAESTH, V15, P56, DOI 10.1097/00003643-199801000-00011; HASHIMOTO T, 1995, ACTA ANAESTH SCAND, V39, P294, DOI 10.1111/j.1399-6576.1995.tb04064.x; HAUSER GJ, 1991, CRIT CARE MED, V19, P874, DOI 10.1097/00003246-199107000-00009; HOLE A, 1983, ACTA ANAESTH SCAND, V27, P135, DOI 10.1111/j.1399-6576.1983.tb01923.x; HOLE A, 1982, ACTA ANAESTH SCAND, V26, P301, DOI 10.1111/j.1399-6576.1982.tb01771.x; Hopf HW, 1997, ARCH SURG-CHICAGO, V132, P997; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; KORPELA R, 1990, EUR J CLIN PHARMACOL, V38, P293, DOI 10.1007/BF00315034; Kost-Byerly Sabine, 2002, Anesthesiol Clin North Am, V20, P115, DOI 10.1016/S0889-8537(03)00057-9; Lydyard P, 1998, IMMUNOLOGY, P13; Mahdy AM, 2002, BRIT J ANAESTH, V88, P797, DOI 10.1093/bja/88.6.797; Mattila-Vuori A, 2000, PAEDIATR ANAESTH, V10, P381, DOI 10.1046/j.1460-9592.2000.00505.x; Mattila-Vuori A, 1999, CAN J ANAESTH, V46, P1036, DOI 10.1007/BF03013198; MAUNUKSELA EL, 1987, CLIN PHARMACOL THER, V42, P137, DOI 10.1038/clpt.1987.123; McBride WT, 1996, CYTOKINE, V8, P724, DOI 10.1006/cyto.1996.0096; MOLLITT DL, 1984, J PEDIATR SURG, V19, P818, DOI 10.1016/S0022-3468(84)80376-0; MOLLITT DL, 1986, J PEDIATR SURG, V21, P633, DOI 10.1016/S0022-3468(86)80420-1; Nelson CJ, 1997, ANESTH ANALG, V85, P620, DOI 10.1097/00000539-199709000-00024; Nevalainen TJ, 2000, BBA-MOL CELL BIOL L, V1488, P83, DOI 10.1016/S1388-1981(00)00112-8; NEVALAINEN TJ, 1992, CLIN CHEM, V38, P1824; Pajulo OT, 2000, ANN CHIR GYNAECOL FE, V89, P107; PIRTTIKANGAS CO, 1995, ANAESTHESIA, V50, P1056, DOI 10.1111/j.1365-2044.1995.tb05951.x; Procopio MA, 2001, ANESTH ANALG, V93, P460, DOI 10.1097/00000539-200108000-00044; PURI P, 1984, J PEDIATR SURG, V19, P823, DOI 10.1016/S0022-3468(84)80377-2; Rittner HL, 2002, ANAESTHESIST, V51, P351, DOI 10.1007/s00101-002-0306-9; Romsing J, 2001, PAEDIATR ANAESTH, V11, P205, DOI 10.1046/j.1460-9592.2001.00660.x; RYHANEN P, 1994, ANAESTHESIA, V49, P57, DOI 10.1111/j.1365-2044.1994.tb03315.x; RYHANEN P, 1977, THESIS U OULU OULU; Sacerdote P, 1997, BRIT J PHARMACOL, V121, P834, DOI 10.1038/sj.bjp.0701138; SALO M, 2001, TRATADO ANESTESIA RE, P519; Schaffer M, 1998, BRIT J SURG, V85, P444; SCHNEIDER W, 1986, J CHROMATOGR, V383, P412, DOI 10.1016/S0378-4347(00)83488-X; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; TONNESEN E, 1988, BRIT J ANAESTH, V60, P500, DOI 10.1093/bja/60.5.500; VILJANTO A, 1995, WOUND HEALING SKIN P, P513; Ward P A, 1989, Baillieres Clin Haematol, V2, P391, DOI 10.1016/S0950-3536(89)80023-X; Webster NR, 1998, BRIT J ANAESTH, V81, P835; YEAGER MP, 1992, CLIN IMMUNOL IMMUNOP, V62, P336, DOI 10.1016/0090-1229(92)90112-2; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; Yeager MP, 2002, ANESTH ANALG, V94, P94, DOI 10.1097/00000539-200201000-00018	58	14	20	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2004	48	6					738	749		10.1111/j.1399-6576.2004.00404.x			12	Anesthesiology	Anesthesiology	828IR	WOS:000221967500011	15196107				2020-06-30	J	Kopka, A; McMenemin, IM; Serpell, MG; Quasim, I				Kopka, A; McMenemin, IM; Serpell, MG; Quasim, I			Anaesthesia for cholecystectomy in two non-parturients with Eisenmenger's syndrome	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anesthetic gases; anesthetic techniques; Eisenmenger's syndrome; laparoscopy	LAPAROSCOPIC CHOLECYSTECTOMY; PULMONARY-HYPERTENSION; CESAREAN-SECTION; PATIENT; PNEUMOPERITONEUM; MANAGEMENT; POSTURE; SURGERY	Eisenmenger's syndrome consists of high pulmonary vascular resistance with reversed or bidirectional shunt at aortopulmonary, ventricular or atrial level. We describe the anaesthetic management of two adult females with Eisenmenger's syndrome admitted for laparoscopic cholecystectomy. One patient suffered post-operative complications, but the other case was uncomplicated. We used sevoflurane and total intravenous anaesthesia to provide general anaesthesia. Both techniques were tolerated.	Univ Glasgow, Western Infirm, Dept Anesthesia, Glasgow G11 6NT, Lanark, Scotland	Kopka, A (reprint author), 3 Carnock Gardens, Milngavie G62 7RU, Scotland.	a.kopka@doctors.org.uk					BIRD TM, 1984, ANAESTHESIA, V39, P48, DOI 10.1111/j.1365-2044.1984.tb09455.x; CALVEY TN, 1997, PRINCIPLES PRACTICE; Cole PJ, 2001, BRIT J ANAESTH, V86, P723, DOI 10.1093/bja/86.5.723; DEVITT JH, 1982, ANESTHESIOLOGY, V57, P335, DOI 10.1097/00000542-198210000-00022; Gannedahl P, 1996, ACTA ANAESTH SCAND, V40, P160, DOI 10.1111/j.1399-6576.1996.tb04414.x; GILMAN DH, 1991, ANAESTHESIA, V46, P371, DOI 10.1111/j.1365-2044.1991.tb09547.x; Gleicher N, 1979, Obstet Gynecol Surv, V34, P721, DOI 10.1097/00006254-197910000-00001; Hofland J, 2001, BRIT J ANAESTH, V86, P882, DOI 10.1093/bja/86.6.882; Koivusalo AM, 2000, ACTA ANAESTH SCAND, V44, P834, DOI 10.1034/j.1399-6576.2000.440709.x; LYONS B, 1995, CAN J ANAESTH, V42, P904, DOI 10.1007/BF03011038; ODEBERG S, 1994, ACTA ANAESTH SCAND, V38, P276, DOI 10.1111/j.1399-6576.1994.tb03889.x; Raines DE, 1996, J CLIN ANESTH, V8, P341, DOI 10.1016/0952-8180(96)00084-0; ROBINSON S, 1983, ANESTHESIOLOGY, V58, P588, DOI 10.1097/00000542-198306000-00031; Sammut MS, 1997, BRIT J ANAESTH, V79, P810; SASADA M, 1998, DRUGS ANAESTHESIA IN; SMEDSTAD KG, 1994, CAN J ANAESTH, V41, P502, DOI 10.1007/BF03011545; WOOD P, 1958, BRIT MED J, V2, P755, DOI 10.1136/bmj.2.5099.755	17	6	7	0	0	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2004	48	6					782	786		10.1111/j.1399-6516.2004.00405.x			5	Anesthesiology	Anesthesiology	828IR	WOS:000221967500017	15196113				2020-06-30	J	Limoge, A; Dixmerias-Iskandar, F				Limoge, A; Dixmerias-Iskandar, F			A personal experience using limoge's current during a major surgery	ANESTHESIA AND ANALGESIA			English	Letter									Univ Paris 05, F-75270 Paris 06, France; Electrophysiol Lab, Montrouge, France; Ctr Lutte Contre Canc, Inst Bergonie, Dept Anesthesiol, Bordeaux, France	Limoge, A (reprint author), Univ Paris 05, F-75270 Paris 06, France.							0	2	2	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2004	99	1					309	309		10.1213/01.ane.0000127906.17306.01			1	Anesthesiology	Anesthesiology	832GW	WOS:000222256400075	15281560				2020-06-30	J	Cooper, DW; Jeyaraj, L; Hynd, R; Thompson, R; Meek, T; Ryall, DM; Kokri, MS				Cooper, DW; Jeyaraj, L; Hynd, R; Thompson, R; Meek, T; Ryall, DM; Kokri, MS			Evidence that intravenous vasopressors can affect rostral spread of spinal anestbesia in pregnancy	ANESTHESIOLOGY			English	Article							SUBARACHNOID ANESTHESIA; CESAREAN-SECTION; EXTRADURAL PRESSURE; HYPOTENSION; EPHEDRINE; VOLUME; PHENYLEPHRINE; BUPIVACAINE; EXTENSION; INJECTION	Background: The authors have previously observed an apparent association between rostral spread of spinal anesthesia and choice of intravenous vasopressor given to maintain maternal systolic arterial pressure during cesarean delivery. This study tested the hypothesis that an intravenous infusion of phenylephrine can reduce rostral spread of spinal anesthesia in pregnancy, compared with ephedrine. Methods: The study was randomized and double blind. It compared phenylephrine 100 mug/ml (phenylephrine group, n = 30), and ephedrine 3 mg/ml (ephedrine group, n = 30), given by infusion, to prevent maternal hypotension during combined spinal-epidural anesthesia for cesarean delivery. Two ml intrathecal plain levobupivacaine, 0.5%, combined with 0.4 ml intrathecal fentanyl, 50 mug/ml, and 10 ml epidural saline was given with the patient in the sitting position. The upper level of neural blockade to cold and light touch sensation was recorded at 10 and 20 min postspinal. Epidural space pressure was recorded at 5, 10, 15, and 20 min. Results: At 20 min, the upper dermatome blocked to cold sensation was median T3 (interquartile range, T2-T4) for the phenylephrine group, compared with T1(T1-T2) for the ephedrine group (P = 0.001). At 20 min, the upper dermatome blocked to light touch sensation was median T5 (T4-T8) for the phenylephrine group, compared with T3 (T2-T6) for the ephedrine group (P = 0.009). The mean epidural space pressure in the phenylephrine group was 16 (13-19) mmHg, compared with 16 (13-18) mmHg in the ephedrine group (P = 0.63). Conclusions: This study provides evidence that intravenous phenylephrine can decrease rostral spread of spinal anesthesia in pregnancy, compared with intravenous ephedrine. Further work is required to investigate possible mechanisms and to assess its clinical significance.	James Cook Univ Hosp, Dept Anaesthesia, Middlesbrough TS4 3BW, Cleveland, England	Cooper, DW (reprint author), James Cook Univ Hosp, Dept Anaesthesia, Middlesbrough TS4 3BW, Cleveland, England.	david.cooper@stecs.nhs.uk					BLUMGART CH, 1992, BRIT J ANAESTH, V69, P457, DOI 10.1093/bja/69.5.457; Carpenter RL, 1998, ANESTHESIOLOGY, V89, P24, DOI 10.1097/00000542-199807000-00007; COLDITZ RB, 1970, OBSTET GYNECOL, V36, P769; Cooper DW, 2003, ANESTHESIOLOGY, V98, P1524, DOI 10.1097/00000542-200306000-00051; Cooper DW, 2002, ANESTHESIOLOGY, V97, P1582, DOI 10.1097/00000542-200212000-00034; CRITCHLEY LAH, 1995, BRIT J ANAESTH, V74, P373, DOI 10.1093/bja/74.4.373; Critchley LAH, 1996, BRIT J ANAESTH, V76, P734; CRITCHLEY LAH, 1994, BRIT J ANAESTH, V72, P151, DOI 10.1093/bja/72.2.151; Gadalla F, 2003, CAN J ANAESTH, V50, P382, DOI 10.1007/BF03021036; Higuchi H, 2004, ANESTHESIOLOGY, V100, P106, DOI 10.1097/00000542-200401000-00019; Hirabayashi Y, 1997, BRIT J ANAESTH, V78, P317; Igarashi T, 2000, ANESTHESIOLOGY, V92, P1631, DOI 10.1097/00000542-200006000-00021; IVAN LP, 1982, J NEUROSURG, V57, P511, DOI 10.3171/jns.1982.57.4.0511; KARINEN J, 1995, BRIT J ANAESTH, V75, P531, DOI 10.1093/bja/75.5.531; Mardirosoff C, 1998, REGION ANESTH PAIN M, V23, P92, DOI 10.1016/S1098-7339(98)90117-1; Nystrom EUM, 1998, ANESTHESIOLOGY, V89, P449, DOI 10.1097/00000542-199808000-00022; PAUL DL, 1989, BRIT J ANAESTH, V62, P368, DOI 10.1093/bja/62.4.368; ROUT CC, 1992, BRIT J ANAESTH, V68, P394, DOI 10.1093/bja/68.4.394; SHAH JL, 1994, BRIT J ANAESTH, V73, P309, DOI 10.1093/bja/73.3.309; SHAH JL, 1984, BRIT J ANAESTH, V56, P1373, DOI 10.1093/bja/56.12.1373; Stienstra R, 1999, ANESTH ANALG, V88, P810, DOI 10.1097/00000539-199904000-00024; Thomas DG, 1996, BRIT J ANAESTH, V76, P61	22	31	32	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUL	2004	101	1					28	33		10.1097/00000542-200407000-00007			6	Anesthesiology	Anesthesiology	832QE	WOS:000222281200006	15220768				2020-06-30	J	Sohn, JT; Ok, SH; Kim, HJ; Moon, SH; Shin, IW; Lee, HK; Chung, YK				Sohn, JT; Ok, SH; Kim, HJ; Moon, SH; Shin, IW; Lee, HK; Chung, YK			Inhibitory effect of fentanyl on acetylcholine-induced relaxation in rat aorta	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 11-15, 2003	SAN FRANCISCO, CA	Amer Soc Anesthesiologists			ENDOTHELIUM-DEPENDENT RELAXATION; MUSCARINIC RECEPTORS; CORONARY-ARTERY; THORACIC AORTA; SMOOTH-MUSCLE; RABBIT AORTA; NITRIC-OXIDE; PLASMA; VASODILATION; ANESTHETICS	Background: Previous study has shown that fentanyl. attenuates acetylcholine-induced vasorelaxation. The goal of the current in vitro study was to Identify the muscarinic receptor subtype that is mainly involved in the fentanyl-induced attenuation of endothelium-dependent relaxation elicited by acetylcholine. Methods: The effects of fentanyl and muscarinic receptor antagonists on the acetylcholine concentration-response curve were assessed in aortic vascular smooth muscle ring preparations precontracted with phenylephrine. In the rings pretreated independently with pirenzepine, 4-diphenylacetoxyl-N-methylpiperidine methiodide, and naloxone, acetylcholine concentration-response curves were generated in the presence and absence of fentanyl. The effect of fentanyl on the concentration-response curve for calcium ionophore A23187 was assessed. Results: Fentanyl (0.297 x 10(-6), 0.785 x 10(-6) m) attenuated acetylcholine-induced vasorelaxation in ring preparations with or without 10(-6) m naloxone. Pirenzepine (10(-7) to 10(-6) m) and 4-diphenylacetoxyl-N-methylpiperidine methiodide (10(-9) to 10(-8) m) produced a parallel rightward shift in the acetylcholine concentration-response curve. The concentrations (- log M) of pirenzepine and 4-diphenylacetoxyl-N-methylpiperidine methiodide necessary to displace the concentration-response curve of an acetylcholine by twofold were estimated to be 6.886 +/- 0.070 and 9.256 +/- 0.087, respectively. Methoctramine, 10(-7) M, did not alter the acetylcholine concentration-response curve. Fentanyl, 0.785 X 10-6 m, attenuated acetylcholine-induced vasorelaxation in the rings pretreated with 10(-7) m pirenzepine but had no effect on vasorelaxation in the rings pretreated with 10(-8) m 4-diphenylacetoxyl-N-methylpiperidine methiodide. Fentanyl, 0.785 X 10-6 m, did not significantly alter calcium ionophore A23187-induced vasorelaxation. Conclusions. These results indicate that fentanyl attenuates acetylcholine-induced vasorelaxation via an inhibitory effect at a level proximal to nitric oxide synthase activation on the pathway involving endothelial M-3 muscarinic receptor activation in rat aorta.	Gyeongsang Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Jinju 660702, South Korea	Sohn, JT (reprint author), Gyeongsang Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, 92 Chilam dong, Jinju 660702, South Korea.	jtsohn@nongae.gsnu.ac.kr					ALEXANDER SPH, 1999, J TRENDS PHARM SCI S, V19, P5; ALEXANDER SPH, 1997, TRENDS PHARM SCI S, V18, P4; ARTRU AA, 2001, CEREBROSPINAL FLUID, P84; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48, DOI 10.1111/j.1476-5381.1959.tb00928.x; BUSSE R, 1993, EUR HEART J, V14, P2; Castillo C, 1999, CAN J PHYSIOL PHARM, V77, P958, DOI 10.1139/cjpp-77-12-958; Chen H, 1998, CHINESE J PHYSIOL, V41, P161; ETCHES RC, 1989, CAN J ANAESTH, V36, P165, DOI 10.1007/BF03011441; FLACKE JW, 1983, ANESTH ANALG, V62, P305; FLACKE JW, 1985, ANESTH ANALG, V64, P1053; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; HARGRAVE SA, 1979, BRIT J ANAESTH, V51, pP569; HOMMA Y, 2001, ANESTHESIOLOGY, V95, pA1361; Horibe M, 2000, ANESTHESIOLOGY, V93, P447, DOI 10.1097/00000542-200008000-00024; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; HYNES MR, 1986, J PHARMACOL EXP THER, V238, P100; Ichinohe T, 1998, ORAL SURG ORAL MED O, V85, P268, DOI 10.1016/S1079-2104(98)90006-3; ITO T, 1985, J PHYSL, V359, P467; JAISWAL N, 1991, J PHARMACOL EXP THER, V258, P842; Johns R A, 1991, J Cardiothorac Vasc Anesth, V5, P69, DOI 10.1016/1053-0770(91)90099-F; JOHNS RA, 1989, ANESTHESIOLOGY, V70, P805, DOI 10.1097/00000542-198905000-00017; KOMORI K, 1987, BRIT J PHARMACOL, V92, P657, DOI 10.1111/j.1476-5381.1987.tb11369.x; Lee K, 1994, Masui, V43, P89; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; MICHEL AD, 1988, EUR J PHARMACOL, V145, P61, DOI 10.1016/0014-2999(88)90349-4; RAPOPORT RM, 1983, CIRC RES, V52, P352, DOI 10.1161/01.RES.52.3.352; SIM MK, 1993, CLIN EXP HYPERTENS, V15, P409, DOI 10.3109/10641969309032943; STONE DJ, 1988, ANESTH ANALG, V67, P663; TODA H, 1992, ANESTH ANALG, V75, P198; TRAISH AM, 1994, J RECEPTOR RES, V14, P153, DOI 10.3109/10799899409066028; UGGERI MJ, 1992, ANESTHESIOLOGY, V76, P1012, DOI 10.1097/00000542-199206000-00023; WYNANDS JE, 1983, ANESTH ANALG, V62, P661; YAMANOUE T, 1992, ANESTH ANALG, V74, P889	33	8	8	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUL	2004	101	1					89	96		10.1097/00000542-200407000-00015			8	Anesthesiology	Anesthesiology	832QE	WOS:000222281200014	15220776				2020-06-30	J	Katz, J; Cohen, L				Katz, J; Cohen, L			Preventive analgesia is associated with reduced pain disability 3 weeks but not 6 months after major gynecologic surgery by laparotomy	ANESTHESIOLOGY			English	Article; Proceedings Paper	20th Annual Scientific Meeting of the American-Pain-Society	APR 19-22, 2001	PHOENIX, AZ	Amer Pain Soc			TERM POSTTHORACOTOMY PAIN; PREEMPTIVE ANALGESIA; EPIDURAL ANALGESIA; THORACIC-SURGERY; PROSTATECTOMY; HYPERALGESIA; AVOIDANCE; MORPHINE	Background: Most studies of preemptive or preventive analgesia restrict outcomes to pain and analgesic consumption in the acute postoperative period. The potential longer-term effects on these and other domains of functioning have received little empirical attention. The purpose of this study was to follow up patients who had received general anesthesia plus epidural fentanyl and lidocaine before (group 1) or after (group 2) incision or general anesthesia plus a sham epidural (group 3). Methods: Patients were contacted approximately 3 weeks and 6 months after surgery. A follow-up pain questionnaire and the McGill Pain Questionnaire were administered by telephone. The Mental Health Inventory and Pain Disability Index were mailed to patients, completed, and mailed back. Results: One hundred thirty-one of the 141 patients (93%) were reached 3 weeks after surgery (n = 41, n = 48, and n = 42 in groups 1, 2, and 3, respectively), and 109 (77%) were reached at 6 months (n = 35, n = 37, and n = 37 in groups 1, 2, and 3, respectively). Multivariate analysis of covariance indicated that that even after controlling for age and presence or absence of preoperative pain, Pain Disability Index scores (mean +/- SD) at the first follow-up were significantly lower in group 1 (17.3 +/- 12.8) and group 2 (18.1 +/- 17.0) compared with group 3 (26.3 +/- 18.3). McGill Pain Questionnaire and Mental Health inventory scores did not differ significantly among the groups. There were no significant differences at the 6-month follow-up. Conclusion: The short-term beneficial effects of preventive epidural analgesia translated into less pain disability 3 weeks after surgery. Progress in understanding the processes Involved in postsurgical recovery and the risk factors for chronic postsurgical pain would be aided by baseline and postsurgical measures of relevant psychological, emotional, and physical variables.	Univ Hlth Network, Toronto Gen Hosp, Dept Anesthesia & Pain Management, Acute Pain Res Unit, Toronto, ON M5G 2C4, Canada; York Univ, Dept Psychol, N York, ON M3J 1P3, Canada; York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada; Mt Sinai Hosp, Toronto, ON, Canada; Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; Univ Texas, MD Anderson Cancer Ctr, Dept Behav Sci, Houston, TX USA	Katz, J (reprint author), Univ Hlth Network, Toronto Gen Hosp, Dept Anesthesia & Pain Management, Acute Pain Res Unit, EN 3-440,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	jkatz@uhnres.utoronto.ca	Katz, Joel/J-7015-2014	Katz, Joel/0000-0002-8686-447X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35480]		Bruce J, 2003, PAIN, V104, P265, DOI 10.1016/S0304-3959(03)00017-4; Celerier E, 1999, BRAIN RES, V847, P18, DOI 10.1016/S0006-8993(99)01998-8; Crombie IK, 1998, PAIN, V76, P167, DOI 10.1016/S0304-3959(98)00038-4; DAJCZMAN E, 1991, CHEST, V99, P270, DOI 10.1378/chest.99.2.270; Gottschalk A, 1998, JAMA-J AM MED ASSOC, V279, P1076, DOI 10.1001/jama.279.14.1076; Gundes H, 2000, Acta Orthop Belg, V66, P341; Hayes C., 2002, ACUTE PAIN, V4, P45; Haythornthwaite JA, 1998, J UROLOGY, V160, P1761, DOI 10.1016/S0022-5347(01)62400-5; Kalso E, 2001, ACTA ANAESTH SCAND, V45, P935, DOI 10.1034/j.1399-6576.2001.450803.x; Katz J, 1997, LANCET, V350, P1338, DOI 10.1016/S0140-6736(05)65130-6; Katz J, 2003, ANESTHESIOLOGY, V98, P1449, DOI 10.1097/00000542-200306000-00023; Katz J, 1996, PAIN, V68, P109, DOI 10.1016/S0304-3959(96)03172-7; Katz J, 1996, CLIN J PAIN, V12, P50, DOI 10.1097/00002508-199603000-00009; Katz J, 1997, PROG PAIN RES MANAG, V8, P231; Katz J, 1999, SURG CLIN N AM, V79, P231, DOI 10.1016/S0039-6109(05)70381-9; Katz J., 2003, CLIN PAIN MANAGEMENT, P113; KISSIN I, 1994, ANESTH ANALG, V79, P809; Li XQ, 2001, ANESTH ANALG, V93, P204; Macrae WA, 2001, BRIT J ANAESTH, V87, P88, DOI 10.1093/bja/87.1.88; McCartney CJL, 2004, ANESTH ANALG, V98, P1385, DOI 10.1213/01.ANE.0000108501.57073.38; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Obata H, 1999, CAN J ANAESTH, V46, P1127, DOI 10.1007/BF03015520; Passlick B, 2001, EUR J CARDIO-THORAC, V19, P355, DOI 10.1016/S1010-7940(01)00568-1; Pellino T, 1998, Orthop Nurs, V17, P48; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Perttunen K, 1999, ACTA ANAESTH SCAND, V43, P563; PHILIPS HC, 1987, BEHAV RES THER, V25, P273, DOI 10.1016/0005-7967(87)90005-2; Poobalan AS, 2003, CLIN J PAIN, V19, P48, DOI 10.1097/00002508-200301000-00006; Reuben SS, 2001, ANESTHESIOLOGY, V95, P390, DOI 10.1097/00000542-200108000-00021; TAIT RC, 1990, PAIN, V40, P171, DOI 10.1016/0304-3959(90)90068-O; Turk DC, 2003, REGION ANESTH PAIN M, V28, P573, DOI 10.1016/S1098-7339(03)00392-4; Turk DC, 2003, PAIN, V106, P337, DOI 10.1016/j.pain.2003.08.001; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; Ware J.E., 1979, CONCEPTUALIZATION ME, V3; WEINSTEIN MC, 1989, MED CARE, V27, P593, DOI 10.1097/00005650-198906000-00003	35	61	66	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUL	2004	101	1					169	174		10.1097/00000542-200407000-00026			6	Anesthesiology	Anesthesiology	832QE	WOS:000222281200025	15220787				2020-06-30	J	Brack, A; Labuz, D; Schiltz, A; Rittner, HL; Machelska, H; Schafer, M; Peszka, R; Stein, C				Brack, A; Labuz, D; Schiltz, A; Rittner, HL; Machelska, H; Schafer, M; Peszka, R; Stein, C			Tissue monocytes/macrophages in inflammation - hyperalgesia versus opioid-mediated peripheral antinociception	ANESTHESIOLOGY			English	Article							CLODRONATE-CONTAINING LIPOSOMES; ANTIGEN-INDUCED ARTHRITIS; MACROPHAGE DEPLETION; NEUROPATHIC PAIN; INFLAMED TISSUE; GENE-EXPRESSION; BETA-ENDORPHIN; IMMUNE CELLS; NERVE INJURY; RAT	Background: Opioid-containing leukocytes migrate to peripheral sites of inflammation. On exposure to stress, opioid peptides are released, bind to opioid receptors on peripheral sensory neurons, and induce endogenous antinociception. In later stages of Freund's complete adjuvant-induced local inflammation, monocytes/macrophages are a major opioid-containing leukocyte subpopulation, but these cells also produce proalgesic cytokines. In this study, the role of tissue monocytes/macrophages in hyperalgesia and in peripheral opioid-mediated antinociception was investigated. Methods: After intraplantar injection of Freund's adjuvant, leukocyte subpopulations and opioid-containing leukocytes were analyzed by flow cytometry in the inflamed paw in the presence or absence of monocyte/macrophage depletion by intraplantar injection of clodronate-containing liposomes (phosphate-buffered saline and empty liposomes served as controls). Paw volume was measured with a plethysmometer. Hyperalgesia was determined by measuring heat-induced paw withdrawal latency and paw pressure threshold. Paw pressure threshold was also measured after swim stress and injection of fentanyl. Results: At 48 and 96 h of inflammation, it was found that (1) monocytes/macrophages were the largest leukocyte subpopulation (> 55% of all leukocytes) and the predominant producers of opioid peptides (71-77% of all opioid-containing leukocytes in the paw), (2) clodronate-containing liposomes depleted monocytes/macrophages by 30-35% (P < 0.05), (3) hyperalgesia was unaltered by liposome injection (P > 0.05), and (4) opioid-containing leukocytes and swim stress but not fentanyl-induced antinociception were significantly decreased by clodronate-containing liposomes (P < 0.05, P > 0.05, all by t test; opioid-containing cells and swim stress-induced increase of paw pressure threshold were reduced by 35-42% and 20%, respectively). Conclusion: Partial depletion of tissue monocytes/macrophages impairs peripheral endogenous opioid-mediated antinociception without affecting hyperalgesia.	Univ Med Berlin Charite, Klin Anaesthesiol & Operat Intensivmed, D-12200 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany	Brack, A (reprint author), Univ Med Berlin Charite, Klin Anaesthesiol & Operat Intensivmed, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	alexander.brack@charite.de	RIttner, Heike/AAC-6523-2019	RIttner, Heike/0000-0003-4867-0188; Stein, Christoph/0000-0001-5240-6836; Machelska, Halina/0000-0001-6315-2958			Abbadie C, 2003, P NATL ACAD SCI USA, V100, P7947, DOI 10.1073/pnas.1331358100; ANTONIJEVIC I, 1995, J NEUROSCI, V15, P165; Baatz H, 2001, EXP EYE RES, V73, P101, DOI 10.1006/exer.2001.1016; Barrera P, 2000, ARTHRITIS RHEUM, V43, P1951, DOI 10.1002/1529-0131(200009)43:9<1951::AID-ANR5>3.0.CO;2-K; BERGH A, 1993, J ENDOCRINOL, V136, P407, DOI 10.1677/joe.0.1360407; Bruck W, 1996, J NEUROSCI RES, V46, P477; Ceponis A, 2001, ARTHRITIS RHEUM, V44, P1908; Cui JG, 2000, PAIN, V88, P239, DOI 10.1016/S0304-3959(00)00331-6; Danenberg HD, 2002, CIRCULATION, V106, P599, DOI 10.1161/01.CIR.0000023532.98469.48; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Khodorova A, 2003, NAT MED, V9, P1055, DOI 10.1038/nm885; Kinne RW, 1995, ARTHRITIS RHEUM-US, V38, P1777, DOI 10.1002/art.1780381211; Koay MA, 2002, AM J RESP CELL MOL, V26, P572, DOI 10.1165/ajrcmb.26.5.4748; Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255; Li L, 2002, EXP NEUROL, V175, P23, DOI 10.1006/exnr.2002.7897; Liu T, 2000, PAIN, V86, P25, DOI 10.1016/S0304-3959(99)00306-1; Machelska H, 1998, NAT MED, V4, P1425, DOI 10.1038/4017; Machelska H, 2003, J NEUROIMMUNOL, V141, P30, DOI 10.1016/S0165-5728(03)00213-3; Machelska H, 2002, J NEUROSCI, V22, P5588; MECHANICK JI, 1992, ENDOCRINOLOGY, V131, P518, DOI 10.1210/en.131.1.518; Monkkonen H, 2001, PHARMACEUT RES, V18, P1550, DOI 10.1023/A:1013026313647; Mousa SA, 2001, J NEUROIMMUNOL, V115, P71, DOI 10.1016/S0165-5728(01)00271-5; Mousa SA, 2002, J NEUROIMMUNOL, V126, P5, DOI 10.1016/S0165-5728(02)00049-8; Mutsaers SE, 2002, AM J PATHOL, V160, P681, DOI 10.1016/S0002-9440(10)64888-2; PRZEWLOCKI R, 1992, NEUROSCIENCE, V48, P491, DOI 10.1016/0306-4522(92)90509-Z; Radhakrishnan R, 2003, PAIN, V104, P567, DOI 10.1016/S0304-3959(03)00114-3; Ribeiro RA, 2000, EUR J PHARMACOL, V387, P111, DOI 10.1016/S0014-2999(99)00790-6; Richards PJ, 1999, RHEUMATOLOGY, V38, P818, DOI 10.1093/rheumatology/38.9.818; Rittner HL, 2003, CURR OPIN ANESTHESIO, V16, P527, DOI 10.1097/00001503-200310000-00014; Rittner HL, 2001, ANESTHESIOLOGY, V95, P500, DOI 10.1097/00000542-200108000-00036; Rutkowski MD, 2000, PHYSIOL BEHAV, V71, P225, DOI 10.1016/S0031-9384(00)00333-4; SchmidtWeber CB, 1996, J LEUKOCYTE BIOL, V60, P230; Selander KS, 1996, MOL PHARMACOL, V50, P1127; Slegers TPAM, 2000, CURR EYE RES, V20, P322, DOI 10.1076/0271-3683(200004)20:4;1-5;FT322; STEIN C, 1990, P NATL ACAD SCI USA, V87, P5935, DOI 10.1073/pnas.87.15.5935; STEIN C, 1990, J NEUROSCI, V10, P1292; Stein C, 2003, NAT MED, V9, P1003, DOI 10.1038/nm908; Sweitzer SM, 2002, PAIN, V100, P163, DOI 10.1016/S0304-3959(02)00257-9; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022-1759(89)90178-6; Watkins LR, 2002, PHYSIOL REV, V82, P981, DOI 10.1152/physrev.00011.2002; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	43	52	53	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUL	2004	101	1					204	211		10.1097/00000542-200407000-00031			8	Anesthesiology	Anesthesiology	832QE	WOS:000222281200030	15220792				2020-06-30	J	Thompson, ES				Thompson, ES			Where is the fentanyl? To the editor	ANESTHESIOLOGY			English	Letter									Univ Iowa, Iowa City, IA USA	Thompson, ES (reprint author), Univ Iowa, Iowa City, IA USA.	e-s-thompson@uiowa.edu						0	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUL	2004	101	1					265	265		10.1097/00000542-200407000-00057			1	Anesthesiology	Anesthesiology	832QE	WOS:000222281200056	15220818				2020-06-30	J	Demirbilek, S; Togal, T; Cicek, M; Aslan, U; Sizanli, E; Ersoy, MO				Demirbilek, S; Togal, T; Cicek, M; Aslan, U; Sizanli, E; Ersoy, MO			Effects of fentanyl on the incidence of emergence agitation in children receiving desflurane or sevoflurane anaesthesia	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthetics, inhalation, desflurane, sevoflurane; children, midazolam, premedication; complications, emergence agitation	POSTOPERATIVE BEHAVIORAL OUTCOMES; PEDIATRIC AMBULATORY PATIENTS; DAY-CASE SURGERY; RECOVERY CHARACTERISTICS; HALOTHANE; PROPOFOL; INDUCTION; PREMEDICATION; MYRINGOTOMY; BOYS	Background and objective: In children, emergence agitation frequently complicates sevoflurane and desflurane anaesthesia. The effect of intravenous fentanyl 2.5 mug kg(-1) was examined on the incidence of emergence agitation in children who received desflurane or sevoflurane after midazolam premedication and intravenous thiopental induction. Methods: One hundred and twenty children (2-7 yr) undergoing adenoidectomy or tonsillectomy, or both, were studied. All children were premedicated orally with midazolam 0.5 mg kg(-1). After intravenous induction with thiopental and atracurium to facilitate endotracheal intubation, patients were randomly assigned to one of four groups: Patients in Groups I and 3 received physiological saline solution, whereas patients in Groups 2 and 4 received intravenous fentanyl 2.5 mug kg(-1) during induction. Anaesthesia was maintained with sevoflurane in Groups I and 2 and with desflurane in Groups 3 and 4. After discontinuation of the volatile anaesthetic, the times to tracheal extubation and response to verbal stimuli (emergence time), and emergence behaviours were recorded. Results: The time to tracheal extubation was significantly shorter in Groups 3 (5.2 +/- 1.7 min) and 4 (6.4 +/- 2.1 min) than in Groups 1 (8.1 +/- 2.1 min) (P = 0.0001 and 0.006, respectively) and 2 (8.8 +/- 1.9 min) (P = 0.0001). The emergence time was significantly shorter in Group 3 (10.0 +/- 3.9 min) than in Groups 1 (13.8 +/- 4.9 min) (P = 0.017) and 2 (14.9 +/- 4.1 min) (P = 0.003). The incidence rate of severe agitation was 13% in Groups 1 and 3, and 7 and 10% in Groups 2 and 4, respectively (P > 0.05). Conclusions: After midazolam premedication and intravenous induction of anaesthesia with thiopental, administration of intravenous fentanyl 2.5 mug kg(-1) did not provide any clinically significant benefit on emergence agitation in children who receive sevoflurane or desflurane anaesthesia.	Inonu Univ, Sch Med, Dept Anaesthesiol, Malatya, Turkey	Demirbilek, S (reprint author), Inonu Univ, Tip Fak, Anesteziyoloji & Reanimasyon AD, TR-44069 Malatya, Turkey.	sedemirbilek@inonu.edu.tr	cicek, muslum/P-5252-2019				Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Aono J, 1999, ACTA ANAESTH SCAND, V43, P542, DOI 10.1034/j.1399-6576.1999.430509.x; BENSHLOMO I, 1990, BRIT J ANAESTH, V64, P45, DOI 10.1093/bja/64.1.45; Cohen IT, 2002, ANESTH ANALG, V94, P1178, DOI 10.1097/00000539-200205000-00023; Cohen IT, 2001, ANESTH ANALG, V93, P88; Cohen IT, 2003, PAEDIATR ANAESTH, V13, P63, DOI 10.1046/j.1460-9592.2003.00948.x; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; DAVIS PJ, 1994, ANESTHESIOLOGY, V80, P298, DOI 10.1097/00000542-199402000-00009; Finkel JC, 2001, ANESTH ANALG, V92, P1164; Grundman U, 1998, ACTA ANAESTH SCAND, V42, P845, DOI 10.1111/j.1399-6576.1998.tb05332.x; Hallen J, 2001, J CLIN ANESTH, V13, P161, DOI 10.1016/S0952-8180(01)00236-7; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; JOHANNESSON GP, 1995, ACTA ANAESTH SCAND, V39, P546, DOI 10.1111/j.1399-6576.1995.tb04116.x; Kain ZN, 1999, ANESTH ANALG, V88, P1042, DOI 10.1097/00000539-199905000-00013; Kain ZN, 1999, ANESTHESIOLOGY, V90, P758, DOI 10.1097/00000542-199903000-00018; Kain ZN, 2000, J CLIN ANESTH, V12, P549, DOI 10.1016/S0952-8180(00)00214-2; Khalil SN, 2003, PAEDIATR ANAESTH, V13, P205, DOI 10.1046/j.1460-9592.2003.01062.x; Korpela R, 1999, ANESTHESIOLOGY, V91, P442, DOI 10.1097/00000542-199908000-00019; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; Lerman J, 1996, ANESTHESIOLOGY, V84, P1332, DOI 10.1097/00000542-199606000-00009; Moore EW, 2002, EUR J ANAESTH, V19, P9, DOI 10.1017/S0265021502000029; Picard V, 2000, ACTA ANAESTH SCAND, V44, P307, DOI 10.1034/j.1399-6576.2000.440315.x; RUNCIE CJ, 1993, BRIT J ANAESTH, V70, P192, DOI 10.1093/bja/70.2.192; SARNER JB, 1995, ANESTHESIOLOGY, V82, P38, DOI 10.1097/00000542-199501000-00006; TVERSKOY M, 1988, ANESTH ANALG, V67, P342; Veyckemans F, 2001, Curr Opin Anaesthesiol, V14, P339, DOI 10.1097/00001503-200106000-00010; Viitanen H, 1999, ANESTH ANALG, V89, P75, DOI 10.1097/00000539-199907000-00014; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005	28	38	46	0	6	GREENWICH MEDICAL MEDIA LTD	LONDON	137 EUSTON RD, 4TH FLOOR, LONDON NW1 2AA, ENGLAND	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	JUL	2004	21	7					538	542		10.1017/S0265021504007069			5	Anesthesiology	Anesthesiology	842DY	WOS:000222984600006	15318465				2020-06-30	J	Magosso, E; Ursino, M; van Oostrom, JH				Magosso, E; Ursino, M; van Oostrom, JH			Opioid-induced respiratory depression: A mathematical model for fentanyl	IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING			English	Article						CO2 ventilatory response; pharmacodynamic modeling; respiratory control system; spontaneous and artificial ventilation	VENTILATORY CONTROL-SYSTEM; CARBON-DIOXIDE; CARDIORESPIRATORY CONTROL; ARTIFICIAL VENTILATION; ISOCAPNIC HYPOXIA; INTEGRATED MODEL; BISPECTRAL INDEX; NITROUS-OXIDE; ALFENTANIL; MORPHINE	In this paper, respiratory depressant effects of fentanyl are described quantitatively by a mathematical model. The model is an extension of a previous one, which reproduces the human ventilatory control system on a physiological basis. It includes the following: three compartments for gas storage and exchange (lungs, body tissue, and brain tissue); the main mechanisms involved in ventilation control (peripheral chemoreceptors, central chemoreceptors, and the central hypoxic depression); and local blood flow regulation. The effects of fentanyl on the respiratory system include a decrease in peripheral and central chemoreceptor gains on ventilation and a direct inhibition of respiratory neural activity. All parameters in the model were chosen according to the literature. The model is able to reproduce the ventilatory effects of fentanyl in several conditions: 1) constant levels of fentanyl; 2) after a bolus injection; 3) at fixed levels of P-ETCO2; and 4) after artificial ventilation. According to the model, in spontaneously breathing subjects, minute ventilation depends on two opposing actions: fentanyl inhibitory influences, which depress ventilation, reducing oxygen tension and increasing CO2 tension, and the consequent activation of chemoreceptors, which stimulates ventilation. Simulations of anesthetized patients resuming spontaneous breathing after artificial ventilation demonstrate the risk of prolonged apnea and tissue hypoxemia. A safe transition can be achieved by increasing patient PCO2 toward the end of artificial ventilation, because an advanced chemoreceptor stimulation is produced, which promptly counteracts fentanyl-induced inhibition at cessation of artificial ventilation.	Univ Bologna, Dept Elect Comp Sci & Syst, I-40136 Bologna, Italy; Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA	Magosso, E (reprint author), Univ Bologna, Dept Elect Comp Sci & Syst, I-40136 Bologna, Italy.	emagosso@deis.unibo.it	van Oostrom, Johannes/B-1407-2008	Magosso, Elisa/0000-0002-4673-2974; Ursino, Mauro/0000-0002-0911-0308			ANDREWS CJH, 1982, BRIT J ANAESTH, V54, P1129; ANDREWS CJH, 1983, BRIT J ANAESTH, V55, P211; Bailey PL, 2000, NEW ENGL J MED, V343, P1228, DOI 10.1056/NEJM200010263431705; Berkenbosch A, 1997, ANESTHESIOLOGY, V86, P1342, DOI 10.1097/00000542-199706000-00016; BERKENBOSCH A, 1994, ANESTHESIOLOGY, V80, P1303, DOI 10.1097/00000542-199406000-00018; Bouillon T, 1999, ANESTHESIOLOGY, V91, P144, DOI 10.1097/00000542-199907000-00023; Brown M.D., 1995, CARDIOVASCULAR REGUL, P113; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; CARWRIGHT CR, 1998, ANESTHESIOLOGY, V89, P612; CUNNINGHAM DJC, 1986, HDB PHYSL 3, V2, P475, DOI DOI 10.1002/CPHY.CP030215; Dahan A, 2001, ANESTHESIOLOGY, V94, P982, DOI 10.1097/00000542-200106000-00011; DOWNES JJ, 1967, J PHARMACOL EXP THER, V158, P416; DUNBAR BS, 1967, BRIT J ANAESTH, V39, P861, DOI 10.1093/bja/39.11.861; FITZGERALD RS, 1971, RESP PHYSIOL, V12, P218, DOI 10.1016/0034-5687(71)90054-5; FRANCHETEAU P, 1993, J PHARMACOKINET BIOP, V21, P489, DOI 10.1007/BF01059111; FUKUI Y, 1981, ANESTHESIOLOGY, V54, P107, DOI 10.1097/00000542-198102000-00003; GREENWAY CV, 1990, CAN J PHYSIOL PHARM, V68, P1299, DOI 10.1139/y90-195; HANKS EC, 1961, ANESTHESIOLOGY, V22, P393, DOI 10.1097/00000542-196105000-00009; HARPER MH, 1976, J PHARMACOL EXP THER, V199, P464; HILL HF, 1990, PAIN, V43, P69, DOI 10.1016/0304-3959(90)90051-E; HUG CC, 1979, ANESTHESIOLOGY, V50, P342, DOI 10.1097/00000542-197904000-00011; IVANOV SD, 1969, BRIT J ANAESTH, V41, P28, DOI 10.1093/bja/41.1.28; KARLSTEN R, 1993, BRIT J ANAESTH, V70, P411, DOI 10.1093/bja/70.4.411; KHAMNEI S, 1990, RESP PHYSIOL, V81, P117, DOI 10.1016/0034-5687(90)90074-9; Mildh L, 1998, ANAESTHESIA, V53, P965, DOI 10.1046/j.1365-2044.1998.00519.x; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Nieuwenhuijs DJF, 2003, ANESTHESIOLOGY, V98, P312, DOI 10.1097/00000542-200302000-00008; NISHINO T, 1994, BRIT J ANAESTH, V73, P583, DOI 10.1093/bja/73.5.583; NUNN JF, 1965, BRIT J ANAESTH, V37, P898, DOI 10.1093/bja/37.12.898; NUNN JF, 1990, BRIT J ANAESTH, V65, P155, DOI 10.1093/bja/65.2.155; PAINTER R, 1993, J APPL PHYSIOL, V74, P2007; READ DJC, 1967, AUSTRALAS ANN MED, V16, P20; REILLY CS, 1984, ANAESTHESIA, V40, P837; ROBBINS PA, 1995, J APPL PHYSIOL, V79, P373; SANTIAGO TV, 1979, J APPL PHYSIOL, V47, P112; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; Sarton E, 1999, ANESTHESIOLOGY, V90, P1329, DOI 10.1097/00000542-199905000-00017; SCAMMAN FL, 1984, ACTA ANAESTH SCAND, V28, P63, DOI 10.1111/j.1399-6576.1984.tb02013.x; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SPENCER JL, 1979, ANN BIOMED ENG, V7, P59, DOI 10.1007/BF02364439; STOECKEL H, 1982, BRIT J ANAESTH, V54, P1087, DOI 10.1093/bja/54.10.1087; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Ursino M, 2001, CLIN PHYSIOL, V21, P447, DOI 10.1046/j.1365-2281.2001.00349.x; Ursino M, 2001, CLIN PHYSIOL, V21, P465, DOI 10.1046/j.1365-2281.2001.00350.x; van Meurs WL, 1998, IEEE T BIO-MED ENG, V45, P582, DOI 10.1109/10.668748; WEIL JV, 1975, NEW ENGL J MED, V292, P1103, DOI 10.1056/NEJM197505222922106	46	9	12	2	8	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855 USA	0018-9294			IEEE T BIO-MED ENG	IEEE Trans. Biomed. Eng.	JUL	2004	51	7					1115	1128		10.1109/TBME.2004.827344			14	Engineering, Biomedical	Engineering	830ON	WOS:000222132200004	15248528				2020-06-30	J	Lim, Y; Loo, CC; Goh, E				Lim, Y; Loo, CC; Goh, E			Ultra low dose combined spinal and epidural anesthesia for cesarean section	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Letter							BUPIVACAINE		KK Womens & Childrens Hosp, Dept Anesthesia, Singapore, Singapore; Natl Univ Singapore Hosp, Dept Anesthesia & Intens Care, Singapore 117548, Singapore	Lim, Y (reprint author), KK Womens & Childrens Hosp, Dept Anesthesia, Singapore, Singapore.	yvel6@hotmail.com					Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Hogan QH, 1996, ANESTHESIOLOGY, V84, P1341, DOI 10.1097/00000542-199606000-00010; Mardirosoff C, 1998, REGION ANESTH PAIN M, V23, P92, DOI 10.1016/S1098-7339(98)90117-1; Reyes M, 2004, INT J OBSTET ANESTH, V13, P99, DOI 10.1016/j.ijoa.2003.09.004; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014	5	9	9	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JUL	2004	13	3					198	200		10.1016/j.ijoa.2004.03.007			3	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	838UL	WOS:000222738700015	15321404				2020-06-30	J	Zhao, SZ; Chung, F; Hanna, DB; Raymundo, AL; Cheung, RY; Chen, C				Zhao, SZ; Chung, F; Hanna, DB; Raymundo, AL; Cheung, RY; Chen, C			Dose-response relationship between opioid use and adverse effects after ambulatory surgery	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Article						opioid dose reduction; opioid-related adverse effects; ambulatory surgery; opioid dose-response relationship	IMPAIR PLATELET-FUNCTION; POSTOPERATIVE PAIN; INTRAVENOUS MORPHINE; SYMPTOM PREVALENCE; CESAREAN DELIVERY; PARECOXIB SODIUM; ANALGESIA; DICLOFENAC; INHIBITOR; TITRATION	This health outcomes analysis based on datafront a randomized, double-blind, placebo-controlled trial determined dose-response relationship between opioid use and related symptoms. All patients received intravenous fentanyl on demand for pain predischarge, and oral acetaminophen 500 mg/hydrocodone 5 mg every 4-6 hours as needed postdischarge for up to 7 days postsurgery. Patients completed an opioid-related Symptom Distress Scale (SDS) questionnaire every 24 hours postdischarge,for 7 days, which assessed 12 opioid-related symptoms by 3 ordinal measures: frequency, severity, and bothersomeness. Clinically meaningful events (CMEs) were defined based on the responses to this questionnaire. Opioid use zoos converted to morphine equivalent dose (MED). The dose-response relationship between composite SDS scores and MED on Day 1, on Days 0 and, 1, and on Days 1-4, was assessed. SDS scores for all 12 symptoms within the 3 dimensions were significantly associated with MED on Day 1 (F-value = 1.56; P = 0.04), as well as cumulative MED used on Days 0 and 1 (F-value = 1. 85; P < 0.01). Patients with a specific CME used a higher MED than those without a CME on Day 1 (P < 0.001). Between Days 1 and 4, patients with a higher number of palient-CME-days used a significantly higher MED. Regression analyses suggested that once the MED reached a threshold, approximately every 4 mg increase in MED was related to 1 additional patient-CME-day (P < 0.01). A dose response relationship empirically exists between MED and directly assessed opioid-related CMEs after ambulatory laparoscopic cholecystectomy. Once daily MED reaches a threshold, every 3-4 mg increase will be associated with 1 additional clinically meaningful opioid-related symptom, or 1 additional patient-day with an opioid-related CME. (C) 2004 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.	Pfizer Inc, Stat Serv, Global Hlth Outcomes Res, Peapack, NJ USA; Pfizer Inc, Global Med Affairs, Peapack, NJ USA; Univ Toronto, Toronto Western Hosp, Dept Anesthesia, Toronto, ON M5T 2S8, Canada; Pfizer Inc, Global Hlth Outcomes, Skokie, IL USA	Cheung, RY (reprint author), Pfizer Global Pharmaceut, 235 E 42nd St, New York, NY 10015 USA.		Chung, Frances/F-5618-2015	Chung, Frances/0000-0001-9576-3606			Aubrun F, 2003, BRIT J ANAESTH, V90, P314, DOI 10.1093/bja/aeg076; Aubrun F, 2002, ANESTHESIOLOGY, V96, P17, DOI 10.1097/00000542-200201000-00009; Aubrun F, 2001, EUR J ANAESTH, V18, P159, DOI 10.1046/j.0265-0215.2000.00796.x; Camu Frederic, 2002, Am J Ther, V9, P43, DOI 10.1097/00045391-200201000-00009; Cardoso MMSC, 1998, ANESTH ANALG, V86, P538, DOI 10.1097/00000539-199803000-00017; Cheng J C, 1997, Am J Ther, V4, P62, DOI 10.1097/00045391-199702000-00002; Chung F, 1997, ANESTH ANALG, V85, P808, DOI 10.1097/00000539-199710000-00017; GAN T, 2002, ANESTHESIOLOGY, V96, pA20; GAN T, 2003, J PAIN S1, V4, pA836; Hubbard RC, 2003, BRIT J ANAESTH, V90, P166, DOI 10.1093/bja/aeg038; Iitomi T, 1995, Masui, V44, P1627; JOSHI G, 2002, ANESTHESIOLOGY, V96, pA29; Joshi GP, 2004, ANESTH ANALG, V98, P336, DOI 10.1213/01.ANE.0000093390.94921.4A; Kehlet H, 1996, J CLIN ANESTH, V8, P441, DOI 10.1016/0952-8180(96)00131-6; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Keita H, 2003, BRIT J ANAESTH, V90, P53, DOI 10.1093/bja/aeg019; Leese PT, 2000, J CLIN PHARMACOL, V40, P124, DOI 10.1177/00912700022008766; Leese PT, 2002, AM J EMERG MED, V20, P275, DOI 10.1053/ajem.2002.32635; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; Malan TP, 2003, ANESTHESIOLOGY, V98, P950, DOI 10.1097/00000542-200304000-00023; Noveck RJ, 2001, CLIN DRUG INVEST, V21, P465, DOI 10.2165/00044011-200121070-00002; Olofsson CI, 2000, EUR J OBSTET GYN R B, V88, P143, DOI 10.1016/S0301-2115(99)00144-X; PARKER RK, 1994, ANESTHESIOLOGY, V80, P6, DOI 10.1097/00000542-199401000-00005; PORTENOY RK, 1994, EUR J CANCER, V30A, P1326, DOI 10.1016/0959-8049(94)90182-1; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; SANTON JM, 1991, ANAESTHESIA, V46, P317; Singh G, 1998, J RHEUMATOL, V25, P8; SINGH G, 1998, AM J MED, V105, P31; SUN HL, 1993, ANESTH ANALG, V76, P284; VISCUSI E, 2002, ANESTHESIOLOGY, V96, pA28; WETCHLER BV, 1992, CLIN ANESTH, P1389; Wheeler M, 2002, J PAIN, V3, P159, DOI 10.1054/jpai.2002.123652; Wu CL, 2002, ANESTHESIOLOGY, V96, P994, DOI 10.1097/00000542-200204000-00030; Zaheer S, 1998, DIS COLON RECTUM, V41, P696, DOI 10.1007/BF02236255; ZHAO S, 2003, J PAIN S1, V4, pA925	36	87	91	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	JUL	2004	28	1					35	46		10.1016/j.jpainsymman.2003.11.001			12	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	837NE	WOS:000222641400007	15223083	Bronze			2020-06-30	J	Delogu, G; Moretti, S; Antonucci, A; Marandola, M; Tellan, G; Sale, P; Carnevali, R; Famularo, G				Delogu, G; Moretti, S; Antonucci, A; Marandola, M; Tellan, G; Sale, P; Carnevali, R; Famularo, G			Apoptogenic effect of fentanyl on freshly isolated peripheral blood lymphocytes	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						fentanyl; surgical trauma; apoptosis; programmed cell death; critically ill patient; lymphocyte; mitachondria; mitochondrial membrane potential; reactive oxygen species; opioids	K-ATP CHANNELS; CELL-DEATH; RESPIRATORY BURST; INDUCED APOPTOSIS; IN-VITRO; MORPHINE; RECEPTOR; OPIOIDS; MITOCHONDRIA; INVOLVEMENT	Background. Opioids may trigger the apoptotic death of widely ranging cell types, and apoptosis contributes to the immune deficiency of critically ill patients and subjects experiencing surgical trauma. There is evidence that an altered mitochondrial membrane potential constitutes an early and irreversible step in the death-signaling pathway of apoptosis. This study investigated whether fentanyl, a opioid widely used in the management of these patients, may induce apoptosis of T cells by altering their mitochondrial membrane potential. Methods. Peripheral blood lymphocytes were cultured in the presence of 30 ng fentanyl for 60 (time 1), 90 (time 2), and 120 (time 3) minutes, respectively. The cells then were processed for assessment of mitochondrial membrane potential by means of flow cytometry and confocal scanning microscopy. Furthermore, production of reactive oxygen species, expression of the Fas-Fas L pro-apoptotic pathway, and apoptosis frequency were measured by means of now cytometry. Control cells were incubated for the same times in the complete culture medium without the drug. Results: Flow cytometry analysis showed a significantly increased rate (p < 0.05) of lymphocytes with disrupted mitochondrial membrane potential after incubation with fentanyl for 90 and 120 minutes, as compared with both control cells and lymphocytes cultured in the presence of fentanyl for 60 minutes. In addition, as early as 60 minutes after exposure to fentanyl, cells displayed a disrupted mitochondrial membrane potential when this was assayed by means of confocal laser scanning. These findings were associated with increased production of reactive oxygen species. The frequency of apoptotic lymphocytes was markedly increased (p < 0.05) after 120 minutes of incubation, as compared with untreated cells and cells exposed to fentanyl for only 60 and 90 minutes. Expression of Fas-FasL was not substantially affected by exposure to fentanyl. Conclusions: Fentanyl may induce a time-dependent apoptosis of lymphocytes by altering their mitochondrial redox metabolism.	Univ Roma La Sapienza, Dept Anestesia & Intens Care, Rome, Italy; Univ Roma La Sapienza, Dept Infect Dis, Rome, Italy; Univ Roma La Sapienza, Dept Expt Med & Pathol, Rome, Italy; San Camillo Hosp, Dept Internal Med, Rome, Italy	Delogu, G (reprint author), Policlin Umberto 1, Dept Anesthesia & Intens Care, I-00161 Rome, Italy.	giovanna.delogu@uniroma1.it	Sale, Patrizio/J-3276-2019; Sale, Patrizio/K-8757-2016	Sale, Patrizio/0000-0002-4850-3673; Sale, Patrizio/0000-0002-4850-3673; TELLAN, GUGLIELMO/0000-0002-4129-3300			BARASH PG, 2001, CLIN ANESTH, P345; Boronat MA, 2001, BRIT J PHARMACOL, V134, P1263, DOI 10.1038/sj.bjp.0704364; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Chatzaki E, 2001, MOL HUM REPROD, V7, P867, DOI 10.1093/molehr/7.9.867; Delogu G, 2000, ARCH SURG-CHICAGO, V135, P1141, DOI 10.1001/archsurg.135.10.1141; Dermitzaki E, 2000, J NEUROCHEM, V74, P960, DOI 10.1046/j.1471-4159.2000.0740960.x; Fleury C, 2002, BIOCHIMIE, V84, P131, DOI 10.1016/S0300-9084(02)01369-X; FREIER DO, 1993, J PHARMACOL EXP THER, V265, P81; FUCHS BA, 1993, J PHARMACOL EXP THER, V266, P417; Gottlieb RA, 2001, BIOL SIGNAL RECEPT, V10, P147; Hauser KF, 2000, EUR J NEUROSCI, V12, P1281, DOI 10.1046/j.1460-9568.2000.01015.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kugawa F, 2000, BIOL PHARM BULL, V23, P930; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Liu HP, 2001, J MOL CELL CARDIOL, V33, P2007, DOI 10.1006/jmcc.2001.1464; Mao JR, 2002, J NEUROSCI, V22, P7650; McCarthy L, 2001, DRUG ALCOHOL DEPEN, V62, P111, DOI 10.1016/S0376-8716(00)00181-2; McPherson BC, 2001, CIRCULATION, V103, P290; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oka M, 1996, ANN SURG, V223, P434, DOI 10.1097/00000658-199604000-00013; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440; Singhal PC, 2002, J IMMUNOL, V168, P4025, DOI 10.4049/jimmunol.168.8.4025; Singhal PC, 1998, J IMMUNOL, V160, P1886; Singhal PG, 1999, J LEUKOCYTE BIOL, V66, P650; Wang JH, 2001, J LEUKOCYTE BIOL, V70, P527; Welters ID, 2000, J NEUROIMMUNOL, V111, P139, DOI 10.1016/S0165-5728(00)00401-X; Yin DL, 1999, NATURE, V397, P218, DOI 10.1038/16612; Yin DL, 1997, NEUROSCI RES, V29, P121, DOI 10.1016/S0168-0102(97)00080-1; Yoshida A, 2000, INT J MOL MED, V6, P329; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	32	19	21	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2004	57	1					75	81		10.1097/01.TA.0000075349.66640.3E			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	844TR	WOS:000223183800018	15284552				2020-06-30	J	Shavit, Y; Ben-Eliyahu, S; Zeidel, A; Beilin, B				Shavit, Y; Ben-Eliyahu, S; Zeidel, A; Beilin, B			Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats - Dose and timing study	NEUROIMMUNOMODULATION			English	Article						opiates; natural killer cells; lung tumor retention and metastasis	OPIOID-PEPTIDES; COMPROMISES RESISTANCE; POSTOPERATIVE PAIN; IMMUNE-RESPONSE; SURGERY; MORPHINE; STRESS; RECEPTORS; CANCER; BLOOD	Objectives: Opiates, which serve an integral role in anesthesia, suppress immune function, particularly natural killer cell cytotoxicity (NKCC). NK cells play an important role in tumor and metastasis surveillance. We reported that large-dose fentanyl anesthesia induced prolonged suppression of NKCC in patients undergoing abdominal surgery. The immune modulatory effects of opiates may depend on the interaction between dose and time of administration. The present study examined the effects of different doses of fentanyl, administered at different time points relative to tumor inoculation, on NKCC and on experimental tumor metastasis in rats. Methods: Fischer 344 rats were injected with low or high doses of fentanyl, 6 or 2 h before, simultaneously with or 1 h after being inoculated intravenously with MADB106 tumor cells. Lung tumor retention (LTR) was assessed 4 h after, and lung tumor metastases were counted 3 weeks after tumor inoculation. NKCC was assessed 1 h after the fentanyl injection. Results: At all time points, except 6 h before tumor inoculation, fentanyl (0.1-0.3 mg/kg) induced a dose-dependent increase in MADB106 LTR (2.3- to 74-fold). An intermediate dose of fentanyl (0.15 mg/kg) doubled the number of lung metastasis, and, within animal, suppressed NKCC and increased MADB106 LTR in a correlated manner. Conclusion: These findings indicate that fentanyl suppresses NKCC and increases the risk of tumor metastasis. Suppression of NK cells at a time when surgery may induce tumor dissemination can prove to be critical to the spread of metastases. It is suggested that the acute administration of a moderate dose of opiates during surgery should be applied cautiously, particularly in cancer patients. Copyright (C) 2004 S. Karger AG, Basel.	Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; Tel Aviv Univ, Dept Psychol, Neuroimmunol Res Unit, IL-69978 Tel Aviv, Israel; Rabin Med Ctr, Dept Anesthesiol, Petah Tiqwa, Israel	Shavit, Y (reprint author), Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel.	Udi.Shavit@huji.ac.il	Ben-Eliyahu, Shamgar/AAE-5444-2020; Shavit, Yehuda/A-1219-2010	Ben-Eliyahu, Shamgar/0000-0003-3832-0678	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA73056]		Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; BARLOZZARI T, 1983, J IMMUNOL, V131, P1024; Beilin B, 1996, ANESTH ANALG, V82, P492, DOI 10.1097/00000539-199603000-00011; Beilin B, 2003, ANESTH ANALG, V97, P822, DOI 10.1213/01.ANE.0000078586.82810.3B; BEILIN B, 1989, Brain Behavior and Immunity, V3, P129, DOI 10.1016/0889-1591(89)90013-5; Ben-Eliyahu S, 1999, ANESTHESIOLOGY, V91, P732, DOI 10.1097/00000542-199909000-00026; Ben-Eliyahu S, 1999, INT J CANCER, V80, P880; Ben-Eliyahu S, 2003, BRAIN BEHAV IMMUN, V17, pS27; Ben-Eliyahu S, 2002, LANCET ONCOL, V3, P578; BenEliyahu S, 1996, NAT MED, V2, P457, DOI 10.1038/nm0496-457; BENELIYAHU S, 1992, PROG NEUROENDOCRINIM, V5, P199; Da Costa ML, 1998, SURGERY, V124, P516, DOI 10.1016/S0039-6060(98)70098-4; Denis MG, 1997, INT J CANCER, V74, P540, DOI 10.1002/(SICI)1097-0215(19971021)74:5<540::AID-IJC11>3.0.CO;2-A; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; ESCHWEGE P, 1995, LANCET, V346, P1528, DOI 10.1016/S0140-6736(95)92054-4; FOSS OP, 1966, SURGERY, V59, P691; Gaspani L, 2002, J NEUROIMMUNOL, V129, P18, DOI 10.1016/S0165-5728(02)00165-0; HANSEN E, 1995, ARCH SURG-CHICAGO, V130, P387; LEWIS J W, 1983, Natural Immunity and Cell Growth Regulation, V3, P43; MELAMED R, 2001, BRAIN BEHAV IMMUN, V15, P169; Mellon RD, 1998, J NEUROIMMUNOL, V83, P19, DOI 10.1016/S0165-5728(97)00217-8; PAGE GG, 1993, PAIN, V54, P21, DOI 10.1016/0304-3959(93)90095-7; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; SALO M, 1992, ACTA ANAESTH SCAND, V36, P201, DOI 10.1111/j.1399-6576.1992.tb03452.x; Shakhar G, 1998, J IMMUNOL, V160, P3251; SHAVIT Y, 1986, P NATL ACAD SCI USA, V83, P7114, DOI 10.1073/pnas.83.18.7114; SHAVIT Y, 1984, SCIENCE, V223, P188, DOI 10.1126/science.6691146; SHAVIT Y, 1985, J IMMUNOL, V135, pS834; SIBINGA NES, 1988, ANNU REV IMMUNOL, V6, P219; WEBER RJ, 1989, SCIENCE, V245, P188, DOI 10.1126/science.2749256; Yamaguchi K, 2000, ANN SURG, V232, P58, DOI 10.1097/00000658-200007000-00009; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008	32	92	106	0	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401			NEUROIMMUNOMODULAT	Neuroimmunomodulation	JUL	2004	11	4					255	260		10.1159/000078444			6	Endocrinology & Metabolism; Immunology; Neurosciences	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	836DG	WOS:000222535000008	15249732				2020-06-30	J	Rorarius, MGF; Mennander, S; Suominen, P; Rintala, S; Puura, A; Pirhonen, R; Salmelin, R; Haanpaa, M; Kujansuu, E; Yli-Hankala, A				Rorarius, MGF; Mennander, S; Suominen, P; Rintala, S; Puura, A; Pirhonen, R; Salmelin, R; Haanpaa, M; Kujansuu, E; Yli-Hankala, A			Gabapentin for the prevention of postoperative pain after vaginal hysterectomy	PAIN			English	Article						clinical trial; gabapentin; preoperatively; postoperative pain; outcome; cumulative fentanyl; nausea; side effects; surgery; vaginal hysterectomy	INFLAMMATORY PAIN; NEURONTIN; MORPHINE; PLACEBO; S-(+)-3-ISOBUTYLGABA; ANALGESIA; EFFICACY; SUBUNIT; SURGERY; SAFETY	Gabapentin alleviates and/or prevents acute nociceptive and inflammatory pain both in animals and volunteers, especially when given before trauma. Gabapentin might also reduce postoperative pain. To test the hypothesis that gabapentin reduces the postoperative need for additional pain treatment (postoperative opioid sparing effect of gabapentin in humans), we gave 1200 mg of gabapentin or 15 mg of oxazepam (active placebo) 2.5 h prior to induction of anaesthesia to patients undergoing elective vaginal hysterectomy in an active placebo-controlled, double blind, randomised study. Gabapentin reduced the need for additional postoperative pain treatment (PCA boluses of 50 mug of fentanyl) by 40% during the first 20 postoperative hours. During the first 2 postoperative hours pain scores at rest and worst pain score (VAS 0-100 mm) were significantly higher in the active placebo group compared to the gabapentin-treated patients. Additionally, pretreatment with gabapentin reduced the degree of postoperative nausea and incidence of vomiting/retching possibly either due to the diminished need for postoperative pain treatment with opioids or because of an anti-emetic effect of gabapentin itself. No preoperative differences between the two groups were encountered with respect to the side effects of the premedication. However, 15 mg oxazepam was more effective in relieving preoperative anxiety than 1200 mg gabapentin. (C) 2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Tampere Univ Hosp, Dept Anaesthesiol & Intens Care, Tampere 33521, Finland; Univ Tampere, Sch Med, Tampere 33500, Finland; Dist Hosp, Dept Anaesthesiol, Mantta 35800, Finland; Dist Hosp, Dept Anaesthesiol, Valkeakoski 37600, Finland; Dist Hosp, Dept Anaesthesiol, Vammala 38201, Finland; Tampere Univ, Dept Biometr, Tampere Sch Publ Hlth, Tampere 33500, Finland; Tampere Univ Hosp, Res Unit, Tampere 33521, Finland; Helsinki Univ Hosp, Pain Clin, Dept Anaesthesia & Intens Care, Helsinki 00029, Finland; Tampere Univ Hosp, Dept Obstet & Gynaecol, Tampere 33521, Finland	Rorarius, MGF (reprint author), Tampere Univ Hosp, Dept Anaesthesiol & Intens Care, POB 2000, Tampere 33521, Finland.	michael.rorarius@pshp.fi					Altman DG, 1999, PRACTICAL STAT MED R; Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; Backonja MM, 2002, NEUROLOGY, V59, pS14, DOI 10.1212/WNL.59.5_suppl_2.S14; BEYDOUN A, 1995, CLIN NEUROPHARMACOL, V18, P469, DOI 10.1097/00002826-199512000-00001; Bjune K, 1996, ACTA ANAESTH SCAND, V40, P399, DOI 10.1111/j.1399-6576.1996.tb04460.x; BLACKBURN A, 1995, J CLIN ANESTH, V7, P103, DOI 10.1016/0952-8180(94)00040-B; Carlton SM, 1998, PAIN, V76, P201, DOI 10.1016/S0304-3959(98)00043-8; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; Eckhardt K, 2000, ANESTH ANALG, V91, P185, DOI 10.1097/00000539-200007000-00035; Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1097/00000539-200210000-00036; Field MJ, 1997, J PHARMACOL EXP THER, V282, P1242; Field MJ, 1997, BRIT J PHARMACOL, V121, P1513, DOI 10.1038/sj.bjp.0701320; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; Gregg AK, 2001, BRIT J ANAESTH, V87, p174P; Guttuso T, 2003, LANCET, V361, P1703, DOI 10.1016/S0140-6736(03)13365-X; Kalso E, 1996, ACTA ANAESTH SCAND, V40, P397, DOI 10.1111/j.1399-6576.1996.tb04459.x; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; Luo ZD, 2001, J NEUROSCI, V21, P1868, DOI 10.1523/JNEUROSCI.21-06-01868.2001; Mellegers MA, 2001, CLIN J PAIN, V17, P284, DOI 10.1097/00002508-200112000-00002; MOON DE, 1999, 9 WORLD C PAIN VIENN, P525; Nicholson B, 2000, ACTA NEUROL SCAND, V101, P359, DOI 10.1034/j.1600-0404.2000.0006a.x; Ottosen C, 2000, BRIT J OBSTET GYNAEC, V107, P1380; Pande AC, 2000, J CLIN PSYCHOPHARM, V20, P467, DOI 10.1097/00004714-200008000-00011; Patel S, 2001, PAIN, V90, P217, DOI 10.1016/S0304-3959(00)00404-8; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; RADULOVIC LL, 1995, DRUG METAB DISPOS, V23, P441; RAMSAY RE, 1994, NEUROLOGY, V44, P23; RORARIUS MGF, 1993, BRIT J ANAESTH, V70, P293, DOI 10.1093/bja/70.3.293; RORARIUS MGF, 1992, EUR J PAIN, V13, P109; Rowbotham M, 1998, JAMA-J AM MED ASSOC, V280, P1837, DOI 10.1001/jama.280.21.1837; Saria A, 1999, EUR J PHARMACOL, V375, P51, DOI 10.1016/S0014-2999(99)00259-9; Shimoyama N, 1997, NEUROSCI LETT, V222, P65, DOI 10.1016/S0304-3940(97)13331-6; Soriano D, 2001, ACTA OBSTET GYN SCAN, V80, P337, DOI 10.1034/j.1600-0412.2001.080004337.x; Stanfa LC, 1997, NEUROREPORT, V8, P587, DOI 10.1097/00001756-199702100-00002; STUBHAUG A, 1995, PAIN, V62, P111, DOI 10.1016/0304-3959(95)00056-X; Viteri C, 2002, REV NEUROLOGIA, V34, P292, DOI 10.33588/rn.3403.2001526; WELTY DF, 1993, EPILEPSY RES, V16, P175, DOI 10.1016/0920-1211(93)90078-L; Werner MU, 2001, REGION ANESTH PAIN M, V26, P322, DOI 10.1053/rapm.2001.25070; Yoon MH, 1999, ANESTHESIOLOGY, V91, P1006, DOI 10.1097/00000542-199910000-00021; Yoon MH, 1999, ANESTH ANALG, V89, P434, DOI 10.1097/00000539-199908000-00034	40	107	111	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	JUL	2004	110	1-2					175	181		10.1016/j.pain.2004.03.023			7	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	845HL	WOS:000223232800021	15275765				2020-06-30	J	Reynolds, L; Rauck, R; Webster, L; DuPen, S; Heinze, E; Portenoy, R; Katz, N; Charapata, S; Wallace, M; Fisher, DM				Reynolds, L; Rauck, R; Webster, L; DuPen, S; Heinze, E; Portenoy, R; Katz, N; Charapata, S; Wallace, M; Fisher, DM			Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain	PAIN			English	Article						opioids; fentanyl; sufentanil; target-controlled infusion; opioids	CANCER PAIN; PHARMACOKINETICS; MODEL; PHARMACODYNAMICS; IDENTIFICATION; PUMP	Sufentanil, a potent mu-opioid agonist, historically has not been been given systemically to treat chronic pain. An implantable, fixed-rate osmotic pump that delivers sufentanil subcutaneously is being developed for this purpose. In that transdermal fentanyl may be a useful intermediary to estimate the appropriate sufentanil dose before implant, accurate information is needed about the relative analgesic potency of sufentanil and fentanyl during continuous infusion. To determine this relative potency, we administered these drugs to opioid-treated chronic pain patients using a target-controlled infusion (TCI). Sixty-three patients with stable chronic pain and daily oral opioid requirements equivalent to 100-1000 mg of morphine received TCI of fentanyl and sufentanil, each for a minimum of 16 h. Drug administration was double-blind and the order of administration was randomly assigned. Target concentration was changed until the patient reported that analgesia was adequate (defined as a pain level equal to or better than baseline). Seven patients did not complete the infusion and protocol violations invalidated data for 15 patients. For the remaining 41 patients, target concentrations associated with adequate analgesia were achieved for both sufentanil and fentanyl. The median value for the equianalgesic concentration ratio (steady-state fentanyl infusion to steady-state sufentanil infusion) was 7.5; mean potency ratio was 7.44 (95% confidence interval 6.8-8.2). During titrated, intermediate-term infusions in patients previously treated with opioids for chronic pain, sufentanil is approximately 7.5 times as potent as fentanyl. (C) 2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	DURECT Corp, Cupertino, CA 95014 USA; Loma Linda Univ, Sch Med, Ctr Pain Management, Loma Linda, CA USA; Bowman Gray Sch Med, Clin Res Ctr, Winston Salem, NC USA; Wasatch Clin Res Pain & Stress Clin, Salt Lake City, UT USA; Cynergy Grp, Bainbridge Isl, WA USA; Radiant Res, Austin, TX USA; Beth Israel Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Pain Management Associates, Kansas City, MO USA; Univ Calif San Diego, Dept Anesthesia, San Diego, CA 92103 USA	Fisher, DM (reprint author), DURECT Corp, 10261 Bubb Rd, Cupertino, CA 95014 USA.	fisher@plessthan.com					Barr J, 2001, ANESTHESIOLOGY, V95, P286, DOI 10.1097/00000542-200108000-00007; Derby S, 1998, CNS DRUGS, V9, P99, DOI 10.2165/00023210-199809020-00003; Feierman DE, 1996, ANESTH ANALG, V82, P936, DOI 10.1097/00000539-199605000-00008; Fisher DM, 2003, ANESTHESIOLOGY, V99, P929, DOI 10.1097/00000542-200310000-00028; GEPTS E, 1995, ANESTHESIOLOGY, V83, P1194, DOI 10.1097/00000542-199512000-00010; Kampe S, 2001, ANAESTHESIA, V56, P1189; Mandema JW, 1996, BRIT J CLIN PHARMACO, V42, P747, DOI 10.1046/j.1365-2125.1996.00481.x; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SHAFER SL, 1992, J PHARMACOKINET BIOP, V20, P147, DOI 10.1007/BF01070999; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; Tateishi T, 1996, ANESTH ANALG, V82, P167; Thomson IR, 2000, J CARDIOTHOR VASC AN, V14, P652, DOI 10.1053/jcan.2000.18307	15	17	20	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	JUL	2004	110	1-2					182	188		10.1016/j.pain.2004.03.024			7	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	845HL	WOS:000223232800022	15275766				2020-06-30	J	Martucci, C; Panerai, AE; Sacerdote, P				Martucci, C; Panerai, AE; Sacerdote, P			Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses	PAIN			English	Article						analgesics; opioid drugs; tolerance; cytokines; natural killer activity	MACROPHAGE CYTOKINE PRODUCTION; KILLER-CELL CYTOTOXICITY; MU-OPIOID RECEPTOR; TOLERANCE DEVELOPMENT; MORPHINE TREATMENT; NERVOUS-SYSTEM; MICE; MODULATION; TRAMADOL; EFFICACY	It is known that morphine has a negative impact on the immune responses. The potent opioids fentanyl and buprenorphine have recently become available as transdermal preparation for the treatment of chronic pain. We analyze the effect of fentanyl and buprenorphine on splenic cellular immune responses in the mouse. The parameters evaluated were lymphoproliferation, natural killer cell activity and interleukin-2 and interferon-gamma production. Drugs were administered acutely at the equianalgesic doses of 0.25 mg/kg for fentanyl and 5 mg/kg for buprenorphine, or delivered continuously with osmotic pumps for 24 h, 3 and 7 days at the rate of 7.5 mug/h per mouse (fentanyl) and 12.5 mug/h per mouse (buprenorphine). After acute administration, a significant decrease of lymphoproliferation is observed in fentanyltreated animals only. After 24 It of fentanyl administration all the parameters were significantly reduced. After 3 days of fentanyl infusion NK activity had returned to normal values, while all the other parameters were still significantly reduced. In 7 day fentanyl-treated animals immunological tolerance had developed, since no differences with controls were present. In contrast no immune alterations were ever present in buprenorphine-treated animals. No tolerance to the antinociceptive effect of drugs had yet developed. After 1 week of infusion with fentanyl and buprenorphine, new pumps were implanted releasing double amounts of drugs. Neither fentanyl nor buprenorphine-treated animals showed altered immune responses at any time considered. These results indicate that fentanyl and buprenorphine exert different immune effects. Opioid-induced immunosuppression is less relevant in chronic administration than in acute or short-time administration. (C) 2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Univ Milan, Dept Pharmacol, I-20129 Milan, Italy	Sacerdote, P (reprint author), Univ Milan, Dept Pharmacol, Via Vanvitelli 32, I-20129 Milan, Italy.	paola.sacerdote@unimi.it					Alicea C, 1996, J NEUROIMMUNOL, V64, P83, DOI 10.1016/0165-5728(95)00159-X; ALONZO N, 2003, J PHARMACOL EXP THER, V2, P793; BOAS RA, 1985, BRIT J ANAESTH, V57, P192, DOI 10.1093/bja/57.2.192; Chan KW, 1997, EUR J PHARMACOL, V319, P225, DOI 10.1016/S0014-2999(96)00960-0; D'Elia M, 2003, CLIN IMMUNOL, V109, P179, DOI 10.1016/S1521-6616(03)00177-3; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; Eisenstein TK, 1998, J NEUROIMMUNOL, V83, P36, DOI 10.1016/S0165-5728(97)00219-1; Evans HC, 2003, DRUGS, V63, P1999, DOI 10.2165/00003495-200363190-00003; Fecho K, 1996, J PHARMACOL EXP THER, V276, P626; Flores LR, 1996, EUR J PHARMACOL, V318, P437, DOI 10.1016/S0014-2999(96)00788-1; FREIER DD, 1994, J PHARMACOL EXP THER, V277, P633; Gomez-Flores R, 2000, IMMUNOPHARMACOLOGY, V48, P145, DOI 10.1016/S0162-3109(00)00198-3; Jacobs R, 1999, INT J IMMUNOPHARMACO, V21, P445, DOI 10.1016/S0192-0561(99)00025-9; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Limiroli E, 2002, J LEUKOCYTE BIOL, V72, P43; McCarthy L, 2001, DRUG ALCOHOL DEPEN, V62, P111, DOI 10.1016/S0376-8716(00)00181-2; PACIFICI R, 1994, J PHARMACOL EXP THER, V269, P1112; PARONIS CA, 1994, PSYCHOPHARMACOLOGY, V114, P601, DOI 10.1007/BF02244991; Risdahl JM, 1998, J NEUROIMMUNOL, V83, P4, DOI 10.1016/S0165-5728(97)00216-6; RUFF CG, 2003, J NEUROIMMUNOL, V134, P72; Sacerdote P, 1997, PAIN, V72, P325, DOI 10.1016/S0304-3959(97)00055-9; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Sacerdote P, 1997, BRIT J PHARMACOL, V121, P834, DOI 10.1038/sj.bjp.0701138; Sacerdote P, 2000, BLOOD, V95, P2031, DOI 10.1182/blood.V95.6.2031; Wang JH, 2002, J LEUKOCYTE BIOL, V71, P782; West JP, 1997, DRUG ALCOHOL DEPEN, V46, P147, DOI 10.1016/S0376-8716(97)00059-8; West JP, 1998, DRUG ALCOHOL DEPEN, V53, P31, DOI 10.1016/S0376-8716(98)00109-4; Will H., 1999, PSYCHOTHER SOZ, V1, P105; YEAGER MP, 1995, ANESTHESIOLOGY, V83, P500, DOI 10.1097/00000542-199509000-00008; YEAGER MP, 1991, ARCH SURG-CHICAGO, V126, P454; Yeager MP, 2002, ANESTH ANALG, V94, P94, DOI 10.1097/00000539-200201000-00018	31	90	98	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	JUL	2004	110	1-2					385	392		10.1016/j.pain.2004.04.020			8	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	845HL	WOS:000223232800046	15275790				2020-06-30	J	Teo, AYH; Goy, RWL; Woon, YS				Teo, AYH; Goy, RWL; Woon, YS			Combined spinal-epidural technique for vaginal hysterectomy in a patient with Machado-Joseph disease	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article						combined spinal-epidural technique; Machado-Joseph disease; spinocerebellar ataxia; pulmonary aspiration	MULTIPLE-SCLEROSIS; SYSTEM; ATAXIA	Objective: Machado-Joseph disease is a form of progressive spino-cerebellar ataxia with both bulbar and peripheral neurological manifestations. To date, anesthesia for patients affected by this disease has not been described. General anesthesia may be problematic because of the risk of pulmonary aspiration and hypoxia. We describe our experience with the successful use of combined spinal-epidural in a patient with Machado-Joseph Disease (MJD). Case Report: A 38-year-old woman with MJD complicated by significant bulbar and peripheral neuropathy presented for an elective vaginal hysterectomy. She bad no other medical history of note. After informed consent, subarachnoid block was performed by combined spinal-epidural anesthesia at the L2-3 lumbar intervertebral space with hyperbaric bupivacaine 12 mg, morphine 100 mug, and fentanyl 10 mug. Surgery proceeded uneventfully, with excellent postoperative analgesia. There was full recovery of preinduction neurologic function by the sixth postoperative hour. Conclusions: Central neuraxial anesthesia is an option for patients with MJD presenting for lower abdominal and lower extremity operations. Combined spinal-epidural anesthesia confers hemodynamic stability yet allows for augmentation of intraoperative anesthesia and postoperative analgesia.	Natl Univ Singapore Hosp, Dept Anaesthesia & Surg Intens Care, Singapore 117548, Singapore; KK Women & Childrens Hosp, Dept Anesthesia, Singapore, Singapore	Teo, AYH (reprint author), Natl Univ Singapore Hosp, Dept Anaesthesia & Surg Intens Care, Singapore 117548, Singapore.	al2001.vin@yahoo.com					Gaspar C, 2001, AM J HUM GENET, V68, P523, DOI 10.1086/318184; Isozaki E, 2002, J NEUROL SCI, V197, P37, DOI 10.1016/S0022-510X(02)00046-1; Jardim LB, 2001, ARCH NEUROL-CHICAGO, V58, P899, DOI 10.1001/archneur.58.6.899; KINOSHITA A, 1995, J NEUROL SCI, V130, P48, DOI 10.1016/0022-510X(94)00285-V; Kobayashi T, 2003, CYTOGENET GENOME RES, V100, P261, DOI 10.1159/000072862; LIU KP, 2000, EUR NEUROL, V48, P210; MORGAN GEJ, 1996, [No title captured], P505; SAKURAI M, 1992, NEUROLOGY, V42, P2088, DOI 10.1212/WNL.42.11.2088; Soong BW, 1997, ANN NEUROL, V41, P446, DOI 10.1002/ana.410410407; Subramony SH, 2002, MOVEMENT DISORD, V17, P1068, DOI 10.1002/mds.10241; SUDARSKY L, 1995, CLIN NEUROSCI, V3, P17; Takiyama Y, 1997, NEUROLOGY, V49, P604, DOI 10.1212/WNL.49.2.604; Vadalouca A, 2002, REGION ANESTH PAIN M, V27, P540, DOI 10.1053/rapm.2002.35148	13	2	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JUL-AUG	2004	29	4					352	354		10.1016/j.rapm.2004.03.011			3	Anesthesiology	Anesthesiology	842FD	WOS:000222987800009	15305255				2020-06-30	J	Ozturk, E; Gokce, M; Gunaydin, B; Babacan, A				Ozturk, E; Gokce, M; Gunaydin, B; Babacan, A			Continuous spinal anesthesia after unintentional dural puncture during attempted epidural anesthesia for mastectomy	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Letter									Gazi Univ, Fac Med, Dept Anesthesiol & Reanimat, Ankara, Turkey	Ozturk, E (reprint author), Gazi Univ, Fac Med, Dept Anesthesiol & Reanimat, Ankara, Turkey.						Ayad S, 2003, REGION ANESTH PAIN M, V28, P512, DOI 10.1016/S1098-7339(03)00393-6; HORLOCKER TT, 1993, ANESTH ANALG, V76, P1015; RAUPEN H, 2001, ANESTHESIOLOGY, V95, P266	3	2	2	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	JUL-AUG	2004	29	4					381	382		10.1016/j.rapm.2004.03.007			2	Anesthesiology	Anesthesiology	842FD	WOS:000222987800022	15305268				2020-06-30	J	Salonia, A; Crescenti, A; Suardi, N; Memmo, A; Naspro, R; Bocciardi, AM; Colombo, R; Da Pozzo, LF; Rigatti, P; Montorsi, F				Salonia, A; Crescenti, A; Suardi, N; Memmo, A; Naspro, R; Bocciardi, AM; Colombo, R; Da Pozzo, LF; Rigatti, P; Montorsi, F			General versus spinal anesthesia in patients undergoing radical retropubic prostatectomy: Results of a prospective, randomized study	UROLOGY			English	Article							RISK-FACTORS; BLOOD-LOSS; RECOVERY; CANCER; HYPOTENSION; PAIN	Objectives. To evaluate the impact of general anesthesia (GA) versus spinal anesthesia (SpA) on intraoperative and postoperative outcome in patients undergoing radical retropubic prostatectomy. Methods. Seventy-two consecutive patients with clinically localized prostate cancer were randomized into group 1 (GA: 34 patients) or group 2 (L2-L3 or L3-L4 SpA: 38 patients) and underwent radical retropubic prostatectomy. The intraoperative and postoperative anesthetic and surgical variables were evaluated. Results. The mean +/- SEM operative time was not significantly different between the two groups (P = 0.43). The overall blood loss was less in group 2 (P = 0.04). The mean +/- SEM postoperative time in the postoperative holding area was significantly shorter after SpA than after GA (P < 0.0001). The perioperative pain outcome in the postoperative holding area was significantly better for group 2 than for group 1 (P = 0.0017), but postoperative pain on day 1 was not significantly different between the two groups. The postoperative sedation score was significantly less in group 2 than in group 1 (P < 0.0001). On day 1, first flatus passed in a significantly larger number of patients in group 2 (P < 0.0001), and the overall gait was greater for group 2 patients (P = 0.02). Conclusions. These results suggest that SpA allows good muscle relaxation and a successful surgical outcome in patients undergoing radical retropubic prostatectomy with pelvic lymphadenectomy for clinically localized prostate cancer. Moreover, SpA results in less intraoperative blood loss, less postoperative pain, and a faster postoperative recovery than GA. (C) 2004 Elsevier Inc.	Univ Vita Salute San Raffaele, Ist Sci H San Raffaele, Cattedra Urol, I-20132 Milan, Italy	Montorsi, F (reprint author), Univ Vita Salute San Raffaele, Ist Sci H San Raffaele, Cattedra Urol, Via Olgettina 60, I-20132 Milan, Italy.		Montorsi, Francesco/AAN-2473-2020; Salonia, Andrea/H-1025-2016; Naspro, Richard/AAP-6154-2020	Salonia, Andrea/0000-0002-0595-7165; Naspro, Richard/0000-0003-2202-8939; Da Pozzo, Luigi Filippo/0000-0002-7051-6980			ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Andreoni C, 2002, J ENDOUROL, V16, P721, DOI 10.1089/08927790260472863; Bromage PR, 1997, ACTA ANAESTH SCAND, V41, P439, DOI 10.1111/j.1399-6576.1997.tb04721.x; Brooks Rebekah R, 2002, AANA J, V70, P449; CARPENTER RL, 1992, ANESTHESIOLOGY, V76, P906, DOI 10.1097/00000542-199206000-00006; Curatolo M, 1996, ANESTH ANALG, V83, P1033, DOI 10.1097/00000539-199611000-00023; DAPOZZO LF, 1995, UROLOGY, V46, P562, DOI 10.1016/S0090-4295(99)80274-X; DAVIS FM, 1987, BRIT J ANAESTH, V59, P561, DOI 10.1093/bja/59.5.561; Faas Ceri L, 2002, AANA J, V70, P441; FRANK SM, 1992, ANESTHESIOLOGY, V77, P252, DOI 10.1097/00000542-199208000-00005; Gaylis FD, 1998, J UROLOGY, V159, P167, DOI 10.1016/S0022-5347(01)64045-X; Gottschalk A, 1998, JAMA-J AM MED ASSOC, V279, P1076, DOI 10.1001/jama.279.14.1076; Hartmann B, 2002, ANESTH ANALG, V94, P1521, DOI 10.1097/00000539-200206000-00027; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; Jellish WS, 2003, ANESTH ANALG, V96, P874, DOI 10.1213/01.ANE.0000049682.48703.44; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; MONTAMAT SC, 1989, NEW ENGL J MED, V321, P303; Oliver SE, 2003, BJU INT, V91, P331, DOI 10.1046/j.1464-410X.2003.04083.x; PC Walsh, 2002, CAMPBELLS UROLOGY, P3107; Sanborn KV, 1996, ANESTHESIOLOGY, V85, P977, DOI 10.1097/00000542-199611000-00004; Scardino PT, 2003, NEW ENGL J MED, V349, P297, DOI 10.1056/NEJMe038109; Sheikh K, 2002, UROLOGY, V59, P378, DOI 10.1016/S0090-4295(01)01588-6; SHIR Y, 1995, UROLOGY, V45, P993, DOI 10.1016/S0090-4295(99)80120-4; SHIR Y, 1994, UROLOGY, V44, P232, DOI 10.1016/S0090-4295(94)80137-1; SHIR Y, 1994, ANESTHESIOLOGY, V80, P49, DOI 10.1097/00000542-199401000-00011; SORENSON RM, 1992, ANESTHESIOLOGY, V77, P1095, DOI 10.1097/00000542-199212000-00009; Stevens RA, 1998, UROLOGY, V52, P213, DOI 10.1016/S0090-4295(98)00147-2; Walsh PC, 2000, UROLOGY, V55, P58, DOI 10.1016/S0090-4295(99)00397-0; Walsh PC, 2000, J UROLOGY, V163, P1802, DOI 10.1016/S0022-5347(05)67547-7; Widman J, 2002, ANESTH ANALG, V95, P1757, DOI 10.1097/00000539-200212000-00053	30	30	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-4295	1527-9995		UROLOGY	Urology	JUL	2004	64	1					95	100		10.1016/j.urology.2004.03.010			6	Urology & Nephrology	Urology & Nephrology	837TL	WOS:000222663100023	15245943				2020-06-30	J	Yackey, M; Ilkiw, JE; Pascoe, PJ; Tripp, LD				Yackey, M; Ilkiw, JE; Pascoe, PJ; Tripp, LD			Effect of transdermally administered fentanyl on the minimum alveolar concentration of isoflurane in cats	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						MAC reduction (minimum alveolar concentration); cats; isoflurane; transdermal fentanyl	DOGS; HALOTHANE; MORPHINE; ENFLURANE; ALFENTANIL; MAC; ANESTHESIA; POTENCY; PATCH	Objective To determine the effect of two doses of fentanyl, administered transdermally, on the minimum alveolar concentration (MAC) of isoflurane in cats. Study design Prospective, randomized study Animals Five healthy, spayed, female cats. Methods Each cat was studied thrice with at least 2 weeks between each study. In study 1, the baseline isoflurane MAC was determined in triplicate for each cat. In studies 2 and 3, isoflurane MAC was determined 24 hours after placement of either a 25 or 50 mug hour(-1) fentanyl patch. In each MAC study, cats were instrumented to allow collection of arterial blood and measurement of arterial blood pressure. Twenty-four hours prior to studies 2 and 3, a catheter was placed and secured in the jugular vein and either a 25 or 50 mug hour(-1) fentanyl patch was placed in random order on the left thorax. Blood samples for plasma fentanyl determination were collected prior to patch placement and at regular intervals up to 144 hours. After determination of MAC in studies 2 and 3, naloxone was administered as a bolus dose (0.1 mg kg(-1)) followed by an infusion (1 mg kg(-1) hour(-1)) and MAC redetermined. Results The baseline isoflurane MAC was 1.51 +/- 0.21% (mean SD). Fentanyl (25 and 50 mug hour(-1)) administered transdermally significantly reduced MAC to 1.25 +/- 0.26 and 1.22 +/- 0.16%, respectively. These MAC reductions were not significantly different from each other. Isoflurane MAC determined during administration of fentanyl 25 mug hour(-1) and naloxone (1.44 +/- 0.16%) and fentanyl 50 mug hour(-1) and naloxone (1.51 +/- 0.19%) was not significantly different from baseline MAC (1.51 0.21%). Conclusions and clinical relevance Fentanyl patches are placed to provide long-lasting analgesia. In order to be effective postoperatively, fentanyl patches must be placed prior to surgery. Plasma fentanyl concentrations achieved intraoperatively decrease the need for potent inhalant anesthetics in cats.	Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA	Ilkiw, JE (reprint author), Univ Calif Davis, Sch Vet Med, Dept Surg & Radiol Sci, Davis, CA 95616 USA.	jeilkiw@ucdavis.edu		Pascoe, Peter/0000-0002-7401-2253			Bailey P. L., 1994, ANESTHESIA, P291; BRUECKER KA, 1998, CALIF VET, V52, P18; CHRISTIANSEN TF, 1981, P INT FED CLIN CHEM, V1, P77; DRUMMOND JC, 1983, J AM VET MED ASSOC, V182, P1099; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Golder F. J., 1998, Journal of Veterinary Anaesthesia, V25, P52; HALL RI, 1987, ANESTH ANALG, V66, P1287; Hellyer PW, 1997, SEMIN VET MED SURG, V12, P106, DOI 10.1016/S1096-2867(97)80007-2; ILKIW JE, 1994, CAN J VET RES, V58, P248; Ilkiw JE, 1997, AM J VET RES, V58, P1274; Kyles AE, 1996, AM J VET RES, V57, P715; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P489, DOI 10.1097/00000542-198212000-00010; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; PASCOE PJ, 1993, AM J VET RES, V54, P1327; Pascoe PJ, 1997, AM J VET RES, V58, P1267; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; ScherkNixon M, 1996, J AM ANIM HOSP ASSOC, V32, P19, DOI 10.5326/15473317-32-1-19; SEVERINGHAUS JW, 1966, J APPL PHYSIOL, V21, P1108; SIGGAARDANDERSEN O, 1988, SCAND J CLIN LAB INV, V48, P7; STEFFEY EP, 1994, J VET PHARMACOL THER, V17, P202, DOI 10.1111/j.1365-2885.1994.tb00234.x; STEFFEY EP, 1977, AM J VET RES, V38, P1833; VALVERDE A, 1992, J VET PHARMACOL THER, V15, P91, DOI 10.1111/j.1365-2885.1992.tb00991.x; VALVERDE A, 1989, CAN J ANAESTH, V36, P629, DOI 10.1007/BF03005412; VALVERDE A, 1991, AM J VET RES, V52, P505; WEBB AI, 1987, AM J VET RES, V48, P1733	27	16	16	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1467-2987	1467-2995		VET ANAESTH ANALG	Vet. Anaesth. Analg.	JUL	2004	31	3					183	189		10.1111/j.1467-2987.2004.00125.x			7	Veterinary Sciences	Veterinary Sciences	845JH	WOS:000223238100005	15268689				2020-06-30	J	Apfel, CC; Korttila, K; Abdalla, M; Kerger, H; Turan, A; Vedder, I; Zernak, C; Danner, K; Jokela, R; Pocock, SJ; Trenkler, S; Kredel, M; Biedler, A; Sessler, DI; Roewer, N				Apfel, CC; Korttila, K; Abdalla, M; Kerger, H; Turan, A; Vedder, I; Zernak, C; Danner, K; Jokela, R; Pocock, SJ; Trenkler, S; Kredel, M; Biedler, A; Sessler, DI; Roewer, N		IMPACT Investigators	A factorial trial of six interventions for the prevention of postoperative nausea and vomiting	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 11-15, 2003	SAN FRANCISCO, CA	Amer Soc Anesthesiologists			SUPPLEMENTAL OXYGEN; COST-EFFECTIVENESS; ONDANSETRON; DROPERIDOL; EFFICACY; DEXAMETHASONE; ANESTHESIA; MANAGEMENT; EMPHYSEMA; REDUCE	BACKGROUND Untreated, one third of patients who undergo surgery will have postoperative nausea and vomiting. Although many trials have been conducted, the relative benefits of prophylactic antiemetic interventions given alone or in combination remain unknown. METHODS We enrolled 5199 patients at high risk for postoperative nausea and vomiting in a randomized, controlled trial of factorial design that was powered to evaluate interactions among as many as three antiemetic interventions. Of these patients, 4123 were randomly assigned to 1 of 64 possible combinations of six prophylactic interventions: 4 mg of ondansetron or no ondansetron; 4 mg of dexamethasone or no dexamethasone; 1.25 mg of droperidol or no droperidol; propofol or a volatile anesthetic; nitrogen or nitrous oxide; and remifentanil or fentanyl. The remaining patients were randomly assigned with respect to the first four interventions. The primary outcome was nausea and vomiting within 24 hours after surgery, which was evaluated blindly. Results Ondansetron, dexamethasone, and droperidol each reduced the risk of postoperative nausea and vomiting by about 26 percent. Propofol reduced the risk by 19 percent, and nitrogen by 12 percent; the risk reduction with both of these agents ( i.e., total intravenous anesthesia) was thus similar to that observed with each of the antiemetics. All the interventions acted independently of one another and independently of the patients' baseline risk. Consequently, the relative risks associated with the combined interventions could be estimated by multiplying the relative risks associated with each intervention. Absolute risk reduction, though, was a critical function of patients' baseline risk. CONCLUSIONS Because antiemetic interventions are similarly effective and act independently, the safest or least expensive should be used first. Prophylaxis is rarely warranted in low-risk patients, moderate-risk patients may benefit from a single intervention, and multiple interventions should be reserved for high-risk patients.	Univ Wurzburg, Wurzburg, Germany; Univ Louisville, Louisville, KY 40292 USA; Univ Helsinki, Cent Hosp, Helsinki, Finland; London Sch Hyg & Trop Med, London WC1, England; Univ Klin Mannheim, Mannheim, Germany; Trakya Univ Hosp, Edirne, Turkey; Bodelschwingsche Anstalten Bethel, Bielefeld, Germany; Kreiskrankenhaus Garmisch Partenkirchen, Garmisch Partenkirchen, Germany; Westpfalz Klinikum, Kaiserslautern, Germany; Reiman Univ Hosp, Presov, Slovakia; Univ Saarlandes Kliniken, Homburg, Germany	Apfel, CC (reprint author), Outcomes Res Inst, 501 E Broadway,Suite 210, Louisville, KY 40202 USA.	apfel@ponv.org	Sessler, Daniel/D-3504-2011; Jokela, Ritva/E-1286-2013; Sneyd, John/B-2957-2012	Sessler, Daniel/0000-0001-9932-3077; Kredel, Markus/0000-0003-2183-033X; Sneyd, John/0000-0003-3546-9856	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 061655, R01 GM061655-03, R01 GM061655]		Apfel CC, 2002, BRIT J ANAESTH, V88, P234, DOI 10.1093/bja/88.2.234; Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Apfel CC, 2003, CONTROL CLIN TRIALS, V24, P736, DOI 10.1016/S0197-2456(03)00107-7; Apfel CC, 2002, ACTA ANAESTH SCAND, V46, P921, DOI 10.1034/j.1399-6576.2002.460801.x; Apfel CC, 2002, BRIT J ANAESTH, V88, P659, DOI 10.1093/bja/88.5.659; BREMNER WGM, 1993, BRIT J ANAESTH, V71, P296, DOI 10.1093/bja/71.2.296; Darkow T, 2001, PHARMACOTHERAPY, V21, P540, DOI 10.1592/phco.21.6.540.34543; Divatia JV, 1996, ANESTHESIOLOGY, V85, P1055, DOI 10.1097/00000542-199611000-00014; Gan TJ, 2002, JAMA-J AM MED ASSOC, V287, P1233, DOI 10.1001/jama.287.10.1233; Gan TJ, 2002, ANESTHESIOLOGY, V97, P287, DOI 10.1097/00000542-200207000-00059; Gan TJ, 2003, ANESTH ANALG, V97, P62, DOI 10.1213/01.ANE.0000068580.00245.95; GOLD BS, 1989, JAMA-J AM MED ASSOC, V262, P3008, DOI 10.1001/jama.262.21.3008; Goll V, 2001, ANESTH ANALG, V92, P112, DOI 10.1097/00000539-200101000-00022; Greif R, 1999, ANESTHESIOLOGY, V91, P1246, DOI 10.1097/00000542-199911000-00014; Henzi I, 2000, ANESTH ANALG, V90, P186, DOI 10.1097/00000539-200001000-00038; Hill RP, 2000, ANESTHESIOLOGY, V92, P958, DOI 10.1097/00000542-200004000-00012; Joris JL, 2003, BRIT J ANAESTH, V91, P857, DOI 10.1093/bja/aeg267; Koivuranta M, 1997, ANAESTHESIA, V52, P443, DOI 10.1111/j.1365-2044.1997.117-az0113.x; Kovac AL, 1999, J CLIN ANESTH, V11, P453, DOI 10.1016/S0952-8180(99)00067-7; Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005; Lim BSL, 1999, ANAESTH INTENS CARE, V27, P371, DOI 10.1177/0310057X9902700407; Liu K, 1999, ANESTH ANALG, V89, P1316, DOI 10.1213/00000539-199911000-00046; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; MELNICK B, 1989, ANESTH ANALG, V69, P748; Pierre S, 2002, CAN J ANAESTH, V49, P237, DOI 10.1007/BF03020521; Purhonen S, 2003, ANESTH ANALG, V96, P91, DOI 10.1097/00000539-200301000-00020; Schumann R, 1999, ANESTH ANALG, V89, P796; Scuderi PE, 2000, ANESTH ANALG, V91, P1408, DOI 10.1097/00000539-200012000-00020; Sinclair DR, 1999, ANESTHESIOLOGY, V91, P109, DOI 10.1097/00000542-199907000-00018; Sneyd JR, 1998, EUR J ANAESTH, V15, P433, DOI 10.1097/00003643-199807000-00009; Tang J, 1998, ANESTH ANALG, V86, P274, DOI 10.1097/00000539-199802000-00010; Tramer MR, 2001, ACTA ANAESTH SCAND, V45, P4, DOI 10.1034/j.1399-6576.2001.450102.x; Wang JJ, 2000, ANESTH ANALG, V91, P136, DOI 10.1097/00000539-200007000-00025; Watcha MF, 2000, ANESTHESIOLOGY, V92, P931, DOI 10.1097/00000542-200004000-00007; WATCHA MF, 2002, [No title captured], V20, P471	35	752	809	2	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 10	2004	350	24					2441	2451		10.1056/NEJMoa032196			11	Medicine, General & Internal	General & Internal Medicine	827GH	WOS:000221887200003	15190136	Green Accepted			2020-06-30	J	Tharp, AM; Winecker, RE; Winston, DC				Tharp, AM; Winecker, RE; Winston, DC			Fatal intravenous fentanyl abuse - Four cases involving extraction of fentanyl from transdermal patches	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						fentanyl; patch; intravenous injection; death		The transdermal fentanyl system delivers a specific dose at a constant rate. Even after the prescribed application time has elapsed, enough fentanyl remains within a patch to provide a potentially lethal dose. Death due to the intravenous injection of fentanyl extracted from transdermal patches has not been previously reported. We present 4 cases in which the source of fentanyl was transdermal patches and was injected. In all of these cases, the victim was a white male who died at home. Case 1 was a 35-year-old with no known history of drug use, who was found by his wife on the floor of his workshop. Police recovered a fentanyl patch, needle, and syringe at the scene. Case 2 was a 38-year-old with a known history of drug use whose family claimed that he was in a treatment program that used fentanyl patches for unknown reasons. His brother found him dead in bed, and law enforcement officers found a hypodermic needle beside the body; a ligature around his left hand, and apparent needle marks between his first and second digits were also noted. Case 3 was a 42-year-old with a recent attempted suicide via overdose who was found dead at his home. An empty box of fentanyl patches, Valium, Ritalin, and 2 syringes were found at the scene. Case 4 was a 39-year-old found by his mother, who admitted to removing a needle with attached syringe from the decedent's arm. Medications at the scene included hydrocodone, alprazolam, zolpidem, and fentanyl patches. All reported deaths were attributed to fentanyl intoxication, with blood concentrations ranging from 5 to 27 mug/L.	Wake Forest Univ, Baptist Med Ctr, Dept Pathol, Winston Salem, NC 27157 USA; Off Chief Med Examiner, Chapel Hill, NC USA; Forens Sci Ctr, Tucson, AZ USA; Univ Arizona, Coll Med, Dept Pathol, Tucson, AZ 85721 USA	Tharp, AM (reprint author), Wake Forest Univ, Baptist Med Ctr, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	atharp@wfubmc.edu					Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; DESIO JM, 1993, ANESTHESIOLOGY, V79, P1139, DOI 10.1097/00000542-199311000-00036; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; LAMBING MK, 2001, P SOC FOR TOX NEW OR; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Purucker M, 2000, ANN EMERG MED, V35, P314, DOI 10.1016/S0196-0644(00)70091-6; SNELL KS, 2002, ANN M AM AC FOR SCI; STERNBACH GL, 1992, POSTGRAD MED, V91, P169; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	12	57	61	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-7910			AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	JUN	2004	25	2					178	181		10.1097/01.paf.0000127398.67081.11			4	Medicine, Legal; Pathology	Legal Medicine; Pathology	824IW	WOS:000221681000020	15166776				2020-06-30	J	Bayshev, FK				Bayshev, FK			The sterility of fentanyl vials	ANAESTHESIA			English	Letter									John Radcliffe Hosp, Oxford OX3 9DU, England	Bayshev, FK (reprint author), John Radcliffe Hosp, Oxford OX3 9DU, England.	b@fidel.freeserve.co.uk						0	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	JUN	2004	59	6					627	627		10.1111/j.1365-2044.2004.03825.x			1	Anesthesiology	Anesthesiology	820PJ	WOS:000221401500033	15144322				2020-06-30	J	Yun, MJ; Kim, YC; Lim, YJ; Choi, GH; Ha, M; Lee, JY; Ham, BM				Yun, MJ; Kim, YC; Lim, YJ; Choi, GH; Ha, M; Lee, JY; Ham, BM			The differential flow of epidural local anaesthetic via needle or catheter: A prospective randomized double-blind study	ANAESTHESIA AND INTENSIVE CARE			English	Article						anaesthetic, anesthetic techniques : epidural, needle, catheter, epidurograph	SINGLE; EPIDUROGRAPHY; INJECTIONS; SPACE	The extent of epidural anaesthesia and pattern of spread of contrast medium, using different injection techniques, has not been well documented. Therefore, in this prospective, randomized, double-blind study, the extent of anaesthesia and pattern of spread of contrast medium following an epidural bolus injection, via either a Tuohy needle or an epidural catheter, were compared. The study had two parts. In the first, 59 of 79 patients scheduled for a lower extremity operation under epidural anaesthesia were randomly allocated to one of the two groups. Anaesthesia was achieved with an epidural injection of 10 to 15 ml (including a 3 ml test dose) of 0.75% ropivacaine and fentanyl 25 mug via either a Tuohy needle (Group N, n=31) or a catheter (Group C, n=28). The level of sensory anaesthesia was recorded. In the second part, the remaining 20 patients were randomized to initially receive 5 ml of contrast medium via either a Tuohy needle (Group NE, n=10) or a catheter (Group CE, n=10). The extent of spread was recorded radiologically. Unilateral or missed blocks and additional dose requirement were absent in Groups N and C. No differences were found in the extent of sensory anaesthesia or the spread of contrast medium. Twenty per cent of catheter tips lay outside the lateral margins of the vertebral bodies. We found that an epidural bolus injection, via either a Tuohy needle or a catheter, made no difference in regard to spread of local anaesthetic or contrast medium in the epidural space.	Seoul Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, Seoul 110744, South Korea; Dankook Univ, Coll Med, Cheonan, South Korea	Kim, YC (reprint author), Seoul Natl Univ, Coll Med, Dept Anesthesiol & Pain Med, 28 Yongondong, Seoul 110744, South Korea.		Kim, Yong Chul/J-5421-2012				Arakawa M, 2002, CAN J ANAESTH, V49, P566, DOI 10.1007/BF03017382; ASATO F, 1990, ANESTH ANALG, V70, P662; BERNARDS CM, 1994, ANESTHESIOLOGY, V80, P853, DOI 10.1097/00000542-199404000-00019; Bromage P R, 1965, Acta Anaesthesiol Scand Suppl, V16, P55; CARRIE LES, 1990, BRIT J ANAESTH, V65, P225, DOI 10.1093/bja/65.2.225; COATES MB, 1982, ANAESTHESIA, V37, P89, DOI 10.1111/j.1365-2044.1982.tb01016.x; COLLIS RE, 1993, LANCET, V341, P767, DOI 10.1016/0140-6736(93)90548-U; Hogan Q, 1999, ANESTHESIOLOGY, V90, P964, DOI 10.1097/00000542-199904000-00006; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Hogan QH, 1998, CAN J ANAESTH, V45, pR40, DOI 10.1007/BF03019206; Johnson BA, 1999, AM J NEURORADIOL, V20, P697; Johnson RA, 1996, VET SURG, V25, P448, DOI 10.1111/j.1532-950X.1996.tb01442.x; KIDO DK, 1978, RADIOLOGY, V128, P119, DOI 10.1148/128.1.119; Kim KM, 2001, J KOREAN MED SCI, V16, P193, DOI 10.3346/jkms.2001.16.2.193; Kim YC, 1998, ACTA ANAESTH SCAND, V42, P1092, DOI 10.1111/j.1399-6576.1998.tb05382.x; LAISHLEY RS, 1988, ANAESTHESIA, V43, P100; Lim YJ, 2002, ACTA ANAESTH SCAND, V46, P603, DOI 10.1034/j.1399-6576.2002.460520.x; Magides AD, 1996, ANAESTHESIA, V51, P757, DOI 10.1111/j.1365-2044.1996.tb06202.x; Okutomi T, 2001, REGION ANESTH PAIN M, V26, P450, DOI 10.1053/rapm.2001.24405; Stojanovic MP, 2002, SPINE, V27, P509, DOI 10.1097/00007632-200203010-00011	20	5	5	0	3	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	JUN	2004	32	3					377	382		10.1177/0310057X0403200313			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	830OM	WOS:000222132100012	15264734	Bronze			2020-06-30	J	Bowdle, TA; Even, A; Shen, DD; Swardstrom, M				Bowdle, TA; Even, A; Shen, DD; Swardstrom, M			Methadone for the induction of anesthesia: Plasma histamine concentration, arterial blood pressure, and heart rate	ANESTHESIA AND ANALGESIA			English	Article							MORPHINE; RELEASE; FENTANYL; PHARMACODYNAMICS; PAIN; PHARMACOKINETICS; HEMODYNAMICS; SUFENTANIL; NARCOTICS; HUMANS	Despite the widespread use of methadone for the treatment of acute and chronic pain, the hemodynamic effects of methadone administered by IV bolus have not been studied. We compared the hemodynamic effects of an W bolus of methadone 20 mg with those of fentanyl 10 mug/kg for the induction of anesthesia in combination with etomidate 0.3 mg/kg. Forty-three patients undergoing major surgery were randomized to one of the two treatments in a double-blinded. fashion. Plasma concentrations of histamine were measured before and 2 min after opioid administration. Heart rate and arterial blood pressure were measured via an arterial line just before opioid administration, etomidate administration, and tracheal intubation; during intubation; and 1 min after intubation. There were no significant differences in mean heart rate between the methadone and fentanyl groups at any time point. Systolic and diastolic blood pressures were significantly lower (P < 0.05) in the fentanyl group just before intubation, during intubation, and 1 min after intubation. Mean plasma concentrations of histamine before and after the administration of methadone or fentanyl were 1.54 ng/mL (SD, 0.65 ng/mL) and 1.57 ng/mL (SD, 1.37 ng/mL) or 1.00 ng/mL (SD, 0.58 ng/mL) and 1.04 ng/mL (SD, 0.47 ng/mL), respectively. Despite the lack of a significant change in mean plasma concentrations of histamine, substantial increases in plasma histamine occurred in 2 of 23 patients who received methadone. There were no obvious hemodynamic effects associated with histamine concentrations up to 6.2 ng/mL. Methadone appears to have the potential for producing histamine release. Although methadone administration did not produce hemodynamic instability in this study, the possible hemodynamic side effects of histamine release should be considered when IV boluses of methadone are given.	Univ Washington, Div Cardiothorac Anesthesiol & Pharmaceut, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmaceut, Seattle, WA 98195 USA; Univ Washington, Dept Pharm, Seattle, WA 98195 USA	Bowdle, TA (reprint author), Univ Washington, Div Cardiothorac Anesthesiol & Pharmaceut, Dept Anesthesiol, Box 35640, Seattle, WA 98195 USA.	bowdle@u.washington.edu					ATKINS PC, 1980, J ALLERGY CLIN IMMUN, V66, P478, DOI 10.1016/0091-6749(80)90009-3; BEAVEN MA, 1982, ANESTHESIOLOGY, V57, P425, DOI 10.1097/00000542-198211000-00020; BOWDLE TA, 1989, ANESTHESIOLOGY, V70, P26, DOI 10.1097/00000542-198901000-00007; CHUI PT, 1992, ANAESTH INTENS CARE, V20, P46, DOI 10.1177/0310057X9202000109; ENNIS M, 1991, AGENTS ACTIONS, V33, P20, DOI 10.1007/BF01993116; FAHMY NR, 1981, ANESTHESIOLOGY, V55, P329, DOI 10.1097/00000542-198109000-00028; FLACKE JW, 1987, ANESTH ANALG, V66, P723; GOODALE DB, 2003, FREE RADICAL HYPOTHE; GOURLAY GK, 1986, ANESTHESIOLOGY, V64, P322; GOURLAY GK, 1982, ANESTHESIOLOGY, V57, P458, DOI 10.1097/00000542-198212000-00005; INTURRISI CE, 1987, CLIN PHARMACOL THER, V41, P392, DOI 10.1038/clpt.1987.47; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; LORENZ W, 1975, AGENTS ACTIONS, V5, P402, DOI 10.1007/BF01972656; Lotsch J, 2001, ANESTHESIOLOGY, V95, P1329; MOSS J, 1983, ANESTHESIOLOGY, V59, P330, DOI 10.1097/00000542-198310000-00011; PHILBIN DM, 1981, ANESTHESIOLOGY, V55, P292, DOI 10.1097/00000542-198109000-00019; REISINE T, 1996, [No title captured], P521; Richlin D M, 1991, J Clin Anesth, V3, P112, DOI 10.1016/0952-8180(91)90007-A; ROSOW CE, 1984, ANESTHESIOLOGY, V60, P489, DOI 10.1097/00000542-198405000-00020; ROSOW CE, 1982, ANESTHESIOLOGY, V56, P93, DOI 10.1097/00000542-198202000-00003; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; Warner M A, 1991, J Cardiothorac Vasc Anesth, V5, P481, DOI 10.1016/1053-0770(91)90123-B	23	14	14	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2004	98	6					1692	1697		10.1213/01.ANE.0000114085.20751.20			6	Anesthesiology	Anesthesiology	823YK	WOS:000221650100034	15155330				2020-06-30	J	Benrath, J; Brechtel, C; Martin, E; Sandkuhler, J				Benrath, J; Brechtel, C; Martin, E; Sandkuhler, J			Low doses of fentanyl block central sensitization in the rat spinal cord in vivo	ANESTHESIOLOGY			English	Article; Proceedings Paper	31st Annual Meeting of the Society-for-Neuroscience	NOV 10-15, 2001	SAN DIEGO, CA	Soc Neurosci			LONG-TERM POTENTIATION; FIBER-EVOKED POTENTIALS; METHYL-D-ASPARTATE; PROTEIN-KINASE-C; DORSAL-HORN; SYNAPTIC PLASTICITY; OPIOID RECEPTORS; ACUTE TOLERANCE; SUBSTANCE-P; NEURONS	Background: mu-Opioid receptor agonists are strong analgesics. However, their usefulness for preemptive analgesia is controversial. The authors tested antinociceptive and preemptive properties of fentanyl as a mu-opioid receptor agonist in a model of spinal nociception in vivo. Methods: C fiber-evoked potentials were recorded in the superficial laminae I-H of the rat lumbar spinal cord with glass microelectrodes in response to electrical stimulation of the sciatic nerve. High-frequency stimulation was applied on the sciatic nerve to induce long-term potentiation of C fiber-evoked field potentials, a form of central sensitization. To test the effect of fentanyl on acute nociception, fentanyl was infused intravenously at increasing doses (6-192 mug . kg(-1) . h(-1)). One hour after start of infusion, high-frequency stimulation was applied to evaluate effects of fentanyl on the induction of long-term potentiation. Results: In the absence of fentanyl, high-frequency stimulation potentiated C fiber-evoked field potentials to 149 +/- 12% of controls (mean +/- SEM; n = 6) for at least 1 h. Increasing doses of fentanyl led to a significant reduction of C fiber-evoked potentials in a dose-dependent manner. The induction of long-term potentiation was blocked by low doses of fentanyl (infusion 12-48 mug . kg(-1) . h(-1)). At high doses, fentanyl did not block the induction of long-term potentiation (infusion 96-192 mug . kg(-1) . h(-1)). Conclusions: Low doses of fentanyl block the synaptic form of central sensitization in the rat spinal cord in vivo, but higher doses do not have this effect.	Univ Heidelberg, Anasthesiol Klin, Heidelberg, Germany	Benrath, J (reprint author), Univ Vienna, Klin Anasthesie & Allgemeine Intens Med B, AKH, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	justus.benrath@univie.ac.at	Sandkuhler, Jurgen/B-6648-2012	Sandkuhler, Jurgen/0000-0002-5209-485X			AIMONE LD, 1989, PEPTIDES, V10, P1127, DOI 10.1016/0196-9781(89)90003-X; Antognini JF, 1999, ANESTHESIOLOGY, V90, P208, DOI 10.1097/00000542-199901000-00027; ASKITOPOULOU H, 1985, ANESTHESIOLOGY, V63, P255, DOI 10.1097/00000542-198509000-00003; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Crombie IK, 1998, PAIN, V76, P167, DOI 10.1016/S0304-3959(98)00038-4; Fairbanks CA, 2000, J BIOMED SCI, V7, P200, DOI 10.1007/BF02255467; HIROTA N, 1985, NEUROPHARMACOLOGY, V24, P567, DOI 10.1016/0028-3908(85)90065-6; Ikeda H, 2003, SCIENCE, V299, P1237, DOI 10.1126/science.1080659; Ingram S L, 2000, Prog Brain Res, V129, P483; Jevtovic-Todorovic V, 1998, NAT MED, V4, P460, DOI 10.1038/nm0498-460; KANGRGA I, 1991, BRAIN RES, V553, P347, DOI 10.1016/0006-8993(91)90848-P; Kozlowski CM, 2000, NEUROGASTROENT MOTIL, V12, P239, DOI 10.1046/j.1365-2982.2000.00205.x; KUMETA Y, 1988, ANESTHESIOLOGY, V69, P371, DOI 10.1097/00000542-198809000-00014; Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3; LIU XG, 1995, NEUROSCI LETT, V191, P43, DOI 10.1016/0304-3940(95)11553-0; Liu XG, 1998, NEUROSCIENCE, V86, P1209, DOI 10.1016/S0306-4522(98)00107-9; Mao JR, 1999, BRAIN RES REV, V30, P289, DOI 10.1016/S0165-0173(99)00020-X; Martin G, 1997, J NEUROSCI, V17, P11; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Reeh P W, 2000, Prog Brain Res, V129, P39; Sandkuhler J, 2000, PAIN, V88, P113, DOI 10.1016/S0304-3959(00)00424-3; Sandkuhler J, 2000, Prog Brain Res, V129, P81; SCHROEDER JE, 1993, J NEUROSCI, V13, P867; SERRAO JM, 1989, ANESTHESIOLOGY, V70, P780, DOI 10.1097/00000542-198905000-00013; Simon W, 2001, ANESTHESIOLOGY, V94, P1058, DOI 10.1097/00000542-200106000-00021; Terman GW, 2001, J NEUROPHYSIOL, V85, P485; Vahle-Hinz C, 2001, ANESTH ANALG, V92, P1578, DOI 10.1097/00000539-200106000-00046; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0	30	21	24	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUN	2004	100	6					1545	1551		10.1097/00000542-200406000-00030			7	Anesthesiology	Anesthesiology	822PE	WOS:000221551300029	15166577	Green Published			2020-06-30	J	Demarosi, F; Lodi, G; Soligo, D; Sardella, A; Della Volpe, A; Carrassi, A; Deliliers, GL				Demarosi, F; Lodi, G; Soligo, D; Sardella, A; Della Volpe, A; Carrassi, A; Deliliers, GL			Transdermal fentanyl in HSCT patients: an open trial using transdermal fentanyl for the treatment of oral mucositis pain	BONE MARROW TRANSPLANTATION			English	Article						fentanyl; mucositis; pain; stem cell transplantation	LONG-TERM TREATMENT; CANCER PAIN; MORPHINE; SYSTEM	Fentanyl is a synthetic opioid that can be delivered through a transdermal therapeutic system (TTS). The aim of this study was to assess the efficacy of fentanyl TTS in treating oral mucositis pain in 75 adult hematopoietic stem cell transplant (HSCT) patients. The analysis was based on 62 patients who developed mucositis. Pain control was assessed by the patients using a visual analogue scale ( VAS) from day 0 to day +33 after HSCT. Fentanyl TTS was administered at the patient's request. In all, 20 patients did not require fentanyl ( group A). The first 22 patients asking for the patch received fentanyl 25 mug/h ( group B) and the subsequent 20 patients received 50 mug/h ( group C). There were no significant differences in pain relief between groups B and C. The expected effect of a decrease in mean pain score ( mean of the VAS scores of all of the patients in the same group each day) following the application of fentanyl TTS was not noted. We can conclude that fentanyl TTS at the doses used in this study may not adequately relieve oral mucositis pain.	Univ Milan, Sch Dent, Dept Med, Unit Oral Pathol & Med, Milan, Italy; Univ Milan, IRCCS, Osped Maggiore, Bone Marrow Transplant Ctr, Milan, Italy	Demarosi, F (reprint author), Dipartimento Med Chirurg & Odontoiatria, Unita Patol & Med Orale, Via Beldiletto 1, I-20142 Milan, Italy.	federica.demarosi@unimi.it	Lodi, Giovanni/C-1049-2013; Sardella, Andrea/C-2671-2012	Lodi, Giovanni/0000-0002-0218-8292; Sardella, Andrea/0000-0003-4491-4640			Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Chapman CR, 1997, PAIN, V71, P213; Demarosi F, 2003, BONE MARROW TRANSPL, V31, pS220; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Eisen D, 1997, SEMIN CUTAN MED SURG, V16, P265, DOI 10.1016/S1085-5629(97)80015-6; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Parulekar W, 1998, ORAL ONCOL, V34, P63, DOI 10.1016/S1368-8375(97)00065-1; Pillitteri LC, 1998, BONE MARROW TRANSPL, V22, P495, DOI 10.1038/sj.bmt.1701370; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Strupp C, 2000, ONCOL REP, V7, P659	14	15	16	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0268-3369	1476-5365		BONE MARROW TRANSPL	Bone Marrow Transplant.	JUN	2004	33	12					1247	1251		10.1038/sj.bmt.1704515			5	Biophysics; Oncology; Hematology; Immunology; Transplantation	Biophysics; Oncology; Hematology; Immunology; Transplantation	827EK	WOS:000221881700014	15094750	Bronze			2020-06-30	J	Nishiyama, T; Hanaoka, K				Nishiyama, T; Hanaoka, K			The A-line ARX index may be a more sensitive detector of arousal than the bispectral index during propofol-fentanyl-nitrous oxide anesthesia: a preliminary investigation	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							AUDITORY-EVOKED POTENTIALS; SPECTRAL EDGE FREQUENCY; GENERAL-ANESTHESIA; MEDIAN FREQUENCY; ELECTROENCEPHALOGRAM; ALFENTANIL; INDUCTION; MIDAZOLAM; PREDICTION; VOLUNTEERS	Purpose: To compare changes in the A-line ARX index (AAI) by the Alaris AEP monitor(TM) with those of the bispectral index (BIS) during propofol-fentanyl-nitrous oxide anesthesia. Methods: Eighty female patients undergoing partial mastectomy were randomly allocated to AN or BIS (40 per group). Anesthesia was induced with propofol 2 mg(.)kg(-1) and fentanyl 3 mug(.)kg(-1) during the inhalation of oxygen. A laryngeal mask airway (LMA) #3 was inserted. Anesthesia was maintained with propofol 4 mg(.)kg(-1.)hr(-1), fentanyl 1 mug(.)kg(-1) given at the start of surgery, and nitrous oxide 4 L(.)min(-1) in oxygen 2 L(.)min(-1). Blood pressure, heart rate, and AAI or BIS were monitored, including recovery time of the index after disturbance by electrocautery. Results: The AN but not the BIS increased significantly with LMA insertion and skin incision, while blood pressure and heart rate did not change. The BIS decreased from 87 +/- 7 to 30-60 while the AN decreased from 75 +/- 8 to 10-25 during anesthesia. The increase of the AN was larger than that of the BIS at recovery from anesthesia. The variation of the index was smaller in the AAI than in the BIS. Recovery time of the index after electrocautery was significantly longer in the BIS group (21 +/- 9 sec) than that in the AAI group (5 +/- 3 sec). Conclusions: During propofol-fentanyl-nitrous oxide anesthesia, the AN responded to LMA insertion or surgical incision, but not the BIS, and the AAI had smaller variations. The AAI recovered faster from the disturbance by electrocautery than the BIS. Thus, the AAI may be a more sensitive and useful detector of arousal than the BIS.	Univ Tokyo, Fac Med, Dept Anesthesiol, Tokyo, Japan	Nishiyama, T (reprint author), 3-2-6-603 Kawaguchi, Kawaguchi, Saitama 3320015, Japan.	nishit-tky@umin.ac.jp					BARNETT TP, 1971, SCIENCE, V172, P401, DOI 10.1126/science.172.3981.401; Barr G, 2000, BRIT J ANAESTH, V84, P749; Barr G, 2002, ANAESTHESIA, V57, P736, DOI 10.1046/j.1365-2044.2002.02693.x; Doi M, 1999, BRIT J ANAESTH, V82, P203, DOI 10.1093/bja/82.2.203; Doi M, 1997, BRIT J ANAESTH, V78, P180; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Hans P, 2001, ANAESTHESIA, V56, P999, DOI 10.1046/j.1365-2044.2001.01974-4.x; Iselin-Chaves IA, 2000, ANESTHESIOLOGY, V92, P1300, DOI 10.1097/00000542-200005000-00018; Jensen EW, 1996, METHOD INFORM MED, V35, P256; JONES JG, 1988, ANAESTH ROUNDS, V21, P1; KEARSE LA, 1994, ELECTROEN CLIN NEURO, V90, P194, DOI 10.1016/0013-4694(94)90091-4; Kreuer S, 2003, BRIT J ANAESTH, V91, P336, DOI 10.1093/bja/aeg189; Kurehara Koukichi, 2002, Masui, V51, P642; Litvan H, 2002, ANESTHESIOLOGY, V97, P351, DOI 10.1097/00000542-200208000-00011; Liu J, 1996, ANESTHESIOLOGY, V84, P64, DOI 10.1097/00000542-199601000-00007; Nieuwenhuijs D, 2002, ANESTH ANALG, V94, P125, DOI 10.1097/00000539-200201000-00024; PICKWORTH WB, 1990, MIL MED, V155, P166; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Rundshagen I, 2002, BRIT J ANAESTH, V89, P376, DOI 10.1093/bja/aef199; SCHWENDER D, 1993, BRIT J ANAESTH, V71, P622, DOI 10.1093/bja/71.5.622; SCHWENDER D, 1993, INT ANESTHESIOL CLIN, V31, P89, DOI 10.1097/00004311-199331040-00009; Sleigh JW, 1999, BRIT J ANAESTH, V82, P666; THORNTON C, 1991, EUR J ANAESTH, V8, P89; Tooley MA, 1996, BRIT J ANAESTH, V77, P720; VERNON JM, 1995, ANESTH ANALG, V80, P780, DOI 10.1097/00000539-199504000-00023; White M, 1999, BRIT J ANAESTH, V82, P333, DOI 10.1093/bja/82.3.333	26	12	17	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JUN-JUL	2004	51	6					539	544		10.1007/BF03018394			6	Anesthesiology	Anesthesiology	832ZU	WOS:000222307000003	15197114	Bronze			2020-06-30	J	Chua, SMH; Sia, ATH				Chua, SMH; Sia, ATH			Automated intermittent epidural boluses improve analgesia induced by intrathecal fentanyl during labour	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							ANESTHESIA; INFUSION	Purpose: We compared the efficacy of epidural continual intermittent boluses (CIB) with a continuous epidural infusion (CEI) in prolonging labour analgesia induced by the combined spinal epidural (CSE) technique. Methods: CSE was instituted in 42 nulliparous parturients at the L3 to 4 level with intrathecal (IT) fentanyl 25 mug followed by an epidural test dose of 3 mL of 1.5% lidocaine. These parturients were then randomly assigned to receive either epidural CIB (n = 21) or CEI (n = 21) with 0.1% ropivacaine and fentanyl 2 mug(.)mL(-1). For the CIB, 5 mL boluses were given hourly, with the first bolus 30 min postinduction. CEI at the rate of 5 mL(.)hr(-1) was initiated in the minute after CSE. The duration of analgesia, pain score, degree of sensorimotor block were compared. Results: From Kaplan Meier survival analysis, the duration of analgesia was significantly longer in CIB (mean survival time 239 +/- SD 24 min vs 181 +/- 17, P < 0.05 using log rank test). During the first three hours postblock, the median sensory block to cold was higher in CIB (P < 0.05, Mann U Whitney test) but no difference in blood pressure was detected [P > 0.05, repeated measure analysis of variance (RMANOVA)]. The serial pain scores were lower in the CIB (P < 0.05, RMANOVA). Conclusion: CIB prolonged the duration and improved the quality of analgesia. CIB could have resulted in an improved spread of analgesics in the epidural space or encouraged a direct passage of infusate into the IT space. This could have also rendered a higher sensory block to cold in the CIB group. CIB is a good alternative to CEI for the maintenance of epidural analgesia after CSE.	Singapore Gen Hosp, Dept Anaesthesia, Singapore 169608, Singapore; KK Women & Childrens Hosp, Singapore, Singapore	Chua, SMH (reprint author), Singapore Gen Hosp, Dept Anaesthesia, Outram Rd, Singapore 169608, Singapore.	sebnjess@singnet.com.sg					Beilin Y, 2002, ANESTH ANALG, V94, P927, DOI 10.1097/00000539-200204000-00029; Bhavani-Shankar K, 2000, ANESTHESIOLOGY, V93, pU214; Gaiser RR, 2000, REGION ANESTH PAIN M, V25, P223, DOI 10.1016/S1098-7339(00)90002-6; Hogan Q, 2002, REGION ANESTH PAIN M, V27, P150, DOI 10.1053/rapm.2002.29748; Kaynar AM, 1999, ANESTH ANALG, V89, P534, DOI 10.1097/00000539-199908000-00063; Leighton BL, 1996, ANESTH ANALG, V83, P526, DOI 10.1097/00000539-199609000-00015; Norris MC, 1999, ANESTH ANALG, V88, P1073, DOI 10.1097/00000539-199905000-00019; Picard J, 2001, REGION ANESTH PAIN M, V26, P588, DOI 10.1053/rapm.2001.25933; Riley ET, 1997, ANESTH ANALG, V84, P346, DOI 10.1097/00000539-199702000-00019; Stienstra R, 1999, ANESTH ANALG, V88, P810, DOI 10.1097/00000539-199904000-00024	10	55	60	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JUN-JUL	2004	51	6					581	585		10.1007/BF03018402			5	Anesthesiology	Anesthesiology	832ZU	WOS:000222307000011	15197122	Bronze			2020-06-30	J	Kuczkowski, KM				Kuczkowski, KM			Spinal anesthesia for Cesarean delivery in a parturient with Arnold-Chiari type I malformation	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter							WOMAN									Heiss JD, 1999, J NEUROSURG, V91, P553, DOI 10.3171/jns.1999.91.4.0553; HULLANDER RM, 1992, ANESTH ANALG, V75, P1025; Landau R, 2003, ANESTH ANALG, V97, P253, DOI 10.1213/01.ANE.0000066312.32029.8B; Semple DA, 1996, ANAESTHESIA, V51, P580, DOI 10.1111/j.1365-2044.1996.tb12570.x; Sicuranza GB, 2003, OBSTET GYNECOL, V102, P1191, DOI 10.1016/S0029-7844(03)00682-3	5	8	9	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JUN-JUL	2004	51	6					639	639		10.1007/BF03018412			1	Anesthesiology	Anesthesiology	832ZU	WOS:000222307000022	15197133	Bronze			2020-06-30	J	Petelenz, M; Gonciarz, M; Macfarlane, P; Rudner, R; Kawecki, P; Musialik, J; Jalowiecki, P; Gonciarz, Z				Petelenz, M; Gonciarz, M; Macfarlane, P; Rudner, R; Kawecki, P; Musialik, J; Jalowiecki, P; Gonciarz, Z			Sympathovagal balance fluctuates during colonoscopy	ENDOSCOPY			English	Article							HEART-RATE; CONSCIOUS SEDATION; COMPLICATIONS; VARIABILITY; MIDAZOLAM; PROPOFOL; HEALTHY; INDEX	Background and Study Aim: Colonoscopy is a common gastroenterological procedure for investigation of the bowel. The main side effects of colonoscopy are pain during investigation, cardiovascular complications and very rarely even death. The aim of this study was to compare the continuous fluctuation of heart rate variability (HRV) components during colonoscopy under normal conditions, analgesia/sedation, and total intravenous anesthesia. Patients and Methods: 37 consecutive patients (aged 35-65), were randomly allocated to three groups: no sedation (control group 1); analgesia/sedation (group 2); and total intravenous anesthesia (group 3). Holter electrocardiography and subsequent frequency domain analysis were undertaken. The low-frequency (LF, 0.04-0.15Hz) and the high-frequency (HF, 0.15-0.40Hz) components were estimated using spectral analysis in the usual way. Normalized units (nu) were calculated from the following equations: LFnu = LF/(LF+HF), and HFnu = HF/(LF+HF). Results: Groups 2 and 3 were found to have a significantly lower HFnu and higher LFnu than group 1 essentially throughout the procedure. A one-way analysis of variance and t-test confirmed that the differences were significant when the colonoscope reached the splenic flexure as were the LF/HF balances at the splenic and hepatic flexures and the cecum. The percentage change in LF/HF was also analyzed, and it was found that in group 3 the mean change was over 136% when the colonoscope reached the sigmoid flexure, which was significantly higher than in the other two groups. Conclusion: Most changes in HRV components occurred during colonoscopy of the left side of the bowel. Analgesia/sedation and total intravenous anesthesia increased HRV by increasing the LF component.	Med Univ Silesia, Dept Internal Med, PL-41200 Sosnowiec, Poland; Univ Glasgow, Cardiol Sect, Div Cardiovasc & Med Sci, Glasgow, Lanark, Scotland; Med Univ Silesia, Dept Anesthesiol Intens Therapy & Emergency Med, Sosnowiec, Poland	Petelenz, M (reprint author), Med Univ Silesia, Dept Internal Med, Pl Medykow 1, PL-41200 Sosnowiec, Poland.	mpet@sla.com.pl		Musialik, Joanna/0000-0002-6146-3805			ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; BIGGER JT, 1995, CIRCULATION, V91, P1936, DOI 10.1161/01.CIR.91.7.1936; Camm AJ, 1996, CIRCULATION, V93, P1043, DOI 10.1016/0044-8486(94)90048-5; DISARIO JA, 1991, AM J GASTROENTEROL, V86, P956; Eckardt VF, 1999, GASTROINTEST ENDOSC, V49, P560, DOI 10.1016/S0016-5107(99)70382-2; Flaishon R, 1997, ANESTHESIOLOGY, V86, P613, DOI 10.1097/00000542-199703000-00013; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; HERMAN LL, 1993, GASTROINTEST ENDOSC, V39, P388, DOI 10.1016/S0016-5107(93)70111-X; Holm C, 1999, EUR J SURG, V165, P755; Holm C, 1998, SCAND J GASTROENTERO, V33, P769; KAMATH M, 1995, P IEEE COMPUT CARDIO, P289; KOMATSU T, 1995, CAN J ANAESTH, V42, P1003, DOI 10.1007/BF03011073; Lazzaroni M, 2003, ENDOSCOPY, V35, P103, DOI 10.1055/s-2003-37012; LOMBARDI F, 1987, AM J CARDIOL, V60, P1239, DOI 10.1016/0002-9149(87)90601-1; MALLIANI A, 1994, AM J CARDIOL, V73, pC3, DOI 10.1016/0002-9149(94)90617-3; Nelson DB, 2002, GASTROINTEST ENDOSC, V55, P307, DOI 10.1067/mge.2002.121883; NotiniGudmarsson AK, 1996, ENDOSCOPY, V28, P283, DOI 10.1055/s-2007-1005454; Petelenz M, 2000, ENDOSCOPY, V32, P683; PODRID PJ, 1990, CIRCULATION, V82, P103; Puchner R, 1996, WIEN KLIN WOCHENSCHR, V108, P142; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Ristikankare M, 2000, GASTROINTEST ENDOSC, V52, P48, DOI 10.1067/mge.2000.105982; Ristikankare M, 2000, SCAND J GASTROENTERO, V35, P990; VARGO J, 2002, SCI SESS HAND DIG DI, P87; Wexner SD, 2001, SURG ENDOSC-ULTRAS, V15, P251, DOI 10.1007/s004640080147; WILLIAMS P, 1989, GRAYS ANATOMY, P1164; WILLIAMS PL, 1989, GRAYS ANATOMY, P1374; Winstanley P, 2002, MED PHARM	29	12	12	0	10	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0013-726X	1438-8812		ENDOSCOPY	Endoscopy	JUN	2004	36	6					508	514		10.1055/s-2004-814402			7	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	828TM	WOS:000221996200004	15202047				2020-06-30	J	Joo, HS; Salasidis, GC; Kataoka, MT; Mazer, CD; Naik, VN; Chen, RB; Levene, RG				Joo, HS; Salasidis, GC; Kataoka, MT; Mazer, CD; Naik, VN; Chen, RB; Levene, RG			Comparison of bolus remifentanil versus bolus fentanyl for induction of anesthesia and tracheal intubation in patients with cardiac disease	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						remifentanil; fentanyl; tracheal intubation; hemodynamic; anesthesia	EARLY EXTUBATION; SURGERY; PROPOFOL; PHARMACOKINETICS; PHARMACODYNAMICS; SEVOFLURANE; BRADYCARDIA; ALFENTANIL; LARYNGOSCOPY; MIDAZOLAM	Objective: Large bolus-dose remifentanil may be advantageous for use during induction of anesthesia because of its short duration of effect. Currently, there are little data on the use of large bolus-dose remifentanil because of reports of severe bradycardia and hypotension. The purpose of this study is to compare the hemodynamic effects of bolus remifentanil versus fentanyl with glycopyrrolate for induction of anesthesia in patients with heart disease. Design: A randomized, double-blinded study. Setting: A tertiary-care academic medical center. Participants: One hundred patients for coronary artery bypass or valvular surgery. Intervention: Subjects received either (1) remifentanil, 5 mug/kg, with glycopyrrolate, 0.2 mg, or (2) fentanyl, 20 mug/kg, with 0.2 mg of glycopyrrolate, and both groups also received midazolam, 70 mug/kg, for induction of anesthesia. Measurements and Main Results: Heart rate, mean arterial pressure, systemic vascular resistance, and cardiac output were similar between the 2 groups during induction of anesthesia and tracheal intubation. The incidence of adverse events such as bradycardia (remifentanil 10%, fentanyl 10%), hypotension (remifentanil 16%, fentanyl 10%), and ischemia (remifentanil 0%, fentanyl 2%) were also similar. A greater percentage of patients in the remifentanil group lost consciousness within 1 minute of opioid administration (86% v 66%, p = 0.034). Conclusion: Remifentanil with glycopyrrolate is associated with rapid and predictable clinical anesthetic effect, cardiac stability, and the ability to blunt the hemodynamic responses to tracheal intubation. Bolus remifentanil may be a feasible alternative to bolus fentanyl for induction of anesthesia in patients with heart disease because of its short duration of action and its ability to blunt the hemodynamic responses to tracheal intubation. (C) 2004 Elsevier Inc. All rights reserved.	Univ Toronto, St Michaels Hosp, Div Cardiovasc Surg, Dept Anesthesia, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Div Cardiovasc Surg, Dept Surg, Toronto, ON M5B 1W8, Canada	Joo, HS (reprint author), Univ Toronto, St Michaels Hosp, Div Cardiovasc Surg, Dept Anesthesia, 30 Bond St, Toronto, ON M5B 1W8, Canada.	hwanjoomd@yahoo.com					Abrams JT, 1996, ANESTH ANALG, V83, P629, DOI 10.1097/00000539-199609000-00034; Altermatt FR, 2000, BRIT J ANAESTH, V84, P696; Barclay K, 2000, ANAESTH INTENS CARE, V28, P403; CODA BA, 1997, OPIOIDS CLIN ANESTHE, P338; Collard E, 1996, J CARDIOTHOR VASC AN, V10, P869, DOI 10.1016/S1053-0770(96)80048-6; DeSouza G, 1997, ANESTHESIOLOGY, V87, P1019, DOI 10.1097/00000542-199710000-00061; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; Egan TD, 1996, ANESTHESIOLOGY, V84, P821, DOI 10.1097/00000542-199604000-00009; GLASS PS, 2000, INTRAVENOUS DRUG DEL, V1, P385; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; GLASS PSA, 1995, J CLIN ANESTH, V7, P558, DOI 10.1016/0952-8180(95)00127-1; Gravel NR, 1999, CAN J ANAESTH, V46, P240, DOI 10.1007/BF03012603; Hall AP, 2000, BRIT J ANAESTH, V84, P100; Howie MB, 2001, ANESTH ANALG, V92, P1084; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; McNeil IA, 2000, BRIT J ANAESTH, V85, P623, DOI 10.1093/bja/85.4.623; Myles PS, 2002, ANESTH ANALG, V95, P805, DOI 10.1097/00000539-200210000-00004; Olivier P, 2000, J CARDIOTHOR VASC AN, V14, P29, DOI 10.1016/S1053-0770(00)90052-1; REITAN JA, 1978, ANESTH ANALG, V57, P31; Shinohara K, 2000, CAN J ANAESTH, V47, P361, DOI 10.1007/BF03020954; Tramer MR, 1997, BRIT J ANAESTH, V78, P642, DOI 10.1093/bja/78.6.642; Wang J, 1998, BRIT J ANAESTH, V81, P994; Wang JYY, 1999, ANAESTH INTENS CARE, V27, P363, DOI 10.1177/0310057X9902700405; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005; Zickmann B, 1996, J CARDIOTHOR VASC AN, V10, P609, DOI 10.1016/S1053-0770(96)80138-8	25	14	20	1	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	JUN	2004	18	3					263	268		10.1053/j.jvca.2004.03.003			6	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	840MR	WOS:000222863400003	15232803				2020-06-30	J	Concha, M; Dagnino, J; Cariaga, M; Aguilera, J; Aparicio, R; Guerrero, M				Concha, M; Dagnino, J; Cariaga, M; Aguilera, J; Aparicio, R; Guerrero, M			Analgesia after thoracotomy: Epidural fentanyl/bupivacaine compared with intercostal nerve block plus intravenous morphine	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						thoracotomy; epidural analgesia; intercostal block; analgesia; postoperative pain; pulmonary function	POSTTHORACOTOMY PAIN RELIEF; POSTOPERATIVE ANALGESIA; FENTANYL; BUPIVACAINE; INFUSIONS; COMPLICATIONS; LUMBAR	Objectives: Intercostal nerve blockade plus intravenous (IV) patient-controlled analgesia (PCA) could be an easier and safer alternative to epidural analgesia for postthoracotomy pain, but information about the efficacy of this technique is scarce. The objective of this randomized study was to compare the quality of analgesia and lung function in 2 groups of patients undergoing pulmonary surgery through a posterolateral thoracotomy. Methods: Two groups were studied: G1 (n = 16) patients received a 5-segment intercostal block plus IV PCA morphine, and G2 (n = 15) patients received a bupivacaine and fentanyl PCA infusion through a thoracic epidural catheter. Resting and dynamic visual analog pain scale (VAS) measurements, forced vital capacity, and forced expiratory volume in 1 second were measured basally, on arrival in the recovery room, then hourly up to 4 hours and then 12, 24 and 48 hours later. Results were analyzed with a 2-way analysis of variance, chi-square, or Fisher exact test. A p value less than or equal to0.05 was considered significant. Results: Resting and dynamic VAS scores were slightly lower in G2 patients, although only resting scores were significant. After the first hour, mean scores were below 4 in both groups. No significant difference was observed between groups in relation to respiratory parameters or side effects. Conclusion: The fact that the difference in pain scores is probably not clinically significant shows that an intercostal block with bupivacaine plus IV morphine PCA is a good alternative for postthoracotomy pain management. (C) 2004 Elsevier Inc. All rights reserved.	Pontificia Univ Catolica Chile, Dept Anesthesiol, Santiago, Chile; Pontificia Univ Catolica Chile, Div Surg, Santiago, Chile	Concha, M (reprint author), Pontificia Univ Catolica Chile, Dept Anesthesiol, POB 114-D, Santiago, Chile.	mconcha@mcd.puc.cl					Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Bloch MB, 2002, ANESTH ANALG, V94, P523, DOI 10.1097/00000539-200203000-00009; Boisseau N, 2001, BRIT J ANAESTH, V87, P564, DOI 10.1093/bja/87.4.564; GEORGE KA, 1991, ANAESTHESIA, V46, P732, DOI 10.1111/j.1365-2044.1991.tb09767.x; Giebler RM, 1997, ANESTHESIOLOGY, V86, P55, DOI 10.1097/00000542-199701000-00009; GUINARD JP, 1992, ANESTHESIOLOGY, V77, P1108, DOI 10.1097/00000542-199212000-00011; KAVANAGH BP, 1994, ANESTHESIOLOGY, V81, P737, DOI 10.1097/00000542-199409000-00028; Kehlet H, 2001, BRIT J ANAESTH, V87, P62, DOI 10.1093/bja/87.1.62; LOPER KA, 1990, ANESTH ANALG, V70, P72; Mahon SV, 1999, ANAESTHESIA, V54, P641, DOI 10.1046/j.1365-2044.1999.00856.x; Miguel R, 1993, J Cardiothorac Vasc Anesth, V7, P529, DOI 10.1016/1053-0770(93)90308-8; Nikolajsen L, 1997, LANCET, V350, P1353, DOI 10.1016/S0140-6736(97)06315-0; PERTTUNEN K, 1992, BRIT J ANAESTH, V68, P474, DOI 10.1093/bja/68.5.474; PERTTUNEN K, 1995, BRIT J ANAESTH, V75, P541, DOI 10.1093/bja/75.5.541; Phillips JMG, 2002, BRIT J ANAESTH, V89, P778, DOI 10.1093/bja/aef260; POWER I, 1994, BRIT J ANAESTH, V72, P224, DOI 10.1093/bja/72.2.224; Richardson J, 1998, ANN THORAC SURG, V65, P300; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010; Salzer GM, 1997, ANN THORAC SURG, V63, P1411, DOI 10.1016/S0003-4975(97)00081-7; SAWCHUK CWT, 1993, ANN THORAC SURG, V55, P1472, DOI 10.1016/0003-4975(93)91090-A; SCOTT DA, 1995, ANESTHESIOLOGY, V83, P727, DOI 10.1097/00000542-199510000-00012; SNEDECOR G, 1980, STAT METHODS, P276; THOMSON CA, 1995, ANESTH ANALG, V81, P973, DOI 10.1097/00000539-199511000-00014; Vaughan RS, 2001, BRIT J ANAESTH, V87, P681, DOI 10.1093/bja/87.5.681; Warner DO, 2000, ANESTHESIOLOGY, V92, P1467, DOI 10.1097/00000542-200005000-00037; WELCHEW EA, 1991, ANAESTHESIA, V46, P438, DOI 10.1111/j.1365-2044.1991.tb11678.x; Wheatley RG, 2001, BRIT J ANAESTH, V87, P47, DOI 10.1093/bja/87.1.47; Wurnig PN, 2002, EUR J CARDIO-THORAC, V21, P1115, DOI 10.1016/S1010-7940(02)00117-3	28	28	31	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	JUN	2004	18	3					322	326		10.1053/j.jvca.2004.03.013			5	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	840MR	WOS:000222863400013	15232813				2020-06-30	J	Nersesyan, H; Hyder, F; Rothman, DL; Blumenfeld, TH				Nersesyan, H; Hyder, F; Rothman, DL; Blumenfeld, TH			Dynamic fMRI and EEG recordings during spike-wave seizures and generalized tonic-clonic seizures in WAG/Rij rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						absence; epilepsy; BOLD; cerebral blood flow; thalamus; bicuculline	CEREBRAL-BLOOD-FLOW; TRIGGERED FUNCTIONAL MRI; ABSENCE SEIZURES; GLUCOSE-METABOLISM; OXYGEN DELIVERY; EPILEPSY; BRAIN; NETWORKS; CORTEX; DISCHARGES	Generalized epileptic seizures produce widespread physiological changes in the brain. Recent studies suggest that "generalized" seizures may not involve the whole brain homogeneously. For example, electrophysiological recordings in WAG/Rij. rats, an established model of human absence seizures, have shown that spike-and-wave discharges are most intense in the perioral somatosensory cortex and thalamus, but spare the occipital cortex. Is this heterogeneous increased neuronal activity matched by changes in local cerebral blood flow sufficient to meet or exceed cerebral oxygen consumption? To investigate this. we per-formed blood oxygen level-dependent functional magnetic resonance imaging (fMRI) measurements at 7T with simultaneous electroencephalogram recordings. During spontaneous spike-wave seizures in WAG/Rij rats under fentanyl-haloperidol anesthesia, we found increased fMRI signals in focal regions including the perioral somatosensory cortex, known to be intensely involved during seizures, whereas the occipital cortex was spared. For comparison, we also studied bicuculline-induced generalized tonic-clonic seizures under the same conditions, and found fMRI increases to be larger and more widespread than during spike-and-wave seizures. These findings suggest that even in regions with intense neuronal activity during epileptic seizures, oxygen delivery exceeds metabolic needs, enabling fMRI to be used for investigation of dynamic cortical and subcortical network involvement in this disorder.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Diagnost Radiol & Biomed Engn, Sect Bioimaging Sci, New Haven, CT 06520 USA; Yale Univ, Sch Med, Magnet Resonance Res Ctr, New Haven, CT 06520 USA	Blumenfeld, TH (reprint author), Yale Univ, Sch Med, Dept Neurol, 333 Cedar St,LLCI 1007, New Haven, CT 06520 USA.	hal.blumenfeld@yale.edu	Hyder, Fahmeed/A-2644-2015	Hyder, Fahmeed/0000-0001-7822-4002	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC-003710]; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-067528]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-037203]		Allen PJ, 2000, NEUROIMAGE, V12, P230, DOI 10.1006/nimg.2000.0599; Andre V, 2002, EPILEPSIA, V43, P1120, DOI 10.1046/j.1528-1157.2002.17702.x; [Anonymous], 1981, Epilepsia, V22, P489; Archer JS, 2003, NEUROLOGY, V60, P415, DOI 10.1212/WNL.60.3.415; AVOLI M, 1990, [No title captured]; Barbier EL, 2001, J MAGN RESON IMAGING, V13, P496, DOI 10.1002/jmri.1073; Benar CG, 2002, NEUROIMAGE, V17, P1182, DOI 10.1006/nimg.2002.1164; Blumenfeld H, 2003, NEUROSCIENTIST, V9, P301, DOI 10.1177/1073858403255624; Blumenfeld H, 2003, NEUROIMAGE, V19, P1556, DOI 10.1016/S1053-8119(03)00204-0; Blumenfeld H, 2003, EPILEPSIA, V44, P7, DOI 10.1046/j.1528-1157.44.s.2.2.x; Blumenfeld H, 2000, J NEUROSCI, V20, P5153; BODE H, 1992, EUR J PEDIATR, V151, P706, DOI 10.1007/BF01957579; COENEN AML, 1992, EPILEPSY RES, V12, P75, DOI 10.1016/0920-1211(92)90029-S; Cohen-Gadol AA, 2003, MAYO CLIN PROC, V78, P238, DOI 10.4065/78.2.238; Coppola R, 1988, ELEMENTS PETIT MAL E, P105; De Simone R, 1998, PEDIATR NEUROL, V18, P132, DOI 10.1016/S0887-8994(97)00165-3; de Vasconcelos AP, 2002, J CEREBR BLOOD F MET, V22, P196, DOI 10.1097/00004647-200202000-00007; Detre JA, 1996, EPILEPSIA, V37, P657, DOI 10.1111/j.1528-1157.1996.tb00630.x; Diehl B, 1998, EPILEPSIA, V39, P1284, DOI 10.1111/j.1528-1157.1998.tb01326.x; Dirnagl U, 1997, ADV EXP MED BIOL, V413, P155; ENGEL J, 1982, SCIENCE, V218, P64, DOI 10.1126/science.6981843; ENGEL J, 1985, ANN NEUROL, V17, P121, DOI 10.1002/ana.410170204; FOLBERGROVA J, 1981, J NEUROCHEM, V37, P1228, DOI 10.1111/j.1471-4159.1981.tb04673.x; Goldman RI, 2000, CLIN NEUROPHYSIOL, V111, P1974, DOI 10.1016/S1388-2457(00)00456-9; HANDFORTH A, 1995, BRAIN RES REV, V20, P1, DOI 10.1016/0165-0173(94)00003-8; Hyder F, 2000, J CEREBR BLOOD F MET, V20, P485, DOI 10.1097/00004647-200003000-00007; HYDER F, 1995, MAGN RESON IMAGING, V13, P97, DOI 10.1016/0730-725X(94)00068-E; Hyder F, 2001, NMR BIOMED, V14, P413, DOI 10.1002/nbm.733; Kida I, 2000, J CEREBR BLOOD F MET, V20, P847, DOI 10.1097/00004647-200005000-00012; KLINGELHOFER J, 1991, NEUROSCI LETT, V127, P77, DOI 10.1016/0304-3940(91)90899-5; KOSTOPOULOS G, 1981, EXP NEUROL, V73, P55, DOI 10.1016/0014-4886(81)90045-5; Krakow K, 1999, BRAIN, V122, P1679, DOI 10.1093/brain/122.9.1679; Lemieux L, 2001, NEUROIMAGE, V14, P780, DOI 10.1006/nimg.2001.0853; MATSUMOTO H, 1964, EXP NEUROL, V9, P305, DOI 10.1016/0014-4886(64)90026-3; Meeren HKM, 2002, J NEUROSCI, V22, P1480, DOI 10.1523/JNEUROSCI.22-04-01480.2002; Meldrum BS, 2002, PROG BRAIN RES, V135, P3; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V28, P10, DOI 10.1001/archneur.1973.00490190028002; Mintun MA, 2001, P NATL ACAD SCI USA, V98, P6859, DOI 10.1073/pnas.111164398; NEHLIG A, 1991, ANN NEUROL, V29, P72, DOI 10.1002/ana.410290113; Nehlig A, 1996, J CEREBR BLOOD F MET, V16, P147, DOI 10.1097/00004647-199601000-00017; NERSESYAN H, 2003, [No title captured]; Norden AD, 2002, EPILEPSY BEHAV, V3, P219, DOI 10.1016/S1525-5050(02)00029-X; OCHS RF, 1987, ANN NEUROL, V21, P458, DOI 10.1002/ana.410210508; Ogawa S, 1998, ANNU REV BIOPH BIOM, V27, P447, DOI 10.1146/annurev.biophys.27.1.447; Opdam HI, 2002, EPILEPSIA, V43, P779, DOI 10.1046/j.1528-1157.2002.04202.x; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pinault D, 1998, J PHYSIOL-LONDON, V509, P449, DOI 10.1111/j.1469-7793.1998.449bn.x; PREVETT MC, 1995, NEUROLOGY, V45, P1396, DOI 10.1212/WNL.45.7.1396; Reinhold H S, 1966, Eur J Cancer, V2, P33, DOI 10.1016/0014-2964(66)90087-9; RODIN E, 1987, ELECTROEN CLIN NEURO, V66, P457, DOI 10.1016/0013-4694(87)90092-7; Rothman DL, 2002, NEUROPSYCHOPHARMACOL, P315; Salek-Haddadi A, 2003, ANN NEUROL, V53, P663, DOI 10.1002/ana.10586; Salek-Haddadi Afraim, 2002, Epilepsia, V43, P123; SANADA S, 1988, PEDIATR NEUROL, V4, P158, DOI 10.1016/0887-8994(88)90003-3; Seeck M, 1998, ELECTROEN CLIN NEURO, V106, P508, DOI 10.1016/S0013-4694(98)00017-0; Shin C, 2000, J CLIN NEUROPHYSIOL, V17, P2, DOI 10.1097/00004691-200001000-00002; Shulman RG, 2002, Q REV BIOPHYS, V35, P287, DOI 10.1017/S0033583502003803; SIMON RP, 1985, EPILEPSIA, V26, pS58, DOI 10.1111/j.1528-1157.1985.tb05725.x; Smith AJ, 2002, P NATL ACAD SCI USA, V99, P10765, DOI 10.1073/pnas.132272199; SOKOLOFF L, 1981, FED PROC, V40, P2311; SPENCER SS, 1995, MAGN RESON IMAGING, V13, P1119, DOI 10.1016/0730-725X(95)02021-K; SPERLING MR, 1995, EPILEPSIA, V36, P156, DOI 10.1111/j.1528-1157.1995.tb00975.x; THEODORE WH, 1985, NEUROLOGY, V35, P684, DOI 10.1212/WNL.35.5.684; Van Camp N, 2003, NEUROIMAGE, V19, P627, DOI 10.1016/S1053-8119(03)00138-1; van Zijl PCM, 1998, NAT MED, V4, P159, DOI 10.1038/nm0298-159; VERGNES M, 1990, BRAIN RES, V523, P87, DOI 10.1016/0006-8993(90)91638-W; Warach S, 1996, NEUROLOGY, V47, P89, DOI 10.1212/WNL.47.1.89; WEIR B, 1965, ELECTROEN CLIN NEURO, V19, P284, DOI 10.1016/0013-4694(65)90208-7; Yang XJ, 1998, P NATL ACAD SCI USA, V95, P7715, DOI 10.1073/pnas.95.13.7715; Yeni SN, 2000, SEIZURE-EUR J EPILEP, V9, P265, DOI 10.1053/seiz.2000.0400	70	111	116	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUN	2004	24	6					589	599		10.1097/01.WCB.0000117688.98763.23			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	826IY	WOS:000221824000001	15181366	Bronze			2020-06-30	J	Liappas, IA; Dimopoulos, NP; Mellos, E; Gitsa, OE; Liappas, AI; Rabavilas, AD				Liappas, IA; Dimopoulos, NP; Mellos, E; Gitsa, OE; Liappas, AI; Rabavilas, AD			Oral transmucosal abuse of transdermal fentanyl	JOURNAL OF PSYCHOPHARMACOLOGY			English	Article						abuse; fentanyl; oral; transdermal; transmucosal	PHARMACOLOGICAL-PROPERTIES; THERAPEUTIC-EFFICACY; PAIN-CONTROL; ABSORPTION; DEATHS	Transdermal fentanyl is an opioid analgesic that is effective on chronic pain, and which appears to be advantageous due to several factors such as ease of administration, the relatively stable serum concentration and tong dose intervals. Nevertheless, the danger of abuse and dependence exists among patients who are prescribed fentanyl patches. We present a case of transdermal fentanyl abuse, where the administration route of the drug was changed. Our patient, who had no history of substance abuse and who suffered from chronic nonmalignant pain, used the fentanyl transdermal patches as oral transmucosal medication, raising the dose by ten-fold. This abuse of the drug was only for analgesic purposes without seeking anxiolysis and/or euphoria. After treatment and progressive reduction of fentanyl, the patient remains in good condition, and is currently taking the initial dose of the drug transdermally, without having experienced any withdrawal symptoms.	Univ Athens, Eginit Hosp, Dept Psychiat, GR-11528 Athens, Greece; Athens Psychiat Hosp Dafni Haidari, Athens, Greece; Laikon Gen Hosp, Dept Gen Practice, Athens, Greece; Univ Cent Lancashire, Sch Biol Sci, Preston PR1 2HE, Lancs, England	Liappas, IA (reprint author), Univ Athens, Eginit Hosp, Dept Psychiat, 72-74 Vas Sophias Ave, GR-11528 Athens, Greece.	drugfree@hol.gr	Ilias, Ioannis/AAA-2927-2020				Berens AIL, 1996, LANCET, V347, P1334, DOI 10.1016/S0140-6736(96)90981-2; BRENNAN M, 2003, PHARM MANAGEMENT BRE; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; DESIO JM, 1993, ANESTHESIOLOGY, V79, P1139, DOI 10.1097/00000542-199311000-00036; HERZ A, 1970, NEUROPHARMACOLOGY, V9, P539, DOI 10.1016/0028-3908(70)90004-3; HIBBS J, 1991, JAMA-J AM MED ASSOC, V265, P1011, DOI 10.1001/jama.265.8.1011; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Joranson DE, 2000, JAMA-J AM MED ASSOC, V283, P1710, DOI 10.1001/jama.283.13.1710; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Radovanovic D, 2002, ARCH ONCOL, V10, P263; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; WARD CF, 1992, ANESTHESIOLOGY, V77, P621, DOI 10.1097/00000542-199210000-00001	17	21	21	0	8	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-8811	1461-7285		J PSYCHOPHARMACOL	J. Psychopharmacol.	JUN	2004	18	2					277	280		10.1177/0269881104042634			4	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	837PZ	WOS:000222649000019	15260918				2020-06-30	J	Romano, MA; McNish, R; Seymour, EM; Traynor, JR; Bolling, SF				Romano, MA; McNish, R; Seymour, EM; Traynor, JR; Bolling, SF			Differential effects of opioid peptides on myocardial ischemic tolerance	JOURNAL OF SURGICAL RESEARCH			English	Article						opioid; myoprotection; ischemia; preconditioning	HIBERNATION INDUCTION TRIGGERS; RECEPTOR; MORPHINE; KAPPA; HEART; CARDIOPROTECTION; ADAPTATION; NEUTROPHIL; ACTIVATION; INJURY	Background. Opioid peptides, which can induce mammalian hibernation, may provide protection against subcellular and molecular changes during hypothermic myocardial ischemia. This study examined the differential effects of the three known myocyte opioid receptors, Mu (mu), Delta (delta), and Kappa (kappa), in augmenting myocardial ischemic tolerance. Methods. Control hearts (CH) were compared to hearts pretreated with either the mu-agonist, fentanyl, the delta-agonist, DADLE, or delta-antagonist, NTB, or the kappa-agonist, U50488H (U50), or kappa-antagonist, nor-BNI. The percent return of isovolemic developed pressure (LVDP), myocardial oxygen consumption (MVO2), and coronary flow (CF) following 2 h of global hypothermic cardioplegic ischemia were recorded in isolated Langendorff perfused hearts. Results. At 45 min of reperfusion, hearts pretreated with either DADLE or U50488H demonstrated significantly improved functional recovery versus controls (P < 0.05) and significantly depressed recovery with NTB or nor-BNI pretreatment (P < 0.05). Pretreatment with fentanyl was not significantly different than controls. Furthermore, DADLE, U50488H, or fentanyl resulted in increased MVO2 versus controls (P < 0.05). There was no difference in CF between all groups. Conclusions. This study demonstrates that the mu-receptor does not appear to confer a beneficial effect. However, selective delta- and kappa-agonists provide significant myocardial protection. Moreover, hearts pretreated with an opioid antagonist showed a marked decrement in both functional and metabolic integrity, These results taken together would imply a positive and negative constitutive role of delta- and kappa-opioids in the regulation of myocardial ischemic tolerance. This utilization of opioid receptor stimulation may have profound clinical applications.	Univ Michigan, Div Cardiac Surg, Ann Arbor, MI 48105 USA; Univ Michigan, Div Pharmacol, Ann Arbor, MI 48105 USA	Bolling, SF (reprint author), Univ Michigan, Div Cardiac Surg, 2120 Taubman Ctr,Box 0348,1500 E Med Ctr Dr, Ann Arbor, MI 48105 USA.	sbolling@umich.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL58781]		Benedict PE, 1999, CIRCULATION, V100, P357; Bofetiado DM, 1996, ANESTH ANALG, V82, P1237, DOI 10.1097/00000539-199606000-00023; Bolling SF, 1997, ANN THORAC SURG, V64, P623, DOI 10.1016/S0003-4975(97)00631-0; Bolling SF, 1997, TRANSPLANTATION, V63, P326, DOI 10.1097/00007890-199701270-00026; Bolling SF, 1998, CIRCULATION, V98, pII220; CHEN Y, 1994, J BIOL CHEM, V269, P7839; CHIEN S, 1994, J THORAC CARDIOV SUR, V107, P964; CHIEN S, 1991, J HEART LUNG TRANSPL, V10, P401; Ela C, 1997, J MOL CELL CARDIOL, V29, P711, DOI 10.1006/jmcc.1996.0313; Horton ND, 1998, COMP BIOCHEM PHYS B, V119, P787, DOI 10.1016/S0305-0491(98)00056-X; Kato R, 2000, BRIT J ANAESTH, V84, P204; Kevelaitis E, 1999, CIRCULATION, V99, P3079, DOI 10.1161/01.CIR.99.23.3079; MAYFIELD KP, 1994, J PHARMACOL EXP THER, V268, P683; MAYFIELD KP, 1994, J PHARMACOL EXP THER, V268, P74; MAYFIELD KP, 1992, BRAIN RES, V582, P226, DOI 10.1016/0006-8993(92)90137-X; MEERSON FZ, 1987, CLIN CARDIOL, V10, P783, DOI 10.1002/clc.4960101202; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; OELTGEN PR, 1988, LIFE SCI, V43, P1565, DOI 10.1016/0024-3205(88)90406-7; Schultz JE, 1998, CIRCULATION, V97, P1282, DOI 10.1161/01.CIR.97.13.1282; Schultz JEJ, 1996, CIRC RES, V78, P1100, DOI 10.1161/01.RES.78.6.1100; Schultz JJ, 1997, J MOL CELL CARDIOL, V29, P2187, DOI 10.1006/jmcc.1997.0454; SCULTZ JE, 1995, AM J PHYSL 2, V268, pH2157; Sigg DC, 2002, AM J PHYSIOL-HEART C, V282, pH1953, DOI 10.1152/ajpheart.01045.2001; Sigg DC, 2001, ANN THORAC SURG, V72, P1576, DOI 10.1016/S0003-4975(01)03084-3; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; Wang GY, 2001, AM J PHYSIOL-HEART C, V280, pH384; Wang TL, 1998, CARDIOVASC RES, V40, P557, DOI 10.1016/S0008-6363(98)00192-8; Wang TL, 1997, AM J CARDIOL, V80, P1532, DOI 10.1016/S0002-9149(97)00788-1; Wu S, 1999, CIRC RES, V84, P1388	29	18	27	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUN 1	2004	119	1					46	50		10.1016/j.jss.2004.01.006			5	Surgery	Surgery	820SN	WOS:000221409700007	15126081				2020-06-30	J	Henke, J; Baumgartner, C; Roltgen, I; Eberspacher, E; Erhardt, W				Henke, J; Baumgartner, C; Roltgen, I; Eberspacher, E; Erhardt, W			Anaesthesia with midazolam/medetomidine/fentanyl in chinchillas (Chinchilla lanigera) compared to anaesthesia with xylazine/ketamine and medetomidine/ketamine	JOURNAL OF VETERINARY MEDICINE SERIES A-PHYSIOLOGY PATHOLOGY CLINICAL MEDICINE			English	Article							DOGS	We studied four different drug regimes for anaesthetic management in chinchillas and evaluated and compared their cardiovascular and respiratory effects. In this randomized, cross-over experimental study, seven adult chinchillas, five females, two males [515 +/- 70 (SD) g] were randomly assigned to one of the following groups: group 1 [midazolam, medetomidine and fentanyl (MMF), flumazenil, atipamezole and naloxone (FAN); MMF-FAN] received 1.0 mg/kg midazolam, 0.05 mg/kg medetomidine and 0.02 mg/kg fentanyl i.m., and for reversal 0.1 mg/kg flumazenil, 0.5 mg/kg atipamezole and 0.05 mg/kg naloxone s.c. after 45 min; group 2 (MMF) 1.0 mg/kg midazolam, 0.05 mg/kg medetomidine and 0.02 mg/kg fentanyl i.m.; group 3 [xylazine/ketamine (X/K)] 2.0 mg/kg xylazine and 40.0 mg/kg ketamine i.m.; and group 4 [medetomidine/ketamine (M/K)] 0.06 mg/kg medetomidine and 5.0 mg/kg ketamine i.m. Reflexes were judged to determine anaesthetic stages and planes. Anaesthesia with X/K and M/K was associated with a prolonged surgical tolerance and recovery period. By reversing MMF, recovery period was significantly shortened (5 +/- 1.3 min versus 40 +/- 10.3 min in MMF without FAN, 73 +/- 15.0 min in X/K, and 31 +/- 8.5 min in M/K). Without reversal, MMF produced anaesthesia lasting 109 +/- 16.3 min. All combinations decreased respiratory and heart rate but compared with X/K and M/K, respiratory and cardiovascular complications were less in the MMF groups. Focussing on the clinical relevance of the tested combinations, completely reversible anaesthesia showed two major advantages: anaesthesia can be antagonized in case of emergency and routinely shortens recovery. In small animals particularly these advantages lead to less complications and discomfort and thus often can be lifesaving. As all analgesic components (medetomidine and fentanyl) are reversed, postoperative analgesia should be provided before reversal of anaesthesia.	Tech Univ Munich, Inst Expt Onkol & Therapieforsch, Arbeitsgrp Expt Chirurg, Munich, Germany	Henke, J (reprint author), Tech Univ Munich, Inst Expt Onkol & Therapieforsch, Arbeitsgrp Expt Chirurg, Munich, Germany.	julia.henke@lrz.tum.de					ALEF M, 1995, NEUE ASPEKTE VETERIN, P75; ANDERSON NL, 1994, SAUNDERS MANUAL SMAL, P1370; DOBROMYLSKYI JP, 2000, PAIN MANAGEMENT ANIM; Erhardt W, 2001, Vet Anaesth Analg, V28, P212, DOI 10.1046/j.1467-2987.2001.temp.doc.x-i1; Erhardt W, 1984, Tierarztl Prax, V12, P391; ERHARDT W, 2000, P 7 WCVA BERN, P102; Frey HH, 1996, LEHRBUCH PHARMAKOLOG, P162; Hall LW, 1991, VET ANAESTHESIA, P58; Hedenqvist P, 2002, VET ANAESTH ANALG, V29, P14, DOI [10.1046/j.1467-2987.2001.00058.x, 10.1046/j.1467-2995.2001.00019.x]; HENKE J, 1998, P AVA SPRING M ED, P70; HENKE J, 1995, TIERAERTZL PRAX, V24, P85; HENKE J, 2002, NARKOSENOTFALLE; HENKE J, 2000, P 7 WCVA BERN, P99; HENKE JU, 1999, P AVA SPRING M NEWC, P45; HOEFER HL, 1994, VET CLIN N AM-SMALL, V24, P103, DOI 10.1016/S0195-5616(94)50005-6; ISENBUGEL E, 1985, HEIMTIERKRANKHEITEN, P100; JEHLE F, 1979, THESIS TH HANNOVER; Kramer S, 1998, TIERARZTL PRAX K H, V26, P129; MASON DE, 1997, FERRETS RABBITS RODE, P378; Merkenschlager M, 1975, Berl Munch Tierarztl Wochenschr, V88, P289; MERO M, 1989, ACTA VET SCAND, P135; NURNBERG A, 2000, P 7 WCVA BERN, P148; ROBERTS U, 1993, NEUE ASPEKTE VETERIN, P295; ROLTGEN I, 2002, THESIS LMU MUNCHEN; SAVOLA JM, 1989, ACTA VET SCAND, P39; SCHALL H, 1990, PRAKT TIERARZT, V71, P15; Schmidt-Oechtering G U, 1992, Tierarztl Prax, V20, P447; VAINIO O, 1989, ACTA VET SCAND, V30, P401; VICKERY RG, 1988, ANESTH ANALG, V67, P611; WRIGHT M, 1982, J AM VET MED ASSOC, V180, P1462	30	25	27	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0931-184X			J VET MED A	J. Vet. Med. Ser. A-Physiol. Pathol. Clin. Med.	JUN	2004	51	5					259	264		10.1111/j.1439-0442.2004.00632.x			6	Veterinary Sciences	Veterinary Sciences	847EP	WOS:000223375800009	15315707				2020-06-30	J	Hunter, RP; Isaza, R; Carpenter, JW; Koch, DE				Hunter, RP; Isaza, R; Carpenter, JW; Koch, DE			Clinical effects and plasma concentrations of fentanyl after transmucosal administration in three species of great ape	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						fentanyl; transmucosal; orangutan (Pongo pygmaeus); chimpanzee (Pan troglodytes); gorilla (Gorilla gorilla)	CITRATE; PHARMACOKINETICS; ABSORPTION	Fentanyl is approved for transmucosal use in the United States as a preanesthetic agent in human pediatric patients and in adults for breakthrough cancer pain. Using this formulation in three species of great ape, including eight orangutans (Pongo pygmaeus), nine chimpanzees (Pan troglodytes), and two gorillas (Gorilla gorilla), fentanyl was offered transmucosally at an intended dose of 10-15 mug/kg based on estimated body weight. The animals were trained to accept and suck slowly on a piece of placebo candy, given as a treat, after an overnight fast. On the day of the study, the animals were given the lollipop formulation of fentanyl. The resulting plasma concentrations of fentanyl supported transmucosal absorption, similar to that reported in humans. This study provides an alternative sedative regimen and yielded half-life data of transmucosal fentanyl in great apes. Although transmucosal fentanyl was a useful adjunct for sedating orangutans and gorillas, its acceptance by chimpanzees before chemical immobilization was suboptimal and unpredictable.	Kansas State Univ, Coll Vet Med, Zool Pharmacol Lab, Dept Anat & Physiol, Manhattan, KS 66506 USA; Kansas State Univ, Coll Vet Med, Dept Clin Sci, Manhattan, KS 66506 USA	Hunter, RP (reprint author), Kansas State Univ, Coll Vet Med, Zool Pharmacol Lab, Dept Anat & Physiol, 129 Coles Hall, Manhattan, KS 66506 USA.		Hunter, Robert P/A-2306-2008	Hunter, Robert P/0000-0003-1224-2376			Dsida RM, 1998, ANESTH ANALG, V86, P66, DOI 10.1097/00000539-199801000-00013; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Feierman DE, 2000, ACTA ANAESTH SCAND, V44, P560, DOI 10.1034/j.1399-6576.2000.00513.x; GIBALDI M, 1982, PHARMOKINETICS; Kearns KS, 2000, J ZOO WILDLIFE MED, V31, P185, DOI 10.1638/1042-7260(2000)031[0185:OIOAWD]2.0.CO;2; KEARNS KS, 1999, ZOO BIOL, V18, P387; Koch DE, 2004, J PHARMACEUT BIOMED, V34, P577, DOI 10.1016/S0731-7085(03)00652-6; RIVIERE JE, 1999, [No title captured]; SILVERSTEIN JH, 1993, ANESTH ANALG, V76, P618; STREISAND JB, 1995, ANESTHESIOLOGY, V82, P759, DOI 10.1097/00000542-199503000-00018; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Tateishi T, 1995, BIOCHEM PHARMACOL, V50, P1921, DOI 10.1016/0006-2952(95)02088-8; THURMON J, 1996, ANESTHESIA WILD EXOT; Valverde CR, 2000, AM J VET RES, V61, P931, DOI 10.2460/ajvr.2000.61.931	15	10	12	0	1	AMER ASSOC ZOO VETERINARIANS	MEDIA	6 NORTH PENNELL ROAD, MEDIA, PA 19063 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	JUN	2004	35	2					162	166		10.1638/03-008			5	Veterinary Sciences	Veterinary Sciences	838HI	WOS:000222703700005	15305510				2020-06-30	J	Van Nimmen, NFJ; Poels, KLC; Veulemans, HAF				Van Nimmen, NFJ; Poels, KLC; Veulemans, HAF			Highly sensitive gas chromatographic-mass spectrometric screening method for the determination of picogram levels of fentanyl, sufentanil and alfentanil and their major metabolites in urine of opioid exposed workers	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						occupational exposure; fentanyl; sufentanil; alfentanil	SOLID-PHASE EXTRACTION; CLINICAL PHARMACOKINETICS; HUMAN PLASMA; INTERINDIVIDUAL VARIABILITY; TRANSDERMAL FENTANYL; CYTOCHROME-P450 3A4; DRUG-INTERACTIONS; RADIOIMMUNOASSAY; DISPOSITION; EFFICACY	Highly sensitive and specific analytical GC-MS procedures were developed and comprehensively validated for the determination of the opioid narcotics fentanyl, sufentanil and alfentanil and their major nor-metabolites in urine of potentially exposed opioid production workers. A simple, one step extraction protocol was developed using commercially available solid phase extraction (SPE) columns to recover all analytes from urine. The secondary amine functionalities of the nor-metabolites were derivatized to form stable, pentafluorobenzamide (PFBA)-derivatives with good chromatographic properties. Using the penta-deuterated analogues as internal standards, a limit-of-detection (LOD) of 2.5 pg fentanyl/ml, 2.5 pg sufentanil/ml and 7.5 pg alfentanil/ml urine was achieved. For the opioid metabolites the LODs were found to be <50 pg/ml urine. The developed analytical procedures show excellent intra-assay accuracy, particularly considering the ultra low levels of the analytes, with relative errors generally below 10%. Overall, an excellent reproducibility was observed with coefficients of variation below 10% at all spike levels for all opioid parent compounds and their metabolites, except for low norfentanyl concentrations. Upon storage at -30 degreesC urine samples were found to be stable for at least 2 months as no significant losses of either compound were observed. The developed analytical procedures have been successfully applied in a biological monitoring survey of fentanyl exposed production workers. (C) 2004 Elsevier B.V. All rights reserved.	Katholieke Univ Leuven, Lab Occupat Hyg & Toxicol, Dept Occupat, B-3000 Louvain, Belgium	Van Nimmen, NFJ (reprint author), Katholieke Univ Leuven, Lab Occupat Hyg & Toxicol, Dept Occupat, Kapucijnenvoer 35,6th Floor, B-3000 Louvain, Belgium.	nadine.vannimmen@med.kuleuven.ac.be					BIAGINI RE, 1992, J ALLERGY CLIN IMMUN, V89, P108, DOI 10.1016/S0091-6749(05)80047-8; Choi HS, 2001, J CHROMATOGR B, V765, P63, DOI 10.1016/S0378-4347(01)00405-4; CLOTZ MA, 1991, CLIN PHARMACY, V10, P581; Dale O, 2002, ACTA ANAESTH SCAND, V46, P759, DOI 10.1034/j.1399-6576.2002.460702.x; Dotsikas Y, 2002, ANAL CHIM ACTA, V459, P177, DOI 10.1016/S0003-2670(02)00133-2; DOWNES JJ, 1967, J PHARMACOL EXP THER, V158, P416; Dufresne C, 2001, CLIN CHEM, V47, P600; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; Gorski P, 1996, Int J Occup Med Environ Health, V9, P245; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Kharasch ED, 1997, ANESTHESIOLOGY, V87, P36, DOI 10.1097/00000542-199707000-00006; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MAUTZ DS, 1994, J CHROMATOGR B, V658, P149, DOI 10.1016/0378-4347(94)00201-0; MEULDERMANS W, 1988, ANESTHESIOLOGY, V69, P527, DOI 10.1097/00000542-198810000-00012; MEULDERMANS W, 1993, MORPHINIQUES, P85; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; MICHIELS M, 1983, J PHARM PHARMACOL, V35, P86, DOI 10.1111/j.2042-7158.1983.tb04275.x; Morgan Michael S., 1997, Environmental Health Perspectives, V105, P105, DOI 10.2307/3433400; Naumann BD, 1996, AM IND HYG ASSOC J, V57, P33, DOI 10.1202/0002-8894(1996)057<0033:PECLFP>2.0.CO;2; PHIPPS JA, 1983, CAN ANAESTH SOC J, V30, P162, DOI 10.1007/BF03009346; Rossi SS, 1996, CLIN CHIM ACTA, V244, P103, DOI 10.1016/0009-8981(95)06195-9; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; SCHUTTLER J, 1984, ANESTHESIOLOGY, V61, P315, DOI 10.1097/00000542-198409000-00010; SCHWARTZ JG, 1994, AM J FOREN MED PATH, V15, P236, DOI 10.1097/00000433-199409000-00011; SHAIKH WA, 1990, ALLERGY, V45, P555, DOI 10.1111/j.1398-9995.1990.tb00532.x; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; STANLEY TH, 1989, ANESTH ANALG, V69, P21; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461; WATTS VW, 1990, J ANAL TOXICOL, V14, P266, DOI 10.1093/jat/14.5.266; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X; WILLENS JS, 1993, HEART LUNG, V22, P239; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	35	38	38	1	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232	1873-376X		J CHROMATOGR B	J. Chromatogr. B	MAY 25	2004	804	2					375	387		10.1016/j.jchromb.2004.01.044			13	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	814XY	WOS:000221008600016	15081933				2020-06-30	J	Griffioen, KJS; Venkatesan, P; Huang, ZG; Wang, X; Bouairi, E; Evans, C; Gold, A; Mendelowitz, D				Griffioen, KJS; Venkatesan, P; Huang, ZG; Wang, X; Bouairi, E; Evans, C; Gold, A; Mendelowitz, D			Fentanyl inhibits GABAergic neurotransmission to cardiac vagal neurons in the nucleus ambiguus	BRAIN RESEARCH			English	Article						fentanyl; opioid; nucleus ambiguus; electrophysiology	MU-OPIOID RECEPTORS; BRAIN-STEM; IN-VITRO; PARASYMPATHETIC NEURONS; RAT HIPPOCAMPUS; OPIATE RECEPTOR; DELTA; ACTIVATION; RESPONSES; INPUTS	Fentanyl citrate is a synthetic opiate analgesic often used clinically for neonatal anesthesia. Although fentanyl significantly depresses heart rate, the mechanism of inducing bradycardia remains unclear. One possible site of action is the cardioinhibitory parasympathetic vagal neurons in the nucleus ambiguus (NA), from which originates control of heart rate and cardiac function. Inhibitory synaptic activity to cardiac vagal neurons is a major determinant of their activity. Therefore, the effect of fentanyl on GABAergic neurotransmission to parasympathetic cardiac vagal neurons was studied using whole-cell patch clamp electrophysiology. Application of fentanyl induced a reduction in both the frequency and amplitude of GABAergic IPSCs in cardiac vagal neurons. This inhibition was mediated at both pre- and postsynaptic sites as evidenced by a dual decrease in the frequency and amplitude of spontaneous miniature IPSCs. Application of the selective mu-antagonist CTOP abolished the fentanyl-mediated inhibition of GABAergic IPSCs. These results demonstrate that fentanyl acts on p-opioid receptors on cardiac vagal neurons and neurons preceding them to reduce GABAergic neurotransmission and increase parasympathetic activity. The inhibition of GABAergic effects may be one mechanism by which fentanyl induces bradycardia. (C) 2004 Elsevier B.V. All rights reserved.	George Washington Univ, Dept Pharmacol & Physiol, Washington, DC 20037 USA	Griffioen, KJS (reprint author), George Washington Univ, Dept Pharmacol & Physiol, 2300 Eye St NW, Washington, DC 20037 USA.	kgriff@gwu.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL59895, HL49965]		Alreja M, 2000, J NEUROSCI, V20, P1179, DOI 10.1523/JNEUROSCI.20-03-01179.2000; BRADFORD HF, 1986, BRIT J PHARMACOL, V88, P87, DOI 10.1111/j.1476-5381.1986.tb09474.x; CAPOGNA M, 1993, J PHYSIOL-LONDON, V470, P539, DOI 10.1113/jphysiol.1993.sp019874; COHEN GA, 1992, NEURON, V9, P325, DOI 10.1016/0896-6273(92)90171-9; DIMICCO JA, 1979, SCIENCE, V204, P1106, DOI 10.1126/science.451556; Ding YQ, 1996, J COMP NEUROL, V367, P375; GAUTRET B, 1985, J CARDIOVASC PHARM, V7, P649, DOI 10.1097/00005344-198507000-00006; Gruber EM, 2001, ANESTH ANALG, V92, P882; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; IMATEN M, 2003, NEUROSCIENCE, V116, P573; JOHNSON PS, 1994, NEUROREPORT, V5, P507, DOI 10.1097/00001756-199401120-00035; Jolas T, 1997, BRAIN RES, V755, P229, DOI 10.1016/S0006-8993(97)00103-0; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; LAUBIE M, 1977, N-S ARCH PHARMACOL, V296, P255, DOI 10.1007/BF00498691; LUPICA CR, 1995, J NEUROSCI, V15, P737; Martin M, 2003, EUR J NEUROSCI, V17, P701, DOI 10.1046/j.1460-9568.2003.02482.x; Mendelowitz D, 1999, NEWS PHYSIOL SCI, V14, P155; Mendelowitz D, 1998, CLIN EXP PHARMACOL P, V25, P453, DOI 10.1111/j.1440-1681.1998.tb02233.x; MENDELOWITZ D, 1991, NEUROSCI LETT, V132, P217, DOI 10.1016/0304-3940(91)90305-D; Neff RA, 2003, CIRC RES, V93, P565, DOI 10.1161/01.RES.0000090361.45027.5B; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; RANDICH A, 1992, J NEUROPHYSIOL, V68, P1027; RAYBURN W, 1989, AM J OBSTET GYNECOL, V161, P202, DOI 10.1016/0002-9378(89)90266-4; RHIM H, 1994, J NEUROSCI, V14, P7608; Sim LJ, 1997, J COMP NEUROL, V386, P562, DOI 10.1002/(SICI)1096-9861(19971006)386:4<562::AID-CNE4>3.0.CO;2-0; Stanford IM, 1999, J NEUROSCI, V19, P4796; Vaughan CW, 1997, J PHYSIOL-LONDON, V498, P463, DOI 10.1113/jphysiol.1997.sp021872; Venkatesan P, 2003, J NEUROPHYSIOL, V90, P1581, DOI 10.1152/jn.01117.2002; Venkatesan P, 2002, NEUROSCIENCE, V113, P975, DOI 10.1016/S0306-4522(02)00244-0; Venkatesan P, 2002, J PHARMACOL EXP THER, V300, P78, DOI 10.1124/jpet.300.1.78; VILLIGER JW, 1983, NEUROPHARMACOLOGY, V22, P447, DOI 10.1016/0028-3908(83)90162-4; Wang JJ, 2001, ANN NY ACAD SCI, V940, P237; Wang JJ, 2001, BRAIN RES, V889, P78, DOI 10.1016/S0006-8993(00)03112-7; WILLETTE RN, 1982, NEUROPHARMACOLOGY, V21, P1019, DOI 10.1016/0028-3908(82)90116-2; WU KM, 1983, EXP THER, V227, P302; XIA Y, 1991, BRAIN RES, V549, P181, DOI 10.1016/0006-8993(91)90457-7; Yuan CS, 1999, NEUROPHARMACOLOGY, V38, P425, DOI 10.1016/S0028-3908(98)00192-0	37	38	38	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 8	2004	1007	1-2					109	115		10.1016/j.brainres.2004.02.010			7	Neurosciences	Neurosciences & Neurology	815AV	WOS:000221016100012	15064141				2020-06-30	J	Van Nimmen, NFJ; Veulemans, HAF				Van Nimmen, NFJ; Veulemans, HAF			Development and validation of a highly sensitive gas chromatographic-mass spectrometric screening method for the simultaneous determination of nanogram levels of fentanyl, sufentanil and alfentanil in air and surface contamination wipes	JOURNAL OF CHROMATOGRAPHY A			English	Article						validation; air analysis; surface contamination; fentanyl; sufentanil; alfentanil; opioids	CLINICAL PHARMACOKINETICS; PHARMACEUTICAL-INDUSTRY; HYGIENE; LIMITS	A highly sensitive gas chromatographic-mass spectrometric (GC-MS) analytical method for the determination of the opioid narcotics fentanyl, alfentanil, and sufentanil in industrial hygiene personal air samples and surface contamination wipes was developed and comprehensively validated. Sample preparation involved a single step extraction of the samples with methanol, fortified with a fixed amount of the penta-deuterated analogues of the opioid narcotics as internal standard. The GC-MS analytical procedure using selected ion monitoring (SIM) was shown to be highly selective. Linearity was shown for levels of extracted wipe and air samples corresponding to at least 0.1-2 times their surface contamination limit (SCL) and accordingly to 0.1-2 times their time weighted average occupational exposure limit (OEL-TWA) based on a full shift 9601 air sample. Extraction recoveries were determined for spiked air samples and surface wipes and were found to be quantitative for both sampling media in the entire range studied. The air sampling method's limit of detection (LOD) was determined to be 0.4 ng per sample for fentanyl and sufentanil and 1.6 ng per sample for alfentanil, corresponding to less than 1 % of their individual OEL for a full shift air sample (9601). The limit of quantification (LOQ) was found to be 1.4, 1.2, and 5.0 ng per filter for fentanyl, sufentanil, and alfentanil, respectively. The wipe sampling method had LODs of 4 ng per wipe for fentanyl and sufentanil and 16 ng per wipe for alfentanil and LOQs of respectively, 14, 12, and 50 ng per wipe. The analytical intra-assay precision of the air sampling and wipe sampling method, defined as the coefficient of variation on the analytical result of six replicate spiked media was below 10 and 5%, respectively, for all opioids at all spike levels. Accuracy expressed as relative error was determined to be below 10%, except for alfentanil at the lowest spike level (-13.1%). The stability of the opioids during simulated air sampling was investigated. For fentanyl and sufentanil a quantitative recovery was observed at all spike levels, while for alfentanil recoveries ranged from 60.3 to 85.4%. When spiked air samples were stored at ambient temperature and at -15 degreesC quantitative recovery was found for fentanyl and sufentanil after 7 and 14 days. For alfentanil a slight loss seemed to occur upon storage during 7 days, being more explicit after 14 days. Ambient storage of spiked wipes seemed to lead to significant losses of all opioids studied, yielding recoveries of 37.7-88.3%. Upon storage of similar wipes at -15 degreesC a significantly higher recovery was found ranging from 77.3 to 88.3%. The developed analytical and sampling procedures have been recently applied in an explorative field study of which the results of surface contamination wipe sampling are presented in this paper. To our knowledge, this is the first study addressing the development and validation of analytical procedures for the assessment of external occupational exposure to potent opioid narcotics. (C) 2004 Elsevier B.V All rights reserved.	Katholieke Univ Leuven, Lab Occupat Hyg & Toxicol, Dept Occupat Environm & Insurance Med, B-3000 Louvain, Belgium	Van Nimmen, NFJ (reprint author), Katholieke Univ Leuven, Lab Occupat Hyg & Toxicol, Dept Occupat Environm & Insurance Med, Kapucijnenvoer 35,6th Floor, B-3000 Louvain, Belgium.	nadine.vannimmen@med.kuleuven.ac.be					Bos PMJ, 1998, OCCUP ENVIRON MED, V55, P795, DOI 10.1136/oem.55.12.795; CLOTZ MA, 1991, CLIN PHARMACY, V10, P581; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Guest I, 1997, OCCUP MED, V12, P81; Lambropoulos J, 2000, J PHARMACEUT BIOMED, V23, P421, DOI 10.1016/S0731-7085(00)00312-5; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; *OSHA, 2001, OSHA TECHN MAN; RACKHAM M, 1989, J SOC OCCUP MED, V39, P15; SARGENT EV, 1988, AM IND HYG ASSOC J, V49, P309, DOI 10.1080/15298668891379792; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Valaer AK, 1997, J CHROMATOGR SCI, V35, P461, DOI 10.1093/chromsci/35.10.461; VANNIMMEN NFJ, 2004, IN PRESS J CHROMAT B; VINCENT JH, 1999, PARTICLE SIZE SELECT, P130	13	15	15	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0021-9673			J CHROMATOGR A	J. Chromatogr. A	MAY 7	2004	1035	2					249	259		10.1016/j.chroma.2004.02.074			11	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	811PF	WOS:000220783100010	15124818				2020-06-30	J	Nelson, TW; Kuczkowski, KM				Nelson, TW; Kuczkowski, KM			Trauma in pregnancy: anesthetic management of a parturient with hypotensive shock and trauma to the gravid uterus	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Letter									Univ Calif San Diego, Med Ctr, Dept Anesthesiol, San Diego, CA 92103 USA	Kuczkowski, KM (reprint author), Univ Calif San Diego, Med Ctr, Dept Anesthesiol, 200 W Arbor Dr, San Diego, CA 92103 USA.	kkuczkowski@ucsd.edu					Baker B. W, 1999, OBSTET ANESTHESIA PR, P1041; Schiff MA, 2002, J TRAUMA, V53, P946, DOI 10.1097/00005373-200211000-00022	2	4	5	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2004	48	5					662	662		10.1111/j.0001-5172.2004.0376a.x			1	Anesthesiology	Anesthesiology	814MI	WOS:000220978400021	15101867				2020-06-30	J	Paech, MJ; Pavy, TJG; Orlikowski, CEP; Yeo, ST; Banks, SL; Evans, SF; Henderson, J				Paech, MJ; Pavy, TJG; Orlikowski, CEP; Yeo, ST; Banks, SL; Evans, SF; Henderson, J			Postcesarean analgesia with spinal morphine, clonidine, or their combination	ANESTHESIA AND ANALGESIA			English	Article							CESAREAN DELIVERY; INTRATHECAL MORPHINE; POSTOPERATIVE ANALGESIA; PAIN RELIEF; PERIOPERATIVE ANALGESIA; EPIDURAL CLONIDINE; HIP-REPLACEMENT; DOSE-RESPONSE; BUPIVACAINE; FENTANYL	In this randomized, double-blind trial in 240 women, we investigated the analgesic efficacy and duration of subarachnoid fentanyl 15 mug with morphine, clonidine, or both morphine and clonidine for cesarean delivery. A dose-finding analysis showed similar postoperative efficacy and side effects for groups receiving morphine 100 mug with clonidine 60, 90, or 150 mug. Data from these groups were combined (MC60-150, n = 113) and compared with groups receiving morphine 100 mug (n = 39), clonidine 150 mug (n = 39), or morphine 100 mug plus clonidine 30 mug (n = 41). The four groups differed in the time to patient-controlled morphine use and cumulative morphine consumption (P < 0.0001 and P < 0.001, respectively), with the longest duration and smallest dose in MC60-150. Pain scores were significantly different among groups. Onset of sensory block, ephedrine requirement and incidence of hypotension, patient satisfaction, and recovery were similar. Groups receiving clonidine had greater sedation, those receiving morphine had more severe pruritus, and group MC60-150 showed a trend to more vomiting intraoperatively. Compared with morphine 100 mug or clonidine 150 mug alone, the combination of subarachnoid morphine 100 mug and at least 60 mug of clonidine was found to increase the duration of postcesarean analgesia, reduce opioid requirement, and increase intraoperative sedation.	King Edward Mem Hosp Women, Dept Anesthesia & Pain Med, Perth, WA, Australia; Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA 6009, Australia; Women & Infants Res Fdn, Res Support, Subiaco, WA, Australia	Paech, MJ (reprint author), King Edward Mem Hosp Women, Dept Anesthesia & Pain Med, 374 Bagot Rd, Subiaco, WA 6008, Australia.			PAECH, MICHAEL/0000-0001-9023-6575			Angle PJ, 2002, ANESTH ANALG, V95, P741, DOI 10.1097/00000539-200209000-00038; Benhamou D, 1998, ANESTH ANALG, V87, P609, DOI 10.1097/00000539-199809000-00022; BONNET F, 1990, REGION ANESTH, V15, P211; CAPOGNA G, 1995, REGION ANESTH, V20, P57; Cardoso MMSC, 1998, ANESTH ANALG, V86, P538, DOI 10.1097/00000539-199803000-00017; CASTRO MI, 1989, ANESTHESIOLOGY, V71, P418, DOI 10.1097/00000542-198909000-00018; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; De Kock M, 2001, ANESTHESIOLOGY, V94, P574, DOI 10.1097/00000542-200104000-00008; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; EISENACH JC, 1994, ANESTH ANALG, V79, P285; FILOS KS, 1992, ANESTHESIOLOGY, V77, P267, DOI 10.1097/00000542-199208000-00008; FOGARTY DJ, 1993, BRIT J ANAESTH, V71, P661, DOI 10.1093/bja/71.5.661; Gerancher JC, 1999, ANESTH ANALG, V88, P346, DOI 10.1097/00000539-199902000-00023; GRACE D, 1995, ANESTH ANALG, V80, P86, DOI 10.1097/00000539-199501000-00015; HARTIKAINENSORRI AL, 1987, OBSTET GYNECOL, V69, P598; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; IWASAKI H, 1991, ANESTH ANALG, V72, P325; Luthman J, 1994, Int J Obstet Anesth, V3, P82, DOI 10.1016/0959-289X(94)90174-0; Paech MJ, 2000, INT J OBSTET ANESTH, V9, P238, DOI 10.1054/ijoa.2000.0758; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097/00000542-199902000-00018; Pan PM, 1998, REGION ANESTH PAIN M, V23, P49, DOI 10.1016/S1098-7339(98)90110-9; Sibilla C, 1997, INT J OBSTET ANESTH, V6, P43, DOI 10.1016/S0959-289X(97)80051-9; Siddik-Sayyid SM, 2002, ANESTH ANALG, V95, P209, DOI 10.1097/00000539-200207000-00037; Sites BD, 2003, ANESTH ANALG, V96, P1083, DOI 10.1213/01.ANE.0000055651.24073.59; Swart M, 1997, ANAESTHESIA, V52, P373, DOI 10.1111/j.1365-2044.1997.az0083c.x; Uchiyama A, 1994, Int J Obstet Anesth, V3, P87, DOI 10.1016/0959-289X(94)90175-9; Yanagidate F, 2001, REGION ANESTH PAIN M, V26, P461, DOI 10.1053/rapm.2001.25934	27	47	50	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAY	2004	98	5					1460	1466		10.1213/01.ANE.0000111208.08867.3C			7	Anesthesiology	Anesthesiology	815KS	WOS:000221041800046	15105231				2020-06-30	J	Cooper, DW				Cooper, DW			Evidence of clinical benefits from the predominant spinal action of bolus-dose epidural fentanyl	ANESTHESIA AND ANALGESIA			English	Letter							ANALGESIA		James Cook Univ Hosp, Middlesbrough, Cleveland, England	Cooper, DW (reprint author), James Cook Univ Hosp, Middlesbrough, Cleveland, England.						Cooper DW, 1999, BRIT J ANAESTH, V82, P366, DOI 10.1093/bja/82.3.366; COOPER DW, 1995, BRIT J ANAESTH, V74, P184, DOI 10.1093/bja/74.2.184; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10	3	0	0	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAY	2004	98	5					1501	1502		10.1213/01.ANE.0000113525.04809.C2			2	Anesthesiology	Anesthesiology	815KS	WOS:000221041800061	15105243				2020-06-30	J	Elsersy, H; Sheng, HX; Lynch, JR; Moldovan, M; Pearlstein, RD; Warner, DS				Elsersy, H; Sheng, HX; Lynch, JR; Moldovan, M; Pearlstein, RD; Warner, DS			Effects of isoflurane versus fentanyl-nitrous oxide anesthesia on long-term outcome from severe forebrain ischemia in the rat	ANESTHESIOLOGY			English	Article							INCOMPLETE CEREBRAL-ISCHEMIA; TOXICITY IN-VIVO; CARDIAC-ARREST; PENTOBARBITAL REDUCE; HIPPOCAMPAL INJURY; MEMORY IMPAIRMENT; FOCAL ISCHEMIA; OCCLUSION; MODEL; CA1	Background: This study examined long-term outcome from severe forebrain ischemia in the rat, as a function of anesthetic given during the ischemic injury. Methods: Rats were subjected to 10 min of near-complete forebrain ischemia while anesthetized with either 1.4% isoflurane or 70% nitrous oxide-fentanyl. Neurologic and histologic outcomes were measured at 5 days, 3 weeks, or 3 months after ischemia. Results: At 5 days, isoflurane-anesthetized rats had less damage than did fentanyl-nitrous oxide-anesthetized rats (mean +/- SD, percent alive hippocampal CA1 neurons = 58 +/- 29 vs. 20 16, respectively; P = 0.011). This was accompanied by improved motor function in the isoflurane group (P = 0.002). At 3 weeks, there was no difference between groups for either outcome variable (percent alive CA1 neurons = 35 +/- 26 and 36 28 for isoflurane and fentanyl-nitrous oxide, respectively). Similarly, at 3 months, there was no difference between groups (percent alive CA1 neurons = 56 +/- 27 and 60 +/- 27 for isoflurane and fentanyl-nitrous oxide, respectively). Morris water maze performance at 3 months was similar between anesthetic groups and was also similar to sham performance. The percent alive CA1 neurons in the fentanyl-nitrous oxide group increased with duration of recovery (P = 0.004). There were no differences among isoflurane groups over time (5 days vs. 3 weeks, P = 0.26; 5 days vs. 3 months, P = 0.99; 3 week vs. 3 months, P = 0.32). Conclusions: This study found no change in the percent alive CA1 hippocampal neurons as a function of duration of recovery from severe forebrain ischemia in isoflurane anesthetized rats. In contrast, the percent alive CA1 neurons in fentanyl-nitrous oxide-anesthetized rats tripled over 3 months of recovery. The natural history of long-term responses to forebrain ischemia requires further study before conclusions can be drawn with respect to the permanence of isoflurane neuroprotection.	Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA	Warner, DS (reprint author), Duke Univ, Med Ctr, Multidisciplinary Neuroprotect Labs, Durham, NC 27710 USA.	warne002@mc.duke.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM67139]		AUER RN, 1985, ACTA NEUROPATHOL, V67, P25, DOI 10.1007/BF00688121; BAUGHMAN VL, 1988, ANESTHESIOLOGY, V69, P192, DOI 10.1097/00000542-198808000-00007; Bickler PE, 2003, ANESTH ANALG, V97, P564, DOI 10.1213/01.ANE.0000068880.82739.7B; Blanck TJJ, 2000, ANESTHESIOLOGY, V93, P1285, DOI 10.1097/00000542-200011000-00023; Block F, 2001, NEUROSCI LETT, V298, P103, DOI 10.1016/S0304-3940(00)01729-8; Colbourne F, 1999, STROKE, V30, P662, DOI 10.1161/01.STR.30.3.662; COMBS DJ, 1987, STROKE, V18, P503, DOI 10.1161/01.STR.18.2.503; CUMMINGS JL, 1984, NEUROLOGY, V34, P679, DOI 10.1212/WNL.34.5.679; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; Felling RJ, 2003, J NEUROSCI RES, V73, P277, DOI 10.1002/jnr.10670; GIONET TX, 1992, BRAIN RES, V586, P188, DOI 10.1016/0006-8993(92)91626-P; GIONET TX, 1991, STROKE, V22, P1040, DOI 10.1161/01.STR.22.8.1040; Grubb NR, 2000, STROKE, V31, P1509, DOI 10.1161/01.STR.31.7.1509; Harada H, 1999, ANESTH ANALG, V89, P1442, DOI 10.1097/00000539-199912000-00022; Holzer M, 2002, NEW ENGL J MED, V346, P549; Homi HM, 2003, ANESTHESIOLOGY, V99, P1145, DOI 10.1097/00000542-200311000-00022; INOUE S, 2003, ANESTHESIOLOGY, V99, pA886; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; Kimbro JR, 2000, ANESTHESIOLOGY, V92, P806, DOI 10.1097/00000542-200003000-00024; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Mackensen GB, 1999, ANESTHESIOLOGY, V90, P873, DOI 10.1097/00000542-199903000-00031; MACKENSEN GB, 2000, ANESTHESIOLOGY, V93, P1101; Miura Y, 1998, ANESTHESIOLOGY, V89, P391, DOI 10.1097/00000542-199808000-00016; MOODY EJ, 1988, J NEUROCHEM, V51, P1386, DOI 10.1111/j.1471-4159.1988.tb01102.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Patel PM, 1998, ANESTH ANALG, V86, P773, DOI 10.1097/00000539-199804000-00018; Schmidt W, 2002, NEUROSCI LETT, V334, P153, DOI 10.1016/S0304-3940(02)01072-8; SMITH ML, 1988, ACTA NEUROPATHOL, V76, P253, DOI 10.1007/BF00687772; SMITH ML, 1984, ACTA NEUROL SCAND, V69, P385, DOI 10.1111/j.1600-0404.1984.tb07822.x; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; Sullivan BL, 2002, ANESTHESIOLOGY, V96, P189, DOI 10.1097/00000542-200201000-00033; VALTYSSON J, 1994, ACTA NEUROCHIR, V129, P58, DOI 10.1007/BF01400874; VERHAEGEN M, 1994, ANESTHESIOLOGY, V81, P965, DOI 10.1097/00000542-199410000-00024; Warner D S, 1989, J Neurosurg Anesthesiol, V1, P219, DOI 10.1097/00008506-198909000-00003; WELLS BA, 1963, SURGERY, V54, P216; WERNER C, 1995, BRIT J ANAESTH, V75, P756, DOI 10.1093/bja/75.6.756; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082; YANG J, 1991, ANN NY ACAD SCI, V625, P287, DOI 10.1111/j.1749-6632.1991.tb33851.x; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	39	73	78	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAY	2004	100	5					1160	1166		10.1097/00000542-200405000-00018			7	Anesthesiology	Anesthesiology	815VS	WOS:000221070400017	15114213				2020-06-30	J	Tan, CNH; Guha, A; Scawn, NDA; Pennefather, SH; Russell, GN				Tan, CNH; Guha, A; Scawn, NDA; Pennefather, SH; Russell, GN			Optimal concentration of epidural fentanyl in bupivacaine 0.1% after thoracotomy	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia, regional; anaesthetic techniques, thoracic epidural; analgesics opioid, fentanyl; surgery, thoracotomy	POSTOPERATIVE ANALGESIA; POSTTHORACOTOMY PAIN; COMBINATION; CLONIDINE; INFUSION; RELIEF	Background. The aim of this prospective, double-blind, randomized controlled trial was to investigate the analgesic and adverse effects of three commonly used concentrations of thoracic epidural fentanyl with bupivacaine in patients undergoing thoracotomy for lung resection. Methods. We studied 99 patients who were randomized to receive fentanyl 2 mug ml(-1) (group 2), fentanyl 5 mug ml(-1) (group 5) and fentanyl 10 mug ml(-1) (group 10) in bupivacaine 0.1% via a thoracic epidural. Postoperatively, pain on coughing was assessed using a visual analogue scale (VAS) and an observer verbal rating score (OVRS) at 2, 8, 16 and 24 h. At the same times, sedation, pruritus and nausea were assessed. Results. Of 29, 28 and 32 patients who completed the study in groups 2, 5 and 10 respectively, there was no significant difference in baseline characteristics between the three groups. The number of patients with episodes of unsatisfactory pain, i.e. VAS scores >30 mm and OVRS >1, at each of the four assessments postoperatively was significantly (P<0.01) higher in group 2 than in groups 5 and 10. In group 10, 16 patients had sedation scores >1 compared with 10 each in groups 2 and 5. In addition, 19 patients in group 10 experienced pruritus compared with 12 each, in groups 2 and 5. These differences were not significant. Nausea was not significantly different between the three groups. Conclusion. We conclude that thoracic epidural fentanyl 5 mug ml(-1) with bupivacaine 0.1% provides the optimum balance between pain relief and side effects following thoracotomy.	Ctr Cardiothorac, Dept Anaesthesia, Liverpool L14 3PE, Merseyside, England	Pennefather, SH (reprint author), Ctr Cardiothorac, Dept Anaesthesia, Thomas Dr, Liverpool L14 3PE, Merseyside, England.	stephen.pennefather@ctc.nhs.uk					CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; CONACHER ID, 1990, BRIT J ANAESTH, V65, P806, DOI 10.1093/bja/65.6.806; Curatolo M, 2000, ANESTHESIOLOGY, V92, P325, DOI 10.1097/00000542-200002000-00012; deLeonCasasola OA, 1996, ANESTH ANALG, V83, P867, DOI 10.1097/00000539-199610000-00038; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; LIU S, 1995, REGION ANESTH, V20, P303; Liu SS, 1999, ANESTHESIOLOGY, V90, P727, DOI 10.1097/00000542-199903000-00014; Lyons G, 1997, BRIT J ANAESTH, V78, P493; MacArthur C, 2001, LANCET, V358, P19; Mahon SV, 1999, ANAESTHESIA, V54, P641, DOI 10.1046/j.1365-2044.1999.00856.x; MOURISSE J, 1992, ACTA ANAESTH SCAND, V36, P70, DOI 10.1111/j.1399-6576.1992.tb03425.x; Romer HC, 1998, ANAESTHESIA, V53, P1016, DOI 10.1046/j.1365-2044.1998.00525.x; Scott DA, 1999, ANESTH ANALG, V88, P857, DOI 10.1097/00000539-199904000-00033; THOMSON CA, 1995, ANESTH ANALG, V81, P973, DOI 10.1097/00000539-199511000-00014; TYLER DC, 1989, ANESTHESIOLOGY, V70, P873, DOI 10.1097/00000542-198905000-00029; WELCHEW EA, 1983, ANAESTHESIA, V38, P1037, DOI 10.1111/j.1365-2044.1983.tb12476.x	16	12	14	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	MAY	2004	92	5					670	674		10.1093/bja/aeh129			5	Anesthesiology	Anesthesiology	816WO	WOS:000221140200008	15033892	Bronze			2020-06-30	J	Finn, J; Wright, J; Fong, J; Mackenzie, E; Wood, F; Leslie, G; Gelavis, A				Finn, J; Wright, J; Fong, J; Mackenzie, E; Wood, F; Leslie, G; Gelavis, A			A randomised crossover trial of patient controlled intranasal fentanyl and oral morphine for procedural wound care in adult patients with burns	BURNS			English	Article						intranasal fentanyl; pain relief; procedural wound care; burns	POSTOPERATIVE PAIN MANAGEMENT; CLINICAL-TRIAL; ANALGESIA; EFFICACY; INJURIES; CITRATE; NURSES; SAFETY	This study sought to compare the analgesic efficacy and safety of patient controlled intra-nasal (PCIN) fentanyl with oral morphine for procedural wound care in burns patients. A randonnised double-blind placebo controlled, two period, two-treatment crossover trial was conducted within the Burns Unit of a major teaching hospital in Perth, Western Australia. Patients requiring identical wound care procedures on two consecutive mornings (and not prescribed intravenous analgesia) were randomised to receive either PCIN fentanyl with oral placebo or oral morphine with intranasal placebo on I day, followed by the alternate active drug on the following day. Twenty-six patients (22 males), aged between 18 and 69 years (35.5 +/- 12.4 years), with total body surface burns (TBSA) range 1-25% (6.9 +/- 4.5%), indicated their level of pain on a 10 point (0-10) numeric scale at various time periods before, during and after the procedure. A mean total dose of 1.48 +/- 0.57 mug/kg of PCIN fentanyl and 0.35 +/- 0.12 mg/kg of oral morphine was administered. No statistically significant difference was found between the pain scores recorded for patients during the procedure with PCIN fentanyl compared to that with oral morphine (mean difference = -0.75, 95% Cl = - 1.97 to 0.47, P = 0.22). Two patients experienced hypotension during the procedure-both had received active oral morphine. No patients experienced respiratory depression or a significant drop in oxygen saturation. There were four episodes (in three patients) where 'rescue analgesia' for severe pain was required - two episodes involving, oral morphine and two involving PCIN fentanyl. It was concluded that PCIN fentanyl is similar in efficacy and safety to oral morphine for relief of procedural wound care pain in burns patients. (C) 2003 Elsevier Ltd and ISBI. All rights reserved.	Univ Western Australia, Sch Populat Hlth M431, Perth, WA 6009, Australia; Royal Perth Hosp, Dept Pharm, Perth, WA, Australia; Royal Perth Hosp, Burns Unit, Perth, WA, Australia; Edith Cowan Univ, Royal Perth Hosp, Perth, WA, Australia	Finn, J (reprint author), Univ Western Australia, Sch Populat Hlth M431, 35 Stirling Highway, Perth, WA 6009, Australia.	jfinn@cyllene.uwa.edu.au	Wood, Fiona/F-4703-2013; Finn, Judith C/B-2678-2010	Wood, Fiona/0000-0001-5427-6588; Finn, Judith C/0000-0002-7307-7944; Leslie, Gavin/0000-0001-8939-9801; Wood, Fiona Melanie/0000-0002-3284-6540			Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Breivik EK, 2000, CLIN J PAIN, V16, P22, DOI 10.1097/00002508-200003000-00005; CHOINIERE M, 1989, J TRAUMA, V29, P1531, DOI 10.1097/00005373-198911000-00013; CHOINIERE M, 1990, PAIN, V40, P143, DOI 10.1016/0304-3959(90)90065-L; Everett John J., 1994, Journal of Burn Care and Rehabilitation, V15, P194; FREEMAN PR, 1989, STAT MED, V8, P1421, DOI 10.1002/sim.4780081202; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Linneman PK, 2000, J BURN CARE REHABIL, V21, P519, DOI 10.1097/00004630-200021060-00008; Nagy S, 1999, J ADV NURS, V29, P1427, DOI 10.1046/j.1365-2648.1999.01030.x; ONeil G, 1997, ANAESTH INTENS CARE, V25, P408, DOI 10.1177/0310057X9702500414; Pal SK, 1997, BURNS, V23, P404, DOI 10.1016/S0305-4179(97)00029-6; SENN S, 1993, [No title captured]; Sharer SR, 1998, J BURN CARE REHABIL, V19, P516, DOI 10.1097/00004630-199811000-00010; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; Sutherland Suzanne, 1996, Journal of Burn Care and Rehabilitation, V17, P457, DOI 10.1097/00004630-199609000-00016; Toussaint S, 2000, CAN J ANAESTH, V47, P299, DOI 10.1007/BF03020941; Ueda W, 2001, ANESTHESIOLOGY, V95, P812, DOI 10.1097/00000542-200109000-00050; Ulmer JF, 1998, J BURN CARE REHABIL, V19, P151, DOI 10.1097/00004630-199803000-00014; WOODS JR, 1989, ANN INTERN MED, V110, P560, DOI 10.7326/0003-4819-110-7-560; Zeppetella G, 2000, J PAIN SYMPTOM MANAG, V20, P253, DOI 10.1016/S0885-3924(00)00180-9	23	56	56	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-4179			BURNS	Burns	MAY	2004	30	3					262	268		10.1016/j.burns.2003.10.017			7	Critical Care Medicine; Dermatology; Surgery	General & Internal Medicine; Dermatology; Surgery	814JA	WOS:000220969800012	15082356				2020-06-30	J	Burton, AW; Driver, LC; Mendoza, TR; Syed, G				Burton, AW; Driver, LC; Mendoza, TR; Syed, G			Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises - A retrospective case series	CLINICAL JOURNAL OF PAIN			English	Article						oral transmucosal fentanyl citrate; cancer pain; breakthrough pain; opioids; pain crisis	BREAKTHROUGH PAIN; PHARMACOKINETICS; MORPHINE	Objective: This retrospective chart review evaluated the efficacy of oral transmucosal fentanyl citrate (OTFC) in an outpatient cancer pain center for patients experiencing severe exacerbations of pain that exceed usual breakthrough pain levels. Patients: Records were reviewed for all patients who received OTFC at M.D. Anderson's outpatient pain clinic over a three-month time period. OTFC was used in thirty-nine patients experiencing a recent onset of severe pain (greater than or equal to7 on a 0-10 scale). All patients had cancer. cancer-related pain syndromes, and were opioid tolerant with an oral morphine equivalent daily dosage (MEDD) of 40 mg/day. Results: Prior to OTFC treatment, all patients reported a mean pain intensity of 9.0 (SD = 1.2). After OTFC treatment, patients reported a mean intensity of 3.0 (SD = 1.4), a significant reduction in pain intensity (P < 0.001). In most cases, OTFC averted the need for an emergency center visit, parenteral opioids, and hospital admission, which suggests that OTFC may be an effective alternative over intravenous Opioids to rapidly titrate analgesia in selected opioid-tolerant cancer patients experiencing severe pain.	Univ Texas, MD Anderson Canc Ctr, Dept Anesthesiol, Sect Canc Pain Management,Unit 42, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Sympton Res, Houston, TX 77030 USA	Burton, AW (reprint author), Univ Texas, MD Anderson Canc Ctr, Dept Anesthesiol, Sect Canc Pain Management,Unit 42, 1515 Holcombe Blvd, Houston, TX 77030 USA.	awburton@mdanderson.org					Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Egan TD, 2000, ANESTHESIOLOGY, V92, P665, DOI 10.1097/00000542-200003000-00009; Fortner BV, 2002, J PAIN, V3, P38, DOI 10.1054/jpai.2002.27136; Grossman SA, 1999, ONCOLOGY-NY, V13, P33; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; TENNANT F, 2002, J PAIN, V3, pA797	9	23	26	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-8047			CLIN J PAIN	Clin. J. Pain	MAY-JUN	2004	20	3					195	197		10.1097/00002508-200405000-00011			3	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	815GG	WOS:000221030200011	15100597				2020-06-30	J	Segev, F; Voineskos, AN; Hui, G; Law, MSH; Paul, R; Chung, F; Slomovic, AR				Segev, F; Voineskos, AN; Hui, G; Law, MSH; Paul, R; Chung, F; Slomovic, AR			Combined topical and intracameral anesthesia in penetrating keratoplasty	CORNEA			English	Article						retrobulbar; intracameral; and topical anesthesia; repeat PKP	CATARACT-SURGERY; RETROBULBAR ANESTHESIA; LENS IMPLANTATION; PHACOEMULSIFICATION; LIDOCAINE; PHACOTRABECULECTOMY; SEDATION; PERIBULBAR; BLOCK	Background: The standard of care for penetrating keratoplasty (PKP) is either retrobulbar or peribulbar anesthesia combined with seventh cranial nerve akinesia or general anesthesia. These methods are known to be associated with rare but potentially serious adverse ocular and systemic events. Purpose: To determine the safety and efficacy of combined topical and intracameral anesthesia in addition to intravenous sedation for repeat penetrating keratoplasty (PKP). Setting: Tertiary-care university hospital. Methods: In this prospective study, combined topical tetracaine 0.5% and 0.2 cc intracameral 1% lidocaine along with IV sedation with midazolam and fentanyl were used for patients undergoing repeat PKP in 15 eyes of 15 selected patients. The indication for surgery was failed corneal graft. Verbal pain scale (VPS, 0-3) was recorded preoperatively, intraoperatively at 3 time-points (after trephination, after placing 8 interrupted sutures, and after placing the running suture), and postoperatively (I hour postoperatively, overnight pain, and I day postoperatively). Patient and surgeon satisfaction were assessed postoperatively using a scale (1-5). After surgery patients were asked for their preferences comparing the current use of topical anesthesia compared with retrobulbar anesthesia used for their initial PKP. Results: The mean intraoperative VPS score was 0.51 +/- 0.32 (range 0-1.33), and the mean postoperative VPS score was 0.47 +/- 0.50 (range 0-1.67). There were no serious intraoperative or postoperative complications. All patients reported high mean satisfaction score of 4.67 +/- 0.49 (range 4-5). The mean satisfaction score reported by the surgeon was 4.47 +/- 0.63 (range 3-5). All patients but 1 (93.3%) preferred combined topical over retrobulbar anesthesia, which they had in their previous surgery. Conclusions: We found combined topical and intracameral anes-thesia to be safe and effective in our selected group of patients undergoing repeat PKP, and it may provide a satisfactory alternative anesthetic modality for patients in whom general, retrobulbar, or peribul-bar anesthesia may be contraindicated.	Univ Toronto, Toronto Western Hosp, Dept Ophthalmol, Univ Hlth Network, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Dept Anesthesiol, Univ Hlth Network, Toronto, ON M5T 2S8, Canada	Slomovic, AR (reprint author), Univ Toronto, Toronto Western Hosp, Dept Ophthalmol, Univ Hlth Network, 399 Bathurst St,7-011 Edith Cavell Wing, Toronto, ON M5T 2S8, Canada.	allan.slomovic@utoronto.ca	Chung, Frances/F-5618-2015	Chung, Frances/0000-0001-9576-3606; Segev, Fani/0000-0003-3879-8831			Ahmed IIK, 2002, J CATARACT REFR SURG, V28, P631, DOI 10.1016/S0886-3350(01)01249-4; Aydin ON, 2002, J CATARACT REFR SURG, V28, P1968, DOI 10.1016/S0886-3350(02)01429-3; Bardocci A, 2003, OPHTHALMOLOGY, V110, P144, DOI 10.1016/S0161-6420(02)01562-2; Carino NS, 1998, J CATARACT REFR SURG, V24, P1602, DOI 10.1016/S0886-3350(98)80350-7; Carter K, 1998, J CATARACT REFR SURG, V24, P1361, DOI 10.1016/S0886-3350(98)80229-0; Gills JP, 1997, J CATARACT REFR SURG, V23, P545, DOI 10.1016/S0886-3350(97)80211-8; Hamilton R. C., 1990, OPHTHALMOLOGY CLIN N, V3, P111; Johnston RL, 1998, J CATARACT REFR SURG, V24, P407, DOI 10.1016/S0886-3350(98)80332-5; Kallio H, 2000, BRIT J ANAESTH, V85, P708, DOI 10.1093/bja/85.5.708; KERSHNER RM, 1993, J CATARACT REFR SURG, V19, P290, DOI 10.1016/S0886-3350(13)80958-3; LAI JS, 2000, J GLAUCOMA, V11, P271; Naor J, 2000, Curr Opin Ophthalmol, V11, P7, DOI 10.1097/00055735-200002000-00003; Nielsen PJ, 1998, J CATARACT REFR SURG, V24, P1136, DOI 10.1016/S0886-3350(98)80110-7; O'Brien PD, 2001, J CATARACT REFR SURG, V27, P880, DOI 10.1016/S0886-3350(00)00757-4; Patel BCK, 1998, J CATARACT REFR SURG, V24, P853, DOI 10.1016/S0886-3350(98)80143-0; Rebolleda G, 2001, J CATARACT REFR SURG, V27, P1214, DOI 10.1016/S0886-3350(00)00883-X; SAUNDERS DC, 1993, OPHTHALMIC SURG LAS, V24, P842; Silvera D, 2000, CAN J OPHTHALMOL, V35, P331, DOI 10.1016/S0008-4182(00)80061-7; SULLIVAN KL, 1983, OPHTHALMOLOGY, V90, P373; Vicary D, 1998, J CATARACT REFR SURG, V24, P1247, DOI 10.1016/S0886-3350(98)80021-7; WEISS JL, 1989, ARCH OPHTHALMOL-CHIC, V107, P96, DOI 10.1001/archopht.1989.01070010098035; WONG DHW, 1993, CAN J ANAESTH, V40, P547, DOI 10.1007/BF03009740; Yavitz EQ, 1997, J CATARACT REFR SURG, V23, P1435, DOI 10.1016/S0886-3350(97)80009-0; Yepez JB, 2002, OPHTHALMIC SURG LAS, V33, P293	24	12	13	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0277-3740	1536-4798		CORNEA	Cornea	MAY	2004	23	4					372	376		10.1097/00003226-200405000-00011			5	Ophthalmology	Ophthalmology	815WW	WOS:000221073400011	15097132				2020-06-30	J	Ali, S; Davidson, DL; Gremse, DA				Ali, S; Davidson, DL; Gremse, DA			Comparison of fentanyl versus meperidine for analgesia in pediatric gastrointestinal endoscopy	DIGESTIVE DISEASES AND SCIENCES			English	Article						sedation; fentanyl; meperidine; endoscopy; pediatrics; midazolam	INTRAVENOUS SEDATION; MIDAZOLAM; CHILDREN; ANESTHESIA; EFFICACY; PATIENT	This study compared the safety and efficacy of fentanyl and meperidine for analgesia in pediatric gastrointestinal endoscopy. In a double-blind, randomized trial, 24 patients ( 11 males) received either fentanyl (1 mug/kg) or meperidine (1 mg/kg). These analgesics were administered in unmarked syringes by an investigator who did not participate in the procedure or in the evaluation of the patient's sedation. There were 17 Caucasians and 7 African-Americans whose mean age was 10.4+/-4.4 years. Thirteen patients received meperidine and 11 received fentanyl. Midazolam was given to all patients as needed to provide sufficient sedation for the procedure. Study subjects underwent EGD (n =17) or colonoscopy (n = 7) . There were no differences as assessed by patient, endoscopist, or assistant for tolerance, discomfort, procedure ease, recovery time, complications, heart rate, blood pressure, or oxygen saturation. We conclude that meperidine and fentanyl are equally effective in providing analgesia for pediatric gastrointestinal endoscopy.	Univ S Alabama, Dept Pediat, Mobile, AL 36688 USA; Univ S Alabama, Div Pediat Gastroenterol, Mobile, AL 36688 USA	Gremse, DA (reprint author), 1504 Springhill Ave,5309, Mobile, AL 36604 USA.	dgremse@usouthal.edu					*AM COLL EM PHYS, 1993, ANN EMERG MED, V22, P626; BAHALOMARA N, 1993, J PEDIATR GASTR NUTR, V16, P387, DOI 10.1097/00005176-199305000-00007; CAULFIELD M, 1989, J PEDIATR-US, V115, P339, DOI 10.1016/S0022-3476(89)80829-7; CHUANG E, 1995, GASTROINTEST ENDOSC, V42, P156, DOI 10.1016/S0016-5107(95)70073-0; Gremse DA, 1997, SOUTH MED J, V90, P821, DOI 10.1097/00007611-199708000-00009; ISRAEL DM, 1994, J PEDIATR GASTR NUTR, V19, P283, DOI 10.1097/00005176-199410000-00004; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Khoshoo V, 2003, J PEDIATR GASTR NUTR, V37, P146, DOI 10.1097/00005176-200308000-00012; Montanari F, 2001, Pediatr Med Chir, V23, P45; NEWMAN MG, 1969, ANESTH ANAL CURR RES, V48, P136, DOI 10.1213/00000539-196948010-00028; SQUIRES RH, 1995, GASTROINTEST ENDOSC, V41, P99, DOI 10.1016/S0016-5107(05)80589-9; STEFFEN RM, 1989, J PEDIATR-US, V115, P507, DOI 10.1016/S0022-3476(89)80272-0; Tolia V, 2000, J PEDIATR GASTR NUTR, V30, P477, DOI 10.1097/00005176-200005000-00003; YASTER M, 1990, PEDIATRICS, V86, P463	14	20	20	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	MAY	2004	49	5					888	891		10.1023/B:DDAS.0000030106.01928.b4			4	Gastroenterology & Hepatology	Gastroenterology & Hepatology	826RU	WOS:000221847000030	15259516				2020-06-30	J	Kudoh, A; Katagai, H; Takase, H; Takazawa, T				Kudoh, A; Katagai, H; Takase, H; Takazawa, T			Effect of preoperative discontinuation of antipsychotics in schizophrenic patients on outcome during and after anaesthesia	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter									Hirosaki Natl Hosp, Dept Anesthesiol, Hirosaki, Aomori 0368545, Japan	Kudoh, A (reprint author), Hirosaki Natl Hosp, Dept Anesthesiol, 1 Tominocho, Hirosaki, Aomori 0368545, Japan.	masuika@cc.hirosaki-u.ac.jp					American Psychiatric Association, 1980, DIAGN STAT MAN MENT; Igarashi Y, 1998, PSYCHIAT CLIN NEUROS, V52, P467, DOI 10.1046/j.1440-1819.1998.00425.x; INNOUYE SK, 1990, ANN INTERN MED, V113, P941; Kudoh A, 1999, NEUROPSYCHOBIOLOGY, V39, P125, DOI 10.1159/000026572; Kudoh A, 1993, Masui, V42, P1056; Molnar G, 1987, PRINCIPLES MED PSYCH, P451; MURRAY AM, 1993, J GERONTOL, V48, pM181, DOI 10.1093/geronj/48.5.M181	7	15	16	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAY	2004	21	5					414	416		10.1017/S026502150422511X			3	Anesthesiology	Anesthesiology	821VN	WOS:000221491200012	15141803				2020-06-30	J	White, SM; Hunt, T				White, SM; Hunt, T			Anaesthesia for homans' procedure	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Letter							LYMPHEDEMA		St Thomas Hosp, Dept Anaesthet, London SE1 7EH, England	White, SM (reprint author), St Thomas Hosp, Dept Anaesthesia, Lambeth Palace Rd, London SE1 7EH, England.	igasbest@hotmail.com					Dumanian GA, 1996, PLAST RECONSTR SURG, V98, P1258, DOI 10.1097/00006534-199612000-00022; Gloviczki P, 1999, INT ANGIOL, V18, P42; Homans J, 1936, NEW ENGL J MED, V215, P1099, DOI 10.1056/NEJM193612102152401; Ko DSC, 1998, ARCH SURG-CHICAGO, V133, P452, DOI 10.1001/archsurg.133.4.452; Mortimer PS, 2000, BRIT MED J, V320, P1527, DOI 10.1136/bmj.320.7248.1527; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493	6	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	MAY	2004	21	5					419	420		10.1017/S0265021504255119			2	Anesthesiology	Anesthesiology	821VN	WOS:000221491200015	15141806				2020-06-30	J	Hung, WT; Liao, SM; Su, JM				Hung, WT; Liao, SM; Su, JM			Laryngeal mask airway in patients with tracheal stents who are undergoing non-airway related interventions: Report of three cases	JOURNAL OF CLINICAL ANESTHESIA			English	Article						Laryngeal Mask Airway; tracheal stent	STENOSIS; LMA	The tracheal stent is an alternative nonsurgical management tool for patients with tracheal stenosis caused by disease or iatrogenic trauma. Some patients with tracheal stent may need to be anesthetized to allow invasive techniques or surgery to be performed. In these patients, general anesthesia by endotracheal intubation may dislodge the stent distally or cause lethal complications such as bleeding. We describe three patients with a tracheal stent in place, who were anesthetized using a Laryngeal Mask Airway for surgery, with smooth results. (C) 2004 by Elsevier Inc.	Chung Shan Med Univ Hosp, Dept Anesthesiol, Taichung, Taiwan	Hung, WT (reprint author), 21 Thornridge Lane, Centereach, NY 11720 USA.	hung@biostat.Columbia.edu					ALEXANDER CA, 1990, ANAESTHESIA, V45, P892, DOI 10.1111/j.1365-2044.1990.tb14601.x; Bailey P, 1998, INT ANESTHESIOL CLIN, V36, P111, DOI 10.1097/00004311-199803620-00009; BERRY A, 1996, LARYNGEAL MASK AIRWA, P117; Brain AIJ, 2000, BRIT J ANAESTH, V84, P650, DOI 10.1093/bja/84.5.650; Ducic Y, 1999, LARYNGOSCOPE, V109, P1130, DOI 10.1097/00005537-199907000-00023; DUMON JF, 1990, CHEST, V97, P328, DOI 10.1378/chest.97.2.328; MAGEE MJ, 1994, ANN THORAC SURG, V57, P1031, DOI 10.1016/0003-4975(94)90236-4; Noppen M, 1999, CHEST, V115, P532, DOI 10.1378/chest.115.2.532; Tanigawa N, 2001, AM J ROENTGENOL, V177, P1423, DOI 10.2214/ajr.177.6.1771423	9	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	MAY	2004	16	3					214	216		10.1016/j.jclinane.2003.07.010			3	Anesthesiology	Anesthesiology	834PI	WOS:000222422600011	15217663				2020-06-30	J	Finsterer, J; Keller, H; Arias, I; Zuntner, G				Finsterer, J; Keller, H; Arias, I; Zuntner, G			Severe withdrawal from short-term transdermal fentanyl after naloxone for uremic pruritus	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter									Krankenanstalt Rudolfstiftung Wien, Vienna, Austria	Finsterer, J (reprint author), Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.						Davies AN, 1996, PALLIATIVE MED, V10, P348; Franck L S, 1998, Am J Crit Care, V7, P364; Han PKJ, 2002, J PAIN SYMPTOM MANAG, V23, P66, DOI 10.1016/S0885-3924(01)00370-0; HIGGS CMB, 1995, J PAIN SYMPTOM MANAG, V10, P4, DOI 10.1016/0885-3924(94)00060-X; Hunt A, 2001, PALLIATIVE MED, V15, P405, DOI 10.1191/026921601680419456; Hunt R, 1996, PALLIATIVE MED, V10, P347; Lugo RA, 2001, PHARMACOTHERAPY, V21, P1566, DOI 10.1592/phco.21.20.1566.34471; Mettang T, 2002, NEPHROL DIAL TRANSPL, V17, P1558, DOI 10.1093/ndt/17.9.1558; Peer G, 1996, LANCET, V348, P1552, DOI 10.1016/S0140-6736(96)04176-1; ZENZ M, 1994, J PAIN SYMPTOM MANAG, V9, P54, DOI 10.1016/0885-3924(94)90149-X	10	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAY	2004	27	5					387	388		10.1016/j.jpainsymman.2004.02.006			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	822BH	WOS:000221508900002	15120761	Bronze			2020-06-30	J	Mercadante, S				Mercadante, S			Opioid consumption in Italy: Industry is not necessarily business - Look at the effects	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							LAW		La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Palermo, Italy.						Chinellato A, 2003, LANCET, V362, P78, DOI 10.1016/S0140-6736(03)13819-6; Mercadante S, 2002, LANCET, V360, P1254, DOI 10.1016/S0140-6736(02)11261-X	2	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924			J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAY	2004	27	5					391	392		10.1016/j.jpainsymman.2004.02.009			2	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	822BH	WOS:000221508900007	15120764	Bronze			2020-06-30	J	Lo, WC; Jackson, E; Merriman, A; Harris, J; Clarke, RW				Lo, WC; Jackson, E; Merriman, A; Harris, J; Clarke, RW			5-HT receptors involved in opioid-activated descending inhibition of spinal withdrawal reflexes in the decerebrated rabbit	PAIN			English	Article						opioid analgesia; descending inhibition; serotonin; 5-HT1B-receptor; 5-HT2-receptor; 5-HT3-receptor	BRAIN-STEM; INDUCED ANTINOCICEPTION; ANTAGONIST GR-127,935; MORPHINE ANALGESIA; HUMAN 5-HT1D-ALPHA; SEROTONIN; RAT; CORD; TRANSMISSION; MODULATION	The role of 5-HT1B/1D, 5-HT2 and 5-HT3 receptors in mediating descending inhibition of spinal reflexes activated by application of fentanyl to the fourth ventricle has been studied in rabbits decerebrated Under N2O/isoflurane anaesthesia. In the control state, intraventricular fentanyl (3-30 mug kg(-1)) depressed, to ail equal extent, short- and long-latency reflexes in the medial gastrocnemius muscle nerve evoked by electrical stimulation of all sural nerve afferents. Inhibition of reflexes resulted from a decreased base line excitability in the reflex pathway accompanied by a reduction in the rate of temporal summation of responses. Fentanyl-induced suppression of short- and long-latency reflexes was significantly reduced after intrathecal administration of the selective 5-HT2-receptor antagonist ICI 170,809 (300 mug). The same dose of the selective 5-HT1B/1D blocker GR 127,935 reduced inhibition from intraventricular fentanyl only for long-latency reflexes (i.e. those parts of the response for which the afferent drive is provided mainly by Adelta and C-fibre afferents). The 5-HT3 antagonist tropisetron (also 300 mug intrathecal) did not significantly alter the descending inhibition of reflexes evoked by fentanyl. Both GR 127,935 and tropisetron reduced temporal Summation of reflexes per se, effects that were reversed by intraventricular fentanyl. These data suggest that the descending pathway(s) activated by intraventricular fentanyl liberate 5-HT in the spinal cord to inhibit withdrawal reflexes by acting at 5-HT2 and 5-HT1B/1D, but not 5-HT3 receptors. 5-HT1B/1D, and to a lesser extent 5-HT3 receptors also appear to have a role in modulating temporal Summation of reflexes evoked by repetitive Stimuli. (C) 2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Univ Nottingham, Sch Biosci, Loughborough LE12 5RD, Leics, England; Univ Nottingham, Inst Neurosci, Loughborough LE12 5RD, Leics, England	Clarke, RW (reprint author), Univ Nottingham, Sch Biosci, Sutton Bonington Capus, Loughborough LE12 5RD, Leics, England.	robert.clarke@nottingham.ac.uk		Harris, John/0000-0001-7815-5385			ARTS KS, 1991, J PHARMACOL EXP THER, V256, P890; ARVIDSSON U, 1995, J NEUROSCI, V15, P1215; Bardin L, 2000, PAIN, V86, P11, DOI 10.1016/S0304-3959(99)00307-3; Bonhaus DW, 1999, BRIT J PHARMACOL, V127, P1075, DOI 10.1038/sj.bjp.0702632; Bromidge SM, 1997, J MED CHEM, V40, P3494, DOI 10.1021/jm970424c; Clarke RW, 1996, BRIT J PHARMACOL, V119, P1167, DOI 10.1111/j.1476-5381.1996.tb16019.x; Clarke RW, 2002, NEUROSCIENCE, V112, P555, DOI 10.1016/S0306-4522(02)00093-3; Clarke RW, 1998, PAIN, V78, P197, DOI 10.1016/S0304-3959(98)00127-4; Clarke RW, 2000, PAIN, V85, P239, DOI 10.1016/S0304-3959(99)00272-9; CODA BA, 1993, PAIN, V52, P85, DOI 10.1016/0304-3959(93)90118-9; Cordero-Erausquin M, 2001, P NATL ACAD SCI USA, V98, P2803, DOI 10.1073/pnas.041600698; Dayer P, 1997, DRUGS, V53, P18, DOI 10.2165/00003495-199700532-00006; DEFELIPE MD, 1986, EUR J PHARMACOL, V125, P193; Desmeules JA, 1996, BRIT J CLIN PHARMACO, V41, P7, DOI 10.1111/j.1365-2125.1996.tb00152.x; Erjavec MK, 2000, J CLIN PHARMACOL, V40, P1286; FREEMAN AJ, 1992, ANTI-CANCER DRUG, V3, P79, DOI 10.1097/00001813-199204000-00001; Gage HD, 2001, PAIN, V91, P139, DOI 10.1016/S0304-3959(00)00426-7; Gao KM, 1998, J NEUROSCI, V18, P1860; Gatch MB, 1998, PSYCHOPHARMACOLOGY, V135, P99, DOI 10.1007/s002130050490; Green GM, 2000, PAIN, V89, P81, DOI 10.1016/S0304-3959(00)00346-8; Hain HS, 1999, J PHARMACOL EXP THER, V291, P444; HARRIS J, 1992, EXP BRAIN RES, V92, P310; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; Hurley RW, 2003, NEUROSCIENCE, V118, P789, DOI 10.1016/S0306-4522(03)00041-1; Jenkins S, 2000, BRIT J PHARMACOL, V131, P974, DOI 10.1038/sj.bjp.0703649; JENSEN TS, 1986, BRAIN RES, V363, P114, DOI 10.1016/0006-8993(86)90663-3; Jensen TS, 1997, ACTA ANAESTH SCAND, V41, P123, DOI 10.1111/j.1399-6576.1997.tb04626.x; JUNG JS, 1994, PHARMACOL BIOCHEM BE, V49, P1037, DOI 10.1016/0091-3057(94)90261-5; Kalyuzhny AE, 1996, J NEUROSCI, V16, P6490; Kalyuzhny AE, 1999, NEUROSCIENCE, V90, P229, DOI 10.1016/S0306-4522(98)00376-5; LO WC, 2003, J PHYSL P, V551, pC19; LO WC, 2003, J PHYSL P, V551, pPC45; Luger TJ, 1999, PHARMACOL TOXICOL, V85, P263, DOI 10.1111/j.1600-0773.1999.tb02020.x; MATOS FF, 1992, PAIN, V48, P439, DOI 10.1016/0304-3959(92)90097-U; Millan MJ, 2002, PROG NEUROBIOL, V66, P355, DOI 10.1016/S0301-0082(02)00009-6; Nemmani KVS, 2003, NEUROPHARMACOLOGY, V44, P304, DOI 10.1016/S0028-3908(02)00374-X; Ogilvie J, 1999, BRIT J PHARMACOL, V128, P781, DOI 10.1038/sj.bjp.0702832; PAUWELS PJ, 1995, NEUROPHARMACOLOGY, V34, P235, DOI 10.1016/0028-3908(95)00007-S; PAUWELS PJ, 1995, EUR J PHARM-MOLEC PH, V290, P95, DOI 10.1016/0922-4106(95)90021-7; Price GW, 1997, N-S ARCH PHARMACOL, V356, P312, DOI 10.1007/PL00005056; Reimann W, 1999, ANESTH ANALG, V88, P141, DOI 10.1097/00000539-199901000-00026; Roberts C, 2001, BRAIN RES BULL, V56, P463, DOI 10.1016/S0361-9230(01)00628-1; Sierralta F, 1995, PSYCHOPHARMACOLOGY, V122, P374, DOI 10.1007/BF02246269; Skingle M, 1996, BEHAV BRAIN RES, V73, P157; SORENSEN SM, 1993, J PHARMACOL EXP THER, V266, P684; Suzuki R, 2002, NAT NEUROSCI, V5, P1319, DOI 10.1038/nn966; TAYLOR JS, 1991, J PHYSIOL-LONDON, V437, P71, DOI 10.1113/jphysiol.1991.sp018584; VOGT M, 1974, J PHYSIOL-LONDON, V236, P483, DOI 10.1113/jphysiol.1974.sp010448; von Cube B, 1970, Naunyn Schmiedebergs Arch Pharmakol, V265, P455; XU W, 1994, J PHARMACOL EXP THER, V269, P1182; XU W, 1994, NEUROREPORT, V5, P2665, DOI 10.1097/00001756-199412000-00065; YAKSH TL, 1979, BRAIN RES, V171, P176, DOI 10.1016/0006-8993(79)90747-9	52	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	MAY	2004	109	1-2					162	171		10.1016/j.pain.2004.01.030			10	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	816XF	WOS:000221141900020	15082138				2020-06-30	J	Rooney, MB; Mehl, M; Monnet, E				Rooney, MB; Mehl, M; Monnet, E			Intercostal thoracotomy closure: Transcostal sutures as a less painful alternative to circuincostal suture placement	VETERINARY SURGERY			English	Article							DOGS; ANALGESIA; BUPIVACAINE; MORPHINE; ANIMALS	Objective-To determine if transcostal thoracotomy closure resulted in less pain than circumcostal closure. Study Design-Experimental cadaver and prospective clinical study. Animals-Two canine cadavers and 13 adult, 22-29 kg dogs. Methods-Phase 1: In 2 cadavers, 4 suture passage techniques were evaluated to determine the incidence of nerve entrapment in circumcostal intercostal thoracotomy closure. Phase 2: Pain after circumcostal closure (7 dogs) or transcostal closure (6 dogs) of a 4th intercostal space thoracotomy was evaluated by use of pain threshold scores, fentanyl administration rates, heart and respiratory rates, and numerical ratings for behavior. Arterial blood gas analyses were obtained 4 hours postoperatively. Transcostal closure was accomplished by drilling 5-6 small holes in the 5th rib and passing sutures through the holes and around the 4th rib to achieve closure. Pain threshold scores (PTS) were measured by an observer unaware of closure assignment, at 2, 4, 12, and 24 hours after closure by applying slowly increasing pressure to the incision line using a load cell. Rates of fentanyl administration were adjusted based on subjective impressions of dog comfort by a second observer unaware of closure assignment. Results-A 70-100% incidence of nerve entrapment was found for all circumcostal techniques. PTS was higher (P = .045) and fentanyl infusion rates were lower (P = .001) for the transcostal group at 2, 4, 12, and 24 hour postoperatively compared with the circumcostal group. Conclusion-There is a high incidence of nerve entrapment using circumcostal closure techniques. A transcostal technique appears to be associated with less pain during the first 24 hours postoperatively. Clinical Relevance-Based on lower pain scores, transcostal thoracotomy closure may be preferable to circumcostal closure techniques. (C) Copyright 2004 by The American College of Veterinary Surgeons.	Colorado State Univ, Vet Teaching Hosp, Dept Clin Sci, Ft Collins, CO 80523 USA	Rooney, MB (reprint author), Colorado State Univ, Vet Teaching Hosp, Dept Clin Sci, 300 W Drake Rd, Ft Collins, CO 80523 USA.	mbrooney@colostate.edu	Monnet, Eric/A-5821-2010	Monnet, Eric/0000-0002-0058-2210			BATESON P, 1991, ANIM BEHAV, V42, P827, DOI 10.1016/S0003-3472(05)80127-7; Conzemius MG, 1997, J AM VET MED ASSOC, V210, P1619; CONZEMIUS MG, 1994, VET SURG, V23, P291, DOI 10.1111/j.1532-950X.1994.tb00487.x; FERRANTE FM, 1991, ANESTH ANALG, V72, P105; Gilroy BA, 1982, J VET CRIT CARE, V6, P1; Hellyer PW, 1999, VET MED-US, V94, P259; HOLTON L, 1998, J SMALL ANIM PRACT, V39, P369; MARKEL MD, 1991, VET SURG, V20, P209, DOI 10.1111/j.1532-950X.1991.tb00336.x; NARODICK BG, 1975, ARCH SURG-CHICAGO, V110, P442; OLEKSAK MK, 1992, J BONE JOINT SURG BR, V74, P129; PASCOE PJ, 1993, VET SURG, V22, P141, DOI 10.1111/j.1532-950X.1993.tb01689.x; Remedios AM, 1996, COMP CONT EDUC PRACT, V18, P1191; THOMPSON SE, 1991, VET SURG, V20, P73, DOI 10.1111/j.1532-950X.1991.tb00309.x	13	18	19	0	3	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0161-3499			VET SURG	Vet. Surg.	MAY-JUN	2004	33	3					209	213		10.1111/j.1532-950X.2004.04031.x			5	Veterinary Sciences	Veterinary Sciences	820JH	WOS:000221384500003	15104626				2020-06-30	J	Kato, K; Mizaki, T; Yamazaki, S; Nitta, M; Hasegawa, M; Kamiya, Y; Hosoda, R				Kato, K; Mizaki, T; Yamazaki, S; Nitta, M; Hasegawa, M; Kamiya, Y; Hosoda, R			A study of transdermal fentanyl in cancer pain at Aichi-Cancer Center	YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN			English	Article						transdermal fentanyl; pain control; opioid rotation; efficacy ratio	ORAL MORPHINE	In Japan, trasdermal fentanyl (Durotep(R) Patch) was launched in March 2002, and it was regarded as making opioid rotation possible. When changing from morphine to transdermal fentanyl, the efficacy ratio of 1 : 150 is used in Japan as well as in many other countries. However, the ratio of 1 : 100 is used in Germany. As a result, a dose increase in transdermal fentanyl is often required to control pain. We studied transdermal fentanyl use in the Aichi Cancer Center (ACC) to investigate the actual conversion ratio and appropriate switching by following up 144 patients (81 men, 63 women) who had received transdermal fentanyl in the ACC from March 19, 2002, to April 30, 2003. Transdermal fentanyl improved pain control in patients who had difficulty in tolerating oral medication or in continuing morphine because of side effects. Regression analysis indicated that the efficacy ratio of oral morphine to transdermal fentanyl was 1 : 78. As the fentanyl dosage was excessive even in some patients who followed the recommended morphine/fentanyl conversion of 150 : 1, it is dangerous to use the conversion ratio of 78 : I at first. Morphine side effects were reduced in some patients who changed to transdermal fentanyl, but there was no reduction in those who needed high-dose morphine for rescue analgesia. Therefore it is safe and effective to use low-dose transdermal fentanyl in the beginning and to control pain promptly using rescue morphine based on the present recommended dosage. For opioid rotation, quick-acting opioids other than morphine are expected to be launched in Japan.	Aichi Canc Ctr Hosp, Dept Pharm, Chikusa Ku, Nagoya, Aichi 4648681, Japan; Aichi Canc Ctr Hosp, Team Pallat Care, Chikusa Ku, Nagoya, Aichi 4648681, Japan	Kato, K (reprint author), Aichi Canc Ctr Hosp, Dept Pharm, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	kkato@aichi-cc.jp					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; *JANSS PHARM CO LT, 2002, PACK INS DUR PATCH; MIZUGUCHI T, 2001, IYAKU J, V37, P239; MIZUGUCHI T, 2001, IYAKU J, V37, P2403; World Health Organization, 1996, CANC PAIN REL GUID O	6	7	7	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0031-6903			YAKUGAKU ZASSHI	Yakugaku Zasshi-J. Pharm. Soc. Jpn.	MAY	2004	124	5					287	291		10.1248/yakushi.124.287			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	817AC	WOS:000221149400005	15118241	Bronze			2020-06-30	J	Liu, ZH; He, Y; Jin, WQ; Chen, XJ; Shen, QX; Chi, ZQ				Liu, ZH; He, Y; Jin, WQ; Chen, XJ; Shen, QX; Chi, ZQ			Effect of chronic treatment of ohmefentanyl stereoisomers on cyclic AMP formation in Sf9 insect cells expressing human mu-opioid receptors	LIFE SCIENCES			English	Article						ohmefentanyl stereoisomer; mu-opioid receptor; binding affinity; cyclic AMP; Sf9 insect cell	ANALGESIC ACTIVITY; ADENYLATE-CYCLASE; DEPENDENCE; MORPHINE; MICE; ACTIVATION; AGONISTS; PROTEINS; EFFICACY; DELTA	The binding affinity of ohmefentanyl stereoisomers for mu-opioid receptors and the effect of chronic ohmefentanyl stereoisomers pretreatments on intracellular cAMP formation were investigated in Sf9 insect cells expressing human mu-opioid receptors (Sf9-mu cells). Competitive assay of [H-3]ohmefentanyl binding revealed that these isomers had high affinity for mu-opioid receptors in Sf9-mu cells. Isomer F9204 had the highest affinity for mu-opioid receptors with the K-i value of 1.66 +/- 0.28 nM. After pretreated Sf9-mu cells with increasing concentrations of these isomers for 6 h, addition of naloxone (1 muM) precipitated an overshoot of foskolin-stimulated cAMP accumulation. The ability of these isomers to induce cAMP overshoot differed greatly with the order of F9202 > F9205 > F9208 > F9206 > F9204 > F9207. Of these isomers, F9202 was 2.7-fold less potent than F9204 in receptor binding affinity, but 71.5-fold more potent in ability to induce cAMP overshoot. These results suggested that there was a significant stereo-structural difference among ohmefentanyl stereoisomers in ability to induce naloxone-precipitated cAMP overshoot in Sf9-mu cells. (C) 2004 Published by Elsevier Inc.	Chinese Acad Sci, Shanghai Inst Biol Sci, Dept Pharmacol 2, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China; Shanghai Inst Planned Parenthood Res, Shanghai 200032, Peoples R China	Jin, WQ (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Dept Pharmacol 2, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.	wqjin@mail.shcnc.ac.cn					Ammer H, 1996, BRAIN RES, V707, P235, DOI 10.1016/0006-8993(95)01265-6; AVIDORREISS T, 1995, J BIOL CHEM, V270, P29732; BENALAL D, 1985, BIOCHEM J, V227, P389, DOI 10.1042/bj2270389; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; DUMAN RS, 1988, J PHARMACOL EXP THER, V246, P1033; Guo GW, 2000, LIFE SCI, V67, P113, DOI 10.1016/S0024-3205(00)00617-2; Guo GW, 2001, LIFE SCI, V68, P2383, DOI 10.1016/S0024-3205(01)01030-X; Jin WQ, 1996, ACTA PHARM SINIC, V17, P421; Liu JG, 2001, MOL PHARMACOL, V60, P53; Liu ZH, 2003, ACTA PHARMACOL SIN, V24, P859; Massotte D, 1999, J BIOTECHNOL, V69, P39, DOI 10.1016/S0168-1656(98)00209-0; Massotte D, 1997, J BIOL CHEM, V272, P19987, DOI 10.1074/jbc.272.32.19987; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; RASMUSSEN K, 1990, J NEUROSCI, V10, P2038; THOMAS JM, 1987, TRENDS PHARMACOL SCI, V8, P308, DOI 10.1016/0165-6147(87)90124-6; WANG H, 1991, SYNAPSE, V8, P177, DOI 10.1002/syn.890080305; WANG Z, 1994, LIFE SCI, V54, P339; Wang ZJ, 2000, EUR J PHARMACOL, V389, P165, DOI 10.1016/S0014-2999(99)00881-X; WANG ZX, 1995, J MED CHEM, V38, P3652, DOI 10.1021/jm00018a026; Wei Q, 1998, CERAM ENG SCI PROC, V19, P3; Wei Q, 2000, CELL RES, V10, P93, DOI 10.1038/sj.cr.7290039; XU H, 1985, SCI SIN B-CHEM B A M, V28, P504; Xu H, 2001, SYNAPSE, V40, P269, DOI 10.1002/syn.1049; XU H, 1997, ANALGESIA, V3, P35	27	5	7	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205	1879-0631		LIFE SCI	Life Sci.	APR 30	2004	74	24					3001	3008		10.1016/j.lfs.2003.10.027			8	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	809HZ	WOS:000220629100006	15051423				2020-06-30	J	Toivonen, J; Permi, J; Rosenberg, PH				Toivonen, J; Permi, J; Rosenberg, PH			Analgesia and discharge following preincisional ilioinguinal and iliohypogastric nerve block combined with general or spinal anaesthesia for inguinal herniorrhaphy	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anaesthesia : day surgery; anaesthetics, local : bupivacaine; anaesthetic techniques : general, subarachnoid, ilioinguinal-iliohypogastric nerve block; pain : postoperative; surgery : inguinal herniorrhaphy	POSTOPERATIVE PAIN; 0.5-PERCENT BUPIVACAINE; POSTHERNIORRHAPHY PAIN; PREEMPTIVE ANALGESIA; WOUND INFILTRATION; RELIEF	Background: Preincisional ilioinguinal and iliohypogastric nerve block (IINB) reduces postoperative analgesics after inguinal herniorrhaphy. The effect of an IINB on postoperative pain and discharge profile was therefore studied in day-surgery patients undergoing inguinal herniorrhaphy with general or spinal anaesthesia. Methods: Seventy ASA I-II adult patients scheduled for inguinal herniorrhaphy received an IINB before the surgical incision with 15 ml of 0.5% bupivacaine. In a randomized fashion half of them received general anaesthesia with spontaneous breathing via a laryngeal mask (GA-group) and the other half received spinal anaesthesia with 5 mg of bupivacaine diluted with sterile water to 2.5-ml volume (SPIN-group). In the postanaesthesia care unit (PACU), pain was assessed on a scale from 0 to 10 (VAS) and ketorolac 30 mg i.v. (VAS < 5), or fentanyl 0.05 mg i.v. (VAS >= 5) was administered as scheduled. In the day surgery unit and at home the analgesic was a tablet of ibuprofen 200 mg + codeine 30 mg (VAS >= 3). Results: Patients in the SPIN-group reported lower postoperative pain scores at 30, 60 min (P < 0.0001) and 120 min (P < 0.05) after surgery, and longer time to first analgesic use (P < 0.0001). Patients in the GA-group had a shorter time to discharge without voiding (P < 0.001) and with voiding (P < 0.05). After discharge, there were no significant differences between the groups regarding pain scores at rest and at walking, or the doses of analgesic. Adverse events were rare in both groups. Conclusion: Only a relatively short immediate analgesic benefit could be demonstrated by a combination of IINB with spinal anaesthesia compared with IINB combined with general anaesthesia. The use of general anaesthesia facilitated an earlier postoperative discharge than spinal anaesthesia.	S Carelian Cent Hosp, Dept Anaesthesiol, FIN-53130 Lappeenranta, Finland; S Carelian Cent Hosp, Dept Surg, FIN-53130 Lappeenranta, Finland; Univ Helsinki Hosp, Dept Anaesthesiol & Intens Care, Helsinki, Finland	Toivonen, J (reprint author), S Carelian Cent Hosp, Dept Anaesthesiol, Valto Kakelankatu 1, FIN-53130 Lappeenranta, Finland.	juhani.toivonen@ekshp.fi					Bay-Nielsen M, 2001, ANN SURG, V233, P1, DOI 10.1097/00000658-200101000-00001; BUGEDO GJ, 1990, REGION ANESTH, V15, P130; Callesen T, 1999, BRIT J SURG, V86, P1528, DOI 10.1046/j.1365-2168.1999.01320.x; Callesen T, 1998, BRIT J SURG, V85, P1412; CHUNG F, 1995, CAN J ANAESTH, V42, P1056, DOI 10.1007/BF03011083; DING YF, 1995, CAN J ANAESTH, V42, P12, DOI 10.1007/BF03010564; Elliott S, 1997, BRIT J ANAESTH, V79, P446, DOI 10.1093/bja/79.4.446; Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x; HARRISON CA, 1994, BRIT J ANAESTH, V72, P691, DOI 10.1093/bja/72.6.691; Jensen P, 2002, REGION ANESTH PAIN M, V27, P612, DOI 10.1053/rapm.2002.37122; KEHLET H, 1993, ANESTH ANALG, V77, P1048; Klein SM, 2002, REGION ANESTH PAIN M, V27, P476, DOI 10.1053/rapm.2002.35147; Lau H, 2001, Hernia, V5, P17, DOI 10.1007/BF01576159; Liu SS, 1996, ANESTHESIOLOGY, V85, P729, DOI 10.1097/00000542-199610000-00007; Moiniche S, 2002, ANESTHESIOLOGY, V96, P725, DOI 10.1097/00000542-200203000-00032; NEHRA D, 1995, BRIT J SURG, V82, P1245, DOI 10.1002/bjs.1800820929; Ozgun H, 2002, EUR J SURG, V168, P455, DOI 10.1080/110241502321116442; ROSARIO DJ, 1994, BRIT J SURG, V81, P897, DOI 10.1002/bjs.1800810634; Song DJ, 2000, ANESTH ANALG, V91, P876, DOI 10.1097/00000539-200010000-00020; Toivonen J, 2001, ACTA ANAESTH SCAND, V45, P603, DOI 10.1034/j.1399-6576.2001.045005603.x; TVERSKOY M, 1990, ANESTH ANALG, V70, P29, DOI 10.1213/00000539-199001000-00006; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	22	23	23	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2004	48	4					480	485		10.1111/j.1399-6576.2004.00346.x			6	Anesthesiology	Anesthesiology	810HR	WOS:000220695900017	15025612				2020-06-30	J	Gurkan, Y; Canatay, H; Ozdamar, D; Solak, M; Toker, K				Gurkan, Y; Canatay, H; Ozdamar, D; Solak, M; Toker, K			Spinal anesthesia for arthroscopic knee surgery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article; Proceedings Paper	1st World Congress on Regional Anaesthesia and Pain Therapy	2002	Barcelona, SPAIN			arthroscopic knee surgery; intrathecal fentanyl; intrathecal morphine; selective spinal anesthesia; spinal anesthesia; urinary retention	INTRATHECAL MORPHINE; HYPERBARIC BUPIVACAINE; AMBULATORY SURGERY; CESAREAN-SECTION; FENTANYL; RECOVERY; PAIN; MG; VOLUNTEERS; DISCHARGE	Background and objective: The purpose of the study was to compare the effects of adding 50 mug of morphine, 25 mug of fentanyl or saline to 6 mg of hyperbaric bupivacaine on postoperative analgesia and time to urination in patients undergoing arthroscopic knee surgery under spinal anesthesia. Methods: The study was designed in a prospective, randomized, double-blinded and placebo-controlled manner. Sixty ASA I-II patients were randomized into the following three groups: Group BM: 6 mg of bupivacaine and 50 mug of morphine, Group BF: 6 mg of bupivacaine and 25 mug of fentanyl, and Group BS: 6 mg of bupivacaine and saline. Selective spinal anesthesia was performed in a lateral decubitus position, with the operative knee dependent for 10 min. Results: In all groups satisfactory anesthesia was provided during the operation. There was a statistically significant difference between all the groups in times to voiding [Group BM 422 +/- 161 min; Group BF 244 +/- 163 min; Group BS 183 +/- 54 min (mean+/-SD)]. The incidence of pruritus was significantly greater in Group BM (80%) and BF (65%) in comparison with Group BS (no pruritus) (P < 0.05). The incidence of nausea was significantly increased in Group BM (35%) in comparison with Group BF (10%) and Group BS (P < 0.05). Analgesic consumption was significantly greater in Group BS in comparison with Groups BM and BF (P < 0.01). Conclusions: We conclude that during spinal anesthesia even mini-dose intrathecal morphine is not acceptable for outpatient surgery due to side-effects, especially severely prolonged time to urination.	Kocaeli Univ, Sch Med, Dept Anesthesiol & Reanimat, Kocaeli, Turkey	Gurkan, Y (reprint author), Ejgarsvej 24, DK-2920 Charlottenlund, Copenhagen, Denmark.	yavuzg@superonline.com					BAILEY PL, 1993, ANESTHESIOLOGY, V79, P49, DOI 10.1097/00000542-199307000-00010; Bailey PL, 2000, NEW ENGL J MED, V343, P1228, DOI 10.1056/NEJM200010263431705; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BenDavid B, 1996, ANESTH ANALG, V83, P716, DOI 10.1097/00000539-199610000-00009; Casati A, 1998, CAN J ANAESTH, V45, P850, DOI 10.1007/BF03012218; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Gurkan Y, 2002, ANESTH ANALG, V95, P1763, DOI 10.1213/01.ANE.0000033097.30674.02; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; HALPERN S, 1994, ANESTHESIOLOGY, V81, P1376, DOI 10.1097/00000542-199412000-00012; Kamphuis ET, 1998, ANESTHESIOLOGY, V88, P310, DOI 10.1097/00000542-199802000-00007; Ko S, 2003, CAN J ANAESTH, V50, P679, DOI 10.1007/BF03018710; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P342, DOI 10.1034/j.1399-6576.2003.00092.x; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; Liu SS, 1996, ANESTHESIOLOGY, V85, P729, DOI 10.1097/00000542-199610000-00007; Liu SS, 1997, REGION ANESTH, V22, P500; Liu SS, 2001, ANESTHESIOLOGY, V94, P888, DOI 10.1097/00000542-200105000-00030; Milner AR, 1996, ANAESTHESIA, V51, P871, DOI 10.1111/j.1365-2044.1996.tb12622.x; Pavlin DJ, 2002, ANESTH ANALG, V95, P627, DOI 10.1097/00000539-200209000-00025; Pavlin DJ, 1998, ANESTH ANALG, V87, P816, DOI 10.1097/00000539-199810000-00014; Pavlin DJ, 1999, ANESTHESIOLOGY, V91, P42, DOI 10.1097/00000542-199907000-00010; Slappendel R, 1999, ANESTH ANALG, V88, P822, DOI 10.1097/00000539-199904000-00026; Vaghadia H, 1998, CAN J ANAESTH, V45, pR64, DOI 10.1007/BF03019208; Valanne JV, 2001, ANESTH ANALG, V93, P1377, DOI 10.1097/00000539-200112000-00005; WANG JK, 1979, ANESTHESIOLOGY, V50, P149, DOI 10.1097/00000542-197902000-00013	24	16	18	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2004	48	4					513	517		10.1111/j.1399-6576.2004.00353.x			5	Anesthesiology	Anesthesiology	810HR	WOS:000220695900022	15025617				2020-06-30	J	Martin-Cancho, MF; Carrasco-Jimenez, MS; Lima, JR; Ezquerra, LJ; Crisostomo, V; Uson-Gargallo, J				Martin-Cancho, MF; Carrasco-Jimenez, MS; Lima, JR; Ezquerra, LJ; Crisostomo, V; Uson-Gargallo, J			Assessment of the relationship of bispectral index values, hemodynamic changes, and recovery times associated with sevoflurane or propofol anesthesia in pigs	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							NITROUS-OXIDE ANESTHESIA; SPECTRAL EDGE FREQUENCY; CARDIAC-SURGERY; SKIN INCISION; BLOOD-FLOW; ISOFLURANE; ELECTROENCEPHALOGRAM; ALFENTANIL; MOVEMENT; FENTANYL	Objective-To evaluate bispectral index (BIS ) values in pigs during anesthesia maintained with sevoflurane-fentanyl or propofol-fentanyl as a predictor of changes in hemodynamic parameters and duration of recovery from anesthesia. Animals-12 pigs. Procedure-Pigs were randomly allocated to undergo I of 2 anesthetic regimens. Anesthesia was induced with propofol (2 mg/kg, IV); 6 pigs were administered sevoflurane via inhalation (1 minimum alveolar concentration [MAC] at a fresh gas flow rate of 3 L/min; group I), and 6 were administered propofol (11 mg/kg/h, IV; group II). All pigs received fentanyl (2.5 mg/kg, IV, q 30 min). After abdominal surgery, pigs were allowed to recover from anesthesia. Cardiovascular variables and BIS values were recorded at intervals throughout the procedure; duration of recovery from anesthesia was noted. Results-No correlation was established between arterial blood pressure and BIS and between heart rate and BIS. Mean BIS at discontinuation of administration of the anesthetic agent was greater in group-II pigs (65.2 +/- 10.6 minutes) than in group-I pigs (55.8 +/- 2.9 minutes). However, recovery from anesthesia was significantly longer in group II (59.80 +/- 2.52 minutes) than in group I (9.80 +/- 2.35 minutes). Conclusions and Clinical Relevance-In swine anesthetized with sevoflurane or propofol and undergoing abdominal surgery, the BIS value derived from an electroencephalogram at the end of anesthesia was not useful for predicting the speed of recovery from anesthesia. Moreover, BIS was not useful as a predictor of clinically important changes in arterial blood pressure and heart rate in those anesthetized pigs.	Minimally Invas Surg Ctr, Caceres 10071, Spain; Univ Cadiz, Univ Hosp, Sch Med, Dept Anesthesiol, Puerto Real 11011, Spain; Univ Extremadura, Coll Vet Med, Dept Surg, Caceres 10071, Spain	Martin-Cancho, MF (reprint author), Minimally Invas Surg Ctr, Avda Univ S-N, Caceres 10071, Spain.			Crisostomo, Veronica/0000-0003-1740-7029			Antognini JF, 2000, VET RES COMMUN, V24, P361, DOI 10.1023/A:1006400315247; BAUMGARTNER A, 1998, ANESTH ANALG, V86, pS198; Billard V, 1997, CLIN PHARMACOL THER, V61, P45, DOI 10.1016/S0009-9236(97)90181-8; Bruhn J, 2000, ANESTHESIOLOGY, V92, P1485, DOI 10.1097/00000542-200005000-00042; CLAEYS MA, 1988, BRIT J ANAESTH, V60, P3, DOI 10.1093/bja/60.1.3; COCKSHOTT ID, 1992, XENOBIOTICA, V22, P369, DOI 10.3109/00498259209046648; Driessen JJ, 1999, EUR J ANAESTH, V16, P622, DOI 10.1046/j.1365-2346.1999.00551.x; Ebert TJ, 1998, ANESTHESIOLOGY, V89, P1524, DOI 10.1097/00000542-199812000-00032; Eger EI, 1998, ANESTH ANALG, V86, P414, DOI 10.1097/00000539-199802000-00037; Flaishon R, 1997, ANESTHESIOLOGY, V86, P613, DOI 10.1097/00000542-199703000-00013; FRINK EJ, 1992, ANESTHESIOLOGY, V76, P85, DOI 10.1097/00000542-199201000-00013; Gajraj RJ, 1999, BRIT J ANAESTH, V82, P672; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; Gavilanes AWD, 2001, CLIN NEUROPHYSIOL, V112, P52, DOI 10.1016/S1388-2457(00)00499-5; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Greene SA, 2002, COMPARATIVE MED, V52, P424; Greif R, 2002, ANESTH ANALG, V94, P604, DOI 10.1097/00000539-200203000-00023; Haga H. A., 1999, Journal of Veterinary Anaesthesia, V26, P3; Haga HA, 2002, AM J VET RES, V63, P438, DOI 10.2460/ajvr.2002.63.438; Haga Henning A, 2001, Vet Anaesth Analg, V28, P126, DOI 10.1046/j.1467-2987.2001.00051.x; Haskins S.C., 1996, LUMB JONES VET ANEST, P409; Heck M, 2000, J CARDIOTHOR VASC AN, V14, P693, DOI 10.1053/jcan.2000.18447; Hikasa Y, 1996, VET SURG, V25, P234, DOI 10.1111/j.1532-950X.1996.tb01407.x; Ibrahim AE, 2001, ANESTHESIOLOGY, V95, P1151, DOI 10.1097/00000542-200111000-00019; Johnson CB, 1998, BRIT J ANAESTH, V81, P748, DOI 10.1093/bja/81.5.748; Katoh T, 1998, ANESTHESIOLOGY, V88, P642, DOI 10.1097/00000542-199803000-00014; KEARSE LA, 1994, ANESTHESIOLOGY, V81, P1365, DOI 10.1097/00000542-199412000-00010; KING BS, 1994, ANESTHESIOLOGY, V81, P1484, DOI 10.1097/00000542-199412000-00024; Kussman BD, 2001, PAEDIATR ANAESTH, V11, P663, DOI 10.1046/j.1460-9592.2001.00740.x; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; MANOHAR M, 1984, J PHARMACOL EXP THER, V231, P640; Martin-Cancho MF, 2003, AM J VET RES, V64, P866, DOI 10.2460/ajvr.2003.64.866; Masuda T, 1999, Masui, V48, P621; Mavoungou P, 2000, ANN FR ANESTH, V19, P582; Mi WD, 1998, CAN J ANAESTH, V45, P19, DOI 10.1007/BF03011986; OTTO K, 1991, VET SURG, V20, P362, DOI 10.1111/j.1532-950X.1991.tb01284.x; Park WK, 1996, ANESTHESIOLOGY, V84, P1166, DOI 10.1097/00000542-199605000-00019; Peduto VA, 2000, EUR J ANAESTH, V17, P138, DOI 10.1046/j.1365-2346.2000.00626.x; PRYNN RB, 1968, AM J VET RES, V29, P1913; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; RAMPIL IJ, 1994, ANESTHESIOLOGY, V80, P606, DOI 10.1097/00000542-199403000-00017; ROBERTSON SA, 1992, AM J VET RES, V53, P1027; Robinson BJ, 1999, ACTA ANAESTH SCAND, V43, P185, DOI 10.1034/j.1399-6576.1999.430211.x; ROSE M, 1972, AM J VET RES, V33, P437; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; SEBEL PS, 1995, J CLIN MONITOR, V11, P83, DOI 10.1007/BF01617729; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; SILVER M, 1980, ANIMAL MODELS FETAL, P89; Singh H, 1999, EUR J ANAESTH, V16, P610, DOI 10.1046/j.1365-2346.1999.00549.x; SMITH AC, 1997, ANESTHESIA ANALGESIA, P321; SMITH I, 1994, ANESTH ANALG, V79, P313; Song DJ, 1998, ANESTH ANALG, V87, P1245, DOI 10.1097/00000539-199812000-00006; STEFFEY EP, 1996, LUMB JONES VET ANEST, P316; Tendillo F J, 1996, Rev Esp Anestesiol Reanim, V43, P126; THURMON JC, 1996, LUMB JONES VET ANEST, P16; VERNON JM, 1995, ANESTH ANALG, V80, P780, DOI 10.1097/00000539-199504000-00023; Vivien B, 2003, ANESTHESIOLOGY, V99, P9, DOI 10.1097/00000542-200307000-00006; WHITE PF, 1989, ANESTH ANALG, V68, P177, DOI 10.1213/00000539-198902000-00020	60	25	25	0	4	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645			AM J VET RES	Am. J. Vet. Res.	APR	2004	65	4					409	416		10.2460/ajvr.2004.65.409			8	Veterinary Sciences	Veterinary Sciences	805LG	WOS:000220367200006	15077681				2020-06-30	J	von Ungern-Sternberg, BS; Regli, A; Bucher, E; Reber, A; Schneider, MC				von Ungern-Sternberg, BS; Regli, A; Bucher, E; Reber, A; Schneider, MC			The effect of epidural analgesia in labour on maternal respiratory function	ANAESTHESIA			English	Article						analgesia, epidural; anaesthesia, obstetric; labour, obstetric; respiratory physiology	PREGNANCY	Lumbar epidural analgesia during labour has gained widespread acceptance. The impact of epidural analgesia based on mixtures of low-dose local anaesthetic solutions and lipophilic opioids on most clinically relevant obstetric outcomes is minimal. Since the pregnant state per se is associated with important alterations in respiration, we assessed whether a subtle degree of motor blockade brought about by epidural analgesia might compromise respiratory function as assessed by spirometry. Sixty consenting parturients receiving epidural analgesia were consecutively included in this prospective study. We performed spirometry during the antepartum visit and in labour after effective epidural analgesia was established; at both assessments the women were pain-free. Values were within normal ranges but increased significantly after effective epidural analgesia; median (IQR [range]) increase for vital capacity 7.4 (3.0-13 [-12-27])% (p < 0.001); forced vital capacity 4.4 (1.7-9.8 [-13-26])% (p < 0.001); forced expiratory volume in 1 s 5.5 (1.7-8.6 [-14-28])% (p < 0.001); and peak expiratory flow rate 2.3 (-1.6-5.8 [-18-16])% (p = 0.01)). We conclude that epidural analgesia for labour significantly improved respiratory function.	Univ Basel, Kantonsspital, Dept Anaesthesia, CH-4031 Basel, Switzerland; Spital Zollikerberg, Dept Anaesthesia, CH-8125 Zollikerberg, Switzerland	von Ungern-Sternberg, BS (reprint author), Univ Basel, Kantonsspital, Dept Anaesthesia, CH-4031 Basel, Switzerland.	bvonungern@uhbs.ch		Regli, Adrian/0000-0002-3960-6013; von Ungern-Sternberg, Britta/0000-0002-8043-8541			BALDWIN GR, 1977, AM J OBSTET GYNECOL, V127, P235, DOI 10.1016/0002-9378(77)90460-4; CAMANN WR, 1990, INT ANESTHESIOL CLIN, V28, P2, DOI 10.1097/00004311-199002810-00002; CORLI O, 1986, PAIN, V26, P53, DOI 10.1016/0304-3959(86)90173-9; Crass C, 2003, ANAESTHESIST, V52, P727, DOI 10.1007/s00101-003-0542-7; DESWIET M, 1980, CLIN PHYSL OBSTETRIC, P79; HAGERDAL M, 1983, ANESTHESIOLOGY, V59, P425; KNUTTGEN HG, 1974, J APPL PHYSIOL, V36, P549; PROWSE CM, 1965, ANESTHESIOLOGY, V26, P381, DOI 10.1097/00000542-196507000-00003; Schneider MC, 2002, ANAESTHESIST, V51, P959, DOI 10.1007/s00101-002-0414-6; 1993, EUR RESP J S, V16, P1	10	16	18	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	APR	2004	59	4					350	353		10.1111/j.1365-2044.2004.03667.x			4	Anesthesiology	Anesthesiology	803VD	WOS:000220257700008	15023105				2020-06-30	J	Ortolani, O; Conti, A; Chan, YK; Sie, MY; Ong, GSY				Ortolani, O; Conti, A; Chan, YK; Sie, MY; Ong, GSY			Comparison of propofol consumption and recovery time in Caucasians from Italy, with Chinese, Malays and Indians from Malaysia	ANAESTHESIA AND INTENSIVE CARE			English	Article						anaesthesia, anesthesia; intravenous : propofol, fentanyl, cytochrome p450, Caucasian, Asian	LIVER-MICROSOMES; ANESTHESIA; RAT	Differences in sensitivity to anaesthetic drugs may exist among different ethnic groups. Allelic variants for drug metabolizing isoenzymes and pharmacokinetic differences may account for a variable response to some anaesthetic drugs. This study was designed to compare propofol consumption and recovery characteristics in four ethnic groups: fo Chinese, Malays, and Indians in Malaysia and Caucasians in Italy. Patients undergoing total intravenous anaesthesia with propofol and fientanyl were evaluated for propofol consumption and recovery time. The Bispectral Index (BIS) was used to maintain the same anaesthesis depth in all patients. The BIS value, the response to verbal stimuli and eye-opening time were used to assess recovery. After propofol discontinuation the BIS values returned to baseline in 11+/-4.2 min for Caucasians, in 12.5+/-5.1 min for Chinese, 15.9+/-6.3 min for Malays and 22.1+/-8.1 for Indians. Time to eye-opening was 11.63+/-4.2 min in Caucasians, 13.23+/-4.9 min in Chinese, 16.97+/-5.2 min in Malays and 22.3+/-6.6 min in Indians. The propofol consumption was significantly lower in Indians compared to the other three groups (P<0.01). The recovery of Indians was much slower compared to Chinese, Malays and Caucasians. The recovery time of Malays is significantly slower compared to Chinese and Caucasians. Differences in propofol consumption and recovery time were not significant between Chinese and Caucasians, but the ratio recovery time/propofol consumption was significantly lower in Caucasians compared to all the othergroup.	Univ Malaya, Med Ctr, Dept Anaesthesiol, Kuala Lumpur, Malaysia; Univ Naples Federico II, Dipartimento Biol & Patol Cellular & Mol, Naples, Italy; Univ Florence, Dipartimento Area Crit Med Chirurg, Sezione Anestesia & Rianimaz, Unita Anestesia & Rianimaz Sperimentali, Florence, Italy	Ortolani, O (reprint author), Via Carducci 42, I-80121 Naples, Italy.		Ong, Gracie/B-8554-2010; Conti, Anna/G-5130-2012	Conti, Anna/0000-0002-2054-7375			Bradford LD, 2002, PHARMACOGENOMICS, V3, P229, DOI 10.1517/14622416.3.2.229; Court MH, 2001, ANESTHESIOLOGY, V94, P110, DOI 10.1097/00000542-200101000-00021; Nakayama M, 2002, J CLIN ANESTH, V14, P146, DOI 10.1016/S0952-8180(01)00375-0; Ortolani O, 2001, ANESTH ANALG, V93, P1222, DOI 10.1097/00000539-200111000-00036; ORTOLANI O, 2003, IN PRESS EUR J ANAES, P20; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Shimizu M, 2003, BIOL PHARM BULL, V26, P216, DOI 10.1248/bpb.26.216; SIMONS PJ, 1991, XENOBIOTICA, V21, P1243, DOI 10.3109/00498259109043199; SUTHERLAND L, 1993, BIOCHEM PHARMACOL, V45, P295, DOI 10.1016/0006-2952(93)90064-4; Vuyk J, 2001, Acta Anaesthesiol Belg, V52, P445; Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815	11	15	17	1	3	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	APR	2004	32	2					250	255		10.1177/0310057X0403200215			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	816GA	WOS:000221097200015	15957725	Bronze			2020-06-30	J	Menzebach, A; Hirsch, J; Nost, R; Mogk, M; Hempelmann, G; Welters, ID				Menzebach, A; Hirsch, J; Nost, R; Mogk, M; Hempelmann, G; Welters, ID			Morphine inhibits complement receptor expression, phagocytosis and oxidative burst by a nitric oxide dependant mechanism	ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE			German	Article						morphine; fentanyl; monocyte; complement receptor expression; phagocytosis; oxidative burst; nitric oxide	MU(3) OPIATE RECEPTOR; RESPIRATORY BURST; ENDOTHELIAL-CELLS; IMMUNOCYTES; NEUTROPHILS; ALFENTANIL; MONOCYTES; METHADONE; CYTOKINE; FENTANYL	Objective: Monocytes play a crucial role in the immune response by recognition, ingestion, and intracellular killing of microorganisms. We investigated whether morphine and fentanyl influence CD 11b and CD35 surface receptor expression, phagocytic activity and superoxide anion generation of monocytes in a whole blood flow cytometric assay. Methods: Whole blood of 13 healthy volunteers was incubated with different morphine and fentanyl concentrations. Expression of surface receptors CD 11b and CD35 was determined by fluorochrome-label led antibodies. Phagocytic activity was assessed by ingestion of fluorescent bacteria. Conversion of dihydrorhodamin served for oxidative burst measurements. Results: Morphine inhibited monocyte function in a concentration and time dependent manner. Morphine-induced changes were abolished by preincubation with the NO synthase inhibitor N-nitro-1-arginine as well as naloxone. Fentanyl failed to inhibit receptor expression, phagocytosis and reactive oxygen production by monocytes in clinically relevant as well as supraclinical concentrations. Conclusion: Our results suggest that these monocyte functions are inhibited by a morphine-stimulated NO release mediated by a p opiate receptor subtype expressed on the surface of monocytes. in contrast, fentanyl did not share morphine's inhibitory effects on monocyte activity.	Univ Giessen Klinikum, Abt Anasthesiol Intens Med & Schmerztherapie, D-35385 Giessen, Germany; Univ Oxford, John Radcliffe Hosp, AICU, Oxford OX3 9DU, England	Menzebach, A (reprint author), Univ Giessen Klinikum, Abt Anasthesiol Intens Med & Schmerztherapie, Rudolf Buchheim Str 7, D-35385 Giessen, Germany.						Beck M, 2002, PAIN, V98, P187, DOI 10.1016/S0304-3959(02)00044-1; Bilfinger TV, 1998, INT J CARDIOL, V64, pS61, DOI 10.1016/S0167-5273(98)00037-0; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Brix-Christensen V, 1998, ACTA ANAESTH SCAND, V42, P63, DOI 10.1111/j.1399-6576.1998.tb05082.x; Cadet P, 2003, J IMMUNOL, V170, P5118, DOI 10.4049/jimmunol.170.10.5118; Cadet P, 2000, ENDOTHELIUM-NEW YORK, V7, P185, DOI 10.3109/10623320009165316; CHUANG TK, 1995, BIOCHEM BIOPH RES CO, V216, P922, DOI 10.1006/bbrc.1995.2709; EDWARDS SW, 1995, IMMUNOL TODAY, V16, P508, DOI 10.1016/0167-5699(95)80041-7; EDWARDS SW, 1994, BIOCH PHYSL NEUROTRO, P30; Endo S, 1996, RES COMMUN MOL PATH, V91, P347; KRUMHOLZ W, 1995, ACTA ANAESTH SCAND, V39, P624, DOI 10.1111/j.1399-6576.1995.tb04138.x; KRUMHOLZ W, 1993, ACTA ANAESTH SCAND, V37, P386, DOI 10.1111/j.1399-6576.1993.tb03734.x; Lotsch J, 2001, ANESTHESIOLOGY, V95, P1329; Luza Jiri, 1992, Acta Universitatis Palackianae Olomucensis Facultatis Medicae, V134, P47; Magazine HI, 1996, J IMMUNOL, V156, P4845; MAKMAN MH, 1994, ADV NEUROIMMUNOL, V4, P69, DOI 10.1016/S0960-5428(05)80002-6; Parratt JR, 1998, J ANTIMICROB CHEMOTH, V41, P31, DOI 10.1093/jac/41.suppl_1.31; PETERSON PK, 1989, J INFECT DIS, V159, P480, DOI 10.1093/infdis/159.3.480; PRIETO J, 1989, SCAND J IMMUNOL, V29, P391, DOI 10.1111/j.1365-3083.1989.tb01138.x; ROTHE G, 1988, NATURWISSENSCHAFTEN, V75, P354, DOI 10.1007/BF00368326; Roy S, 1999, J NEUROIMMUNOL, V95, P107, DOI 10.1016/S0165-5728(98)00265-3; Roy S, 1998, BIOCHEM BIOPH RES CO, V245, P392, DOI 10.1006/bbrc.1998.8415; Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018; STEFANO GB, 1994, ADV NEUROIMMUNOL, V4, P57, DOI 10.1016/S0960-5428(05)80001-4; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; Stefano GB, 1996, CRIT REV IMMUNOL, V16, P109, DOI 10.1615/CritRevImmunol.v16.i2.10; Welters I, 2003, ANAESTHESIST, V52, P442, DOI 10.1007/s00101-003-0506-y; Welters ID, 2000, ANESTHESIOLOGY, V92, P1677, DOI 10.1097/00000542-200006000-00027; Welters ID, 2000, J NEUROIMMUNOL, V111, P139, DOI 10.1016/S0165-5728(00)00401-X; Welters ID, 2000, MED HYPOTHESES, V54, P263, DOI 10.1054/mehy.1999.0032	30	13	15	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0939-2661	1439-1074		ANASTH INTENSIV NOTF	Anasthesiol. Intensivmed. NotfMed. Schmerzther.	APR	2004	39	4					204	211		10.1055/s-2004-814389			8	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	816DV	WOS:000221091500004	15098168				2020-06-30	J	Hagihira, S; Takashina, M; Mori, T; Ueyama, H; Mashimo, T				Hagihira, S; Takashina, M; Mori, T; Ueyama, H; Mashimo, T			Electroencephalographic bicoherence is sensitive to noxious stimuli during isoflurane or sevoflurane Anesthesia	ANESTHESIOLOGY			English	Article							BISPECTRAL ANALYSIS; ANALGESIA; RESPONSES; FENTANYL; DEPTH	Background: The authors previously reported changes in electroencephalographic bicoherence during isoflurane anesthesia combined with epidural anesthesia. Here, they examined the influence of noxious stimuli on electroencephalographic bicoherence as well as on the Bispectral Index (BIS) and the 95% spectral edge frequency (SEF95). Methods: The authors enrolled 48 elective abdominal surgery patients (aged 22-77 years; American Society of Anesthesiologists physical status I or II). Raw electroencephalographic signals as well as BIS and SEF95 were recorded on a computer using a BIS(R) monitor (A-1050) and Bispectrum Analyzer (BSA) for BIS (the authors' original software). Using BSA for BIS, the authors evaluated the two peak heights of electroencephalographic bicoherence. Anesthesia was induced with 3 mg/kg thriopental and was maintained with, in air-oxygen, 1.0% isoflurane or 1.5% sevoflurane. After confirming the steady state, the authors recorded baseline values. In experiment 1, they administered 3 mug/kg fentanyl 5 min after incision and investigated the changes in electroencephalographic derivatives at 5 and 10 min after incision. In experiment 2, they administered a similar dose of fentanyl 5 min before incision and investigated the changes in electroencephalographic derivatives immediately before and 5 min after incision. Results: In experiment 1, after incision, both peak heights of electroencephalographic bicoherence significantly decreased but returned to control values after fentanyl administration. By contrast, after incision, BIS and SEF95 showed individual variability. In experiment 2, although fentanyl itself did not affect all electroencephalographic derivatives before incision, the variables remained unchanged after incision. Conclusion: Noxious stimuli decreased the peak heights of electroencephalographic bicoherence, an effect that was counteracted by fentanyl analgesia.	Osaka Univ, Grad Sch Med, Dept Anesthesiol, Suita, Osaka 5650871, Japan; Osaka Prefectural Habikino Hosp, Osaka, Japan	Hagihira, S (reprint author), Osaka Univ, Grad Sch Med, Dept Anesthesiol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	hagihira@masui.med.osaka-u.ac.jp					Antognini JF, 2002, BRIT J ANAESTH, V89, P156, DOI 10.1093/bja/aef156; BISCHOFF P, 1993, ANAESTHESIST, V42, P142; Goto T, 2001, Masui, V50 Suppl, pS131; Guignard B, 2000, ANESTH ANALG, V90, P161, DOI 10.1097/00000539-200001000-00034; Hagihira S, 2002, ANESTHESIOLOGY, V97, P1409, DOI 10.1097/00000542-200212000-00012; Hagihira S, 2001, ANESTH ANALG, V93, P966, DOI 10.1097/00000539-200110000-00032; Hodgson PS, 2001, ANESTHESIOLOGY, V94, P799, DOI 10.1097/00000542-200105000-00018; KAADA BR, 1967, ELECTROEN CLIN NEURO, V22, P220, DOI 10.1016/0013-4694(67)90224-6; Kiyama S, 1997, BRIT J ANAESTH, V79, P750; KOCHS E, 1994, ANESTHESIOLOGY, V80, P1026, DOI 10.1097/00000542-199405000-00012; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Ropcke H, 2001, ANESTHESIOLOGY, V94, P390; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; Segawa H, 1998, ANESTHESIOLOGY, V89, P1407, DOI 10.1097/00000542-199812000-00018; SIGL JC, 1994, J CLIN MONITOR, V10, P392, DOI 10.1007/BF01618421; ZBINDEN AM, 1994, ANESTHESIOLOGY, V80, P261, DOI 10.1097/00000542-199402000-00005	17	49	50	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	APR	2004	100	4					818	825		10.1097/00000542-200404000-00011			8	Anesthesiology	Anesthesiology	806LZ	WOS:000220436700010	15087616				2020-06-30	J	Pandey, CK; Priye, S; Singh, S; Singh, U; Singh, RB; Singh, PK				Pandey, CK; Priye, S; Singh, S; Singh, U; Singh, RB; Singh, PK			Preemptive use of gabapentin significantly decreases postoperative pain and rescue analgesic requirements in laparoscopic cholecystectomy	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							NEUROPATHIC PAIN; RAT MODEL; TRAMADOL; MORPHINE; SENSITIZATION; PLACEBO	Purpose: To evaluate the comparative preemptive effects of gabapentin and tramadol on postoperative pain and fentanyl requirement in laparoscopic cholecystectomy. Methods: Four hundred fifty-nine ASA I and II patients were randomly assigned to receive 300 mg gabapentin, 100 mg tramadol or placebo in a double-blind manner two hours before laparoscopic cholecystectomy under general anesthesia. Postoperatively, patients' pain scores were recorded on a visual analogue scale every two hours for the initial 12 hr and thereafter every three hours for the next 12 hr. Patients received fentanyl 2 mug.k(-1) intravenously on demand. The total fentanyl consumption for each patient was recorded. Results: Patients in the gabapentin group had significantly lower pain scores at all time intervals (2.65 +/- 3.00, 1.99 +/- 1.48, 1.40 +/- 0.95, 0.65 +/- 0.61) in comparison to tramadol (2.97 +/- 2.35, 2.37 +/- 1.45, 1.89 +/- 1.16, 0.87 +/- 0.50) and placebo (5.53 +/- 2.22, 3.33 +/- 1.37, 2.41 +/- 1.19, 1.19 +/- 0.56). Significantly less fentanyl was consumed in the gabapentin group (221.16 +/- 52.39 mug) than in the tramadol (269.60 +/- 44.17 mug) and placebo groups (355.86 +/- 42.04 mug; P < 0.05). Sedation (33.98%), nausea/retching/vomiting (24.8%) were the commonest side effects in the gabapentin group whereas respiratory depression (3.9%) was the commonest in the tramadol group and vertigo (7.8%) in the placebo group. Conclusion: Preemptive use of gabapentin significantly decreases postoperative pain and rescue analgesic requirement in laparoscopic cholecystectomy.	Sanjay Gandhi Postgrad Inst Med Sci, Dept Anaesthesiol & Biostat, Lucknow 226014, Uttar Pradesh, India	Pandey, CK (reprint author), Sanjay Gandhi Postgrad Inst Med Sci, Dept Anesthesiol, Lucknow 226014, Uttar Pradesh, India.	ckpandey@sgpgi.ac.in					Abdi S, 1998, ANESTH ANALG, V87, P1360, DOI 10.1097/00000539-199812000-00027; Chiaretti A, 2000, CHILD NERV SYST, V16, P93, DOI 10.1007/s003810050019; Dirks J, 2002, ANESTHESIOLOGY, V97, P102, DOI 10.1097/00000542-200207000-00015; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; Eckhardt K, 2000, ANESTH ANALG, V91, P185, DOI 10.1097/00000539-200007000-00035; Fassoulaki A, 2002, ANESTH ANALG, V95, P985, DOI 10.1097/00000539-200210000-00036; Field MJ, 1997, J PHARMACOL EXP THER, V282, P1242; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; GOA KL, 1993, DRUGS, V46, P409, DOI 10.2165/00003495-199346030-00007; Jun JH, 1998, ANESTH ANALG, V86, P348, DOI 10.1097/00000539-199802000-00025; LEE CR, 1993, DRUGS, V46, P313, DOI 10.2165/00003495-199346020-00008; Mao JR, 2000, ANESTH ANALG, V91, P680, DOI 10.1213/00000539-200009000-00034; Naguib M, 1998, CAN J ANAESTH, V45, P1168, DOI 10.1007/BF03012458; Nicholson B, 2000, ACTA NEUROL SCAND, V101, P359, DOI 10.1034/j.1600-0404.2000.0006a.x; Pandey CK, 2002, ANESTH ANALG, V95, P1719, DOI 10.1097/00000539-200212000-00046; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Taylor CP, 1998, EPILEPSY RES, V29, P233, DOI 10.1016/s0920-1211(97)00084-3; Werner MU, 2001, REGION ANESTH PAIN M, V26, P322, DOI 10.1053/rapm.2001.25070; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; Wu CT, 1999, ANESTH ANALG, V88, P1331, DOI 10.1097/00000539-199906000-00025	20	128	132	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	APR	2004	51	4					358	363		10.1007/BF03018240			6	Anesthesiology	Anesthesiology	812ZF	WOS:000220876700012	15064265	Bronze			2020-06-30	J	Ting, CK; Hu, JS; Teng, YH; Chang, YY; Tsou, MY; Tsai, SK				Ting, CK; Hu, JS; Teng, YH; Chang, YY; Tsou, MY; Tsai, SK			Desflurane accelerates patient response during the wake-up test for scoliosis surgery	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							BISPECTRAL ELECTROENCEPHALOGRAM ANALYSIS; MONITORING DEPTH; ANESTHESIA; PROPOFOL; RECALL; INDEX; ISOFLURANE; CONSCIOUSNESS; ALFENTANIL; INDUCTION	Purpose: To evaluate if desflurane possesses a shorter wake-up onset time and less incidence of recall than fentanyl-based anesthesia. Methods: Forty ASA class I-II adolescents, were enrolled into either a desflurane (DES) group, or a fentanyl (FEN) group for scoliosis surgery. Bispectral index (BIS) was monitored continuously in all patients throughout the procedure; the relationship between the wake-up time and BIS value was evaluated. Results: Patients in the DES group had a significantly shorter wakeup onset than patients in the FEN group (4.1 +/- 0.6 vs 8.9 +/- 2.1 min, P < 0.0 1). No recall occurred during the wake-up test in the DES group, while five patients had recall in the FEN group, including two patients who recalled a given colour. Extubation time was significantly shorter in the DES group than in the FEN group (7.2 +/- 0.6 vs 16 +/- 11.9 min, P < 0.0 1). BIS values were significantly higher in the FEN group than in the DES group during anesthesia. (62 +/- 4.5 vs 42 +/- 5.3, P < 0,05) BIS after the wake-up test was similar in both groups (90 +/- 2.9 vs 93.8 +/- 2.5). There was a latency period (3.3 +/- 1.2 min) between the maximal BIS value and wake-up time in the FEN group but not in the DES group. Conclusions: DES provides a significantly shorter onset time during the wake-up test and a rapid emergence after scoliosis surgery. BIS monitoring during the wake-up test was more informative when anesthesia was maintained with DES compared to FEN infusion.	Natl Yang Ming Univ, Vet Gen Hosp, Sch Med, Dept Anesthesiol, Taipei 112, Taiwan	Tsai, SK (reprint author), Natl Yang Ming Univ, Dept Anesthesiol, Sec 2,201 Shi Pai Rd, Taipei 112, Taiwan.	sktsai@vghtpe.gov.tw	Ting, Chien-Kun/C-1389-2012	Ting, Chien-Kun/0000-0002-3156-8139			Barr G, 2000, BRIT J ANAESTH, V84, P749; DEXTER F, 1995, ANESTHESIOLOGY, V83, P77; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; Gajraj RJ, 1998, BRIT J ANAESTH, V80, P46; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; HALL JE, 1978, J BONE JOINT SURG AM, V60, P533, DOI 10.2106/00004623-197860040-00017; Iselin-Chaves Irene A., 1998, Anesthesia and Analgesia, V87, P949, DOI 10.1097/00000539-199810000-00038; LEE CM, 1993, CAN J ANAESTH, V40, P487, DOI 10.1007/BF03009728; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; McCann ME, 2002, ANESTH ANALG, V94, P1474, DOI 10.1097/00000539-200206000-00018; Mi WD, 1998, CAN J ANAESTH, V45, P19, DOI 10.1007/BF03011986; Mychaskiw G, 2001, ANESTH ANALG, V92, P808; PATEL SS, 1995, DRUGS, V50, P742, DOI 10.2165/00003495-199550040-00010; Schneider G, 1997, EUR J ANAESTH, V14, P21, DOI 10.1097/00003643-199705001-00005; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; SUDHIR KG, 1976, ANESTH ANALG, V55, P526; TSAI SK, 1992, BRIT J ANAESTH, V69, P255, DOI 10.1093/bja/69.3.255	17	9	18	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	APR	2004	51	4					393	397		10.1007/BF03018246			5	Anesthesiology	Anesthesiology	812ZF	WOS:000220876700018	15064271	Bronze			2020-06-30	J	Martin-Larrauri, R; Gilsanz, E; Rodrigo, J; Vila, P; Ledesma, M; Casimiro, C				Martin-Larrauri, R; Gilsanz, E; Rodrigo, J; Vila, P; Ledesma, M; Casimiro, C			Conventional stepwise vs. vital capacity rapid inhalation induction at two concentrations of sevoflurane	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthesia, inhalation; anaesthetics, inhalation, nitrous oxide; anaesthetics, volatile, sevoflurane; intubation, intratracheal, laryngeal masks	TIDAL BREATHING TECHNIQUES; LARYNGEAL MASK AIRWAY; NITROUS-OXIDE; INTRAVENOUS INDUCTION; ANESTHESIA; HALOTHANE; PROPOFOL; ADULTS; OXYGEN; MAINTENANCE	Background and objective: A multicentre study was conducted to compare three methods of inhalation induction with sevoflurane in adult premedicated patients. Methods: One-hundred-and-twenty-five adult patients of ASA I-II were scheduled for short elective surgical procedures (<90 min) under general anaesthesia with spontaneous ventilation of the lungs via a laryngeal mask airway. Patients were randomly assigned to one of three groups: conventional stepwise inhalation induction group (Group Q or vital capacity rapid inhalation induction groups at 4.5% (Group VC4.5) or at 8% sevoflurane (Group VC8). Before anaesthetic induction, fentanyl 1 mu g kg(-1) was given and the face mask applied with the anaesthetic breathing system primed with sevoflurane 4.5% or 8976 in the respective vital capacity groups. Loss of eyelash reflex, time to cessation of finger tapping, laryngeal mask insertion, side-effects and adequacy of induction were recorded. Results: The time to loss of eyelash reflex was significantly shorter in both vital capacity groups vs. the control group: VC8: 68 +/- 7 s; and VC4.5: 94 +/- 6.5 s vs. C: 118 +/- 6.4 s (P < 0.0001). Significant differences were found in all pairwise comparisons for time to cessation of tapping: Group VC8 (62 +/- 7 s), Group VC4.5 (85 +/- 6 s) and Group C (116 +/- 6 s; P < 0.0001). The time to laryngeal mask insertion was significantly shorter in the Group VC8 (176 +/- 13 s) compared with the other two groups, Group VC4.5 (219 +/- 13 s) and Group C (216 +/- 9 s). There were no significant differences in the incidence of side-effects between the three groups. Conclusions: Inhalation induction of anaesthesia with sevoflurane with the three techniques tested is safe, reliable and well accepted by the patients. The vital capacity rapid inhalation group primed with sevoflurane 8% was the fastest method with no relevant side-effects.	Hosp La Milagrosa, Dept Anaesthesiol, Madrid 28010, Spain; Hosp La Paz, Dept Anaesthesiol, Madrid, Spain; Fdn Jimenez Diaz, Dept Anesthesiol, E-28040 Madrid, Spain; Hosp Badalona Germans Trias & Pujol, Dept Anaesthesiol, Badalona, Spain; Abbott Labs, Dept Med, Madrid, Spain	Martin-Larrauri, R (reprint author), Hosp La Milagrosa, Dept Anaesthesiol, Modesto Lafuente 14, Madrid 28010, Spain.	rmlarrauri@adv.es		Vila Caral, Pere/0000-0003-1436-6604			Baker CE, 1999, ANAESTHESIA, V54, P841; Campbell IT, 1996, EUR J ANAESTH, V13, P1, DOI 10.1097/00003643-199601000-00001; Djaiani GN, 2001, J CARDIOTHOR VASC AN, V15, P169, DOI 10.1053/jcan.2001.21940; DOI M, 1993, CAN J ANAESTH, V40, P122, DOI 10.1007/BF03011308; Goresky GV, 1996, CAN J ANAESTH, V43, P1085, DOI 10.1007/BF03011832; Hall JE, 2000, ANAESTHESIA, V55, P545, DOI 10.1046/j.1365-2044.2000.01476.x; Hall JE, 1997, BRIT J ANAESTH, V79, P342, DOI 10.1093/bja/79.3.342; Hall JE, 1997, ANAESTHESIA, V52, P410, DOI 10.1111/j.1365-2044.1997.091-az0086.x; HALL JE, 1977, BR J ANESTH, V79, P285; Hendrickx JFA, 2000, J CLIN ANESTH, V12, P100, DOI 10.1016/S0952-8180(00)00115-X; ISHII M, 1966, EUR J ANAESTH, V13, P21; Jellish WS, 1996, ANESTH ANALG, V82, P479, DOI 10.1097/00000539-199603000-00009; Lien CA, 1996, J CLIN ANESTH, V8, P639, DOI 10.1016/S0952-8180(96)00172-9; Mendonca C, 2001, ANAESTHESIA, V56, P19, DOI 10.1046/j.1365-2044.2001.01790.x; Moore EW, 2000, EUR J ANAESTH, V17, P33, DOI 10.1046/j.1365-2346.2000.00595.x; Muzi M, 1996, ANESTHESIOLOGY, V85, P536, DOI 10.1097/00000542-199609000-00012; Muzi M, 1997, ANESTH ANALG, V85, P1143, DOI 10.1097/00000539-199711000-00034; Nishiyama T, 2002, J CLIN ANESTH, V14, P290, DOI 10.1016/S0952-8180(02)00361-6; Nishiyama T, 1997, CAN J ANAESTH, V44, P1066; Philip BK, 1999, ANESTH ANALG, V89, P623, DOI 10.1097/00000539-199909000-00014; Plastow SE, 2000, ANAESTHESIA, V55, P475, DOI 10.1046/j.1365-2044.2000.01268.x; RUFFLE JM, 1985, BRIT J ANAESTH, V57, P607, DOI 10.1093/bja/57.6.607; Sloan MH, 1996, ANESTH ANALG, V82, P528, DOI 10.1097/00000539-199603000-00018; Smith CE, 2000, J CLIN ANESTH, V12, P392, DOI 10.1016/S0952-8180(00)00177-X; Smith I, 1997, Acta Anaesthesiol Belg, V48, P161; Thwaites A, 1997, BRIT J ANAESTH, V78, P356; Vanacker B F, 1997, Acta Anaesthesiol Belg, V48, P147; WILTON NCT, 1986, ANAESTHESIA, V41, P472, DOI 10.1111/j.1365-2044.1986.tb13269.x; Wong AYC, 2000, ANAESTH INTENS CARE, V28, P196, DOI 10.1177/0310057X0002800213; YURINO M, 1995, ANAESTHESIA, V50, P308, DOI 10.1111/j.1365-2044.1995.tb04605.x; YURINO M, 1993, CAN J ANAESTH, V40, P440, DOI 10.1007/BF03009514; YURINO M, 1995, ACTA ANAESTH SCAND, V39, P356, DOI 10.1111/j.1399-6576.1995.tb04077.x; YURINO M, 1995, J CLIN ANESTH, V7, P228, DOI 10.1016/0952-8180(95)00006-4; YURINO M, 1993, ANESTH ANALG, V76, P598	34	9	15	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	APR	2004	21	4					265	271		10.1017/S026502150400403X			7	Anesthesiology	Anesthesiology	812JN	WOS:000220835900003	15109188				2020-06-30	J	Ortolani, O; Conti, A; Ngumi, ZW; Texeira, L; Olang, P; Amani, I; Medrado, VC				Ortolani, O; Conti, A; Ngumi, ZW; Texeira, L; Olang, P; Amani, I; Medrado, VC			Ethnic differences in propofol and fentanyl response: a comparison among Caucasians, Kenyan Africans and Brazilians	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthetics, intravenous, propofol; analgesics, opioid, fentanyl; anthropology, physical, racial stocks, Caucasoid race, Negroid race; cytochrome P450 enzyme system; pharmacogenetics; pharmacokinetics	HUMAN LIVER; POPULATION; ANESTHESIA; BAHIA	Background and objective: Differences in sensitivity to anaesthetic drugs may exist among human races. Allelic variants for drug metabolizing isoenzymes and other pharmacokinetic/pharmacodynamic differences may account for a variable response to anaesthetic drugs. This study was designed to investigate comparatively the anaesthetic requirements and the recovery trends of three different ethnic groups: Caucasians, African blacks and Brazilians. Methods: The anaesthetic depth and recovery of groups of 45 patients undergoing total intravenous anaesthesia with propofol and fentanyl were compared. The bispectral index and clinical parameters were used to assess the depth of anaesthesia. The bispectral index, the response to verbal stimuli and the eye opening time were used to assess recovery. Results: After stopping propofol, the bispectral index values of Caucasians returned to the baseline in about 10.8 +/- 4 min, that of Kenyan African blacks in 18 +/- 7 min and that of Brazilians in a highly variable time ranging from 5 to 25 min, (14.9 +/- 9.9). The time from discontinuation of propofol and fentanyl infusion to eye opening was 18.8 +/- 7.1 min in African blacks (P < 0.01) and 13.5 +/- 8.8 min in Brazilians (P > 0.05) vs. 11.6 +/- 4.5 min in Caucasians. Time to respond to verbal commands was 16.8 +/- 8 min in African blacks (P < 0.01) and 12.8 +/- 8.1 min in Brazilians (P > 0.05) vs. 9.9 +/- 4.5 min in Caucasians. Conclusions: The recovery of Kenyan African blacks from anaesthesia with propofol and fentanyl is much slower, in comparison with Caucasians. The recovery time of Brazilians is much more variable, in comparison with Caucasians.	Univ Florence, Dipartimento Area Crit Med Chirurg, Florence, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy; Univ Nairobi, Kenyatta Hosp, Dept Surg, Nairobi, Kenya; Hosp Univ Sao Rafael, Salvador, BA, Brazil	Ortolani, O (reprint author), Via Carducci 42, I-80121 Naples, Italy.	o.ortolani@dfc.unifi.it	Conti, Anna/G-5130-2012	Conti, Anna/0000-0002-2054-7375; NGUMI, ZIPPORAH/0000-0002-8918-7021			AZEVEDO ES, 1980, ANN HUM GENET, V44, P55, DOI 10.1111/j.1469-1809.1980.tb00945.x; AZEVEDO ES, 1982, HUM BIOL, V54, P329; Bradford LD, 2002, PHARMACOGENOMICS, V3, P229, DOI 10.1517/14622416.3.2.229; Court MH, 2001, ANESTHESIOLOGY, V94, P110, DOI 10.1097/00000542-200101000-00021; Favetta P, 2002, BRIT J ANAESTH, V88, P653, DOI 10.1093/bja/88.5.653; Isaza CA, 2000, METHOD FIND EXP CLIN, V22, P695, DOI 10.1358/mf.2000.22.9.802286; Ortolani O, 2001, ANESTH ANALG, V93, P1222, DOI 10.1097/00000539-200111000-00036; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; SIMONS PJ, 1991, XENOBIOTICA, V21, P1243, DOI 10.3109/00498259109043199; SUTHERLAND L, 1993, BIOCHEM PHARMACOL, V45, P295, DOI 10.1016/0006-2952(93)90064-4; Vuyk J, 2001, Acta Anaesthesiol Belg, V52, P445; Wennerholm A, 2001, PHARMACOGENETICS, V11, P417, DOI 10.1097/00008571-200107000-00005; Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815	13	14	19	1	6	GREENWICH MEDICAL MEDIA LTD	LONDON	137 EUSTON RD, 4TH FLOOR, LONDON NW1 2AA, ENGLAND	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	APR	2004	21	4					314	319		10.1017/S0265021504004119			6	Anesthesiology	Anesthesiology	812JN	WOS:000220835900011	15109196				2020-06-30	J	Ng, A; Shah, J; Smith, G				Ng, A; Shah, J; Smith, G			Is continuous spinal analgesia via an epidural catheter appropriate after accidental subarachnoid administration of 15 mL of bupivacaine 0.1% containing fentanyl 2 mu g/mL?	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article							DURAL PUNCTURE; ANESTHESIA; DELIVERY	We report a case of accidental insertion of an epidural catheter into the subarachnoid space and accidental administration of 15 mL of bupivacaine 0.1% with fentanyl 2 mug/mL, in the sitting position, during labour. Within 5 min, the patient was unable to move her lower limbs. Although the upper level of the sensory block using ethyl chloride was found to be T5, there was no cardiovascular depression. The catheter was left in situ and used for continuous spinal analgesia. Further administration of the bupivacaine-fentanyl solution was not required until after 315 min. The patient was given five further 2- to 3-mL top-up doses of bupivacaine-fentanyl at intervals of 105 to 145 min. After 16 h, caesarean section was performed for failure to progress in the first stage of labour. This was conducted under spinal anaesthesia using 2 mL of hyperbaric bupivacaine 0.5% with fentanyl 20 mug. A healthy baby was delivered with Apgar scores of 10 and 10, at 1 and 5 min, respectively. There was no postdural puncture headache or any neurological complications. (C) 2003 Elsevier Ltd. All rights reserved.	Univ Leicester, Dept Anaesthesia Crit Care & Pain Management, Leicester Royal Infirm, Leicester LE5 4PW, Leics, England	Ng, A (reprint author), Univ Leicester, Dept Anaesthesia Crit Care & Pain Management, Leicester Royal Infirm, Gwendolen Rd, Leicester LE5 4PW, Leics, England.	anae@le.ac.uk					Biboulet P, 1998, ANESTHESIOLOGY, V88, P1487, DOI 10.1097/00000542-199806000-00011; COHEN S, 1994, ACTA ANAESTH SCAND, V38, P716, DOI 10.1111/j.1399-6576.1994.tb03983.x; Denny NM, 1998, BRIT J ANAESTH, V81, P590, DOI 10.1093/bja/81.4.590; Horlocker TT, 1997, ANESTH ANALG, V84, P1063, DOI 10.1097/00000539-199705000-00020; Ilias WK, 1998, ANAESTHESIA, V53, P618, DOI 10.1046/j.1365-2044.1998.408-az0514.x; LAMBERT LA, 1994, ANESTHESIOLOGY, V80, P1082, DOI 10.1097/00000542-199405000-00017; MacArthur C, 2001, LANCET, V358, P19; RIGER ML, 1991, ANESTH ANALG, V72, P275; Russell I, 2002, INT J OBSTET ANESTH, V11, P23, DOI 10.1054/ijoa.2001.0883; VUCEVIC M, 1992, BRIT J ANAESTH, V68, P590, DOI 10.1093/bja/68.6.590	10	3	3	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	APR	2004	13	2					107	109		10.1016/j.ijoa.2003.09.002			3	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	806HH	WOS:000220424500010	15321415				2020-06-30	J	Odegard, KC; Schure, A; Saiki, Y; Hansen, DD; Jonas, RA; Laussen, PC				Odegard, KC; Schure, A; Saiki, Y; Hansen, DD; Jonas, RA; Laussen, PC			Anesthetic considerations during caval inflow occlusion in children with congenital heart disease	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						inflow occlusion; atrial septectomy; congenital heart defects; children	STRESS RESPONSES; MANAGEMENT; STENOSIS; CREATION; INFANTS	Objective: Caval inflow occlusion (IO) was introduced to facilitate surgical pulmonary and aortic valvotomy without cardiopulmonary bypass (CPB). Although a technique that is used infrequently today, it remains useful in some patients with complex single-ventricle congenital cardiac defects who require an atrial septectomy. The potential for complications and anesthetic considerations have not been described previously. Design: Retrospective review. Setting: A tertiary care university teaching children's hospital. Participants: Eleven children, median age 3 months (range 3 days-3 years) who underwent (IO) technique for atrial septectomy. Interventions: Atrial septectomy under 10 in patients with restrictive atrial septum. Measurements and Main Results: Eleven children, median age 3 months (range 3 days-3 years), underwent IO for atrial septectomy. Mean duration of IO was 87.7 +/- 25.5 seconds. There was 1 intraoperative death (9%). After release of the caval clamps, inotropic support was necessary in 7 of 11 patients, arrhythmias occurred in 4 of 11 patients (2 atrial and 2 ventricular fibrillation), and 10 of 11 patients required blood transfusion along with boluses of calcium gluconate and sodium bicarbonate to support the circulation immediately post-IO. Duration of postoperative mechanical ventilation was 2.2 +/- 1.6 days; 10 of 11 patients (91%) survived to discharge with mean length of intensive care unit stay 3.7 +/- 2.2 days. Conclusion: IO is an effective technique for short intracardiac procedures without the need for CPB. Close collaboration between anesthesia and surgical staff is essential to keep the duration of 10 as short as possible and because of the potential for hemodynamic instability. (C) 2004 Elsevier Inc. All rights reserved	Childrens Hosp, Cardiac Anesthesia Serv, Dept Anesthesia, Boston, MA 02115 USA; Childrens Hosp, Dept Cardiac Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Odegard, KC (reprint author), Childrens Hosp, Cardiac Anesthesia Serv, Dept Anesthesia, 300 Longwood Ave, Boston, MA 02115 USA.	kirsten.odegard@tch.harvard.edu					ANAND KJS, 1990, CLIN PERINATOL, V17, P207; ANAND KJS, 1990, ANESTHESIOLOGY, V73, P661, DOI 10.1097/00000542-199010000-00012; AWARIEFE SO, 1983, J THORAC CARDIOV SUR, V85, P375; Balfour, 2000, Curr Treat Options Cardiovasc Med, V2, P489, DOI 10.1007/s11936-000-0044-8; BRODMAN R, 1992, J THORAC CARDIOV SUR, V103, P649; Cheung YF, 2000, CARDIOL YOUNG, V10, P186; JONAS RA, 1985, AUST NZ J SURG, V55, P39, DOI 10.1111/j.1445-2197.1985.tb00852.x; JONAS RA, 1985, J THORAC CARDIOV SUR, V89, P780; MARKUS HS, 1995, J CLIN ULTRASOUND, V23, P81, DOI 10.1002/jcu.1870230204; PERRY SB, 1986, AM J CARDIOL, V58, P622, DOI 10.1016/0002-9149(86)90288-2; RASHKIND WJ, 1966, J AMER MED ASSOC, V196, P991; SADE RM, 1982, ANN THORAC SURG, V33, P570, DOI 10.1016/S0003-4975(10)60815-6; SINK JD, 1984, J THORAC CARDIOV SUR, V87, P82; VANSON JAM, 1995, ANN THORAC SURG, V59, P384, DOI 10.1016/0003-4975(94)00841-T; VARCO R, 1951, SURGERY, V30, P29; VOSLOO SM, 1990, J TRAUMA, V30, P514, DOI 10.1097/00005373-199030040-00029	16	4	5	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	APR	2004	18	2					144	147		10.1053/j.jvca.2004.01.017			4	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	813YD	WOS:000220941500005	15073701				2020-06-30	J	Cotter, T; Russo, P; Tobias, JD				Cotter, T; Russo, P; Tobias, JD			Intraoperative jet ventilation during aortic coarctation repair in an infant	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						high-frequency jet ventilation; aortic coarctation; one-lung ventilation; pediatric anesthesia	HIGH-FREQUENCY JET; RESPIRATORY-DISTRESS SYNDROME; OSCILLATORY VENTILATION; TRACHEAL STENOSIS; CHILDREN		Univ Missouri, Dept Anesthesiol, Div Cardiothorac Surg, Columbia, MO 65212 USA; Univ Missouri, Dept Pediat, Div Cardiothorac Surg, Columbia, MO 65212 USA; Univ Missouri, Div Surg, Div Cardiothorac Surg, Columbia, MO 65212 USA	Tobias, JD (reprint author), Univ Missouri, Dept Anesthesiol, Div Cardiothorac Surg, 3W-27G,1 Hosp Dr, Columbia, MO 65212 USA.	Tobiasj@health.missouri.edu		Cotter, Thomas/0000-0003-4626-5613			ARNOLD JH, 1993, CRIT CARE MED, V21, P272, DOI 10.1097/00003246-199302000-00021; Berkenbosch JW, 2002, CRIT CARE MED, V30, P1024, DOI 10.1097/00003246-200205000-00011; BOROS SJ, 1985, PEDIATRICS, V75, P657; DAVIS DA, 1994, ANN THORAC SURG, V57, P846, DOI 10.1016/0003-4975(94)90187-2; DURAND DJ, 1993, J PEDIATR-US, V122, P609; Goto E, 1998, Eur J Emerg Med, V5, P451; Keszler M, 1997, PEDIATRICS, V100, P593, DOI 10.1542/peds.100.4.593; MacIntyre N R, 2001, Respir Care Clin N Am, V7, P599; MELIONES JN, 1991, CIRCULATION, V84, P364; OBARA H, 1988, ANESTHESIOLOGY, V68, P441; Paulson TE, 1996, J PEDIATR-US, V129, P566, DOI 10.1016/S0022-3476(96)70122-1; SCHUR MS, 1988, ANESTHESIOLOGY, V68, P952, DOI 10.1097/00000542-198806000-00024; SMITH DW, 1993, PEDIATR PULM, V15, P279, DOI 10.1002/ppul.1950150504; TOBIAS JD, 2001, CURR OPIN ANESTH, V47, P77; Vernon D, 1996, Respir Care Clin N Am, V2, P559	15	1	1	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	APR	2004	18	2					207	209		10.1053/j.jvca.2004.01.012			3	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	813YD	WOS:000220941500019	15073715				2020-06-30	J	Wolfe, LL; Lance, WR; Miller, MW				Wolfe, LL; Lance, WR; Miller, MW			Immobilization of mule deer with thiafentanil (A-3080) or thiafentanil plus xylazine	JOURNAL OF WILDLIFE DISEASES			English	Article						A-3080; chemical immobilization; Colorado; mule deer; naltrexone; Odocoileus hemionus; opioid narcotics; thiafentanil; xylazine	ELK	We evaluated thiafentanil oxalate (A-3080) for the immobilization of mule deer (Odocoileus hemionus) under laboratory and field conditions. In a crossover experiment comparing recommended (0.1 mg/kg) and 2x recommended thiafentanil doses in captive deer, both produced rapid induction and immobilization. Mean induction was shorter (P=0.013) for the 2x group (1.9 vs. 3 min); mean reversals for both groups were rapid (recommended=0.9 min after naltrexone injection; 2x = 1 min) and did not differ (P=0.29). Six free-ranging mule deer were immobilized with 7 mg thiafentanil and four with 10 mg; mean induction was 2.3 min for both groups (95% confidence interval [CI]: 7 mg, 1.2-3.4; 10 mg, 1.9-2.8), and mean reversal was <1 min for both groups. Of 1.65 free-ranging deer darted with various combinations of thiafentanil and xylazine, we successfully immobilized 148 (90%). Mean induction ranged front 2.1 to 4.9 min for different drug combinations. Reversals were not compared because naltrexone and yo-himbine doses varied, but overall mean reversal was 1.9 min (95% CI, 1.7-2.1 min) after injection of naltrexone and yohimbine intravenously (IV); naltrexone:thiafentanil ratios ranging from 10:1 to 43:1 provided mean recoveries ranging from 1.5 to 2.3 min. All 25 deer fitted with radio collars were alive at 30 days postcapture. On the basis of overall reliability and effectiveness, drug volumes, and ease of handling drugged animals, we recommend using a combination of 10-12 mg thiafentanil (0.15-0.2 mg/kg) and 100 mg xylazine to immobilize mule deer; immobilization can be effectively reversed with 100 mg naltrexone or more and 15 mg yohimbine or more IV Where feasible, we also recommend the use of transmitter darts when immobilizing mule deer with opioids in order to maximize recovery of darted deer and to ensure that missed darts are found.	Wildlife Res Ctr, Colorado Div Wildlife, Ft Collins, CO 80526 USA; Wildlife Pharmaceut Inc, Ft Collins, CO 80522 USA	Wolfe, LL (reprint author), Wildlife Res Ctr, Colorado Div Wildlife, 317 W Prospect Rd, Ft Collins, CO 80526 USA.	lisa.wolfe@state.co.us					ALLEN JL, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P343; JANSSEN DL, 1993, J ZOO WILDLIFE MED, V24, P11; JANSSEN DL, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P340; Kilpatrick HJ, 1997, WILDLIFE SOC B, V25, P542; Kreeger T. J., 2002, HDB WILDLIFE CHEM IM; Kreeger TJ, 2001, J WILDLIFE MANAGE, V65, P25, DOI 10.2307/3803272; LANCE WR, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P354; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; STANLEY TH, 1988, J WILDLIFE MANAGE, V52, P577, DOI 10.2307/3800910; STANLEY TH, 1988, CRDECCR88077 US ARM, P122; THORNE ET, 1982, CHEM IMMOBILIZATION, P304; Wolfe LL, 2002, J WILDLIFE MANAGE, V66, P564, DOI 10.2307/3803124	12	14	15	0	4	WILDLIFE DISEASE ASSN, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.	APR	2004	40	2					282	287		10.7589/0090-3558-40.2.282			6	Veterinary Sciences	Veterinary Sciences	836JY	WOS:000222553000014	15362828	Bronze			2020-06-30	J	Jewett, DM; Kilbourn, MR				Jewett, DM; Kilbourn, MR			In vivo evaluation of new carfentanil-based radioligands for the mu opiate receptor	NUCLEAR MEDICINE AND BIOLOGY			English	Article						[C-11]carfentanil; opioid receptor; positron emission tomography	OPIOID RECEPTOR; PET; BRAIN	Eight derivatives of [C-11]carfentanil were evaluated as alternative mu opiod receptor radioligands with the potential for lower pharmacological activity, faster pharmacokinetics, and/or lower non-specific binding. Derivatives with aryl ring substituents or alkyl group substitutions were prepared in carbon- I I labeled form and examined for initial brain uptake and regional brain tissue pharmacokinetics in mouse brain. Promising derivatives with chloro, methoxy and methyl substituents on one aryl ring were then evaluated for specific binding in an equilibrium infusion rat model of regional brain distributions. Although no derivatives were identified with improved pharmacokinetics or lower non-specific binding, several derivatives show acceptable in vivo specific binding properties and may deserve further evaluation as less potent and thus safer compounds for in vivo imaging studies. (C) 2004 Elsevier Inc. All rights reserved.	Univ Michigan, Sch Med, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA	Kilbourn, MR (reprint author), Univ Michigan, Sch Med, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA.	mkilbour@umich.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH47611]		Frost JJ, 2001, NUCL MED BIOL, V28, P509, DOI 10.1016/S0969-8051(01)00221-9; Janssen P. A. J, 1979, US Patent, Patent No. [4179569, US4179569A]; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Kilbourn MR, 2002, SYNAPSE, V43, P188, DOI 10.1002/syn.10039; Koepp M J, 2000, Adv Neurol, V83, P145; Skaddan MB, 2002, SYNAPSE, V45, P31, DOI 10.1002/syn.10079; Subramanian G, 2000, J MED CHEM, V43, P381, DOI 10.1021/jm9903702; Zubieta JK, 2000, NEUROPSYCHOPHARMACOL, V23, P326, DOI 10.1016/S0893-133X(00)00110-X; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	11	13	15	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0969-8051	1872-9614		NUCL MED BIOL	Nucl. Med. Biol.	APR	2004	31	3					321	325		10.1016/j.nucmedbio.2003.10.009			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	804TK	WOS:000220320800003	15028244				2020-06-30	J	Gaszynski, TM; Strzelczyk, JM; Gaszynski, WP				Gaszynski, TM; Strzelczyk, JM; Gaszynski, WP			Post-anesthesia recovery after infusion of propofol with remifentanil or alfentanil or fentanyl in morbidly obese patients	OBESITY SURGERY			English	Article						general anesthesia; intravenous anesthesia; analgesics; opioids; remifentanil; alfentanil; fentanyl; recovery period; postoperative pain; postoperative nausea and vomiting; morbid obesity; bariatric surgery; gastric bypass	GENERAL-ANESTHESIA	Background: The type of opioid used during general anesthesia in the morbidly obese influences recovery and the postoperative period. In a randomized clinical trial, the postoperative recovery profile and early period after general anesthesia with remifentanil, fentanyl and alfentanil were compared in morbidly obese patients. Material and Method: 60 morbidly obese patients with BMI >35 kg/m(2) (mean 43.31) undergoing open Roux-en-y gastric bypass were randomly divided into 3 groups: remifentanil (R), fentanyl (F), and alfentanil (A). Dosage of opioids was based on ideal body weight (IBW): fentanyl 5 mcg/kg for intubation followed by infusion of 0.025-0.05 mcg/kg/min; alfentanil 15 mcg/kg initially, then 1.0-1.5 mcg kg/min; and remifentanil 1 mcg/kg followed by infusion of 0.25-1.5 mcg/kg/min. Anesthesia was induced with infusion of propofol and oxygen with N2O (1:1). After anesthesia, the duration to response to verbal command, spontaneous respiration, adequate respiration, and safe extubation were recorded. The incidence of postoperative nausea and vomiting were recorded. Using verbal scale for evaluation of postoperative pain, the early postoperative analgesia requirements were assessed. Results: Demographic profiles and duration of procedure did not differ between groups. A total dose of propofol was significantly lower in Group R compared with Groups A and F (P<0.05). Duration to spontaneous respiration, adequate respiration and safe extubation were significantly shorter in Group R compared with Group F (P<0.05). Shortly after anesthesia, significantly More patients in Group R required additional dose of analgesic than in Group F (P<0.05). Postoperative nausea and vomiting (PONV) occurred significantly more often in Group R compared with Group F (P<0.05). Recovery profile of Group A was more similar to Group R, and postoperative pain and PONV evaluation more similar to Group F. Conclusion: In morbidly obese individuals, alfentanil or fentanyl and remifentanil can be safely used, but there is a higher rate of PONV and postoperative pain in the rernifentanil group.	Med Univ Lodz, Dept Anaesthesiol & Intens Therapy, PL-90153 Lodz, Poland; Barlicki Univ Hosp, Dept Gen & Transplant Surg, Lodz, Poland	Gaszynski, TM (reprint author), Med Univ Lodz, Barlicki Univ Hosp, Dept Anaesthesiol & Intens Therapy, Ul Kopcinskiego 22, PL-90153 Lodz, Poland.	tomgaszyn@poczta.onet.pl					Bentley J, 1983, ANESTH ANALG, V62, P251; BENTLEY JB, 1981, ANESTHESIOLOGY, V55, pA117; BRAY GA, 1978, INT J OBESITY, V2, P99; Egan TD, 1998, ANESTHESIOLOGY, V89, P562, DOI 10.1097/00000542-199809000-00004; FORREST JB, 1992, ANESTHESIOLOGY, V76, P3, DOI 10.1097/00000542-199201000-00002; Gaszynski T, 2003, EUR J ANAESTH, V20, P77, DOI 10.1097/00003643-200301000-00017; PHILIP BK, 1995, ANESTHESIOLOGY, V83, pA3; ROSE DK, 1994, ANESTHESIOLOGY, V81, P410, DOI 10.1097/00000542-199408000-00020; Salihoglu Z, 2002, EUR J ANAESTH, V19, P125, DOI 10.1017/S0265021502000224; SERVIN F, 1993, ANESTHESIOLOGY, V78, P657, DOI 10.1097/00000542-199304000-00008; Song DJ, 2000, ANESTH ANALG, V90, P1111, DOI 10.1097/00000539-200005000-00020	11	29	33	0	4	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0960-8923	1708-0428		OBES SURG	Obes. Surg.	APR	2004	14	4					498	503		10.1381/096089204323013488			6	Surgery	Surgery	816XD	WOS:000221141700089	15130225				2020-06-30	J	Keidan, I; Zaslansky, R; Eviatar, E; Segal, S; Sarfaty, SM				Keidan, I; Zaslansky, R; Eviatar, E; Segal, S; Sarfaty, SM			Intraoperative ketorolac is an effective substitute for fentanyl in children undergoing outpatient adeno tonsillectomy	PEDIATRIC ANESTHESIA			English	Article						postoperative nausea and vomiting; adenoidectomy; tonsillectomy; children; fentanyl; ketorolac	EMESIS; SURGERY; DEXAMETHASONE; ONDANSETRON; ANALGESIA; MORPHINE; PAIN	Background: In this prospective randomized double-blind study, we compared the incidence of emesis and 48-h recovery profiles after a single dose of ketorolac vs fentanyl in dexamethasone-pretreated children undergoing ambulatory adenoidectomy and laser-assisted tonsillectomy (ADLAT). We evaluated the hypothesis that avoiding the use of opioids and replacing them with an equianalgesic dose of ketorolac, a nonsteroidal anti-inflammatory drug, would reduce the incidence of postoperative nausea and vomiting (PONV). Methods: Fifty-seven ASA I and II children aged 1.710 years who underwent ADLAT were randomized to receive either intravenous ketorolac (1 mg(.)kg(-1)) or fentanyl (2 mug(.)kg(-1)) for pain control during a standardized general anaesthetic with propofol infusion. The early (postanaesthesia care unit, day surgical area) and late postoperative courses were compared between the groups. Results: The incidence of PONV was low and equal in both groups. Postoperative pain scores were equal at all stages of followup. Agitation scores in the postanaesthesia care unit were significantly higher in the ketorolac group, but this had no effect on the late variables of behaviour studied. Conclusions: Ketorolac showed no advantage over fentanyl in reducing the incidence of PONV in children undergoing ADLAT.	Tel Aviv Univ, Sackler Fac Med, Chaim Sheba Med Ctr, Dept Anaesthesia & Intens Care, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Assaf Harofeh Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, IL-69978 Tel Aviv, Israel	Keidan, I (reprint author), Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel.	keidan@012.net.il					Apfel CC, 1999, ANESTHESIOLOGY, V91, P693, DOI 10.1097/00000542-199909000-00022; Broadman L, 1988, ANESTHESIOLOGY, V69, pA770; BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495-199039010-00008; Courtman SP, 1999, PAEDIATR ANAESTH, V9, P467, DOI 10.1046/j.1460-9592.1999.00416.x; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; JAFFEE JH, 1985, PHARMACOL BASIS THER, P501; KERMODE J, 1995, ANAESTH INTENS CARE, V23, P196, DOI 10.1177/0310057X9502300213; Lieh-Lai MW, 1999, CRIT CARE MED, V27, P2786, DOI 10.1097/00003246-199912000-00030; LITMAN RS, 1994, ANESTH ANALG, V78, P478; MARTIN TM, 1993, ANESTH ANALG, V76, P144; NIKKANE E, 1999, BRIT J ANAESTH, V82, P886; Pappas ALS, 1998, ANESTH ANALG, V87, P57, DOI 10.1097/00000539-199807000-00013; Purday JP, 1996, CAN J ANAESTH, V43, P221, DOI 10.1007/BF03011738; Romsing J, 1998, PAEDIATR ANAESTH, V8, P235, DOI 10.1046/j.1460-9592.1998.00768.x; Splinter WM, 1996, CAN J ANAESTH, V43, P560, DOI 10.1007/BF03011766; Splinter WM, 1996, ANESTH ANALG, V83, P913, DOI 10.1097/00000539-199611000-00004; WEIR PM, 1993, ANESTH ANALG, V76, P760	17	17	17	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PEDIATR ANESTH	Pediatr. Anesth.	APR	2004	14	4					318	323		10.1046/j.1460-9592.2003.01212.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	837CY	WOS:000222606900006	15078377				2020-06-30	J	Torres, J; Russo, P; Tobias, JD				Torres, J; Russo, P; Tobias, JD			Anaesthetic implications of LEOPARD syndrome	PEDIATRIC ANESTHESIA			English	Article						LEOPARD syndrome; congenital heart disease; cardiomyopathy; lentigines : craniofacial abnormality; anaesthesia	MULTIPLE LENTIGINES SYNDROME; LEFT ATRIAL-MYXOMA; ELECTROCARDIOGRAPHIC ABNORMALITIES; GENERALIZED LENTIGO	LEOPARD syndrome is a neuroectodermal disorder presumed to result from an abnormality in neural crest cells. The acronym 'LEOPARD' is derived from the clinical features which include multiple lentigines, electrocardiographic abnormalities, ocular hypertelorism, pulmonary stenosis, abnormal genitalia, retarded growth, and deafness. Given the multisystem nature of the disease process, several issues may affect the perioperative care of these patients. Of primary importance are associated conditions of the cardiovascular system including congenital heart disease, conduction disturbances, and progressive hypertrophic obstructive cardiomyopathy. The authors present a 4-year old boy who presented for anaesthetic care for repair of a ventricular septal defect and pulmonary valvotomy for congenital pulmonary stenosis. The potential perioperative implications of LEOPARD syndrome are discussed.	Univ Missouri, Dept Anesthesiol, Div Pediat Crit Care Pediat Anesthesiol, Columbia, MO 65212 USA; Univ Missouri, Dept Child Hlth, Div Pediat Crit Care Pediat Anesthesiol, Columbia, MO 65212 USA; Univ Missouri, Dept Cardiothorac Surg, Div Pediat Crit Care Pediat Anesthesiol, Columbia, MO 65212 USA	Tobias, JD (reprint author), Univ Missouri, Dept Anesthesiol, Div Pediat Crit Care Pediat Anesthesiol, 3W40H,1 Hosp Dr, Columbia, MO 65212 USA.	Tobiasj@health.missouri.edu					Agha Amr, 1995, Journal of Dermatology (Tokyo), V22, P520; Bonioli E, 1999, INT J DERMATOL, V38, P855, DOI 10.1046/j.1365-4362.1999.00834.x; CARNEY JA, 1995, SEMIN DERMATOL, V14, P90, DOI 10.1016/S1085-5629(05)80003-3; Coppin BD, 1997, J MED GENET, V34, P582, DOI 10.1136/jmg.34.7.582; CRONJE RE, 1973, S AFR MED J, V47, P15; EINHORN S, 1986, ARCH FR PEDIATR, V43, P368; GORLIN R J, 1971, Birth Defects Original Article Series, V7, P110; GORLIN RJ, 1969, AM J DIS CHILD, V117, P652, DOI 10.1001/archpedi.1969.02100030654006; Jozwiak S, 1996, CUTIS, V57, P208; Kakar A, 1998, J Assoc Physicians India, V46, P821; MOYNHAN EJ, 1970, P ROY SOC MED, V63, P448; NORDLUND JJ, 1973, ARCH DERMATOL, V107, P259, DOI 10.1001/archderm.107.2.259; PETER JR, 1990, AM J MED GENET, V37, P340, DOI 10.1002/ajmg.1320370309; PETERSON LL, 1984, J AM ACAD DERMATOL, V10, P337, DOI 10.1016/S0190-9622(84)80002-X; Reddy TD, 2001, J PEDIATR-US, V139, P901, DOI 10.1067/mpd.2001.119595; REEM OM, 1986, J AM ACAD DERMATOL, V15, P398; REES JR, 1973, BRIT HEART J, V35, P874; Robain A, 2000, ACTA CARDIOL, V55, P45, DOI 10.2143/AC.55.1.2005718; RODRIGO MRC, 1990, ANAESTHESIA, V45, P30, DOI 10.1111/j.1365-2044.1990.tb14499.x; Sheehy E C, 2000, Int J Paediatr Dent, V10, P158, DOI 10.1046/j.1365-263x.2000.00187.x; SMITH RF, 1970, AM J CARDIOL, V25, P501, DOI 10.1016/0002-9149(70)90021-4; VORON DA, 1976, AM J MED, V60, P447, DOI 10.1016/0002-9343(76)90764-6; WALTHER RJ, 1966, NEW ENGL J MED, V275, P1220, DOI 10.1056/NEJM196612012752203; Woywodt A, 1998, CHEST, V113, P1415, DOI 10.1378/chest.113.5.1415; Yam AA, 2001, ORAL DIS, V7, P200, DOI 10.1034/j.1601-0825.2001.0070311.x	25	2	2	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645	1460-9592		PEDIATR ANESTH	Pediatr. Anesth.	APR	2004	14	4					352	356		10.1046/j.1460-9592.2003.01189.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	837CY	WOS:000222606900012	15078383				2020-06-30	J	Shaiova, L; Lapin, J; Manco, LS; Shasha, D; Hu, K; Harrison, L; Portenoy, RK				Shaiova, L; Lapin, J; Manco, LS; Shasha, D; Hu, K; Harrison, L; Portenoy, RK			Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis	SUPPORTIVE CARE IN CANCER			English	Article						oral transmucosal fentanyl citrate; mucositis; pain; cancer	BONE-MARROW-TRANSPLANTATION; BREAKTHROUGH PAIN; CANCER-PATIENTS; DOSE-TITRATION; MORPHINE; HYDROMORPHONE; TRIAL	Background. Oral transmucosal fentanyl citrate (OTFC; ACTIQ) incorporates fentanyl into a lozenge allowing drug delivery through the oral mucosa resulting in rapid pain relief. OTFC is effective for breakthrough pain and could be particularly useful in patients with mucositis. Methods. This randomized, double-blind, crossover study assessed two formulations of OTFC for tolerability in 14 patients with radiation-induced mucositis. On four separate days, patients with grade 3 or 4 mucositis received an OTFC unit 45 min before radiation treatment. Two units had a sweetened matrix formulation and two had a compressed powder formulation. One unit of each formulation contained 200 mug fentanyl and one was placebo. Tolerability, mucositis pain, and formulation preference were evaluated. Changes in oral mucosa were recorded. Results. Both formulations of OTFC were well tolerated. There were no significant differences between formulations in tolerability, patient preference, or VAS pain scores. No changes in oral mucosa were noted. Common treatment-related adverse events included a burning sensation in the mouth, nausea, and vomiting. Conclusions. Both formulations of OTFC are well tolerated. The presence of fentanyl in either the sweetened matrix or the compressed powder did not alter tolerability or safety. The dose of fentanyl tested did not yield analgesia greater than placebo; future studies of OTFC efficacy in mucositis should evaluate higher doses than 200 mug.	Beth Israel Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA; Beth Israel Med Ctr, Dept Radiat Oncol, New York, NY 10003 USA	Shaiova, L (reprint author), Beth Israel Med Ctr, Dept Pain Med & Palliat Care, 1st Ave,16th St, New York, NY 10003 USA.	lshaiova@bethisraelny.org		Shasha, Daniel/0000-0003-4798-1064			Anderson PM, 1998, BONE MARROW TRANSPL, V22, P339, DOI 10.1038/sj.bmt.1701317; Capelli D, 2000, BRIT J HAEMATOL, V110, P300, DOI 10.1046/j.1365-2141.2000.02149.x; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coda BA, 1997, PAIN, V72, P333, DOI 10.1016/S0304-3959(97)00059-6; Collins JJ, 1996, J PEDIATR-US, V129, P722, DOI 10.1016/S0022-3476(96)70156-7; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; *CTEP, 1998, COMM TOX CRIT CTC VE, P12; Dunbar PJ, 1996, PAIN, V68, P265, DOI 10.1016/S0304-3959(96)03213-7; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; HOLLANDER M, 1999, NONPARAMETRIC STAT M, P46; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1	12	28	33	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0941-4355			SUPPORT CARE CANCER	Support. Care Cancer	APR	2004	12	4					268	273		10.1007/s00520-004-0595-4			6	Oncology; Health Care Sciences & Services; Rehabilitation	Oncology; Health Care Sciences & Services; Rehabilitation	814HX	WOS:000220966900008	14750002				2020-06-30	J	Pettifer, GR; Hosgood, G				Pettifer, GR; Hosgood, G			The effect of inhalant anesthetic and body temperature on peri-anesthetic serum concentrations of transdermally administered fentanyl in dogs	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						anesthesia; dogs; halothane; hypothermia; isoflurane; transdermal fentanyl	CUTANEOUS HEAT-LOSS; BLOOD-FLOW; THERMOREGULATORY VASOCONSTRICTION; ISOFLURANE ANESTHESIA; HALOTHANE ANESTHESIA; ORTHOPEDIC-SURGERY; DOUBLE-BLIND; PHARMACOKINETICS; DISPOSITION; ENFLURANE	Objectives To determine whether moderate hypothermia during anesthesia significantly affects the serum concentration of transdermally delivered fentanyl and whether halothane or isoflurane affect these concentrations. Study Design Randomized cross-over experimental trial. Animals Six mature, healthy Beagles (three males, three females) weighing 10.6 +/- 0.43 kg. Methods A 50-mug hour(-1) fentanyl patch was applied 36 hours prior to anesthesia. Anesthesia was induced at time 0 (t = 0). Each dog received four treatments: isoflurane + normothermia (ISO-NORM), isoflurane + hypothermia (ISO-HYPO), halothane + normothermia (HAL-NORM), and halothane + hypothermia (HAL-HYPO). Dogs were intubated and maintained at 1.5 times MAC. Animals in the hypothermia treatments were cooled to 35degreesC during anesthesia. Serum fentanyl analysis was performed at -36, -24, -12, 0.05, 1, 1.5,2,2.5,3,3.5,4,4.5,5,6,7,8,9,10,18, and 26 hours. Direct arterial blood pressures and arterial blood gases were monitored. Results The mean body temperatures (+/-SEM) during the anesthetic period for the four treatments were: ISO-NORM = 37.7 +/- 0.07degreesC, ISO-HYPO = 35.8 +/- 0.1degreesC, HAL-NORM 37.7 +/- 0.06degreesC, and HAL-HYPO = 35.8 +/- 0.13degreesC. The mean (+/-SEM) serum fentanyl concentrations (SFC) for both hypothermia treatments were significantly lower than baseline concentrations at t = I hour and persisted for the duration of anesthesia for the ISO-HYPO treatment but only from t = 1 to 2 hours for the HAL-HYPO treatment. Serum fentanyl concentrations returned to baseline within one hour of the end of anesthesia, regardless of body temperature. There were no significant differences between treatments for systolic or diastolic blood pressure but mean blood pressures were higher during normothermia versus hypothermia during the last hour of anesthesia. Conclusions and clinical relevance Hypothermia during inhalation anesthesia produced a significant reduction in SFC using transdermal administration and was more protracted with isoflurane than halothane anesthesia. While significant reductions in SFC occurred, the SFC were still within the range believed to confer analgesia.	Louisiana State Univ, Sch Vet Med, Dept Vet Clin Sci, Baton Rouge, LA 70803 USA	Pettifer, GR (reprint author), Louisiana State Univ, Sch Vet Med, Dept Vet Clin Sci, Baton Rouge, LA 70803 USA.	gpettifer@vetmed.lsu.edu		Hosgood, Giselle/0000-0002-8851-8597			BAILEY PL, 1987, ANESTH ANALG, V66, P542; BAILEY PL, 2000, ANESTHESIA, V1, P237; BONAGURA J, 1995, KIRKS CURRENT VET TH, V12, P1407; Carroll GL, 1999, AM J VET RES, V60, P986; COPLAND VS, 1987, AM J VET RES, V48, P1626; CROMWELL TH, 1971, ANESTHESIOLOGY, V35, P17, DOI 10.1097/00000542-197107000-00007; Dowd G, 1997, VET SURG, V27, P168; DOWNES JJ, 1967, J PHARMACOL EXP THER, V158, P416; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; Egger C M, 2001, Vet Anaesth Analg, V28, P102, DOI 10.1046/j.1467-2987.2001.temp.doc.x-i4; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Foley PL, 2001, COMPARATIVE MED, V51, P239; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; FRINK EJ, 1992, ANESTHESIOLOGY, V76, P85, DOI 10.1097/00000542-199201000-00013; GELMAN S, 1984, ANESTH ANALG, V63, P557; GELMAN S, 1984, ANESTHESIOLOGY, V61, P726, DOI 10.1097/00000542-198412000-00017; GREENBLATT EP, 1992, ANESTHESIOLOGY, V77, P1178, DOI 10.1097/00000542-199212000-00020; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Grundmann U, 1997, ACTA ANAESTH SCAND, V41, P760, DOI 10.1111/j.1399-6576.1997.tb04780.x; HADIE E, 1998, CURRENT TECHNIQUES S, P3; Harvey-Clark CJ, 2000, LAB ANIM-UK, V34, P386, DOI 10.1258/002367700780387750; KOREN G, 1987, EUR J CLIN PHARMACOL, V32, P373, DOI 10.1007/BF00543972; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Kyles AE, 1996, AM J VET RES, V57, P715; LONGNECKER DE, 1984, MICROCIRC ENDOTH LYM, V1, P129; LUNDEEN G, 1983, ANESTH ANALG, V62, P499; MATTHEWS NS, 1997, P 6 INT C VET AN THE, P116; McDonell W, 1996, LUMB JONES VET ANEST, V1, P115; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; MURRAY JM, 1992, BRIT J ANAESTH, V68, P168, DOI 10.1093/bja/68.2.168; Paut O, 2000, ANAESTHESIA, V55, P1202, DOI 10.1046/j.1365-2044.2000.01615-3.x; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; ROWBOTHAM DJ, 1989, BRIT J ANAESTH, V63, P56, DOI 10.1093/bja/63.1.56; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; Sessler DI, 2000, ANESTHESIOLOGY, V92, P578, DOI 10.1097/00000542-200002000-00042; SESSLER DI, 1992, ANESTHESIOLOGY, V76, P670, DOI 10.1097/00000542-199205000-00002; SESSLER DI, 1990, ANESTHESIOLOGY, V73, P656, DOI 10.1097/00000542-199010000-00011; SESSLER DI, 1991, ANESTHESIOLOGY, V74, P226, DOI 10.1097/00000542-199102000-00006; SONG CW, 1989, INT J RADIAT ONCOL, V17, P1041, DOI 10.1016/0360-3016(89)90153-3; STEFFEY EP, 1977, AM J VET RES, V38, P1833; STEFFEY EP, 1978, AM J VET RES, V39, P573; STEVENS WC, 1971, ANESTHESIOLOGY, V35, P8, DOI 10.1097/00000542-197107000-00005; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; VANBASTELAERE M, 1995, J CLIN ANESTH, V7, P26, DOI 10.1016/0952-8180(94)00000-T; Welch JA, 2002, J VET EMERG CRIT CAR, V12, P81, DOI 10.1046/j.1435-6935.2002.00021.x; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12; WILKINSON GR, 1975, DRUG METAB REV, V4, P139, DOI 10.3109/03602537508993754	48	19	20	0	9	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	APR	2004	31	2					109	120		10.1111/j.1467-2987.2004.00158.x			12	Veterinary Sciences	Veterinary Sciences	812LR	WOS:000220841500006	15053749				2020-06-30	J	Viscusi, ER; Reynolds, L; Chung, F; Atkinson, LE; Khanna, S				Viscusi, ER; Reynolds, L; Chung, F; Atkinson, LE; Khanna, S			Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED ANALGESIA; EFFICACY; MANAGEMENT; SAFETY	Context Patient-controlled analgesia (PCA) with morphine is commonly used to provide acute postoperative pain control after major surgery. The fentanyl hydrochloride patient-controlled transdermal system eliminates the need for venous access and complicated programming of pumps. Objective To assess the efficacy and safety of an investigational patient-controlled iontophoretic transdermal system using fentanyl hydrochloride compared with a standard intravenous morphine patient-controlled pump. Design, Setting, and Patients Prospective randomized controlled parallel-group trial conducted between September 2000 and March 2001 at 33 North American hospitals, enrolling 636 adult patients who had just undergone major surgery. Interventions In surgical recovery rooms, patients were randomly assigned to intravenous morphine (1-mg bolus every 5 minutes; maximum of 10 mg/h) by a patient-controlled analgesia pump (n=320) or iontophoretic fentanyl hydrochloride (40-mug infusion over 10 minutes) by a patient-controlled transdermal system (n =316). Supplemental analgesia (morphine or fentanyl intravenous boluses) was administered as needed before and for the first 3 hours after activation of the PCA treatments. Patients then used the PCA treatments without additional analgesics for up to 72 hours. Main Outcome Measures The primary efficacy variable was patient global assessment of the method of pain control during the first 24 hours. Additional efficacy measures were the proportion of patients discontinuing the study because of inadequate analgesia for any reason, patient-reported pain intensity scores on a 100-mm visual analog scale WAS), and patient global assessments at 48 and 72 hours. Adverse effects were also recorded. Results Ratings of good or excellent after 24 hours of treatment for the method of pain control were given by 73.7% of patients (233/316) who used transdermal fentanyl PCA and 76.9% of patients (246/320) who used intravenous morphine PCA-1 treatment difference was -3.2% (95% confidence interval, -9.9% to 3.5%; P=36). Early patient discontinuations (25.9% fentanyl vs 25.0% morphine; P=.78) and last pain intensity scores (32.7 fentanyl vs 31.1 morphine on the VAS; P=.45) were not different between the 2 treatments. With continued treatment for up to 48 or 72 hours, more than 80% of patient assessments in each treatment group were good or excellent. The incidence of opioid-related adverse events was similar between the Conclusion An investigational PCA transclermal system using iontophoresis to deliver fentanyl provided postsurgical pain control equivalent to that of a standard intravenous morphine regimen delivered by a PCA pump.	Thomas Jefferson Univ, Dept Anesthesiol, Philadelphia, PA 19107 USA; Loma Linda Univ, Ctr Pain Management, Loma Linda, CA 92350 USA; Univ Toronto, Toronto Western Hosp, Dept Anesthesiol, Toronto, ON, Canada; ALZA Corp, Stat & Data Management, Mountain View, CA USA; ALZA Corp, Clin Dev, Mountain View, CA USA	Viscusi, ER (reprint author), Thomas Jefferson Univ, Dept Anesthesiol, 111 S 11th St,Suite G 8490, Philadelphia, PA 19107 USA.	eugene.viscusi@jefferson.edu	Chung, Frances/F-5618-2015	Chung, Frances/0000-0001-9576-3606			*AC PAIN MAN PAN, 1992, AC PAIN MAN OP MED P; *AM PAIN SOC, 1999, PRINC AN US TREATM A; BALLANTYNE JC, 1993, J CLIN ANESTH, V5, P182, DOI 10.1016/0952-8180(93)90013-5; Byrom B., 2002, APPL CLIN TRIALS, V2002, P36; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Chelly JE, 2004, ANESTH ANALG, V98, P427, DOI 10.1213/01.ANE.0000093314.13848.7E; GINSBERG B, 1995, PAIN, V62, P95, DOI 10.1016/0304-3959(94)00255-D; GLASS PSA, 1992, ANESTH ANALG, V74, P345; HOWELL PR, 1995, CAN J ANAESTH, V42, P41, DOI 10.1007/BF03010570; Lehmann KA, 1999, EUR SURG RES, V31, P112, DOI 10.1159/000008629; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; OWEN H, 1989, ANAESTHESIA, V44, P7, DOI 10.1111/j.1365-2044.1989.tb11087.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; ROWBOTHAM DJ, 1989, ANAESTHESIA, V44, P922, DOI 10.1111/j.1365-2044.1989.tb09151.x; Schumann R, 2003, ANESTH ANALG, V96, P469, DOI 10.1097/00000539-200302000-00032; SINATRA RS, 1989, ANESTHESIOLOGY, V70, P585, DOI 10.1097/00000542-198904000-00005; WELCHEW EA, 1983, ANAESTHESIA, V38, P19, DOI 10.1111/j.1365-2044.1983.tb10367.x; Woodhouse A, 1996, PAIN, V64, P115, DOI 10.1016/0304-3959(95)00082-8	19	137	146	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2004	291	11					1333	1341		10.1001/jama.291.11.1333			9	Medicine, General & Internal	General & Internal Medicine	802PF	WOS:000220174700027	15026400	Bronze			2020-06-30	J	Ganidagli, S; Cetin, H; Biricik, HS; Cimtay, I				Ganidagli, S; Cetin, H; Biricik, HS; Cimtay, I			Comparison of ropivacaine with a combination of ropivacaine and fentanyl for the caudal epidural anaesthesia of mares	VETERINARY RECORD			English	Article							CESAREAN-SECTION; 0.5-PERCENT BUPIVACAINE; ADMINISTERED MORPHINE; ANALGESIA; LABOR; LIDOCAINE; DELIVERY; HORSES; BLOCK; DOGS	Two groups of six mares aged from eight to 18 years were anaesthetised by caudal epidural injections of ropivacaine (0(.)5 per cent, 0(.)1 mg/kg) or a combination of ripovacaine (0(.)08 mg/kg) and fentanyl (100 mug) in a randomised study. The onset of anaesthesia was significantly more rapid (P<0(.)001) and it lasted significantly longer (P<0(.)001) in the group anaesthetised with the combination of drugs. The surgical comfort scores of the group anaesthetised with the combination were higher than those of the group anaesthetised with ropivacaine alone (P<0.001), and the quality of intraoperative analgesia, as assessed by the surgeon, was significantly improved. There were no differences between the groups in their average scores for the levels of ataxia and sedation, in their behaviour, or in the incidence of side effects.	Harran Univ, Sch Med, Dept Anaesthesiol & Reanimat, Fac Med, TR-63100 Sanliurfa, Turkey; Harran Univ, Fac Vet Med, Dept Obstet & Gynaecol, TR-63100 Sanliurfa, Turkey; Harran Univ, Fac Vet Med, Dept Surg, TR-63100 Sanliurfa, Turkey; Harran Univ, Fac Vet Med, Dept Internal Med, TR-63100 Sanliurfa, Turkey	Ganidagli, S (reprint author), Harran Univ, Sch Med, Dept Anaesthesiol & Reanimat, Fac Med, TR-63100 Sanliurfa, Turkey.						AITHAL HP, 1996, SMALL RUMINANT RES, V24, P55; ALAHUHTA S, 1995, ANESTHESIOLOGY, V83, P23, DOI 10.1097/00000542-199507000-00004; BRANSON KR, 1993, J VET PHARMACOL THER, V16, P369, DOI 10.1111/j.1365-2885.1993.tb00184.x; Cherng CH, 2001, REGION ANESTH PAIN M, V26, P523, DOI 10.1053/rapm.2001.27852; Cohen S, 2002, ANESTH ANALG, V94, P674, DOI 10.1097/00000539-200203000-00036; Crosby E, 1998, CAN J ANAESTH, V45, P1066, DOI 10.1007/BF03012393; Eddleston JM, 1996, BRIT J ANAESTH, V76, P66; Fischer C, 2000, ANESTHESIOLOGY, V92, P1588, DOI 10.1097/00000542-200006000-00015; Gaiser RR, 1997, J CLIN ANESTH, V9, P564, DOI 10.1016/S0952-8180(97)00145-1; GOMEZ CF, 2000, REV ESPANOLA ANESTES, V47, P332; GRIFFIN RP, 1995, BRIT J ANAESTH, V74, P512, DOI 10.1093/bja/74.5.512; GRUBB TL, 1992, J AM VET MED ASSOC, V201, P1187; HALONEN PM, 1993, ACTA ANAESTH SCAND, V37, P774, DOI 10.1111/j.1399-6576.1993.tb03808.x; Ivani G, 1998, BRIT J ANAESTH, V81, P247; Jones RS, 2001, VET J, V161, P123, DOI 10.1053/tvjl.2000.0528; LUNA SPL, 2000, VET ANAESTH ANALG, V27, P54; McClellan KJ, 2000, DRUGS, V60, P1065, DOI 10.2165/00003495-200060050-00007; Meister GC, 2000, ANESTH ANALG, V90, P632, DOI 10.1097/00000539-200003000-00024; Natalini CC, 2000, AM J VET RES, V61, P1579, DOI 10.2460/ajvr.2000.61.1579; PAECH MJ, 1990, ANAESTH INTENS CARE, V18, P22, DOI 10.1177/0310057X9001800105; Skarda Roman T, 2001, Vet Anaesth Analg, V28, P61, DOI 10.1046/j.1467-2995.2001.00025.x; SKARDA RT, 1999, P 24 ANN M AM COLL V, P14; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019; Wittern C, 1998, J AM VET MED ASSOC, V213, P516	24	11	13	0	5	BRITISH VETERINARY ASSOC	LONDON	7 MANSFIELD ST, LONDON W1M 0AT, ENGLAND	0042-4900			VET REC	Vet. Rec.	MAR 13	2004	154	11					329	332		10.1136/vr.154.11.329			4	Veterinary Sciences	Veterinary Sciences	808YN	WOS:000220604500015	15068041				2020-06-30	J	Nikkola, EM; Leino, KA; Takala, RSK; Kirvela, OA; Salonen, MAO				Nikkola, EM; Leino, KA; Takala, RSK; Kirvela, OA; Salonen, MAO			The validity of the static-charge-sensitive bed in the detection of fentanyl-induced respiratory depression	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						fentanyl; opioid; respiratory depression; respiratory inductive plethysmography; static-charge-sensitive bed	PERIODIC LEG MOVEMENTS; BODY MOVEMENTS; YOUNG-CHILDREN; HUMAN INFANTS; TIDAL VOLUME; SLEEP; WAKEFULNESS; APNEA; PATTERNS; MORPHINE	Background: Only a few methods for the measurement of breathing are non-invasive and do not interfere with measured parameters. The static-charge-sensitive bed (SCSB) could be such a monitor. The aim of this study was to evaluate the validity of the SCSB compared with the respiratory inductive plethysmograph (RIP) using a fentanyl-induced respiratory depression model. Methods: Eight healthy male volunteers were infused with intravenous (i.v.) fentanyl (15 mug/kg/h) until a decrease in SpO(2) below 90% for 1 min emerged. Breathing was continuously and simultaneously measured with SCSB and RIP. Oxygenation, hemodynamics, arterial blood gas analysis, and subjective opioid-related effects were monitored. Fentanyl concentration was measured from an arterial blood sample. The respiratory rate data of the SCSB (automated analysis and manual calculation) were compared with the corresponding RIP data, using analysis of variance for repeated measures. The validity of the SCSB compared with RIP was evaluated using an intra-class correlation coefficient. Results: Mean fentanyl dose was 629 mug. A statistically significant association was found between the RIP and SCSB data in the manual SCSB analysis (P < 0.0001), but not in the automated SCSB analysis (P = 0.91). After adjusting for the effect of time and the SCSB method, an intra-class correlation coefficient between the manually calculated SCSB values and the RIP values was 0.66. Conclusion: Clinically significant changes in respiratory rate were detected with the SCSB, but the results had to be analyzed manually. The SCSB best suits situations, where comprehensive data are needed. It is not suitable for on-line respiratory monitoring, as the automated analysis did not calculate the respiratory rate correctly.	Helsinki Univ Hosp, Dept Anesthesia & Intens Care Med, Helsinki, Finland; Turku Univ Hosp, Dept Anesthesiol & Intens Care, FIN-20520 Turku, Finland; Turku Univ Hosp, Dept Pediat, FIN-20520 Turku, Finland	Nikkola, EM (reprint author), Univ Helsinki, Hosp Children & Adolescents, PB 281, Hus 00029, Finland.	eeva.nikkola@hus.fi					ACEBO C, 1991, SLEEP, V14, P56, DOI 10.1093/sleep/14.1.56; ALIHANKA J, 1981, AM J PHYSIOL, V240, P384; BLAKE AM, 1970, LANCET, V2, P183; EKHOLM EMK, 1992, AM J OBSTET GYNECOL, V167, P1262, DOI 10.1016/S0002-9378(11)91698-6; EPSTEIN RA, 1980, J APPL PHYSIOL, V49, P1107; ERKINJUNTTI M, 1987, THESIS U TURKU TURKU, P1; FAITHFULL D, 1979, BRIT J ANAESTH, V51, P391, DOI 10.1093/bja/51.5.391; Flisberg P, 2002, J CLIN ANESTH, V14, P129, DOI 10.1016/S0952-8180(01)00369-5; FREUNDLICH JJ, 1974, CHEST, V65, P181, DOI 10.1378/chest.65.2.181; GORDH T, 1995, J CLIN MONITOR, V11, P365, DOI 10.1007/BF01616742; Kirjavainen T, 1996, J SLEEP RES, V5, P186, DOI 10.1046/j.1365-2869.1996.t01-1-00003.x; Kirjavainen T, 1996, ACTA PAEDIATR, V85, P1146; KIRJAVAINEN T, 1997, ANN U TURK D, V263, P1; Leino K, 1999, ANAESTHESIA, V54, P835; Leino K, 2001, ACTA ANAESTH SCAND, V45, P104, DOI 10.1034/j.1399-6576.2001.450116.x; LINDBERG LG, 1992, MED BIOL ENG COMPUT, V30, P533, DOI 10.1007/BF02457833; MEAD J, 1967, SCIENCE, V156, P1383, DOI 10.1126/science.156.3780.1383; Mildh L, 1998, ANAESTHESIA, V53, P965, DOI 10.1046/j.1365-2044.1998.00519.x; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; MOORE LRC, 1990, METHOD FIND EXP CLIN, V12, P29; Nikkola E, 1996, AM J OBSTET GYNECOL, V174, P1622, DOI 10.1016/S0002-9378(96)70618-X; NINOMURCIA G, 1991, SLEEP RES, V20, P329; POLO O, 1988, EUR RESPIR J, V1, P330; POLO O, 1992, EUR RESPIR J, V5, P257; POLO O, 1992, ACTA PHYSL SCAN S606, V145, P1; POLOKANTOLA P, 1999, ANN U TURKENSIS D, V367, P1; Rauhala E, 1996, J SLEEP RES, V5, P246, DOI 10.1111/j.1365-2869.1996.00246.x; ROY J, 1991, J CLIN MONITOR, V7, P249, DOI 10.1007/BF01619269; SCAMMAN FL, 1983, ANESTH ANALG, V62, P332; SIIVOLA J, 1989, MED BIOL ENG COMPUT, V27, P423, DOI 10.1007/BF02441435; SPENCER JL, 1972, J APPL PHYSIOL, V33, P523; Tallila T, 1998, J CLIN MONITOR COMP, V14, P239, DOI 10.1023/A:1009966002366; THOMAN EB, 1987, SLEEP, V10, P122, DOI 10.1093/sleep/10.2.122; THOMAN EB, 1979, PHYSIOL BEHAV, V23, P519, DOI 10.1016/0031-9384(79)90052-0	34	1	1	0	2	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2004	48	3					371	376		10.1111/j.0001-5172.2004.0291.x			6	Anesthesiology	Anesthesiology	803SS	WOS:000220251400017	14982573				2020-06-30	J	Sommer, M; Schuldt, M; Runge, U; Gielen-Wijffels, S; Marcus, MAE				Sommer, M; Schuldt, M; Runge, U; Gielen-Wijffels, S; Marcus, MAE			Bilateral hypoglossal nerve injury following the use of the laryngeal mask without the use of nitrous oxide	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						hypoglossal nerve injury; laryngeal mask; nitrous oxide	AIRWAY; PARALYSIS	Hypoglossal nerve injury is a rare complication of anaesthesia airway management in adults. Until now the use of nitrous oxide for anaesthesia supposedly contributed to this complication. We present a case of bilateral hypoglossal nerve injury following the use of a laryngeal mask airway without the use of nitrous oxide. At the conclusion of 3 h of surgery in extreme side rotation, a 15-year-old boy of 88 kg could not extend his tongue beyond his teeth. An MRI confirmed the absence of pharyngeal haematoma and the absence of thrombosis of the basilar artery. We conclude that even when patients have no medical history and nitrous oxide is not being used, prolongation of the operation in an extreme position might increase the risk of major complications with a laryngeal mask.	Univ Hosp Maastricht, Dept Anaesthesiol, NL-6202 AZ Maastricht, Netherlands; Univ Hosp Greifswald, Dept Paediat Surg, Greifswald, Germany; Univ Hosp Greifswald, Dept Neurol, Greifswald, Germany	Sommer, M (reprint author), Univ Hosp Maastricht, Dept Anaesthesiol, POB 5800, NL-6202 AZ Maastricht, Netherlands.	mso@sane.azm.nl					BRAIN AIJ, 1995, ANAESTHESIA, V50, P82, DOI 10.1111/j.1365-2044.1995.tb04521.x; Harnett M, 2000, CAN J ANAESTH, V47, P315, DOI 10.1007/BF03020944; KING C, 1994, ANAESTHESIA, V49, P786; NGAI K, 1994, ANAESTHESIA, V49, P603; Stewart A, 2002, ANAESTHESIA, V57, P264, DOI 10.1046/j.1365-2044.2002.02231.x; Umapathy N, 2001, BRIT J ANAESTH, V87, P322	6	19	21	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2004	48	3					377	378		10.1111/j.0001-5172.2004.0332.x			2	Anesthesiology	Anesthesiology	803SS	WOS:000220251400018	14982574				2020-06-30	J	Smith, RP; Miller, SL; Igosheva, N; Peebles, DM; Glover, V; Jenkin, G; Hanson, MA; Fisk, NM				Smith, RP; Miller, SL; Igosheva, N; Peebles, DM; Glover, V; Jenkin, G; Hanson, MA; Fisk, NM			Cardiovascular and endocrine responses to cutaneous electrical stimulation after fentanyl in the ovine fetus	AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY			English	Article						sheep; opioid; analgesia; electric stimulation	STRESS-RESPONSE; FETAL SHEEP; INVASIVE PROCEDURES; RECEPTOR SUBTYPES; OPIOID MODULATION; LAMBS; CORTISOL	Objective: The purpose of this study was to determine whether physical stimulation is stressful to the ovine fetus, as judged from physiologic changes that are similar to those reported for other stressors (such as hypoxia); whether any stress response could be blocked by clinically used doses of fentanyl; and whether fentanyl alone had any potentially deleterious physiologic effects in the fetus. Study design: We investigated the effect of fentanyl analgesia on the cardiovascular and endocrine response to cutaneous electrical stimulation in the late gestation ( > 125 days) ovine fetus, (n = 7 fetuses). Chronically implanted catheters and blood flow probes were used to measure fetal arterial blood pressure, heart rate, carotid and femoral blood flow, pH, PO2, PCO2, lactate, cortisol, and P-endorphin levels before, during, and for 1 hour after 5 minutes of cutaneous electrical stimulation to the lip, forelimb, and abdomen, in a crossover design. Clinically used 30 or 150 mug doses of fentanyl (which approximated 10 or 50 mug/kg estimated fetal weight) or saline solution were given intravenously to the fetus 2 minutes before stimulation. Results: When compared with the control, stimulation caused a significant rise in fetal heart rate (P = .003; mean maximal rise, 48.6 +/- 14.0 beats/min, 0-10 minutes after the start of stimulation) but caused no change in any other parameters studied. Neither dose of fentanyl attenuated the changes in heart rate that were observed in response to stimulation alone. Fentanyl alone significantly increased fetal heart rate, carotid blood flow, and lactate and cortisol levels and significantly decreased pH and PO2. Conclusion: Cutaneous electrical stimulation in the fetal sheep causes an increase in heart rate, which fentanyl does not block. Fentanyl itself has significant effects on the cardiovascular and endocrine system, which might adversely affect the fetus. (C) 2004 Elsevier Inc. All rights reserved.	Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Dept Maternal & Fetal Med, London, England; Royal Free Hosp, Dept Obstet & Gynecol, Sch Med, London NW3 2QG, England; Monash Univ, Dept Physiol, Clayton, Vic 3168, Australia	Smith, RP (reprint author), Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Dept Maternal & Fetal Med, Hammersmith Campus, London, England.		Glover, Vivette/M-2711-2016; Hanson, Mark/AAE-8236-2019; Fisk, Nicholas M/B-2126-2009	Glover, Vivette/0000-0001-6543-1651; Fisk, Nicholas M/0000-0003-0031-7975; Hanson, Mark/0000-0002-6907-613X; Miller, Suzanne/0000-0002-0451-8304			ANAND KJS, 1987, LANCET, V1, P62; Anand KJS, 2001, ANESTHESIOLOGY, V95, P823, DOI 10.1097/00000542-200110000-00006; CLOETE J, 1939, PRENATAL GROWTH MERI, P417; Fisk NM, 2001, ANESTHESIOLOGY, V95, P828, DOI 10.1097/00000542-200110000-00008; GAGNON R, 1989, SEMIN PERINATOL, V13, P393; GIANNAKOULOPOULOS X, 1994, LANCET, V344, P77, DOI 10.1016/S0140-6736(94)91279-3; Giannakoulopoulos X, 1999, PEDIATR RES, V45, P494, DOI 10.1203/00006450-199904010-00007; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; Holsey YS, 1999, AM J OBSTET GYNECOL, V180, P1127, DOI 10.1016/S0002-9378(99)70605-8; IOFFE S, 1980, PFLUG ARCH EUR J PHY, V388, P143, DOI 10.1007/BF00584120; KYLES AE, 1993, AM J VET RES, V54, P1483; Mather LE, 2000, REGION ANESTH PAIN M, V25, P174, DOI 10.1053/rapm.2000.0250174; NATALE R, 1986, AM J OBSTET GYNECOL, V154, P321, DOI 10.1016/0002-9378(86)90665-4; NEWNHAM JP, 1994, AM J OBSTET GYNECOL, V171, P460, DOI 10.1016/0002-9378(94)90283-6; PARKES MJ, 1991, AM J OBSTET GYNECOL, V164, P1336, DOI 10.1016/0002-9378(91)90710-9; RIGATTO H, 1982, Journal of Developmental Physiology (Eynsham), V4, P175; Royal College of Obstetricians and Gynaecologists, 1997, FET AW REP WORK PART; SZETO HH, 1995, J PHARMACOL EXP THER, V275, P334; Taylor CC, 1997, PEDIATR RES, V41, P411, DOI 10.1203/00006450-199703000-00018; Taylor CC, 1997, J PHARMACOL EXP THER, V281, P129; Teixeira JMA, 1999, AM J OBSTET GYNECOL, V181, P1018, DOI 10.1016/S0002-9378(99)70340-6; WATERMAN AE, 1991, J VET PHARMACOL THER, V14, P230, DOI 10.1111/j.1365-2885.1991.tb00831.x; WATERMAN AE, 1991, RES VET SCI, V51, P19, DOI 10.1016/0034-5288(91)90024-I; Waterman AE, 1990, J ASS VET ANAESTH, V17, P20; YASTER M, 1987, ANESTHESIOLOGY, V66, P524, DOI 10.1097/00000542-198704000-00013; ZHU YS, 1989, J PHARMACOL EXP THER, V249, P78	26	8	8	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0002-9378			AM J OBSTET GYNECOL	Am. J. Obstet. Gynecol.	MAR	2004	190	3					836	842		10.1016/j.ajog.2003.09.064			7	Obstetrics & Gynecology	Obstetrics & Gynecology	808OH	WOS:000220577900039	15042022				2020-06-30	J	Rasmussen, M; Tankisi, A; Cold, GE				Rasmussen, M; Tankisi, A; Cold, GE			The effects of indomethacin on intracranial pressure and cerebral haemodynamics in patients undergoing craniotomy: A randomised prospective study	ANAESTHESIA			English	Article						indomethacin; intracranial pressure	BULB OXYGEN-SATURATION; SEVERE HEAD-INJURY; BLOOD-FLOW; HEALTHY-VOLUNTEERS; PROPOFOL-FENTANYL; ANESTHESIA; HYPERTENSION; METABOLISM; TUMORS; HYPERVENTILATION	We compared the effects of indomethacin (bolus of 0.2 mg.kg(-1) followed by an infusion of 0.2 mg.kg(-1).h(-1)) and placebo on intracranial pressure and cerebral haemodynamics in 30 patients undergoing craniotomy for supratentorial brain tumours under propofol and fentanyl anaesthesia. Indomethacin was given before induction of anaesthesia and the infusion was terminated after opening of the dura. Subdural intracranial pressure was measured through the first burr hole and before opening the dura. Cerebral blood flow velocity, cerebral perfusion pressure, jugular bulb oxygen saturation, arterio-venous oxygen difference and carbon dioxide reactivity were measured; dural tension and the degree of brain swelling were estimated. Before induction of anaesthesia, indomethacin administration was associated with a significant decrease in cerebral blood flow velocity compared with placebo. After induction of anaesthesia, cerebral blood flow velocity and mean arterial blood pressure decreased significantly in both groups. Indomethacin was not associated with a decrease in intracranial pressure. There were no differences in cerebral perfusion pressure, dural tension or degree of brain swelling between the two groups. Carbon dioxide reactivity measured after induction of anaesthesia was significantly lower in the indomethacin group (p < 0.05). After removal of the bone flap, no significant difference in carbon dioxide reactivity was observed. We suggest that these findings are explained by propofol-induced cerebral vasoconstriction.	Aarhus Univ Hosp, Dept Neuroanaesthesia, DK-8000 Aarhus C, Denmark; Viborg Gen Hosp, Dept Anaesthesia, DK-8800 Viborg, Denmark	Rasmussen, M (reprint author), Aarhus Univ Hosp, Dept Neuroanaesthesia, DK-8000 Aarhus C, Denmark.	maras@akh.aaa.dk	Rasmussen, Mads/R-4876-2019	Rasmussen, Mads/0000-0002-0416-6767			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; BEDFORD RF, 1980, ANESTH ANALG, V59, P435; BIESTRO AA, 1995, J NEUROSURG, V83, P627, DOI 10.3171/jns.1995.83.4.0627; Bundgaard H, 1996, J NEUROSURG ANESTH, V8, P273, DOI 10.1097/00008506-199610000-00003; Cenic A, 2000, ANESTH ANALG, V90, P1376, DOI 10.1097/00000539-200006000-00021; Chieregato A, 2003, J NEUROL NEUROSUR PS, V74, P784, DOI 10.1136/jnnp.74.6.784; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; Cold GE, 1996, BRIT J NEUROSURG, V10, P69; Dahl B, 1996, ACTA NEUROCHIR, V138, P265, DOI 10.1007/BF01411736; DATSUR DK, 1963, HUMAN AGING BIOL BEH, P59; Ederberg S, 1998, ANESTH ANALG, V86, P1201, DOI 10.1097/00000539-199806000-00011; Gibbs EL, 1942, J BIOL CHEM, V144, P325; Gopinath SP, 1996, ANESTH ANALG, V83, P1014, DOI 10.1097/00000539-199611000-00020; Jansen GFA, 1999, ANESTH ANALG, V89, P358, DOI 10.1097/00000539-199908000-00021; Jensen K, 1996, J NEUROSURG ANESTH, V8, P111, DOI 10.1097/00008506-199604000-00002; JENSEN K, 1993, ACTA NEUROCHIR, V124, P114, DOI 10.1007/BF01401132; JENSEN K, 1991, ACTA NEUROCHIR, V108, P116, DOI 10.1007/BF01418518; Kaisti KK, 2002, ANESTHESIOLOGY, V96, P1358, DOI 10.1097/00000542-200206000-00015; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Lagerkranser M, 1997, J NEUROSURG ANESTH, V9, P188, DOI 10.1097/00008506-199704000-00015; MILLER JD, 1975, J NEUROSURG, V42, P274, DOI 10.3171/jns.1975.42.3.0274; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NILSSON F, 1995, ANESTHESIOLOGY, V83, P1283, DOI 10.1097/00000542-199512000-00019; Petersen KD, 2003, ANESTHESIOLOGY, V98, P329, DOI 10.1097/00000542-200302000-00010; PICHARD JD, 1973, NATURE-NEW BIOL, V245, P187; Raichle ME, 1972, STROKE, V3, P566, DOI 10.1161/01.STR.3.5.566; Tankisi A, 2002, ACTA NEUROCHIR, V144, P665, DOI 10.1007/s00701-002-0957-y; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002; Vandesteene A, 1988, Anaesthesia, V43 Suppl, P42, DOI 10.1111/j.1365-2044.1988.tb09067.x; VANHEMELRIJCK J, 1990, ANESTH ANALG, V71, P49; WENNMALM A, 1981, CLIN PHYSIOL, V1, P227, DOI 10.1111/j.1475-097X.1981.tb00891.x	31	17	18	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAR	2004	59	3					229	236		10.1111/j.1365-2044.2004.03604.x			8	Anesthesiology	Anesthesiology	771WH	WOS:000188808700005	14984519				2020-06-30	J	Berger, A; Hoffman, DL; Goodman, S; Delea, TE; Seifeldin, R; Oster, G				Berger, A; Hoffman, DL; Goodman, S; Delea, TE; Seifeldin, R; Oster, G			Therapy switching in patients receiving long-acting opioids	ANNALS OF PHARMACOTHERAPY			English	Article						healthcare costs; opiod analgesics; pharmacotherapy	TRANSDERMAL FENTANYL; CANCER PAIN; MORPHINE; TERM	BACKGROUND: Patterns of therapy switching in patients receiving long-acting opioids have not been well documented. OBJECTIVE: To compare therapy switching among patients beginning treatment with control led-release (CR) oxycodone, transdermal fentanyl, or CR morphine sulfate. METHODS: Using a US healthcare claims database, we identified patients beginning treatment with CR oxycodone, transdermal fentanyl, or CR morphine sulfate between July 1, 1998, and December 31, 1999. We compiled claims for each patient for 6 months following therapy initiation and compared the incidence of therapy switching among the 3 groups. We also estimated total healthcare charges for patients who switched therapy versus those who did not. RESULTS: We identified 1931, 668, and 449 patients beginning therapy with CR oxycodone, transdermal fentanyl, and CR morphine sulfate, respectively; 16.7%, 25.0%, and 35.9%, respectively, had cancer. For patients without cancer, rates of therapy switching at 6 months were 10.6% (CR oxycodone), 19.0% (transdermal fentanyl), and 26.0% (CR morphine sulfate); for those with cancer, rates were 23.8%, 24.6%, and 29.8%, respectively. Multivariate hazard ratios (vs CR morphine sulfate) for therapy switching in patients without cancer were 0.36 (95% CI, 0.27 to 0.47) for CR oxycodone and 0.69 (0.51 to 0.94) for transdermal fentanyl; for those with cancer, corresponding hazard ratios were 0.72 (0.50 to 1.03) and 0.76 (0.50 to 1.16). Total healthcare charges were significantly (p < 0.01) higher for patients who switched therapy than those who did not ($23 965 vs $14 299 in pts. without cancer; $58 259 vs $39 618 for those with cancer). CONCLUSIONS: Patients without cancer who receive CR oxycodone or transdermal fentanyl are less likely to switch therapy than those receiving CR morphine sulfate. Total healthcare charges are higher for patients who switch therapy.	Policy Anal Inc, Brookline, MA 02445 USA; Purdue Pharma LP, Hlth Econ & Outcomes Res, Stamford, CT USA; Purdue Pharma LP, World Wide Hlth Econ & Outcomes Res, Stamford, CT USA	Oster, G (reprint author), Policy Anal Inc, 4 Davis Ct, Brookline, MA 02445 USA.	goster@pai2.com					Allan L, 2001, BRIT MED J, V322, P1; Allison PD, 1995, SURVIVAL ANAL USING, V1, P29; *AM MED ASS, 2000, CURR PROC TECHN; *AM PAIN SOC, 2002, GUID MAN PAIN OST RH, P54; Breitbart W, 2000, ONCOLOGY-NY, V14, P695; DONNER B, 1995, ANTI-CANCER DRUG, V6, P39, DOI 10.1097/00001813-199504003-00007; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Ghali WA, 2001, JAMA-J AM MED ASSOC, V286, P1494, DOI 10.1001/jama.286.12.1494; Hensley PL, 2001, PHARMACOECONOMICS, V19, P973, DOI 10.2165/00019053-200119100-00001; Hughes D, 1998, J HUM HYPERTENS, V12, P533, DOI 10.1038/sj.jhh.1000649; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; Johanson G A, 1992, Am J Hosp Palliat Care, V9, P4, DOI 10.1177/104990919200900405; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; Mucci-LoRusso P, 1998, EUR J PAIN-LONDON, V2, P239, DOI 10.1016/S1090-3801(98)90020-9; Pappagallo M, 1999, RHEUM DIS CLIN N AM, V25, P193, DOI 10.1016/S0889-857X(05)70060-0; Parrott T, 1999, J Am Board Fam Pract, V12, P293; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Robards M, 2001, Am J Hosp Palliat Care, V18, P47, DOI 10.1177/104990910101800112; *SAS I, 1992, SAS STAT US GUID VER, V2; *SAS I, 1992, SAS STAT US GUID VER, V1; 2000, PROFESSIONAL ICD 9 C	21	12	12	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1060-0280	1542-6270		ANN PHARMACOTHER	Ann. Pharmacother.	MAR	2004	38	3					389	395		10.1345/aph.1D109			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	774HE	WOS:000188973100003	14742831				2020-06-30	J	Mystakidou, K; Tsilika, E; Parpa, E; Papageorgiou, C; Georgaki, S; Vlahos, L				Mystakidou, K; Tsilika, E; Parpa, E; Papageorgiou, C; Georgaki, S; Vlahos, L			Investigating the effects of TTS-fentanyl for cancer pain on the psychological status of patients naive to strong opioids - An open label study	CANCER NURSING			English	Article						cancer; palliative care; psychological; severe pain; TTS-fentanyl	QUALITY-OF-LIFE; RATING DEPRESSION SCALE; TRANSDERMAL FENTANYL; PALLIATIVE CARE; ORAL MORPHINE; EFFICACY; MANAGEMENT; MODERATE	Few studies have investigated the effect of fentanyl delivered via the transdermal route with regard to the patient's psychological status. Patients who were naive to strong opioids and were attending a palliative care unit for pain relief from advanced cancer participated in this study to determine the effect of transdermal therapeutic system fentanyl (TTS-F) on their psychological condition. Spielberger State-Trait Anxiety Inventory (STAI), Zung Self-Rating Depression Scale (SDS), the Karnofsky Performance Scale (100-0, optimum-death), and a Visual Analogue Scale (VAS) (0: no pain; 10: worst pain) were used to measure the level of pain. Data were collected at baseline (TO), on the 7th day (T1), and on the 14th day (T2) of TTS-F application in order to determine changes in correlation to TTS-F dose. Patients' status improved according to the Zung SIDS questionnaire (P <.0005) and with each of its subscales (P <.05). A similar improvement was observed according to the Spielberger STAI questionnaire (P =.002). Moreover, VAS measures demonstrated that patients achieved significant pain relief (P <.0005), while patients' performance status did not alter significantly over the study period. Furthermore, the Zung SIDS showed a statistically significant correlation when compared with the Spielberger STAI (P<.01). These data provide some evidence that the psychological status, as measured with respect to depression and anxiety in patients with advanced cancer, is improved in patients receiving TTS-fentanyl. Future research should use a broad range of psychological measurements in order to assist the development of practices, which are aimed at the improvement of quality of life in these patients.	Univ Athens, Areteion Hosp, Sch Med, Pain Relief & Palliat Care Unit, Athens 11526, Greece; Univ Athens, Areteion Hosp, Dept Radiol, Athens 11526, Greece; Univ Athens, Sch Med, Aeginition Hosp, Athens 11526, Greece	Mystakidou, K (reprint author), Univ Athens, Areteion Hosp, Sch Med, Pain Relief & Palliat Care Unit, 27 Korinthias St, Athens 11526, Greece.	mistakidou@yahoo.com					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; AHMEDZAI S, 1997, J PAIN SYMPTOM MANAG, V13, P256; *AM AC PAIN MED, 1996, US OP TREATM CHRON P; BAGLEY JR, 1989, J MED CHEM, V32, P663, DOI 10.1021/jm00123a028; Block SD, 2000, ANN INTERN MED, V132, P209, DOI 10.7326/0003-4819-132-3-200002010-00007; BLOCK SD, 1998, END OF LIFE DECISION, P205; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P287, DOI 10.1016/0885-3924(95)00005-J; Dugan W, 1998, PSYCHO-ONCOLOGY, V7, P483, DOI 10.1002/(SICI)1099-1611(199811/12)7:6<483::AID-PON326>3.0.CO;2-M; Fritzsche K, 1998, ONKOLOGIE, V21, P150, DOI 10.1159/000026797; Hammack JE, 1996, J PAIN SYMPTOM MANAG, V12, P234, DOI 10.1016/0885-3924(96)00191-1; Iconomou G, 2000, ANTICANCER RES, V20, P4821; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; KORTE W, 1994, SUPPORT CARE CANCER, V2, P123, DOI 10.1007/BF00572094; LARNE F, 1995, BRIT MED J, V310, P1034; Lloyd-Williams M, 2003, PALLIATIVE MED, V17, P40, DOI 10.1191/0269216303pm664oa; MASSIE MJ, 1992, J PAIN SYMPTOM MANAG, V7, P99, DOI 10.1016/0885-3924(92)90121-W; MEYERS CA, 1994, J CLIN ONCOL, V12, P820, DOI 10.1200/JCO.1994.12.4.820; Morasso G, 1996, ONCOLOGY-BASEL, V53, P295; Mystakidou K, 2001, ANTICANCER RES, V21, P2225; Mystakidou K, 1999, PALLIATIVE MED, V13, P385, DOI 10.1191/026921699669663451; NIMMO WS, 1986, ANESTHESIOLOGY, V65, pA559; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; PAYNE R, 1995, ANTI-CANCER DRUG, V6, P50, DOI 10.1097/00001813-199504003-00009; REITAN RM, 1993, HALSTEAD REITAN NEUR; Schwenk TL, 1998, PRIMARY CARE, V25, P505, DOI 10.1016/S0095-4543(05)70079-8; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Spiegel D, 1996, BRIT J PSYCHIAT, V168, P109, DOI 10.1192/S0007125000298486; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; Stoner S.C., 1998, MED UPDATE PSYCHIAT, V3, P64; Strang P, 1997, PALLIATIVE MED, V11, P299, DOI 10.1177/026921639701100406; VACHON MLS, 1995, J PAIN SYMPTOM MANAG, V10, P142, DOI 10.1016/0885-3924(94)00076-W; VAINIO A, 1988, ACTA ANAESTH SCAND, V32, P179, DOI 10.1111/j.1399-6576.1988.tb02711.x; VELKOVA AB, 1995, PSYCHOTHER PSYCHOSOM, V63, P181; VILLIGER JW, 1983, NEUROPHARMACOLOGY, V22, P447, DOI 10.1016/0028-3908(83)90162-4; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008; 1995, ABPI DATA SHEET COMP, V96, P724	38	6	9	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0162-220X			CANCER NURS	Cancer Nurs.	MAR-APR	2004	27	2					127	133		10.1097/00002820-200403000-00005			7	Oncology; Nursing	Oncology; Nursing	811MN	WOS:000220776100005	15253170				2020-06-30	J	Tawfik, MO; Bryuzgin, V; Kourteva, G				Tawfik, MO; Bryuzgin, V; Kourteva, G		FEN-INT Study Grp	Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						analgesics, opioid; fentanyl; pain; palliative care	MANAGEMENT; TERM	Objective: To determine the safety and efficacy of transdermal fentanyl for pain relief in cancer patients and to compare the effects on patients according to whether they had previously received strong opioids, weak opioids or non-opioid analgesia. Methods: Cancer patients requiring strong analgesia were recruited into an open-label, multicentre study, conducted in eight countries. Patients received transdermal fentanyl treatment for 28 days. Pain severity, overall satisfaction with pain control, convenience of use of patches and treatment preferences were recorded daily. Results: Of the 292 participants, 135 had previously received a strong opioid, 84 had previously received a weak opioid and 73 had received no regular opioids. Thirty-eight patients did not complete the study, mainly due to adverse events. For all groups the proportion of patients with 'good to excellent' pain control increased after transdermal fentanyl treatment. Transdermal fentanyl was well tolerated, with the most common treatment-related adverse events being nausea, vomiting and constipation. The percentage of strong-opioid-tolerant patients with constipation decreased following transdermal fentanyl treatment and increased slightly in the strong-opioid-naive groups. Most patients rated the convenience of the patches as 'good to excellent', and most preferred transdermal fentanyl to their previous therapy. Conclusions: Transdermal fentanyl is an effective and well-tolerated treatment for cancer-related pain for patients regardless of whether they have previously received opioids. Previous guidelines have often advocated initial dose finding with short-acting opioids but this study demonstrates that such a complex titration and conversion schedule may not be necessary, and that treatment may be initiated directly with long-acting formulations such as transdermal fentanyl when previous analgesic therapy fails to provide adequate relief.	Cairo Univ, Natl Canc Inst, Cairo, Egypt; Blokhin Canc Res Ctr, Moscow, Russia; Natl Oncol Ctr, BU-1157 Sofia, Bulgaria	Tawfik, MO (reprint author), Cairo Univ, Natl Canc Inst, Cairo, Egypt.	tawfik@ie-eg.com					AHMEDZAI S, 1994, J DRUG DEV, V6, P93; Chandler S, 1998, Am J Hosp Palliat Care, V15, P223, DOI 10.1177/104990919801500408; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Hammack JE, 1996, J PAIN SYMPTOM MANAG, V12, P234, DOI 10.1016/0885-3924(96)00191-1; JADAD AR, 1995, JAMA-J AM MED ASSOC, V274, P1870, DOI 10.1001/jama.274.23.1870; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; MAVES TJ, 1992, J PAIN SYMPTOM MAN S, V7, P58; Merskey H., 1994, CLASSIFICATION CHRON; SLAPPENDEL R, 1994, ANN ONCOL S8, V5, P200; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; TOOLEY PJH, 2000, J OUTCOMES RES, V4, P1; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; World Health Organization, 1990, WHO TECHN REP SER, P804; Yeo W, 1997, PALLIATIVE MED, V11, P233, DOI 10.1177/026921639701100308; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9	17	27	31	1	4	LIBRAPHARM	NEWBURY	C/O DR. PETER L CLARKE, 26-32 VENTURE WEST, NEW GREENHAM PARK, NEWBURY RG19 6HX, BERKSHIRE, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	MAR	2004	20	3					259	267		10.1185/030079903125003026			9	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	806CP	WOS:000220412300002	15025835				2020-06-30	J	Sen, S; Ytrebo, LM; Rose, C; Fuskevaag, OM; Davies, NA; Nedredal, GI; Williams, R; Revhaug, A; Jalan, R				Sen, S; Ytrebo, LM; Rose, C; Fuskevaag, OM; Davies, NA; Nedredal, GI; Williams, R; Revhaug, A; Jalan, R			Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs	INTENSIVE CARE MEDICINE			English	Article						albumin dialysis; charcoal; adsorption; midazolam; fentanyl	BIOARTIFICIAL LIVER; ACTIVATED-CHARCOAL; FENTANYL; TOXINS; SYSTEM; BLOOD	Objective: Although water-soluble drugs can be removed by haemofiltration/haemodialysis, morbidity and mortality from intoxication with protein-bound drugs remains high. The present study investigates whether albumin dialysis in the form of the Molecular Adsorbents Recirculating System (MARS) is effective in removal of protein-bound drugs. Design: Prospective animal study. Setting: Surgical research laboratory in a university hospital. Subjects: Seven female Norwegian Landrace pigs. Intervention: We studied whether midazolam (97% albumin-bound) and fentanyl (85% alpha-1-acid glycoprotein-bound), administered as anaesthetics to pigs with induced acute liver failure, could be removed by MARS dialysis lasting for 4 h. Measurements: After 4 h of dialysis, total and free anaesthetic concentrations were measured in the blood and dialysate from different segments of the MARS circuit. Main results: Midazolam: total plasma concentrations fell by 47.1+/-2.1% (in 4 h) across the MARS filter (p<0.01). The charcoal component of the system reduced the total dialysate drug concentration by 16.4 +/- 2.2% (p<0.05). Free midazolam removal followed a similar pattern. Fentanyl: total plasma concentrations fell by 56.1+/-2.4% (in 4 h) across the MARS filter (p<0.01). Clearance of fentanyl from the dialysate by the charcoal was 70 +/- 0.7% at 4 h (p<0.001). Conclusions: The results of the study show that MARS can remove both albumin and other protein-bound drugs efficiently from the plasma, and it may have a place for the treatment of patients suffering from intoxication with this class of compounds.	Inst Hepatol, Liver Failure Grp, London WC1E 6HX, England; Univ Hosp No Norway, Dept Digest Surg, Tromso, Norway; Max Delbruck Ctr Mol Med, Dept Cellular Neurosci, Berlin, Germany; Univ Hosp No Norway, Dept Clin Pharmacol, Tromso, Norway	Jalan, R (reprint author), Inst Hepatol, Liver Failure Grp, 69-75 Chenies Mews, London WC1E 6HX, England.	rjalan@ucl.ac.uk	Rose, Christopher F/F-1105-2010	Rose, Christopher F/0000-0001-9854-6834			ELSAYED YM, 1990, J PHARM PHARMACOL, V42, P538, DOI 10.1111/j.2042-7158.1990.tb07054.x; KOFFLER A, 1978, ARCH INTERN MED, V138, P1691, DOI 10.1001/archinte.138.11.1691; Lapatto-Reiniluoto O, 1999, BRIT J CLIN PHARMACO, V48, P148, DOI 10.1046/j.1365-2125.1999.00995.x; LEHMANN KA, 1983, ANAESTHESIST, V32, P329; Litovitz TL, 2002, AM J EMERG MED, V20, P391, DOI 10.1053/ajem.2002.34955; *MED EC, 2002, [No title captured]; Sen S, 2003, EPILEPSIA, V44, P265, DOI 10.1046/j.1528-1157.2003.31402.x; Stange J, 1996, INT J ARTIF ORGANS, V19, P677; STANGE J, 1993, ARTIF ORGANS, V17, P809; STANGE J, 1993, [No title captured], V39, P621; TORRENTE AD, 1979, NEPHRON, V24, P71, DOI 10.1159/000181697; Wiesner G, 1996, ANAESTHESIST, V45, P323, DOI 10.1007/s001010050267; Ytrebo LM, 2002, SCAND J GASTROENTERO, V37, P1077, DOI 10.1080/003655202320378293; Ytrebo LM, 2001, SCAND J CLIN LAB INV, V61, P217	14	43	46	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2004	30	3					496	501		10.1007/s00134-003-2141-0			6	Critical Care Medicine	General & Internal Medicine	780GQ	WOS:000189364300023	14735236				2020-06-30	J	Wootton, M				Wootton, M			Morphine is not the only analgesic in palliative care: literature review	JOURNAL OF ADVANCED NURSING			English	Review						nursing; literature review; palliative care; pain; morphine	ADVANCED CANCER-PATIENTS; CLINICAL-EXPERIENCE; PAIN; METHADONE; KETAMINE; FENTANYL; INFUSION; MANAGEMENT; PATIENT; UNIT	Background. No comprehensive review has been published to date, which provides information for nurses on pharmaceutical alternatives to morphine in palliative care. As nurses are often the health professional most involved with terminally ill patients, there is a clear need for a review of current practices which is accessible to nurses. Aim. The aim of this review is to examine the pharmaceutical alternatives to morphine use in palliative care that are currently available. Methods. Searches were made of the CINAHL and MEDLINE databases for articles published between 1990 and 2000, using the keywords 'pain management',,cancer pain' and 'morphine'. Findings. Most evidence on the use of pharmaceutical alternatives to morphine is anecdotal, demonstrating a need for more research to be conducted in this field. Evidence presented in this review shows encouraging results following the administration of methadone, fentanyl or ketamine to patients with difficult pain problems. Conclusion. Nurses need to be aware of treatment options that may benefit patients with difficult pain problems. Although positive experiences have been documented when using alternatives to morphine, more research must be conducted to allow practitioners to add more pharmaceutical alternatives to their pain management armouries.	Royal Victoria Infirm, Anaesthet & Recovery Dept, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Wootton, M (reprint author), Royal Victoria Infirm, Anaesthet & Recovery Dept, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	mawootton@hotmail.com					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Atkinson CV, 1999, PALLIATIVE MED, V13, P145, DOI 10.1191/026921699676057177; *BRIT MED ASS, 2003, BNF 42; Broadley KE, 1996, PALLIATIVE MED, V10, P247, DOI 10.1177/026921639601000309; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P372, DOI 10.1016/0885-3924(92)90093-W; Coluzzi P H, 1998, Am J Hosp Palliat Care, V15, P13, DOI 10.1177/104990919801500105; DeConno F, 1996, J CLIN ONCOL, V14, P2836, DOI 10.1200/JCO.1996.14.10.2836; *DEP HLTH, 1999, DRUG MIS DEP GUID CL; Drummond SH, 1996, PALLIATIVE MED, V10, P119, DOI 10.1177/026921639601000206; DYMOCK B, 1999, RELIEF PAIN RELATED; Enarson MC, 1999, J PAIN SYMPTOM MANAG, V17, P384, DOI 10.1016/S0885-3924(99)00011-1; Fainsinger RL, 1996, J PALLIAT CARE, V12, P6, DOI 10.1177/082585979601200402; Fine PG, 1999, J PAIN SYMPTOM MANAG, V17, P296, DOI 10.1016/S0885-3924(98)00144-4; FOLEY KM, 1996, SCI AM, V275, P128; Gagnon B, 1999, J PAIN SYMPTOM MANAG, V18, P120, DOI 10.1016/S0885-3924(99)00049-4; Gannon C, 1997, EUR J PALLIAT CARE, V4, P152; Genf World Health Organization, 1986, CANC PAIN REL; Gordon D B, 1999, J Palliat Med, V2, P209, DOI 10.1089/jpm.1999.2.209; Hagen NA, 1999, J PAIN SYMPTOM MANAG, V18, P369, DOI 10.1016/S0885-3924(99)00083-4; HANKS GW, 1992, LANCET, V339, P1031; HAWA L, 1998, EUROPEAN J PALLIATIV, V5, P77; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; JOSHUA A, 1997, GUYS HOSP NURSING DR; KINDLEN M, 1996, NURSING PRACTICE HOS; LAIRD D, 1993, LANCET, V341, P241, DOI 10.1016/0140-6736(93)90104-O; MCMENEMIN I, 1999, J ONE DAY SURG   WIN, P10; Mercadante S, 1997, J PAIN SYMPTOM MANAG, V13, P241, DOI 10.1016/S0885-3924(97)00076-6; MERCADANTE S, 1995, J PAIN SYMPTOM MANAG, V10, P564, DOI 10.1016/0885-3924(95)00102-5; Mercadante S, 1996, PALLIATIVE MED, V10, P225; Mercadante S, 1999, J PAIN SYMPTOM MANAG, V18, P188, DOI 10.1016/S0885-3924(99)00048-2; MERCADANTE S, 1998, AM J HOSPICE PAL NOV, P333; Parahoo K., 1997, NURSING RES PRINCIPL; RAY DJ, 1998, OXFORD TXB PALLIATIV; SEERS K, 1996, NURSING PRACTICE HOS; SINGER M, 1993, J PAIN SYMPTOM MANAG, V8, P215, DOI 10.1016/0885-3924(93)90130-N; THOMAS Z, 1995, J PAIN SYMPTOM MANAG, V10, P315, DOI 10.1016/0885-3924(95)00011-M; TWYCROSS R, 1997, [No title captured]; TWYCROSS R, 1995, PAIN RELIEF ADV CANC; WALSH TD, 1988, BRIT MED J, V296, P477, DOI 10.1136/bmj.296.6620.477; *WHO, 1996, FREED CANC PAIN	40	12	12	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0309-2402			J ADV NURS	J. Adv. Nurs.	MAR	2004	45	5					527	532		10.1046/j.1365-2648.2003.02936.x			6	Nursing	Nursing	802SL	WOS:000220183100010	15009356				2020-06-30	J	Kotake, Y; Matsumoto, M; Morisaki, H; Takeda, J				Kotake, Y; Matsumoto, M; Morisaki, H; Takeda, J			The effectiveness of continuous epidural infusion of low-dose fentanyl and mepivacaine in perioperative analgesia and hemodynamic control in mastectomy patients	JOURNAL OF CLINICAL ANESTHESIA			English	Article						cervical epidural block; fentanyl; mastectomy; mepivacaine	MODIFIED RADICAL-MASTECTOMY; ANESTHESIA; BREAST; MANAGEMENT; SURGERY; PAIN	Study Objectives: To investigate, in mastectomy patients, the effectiveness of continuous cervical epidural block using a low-dose fentanyl infusion in combination with local anesthetics. Design: Prospective, observational study. Setting: 450-bed, university-affiliated hospital. Patients: 21 ASA physical status I and II female patients undergoing modified radical mastectomy. Interventions: An epidural catheter was inserted at the CTTh1 interspace before the induction Of anesthesia. Anesthesia was maintained using a low concentration of sevoflurane with nitrous oxide-oxygen (N2O-O-2). A mixture of 100 mug fentanyl and 49 mL of 1% mepivacaine was prepared, and 7 mL of this solution was epidurally injected before the initial incision. This same solution was continuously infused at a rate of 7 mL/hr (fentanyl 17.5 mug/hr) throughout the anesthesia, and at 2 mL/hr (fentanyl 5 mug/hr) postoperatively. Measurements and Main Results: Intraoperative mean arterial pressure (ALAP) and heart rate (HR), postoperative pain and analgesic use, and the frequency of postoperative side effects of anesthesia, including nausea, dizziness, and respiratory depression, were recorded. The protocol described provided stable intraoperative hemodynamic control with no or low-dose nicardipine infusion. Sufficient Postoperative analgesia was achieved in 18 of 21 patients. One patient reported postoperative nausea, and no other side effects were reported. Conclusions: Continuous epidural infusion of the low-dose fentanyl mixture described above provides adequate intraoperative hemodynamic control and postoperative pain relief, with a low rate of side effects in mastectomy patients. (C) 2004 by Elsevier Inc.	Tachikawa Kyosai Hosp, Dept Anesthesiol, Tokyo, Japan	Kotake, Y (reprint author), Keio Univ, Sch Med, Dept Anesthesiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	ykotake@sc.itc.keio.ac.jp	Morisaki, Hiroshi/J-5960-2013				Benzon Honorio T., 1996, P173; BLOOMSTONE J, 1997, CLIN ANESTHESIA PROC, P661; Correll DJ, 2001, REGION ANESTH PAIN M, V26, P444, DOI 10.1053/rapm.2001.26219; Cousins M. J., 1998, NEURAL BLOCKADE CLIN, P243; Doss NW, 2001, ANESTH ANALG, V92, P1552; JAROSZ J, 1991, EUR J SURG ONCOL, V17, P599; Kosaka Y, 1978, Masui, V27, P606; LYNCH EP, 1995, ANN SURG, V222, P663, DOI 10.1097/00000658-199511000-00009; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; STAPS T, 1985, CANCER, V56, P2898, DOI 10.1002/1097-0142(19851215)56:12<2898::AID-CNCR2820561229>3.0.CO;2-J; Stevens RA, 1998, REGION ANESTH PAIN M, V23, P20, DOI 10.1016/S1098-7339(98)90106-7; Yeh CC, 1999, WORLD J SURG, V23, P256, DOI 10.1007/PL00013180	12	9	9	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180			J CLIN ANESTH	J. Clin. Anesth.	MAR	2004	16	2					88	91		10.1016/j.jclinane.2003.05.005			4	Anesthesiology	Anesthesiology	818XJ	WOS:000221277500003	15110368				2020-06-30	J	Aydin, ON; Ugur, B; Kir, E; Ozkan, SB				Aydin, ON; Ugur, B; Kir, E; Ozkan, SB			Effect of single-dose fentanyl on the cardiorespiratory system in elderly patients undergoing cataract surgery	JOURNAL OF CLINICAL ANESTHESIA			English	Article						anesthesia; topical; cardiorespiratory system; cataract surgery; fentanyl; geriatric surgery; phacoemulsification	CARBON-DIOXIDE; EYE SURGERY; RETROBULBAR ANESTHESIA; INTRAVENOUS SEDATION; OXYGENATION; PROPOFOL; PHACOEMULSIFICATION; ACCUMULATION; CO2	Study Objectives: To evaluate the effects of fentanyl on the cardiorespiratory system in elderly patients undergoing cataract surgery with phacoemulsification method. Design: Randomized, prospective, double-blind study. Setting: University hospital. Patients: 70 ASA physical status I, II, and III patients (>60 years) who underwent cataract surgery with topical anesthesia. Interventions: Patients were randomly divided into two groups. The fentanyl group (35 patients) received fentanyl in 0.7 mug/kg bolus doses in a 2-mL balanced salt solution prior to surgery. The control group (35 patients) received a 2-mL balanced salt solution without any analgesic drug. Measurements and Main Results: Systolic (SBP), diastolic (DBP), mean arterial pressure (MAP), heart rate (HR), peripheral oxygen saturation (SpO(2)), respiratory rate (RR), end-tidal carbon dioxide (ETCO2), inspired CO2 concentration, and sedation scares were measured preoperatively and at 5, 10, 15, 20, and 30 minutes intraoperatively. Postoperatively, patients were questioned about the presence of intraoperative pain. In the fentanyl group, no significant differences were observed in SPB, DBP, MAP, W or peripheral SpO(2). In the control group, RR was higher than baseline values at 10, 15, and 20 minutes. Diastolic blood pressure was higher than baseline values at 20 minutes. End-tidal CO2 and inspired CO2 levels were higher than baseline levels in both groups at all measurement times. Intraoperative ETCO2 levels were higher in the fentanyl group than the control group (p < 0.01). Finally, no hypoxemia was observed in either group. Conclusion: Fentanyl can be used safely in 0.7-mug/kg dosages in elderly patients to improve Patient comfort without any cardiorespiratory side effects, when undergoing cataract surgery with topical anesthesia. (C) 2004 by Elsevier Inc.	Adnan Menderes Univ, Tip Fak, Anesteziyoloji Reanimasyon Dept, TR-09100 Aydin, Turkey	Aydin, ON (reprint author), Adnan Menderes Univ, Tip Fak, Anesteziyoloji Reanimasyon Dept, TR-09100 Aydin, Turkey.	onaydin@superonline.com	Ozkan, Seyhan B./Y-2773-2019				Aydin ON, 2002, J CATARACT REFR SURG, V28, P1968, DOI 10.1016/S0886-3350(02)01429-3; Boezaart AP, 2001, J CLIN ANESTH, V13, P422, DOI 10.1016/S0952-8180(01)00296-3; Casati A, 2001, Minerva Anestesiol, V67, P161; CHERNY NI, 1994, TXB PAIN, P1437; EDMONDSSEAL J, 1988, ANAESTHESIA, V43, P603, DOI 10.1111/j.1365-2044.1988.tb06707.x; Eong KGA, 2000, OPHTHALMOLOGY, V107, P248, DOI 10.1016/S0161-6420(99)00080-9; FITZGIBBON DR, 2001, BONICAS MANAGEMENT P, P623; FREEMAN ML, 1993, GASTROENTEROLOGY, V105, P331, DOI 10.1016/0016-5085(93)90705-H; Friesen RH, 1996, J CLIN MONITOR, V12, P155, DOI 10.1007/BF02078136; GOOD ML, 1993, ANESTHESIA EQUIPMENT, P237; Hampl KF, 1996, ACTA ANAESTH SCAND, V40, P53, DOI 10.1111/j.1399-6576.1996.tb04388.x; Jayamanne DGR, 1996, EYE, V10, P130, DOI 10.1038/eye.1996.23; KOBEL M, 1984, OPHTHALMOLOGICA, V188, P135, DOI 10.1159/000309355; Loughnan TE, 2000, ANAESTH INTENS CARE, V28, P151, DOI 10.1177/0310057X0002800204; Lynch D, 2000, PRACTICAL MANAGEMENT, P270; MICHELSON G, 1991, OPHTHALMIC SURG LAS, V22, P615; MURPHY MR, 1995, CLIN ANAESTHESIA, P413; NIKKI P, 1990, SCAND J CLIN LAB INV, V50, P213, DOI 10.3109/00365519009087512; OSBORNE GA, 1991, ANAESTHESIA, V46, P553, DOI 10.1111/j.1365-2044.1991.tb09654.x; PacSoo CK, 1996, BRIT J ANAESTH, V77, P370; PALVE H, 1991, ACTA ANAESTH SCAND, V35, P181; Patel BCK, 1998, J CATARACT REFR SURG, V24, P853, DOI 10.1016/S0886-3350(98)80143-0; Patel BCK, 1996, OPHTHALMOLOGY, V103, P1196, DOI 10.1016/S0161-6420(96)30522-8; Prause G, 1997, RESUSCITATION, V35, P145, DOI 10.1016/S0300-9572(97)00043-9; Risdall JE, 1997, ANAESTHESIA, V52, P492, DOI 10.1111/j.1365-2044.1997.110-az0104.x; RUDKIN GE, 1992, ANAESTHESIA, V47, P376, DOI 10.1111/j.1365-2044.1992.tb02216.x; Schlager A, 1999, BRIT J OPHTHALMOL, V83, P1131, DOI 10.1136/bjo.83.10.1131; Schlager A, 1998, ANAESTHESIA, V53, P1212, DOI 10.1046/j.1365-2044.1998.00652.x; Schlager A, 1999, ANAESTHESIA, V54, P690, DOI 10.1046/j.1365-2044.1999.00889.x; Schlager A, 2000, BRIT J OPHTHALMOL, V84, P399, DOI 10.1136/bjo.84.4.399; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; TOBIAS JD, 1994, CRIT CARE MED, V22, P1805; WILSON E, 1990, BRIT J ANAESTH, V64, P48, DOI 10.1093/bja/64.1.48; Wong DHW, 1996, CAN J ANAESTH, V43, P1115, DOI 10.1007/BF03011837; YELDERMAN M, 1983, ANESTHESIOLOGY, V59, P349, DOI 10.1097/00000542-198310000-00015; Zeitlin G L, 1989, J Clin Anesth, V1, P262, DOI 10.1016/0952-8180(89)90024-X	36	8	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	MAR	2004	16	2					98	103		10.1016/j.jclinane.2003.05.008			6	Anesthesiology	Anesthesiology	818XJ	WOS:000221277500005	15110370				2020-06-30	J	Kharasch, ED; Hoffer, C; Altuntas, TG; Whittington, D				Kharasch, ED; Hoffer, C; Altuntas, TG; Whittington, D			Quinidine as a probe for the role of P-glycoprotein in the intestinal absorption and clinical effects of fentanyl	JOURNAL OF CLINICAL PHARMACOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics	APR 02-05, 2003	WASHINGTON, D.C.	Amer Soc Clin Pharmacol Therapeut		quinidine; P-glycoprotein; intestinal absorption; fentanyl; drug metabolism	BLOOD-BRAIN-BARRIER; DRUG TRANSPORTERS; IN-VITRO; CYTOCHROME-P450 3A4; PHARMACOKINETICS; INHIBITION; ALFENTANIL; ANALGESIA; MICE; PAIN	The mechanism of individual variability in the fentanyl dose-effect relationship is unknown. The efflux pump P-glycoprotein (P-gp) regulates brain access and intestinal absorption of numerous drugs. Evidence exists that fentanyl is a P-gp substrate in vitro, and P-gp affects fentanyl analgesia in animals. However, the role of P-gp in human fentanyl disposition and clinical effects is unknown. This investigation tested the hypothesis that plasma concentrations and clinical effects of oral and intravenous fentanyl are greater after inhibition of intestinal and brain P-gp, using the P-gp inhibitor quinidine as an in vivo probe. Two randomized, double-blind, placebo-controlled, balanced, two-period crossover studies were conducted in normal healthy volunteers (6 males and 6 females) after obtaining informed consent. Pupil diameters and/or plasma concentrations of fentanyl and norfentanyl were evaluated after oral or intravenous fentanyl (2.5 mug/kg), dosed 1 hour after oral quinidine (600 mg) or placebo. Quinidine did not alter the magnitude or time to maximum miosis, time-specific pupil diameter, or subjective self-assessments after intravenous fentanyl but did increase the area under the curve (AUC) of miosis versus time (13.6 +/- 5.3 vs. 8.7 +/- 5.0 mm.h, p < 0.05) and decreased the effect of elimination (k(el) 0.35 +/- 0.16 vs. 0.52 +/- 0.24 h(-1), p < 0.05). Quinidine increased oral fentanyl plasma C-max (0.55 +/- 0.19 vs. 0.21 +/- 0.1 ng/mL) and AUC (1.9 +/- 0.5 vs. 0.7 +/- 0.3 ng.h.mL(-1)) (both p < 0.05) but had no effect on apparent elimination. Plasma norfentanyl/fentanyl AUC ratios were not diminished by quinidine. Quinidine significantly increased maximum miosis after oral fentanyl (3.4 +/- 1.3 vs. 2.3 +/- 1.3 mm, p < 0.05), commensurate with increases in plasma concentrations, but concentration-effect relationships and the rate constant for the transfer between plasma and effect comportment (k(e0)) (1.9 +/- 1.0 vs. 3.6 +/- 2.6 h(-1)) were not significantly different. Quinidine increased oral fentanyl plasma concentrations, suggesting that intestinal P-gp or some other quinidine-sensitive transporter affects the absorption, bioavoilability, and hence clinical effects of oral fentanyl. Quinidine had less effect on fentanyl pharma- codynamics, suggesting that if quinidine is an effective inhibitor of brain P-gp, then P-gp appears to have less effect on brain access of fentanyl.	Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA	Kharasch, ED (reprint author), Univ Washington, Dept Anesthesiol, Box 356540,1959 NE Pacific St,RR-442, Seattle, WA 98195 USA.		Altuntas, Tunca Gul/AAF-8075-2020	Altuntas, Tunca Gul/0000-0003-1194-8588	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR00037]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K24-DA00417]		Arndt P, 2001, AM J PHYSIOL-RENAL, V281, pF454; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; CHAPMAN CR, 1990, PAIN, V43, P47, DOI 10.1016/0304-3959(90)90049-J; CIRELLA VN, 1987, ANESTH ANALG, V66, P703; de Boer AG, 2003, ANNU REV PHARMACOL, V43, P629, DOI 10.1146/annurev.pharmtox.43.100901.140204; de Maat MMR, 2003, CLIN PHARMACOKINET, V42, P223, DOI 10.2165/00003088-200342030-00002; Deferme S, 2003, J PHARM PHARMACOL, V55, P153, DOI 10.1211/002235702603; Donahue JP, 2003, CLIN PHARMACOL THER, V73, P78, DOI 10.1067/mcp.2003.11; Fricker G, 2002, PHARMACOL TOXICOL, V90, P5, DOI 10.1034/j.1600-0773.2002.900103.x; Fromm MF, 2000, INT J CLIN PHARM TH, V38, P69; FUSEAU E, 1984, CLIN PHARMACOL THER, V35, P733, DOI 10.1038/clpt.1984.104; HEDMAN A, 1990, CLIN PHARMACOL THER, V47, P20, DOI 10.1038/clpt.1990.3; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; KHARASCH ED, IN PRESS CLIN PHARM; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; Lamhonwah AM, 2003, BIOCHEM BIOPH RES CO, V301, P98, DOI 10.1016/S0006-291X(02)02946-7; Lee G, 2001, PHARMACOL REV, V53, P569; Levy G, 1998, CLIN PHARMACOKINET, V34, P323, DOI 10.2165/00003088-199834040-00005; Lin JH, 2003, CLIN PHARMACOKINET, V42, P59, DOI 10.2165/00003088-200342010-00003; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; Payne R, 2001, J PAIN SYMPTOM MANAG, V22, P575, DOI 10.1016/S0885-3924(01)00306-2; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Perloff MD, 2002, J CLIN PHARMACOL, V42, P1269, DOI 10.1177/009127002762491370; Phimmasone S, 2001, CLIN PHARMACOL THER, V70, P505, DOI 10.1067/mcp.2001.119994; Polli JW, 2001, J PHARMACOL EXP THER, V299, P620; Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; Skarke Carsten, 2003, Pharmacogenetics, V13, P651, DOI 10.1097/00008571-200311000-00001; Slitt AL, 2002, DRUG METAB DISPOS, V30, P212, DOI 10.1124/dmd.30.2.212; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; Wandel C, 1999, CANCER RES, V59, P3944; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; Wheeler M, 2002, PAEDIATR ANAESTH, V12, P594, DOI 10.1046/j.1460-9592.2002.00949.x; Yamazaki M, 2001, J PHARMACOL EXP THER, V296, P723	37	56	57	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0091-2700			J CLIN PHARMACOL	J. Clin. Pharmacol.	MAR	2004	44	3					224	233		10.1177/0091270003262075			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	776AY	WOS:000189093900002	14973303				2020-06-30	J	Mystakidou, K; Parpa, E; Tsilika, E; Katsouda, E; Kouloulias, V; Kouvaris, J; Georgaki, S; Vlahos, L				Mystakidou, K; Parpa, E; Tsilika, E; Katsouda, E; Kouloulias, V; Kouvaris, J; Georgaki, S; Vlahos, L			Pain management of cancer patients with transdermal fentanyl: A study of 1828 step I, II, & III transfers	JOURNAL OF PAIN			English	Article						nociceptive; neuropathic; chronic pain; intolerable pain; analgesia	QUALITY-OF-LIFE; EFFICACY CLINICAL-TRIAL; LONG-TERM TREATMENT; ORAL MORPHINE; ASSURANCE STANDARDS; SATISFACTION; GUIDELINES; VALIDATION; RELIEF; SAFETY	The aim of this observational study was to examine pain management outcomes and quality of life (QoL) measures in cancer patients with intolerable or chronic severe pain transferring from World Health Organization's step I, II, and III analgesics to the transdermal therapeutic fentanyl system (TTS-F). This study examines the safety and efficacy of TTS-F in long-term pain management, addressing the role of TTS-F in cancer pain. Pain measures were assessed in 1828 patients (step I [naive], 268; step II [codeine], 1239; and step III [morphine], 321) on the basis of selected questions from the Greek-Brief Pain Inventory. Overall treatment satisfaction (scale, 1 to 4), QoL, and European Collaborative Oncology Group (ECOG) status were also recorded. These were assessed in relation to TTS-F dose, stratified by transfer step, primary cancer, metastases, type of pain, and concomitant use of anti-inflammatory drugs. Of 1828 patients, 100 (5.5%) withdrew, and an addition 14 (0.8%) discontinued because of side effects. A total of 1714 continued on study; 744 patients died, and 970 departed during the study period. In total, 93.8% were satisfied with their pain relief, and complete patient satisfaction was obtained within 2 months. Pain, QoL, and treatment satisfaction measures demonstrated statistically significant improvements over time, independent of the step transfer. Although doses of TTS-F were higher for step III > II > I and for metastatic than nonmetastatic, the median dose for all groups remained 50 mug/h throughout the study period. Pain and QoL improvements were independent of patient characteristic(s). Direct transfer to TTS-F for patients with intolerable or chronic moderate to severe cancer pain offers an efficient and safe long-term analgesic option for palliative care patients. Careful selection and follow-up by experienced palliative care specialists are mandatory. TTS-F as a first-line analgesic approach for severe cancer pain should be considered a viable option because of its durable efficacy and low incidences of side effects. Perspective: At a fairly constant dose of 50 mug/h, the transdermal therapeutic fentanyl system offers a safe, well-tolerated pain relief treatment for carefully monitored patients with cancer pain. The authors stress that this includes patients who experience difficulties in their pain management while progressing through the WHO's ladder for pain management. (C) 2004 by the American Pain Society.	Univ Athens, Sch Med, Areteion Hosp, Dept Radiol,Pain Relief & Palliat Care Unit, Athens 11526, Greece; Univ Athens, Sch Med, Dept Gen Surg, Radiotherapy Unit, GR-11527 Athens, Greece	Mystakidou, K (reprint author), Univ Athens, Sch Med, Areteion Hosp, Dept Radiol,Pain Relief & Palliat Care Unit, Korinthias 27 St, Athens 11526, Greece.	mistakidou@yahoo.com					AHMEDZAI S, 1994, J DRUG DEV, V6, P93; Ahmedzai S, 1997, EUR J CANCER, V33, pS8, DOI 10.1016/S0959-8049(97)00205-0; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; ASBURY AK, 1984, NEUROLOGY, V34, P1587, DOI 10.1212/WNL.34.12.1587; CREWS JC, 1990, CANCER, V66, P2642, DOI 10.1002/1097-0142(19901215)66:12<2642::AID-CNCR2820661229>3.0.CO;2-B; de Wit R, 1999, J PAIN SYMPTOM MANAG, V17, P333, DOI 10.1016/S0885-3924(98)00150-X; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Grond S, 1996, PAIN, V64, P107, DOI 10.1016/0304-3959(95)00076-3; Grond S, 1999, PAIN, V79, P15, DOI 10.1016/S0304-3959(98)00138-9; HERBST LH, 1992, J PAIN SYMPTOM MAN S, V7, P54; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; KlockgetherRadke A, 1997, ANAESTHESIST, V46, P428, DOI 10.1007/s001010050420; LEVY MH, 1992, J PAIN SYMPTOM MAN S, V7, P48; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; McCracken LM, 1997, J PAIN SYMPTOM MANAG, V14, P292, DOI 10.1016/S0885-3924(97)00225-X; MIASKOWSKI C, 1994, J PAIN SYMPTOM MANAG, V9, P5, DOI 10.1016/0885-3924(94)90140-6; Mystakidou K, 1998, CANCER-AM CANCER SOC, V83, P1214, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1214::AID-CNCR22>3.0.CO;2-7; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Mystakidou K, 2001, ONCOLOGY-BASEL, V60, P35, DOI 10.1159/000055294; Mystakidou K, 2001, ANTICANCER RES, V21, P2225; *NCI, 1998, COMM TOX CRIT CANC T; Payne R, 1998, SEMIN ONCOL, V25, P47; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; PAYNE R, 1995, ANTI-CANCER DRUG, V6, P50, DOI 10.1097/00001813-199504003-00009; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Twycross R, 1996, J PAIN SYMPTOM MANAG, V12, P273, DOI 10.1016/S0885-3924(96)00149-2; VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1; WARD SE, 1994, PAIN, V56, P299, DOI 10.1016/0304-3959(94)90168-6; *WHO, 1999, WHO LAB MAN EX HUM S, P4; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	35	35	35	0	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	MAR	2004	5	2					119	132		10.1016/j.jpain.2003.12.003			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	811KP	WOS:000220771100007	15042520				2020-06-30	J	Ripamonti, C; Campa, T; De Conno, F				Ripamonti, C; Campa, T; De Conno, F			Withdrawal symptoms during chronic transdermal fentanyl administration managed with oral methadone	JOURNAL OF PAIN AND SYMPTOM MANAGEMENT			English	Letter							CANCER PAIN; PHARMACOKINETICS; MORPHINE		Natl Canc Inst, Rehabil & Palliat Care Operat Unit, I-20133 Milan, Italy	Ripamonti, C (reprint author), Natl Canc Inst, Rehabil & Palliat Care Operat Unit, I-20133 Milan, Italy.		Ripamonti, Carla/C-4557-2017	Ripamonti, Carla/0000-0001-5495-5054			Burza M, 1998, Clin Ter, V149, P277; Davies AN, 1996, PALLIATIVE MED, V10, P348; Gourlay G K, 2001, Lancet Oncol, V2, P165, DOI 10.1016/S1470-2045(00)00258-8; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Han PKJ, 2002, J PAIN SYMPTOM MANAG, V23, P66, DOI 10.1016/S0885-3924(01)00370-0; HIGGS CMB, 1995, J PAIN SYMPTOM MANAG, V10, P4, DOI 10.1016/0885-3924(94)00060-X; Hunt R, 1996, PALLIATIVE MED, V10, P347; Mercadante S, 2001, J CLIN ONCOL, V19, P2898, DOI 10.1200/JCO.2001.19.11.2898; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Ripamonti C, 1998, J CLIN ONCOL, V16, P3216, DOI 10.1200/JCO.1998.16.10.3216	10	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0885-3924	1873-6513		J PAIN SYMPTOM MANAG	J. Pain Symptom Manage.	MAR	2004	27	3					191	194		10.1016/j.jpainsymman.2003.12.003			4	Health Care Sciences & Services; Medicine, General & Internal; Clinical Neurology	Health Care Sciences & Services; General & Internal Medicine; Neurosciences & Neurology	806OV	WOS:000220444100001	15010096	Bronze			2020-06-30	J	Menefee, LA; Frank, ED; Crerand, C; Jalali, S; Park, J; Sanschagrin, K; Besser, M				Menefee, LA; Frank, ED; Crerand, C; Jalali, S; Park, J; Sanschagrin, K; Besser, M			The effects of transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions	PAIN MEDICINE			English	Article						opioids; transdermal fentanyl; driving; cognition; nonmalignant pain	OPIOID THERAPY; NONCANCER PAIN; TERM; MORPHINE; CANCER; ABILITY	Objective. To evaluate driving performance, cognition, and balance in patients with chronic nonmalignant pain before and after the addition of transdermal fentanyl to their treatments. Design. Prospective, one-group pretest-posttest design. Setting. Outpatient pain center associated with a large, urban medical school. Interventions. Patients taking less than a 15-mg equivalent of oxycodone per day took baseline driving performance, cognitive, and balance tests. Transdermal fentanyl was initiated and titrated in 25-mug/hour increments, weighing benefits and side effects. At the end of a 1-month period, the achieved dose was maintained for another month. After they were stabilized for 1 month, patients repeated driving, cognitive, and balance tests. Results. Twenty three patients completed the study; three discontinued secondary to side effects. The median dose at the end of the titration period was 50 mug/hour (48%). No differences were found in driving simulation measures between the pretreatment and posttreatment periods. No decrements in cognitive performance were found. Improvements in visual motor tracking, visual memory, and attention were found during treatment with transdermal fentanyl. No differences in balance or body sway were found. Pain decreased over the course of treatment. Conclusions. The addition of transdermal fentanyl to a treatment regimen containing no opiates or small amounts of opiates for patients with chronic nonmalignant pain did not negatively affect their driving performances, reaction times, cognition, or balance. Future studies in this area are needed to guide treatment decisions.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Anesthesiol, Philadelphia, PA 19107 USA	Menefee, LA (reprint author), Jefferson Pain Ctr, 834 Chestnut,T-150, Philadelphia, PA 19107 USA.	Lynette.Menefee@jefferson.edu	Crerand, Canice/J-7983-2013				BANNING A, 1990, CLIN J PAIN, V6, P91, DOI 10.1097/00002508-199006000-00003; BERG K, 1989, Physiotherapy Canada, V41, P304; Brickenkamp R, 1998, D2 TEST ATTENTION; BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; Chapman SL, 2002, CLIN J PAIN, V18, pS83, DOI 10.1097/00002508-200207001-00010; Clemons M, 1996, CANCER TREAT REV, V22, P451, DOI 10.1016/S0305-7372(96)90026-2; Conners CK, 2000, CONNERS CONTINUOUS P; First MB, 2001, STRUCTURED CLIN INTE; Galski T, 2000, J PAIN SYMPTOM MANAG, V19, P200, DOI 10.1016/S0885-3924(99)00158-X; Haythornthwaite JA, 1998, J PAIN SYMPTOM MANAG, V15, P185, DOI 10.1016/S0885-3924(97)00352-7; Lorenz J, 1997, PAIN, V73, P369, DOI 10.1016/S0304-3959(97)00123-1; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; Myers J., 1995, REY COMPLEX FIGURE T; REITAN RM, 1997, WECHSLER MEMORY SCAL, V3; REITAN RM, 1985, HALSTEADREITAN NEURO; Sabatowski R, 2003, J PAIN SYMPTOM MANAG, V25, P38, DOI 10.1016/S0885-3924(02)00539-0; Sjogren P, 2000, J PAIN SYMPTOM MANAG, V19, P100, DOI 10.1016/S0885-3924(99)00143-8	17	44	44	0	1	BLACKWELL PUBLISHING INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	1526-2375			PAIN MED	Pain Med.	MAR	2004	5	1					42	49		10.1111/j.1526-4637.2004.04005.x			8	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	774PK	WOS:000188991600007	14996236	Bronze			2020-06-30	J	Yildizdas, D; Yapicioglu, H; Yilmaz, HL				Yildizdas, D; Yapicioglu, H; Yilmaz, HL			The value of capnography during sedation or sedation/analgesia in pediatric minor procedures	PEDIATRIC EMERGENCY CARE			English	Article						capnography; sedation; analgesia; ketamine; midazolam; propofol; fentanyl	END-TIDAL CO2; INVASIVE PROCEDURES; KETAMINE; CHILDREN; PROPOFOL	Objective: To measure changes in end-tidal carbon dioxide levels (ETco(2)) with different sedation/analgesia (midazolam, ketamine ketamine plus midazolam, midazolam plus fentanyl, and propofol during pediatric minor surgical procedures and to determine whether there were significant increases in ETco(2) with different drugs. Methods: We conducted a prospective, randomized, clinical trial of 126 children who needed sedation/analgesia in pediatric intensive care unit in a university hospital. Patients were randomly assigned to I of 5 treatment groups. Group K received only intravenous (IV) ketamine 1 mg/kg; group M, TV midazolam 0.15 mg/kg; group KM, IV ketamine I mg/kg plus IV midazolam 0.1 mg/kg; group MF, IV midazolam 0.1 mg/kg plus IV fentanyl 2 mug/kg; and group P, IV propofol 2 mg/kg. Side stream, nasal cannula ETco(2) tracings were recorded on a capnograph (Capnostat, Marquette). Recordings began prior to the administration of medications and continued throughout the procedure until the patient was fully awake. The primary outcome variable was the difference between peak ETco(2) before and during sedation/analgesia. This value was determined by scanning the records for the peak ETco(2) averaged over 5 breaths before and after the administration of medications. Results: There was neither any statistical difference between presedation/analgesia and postsedation/analgesia ETco(2) levels in the 5 groups (P > 0.05) nor any difference in the first 3 groups between presedation/analgesia, sedation/analgesia, and postsedation/analgesia (K, M, and KM) (P > 0.05). In the midazolam plus fentanyl and propofol groups, mean ETco(2) during sedation/ analgesia was higher than the mean ETco(2) during presedation/ analgesia and postsedation/analgesia (P < 0.05). Twenty-one patients (16, 6%) had respiratory depression [hypercarbia (ETco(2) > 50 min Hg) or hypoxia (oxygen saturation > 90% for over I minute)], 21 patients (16, 6%) had hypercarbia, and 4 patients (3.2%) had both hypoxia and hypercarbia. One of 4 patients was in the MF group, and 3 were in the P group. Two subjects (8%) in the KM group, 7 (28%) in the MF group, and 13 (52%) in the P group had hypercarbia. Conclusions: This study demonstrated that propofol and midazolam-fentanyl produced a higher incidence of respiratory depression and higher mean ETco(2) during sedation/analgesia than presedation and postsedation/analgesia. Capnography can serve as a useful monitoring tool in the evaluation of ventilation during sedation or sedation/analgesia in clinically stable children.	Cukurova Univ, Pediat Intens Care Unit, Fac Med, TR-01330 Adana, Turkey; Cukurova Univ, Div Neonatol, Fac Med, TR-01330 Adana, Turkey; Cukurova Univ, Fac Med, Dept Pediat Emergency Med, Adana, Turkey	Yildizdas, D (reprint author), Cukurova Univ, Pediat Intens Care Unit, Fac Med, TR-01330 Adana, Turkey.	rdy90@hotmail.com	Yapicioglu Yildizdas, Hacer/E-9649-2018; YILMAZ, Hayri Levent/J-3393-2018	Yapicioglu Yildizdas, Hacer/0000-0001-6295-553X; YILMAZ, Hayri Levent/0000-0003-0873-9814			BARTON CW, 1994, ANN EMERG MED, V23, P560, DOI 10.1016/S0196-0644(94)70078-8; Bongard F, 1994, J Invest Surg, V7, P259, DOI 10.3109/08941939409018291; CAMPBELL F, 1991, CAN J ANAESTH, V38, pA138; FLANAGAN JFK, 1995, ANESTH ANALG, V80, P128; HART LS, 1997, PEDIATR EMERG CARE, V13, P188; Hertzog JH, 1997, J INTENSIVE CARE MED, V12, P264, DOI 10.1177/088506669701200507; JONES NL, 1979, J APPL PHYSIOL, V47, P954; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; LIU SY, 1992, CHEST, V102, P1512, DOI 10.1378/chest.102.5.1512; McQuillen KK, 2000, PEDIATR EMERG CARE, V16, P401, DOI 10.1097/00006565-200012000-00005; Meliones Jon N., 1996, P331; Neidhart G, 2001, ANAESTHESIST, V50, P242, DOI 10.1007/s001010050998; PRSTOJEVICH SJ, 1992, J ORAL MAXIL SURG, V50, P37, DOI 10.1016/0278-2391(92)90192-3; Reinhold P, 1999, KLIN PADIATR, V211, P40, DOI 10.1055/s-2008-1043761; ROBERTON NRC, 1996, NEONATAL RESP DISORD, P152; Tobias JD, 1999, PEDIATR EMERG CARE, V15, P173, DOI 10.1097/00006565-199906000-00002; TOBIAS JD, 1992, PEDIATRICS, V90, P537; TOBIAS JD, 1994, CRIT CARE MED, V22, P1805; Wilson S, 2001, Pediatr Dent, V23, P307	19	58	59	2	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	MAR	2004	20	3					162	165		10.1097/01.pec.0000117922.65522.26			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	803LX	WOS:000220233700003	15094573				2020-06-30	J	Lalley, PM				Lalley, PM			Dopamine(1) receptor agonists reverse opioid respiratory network depression, increase CO2 reactivity	RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY			English	Article						control of breathing, mu-opioid, dopamine; mammals, cat; mediators, dopamine; nerve, phrenic; neuron, central; mu-opioid and dopamine receptors	CAROTID-BODY; MESSENGER-RNA; NEURONS; RAT; CHEMORECEPTORS; VENTILATION; EXPRESSION; MORPHINE; DOXAPRAM; RABBITS	In adult pentobarbital-anesthetized and unanesthetized decerebrate cats, the D1R agonists (6-chloro-APB, SKF-38393, dihydrexidine) given intravenously restored phrenic nerve and vagus nerve respiratory discharges and firing of bulbar post-inspiratory neurons after the discharges were abolished by the mu-opioid receptor agonist fentanyl given intravenously. Reversal of opioid-mediated discharge depression was prevented by the D1R antagonist SCH23390. Iontophoresis of the mu-opioid receptor agonist DAMGO depressed firing of medullary bulbospinal inspiratory neurons. Co-iontophoresis of SKF-38393 did not restore firing and had no effect on bulbospinal inspiratory neuron discharges when applied alone. The D1R agonists given intravenously prolonged and intensified phrenic nerve and bulbospinal inspiratory neuron discharges. They also increased reactivity to CO2 by lowering the phrenic nerve apnea threshold and shifting the phrenic nerve-CO2 response curve to lower ET CO2 levels. Intravenous fentanyl on the other hand decreased CO2 reactivity by shifting the phrenic nerve apnea threshold and the response curve to higher ETCO2 levels. Fentanyl effects on reactivity were partially reversed by DIR agonists. (C) 2003 Elsevier B.V. All rights reserved.	Univ Wisconsin, Med Sci Ctr, Dept Physiol, Madison, WI 53706 USA	Lalley, PM (reprint author), Univ Wisconsin, Med Sci Ctr, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.	pmlalley@facstaff.wisc.edu			NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL65526]		ARATA A, 1993, BRAIN RES, V605, P193, DOI 10.1016/0006-8993(93)91740-J; Bairam A, 1998, NEUROSCI RES, V31, P147, DOI 10.1016/S0168-0102(98)00033-9; BALLANTYNE D, 1984, J PHYSIOL-LONDON, V348, P67, DOI 10.1113/jphysiol.1984.sp015100; Ballantyne D, 2000, J PHYSIOL-LONDON, V525, P567, DOI 10.1111/j.1469-7793.2000.00567.x; Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; Becker A, 2001, N-S ARCH PHARMACOL, V363, P562, DOI 10.1007/s002100100404; BEDFORD RF, 1975, ANESTHESIOLOGY, V43, P1, DOI 10.1097/00000542-197507000-00001; BIANCHI AL, 1988, J PHYSIOL-LONDON, V407, P293, DOI 10.1113/jphysiol.1988.sp017416; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; BURGESS KR, 1994, CRIT CARE MED, V22, P413, DOI 10.1097/00003246-199403000-00010; CZYZYKKRZESKA MF, 1992, J AUTONOM NERV SYST, V41, P31, DOI 10.1016/0165-1838(92)90124-Y; ELDRIDGE FL, 1971, AM J PHYSIOL, V221, P535; EZURE K, 1990, PROG NEUROBIOL, V35, P429, DOI 10.1016/0301-0082(90)90030-K; Farney RJ, 2003, CHEST, V123, P632, DOI 10.1378/chest.123.2.632; Gao X, 2000, EUR J PHARMACOL, V406, P53, DOI 10.1016/S0014-2999(00)00649-X; GIANFORNINA MD, 1992, J GEN PHYSIOL, V100, P401; GRUDT TJ, 1995, REV NEUROSCIENCE, V6, P279; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Hagelberg N, 2003, PAIN, V101, P149, DOI 10.1016/S0304-3959(02)00323-8; HORITA A, 1976, PSYCHOPHARMACOLOGY, V49, P57; Inoue T, 2000, PHARMACOL BIOCHEM BE, V66, P573, DOI 10.1016/S0091-3057(00)00254-9; JAFFE J H, 1990, P485; Karper PE, 2000, PHYSIOL BEHAV, V68, P585, DOI 10.1016/S0031-9384(99)00223-1; KIRSTEN EB, 1978, J PHARMACOL METHOD, V1, P263, DOI 10.1016/0160-5402(78)90057-8; Lalley P., 1999, MODERN TECHNIQUES NE, P193; LALLEY PM, 1997, J NEUROPHYSIOL, V77, P1131; LALLEY PM, 2000, 31 ANN M, V31, P468; LALLEY PM, 2003, IN PRESS AM J PHYSL; LOESCHCKE HH, 1973, ACTA NEUROBIOL EXP, V33, P97; LOVENBERG TW, 1989, EUR J PHARMACOL, V166, P111, DOI 10.1016/0014-2999(89)90690-0; Magnusson JE, 2000, BRAIN RES, V855, P260, DOI 10.1016/S0006-8993(99)02396-3; Manzke T, 2003, SCIENCE, V301, P226, DOI 10.1126/science.1084674; Merrill EG, 1974, ESSAYS NERVOUS SYSTE, P451; MIR AK, 1984, BRAIN RES, V291, P273, DOI 10.1016/0006-8993(84)91259-9; Mitchell R A, 1970, Annu Rev Physiol, V32, P415, DOI 10.1146/annurev.ph.32.030170.002215; MITCHELL RA, 1975, ANESTHESIOLOGY, V42, P559, DOI 10.1097/00000542-197505000-00009; MORGAN MJ, 1991, PHARMACOL BIOCHEM BE, V40, P317, DOI 10.1016/0091-3057(91)90560-O; Murphy DA, 2000, AIDS PATIENT CARE ST, V14, P47, DOI 10.1089/108729100318127; Mutolo D, 2002, AM J PHYSIOL-REG I, V283, pR227, DOI 10.1152/ajpregu.00579.2001; Nattie E, 1999, PROG NEUROBIOL, V59, P299, DOI 10.1016/S0301-0082(99)00008-8; Nattie EE, 1996, J APPL PHYSIOL, V81, P1987; Ng SSW, 2000, BRIT J PHARMACOL, V129, P853, DOI 10.1038/sj.bjp.0703119; NISHINO T, 1982, J APPL PHYSIOL, V52, P1261; PEERS C, 1991, BRAIN RES, V568, P116, DOI 10.1016/0006-8993(91)91386-F; RICHTER DW, 1996, [No title captured], V2, P2079, DOI DOI 10.1007/978-3-642-60946-6_106; RIGG JRA, 1978, BRIT J ANAESTH, V50, P759, DOI 10.1093/bja/50.8.759; Ruskin DN, 1997, NEUROSCIENCE, V81, P79, DOI 10.1016/S0306-4522(97)00113-9; Schindler CW, 2002, J PHARMACOL EXP THER, V300, P180, DOI 10.1124/jpet.300.1.180; Shook J.E., 1990, AM REV RESPIR DIS, V33, P1; Staub N.C., 1998, PHYSIOLOGY, P572; von Euler C., 1986, HDB PHYSL RESPIRATOR, VII, P1; Wang WG, 2002, J PHYSIOL-LONDON, V540, P951, DOI 10.1113/jphysiol.2001.013443; WATLING A, 2001, SIGMA RBI HDB RECEPT, P71; Yatsu T, 1997, J CARDIOVASC PHARM, V29, P382, DOI 10.1097/00005344-199703000-00012; YEADON M, 1989, PROG NEUROBIOL, V33, P1, DOI 10.1016/0301-0082(89)90033-6	56	27	29	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1569-9048			RESP PHYSIOL NEUROBI	Respir. Physiol. Neuro.	FEB 25	2004	139	3					247	262		10.1016/j.resp.2003.10.007			16	Physiology; Respiratory System	Physiology; Respiratory System	808FC	WOS:000220554000003	15122991				2020-06-30	J	Jost, U; Wolter, E; Bohrer, H				Jost, U; Wolter, E; Bohrer, H			Repeated improper intravenous injection of fentanyl from a transdermal system	DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT			German	Article							ABUSE; MISUSE; PATCH		Zentrum Anasthesiol, Caritas Krankenhauses Bad Mergentheim, D-97980 Bad Mergentheim, Germany	Jost, U (reprint author), Zentrum Anasthesiol, Caritas Krankenhauses Bad Mergentheim, Uhlandstr 7, D-97980 Bad Mergentheim, Germany.	jost.ulrich@ckbm.de					Arvanitis ML, 2002, AM J EMERG MED, V20, P58, DOI 10.1053/ajem.2002.29562; Flannagan LM, 1996, J FORENSIC SCI, V41, P320; KlockgetherRadke A, 1997, ANAESTHESIST, V46, P428, DOI 10.1007/s001010050420; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; Purucker M, 2000, ANN EMERG MED, V35, P314, DOI 10.1016/S0196-0644(00)70091-6; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x	7	5	5	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0012-0472			DEUT MED WOCHENSCHR	Dtsch. Med. Wochenschr.	FEB 13	2004	129	7					313	314		10.1055/s-2004-818627			2	Medicine, General & Internal	General & Internal Medicine	774CP	WOS:000188962400006	14765330				2020-06-30	J	Axelsen, SM; Bek, KM				Axelsen, SM; Bek, KM			Anterior vaginal wall repair using local anaesthesia	EUROPEAN JOURNAL OF OBSTETRICS GYNECOLOGY AND REPRODUCTIVE BIOLOGY			English	Article						anterior vaginal wall repair; local anaesthesia; propofol (diprivan); fentanyl (haldid); alfentanil (rapifen); bupivacaine (marcain); adrenalin (adrenalin)	URINARY-INCONTINENCE; PROLAPSE; WOMEN	Background: The purpose of the present study was to describe the possibility of surgical repair of anterior vaginal prolapse including amputation of the cervix using local anaesthesia. The description was made according to postoperative complication, recurrence rate, influence on urinary incontinence, and satisfaction of the patient. Material and methods: Eighty-three women were consecutively operated in the anterior wall of the vagina using local anaesthesia and intravenously supplemented with propofol and fentanyl if needed, from January 1998 until September 2000 at a university clinic in Denmark. Operations executed by 16 different surgeons. Seventy patients were operated exclusively by anterior vaginal wall repair, 13 women were operated by other kinds of vaginal repair at the same time. All patients but one were interviewed by telephone. Ten patients reporting a sense of recurrence were called in for clinical examination. Results: The median age was 64.5 years (range 37-85). The median follow-up period was 12.5 months (range 3-35). Median time of the operation was 25 min (range 10-60) including all patients, 20 min (range 10-60) for the patients solely operated in the anterior vaginal wall. The median time spent in hospital was 1 day (range 0-4). One patient was readmitted. Seven patients (8.4%) suffered from complications postoperatively including the patient readmitted, four of these patients were reoperated. By interview 10 women (12%) reported symptoms of prolapse again. By examination two women (2.4%) were diagnosed as recurrence, and were offered a new operation using local anaesthesia. The incontinence patterns before and after the operation are described. Seventy-nine women (95.2%) were totally satisfied with the type of anaesthesia, two women would not choose local anaesthesia for an eventually new operation, one patient did not know, and one patient was unsolved. Conclusions: The study illustrates an acceptable duration of the operation despite many different surgeons, a need of short time postoperative observation, low postoperative complication rate, low recurrence rate, and a high level of satisfaction reported by the patients. Surgical repair of anterior vaginal prolapse using local anaesthesia is described according to postoperative complication, recurrence rate, influence on urinary incontinence, and satisfaction of the patient. It is concluded that this way of handling anterior vaginal prolapse is suitable for all kinds of patients and in the out-patient clinic. (C) 2003 Elsevier Ireland Ltd. All rights reserved.	Skejby Hosp, Dept Obstet & Gynecol, DK-8200 Aarhus N, Denmark	Axelsen, SM (reprint author), Skejby Hosp, Dept Obstet & Gynecol, Brendstrupgaardsvej, DK-8200 Aarhus N, Denmark.	susanne.axelsen@dadlnet.dk; karl.moeller.bek@dadlnet.dk					Acharya R, 2001, BRIT J ANAESTH, V86, P893, DOI 10.1093/bja/86.6.893; BORSTAD E, 1989, ACTA OBSTET GYN SCAN, V68, P545, DOI 10.3109/00016348909015754; Borstad E, 1991, ACTA OBSTET GYN SCAN, V70, P501, DOI 10.3109/00016349109007168; DEALERE KP, 1979, EUR UROL, V5, P190; FOTHERGILL WE, 1915, AM J SURG, V29, P162; GLAZENET CMA, 2000, COCHRANCE LIB; Jomaa M, 2001, GYNECOL OBSTET INVES, V51, P184, DOI 10.1159/000052921; MIKLOS JR, 1995, OBSTET GYNECOL, V86, P922; Olsen AL, 1997, OBSTET GYNECOL, V89, P501, DOI 10.1016/S0029-7844(97)00058-6; Samuelsson EC, 1999, AM J OBSTET GYNECOL, V180, P299, DOI 10.1016/S0002-9378(99)70203-6; SHULL BL, 1994, AM J OBSTET GYNECOL, V171, P1429, DOI 10.1016/0002-9378(94)90384-0; Versi E, 2001, INT UROGYNECOL J, V12, P107, DOI 10.1007/s001920170074; WALTERS M, 1999, UROGYNECLOGY RECONST, P219	13	20	21	0	0	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0301-2115			EUR J OBSTET GYN R B	Eur. J. Obstet. Gynecol. Reprod. Biol.	FEB 10	2004	112	2					214	216		10.1016/j.ejogrb.2003.06.011			3	Obstetrics & Gynecology; Reproductive Biology	Obstetrics & Gynecology; Reproductive Biology	773FV	WOS:000188887800019	14746962				2020-06-30	J	Purdie, NL; McGrady, EM				Purdie, NL; McGrady, EM			Comparison of patient-controlled epidural bolus administration of 0.1% ropivacaine and 0.1% levobupivacaine, both with 0.0002% fentanyl, for analgesia during labour	ANAESTHESIA			English	Article						analgesia, patient-controlled, epidural; anaesthetics, local	0.125-PERCENT BUPIVACAINE; POTENCIES; SUFENTANIL; TOXICITY	The aim of the study was to compare the relative potencies and clinical characteristics of epidural ropivacaine and levobupivacaine in labour using patient-controlled epidural analgesia (PCEA). In a randomised double-blinded study, 60 ASA I or II primigravidae requesting epidural analgesia in early labour were allocated to receive either 0.1% ropivacaine with fentanyl 0.0002% or 0.1% levobupivacaine with 0.0002% fentanyl via a patient-controlled analgesia pump. Analgesia was established with 15 ml of study solution and maintained using 5-ml boluses of study solution with a 5-min lockout interval. There were no significant differences in onset time, duration and quality of analgesia, motor and sensory blockade, local anaesthetic consumption, mode of delivery, neonatal outcome or maternal satisfaction between the groups. We conclude that 0.1% ropivacaine with 0.0002% fentanyl and 0.1% levobupivacaine with 0.0002% fentanyl are clinically indistinguishable for labour analgesia and appear pharmacologically equipotent when using PCEA.	Univ Glasgow, Glasgow Royal Infirm, Dept Anaesthesia, Glasgow G31 2ER, Lanark, Scotland; Glasgow Royal Infirm, Dept Anaesthesia, Glasgow G4 0SF, Lanark, Scotland	Purdie, NL (reprint author), Univ Glasgow, Glasgow Royal Infirm, Dept Anaesthesia, Alexandra Parade, Glasgow G31 2ER, Lanark, Scotland.	niall.purdie@utoronto.ca					ALBRIGHT GA, 1979, ANESTHESIOLOGY, V51, P285, DOI 10.1097/00000542-197910000-00001; Asik I, 2002, EUR J ANAESTH, V19, P263; Breen TW, 2000, ANESTHESIOLOGY, V93, pU216; Burke D, 1999, BRIT J ANAESTH, V83, P750; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; CONVERY P, 1999, INT J OBSTET ANESTH, V8, P196; Fischer C, 2000, ANESTHESIOLOGY, V92, P1588, DOI 10.1097/00000542-200006000-00015; Gautier P, 1999, ANESTHESIOLOGY, V90, P772, DOI 10.1097/00000542-199903000-00020; Gristwood RW, 2002, DRUG SAFETY, V25, P153, DOI 10.2165/00002018-200225030-00002; Lyons G, 2001, INT J OBSTET ANESTH, V10, P259, DOI 10.1054/ijoa.2001.0859; Lyons G, 1998, BRIT J ANAESTH, V81, P899; MacArthur C, 2001, LANCET, V358, P19; Meister GC, 2000, ANESTH ANALG, V90, P632, DOI 10.1097/00000539-200003000-00024; Neal SM, 2001, BRIT J ANAESTH, V87, p658P; Owen MD, 2002, ANESTH ANALG, V94, P179, DOI 10.1097/00000539-200201000-00034; Pirbudak L, 2002, EUR J ANAESTH, V19, P271, DOI 10.1017/S0265021502000431; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Smiley RM, 2000, ANESTHESIOLOGY, V93, pU213	18	22	26	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	FEB	2004	59	2					133	137		10.1111/j.1365-2044.2004.03582.x			5	Anesthesiology	Anesthesiology	764VK	WOS:000188226600006	14725515				2020-06-30	J	Baines, D				Baines, D			Anaesthesia for quinsy	ANAESTHESIA			English	Letter									Childrens Hosp, Westmead, NSW 2154, Australia	Baines, D (reprint author), Childrens Hosp, Westmead, NSW 2154, Australia.	DavidB@chw.edu.au					Tamhane P, 2003, ANAESTHESIA, V58, P821, DOI 10.1046/j.1365-2044.2003.03295_27.x	1	1	1	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	FEB	2004	59	2					198	199		10.1111/j.1365-2044.2003.03650.x			2	Anesthesiology	Anesthesiology	764VK	WOS:000188226600034	14725540				2020-06-30	J	Chelly, JE; Grass, J; Houseman, TW; Minkowitz, H; Pue, A				Chelly, JE; Grass, J; Houseman, TW; Minkowitz, H; Pue, A			The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: A multicenter, placebo-controlled trial	ANESTHESIA AND ANALGESIA			English	Article							PAIN RELIEF; PHARMACOLOGICAL-PROPERTIES; INTRAVENOUS FENTANYL; THERAPEUTIC-EFFICACY; SURGERY; IONTOPHORESIS; MORPHINE	A noninvasive method of delivery of parenteral opioids for management of acute pain may offer logistic advantages for patients and nursing staff. A patient-controlled transdermal system (PCTS) under development consists of a preprogrammed, self-contained drug-delivery system that uses electrotransport technology (E-TRANS(R), ALZA Corp, Mountain View, CA) to deliver 40 mug of fentanyl HCl over 10 min per on-demand dose for patient-controlled analgesia (PCA). In this randomized, double-blinded, placebo-controlled trial we compared the efficacy and safety of on-demand fentanyl HCl PCTS 40 mug against placebo for postoperative pain up to 24 h after major abdominal, orthopedic, or thoracic surgery in 205 patients. The primary efficacy measurement was the percentage of patients withdrawn from the study because of inadequate analgesia after completing at least 3 h of treatment. Secondary efficacy measures included mean pain intensity (using visual analog scales), patient global assessments, and investigator global assessments. Of 189 patients considered evaluable for efficacy, 25% of patients in the fentanyl HCl PCTS 40 mug group withdrew because of inadequate analgesia, compared with 40.4% of the placebo group (P < 0.05). Use of fentanyl HCl PCTS 40 mug was associated with lower VAS scores and higher mean patient and investigator global assessment scores compared with placebo. No patient experienced clinically relevant respiratory depression. This study showed that a fentanyl HCl PCTS 40 mug for PCA was superior to placebo and well tolerated for the control of moderate to severe postoperative pain for up to 24 h after major surgery.	Univ Pittsburgh, Sch Med, Dept Anesthesiol, Orthoped Anethesia & Acute Pain Serv,Med Ctr, Pittsburgh, PA 15261 USA; Western Penn Hosp, Pittsburgh, PA 15224 USA; Mem City Hosp, Houston, TX USA; Thomas Hosp, Fairhope, AL USA; Mary Birch Hosp Women, San Diego, CA USA	Chelly, JE (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, Orthoped Anethesia & Acute Pain Serv,Med Ctr, A-1305 Scaife Hall,3550 Terrace Str, Pittsburgh, PA 15261 USA.	chelje@anes.upmc.edu					ASHBURN MA, 1995, ANESTHESIOLOGY, V82, P1146, DOI 10.1097/00000542-199505000-00009; Camu F, 1998, ANESTH ANALG, V87, P890, DOI 10.1097/00000539-199810000-00027; Cherny NI, 1996, DRUGS, V51, P713, DOI 10.2165/00003495-199651050-00002; COOPER DW, 1995, BRIT J ANAESTH, V74, P184, DOI 10.1093/bja/74.2.184; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; ETCHES RC, 1994, CAN J ANAESTH, V41, P125, DOI 10.1007/BF03009805; Filos KS, 1999, EUR SURG RES, V31, P97, DOI 10.1159/000008627; GINSBERG B, 1995, PAIN, V62, P95, DOI 10.1016/0304-3959(94)00255-D; GLASS PSA, 1992, ANESTH ANALG, V74, P345; Gupta SK, 1998, J CLIN PHARMACOL, V38, P951, DOI 10.1002/j.1552-4604.1998.tb04392.x; HOWELL PR, 1995, CAN J ANAESTH, V42, P41, DOI 10.1007/BF03010570; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; KUHN S, 1990, BMJ-BRIT MED J, V300, P1687, DOI 10.1136/bmj.300.6741.1687; LAITINEN J, 1992, ANESTHESIOLOGY, V76, P194, DOI 10.1097/00000542-199202000-00006; Lehmann K A, 1991, J Clin Anesth, V3, P194, DOI 10.1016/0952-8180(91)90158-J; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; LEWIS KS, 1994, AM J HOSP PHARM, V51, P1539, DOI 10.1093/ajhp/51.12.1539; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; OATES JDL, 1994, ANAESTHESIA, V49, P755; OWEN H, 1988, ANAESTH INTENS CARE, V16, P437, DOI 10.1177/0310057X8801600409; SIMS SM, 1992, PHARMACEUT RES, V9, P1402, DOI 10.1023/A:1015898510531; Viscusi E. R., 2002, Anesthesia and Analgesia, V94; WELCHEW EA, 1983, ANAESTHESIA, V38, P19, DOI 10.1111/j.1365-2044.1983.tb10367.x; 2001, DUROGESIC FENTANYL T	24	93	96	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2004	98	2					427	433		10.1213/01.ANE.0000093314.13848.7E			7	Anesthesiology	Anesthesiology	767KL	WOS:000188438700029	14742382				2020-06-30	J	Lewis, AK; Osborn, IP; Roth, R				Lewis, AK; Osborn, IP; Roth, R			The effect of hemispheric synchronization on intraoperative analgesia	ANESTHESIA AND ANALGESIA			English	Article							PROPOFOL SEDATION; BISPECTRAL INDEX; HYPNOSIS; ANESTHESIA; THERAPY; PAIN	In this double-blinded randomized study, we sought to confirm that patients undergoing general anesthesia who were exposed to a hemispheric synchronization (Hemi-Sync) musical recording during surgery had a smaller analgesia requirement, as was suggested in a previous study. Bispectral index monitoring was used to adjust depth of hypnosis, and hemodynamic variables were used to determine analgesia administration. Consented patients underwent either laparoscopic bariatric or one-level lumbar disk surgery. After endotracheal intubation and application of headphones, baseline heart rate and arterial blood pressure were established. Isoflurane was titrated to maintain sedation on the basis of a target bispectral index range of 40-60, and 25-mug increments of fentanyl were administered in response to increases in heart rate and systolic arterial blood pressure. Bariatric patients who listened to Hemi-Sync required one-third less fentanyl than the control roup (mean [SD]: 0.015 [0.01] vs 0.024 mug . kg(-1) . min(-1) [0.01]) (P = 0.009). It is interesting to note that lumbar patients in the experimental and control groups required similar amounts of fentanyl (0.012 [0.01] vs 0.015 mug . kg(-1) . min(-1) [0.01]). End-tidal isoflurane concentration was similar for Hemi-Sync and blank-tape patients (bariatric, 0.74% (0.14) vs 0.77% (0.21); lumbar, 0.36% [0.16] vs 0.39% [0.12]). The bariatric patients in this study demonstrated that Hemi-Sync may be an innovative intraoperative supplement to analgesia.	CUNY Mt Sinai Sch Med, Dept Anesthesiol, New York, NY 10029 USA	Osborn, IP (reprint author), Box 1010,1 Gustave L Levy Pl, New York, NY 10029 USA.	Irene.osbom@mssm.edu		Lewis, Ariane/0000-0002-0756-7320			Bonhomme V, 2000, ANESTH ANALG, V91, P1398, DOI 10.1097/00000539-200012000-00018; Diette GB, 2003, CHEST, V123, P941, DOI 10.1378/chest.123.3.941; Gay MC, 2002, EUR J PAIN-LONDON, V6, P1, DOI 10.1053/eujp.2001.0263; GOOD M, 1999, PAIN, V81, P63; Halliburton J R, 2000, AANA J, V68, P333; HIRVONEN EA, 1995, ACTA ANAESTH SCAND, V39, P949, DOI 10.1111/j.1399-6576.1995.tb04203.x; Horne RSC, 2002, EARLY HUM DEV, V69, P25, DOI 10.1016/S0378-3782(02)00025-7; JOHANSEN JW, 2000, J CLIN ANESTH, V19, P582; Kearse LA, 1998, ANESTHESIOLOGY, V88, P25, DOI 10.1097/00000542-199801000-00007; Kliempt P, 1999, ANAESTHESIA, V54, P769, DOI 10.1046/j.1365-2044.1999.00958.x; KUMAR A, 1992, ANAESTHESIA, V47, P438, DOI 10.1111/j.1365-2044.1992.tb02230.x; MCLAUGHLIN JG, 1995, SURG ENDOSC-ULTRAS, V9, P121; Quinn C, 2002, AM J PUBLIC HEALTH, V92, P1657, DOI 10.2105/AJPH.92.10.1657; Sim Chin-Keng, 2002, Acupunct Med, V20, P56; Song DJ, 1997, ANESTHESIOLOGY, V87, P842, DOI 10.1097/00000542-199710000-00018	15	13	13	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2004	98	2					533	536		10.1213/01.ANE.0000096181.89116.D2			4	Anesthesiology	Anesthesiology	767KL	WOS:000188438700048	14742401				2020-06-30	J	Bencherif, B; Wand, GS; McCaul, ME; Kim, YK; Iigin, N; Dannals, RF; Frost, JJ				Bencherif, B; Wand, GS; McCaul, ME; Kim, YK; Iigin, N; Dannals, RF; Frost, JJ			Mu-opioid receptor binding measured by [C-11]carfentanil positron emission tomography is related to craving and mood in alcohol dependence	BIOLOGICAL PSYCHIATRY			English	Article						Mu opioid receptors; alcoholism; craving; depression; PET imaging	COMPULSIVE DRINKING SCALE; BRAIN METABOLIC-CHANGES; FAMILY-HISTORY; ETHANOL-CONSUMPTION; BETA-ENDORPHIN; PSYCHOMETRIC PROPERTIES; NALTREXONE; RATS; NALOXONE; PREFERENCE	Background: The endogenous opioid system has been linked to alcohol dependence through animal and human studies. We investigated the relationship between alcohol craving and brain mu opioid receptors (R-OR) in alcohol-dependent subjects. Methods: Regional brain mu-OR binding potential (BP) was measured using [C-11]carfentanil positron emission tomography in eight male alcohol-dependent subjects undergoing alcohol withdrawal and eight matched control subjects. Self-reported alcohol craving, withdrawal, and mood were measured. Results. Lower mu-OR BP was associated with higher craving in the right dorsal lateral prefrontal cortex, the fight anterior frontal cortex, and right parietal cortex. In these regions, alcoholics showed lower mean mu-OR BP compared with control subjects. Mu-OR BP in four other brain regions also correlated with craving, but there were no group differences in receptor binding potential. Mu-OR BP also correlated with depressive symptoms in five brain regions, three of which were identified in the craving analyses. Conclusions: Results show a strong functional relationship between alcohol craving, mood, and R-OR binding in specific brain regions of recently abstinent, alcohol-dependent men.	Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA	Frost, JJ (reprint author), Johns Hopkins Univ, Sch Med, Dept Radiol & Radiol Sci, JHOC 3225,601 N Caroline St, Baltimore, MD 21287 USA.				NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA 11872, AA 12303, AA 11855]		ALTSHULER HL, 1980, LIFE SCI, V26, P679, DOI 10.1016/0024-3205(80)90257-X; Anton RF, 1996, ARCH GEN PSYCHIAT, V53, P225; Anton RF, 1996, ALCOHOL ALCOHOLISM, V31, P43; BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; Brody AL, 2001, ARCH GEN PSYCHIAT, V58, P631, DOI 10.1001/archpsyc.58.7.631; Brody AL, 1999, PSYCHIAT RES-NEUROIM, V91, P127, DOI 10.1016/S0925-4927(99)00034-7; BUCHOLZ KK, 1994, J STUD ALCOHOL, V55, P149, DOI 10.15288/jsa.1994.55.149; CHILDRESS AR, 1994, J SUBST ABUSE TREAT, V11, P17, DOI 10.1016/0740-5472(94)90060-4; Cowen MS, 2001, ALCOHOL CLIN EXP RES, V25, P1126, DOI 10.1097/00000374-200108000-00006; CZIRR SA, 1987, ALCOHOL, V4, P117, DOI 10.1016/0741-8329(87)90008-5; DEROGATIS LR, 1983, ADM SCORING PROCEDUR; DESOTO CB, 1985, ALCOHOL CLIN EXP RES, V9, P505; Drobes DJ, 2003, NEUROPSYCHOPHARMACOL, V28, P755, DOI 10.1038/sj.npp.1300101; Flannery BA, 1999, ALCOHOL CLIN EXP RES, V23, P1289, DOI 10.1111/j.1530-0277.1999.tb04349.x; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; FROEHLICH JC, 1990, PHARMACOL BIOCHEM BE, V35, P385, DOI 10.1016/0091-3057(90)90174-G; FROEHLICH JC, 1991, PSYCHOPHARMACOLOGY, V103, P467, DOI 10.1007/BF02244246; George MS, 2001, ARCH GEN PSYCHIAT, V58, P345, DOI 10.1001/archpsyc.58.4.345; GIANOULAKIS C, 1983, CAN J PHYSIOL PHARM, V61, P967, DOI 10.1139/y83-145; GIANOULAKIS C, 1990, EUR J PHARMACOL, V180, P21, DOI 10.1016/0014-2999(90)90588-W; Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040; HUBBELL CL, 1986, ALCOHOL, V3, P39, DOI 10.1016/0741-8329(86)90070-4; HUBBELL CL, 1991, ALCOHOL, V8, P355, DOI 10.1016/0741-8329(91)90573-F; Kiefer F, 2002, PSYCHOPHARMACOLOGY, V162, P433, DOI 10.1007/s00213-002-1118-y; KORNET M, 1991, PSYCHOPHARMACOLOGY, V104, P367, DOI 10.1007/BF02246038; KRANZLER HR, 1994, J CONSULT CLIN PSYCH, V62, P1116; KRISHNANSARIN S, 1995, PHARMACOL BIOCHEM BE, V52, P153, DOI 10.1016/0091-3057(95)00080-G; KRISHNANSARIN S, 1995, PSYCHOPHARMACOLOGY, V120, P177, DOI 10.1007/BF02246191; Krystal JH, 2001, NEW ENGL J MED, V345, P1734, DOI 10.1056/NEJMoa011127; Li XW, 1998, BRAIN RES, V794, P35, DOI 10.1016/S0006-8993(98)00191-7; LINSEMAN MA, 1990, PHARMACOL BIOCHEM BE, V36, P405, DOI 10.1016/0091-3057(90)90423-F; LITT MD, 1990, ADDICT BEHAV, V15, P137, DOI 10.1016/0306-4603(90)90017-R; Maas LC, 1998, AM J PSYCHIAT, V155, P124, DOI 10.1176/ajp.155.1.124; Mangold DL, 2000, NEUROPSYCHOPHARMACOL, V22, P595, DOI 10.1016/S0893-133X(99)00149-9; Mann K, 2001, ALCOHOL CLIN EXP RES, V25, p104S, DOI 10.1111/j.1530-0277.2001.tb02383.x; MARFAINGJALLAT P, 1983, PHARMACOL BIOCHEM BE, V18, P537, DOI 10.1016/0091-3057(83)90232-0; Marlatt G. A., 1985, RELAPSE PREVENTION; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; McCaul ME, 2000, NEUROPSYCHOPHARMACOL, V22, P480, DOI 10.1016/S0893-133X(99)00147-5; McNair DM, 1992, EDITS MANUAL PROFILE; MERCIER C, 1992, INT J ADDICT, V27, P1267, DOI 10.3109/10826089209047349; Moak DH, 1998, AM J ADDICTION, V7, P14; MODELL JG, 1992, ALCOHOL CLIN EXP RES, V16, P266, DOI 10.1111/j.1530-0277.1992.tb01374.x; MYERS RD, 1986, ALCOHOL, V3, P383, DOI 10.1016/0741-8329(86)90058-3; O'Malley SS, 2002, PSYCHOPHARMACOLOGY, V160, P19, DOI 10.1007/s002130100919; O'Malley SS, 2000, J CLIN PSYCHOPHARM, V20, P69, DOI 10.1097/00004714-200002000-00012; OBrien CP, 1996, ALCOHOL, V13, P35, DOI 10.1016/0741-8329(95)02038-1; OMalley SS, 1996, ALCOHOL ALCOHOLISM, V31, P77; REID LD, 1991, ALCOHOL, V8, P247, DOI 10.1016/0741-8329(91)90305-G; REID LD, 1987, ALCOHOL, V4, P161, DOI 10.1016/0741-8329(87)90038-3; Roberts JS, 1999, ALCOHOL CLIN EXP RES, V23, P1484, DOI 10.1097/00000374-199909000-00010; SAMSON HH, 1985, PHARMACOL BIOCHEM BE, V22, P91, DOI 10.1016/0091-3057(85)90491-5; SCHULZ R, 1980, PSYCHOPHARMACOLOGY, V68, P221, DOI 10.1007/BF00428107; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; SWIFT RM, 1994, AM J PSYCHIAT, V151, P1463; TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147; VOLKOW ND, 1991, AM J PSYCHIAT, V148, P621; VOLPICELLI JR, 1986, LIFE SCI, V38, P841, DOI 10.1016/0024-3205(86)90601-6; Wand G, 2001, ALCOHOL CLIN EXP RES, V25, P1134, DOI 10.1097/00000374-200108000-00007; Wand GS, 1998, ARCH GEN PSYCHIAT, V55, P1114, DOI 10.1001/archpsyc.55.12.1114; Wand GS, 1999, ALCOHOL CLIN EXP RES, V23, P1185, DOI 10.1097/00000374-199907000-00007; WEISS F, 1990, PSYCHOPHARMACOLOGY, V101, P178, DOI 10.1007/BF02244123; Whalen Paul J, 2002, Semin Clin Neuropsychiatry, V7, P234, DOI 10.1053/scnp.2002.35219	64	63	67	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	FEB 1	2004	55	3					255	262		10.1016/j.biopsych.2003.07.007			8	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	767HK	WOS:000188434000008	14744466				2020-06-30	J	Kodaka, M; Okamoto, Y; Handa, F; Kawasaki, J; Miyao, H				Kodaka, M; Okamoto, Y; Handa, F; Kawasaki, J; Miyao, H			Relation between fentanyl dose and predicted EC50 of propofol for laryngeal mask insertion	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics i.v., propofol; analgesics opioid, fentanyl; equipment, laryngeal mask airway	AIRWAY; CONSCIOUSNESS; ALFENTANIL; INFUSION; CHILDREN	Background. This study sought to determine the effective concentration for 50% of the attempts to secure laryngeal mask insertion (predicted EC50LMA) of propofol using a target-controlled infusion (Diprifusor(TM)) and investigated whether fentanyl influenced these required concentrations, respiratory rate (RR) and bispectral index (BIS). Methods. Sixty-four elective unpremedicated patients were randomly assigned to four groups (n=16 for each group) and given saline (control) or fentanyl 0.5, 1 or 2 mug kg(-1). Propofol target concentration was determined by a modification of Dixon's up-and-down method. Laryngeal mask airway insertion was attempted without neuromuscular blocking drugs after equilibration had been established for >10 min. Movement was defined as presence of bucking or gross purposeful muscular movement within 1 min after insertion. EC50LMA values were obtained by calculating the mean of 16 patients in each group. Results. Predicted EC50LMA of the control, fentanyl 0.5, 1 and 2 mug kg(-1) groups were 3.25 (0.20), 2.06 (0.55), 1.69 (0.38) and 1.50 (0.54) mug ml(-1) respectively; those of all fentanyl groups were significantly lower than that of control. RR was decreased in relation to the fentanyl dose up to 1 mug kg(-1). BIS values after fentanyl 1 and 2 mug kg(-1) were significantly greater than in the control and 0.5 mug kg(-1) groups. Conclusions. A fentanyl dose of 0.5 mug kg(-1) is sufficient to decrease predicted EC50LMA with minimum respiratory depression and without a high BIS value.	Saitama Med Sch, Saitama Med Ctr, Dept Anesthesiol, Kawagoe, Saitama 3508550, Japan	Kodaka, M (reprint author), Saitama Med Sch, Saitama Med Ctr, Dept Anesthesiol, 1981 Tsujido Cho, Kawagoe, Saitama 3508550, Japan.	kmkodaka@cb3.so-net.ne.jp					Casati A, 1999, ANESTH ANALG, V88, P917, DOI 10.1097/00000539-199904000-00043; DIXON WJ, 1991, NEUROSCI BIOBEHAV R, V15, P47, DOI 10.1016/S0149-7634(05)80090-9; GEPTS E, 1987, ANESTH ANALG, V66, P1256; Hui JKL, 2002, CAN J ANAESTH, V49, P508, DOI 10.1007/BF03017932; Iselin-Chaves IA, 1998, ANESTH ANALG, V87, P949; Kazama T, 1997, ANESTHESIOLOGY, V87, P213, DOI 10.1097/00000542-199708000-00007; Kodaka M., 2002, Anesthesia and Analgesia, V94; MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41; Nakazawa K, 1999, EUR J ANAESTH, V16, P550, DOI 10.1046/j.1365-2346.1999.00540.x; Nishina K, 1997, ANESTHESIOLOGY, V87, P1324, DOI 10.1097/00000542-199712000-00010; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; Swinhoe CF, 1998, ANAESTHESIA, V53, P61, DOI 10.1111/j.1365-2044.1998.53s104.x; Taylor IN, 1998, ANAESTHESIA, V53, P222, DOI 10.1046/j.1365-2044.1998.00316.x	14	30	35	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	FEB	2004	92	2					238	241		10.1093/bja/aeh033			4	Anesthesiology	Anesthesiology	769KW	WOS:000188650100016	14722176	Bronze			2020-06-30	J	Ray, BK; Vallejo, MC; Creinin, MD; Shannon, KT; Mandell, GL; Kaul, B; Ramanathan, S				Ray, BK; Vallejo, MC; Creinin, MD; Shannon, KT; Mandell, GL; Kaul, B; Ramanathan, S			Amniotic fluid embolism with second trimester pregnancy termination; a case report	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article								Purpose: Describe the diagnosis, clinical features, pathophysiology, treatment and anesthetic management of amniotic fluid embolism (AFE) in a patient undergoing second trimester pregnancy termination. Clinical features: A 30-yr-old gravida 2, para 1, woman was admitted for a dilatation and evacuation procedure for underlying intra-uterine fetal demise in her second trimester of pregnancy. Hypotension, shock, respiratory arrest, pulseless electrical activity, hemorrhage, disseminated intravascular coagulopathy, requiring cardiopulmonary resuscitation and blood transfusion complicated her intraoperative care. AFE was considered the most likely cause of this intraoperative event. Conclusions: It is now recognized that the pathophysiological features of AFE are similar to a type-1 hypersensitivity reaction ranging from mild systemic reaction to anaphylaxis and shock. AFE has a high maternal and fetal morbidity and mortality rate, requiring prompt recognition and treatment. In patients with cardiovascular instability, the treatment of AFE is similar to anaphylaxis requiring aggressive fluid hydration, cardiopulmonary resuscitation, administration of blood products and the use of vasopressors.	Univ Pittsburgh, Magee Womens Hosp, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Magee Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA 15213 USA	Vallejo, MC (reprint author), Univ Pittsburgh, Magee Womens Hosp, Sch Med, Dept Anesthesiol, 300 Halket St, Pittsburgh, PA 15213 USA.	vallejomc@anes.upmc.edu	Vallejo, Manuel C/X-5544-2019	Vallejo, Manuel C/0000-0002-1240-3670			American College of Radiology, 2003, PROL OBST, P27; CLARK SL, 1995, AM J OBSTET GYNECOL, V172, P1158, DOI 10.1016/0002-9378(95)91474-9; CLARK SL, 1986, AM J OBSTET GYNECOL, V154, P104, DOI 10.1016/0002-9378(86)90402-3; CROMEY MG, 1983, J REPROD MED, V28, P209; CUMMINS RO, 2001, ACLS PROVIDER MANUAL; de Swiet J, 2000, AM J OBSTET GYNECOL, V182, P760; ESPOSITO RA, 1990, AM J OBSTET GYNECOL, V163, P572, DOI 10.1016/0002-9378(90)91200-V; HOGBERG U, 1985, GYNECOL OBSTET INVES, V20, P130; KANAYAMA N, 1992, CLIN CHEM, V38, P526; KOBAYASHI H, 1993, AM J OBSTET GYNECOL, V168, P848, DOI 10.1016/S0002-9378(12)90832-7; LAWSON HW, 1990, AM J OBSTET GYNECOL, V162, P986, DOI 10.1016/0002-9378(90)91301-R; Levy Jerrold H., 1997, P1205; Martin RW, 1996, CLIN OBSTET GYNECOL, V39, P101, DOI 10.1097/00003081-199603000-00010; MORGAN M, 1979, ANAESTHESIA, V34, P20, DOI 10.1111/j.1365-2044.1979.tb04862.x; SHARMA SK, 1999, OBSTET ANESTHESIA PR, P842; Shechtman M, 1999, ANESTH ANALG, V89, P1456, DOI 10.1097/00000539-199912000-00025; STEINER P. E., 1941, Journal of the American Medical Association, V117, P1340	17	16	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	FEB	2004	51	2					139	144		10.1007/BF03018773			6	Anesthesiology	Anesthesiology	777NG	WOS:000189184000009	14766690	Bronze			2020-06-30	J	Hemmerling, TM; Prieto, I; Choiniere, JL; Basile, F; Fortier, JD				Hemmerling, TM; Prieto, I; Choiniere, JL; Basile, F; Fortier, JD			Ultra-fast-track anesthesia in off-pump coronary artery bypass grafting: a prospective audit comparing opioid-based anesthesia vs thoracic epidural-based anesthesia	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							ROUTINE IMMEDIATE EXTUBATION; CARDIAC-SURGERY; POSTOPERATIVE ANALGESIA; PATIENT	Purpose: To examine the feasibility of immediate extubation after off-pump coronary artery bypass grafting (OPCAB) using opioid based analgesia or high thoracic epidural analgesia (TEA) and compare postoperative analgesia with continuous TEA vs patient-controlled analgesia (PCA). Methods: One hundred consecutive patients undergoing OPCAB were included in this prospective audit. After induction of anesthesia using fentanyl 2 to 5 mug.kg(-1), propofol 1 to 2 mg.kg(-1) and enclotracheal intubation facilitated by rocuronium, anesthesia was maintained using sevoflurane titrated according to bispectral index monitoring. Perioperative analgesia was provided by TEA (n=63) at the T3/T4 inter-space or T4/T5 interspace using bupivacaine 0.125% 8 to 14 mL.hr(-1) and repetitive boluses of bupivacaine 0.25% during surgery. In patients who were fully anticoagulated or refused TEA, perioper-ative analgesia was achieved by iv fentanyl boluses (up to 15 mug-kg(-1)) and remifentanil 0.1 to 0.2 mug-kg(-1).min(-1), followed by morphine PCA after surgery (n=37). Maintenance of body temperature was achieved by a heated operating room and forced-air warming blankets. Results: Ninety-five patients were extubated within 25 min after surgery (PCA, n=33; TEA, n=62). Five patients were not extubated immediately because their core temperature was lower than 35degreesC. One patient was re-intubated because of agitation (TEA group); one was re-intubated because of severe pain and morphine-induced respiratory depression (PCA group). Pain scores were low after surgery, with pain scores in the TEA group being significantly lower immediately, at six hours, 24 hr and 48 hr after surgery(P<0.05). Conclusion: Immediate extubation is possible after OPCAB using either opioid-based analgesia or TEA. TEA provides significantly lower pain scores after surgery in comparison to morphine PCA.	Univ Montreal, CHUM, Dept Anesthesiol, Hotel Dieu, Montreal, PQ H2W 1T8, Canada; Univ Montreal, CHUM, Dept Surg, Hotel Dieu, Montreal, PQ H2W 1T8, Canada	Hemmerling, TM (reprint author), Univ Montreal, CHUM, Dept Anesthesiol, Hotel Dieu, 3840 Rue Saint Urbain, Montreal, PQ H2W 1T8, Canada.	thomashemmerling@hotmail.com					de Vries AJ, 2002, J CARDIOTHOR VASC AN, V16, P21, DOI 10.1053/jcan.2002.29645; Dhole S, 2001, J CARDIOTHOR VASC AN, V15, P288, DOI 10.1053/jcan.2001.23271; Djaiani GN, 2001, J CARDIOTHOR VASC AN, V15, P152, DOI 10.1053/jcan.2001.21936; Dopfmer UR, 2002, ACTA ANAESTH SCAND, V46, P338; Fawcett WJ, 1997, ANAESTHESIA, V52, P294, DOI 10.1111/j.1365-2044.1997.80-az0088.x; Fillinger MP, 2002, J CARDIOTHOR VASC AN, V16, P15, DOI 10.1053/jcan.2002.29639; Flisberg P, 2001, J CARDIOTHOR VASC AN, V15, P282, DOI 10.1053/jcan.2001.23270; Ho AMH, 2000, CHEST, V117, P551, DOI 10.1378/chest.117.2.551; Loick HM, 1999, ANESTH ANALG, V88, P701, DOI 10.1097/00000539-199904000-00001; Nakamura T, 1994, Masui, V43, P1024; Norris EJ, 2001, ANESTHESIOLOGY, V95, P1054, DOI 10.1097/00000542-200111000-00006; Overdyk FJ, 1997, ANESTH ANALG, V84, P213, DOI 10.1097/00000539-199701000-00038; Priestley MC, 2002, ANESTH ANALG, V94, P275, DOI 10.1097/00000539-200202000-00009; Riedel BJCJ, 1997, CURR OPIN CARDIOL, V12, P515, DOI 10.1097/00001573-199711000-00003; Royse CF, 1999, ANN THORAC SURG, V68, P1326, DOI 10.1016/S0003-4975(99)00829-2; Scott NB, 2001, ANESTH ANALG, V93, P528, DOI 10.1097/00000539-200109000-00003; Straka Z, 2002, ANN THORAC SURG, V74, P1544, DOI 10.1016/S0003-4975(02)03934-6; Visser WA, 2001, J CARDIOTHOR VASC AN, V15, P758, DOI 10.1053/jcan.2001.28334; WILLIAMS JP, 2002, CAN J ANESTH, V49, pR7	19	24	24	0	3	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	FEB	2004	51	2					163	168		10.1007/BF03018777			6	Anesthesiology	Anesthesiology	777NG	WOS:000189184000013	14766694	Bronze			2020-06-30	J	Muellejans, B; Lopez, A; Cross, MH; Bonome, C; Morrison, L; Kirkham, AJ				Muellejans, B; Lopez, A; Cross, MH; Bonome, C; Morrison, L; Kirkham, AJ			Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial [ISRCTN43755713]	CRITICAL CARE			English	Article						analgesia; analgesia based sedation; critical care; fentanyl; propofol; remifentanil; renal function; sedation	CRITICALLY-ILL PATIENTS; PHARMACOKINETICS; PHARMACODYNAMICS; MIDAZOLAM; PROPOFOL; INFUSION	Introduction This double-blind, randomized, multicentre study was conducted to compare the efficacy and safety of remifentanil and fentanyl for intensive care unit (ICU) sedation and analgesia. Methods Intubated cardiac, general postsurgical or medical patients (aged=18 years), who were mechanically ventilated for 12-72 hours, received remifentanil (9 mug/kg per hour; n=77) or fentanyl (1.5 mug/kg per hour; n=75). Initial opioid titration was supplemented with propofol (0.5 mg/kg per hour), if required, to achieve optimal sedation (i.e. a Sedation-Agitation Scale score of 4). Results The mean percentages of time in optimal sedation were 88.3% for remifentanil and 89.3% for fentanyl (not significant). Patients with a Sedation-Agitation Scale score of 4 exhibited significantly less between-patient variability in optimal sedation on remifentanil (variance ratio of fentanyl to remifentanil 1.84; P=0.009). Of patients who received fentanyl 40% required propofol, as compared with 35% of those who received remifentanil (median total doses 683 mg and 378 mg, respectively; P=0.065). Recovery was rapid (median time to extubation: 1.1 hours for remifentanil and 1.3 hours for fentanyl; not significant). Remifentanil patients who experienced pain did so for significantly longer during extubation (6.5% of the time versus 1.4%; P=0.013), postextubation (10.2% versus 3.6%; P=0.001) and post-treatment (13.5% versus 5.1%; P=0.001), but they exhibited similar haemodynamic stability with no significant differences in adverse event incidence. Conclusion Analgesia based sedation with remifentanil titrated to response provided effective sedation and rapid extubation without the need for propofol in most patients. Fentanyl was similar, probably because the dosing algorithm demanded frequent monitoring and adjustment, thereby preventing over-sedation. Rapid offset of analgesia with remifentanil resulted in a greater incidence of pain, highlighting the need for proactive pain management when transitioning to longer acting analgesics, which is difficult within a double-blind study but would be quite possible under normal circumstances.	Klinikum Karlsburg, Herz Diabet Zentrum Mecklenburg Vorpomern, Klin Anaesthesiol & Intens Med, Karlsburg, Germany; Hosp Univ Infanta Cristina, Serv Med Intens, Badajoz, Spain; Leeds Gen Infirm, Dept Anaesthesia, Leeds, W Yorkshire, England; Hosp Juan Canalejo, Dept Anaesthesiol, Serv Anestesiol & Reanimac, La Coruna, Spain; St Johns Hosp, Dept Anaesthesia, Livingston, Scotland; GlaxoSmithKline Res & Dev Ltd, Greenford, Middx, England	Muellejans, B (reprint author), Klinikum Karlsburg, Herz Diabet Zentrum Mecklenburg Vorpomern, Klin Anaesthesiol & Intens Med, Karlsburg, Germany.	dr.muellejans@drguth.de					Breen D, 2001, INTENS CARE MED, V27, pS207; Breen DP, 2002, INTENS CARE MED, V28, pS180; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; Carrasco G, 1998, CRIT CARE MED, V26, P844, DOI 10.1097/00003246-199805000-00015; Cavaliere F, 2002, CAN J ANAESTH, V49, P1088, DOI 10.1007/BF03017909; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; De Bellis P, 2002, Minerva Anestesiol, V68, P765; Dershwitz M, 1996, ANESTHESIOLOGY, V84, P812, DOI 10.1097/00000542-199604000-00008; Gupta S, 2000, ANAESTHESIA, V55, P491; HIGGINS TL, 1994, CRIT CARE MED, V22, P1415, DOI 10.1097/00003246-199409000-00011; Hoke JF, 1997, ANESTHESIOLOGY, V87, P533, DOI 10.1097/00000542-199709000-00012; KAPILA A, 1995, ANESTHESIOLOGY, V83, P968, DOI 10.1097/00000542-199511000-00009; Karabinis A, 2001, INTENS CARE MED, V27, pS275; Kessler P, 2001, INTENS CARE MED, V27, pS239; LANE M, 2002, CARE CRIT ILL, V18, P144; LANE M, 2002, CARE CRIT ILL, V18, P140; Lane M, 2002, CARE CRIT ILL, V18, P146; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LENHART A, 2000, J ANASTH INTENSIVBEH, V7, P123; Main A, 1998, ANAESTHESIA, V53, P823, DOI 10.1046/j.1365-2044.1998.0584a.x; Mastronardi P, 2000, Minerva Anestesiol, V66, P417; Park G, 2002, Minerva Anestesiol, V68, P505; Park GR, 2000, EUR J ANAESTH, V17, P111, DOI 10.1046/j.1365-2346.2000.00618.x; PARK GR, 1996, [No title captured], V6, P330; QUINTON P, 2000, INTENS CARE MED S, V3, pS304; Reeker W, 1997, ANESTHESIOLOGY, V87, pA203, DOI 10.1097/00000542-199709001-00203; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Soltesz S, 2001, BRIT J ANAESTH, V86, P763, DOI 10.1093/bja/86.6.763; Szalados J E, 1998, Curr Opin Anaesthesiol, V11, P147, DOI 10.1097/00001503-199804000-00006; Tipps LB, 2000, NEUROSURGERY, V46, P596, DOI 10.1097/00006123-200003000-00015; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005; Wilhelm W, 1999, ANAESTHESIST, V48, P625, DOI 10.1007/s001010050762	32	87	96	0	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care	FEB	2004	8	1					R1	R11		10.1186/cc2398			11	Critical Care Medicine	General & Internal Medicine	770JU	WOS:000188720100001	14975049	DOAJ Gold, Green Published			2020-06-30	J	Sator-Katzenschlager, SM; Oehmke, MJ; Deusch, E; Dolezal, S; Heinze, G; Wedrich, A				Sator-Katzenschlager, SM; Oehmke, MJ; Deusch, E; Dolezal, S; Heinze, G; Wedrich, A			Effects of remifentanil and fentanyl on intraocular pressure during the maintenance and recovery of anaesthesia in patients undergoing non-ophthalmic surgery	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						analgesics, opioid, fentanyl, remifentanil; ocular physiology, intraocular pressure; surgical procedures, operative, intraoperative period, postoperative period	OCULAR BLOOD-FLOW; APPLANATION TONOMETER; TRACHEAL INTUBATION; NITROUS-OXIDE; PROPOFOL; SUCCINYLCHOLINE; ISOFLURANE; MANAGEMENT	Background and objective: To compare the effects of remifentanil and fentanyl on intraocular pressure during the maintenance and recovery of anaesthesia in patients undergoing elective non-ophthalmic surgery. Methods: Thirty-two patients (ASA I-II) were randomized into two groups to receive either a continuous infusion of remifentanil (0.25-0.5 mug kg(-1) min(-1), n = 16, Group R) or an intermittent bolus of fentanyl (2-5 mug kg(-1), n = 16, Group F) during the maintenance of anaesthesia. For the induction of anaesthesia, Group R received remifentanil 1 mug kg(-1) and Group F received fentanyl 2 mug kg(-1); both groups then received propofol 2 mg kg(-1) with vecuronium 0.1 mg kg(-1). Anaesthesia in both groups was maintained with a continuous infusion of propofol 4-8 mg kg(-1) h(-1). Ventilation of the lungs was controlled to a constant end-tidal PCO2 of 4.7-5.4 kPa. Blood pressure, electrocardiography, heart rate and oxygen saturation were monitored throughout anaesthesia. Intraocular pressure was determined before surgery, during the maintenance of anaesthesia, 2 min after emergence and in the recovery room using a Perkins hand-held applanation tonometer by an ophthalmologist blinded to the anaesthetic technique. Results: After induction of anaesthesia, a significant decrease in intraocular pressure in the remifentanil group from 13.6 +/- 2.6 to 7.1 +/- 3.1 mmHg (P < 0.001) and in the fentanyl group from 13.7 +/- 2.2 to 9.7 +/- 3.4 mmHg (P < 0.001) was observed and maintained during anaesthesia. Thirty minutes after the end of anaesthesia, intraocular pressure returned to baseline values in both groups (remifentanil: 13.9 +/- 2.8 mmHg, P = 0.28; fentanyl: 13.6 +/- 2.3 mmHg, P = 0.59). The intraocular pressure and haemodynamic variables did not differ significantly between the two groups (intraocular pressure, P = 0.7327; blood pressure, P = 0.1295; heart rate, P = 0.8601). Conclusions: Remifentanil maintains intraocular pressure at an equally reduced level compared with fentanyl.	Univ Vienna, Dept Anaesthesiol & Gen Intens Care B, A-1090 Vienna, Austria; Univ Vienna, Dept Anaesthesiol & Gen Intens Care A, A-1090 Vienna, Austria; Univ Vienna, Dept Med Comp Sci, A-1090 Vienna, Austria; Univ Vienna, Dept Ophthalmol & Optometr, A-1090 Vienna, Austria	Oehmke, MJ (reprint author), Univ Vienna, Dept Anaesthesiol & Gen Intens Care B, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	marthias.oehmke@univie.ac.at	Wedrich, Andreas/AAE-9171-2020	Heinze, Georg/0000-0003-1147-8491			Alexander R, 1998, BRIT J ANAESTH, V81, P606, DOI 10.1093/bja/81.4.606; ARTRU AA, 1993, ANESTH ANALG, V77, P564; Bekker AY, 2000, ANESTH ANALG, V91, P117, DOI 10.1097/00000539-200007000-00022; Coupland SG, 2001, CAN J OPHTHALMOL, V36, P140, DOI 10.1016/S0008-4182(01)80005-3; CUNNINGHAM AJ, 1986, CAN ANAESTH SOC J, V33, P195, DOI 10.1007/BF03010831; Donlon JR, 2000, ANESTHESIA, P2173; DUNN JS, 1973, ARCH OPHTHALMOL-CHIC, V89, P149, DOI 10.1001/archopht.1973.01000040151020; Findl O, 1999, AM J OPHTHALMOL, V127, P645, DOI 10.1016/S0002-9394(99)00066-5; Glass PSA, 1999, ANESTH ANALG, V89, pS7; JANTZEN JPAH, 1988, ANAESTHESIST, V37, P458; Lauwers M, 1997, CNS DRUGS, V8, P189, DOI 10.2165/00023210-199708030-00001; Minkowitz HS, 2000, CAN J ANAESTH, V47, P522, DOI 10.1007/BF03018943; Ng HP, 2000, BRIT J ANAESTH, V85, P785, DOI 10.1093/bja/85.5.785; PERKINS ES, 1965, BRIT J OPHTHALMOL, V49, P591, DOI 10.1136/bjo.49.11.591; *SAS I INC, 1999, SAS STAT US GUID VER, P1562; Sator S, 1998, BRIT J ANAESTH, V80, P243, DOI 10.1093/bja/80.2.243; Sator-Katzenschlager SM, 2002, EUR J ANAESTH, V19, P823, DOI 10.1017/S0265021502001333; Schafer R, 2002, ACTA ANAESTH SCAND, V46, P703, DOI 10.1034/j.1399-6576.2002.460612.x; Tramer M, 1997, BRIT J ANAESTH, V78, P247	19	15	16	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.	FEB	2004	21	2					95	100		10.1017/S0265021504002030			6	Anesthesiology	Anesthesiology	779PY	WOS:000189310300003	14977339				2020-06-30	J	Kuczkowski, IM				Kuczkowski, IM			Severe persistent fetal bradycardia following subarachnoid administration of fentanyl and bupivacaine for induction of a combined spinal-epidural analgesia for labor pain	JOURNAL OF CLINICAL ANESTHESIA			English	Letter							RESPIRATORY ARREST; SUFENTANIL		Univ Calif San Diego, Med Ctr, Dept Anesthesiol, San Diego, CA 92103 USA	Kuczkowski, IM (reprint author), Univ Calif San Diego, Med Ctr, Dept Anesthesiol, San Diego, CA 92103 USA.						DAngelo R, 1997, ANESTHESIOLOGY, V87, P166, DOI 10.1097/00000542-199707000-00023; Ferouz Fazeela, 1997, Anesthesia and Analgesia, V85, P1088, DOI 10.1097/00000539-199711000-00022; Friedlander JD, 1997, REGION ANESTH, V22, P378, DOI 10.1016/S1098-7339(97)80015-6; Greenhalgh CA, 1996, ANAESTHESIA, V51, P173, DOI 10.1111/j.1365-2044.1996.tb07708.x	4	9	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0952-8180	1873-4529		J CLIN ANESTH	J. Clin. Anesth.	FEB	2004	16	1					78	79		10.1016/j.jclinane.2003.12.004			2	Anesthesiology	Anesthesiology	800TD	WOS:000220049700017	14984867				2020-06-30	J	Bardutzky, J; Georgiadis, D; Kollmar, R; Schwarz, S; Schwab, S				Bardutzky, J; Georgiadis, D; Kollmar, R; Schwarz, S; Schwab, S			Energy demand in patients with stroke who are sedated and receiving mechanical ventilation	JOURNAL OF NEUROSURGERY			English	Article						energy expenditure; cerebral ischemia; intracerebral hemorrhage; hemicraniectomy	HEAD-INJURED PATIENTS; TOTAL PARENTERAL-NUTRITION; CRITICALLY ILL PATIENTS; INDIRECT CALORIMETRY; METABOLIC-CHANGES; BODY-TEMPERATURE; ISCHEMIC STROKE; SEVERE SEPSIS; MAJOR TRAUMA; EXPENDITURE	Object. The purpose of this study was 1) to determine the total energy expenditure (TEE) in patients with acute stroke who are sedated and receiving mechanical ventilation; and 2) to compare the TEE between patients with ischemic and hemorrhagic stroke. Methods. Thirty-four consecutive nonseptic patients with stroke requiring sedation and mechanical ventilation were prospectively examined; 13 of the patients had experienced spontaneous intracerebral hemorrhage and 21 cerebral ischemia of the middle cerebral artery territory. The TEE was evaluated using continuous indirect calorimetry during the first 5 days after admission to the intensive care unit. The serum albumin concentration was determined on admission and on Day 5. The TEE varied from 1560 +/- 240 to 1623 +/- 251 kcal/day. A highly significant correlation between the TEE and the basal energy expenditure (BEE), as predicted using the Harris-Benedict equation, was observed in both groups. No significant differences in the TEE were detected between the two groups or among the different study days. Conclusions. A highly significant correlation was found between the TEE and the predicted BEE in patients with acute stroke who have been sedated and have received mechanical ventilation. No significant differences were observed between patients with hemorrhagic and ischemic stroke. Further studies are needed to evaluate the effect of tailored feeding on clinical outcome in these patients.	Univ Heidelberg, Dept Neurol, D-6900 Heidelberg, Germany	Bardutzky, J (reprint author), Univ Massachusetts, Sch Med, Dept Psychiat, Ctr Comparat NeuroImaging, 55 Lake Ave N, Worcester, MA 01655 USA.	juergen.bardutzky@umassmed.edu					ASKANAZI J, 1980, JAMA-J AM MED ASSOC, V243, P1444, DOI 10.1001/jama.243.14.1444; AXELSSON K, 1988, ACTA MED SCAND, V224, P217; BARTON D, 1994, APPL GEOCHEM, V9, P127, DOI 10.1016/0883-2927(94)90002-7; Biolo G, 2002, INTENS CARE MED, V28, P1512, DOI 10.1007/s00134-002-1512-2; Blunt MC, 1998, ANAESTHESIA, V53, P755, DOI 10.1046/j.1365-2044.1998.00488.x; Bruder N, 1998, CRIT CARE MED, V26, P568, DOI 10.1097/00003246-199803000-00033; BRUDER N, 1994, CRIT CARE MED, V22, P1114, DOI 10.1097/00003246-199407000-00011; BRUDER N, 1991, CRIT CARE MED, V19, P43, DOI 10.1097/00003246-199101000-00013; BURSZTEIN S, 1989, AM J CLIN NUTR, V50, P227; BUZBY GP, 1981, J SURG RES, V31, P46, DOI 10.1016/0022-4804(81)90028-7; CARLSSON M, 1984, CLIN NUTR, V3, P103, DOI 10.1016/S0261-5614(84)80008-4; Davalos A, 1996, STROKE, V27, P1028, DOI 10.1161/01.STR.27.6.1028; FLECK A, 1985, LANCET, V1, P781; Gariballa SE, 1998, AM J CLIN NUTR, V68, P275; Gariballa SE, 1998, JPEN-PARENTER ENTER, V22, P315, DOI 10.1177/0148607198022005315; HAIDER W, 1975, EUR J INTEN CARE MED, V1, P19, DOI 10.1007/BF00735865; Harris JA, 1919, BIOMETRIC STUDY BASA; Jolliet P, 1998, INTENS CARE MED, V24, P848, DOI 10.1007/s001340050677; McClave SA, 2001, J CLIN GASTROENTEROL, V33, P14, DOI 10.1097/00004836-200107000-00005; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; Plank LD, 2000, WORLD J SURG, V24, P630, DOI 10.1007/s002689910104; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; RODRIGUEZ DJ, 1995, J SURG RES, V59, P455, DOI 10.1006/jsre.1995.1191; SUN XL, 1993, CRIT CARE MED, V21, P555, DOI 10.1097/00003246-199304000-00017; Uehara M, 1999, CRIT CARE MED, V27, P1295, DOI 10.1097/00003246-199907000-00015; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WALLACE BH, 1992, J TRAUMA, V32, P154, DOI 10.1097/00005373-199202000-00007; WEEKES E, 1992, CLIN NUTR, V11, P18, DOI 10.1016/0261-5614(92)90058-X; Weir CJ, 1997, BMJ-BRIT MED J, V314, P1303, DOI 10.1136/bmj.314.7090.1303; Williams LS, 2002, NEUROLOGY, V59, P67, DOI 10.1212/WNL.59.1.67; Wilson RF, 2001, NEUROL RES, V23, P121, DOI 10.1179/016164101101198451; WOO E, 1988, STROKE, V19, P185, DOI 10.1161/01.STR.19.2.185; Zauner C, 2001, AM J CLIN NUTR, V74, P265	33	11	12	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	FEB	2004	100	2					266	271		10.3171/jns.2004.100.2.0266			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	768TT	WOS:000188551700013	15086234				2020-06-30	J	Eisenach, JC; Hood, DD; Curry, R; Sawynok, J; Yaksh, TL; Li, XH				Eisenach, JC; Hood, DD; Curry, R; Sawynok, J; Yaksh, TL; Li, XH			Intrathecal but not intravenous opioids release adenosine from the spinal cord	JOURNAL OF PAIN			English	Article						adenosine; cerebrospinal fluid; human; morphine; opioid; spinal analgesia	NEUROPATHIC PAIN; MORPHINE; RECEPTORS; HUMANS; RATS; HYPERALGESIA; VOLUNTEERS; INJECTION; CAPSAICIN; ANALGESIA	Opioids increase spinal release of adenosine in rats, and analgesia from systemic and intrathecal morphine is reduced in animals by adenosine receptor antagonists. We performed 3 studies to determine whether opioid administration also induces adenosine release in humans. To determine the effect of intrathecal opioid exposure, 15 women received intrathecal fentanyl, 50 mug, or saline, and cerebrospinal fluid was sampled at 2-minute intervals for 6 minutes before surgery. In a second study, 8 healthy volunteers received intrathecal morphine, 50 mug, plus fentanyl, 50 mug, with cerebrospinal fluid sampled 20 and 60 minutes later. To determine the effect of intravenous opioid exposure, 9 healthy volunteers received intravenous remifentanil for 60 minutes, and cerebrospinal fluid was sampled before and at the end of the infusion. Adenosine concentrations were similar in the 3 studies before opioid administration. Intrathecal fentanyl or saline did not affect adenosine concentrations during the 6 minutes in the first study. Adenosine concentrations increased significantly 20 and 60 minutes after intrathecal morphine plus fentanyl was administered. In contrast, adenosine concentrations were unaffected by intravenous remifentanil. These results suggest that intrathecal but not systemic opioid analgesia in humans is associated with spinal release of adenosine. Perspective: Although the role of adenosine release in the spinal cord for opioid receptor activation in subsequent analgesia from opioids is controversial in laboratory studies, these clinical data suggest that local opioid receptor stimulation in the spinal cord of humans does release adenosine. Whether adenosine participates in analgesia from spinal opioids in humans is not known, but spinal adenosine itself is analgesic in humans, consistent with an opioid-adenosine role in analgesia. (C) 2004 by the American Pain Society.	Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Study Pharmacol Plast Presence Pain, Winston Salem, NC 27157 USA; Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada; Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA	Eisenach, JC (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	eisenach@wfubmc.edu	Yaksh, Tony/D-4119-2009		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR07122]; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM48085]		BIAN D, 1995, NEUROREPORT, V6, P1981, DOI 10.1097/00001756-199510010-00007; CAHILL CM, 1995, J PHARMACOL EXP THER, V275, P84; Cahill CM, 1996, EUR J PHARMACOL, V298, P45, DOI 10.1016/0014-2999(95)00775-X; DELANDER GE, 1986, J PHARMACOL EXP THER, V239, P88; Eisenach JC, 2003, ANESTHESIOLOGY, V99, P166, DOI 10.1097/00000542-200307000-00027; Eisenach JC, 2002, ANESTHESIOLOGY, V96, P29, DOI 10.1097/00000542-200201000-00011; Guieu R, 1996, PAIN, V68, P271, DOI 10.1016/S0304-3959(96)03214-9; Hood DD, 2003, ANESTH ANALG, V97, P810, DOI 10.1213/01.ANE.0000078811.80093.88; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; MATSUMIYA N, 1983, ANESTHESIOLOGY, V59, P175; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Rane K, 1998, ANESTHESIOLOGY, V89, P1108, DOI 10.1097/00000542-199811000-00010; Sandner-Kiesling A, 2001, ANESTHESIOLOGY, V95, P1455, DOI 10.1097/00000542-200112000-00026; SAWYNOK J, 1989, TRENDS PHARMACOL SCI, V10, P186, DOI 10.1016/0165-6147(89)90235-6; Shafer SL, 1998, ANESTHESIOLOGY, V89, P1074, DOI 10.1097/00000542-199811000-00007; SWEENEY MI, 1989, J PHARMACOL EXP THER, V248, P447; SWEENEY MI, 1987, EUR J PHARMACOL, V141, P169, DOI 10.1016/0014-2999(87)90428-6; SWEENEY MI, 1991, J PHARMACOL EXP THER, V259, P1013; TAO PL, 1995, EUR J PHARMACOL, V278, P233, DOI 10.1016/0014-2999(95)00124-4; TAO PL, 1992, EUR J PHARMACOL, V215, P301, DOI 10.1016/0014-2999(92)90044-5; WANG JK, 1979, ANESTHESIOLOGY, V50, P149, DOI 10.1097/00000542-197902000-00013	21	26	28	0	0	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1526-5900			J PAIN	J. Pain	FEB	2004	5	1					64	68		10.1016/j.jpain.2003.10.001			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	780CL	WOS:000189353700007	14975380				2020-06-30	J	Celerier, E; Simonnet, G; Maldonado, R				Celerier, E; Simonnet, G; Maldonado, R			Prevention of fentanyl-induced delayed pronociceptive effects in mice lacking the protein kinase C gamma gene	NEUROPHARMACOLOGY			English	Article						opioids; delayed hyperalgesia; pain sensitisation; tolerance; knock-out mice	OPIOID-INDUCED HYPERALGESIA; LONG-LASTING HYPERALGESIA; INDUCED ABNORMAL PAIN; PKC-GAMMA; MORPHINE-TOLERANCE; PERSISTENT PAIN; TERM POTENTIATION; MUTANT MICE; SPINAL-CORD; NMDA	It has recently been reported in several nociceptive models of rats that the antinociceptive effect of fentanyl, an opioid analgesic widely used in the management of per-operative pain, was followed by paradoxical delayed hyperalgesia dependent on N-methyl-D-aspartate (NMDA) mechanisms. Events upstream of the NMDA receptor, especially the activation of the protein kinase Cgamma (PKCgamma), have been involved in the persistence of pain states associated with central sensitisation. In order to evaluate the contribution of the PKCgamma in early and delayed fentanyl nociceptive responses, we studied these effects in knock-out mice deficient in such a protein. We found that fentanyl antinociception was followed by the spontaneous appearance of prolonged hyperalgesia in the paw pressure and formalin tests, and allodynia in the Von Frey paradigm. In PKCgamma deficient mice, an enhancement of the early fentanyl antinociceptive effects was observed, as well as a complete prevention of the fentanyl delayed hyperalgesic/allodynic effects. Finally, naloxone administration in mice that had recovered their pre-fentanyl nociceptive threshold, precipitated hyperalgesia/allodynia in wild-type but not in mutant mice. This study identifies the PKCgamma as a key element that links opioid receptor activation with the recruitment of opposite systems to opioid analgesia involved in a physiological compensatory pain enhancement. (C) 2003 Elsevier Ltd. All rights reserved.	Univ Pompeu Fabra, Fac Ciencies Salut & Vida, Lab Neurofarmacol, E-08003 Barcelona, Spain; Univ Bordeaux 2, Lab Homeostasie Allostasie Pathol, F-33076 Bordeaux, France	Celerier, E (reprint author), Univ Pompeu Fabra, Fac Ciencies Salut & Vida, Lab Neurofarmacol, C Doctor Aiguader 80, E-08003 Barcelona, Spain.	e_celerier@yahoo.com	Maldonado, Rafael/F-5657-2014	Maldonado, Rafael/0000-0002-4359-8773			ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; AMIR S, 1978, LIFE SCI, V23, P1143, DOI 10.1016/0024-3205(78)90348-X; Basbaum AI, 1999, P NATL ACAD SCI USA, V96, P7739, DOI 10.1073/pnas.96.14.7739; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 2001, J NEUROSCI, V21, P4074, DOI 10.1523/JNEUROSCI.21-11-04074.2001; Celerier E, 1999, BRAIN RES, V847, P18, DOI 10.1016/S0006-8993(99)01998-8; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; Coderre TJ, 1997, BEHAV BRAIN SCI, V20, P404, DOI 10.1017/S0140525X97251484; Gardell LR, 2002, J NEUROSCI, V22, P6747; JANSSEN PAJ, 1963, ARZNEIMITTEL-FORSCH, V13, P502; Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; Laulin JP, 1999, NEUROSCIENCE, V89, P631, DOI 10.1016/S0306-4522(98)00652-6; Laulin JP, 1998, EUR J NEUROSCI, V10, P782, DOI 10.1046/j.1460-9568.1998.00083.x; Li XQ, 2001, MOL BRAIN RES, V86, P56, DOI 10.1016/S0169-328X(00)00260-6; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; MAO J, 1994, J NEUROSCI, V14, P2301; Mao JR, 2002, PAIN, V100, P213, DOI 10.1016/S0304-3959(02)00422-0; Mao JR, 1999, BRAIN RES REV, V30, P289, DOI 10.1016/S0165-0173(99)00020-X; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; MAO JR, 1995, BRAIN RES, V677, P257, DOI 10.1016/0006-8993(95)00161-I; Martin WJ, 1999, NEUROSCIENCE, V88, P1267, DOI 10.1016/S0306-4522(98)00314-5; Martin WJ, 2001, J NEUROSCI, V21, P5321, DOI 10.1523/JNEUROSCI.21-14-05321.2001; Nicoll RA, 1999, ANN NY ACAD SCI, V868, P515, DOI 10.1111/j.1749-6632.1999.tb11320.x; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; Simonnet G, 2003, NEUROREPORT, V14, P1, DOI 10.1097/00001756-200301200-00001; Suen P, 1998, MOL BRAIN RES, V59, P215, DOI 10.1016/S0169-328X(98)00157-0; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.neuro.17.1.551; Vanderah TW, 2001, J NEUROSCI, V21, P279, DOI 10.1523/JNEUROSCI.21-01-00279.2001; Zeitz KP, 2001, PAIN, V94, P245, DOI 10.1016/S0304-3959(01)00353-0	32	23	27	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB	2004	46	2					264	272		10.1016/j.neuropharm.2003.08.008			9	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	776FR	WOS:000189106400012	14680764				2020-06-30	J	Murray, DM; Thorne, GC; Rigby-Jones, AE; Tonucci, D; Grimes, S; Tooley, MA; Wolf, AR				Murray, DM; Thorne, GC; Rigby-Jones, AE; Tonucci, D; Grimes, S; Tooley, MA; Wolf, AR			Electroencephalograph variables, drug concentrations and sedation scores in children emerging from propofol infusion anaesthesia	PAEDIATRIC ANAESTHESIA			English	Article						paediatric intensive care; electroencephalography; sedation scores; anaesthetics : propofol; anaesthesia : depth	INTENSIVE-CARE-UNIT; EVOKED POTENTIAL INDEX; BISPECTRAL INDEX; MECHANICAL VENTILATION; CRITICALLY ILL; CONSCIOUSNESS; BLOOD; PHARMACOKINETICS; PERFORMANCE; SCALE	Background: Inadequate sedation or oversedation are common problems in Paediatric Intensive Care because of wide variations in drug response and the lack of objective tests for sedative depth. We undertook a pilot study to try to identify correlates of propofol drug concentration, electroencephalographic (EEG) variables and observed behaviour during a stepwise reduction in propofol infusion after paediatric cardiac surgery. Methods: This was a prospective pilot study with 10 children (5 months to 8 years) emerging from propofol anaesthesia following cardiac surgery with cardiopulmonary bypass (CPB). Patients underwent a stepped wake-up from propofol anaesthesia during which the propofol infusion rate was decreased from 4 mg.kg(-1).h(-1) in 1 mg.kg(-1).h(-1) steps at 30 min intervals. EEG variables, propofol blood concentrations and clinical sedation scores (COMFORT scale) were recorded during the stepped wakeup. Analgesia was maintained with a standardized continuous infusion of fentanyl. Results: Mean (SD) whole blood propofol concentrations at arousal varied considerably [973 ng.ml(-1) (SD 523 ng.ml(-1))]. The summed ratio (SR) of high frequency to low frequency bands correlated with both propofol infusion rate (R-2 value = 0.47) and propofol blood concentrations (R-2 value = 0.64). The mean SR in deeply sedated patients was significantly different from that in the 5 min prior to wakening (6.84 vs 1.55, P = 0.00002). There was no relationship between COMFORT scores and SR. Conclusions: In this group of patients receiving opioid analgesia and relatively high doses of propofol, sedation scores were unhelpful in predicting arousal. The SR correlated with propofol blood concentrations and clinical arousal and may have potential as a predictive tool for arousal in children.	Bristol Royal Hosp Children, Paediat Intens Care Unit, Bristol BS2 8BJ, Avon, England; United Bristol Hlth Care Trust, Dept Med Phys, Bristol, Avon, England; Univ Bristol, Bristol, Avon, England; Univ Plymouth, Plymouth Postgrad Med Sch, Plymouth PL4 8AA, Devon, England	Wolf, AR (reprint author), Bristol Royal Hosp Children, Paediat Intens Care Unit, Level 4,Paul Ogorman Bldg,Upper Maudlin St, Bristol BS2 8BJ, Avon, England.	awolfbch@aol.com	Rose, Rebecca J/B-7812-2011	Rigby-Jones, Ann/0000-0001-9879-3974; Murray, Deirdre/0000-0002-2201-9912			AMBUEL B, 1992, J PEDIATR PSYCHOL, V17, P95, DOI 10.1093/jpepsy/17.1.95; Bennett NR, 1999, BRIT J ANAESTH, V83, P139; Berkenbosch JW, 2002, ANESTH ANALG, V94, P506, DOI 10.1097/00000539-200203000-00006; Bonhomme V, 2000, ANESTH ANALG, V91, P1398, DOI 10.1097/00000539-200012000-00018; Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; Dawidowicz AL, 2000, BIOMED CHROMATOGR, V14, P493, DOI 10.1002/1099-0801(200011)14:7<493::AID-BMC999>3.0.CO;2-T; Degoute CS, 2001, BRIT J ANAESTH, V86, P209, DOI 10.1093/bja/86.2.209; Doi M, 1997, BRIT J ANAESTH, V78, P180; FORREST FC, 1994, BRIT J ANAESTH, V72, P35, DOI 10.1093/bja/72.1.35; JONES RDM, 1990, BRIT J ANAESTH, V65, P661, DOI 10.1093/bja/65.5.661; Kenny GNC, 1999, BRIT J ANAESTH, V83, P223, DOI 10.1093/bja/83.2.223; MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41; MARX CM, 1994, CRIT CARE MED, V22, P163, DOI 10.1097/00003246-199401000-00029; PLAYFOR SD, 2000, CARE CRIT ILL, V16, P158; Ragno G, 1997, J PHARMACEUT BIOMED, V15, P1633, DOI 10.1016/S0731-7085(96)01946-2; RAMSAY MAE, 2000, JAMA, V284; Reed MD, 1996, CRIT CARE MED, V24, P1473, DOI 10.1097/00003246-199609000-00008; Rigby-Jones AE, 2002, ANESTHESIOLOGY, V97, P1393, DOI 10.1097/00000542-200212000-00010; Schraag S, 1999, ANESTH ANALG, V89, P1311, DOI 10.1213/00000539-199911000-00045; Simmons LE, 1999, CRIT CARE MED, V27, P1499, DOI 10.1097/00003246-199908000-00016; Struys M, 1998, ANAESTHESIA, V53, P4, DOI 10.1046/j.1365-2044.1998.00279.x; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Yeganeh MH, 1997, J CHROMATOGR B, V691, P478, DOI 10.1016/S0378-4347(96)00469-0; Young C, 2000, CRIT CARE MED, V28, P854, DOI 10.1097/00003246-200003000-00041; 2001, CURRENT PROBL PHARMA, V27, P10	26	11	12	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	FEB	2004	14	2					143	151		10.1046/j.1460-9592.2003.01175.x			9	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	774PJ	WOS:000188991500005	14962330				2020-06-30	J	Leelanukrom, R; Somboonviboon, W; Bunburaphong, P; Kiatkungwanklai, P				Leelanukrom, R; Somboonviboon, W; Bunburaphong, P; Kiatkungwanklai, P			Anaesthetic experiences in three sets of conjoined twins in King Chulalongkorn Memorial Hospital	PAEDIATRIC ANAESTHESIA			English	Article						conjoined twins; anaesthesia; magnetic resonance imaging; angiography	SURGICAL SEPARATION; CRANIOPAGUS TWINS; MANAGEMENT	We describe the anaesthetic management for magnetic resonance image scanning, angiography and surgical operations in three sets of conjoined twins (ischiopagus, throracopagus and pygopagus) in King Chulalongkorn Memorial Hospital during 1996-2002. The anaesthetic technique and associated problems are summarized.	Chulalongkorn Univ, Fac Med, Dept Anesthesiol, Bangkok 10330, Thailand	Leelanukrom, R (reprint author), Chulalongkorn Univ, Fac Med, Dept Anesthesiol, Rama Rd 4, Bangkok 10330, Thailand.	fmedrll@md2.md.chula.ac.th					BALLANTINE RIW, 1964, BMJ-BRIT MED J, V1, P1339, DOI 10.1136/bmj.1.5394.1339; CHAO CC, 1980, CAN ANAESTH SOC J, V27, P565, DOI 10.1007/BF03006887; Clemessy JL, 1996, PAEDIATR ANAESTH, V6, P160, DOI 10.1111/j.1460-9592.1996.tb00385.x; DIAZ JH, 1987, ANESTHESIOLOGY, V67, P965, DOI 10.1097/00000542-198712000-00015; FURMAN EB, 1971, ANESTHESIOLOGY, V34, P95, DOI 10.1097/00000542-197101000-00026; Greenberg M, 2001, CAN J ANAESTH, V48, P478, DOI 10.1007/BF03028313; HALL KD, 1957, ANESTHESIOLOGY, V18, P908; HOYLE RM, 1990, SURG GYNECOL OBSTET, V170, P549; JAMES PD, 1985, CAN ANAESTH SOC J, V32, P402, DOI 10.1007/BF03011351; Khan ZH, 1999, SURG NEUROL, V52, P62, DOI 10.1016/S0090-3019(99)00032-4; ONEILL JA, 1998, CONJOINTED TWINS PED, V2, P1925; PENTOGALOS GE, 1984, B HIST MED, V58, P99; Spitz L, 2002, BRIT J SURG, V89, P1188, DOI 10.1046/j.1365-2168.2002.02193.x; Suan C, 1998, PAEDIATR ANAESTH, V8, P255, DOI 10.1046/j.1460-9592.1998.00722.x; SURY MRJ, 1994, EUR J ANAESTH, V11, P139; TANDAN GC, 1970, ANESTHESIOLOGY, V33, P116, DOI 10.1097/00000542-197007000-00025; TOWEY RM, 1979, ANAESTHESIA, V34, P187, DOI 10.1111/j.1365-2044.1979.tb06277.x; WONG KC, 1980, ANESTH ANALG, V59, P883	18	11	13	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	FEB	2004	14	2					176	183		10.1111/j.1460-9592.2004.01131.x			8	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	774PJ	WOS:000188991500010	14962335				2020-06-30	J	Barros, F				Barros, F			Continuous thoracic epidural analgesia with 0.2% ropivacaine for pectus excavatum repair in children	PAEDIATRIC ANAESTHESIA			English	Letter									Hosp S Joao Porto, Dept Anaesthesia & Intens Care, Oporto, Portugal	Barros, F (reprint author), Hosp S Joao Porto, Dept Anaesthesia & Intens Care, Oporto, Portugal.	mfbarros@portugalmail.pt					DALENS B, 1995, REGIONAL ANESTHESIA, P249; Engum S, 2000, J PEDIATR SURG, V35, P246, DOI 10.1016/S0022-3468(00)90018-6; Hebra A, 2000, J PEDIATR SURG, V35, P252, DOI 10.1016/S0022-3468(00)90019-8; Khalil S, 1999, ANESTHESIOLOGY, V91, P1279, DOI 10.1097/00000542-199911000-00018; MARTINEZ LC, 1998, REV ESP ANESTESIOL R, V45, P148; McBride WJ, 1996, J PEDIATR SURG, V31, P105, DOI 10.1016/S0022-3468(96)90329-2; Nuss D, 1998, J PEDIATR SURG, V33, P545, DOI 10.1016/S0022-3468(98)90314-1; Robicsek S A, 2000, Chest Surg Clin N Am, V10, P253; Saxena AK, 1999, LANGENBECK ARCH SURG, V384, P187, DOI 10.1007/s004230050190	9	2	2	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	FEB	2004	14	2					192	194		10.1111/j.1460-9592.2004.01137.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	774PJ	WOS:000188991500014	14962339				2020-06-30	J	Staats, PS; Markwitz, J; Schein, J				Staats, PS; Markwitz, J; Schein, J			Incidence of constipation associated with long-acting opioid therapy: A comparative study	SOUTHERN MEDICAL JOURNAL			English	Article						constipation; fentanyl transdermal system; morphine; controlled-release; opioid analgesics; oxycodone controlled-release	PLACEBO-CONTROLLED TRIAL; RELEASE ORAL MORPHINE; TRANSDERMAL FENTANYL; CANCER PAIN; DOUBLE-BLIND; MULTICENTER; EFFICACY; INSIGHTS	Background: Opioid therapy plays a key role in the management of chronic pain. Constipation is one of the more frequently occurring adverse effects associated with opioid therapy. Methods: A retrospective cohort design study was conducted determine the incidence of constipation in chronic pain patients who received three different long-acting opioids (transdermal fentanyl, oxycodone HCl controlled-release [CR], or morphine CR) for malignant or nonmalignant chronic pain. The data source was claims data (January 1996 through March 2001) from a 20% random sample of the California Medicaid (Medi-Cal) database. Claims data were from adult patients with chronic pain (malignant or nonmalignant) who had no prior diagnosis of constipation and no prior usage of long-acting opioids for at least 3 months before the observation period. Patients were followed for at least 3 months after the initiation of opioid therapy. ICD-9 code for diagnosis of constipation was the main outcome variable. Crude rates of constipation, annual incidence density, relative risk, and adjusted odds ratios were compared. Results: A total of 1,836 patients (601 receiving transdermal fentanyl, 721 receiving oxycodone CR, and 514 receiving morphine CR) were included in the analysis. Crude (unadjusted) rates of constipation were 3.7% for transdermal fentanyl, 6.1% for oxycodone CR, and 5.1% for morphine CR (P > 0.05). Transdermal fentanyl had a lower annual incidence density and risk of constipation than oxycodone CR and morphine CR (P > 0.05). After adjusting for confounding variables, including race and supplemental opioid use, the adjusted risk of constipation was 78% greater in the oxycodone CR group (P = 0.0337) and 44% greater in the morphine CR group (P = 0.2242) than in the transdermal fentanyl group. Conclusion: In this population, patients receiving transdermal fentanyl had a lower risk of developing constipation compared with those receiving oxycodone CR or morphine CR.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Div Pain Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Hlth Data Analyt, Princeton, NJ USA; Janssen Pharmaceut Prod LP, Titusville, NJ USA	Staats, PS (reprint author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Div Pain Med, 550 N Broadway,Suite 301, Baltimore, MD 21205 USA.	pstaats@jhmi.edu					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Caldwell JR, 1999, J RHEUMATOL, V26, P862; CAMERON JC, 1992, CANCER NURS, V15, P372; DeLuca A, 1996, PHARMACOL THERAPEUT, V69, P103, DOI 10.1016/0163-7258(95)02053-5; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; DONNER B, 1995, ANTI-CANCER DRUG, V6, P39, DOI 10.1097/00001813-199504003-00007; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; GUTSTEIN HB, 2001, GOODMAN GILMANS PHAR, P569; Maier C, 2002, PAIN, V97, P223, DOI 10.1016/S0304-3959(02)00020-9; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; Pasternak GW, 2001, LIFE SCI, V68, P2213, DOI 10.1016/S0024-3205(01)01008-6; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Robinson C B, 2000, Clin J Oncol Nurs, V4, P79	14	44	46	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0038-4348			SOUTH MED J	South.Med.J.	FEB	2004	97	2					129	134		10.1097/01.SMJ.0000109215.54052.D8			6	Medicine, General & Internal	General & Internal Medicine	831CY	WOS:000222171700005	14982259				2020-06-30	J	Dardonville, C; Jagerovic, N; Callado, LF; Meana, JJ				Dardonville, C; Jagerovic, N; Callado, LF; Meana, JJ			Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for mu-opioid receptors and I-2-imidazoline binding sites	BIOORGANIC & MEDICINAL CHEMISTRY LETTERS			English	Article						I-2-imidazoline binding site affinity; mu-opioid affinity; alane guanidine; dual acting drug; opioid tolerance; opioid withdrawal; human brain	INDUCED ANTINOCICEPTION; MORPHINE; ATTENUATION; IDAZOXAN; AGMATINE; LIGANDS; AGONIST; BRAIN; TOLERANCE; MICE	A new series of fentanyl derivatives [i.e., N-[1-(2-phenethyl)-4-piperidyl]-N-(guanidinoalkyl)propanamide] bearing aliphatic alkaneguanidinium moieties were prepared. Their affinities for the V opioid receptors and for the I-2-imidazoline binding sites (I-2-IBS) were determined on human post-mortem prefrontal cortex membranes. All of these hybrid compounds had significant and/or very high affinity for both receptors in the nanomolar range, meaning an improvement compared to the prototype N-[1-(2-phenethyl)-4-piperidyl]-N-(guanidinopropyl)propanamide previously reported. (C) 2003 Elsevier Ltd. All rights reserved.	CSIC, Inst Quim Med, E-28006 Madrid, Spain; Univ Basque Country, Dept Farmacol, E-48940 Bizkaia, Spain	Dardonville, C (reprint author), CSIC, Inst Quim Med, Juan Cierva 3, E-28006 Madrid, Spain.	dardonville@iqm.csic.es	Callado, Luis F/A-7024-2008	Callado, Luis F/0000-0001-9941-012X; , Christophe/0000-0001-5395-1932; CALLADO HERNANDO, LUIS FELIPE/0000-0002-5564-3447; MEANA, JOSE JAVIER/0000-0002-7913-6714; Jagerovic, Nadine/0000-0003-2642-6969			Aricioglu-Kartal F, 2002, LIFE SCI, V71, P1695, DOI 10.1016/S0024-3205(02)01911-2; Boronat MA, 1998, BRIT J PHARMACOL, V125, P175, DOI 10.1038/sj.bjp.0702031; Boronat MA, 1999, ANN NY ACAD SCI, V881, P359, DOI 10.1111/j.1749-6632.1999.tb09380.x; Dardonville C, 2002, BIOORGAN MED CHEM, V10, P1525, DOI 10.1016/S0968-0896(01)00420-5; ESSAWI MYH, 1990, B FAC PHARM CAIRO, V28, P11; Fairbanks CA, 2000, PAIN, V84, P13, DOI 10.1016/S0304-3959(99)00171-2; GABILONDO AM, 1994, PSYCHOPHARMACOLOGY, V115, P135, DOI 10.1007/BF02244763; MIRALLES A, 1993, J PHARMACOL EXP THER, V264, P1187; Montero A, 2002, BIOORGAN MED CHEM, V10, P1009, DOI 10.1016/S0968-0896(01)00356-X; Morgan AD, 2002, PHARMACOL BIOCHEM BE, V72, P873, DOI 10.1016/S0091-3057(02)00774-8; POSS MA, 1992, TETRAHEDRON LETT, V33, P5933, DOI 10.1016/S0040-4039(00)61092-4; Reis DJ, 2000, TRENDS PHARMACOL SCI, V21, P187, DOI 10.1016/S0165-6147(00)01460-7; Ruiz-Durantez E, 2003, BRIT J PHARMACOL, V138, P494, DOI 10.1038/sj.bjp.0705052; Sanchez-Blazquez P, 2000, BRIT J PHARMACOL, V130, P146, DOI 10.1038/sj.bjp.0703294	14	19	19	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-894X			BIOORG MED CHEM LETT	Bioorg. Med. Chem. Lett.	JAN 19	2004	14	2					491	493		10.1016/j.bmcl.2003.10.048			3	Chemistry, Medicinal; Chemistry, Organic	Pharmacology & Pharmacy; Chemistry	763UU	WOS:000188119500042	14698188				2020-06-30	J	Dagenais, C; Graff, CL; Pollack, GM				Dagenais, C; Graff, CL; Pollack, GM			Variable modulation of opioid brain uptake by P-glycoprotein in mice	BIOCHEMICAL PHARMACOLOGY			English	Article						analgesia; blood-brain barrier; efflux; opioids; permeability; P-glycoprotein	D-PENICILLAMINE(2,5) ENKEPHALIN; MULTIDRUG TRANSPORTER; MEDIATED TRANSPORT; ENDOTHELIAL-CELLS; DEFICIENT MICE; IN-VITRO; BARRIER; MORPHINE; DRUG; MDR1A	The efflux transporter P-glycoprotein (P-gp) is an important component of the blood-brain barrier (BBB) that limits accumulation of many compounds in brain. Some opioids have been shown to interact with P-gp in vitro and in vivo. Genetic or chemical disruption of P-gp has been shown to enhance the antinociceptive and/or toxic effects of some opioids, although the extent of this phenomenon has yet to be understood. The purpose of this study was to assess quantitatively the influence of mdr1a P-gp on initial brain uptake of chemically diverse opioids in mice. The brain uptake of opioids selective for the mu (fentanyl, loperamide, meperidine, methadone, and morphine), delta (deltorphin II, DPDPE, naltrindole, SNC 121) and kappa (bremazocine and U-69593) receptor subtypes was determined in P-gp-competent (wild-type) and P-gp-deficient [mdr1a(-/-)] mice with an in situ brain perfusion model. BBB permeability of the opioids varied by several orders of magnitude in both mouse strains. The difference in brain uptake between P-gp-competent and P-gp-deficient mice ranged from no detectable effect (meperidine) to greater than or equal to8-fold increase in uptake (DPDPE, loperamide, and SNC 121). In addition, loperamide efflux at the BBB was inhibited by quinidine. These results demonstrate that P-gp modulation of opioid brain uptake varies substantially within this class of compounds, regardless of receptor subtype. P-gp-mediated efflux of opioids at the BBB may influence the onset, magnitude, and duration of analgesic response. The variable influence of P-gp on opioid brain distribution may be an important issue in the context of pharmacologic pain control and drug interactions. (C) 2003 Elsevier Inc. All rights reserved.	Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA; AstraZeneca Pharmaceut LP, Drug Metabol & Pharmacokinet, Wilmington, DE 19850 USA	Pollack, GM (reprint author), Univ N Carolina, Sch Pharm, Div Drug Delivery & Disposit, Chapel Hill, NC 27599 USA.	gary_pollack@unc.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM61191]		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bouer R, 1999, FUNDAM CLIN PHARM, V13, P494, DOI 10.1111/j.1472-8206.1999.tb00009.x; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; Chen CP, 1999, PHARMACEUT RES, V16, P296, DOI 10.1023/A:1018892811980; Chen CP, 1998, J PHARMACOL EXP THER, V287, P545; CIRELLA VN, 1987, ANESTH ANALG, V66, P703; CORDONCARDO C, 1989, P NATL ACAD SCI USA, V86, P695, DOI 10.1073/pnas.86.2.695; Dagenais C, 2000, J CEREBR BLOOD F MET, V20, P381, DOI 10.1097/00004647-200002000-00020; Dagenais C, 2001, PHARMACEUT RES, V18, P957, DOI 10.1023/A:1010984110732; ECKER G, 1995, WIEN KLIN WOCHENSCHR, V107, P681; Fromm MF, 1997, PAIN, V72, P261, DOI 10.1016/S0304-3959(97)00044-4; Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084; HUANG JT, 1975, NEUROPHARMACOLOGY, V14, P241, DOI 10.1016/0028-3908(75)90012-X; Huwyler J, 1996, BRIT J PHARMACOL, V118, P1879, DOI 10.1111/j.1476-5381.1996.tb15619.x; INTURRISI CE, 1987, CLIN PHARMACOL THER, V41, P392, DOI 10.1038/clpt.1987.47; Jonker JW, 1999, BRIT J PHARMACOL, V127, P43, DOI 10.1038/sj.bjp.0702497; Koszdin KL, 2000, ANESTHESIOLOGY, V92, P156, DOI 10.1097/00000542-200001000-00027; KRISTENSEN K, 1995, LIFE SCI, V56, P45; Lang VB, 1997, J PHARM SCI-US, V86, P846, DOI 10.1021/js960387x; Letrent SP, 1999, DRUG METAB DISPOS, V27, P827; Letrent SP, 1999, BIOCHEM PHARMACOL, V58, P951, DOI 10.1016/S0006-2952(99)00180-X; Letrent SP, 1998, PHARMACEUT RES, V15, P599, DOI 10.1023/A:1011938112599; Lin JH, 2003, ADV DRUG DELIVER REV, V55, P53, DOI 10.1016/S0169-409X(02)00171-0; Lotsch J, 2000, LIFE SCI, V66, P2393, DOI 10.1016/S0024-3205(00)00569-5; Matheny CJ, 2001, PHARMACOTHERAPY, V21, P778, DOI 10.1592/phco.21.9.778.34558; MAURER PM, 1993, DRUG SAFETY, V8, P30, DOI 10.2165/00002018-199308010-00005; Mayer U, 1997, J CLIN INVEST, V100, P2430, DOI 10.1172/JCI119784; OLDENDORF WH, 1972, SCIENCE, V178, P984, DOI 10.1126/science.178.4064.984; Rao VV, 1999, P NATL ACAD SCI USA, V96, P3900, DOI 10.1073/pnas.96.7.3900; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; Sadeque AJM, 2000, CLIN PHARMACOL THER, V68, P231, DOI 10.1067/mcp.2000.109156; Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; Schinkel AH, 1997, SEMIN CANCER BIOL, V8, P161, DOI 10.1006/scbi.1997.0068; SCHINKEL AH, 1995, J CLIN INVEST, V96, P1698, DOI 10.1172/JCI118214; Thompson SJ, 2000, ANESTHESIOLOGY, V92, P1392, DOI 10.1097/00000542-200005000-00030; Walter W, 2001, BASIC CLIN PHARM, P512; Wandel C, 2002, ANESTHESIOLOGY, V96, P913, DOI 10.1097/00000542-200204000-00019; WANG C, 1975, NUCL STAT RADIOTRACE; Xie RJ, 1999, BRIT J PHARMACOL, V128, P563, DOI 10.1038/sj.bjp.0702804; Yamazaki M, 2001, J PHARMACOL EXP THER, V296, P723; Zong J, 2000, PHARMACEUT RES, V17, P749, DOI 10.1023/A:1007546719287	42	156	163	0	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952			BIOCHEM PHARMACOL	Biochem. Pharmacol.	JAN 15	2004	67	2					269	276		10.1016/j.bcp.2003.08.027			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	763KG	WOS:000188083800007	14698039				2020-06-30	J	Hansen, JJ; Ulmer, BJ; Rex, DK				Hansen, JJ; Ulmer, BJ; Rex, DK			Technical performance of colonoscopy in patients sedated with nurse-administered propofol	AMERICAN JOURNAL OF GASTROENTEROLOGY			English	Article							UPPER GASTROINTESTINAL ENDOSCOPY; CONSCIOUS SEDATION; SYNERGISTIC SEDATION; INTRAVENOUS PROPOFOL; CONTROLLED INFUSION; NATIONWIDE SURVEY; MIDAZOLAM; PREMEDICATION; SURVEILLANCE; SAFETY	OBJECTIVES: Nurse-administered propofol has gained attention as a safe and effective means of sedation for patients undergoing endoscopic procedures. However, little is known about the effect of propofol on the technical performance of colonoscopy. METHODS: Three separate studies were conducted. In the first study, we reviewed procedure notes from consecutive colonoscopies performed by a single experienced endoscopist at our hospital endoscopy unit on patients sedated with either nurse-administered propofol (n = 162) or midazolam/narcotic (n = 164). In the second study, 100 eligible colonoscopy outpatients were randomized to receive either nurse-administered propofol (n = 50) or midazolam/fentanyl (n = 50). In both studies, the measured parameters included visualization of the cecum, time required to reach the cecum, repositioning of the patient, and the application of abdominal counterpressure. In a third study, we reviewed the rate of cecal intubation and colonic perforation in the first 2357 patients in our unit receiving nurse-ad ministered propofol. RESULTS: In the retrospective comparative study, there was no difference in the cecal intubation rate in those receiving propofol (99.4%) compared to those receiving midazolam/narcotic (97%; p = 0.1), and three of five failed cecal intubations in the latter group resulted from obstructing masses. Patients sedated with propofol were repositioned less frequently compared to those receiving midazolam/narcotic (3.7% vs 26.2%) (p < 0.0001). Abdominal pressure was employed in 9.9% of patients sedated with propofol compared to 19.5% (p = 0.01) of those given midazolam/narcotic. The mean time to reach the cecum was lower in the propofol group than in the midazolam/narcotic group (4.6 min vs 6.0 min, p = 0.002). In the prospective randomized study, the endoscopist intubated the cecum in all 100 patients. Patients in the propofol group were repositioned less frequently than those in the midazolam/fentanyl group (2% vs 24%, respectively, p = 0.001). The number of cases requiring abdominal counterpressure was not significantly different between the propofol and midazolam/fentanyl groups (12% vs 24%, respectively, p = 0.1). The mean time to reach the cecum in the propofol group (3.2 min) was similar to that in the midazolam/fentanyl group (3.8 min, p = 0.08). Among the first 2357 patients in our unit undergoing colonoscopy with nurse-administered propofol, the rate of complete colonoscopy was 99.2% and there were no perforations. CONCLUSION: Nurse-administered propofol sedation is safe and simplifies the technical performance of colonoscopy compared to midazolam/narcotic sedation.	Indiana Univ, Sch Med, Div Gastroenterol, Dept Med, Bloomington, IN 47405 USA	Rex, DK (reprint author), Indiana Univ Hosp, Suite 4100,550 N Univ Blvd, Indianapolis, IN 46202 USA.						ADAM HK, 1983, BRIT J ANAESTH, V55, P97, DOI 10.1093/bja/55.2.97; AMREIN R, 1981, ARZNEIMITTEL-FORSCH, V31-2, P2202; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; BAILEY PL, 1990, ANESTHESIOLOGY, V73, P826, DOI 10.1097/00000542-199011000-00005; Bell GD, 2000, ENDOSCOPY, V32, P92; Bell GD, 2002, ENDOSCOPY, V34, P2, DOI 10.1055/s-2002-19389; Bell GD, 2000, ENDOSCOPY, V32, P264, DOI 10.1055/s-2000-97; BOLDY DAR, 1984, BRIT J ANAESTH, V56, P1109, DOI 10.1093/bja/56.10.1109; CARLSSON U, 1995, ENDOSCOPY, V27, P240, DOI 10.1055/s-2007-1005678; CARRASCO G, 1993, CHEST, V103, P557, DOI 10.1378/chest.103.2.557; CHURCH JA, 1991, GASTROINTEST ENDOSC, V37, P175, DOI 10.1016/S0016-5107(91)70680-9; Clarke AC, 2002, MED J AUSTRALIA, V176, P158, DOI 10.5694/j.1326-5377.2002.tb04345.x; DANESHMEND TK, 1991, GUT, V32, P12, DOI 10.1136/gut.32.1.12; Diab FH, 1996, AM J GASTROENTEROL, V91, P1120; FROEHLICH F, 1994, ENDOSCOPY, V26, P231, DOI 10.1055/s-2007-1008949; GAMBLE JAS, 1981, ANAESTHESIA, V36, P868, DOI 10.1111/j.1365-2044.1981.tb08859.x; GEPTS E, 1985, POSTGRAD MED J, V61, P120; Gillham MJ, 2001, GASTROINTEST ENDOSC, V54, P14, DOI 10.1067/mge.2001.116358; Graber RG, 1999, GASTROINTEST ENDOSC, V49, P803, DOI 10.1016/S0016-5107(99)70308-1; Jimenez-Perez J, 2000, GASTROINTEST ENDOSC, V51, pAB68, DOI 10.1016/S0016-5107(00)14051-9; KEEFFE E B, 1990, Gastrointestinal Endoscopy, V36, pS13; Koshy G, 2000, AM J GASTROENTEROL, V95, P1476; Kulling D, 2001, GASTROINTEST ENDOSC, V54, P1, DOI 10.1067/mge.2001.116174; Lazzaroni M, 1998, ENDOSCOPY, V30, P53, DOI 10.1055/s-2007-1001231; LO MW, 1987, EUR J CLIN PHARMACOL, V33, P297, DOI 10.1007/BF00637566; McCloy R, 1996, EUR J GASTROEN HEPAT, V8, P1233, DOI 10.1097/00042737-199612000-00019; Ng JM, 2001, GASTROINTEST ENDOSC, V54, P8, DOI 10.1067/mge.2001.116110; Paspatis GA, 2002, AM J GASTROENTEROL, V97, P1963; PATTERSON KW, 1991, BRIT J ANAESTH, V67, P108, DOI 10.1093/bja/67.1.108; Reimann FM, 2000, ENDOSCOPY, V32, P239, DOI 10.1055/s-2000-134; Rex DK, 2002, AM J GASTROENTEROL, V97, P1296, DOI 10.1016/S0002-9270(02)04168-0; Rex DK, 2002, AM J GASTROENTEROL, V97, P1159; Rex Douglas K, 2003, Rev Gastroenterol Disord, V3, P70; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; SEARLE NR, 1993, CAN J ANAESTH, V40, P730, DOI 10.1007/BF03009770; SEBEL PS, 1989, ANESTHESIOLOGY, V71, P260, DOI 10.1097/00000542-198908000-00015; Seifert H, 2000, ALIMENT PHARM THERAP, V14, P1207; Sipe BW, 2002, GASTROINTEST ENDOSC, V55, P815, DOI 10.1067/mge.2002.124636; THOMPSON DG, 1980, LANCET, V2, P469; Walker JA, 2000, GASTROINTEST ENDOSC, V51, pAB59, DOI 10.1016/S0016-5107(00)14018-0; Wehrmann T, 1999, GASTROINTEST ENDOSC, V49, P677, DOI 10.1016/S0016-5107(99)70281-6	41	48	52	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9270			AM J GASTROENTEROL	Am. J. Gastroenterol.	JAN	2004	99	1					52	56		10.1046/j.1572-0241.2003.04022.x			5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	763AV	WOS:000188047200012	14687141				2020-06-30	J	Vath, JS; Kopacz, DJ				Vath, JS; Kopacz, DJ			Spinal 2-chloroprocaine: The effect of added fentanyl	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	41st Annual Western Anesthesia Residents Conference	APR, 2003	PALO ALTO, CA				TRANSIENT NEUROLOGIC SYMPTOMS; INTRATHECAL FENTANYL; PROLONGING RECOVERY; CESAREAN DELIVERY; BUPIVACAINE; ANESTHESIA; LIDOCAINE; ANALGESIA; ENHANCEMENT; ANTAGONISM	Chloroprocaine is being investigated as a possible replacement for spinal lidocaine. Adding fentanyl to lidocaine increases the quality of spinal anesthesia without prolongation of block. We report the characteristics of 2-chloroprocaine (2-CP) spinal anesthesia with or without fentanyl in 8 volunteers receiving 40 mg 2-CP with saline or 20 mug fentanyl in a double-blinded, randomized, crossover manner. Spinal anesthesia was successful for all subjects with complete block regression, ambulation, and void by 110 min. Itching occurred in all subjects receiving fentanyl, though medication was not required. No subject reported signs of transient neurological symptoms. Peak block with fentanyl averaged T5 (T3-7) and without fentanyl T9 (L1-T4) (P = 0.005). Regression to L1 was 78 +/- 7 min with fentanyl and 53 +/- 19 min without fentanyl (P = 0.02). Tourniquet was tolerated for 51 +/- 8 min with fentanyl and for 34 +/- 14 min without fentanyl (P = 0.02). Complete regression of block occurred at 104 +/- 7 min with fentanyl and by 95 +/- 9 min without fentanyl (P = 0.02). We conclude that 2-CP spinal anesthesia provides rapid onset and adequate potency, giving it a positive profile for ambulatory surgery. The addition of fentanyl lengthens regression to L1 and tourniquet tolerance while minimally lengthening block duration.	Virginia Mason Med Ctr, Dept Anesthesiol, Seattle, WA 98101 USA	Kopacz, DJ (reprint author), Virginia Mason Clin, Dept Anesthesiol, 1100 9th Ave,B2-AN,POB 900, Seattle, WA 98111 USA.	anedjk@vmmc.org					BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; CAMANN WR, 1990, ANESTHESIOLOGY, V73, P860, DOI 10.1097/00000542-199011000-00011; Chilvers CR, 1997, ANESTH ANALG, V84, P65, DOI 10.1097/00000539-199701000-00012; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; FASSOULAKI A, 1991, BRIT J ANAESTH, V67, P437, DOI 10.1093/bja/67.4.437; FOLDES FF, 1952, ANESTHESIOLOGY, V13, P287, DOI 10.1097/00000542-195205000-00009; GISSEN AJ, 1984, [No title captured], V9, P124; GRICE SC, 1990, ANESTHESIOLOGY, V72, P623, DOI 10.1097/00000542-199004000-00008; Hodgson PS, 2000, REGION ANESTH PAIN M, V25, P218, DOI 10.1016/S1098-7339(00)90001-4; HUNTOON M, 1992, ANESTHESIOLOGY, V76, P187, DOI 10.1097/00000542-199202000-00005; Karambelkar DJ, 1997, ACTA ANAESTH SCAND, V41, P774, DOI 10.1111/j.1399-6576.1997.tb04782.x; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; PENNING JP, 1992, ANESTHESIOLOGY, V77, P1186, DOI 10.1097/00000542-199212000-00021; PETERSENFELIX S, 1993, ANESTHESIOLOGY, V79, P959, DOI 10.1097/00000542-199311000-00014; Pollock JE, 2002, REGION ANESTH PAIN M, V27, P581, DOI 10.1053/rapm.2002.36457; REUBEN SS, 1994, ANESTHESIOLOGY, V81, P1371, DOI 10.1097/00000542-199412000-00011; SARANTOPOULOS C, 1994, ANESTH ANALG, V79, P94; Siddik-Sayyid SM, 2002, ANESTH ANALG, V95, P209, DOI 10.1097/00000539-200207000-00037; VARRASSI G, 1992, ANAESTHESIA, V47, P558, DOI 10.1111/j.1365-2044.1992.tb02323.x; WANG BC, 1984, ANESTH ANALG, V63, P445; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019; Winnie AP, 2001, REGION ANESTH PAIN M, V26, P558, DOI 10.1053/rapm.2001.27169	22	23	27	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JAN	2004	98	1					89	94		10.1213/01.ANE.0000093360.02058.ED			6	Anesthesiology	Anesthesiology	757KK	WOS:000187561400022	14693593				2020-06-30	J	Aretz, S; Licht, C; Roth, B				Aretz, S; Licht, C; Roth, B			Endogenous distress in ventilated full-term newborns with acute respiratory failure	BIOLOGY OF THE NEONATE			English	Article						oxygenation index; neonatal distress; endogenous distress; analgesia; sedation; neonatal intensive care	INTENSIVE-CARE-UNIT; PERSISTENT PULMONARY-HYPERTENSION; ANALGESIA; STRESS; FENTANYL; INFANTS; PAIN; RESPONSES; SEDATION; EPIDEMIOLOGY	Objective: The main rationale behind the continuous analgesia/sedation currently practiced in the treatment of neonates with severe respiratory failure in intensive care is an attempt at shielding the sick newborn from exogenous stress and pain caused by diagnostic and therapeutic interventions. Until now, however, the factors which influence endogenous, disease-related distress have been largely ignored. Method: We retrospectively studied the daily need for analgesics and sedatives ( fentanyl, midazolam, pentobarbital, thiopental) of 40 full-term newborns with severe respiratory failure who had been ventilated for at least 48 h over an observational period of 2 - 5 days. Dosing of the analgesics and sedatives was based on a neonatal sedation score for ventilated infants. These daily amounts were converted to a normative comparative dose (analgesic/sedative need = ASN) and compared with the oxygenation index (OI) as a measure of the degree of pulmonary insufficiency. Results: Depending on the duration of ventilation, an increasingly close correlation between the ASN and the OI was detected: the index of correlation (r) was detected to be 0.65 on the second day, but increased up to 0.94 after 5 days. The subgroup of patients who had been ventilated for more than 3 days (n = 8) consistently showed a very high correlation, ranging from r = 0.86 to r = 0.94. Conclusion: Our results indicate a direct relationship between severity of pulmonary failure ( expressed as OI) and degree of disease-related distress ( reflected by ASN). This supports the hypothesis that in full-term neonates under mandatory intensive care for severe respiratory failure, endogenous distress caused by the primary disease itself, in addition to exogenous distress caused by therapeutic and diagnostic interventions, is key factor for the determination of the required amount of analgesic and sedative drugs. Copyright (C) 2004 S. Karger AG, Basel.	Univ Cologne, Childrens Hosp, Dept Neonatol, Cologne, Germany	Aretz, S (reprint author), Univ Bonn, Inst Human Genet, Wilhelmstr 31, DE-53111 Bonn, Germany.	Stefan.Aretz@ukb.uni-bonn.de	Aretz, Stefan/C-1241-2008	Aretz, Stefan/0000-0002-5228-1890			ANAND KJS, 1989, PEDIATR CLIN N AM, V36, P795; ARNOLD JH, 1992, J INTENSIVE CARE MED, V7, P244; BARKER DP, 1995, ARCH DIS CHILD-FETAL, V72, pF47, DOI 10.1136/fn.72.1.F47; BARKER DP, 1996, ARCH DIS CHILD, V75, P187; BECK R, 1986, J PEDIATR SURG, V21, P297, DOI 10.1016/S0022-3468(86)80188-9; BERGER G, 1979, THESIS U COLOGNE; CHAN JO, 1994, PEDIATR PULM, V17, P246; DESHPANDE S, 1993, CRIT CARE MED S, V21, P359; GILBERT R, 1974, AM REV RESPIR DIS, V109, P142; GRAY JE, 1992, PEDIATRICS, V90, P561; Guinsburg R, 1998, J PEDIATR-US, V132, P954, DOI 10.1016/S0022-3476(98)70390-7; GUNNAR MR, 1991, DEV PSYCHOBIOL, V24, P487, DOI 10.1002/dev.420240704; HARTWIG S, 1991, EUR J PEDIATR, V150, P784, DOI 10.1007/BF02026712; HJALMARSON O, 1981, ACTA PAEDIATR SCAND, V70, P773, DOI 10.1111/j.1651-2227.1981.tb06228.x; HUGHES D, 1987, ARCH DIS CHILD, V62, P1014, DOI 10.1136/adc.62.10.1014; Kim JJ, 1996, P NATL ACAD SCI USA, V93, P4750, DOI 10.1073/pnas.93.10.4750; LOU HC, 1994, DEV MED CHILD NEUROL, V36, P826; Menon G, 1998, SEMIN PERINATOL, V22, P417, DOI 10.1016/S0146-0005(98)80057-8; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; Patchev VK, 1997, J CLIN INVEST, V99, P962, DOI 10.1172/JCI119261; PFENNINGER J, 1991, PEDIATR PULM, V10, P18, DOI 10.1002/ppul.1950100105; POKELA ML, 1993, BIOL NEONATE, V64, P360; POUNDER DR, 1992, CAN J ANAESTH, V39, P969, DOI 10.1007/BF03008348; ROTH B, 1991, DEV PHARMACOL THERAP, V17, P121, DOI 10.1159/000457510; Rubaltelli FF, 1998, BIOL NEONATE, V74, P7, DOI 10.1159/000014005; SAPOLSKY RM, 1990, J NEUROSCI, V10, P2897, DOI 10.1523/jneurosci.10-09-02897.1990; Sasse S, 1997, KLIN PADIATR, V209, P301, DOI 10.1055/s-2008-1043968; SCHMELING DJ, 1991, JPEN-PARENTER ENTER, V15, P215, DOI 10.1177/0148607191015002215; Taddio A, 1997, LANCET, V349, P599, DOI 10.1016/S0140-6736(96)10316-0; YASTER M, 1988, J PEDIATR-US, V113, P421, DOI 10.1016/S0022-3476(88)80622-X	30	14	15	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0006-3126			BIOL NEONATE	Biol. Neonate		2004	85	4					243	248		10.1159/000076238			6	Pediatrics	Pediatrics	831FB	WOS:000222178200006	14730157				2020-06-30	J	Rundshagen, I; Schroder, T; Prichep, LS; John, ER; Kox, WJ				Rundshagen, I; Schroder, T; Prichep, LS; John, ER; Kox, WJ			Changes in cortical electrical activity during induction of anaesthesia with thiopental/fentanyl and tracheal intubation: a quantitative electroencephalographic analysis	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthesia, depth; anaesthetics i. v., thiopental; analgesics opioid, fentanyl; intubation; monitoring, electroencephalography	BISPECTRAL INDEX; NITROUS-OXIDE; EEG CHANGES; PROPOFOL; PHARMACODYNAMICS; AROUSAL; DEPTH; CONSCIOUSNESS; THIOPENTONE; ETOMIDATE	Background. There are regional differences in the effects of anaesthetics agents and perioperative stimuli on the EEG. We studied the topography of the EEG during induction of anaesthesia and intubation in patients receiving thiopental and fentanyl to document regional electrical brain activity. Methods. EEG was recorded in 25 patients in the awake state, after pre-medication, during induction, at loss of consciousness and after intubation. Eight bipolar recordings were made and the relative power of the frequency bands delta, theta, alpha, and beta were used (after z-score transformation for age) to measure changes in regional EEG activity. Results. Noxious stimulation during tracheal intubation partially reversed the slowing of the EEG caused by anaesthesia. During induction of anaesthesia alpha activity was most reduced in temporal and occipital regions. The most prominent EEG changes after intubation were an increase in alpha and a decrease in delta power (P<0.001). The largest changes were in the frontal and temporal leads for alpha and in the frontal and central leads for delta. Heart rate and arterial pressure remained constant during intubation. Conclusions. Changes in alpha and delta power were identified as the most sensitive EEG measures of regional changes in electrical brain activity during anaesthesia and noxious stimulation.	Humboldt Univ, Univ Hosp Charite, Dept Anaesthesiol, Berlin, Germany; NYU, Sch Med, Brain Res Labs, New York, NY USA	Rundshagen, I (reprint author), Humboldt Univ, Univ Hosp Charite, Dept Anaesthesiol, Campus Charite Mitte, Berlin, Germany.						Berger H., 1931, ARCH PSYCHIAT, V101, P452; Bergman IJ, 2002, ANAESTHESIA, V57, P549, DOI 10.1046/j.1365-2044.2002.02565.x; BIMAR J, 1977, ANESTHESIOLOGY, V47, P449, DOI 10.1097/00000542-197711000-00013; Bischoff P, 2000, ANESTHESIOLOGY, V92, P1545, DOI 10.1097/00000542-200006000-00010; BUHRER M, 1992, ANESTHESIOLOGY, V77, P226; DIERKS T, 1992, PHARMACOPSYCHIATRY, V25, P224, DOI 10.1055/s-2007-1014410; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; GHONEIM MM, 1977, ANESTH ANALG, V56, P479; Gugino LA, 2001, BRIT J ANAESTH, V87, P421, DOI 10.1093/bja/87.3.421; HUNG OR, 1992, ANESTHESIOLOGY, V77, P237, DOI 10.1097/00000542-199208000-00003; JOHN ER, 1987, METHODS ANAL BRAIN E, P449; Kalkman CJ, 2002, ANESTHESIOLOGY, V96, P784, DOI 10.1097/00000542-200204000-00003; Kishimoto T, 1995, CLIN PHARMACOL THER, V58, P666, DOI 10.1016/0009-9236(95)90023-3; KOCHS E, 1994, ANESTHESIOLOGY, V80, P1026, DOI 10.1097/00000542-199405000-00012; Kuizenga K, 2001, BRIT J ANAESTH, V86, P354, DOI 10.1093/bja/86.3.354; LANIER WL, 1994, ANESTHESIOLOGY, V80, P392, DOI 10.1097/00000542-199402000-00019; LINDGREN L, 1993, BRIT J ANAESTH, V70, P306, DOI 10.1093/bja/70.3.306; Schmidt GN, 2002, ANESTH ANALG, V95, P1324, DOI 10.1097/00000539-200211000-00042; Schneider G, 2002, J NEUROSURG ANESTH, V14, P7, DOI 10.1097/00008506-200201000-00002; SCHWARTZ MS, 1978, ACTA NEUROL SCAND, V57, P300, DOI 10.1111/j.1600-0404.1978.tb04504.x; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; SEBEL PS, 1981, ANESTHESIOLOGY, V55, P203, DOI 10.1097/00000542-198109000-00004; SHAFER SL, 1991, ANESTHESIOLOGY, V74, P53, DOI 10.1097/00000542-199101000-00010; WILDERSMITH OHG, 1995, BRIT J ANAESTH, V75, P441, DOI 10.1093/bja/75.4.441; ZICKMANN B, 1994, ANAESTHESIST, V43, pS59	25	14	17	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	JAN	2004	92	1					33	38		10.1093/bja/aeh020			6	Anesthesiology	Anesthesiology	753ED	WOS:000187218400008	14665550	Bronze			2020-06-30	J	Terman, GW; Jin, WZ; Cheong, YP; Lowe, J; Caron, MG; Lefkowitz, RJ; Chavkin, C				Terman, GW; Jin, WZ; Cheong, YP; Lowe, J; Caron, MG; Lefkowitz, RJ; Chavkin, C			G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						GRK3; tolerance; withdrawal; phosphorylation; opioid receptor; receptor desensitization; fentanyl; morphine	KNOCK-OUT MICE; MORPHINE-TOLERANCE; ANTINOCICEPTIVE TOLERANCE; OPIATE TOLERANCE; MOUSE STRAINS; CURRENT VIEW; DESENSITIZATION; DEPENDENCE; MECHANISMS; BETA-ARRESTIN-2	1 Tolerance to opioids frequently follows repeated drug administration and affects the clinical utility of these analgesics. Studies in simple cellular systems have demonstrated that prolonged activation of opioid receptors produces homologous receptor desensitization by G-protein receptor kinase mediated receptor phosphorylation and subsequent beta-arrestin binding. To define the role of this regulatory mechanism in the control of the electrophysiological and behavioral responses to opioids, we used mice having a targeted disruption of the G-protein receptor kinase 3 (GRK3) gene. 2 Mice lacking GRK3 did not differ from wild-type littermates neither in their response latencies to noxious stimuli on the hot-plate test nor in their acute antinociceptive responses to fentanyl or morphine. 3 Tolerance to the electrophysiological response to the opioid fentanyl, measured in vitro in the hippocampus, was blocked by GRK3 deletion. In addition, tolerance to the antinociceptive effects of fentanyl was significantly reduced in GRK3 knockouts compared to wild-type littermate controls. 4 Tolerance to the antinociceptive effects of morphine was not affected by GRK3 deletion although morphine tolerance in hippocampal slices from GRK3 knockout mice was significantly inhibited. Tolerance developed more slowly in vitro to morphine than fentanyl supporting previous work in in vitro systems showing a correlation between agonist efficacy and GRK3-mediated desensitization. 5 The results of these studies suggest that GRK3-mediated mechanisms are important components of both electrophysiologic and behavioral opioid tolerance. Fentanyl, a high efficacy opioid, more effectively produced GRK3-dependent effects than morphine, a low efficacy agonist.	Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Grad Program Neurobiol & Behav, Seattle, WA 98195 USA; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Howard Hughes Med Inst Labs, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst Labs, Durham, NC 27710 USA	Terman, GW (reprint author), Univ Washington, Sch Med, Dept Anesthesiol, Seattle, WA 98195 USA.	gwt@u.washington.edu	Chavkin, Charles/G-2797-2010		NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA011672, DA11672, P50 DA000266, R01 DA014588, R37 DA011672, DA14588, DA00266]		Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Appleyard SM, 1997, J NEUROCHEM, V69, P2405; BENOVIC JL, 1988, J BIOL CHEM, V263, P3893; Bilsky EJ, 1996, PAIN, V68, P229, DOI 10.1016/S0304-3959(96)03185-5; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 2002, J NEUROSCI, V22, P10494; Cen B, 2001, J NEUROCHEM, V76, P1887, DOI 10.1046/j.1471-4159.2001.00204.x; CROCKETT RS, 1977, PHYSIOL BEHAV, V18, P193, DOI 10.1016/0031-9384(77)90120-2; DUTTAROY A, 1995, ANESTHESIOLOGY, V82, P1226, DOI 10.1097/00000542-199505000-00018; ESPEJO EF, 1994, PHYSIOL BEHAV, V55, P1157, DOI 10.1016/0031-9384(94)90404-9; Ferguson SSG, 1996, CAN J PHYSIOL PHARM, V74, P1095, DOI 10.1139/cjpp-74-10-1095; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Fundytus ME, 1999, PAIN FORUM, V8, P3; Gintzler AR, 2000, MOL NEUROBIOL, V21, P21, DOI 10.1385/MN:21:1-2:021; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Harrison LM, 1998, PEPTIDES, V19, P1603, DOI 10.1016/S0196-9781(98)00126-0; He L, 2002, CELL, V108, P271, DOI 10.1016/S0092-8674(02)00613-X; JIN W, 2000, SOC NEUR ABSTR, V26, P636; Keith DE, 1998, MOL PHARMACOL, V53, P377; Kieffer BL, 2002, CELL, V108, P587, DOI 10.1016/S0092-8674(02)00666-9; Kim JA, 1999, J EXP PSYCHOL ANIM B, V25, P491, DOI 10.1037/0097-7403.25.4.491; Kissin I, 1996, ANESTH ANALG, V83, P600, DOI 10.1097/00000539-199609000-00029; Kolesnikov Y, 1998, J PHARMACOL EXP THER, V284, P455; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Li AH, 2001, J NEUROCHEM, V77, P435, DOI 10.1046/j.1471-4159.2001.00267.x; Liu JG, 2001, BRAIN RES REV, V38, P1, DOI 10.1016/S0165-0173(01)00057-1; Lowe JD, 2002, J BIOL CHEM, V277, P15729, DOI 10.1074/jbc.M200612200; MAO JR, 1995, PAIN, V62, P259, DOI 10.1016/0304-3959(95)00073-2; Masukawa L M, 1997, Adv Neurol, V72, P53; Mayer DJ, 1999, PAIN FORUM, V8, P14; Mitchell JM, 2000, NAT NEUROSCI, V3, P47; Mogil JS, 1996, J PHARMACOL EXP THER, V276, P532; Mogil JS, 1999, PAIN, V80, P67, DOI 10.1016/S0304-3959(98)00197-3; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Nitsche JF, 2002, J NEUROSCI, V22, P10906; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Patel MB, 2002, MOL PHARMACOL, V62, P1464, DOI 10.1124/mol.62.6.1464; Peppel K, 1997, J BIOL CHEM, V272, P25425, DOI 10.1074/jbc.272.41.25425; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Siegel S, 2000, EXP CLIN PSYCHOPHARM, V8, P276, DOI 10.1037/1064-1297.8.3.276; SIMMONS M, 1996, INT REV NEUROBIOL, P146; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; Vanderah TW, 2001, PAIN, V92, P5, DOI 10.1016/S0304-3959(01)00311-6; Varnado-Rhodes Y, 2000, P W PHARMACOL SOC, V43, P15; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1997, RECEPTOR CHANNEL, V5, P193	50	71	72	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-1188			BRIT J PHARMACOL	Br. J. Pharmacol.	JAN	2004	141	1					55	64		10.1038/sj.bjp.0705595			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	773LY	WOS:000188926300008	14662727	Green Published			2020-06-30	J	Vinch, CS; Rashkin, J; Logsetty, G; Tighe, DA; Hill, JC; Meyer, TE; Rosenthal, LS; Aurigemma, GP				Vinch, CS; Rashkin, J; Logsetty, G; Tighe, DA; Hill, JC; Meyer, TE; Rosenthal, LS; Aurigemma, GP			Brain natriuretic peptide levels fall rapidly after cardioversion of atrial fibrillation to sinus rhythm	CARDIOLOGY			English	Article						atrial fibrillation; brain natriuretic peptide; cardioversion; intravenous conscious sedation; heart failure	CONGESTIVE-HEART-FAILURE; MAZE PROCEDURE; SECRETION	Background: Brain natriuretic peptide (BNP) levels have been reported to fall following cardioversion of atrial fibrillation (AF). The mechanism for the fall in BNP has not been elucidated and the potential confounding effects of sedation have not been investigated. Sedation may alter BNP levels via its effects on loading conditions. Accordingly, we studied whether BNP levels change shortly after cardioversion and attempted to control for possible effects of sedation. Methods: BNP levels were obtained before and after cardioversion in patients with AF and in a control group of patients undergoing intravenous conscious sedation for transesophageal echocardiography. Results: BNP levels dropped (260 +/- 255 vs. 190 +/- 212 pg/ml, p < 0.05) 40 min after cardioversion, decreasing in 33 of 41 subjects who achieved sinus rhythm. By contrast, mean BNP did not fall in subjects in whom cardioversion was not successful. The change in BNP level was not related to the degree of change in heart rate. No control subject experienced a change in cardiac rhythm; BNP levels increased (195 +/- 407 vs. 238 +/- 458 pg/ml, p < 0.05) in 18/22 subjects after sedation. Baseline BNP levels were elevated in subjects with AF, and BNP levels were elevated in parallel with heart failure symptoms. Conclusions: The rapid fall in BNP after cardioversion ( 1) may reflect prompt hemodynamic improvement associated with rhythm change and ( 2) does not appear to be due to the effects of sedation. Copyright (C) 2004 S. Karger AG, Basel.	Univ Massachusetts, Med Ctr, Sch Med, Dept Med,Div Cardiol, Worcester, MA 01655 USA; Harvard Univ, Sch Med, Dept Med, Div Cardiol, Boston, MA USA	Aurigemma, GP (reprint author), Univ Massachusetts, Med Ctr, Sch Med, Dept Med,Div Cardiol, 55 Lake Ave N, Worcester, MA 01655 USA.	aurigemg@ummhc.org					Albage A, 2003, ANN THORAC SURG, V75, P790, DOI 10.1016/S0003-4975(02)04543-5; Bailey P. L., 1994, ANESTHESIA, P291; Blondheim DS, 2004, ECHOCARDIOGR-J CARD, V21, P241, DOI 10.1111/j.0742-2822.2004.03075.x; Clark DM, 1997, J AM COLL CARDIOL, V30, P1039, DOI 10.1016/S0735-1097(97)00254-4; Dao Q, 2001, J AM COLL CARDIOL, V37, P379, DOI 10.1016/S0735-1097(00)01156-6; Jourdain P, 2002, EUR J HEART FAIL, V4, P263, DOI 10.1016/S1388-9842(02)00004-1; Maeda K, 1998, AM HEART J, V135, P825, DOI 10.1016/S0002-8703(98)70041-9; MANNING WJ, 1994, J AM COLL CARDIOL, V23, P1535, DOI 10.1016/0735-1097(94)90652-1; MUKOYAMA M, 1991, J CLIN INVEST, V87, P1402, DOI 10.1172/JCI115146; Nakamura M, 1997, AM J CARDIOL, V79, P966, DOI 10.1016/S0002-9149(97)00023-4; Ohta Y, 2001, CAN J CARDIOL, V17, P415; RASHKIN JM, 2003, PACING CLIN ELECTR 2, V26, P967; REVES JG, 1994, ANESTHESIA, P247; Shinbane JS, 1997, J AM COLL CARDIOL, V29, P709, DOI 10.1016/S0735-1097(96)00592-X; Silvet H, 2003, AM J CARDIOL, V92, P1124, DOI 10.1016/j.amjcard.2003.07.010; Vinch CS, 2003, AM J CARDIOL, V91, P1140, DOI 10.1016/S0002-9149(03)00170-X; Viswanathan K, 2001, AM J CARDIOL, V88, P439, DOI 10.1016/S0002-9149(01)01699-X; YASUE H, 1994, CIRCULATION, V90, P195, DOI 10.1161/01.CIR.90.1.195; YOSHIMURA M, 1993, CIRCULATION, V87, P464, DOI 10.1161/01.CIR.87.2.464; YOSHIMURA M, 1991, CIRCULATION, V84, P1581, DOI 10.1161/01.CIR.84.4.1581	20	28	32	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0008-6312	1421-9751		CARDIOLOGY	Cardiology		2004	102	4					188	193		10.1159/000081009			6	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	861ZU	WOS:000224459500003	15452391				2020-06-30	J	Pistevou-Gompaki, K; Kouloulias, VE; Varveris, C; Mystakidou, K; Georgakopoulos, G; Eleftheriadis, N; Gompakis, N; Kouvaris, J				Pistevou-Gompaki, K; Kouloulias, VE; Varveris, C; Mystakidou, K; Georgakopoulos, G; Eleftheriadis, N; Gompakis, N; Kouvaris, J			Radiotherapy plus either transdermal fentanyl or paracetamol and codeine for painful bone metastases: a randomised study of pain relief and quality of life	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						bone metastases; Greek Brief Pain Inventory; quality of life; transdermal fentanyl	CHRONIC CANCER PAIN; MANAGEMENT	Objective: To compare the effects of providing analgesia with either transdermal fentanyl (TTS-fentanyl) or paracetamol and codeine (P/C) in addition to radiotherapy in patients with metastatic bone pain. Methods: In a prospective study, 26 patients with radiologically confirmed bony metastases received radiotherapy (R/T). They were randomised to receive either 500 mg paracetamol and 30 mg codeine four times per day (P/C group), or transdermal fentanyl patches delivering 25 mug fentanyl/h (TTS-fentanyl group). Pain was assessed using visual analogue pain ratings (VAS) and the Greek Brief Pain Inventory (G-BPI) questionnaire administered before R/T and after 3 months. Results: Data were available from 24 eligible patients. Use of TTS-fentanyl was associated with significantly superior pain relief. Mean VAS fell from 7.0 to 1.1 with TTS-fentanyl and from 8.3 to 4.3 with P/C, p < 0.01. The TTS-fentanyl group also showed significantly greater improvements of important G-BPI domains including global quality of life, pain, and physical, cognitive, and role functioning, than the P/C group (p < 0.01). Four patients receiving TTS-fentanyl and three receiving P/C reported severe nausea/vomiting. Conclusions: Transdermal fentanyl combined with R/T was more effective in reducing metastatic bone pain and resulted in greater improvements in quality of life than paracetamol and codeine.	Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Radiat Oncol Dept, Thessaloniki 57019, Greece; Arete Univ Hosp, Radiotherapy Dept, Athens, Greece; Univ Crete, Dept Radiat Oncol, Rethimnon, Greece; 6th IKA Hosp Athens, Dept Radiotherapy, Athens, Greece; Aristotle Univ Thessaloniki, Dept Pediat Clin 1, Thessaloniki, Greece	Pistevou-Gompaki, K (reprint author), Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Radiat Oncol Dept, Gigenon 2,N Mihaniona, Thessaloniki 57019, Greece.	pipinely@yahoo.com	Kouloulias, Vassilis/AAD-7348-2019	Kouloulias, Vassilis/0000-0003-2082-7323; Eleftheriadis, Nikolaos/0000-0001-5146-0937			Cherny NI, 1996, HEMATOL ONCOL CLIN N, V10, P79, DOI 10.1016/S0889-8588(05)70328-2; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Fine P G, 1997, Semin Oncol, V24, pS16; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; FORMAN S, 1984, CLIN ONCOL, V10, P5; GALASKO CSB, 1986, CLIN ORTHOP RELAT R, P18; Gralla RJ, 1999, J CLIN ONCOL, V17, P2971, DOI 10.1200/JCO.1999.17.9.2971; GROSSMAN SA, 1993, SUPPORT CARE CANCER, V1, P74, DOI 10.1007/BF00366899; Hammack JE, 1996, J PAIN SYMPTOM MANAG, V12, P234, DOI 10.1016/0885-3924(96)00191-1; HOSKIN PJ, 1995, PAIN, V63, P137, DOI 10.1016/0304-3959(95)00044-S; Janjan N A, 1998, J Cancer Educ, V13, P65; Kongsgaard UE, 1998, EUR J PAIN-LONDON, V2, P53, DOI 10.1016/S1090-3801(98)90046-5; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507; LOTE K, 1986, Acta Radiologica Oncology, V25, P227; McEwan AJB, 2000, SEMIN RADIAT ONCOL, V10, P103, DOI 10.1016/S1053-4296(00)80047-8; McQuay H J, 1997, Clin Oncol (R Coll Radiol), V9, P150, DOI 10.1016/S0936-6555(97)80070-2; Mohide E A, 1988, J Palliat Care, V4, P9; Mystakidou K, 2001, ONCOLOGY-BASEL, V60, P35, DOI 10.1159/000055294; NILSEN OS, 1986, J CLIN ONCOL, V68, P308; Payne R, 1997, CANCER, V80, P1608, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1608::AID-CNCR11>3.0.CO;2-3; Pistevou-Gombaki K, 2002, J EXP CLIN CANC RES, V21, P429; PORTENOY RK, 1989, CANCER, V63, P2298, DOI 10.1002/1097-0142(19890601)63:11<2298::AID-CNCR2820631140>3.0.CO;2-A; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Roth AJ, 1998, CANCER, V82, P1904, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1904::AID-CNCR13>3.0.CO;2-X; Siegel S., 1988, NONPARAMETRIC STAT B; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; Twycross R G, 1988, Recent Results Cancer Res, V108, P9; van Seventer R, 2003, CURR MED RES OPIN, V19, P457, DOI 10.1185/030079903125002045; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; *WHO, 1990, [No title captured], V804, P1; Yeo W, 1997, PALLIATIVE MED, V11, P233, DOI 10.1177/026921639701100308	33	10	11	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.		2004	20	2					159	163		10.1185/030079903125002829			5	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	771WD	WOS:000188808300004	15006009				2020-06-30	J	Myers, LB; Watcha, MF				Myers, LB; Watcha, MF			Epidural versus general anesthesia for twin-twin transfusion syndrome requiring fetal surgery	FETAL DIAGNOSIS AND THERAPY			English	Article						anesthesia; fetoscopic surgery; twin-twin transfusion syndrome	PLACENTAL VESSELS; OLIGOHYDRAMNIOS; POLYHYDRAMNIOS; ISOFLURANE; HALOTHANE	Objectives: This paper describes our experiences with epidural and general anesthesia for selective fetoscopic laser photocoagulation (SFLP) of placental vascular anastomoses in patients with severe twin-twin transfusion syndrome (TTTS). Methods: Retrospective review of 29 anesthetic and surgical operative records of 28 women undergoing SFLP at The Children's Hospital of Philadelphia from July 1996 to June 2001. Results: Patients with anterior placentas were more likely to receive a general anesthetic. Patients receiving an epidural anesthetic received significantly more intravenous (i.v.) crystalloid but less i.v. fentanyl than those receiving a general or combined technique. Conclusions: The advantages of general anesthesia include increased ability of the patient to tolerate extreme positions and the surgical manipulation of the uterus ( required in the technically more difficult cases), greater uterine relaxation, decreased use of i.v. fluids, but increased fentanyl requirements. Epidural anesthesia avoids the risks of failed tracheal intubation in pregnant women but may not reduce fetal responses to surgical stimuli unless the mother receives supplemental intravenous drugs. However, this may increase the risk of respiratory depression. The choice of anesthetic technique for SFLP in patients with severe TTTS must be made after careful consideration of maternal and fetal factors. Copyright (C) 2004 S. Karger AG, Basel.	Harvard Univ, Childrens Hosp, Sch Med, Dept Anesthesia, Boston, MA 02115 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA	Myers, LB (reprint author), Harvard Univ, Childrens Hosp, Sch Med, Dept Anesthesia, Bader 3,300 Longwood Ave, Boston, MA 02115 USA.	laura.myers@tch.harvard.edu					Allen MH, 2000, AORN J, V71, P801; Auroy Y, 1997, ANESTHESIOLOGY, V87, P479, DOI 10.1097/00000542-199709000-00005; BARON JF, 1986, ANESTHESIOLOGY, V64, P188, DOI 10.1097/00000542-198602000-00010; BIANCHI DW, 2000, FETOLOGY DIAGNOSIS M, P919; BIEHL DR, 1983, CAN ANAESTH SOC J, V30, P581, DOI 10.1007/BF03015226; CHESCHEIR NC, 1988, OBSTET GYNECOL, V71, P882; CINOTTA RB, 2000, ARCH DIS CHILD, V83, pF171; De Lia J, 2000, ULTRASOUND OBST GYN, V16, P210; DELIA JE, 1990, OBSTET GYNECOL, V75, P1046; DELIA JE, 1995, AM J OBSTET GYNECOL, V172, P1202, DOI 10.1016/0002-9378(95)91480-3; DiFederico EM, 1998, AM J OBSTET GYNECOL, V179, P925, DOI 10.1016/S0002-9378(98)70190-5; EKHOLM EMK, 1992, CLIN PHYSIOL, V12, P527, DOI 10.1111/j.1475-097X.1992.tb00356.x; Fauza DO, 1999, J PEDIATR SURG, V34, P540, DOI 10.1016/S0022-3468(99)90068-4; Fisk NM, 2001, ANESTHESIOLOGY, V95, P828, DOI 10.1097/00000542-200110000-00008; Galinkin JL, 2000, ANESTH ANALG, V91, P1394, DOI 10.1097/00000539-200012000-00017; Geffin B, 1998, J CLIN ANESTH, V10, P278, DOI 10.1016/S0952-8180(98)00028-2; GONSOULIN W, 1990, OBSTET GYNECOL, V75, P214; Harrison MR, 1996, AM J OBSTET GYNECOL, V174, P1255, DOI 10.1016/S0002-9378(96)70668-3; Hecher K, 1999, AM J OBSTET GYNECOL, V180, P717, DOI 10.1016/S0002-9378(99)70278-4; Hecher K, 2000, EUR J OBSTET GYN R B, V92, P135, DOI 10.1016/S0301-2115(00)00437-1; MAHONE PR, 1993, AM J OBSTET GYNECOL, V169, P166, DOI 10.1016/0002-9378(93)90155-C; Mari G, 2000, AM J OBSTET GYNECOL, V183, P211, DOI 10.1067/mob.2000.105583; Milner R, 1999, SEMIN PERINATOL, V23, P474, DOI 10.1016/S0146-0005(99)80026-3; PALAHNIUK RJ, 1974, ANESTHESIOLOGY, V41, P462, DOI 10.1097/00000542-197411000-00010; Pollard JB, 2001, ANESTH ANALG, V92, P252; Quintero RA, 2000, ULTRASOUND OBST GYN, V16, P230, DOI 10.1046/j.1469-0705.2000.00265.x; Saade GR, 1998, FETAL DIAGN THER, V13, P86, DOI 10.1159/000020812; SABIK JF, 1993, J PEDIATR SURG, V28, P542, DOI 10.1016/0022-3468(93)90613-P; Seng YC, 2000, ARCH DIS CHILD-FETAL, V83, pF168, DOI 10.1136/fn.83.3.F168; SHNIDER SM, 1999, ANESTHESIA OBSTET; Skupski DW, 2002, TWIN RES, V5, P1; Tame JD, 1999, AM J OBSTET GYNECOL, V180, P1196, DOI 10.1016/S0002-9378(99)70616-2; Ville Y, 1998, BRIT J OBSTET GYNAEC, V105, P446, DOI 10.1111/j.1471-0528.1998.tb10132.x	33	8	9	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-3837	1421-9964		FETAL DIAGN THER	Fetal Diagn. Ther.		2004	19	3					286	291		10.1159/000076713			6	Obstetrics & Gynecology	Obstetrics & Gynecology	809QD	WOS:000220650300015	15067242				2020-06-30	J	Wells, J; Paech, MJ; Evans, SF				Wells, J; Paech, MJ; Evans, SF			Intrathecal fentanyl-induced pruritus during labour: the effect of prophylactic ondansetron	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article							MORPHINE-INDUCED PRURITUS; OPIOID-INDUCED PRURITUS; CESAREAN DELIVERY; INTRAVENOUS ONDANSETRON; HYPEREMESIS GRAVIDARUM; BUPIVACAINE; ANALGESIA	Fentanyl is commonly used for spinal analgesia during labour but it is associated with a high incidence of pruritus. This randomised, double-blind, placebo-controlled study was performed to evaluate the effect of prophylactic ondansetron on the incidence and severity of pruritus among parturients receiving intrathecal fentanyl as part of combined spinal-epidural analgesia. Seventy-three women were randomised to receive either saline placebo (group P, n = 25), ondansetron 4 mg (group 04, n = 23) or ondansetron 8 mg (group 08, n = 25) intravenously before intrathecal fentanyl 25 mug and bupivacaine 2 mg. The incidence and severity of pruritus were measured using a verbal rating and a visual analogue scale, and by the requirement for rescue anti-pruritic medication (naloxone). The overall incidence of pruritus was 95% (group P 100%, group 04 95%, group 08 90%). There were no significant differences between groups for severity of pruritus or requirement for treatment (naloxone given to 45%, 28% and 35% of groups P, O4 and O8 respectively). Secondary outcomes such as the incidence of headache, pain and nausea were not significantly different between groups. We conclude that prophylactic ondansetron 4 or 8 mg intravenously was ineffective in reducing the incidence or severity of intrathecal fentanyl-induced pruritus during labour. Crown Copyright (C) 2003 Published by Elsevier Ltd. All rights reserved.	Fremantle Hosp, Dept Anaesthesia, Fremantle, WA, Australia; Univ Western Australia, King Edward Mem Hosp Women, Dept Anaesthesia & Pain Med, Perth, WA 6009, Australia; Univ Western Australia, Womens & Childrens Hlth Serv, Sch Women & Infants Hlth, Perth, WA 6009, Australia	Wells, J (reprint author), Fremantle Hosp, Dept Anaesthesia, Fremantle, WA, Australia.	jason.wells@health.wa.gov.au		PAECH, MICHAEL/0000-0001-9023-6575			Asokumar B, 1998, ANESTH ANALG, V87, P1309, DOI 10.1097/00000539-199812000-00018; BALLANTYNE JC, 1988, PAIN, V33, P149, DOI 10.1016/0304-3959(88)90085-1; Borgeat A, 1999, ANESTHESIOLOGY, V90, P432, DOI 10.1097/00000542-199902000-00017; Charuluxananan S, 2000, REGION ANESTH PAIN M, V25, P535, DOI 10.1053/rapm.2000.7809; Dimitriou V, 1999, BRIT J ANAESTH, V83, P822; Gurkan Y, 2002, ANESTH ANALG, V95, P1763, DOI 10.1213/01.ANE.0000033097.30674.02; Harnett MJP, 2003, ANESTHESIOLOGY, V98, P64; Kam PCA, 1996, ANAESTHESIA, V51, P1133, DOI 10.1111/j.1365-2044.1996.tb15050.x; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046/j.0265-0215.2000.00826.x; Kyriakides K, 1999, BRIT J ANAESTH, V82, P439, DOI 10.1093/bja/82.3.439; Morales R, 1998, J COMP NEUROL, V402, P385; NELSON KE, 1996, ANESTHESIOLOGY 2002, P1070; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097/00000542-199902000-00018; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Palmer CM, 1999, ANESTHESIOLOGY, V91, P84, DOI 10.1097/00000542-199907000-00015; Shah MK, 2000, ANAESTHESIA, V55, P1008, DOI 10.1046/j.1365-2044.2000.01618-2.x; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; Sullivan CA, 1996, AM J OBSTET GYNECOL, V174, P1565, DOI 10.1016/S0002-9378(96)70607-5; Tincello DG, 1996, POSTGRAD MED J, V72, P688, DOI 10.1136/pgmj.72.853.688; WAHLGREN CF, 1995, SEMIN DERMATOL, V14, P277, DOI 10.1016/S1085-5629(05)80048-3; Wilde MI, 1996, DRUGS, V52, P773, DOI 10.2165/00003495-199652050-00010; Yazigi A, 2002, J CLIN ANESTH, V14, P183, DOI 10.1016/S0952-8180(01)00381-6; Yeh HM, 2000, ANESTH ANALG, V91, P172, DOI 10.1097/00000539-200007000-00032	23	20	22	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2004	13	1					35	39		10.1016/j.ijoa.2003.07.001			5	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	764WG	WOS:000188228500008	15321438				2020-06-30	J	Scicluna, JK; Alderson, JD; Webster, VJ; Whiting, P				Scicluna, JK; Alderson, JD; Webster, VJ; Whiting, P			Epidural analgesia for acute symphysis pubis dysfunction in the second trimester	INTERNATIONAL JOURNAL OF OBSTETRIC ANESTHESIA			English	Article							PREGNANCY; SEPARATION	We report a case of severe symphysis pubis dysfunction in a parturient during her second trimester of a twin pregnancy. Symphysis pubis dysfunction produces pain, instability and limitation of mobility and function, of the symphysis pubis during pregnancy and labour. It is often under-treated. We provided lumbar epidural analgesia with intermittent top-ups of bupivacaine 0.1% with fentanyl 2 mug/mL for 72 h. This provided initial analgesia, breaking a vicious cycle of pain and muscle spasm. The benefits extended into the remainder of her pregnancy. Subsequently, simple analgesics and physiotherapy allowed control of pain until vaginal delivery 15 weeks later. (C) 2003 Elsevier Ltd. All rights reserved.	Royal Hallamshire Hosp, Dept Anaesthesia, Sheffield S10 2JF, S Yorkshire, England	Webster, VJ (reprint author), Royal Hallamshire Hosp, Dept Anaesthesia, Jessop Wing, Sheffield S10 2JF, S Yorkshire, England.	vicky.webster@sth.nhs.uk	Corteling, Shavonne/A-8424-2012				[Anonymous], 2001, WHY MOTHERS DIE 1997; Davidson MR, 1996, J NURSE-MIDWIFERY, V41, P259, DOI 10.1016/0091-2182(95)00071-2; FULLER JG, 1989, OBSTET GYNECOL, V73, P855; Kristiansson P, 1996, AM J OBSTET GYNECOL, V175, P1342, DOI 10.1016/S0002-9378(96)70052-2; KUBITZ RL, 1986, SOUTHERN MED J, V79, P578, DOI 10.1097/00007611-198605000-00014; LUGER EJ, 1995, J TRAUMA, V38, P255, DOI 10.1097/00005373-199502000-00021; SCRIVEN MW, 1995, J BONE JOINT SURG AM, V77, P1465, DOI 10.2106/00004623-199509000-00025; Shepherd J, 1996, Midwives (1995), V109, P199; Shepherd J, 2000, PAIN CHILDBEARING KE, P17; Snow R E, 1997, Obstet Gynecol Surv, V52, P438, DOI 10.1097/00006254-199707000-00023; WILLIAMS JW, 1966, WILLIAMS OBSTETRICS, P820	11	10	13	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0959-289X	1532-3374		INT J OBSTET ANESTH	Int. J. Obstet. Anesth.	JAN	2004	13	1					50	52		10.1016/j.ijoa.2003.08.006			3	Anesthesiology; Obstetrics & Gynecology	Anesthesiology; Obstetrics & Gynecology	764WG	WOS:000188228500012	15321442				2020-06-30	J	Naganobu, K; Maeda, N; Miyamoto, T; Hagio, M; Nakamura, T; Takasaki, M				Naganobu, K; Maeda, N; Miyamoto, T; Hagio, M; Nakamura, T; Takasaki, M			Cardiorespiratory effects of epidural administration of morphine and fentanyl in dogs anesthetized with sevoflurane	JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article							ADMINISTERED MORPHINE; BUPIVACAINE; ANALGESIA; COMBINATION; SUFENTANIL; ANESTHESIA; HALOTHANE; CATS	Objective-To determine the cardiorespiratory effects of epidural administration of morphine alone and in combination with fentanyl in dogs anesthetized with sevoflurane. Design-Prospective study. Animals-6 dogs. Procedure-Dogs were anesthetized with sevoflurane and allowed to breathe spontaneously. After a stable plane of anesthesia was achieved, morphine (0.1 mg/kg [0.045 mg/lb]) or a combination of morphine and fentanyl (10 mug/kg [4.5 mug/lb) was administered through an epidural catheter, the tip of which was positioned at the level of L6 or L7. Cardiorespiratory variables were measured for 90 minutes. Results-Epidural administration of morphine alone did not cause any significant changes in cardiorespiratory measurements. However, epidural administration of morphine and fentanyl induced significant decreases in diastolic and mean arterial blood pressures and total peripheral resistance. Stroke volume was unchanged, PaCO2 was significantly increased, and arterial pH and base excess were significantly decreased. Heart rate was significantly lower after epidural administration of morphine and fentanyl than after administration of morphine alone. None of the dogs had any evidence of urine retention, vomiting, or pruritus after recovery from anesthesia. Conclusions and Clinical Relevance-Results suggest that epidural administration of morphine at a dose of 0.1 mg/kg in combination with fentanyl at a dose of 10 mug/kg can cause cardiorespiratory depression in dogs anesthetized with sevoflurane.	Miyazaki Univ, Fac Agr, Vet Teaching Hosp, Miyazaki 8892192, Japan; Miyazaki Med Coll, Dept Anesthesiol, Miyazaki 8891692, Japan	Naganobu, K (reprint author), Miyazaki Univ, Fac Agr, Vet Teaching Hosp, Miyazaki 8892192, Japan.						Bailey P. L., 1994, ANESTHESIA, P291; DOBROMYLSKYJ P, 2000, PAIN MANAGEMENT ANIM, P81; DUKE T, 1994, VET SURG, V23, P149, DOI 10.1111/j.1532-950X.1994.tb00460.x; DURANT PAC, 1986, ANESTH ANALG, V65, P583; GISSEN AJ, 1987, ANESTH ANALG, V66, P1272; Goodarzi M, 2001, ANESTH ANALG, V93, P456, DOI 10.1097/00000539-200108000-00043; HANSEN B, 2000, KIRKS CURRENT VET TH, V13, P126; Hansen B. D., 2001, Journal of Veterinary Emergency and Critical Care, V11, P95, DOI 10.1111/j.1476-4431.2001.tb00075.x; HARDIE EM, 1998, CURRENT TECHNIQUES S, P3; Hendrix PK, 1996, J AM VET MED ASSOC, V209, P598; JUSTINS DM, 1983, ANAESTHESIA, V38, P937, DOI 10.1111/j.1365-2044.1983.tb12022.x; KEEGAN RD, 1995, AM J VET RES, V56, P496; NEGRE I, 1987, ANESTH ANALG, V66, P707; PASCOE PJ, 1993, VET SURG, V22, P141, DOI 10.1111/j.1532-950X.1993.tb01689.x; Popilskis S., 1993, Journal of Veterinary Anaesthesia, V20, P21; ROTHE CF, 1990, CAN J PHYSIOL PHARM, V68, P384, DOI 10.1139/y90-054; Skarda RT, 1996, LUMB JONES VET ANEST, P426; STEFFEY EP, 1974, AM J VET RES, V35, P1289; Tanaka M, 1997, CAN J ANAESTH, V44, P1047, DOI 10.1007/BF03019225; Troncy E, 2002, J AM VET MED ASSOC, V221, P666, DOI 10.2460/javma.2002.221.666; VALVERDE A, 1992, J VET PHARMACOL THER, V15, P91, DOI 10.1111/j.1365-2885.1992.tb00991.x; VALVERDE A, 1991, AM J VET RES, V52, P505; WHITE DA, 1990, ANESTH ANALG, V71, P29	23	13	13	0	0	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488			JAVMA-J AM VET MED A	JAVMA-J. Am. Vet. Med. Assoc.	JAN 1	2004	224	1					67	70		10.2460/javma.2004.224.67			4	Veterinary Sciences	Veterinary Sciences	802BM	WOS:000220139000014	14710878				2020-06-30	J	Grund, F; Tjomsland, O; Sjaastad, I; Ilebekk, A; Kirkeboen, KA				Grund, F; Tjomsland, O; Sjaastad, I; Ilebekk, A; Kirkeboen, KA			Pentobarbital versus medetomidine-ketamine-fentanyl anaesthesia: effects on haemodynamics and the incidence of ischaemia-induced ventricular fibrillation in swine	LABORATORY ANIMALS			English	Article						anaesthesia; arrhythmias; fentanyl; haemodynamics; ischaemia; ketamine; pentobarbital; swine; ventricular fibrillation	CORONARY-ARTERY OCCLUSION; ALPHA-CHLORALOSE; PIGS; DOGS; SODIUM; SIZE; VULNERABILITY; TACHYCARDIA; ARRHYTHMIAS; MYOCARDIUM	The present study was performed to compare haemodynamic variables at baseline and the incidence of ventricular fibrillation during the early phase of ischaemia in swine during pentobarbital or medetomidine-ketamine-fentanyl anaesthesia. Twenty-two swine (mean +/- SD: 29 +/- 3 kg) were anaesthetized with sodium pentobarbital (induction with 36 mg/kg intraperitoneally, and maintenance with 5-20 mg/kg/h intravenously [i.v.]) and 6 swine (27 3 kg) were anaesthetized with ketamine and fentanyl (premedicated with medetomidine 0.1 mg/kg and ketamine 10 mg/kg intramuscularly, induction with ketamine 20 mg/kg and fentanyl 0.025 mg/kg i.v., and maintenance with ketamine 20 mg/kg/h and fentanyl 0.025 mg/kg/h i.v.). After a stabilization period of 30 min, the left anterior descending coronary artery (LAD) was occluded for 10 min. Haemodynamic data and occurrence of ventricular fibrillation were recorded. The ischaemic area was measured by fluorescing microspheres. Swine anaesthetized with medetomidine-ketamine-fentanyl had significantly lower heart rate, myocardial contractility, peak left ventricular pressure, arterial blood pressure, aortic blood flow, myocardial blood flow and cardiac index at baseline, than swine anaesthetized with pentobarbital. Whereas none of the swine anaesthetized with pentobarbital fibrillated during the LAD occlusion, ventricular fibrillation occurred in 83% of the animals anaesthetized with medetomidine-ketamine-fentanyl (P < 0.001). No significant difference was found in size of ischaemic area between the two groups. Thus, we show a depression in haemodynamic variables at baseline and a higher incidence of ventricular fibrillation during the early phase of ischaemia in swine anaesthetized with medetomidine-ketamine-fentanyl compared to swine anaesthetized with pentobarbital.	Univ Oslo, Expt Med Res Inst, N-0316 Oslo, Norway; Ullevaal Univ Hosp, Dept Cardiovasc Surg, Oslo, Norway; Ullevaal Univ Hosp, Dept Anaesthesia, Oslo, Norway	Grund, F (reprint author), Ulven, N-2372 Brottum, Norway.	frank.grund@c2i.net					BAILIE MD, 1979, J PHARMACOL EXP THER, V208, P298; BARDAJI A, 1990, CARDIOVASC RES, V24, P227, DOI 10.1093/cvr/24.3.227; BOGETZ M S, 1982, Anesthesiology (Hagerstown), V57, pA29, DOI 10.1097/00000542-198209001-00029; Boschert K, 1996, LAB ANIM, V30, P209, DOI 10.1258/002367796780684863; Braunwald E., 1997, HEART DIS TXB CARDIO, P640; Cullen LK, 1996, BRIT VET J, V152, P519, DOI 10.1016/S0007-1935(96)80005-4; DAWSON AK, 1980, AM J PHYSIOL, V239, pH427; DONG E, 1967, SURGERY, V61, P602; Grund F, 1999, J MOL CELL CARDIOL, V31, P1369, DOI 10.1006/jmcc.1999.0971; Grund F, 1997, J MOL CELL CARDIOL, V29, P3067, DOI 10.1006/jmcc.1997.0521; HADDAD LM, 1998, CLIN MANAGEMENT POIS, P521; HAESSLER R, 1994, CARDIOVASC RES, V28, P1574, DOI 10.1093/cvr/28.10.1574; HANNON JP, 1990, LAB ANIM SCI, V40, P293; HOFFMEISTER F S, 1958, Surg Forum, V9, P242; HOLZGREFE HH, 1987, LAB ANIM SCI, V37, P587; HUNT GB, 1988, CIRCULATION, V78, P221, DOI 10.1161/01.CIR.78.1.221; Ilkiw JE, 1999, CLIN TECH SMALL AN P, V14, P27, DOI 10.1016/S1096-2867(99)80024-3; Jasani MS, 1997, RESUSCITATION, V35, P69, DOI 10.1016/S0300-9572(96)01094-5; Kirby DA, 1997, PHYSIOL BEHAV, V61, P145, DOI 10.1016/S0031-9384(96)00320-4; LAFORET EG, 1958, AM J PHYSIOL, V189, P596; MANDERS WT, 1976, CIRC RES, V39, P512, DOI 10.1161/01.RES.39.4.512; Mortensen Elin, 1993, Journal of Basic and Clinical Physiology and Pharmacology, V4, P313; Mouritzen CV, 1966, J THORAC CARDIOVASC, V51, P579; NAMBA T, 1994, CARDIOVASC RES, V28, P557, DOI 10.1093/cvr/28.4.557; NATTEL S, 1990, AM J PHYSIOL, V259, pH1743; OLICHNEY M, 1958, FED PROC, P401; PICH S, 1988, BASIC RES CARDIOL, V83, P550, DOI 10.1007/BF01906684; PRIANO LL, 1969, J PHARMACOL EXP THER, V165, P126; RATH DP, 1995, CIRCULATION, V91, P471, DOI 10.1161/01.CIR.91.2.471; RUSY BF, 1987, ANESTHESIOLOGY, V67, P745; SAWYER DC, 1971, J APPL PHYSIOL, V30, P36; Sedlis S P, 1992, Cardiovasc Clin, V22, P3; SKINNER JE, 1975, CIRCULATION, V51, P656, DOI 10.1161/01.CIR.51.4.656; Smith A.C., 1997, AM COLL LAB, P313; Swindle M M, 1988, J Invest Surg, V1, P65, DOI 10.3109/08941938809141077; SWINDLE MM, 1994, RES ANIMAL ANESTHESI, P107; THURMON JC, 1986, SWINE CARDIOVASCULAR, P39; Tjomsland O, 2000, J CARDIOVASC SURG, V41, P675; Trevor AJ, 1998, BASIC CLIN PHARM, P409; VAINIO OM, 1992, LAB ANIM SCI, V42, P582; VERDOUW PD, 1986, CARDIOVASC RES, P126; VONMUTIUS S, 1988, BASIC RES CARDIOL, V83, P94; WAINWRIGHT CL, 1993, CARDIOVASC RES, V27, P84, DOI 10.1093/cvr/27.1.84; WHITE FC, 1981, BASIC RES CARDIOL, V76, P189, DOI 10.1007/BF01907957; YOSHIDA S, 1986, Canadian Journal of Cardiology, V2, P295	45	16	18	0	2	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND	0023-6772			LAB ANIM-UK	Lab. Anim.	JAN	2004	38	1					70	78		10.1258/00236770460734425			9	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	764CA	WOS:000188172800010	14979991	Bronze			2020-06-30	J	McDowell, TS				McDowell, TS			Exogenous nerve growth factor attenuates opioid-induced inhibition of voltage-activated Ba2+ currents in rat sensory neurons	NEUROSCIENCE			English	Article						neurotrophins; DRG neurons; G proteins; patch clamp	BETA-GAMMA-SUBUNITS; PROTEIN-KINASE-C; ROOT GANGLION NEURONS; DEPENDENT CALCIUM-CHANNELS; CAPSAICIN-EVOKED RELEASE; GTP-BINDING PROTEIN; SYMPATHETIC NEURONS; CA2+ CHANNELS; ADULT-RAT; INFLAMMATION INCREASES	Nerve growth factor (NGF) promotes the survival of embryonic sensory neurons and maintains the phenotypic characteristics of primary nociceptive neurons postnatally. NGF also contributes to nociceptor activation and hyperalgesia during inflammatory pain states. The purpose of this study was to determine whether NGF might have an additional pronociceptive action by interfering with opioidmediated analgesia in primary nociceptive neurons. Sensory neurons were isolated from the dorsal root ganglia of weanling rats and kept in standard culture conditions either with or without exogenous NGF (50 ng/ml). Currents through voltage-gated calcium channels were recorded from individual neurons using the whole cell patch clamp technique with Ba2+ as the charge carrier (I-Ba). The mu-opioid agonist fentanyl (1 muM) and the GABA(B) agonist baclofen (50 muM) were used to test G protein-dependent inhibition of I-Ba. Fentanyl inhibited I-Ba by an average of 38 +/- 4% in untreated cells vs. 25 +/- 2% in NGF-treated cells (P<0.01). NGF had no effect on I-Ba current magnitude or kinetics. The NGF-induced attenuation of opiold action was observed as early as 4 h after exposure, but was not seen when NGF was applied by bath perfusion for up to 40 min, suggesting that the effect was not mediated by a rapid phosphorylation event. The effect of NGF was prevented by K-252a (100 nM), an inhibitor of TrkA autophosphorylation. Baclofen-induced inhibition of I-Ba, on the other hand, was not affected by NGF treatment, suggesting that NGF modulation of opioid-mediated inhibition occurred upstream from the G protein. This was supported by the finding that GTP-gamma-S, an agonist independent G protein activator, inhibited I-Ba similarly in both untreated and NGF treated cells. The results show that NGF selectively attenuated opioidmediated inhibition of I-Ba via TrkA receptor activation, possibly by altering opioid receptor function. (C) 2004 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Wisconsin, Sch Med, Dept Anesthesiol, Madison, WI 53792 USA	McDowell, TS (reprint author), Univ Wisconsin, Sch Med, Dept Anesthesiol, B6-319 Clin Sci Ctr,600 Highland Ave, Madison, WI 53792 USA.	tsmcdowe@wisc.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K08 GM064672, K08 GM064672-01, K08 GM64672-01]		AIMONE LD, 1989, PEPTIDES, V10, P1127, DOI 10.1016/0196-9781(89)90003-X; Barrett CF, 2000, J GEN PHYSIOL, V115, P277, DOI 10.1085/jgp.115.3.277; Bennett DLH, 1998, EUR J NEUROSCI, V10, P1282, DOI 10.1046/j.1460-9568.1998.00139.x; BERG MM, 1992, J BIOL CHEM, V267, P13; Borgland SL, 2001, J PHYSIOL-LONDON, V536, P35, DOI 10.1111/j.1469-7793.2001.t01-1-00035.x; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Delmas P, 1998, J PHYSIOL-LONDON, V506, P319, DOI 10.1111/j.1469-7793.1998.319bw.x; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; Fitzgerald EM, 1997, EUR J NEUROSCI, V9, P1252, DOI 10.1111/j.1460-9568.1997.tb01480.x; Fitzgerald EM, 2000, J PHYSIOL-LONDON, V527, P433, DOI 10.1111/j.1469-7793.2000.00433.x; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Jia M, 1999, J NEUROPHYSIOL, V82, P2847; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3269, DOI 10.1073/pnas.95.6.3269; Kajikawa Y, 2001, P NATL ACAD SCI USA, V98, P8054, DOI 10.1073/pnas.141031298; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; King APJ, 1999, J PHARMACOL EXP THER, V289, P312; Koltzenburg M, 1999, EUR J NEUROSCI, V11, P1698, DOI 10.1046/j.1460-9568.1999.00590.x; Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389; Lei S, 1997, J NEUROPHYSIOL, V78, P3359; LESSER SS, 1995, J NEUROSCI, V15, P253; LEVINE ES, 1995, J NEUROSCI, V15, P3084; LEWIN GR, 1993, J NEUROSCI, V13, P2136; LEWIN GR, 1994, J NEUROPHYSIOL, V71, P941; MACDONALD RL, 1978, SCIENCE, V199, P1449, DOI 10.1126/science.204015; McDowell TS, 2003, ANESTHESIOLOGY, V98, P223, DOI 10.1097/00000542-200301000-00034; MCMAHON SB, 1995, NAT MED, V1, P774, DOI 10.1038/nm0895-774; Mendell LM, 1999, MICROSC RES TECHNIQ, V45, P252, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<252::AID-JEMT9>3.0.CO;2-N; MENONJOHANSSON AS, 1993, PFLUG ARCH EUR J PHY, V425, P335, DOI 10.1007/BF00374184; Miller FD, 2001, NEURON, V32, P767, DOI 10.1016/S0896-6273(01)00529-3; MOISES HC, 1994, J NEUROSCI, V14, P3842; Molliver DC, 1997, J COMP NEUROL, V381, P428, DOI 10.1002/(SICI)1096-9861(19970519)381:4<428::AID-CNE3>3.0.CO;2-4; Nicholas RS, 1999, NEUROSCIENCE, V91, P1425, DOI 10.1016/S0306-4522(98)00706-4; Patel TD, 2000, NEURON, V25, P345, DOI 10.1016/S0896-6273(00)80899-5; RITTER AM, 1991, NATURE, V350, P500, DOI 10.1038/350500a0; Rueff A, 1996, J NEUROPHYSIOL, V76, P3593; Sawynok J, 2003, PHARMACOL REV, V55, P1, DOI 10.1124/pr.55.1.1; Schmidt H, 2000, J NEUROCHEM, V74, P414, DOI 10.1046/j.1471-4159.2000.0740414.x; Shu X, 2001, J NEUROPHYSIOL, V86, P2931; Stucky CL, 1999, J NEUROSCI, V19, P8509; Stucky CL, 1999, J NEUROSCI, V19, P6497; SWARTZ KJ, 1993, NEURON, V11, P305, DOI 10.1016/0896-6273(93)90186-U; Tan M, 2003, J NEUROSCI, V23, P10292; UEDA M, 1995, NEUROPHARMACOLOGY, V34, P303, DOI 10.1016/0028-3908(94)00160-T; WESKAMP G, 1987, J NEUROCHEM, V48, P1779, DOI 10.1111/j.1471-4159.1987.tb05736.x; Wildering WC, 1995, J NEUROPHYSIOL, V74, P2778; WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2; Xie W, 1999, P NATL ACAD SCI USA, V96, P10385, DOI 10.1073/pnas.96.18.10385; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035; ZHU Y, 1994, J NEUROPHYSIOL, V72, P1549; Zhu Y, 1997, J NEUROPHYSIOL, V78, P780	54	8	8	1	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2004	125	4					1029	1037		10.1016/j.neuroscience.2004.03.009			9	Neurosciences	Neurosciences & Neurology	824IF	WOS:000221679300020	15120862	Green Accepted			2020-06-30	J	Mercadante, S				Mercadante, S			Cancer pain management in children	PALLIATIVE MEDICINE			English	Review						cancer pain; children; opioids; procedural pain; regional anaesthesia; spinal opioids	PATIENT-CONTROLLED ANALGESIA; PEDIATRIC ONCOLOGY PATIENTS; NURSE-CONTROLLED ANALGESIA; PALLIATIVE CARE; TRANSDERMAL FENTANYL; GENERAL-ANESTHESIA; MEDICAL PROCEDURES; CHILDHOOD-CANCER; REFRACTORY PAIN; MORPHINE	Unrelieved pain may have a major impact on the care of children with cancer. The type and severity of pain experienced by children with cancer varies from acute, procedure-related pain to progressive chronic pain associated with the progression of the disease or sequelae of treatment. Drugs are the mainstay of treatment. Regular pain assessments combined with appropriate analgesic administration at regular dosing intervals, adjunctive drug therapy for control of adverse effects and associated symptoms, and nonpharmacological interventions are recommended. Although standard dosing of opioids adequately treats most cancer pain in children, more complex treatment is required by a significant group. Strategies to improve analgesia include the use of epidural or intrathecal infusions of a combination of opioids and other adjuvants, or other regional anaesthesia techniques. Procedure- and treatment-related pain is an even greater problem than cancer pain. Recommendations have been published with regard to the monitoring and personnel required when children are sedated which aim to set the standard of care and minimize both physical discomfort or pain and negative psychological responses, by providing analgesia; and to maximize the potential for amnesia; and to control behaviour.	La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, I-90146 Palermo, Italy	Mercadante, S (reprint author), La Maddalena Canc Ctr, Pain Relief & Palliat Care Unit, Cia San Lorenzo 312, I-90146 Palermo, Italy.	terapiadeldolore@la-maddalena.it					Abbott K, 1995, J PAIN SYMPTOM MANAG, V10, P584, DOI 10.1016/0885-3924(95)00086-0; Aram L, 2001, ANESTH ANALG, V92, P1432; Babul N, 1993, J Palliat Care, V9, P19; BERDE C, 1990, Pediatrics, V86, P818; BERDE CB, 1989, PAIN, V36, P219, DOI 10.1016/0304-3959(89)90026-2; BERDE CB, 1990, PEDIATRICS, V86, P779; BERDE CB, 1990, ANESTHESIOLOGY, V72, P1094, DOI 10.1097/00000542-199006000-00025; BLOUNT RL, 1994, BEHAV MODIF, V18, P6, DOI 10.1177/01454455940181002; Calamandrei M, 1996, REGION ANESTH, V21, P557; Colcanap O, 1996, ARCH PEDIATRIE, V3, P1032, DOI 10.1016/0929-693X(96)81728-3; Collins JJ, 1996, J PEDIATR-US, V129, P722, DOI 10.1016/S0022-3476(96)70156-7; Collins JJ, 2001, EUR J PAIN-LONDON, V5, P37, DOI 10.1053/eujp.2001.0278; COLLINS JJ, 1995, PAIN, V63, P271, DOI 10.1016/0304-3959(95)00094-9; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Collins JJ, 1996, PAIN, V65, P63, DOI 10.1016/0304-3959(95)00193-X; COLLINS JJ, 1995, J PEDIATR-US, V126, P653, DOI 10.1016/S0022-3476(95)70370-5; COOPER MG, 1994, J PAIN SYMPTOM MANAG, V9, P277, DOI 10.1016/0885-3924(94)90106-6; DAMPIER CD, 1995, J PEDIATR-US, V126, P461, DOI 10.1016/S0022-3476(95)70472-8; Duval M, 2000, ARCH PEDIATRIE, V7, P474, DOI 10.1016/S0929-693X(00)89002-8; ELLIOTT SC, 1991, CLIN J PAIN, V7, P263, DOI 10.1097/00002508-199112000-00003; Fernandez Navarro J M, 2000, An Esp Pediatr, V52, P41; Ferrell B R, 1994, Cancer Pract, V2, P441; Ferrell B R, 1994, J Pediatr Nurs, V9, P368; GOLDMAN A, 1991, BRIT MED BULL, V47, P676, DOI 10.1093/oxfordjournals.bmb.a072500; Hain RDW, 2001, ARCH DIS CHILD, V85, P12, DOI 10.1136/adc.85.1.12; Heger S, 1999, BRIT MED J, V319, P627, DOI 10.1136/bmj.319.7210.627; Hunt A, 1999, J PEDIATR-US, V135, P47, DOI 10.1016/S0022-3476(99)70326-4; Hunt A, 2001, PALLIATIVE MED, V15, P405, DOI 10.1191/026921601680419456; JAJABOSE S, 2001, J PEDIAT HEMATOL ONC, V23, P290; JAY S, 1995, PAIN, V62, P3, DOI 10.1016/0304-3959(94)00216-2; Jones PD, 1996, J PEDIATR-US, V128, P864, DOI 10.1016/S0022-3476(96)70348-7; Kanagasundaram SA, 1997, J PAEDIATR CHILD H, V33, P352, DOI 10.1111/j.1440-1754.1997.tb01616.x; Kart T, 1997, PAEDIATR ANAESTH, V7, P93; Kasai Hiroko, 1995, Japanese Journal of Anesthesiology, V44, P885; Kopecky EA, 1997, J PALLIATIVE CARE, V13, P28, DOI 10.1177/082585979701300405; KOREN G, 1989, PEDIATR CLIN N AM, V36, P1141; Leahy S, 1994, Cancer Pract, V2, P37; Liossi C, 1999, INT J CLIN EXP HYP, V47, P104, DOI 10.1080/00207149908410025; Ljungman G, 1999, ACTA PAEDIATR, V88, P623, DOI 10.1080/08035259950169279; Ljungman G, 2000, PEDIATR HEMAT ONCOL, V17, P211, DOI 10.1080/088800100276389; Ljungman G, 2001, MED PEDIATR ONCOL, V36, P372, DOI 10.1002/mpo.1088; LJUNGMAN G, 1996, PAIN, V88, P623; Lundeberg S, 1996, ACTA ANAESTH SCAND, V40, P445, DOI 10.1111/j.1399-6576.1996.tb04467.x; MANNE SL, 1990, J CONSULT CLIN PSYCH, V58, P565, DOI 10.1037/0022-006X.58.5.565; McDonald AJ, 2001, PEDIATR DRUGS, V3, P273, DOI 10.2165/00128072-200103040-00004; MCGRATH P J, 1990, Pediatrics, V86, P814; McGrath P. J., 1995, PAIN CLIN UPDATES, VIII, P1; McGrath PA, 1996, J PAIN SYMPTOM MANAG, V12, P87, DOI 10.1016/0885-3924(96)00099-1; Meignier M, 1992, Cah Anesthesiol, V40, P487; MERCADANTE S, 2000, RIV ITAL CURE PALLIA, V2, P85; MISER AW, 1987, PAIN, V29, P73, DOI 10.1016/0304-3959(87)90180-1; MISER AW, 1994, J PAIN SYMPTOM MANAG, V9, P259, DOI 10.1016/0885-3924(94)90103-1; Mollet A, 1999, ARCH PEDIATRIE, V6, P477, DOI 10.1016/S0929-693X(99)80234-6; Noyes M, 2001, Am J Hosp Palliat Care, V18, P411, DOI 10.1177/104990910101800612; OLNESS K, 1981, AM J PEDIAT HEMATOL, V3, P313; Parker RI, 1997, PEDIATRICS, V99, P427, DOI 10.1542/peds.99.3.427; Paut O, 2000, ANAESTHESIA, V55, P1202, DOI 10.1046/j.1365-2044.2000.01615-3.x; Pellier I, 1999, PAEDIATR ANAESTH, V9, P61, DOI 10.1046/j.1460-9592.1999.00280.x; PFEFFERBAUM B, 1990, J AM ACAD CHILD PSY, V29, P642, DOI 10.1097/00004583-199007000-00020; PICHARDLEANDRI E, 1995, REV MED INTERNE, V16, P708, DOI 10.1016/0248-8663(96)80776-4; PLANCARTE R, 1991, J PAIN SYMPTOM MANAG, V6, P98, DOI 10.1016/0885-3924(91)90524-8; Portas M, 1998, ARCH PEDIATRIE, V5, P851, DOI 10.1016/S0929-693X(98)80125-5; POULAIN P, 1993, EUR J PALLIAT CARE, V1, P31; Queinnec MC, 1999, PAIN, V83, P383, DOI 10.1016/S0304-3959(99)00092-5; Sabatowski R, 2002, J PAIN SYMPTOM MANAG, V23, P3, DOI 10.1016/S0885-3924(01)00389-X; SANDLER ES, 1992, PEDIATRICS, V89, P631; SCHECHTER NL, 1990, ADV PAIN RES THER, V15, P209; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; Schmidt K, 1994, J Pediatr Oncol Nurs, V11, P4, DOI 10.1177/104345429401100103; Shir Yoram, 1998, Harefuah, V134, P438; Sirkia K, 1998, J PAIN SYMPTOM MANAG, V15, P220, DOI 10.1016/S0885-3924(98)00366-2; Smith JT, 1996, J COUNS PSYCHOL, V43, P187, DOI 10.1037/0022-0167.43.2.187; STAATS PS, 1995, J PAIN SYMPTOM MANAG, V10, P321, DOI 10.1016/0885-3924(95)00014-P; Steif B L, 1989, J Pain Symptom Manage, V4, P191, DOI 10.1016/0885-3924(89)90042-0; STEVENS MM, 1994, CANCER SURV, V21, P211; Tobias JD, 2000, PAEDIATR ANAESTH, V10, P367, DOI 10.1046/j.1460-9592.2000.00499.x; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; Wagner HP, 1997, ANN NY ACAD SCI, V824, P193, DOI 10.1111/j.1749-6632.1997.tb46222.x; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147; WELDON BC, 1993, CLIN J PAIN, V9, P26, DOI 10.1097/00002508-199303000-00004; Wolfe J, 2000, NEW ENGL J MED, V342, P326, DOI 10.1056/NEJM200002033420506; Yaster Myron, 2001, Indian Journal of Pediatrics, V68, P749, DOI 10.1007/BF02752416; YEE JD, 1994, J PAIN SYMPTOM MANAG, V9, P122, DOI 10.1016/0885-3924(94)90165-1; Yeh CH, 1999, J ADV NURS, V30, P193, DOI 10.1046/j.1365-2648.1999.01064.x; ZELTZER L, 1982, J PEDIATR-US, V101, P1032; Zernikow B, 2001, MED PEDIATR ONCOL, V36, P451, DOI 10.1002/mpo.1109	86	24	26	0	8	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163	1477-030X		PALLIATIVE MED	Palliat. Med.		2004	18	7					654	662		10.1191/0269216304pm945rr			9	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	867UK	WOS:000224867800012	15540676				2020-06-30	J	Botterman, J; De Meester, C; Eeckhaut, K				Botterman, J; De Meester, C; Eeckhaut, K			Transdermal fentanyl: caution in the use of high doses	PALLIATIVE MEDICINE			English	Letter							MORPHINE		St Lucas Hosp, Dept Oncol, Palliat Care Unit, B-9000 Ghent, Belgium	Botterman, J (reprint author), St Lucas Hosp, Dept Oncol, Palliat Care Unit, B-9000 Ghent, Belgium.	j_botterman@hotmail.com					Cherny N, 2001, J CLIN ONCOL, V19, P2542, DOI 10.1200/JCO.2001.19.9.2542; Davies A, 1997, PALLIATIVE MED, V11, P168; FEELY J, 1990, BRIT MED J, V300, P22, DOI 10.1136/bmj.300.6716.22; McLoughlin R, 1997, PALLIATIVE MED, V11, P419; McNamara P, 2002, PALLIATIVE MED, V16, P425, DOI 10.1191/0269216302pm536oa; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296	6	1	1	0	0	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.		2004	18	7					663	663		10.1191/0269216304pm915xx			1	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	867UK	WOS:000224867800013	15540677				2020-06-30	J	Hanks, GW; Nugent, M; Higgs, CMB; Busch, MA				Hanks, GW; Nugent, M; Higgs, CMB; Busch, MA			Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study	PALLIATIVE MEDICINE			English	Article						breakthrough pain; open multicentre study; OTFC	MORPHINE; TRIAL	Sixty-six patients with cancer-related pain entered an open multicentre study to examine the safety and efficacy of oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain. Patients were eligible for the study if they were stabilized on a long-acting opioid but were experiencing up to four episodes of breakthrough pain a day and achieving at least partial relief from breakthrough pain using conventional medication ( normal release oral morphine in the majority of patients). The efficacy of the conventional medication was documented in a run-in phase and patients then changed to OTFC. All patients were treated initially with a 200 mcg unit of OTFC and the dose was increased if necessary to a level that produced relief of breakthrough pain without troublesome adverse effects. Fifty-eight patients completed the run-in phase using their usual medication and entered the dose titration phase with OTFC and 57 patients received at least one dose of OTFC. Forty-two patients (72%) found a successful dose of OTFC. The primary outcome measures were the Summed Pain Intensity Differences (SPID) and Total Pain Relief (TOTPAR) scores at 60 min. There was a significant difference in both measures in favour of OTFC compared with conventional medication in these patients. Twenty-eight of the 42 patients (67%) preferred OTFC to their usual medication. The most common adverse effects attributed to OTFC were nausea, stomatitis, vomiting and dizziness but there were no unpredicted or severe problems. Thirty-seven patients continued into the long-term study and 12 of these completed six months treatment. Most drop-outs in this phase were associated with progression of the underlying disease. No patient stopped using OTFC because of dissatisfaction with the drug. OTFC appears to be a safe and effective treatment for breakthrough pain in cancer patients and may have advantages over currently available opioid formulations.	Univ Bristol, Bristol Haematol & Oncol Ctr, Bristol BS2 8ED, Avon, England; St Lukes Hospice, Plymouth, Devon, England; Anesta Corp, Salt Lake City, UT USA	Hanks, GW (reprint author), Univ Bristol, Bristol Haematol & Oncol Ctr, Horfield Rd, Bristol BS2 8ED, Avon, England.	Debbie.Ashby@bristol.ac.uk					Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Christie JM, 1998, J CLIN ONCOL, V16, P3238, DOI 10.1200/JCO.1998.16.10.3238; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Farrar JT, 1998, JNCI-J NATL CANCER I, V90, P611, DOI 10.1093/jnci/90.8.611; Lichtor JL, 1999, ANESTH ANALG, V89, P732, DOI 10.1097/00000539-199909000-00038; POCOCK SH, 2000, NEW ENGL J MED, V342, P1887; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, PAIN, V79, P303, DOI 10.1016/S0304-3959(98)00179-1; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Sykes J, 1997, BRIT MED J, V315, P867, DOI 10.1136/bmj.315.7112.867	10	42	43	0	1	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0269-2163	1477-030X		PALLIATIVE MED	Palliat. Med.		2004	18	8					698	704		10.1191/0269216304pm966oa			7	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	881KB	WOS:000225865300005	15623166				2020-06-30	J	Wakonigg, G; Sturm, K; Saria, A; Zernig, G				Wakonigg, G; Sturm, K; Saria, A; Zernig, G			Drug history overrides opioid reinforcement in a rat runway procedure	PHARMACOLOGY			English	Article						drug history; runway; morphine; remifentanil; food; Sprague-Dawley rats	NUCLEUS-ACCUMBENS; RHESUS-MONKEYS; COCAINE; MORPHINE; BEHAVIOR; NAIVE	To determine the effect of the drug history of rats on their subsequent operant behaviour in the rat runway procedure, we tested the mu opioid receptor agonists morphine and remifentanil and found a carryover of previous drug/ saline experience that was not found for a food reinforcer. Previous exposure to saline significantly decreased the apparent reinforcing effect of subsequently offered morphine or remifentanil, while previous experience with morphine or remifentanil significantly increased responding for saline. This carryover of a previous learning experience on subsequent operant performance in the rat runway procedure cautions that the drug history should be considered and might even invalidate subsequent findings when testing drugs of abuse or other reinforcers. Copyright (C) 2004 S. Karger AG, Basel.	Med Univ Innsbruck, Div Neurochem, Dept Psychiat, AT-6020 Innsbruck, Austria	Zernig, G (reprint author), Med Univ Innsbruck, Div Neurochem, Dept Psychiat, Anichstr 35, AT-6020 Innsbruck, Austria.	gerald.zernig@uibk.ac.at					Ahmed SH, 1998, SCIENCE, V282, P298, DOI 10.1126/science.282.5387.298; COMER SD, 1993, J PHARMACOL EXP THER, V267, P1470; Crespo JA, 2003, MOL BRAIN RES, V117, P160, DOI 10.1016/s0169-328X(03)00316-4; EMMETTOGLESBY MW, 1993, DRUG ALCOHOL DEPEN, V32, P247, DOI 10.1016/0376-8716(93)90089-9; Ettenberg A, 2003, PSYCHOPHARMACOLOGY, V168, P139, DOI 10.1007/s00213-002-1266-0; Geist TD, 1997, PHARMACOL BIOCHEM BE, V57, P145, DOI 10.1016/S0091-3057(96)00300-0; GEIST TD, 1990, PHARMACOL BIOCHEM BE, V36, P703, DOI 10.1016/0091-3057(90)90278-P; Grimes JA, 2001, J EXP ANAL BEHAV, V76, P179, DOI 10.1901/jeab.2001.76-179; HURD YL, 1989, BRAIN RES, V498, P199, DOI 10.1016/0006-8993(89)90422-8; Justinova Z, 2003, PSYCHOPHARMACOLOGY, V169, P135, DOI 10.1007/s00213-003-1484-0; Mets B, 1998, P NATL ACAD SCI USA, V95, P10176, DOI 10.1073/pnas.95.17.10176; Mierzejewski P, 2003, POL J PHARMACOL, V55, P713; Morgan D, 2002, BEHAV PHARMACOL, V13, P389, DOI 10.1097/00008877-200209000-00012; NADER MA, 1994, PSYCHOPHARMACOLOGY, V115, P53, DOI 10.1007/BF02244751; Oittinen H, 2001, PHARMACOLOGY, V62, P124, DOI 10.1159/000056083; Ratzenboeck E, 2001, PHARMACOLOGY, V62, P138, DOI 10.1159/000056086; Sahraei H, 2004, PHARMACOL BIOCHEM BE, V77, P111, DOI 10.1016/j.pbb.2003.10.008; SCHUSTER CR, 1981, NEUROSCI BIOBEHAV R, V5, P315, DOI 10.1016/0149-7634(81)90026-9; Wakionigg G, 2003, PHARMACOLOGY, V69, P180, DOI 10.1159/000073661; Wakonigg G, 2003, PSYCHOPHARMACOLOGY, V169, P52, DOI 10.1007/s00213-003-1488-9; WEEKS JR, 1978, PHARMACOL BIOCHEM BE, V9, P703, DOI 10.1016/0091-3057(78)90225-3; WISE RA, 1995, PSYCHOPHARMACOLOGY, V120, P10, DOI 10.1007/BF02246140; Wojnicki FHE, 1996, PSYCHOPHARMACOLOGY, V123, P34, DOI 10.1007/BF02246278; WOODS JH, 1980, DRUG ALCOHOL DEPEN, V5, P223, DOI 10.1016/0376-8716(80)90182-9; WOOLVERTON WL, 1978, PHARMACOL BIOCHEM BE, V9, P327, DOI 10.1016/0091-3057(78)90293-9; Zapata A, 2003, EUR J NEUROSCI, V17, P590, DOI 10.1046/j.1460-9568.2003.02491.x	26	5	5	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0031-7012	1423-0313		PHARMACOLOGY	Pharmacology		2004	72	4					225	230		10.1159/000080377			6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	868EX	WOS:000224898000003	15539882				2020-06-30	J	Sur, RL; Borboroglu, PG; Roberts, JL; Amling, CL				Sur, RL; Borboroglu, PG; Roberts, JL; Amling, CL			A prospective randomized comparison of extensive prostate biopsy to standard biopsy with assessment of diagnostic yield, biopsy pain and morbidity	PROSTATE CANCER AND PROSTATIC DISEASES			English	Article						prostate biopsy; anesthesia	LOCAL-ANESTHESIA; SEXTANT; LIDOCAINE	In a prospective randomized study, we compare standard prostate biopsy to extensive biopsy utilizing intravenous conscious sedation (IVCS). Initial biopsy patients (n = 197) were randomized to either standard biopsy using intrarectal lidocaine gel (6-12 biopsies, mean 10.1) or extensive biopsy (24 biopsies) using IVCS. Cancer detection and urinary symptoms were no different between groups. However, biopsy pain was rated significantly lower and satisfaction significantly higher in the extensive biopsy group. Temporary urinary retention occurred in 4% of the extensive biopsy group. Extended biopsy with 24 samples does not improve cancer detection compared to standard biopsy when 10 cores are obtained. Extensive biopsy is very well tolerated and associated with less pain and more satisfaction than standard biopsy.	Naval Med Ctr San Diego, Dept Urol, San Diego, CA 92134 USA	Amling, CL (reprint author), Naval Med Ctr San Diego, Dept Urol, 34800 Bob Wilson Dr, San Diego, CA 92134 USA.	clamling@nmcsd.med.navy.mil					Alavi AS, 2001, J UROLOGY, V166, P1343, DOI 10.1016/S0022-5347(05)65765-5; Babaian RJ, 2000, J UROLOGY, V163, P152, DOI 10.1016/S0022-5347(05)67993-1; Borboroglu PG, 2000, J UROLOGY, V163, P158, DOI 10.1016/S0022-5347(05)67994-3; Chang SS, 2001, J UROLOGY, V166, P2178, DOI 10.1016/S0022-5347(05)65529-2; Davis M, 2002, J UROLOGY, V167, P566, DOI 10.1016/S0022-5347(01)69087-6; Eskew LA, 1997, J UROLOGY, V157, P199, DOI 10.1016/S0022-5347(01)65322-9; Gore JL, 2001, J UROLOGY, V165, P1554, DOI 10.1016/S0022-5347(05)66347-1; HODGE KK, 1989, J UROLOGY, V142, P71, DOI 10.1016/S0022-5347(17)38664-0; Karakiewicz PI, 1997, UROLOGY, V49, P55, DOI 10.1016/S0090-4295(96)00360-3; Leibovici D, 2002, J UROLOGY, V167, P563, DOI 10.1016/S0022-5347(01)69086-4; Levine MA, 1998, J UROLOGY, V159, P471, DOI 10.1016/S0022-5347(01)63951-X; Naughton CK, 2000, J UROLOGY, V164, P388, DOI 10.1016/S0022-5347(05)67367-3; Norberg M, 1997, UROLOGY, V50, P562, DOI 10.1016/S0090-4295(97)00306-3; Presti JC, 2000, J UROLOGY, V163, P163, DOI 10.1016/S0022-5347(05)67995-5; Presti JC, 2003, J UROLOGY, V169, P125, DOI 10.1016/S0022-5347(05)64051-7; Rabbani F, 1998, J UROLOGY, V159, P1247, DOI 10.1016/S0022-5347(01)63574-2; Stewart CS, 2001, J UROLOGY, V166, P86, DOI 10.1016/S0022-5347(05)66083-1	17	8	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1365-7852	1476-5608		PROSTATE CANCER P D	Prostate Cancer Prostatic Dis.		2004	7	2					126	131		10.1038/sj.pcan.4500713			6	Oncology; Urology & Nephrology	Oncology; Urology & Nephrology	837TM	WOS:000222663200008	15111980	Bronze			2020-06-30	J	Graff, GR; Stark, JM; Grueber, R				Graff, GR; Stark, JM; Grueber, R			Nebulized fentanyl for palliation of dyspnea in a cystic fibrosis patient	RESPIRATION			English	Article						cystic fibrosis; dyspnea; fentanyl	INHALED MORPHINE; LUNG	Dyspnea, the subjective symptom feeling of breathlessness, is a common symptom in terminally ill patients with cystic fibrosis (CF). The palliation of the dyspnea is a reasonable goal to improve patient comfort as the progression of the disease worsens. We report the successful use of inhaled fentanyl for 3 days in a 17-year-old female with terminal CF lung disease, as measured by improved oxygenation and a reduction in the modified Borg score, and the subjective feeling of less air hunger reported by parents and patient. Copyright (C) 2004 S. Karger AG, Basel.	Penn State Milton S Hershey Med Ctr, Penn State Coll Med, Dept Pediat, Hershey, PA 17033 USA; Univ Missouri Hlth Care, Dept Resp Therapy, Columbia, MO USA; Univ Missouri Hlth Care, Dept Mol Microbiol & Child Hlth, Columbia, MO USA	Graff, GR (reprint author), Penn State Milton S Hershey Med Ctr, Penn State Coll Med, Dept Pediat, H085,500 Univ Dr, Hershey, PA 17033 USA.	ggraff@psu.edu					BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Cabot PJ, 2001, CLIN EXP PHARMACOL P, V28, P230, DOI 10.1046/j.1440-1681.2001.03425.x; CHRUBASIK J, 1988, BRIT J ANAESTH, V61, P228, DOI 10.1093/bja/61.2.228; Cohen SP, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e38; Coyne PJ, 2002, J PAIN SYMPTOM MANAG, V23, P157, DOI 10.1016/S0885-3924(01)00391-8; Janahi IA, 2000, PEDIATR PULM, V30, P257, DOI 10.1002/1099-0496(200009)30:3<257::AID-PPUL10>3.0.CO;2-R; Jennings AL, 2001, COCHRANE DB SYST REV, V4; KACMAREK RM, 1991, CHEST, V100, P1104, DOI 10.1378/chest.100.4.1104; Lang E, 1998, CAN J ANAESTH, V45, P60, DOI 10.1007/BF03011995; Manning H L, 2000, Respir Care, V45, P1342; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; MESTIRI M, 1991, EUR J CLIN PHARMACOL, V41, P621, DOI 10.1007/BF00314998; Robinson WM, 1997, PEDIATRICS, V100, P205, DOI 10.1542/peds.100.2.205; SATO H, 1988, BIOCHEM PHARMACOL, V37, P2273; Zebraski SE, 2000, LIFE SCI, V66, P2221, DOI 10.1016/S0024-3205(00)00434-3	15	21	21	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0025-7931			RESPIRATION	Respiration		2004	71	6					646	649		10.1159/000081769			4	Respiratory System	Respiratory System	883XB	WOS:000226047900020	15627879				2020-06-30	J	Tobias, JD; Del Campo, L; Kenter, K; Groeper, K; Gray, B; Edwards, J				Tobias, JD; Del Campo, L; Kenter, K; Groeper, K; Gray, B; Edwards, J			Changes in transcutaneous carbon dioxide, oxygen saturation, and respiratory rate after interscalene block	SOUTHERN MEDICAL JOURNAL			English	Article						brachial plexus anesthesia; hypercarbia; interscalene anesthesia; regional anesthesia; transcutaneous carbon dioxide monitoring	BRACHIAL-PLEXUS BLOCK; HEMIDIAPHRAGMATIC PARESIS; PULMONARY-FUNCTION	Background: We used transcutaneous (TC) carbon dioxide (CO,) monitoring to prospectively evaluate changes in respiratory status after interscalene anesthesia in 45 adults (40 Successful and 5 unsuccessful blocks). Methods: TC-CO2 oxygen saturation and respiratory rate were recorded every minute for 5 minutes before block and every 2 minutes for a total of 30 minutes (15 data sets) after injection of the local anesthetic solution. Results: After successful block, TC-CO2 increased from 41 +/- 5 mm Ha to a maximum value of 44 +/- 6 mm Hg (P < 0.0001) and the respiratory rate increased from 14 +/- 2 breaths/min to a maximum of 20 +/- 4 breaths/min (P < 0.001). The increase in TC-CO2 was greater than or equal to5 mm Hg in 11 patients and greater than or equal to10 mm Hg in 4 patients, with a maximum increase of 12 mm Hg. Of the 600 TC-CO2 data points recorded (15 each from the 40 patients with a successful block), 62 (10.3%) showed a TC-CO2 value of 50 mm Hg or greater, with a maximum value of 5 7 mm Hg. No significant change in TC-CO2 or respirator), rate was seen in the five patients with unsuccessful block. Conclusion: After interscalene blockade, we found an increase in respiratory rate and hypercarbia that resulted in no clinically significant effect.	Univ Missouri, Dept Anesthesiol, Columbia, MO 65212 USA; Univ Missouri, Dept Orthoped Surg, Columbia, MO 65212 USA; Univ Missouri, Dept Child Hlth, Columbia, MO 65212 USA	Tobias, JD (reprint author), Univ Missouri, Dept Anesthesiol, 3W40H,1 Hosp Dr, Columbia, MO 65212 USA.	tobiasj@health.missouri.edu					Berkenbosch JW, 2001, ANESTH ANALG, V92, P1427; McBride DS, 2002, SOUTHERN MED J, V95, P870; PERE P, 1993, REGION ANESTH, V18, P93; PERE P, 1992, ACTA ANAESTH SCAND, V36, P53, DOI 10.1111/j.1399-6576.1992.tb03421.x; URMEY WF, 1992, ANESTH ANALG, V74, P352; URMEY WF, 1993, REGION ANESTH, V18, P244; URMEY WF, 1991, ANESTH ANALG, V72, P498	7	1	1	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0038-4348	1541-8243		SOUTH MED J	South.Med.J.	JAN	2004	97	1					21	24		10.1097/01.SMJ.0000054425.08030.B0			4	Medicine, General & Internal	General & Internal Medicine	831CV	WOS:000222171400006	14746417				2020-06-30	S	Pace, MC; Aurilio, C; Bulletti, C; Iannotti, M; Passavanti, MB; Palagiano, A		Bulleti, C; DeZiegler, D; Flamigni, C		Pace, MC; Aurilio, C; Bulletti, C; Iannotti, M; Passavanti, MB; Palagiano, A			Subarachnoid analgesia in advanced labor - A comparison of subarachnoid analgesia and pudendal block in advanced labor: Analgesic quality and obstetric outcome	UTERUS AND HUMAN REPRODUCTION	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	5th Conference on the Uterus and Human Reproduction	JUN 03-05, 2004	Marignano, ITALY	Italian Minist Educ, Higher Educ & Res, Italian Minist Hlth, Alma Mater Studiorum, Univ Bologna		subarachnoid analgesia; pudendal block; advanced labor; labor analgesia	REGIONAL ANALGESIA; SPINAL ANALGESIA; BUPIVACAINE; SUFENTANIL; FENTANYL; ANESTHESIA; CLONIDINE; RELIEF	Pain control during labor is a primary objective of antalgic therapy. The use of the peridural as an elective procedure for labor analgesia is now corroborated by the international scientific community. Sometimes a combined spinal-peridural procedure is used together with the intratbecal administration of opioids to also cover the first stage of labor. Unfortunately, patients and/or gynecologists often request analgesia in a late stage of labor. The aim of our study was to evaluate the possibility of using a subarachnoid block alone for labor analgesia when this is requested at a late stage, that is, in advanced labor with cervical dilation greater than 7 cm. After approval by our ethics committee and the written and informed consent of the patients, 111 women were enrolled in this study and randomly divided into two groups. The first group (Group S: 55 patients) received a subarachnoid block with 2.5 mg hyperbaric bupivacaine + 25 mu g fentanyl + 1 mL 10% glucose. A pudendal nerve block with 7 mL 2% mepivacaine in each side was administered to the second group (Group P: 56 patients). In both groups, careful maternal-fetal monitoring was conducted, and pain was scored on a numerical scale from 0 to 4, 10 minutes after placement of the block (time [T] 0), at delivery (T1), and at episiorrhaphy (T2). In all patients, we recorded any side effects, the Apgar score at birth and after 5 minutes, the administration of other analgesic and/or sedative drugs, the degree of satisfaction, and the time of hospitalization after delivery. Evaluations were performed by anesthesiologists unaware of patients' treatment group. The duration of spinal analgesia was considered to be the time from injection of study drugs to the time of the patient's first request for additional analgesia. In no cases were there any side effects worthy of note, and hospitalization never exceeded 72 hours. The Apgar score was always between 7 and 10. All except one of the women in Group S were satisfied or more than satisfied with their pain management, whereas 50 women in Group P expressed only moderate satisfaction or dissatisfaction (P < 0.0001). In most patients in Group S, complete analgesia was obtained. In Group P, however, 10 minutes after placement of the pudendal nerve block, 40 patients reported no improvement in pain symptomatology during contractions and only 16 reported less painful contractions (P < 0.0001). The duration of spinal analgesia (128 +/- 38 minutes) was enough in most cases for delivery to be completed. These results suggest that low-dose bupivacaine-fentanyl spinal analgesia represents an important option for pain relief in late labor, not the least because the procedure does not upset the dynamics of delivery or alter vital parameters and is welcomed by women in labor who are still able to collaborate actively in the birth of their baby.	Univ Naples 2, Dept Anaesthet Surg & Emergency Sci, Naples, Italy; Riminis Hosp, Unit Physiopathol Reprod, Bologna, Italy; Univ Bologna, Bologna, Italy; Mauro Scarlato Hosp, Unit Anaesthesia & Resuscitat, Scafati, Italy; Univ Naples 2, Dept Obstet Gynecol & Reprod Sci, Naples, Italy	Pace, MC (reprint author), Via Eldorado 13, I-80132 Naples, Italy.	caterina.pace@libero.it	Pace, Maria Caterina/L-5452-2016	Pace, Maria Caterina/0000-0002-9352-4780			*AM SOC AN, 1909, ANESTHESIOLOGY, V90, P600; Bergeret S, 2000, ANN FR ANESTH, V19, P530; D'Angelo R, 2001, ANESTH ANALG, V93, P1560, DOI 10.1097/00000539-200112000-00048; Eriksson SL, 2003, EUR J OBSTET GYN R B, V110, P131, DOI 10.1016/S0301-2115(03)00049-6; Macarthur A, 1999, CAN J ANAESTH, V46, pR111, DOI 10.1007/BF03013187; Meuser T, 1997, ANAESTHESIST, V46, P532, DOI 10.1007/s001010050434; Nelson KE, 2002, ANESTHESIOLOGY, V96, P1070, DOI 10.1097/00000542-200205000-00007; Nickells JS, 2000, ANAESTHESIA, V55, P17, DOI 10.1046/j.1365-2044.2000.01071.x; Paech MJ, 2002, ANESTH ANALG, V95, P1396, DOI 10.1097/00000539-200211000-00054; Parry MG, 1998, ANAESTHESIA, V53, P382, DOI 10.1046/j.1365-2044.1998.00295.x; Pollard JB, 2003, BRIT J ANAESTH, V90, P525, DOI 10.1093/bja/aeg546; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; Teoh WHL, 2003, ANESTH ANALG, V97, P873, DOI 10.1213/01.ANE.0000076388.17223.37; Tetzschner T, 1997, ACTA OBSTET GYN SCAN, V76, P324, DOI 10.1111/j.1600-0412.1997.tb07986.x; Thallon A, 2001, CURR OPIN OBSTET GYN, V13, P583, DOI 10.1097/00001703-200112000-00006; Yeh HM, 2001, ANESTH ANALG, V92, P665, DOI 10.1097/00000539-200103000-00022	16	14	15	0	5	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-536-2; 1-57331-535-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2004	1034						356	363		10.1196/annals.1335.037			8	Multidisciplinary Sciences; Obstetrics & Gynecology; Reproductive Biology	Science & Technology - Other Topics; Obstetrics & Gynecology; Reproductive Biology	BBW46	WOS:000228130100031	15731325				2020-06-30	J	Statler, KD; Janesko, KL; Melick, JA; Clark, RSB; Jenkins, LW; Kochanek, PM				Statler, KD; Janesko, KL; Melick, JA; Clark, RSB; Jenkins, LW; Kochanek, PM			Hyperglycolysis is exacerbated after traumatic brain injury with fentanyl vs. isoflurane anesthesia in rats	BRAIN RESEARCH			English	Article						head injury; excitotoxicity; sedation; narcotics; metabolism	CEREBRAL BLOOD-FLOW; TOXICITY IN-VIVO; GLUCOSE-UTILIZATION; INTRACRANIAL-PRESSURE; PENTOBARBITAL REDUCE; AEROBIC GLYCOLYSIS; FOREBRAIN ISCHEMIA; INDUCED SEIZURES; AMINO-ACIDS; HIPPOCAMPAL	Despite common use of narcotics in the clinical management of severe traumatic brain injury (TBI), in experimental models rats treated with fentanyl have exhibited worse functional outcome and more CA1 hippocampal death than rats treated with standard isoflurane anesthesia. We hypothesized that greater post-traumatic excitotoxicity, reflected by cerebral glucose utilization (CMRglu), may account for detrimental effects of fentanyl vs. isoflurane. Rats were anesthetized with either isoflurane (1% by inhalation) or fentanyl (10 mcg/kg iv bolus then 50 mcg/kg/h infusion). C-14-deoxyglucose autoradiography was performed 45 min after controlled cortical impact (CCI) to left parietal cortex (n = 4 per anesthetic group) or in uninjured rats after 45 min of anesthesia (n = 3 per anesthetic group). Uninjured rats treated with fentanyl vs. isoflurane showed 35-45% higher CMRglu in all brain structures (p < 0.05) except CA3. After TBI in rats treated with isoflurane, CMRglu increased significantly only in ipsilateral CA1 and ipsilateral parietal cortex (p<0.05 vs. isoflurane uninjured). Conversely, after TBI in rats treated with fentanyl, CMRglu increased markedly and bilaterally in CA1 and CA3 (p < 0.05 vs. fentanyl uninjured), but not ipsilateral parietal cortex. In contralateral CA1, CMRglu was nearly two times greater after TBI in fentanyl vs. isoflurane treated rats (p < 0.05). Hyperglycolysis was exacerbated in CA1 and CA3 hippocampus after TBI in rats treated with fentanyl vs. isoflurane anesthesia. This post-traumatic hyperglycolysis suggests greater excitotoxicity and concurs with reports of worse functional outcome and more CA1 hippocampal death after TBI with fentanyl vs. isoflurane anesthesia. (C) 2003 Elsevier B.V. All rights reserved.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15260 USA	Kochanek, PM (reprint author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40686]		*AANS BRAIN TRAUM, 2000, J NEUROTRAUM, V17, P463; ARCHER DP, 1990, J CEREBR BLOOD F MET, V10, P624, DOI 10.1038/jcbfm.1990.114; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Boyeson MG, 1991, J NEUROTRAUM, V8, P205, DOI 10.1089/neu.1991.8.205; BRADLEY PB, 1984, BRIT J PHARMACOL, V83, P763, DOI 10.1111/j.1476-5381.1984.tb16231.x; Goren S, 2001, J NEUROSURG ANESTH, V13, P113, DOI 10.1097/00008506-200104000-00008; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; Harada H, 1999, ANESTH ANALG, V89, P1442, DOI 10.1097/00000539-199912000-00022; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; Izumi Y, 2002, J CLIN NEUROSCI, V9, P289, DOI 10.1054/jocn.2001.0966; Kahveci FS, 2001, SURG NEUROL, V56, P206, DOI 10.1016/S0090-3019(01)00555-9; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KEARSE LA, 1993, ELECTROEN CLIN NEURO, V87, P374, DOI 10.1016/0013-4694(93)90150-T; Kimbro JR, 2000, ANESTHESIOLOGY, V92, P806, DOI 10.1097/00000542-200003000-00024; KISSIN I, 1983, CAN ANAESTH SOC J, V30, P623, DOI 10.1007/BF03015233; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; MAEKAWA T, 1986, ANESTHESIOLOGY, V65, P144, DOI 10.1097/00000542-198608000-00003; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; Miura Y, 1999, ANESTH ANALG, V88, P787, DOI 10.1097/00000539-199904000-00020; Miura Y, 1998, ANESTHESIOLOGY, V89, P391, DOI 10.1097/00000542-199808000-00016; Nellgard B, 2000, ANESTH ANALG, V91, P145, DOI 10.1097/00000539-200007000-00027; NEUMAIER JF, 1998, J PHARMACOL EXP THER, V244, P564; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PATEL PM, 1995, ANESTHESIOLOGY, V82, P996, DOI 10.1097/00000542-199504000-00024; Patel PM, 1998, ANESTH ANALG, V86, P773, DOI 10.1097/00000539-199804000-00018; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Popovic R, 2000, ANESTHESIOLOGY, V92, P1343, DOI 10.1097/00000542-200005000-00024; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; Smolders I, 1997, EUR J PHARMACOL, V319, P21, DOI 10.1016/S0014-2999(96)00830-8; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; Statler KD, 2000, CRIT CARE MED, V28, pA53; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; TOMMASINO C, 1984, ANESTHESIOLOGY, V60, P283, DOI 10.1097/00000542-198404000-00003; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	41	17	17	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 19	2003	994	1					37	43		10.1016/j.brainres.2003.09.042			7	Neurosciences	Neurosciences & Neurology	753UT	WOS:000187249500004	14642446				2020-06-30	J	Lalley, PM				Lalley, PM			mu-opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for involvement in certain types of ventilatory disturbances	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						fentanyl; DAMGO; ventral group respiratory neurons; decreased chest wall compliance; decreased tidal volume; upper airway obstruction	EXPIRATORY BULBOSPINAL NEURONS; LOCUS-COERULEUS NEURONS; PRE-BOTZINGER COMPLEX; SPINAL-CORD; METHIONINE-ENKEPHALIN; INSPIRATORY NEURONS; RHYTHM; FENTANYL; DEPRESSION; ANESTHESIA	mu-Opioid receptor agonists depress tidal volume, decrease chest wall compliance, and increase upper airway resistance. In this study, potential neuronal sites and mechanisms responsible for the disturbances were investigated, dose-response relationships were established, and it was determined whether general anesthesia plays a role. Effects of mu-opioid agonists on membrane properties and discharges of respiratory bulbospinal, vagal, and propriobulbar neurons and phrenic nerve activity were measured in pentobarbital-anesthetized and unanesthetized decerebrate cats. In all types of respiratory neurons tested, threshold intravenous doses of the mu-opioid agonist fentanyl slowed discharge frequency and prolonged duration without altering peak discharge intensity. Larger doses postsynaptically depressed discharges of inspiratory bulbospinal and inspiratory propriobulbar neurons that might account for depression of tidal volume. Iontophoresis of the mu-opioid agonist DAMGO also depressed the intensity of inspiratory bulbospinal neuron discharges. Fentanyl given intravenously prolonged discharges leading to tonic firing of bulbospinal expiratory neurons in association with reduced hyperpolarizing synaptic drive potentials, perhaps explaining decreased inspiratory phase chest wall compliance. Lowest effective doses of fentanyl had similar effects on vagal postinspiratory ( laryngeal adductor) motoneurons, whereas in vagal laryngeal abductor and pharyngeal constrictor motoneurons, depression of depolarizing synaptic drive potentials led to sparse, very-low-frequency discharges. Such effects on three types of vagal motoneurons might explain tonic vocal fold closure and pharyngeal obstruction of airflow. Measurements of membrane potential and input resistance suggest the effects on bulbospinal Aug-E neurons and vagal motoneurons are mediated presynaptically. Opioid effects on the respiratory neurons were similar in anesthetized and decerebrate preparations.	Univ Wisconsin, Dept Physiol, Med Sci Ctr, Madison, WI 53706 USA	Lalley, PM (reprint author), Univ Wisconsin, Dept Physiol, Med Sci Ctr, 1300 Univ Ave, Madison, WI 53706 USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-65526]		Abrams JT, 1996, ANESTH ANALG, V83, P629, DOI 10.1097/00000539-199609000-00034; ALREJA M, 1993, J NEUROSCI, V13, P3525; ARANDIA HY, 1987, ANESTHESIOLOGY, V66, P574, DOI 10.1097/00000542-198704000-00030; ARMIS TC, 1992, J APPL PHYSIOL, V72, P2329; BALLANTYNE D, 1986, J PHYSIOL-LONDON, V370, P433, DOI 10.1113/jphysiol.1986.sp015943; Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; BENTHUYSEN JL, 1986, ANESTHESIOLOGY, V64, P440, DOI 10.1097/00000542-198604000-00005; BERGER AJ, 1984, J COMP NEUROL, V224, P60, DOI 10.1002/cne.902240106; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Booth N., 1982, VET PHARM THERAPEUTI, P274; BOURGOIN S, 1986, J PHARMACOL EXP THER, V238, P360; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; Broussard Delma L., 2000, American Journal of Medicine, V108, p62S; DENAVITSAUBIE M, 1978, BRAIN RES, V155, P55, DOI 10.1016/0006-8993(78)90305-0; ELDRIDGE FL, 1971, AM J PHYSIOL, V221, P535; EZURE K, 1990, PROG NEUROBIOL, V35, P429, DOI 10.1016/0301-0082(90)90030-K; FEDORKO L, 1989, EXP NEUROL, V105, P306, DOI 10.1016/0014-4886(89)90134-9; FELDMAN JL, 1980, J NEUROPHYSIOL, V43, P1284; FELDMAN JL, 2002, FUNDAMENTAL NEUROSCI, P967; FONE KCF, 1986, BRIT J PHARMACOL, V89, P67, DOI 10.1111/j.1476-5381.1986.tb11121.x; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; GRUDT TJ, 1995, REV NEUROSCIENCE, V6, P279; Haji A, 2001, JPN J PHARMACOL, V87, P333, DOI 10.1254/jjp.87.333; HERBERT DA, 1971, J APPL PHYSIOL, V30, P434; HILAIRE G, 1984, BRAIN RES, V302, P19, DOI 10.1016/0006-8993(84)91281-2; Howard RS, 1990, J PHYSL, V437, P181; HUFF BB, 1986, PHYSICIANS DESK REFE, P957; HURLE MA, 1985, NEUROPHARMACOLOGY, V24, P597, DOI 10.1016/0028-3908(85)90100-5; JAFFE J H, 1990, P485; Johnson SM, 1996, J APPL PHYSIOL, V80, P2120; KIRKWOOD PA, 1995, J PHYSIOL-LONDON, V484, P201, DOI 10.1113/jphysiol.1995.sp020659; KIRSTEN EB, 1978, J PHARMACOL METHOD, V1, P263, DOI 10.1016/0160-5402(78)90057-8; KREUTER F, 1977, PFLUG ARCH EUR J PHY, V372, P7, DOI 10.1007/BF00582200; Lalley P., 1999, MODERN TECHNIQUES NE, P193; LALLEY PM, 1997, J NEUROPHYSIOL, V77, P1191; LALLEY PM, 2002, SOC NEUR ABSTR, V31, P468; LALLEY PM, 2002, SOC NEUR ABSTR, V32, P72; LAUBIE M, 1986, EUR J PHARMACOL, V122, P301, DOI 10.1016/0014-2999(86)90410-3; LONG S, 1986, PROG NEUROBIOL, V27, P101, DOI 10.1016/0301-0082(86)90007-9; MARTY J, 1981, ACTA ANAESTH SCAND, V25, P293, DOI 10.1111/j.1399-6576.1981.tb01654.x; MORINSURUN MP, 1984, EUR J PHARMACOL, V98, P235, DOI 10.1016/0014-2999(84)90594-6; MURAKOSHI T, 1985, BRIT J PHARMACOL, V86, P95, DOI 10.1111/j.1476-5381.1985.tb09439.x; Mutolo D, 2002, AM J PHYSIOL-REG I, V283, pR227, DOI 10.1152/ajpregu.00579.2001; NEIDHART P, 1989, ACTA ANAESTH SCAND, V33, P1, DOI 10.1111/j.1399-6576.1989.tb02849.x; Pierrefiche O, 1998, J PHYSIOL-LONDON, V509, P245, DOI 10.1111/j.1469-7793.1998.245bo.x; Rekling J. C., 1998, Society for Neuroscience Abstracts, V24, P914; RICHTER DW, 1996, [No title captured], V2, P2079, DOI DOI 10.1007/978-3-642-60946-6_106; RICHTER DW, 1986, NEWS PHYSIOL SCI, V1, P109; SALES N, 1985, BRAIN RES, V344, P382, DOI 10.1016/0006-8993(85)90820-0; SANTIAGO TV, 1985, J APPL PHYSIOL, V59, P1675; SCAMMAN FL, 1983, ANESTH ANALG, V62, P332; SESSLE BJ, 1985, BRAIN RES, V327, P221, DOI 10.1016/0006-8993(85)91515-X; Shook J.E., 1990, AM REV RESPIR DIS, V33, P1; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; SPECK DF, 1982, J NEUROSCI, V2, P744; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Travagli RA, 1996, J NEUROPHYSIOL, V75, P2029; von Euler C., 1986, HDB PHYSL RESPIRATOR, VII, P1; WILLETTE RN, 1982, EUR J PHARMACOL, V80, P57, DOI 10.1016/0014-2999(82)90177-7; WILLIAMS JT, 1988, J NEUROSCI, V8, P4299; YEADON M, 1989, PROG NEUROBIOL, V33, P1, DOI 10.1016/0301-0082(89)90033-6; Zoungrana OR, 1997, J NEUROPHYSIOL, V77, P909	64	88	89	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119			AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	DEC 1	2003	285	6					R1287	R1304		10.1152/ajpregu.00199.2003			18	Physiology	Physiology	742ZE	WOS:000186547300005	12881202				2020-06-30	J	Connor, L; Burrows, PE; Zurakowski, D; Bucci, K; Gagnon, DA; Mason, KP				Connor, L; Burrows, PE; Zurakowski, D; Bucci, K; Gagnon, DA; Mason, KP			Effects of IV pentobarbital with and without fentanyl on end-tidal carbon dioxide levels during deep sedation of pediatric patients undergoing MRI	AMERICAN JOURNAL OF ROENTGENOLOGY			English	Article							CHILDREN; CAPNOGRAPHY; PAINFUL; CO2	OBJECTIVE. IV pentobarbital is used in radiology departments for sedating pediatric patients undergoing diagnostic imaging. To our knowledge, no published studies have documented end-tidal carbon dioxide levels during sedation with IV pentobarbital. The purpose of this prospective study was to determine the effects of different doses of IV pentobarbital with or without fentanyl on end-tidal carbon dioxide levels during deep sedation of pediatric patients undergoing MRI. SUBJECTS AND METHODS. One hundred sixty-five patients (70 girls, 95 boys) having a mean age of 3.4 years received IV pentobarbital sedation with or without fentanyl for undergoing MRI from January through March 2002. Each child was sedated with 2-6 mg/kg of body weight of IV pentobarbital and an additional 1-3 mug/kg of fentanyl if needed. After the administration of sedation, a 28-ft (8.5 m) nasal cannula with capnography capability was applied to each patient, and capnogram tracings and values were recorded every 5 min. RESULTS. Mean values of end-tidal carbon dioxide were between 37 and 42 min Hg during 60 min of sedation for both groups. When IV pentobarbital was used alone, no significant difference was seen between patients who received 3-5 mg of pentobarbital and those who received more than 5 mg (p = 0.97, F test). CONCLUSION. End-tidal carbon dioxide levels remain within normal clinical range during sedation with IV pentobarbital with or without fentanyl. Our sedation protocol produced no significant deviations from normal respiratory parameters.	Harvard Univ, Sch Med, Childrens Hosp, Dept Radiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Anesthesia, Boston, MA 02115 USA	Connor, L (reprint author), Harvard Univ, Sch Med, Childrens Hosp, Dept Radiol, Boston, MA 02115 USA.						*AM SOC AN, 2003, [No title captured]; ARMITAGE P, 1994, STAT METHODS MED RES, P301; Bhende M, 1999, PEDIATR EMERG CARE, V15, P64, DOI 10.1097/00006565-199902000-00019; CAULDWELL CB, 2002, PEDIAT ANESTHESIA, P217; Chung T, 2000, PEDIATR RADIOL, V30, P332, DOI 10.1007/s002470050752; Curley M A, 1990, Pediatr Nurs, V16, P397; Egelhoff JC, 1997, AM J ROENTGENOL, V168, P1259, DOI 10.2214/ajr.168.5.9129423; Hart LS, 1997, PEDIATR EMERG CARE, V13, P189, DOI 10.1097/00006565-199706000-00004; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; *JOINT COMM RES, 2001, TOP CLIN CAR IMPR AN, P37; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lang TA, 1997, REPORT STAT MED, P65; Mason KP, 2000, J CLIN MONITOR COMP, V16, P259, DOI 10.1023/A:1011436329848; Mason KP, 2001, AM J ROENTGENOL, V177, P427, DOI 10.2214/ajr.177.2.1770427; McQuillen KK, 2000, PEDIATR EMERG CARE, V16, P401, DOI 10.1097/00006565-200012000-00005; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; Nobel JJ, 1996, PEDIATR EMERG CARE, V12, P128, DOI 10.1097/00006565-199604000-00017; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; THOMPSON JR, 1982, RADIOLOGY, V143, P475, DOI 10.1148/radiology.143.2.7071350; Tobias JD, 1999, PEDIATR EMERG CARE, V15, P173, DOI 10.1097/00006565-199906000-00002; TOBIAS JD, 1994, CRIT CARE MED, V22, P1805; Vargo JJ, 2002, GASTROINTEST ENDOSC, V55, P826, DOI 10.1067/mge.2002.124208	23	16	16	0	1	AMER ROENTGEN RAY SOC	LEESBURG	44211 SLATESTONE CT, LEESBURG, VA USA	0361-803X	1546-3141		AM J ROENTGENOL	Am. J. Roentgenol.	DEC	2003	181	6					1691	1694		10.2214/ajr.181.6.1811691			4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	746MG	WOS:000186749700043	14627598				2020-06-30	J	Pettifer, GR; Hosgood, G				Pettifer, GR; Hosgood, G			The effect of rectal temperature on perianesthetic serum concentrations of transdermally administered fentanyl in cats anesthetized with isoflurane	AMERICAN JOURNAL OF VETERINARY RESEARCH			English	Article							CUTANEOUS HEAT-LOSS; THERMOREGULATORY VASOCONSTRICTION; ORTHOPEDIC-SURGERY; DOUBLE-BLIND; DOGS; PHARMACOKINETICS; ANALGESIA; OVARIOHYSTERECTOMY; OXYMORPHONE; PLACEBO	Objectives-To determine whether moderate hypothermia during 4 hours of anesthesia with isoflurane substantially affects serum concentrations of transdermally administered fentanyl in the perianesthetic period in cats. Animals-7 healthy mature cats. Procedure-A fentanyl patch (25 mug/h) was applied to the shaved thorax 24 hours before induction of anesthesia. Anesthesia was induced at time 0. Each cat received 2 treatments in a random order. Treatments were isoflurane anesthesia with normothermia and isoflurane anesthesia with hypothermia. Cats were intubated, connected to a nonrebreathing circuit, and maintained at 1.3X minimum alveolar concentration for 4 hours. Cats in the hypothermia treatment groups were actively cooled to 35degreesC following the induction of anesthesia. Serum fentanyl analysis was performed at -24, -12, 0, 1, 2, 3, 4, 4.5, 5, 6, 7, 8, 9, 10, 12, and 24 hours. Results-Mean +/- SEM serum fentanyl concentration (SFC) for the hypothermia treatment group (0.598 +/- 0.3048 ng/mL) was significantly lower than the baseline concentration (1.834 +/- 0.6393 ng/mL) at 1 hour. This significant reduction persisted for the duration of anesthesia for the hypothermia treatment group. Serum fentanyl concentrations returned to baseline values within 1 hour of the end of anesthesia, regardless of body temperature. Conclusions and Clinical Relevance-Hypothermia during inhalant anesthesia induced a significant reduction in SFC obtained with transdermal administration. The impact of this reduction in SFC on the contribution of transdermally administered fentanyl to any reduction in the need for inhalant anesthesia remains to be determined.	Louisiana State Univ, Sch Vet Med, Dept Vet Clin Sci, Baton Rouge, LA 70803 USA	Pettifer, GR (reprint author), Louisiana State Univ, Sch Vet Med, Dept Vet Clin Sci, Baton Rouge, LA 70803 USA.			Hosgood, Giselle/0000-0002-8851-8597			Bailey P.L., 2000, ANESTHESIA, P273; Carroll GL, 1999, AM J VET RES, V60, P986; COPLAND VS, 1987, AM J VET RES, V48, P1626; DOWNES JJ, 1967, J PHARMACOL EXP THER, V158, P416; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; Egger C M, 2001, Vet Anaesth Analg, V28, P102, DOI 10.1046/j.1467-2987.2001.temp.doc.x-i4; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Foley PL, 2001, COMPARATIVE MED, V51, P239; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; Glerum LE, 2001, VET SURG, V30, P351, DOI 10.1053/jvet.2001.24387; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; Harvey-Clark CJ, 2000, LAB ANIM-UK, V34, P386, DOI 10.1258/002367700780387750; Kyles AE, 1998, RES VET SCI, V65, P245, DOI 10.1016/S0034-5288(98)90151-5; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; McDonell W, 1996, LUMB JONES VET ANEST, V1, P115; MURPHY MR, 1983, ANESTHESIOLOGY, V59, P537, DOI 10.1097/00000542-198312000-00009; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; ROWBOTHAM DJ, 1989, BRIT J ANAESTH, V63, P56, DOI 10.1093/bja/63.1.56; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; Sessler DI, 2000, ANESTHESIOLOGY, V92, P578, DOI 10.1097/00000542-200002000-00042; SESSLER DI, 1992, ANESTHESIOLOGY, V76, P670, DOI 10.1097/00000542-199205000-00002; SESSLER DI, 1990, ANESTHESIOLOGY, V73, P656, DOI 10.1097/00000542-199010000-00011; SESSLER DI, 1991, ANESTHESIOLOGY, V74, P226, DOI 10.1097/00000542-199102000-00006; SONG CW, 1989, INT J RADIAT ONCOL, V17, P1041, DOI 10.1016/0360-3016(89)90153-3; STEFFEY EP, 1977, AM J VET RES, V38, P1833; VANBASTELAERE M, 1995, J CLIN ANESTH, V7, P26, DOI 10.1016/0952-8180(94)00000-T; Welch JA, 2002, J VET EMERG CRIT CAR, V12, P81, DOI 10.1046/j.1435-6935.2002.00021.x; Wilkinson AC, 2001, CONTEMP TOP LAB ANIM, V40, P12; YACKEY M, 2002, VET ANAESTH ANALG, V29, P1	29	16	17	0	4	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0002-9645			AM J VET RES	Am. J. Vet. Res.	DEC	2003	64	12					1557	1561		10.2460/ajvr.2003.64.1557			5	Veterinary Sciences	Veterinary Sciences	746JX	WOS:000186744200017	14672436				2020-06-30	J	Demeere, JL				Demeere, JL			Pulmonary mechanics and volatile anaesthesia	ANAESTHESIA			English	Letter									Clin Gen St Jean, B-1000 Brussels, Belgium	Demeere, JL (reprint author), Clin Gen St Jean, B-1000 Brussels, Belgium.		Dikmen, Yalim/G-6301-2012	Dikmen, Yalim/0000-0002-3122-5099			DIKMEN, 2003, ANAESTHESIA, V58, P745; EBERT TJ, 1993, ANESTHESIOLOGY, V79, P444, DOI 10.1097/00000542-199309000-00006	2	0	0	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	DEC	2003	58	12					1248	1248		10.1046/j.1365-2044.2003.03552.x			1	Anesthesiology	Anesthesiology	744RR	WOS:000186646600042	14705712				2020-06-30	J	Davis, JJ; Johnson, KB; Egan, TD; Vezina, DP; Snell, TE; Swenson, JD				Davis, JJ; Johnson, KB; Egan, TD; Vezina, DP; Snell, TE; Swenson, JD			Preoperative fentanyl infusion with pharmacokinetic simulation for anesthetic and perioperative management of an opioid-tolerant patient	ANESTHESIA AND ANALGESIA			English	Article							ACUTE PAIN MANAGEMENT	For opioid-tolerant patients, conventional patient-controlled analgesia dosing may be ineffective. We present a cardiac surgery patient with a history of significant opioid tolerance and prior episodes of severe postoperative pain. Using the patient's response to a large-dose fentanyl infusion in conjunction with a pharmacokinetic simulation, effective intraoperative and postoperative fentanyl plasma concentrations were achieved.	Univ Utah, Med Ctr, Dept Anesthesiol, Salt Lake City, UT 84132 USA	Davis, JJ (reprint author), Univ Utah, Med Ctr, Dept Anesthesiol, 50 N Med Dr, Salt Lake City, UT 84132 USA.						GOURLAY GK, 1988, ANESTH ANALG, V67, P329; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; RAPP SE, 1995, PAIN, V61, P195, DOI 10.1016/0304-3959(94)00168-E; RAPP SE, 1994, CLIN J PAIN, V10, P133, DOI 10.1097/00002508-199406000-00007; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Zagari MJ, 1996, PHARMACOECONOMICS, V10, P356, DOI 10.2165/00019053-199610040-00005	6	4	4	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2003	97	6					1661	1662		10.1213/01.ANE.0000090151.13573.42			2	Anesthesiology	Anesthesiology	747QZ	WOS:000186816900022	14633538				2020-06-30	J	Law, ACS; Lam, KK; Irwin, MG				Law, ACS; Lam, KK; Irwin, MG			The effect of right versus left lateral decubitus positions on induction of spinal anesthesia for cesarean delivery	ANESTHESIA AND ANALGESIA			English	Article							HYPERBARIC 0.5-PERCENT BUPIVACAINE; SUBARACHNOID ANALGESIA; MATERNAL POSITION; PLAIN BUPIVACAINE; SECTION; FENTANYL; SPREAD; COMBINATIONS; POSTURE; VOLUME	Induction of spinal anesthesia for cesarean delivery in the left lateral (LL) decubitus position combined with intraoperative left uterine displacement may result in pooling of local anesthetic onto one side of the body. We studied the effect of the right lateral (RL) and LL decubitus positions during placement of spinal anesthesia on the intrathecal spread of 0.5% hyperbaric bupivacaine plus fentanyl in 60 term parturients. Though all parturients acquired a loss of cold sensation at T4 15 min after intrathecal injection, more parturients in the LL group than in the RL group did so at 5 min (P < 0.05). The maximum levels of sensory blockades, amounts of fluid, vasopressor, and supplementary analgesia used, and the incidence of postoperative complications were similar. We conclude that the two positions can be used equally well when hyperbaric bupivacaine and fentanyl are used in cesarean delivery under spinal anesthesia.	Tuen Mun Hosp, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Anaesthesiol, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China	Lam, KK (reprint author), Tuen Mun Hosp, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China.		Irwin, Michael/C-4286-2009	Irwin, Michael/0000-0001-5801-274X			BROWN DL, 1994, ANESTHESIA, P1519; CHAMBERS WA, 1981, BRIT J ANAESTH, V53, P279, DOI 10.1093/bja/53.3.279; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Chung CJ, 1996, BRIT J ANAESTH, V77, P145, DOI 10.1093/bja/77.2.145; Hallworth SP, 2002, ANESTH ANALG, V94, P1621, DOI 10.1097/00000539-200206000-00048; INGLIS A, 1995, ANAESTHESIA, V50, P363, DOI 10.1111/j.1365-2044.1995.tb04620.x; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; MARTINSALVAJ G, 1994, ANESTH ANALG, V79, P1107; NORRIS MC, 1990, ANESTHESIOLOGY, V72, P478, DOI 10.1097/00000542-199003000-00015; OSTHEIMER GW, 1992, MANUAL OBSTET ANESTH, P189; PATEL M, 1993, CAN J ANAESTH, V40, P943, DOI 10.1007/BF03010097; POVEY HMR, 1989, ACTA ANAESTH SCAND, V33, P295, DOI 10.1111/j.1399-6576.1989.tb02911.x; REISNER LS, 1994, OBSTET ANESTHESIA PR, P467; Richardson MG, 1997, ANESTH ANALG, V84, P95, DOI 10.1097/00000539-199701000-00018; Richardson MG, 1998, ANESTH ANALG, V87, P336, DOI 10.1097/00000539-199808000-00019; RUSSELL IF, 1987, BRIT J ANAESTH, V59, P347, DOI 10.1093/bja/59.3.347; RUSSELL IF, 1987, BRIT J ANAESTH, V59, P342, DOI 10.1093/bja/59.3.342; RUSSELL IF, 1991, REGION ANESTH, V16, P130; Sarvela PJ, 1999, ANESTH ANALG, V89, P1257, DOI 10.1213/00000539-199911000-00033; SCHNIDER SM, 1994, ANESTHESIA, P2057; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; VANGESSEL EF, 1991, ANESTH ANALG, V72, P779; Vercauteren MP, 1998, ANESTH ANALG, V86, P989, DOI 10.1097/00000539-199805000-00014; Yun EM, 1998, ANESTH ANALG, V87, P614, DOI 10.1097/00000539-199809000-00023	24	11	12	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2003	97	6					1795	1799		10.1213/01.ANE.0000086733.92150.47			5	Anesthesiology	Anesthesiology	747QZ	WOS:000186816900046	14633562				2020-06-30	J	Bernard, JM; Le Roux, D; Frouin, J				Bernard, JM; Le Roux, D; Frouin, J			Ropivacaine and fentanyl concentrations in patient-controlled epidural analgesia during labor: A volume-range study	ANESTHESIA AND ANALGESIA			English	Article							0.125-PERCENT BUPIVACAINE; LOCKOUT INTERVAL; PAIN RELIEF; BOLUS; 0.1-PERCENT; SUFENTANIL; 2-MU-G/ML	We enrolled nulliparous women in induced labor in a randomized study to determine whether increasing the concentration of the solution used in a patient-controlled epidural analgesia (PCEA) device was required as labor progressed. Patients were assigned to 6 groups (n = 25 in each group), receiving ropivacaine/ fentanyl in concentrations of either 0.1%/0.5 mug/mL or 0.2%/1 mug/mL via a PCEA pump. Three groups received boluses of 12,16, or 20 mL dilute solution in early labor (uterine contractions every 3 min and 4-cm cervical dilation) then 6, 8, and 10 mL concentrated solution in late labor. Three other groups received boluses of 12, 16, or 20 mL dilute solution during both periods. The lockout interval was 25 min. The primary outcome was time until the first request for staff-administered analgesia supplement. Hourly assessments included pain scores on a visual analog scale (VAS) graded from 0 to 10, satisfaction scores, arterial blood pressure, motor block intensity, and the upper sensory level of epidural anesthesia. Patients, midwives, and the observer were unaware of study solutions and PCEA settings. The maximum pain score was defined as the highest score experienced by each patient during each period. Duration of analgesia was defined as the time from the start of each period to the first injection of rescue analgesia and was compared using a survival analysis. There were no differences among the groups with regard to demographic and obstetric variables, arterial blood pressure, motor block intensity, upper sensory level, or satisfaction scores. At least 75% of the women rated their satisfaction as either good or excellent during each period. During late labor, the maximum pain score was lower in the group receiving 20 ml, dilute solution compared with the group receiving 6 mL concentrated solution. Maximum pain score was not significantly different between 20 mL dilute solution and 10 mL concentrated solution (difference between VAS values = -0.4; 95% confidence limits, -1.599 and 0.799; P = 0.5055). During late labor, the duration of analgesia was longer in groups receiving 20 mL dilute solution (99 4 min) (mean +/- SD) than in those receiving 12 ml, (77 +/- 30 min) and 16 mL (80 +/- 23 min). Duration of analgesia did not differ between groups receiving 20 mL and 10 ml, (92 +/- 23 min) or between groups receiving 12 ml, and 6 mL (78 +/- 30 min) of each respective solution. Duration of analgesia was longer in the groups receiving 8 mL concentrated solution (94 +/- 16 min) than in those receiving 16 mL dilute solution. We concluded that 0.1%/0.5 mug/ml, ropivacaine/fentanyl was effective throughout labor when 20 mL was injected with each PCEA demand. With 16 mg ropivacaine and 8 mug fentanyl, the duration of analgesia was prolonged by doubling the concentration when labor became active. When 12 mg ropivacaine and 6 mug fentanyl were injected at each demand, analgesia was less satisfactory and doubling the concentration was not clinically effective. These results suggest that the effectiveness of PCEA is dependent on drug mass rather than the volume or concentration administered with each successful pump demand.	Polyclin jean Villar, Dept Anesthesie Reanimat, F-33520 Bruges Bordeaux, France	Bernard, JM (reprint author), Polyclin jean Villar, Dept Anesthesie Reanimat, BP 61, F-33520 Bruges Bordeaux, France.						Beilin Y, 1999, ANESTH ANALG, V88, P1340, DOI 10.1097/00000539-199906000-00027; Bell ED, 2000, ANESTHESIOLOGY, V92, P851, DOI 10.1097/00000542-200003000-00029; Benhamou D, 1997, BRIT J ANAESTH, V78, P748, DOI 10.1093/bja/78.6.748; Bernard JM, 2001, ANESTH ANALG, V92, P184; Bernard JM, 2000, ANESTH ANALG, V90, P328, DOI 10.1097/00000539-200002000-00017; Campbell DC, 2000, ANESTH ANALG, V90, P1384, DOI 10.1097/00000539-200006000-00023; Capogna G, 1998, BRIT J ANAESTH, V80, P11; Curatolo M, 2000, ANESTHESIOLOGY, V92, P325, DOI 10.1097/00000542-200002000-00012; Dresner M, 2000, BRIT J ANAESTH, V85, P826, DOI 10.1093/bja/85.6.826; Fischer C, 2000, ANESTHESIOLOGY, V92, P1588, DOI 10.1097/00000542-200006000-00015; GAMBLING DR, 1993, CAN J ANAESTH, V40, P211, DOI 10.1007/BF03037032; Liu SS, 1997, ANESTHESIOLOGY, V86, P1288, DOI 10.1097/00000542-199706000-00009; Liu SS, 1999, ANESTHESIOLOGY, V90, P727, DOI 10.1097/00000542-199903000-00014; LYONS G, 1998, BRIT J ANAESTH, V80, P149; Meister GC, 2000, ANESTH ANALG, V90, P632, DOI 10.1097/00000539-200003000-00024; Owen MD, 2002, ANESTH ANALG, V94, P179, DOI 10.1097/00000539-200201000-00034; PAECH MJ, 1995, ANAESTH INTENS CARE, V23, P459, DOI 10.1177/0310057X9502300408; PEISNER DB, 1985, OBSTET GYNECOL, V66, P644; Smedvig JP, 2001, ACTA ANAESTH SCAND, V45, P595, DOI 10.1034/j.1399-6576.2001.045005595.x; Whiteside R, 2000, BRIT J ANAESTH, V84, P720	20	16	22	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2003	97	6					1800	1807		10.1213/01.ANE.0000090149.42478.B5			8	Anesthesiology	Anesthesiology	747QZ	WOS:000186816900047	14633563				2020-06-30	J	Maegawa, FAB; Tonussi, CR				Maegawa, FAB; Tonussi, CR			The L-arginine/nitric oxide/cyclic-GMP pathway apparently mediates the peripheral antihyperalgesic action of fentanyl in rats	BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH			English	Article						opioid; guanylate cyclase; prostaglandin; PDE5; UK-114,542-27	POTASSIUM CHANNELS; OPIATE RECEPTOR; PROSTAGLANDIN HYPERALGESIA; OPIOID-ANTAGONISTS; METHYLENE-BLUE; SMOOTH-MUSCLE; K+ CHANNELS; MORPHINE; ANALGESIA; INVOLVEMENT	There are only a few studies on the molecular mechanisms underlying the peripheral antihyperalgesic effect of opioids. The aim of this study was to investigate the molecular bases of the peripheral antihyperalgesic effect of fentanyl in a model of prostaglandin-induced chemical hyperalgesia. Prostaglandin E-2 (1.4 nmol) injected into one hind paw of male Wistar rats (200-250 g, N = 6 in each experimental or control group) pretreated with indomethacin (2.5 mg/kg) potentiated the nocifensive response to formalin (1%) injection made 60 min later. Drugs applied locally 30 min after prostaglandin E2 induced the following effects: fentanyl (0.1-1.0 nmol) caused a dose-dependent reversal of the hyperalgesic state, naloxone (2 nmol) co-injected with fentanyl (1 nmol) completely reversed the antihyperalgesic effect, N-omega- nitro-L-arginine (NOARG, 0.05-0.2 mumol) in combination with fentanyl (1.0 nmol) caused a dose-dependent inhibition of the antihyperalgesic effect of fentanyl, co-administration of L-arginine (0.5 mumol) with NOARG (0.2 mumol) plus fentanyl (1.0 nmol) fully restored the antihyperalgesic effect, and the cyclic-GMP phosphodiesterase inhibitor UK-114,542-27 (5-[2-ethoxy-5-(morpholinylacetyl) phenyl]-1,6-dihydro-1-methyl-3-propyl-7H-pyrazolo [4,3-d] -pyrimidin-7-one methanesulfonate monohydrate; 0.5-2.0 mumol) potentiated a sub-effective dose of fentanyl (0.1 nmol) in a dose-dependent manner. However, UK-114,542-27 (2.0 mumol) injected alone did not produce this antihyperalgesic effect. Systemically administered fentanyl (1.0 nmol, sc) did not cause antinociception. Taken together, these results support the view that fentanyl reverses prostaglandin E-2-induced hyperalgesia, probably by activating an opioid receptor at the periphery, and furthermore the L-arginine/nitric oxide/cyclic-GMP pathway may mediate this peripheral effect of fentanyl.	Univ Fed Santa Catarina, Dept Farmacol, Florianopolis, SC, Brazil	Tonussi, CR (reprint author), R Ferreira Lima 82, BR-88015420 Florianopolis, SC, Brazil.		Tonussi, Carlos/E-6985-2013				Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; DUARTE IDG, 1990, EUR J PHARMACOL, V186, P289, DOI 10.1016/0014-2999(90)90446-D; FERREIRA SH, 1979, PROSTAGLANDINS, V18, P191, DOI 10.1016/0090-6980(79)90104-7; FERREIRA SH, 1991, EUR J PHARMACOL, V201, P121, DOI 10.1016/0014-2999(91)90333-L; FERREIRA SH, 1984, EUR J PHARMACOL, V99, P23, DOI 10.1016/0014-2999(84)90428-X; FERREIRA SH, 1979, PROSTAGLANDINS, V18, P201, DOI 10.1016/0090-6980(79)90105-9; FERREIRA SH, 1990, MIGRAINE SPEECTRUM I; Granados-Soto V, 1997, EUR J PHARMACOL, V340, P177, DOI 10.1016/S0014-2999(97)01399-X; Lazaro-Ibanez GG, 2001, EUR J PHARMACOL, V426, P39, DOI 10.1016/S0014-2999(01)01206-7; LEVINE JD, 1989, NEUROSCIENCE, V32, P571, DOI 10.1016/0306-4522(89)90279-0; Lorenzetti BB, 1996, INFLAMM RES, V45, P308, DOI 10.1007/BF02280997; LORENZETTI BB, 1982, BRAZ J MED BIOL RES, V15, P285; MAYER B, 1993, BIOCHEM PHARMACOL, V45, P367, DOI 10.1016/0006-2952(93)90072-5; NEGUS SS, 1993, J PHARMACOL EXP THER, V266, P1355; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; OUSEPH AK, 1995, NEUROSCIENCE, V64, P769, DOI 10.1016/0306-4522(94)00397-N; RIOS L, 1983, EUR J PHARMACOL, V96, P277, DOI 10.1016/0014-2999(83)90317-5; Rodrigues ARA, 2000, BRIT J PHARMACOL, V129, P110, DOI 10.1038/sj.bjp.0703038; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; TAIWO YO, 1991, J NEUROSCI, V11, P928; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TONUSSI CR, 1994, EUR J PHARMACOL, V251, P173, DOI 10.1016/0014-2999(94)90398-0; VILLIGER JW, 1983, NEUROPHARMACOLOGY, V22, P447, DOI 10.1016/0028-3908(83)90162-4; Volke V, 1999, BRAIN RES, V826, P303, DOI 10.1016/S0006-8993(99)01253-6; Yonehara N, 1997, REGUL PEPTIDES, V68, P147, DOI 10.1016/S0167-0115(96)02102-7; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	28	4	4	0	1	ASSOC BRAS DIVULG CIENTIFICA	SAO PAULO	FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL	0100-879X			BRAZ J MED BIOL RES	Brazilian J. Med. Biol. Res.	DEC	2003	36	12					1701	1707		10.1590/S0100-879X2003001200012			7	Biology; Medicine, Research & Experimental	Life Sciences & Biomedicine - Other Topics; Research & Experimental Medicine	752NX	WOS:000187175000012	14666255	DOAJ Gold			2020-06-30	J	Kurita, T; Morita, K; Kazama, T; Sato, S				Kurita, T; Morita, K; Kazama, T; Sato, S			Comparison of isoflurane and propofol-fentanyl anaesthesia in a swine model of asphyxia	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics i.v.; anaesthetics i.v., propofol; anaesthetic techniques, inhalation; heart, resuscitation	VASCULAR CAPACITANCE; CARDIAC-OUTPUT; INCREASES; INFUSION; HYPOXIA; SURGERY; DOGS	Background. There have been few studies comparing the response to asphyxia and the effectiveness of typical cardiopulmonary resuscitation (CPR) using exogenous epinephrine administration and manual closed-chest compression between total intravenous anaesthesia (TIVA) and inhalational anaesthesia. Methods. Twenty pigs were randomly assigned to two study groups anaesthetized using either 2% end-tidal isoflurane (n=10) or propofol (12 mg kg(-1) h(-1))-fentanyl (50 mug kg(-1)) (n=10). Asphyxia was induced by clamping the tracheal tube until the mean arterial pressure (MAP) decreased to 40% of the baseline value (40% MAP time). The tracheal tube was declamped at that point, and CPR was performed. Haemodynamic parameters and blood samples were obtained before the induction of asphyxia, at I-min intervals during asphyxia, and 1, 2, 3, 5, 10, 30 and 60 min after asphyxia. Results. TIVA maintained the MAP against hypoxia-hypercapnia stress significantly longer than isoflurane anaesthesia (mean (SD) 40% MAP time 498 (95) and 378 (104) s respectively). In all animals in the isoflurane group, spontaneous circulation returned within I min of the start of CPR. In six of the TIVA animals, spontaneous circulation returned for 220 (12 1) s; spontaneous circulation did not return within 5 min in the remaining four animals. Conclusions. Although TIVA is less prone than isoflurane anaesthesia to primary cardiovascular depression leading to asphyxia, TIVA is associated with reduced effectiveness of CPR in which resuscitation because of asphyxic haemodynamic depression occurs.	Hamamatsu Univ Sch Med, Dept Anesthesiol & Intens Care, Hamamatsu, Shizuoka 4313192, Japan; Natl Def Med Coll, Dept Anesthesiol, Tokorozawa, Saitama 3598513, Japan	Kurita, T (reprint author), Hamamatsu Univ Sch Med, Dept Anesthesiol & Intens Care, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan.	tadkur@hama-med.ac.jp					CRYER PE, 1980, NEW ENGL J MED, V303, P436; Daniel M, 1996, ANESTHESIOLOGY, V84, P75, DOI 10.1097/00000542-199601000-00009; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; Hoka S, 1998, ANESTHESIOLOGY, V89, P1495, DOI 10.1097/00000542-199812000-00028; Jasani MS, 1997, RESUSCITATION, V35, P69, DOI 10.1016/S0300-9572(96)01094-5; KERN KB, 1996, CARDIAC ARREST SCI P, P270; Kurita T, 2002, ANESTHESIOLOGY, V96, P1498, DOI 10.1097/00000542-200206000-00033; LEHOT JJ, 1991, ANESTH ANALG, V72, P737; LERMAN J, 1990, ANESTHESIOLOGY, V73, P717, DOI 10.1097/00000542-199010000-00018; Minami K, 1996, N-S ARCH PHARMACOL, V353, P572; NG A, 1995, ANAESTH INTENS CARE, V23, P543, DOI 10.1177/0310057X9502300502; PLUMMER GF, 1987, J CHROMATOGR-BIOMED, V421, P171, DOI 10.1016/0378-4347(87)80394-8; Rosenberg JM, 1998, CRIT CARE MED, V26, P533, DOI 10.1097/00003246-199803000-00028; Rosenberg JM, 1996, ANESTH ANALG, V82, P84, DOI 10.1097/00000539-199601000-00014; ROTHE CF, 1990, CAN J PHYSIOL PHARM, V68, P384, DOI 10.1139/y90-054; Schwall B, 2000, ACTA ANAESTH SCAND, V44, P343, DOI 10.1034/j.1399-6576.2000.440322.x; WALLEY KR, 1990, CIRC RES, V67, P628, DOI 10.1161/01.RES.67.3.628; Yamamoto K, 1999, CAN J ANAESTH, V46, P1150, DOI 10.1007/BF03015525; Zhou WG, 1999, ANESTH ANALG, V89, P604, DOI 10.1097/00000539-199909000-00011	19	18	22	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	DEC	2003	91	6					871	877		10.1093/bja/aeg259			7	Anesthesiology	Anesthesiology	752EQ	WOS:000187147200019	14633760	Bronze			2020-06-30	J	Castro, C; Tharmaratnam, U; Brockhurst, N; Tureanu, L; Tam, K; Windrim, R				Castro, C; Tharmaratnam, U; Brockhurst, N; Tureanu, L; Tam, K; Windrim, R			Patient-controlled analgesia with fentanyl provides effective analgesia for second trimester labour: a randomized controlled study	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							INTRAVENOUS FENTANYL; PARTURIENT; REMIFENTANIL; MORPHINE; PCA; METOCLOPRAMIDE; PREGNANCY	Purpose: To examine dose and lockout intervals for effective fentanyl patient-controlled analgesia (PCA) in second trimester genetic termination of pregnancy, and compare three different fentanyl PCA regimes with morphine PCA. Methods: In a double-blind randomized study, 60 ASA physical status I-II patients received one of three fentanyl PCAs or morphine PCA. Labour was induced with prostaglandins and PCA use continued until delivery. Within two hours following delivery, four visual analogue scales (VAS) were administered measuring anticipated pain, pain relief in labour and delivery and overall satisfaction. The drug delivery/demand ratio for two hours preceding delivery was obtained from the PCA pump. The outcome variables were analyzed using the Chi square test and analysis of variance as appropriate. Results: The delivery/demand ratio was 0.71 +/- 0.27 (mean +/- standard deviation) for morphine; 0.67 +/- 0.21 for fentanyl 50 mug, lockout six-minute; 0.63 +/- 0.21 for fentanyl 25 mug, lockout three-minute; and 0.81 +/- 0.17 for fentanyl 50 mug, lockout three-minute groups. We found no significant differences among the four groups with respect to using delivery/demand ratio as a measure of pain relief. Morphine had the highest rate of side effects compared to fentanyl. There was strong evidence of differences among groups with regard to patient satisfaction and expected pain, and moderate evidence of differences in the delivery and labour pain scores. Conclusion: This study found PCA fentanyl 50 mug with a lockout period of six minutes provided satisfactory analgesia for second trimester labour.	Mt Sinai Hosp, Dept Anesthesia, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Dept Nursing, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Dept Obstet, Toronto, ON M5G 1X5, Canada	Castro, C (reprint author), Mt Sinai Hosp, Dept Anesthesia, Toronto, ON M5G 1X5, Canada.		Windrim, Rory/B-7617-2016; Windrim, Rory/AAC-6038-2020				Austrup ML, 1999, SURG CLIN N AM, V79, P253, DOI 10.1016/S0039-6109(05)70382-0; CRAFT JB, 1983, ANESTH ANALG, V62, P894; CROWHURST JA, 1994, INT ANESTHESIOL CLIN, V32, P45; DAVIS VJ, 1999, J SOC OBSTET GYNAECO, V82, P1169; GAMBLING DR, 1993, CAN J ANAESTH, V40, P211, DOI 10.1007/BF03037032; GAVELIN RJ, 1992, CAN J ANAESTH, V39, P1116, DOI 10.1007/BF03008383; HOWELL PR, 1995, CAN J ANAESTH, V42, P41, DOI 10.1007/BF03010570; Jones R, 1999, ANAESTHESIA, V54, P461, DOI 10.1046/j.1365-2044.1999.00857.x; KLEIMAN SJ, 1991, CAN J ANAESTH, V38, P489, DOI 10.1007/BF03007585; KOEHNTOP DE, 1986, ANESTH ANALG, V65, P227; LOVELL M, 2000, INT J OBSTET ANESTH, V85, P176; MCINTOSH DG, 1991, OBSTET GYNECOL, V78, P1129; Morley-Forster PK, 2000, CAN J ANAESTH, V47, P113, DOI 10.1007/BF03018845; Nikkola EM, 1997, CAN J ANAESTH, V44, P1248, DOI 10.1007/BF03012771; OWEN H, 1989, ANAESTHESIA, V44, P7, DOI 10.1111/j.1365-2044.1989.tb11087.x; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; Roelants F, 2001, CAN J ANAESTH, V48, P175, DOI 10.1007/BF03019731; ROSAEG OP, 1992, CAN J ANAESTH, V39, P277, DOI 10.1007/BF03008789; ROSEN M, 1986, SEMIN ANESTH PERIO M, V5, P108; ROSENBLATT WH, 1992, ANESTH ANALG, V75, P760; ROSENBLATT WH, 1991, ANESTH ANALG, V73, P553; Thurlow JA, 2000, BRIT J ANAESTH, V84, P411; WASYLAK TJ, 1990, CAN J ANAESTH, V37, P726, DOI 10.1007/BF03006529; WELCHEW EA, 1983, ANAESTHESIA, V38, P19, DOI 10.1111/j.1365-2044.1983.tb10367.x; Westfall P.H., 1999, MULTIPLE COMP MULTIP	25	22	22	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	DEC	2003	50	10					1039	1046		10.1007/BF03018370			8	Anesthesiology	Anesthesiology	754BU	WOS:000187283500016	14656784	Bronze			2020-06-30	J	Neema, PK; Unnikrishnan, M; Sinha, PK; Rathod, RC				Neema, PK; Unnikrishnan, M; Sinha, PK; Rathod, RC			Anesthetic management for a hypertensive patent ductus arteriosus (PDA) closure in a patient with surgically uncorrectable long-segment right pulmonary artery hypoplasia and a ventricular septal defect	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						patent ductus arteriosus; right pulmonary artery hypoplasia; ventricular septal defect; pediatrics	EXPERIENCE		Sree Chitra Tirunal Inst Med Sci & Technol, Dept Anesthesiol, Trivandrum 695011, Kerala, India; Sree Chitra Tirunal Inst Med Sci & Technol, Dept Cardiothorac & Vasc Surg, Trivandrum 695011, Kerala, India	Neema, PK (reprint author), Sree Chitra Tirunal Inst Med Sci & Technol, Dept Anesthesiol, Trivandrum 695011, Kerala, India.						BARAKA AS, 1991, ANESTH ANALG, V72, P238, DOI 10.1213/00000539-199102000-00017; BRANTHWATE MA, 1980, ANESTHESIA CARDIAC S, P59; HICKEY PR, 1993, CARDIAC ANESTHESIA, P681; JOHN S, 1981, J THORAC CARDIOV SUR, V82, P314; KIRKLIN JW, 1993, CARDIAC SURG, V1, P841; LABORDE F, 1995, J THORAC CARDIOV SUR, V110, P1681, DOI 10.1016/S0022-5223(95)70031-5; MACINTOSH R, 1962, PHYS ANAESTHERIST, P156; MOORE P, 2001, MOSS ADAMS HEART DIS, P652; Mullins CE, 1998, SCI PRACTICE PEDIAT, VI, P1181; ROBERTS JD, 1993, CIRCULATION, V87, P447, DOI 10.1161/01.CIR.87.2.447; ROSEN DA, 1998, PEDIAT CARDIAC ANEST, P431; SCHWARTZ AJ, 1998, PEDIAT CARDIAC ANEST, P7; STOELTING RK, 1993, ANESTHESIA COEXISTIN, P37	13	2	3	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	DEC	2003	17	6					740	743		10.1053/j.jvca.2003.09.016			4	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	758ZP	WOS:000187712900014	14689417				2020-06-30	J	Mizoguchi, H; Wu, HE; Narita, M; Sora, I; Hall, FS; Uhl, GR; Loh, HH; Nagase, H; Tseng, LF				Mizoguchi, H; Wu, HE; Narita, M; Sora, I; Hall, FS; Uhl, GR; Loh, HH; Nagase, H; Tseng, LF			Lack of mu-opioid receptor-mediated G-protein activation in the spinal cord of mice lacking exon 1 or exons 2 and 3 of the MOR-1 gene	JOURNAL OF PHARMACOLOGICAL SCIENCES			English	Article						mu-opioid receptor; exon; knockout mice; G-protein activation; spinal cord	MORPHINE-INDUCED ANALGESIA; BETA-ENDORPHIN; KNOCKOUT MICE; GUANOSINE-5'-O-(3-<S-35>THIO)TRIPHOSPHATE BINDING; DIFFERENTIAL MECHANISM; MOUSE PONS/MEDULLA; OPIATE RECEPTOR; ENDOMORPHIN; STIMULATION; EXPRESSION	The G-protein activation induced by mu-opioid receptor agonists was determined in spinal cord membranes from two types of mu-opioid receptor knockout mice: mice with a disruption of exon 1 (MOR (Exon 1)-KO) or exons 2 and 3 (MOR (Exons 2 and 3)-KO) of the mu-opioid receptor gene. The G-protein activation induced by the opioid agonists was measured by monitoring the increases of guanosine-5'-O-(3- [S-35]thio)triphosphate ([S-35]GTPgammaS) binding. The mu-opioid receptor agonists (D-Ala(2),N-MePhe(4),Gly-ol(5)]enkephalin, endomorphin-1, endomorphin-2, morphine, morphine-6beta-glucuronide, and fentanyl produced concentration-dependent increases of [S-35]GTPgammaS binding to spinal cord membranes in wild-type mice, but not in MOR (Exon 1)-KO mice or MOR (Exons 2 and 3)-KO mice. On the other hand, the delta-opioid receptor agonist [D-Pen(2,5)]enkephalin, the kappa-opioid receptor agonist (-)U50,488H, or the ORL1-receptor agonist nociception increased [S-35]GTPgammaS binding in the spinal cord membranes from both MOR (Exon 1)-KO mice and MOR (Exons 2 and 3)-KO mice to the same extent as in the corresponding wild-type mice. The results provide further information about the important roles of the sequences encoded within exon 1 and exons 2 and 3 of mu-opioid receptor gene for the activation of G-proteins by mu-opioid receptor agonists in the mouse spinal cord.	Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA; Hoshi Univ, Sch Pharm, Dept Toxicol, Tokyo 1428501, Japan; Tokyo Inst Psychiat, Dept Psychopharmacol, Tokyo 1568585, Japan; NIDA, Mol Neurobiol Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA; Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA; Toray Industries Ltd, Pharmaceut Res Lab, Kamakura, Kanagawa 2488555, Japan	Tseng, LF (reprint author), Med Coll Wisconsin, Dept Anesthesiol, Milwaukee, WI 53226 USA.	ltseng@mcw.edu	Hall, F. Scott/C-3036-2013	Hall, F. Scott/0000-0002-0822-4063	NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 03811]		Alt A, 1998, J PHARMACOL EXP THER, V286, P282; CHEN Y, 1993, MOL PHARMACOL, V44, P8; Kitanaka N, 1998, EUR J PHARMACOL, V355, pR1, DOI 10.1016/S0014-2999(98)00516-0; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mayer P, 1996, J NEUROCHEM, V66, P2272; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; Mizoguchi H, 2000, LIFE SCI, V67, P2733, DOI 10.1016/S0024-3205(00)00852-3; Mizoguchi H, 1999, NEUROSCIENCE, V94, P203, DOI 10.1016/S0306-4522(99)00298-5; Mizoguchi H, 2000, NEUROSCIENCE, V100, P835, DOI 10.1016/S0306-4522(00)00306-7; Mizoguchi H, 2002, NEUROSCI LETT, V335, P91, DOI 10.1016/S0304-3940(02)01171-0; Mizoguchi H, 2002, JPN J PHARMACOL, V89, P229, DOI 10.1254/jjp.89.229; Narita M, 2002, JPN J PHARMACOL, V89, P224, DOI 10.1254/jjp.89.224; Narita M, 1998, EUR J PHARMACOL, V351, P383, DOI 10.1016/S0014-2999(98)00395-1; Narita M, 2000, J BIOMED SCI, V7, P221, DOI 10.1007/BF02255469; Pan YX, 1999, MOL PHARMACOL, V56, P396; Pan YX, 2001, P NATL ACAD SCI USA, V98, P14084, DOI 10.1073/pnas.241296098; Schuller AGP, 1999, NAT NEUROSCI, V2, P151; Selley DE, 1997, MOL PHARMACOL, V51, P87; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230	22	18	19	0	2	JAPANESE PHARMACOLOGICAL SOC	KYOTO	EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604, JAPAN	1347-8613	1347-8648		J PHARMACOL SCI	J. Pharmacol. Sci.	DEC	2003	93	4					423	429		10.1254/jphs.93.423			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	757MN	WOS:000187566200007	14737012	Bronze			2020-06-30	J	Mendes, GM; Selmi, AL				Mendes, GM; Selmi, AL			Use of a combination of propofol and fentanyl, alfentanil, or sufentanil for total intravenous anesthesia in cats	JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article							MINIMUM ALVEOLAR CONCENTRATION; CONTROLLED INFUSION; ICI 35-868; ISOFLURANE; SURGERY; DOGS; PHARMACOKINETICS; METHOHEXITONE; HALOTHANE; MULTIPLE	Objective-To determine the cardiorespiratory effects of an IV infusion of propofol alone or in association with fentanyl, alfentanil, or sufentanil in cats and, for each combination, the minimal infusion rate of propofol that would inhibit a response to noxious stimuli. Design-Randomized crossover study. Animals-6 cats. Procedure-Cats were anesthetized 4 times in random order. After IV administration of fentanyl, alfentanil, sufentanil, or saline (0.9% NaCl) solution, anesthesia was induced with propofol (7 mg/kg [3.2 mg/lb], IV) and maintained for 90 minutes with a continuous infusion of propofol in conjunction with fentanyl (0.1 mug/kg/min [0.045 mug/lb/min]), alfentanil (0.5 mug/kg/min [0.23 mug/lb/min]), sufentanil (0.01 mug/kg/min [0.004 mug/lb/min]), or saline solution (0.08 mL/kg/min [0.036 mL/lb/min]). Results-Minimal infusion rate of propofol required to prevent a response to a noxious stimulus was higher when cats received saline solution. After 70 minutes, minimal infusion rate of propofol was significantly higher with fentanyl than with sufentanil. Decreases in heart rate, systolic blood pressure, rectal temperature, and respiratory rate were detected with all treatments. Oxygen saturation did not change significantly, but end-tidal partial pressure of carbon dioxide increased with all treatments. There were no significant differences in recovery times or sedation and recovery scores among treatments. Conclusions and Clinical Relevance-Results suggest that infusion of propofol in combination with fentanyl, alfentanil, or sufentanil results in satisfactory anesthesia in cats.	Univ Brasilia, Fac Agron & Med Vet, Vet Teaching Hosp, BR-70910970 Brasilia, DF, Brazil	Selmi, AL (reprint author), Univ Anhembi Morumbi, Rua Conselheiro Lafaiete,64 Bras, BR-03164110 Sao Paulo, Brazil.						ADAM HK, 1980, BRIT J ANAESTH, V52, P743, DOI 10.1093/bja/52.8.743; Ahonen J, 2000, BRIT J ANAESTH, V85, P533, DOI 10.1093/bja/85.4.533; Beths T, 2001, VET REC, V148, P198, DOI 10.1136/vr.148.7.198; Bettschart-Wolfensberger R, 2001, AM J VET RES, V62, P500, DOI 10.2460/ajvr.2001.62.500; BOVILL JG, 1984, ANESTH ANALG, V63, P1081; BREARLEY JC, 1988, J SMALL ANIM PRACT, V29, P315, DOI 10.1111/j.1748-5827.1988.tb02290.x; CULLEN PM, 1987, ANESTH ANALG, V71, P827; ERIKSEN J, 1981, ACTA ANAESTH SCAND, V25, P33, DOI 10.1111/j.1399-6576.1981.tb01602.x; Fantoni D. T., 1999, Ciencia Rural, V29, P681, DOI 10.1590/S0103-84781999000400019; GAUMANN DM, 1988, NEUROSCI LETT, V91, P30, DOI 10.1016/0304-3940(88)90244-3; GLEN JB, 1980, BRIT J ANAESTH, V52, P731, DOI 10.1093/bja/52.8.731; HALL LW, 1987, J SMALL ANIM PRACT, V28, P623, DOI 10.1111/j.1748-5827.1987.tb01277.x; Hug Jr CC, 1999, OPIOIDS PAIN CONTROL, P234; Ilkiw JE, 1997, AM J VET RES, V58, P1274; KEEGAN RD, 1993, VET SURG, V22, P537, DOI 10.1111/j.1532-950X.1993.tb00434.x; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; Lehmann A, 2002, ANESTH ANALG, V95, P639, DOI 10.1097/00000539-200209000-00027; MATOT I, 1993, ANESTHESIOLOGY, V78, P1157, DOI 10.1097/00000542-199306000-00021; Muir WW, 2002, AM J VET RES, V63, P1241, DOI 10.2460/ajvr.2002.63.1241; NOLAN A, 1993, BRIT J ANAESTH, V70, P546, DOI 10.1093/bja/70.5.546; PASCOE PJ, 1993, AM J VET RES, V54, P1327; Pascoe PJ, 1997, AM J VET RES, V58, P1267; SCHAFER SL, 1993, SEMIN ANESTH, V12, P222; SEAR JW, 1983, ANAESTHESIA, V38, P931, DOI 10.1111/j.1365-2044.1983.tb12021.x; SELLGREN J, 1992, ACTA ANAESTH SCAND, V36, P784, DOI 10.1111/j.1399-6576.1992.tb03565.x; Short CE, 1999, VET CLIN N AM-SMALL, V29, P747, DOI 10.1016/S0195-5616(99)50059-4; TAYLOR PM, 1994, ANAESTHESIA CAT, P249; TRIM JE, 1994, ANAESTHESIA CAT, P194; ZBINDEN AM, 1994, ANESTHESIOLOGY, V80, P253, DOI 10.1097/00000542-199402000-00004	29	30	35	0	3	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA				J AM VET MED ASSOC	J. Am. Vet. Med. Assoc.	DEC 1	2003	223	11					1608	1613		10.2460/javma.2003.223.1608			6	Veterinary Sciences	Veterinary Sciences	746AB	WOS:000186722900021	14664447				2020-06-30	J	Pollock, CG; Ramsay, EC				Pollock, CG; Ramsay, EC			Serial immobilization of a Brazilian tapir (Tapirus terrestrus) with oral detomidine and oral carfentanil	JOURNAL OF ZOO AND WILDLIFE MEDICINE			English	Article						tapir; Tapirus terrestrus; transmucosal; anesthesia; detomidine; carfentanil		Detomidine (0.17 +/- 0.03 mg/kg, p.o.) followed in 20 min by carfentanil (7.88 +/- 1.85 mug/kg, p.o.) reliably restrained an adult Brazilian tapir (Tapirus terrestrus) eight times for short medical procedures. Detomidine caused head droop, sawhorse stance, ataxia or head pressing (or both). Sternal or lateral recumbency was reached within 10.75 +/- 7.6 min of carfentanil administration. Recoveries after i.v. and s.c. administration of yohimbine and naltrexone were smooth and rapid, with the tapir standing within 2-5 min.	Univ Tennessee, Coll Vet Med, Dept Comparat Med, Knoxville, TN 37901 USA	Pollock, CG (reprint author), Kansas State Univ, Dept Clin Sci, 1800 Denison Ave, Manhattan, KS 66506 USA.						Chevlen Eric, 2003, Curr Pain Headache Rep, V7, P15, DOI 10.1007/s11916-003-0005-5; Foerster SH, 2000, J WILDLIFE DIS, V36, P335, DOI 10.7589/0090-3558-36.2.335; JANSSEN DL, 1999, ZOO WILD ANIMAL MED, V4, P562; Kuehn G., 1986, P931; Malone JH, 1993, J VET ANAESTHESIA, V20, P73; Miller-Edge M., 1994, Proceedings American Association of Zoo Veterinarians and Association of Reptilian and Amphibian Veterinarians Annual Conference Pittsburgh, USA, 22-27, October, 1994., P192; MUIR WW, 2000, HDB VET ANESTHESIA, P19; Trim CM, 1998, J ZOO WILDLIFE MED, V29, P195; WONG HM, 2000, ACTA ANAESTHESIOL SI, V383, P155; ZANDSBERG S, 1994, ANESTHESIOL CLIN N A, V12, P17	10	6	9	1	7	AMER ASSOC ZOO VETERINARIANS	MEDIA	6 NORTH PENNELL ROAD, MEDIA, PA 19063 USA	1042-7260			J ZOO WILDLIFE MED	J. Zoo Wildl. Med.	DEC	2003	34	4					408	410		10.1638/01-061			3	Veterinary Sciences	Veterinary Sciences	803GU	WOS:000220220400012	15077719				2020-06-30	J	Lee, PW; Lee, YM				Lee, PW; Lee, YM			Transcriptional regulation of mu opioid receptor gene by cAMP pathway	MOLECULAR PHARMACOLOGY			English	Article							MORPHINE-INDUCED ANALGESIA; MESSENGER-RNA; SIGNAL-TRANSDUCTION; MICE LACKING; FENTANYL; PROTEIN; CREB; PROMOTER; KNOCKOUT; ELEMENT	The utility of morphine for the treatment of chronic pain is hindered by the development of tolerance. Fentanyl has been shown to be a potent analgesic with a lower propensity to produce tolerance and physical dependence in the clinical setting. Previous finding has shown that fentanyl induces mu opioid receptor gene expression in PC-12 cells (Brain Res 859: 217 223, 2000). In this report, we aim to identify the molecular mechanism of mu-opioid receptor (MOR) gene regulation by fentanyl. We demonstrated that the 4.7-kilobase MOR promoter could be induced by fentanyl in PC-12 cells, and we defined a partial cAMP response element (CRE) located at -106/-111 in 5'-untranslated region of the MOR gene. In electrophoretic mobility shift assay, cAMP response element-binding protein (CREB) was found in the protein-DNA complex formed on the CRE box. CREB was phosphorylated after forskolin induction, and both CREB and CREB-binding protein (CBP) binding to the endogenous MOR promoter was increased by forskolin in chromatin immunoprecipitation assay. The functional role of CREB in the induction of MOR gene was further elucidated by an experiment in which a dominant-negative mutant CREB, CREB-S133A, abolished the forskolin-mediated MOR induction. Moreover, we found that this CRE box is conserved in mouse, rat, and human MOR gene, implying physiological relevance in different species. Collectively, this study demonstrated that fentanyl-triggered MOR gene induction was mediated by the sequential activation of CREB and the binding of CREB and CBP to MOR promoter, thus provides direct evidence for lower propensity of fentanyl to produce tolerance.	Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan; Natl Taiwan Univ, Dept Biol Sci, Taipei, Taiwan	Lee, YM (reprint author), Acad Sinica, Inst Biol Chem, 128 Sect 2,Acad Rd, Taipei 115, Taiwan.	ym16120@gate.sinica.edu.tw					AvidorReiss T, 1996, J BIOL CHEM, V271, P21309, DOI 10.1074/jbc.271.35.21309; Azaryan AV, 1996, J NEUROCHEM, V66, P443; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Chan HM, 2001, J CELL SCI, V114, P2363; Chieng B, 1998, J NEUROSCI, V18, P7033; Choe CY, 1998, J BIOL CHEM, V273, P34926, DOI 10.1074/jbc.273.52.34926; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Crain SM, 2000, PAIN, V84, P121, DOI 10.1016/S0304-3959(99)00223-7; DELFS JM, 1994, J NEUROCHEM, V63, P777; DEVRIES TJ, 1993, LIFE SCI, V52, P1685, DOI 10.1016/0024-3205(93)90476-J; Hwu WL, 1997, DNA CELL BIOL, V16, P449, DOI 10.1089/dna.1997.16.449; Hyman SE, 1996, SCIENCE, V273, P611, DOI 10.1126/science.273.5275.611; Jordan B, 1998, BRIT J ANAESTH, V81, P12; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kitchen I, 1997, BRAIN RES, V778, P73, DOI 10.1016/S0006-8993(97)00988-8; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; Kraus J, 2001, J BIOL CHEM, V276, P43901, DOI 10.1074/jbc.M107543200; LI H, 2002, CELL, V108, P271; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; Maldonado R, 1996, SCIENCE, V273, P657, DOI 10.1126/science.273.5275.657; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MIN BH, 1994, P NATL ACAD SCI USA, V91, P9081, DOI 10.1073/pnas.91.19.9081; MINAMI M, 1995, NEUROSCI RES, V23, P121, DOI 10.1016/0168-0102(95)00933-K; Narita M, 2002, LIFE SCI, V70, P2341, DOI 10.1016/S0024-3205(01)01550-8; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; NESTLER EJ, 1994, BRAIN RES BULL, V35, P521, DOI 10.1016/0361-9230(94)90166-X; Ngo TT, 2002, J BIOL CHEM, V277, P33901, DOI 10.1074/jbc.M202135200; PAIX A, 1995, PAIN, V63, P263, DOI 10.1016/0304-3959(95)00084-6; PARONIS CA, 1992, J PHARMACOL EXP THER, V262, P1; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Ronnekleiv OK, 1996, NEUROSCI LETT, V216, P129; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; Vitolo OV, 2002, P NATL ACAD SCI USA, V99, P13217, DOI 10.1073/pnas.172504199; Wood P. L., 1988, OPIATE RECEPTORS, P307; Yoshikawa M, 2000, BRAIN RES, V859, P217, DOI 10.1016/S0006-8993(00)01961-2; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157	40	27	29	0	4	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0026-895X	1521-0111		MOL PHARMACOL	Mol. Pharmacol.	DEC	2003	64	6					1410	1418		10.1124/mol.64.6.1410			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	748DM	WOS:000186846900017	14645671				2020-06-30	J	Gaitan, G; Del Soldato, P; Herrero, JF				Gaitan, G; Del Soldato, P; Herrero, JF			Low doses of nitroparacetamol or dexketoprofen trometamol enhance fentanyl antinociceptive activity	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						pain; analgesia; spinal cord; opioid; nonsteroidal anti-inflammatory drug; wind-up	WIND-UP; NOCICEPTIVE REFLEXES; WITHDRAWAL REFLEXES; DORSAL HORN; RAT; MORPHINE; NEURONS; STIMULATION; INVOLVEMENT; PARACETAMOL	We have reported that subeffiective doses of the nonsteroidal anti-inflammatory drug (NSAID) dexketoprofen trometamol enhances mu-opioid receptor agonist fentanyl antinociception. The aim of this study was to assess if this effect can also be observed with other new cyclooxygenase-inhibitors such as nitroparacetamol, and in responses to high intensity electrical stimulation (wind-up). Single motor units were recorded in male Wistar rats under alpha-chloralose anaesthesia. The antinociceptive effect of fentanyl was studied alone and in the presence of subeffective doses of dexketoprofen trometamol or nitroparacetamol. In responses to noxious mechanical stimulation, the potency of fentanyl was enhanced by more than threefold in the presence of the NSAIDs and no significant recovery was observed after 45 min. The opioid antagonist naloxone and the alpha(2)-adrenoceptor antagonist atipamezol did not reverse the effect. The enhancement of the effect of fentanyl in wind-up was lower though significant. We conclude that the co-administration of subeffective doses of new cyclooxygenase-inhibitors and the mu-opioid receptor agonist fentanyl should be considered as a potential pain therapy. (C) 2003 Elsevier B.V. All rights reserved.	Univ Alcala de Henares, Fac Med, Dept Fisiol, Madrid 28871, Spain; NicOx SA, Sophia Antipolis, France	Herrero, JF (reprint author), Univ Alcala de Henares, Fac Med, Dept Fisiol, Campus Univ, Madrid 28871, Spain.			Herrero, Juan F./0000-0003-1986-3482			al-Swayeh OA, 2000, BRIT J PHARMACOL, V130, P1453, DOI 10.1038/sj.bjp.0703509; BEAVER WT, 1984, AM J MED, V77, P38, DOI 10.1016/S0002-9343(84)80101-1; DAVIES SN, 1987, BRAIN RES, V424, P402, DOI 10.1016/0006-8993(87)91487-9; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; del Soldato P, 1999, TRENDS PHARMACOL SCI, V20, P319, DOI 10.1016/S0165-6147(99)01353-X; DICKENSON AH, 1987, NEUROPHARMACOLOGY, V26, P1235, DOI 10.1016/0028-3908(87)90275-9; Fiorucci S, 2002, BRIT J PHARMACOL, V135, P589, DOI 10.1038/sj.bjp.0704500; Futter LE, 2001, BRIT J PHARMACOL, V132, P10, DOI 10.1038/sj.bjp.0703837; Gaitan G, 2002, BRIT J PHARMACOL, V135, P393, DOI 10.1038/sj.bjp.0704491; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; Herrero JF, 1996, BRAIN RES, V717, P62, DOI 10.1016/0006-8993(95)01585-X; Herrero JF, 1999, BRAIN RES, V840, P106, DOI 10.1016/S0006-8993(99)01780-1; HERRERO JF, 1991, BRIT J PHARMACOL, V104, P166, DOI 10.1111/j.1476-5381.1991.tb12402.x; MALMBERG AB, 1993, ANESTHESIOLOGY, V79, P270, DOI 10.1097/00000542-199308000-00012; MASNIETO M, 2001, [No title captured], V41, P496; MAVES TJ, 1994, ANESTHESIOLOGY, V80, P1094, DOI 10.1097/00000542-199405000-00018; Mazario J, 2001, NEUROPHARMACOLOGY, V40, P937, DOI 10.1016/S0028-3908(01)00020-X; Mazario J, 1999, BRAIN RES, V816, P512, DOI 10.1016/S0006-8993(98)01203-7; Melis M, 2000, EUR J PHARMACOL, V387, pR1, DOI 10.1016/S0014-2999(99)00799-2; Romero-Sandoval EA, 2002, BRIT J PHARMACOL, V135, P1556, DOI 10.1038/sj.bjp.0704589; Sandrini M, 1998, EUR J PHARMACOL, V355, P133, DOI 10.1016/S0014-2999(98)00496-8; SCHOUENBORG J, 1994, EXP BRAIN RES, V100, P170; Solano R, 1997, J NEUROSCI METH, V73, P135, DOI 10.1016/S0165-0270(96)02220-0; TJOLSEN A, 1991, EUR J PHARMACOL, V193, P193, DOI 10.1016/0014-2999(91)90036-P; Vaughan CW, 1997, NATURE, V390, P611, DOI 10.1038/37610	25	12	12	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	NOV 28	2003	481	2-3					181	188		10.1016/j.ejphar.2003.09.024			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	749MW	WOS:000186925400008	14642784				2020-06-30	J	Mystakidou, K; Tsilika, E; Parpa, E; Kouloulias, V; Kouvaris, I; Georgaki, S; Vlahos, L				Mystakidou, K; Tsilika, E; Parpa, E; Kouloulias, V; Kouvaris, I; Georgaki, S; Vlahos, L			Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl	INTERNATIONAL JOURNAL OF CANCER			English	Article						cancer; pain management; TTS-F; morphine; opioid-naive	QUALITY-OF-LIFE; EFFICACY CLINICAL-TRIAL; ORAL MORPHINE; SAFETY; VALIDATION; CODEINE; RELIEF	There is emerging data supporting the use of TTS-F (transdermal therapeutic system-fentanyl) in opioid naive patients. Our study examines the safety and efficacy of TTS-F in the long-term control of cancer pain in opioid naive patients and those transferring from oral morphine. Pain was assessed in 589 patients (Group A: 268 opioid naive, Group B: 321 transferring from morphine) using a Visual Analogue Scale (VAS; 0-10), based on selected questions from the Greek Brief Pain Inventory (GBPI). Overall treatment satisfaction was assessed on a 4-point scale. Quality of Life (QOL) and ECOG (0-4) status were also recorded. These were assessed in relation to TTS-F dose, pain type (neuropathic, combined, nociceptive), concomitant use of anti-inflammatory drugs and other demographic data. Of 589 patients, 59 (10%) withdrew as a result of inadequate pain satisfaction or for other reasons. There were no discontinuations due to side effects; no Grade 3-4 events occurred. A total of 530 continued on-study, 211 patients died during study period and 295 departed; all (506; 89%) were satisfied with their pain relief. Analysis of patients at baseline, 28 days, 6 and 12 month time points (n = 153 Group A; n = 214 Group B) with respect to QOL and pain measures indicated a statistically significant (p < 0.001) improvement in all measures across time independent of pain type, or any other patient characteristic(s). In patients with intolerable pain, transfer to TTS-F offers an efficient and safe long-term analgesic option. TTS-F offers durable long-term maintenance of pain relief with acceptable side effects in opioid naive patients. In general, TTS-F as a first line analgesic approach for carefully selected and monitored patients experiencing moderate to severe cancer pain should be considered. (C) 2003 Wiley-Liss, Inc.	Univ Athens, Pain Relief & Palliat Care Unit, Dept Radiol, Areteion Hosp,Sch Med, Athens 11528, Greece; Univ Athens, Radiotherapy Unit, Dept Radiol, Sch Med,Areteion Hosp, Athens, Greece	Mystakidou, K (reprint author), Univ Athens, Pain Relief & Palliat Care Unit, Dept Radiol, Areteion Hosp,Sch Med, Vas Sofias 76, Athens 11528, Greece.		Kouloulias, Vassilis/AAD-7348-2019				Ahmedzai S, 1997, EUR J CANCER, V33, pS8, DOI 10.1016/S0959-8049(97)00205-0; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; ARMER S, 1998, PAIN, V33, P11; BURZA M, 1998, CLIN TER, V149, P227; Cancer Therapy Evaluation Program, 1998, COMM TOX CRIT VERS 2; Cherny N, 2000, J Oncol Manag, V9, P8; DELLEMIJN PLI, 1977, LANCET, V347, P753; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; KORTE W, 1994, SUPPORT CARE CANCER, V2, P123, DOI 10.1007/BF00572094; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; Mystakidou K, 1998, CANCER-AM CANCER SOC, V83, P1214, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1214::AID-CNCR22>3.0.CO;2-7; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; Mystakidou K, 2001, ONCOLOGY-BASEL, V60, P35, DOI 10.1159/000055294; Mystakidou K, 2001, ANTICANCER RES, V21, P2225; MYSTAKIDOU K, 2003, IN PRESS J PAIN; Nugent M, 2001, J PAIN SYMPTOM MANAG, V21, P385, DOI 10.1016/S0885-3924(01)00257-3; Payne R, 1998, SEMIN ONCOL, V25, P47; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; SIMMONDS M, 1997, SEMIN ONCOL, V24; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; SPITZER WO, 1981, J CHRON DIS, V34, P585, DOI 10.1016/0021-9681(81)90058-8; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M	27	29	31	1	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0020-7136			INT J CANCER	Int. J. Cancer	NOV 10	2003	107	3					486	492		10.1002/ijc.11416			7	Oncology	Oncology	733DK	WOS:000185984500022	14506751				2020-06-30	J	Korhonen, AM; Valanne, JV; Jokela, RM; Ravaska, P; Korttila, K				Korhonen, AM; Valanne, JV; Jokela, RM; Ravaska, P; Korttila, K			Ondansetron does not prevent pruritus induced by low-dose intrathecal fentanyl	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						ambulatory surgery; bupivacaine; intrathecal fentanyl; ondansetron; pruritus; spinal anesthesia	OUTPATIENT KNEE ARTHROSCOPY; MORPHINE-INDUCED PRURITUS; OPIOID-INDUCED PRURITUS; SPINAL-ANESTHESIA; CESAREAN DELIVERY; BUPIVACAINE; ANALGESIA; SECTION; RELIEF; MG	Background: Addition of an opioid to low-dose spinal anesthesia with bupivacaine improves the quality and success of anesthesia. However, the intrathecal fentanyl-induced pruritus is as high as 75%. We hypothesized that after administration of 4 or 8 mg of prophylactic IV ondansetron, the incidence of pruritus induced by low-dose intrathecal fentanyl would be significantly lower than after placebo. Methods: In this double-blind study, 90 outpatients undergoing knee arthroscopy received 3 mg of bupivacaine + 10 mug fentanyl intrathecally. Before spinal puncture, the patients received randomly either saline (P) or ondansetron 4 mg (O4) or 8 mg (O8) IV. They were asked about pruritus frequently, and they estimated its severity on a scale of 0-10. Results: There was no difference in the incidence of pruritus between the three groups: pruritus occurred in 17 (57%), in 21 (75%) and in 19 patients (70%) in P, O4 and O8 groups, respectively. The pruritus was mostly mild. Four patients in the placebo group, three in the O4 and four patients in the O8 groups considered it severe. One patient in each group requested treatment for pruritus; after IV naloxone their pruritus was relieved. Neither time to pruritus nor duration of pruritus differed between the groups. One patient in each group developed a long-lasting (>10 h) pruritus. Conclusions: After prophylactic administration of 4 or 8 mg of ondansetron IV, the incidence, duration and severity of pruritus were similar to placebo. Ondansetron does not prevent pruritus induced by low-dose intrathecal fentanyl.	Lapland Cent Hosp, Dept Anesthesia, FIN-96400 Rovaniemi, Finland; Univ Helsinki, Dept Anesthesia & Intens Care, Helsinki, Finland	Korhonen, AM (reprint author), Lapland Cent Hosp, Dept Anesthesia, Ounasrinteentie 22, FIN-96400 Rovaniemi, Finland.	anna-maija.korhonen@hus.fi	Jokela, Ritva/E-1286-2013				Altman DG, 2000, STAT CONFIDENCE; Beilin Y, 1998, ANESTH ANALG, V86, P310, DOI 10.1097/00000539-199802000-00018; Ben-David B, 2001, ANESTH ANALG, V93, P319, DOI 10.1097/00000539-200108000-00016; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Borgeat A, 1999, ANESTHESIOLOGY, V90, P432, DOI 10.1097/00000542-199902000-00017; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; FAN P, 1995, MOL PHARMACOL, V47, P491; GRIGHTON IM, 1996, ANAESTHESIA, V51, P199; Gurkan Y, 2002, ANESTH ANALG, V95, P1763, DOI 10.1213/01.ANE.0000033097.30674.02; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; HARRISON DM, 1988, ANESTHESIOLOGY, V68, P454, DOI 10.1097/00000542-198803000-00025; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046/j.0265-0215.2000.00826.x; Korhonen AM, 2003, ACTA ANAESTH SCAND, V47, P342, DOI 10.1034/j.1399-6576.2003.00092.x; Larijani GE, 1996, PHARMACOTHERAPY, V16, P958; Mulroy MF, 2000, ANESTH ANALG, V91, P860, DOI 10.1097/00000539-200010000-00017; RADERER M, 1994, NEW ENGL J MED, V330, P1540, DOI 10.1056/NEJM199405263302117; Rawal N, 1999, SURG CLIN N AM, V79, P313, DOI 10.1016/S0039-6109(05)70385-6; SCHWORER H, 1995, PAIN, V61, P33, DOI 10.1016/0304-3959(94)00145-5; Valanne JV, 2001, ANESTH ANALG, V93, P1377, DOI 10.1097/00000539-200112000-00005; Warwick JP, 1997, ANAESTHESIA, V52, P270, DOI 10.1111/j.1365-2044.1997.069-az0060.x; Yazigi A, 2002, J CLIN ANESTH, V14, P183, DOI 10.1016/S0952-8180(01)00381-6; Yeh HM, 2000, ANESTH ANALG, V91, P172, DOI 10.1097/00000539-200007000-00032	23	21	21	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2003	47	10					1292	1297		10.1046/j.1399-6576.2003.00206.x			6	Anesthesiology	Anesthesiology	740DJ	WOS:000186385900019	14616330				2020-06-30	J	Mather, LE; Cousins, MJ				Mather, LE; Cousins, MJ			The site of action of epidural fentanyl: What can be learned by studying the difference between infusion and bolus administration? The importance of history, one hopes	ANESTHESIA AND ANALGESIA			English	Editorial Material							ANTINOCICEPTIVE ACTION; PHARMACOKINETICS; ANALGESIA; MORPHINE; OPIOIDS; CSF		Univ Sydney, Royal N Shore Hosp, Pain Management Res Inst, St Leonards, NSW 2065, Australia	Mather, LE (reprint author), Univ Sydney, Royal N Shore Hosp, Pain Management Res Inst, St Leonards, NSW 2065, Australia.		Mather, Laurence E/G-8155-2011	Mather, Laurence/0000-0001-8174-7752			COUSINS MJ, 1979, LANCET, V1, P1141; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; GLYNN CJ, 1981, ANESTHESIOLOGY, V55, P520, DOI 10.1097/00000542-198111000-00007; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Tucker GT, 1998, NEURAL BLOCKADE CLIN, P55; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7; YEUNG JC, 1980, J PHARMACOL EXP THER, V215, P626; YEUNG JC, 1980, J PHARMACOL EXP THER, V215, P633	12	11	12	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2003	97	5					1211	1213		10.1213/01.ANE.0000092951.32643.A6			3	Anesthesiology	Anesthesiology	735YZ	WOS:000186143600001	14570625				2020-06-30	J	Reinsfelt, B; Westerlind, A; Houltz, E; Ederberg, S; Elam, M; Ricksten, SE				Reinsfelt, B; Westerlind, A; Houltz, E; Ederberg, S; Elam, M; Ricksten, SE			The effects of isoflurane-induced electroencephalographic burst suppression on cerebral blood flow velocity and cerebral oxygen extraction during cardiopulmonary bypass	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	Annual Meeting of the European-Association-of-Cardiothoracic-Anaesthesiologists	JUN 12-15, 2002	DUBLIN, IRELAND	European Assoc Cardiothorac Anaesthesiologists			CENTRAL-NERVOUS-SYSTEM; CARDIAC-SURGERY; AUTOREGULATION; PROTECTION; COMPLICATIONS; METABOLISM; ANESTHESIA; PRESSURE; INFUSION; HUMANS	We investigated the effects of isoflurane-induced burst suppression, monitored with electroencephalography (EEG), on cerebral blood flow velocity (CBFV), cerebral oxygen extraction (COE), and autoregulation in 16 patients undergoing cardiac surgery. The experimental procedure was performed during nonpulsatile cardiopulmonary bypass (CPB) with mild hypothermia (32degreesC) in fentanyl-anesthestized patients. Middle cerebral artery transcranial Doppler flow velocity, right jugular vein bulb oxygen saturation, and jugular venous pressure (JVP) were continuously measured. Autoregulation was tested during changes in mean arterial blood pressure (MAP) within a range of 40-80 mm Hg, induced by sodium nitroprusside and phenylephrine before (control) and during additional isoflurane administration to an EEG burst-suppression level of 6-9 /min. Isoflurane induced a 27% decrease in CBFV (P < 0.05) and a 13% decrease in COE (P < 0.05) compared with control. The slope of the positive relationship between CBFV and cerebral perfusion pressure (CPP = MAP - JVP) was steeper with isoflurane (P < 0.05) compared with control, as was the slope of the negative relationship between CPP and COE (P < 0.05). We conclude that burst-suppression doses of isoflurane decrease CBFV and impair autoregulation of cerebral blood flow during mildly hypothermic CPB. Furthermore, during isoflurane administration, blood flow was in excess relative to oxygen demand, indicating a loss of metabolic autoregulation of flow.	Sahlgrens Univ Hosp, Dept Cardiothorac Anesthesia & Intens Care, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Clin Neurophysiol, S-41345 Gothenburg, Sweden	Ricksten, SE (reprint author), Sahlgrens Univ Hosp, Dept Cardiothorac Anesthesia & Intens Care, S-41345 Gothenburg, Sweden.						AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; ALADJ LJ, 1991, ANESTH ANALG, V72, P48; ALGOTSSON L, 1988, ACTA ANAESTH SCAND, V32, P15, DOI 10.1111/j.1399-6576.1988.tb02678.x; Arrowsmith JE, 2000, BRIT J ANAESTH, V84, P378; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; Ederberg S, 1998, ANESTH ANALG, V86, P1201, DOI 10.1097/00000539-199806000-00011; MADSEN JB, 1987, ANESTHESIOLOGY, V66, P332, DOI 10.1097/00000542-198703000-00012; MURKIN JM, 1987, ANESTH ANALG, V66, P825; NAKAJIMA T, 1993, ANESTH ANALG, V77, P1111; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; NEWMAN MF, 1995, ANESTH ANALG, V81, P236, DOI 10.1097/00000539-199508000-00005; Newman MF, 1996, CIRCULATION, V94, P353; Newman MF, 1996, J CLIN ANESTH, V8, pS53, DOI 10.1016/S0952-8180(96)90013-6; Newman MF, 1998, ANESTH ANALG, V86, P246, DOI 10.1097/00000539-199802000-00005; NUSSMEIER NA, 1986, ANESTHESIOLOGY, V64, P165, DOI 10.1097/00000542-198602000-00006; ROGERS AT, 1988, ANESTHESIOLOGY, V69, P547, DOI 10.1097/00000542-198810000-00015; ROGERS AT, 1989, ANESTH ANALG, V68, P122, DOI 10.1213/00000539-198902000-00010; Summors AC, 1999, ANESTH ANALG, V88, P341, DOI 10.1097/00000539-199902000-00022; TODD MM, 1992, ANESTHESIOLOGY, V76, P161; Trivedi UH, 1997, ANN THORAC SURG, V63, P167; WOODCOCK TE, 1987, ANESTHESIOLOGY, V67, P218, DOI 10.1097/00000542-198708000-00011; ZAIDAN JR, 1991, ANESTHESIOLOGY, V74, P406, DOI 10.1097/00000542-199103000-00003	22	12	12	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2003	97	5					1246	1250		10.1213/01.ANE.0000086732.97924.BE			5	Anesthesiology	Anesthesiology	735YZ	WOS:000186143600006	14570630				2020-06-30	J	Mi, WD; Ishihara, H; Sakai, T; Matsuki, A				Mi, WD; Ishihara, H; Sakai, T; Matsuki, A			Possible overestimation of indocyanine green-derived plasma volume early after induction of anesthesia with propofol/fentanyl	ANESTHESIA AND ANALGESIA			English	Article							ACUTE NORMOVOLEMIC HEMODILUTION; ENDOTHELIAL SURFACE-LAYER; RADICAL HYSTERECTOMY; PROPOFOL ANESTHESIA; BLOOD-VOLUME; ISOFLURANE; BINDING; PHARMACOKINETICS; HEMATOCRIT; SEVOFLURANE	Apparently large plasma volumes derived by indocyanine green (PV-ICG) have been determined in the initial period after induction of anesthesia. We tested the hypothesis that possible overestimation of PV-ICG occurs shortly after anesthetic induction. Anesthesia was induced in 13 patients with fentanyl bolus 2 mug/kg and propofol infusion 0.5 mg(.)kg(-1.)min(-1) IV until patients lost consciousness and was then maintained with a propofol infusion. PV-ICG and the initial distribution volume of glucose (IDVG) were assessed at 15 min before and at 15 min after anesthetic induction. Plasma ICG and glucose concentrations were measured from serial blood samples taken before and through 7 min after injection of ICG 25 mg and glucose 5 g. PV-ICG and IDVG were calculated using a one-compartment model. PV-ICG was significantly increased by an average of 15.3% after induction, from 2.29 +/- 0.38 (SD) L to 2.64 +/- 0.31 L (P < 0.001). The mean hematocrit (Hct), concentrations of hemoglobin (Hb), and total plasma proteins at postinduction decreased compared with those at preinduction by 2.9%, 2.2%, and 2.3%, respectively (P < 0.05). Percentile increase in plasma volume calculated from Hb and Hct before and after induction was 4%. Consequently, an 11% overestimation in PV-ICG was observed. IDVG remained unchanged. Therefore, the ratio of PV-ICG/IDVG increased from 0.40 +/- 0.05 before induction to 0.48 +/- 0.06 after induction (P < 0.01). These results validate the hypothesis that possible overestimation of PV-ICG occurs during a definable period of time after propofol anesthetic induction. The present results also support the PV-ICG/IDVG ratio as a measure of possible overestimation of PV-ICG or fluid redistribution from the central to the peripheral tissues.	Hirosaki Univ, Sch Med, Dept Anesthesiol, Hirosaki, Aomori 0368562, Japan	Ishihara, H (reprint author), Hirosaki Univ, Sch Med, Dept Anesthesiol, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.						Akaike H., 1974, IEEE T AUTOMATIC CON, V19, P16; Avram MJ, 2000, ANESTHESIOLOGY, V92, P1757, DOI 10.1097/00000542-200006000-00036; Brauer KI, 2002, ANESTHESIOLOGY, V96, P442, DOI 10.1097/00000542-200202000-00033; Bruegger D, 2002, ACTA ANAESTH SCAND, V46, P481, DOI 10.1034/j.1399-6576.2002.460502.x; BRULISAUER M, 1991, INT J MICROCIRC, V10, P21; BUSSE MW, 1993, ANAESTHESIA, V48, P41; CHERRICK GR, 1960, J CLIN INVEST, V39, P592, DOI 10.1172/JCI104072; Deryck YLJM, 1996, ANESTH ANALG, V83, P958, DOI 10.1097/00000539-199611000-00011; Ebert TJ, 2000, ANESTHESIOLOGY, V93, P1401, DOI 10.1097/00000542-200012000-00010; FLECK A, 1985, LANCET, V1, P781; Ishihara H, 1999, INTENS CARE MED, V25, P1252, DOI 10.1007/s001340051053; Ishihara H, 2000, CRIT CARE MED, V28, P620, DOI 10.1097/00003246-200003000-00003; Jones JG, 2000, BRIT J ANAESTH, V84, P226; KREJCIE TC, 1992, J PHARMACOL EXP THER, V200, P296; Matsui A, 2000, INTENS CARE MED, V26, P1131, DOI 10.1007/s001340051328; Mazoit JX, 1999, BRIT J CLIN PHARMACO, V47, P35, DOI 10.1046/j.1365-2125.1999.00860.x; MEIJER DKF, 1984, J PHARMACOKINET BIOP, V12, P43, DOI 10.1007/BF01063610; Menth-Meier SE, 2001, INTENS CARE MED, V27, P925, DOI 10.1007/s001340100942; Myburgh JA, 2002, ANAESTH INTENS CARE, V30, P725, DOI 10.1177/0310057X0203000602; Ott P, 1997, AM J PHYSIOL-GASTR L, V273, pG227; PEARSON TC, 1995, BRIT J HAEMATOL, V89, P748; Pries AR, 2000, PFLUG ARCH EUR J PHY, V440, P653, DOI 10.1007/s004240000307; Rehm M, 2001, ANESTHESIOLOGY, V95, P849, DOI 10.1097/00000542-200110000-00011; Rehm M, 2000, ANESTH ANALG, V90, P852, DOI 10.1213/00000539-200004000-00014; Rehm M, 2000, ANESTHESIOLOGY, V92, P657, DOI 10.1097/00000542-200003000-00008; SELLGREN J, 1994, ANESTHESIOLOGY, V80, P534, DOI 10.1097/00000542-199403000-00009; Vink H, 2000, AM J PHYSIOL-HEART C, V278, pH285; Zamacona MK, 1998, ANESTH ANALG, V87, P1147, DOI 10.1097/00000539-199811000-00032	28	5	5	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2003	97	5					1421	1427		10.1213/01.ANE.0000084361.12884.D1			7	Anesthesiology	Anesthesiology	735YZ	WOS:000186143600036	14570660				2020-06-30	J	Ginosar, Y; Riley, ET; Angst, MS				Ginosar, Y; Riley, ET; Angst, MS			The site of action of epidural fentanyl in humans: The difference between infusion and bolus administration	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	Annual Meeting of the Society of Obstetric Anesthesiology and Perinatology	MAY, 2002	HILTON HEAD ISL, SOUTH CAROLINA	Soc Obstetr Anesthesiol & Perinatol			PATIENT-CONTROLLED ANALGESIA; INTRAVENOUS FENTANYL; POSTOPERATIVE PAIN; SPINAL MECHANISM; MORPHINE; ALFENTANIL; SUFENTANIL; LUMBAR; LABOR; EQUIVALENT	Most published studies suggesting that epidural fentanyl acts predominantly at spinal sites administered the drug as a bolus injection, whereas most studies suggesting that it acts predominantly at supraspinal sites administered the drug as an infusion. In this study we tested the hypothesis that the mode of administration (bolus versus infusion) of epidural fentanyl determines its site of action. Ten healthy volunteers were enrolled in this randomized, double-blinded, cross-over study. On separate study days fentanyl was administered into the epidural space as a bolus (0.03 mg followed by 0.1 mg 210 min later) and as an infusion (0.03 mg/h followed by 0.1 mg/hr 210 min later for 200 min). Using a thermal and electrical experimental pain model, the heat (degreesC) and electrical current (mA) causing maximum tolerable pain were assessed repetitively over a period of 420 min. The analgesic efficacy measures were obtained at a lumbar and a cranial dermatome. Plasma fentanyl concentrations were determined throughout the study. Epidural bolus administration of fentanyl resulted in segmental analgesia (leg > head), whereas the epidural infusion of fentanyl produced nonsegmental analgesia (leg = head). There was a significant linear relationship between the analgesic effect and the Plasma concentration of fentanyl for the epidural infusion but not for the epidural bolus administration of fentanyl. These findings support our hypothesis and might explain the apparent conflict in the literature regarding the site of action of epidural fentanyl.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anesthesiol & Crit Care Med, IL-91120 Jerusalem, Israel; Stanford Univ, Dept Anesthesia, Stanford, CA 94305 USA	Ginosar, Y (reprint author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anesthesiol & Crit Care Med, POB 12000, IL-91120 Jerusalem, Israel.						AKERMAN B, 1988, ANESTH ANALG, V67, P943; Angst MS, 2001, ANESTHESIOLOGY, V94, P63, DOI 10.1097/00000542-200101000-00014; Angst MS, 2000, ANESTHESIOLOGY, V92, P312, DOI 10.1097/00000542-200002000-00011; BEHAR M, 1979, LANCET, V1, P527; BERNARDS CM, 1990, ANESTHESIOLOGY, V73, P1214, DOI 10.1097/00000542-199012000-00020; BERNARDS CM, 1992, ANESTHESIOLOGY, V77, P750, DOI 10.1097/00000542-199210000-00020; CAMU F, 1991, ANESTHESIOLOGY, V75, P171, DOI 10.1097/00000542-199108000-00001; CHAUVIN M, 1993, ANESTH ANALG, V76, P1251, DOI 10.1213/00000539-199376060-00012; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; Coda BA, 1999, ANESTHESIOLOGY, V90, P98, DOI 10.1097/00000542-199901000-00015; Cohen S, 2002, ANESTH ANALG, V94, P674, DOI 10.1097/00000539-200203000-00036; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; D'Angelo R, 1998, ANESTHESIOLOGY, V88, P1519, DOI 10.1097/00000542-199806000-00016; ELLIS DJ, 1990, ANESTHESIOLOGY, V72, P981, DOI 10.1097/00000542-199006000-00006; GELLER E, 1993, ANESTH ANALG, V76, P1243, DOI 10.1213/00000539-199376060-00011; Ginosar Y, 2003, ANESTH ANALG, V97, P1439, DOI 10.1213/01.ANE.0000081792.84877.A2; GLASS PSA, 1992, ANESTH ANALG, V74, P345; GOURLAY GK, 1985, PAIN, V23, P317, DOI 10.1016/0304-3959(85)90001-6; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; GUINARD JP, 1995, ANESTHESIOLOGY, V82, P377, DOI 10.1097/00000542-199502000-00008; GUINARD JP, 1992, ANESTHESIOLOGY, V77, P1108, DOI 10.1097/00000542-199212000-00011; HARUKUNI I, 1995, ANESTH ANALG, V81, P1169, DOI 10.1097/00000539-199512000-00009; HERZ A, 1970, NEUROPHARMACOLOGY, V9, P539, DOI 10.1016/0028-3908(70)90004-3; INAGAKI Y, 1992, ANESTH ANALG, V74, P856; JUSTINS DM, 1982, BRIT J ANAESTH, V54, P409, DOI 10.1093/bja/54.4.409; LEBARS D, 1976, BRAIN RES, V115, P518, DOI 10.1016/0006-8993(76)90370-X; Liu SS, 1996, ANESTH ANALG, V82, P98, DOI 10.1097/00000539-199601000-00017; LOMESSY A, 1984, ANESTHESIOLOGY, V61, P466, DOI 10.1097/00000542-198410000-00020; LOPER KA, 1990, ANESTH ANALG, V70, P72; Lotsch J, 2003, PAIN, V102, P151, DOI 10.1016/S0304-3959(02)00349-4; MAGORA F, 1980, BRIT J ANAESTH, V52, P247, DOI 10.1093/bja/52.3.247; Menigaux C, 2001, ANESTH ANALG, V93, P472, DOI 10.1097/00000539-200108000-00046; MIGUEL R, 1994, ANESTHESIOLOGY, V81, P346, DOI 10.1097/00000542-199408000-00012; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; Saito Y, 1998, ANESTHESIOLOGY, V89, P1455, DOI 10.1097/00000542-199812000-00023; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010; SANDLER AN, 1992, ANESTHESIOLOGY, V77, P626, DOI 10.1097/00000542-199210000-00003; Sinatra RS, 1996, J CLIN ANESTH, V8, P123, DOI 10.1016/0952-8180(95)00196-4; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; van den Nieuwenhuyzen MCO, 1998, ANESTH ANALG, V86, P574, DOI 10.1097/00000539-199803000-00026; vandenNieuwenhuyzen MCO, 1996, ACTA ANAESTH SCAND, V40, P1112; VELLA LM, 1985, ANAESTHESIA, V40, P741, DOI 10.1111/j.1365-2044.1985.tb10997.x; Yeomans DC, 1996, PAIN, V68, P133, DOI 10.1016/S0304-3959(96)03176-4	43	57	68	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2003	97	5					1428	1438		10.1213/01.ANE.0000081793.60059.10			11	Anesthesiology	Anesthesiology	735YZ	WOS:000186143600037	14570661				2020-06-30	J	Ginosar, Y; Columb, MO; Cohen, SE; Mirikatani, E; Tingle, MS; Ratner, EF; Angst, MS; Riley, ET				Ginosar, Y; Columb, MO; Cohen, SE; Mirikatani, E; Tingle, MS; Ratner, EF; Angst, MS; Riley, ET			The site of action of epidural fentanyl infusions in the presence of local anesthetics: A minimum local analgesic concentration infusion study in nulliparous labor	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	Annual Meeting of the Society of Obstetric Anesthesiology and Perinatology	MAY, 2002	HILTON HEAD ISL, SOUTH CAROLINA	Soc Obstetr Anesthesiol & Perinatol			PATIENT-CONTROLLED ANALGESIA; PAIN RELIEF; POSTOPERATIVE ANALGESIA; INTRAVENOUS SUFENTANIL; INTRATHECAL MORPHINE; EXTRADURAL FENTANYL; SPINAL MECHANISM; BUPIVACAINE; ALFENTANIL; LIDOCAINE	We have previously demonstrated that continuous epidural infusions of fentanyl without local anesthetics elicit analgesia by a systemic mechanism. In this study, we examined the hypothesis that, in the presence of epidural bupivacaine, continuous infusions of epidural fentanyl elicit analgesia by a spinal mechanism. Forty-eight nulliparous women in active labor participated in this prospective, randomized, double-blinded study. Women received lumbar epidural analgesia with 20-30 mL bupivacaine 0.125% until pain free. Subjects were then randomized to either TV or epidural (EPI) fentanyl infusion groups. Each infusion delivered fentanyl 30 mug/h. All women received an epidural infusion of bupivacaine at a rate of 20 mL/h, the concentration of which was determined by the response of the previous woman in the same group to the analgesic regimen used. Unlike previous studies that assessed the minimum local analgesic concentration (MLAC) for bolus administration at the initiation of analgesia, this study assessed MLAC(infusion) for the maintenance of analgesia throughout the first stage of labor. MLAC(infusion) was determined using the up-down sequential analysis described by Dixon and Massey. The MLAC(infusion) of epidural bupivacaine was 0.063% (95% confidence interval, 0.058-0.068) and 0.019% (95% confidence interval, 0.000-0.038) in the IV and EPI groups respectively. A continuous infusion of fentanyl was more than three times as potent when administered by the epidural than by the IV route. This marked increase in potency for the epidural route is highly suggestive for a predominantly spinal mechanism of action for infused epidural fentanyl under the conditions of this study.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anesthesiol & Crit Care Med, IL-91120 Jerusalem, Israel; Univ S Manchester Hosp, Dept Anaesthesia & Intens Care Med, Wythenshawe, England; Stanford Univ, Dept Anesthesia, Stanford, CA 94305 USA	Ginosar, Y (reprint author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anesthesiol & Crit Care Med, POB 12000, IL-91120 Jerusalem, Israel.		Columb, Malachy/F-9588-2016	Columb, Malachy/0000-0001-7837-4262			AKERMAN B, 1988, ANESTH ANALG, V67, P943; BERNARDS CM, 1992, ANESTHESIOLOGY, V77, P750, DOI 10.1097/00000542-199210000-00020; Camann W, 1998, REGION ANESTH PAIN M, V23, P457, DOI 10.1016/S1098-7339(98)90027-X; CAMU F, 1991, ANESTHESIOLOGY, V75, P171, DOI 10.1097/00000542-199108000-00001; Capogna G, 1998, BRIT J ANAESTH, V80, P11; Capogna G, 2001, ANESTHESIOLOGY, V94, P740, DOI 10.1097/00000542-200105000-00009; Capogna G, 1999, BRIT J ANAESTH, V82, P371, DOI 10.1093/bja/82.3.371; CHAUVIN M, 1993, ANESTH ANALG, V76, P1251, DOI 10.1213/00000539-199376060-00012; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; Coda BA, 1999, ANESTHESIOLOGY, V90, P98, DOI 10.1097/00000542-199901000-00015; Cohen S, 2002, ANESTH ANALG, V94, P674, DOI 10.1097/00000539-200203000-00036; COLUMB MO, 1995, ANESTH ANALG, V81, P833, DOI 10.1097/00000539-199510000-00030; D'Angelo R, 1998, ANESTHESIOLOGY, V88, P1519, DOI 10.1097/00000542-199806000-00016; Dixon WJ, 1983, INTRO STAT ANAL; ELLIS DJ, 1990, ANESTHESIOLOGY, V72, P981, DOI 10.1097/00000542-199006000-00006; GELLER E, 1993, ANESTH ANALG, V76, P1243, DOI 10.1213/00000539-199376060-00011; Ginosar Y, 2003, ANESTH ANALG, V97, P1428, DOI 10.1213/01.ANE.0000081793.60059.10; GLASS PSA, 1992, ANESTH ANALG, V74, P345; GUINARD JP, 1995, ANESTHESIOLOGY, V82, P377, DOI 10.1097/00000542-199502000-00008; INAGAKI Y, 1992, ANESTH ANALG, V74, P856; JUSTINS DM, 1982, BRIT J ANAESTH, V54, P409, DOI 10.1093/bja/54.4.409; KANEKO M, 1994, ANESTHESIOLOGY, V80, P137, DOI 10.1097/00000542-199401000-00021; Liu SS, 1996, ANESTH ANALG, V82, P98, DOI 10.1097/00000539-199601000-00017; LOMESSY A, 1984, ANESTHESIOLOGY, V61, P466, DOI 10.1097/00000542-198410000-00020; LOPER KA, 1990, ANESTH ANALG, V70, P72; Lyons G, 1997, BRIT J ANAESTH, V78, P493; Lyons G, 1998, BRIT J ANAESTH, V81, P899; MAVES TJ, 1992, ANESTHESIOLOGY, V76, P91, DOI 10.1097/00000542-199201000-00014; MIGUEL R, 1994, ANESTHESIOLOGY, V81, P346, DOI 10.1097/00000542-199408000-00012; PENNING JP, 1992, ANESTHESIOLOGY, V77, P1186, DOI 10.1097/00000542-199212000-00021; Polley LS, 1996, ANESTH ANALG, V83, P987, DOI 10.1097/00000539-199611000-00015; Polley LS, 1998, ANESTHESIOLOGY, V89, P626, DOI 10.1097/00000542-199809000-00011; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; Saito Y, 1998, ANESTHESIOLOGY, V89, P1455, DOI 10.1097/00000542-199812000-00023; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010; SANDLER AN, 1992, ANESTHESIOLOGY, V77, P626, DOI 10.1097/00000542-199210000-00003; Sinatra RS, 1996, J CLIN ANESTH, V8, P123, DOI 10.1016/0952-8180(95)00196-4; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; VELLA LM, 1985, ANAESTHESIA, V40, P741, DOI 10.1111/j.1365-2044.1985.tb10997.x; Vercauteren M, 1997, PHARMACOL BIOCHEM BE, V58, P237, DOI 10.1016/S0091-3057(97)00011-7; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019	41	34	37	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2003	97	5					1439	1445		10.1213/01.ANE.0000081792.84877.A2			7	Anesthesiology	Anesthesiology	735YZ	WOS:000186143600038	14570662				2020-06-30	J	Cepeda, MS; Carr, DB				Cepeda, MS; Carr, DB			Women experience more pain and require more morphine than men to achieve a similar degree of analgesia	ANESTHESIA AND ANALGESIA			English	Article							SEX-DIFFERENCES; GENDER; PERCEPTION	Sex differences in pain perception and in response to opioids have been described, but the findings are inconsistent. We sought to determine the effect of sex on pain perception, morphine consumption, and morphine analgesia after surgery. We designed a prospective cohort study and included 423 women and 277 men who emerged from general anesthesia after surgical procedures and who reported pain intensity of greater than or equal to 5 on the 0-10 numeric rating scale (NRS). We administered 2.5 mg of morphine IV every 10 min until the pain intensity was less than or equal to 4 of 10. Every 10 min, patients rated their pain on the NRS and indicated the degree of pain relief on a 5-point Likert scale. After adjustment for type of operation and age, we found that women had more intense pain and had larger morphine consumption than men. The difference in NRS pain intensity was 0.4 U (95% confidence interval, 0.1-0.6 U). Women required 0.03 mg/kg more morphine than men (95% confidence interval, 0.02-0.04 mg/kg). We conclude that women have more intense pain and require 30% more morphine to achieve a similar degree of analgesia compared with men. Clinicians should anticipate the differences in opioid requirement to avoid undertreatment of pain in women.	Tufts Univ New England Med Ctr, Dept Anesthesia, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; Javeriana Univ, Sch Med, San Ignacio Hosp, Dept Anesthesia, Bogota, Colombia	Carr, DB (reprint author), Tufts Univ New England Med Ctr, Dept Anesthesia, 750 Washington St,298, Boston, MA 02111 USA.	daniel.carr@tufts.edu					Averbuch M, 2000, ARCH INTERN MED, V160, P3424, DOI 10.1001/archinte.160.22.3424; Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x; Bouillon T, 1999, ANESTHESIOLOGY, V91, P144, DOI 10.1097/00000542-199907000-00023; BURNS JW, 1989, ANAESTHESIA, V44, P2, DOI 10.1111/j.1365-2044.1989.tb11086.x; Cepeda MS, 2003, PROG PAIN RES MANAG, V24, P601; Cepeda MS, 2001, CLIN PHARMACOL THER, V70, P351, DOI 10.1067/mcp.2001.118632; Cepeda MS, 2002, PAIN, V96, P73, DOI 10.1016/S0304-3959(01)00425-0; CEPEDA MS, 2003, OVERVIEW PAIN MAMAGE, P1; Chia YY, 2002, CAN J ANAESTH, V49, P249, DOI 10.1007/BF03020523; Cicero TJ, 1997, J PHARMACOL EXP THER, V282, P939; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; FOX J, 1991, REGRESSION DIAGNOSTI, P21; Gear RW, 1996, NAT MED, V2, P1248, DOI 10.1038/nm1196-1248; Gear RW, 1996, NEUROSCI LETT, V205, P207, DOI 10.1016/0304-3940(96)12402-2; GORDON NC, 1995, NEUROSCIENCE, V69, P345, DOI 10.1016/0306-4522(95)00335-G; KEPLER KL, 1991, PAIN, V45, P87, DOI 10.1016/0304-3959(91)90168-W; Kest B, 2000, ANESTHESIOLOGY, V93, P539, DOI 10.1097/00000542-200008000-00034; MOSTELLER F, 1997, DATA ANAL REGRESSION, P333; Riley JL, 1999, PAIN, V81, P225, DOI 10.1016/S0304-3959(98)00258-9; Riley JL, 1998, PAIN, V74, P181, DOI 10.1016/S0304-3959(97)00199-1; Sarton E, 2000, ANESTHESIOLOGY, V93, P1245, DOI 10.1097/00000542-200011000-00018; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; Unruh AM, 1996, PAIN, V65, P123, DOI 10.1016/0304-3959(95)00214-6; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	25	172	185	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2003	97	5					1464	1468		10.1213/01.ANE.0000080153.36643.83			5	Anesthesiology	Anesthesiology	735YZ	WOS:000186143600042	14570666				2020-06-30	J	Schmidt, GN; Bischoff, P; Standl, T; Jensen, K; Voigt, M; Esch, JSA				Schmidt, GN; Bischoff, P; Standl, T; Jensen, K; Voigt, M; Esch, JSA			Narcotrend (R) and Bispectral Index (R) monitor are superior to classic electroencephalographic parameters for the assessment of anesthetic states during propofol-remifentanil anesthesia	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 12-16, 2002	ORLANDO, FLORIDA	Amer Soc Anesthesiologists			AUDITORY-EVOKED POTENTIALS; QUANTITATIVE EEG ANALYSIS; LOOP FEEDBACK-CONTROL; GENERAL-ANESTHESIA; ISOFLURANE ANESTHESIA; NITROUS-OXIDE; DEPTH; PERFORMANCE; INDEX; INDICATORS	Background: A new electroencephalogram monitor, the Narcotrend(R), was developed to measure anesthetic depth. The authors compared the Narcotrend(R), the Bispectral Index(R), and classic electroencephalographic and hemodynamic parameters during anesthesia with propofol and remifentanil. Methods: The authors investigated 25 patients undergoing laminectomy at different anesthetic states: awake, steady state anesthesia, first reaction during emergence, and extubation. Narcotrend(R) value; BIS; relative power (percent) in delta, theta, alpha, and beta; median frequency; spectral edge frequency; and hemodynamic parameters were recorded simultaneously. The ability of the classic and processed electroencephalographic and hemodynamic parameters to predict the clinically relevant anesthetic states of awake, steady state anesthesia, first reaction, and extubation was tested using prediction probability. Results: Only the Narcotrend(R) was able to differentiate between awake versus steady state anesthesia and steady state anesthesia versus first reaction/extubation with a prediction probability value of more than 0.90. Conclusions: Modern electroencephalographic parameters, especially Narcotrend(R), are more reliable indicators for the clinical assessment of anesthetic states than classic parameters.	Univ Hamburg, Hosp Eppendorf, Dept Anesthesiol, D-20246 Hamburg, Germany							Baker GW, 2000, ANAESTH INTENS CARE, V28, P386, DOI 10.1177/0310057X0002800405; CHEN YD, 1994, LITHOS, V32, P77, DOI 10.1016/0024-4937(94)90022-1; CHERNIK DA, 1990, J CLIN PSYCHOPHARM, V10, P244; COETZEE JF, 1995, ANESTHESIOLOGY, V82, P1328, DOI 10.1097/00000542-199506000-00003; DAVIDSON JAH, 1993, ACTA ANAESTH SCAND, V37, P458, DOI 10.1111/j.1399-6576.1993.tb03746.x; DRUMMOND JC, 1991, ACTA ANAESTH SCAND, V35, P693, DOI 10.1111/j.1399-6576.1991.tb03374.x; DWYER RC, 1994, ANESTHESIOLOGY, V81, P403, DOI 10.1097/00000542-199408000-00019; Gray JM, 1998, ANAESTHESIA, V53, P22, DOI 10.1111/j.1365-2044.1998.53s114.x; Jensen EW, 2001, ANESTHESIOLOGY, V94, P718, DOI 10.1097/00000542-200104000-00039; Johansen JW, 2000, ANESTHESIOLOGY, V93, P1336, DOI 10.1097/00000542-200011000-00029; KATO M, 1992, ANESTHESIOLOGY, V77, P669, DOI 10.1097/00000542-199210000-00009; Kreuer S, 2001, ANAESTHESIST, V50, P921, DOI 10.1007/s00101-001-0242-0; Kugler J, 1981, ELEKTROENZEPHALOGRAP; Leslie K, 1996, ANESTHESIOLOGY, V84, P52, DOI 10.1097/00000542-199601000-00006; Mantzaridis H, 1997, ANAESTHESIA, V52, P1030, DOI 10.1111/j.1365-2044.1997.185-az0327.x; Schmidt GN, 2002, ANESTH ANALG, V95, P1324, DOI 10.1097/00000539-200211000-00042; Schnider TW, 1999, ANESTHESIOLOGY, V90, P1502, DOI 10.1097/00000542-199906000-00003; Schultz B, 2002, BIOMED TECH, V47, P9, DOI 10.1515/bmte.2002.47.1-2.9; SCHWILDEN H, 1987, ANESTHESIOLOGY, V67, P341, DOI 10.1097/00000542-198709000-00011; SCHWILDEN H, 1989, BRIT J ANAESTH, V62, P290, DOI 10.1093/bja/62.3.290; Smith WD, 1996, ANESTHESIOLOGY, V84, P38, DOI 10.1097/00000542-199601000-00005; Struys MMRF, 2002, ANESTHESIOLOGY, V96, P803, DOI 10.1097/00000542-200204000-00006; Swinhoe CF, 1998, ANAESTHESIA, V53, P61, DOI 10.1111/j.1365-2044.1998.53s104.x; WHITE PF, 1989, ANESTH ANALG, V68, P177, DOI 10.1213/00000539-198902000-00020	24	40	56	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	NOV	2003	99	5					1072	1077		10.1097/00000542-200311000-00012			6	Anesthesiology	Anesthesiology	737NZ	WOS:000186239800011	14576542				2020-06-30	J	Lerman, J; Nolan, J; Eyres, P; Schily, M; Stoddart, P; Bolton, CM; Mazzeo, F; Wolf, AR				Lerman, J; Nolan, J; Eyres, P; Schily, M; Stoddart, P; Bolton, CM; Mazzeo, F; Wolf, AR			Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children - A multicenter trial	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 10-20, 2001	NEW ORLEANS, LA	Amer Soc Anesthesiologists			POSTOPERATIVE PAIN; BUPIVACAINE; EPINEPHRINE; ENANTIOMERS; ANALGESIA; TOXICITY; MORPHINE; INFANTS	Background: Levobupivacaine, the levo-enantiomer of bupivacaine, is as potent as bupivacaine but less toxic. Therefore, the authors investigated the efficacy, safety, and pharmacokinetics of perioperative epidural levobupivacaine with and without fentanyl in children. Methods: After Research Ethics Board approval and informed written consent, 120 healthy children aged 6 months to 12 yr who were scheduled to undergo urologic or abdominal surgery were randomized in a double-blinded and concealed manner to receive one of four epidural solutions as a continuous infusion for 24 h: 0.125% levobupivacaine; 0.0625% levobupivacaine; 1 mug/ml fentanyl; or the combination, 0.0625 levobupivacaine and I mug/ml fentanyl. After induction of anesthesia and tracheal intubation, a lumbar epidural catheter was sited, a loading dose was administered (0.75 ml/kg levobupivacaine, 0.175%), and the epidural infusion was commenced. The primary endpoint was the need for rescue analgesia (morphine) in the first 10 h after surgery. Pain, motor strength, and side effects were recorded for 24 h. Venous blood was collected from 18 children to determine the plasma concentrations of levobupivacaine and/or fentanyl before and 2, 4, 8, 16, 24, and 26 or 30 h after the start of the epidural infusion. Results: Of the 114 children who were analyzed for intention to treat, a similar number of children in each group reached the 10-h mark. The time to the first dose of morphine in the first 10 h was less in the plain fentanyl group (P < 0.044). All other effects were similar among the four groups. The plasma concentration of levobupivacaine increased during the infusion period, reaching a maximum of 0.76 +/- 0.11 mug/ml in the 0.125% group and 0.48 +/- 0.12 mug/ml in the 0.0625% group by 24 h. The plasma concentration of fentanyl also increased steadily, reaching a maximum concentration of 0.37 +/- 0.11 ng/ml by 24 h. Conclusion: We conclude that 0.0625% levobupivacaine without fentanyl is an effective perioperative epidural solution in children when infused at a rate of 0.3 ml (.) kg(-1) (.) h(-1). The plasma concentrations of 0.125% and 0.0625% levobupivacaine and fentanyl (I mug/ml) at the end of a 24-h infusion are low.	SUNY Buffalo, Childrens Hosp Buffalo, Dept Anesthesiol, Buffalo, NY 14222 USA; Bristol Royal Hosp Sick Children, Sir Humphry Davy Dept Anaesthesia, Bristol, Avon, England; Royal Childrens Hosp, Dept Anaesthesia, Melbourne, Vic, Australia; Univ Toronto, Toronto, ON, Canada	Lerman, J (reprint author), SUNY Buffalo, Childrens Hosp Buffalo, Dept Anesthesiol, 219 Bryant St, Buffalo, NY 14222 USA.	jlerman@adelphia.net		Lerman, Jerrold/0000-0003-4408-9847			AGARWAL R, 1992, ANESTH ANALG, V75, P284; APS C, 1978, BRIT J CLIN PHARMACO, V6, P63, DOI 10.1111/j.1365-2125.1978.tb01683.x; Carr AS, 1998, CAN J ANAESTH, V45, P1054, DOI 10.1007/BF03012391; FREID EB, 1993, ANESTHESIOLOGY, V79, P394, DOI 10.1097/00000542-199308000-00029; GRECO CD, 2002, PEDIAT PAIN MANAGEME, P757; Kart T, 1997, ACTA ANAESTH SCAND, V41, P461, DOI 10.1111/j.1399-6576.1997.tb04724.x; Ladd LA, 2000, J PHARMACOL TOX MET, V44, P467, DOI 10.1016/S1056-8719(01)00109-5; LEJUS C, 1994, BRIT J ANAESTH, V72, P156, DOI 10.1093/bja/72.2.156; MAZOIT JX, 1993, ANESTH ANALG, V77, P477; MCCLOSKEY JJ, 1992, ANESTH ANALG, V75, P287; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; McLeod GA, 2001, ANAESTHESIA, V56, P331, DOI 10.1046/j.1365-2044.2001.01964.x; VANHOUTTE F, 1991, BRIT J PHARMACOL, V103, P1275, DOI 10.1111/j.1476-5381.1991.tb12336.x; VED SA, 1993, ANESTHESIOLOGY, V79, P1121, DOI 10.1097/00000542-199311000-00030; Veering BT, 2002, ANESTHESIOLOGY, V96, P1062, DOI 10.1097/00000542-200205000-00006; YASTER M, 2002, PEDIAT ANESTHESIA PR, P705; ZWASS MS, 2001, PRACTICE ANESTHESIA, P681	17	27	29	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	NOV	2003	99	5					1166	1174		10.1097/00000542-200311000-00025			9	Anesthesiology	Anesthesiology	737NZ	WOS:000186239800024	14576555				2020-06-30	J	Zubieta, JK; Ketter, TA; Bueller, JA; Xu, YJ; Kilbourn, MR; Young, EA; Koeppe, RA				Zubieta, JK; Ketter, TA; Bueller, JA; Xu, YJ; Kilbourn, MR; Young, EA; Koeppe, RA			Regulation of human affective responses by anterior cingulate and limbic mu-opioid neurotransmission	ARCHIVES OF GENERAL PSYCHIATRY			English	Article; Proceedings Paper	57th Annual Meeting of the Society-of-Biological-Psychiatry	MAY 16-18, 2002	PHILADELPHIA, PA	Soc Biol Psychiat			POSITRON-EMISSION-TOMOGRAPHY; STRESS-INDUCED ANALGESIA; CEREBRAL-BLOOD-FLOW; HUMAN BRAIN; FUNCTIONAL NEUROANATOMY; FACIAL EXPRESSIONS; ENDOGENOUS OPIOIDS; MAJOR DEPRESSION; SUICIDE VICTIMS; HUMAN AMYGDALA	Background: Human affective responses appear to be regulated by limbic and paralimbic circuits. However, much less is known about the neurochemical systems engaged in this regulation. The mu-opioid neurotransmitter system is distributed in, and thought to regulate the function of, brain regions centrally implicated in affective processing. Objective: To examine the involvement of mu-opioid neuretransmission in the regulation of affective states in healthy human volunteers. Design: Measures of mu-opioid receptor availability in vivo were obtained with positron emission tomography and the mu-opioid receptor selective rachotracer [C-11]carfen-tanil during a neutral state and during a sustained sadness state. Subtraction analyses of the binding potential maps were then performed within subjects, between conditions, on a voxel-by-voxel basis. Setting: Imaging center at a university medical center Participants: Fourteen healthy female volunteers. Intervention: Sustained neutral and sadness states, randomized and counterbalanced in order, elicited by the cued recall of an autobiographical event associated with that emotion. Main Outcome Measures: Changes in mu-opioid receptor availability and negative and positive affect ratings between conditions. Increases or reductions in the in vivo receptor measure reflect deactivation or activation of neuro transmitter release, respectively. Results: The sustained sadness condition was associated with a statistically significant deactivation in mu-opioid neuro transmission in the rostral anterior cingulate, ventral pallidum, amygdala, and inferior temporal cortex. This deactivation was reflected by increases in mu-opioid receptor availability in vivo. The deactivation of mu-opioid neuro transmission in the rostral anterior cingulate, ventral pallidum, and amygdala was correlated with the increases in negative affect ratings and the reductions in positive affect ratings during the sustained sadness state. Conclusions: These data demonstrate dynamic changes in mu-opioid neuro transmission in response to an experimentally induced negative affective state. The direction and localization of these responses confirms the role of the mu-opioid receptor system in the physiological regulation of affective experiences in humans.	Mental Hlth Res Inst, Ann Arbor, MI 48109 USA; Dept Psychiat, Ann Arbor, MI USA; Univ Michigan, Dept Radiol, Ann Arbor, MI 48109 USA; Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA	Zubieta, JK (reprint author), Mental Hlth Res Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	zubieta@umich.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P01 MH 42251]		Adolphs R, 1996, J NEUROSCI, V16, P7678; AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; AUSTIN MC, 1991, BRAIN RES, V542, P123, DOI 10.1016/0006-8993(91)91005-L; BENCH CJ, 1995, PSYCHOL MED, V25, P247, DOI 10.1017/S0033291700036151; Breiter HC, 1996, NEURON, V17, P875, DOI 10.1016/S0896-6273(00)80219-6; Cahill L, 2001, NEUROBIOL LEARN MEM, V75, P1, DOI 10.1006/nlme.2000.3999; Calder AJ, 2001, NAT REV NEUROSCI, V2, P352, DOI 10.1038/35072584; CHROBAK JJ, 1993, J NEURAL TRANSM-GEN, V93, P123, DOI 10.1007/BF01245342; Curtis AL, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-13-j0001.2001; Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871; DANNALS RF, 1985, INT J APPL RADIAT IS, V36, P303, DOI 10.1016/0020-708X(85)90089-4; Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591; Davidson RJ, 1999, TRENDS COGN SCI, V3, P11, DOI 10.1016/S1364-6613(98)01265-0; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Enoch MA, 2003, PSYCHIAT GENET, V13, P33, DOI 10.1097/00041444-200303000-00006; Filliol D, 2000, NAT GENET, V25, P195, DOI 10.1038/76061; First M.B., 1995, STRUCTURED CLIN INTE; Friston KJ, 1994, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; GABILONDO AM, 1995, BRAIN RES, V682, P245, DOI 10.1016/0006-8993(95)00333-L; GEAR RW, 1995, J NEUROSCI, V15, P3154; George MS, 1996, BIOL PSYCHIAT, V40, P859, DOI 10.1016/0006-3223(95)00572-2; GEORGE MS, 1995, AM J PSYCHIAT, V152, P341; Gestreau C, 2000, J COMP NEUROL, V427, P285, DOI 10.1002/1096-9861(20001113)427:2<285::AID-CNE9>3.0.CO;2-T; GOOD AJ, 1995, BEHAV NEUROSCI, V109, P631, DOI 10.1037/0735-7044.109.4.631; GROSSISSEROFF R, 1990, BRAIN RES, V530, P312, DOI 10.1016/0006-8993(90)91301-V; Jewett DM, 2001, NUCL MED BIOL, V28, P733, DOI 10.1016/S0969-8051(01)00226-8; Johnson PI, 1997, NEUROSCIENCE, V77, P187, DOI 10.1016/S0306-4522(96)00482-4; KALIN NH, 1988, BRAIN RES, V440, P285, DOI 10.1016/0006-8993(88)90997-3; KALIN NH, 1989, SCIENCE, V243, P1718, DOI 10.1126/science.2564702; Kalivas PW, 1999, ANN NY ACAD SCI, V877, P64, DOI 10.1111/j.1749-6632.1999.tb09261.x; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; Kessler RC, 1997, ANNU REV PSYCHOL, V48, P191, DOI 10.1146/annurev.psych.48.1.191; KETTER TA, 2002, COMMONALITIES DISSOC, V147; KETTER TA, 2002, HDB AFFECTIVE SCI, P930; Kraus MA, 1996, BRAIN RES, V724, P33, DOI 10.1016/0006-8993(96)00263-6; LaBuda CJ, 2000, BRAIN RES, V869, P1, DOI 10.1016/S0006-8993(00)02196-X; Lane RD, 1997, AM J PSYCHIAT, V154, P926; Laruelle M, 2000, J CEREBR BLOOD F MET, V20, P423, DOI 10.1097/00004647-200003000-00001; Liberzon I, 2002, P NATL ACAD SCI USA, V99, P7084, DOI 10.1073/pnas.102174799; Logan J, 1996, J CEREBR BLOOD F MET, V16, P834, DOI 10.1097/00004647-199609000-00008; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Marek GJ, 1998, NEUROSCIENCE, V86, P485, DOI 10.1016/S0306-4522(98)00043-8; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Mayberg HS, 2000, BIOL PSYCHIAT, V48, P830, DOI 10.1016/S0006-3223(00)01036-2; Mayberg HS, 1997, NEUROREPORT, V8, P1057, DOI 10.1097/00001756-199703030-00048; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Meyer C R, 1997, Med Image Anal, V1, P195, DOI 10.1016/S1361-8415(97)85010-4; MINOSHIMA S, 1993, J NUCL MED, V34, P322; MOGENSON GJ, 1991, ADV EXP MED BIOL, V295, P267; Morris JS, 1998, BRAIN, V121, P47, DOI 10.1093/brain/121.1.47; Napier TC, 1999, ANN NY ACAD SCI, V877, P176, DOI 10.1111/j.1749-6632.1999.tb09268.x; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Quirarte GL, 1998, BRAIN RES, V808, P134, DOI 10.1016/S0006-8993(98)00795-1; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Reiman EM, 1997, AM J PSYCHIAT, V154, P918; Rubinstein M, 1996, P NATL ACAD SCI USA, V93, P3995, DOI 10.1073/pnas.93.9.3995; SASTRE M, 1994, J PHARMACOL EXP THER, V269, P1062; Sheline YI, 1996, P NATL ACAD SCI USA, V93, P3908, DOI 10.1073/pnas.93.9.3908; Smith YR, 1998, J CLIN ENDOCR METAB, V83, P4498, DOI 10.1210/jc.83.12.4498; Steiner H, 1998, EXP BRAIN RES, V123, P60, DOI 10.1007/s002210050545; Taylor SF, 1998, NEUROIMAGE, V8, P188, DOI 10.1006/nimg.1998.0356; Taylor SF, 2000, NEUROPSYCHOLOGIA, V38, P1415, DOI 10.1016/S0028-3932(00)00032-4; TITELER M, 1989, EUR J PHARMACOL, V167, P221, DOI 10.1016/0014-2999(89)90582-7; Tolle TR, 1999, ANN NEUROL, V45, P40, DOI 10.1002/1531-8249(199901)45:1<40::AID-ART8>3.0.CO;2-L; VOGT BA, 1995, EXP NEUROL, V135, P83, DOI 10.1006/exnr.1995.1069; Wand GS, 2002, NEUROPSYCHOPHARMACOL, V26, P106, DOI 10.1016/S0893-133X(01)00294-9; WATKINS LR, 1982, SCIENCE, V216, P1185, DOI 10.1126/science.6281891; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; Zubieta JK, 1999, AM J PSYCHIAT, V156, P842, DOI 10.1176/ajp.156.6.842; Zubieta JK, 2002, J NEUROSCI, V22, P5100, DOI 10.1523/JNEUROSCI.22-12-05100.2002; Zubieta JK, 2003, SCIENCE, V299, P1240, DOI 10.1126/science.1078546; Zubieta JK, 2001, SCIENCE, V293, P311, DOI 10.1126/science.1060952	75	249	251	1	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	NOV	2003	60	11					1145	1153		10.1001/archpsyc.60.11.1145			9	Psychiatry	Psychiatry	744DH	WOS:000186612300010	14609890	Bronze			2020-06-30	J	Goldszmidt, E; Davies, S				Goldszmidt, E; Davies, S			Two cases of hemorrhage secondary to amniotic fluid embolus managed with uterine artery embolization	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							POSTPARTUM HEMORRHAGE; COAGULATION	Purpose: To describe the anesthetic management of two cases of amniotic fluid embolus (AFE) and disseminated intravascular coagulation (DIC) who underwent bilateral uterine artery embolization to control their postpartum hemorrhage. Clinical features: We report the clinical course and management of two women who suffered sudden cardiorespiratory events during labour. The first patient had a cardiac arrest whereas the second developed respiratory failure and altered neurological status. They were diagnosed as having had an AFE. Both of these events were accompanied by severe postpartum hemorrhage and DIC. They suffered prolonged bleeding and received massive transfusions. Successful management of hemorrhage was optimized by uterine artery embolization, thus avoiding ongoing problems with bleeding and possible hysterectomy. The role of uterine artery embolization is described, along with its advantages and anesthetic considerations. Conclusion: Women with severe postpartum hemorrhage, with or without DIC, should be considered for uterine artery embolization.	Univ Toronto, Dept Anesthesia, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada	Goldszmidt, E (reprint author), Univ Toronto, Dept Anesthesia, Mt Sinai Hosp, 600 Univ Ave,Suite 1514, Toronto, ON M5G 1X5, Canada.						Badawy SZA, 2001, CLIN IMAG, V25, P288, DOI 10.1016/S0899-7071(01)00307-2; BROWN BJ, 1979, OBSTET GYNECOL, V54, P361; CLARK SL, 1995, AM J OBSTET GYNECOL, V172, P1158, DOI 10.1016/0002-9378(95)91474-9; Davies S, 1999, CAN J ANAESTH, V46, P456, DOI 10.1007/BF03012944; Davies S, 2001, CAN J ANAESTH, V48, P88, DOI 10.1007/BF03019822; Deux JF, 2001, AM J ROENTGENOL, V177, P145, DOI 10.2214/ajr.177.1.1770145; Dorne R, 2002, ANN FR ANESTH, V21, P431, DOI 10.1016/S0750-7658(02)00638-X; LOCKWOOD CJ, 1991, AM J OBSTET GYNECOL, V165, P1335; Merland JJ, 1996, EUR J OBSTET GYN R B, V65, P141, DOI 10.1016/0028-2243(95)02319-N; MORGAN M, 1979, ANAESTHESIA, V34, P20, DOI 10.1111/j.1365-2044.1979.tb04862.x; Pelage JP, 1998, RADIOLOGY, V208, P359, DOI 10.1148/radiology.208.2.9680559; StancatoPasik A, 1997, RADIOLOGY, V204, P791, DOI 10.1148/radiology.204.3.9280261	12	20	25	0	3	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	NOV	2003	50	9					917	921		10.1007/BF03018739			5	Anesthesiology	Anesthesiology	748LF	WOS:000186862800010	14617589	Bronze			2020-06-30	J	Gelb, AW; Salevsky, F; Chung, F; Ringaert, K; McTaggart-Cowan, RMC; Wong, T; Manninen, PH				Gelb, AW; Salevsky, F; Chung, F; Ringaert, K; McTaggart-Cowan, RMC; Wong, T; Manninen, PH			Remifentanil with morphine transitional analgesia shortens neurological recovery compared to fentanyl for supratentorial craniotomy	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							CEREBRAL BLOOD-FLOW; INTRACRANIAL-PRESSURE; NITROUS-OXIDE; ANESTHESIA; ISOFLURANE; ALFENTANIL; PROPOFOL; LESIONS; SURGERY	Purpose: To compare the recovery profiles, efficacy and safety of remifentanil and morphine for transitional analgesia with fentanyl in patients undergoing elective craniotomy for supratentorial mass lesions. Methods: Ninety-one patients were enrolled in this prospective, randomized, multicentre study. Anesthesia was induced with thiopental and remifentanil (1.0 mug(.)kg(-1) bolus and a 1 mug(.)kg(-1.)min(-1) infusion) or fentanyl (1 mug(.)kg(-1) bolus and a 1.0 mug(.)kg(-1.)min(-1) infusion). The opioid infusion continued until the level of anesthesia was deemed appropriate for intubation. Anesthesia was maintained with N2O/O-2, isoflurane 0.5 MAC and remifentanil 0.2 mug(.)kg(-1.)min(-1) or fentanyl 0.04 mug(.)kg(-1.)min(-1). At bone flap replacement, either morphine 0.08 mg(.)kg(-1) (remifentanil group) or saline (fentanyl group) was given. Results: Systolic blood pressure was greater in those receiving fentanyl during induction (145.6 +/- 17.5 mmHg vs 128.8 +/- 18.3 mmHg; P = 0.006) and intubation (126.9 +/- 17.1 vs 110.9 +/- 16.5 mmHg; P < 0.001). Median time to tracheal extubation was similar but less variable in the remifentanil group (remifentanil = 8 min: range = 2-44 min; fentanyl = 8 min: range = 1-732 min). The fentanyl patients required a longer time to achieve the first normal neurological score (fentanyl = 38.0 min; remifentanil = 26.0 min; P = 0.035). Both the anesthesiologists and the recovery room nurses rated remifentanil better with respect to level of consciousness. Analgesics were required earlier in patients receiving remifentanil; median time 0.5 vs 1.08 hr, P < 0.001. Conclusions: Remifentanil is a suitable alternative to fentanyl in supratentorial craniotomy. Time to preoperative neurological recovery is faster and morphine provides some transitional analgesia without compromising the quality of recovery.	London Hlth Sci Ctr, Dept Anaesthesia, London, ON N6A 5A5, Canada; Montreal Neurol Hosp, Montreal, PQ, Canada; Univ Toronto, Toronto Western Hosp, Hlth Network, Toronto, ON M5T 2S8, Canada; Hlth Sci Ctr, Winnipeg, MB, Canada; Foothills Prov Gen Hosp, Calgary, AB T2N 2T9, Canada	Gelb, AW (reprint author), London Hlth Sci Ctr, Dept Anaesthesia, Univ Campus,339 Windermere Rd, London, ON N6A 5A5, Canada.		Chung, Frances/F-5618-2015	Chung, Frances/0000-0001-9576-3606			Balakrishnan G, 2000, ANESTH ANALG, V91, P163, DOI 10.1097/00000539-200007000-00030; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; FROM RP, 1990, ANESTHESIOLOGY, V73, P896, DOI 10.1097/00000542-199011000-00017; Guy J, 1997, ANESTHESIOLOGY, V86, P514, DOI 10.1097/00000542-199703000-00002; HOFFMAN WE, 1993, ANESTHESIOLOGY, V79, P107, DOI 10.1097/00000542-199307000-00016; Hogue CW, 1996, ANESTH ANALG, V83, P279, DOI 10.1097/00000539-199608000-00014; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; Ostapkovich ND, 1998, ANESTHESIOLOGY, V89, P358, DOI 10.1097/00000542-199808000-00011; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002; Twersky RS, 2001, J CLIN ANESTH, V13, P407, DOI 10.1016/S0952-8180(01)00292-6; Warner DS, 1996, ANESTH ANALG, V83, P348, DOI 10.1097/00000539-199608000-00025	11	20	25	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	NOV	2003	50	9					946	952		10.1007/BF03018745			7	Anesthesiology	Anesthesiology	748LF	WOS:000186862800016	14617595	Bronze			2020-06-30	J	Okutomi, T; Saito, M; Mochizuki, J; Amano, K				Okutomi, T; Saito, M; Mochizuki, J; Amano, K			Prophylactic epidural naloxone reduces the incidence and severity of neuraxial fentanyl-induced pruritus during labour analgesia in primiparous parturients	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter							RATS									Gan TJ, 1997, ANESTHESIOLOGY, V87, P1075, DOI 10.1097/00000542-199711000-00011; Kofke WA, 1996, ANESTH ANALG, V83, P1298, DOI 10.1097/00000539-199612000-00029; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; Sinz EH, 2000, ANESTH ANALG, V91, P1443, DOI 10.1097/00000539-200012000-00027; WIENER PC, 1977, BRIT MED J, V2, P229, DOI 10.1136/bmj.2.6081.229	5	15	16	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	NOV	2003	50	9					961	962		10.1007/BF03018748			2	Anesthesiology	Anesthesiology	748LF	WOS:000186862800019	14617598	Bronze			2020-06-30	J	Bredenberg, S; Duberg, M; Lennernas, B; Lennernas, H; Pettersson, A; Westerberg, M; Nystrom, C				Bredenberg, S; Duberg, M; Lennernas, B; Lennernas, H; Pettersson, A; Westerberg, M; Nystrom, C			In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance	EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES			English	Article						sublingual tablet; fentanyl; oromucosal delivery; interactive mixture; ordered mixture; bioadhesion	CARRIER PARTICLE PROPERTIES; PHYSICOCHEMICAL ASPECTS; DRUG RELEASE; ORDERED MIXTURES; DIRECT COMPRESSION; DISSOLUTION RATE; SURFACE-AREA; BREAKTHROUGH PAIN; BINDER PROPERTIES; CANCER PAIN	Oromucosal delivery of drugs promotes rapid absorption and high bioavailability, with subsequent almost immediate onset of pharmacological effect. However, many oromucosal delivery systems are compromised by the possibility of the patient swallowing the active substance before it has been released and absorbed locally into the systemic circulation. This paper introduces a new tablet system for sublingual administration and rapid drug absorption. The tablet is based on interactive mixtures of components, consisting of carrier particles partially covered by fine dry particles of the drug, in this case fentanyl citrate. In the interests of increasing retention of the drug at the site of absorption in the oral cavity, a bioadhesive component was also added to the carrier particles. Tablets containing 100, 200 and 400 mug of fentanyl were tested both in vitro and in vivo. The tablets disintegrated rapidly and dissolution tests revealed that fentanyl citrate was dissolved from the formulation almost instantly. Plasma concentrations of fentanyl were obtained within 10 min, with no second peak. These results indicated that the bioadhesive component prevented the fentanyl from being swallowed (the fraction swallowed was considered smaller compared to other mucosal delivery systems), without hindering its release and absorption. This new sublingual tablet formulation may also hold potential for other substances where a rapid onset of effect is desirable. (C) 2003 Elsevier B.V. All rights reserved.	Uppsala Univ, Dept Pharm, SE-75123 Uppsala, Sweden; Orexo AB, Uppsala, Sweden; Sahlgrenska Acad, Dept Oncol, Gothenburg, Sweden; Sahlgrenska Acad, Dept Gastro Res, Gothenburg, Sweden	Nystrom, C (reprint author), Uppsala Univ, Dept Pharm, Box 580, SE-75123 Uppsala, Sweden.						ALDERBORN G, 1985, POWDER TECHNOL, V41, P49, DOI 10.1016/0032-5910(85)85074-9; [Anonymous], 1997, EUR PHARM, P127; ASHBURN MA, 1989, ANESTHESIOLOGY, V71, P615, DOI 10.1097/00000542-198910000-00026; BISRAT M, 1992, INT J PHARM, V80, P191, DOI 10.1016/0378-5173(92)90277-9; Bredenberg S, 2003, J PHARM PHARMACOL, V55, P169, DOI 10.1211/002235702423; *BRIT STAND I, 1958, 2955 BS BRIT STAND I; Corveleyn S, 1998, INT J PHARM, V173, P149, DOI 10.1016/S0378-5173(98)00216-6; DOLLERY C, 1991, THERAPEUTIC DRUGS, pF26; ERIKSSON M, 1990, INT J PHARM, V63, P189, DOI 10.1016/0378-5173(90)90124-M; FERRARI F, 1995, STP PHARMA SCI, V5, P116; HANKS GWC, 1998, OXFORD TXB PALLIATIV, P463; JERWANSKA E, 1995, INT J PHARM, V121, P65, DOI 10.1016/0378-5173(95)00007-6; KAYE BH, 1967, POWDER TECHNOL, V1, P11; KORNBLUM SS, 1973, J PHARM SCI, V62, P43, DOI 10.1002/jps.2600620107; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; LENNERNAS B, UNPUB CLIN PHARMACOK; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Mattsson S, 2001, STP PHARMA SCI, V11, P211; Mattsson S, 2001, DRUG DEV IND PHARM, V27, P181, DOI 10.1081/DDC-100000236; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Mock DL, 1986, ANESTH ANALG, V65, pS102; MOFFAT AC, 1971, TOP MED CHEM, V4, P21; Noyes A, 1897, J AM CHEM SOC, V19, P930, DOI DOI 10.1021/JA02086A003; NYSTROM C, 1985, J PHARM PHARMACOL, V37, P217, DOI 10.1111/j.2042-7158.1985.tb05048.x; NYSTROM C, 1980, ACTA PHARM SUEC, V17, P282; NYSTROM C, 1982, INT J PHARM, V10, P209, DOI 10.1016/0378-5173(82)90071-0; NYSTROM C, 1986, J PHARM PHARMACOL, V38, P161, DOI 10.1111/j.2042-7158.1986.tb04537.x; PORTENOY RK, 1990, PAIN, V41, P273, DOI 10.1016/0304-3959(90)90004-W; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; ROY SD, 1989, PHARMACEUT RES, V6, P147, DOI 10.1023/A:1015932610010; Shangraw R., 1980, PHARM TECH, V4, P49; Streisand JB, 1998, ANESTHESIOLOGY, V88, P305, DOI 10.1097/00000542-199802000-00006; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Sundell-Bredenberg S, 2001, EUR J PHARM SCI, V12, P285, DOI 10.1016/S0928-0987(00)00176-7; Wade A., 1994, HDB PHARM EXCIPIENTS; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; WESTERBERG M, 1991, INT J PHARM, V69, P129, DOI 10.1016/0378-5173(91)90218-D; WESTERBERG M, 1986, INT J PHARM, V28, P23, DOI 10.1016/0378-5173(86)90143-2; WESTERBERG M, 1993, INT J PHARM, V90, P1, DOI 10.1016/0378-5173(93)90291-M; WESTERBERG M, 1992, THESIS UPPSALA U UPP; Zeppetella G, 2001, PALLIATIVE MED, V15, P323, DOI 10.1191/026921601678320304; Zhang H, 2002, CLIN PHARMACOKINET, V41, P661, DOI 10.2165/00003088-200241090-00003	42	73	76	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0928-0987			EUR J PHARM SCI	Eur. J. Pharm. Sci.	NOV	2003	20	3					327	334		10.1016/j.ejps.2003.07.002			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	748JG	WOS:000186858300008	14592698				2020-06-30	J	Robert, R; Brack, A; Blakeney, P; Villarreal, C; Rosenberg, L; Thomas, C; Meyer, WJ				Robert, R; Brack, A; Blakeney, P; Villarreal, C; Rosenberg, L; Thomas, C; Meyer, WJ			A double-blind study of the analgesic efficacy of oral transmucosal fentanyl citrate and oral morphine in pediatric patients undergoing burn dressing change and tubbing	JOURNAL OF BURN CARE & REHABILITATION			English	Article; Proceedings Paper	33rd Annual Meeting of the American-Burn-Association	APR 18-21, 2001	BOSTON, MASSACHUSETTS	Amer Burn Assoc			PAIN	Burn wound care is extremely painful. The pain leads to added anxiety and therefore a distressing treatment that can negatively impact healing. Pain and anxiety management with oral transmucosal fentanyl citrate was compared with this institution's standard procedural pain medication, morphine. With a double-blinded, reverse crossover, time-randomized, and placebo-controlled design, the efficacy of morphine and fentanyl citrate was assessed with patients undergoing two consecutive days of tubbing. Pain and anxiety was assessed before, during, and after the tubbing procedure using the Faces Pain Rating Scale (Whaley and Wong, 1987) and the Fear Thermometer (Silverman and Kurtines, 1996). Data were analyzed with repeated measures analysis of variance. Pain and anxiety appeared better managed with fentanyl citrate. Generalization is limited by small sample size, yet findings warrant additional investigation.	Shriners Burns Hosp, Galveston, TX USA; Univ Texas, Med Branch, Galveston, TX 77550 USA	Robert, R (reprint author), 815 Market St, Galveston, TX USA.						*ASS CAR CHILDR HL, 1994, DID YOU KNOW INF CHI; HESTER C, 1996, J BURN CARE REHABIL, V28, P66; Leo RJ, 2003, PAIN MANAGEMENT PSYC; PERRY S, 1982, PAIN, V13, P267, DOI 10.1016/0304-3959(82)90016-1; Silverman W. K., 1996, ANXIETY PHOBIC DISOR; WALCO GA, 1994, NEW ENGL J MED, V331, P541, DOI 10.1056/NEJM199408253310812; Whaley L, 1987, NURSING CARE INFANTS	7	24	26	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0273-8481			J BURN CARE REHABIL	J. Burn Care Rehabil.	NOV-DEC	2003	24	6					351	355		10.1097/01.BCR.0000095504.69283.F2			5	Emergency Medicine; Rehabilitation; Surgery	Emergency Medicine; Rehabilitation; Surgery	745JH	WOS:000186685200001	14610417				2020-06-30	J	Oefelein, MG; Bayazit, Y				Oefelein, MG; Bayazit, Y			Chronic pain syndrome after laparoscopic radical nephrectomy	JOURNAL OF UROLOGY			English	Article						laparoscopy; nephrectomy; flank pain; chronic disease			Case Western Reserve Univ, Sch Med, Dept Urol, Cleveland, OH USA; Cukurova Univ, Fac Med, Dept Urol, Adana, Turkey	Oefelein, MG (reprint author), Case Western Reserve Univ, Univ Hosp Cleveland, Sch Med, Dept Urol, 11100 Euclid Ave, Cleveland, OH 44106 USA.						Abbou CC, 1999, J UROLOGY, V161, P1776, DOI 10.1016/S0022-5347(05)68797-6; Cadeddu JA, 2001, J UROLOGY, V166, P2109, DOI 10.1016/S0022-5347(05)65515-2; Gill IS, 1999, UROLOGY, V54, P734, DOI 10.1016/S0090-4295(99)00302-7	3	5	5	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5347			J UROLOGY	J. Urol.	NOV	2003	170	5					1939	1940		10.1097/01.ju.0000092633.59841.59			2	Urology & Nephrology	Urology & Nephrology	730YU	WOS:000185858400058	14532814				2020-06-30	J	Siddappa, R; Fletcher, JE; Heard, AMB; Kielma, D; Cimino, M; Heard, CMB				Siddappa, R; Fletcher, JE; Heard, AMB; Kielma, D; Cimino, M; Heard, CMB			Methadone dosage for prevention of opioid withdrawal in children	PAEDIATRIC ANAESTHESIA			English	Article						critical care; drug tolerance; methadone; narcotics; pediatrics; substance; withdrawal syndrome	INTENSIVE-CARE-UNIT; PROLONGED SEDATION; DEPENDENCE; TOLERANCE; MORPHINE; ANALGESIA; FENTANYL; INFANTS	Background: Opioids are frequently used for sedation in the Paediatric Intensive Care Unit (PICU). With time the dosing often increases because of tolerance. On cessation of the sedation there is a risk of the opioid withdrawal syndrome. The aim of our study was to evaluate methadone dosing as a risk factor for opioid withdrawal and to determine optimal dose and efficacy of methadone to prevent withdrawal. Method: We undertook a clinical, retrospective, chart review study. Data were analysed from the quality improvement initiative database of a tertiary-care 18 bed PICU. Results: Data from 30 children who received an opioid infusion for greater than or equal to7 days and subsequently received methadone for opioid withdrawal (between January 2000 and July 2001) were analysed. Nurses documented the presence or absence of withdrawal signs daily. Our unit protocol has recommended converting the patient's opioid dose into fentanyl equivalents and a dose of methadone equal to the total daily dose of fentanyl to be given three times a day. Twenty patients had no or minimal withdrawal symptoms and 10 experienced significant withdrawal. Age, weight, PRISM score, lorazepam dose, muscle relaxant use and fentanyl dose were not statistically significantly between these groups. Receiver Operator Characteristics analysis showed that 80% of the suggested methadone dose was effective in minimizing withdrawal symptoms. The odds ratio for withdrawal with <80% of the predicted methadone dose was 21. Conclusions: Inadequate methadone is a risk factor for opioid withdrawal. A daily starting methadone dose equivalent to 2.5 times the daily fentanyl dose is effective in minimizing withdrawal symptoms.	Childrens Hosp Buffalo, Div Pediat Crit Care, Buffalo, NY USA; Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC USA; Royal Perth Hosp, Dept Anesthesia, Perth, WA, Australia	Heard, CMB (reprint author), Childrens Hosp Buffalo, Div Pediat Crit Care, 219 Bryant St, Buffalo, NY USA.	heardop1@adelphia.net	Heard, Christopher/M-4254-2015				ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1994, CRIT CARE MED, V22, P334, DOI 10.1097/00003246-199402000-00027; DESHPANDE JK, 1996, PEDIAT PAIN HDB, P18; Deutsch ES, 1996, ARCH OTOLARYNGOL, V122, P1234; HOLDER EL, 1981, NEW ENGL J MED, V305, P1284; JOSEPH JD, 1990, CRIT CARE MED, V18, P1292; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; MARX CM, 1993, PEDIATRICS, V91, P369; Meyer M M, 2001, Pediatr Crit Care Med, V2, P329, DOI 10.1097/00130478-200110000-00009; Puntillo K, 1997, HEART LUNG, V26, P317, DOI 10.1016/S0147-9563(97)90089-3; QUINN MW, 1993, LANCET, V342, P324, DOI 10.1016/0140-6736(93)91472-X; Robert L, 2000, BIOGERONTOLOGY, V1, P123, DOI 10.1023/A:1010048014925; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079; TOBIAS JD, 1994, INTENS CARE MED, V20, P504, DOI 10.1007/BF01711905; Tobias JD, 1999, CRIT CARE MED, V27, P2262, DOI 10.1097/00003246-199910000-00033; Williams PI, 1998, BRIT J ANAESTH, V80, P92; Yaster M, 1996, PEDIATRICS, V98, P135	17	44	44	0	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	NOV	2003	13	9					805	810		10.1046/j.1460-9592.2003.01153.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	744WC	WOS:000186655000009	14617122				2020-06-30	J	Szmuk, P; Kee, S; Pivalizza, EG; Warters, RD; Abramson, DC; Ezri, T				Szmuk, P; Kee, S; Pivalizza, EG; Warters, RD; Abramson, DC; Ezri, T			Anaesthesia for magnetoencephalography in children with intractable seizures	PAEDIATRIC ANAESTHESIA			English	Article						magnetoencephalography; epilepsy; seizures anaesthesia	EPILEPSY SURGERY; SEVOFLURANE ANESTHESIA; STATUS EPILEPTICUS; LOCALIZATION; PROPOFOL; ELECTROENCEPHALOGRAPHY; CONVULSIONS; KETAMINE; CATS; EEG	Background: Magnetoencephalography (MEG), a noninvasive technique for evaluation of epileptic patients, records magnetic fields during neuronal electrical activity within the brain. Anaesthesia experience for MEG has not yet been reported. Methods: We retrospectively reviewed records of 48 paediatric patients undergoing MEG under anaesthesia. Thirty-one patients (nonprotocol group) were managed according to the anaesthesiologist's discretion. Premedication included oral midazolam, chloral hydrate or fentanyl oralet, intravenous midazolam or inhalational anaesthesia with sevoflurane. Anaesthesia was maintained with propofol, midazolam, fentanyl, alone or in combination. A subsequent protocol group (17 patients) received chloral hydrate as premedication and propofol for maintenance of anaesthesia. Results: There was an overall 25% failure of interictal activity and localization on the MEG scan. In the nonprotocol group, 11 scans failed (35.5%). Of these, eight (72.7%) received midazolam orally. Only one failure (5.8%) was recorded in the protocol group in a patient who received chloral hydrate as sedation supplemented by sevoflurane. Conclusions: In our experience, midazolam premedication resulted in a high MEG failure rate (73%). Chloral hydrate premedication and propofol maintenance resulted in a lower incidence of MEG failure (5.8%). General anaesthesia with a continuous infusion of propofol or sevoflurane appears acceptable, although, lighter levels of anaesthesia might be required to avoid interference with interictal activity of the brain.	Univ Texas, Sch Med, Dept Anesthesiol, Post Anesthesia Care Unit, Houston, TX 77030 USA; Wolfson Med Ctr, Sackler Sch Med, Dept Anesthesia, Tel Aviv, Israel; Outcomes Res TM Inst, Louisville, KY USA	Szmuk, P (reprint author), Univ Texas, Sch Med, Dept Anesthesiol, Post Anesthesia Care Unit, MSB 5020,6431 Fannin, Houston, TX 77030 USA.		Kee, Spencer/D-3640-2012	Kee, Spencer/0000-0003-2090-5141			BORGEAT A, 1991, ANESTHESIOLOGY, V74, P24, DOI 10.1097/00000542-199101000-00005; Cheng MA, 1996, ANESTH ANALG, V83, P169, DOI 10.1097/00000539-199607000-00029; Constant I, 1999, ANESTHESIOLOGY, V91, P1604, DOI 10.1097/00000542-199912000-00010; DEFRIEZ CB, 1992, ANESTH ANALG, V75, P630; Diekmann V, 1998, ELECTROEN CLIN NEURO, V106, P297, DOI 10.1016/S0013-4694(97)00142-9; Ebersole J S, 1996, Epilepsy Res Suppl, V11, P227; Ebersole JS, 1997, EPILEPSIA, V38, pS1, DOI 10.1111/j.1528-1157.1997.tb04533.x; FERRERALLADO T, 1973, ANESTHESIOLOGY, V38, P333, DOI 10.1097/00000542-197304000-00006; FREDMAN B, 1994, ANESTH ANALG, V79, P75; GUMPERT J, 1971, J NEUROL NEUROSUR PS, V34, P646, DOI 10.1136/jnnp.34.5.646; Kirchberger K, 1998, ACTA NEUROL SCAND, V98, P1, DOI 10.1111/j.1600-0404.1998.tb07370.x; Kirchberger K, 1998, EPILEPSIA, V39, P1104, DOI 10.1111/j.1528-1157.1998.tb01297.x; Knowlton RC, 1997, ANN NEUROL, V42, P622, DOI 10.1002/ana.410420413; Ko DY, 1998, NEUROSURGERY, V42, P414, DOI 10.1097/00006123-199802000-00142; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; KOMATSU H, 1994, ANESTHESIOLOGY, V81, P1535, DOI 10.1097/00000542-199412000-00030; LAMPL Y, 1990, ANN EMERG MED, V19, P674, DOI 10.1016/S0196-0644(05)82475-8; MCBURNEY JW, 1994, J EPILEPSY, V7, P21, DOI 10.1016/0896-6974(94)90114-7; Minassian BA, 1999, ANN NEUROL, V46, P627, DOI 10.1002/1531-8249(199910)46:4<627::AID-ANA11>3.0.CO;2-C; Miyazaki Y, 1999, BRIT J ANAESTH, V82, P935; MODICA PA, 1990, ANESTH ANALG, V70, P303; OSAWA M, 1994, ANESTH ANALG, V79, P52; RAO TLK, 1982, ANESTH ANALG, V61, P1020; Saitoh K, 1996, PAEDIATR ANAESTH, V6, P495, DOI 10.1046/j.1460-9592.1996.d01-15.x; Wheless JW, 1999, EPILEPSIA, V40, P931, DOI 10.1111/j.1528-1157.1999.tb00800.x	25	18	18	1	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	NOV	2003	13	9					811	817		10.1046/j.1460-9592.2003.01159.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	744WC	WOS:000186655000010	14617123				2020-06-30	J	Kill, C; Leonhardt, A; Wulf, H				Kill, C; Leonhardt, A; Wulf, H			Lacticacidosis after short-term infusion of propofol for anaesthesia in a child with osteogenesis imperfecta	PAEDIATRIC ANAESTHESIA			English	Article						anaesthesia; propofol; lacticacidosis; osteogenesis imperfecta; profol infusion syndrome	CRITICALLY ILL; HYPERTHERMIA; HYPERPYREXIA; PATIENT	We describe the case of a 7-year-old boy with osteogenesis imperfecta, who underwent anaesthesia with propofol-fentanyl-nitrous oxide-suxamethonium for orthopaedic surgery of a distal femur fracture. He developed lacticacidosis after short-term propofol infusion (150 min, mean infusion rate 13.5 mg.kg(-1).h(-1)) associated with a prolonged recovery time without serious haemodynamic changes. The highest lactate concentration was 9.2 mmol.l(-1) at 160 min after discontinuation of propofol. There was no significant increase in body temperature. The boy fully recovered.	Univ Marburg, Dept Anaesthesiol & Intens Care Med, D-35033 Marburg, Germany; Univ Marburg, Dept Paediat, D-35033 Marburg, Germany	Kill, C (reprint author), Univ Marburg, Dept Anaesthesiol & Intens Care Med, D-35033 Marburg, Germany.	killc@mailer.uni-marburg.de					Bray RJ, 1998, PAEDIATR ANAESTH, V8, P491; Cornfield DN, 2002, PEDIATRICS, V110, P1177, DOI 10.1542/peds.110.6.1177; Cray SH, 1998, CRIT CARE MED, V26, P2087, DOI 10.1097/00003246-199812000-00046; Fernandes J, 2000, INBORN METABOLIC DIS; Furderer S, 2000, Z ORTHOP GRENZGEB, V138, P136; KATARIA BK, 1994, ANESTHESIOLOGY, V80, P104, DOI 10.1097/00000542-199401000-00018; Markovitz BP, 2000, CRIT CARE MED, V28, P2178, DOI 10.1097/00003246-200006000-00116; Mehta N, 1999, LANCET, V354, P866, DOI 10.1016/S0140-6736(05)75936-5; PARKE TJ, 1992, BRIT MED J, V305, P613, DOI 10.1136/bmj.305.6854.613; Porsborg P, 1996, ANAESTHESIA, V51, P863, DOI 10.1111/j.1365-2044.1996.tb12619.x; RAMPTON AJ, 1984, BRIT J ANAESTH, V56, P1443, DOI 10.1093/bja/56.12.1443; Reed MD, 1996, CRIT CARE MED, V24, P175, DOI 10.1097/00003246-199601000-00030; RYAN CA, 1989, ANESTH ANALG, V68, P811; Schenkman KA, 2000, CRIT CARE MED, V28, P172, DOI 10.1097/00003246-200001000-00028; Wolf A, 2001, LANCET, V357, P606, DOI 10.1016/S0140-6736(00)04064-2; WOLFSDORF JI, 1982, EUR J PEDIATR, V138, P141, DOI 10.1007/BF00441141	16	47	47	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	NOV	2003	13	9					823	826		10.1046/j.1460-9592.2003.01114.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	744WC	WOS:000186655000012	14617125				2020-06-30	J	Hepaguslar, H; Oztekin, S; Capar, E; Elar, Z				Hepaguslar, H; Oztekin, S; Capar, E; Elar, Z			Recovery from remifentanil after plasmapheresis in a paediatric patient with myasthenia gravis	PAEDIATRIC ANAESTHESIA			English	Letter							PLASMA CHOLINESTERASE		Dokuz Eylul Univ Hosp, Dept Anaesthesiol, Izmir, Turkey	Hepaguslar, H (reprint author), Dokuz Eylul Univ Hosp, Dept Anaesthesiol, Izmir, Turkey.						Clark WF, 1999, ANN INTERN MED, V131, P453, DOI 10.7326/0003-4819-131-6-199909210-00011; CULLEY DJ, 2000, HDB PREOPERATIVE ASS, P255; Davis L, 1997, ANAESTHESIA, V52, P244, DOI 10.1111/j.1365-2044.1997.084-az0080.x; Davis PJ, 2002, ANESTH ANALG, V95, P1305, DOI 10.1097/00000539-200211000-00038; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; EVANS RT, 1980, ANAESTHESIA, V35, P198, DOI 10.1111/j.1365-2044.1980.tb03801.x; Granell Gil M, 2001, Rev Esp Anestesiol Reanim, V48, P85; JACKSON SH, 1982, ANAESTHESIA, V37, P319, DOI 10.1111/j.1365-2044.1982.tb01107.x; Kuks JBM, 1998, TRANSFUS SCI, V19, P129, DOI 10.1016/S0955-3886(98)00022-8; Lorimer M, 1998, ANAESTH INTENS CARE, V26, P210, DOI 10.1177/0310057X9802600216; Manullang J, 1999, ANESTH ANALG, V89, P529, DOI 10.1097/00000539-199908000-00053; Naik B, 2002, J CLIN ANESTH, V14, P381, DOI 10.1016/S0952-8180(02)00382-3; Rosow CE, 1999, ANESTH ANALG, V89, pS1; Vincent A, 2001, LANCET, V357, P2122, DOI 10.1016/S0140-6736(00)05186-2; WOOD GJ, 1978, BRIT J ANAESTH, V50, P945, DOI 10.1093/bja/50.9.945	15	5	5	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	NOV	2003	13	9					842	844		10.1046/j.1460-9592.2003.01157.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	744WC	WOS:000186655000018	14617131				2020-06-30	J	Larsen, RH; Nielsen, F; Sorensen, JA; Nielsen, JB				Larsen, RH; Nielsen, F; Sorensen, JA; Nielsen, JB			Dermal penetration of fentanyl: Inter- and intraindividual variations	PHARMACOLOGY & TOXICOLOGY			English	Article							TRANSDERMAL DRUG-DELIVERY; HUMAN CADAVER SKIN; NARCOTIC ANALGESICS; PERCUTANEOUS-ABSORPTION; CANCER PAIN; BACK-PAIN; PERMEABILITY; PHARMACOKINETICS; METABOLISM	Fentanyl is a potent synthetic opioid that is increasingly being used in transdermal drug delivery systems. The target organ concentration of a drug administered dermally will depend on the rate of dermal absorption and the systemic elimination. We have studied the intra- and interindividual variation in dermal penetration of fentanyl in an in vitro model (static diffusion cells) with human skin, and compared the absorption of fentanyl from an aqueous solution with absorption from a commercial patch. The intraindividual variation in dermal penetration of fentanyl in aqueous solution was limited (18%) and no differences in penetration characteristics were observed between breast and abdominal skin. The interindividual variation in dermal penetration of fentanyl was extensive, with maximal fluxes ranging from 21-105 ng/ cm(2)/hr following application of an infinite dose of fentanyl to the donor chamber. Use of transdermal drug delivery systems (patches) reduced the inter-individual variation. The permeability coefficients after application of fentanyl in aqueous solution and through patches were identical (0.0011 cm/hr). One person had a higher than average penetration rate following patch application, which may indicate that the human skin and not the patch barrier was the rate-determining factor for the other individuals included in this study.	Univ So Denmark, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Plast Surg, DK-5000 Odense, Denmark	Nielsen, JB (reprint author), Univ So Denmark, Winslowparken 17, DK-5000 Odense C, Denmark.		sorensen, jens/D-6279-2014	Sorensen, Jens Ahm/0000-0003-4903-0094; Nielsen, Flemming/0000-0002-5657-405X			BRONAUGH RL, 1986, J PHARM SCI, V75, P1094, DOI 10.1002/jps.2600751115; Bronaugh RL, 1985, PERCUTANEOUS ABSORPT; CHERNY NJ, 1995, CANCER-AM CANCER SOC, V76, P1283, DOI 10.1002/1097-0142(19951001)76:7<1283::AID-CNCR2820760728>3.0.CO;2-0; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; FELDMANN RJ, 1967, J INVEST DERMATOL, V48, P181, DOI 10.1038/jid.1967.29; FRANZ TJ, 1975, J INVEST DERMATOL, V64, P190, DOI 10.1111/1523-1747.ep12533356; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUY RH, 1987, XENOBIOTICA, V17, P325, DOI 10.3109/00498258709043943; Jakobsson M, 1999, ANTICANCER RES, V19, P4441; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; Nielsen J B, 2000, Int J Occup Environ Health, V6, P143; Nielsen JB, 2000, OCCUP ENVIRON MED, V57, P734, DOI 10.1136/oem.57.11.734; REILLY CS, 1985, ANAESTHESIA, V40, P837, DOI 10.1111/j.1365-2044.1985.tb11043.x; Ringe JD, 2002, RHEUMATOL INT, V22, P199, DOI 10.1007/s00296-002-0217-8; Roberge RJ, 2000, J EMERG MED, V18, P147, DOI 10.1016/S0736-4679(99)00185-7; ROY SD, 1994, J PHARM SCI, V83, P1723, DOI 10.1002/jps.2600831215; ROY SD, 1989, PHARM RES-DORDR, V6, P825, DOI 10.1023/A:1015944018555; Roy SD, 1996, J PHARM SCI, V85, P491, DOI 10.1021/js950415w; ROY SD, 1988, PHARMACEUT RES, V5, P580, DOI 10.1023/A:1015994030251; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; SOUTHWELL D, 1984, INT J PHARM, V18, P299, DOI 10.1016/0378-5173(84)90145-5; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	26	38	40	0	11	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0901-9928			PHARMACOL TOXICOL	Pharmacol. Toxicol.	NOV	2003	93	5					244	248		10.1046/j.1600-0773.2003.pto930508.x			5	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	751UY	WOS:000187107300007	14629737				2020-06-30	J	Hasen, KV; Samartzis, D; Casas, LA; Mustoe, TA				Hasen, KV; Samartzis, D; Casas, LA; Mustoe, TA			An outcome study comparing intravenous sedation with midazolam/fentanyl (conscious sedation) versus propofol infusion (deep sedation) for aesthetic surgery	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article; Proceedings Paper	35th Annual Meeting of the American-Society-for-Aesthetic-Plastic-Surgery	APR 30-MAY 03, 2002	Las Vegas, NV	Amer Soc Aesthet Plast Surg			FACE-LIFT; VENOUS THROMBOSIS; PULMONARY EMBOLUS; PLASTIC-SURGERY; PROPHYLAXIS		Northwestern Univ, Feinberg Sch Med, Div Plast & Reconstruct Surg, McGaw Med Ctr, Chicago, IL 60611 USA	Mustoe, TA (reprint author), Northwestern Univ, Feinberg Sch Med, Div Plast & Reconstruct Surg, McGaw Med Ctr, 675 N St Clair St,19-250, Chicago, IL 60611 USA.	tmustoe@nmh.org	FACS, LAurie A. Casas MD/AAM-5075-2020				BAKER TJ, 1988, PLAST RECONSTR SURG, V82, P244, DOI 10.1097/00006534-198808000-00005; Bun MY, 1999, PLAST RECONSTR SURG, V103, P1260; KISSIN I, 1990, ANESTH ANALG, V71, P65; Marcus JR, 1999, PLAST RECONSTR SURG, V104, P1338, DOI 10.1097/00006534-199910000-00015; MICHELSON LN, 1987, AESTHET PLAST SURG, V11, P207, DOI 10.1007/BF01575512; MOSCONA RK, 1995, PLAST RECONSTR SURG, V96, P1066, DOI 10.1097/00006534-199510000-00009; Reinisch JF, 2001, PLAST RECONSTR SURG, V107, P1570, DOI 10.1097/00006534-200105000-00044; STEIN JM, 1982, PLAST RECONSTR SURG, V70, P505, DOI 10.1097/00006534-198210000-00018; Stuzin JM, 2001, PLAST RECONSTR SURG, V107, P1576, DOI 10.1097/00006534-200105000-00045; THOMPSON DP, 1978, PLAST RECONSTR SURG, V61, P40, DOI 10.1097/00006534-197801000-00008; Vance J P, 1973, Br J Plast Surg, V26, P336, DOI 10.1016/S0007-1226(73)90035-0	11	29	31	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	NOV	2003	112	6					1683	1689		10.1097/01.PRS.0000086363.34535.A4			7	Surgery	Surgery	800YF	WOS:000220062900029	14578803				2020-06-30	J	Kararmaz, A; Kaya, S; Turhanoglu, S; Ozyilmaz, MA				Kararmaz, A; Kaya, S; Turhanoglu, S; Ozyilmaz, MA			Which administration route of fentanyl better enhances the spread of spinal anaesthesia: intravenous, intrathecal or both?	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						analgesics; fentanyl; local anesthetics; bupivacaine; anesthetic techniques; spinal	CESAREAN-SECTION; MULTIPLICATIVE INTERACTION; DORSAL HORN; MORPHINE; BUPIVACAINE; BLOCK; ANTINOCICEPTION; DIAMORPHINE; ANALGESIA; OPIOIDS	Background: To enhance the spread of spinal anaesthesia, fentanyl may be administered intrathecally (i.t.) or intravenously (i.v.). The purpose of this prospective study was to investigate the effects of fentanyl administered i.v., i.t. or concurrently by both i.v. and spinal routes on the spread of spinal anaesthesia. Methods: Sixty patients were randomly assigned to one of three groups. In Groups I and II, spinal anaesthesia was performed with plain bupivacaine 10 mg plus 20 mg fentanyl and in Group III with 10 mg of plain bupivacaine. The level of first peak sensory block was marked. In addition, fentanyl 50 mg was administered i.v. in Groups II and III or by saline in Group I after the sensory blockade reached the highest dermatomal level. Ten minutes after i.v. administration, the level of the second peak sensory block was marked. The distance between the first- and second-highest levels of sensory block was measured. Results: The distance between the first- and second-highest level of sensory block was significantly different for the three groups: Group II ( 5.8 +/- 2.6 cm)> Group III (2.9 +/- 2.1 cm) > Group I ( - 0.15 +/- 1.7 cm). The peak dermatomal level of spinal block was significantly higher in Group II [ T4 ( T3 - T7)] than in Group I [ T6 ( T4 - T9)] and Group III [ T6 ( T4-T8)]. In Groups I and II the sensory block regressed to S2 for a longer period of time than it did in Group III. Conclusion: Both the spinal and systemic administration of fentanyl enhanced the spread of spinal anaesthesia. The co-administration of spinal and i.v. fentanyl produced a greater increase in the cephalad spread of spinal block.	Dicle Univ Hosp, Dept Anaesthesiol, TR-21280 Diyarbakir, Turkey	Kararmaz, A (reprint author), Dicle Univ Hosp, Dept Anaesthesiol, TR-21280 Diyarbakir, Turkey.						Ben-David B, 2002, ANESTH ANALG, V95, P1596, DOI 10.1097/00000539-200212000-00023; Bouaziz H, 1996, ANESTHESIOLOGY, V84, P143, DOI 10.1097/00000542-199601000-00017; Cooper DW, 2002, ANAESTHESIA, V57, P266, DOI 10.1046/j.1365-2044.2002.2366_1.x; Fassoulaki A, 1997, ANESTH ANALG, V85, P1108, DOI 10.1097/00000539-199711000-00027; FASSOULAKI A, 1991, BRIT J ANAESTH, V67, P437, DOI 10.1093/bja/67.4.437; Gupta A, 2003, ACTA ANAESTH SCAND, V47, P13, DOI 10.1034/j.1399-6576.2003.470103.x; HEADLEY PM, 1978, BRAIN RES, V145, P185, DOI 10.1016/0006-8993(78)90809-0; HENDERSON DJ, 1995, BRIT J ANAESTH, V74, P610, DOI 10.1093/bja/74.5.610; LUND C, 1985, LANCET, V2, P1156; McHutchon A, 1999, ANAESTHESIA, V54, P1119, DOI 10.1046/j.1365-2044.1999.01186.x; Niv D, 1998, ANESTH ANALG, V87, P583, DOI 10.1097/00000539-199809000-00016; NIV D, 1995, ANESTH ANALG, V80, P886, DOI 10.1097/00000539-199505000-00006; Olofsson C, 1997, ACTA ANAESTH SCAND, V41, P332, DOI 10.1111/j.1399-6576.1997.tb04694.x; POWER I, 1991, REGION ANESTH, V16, P204; ROERIG SC, 1989, J PHARMACOL EXP THER, V249, P762; Saraya A. K., 1994, National Medical Journal of India, V7, P5; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; YEUNG JC, 1980, J PHARMACOL EXP THER, V215, P633	18	5	7	0	1	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2003	47	9					1096	1100		10.1034/j.1399-6576.2003.00231.x			5	Anesthesiology	Anesthesiology	720FP	WOS:000185251000009	12969102				2020-06-30	J	Forster, JG; Niemi, TT; Aromaa, U; Neuvonen, PJ; Seppala, TA; Rosenberg, PH				Forster, JG; Niemi, TT; Aromaa, U; Neuvonen, PJ; Seppala, TA; Rosenberg, PH			Epinephrine added to a lumbar epidural infusion of a small-dose ropivacaine-fentanyl mixture after arterial bypass surgery of the lower extremities	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						epidural; epinephrine; fentanyl; postoperative analgesia; ropivacaine; synergy	PLASMA-CONCENTRATION; ANALGESIA; BUPIVACAINE; LIDOCAINE; PAIN	Background: The addition of epinephrine (2 mug . ml(-1)) to a thoracic epidural infusion of an opioid-local anesthetic mixture improves analgesia. Here, we studied whether epinephrine could improve analgesia also at lumbar level, when added to an epidural infusion of a low-dose ropivacaine-fentanyl mixture after arterial bypass surgery of the legs. Methods: Patients in group RFE ( n = 21) received a postoperative epidural infusion containing ropivacaine (1 mg . ml(-1)), fentanyl (2 mug . ml(-1)), and epinephrine (2 mug . ml(-1)). Patients in group RF ( n = 25) received a similar infusion without epinephrine. The infusion speed was 1 ml . 10 kg(-1) . h(-1). The infusion was scheduled for 48 h. Results: Epinephrine did not reduce the need for rescue pain medication. Visual analog scale scores ( VAS) for pain at rest were low and similar in the groups. Pain intensity was stronger during leg movement [ mean VAS 1.5 - 2.6 ( range 0 - 9)], but it was not affected by the coadministration of epinephrine. The groups did not differ concerning frequency and severity of side-effects. Epinephrine did not reduce fentanyl plasma concentrations. Ropivacaine concentrations were slightly lower in group RFE only in the samples 6 h from the start of the infusion, but not anymore on the first and second postoperative day. Conclusion: In the dosage used here, epinephrine did not improve epidural lumbar analgesia. Different distances from the epidural application site to the alpha2-adrenergic receptors of the spinal cord, and differing epinephrine dose requirements may explain why epinephrine as an additive improves epidural analgesia at thoracic, but not at lumbar level.	Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, FIN-00029 Helsinki, Finland; Univ Helsinki, Dept Clin Pharmacol, SF-00250 Helsinki, Finland; Natl Publ Hlth Inst, Dept Biochem, Helsinki, Finland	Forster, JG (reprint author), Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, Kasarmikatu 11-13, FIN-00029 Helsinki, Finland.		Neuvonen, Pertti/Z-4818-2019; Neuvonen, Pertti J/G-4675-2011	Neuvonen, Pertti/0000-0003-3631-9411; Forster, Johannes Georg/0000-0001-5344-9926			ARVIDSSON T, 1994, CHIRALITY, V7, P272; Baron CM, 1996, ANESTH ANALG, V82, P760, DOI 10.1097/00000539-199604000-00015; BJORKMAN S, 1989, ACTA PHARM NORDICA, V1, P211; Bromage P R, 1965, Acta Anaesthesiol Scand Suppl, V16, P55; BROMAGE PR, 1975, BRIT J ANAESTH, V47, P199; Bromage PR, 1978, EPIDURAL ANALGESIA, P8; BURM AGL, 1986, ANESTH ANALG, V65, P1281; COHEN S, 1992, ANESTH ANALG, V74, P226, DOI 10.1213/00000539-199202000-00009; Cousins MJ, 1988, NEURAL BLOCKADE CLIN, P253; COVINO BG, 1998, NEURAL BLOCKADE CLIN, P102; Curatolo M, 2002, ANESTH ANALG, V94, P1381, DOI 10.1097/00000539-200206000-00001; Curatolo M, 1997, ANESTHESIOLOGY, V87, P785, DOI 10.1097/00000542-199710000-00011; EMANUELSSON BMK, 1995, ANESTH ANALG, V81, P1163, DOI 10.1097/00000539-199512000-00008; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; GUINARD JP, 1995, REGION ANESTH, V20, P193; KERN C, 1995, ANESTHESIOLOGY, V83, P1078, DOI 10.1097/00000542-199511000-00021; Kihara S, 1999, REGION ANESTH PAIN M, V24, P529, DOI 10.1016/S1098-7339(99)90044-5; Miyabe M, 2002, CAN J ANAESTH, V49, P706, DOI 10.1007/BF03017450; MYLLYLA G, 1988, ACTA ANAESTH SCAND, V32, P76, DOI 10.1111/j.1399-6576.1988.tb02848.x; Niemi G, 1998, ACTA ANAESTH SCAND, V42, P897, DOI 10.1111/j.1399-6576.1998.tb05348.x; Niemi G, 2002, ANESTH ANALG, V94, P1598, DOI 10.1097/00000539-200206000-00044; PRIDDLE HD, 1950, ANESTH ANALG, V29, P156; RAMANATHAN S, 1995, REGION ANESTH, V20, P199; *TASC WORK GROUP, 2000, INT ANGIOL S1, V19, P70; TIGERSTEDT I, 1988, SCHMERZ PAIN DOULEUR, V9, P66; WHITE MJ, 1992, CAN J ANAESTH, V39, P576, DOI 10.1007/BF03008321; WOHLBERG CJ, 1985, BRAIN RES, V327, P289, DOI 10.1016/0006-8993(85)91522-7	27	7	7	0	1	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	OCT	2003	47	9					1106	1113		10.1034/j.1399-6576.2003.00211.x			8	Anesthesiology	Anesthesiology	720FP	WOS:000185251000011	12969104				2020-06-30	J	Duggan, AB; Katz, SG				Duggan, AB; Katz, SG			Combined spinal and epidural anaesthesia for caesarean section in a parturient with severe primary pulmonary hypertension	ANAESTHESIA AND INTENSIVE CARE			English	Article						anaesthetic, anesthetic techniques : regional, combined spinal-epidural; caesarean, cesarean section	INHALED NITRIC-OXIDE; PREGNANCY; BUPIVACAINE; DELIVERY	We describe the management of a parturient with severe primary pulmonary hypertension who underwent caesarean section. A multi-disciplinary approach was used. She was admitted to the intensive care unit perioperatively for invasive monitoring and trial of inhaled nitric oxide. Anaesthesia was provided by combined spinal-epidural block. We discuss controversies about the management of obstetric patients with this rare and serious condition.	Royal Hosp Women, Dept Anaesthesia, Randwick, NSW 2031, Australia; Prince Wales Hosp, Dept Anaesthesia & Intens Care, Sydney, NSW, Australia	Duggan, AB (reprint author), Royal Hosp Women, Dept Anaesthesia, Level 1,Barker St, Randwick, NSW 2031, Australia.						Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; ABOULEISH E, 1991, REGION ANESTH, V16, P137; BARASH PG, 1981, J THORAC CARDIOV SUR, V82, P5; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; Decoene C, 2001, CAN J ANAESTH, V48, P584, DOI 10.1007/BF03016836; Fontaine H, 2000, LANCET, V356, P1328, DOI 10.1016/S0140-6736(00)02823-3; Gaine SP, 1998, LANCET, V352, P719, DOI 10.1016/S0140-6736(98)02111-4; Hart CM, 1999, CHEST, V115, P1407, DOI 10.1378/chest.115.5.1407; Lam GK, 2001, OBSTET GYNECOL, V98, P895, DOI 10.1016/S0029-7844(01)01549-6; MCCAFFREY R M, 1964, Obstet Gynecol Surv, V19, P567, DOI 10.1097/00006254-196408000-00001; MILLER OI, 1995, LANCET, V346, P51, DOI 10.1016/S0140-6736(95)92681-X; Monnery L, 2001, BRIT J ANAESTH, V87, P295, DOI 10.1093/bja/87.2.295; NELSON DM, 1983, OBSTET GYNECOL, V62, pS58; O'Hare R, 1998, BRIT J ANAESTH, V81, P790, DOI 10.1093/bja/81.5.790; Olofsson C, 2001, ACTA ANAESTH SCAND, V45, P258, DOI 10.1034/j.1399-6576.2001.450220.x; Olschewski H, 2002, NEW ENGL J MED, V347, P322, DOI 10.1056/NEJMoa020204; PALEVSKY HI, 1989, CIRCULATION, V80, P1207, DOI 10.1161/01.CIR.80.5.1207; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; ROBERTS NV, 1990, ANAESTH INTENS CARE, V18, P366, DOI 10.1177/0310057X9001800314; ROBINSON DE, 1988, ANESTHESIOLOGY, V68, P285, DOI 10.1097/00000542-198802000-00020; Robinson JN, 1999, AM J OBSTET GYNECOL, V180, P1045, DOI 10.1016/S0002-9378(99)70686-1; ROESSLER P, 1986, ANAESTH INTENS CARE, V14, P317, DOI 10.1177/0310057X8601400312; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; Stewart R, 2001, CHEST, V119, P973, DOI 10.1378/chest.119.3.973; Weiss BM, 1998, J AM COLL CARDIOL, V31, P1650, DOI 10.1016/S0735-1097(98)00162-4	26	19	19	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0310-057X	1448-0271		ANAESTH INTENS CARE	Anaesth. Intensive Care	OCT	2003	31	5					565	569		10.1177/0310057X0303100511			5	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	738WX	WOS:000186311800012	14601281	Bronze			2020-06-30	J	Stannard, K; Wells, J; Cokis, C				Stannard, K; Wells, J; Cokis, C			Tracheal rupture following endotracheal intubation	ANAESTHESIA AND INTENSIVE CARE			English	Article						anaesthesia, complications : endotracheal intubation, tracheal rupture	TRACHEOSTOMY	We describe a case of tracheal rupture diagnosed after an apparently routine endotracheal intubation for otherwise uneventful lower abdominal surgery in a 33-year-old woman. Risk factors for tracheal rupture, presenting symptoms and signs, management of tracheal rupture and methods of airway management during the surgical repair of the tracheal laceration are discussed. In this case, "side-by-side" microlaryngoscopy tubes, one endobronchial and the other with the tip in the upper trachea, placed with fibreoptic assistance were used for airway management during the tracheal repair.	Royal Perth Hosp, Dept Anaesthesia & Pain Med, Perth, WA, Australia	Stannard, K (reprint author), Royal Perth Hosp, Dept Anaesthet, Wellington Campus,GPO Box X2213, Perth, WA 6847, Australia.						Ambrogi MC, 2001, EUR J CARDIO-THORAC, V19, P932, DOI 10.1016/S1010-7940(01)00678-9; Chen EH, 2001, ANESTH ANALG, V93, P1270, DOI 10.1097/00000539-200111000-00047; Cokis C, 2000, ANAESTH INTENS CARE, V28, P566, DOI 10.1177/0310057X0002800516; CONACHER ID, 1992, ANAESTHESIA, V47, P589, DOI 10.1111/j.1365-2044.1992.tb02330.x; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; Jougon J, 2000, ANN THORAC SURG, V69, P216, DOI 10.1016/S0003-4975(99)01129-7; Kadry M, 1999, ANAESTHESIA, V54, P404, DOI 10.1046/j.1365-2044.1999.00876.x; Kaloud H, 1997, CHEST, V112, P774, DOI 10.1378/chest.112.3.774; Latto IP, 2002, ANAESTHESIA, V57, P379, DOI 10.1046/j.1365-2044.2002.02411.x; MARTYANE CH, 1995, ANN THORAC SURG, V60, P1367, DOI 10.1016/0003-4975(95)00643-Y; Massard G, 1996, ANN THORAC SURG, V61, P1483, DOI 10.1016/0003-4975(96)00083-5; Pinsonneault C, 1999, CAN J ANAESTH, V46, P439, DOI 10.1007/BF03012943; VANKLARENBOSCH J, 1994, BRIT J ANAESTH, V73, P550, DOI 10.1093/bja/73.4.550	13	7	8	0	1	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	OCT	2003	31	5					588	591		10.1177/0310057X0303100518			4	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	738WX	WOS:000186311800019	14601288	Bronze			2020-06-30	J	Hudson, RJ; Thomson, IR; Jassal, R; Peterson, DJ; Brown, AD; Freedman, JI				Hudson, RJ; Thomson, IR; Jassal, R; Peterson, DJ; Brown, AD; Freedman, JI			Cardiopulmonary bypass has minimal effects on the pharmacokinetics of fentanyl in adults	ANESTHESIOLOGY			English	Article							SUFENTANIL; PROPOFOL; INFUSION; CHILDREN; SURGERY	Background: Although fentanyl has been widely used in cardiac anesthesia, no complete pharmacokinetic model that has assessed the effect of cardiopulmonary bypass (CPB) and that has adequate predictive accuracy has been defined. The aims of this investigation were to determine whether CPB had a clinically significant impact on fentanyl pharmacokinetics and to determine the simplest model that accurately predicts fentanyl concentrations during cardiac surgery using CPB. Methods: Population pharmacokinetic modeling was applied to concentration-versus-time data from 61 patients undergoing coronary artery bypass grafting using CPB. Predictive ability of models was assessed by calculating bias (prediction error), accuracy (absolute prediction error), and measured:predicted concentration ratios versus time. The predictive ability of a simple three-compartment model with no covariates was initially compared to models with premedication (lorazepam vs. clonidine), sex, or weight as covariates. This simple model was then compared to 18 CPB-adjusted models that allowed for step changes in pharmacokinetic parameters at the start and/or end of CPB. The predictive ability of the final model was assessed prospectively in a second group of 29 patients. Results: None of the covariate (premedication, sex, weight) models nor any of the CPB-adjusted models significantly improved prediction error or absolute prediction error, compared to the simple three-compartment model. Thus, the simple three-compartment model was selected as the final model. Prospective assessment of this model yielded a median prediction error of +3.8%, with a median absolute prediction error of 15.8%. The model parameters were as follows: V-1, 14.4 1; V-2, 36.4 1; V-3, 169 1; Cl-1, 0.82 1 (.) min(-1); Cl-2, 2.31 1 (.) min(-1); Cl-3, 1.35 1 (.) min(-1). Conclusions: Compared to other factors that cause pharmacokinetic variability, the effect of CPB on fentanyl kinetics is clinically insignificant. A simple three-compartment model accurately predicts fentanyl concentrations throughout surgery using CPB.	Univ Manitoba, St Boniface Gen Hosp, Dept Anesthesia, Winnipeg, MB, Canada	Hudson, RJ (reprint author), Univ Alberta, Dept Anaesthesiol & Pain Med, Room WMC 3B2-32,8440 112th St, Edmonton, AB T6G 2B7, Canada.						Bailey JM, 1996, ANESTHESIOLOGY, V84, P1288, DOI 10.1097/00000542-199606000-00003; BENTLEY JB, 1983, CLIN PHARMACOL THER, V34, P703, DOI 10.1038/clpt.1983.235; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; FISET P, 1995, ANESTHESIOLOGY, V83, P944, DOI 10.1097/00000542-199511000-00006; FISHER DM, 1994, ANESTHESIOLOGY, V80, P2; GEPTS E, 1995, ANESTHESIOLOGY, V83, P1194, DOI 10.1097/00000542-199512000-00010; GLASS PSA, 1990, ANESTHESIOLOGY, V73, P1082, DOI 10.1097/00000542-199012000-00004; GLASS PSA, 2000, ANESTHESIA, P377; Hall RI, 2002, J CARDIOTHOR VASC AN, V16, P83, DOI 10.1053/jcan.2002.29690; Hudson RJ, 2002, CAN J ANAESTH, V49, P388, DOI 10.1007/BF03017328; Hudson RJ, 2001, J CARDIOTHOR VASC AN, V15, P693, DOI 10.1053/jcan.2001.28311; HUG CC, 1994, ANESTH ANALG, V78, P231, DOI 10.1213/00000539-199402000-00007; KATARIA BK, 1994, ANESTHESIOLOGY, V80, P104, DOI 10.1097/00000542-199401000-00018; ROERIG DL, 1987, ANESTHESIOLOGY, V67, P466, DOI 10.1097/00000542-198710000-00004; SCOTT JC, 1991, ANESTHESIOLOGY, V74, P34, DOI 10.1097/00000542-199101000-00007; Seber GAF, 1989, NONLINEAR REGRESSION, P197; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; Thomson IR, 1998, ANESTHESIOLOGY, V89, P852, DOI 10.1097/00000542-199810000-00009	18	8	8	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	OCT	2003	99	4					847	854		10.1097/00000542-200310000-00016			8	Anesthesiology	Anesthesiology	725ZV	WOS:000185573500014	14508316				2020-06-30	J	Senagore, AJ; Delaney, CP; Mekhail, N; Dugan, A; Fazio, VW				Senagore, AJ; Delaney, CP; Mekhail, N; Dugan, A; Fazio, VW			Randomized clinical trial comparing epidural anaesthesia and patient-controlled analgesia after laparoscopic segmental colectomy	BRITISH JOURNAL OF SURGERY			English	Article							POSTOPERATIVE PARALYTIC ILEUS; COLONIC RESECTION; SURGERY; BUPIVACAINE; RECOVERY; MOTILITY; CYTOKINE; PAIN	Background: This randomized clinical trial compared the use of thoracic epidural anaesthesia-analgesia (TEA) with morphine patient-controlled analgesia (PCA) for pain relief after laparoscopic colectomy. Methods: Patients scheduled for segmental laparoscopic colectomy were randomized to receive TEA or PCA. Patients in the TEA group received bupivacaine and fentanyl before incision and after surgery by continuous infusion for 18 h. Patients in the PCA group self-administered morphine using an intravenous pump. The postoperative care plan was otherwise identical for the two groups. Postoperative pain was measured during ambulation using a visual analogue pain score. Results: The study included 3 8 patients (18 TEA, 20 PCA), 16 of whom underwent right hemicolectomy or ileocolectomy and 22 sigmoid colectomy. Operating times, patient weight and distribution of American Society of Anesthesiologists grade were similar in the two groups. The mean(s.e.m.) total dose of drugs administered was 64(41) mg morphine in the PCA group, and 79(42) mg bupivacaine and 205(140) mug fentanyl in the TEA group. Postoperative pain scores were significantly better in the TEA group at 6 h (mean(s.e.m.) 2.2(0.4) versus 6.6(0.5) with PCA; P = 0.001) and 18 h (2.2(0.3) versus 4.0(0.4); P = 0.003). Hospital stay was similar in the two groups. Conclusion: TEA significantly improved early analgesia following laparoscopic colectomy but did not affect the length of hospital stay.	Cleveland Clin Fdn, Dept Colorectal Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Minimally Invas Surg Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Pain Management Ctr, Cleveland, OH 44195 USA	Senagore, AJ (reprint author), Cleveland Clin Fdn, Dept Colorectal Surg, Cleveland, OH 44195 USA.	senagoa@ccf.org					BARDRAM L, 1995, LANCET, V345, P763, DOI 10.1016/S0140-6736(95)90643-6; Basse L, 2000, ANN SURG, V232, P51, DOI 10.1097/00000658-200007000-00008; BENHAMOU D, 1983, ACTA ANAESTH SCAND, V27, P22, DOI 10.1111/j.1399-6576.1983.tb01899.x; BREDTMANN RD, 1990, BRIT J SURG, V77, P638, DOI 10.1002/bjs.1800770615; CULLEN ML, 1985, SURGERY, V98, P718; Delaney CP, 2001, BRIT J SURG, V88, P1533, DOI 10.1046/j.0007-1323.2001.01905.x; EGBERT AM, 1990, ARCH INTERN MED, V150, P1897, DOI 10.1001/archinte.150.9.1897; Friedrich M., 1999, Clinical and Experimental Obstetrics and Gynecology, V26, P71; HARMON GD, 1994, DIS COLON RECTUM, V37, P754, DOI 10.1007/BF02050137; Kehlet H, 1997, BRIT J ANAESTH, V78, P606; KEHLET H, 1998, NEURAL BLOCKADE CLIN, P129; Kuntz C, 1998, SURG ENDOSC-ULTRAS, V12, P963, DOI 10.1007/s004649900757; Leung KL, 2000, ANN SURG, V231, P506, DOI 10.1097/00000658-200004000-00008; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; Neudecker J, 1999, BRIT J SURG, V86, P1292, DOI 10.1046/j.1365-2168.1999.01242.x; Ozawa A, 2000, SURG TODAY, V30, P107, DOI 10.1007/s005950050024; RIWAR A, 1992, HELV CHIR ACTA, V58, P729; Safwat A M, 1989, J Cardiothorac Anesth, V3, P505, DOI 10.1016/S0888-6296(89)98083-6; SCHEININ B, 1987, ACTA ANAESTH SCAND, V31, P161, DOI 10.1111/j.1399-6576.1987.tb02541.x; Scott NB, 1996, ACTA ANAESTH SCAND, V40, P691, DOI 10.1111/j.1399-6576.1996.tb04512.x; Senagore AJ, 2001, SURGERY, V129, P672, DOI 10.1067/msy.2001.114648; Steinbrook RA, 1998, ANESTH ANALG, V86, P837, DOI 10.1097/00000539-199804000-00029; WALLIN G, 1986, ANESTHESIOLOGY, V65, P292; WATTWIL M, 1989, ANESTH ANALG, V68, P353	24	104	109	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1323	1365-2168		BRIT J SURG	Br. J. Surg.	OCT	2003	90	10					1195	1199		10.1002/bjs.4223			5	Surgery	Surgery	734TE	WOS:000186073400005	14515286				2020-06-30	J	Kuhlman, JJ; McCaulley, R; Valouch, TJ; Behonick, GS				Kuhlman, JJ; McCaulley, R; Valouch, TJ; Behonick, GS			Fentanyl use, misuse, and abuse: A summary of 23 postmortem cases	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							TRANSDERMAL FENTANYL; DRUG; DEATHS; PATCH		Virginia Div Forens Sci, Westerm Lab, Roanoke, VA 24019 USA; Univ Alabama, Dept Justice Sci, Birmingham, AL 35294 USA	Kuhlman, JJ (reprint author), Virginia Div Forens Sci, Westerm Lab, 6600 Northside High Sch Rd, Roanoke, VA 24019 USA.						Anderson DT, 2000, J ANAL TOXICOL, V24, P627, DOI 10.1093/jat/24.7.627; Baselt R.C., 2002, DISPOSITION TOXIC DR, P430; BEHONICK GS, 2003, P AM AC FOR SCI 55 A, P312; Booth JV, 2002, ANESTH ANALG, V95, P1024, DOI 10.1213/01.ANE.0000026379.66419.DB; DESIO JM, 1993, ANESTHESIOLOGY, V79, P1139, DOI 10.1097/00000542-199311000-00036; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Flannagan LM, 1996, J FORENSIC SCI, V41, P320; HENDERSON GL, 1991, J FORENSIC SCI, V36, P422; Joranson DE, 2000, JAMA-J AM MED ASSOC, V284, P564; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; Kronstrand R, 1997, FORENSIC SCI INT, V88, P185, DOI 10.1016/S0379-0738(97)00068-6; KWONG TC, 1989, AM ASS CLIN CHEM IN, V10, P3; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MCGEE MP, 1992, FENTANYL RELATED DEA; POKLIS A, 1995, J TOXICOL-CLIN TOXIC, V33, P439, DOI 10.3109/15563659509013752; Reeves MD, 2002, MED J AUSTRALIA, V177, P552, DOI 10.5694/j.1326-5377.2002.tb04951.x; SMIALEK JE, 1994, J FORENSIC SCI, V39, P159; SNELL KS, 2002, P AM AC FOR SCI 54 A, P284; WAHBA W, 1989, 19 ANN M CHIC IL OCT	20	87	91	0	14	PRESTON PUBLICATIONS INC	NILES	7800 MERRIMAC AVE PO BOX 48312, NILES, IL 60648 USA	0146-4760			J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2003	27	7					499	504		10.1093/jat/27.7.499			6	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	728JW	WOS:000185714900016	14607006	Bronze			2020-06-30	J	Day, J; Slawson, M; Lugo, RA; Wilkins, D				Day, J; Slawson, M; Lugo, RA; Wilkins, D			Analysis of fentanyl and norfentanyl in human plasma by liquid chromatography-tandem mass spectrometry using electrospray ionization	JOURNAL OF ANALYTICAL TOXICOLOGY			English	Article							GAS-CHROMATOGRAPHY; ASSAY; RADIOIMMUNOASSAY; ALFENTANIL; SERUM		Univ Utah, Ctr Human Toxicol, Salt Lake City, UT 84112 USA	Wilkins, D (reprint author), Univ Utah, Ctr Human Toxicol, 490 Biomed Polymers Bldg,20 South 2030 East, Salt Lake City, UT 84112 USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA09096, 5 R01 DA10779-02]		Choi HS, 2001, J CHROMATOGR B, V765, P63, DOI 10.1016/S0378-4347(01)00405-4; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; GOODMAN AG, 1996, PHARMACOL BASIS THER, P543; KUMAR K, 1987, J CHROMATOGR-BIOMED, V419, P464, DOI 10.1016/0378-4347(87)80317-1; Lambropoulos J, 1999, J PHARMACEUT BIOMED, V20, P705, DOI 10.1016/S0731-7085(99)00077-1; LIN SN, 1981, J PHARM SCI, V70, P1276, DOI 10.1002/jps.2600701124; PHIPPS JA, 1983, CAN ANAESTH SOC J, V30, P162, DOI 10.1007/BF03009346; PHIPPS JA, 1983, J CHROMATOGR, V272, P392, DOI 10.1016/S0378-4347(00)86145-9; SCHUTTLER J, 1984, ANESTHESIOLOGY, V61, P315, DOI 10.1097/00000542-198409000-00010; Shou WZ, 2001, RAPID COMMUN MASS SP, V15, P466, DOI 10.1002/rcm.255; Szeitz A, 1996, J CHROMATOGR B, V675, P33, DOI 10.1016/0378-4347(95)00350-9; Weng ND, 2002, J PHARMACEUT BIOMED, V28, P1115, DOI 10.1016/S0731-7085(02)00002-X; WOESTENBORGHS RJH, 1987, ANESTHESIOLOGY, V67, P85, DOI 10.1097/00000542-198707000-00015	13	27	28	0	2	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-4760	1945-2403		J ANAL TOXICOL	J. Anal. Toxicol.	OCT	2003	27	7					513	516		10.1093/jat/27.7.513			4	Chemistry, Analytical; Toxicology	Chemistry; Toxicology	728JW	WOS:000185714900018	14607008	Bronze			2020-06-30	J	Baik, SW; Kim, KH; Ki, YC; Lee, SC; Kim, DK; Jung, JE				Baik, SW; Kim, KH; Ki, YC; Lee, SC; Kim, DK; Jung, JE			Initial dose cascade of TTS fentanyl with proper adjuvant medications in cancer pain	JOURNAL OF KOREAN MEDICAL SCIENCE			English	Article						adjuvants; pharmaceutic; analgesics; drug delivery systems; fentanyl	TRANSDERMAL FENTANYL; ORAL MORPHINE; PHARMACOKINETICS; EFFICACY	According to the three step-ladder analgesics in patients with cancer pain, adjuvant drugs are required for pain relief according to the pain character and also to reduce side effects of opioids. Pain clinicians sometimes want to decide to jump directly from naive and mild opioid to transdermal therapeutic system (TTS) fentanyl with less side effects. We investigated the safety, efficacy, and satisfaction of the patients of TTS fentanyl converting from opioid-naive and mild-opioid with adjuvant drug medications in related to dose cascade of TTS fentanyl. Both opioid-naive (n=3) and opioid-using (n=34) patients started with TrS fentanyl in the lowest available delivery rate (25 mug/hr) with rescue medication. A numeric rating scale (NRS, from 0=no pain to 10=worst pain imaginable), satisfaction of the patients with the transdermal therapy and side effects were recorded everyday during 29 days. Average reductions of NRS scores were 1.79 and 2.77, and the mean doses were 35.14 and 44.12 mug/hr on the 15th and 29th day, respectively. Reported level of satisfaction with the transdermal patch and generalized pain management were 'completely satisfied' and 'satisfied'. Frequent side effects were nausea, vomiting, and constipation. In conclusion, initial application of TTS fentanyl with proper adjuvant medications is effective, safe, and well tolerated.	Pusan Natl Univ, Coll Med, Dept Anesthesia & Pain Med, Pusan 602739, South Korea; Seoul Natl Univ, Coll Med, Dept Anesthesia & Pain Med, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Med Stat, Seoul, South Korea; Janssen Korea Ltd, Gastointestinal & Pain Med Dept, Seoul, South Korea	Kim, KH (reprint author), Pusan Natl Univ, Coll Med, Dept Anesthesia & Pain Med, 1-10 Ami Dong, Pusan 602739, South Korea.		Lee, Sang Chul/E-4151-2012; Kim, Yong Chul/J-5421-2012				Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Catterall RA, 1997, PALLIATIVE MED, V11, P169; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Genf World Health Organization, 1986, CANC PAIN REL; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; KIM BH, 1998, KOREAN J ANESTHESIOL, V34, P852; Meuser T, 2001, PAIN, V93, P247, DOI 10.1016/S0304-3959(01)00324-4; Mystakidou K, 2002, ONCOLOGY-BASEL, V62, P9, DOI 10.1159/000048241; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007	11	2	2	0	1	KOREAN ACAD MEDICAL SCIENCES	SEOUL	302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA	1011-8934			J KOREAN MED SCI	J. Korean Med. Sci.	OCT	2003	18	5					733	737		10.3346/jkms.2003.18.5.733			5	Medicine, General & Internal	General & Internal Medicine	737MZ	WOS:000186237500018	14555829	Green Published, Bronze			2020-06-30	J	Miller, BF; Muller, LI; Storms, TN; Ramsay, EC; Osborn, DA; Warren, RJ; Miller, KV; Adams, KA				Miller, BF; Muller, LI; Storms, TN; Ramsay, EC; Osborn, DA; Warren, RJ; Miller, KV; Adams, KA			A comparison of carfentanil/xylazine and Telazol (R)/xylazine for immobilization of white-tailed deer	JOURNAL OF WILDLIFE DISEASES			English	Article						carfentanil citrate; hyperthermia; induction; naltrexone hydrochloride; Odocoileus virginianus; reversal; Telazol (R); white-tailed deer; yohimbine hydrochloride	ROCKY-MOUNTAIN ELK; MULE DEER; XYLAZINE; HYDROCHLORIDE; NALTREXONE; ANTAGONISM	From October 2001 to January 2002, captive free-ranging white-tailed deer (Odocoileus virginianus) were immobilized with a combination of carfentanil citrate and xylazine hydrochloride. From this study, we selected a dose of carfentanil/xylazine for the purpose of comparing inn mobilization parameters and physiologic effects with those of a combination of tiletamine and zolazepam (Telazol(R)) and xylazine. Animals were initially given intramuscular injections of 10 mg xylazine and one of four doses of carfentanil (i.e., 0.5, 1.0, 1.5, and 2.0 mg). A carfentanil dose of 1.2 mg ((x) over bar +/-SD=23.5+/-3.2 mug/kg) and 10 mg xylazine (0.2+/-0.03 mg/kg) were selected, based on induction times and previously published reports, to compare with a combination of 230 mg of Telazol(R) (4.5+/-0.6 mg/kg) and 120 mg xylazine (2.3+/-0.3 mg/kg). Time to first observable drug effects and to induction were significantly longer for deer treated with carfentanil/xylazine than with Telazol(R)/xylazine (P<0.01). Hyperthermia was common in deer immobilized with carfentanil/xylazine, but heart rate, respiration rate, and hemoglobin saturation were within acceptable levels. Degree of anesthesia of deer immobilized with Telazol(R)/xylazine was superior to deer immobilized with carfentanil/xylazine. The combination of 120 mg of naltrexone hydrochloride and 6.5 mg of yohimbine hydrochloride provided rapid and complete reversal (1.9+/-1.1 min) of carfentanil/xylazine immobilization. Animals immobilized with Telazol(R)/xylazine had long recovery times with occasional resedation after antagonism with 6.5 mg of yohimbine. The combination of carfentanil and xylazine at the doses tested did not provide reliable induction or immobilization of white-tailed deer even though drug reversal was rapid and safe using naltrexone and yohimbine.	Univ Tennessee, Dept Forestry Fisheries & Wildlife, Knoxville, TN 37996 USA; Univ Tennessee, Coll Vet Med, Dept Comparat Med, Knoxville, TN 37996 USA; Univ Tennessee, Coll Vet Med, Vet Teaching Hosp, Dept Small Anim Clin Sci, Knoxville, TN 37996 USA; Univ Georgia, Warnell Sch Forest Resources, Athens, GA 30602 USA	Muller, LI (reprint author), Univ Tennessee, Dept Forestry Fisheries & Wildlife, 274 Ellington Hall, Knoxville, TN 37996 USA.			Muller, Lisa/0000-0001-7833-2273			Allen JL, 1996, J ZOO WILDLIFE MED, V27, P496; Caulkett NA, 2000, CAN J VET RES, V64, P64; HAIGH JC, 1991, J ZOO WILDLIFE MED, V22, P318; HAIGH JC, 1990, J ZOO WILDLIFE MED, V21, P391; JESSUP DA, 1984, J ZOO ANIM MED, V15, P8, DOI 10.2307/20094672; Kilpatrick HJ, 1999, WILDLIFE SOC B, V27, P566; Kilpatrick HJ, 1996, WILDLIFE SOC B, V24, P306; KLEIN LV, 1989, J ZOO WILDLIFE MED, V20, P138; KOCK MD, 1987, J WILDLIFE DIS, V23, P625, DOI 10.7589/0090-3558-23.4.625; KREEGER TJ, 1996, HDB WILDLIFE CHEM IM; MEULEMAN T, 1984, J WILDLIFE MANAGE, V48, P258, DOI 10.2307/3808484; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; MILLSPAUGH JJ, 1995, J WILDLIFE DIS, V31, P259, DOI 10.7589/0090-3558-31.2.259; Murray S, 2000, J WILDLIFE DIS, V36, P670, DOI 10.7589/0090-3558-36.4.670; NIELSEN L, 1999, CHEM IMMOBILIZATION; Ryeng KA, 2001, AM J VET RES, V62, P119, DOI 10.2460/ajvr.2001.62.119	16	26	28	0	6	WILDLIFE DISEASE ASSN, INC	LAWRENCE	810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA	0090-3558			J WILDLIFE DIS	J. Wildl. Dis.	OCT	2003	39	4					851	858		10.7589/0090-3558-39.4.851			8	Veterinary Sciences	Veterinary Sciences	760BX	WOS:000187791800012	14733280				2020-06-30	J	Sahajananda, H; Sanjay, OP; Thomas, J; Daniel, B				Sahajananda, H; Sanjay, OP; Thomas, J; Daniel, B			General anaesthesia for lobectomy in an 8-year-old child with Kartagener's syndrome	PAEDIATRIC ANAESTHESIA			English	Article						Kartagener's syndrome; anaesthesia, general	IMMOTILE CILIA SYNDROME; PATIENT	Kartagener's syndrome (KGS) is an autosomal recessive disorder characterized by the clinical triad of bronchiectasis, sinusitis and dextrocardia (situs inversus ). Reports of general anaesthesia in a child with KGS are rare in medical literature. We describe the case of a young boy who underwent lobectomy under general anaesthesia using a single lumen tube. Anaesthetic implications of this syndrome are mentioned. Key points in the management of anaesthesia in KGS are discussed.	St Johns Med Coll & Hosp, Dept Anaesthesiol, Bangalore, Karnataka, India	Sahajananda, H (reprint author), St Johns Med Coll Hosp Residential Campus,D-13,St, Bangalore 34, Karnataka, India.			H, sahajananda/0000-0001-8468-0266			Anthony M-H, 1992, ANESTHESIOLOGY, V77, P386; BRADFORD JK, 1966, SURG CLIN N AM, V46, P1485; BROWN TCK, 1992, ANAESTHESIA CHILDREN, P171; KAPLAN S, 1988, TXB MED, P315; Kartagener M, 1933, BEITR KLIN ERFORSCH, V83, P489, DOI DOI 10.1007/BF02141468; Knuttgen D, 1999, ANAESTHESIST, V48, P817, DOI 10.1007/s001010050791; KUBOTOVA H, 1987, ANESTHESIOLOGY, V67, P5987; Lin W T, 1998, Acta Anaesthesiol Sin, V36, P229; MAYO P, 1961, J THORAC CARDIOV SUR, V42, P39; MICHAEL L, 1976, SURG TREATMENT BRONC, V63, P494; NADEL HR, 1985, RADIOLOGY, V154, P651, DOI 10.1148/radiology.154.3.3969467; NUGENT EW, 1986, HEART, P689; Perry KM, 1940, AMER REV TUBERC, V41, P531; Reidy J, 2000, BRIT J ANAESTH, V85, P919, DOI 10.1093/bja/85.6.919; ROSSMAN CM, 1980, AM REV RESPIR DIS, V121, P1011; RUBIN BK, 1988, CLIN CHEST MED, V9, P657; Schwarzenberg H, 1997, ANN THORAC SURG, V64, P852, DOI 10.1016/S0003-4975(97)00689-9; Teknos TN, 1997, OTOLARYNG HEAD NECK, V116, P68, DOI 10.1016/S0194-5998(97)70354-1	18	11	11	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	OCT	2003	13	8					714	717		10.1046/j.1460-9592.2003.01039.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	731FM	WOS:000185873900012	14535911				2020-06-30	J	Lirk, P; Rieder, J; Schuerholz, A; Keller, C				Lirk, P; Rieder, J; Schuerholz, A; Keller, C			Anaesthetic implications of Robinow syndrome	PAEDIATRIC ANAESTHESIA			English	Article						Robinow syndrome; liver function; congenital heart disease; intubation difficulty	CONGENITAL HEART-DISEASE	Robinow (fetal face) syndrome is a rare inherited multisystem disorder featuring mesomelic or acromesomelic limb shortening, facial and spinal deformities, hypoplastic genitalia, kidney disease and congenital heart defects. We report the anaesthetic management of a patient with Robinow syndrome presenting for elective surgery and review specific issues of interest in the perioperative workup.	Univ Innsbruck, Dept Anaesthesiol & Crit Care Med, A-6020 Innsbruck, Austria	Lirk, P (reprint author), Univ Innsbruck, Dept Anaesthesiol & Crit Care Med, Anichstr 35, A-6020 Innsbruck, Austria.	philipp.lirk@uibk.ac.at					Al-Ata J, 1998, AM J MED GENET, V77, P332, DOI 10.1002/(SICI)1096-8628(19980526)77:4<332::AID-AJMG16>3.0.CO;2-J; Grassi V, 1993, Monaldi Arch Chest Dis, V48, P183; KHAYAT D, 1983, ARCH FR PEDIATR, V40, P327; Lee HT, 1998, J CLIN ANESTH, V10, P156, DOI 10.1016/S0952-8180(97)00260-2; LEE PA, 1982, AM J DIS CHILD, V136, P327, DOI 10.1001/archpedi.1982.03970400045014; MACDONALD I, 1995, ANAESTHESIA, V50, P1097, DOI 10.1111/j.1365-2044.1995.tb05973.x; NAZER H, 1990, AM J MED GENET, V37, P516, DOI 10.1002/ajmg.1320370417; Patton MA, 2002, J MED GENET, V39, P305, DOI 10.1136/jmg.39.5.305; PRAGER MC, 1992, ANESTH ANALG, V74, P162; ROBINOW M, 1969, AM J DIS CHILD, V117, P645, DOI 10.1001/archpedi.1969.02100030647005; Seefelder C, 2000, PAEDIATR ANAESTH, V10, P682, DOI 10.1046/j.1460-9592.2000.0566c.x; Soliman AT, 1998, METABOLISM, V47, P1337, DOI 10.1016/S0026-0495(98)90301-8; van Bokhoven H, 2000, NAT GENET, V25, P423; WEBBER SA, 1990, AM J MED GENET, V37, P519, DOI 10.1002/ajmg.1320370418; WIENS L, 1990, CLIN GENET, V37, P481	15	4	4	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	OCT	2003	13	8					725	727		10.1046/j.1460-9592.2003.01123.x			3	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	731FM	WOS:000185873900015	14535914				2020-06-30	J	Egger, CM; Glerum, LE; Allen, SW; Haag, M				Egger, CM; Glerum, LE; Allen, SW; Haag, M			Plasma fentanyl concentrations in awake cats and cats undergoing anesthesia and ovariohysterectomy using transdermal administration	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article							ISOFLURANE-ANESTHETIZED CATS; LUMBOSACRAL EPIDURAL SPACE; CANADIAN VETERINARIANS; POSTOPERATIVE USE; ANALGESICS; DOGS; MEDETOMIDINE; ONYCHECTOMY; PATCH; PAIN									ANDREWS CJH, 1983, BRIT J ANAESTH, V55, pS211; BENSON GJ, 1987, J AM VET MED ASSOC, V191, P1227; BENSON GJ, 1991, VET SURG, V20, P222, DOI 10.1111/j.1532-950X.1991.tb00340.x; Cambridge AJ, 2000, J AM VET MED ASSOC, V217, P685, DOI 10.2460/javma.2000.217.685; CARDOCKI JF, 1964, TOXICOL APPL PHARM, V6, P48; CARTWRIGHT P, 1983, ANESTH ANALG, V62, P966; Dohoo SE, 1996, CAN VET J, V37, P546; Dohoo SE, 1996, CAN VET J, V37, P552; DUKE T, 1994, VET SURG, V23, P143, DOI 10.1111/j.1532-950X.1994.tb00459.x; DUKE T, 1994, VET SURG, V23, P149, DOI 10.1111/j.1532-950X.1994.tb00460.x; Egger CM, 1998, VET SURG, V27, P159, DOI 10.1111/j.1532-950X.1998.tb00114.x; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; Glerum LE, 2001, VET SURG, V30, P351, DOI 10.1053/jvet.2001.24387	13	26	27	0	14	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	OCT	2003	30	4					229	236		10.1046/j.1467-2995.2003.00109.x			8	Veterinary Sciences	Veterinary Sciences	720YM	WOS:000185290300005	12925180				2020-06-30	J	Criado, AB; de Segura, IAG				Criado, AB; de Segura, IAG			Reduction of isoflurane MAC by fentanyl or remifentanil in rats	VETERINARY ANAESTHESIA AND ANALGESIA			English	Article						fentanyl; isoflurane; MAC reduction; rats; remifentanil	ALVEOLAR ANESTHETIC CONCENTRATION; MORPHINE; POTENCY; ALFENTANIL; DOGS	Objective The main objective of the study was to determine the effects of three different infusion rates of fentanyl and remifentanil on the minimum alveolar concentration (MAC) of isoflurane in the rat. A secondary objective was to assess the cardiovascular and respiratory effects of the two opioid drugs. Animal population Thirty-seven male Wistar rats were randomly allocated to one of six treatment groups. Material and methods For all treatment groups anaesthesia was induced with 5% isoflurane in oxygen using an induction chamber. A 14-gauge catheter was used for endotracheal intubation, and anaesthesia was maintained with isoflurane delivered in oxygen via a T-piece breathing system. A baseline determination of the minimum alveolar concentration of isoflurane (MAC(ISO)) was made for each animal. Fentanyl (15, 30, 60 mug kg(-1) hour(-1)) or remifentanil (60, 120, 240 mug kg(-1) hour(-1)) were infused intravenously into a previously cannulated tail vein. Thirty minutes after the infusion started, a second MAC(ISO) (MAC(ISO+drug)) was determined. The carotid artery was cannulated to monitor the arterial pressure and to take samples for arterial gas measurements. Cardiovascular (heart rate and arterial pressure) and respiratory (respiratory rate and presence/absence of apnoea) effects after opioid infusion were also recorded. Results Fentanyl (15, 30, 60 mug kg(-1) hour(-1)) and remifentanil (60,120, 240 mug kg(-1) hour) similarly reduced isoflurane MAC in a dose-dependent fashion: by 10% at lower doses, 25% at medium doses and by 60% at higher doses of both the drugs. Both opioids reduced the respiratory rate in a similar way for all. doses tested. No episodes of apnoea were recorded in the remifentanil groups, while administration of fentanyl resulted in apnoea in three animals (one at each dose level). The effects on the cardiovascular system were similar with both drugs. Conclusions We conclude that the intraoperative use of remifentanil in the rat reduces the MAC of isoflurane, and that this anaesthetic sparing effect is dose-dependent and similar to that produced by fentanyl at the doses tested. Clinical relevance The use of remifentanil during inhalant anaesthesia in the rat can be considered an intravenous alternative to fentanyl, providing similar reduction in isoflurane requirements. Due to its rapid offset, it is recommended that alternative pain relief be instituted before it is discontinued.	GlaxoSmithKline, Med Res Ctr, LAS Dept, Stevenage SG1 2NY, Herts, England; Univ Hosp La Paz, Dept Expt Surg, Madrid, Spain	Criado, AB (reprint author), GlaxoSmithKline, Med Res Ctr, LAS Dept, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.		de Segura, Ignacio Alvarez Gomez/E-4687-2010	de Segura, Ignacio Alvarez Gomez/0000-0001-5436-5396			AMIN HM, 1995, J PHARMACOL EXP THER, V274, P34; Criado AB, 2000, LAB ANIM, V34, P252, DOI 10.1258/002367700780384717; de Segura IAG, 1998, ANESTHESIOLOGY, V89, P1489, DOI 10.1097/00000542-199812000-00027; EGER EI, 1965, ANESTHESIOLOGY, V26, P756, DOI 10.1097/00000542-196511000-00010; Glass P S, 1995, Eur J Anaesthesiol Suppl, V10, P73; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; HECKER BR, 1983, ANESTH ANALG, V62, P987; HUGHES MA, 1992, ANESTHESIOLOGY, V76, P334, DOI 10.1097/00000542-199203000-00003; JOSHI P, 1993, ANESTHESIOLOGY S3A, V79, P379; LAKE CL, 1985, ANESTH ANALG, V64, P807; Lang E, 1996, ANESTHESIOLOGY, V85, P721, DOI 10.1097/00000542-199610000-00006; Lauwers M, 1997, CNS DRUGS, V8, P189, DOI 10.2165/00023210-199708030-00001; MCEWAN AI, 1993, ANESTHESIOLOGY, V78, P864, DOI 10.1097/00000542-199305000-00009; Michelsen LG, 1996, ANESTHESIOLOGY, V84, P865, DOI 10.1097/00000542-199604000-00014; MUNDAY IT, 1995, ANESTHESIOLOGY, V83, pA23; MURPHY MR, 1982, ANESTHESIOLOGY, V57, P485, DOI 10.1097/00000542-198212000-00009; Pajewski TN, 1996, ANESTHESIOLOGY, V85, P1111, DOI 10.1097/00000542-199611000-00020; PITTS MC, 1992, ANESTHESIOLOGY S3A, V77, P101; QUASHA AL, 1980, ANESTHESIOLOGY, V53, P315, DOI 10.1097/00000542-198010000-00008; STEFFEY EP, 1994, J VET PHARMACOL THER, V17, P202, DOI 10.1111/j.1365-2885.1994.tb00234.x	20	45	46	1	6	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1467-2987			VET ANAESTH ANALG	Vet. Anaesth. Analg.	OCT	2003	30	4					250	256		10.1046/j.1467-2995.2003.00123.x			7	Veterinary Sciences	Veterinary Sciences	720YM	WOS:000185290300007	12925182				2020-06-30	J	Turker, G; Uckunkaya, N; Yilmazlar, A; Demirag, B; Tokat, O				Turker, G; Uckunkaya, N; Yilmazlar, A; Demirag, B; Tokat, O			Effects of adding epinephrine plus fentanyl to low-dose lidocaine for spinal anesthesia in outpatient knee arthroscopy	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anesthesia-ambulatory; epinephrine; fentanyl; knee arthroscopy; lidocaine; spinal	TRANSIENT NEUROLOGIC SYMPTOMS; TOURNIQUET PAIN; POSTOPERATIVE COMPLAINTS; HYPERBARIC BUPIVACAINE; GENERAL-ANESTHESIA; AMBULATORY SURGERY; BLOOD-FLOW; CORD; PHENYLEPHRINE; LAPAROSCOPY	Background: This study investigated whether addition of 15 mug epinephrine plus 25 mug fentanyl to lidocaine spinal anesthesia for outpatient knee arthroscopy makes it possible to use a subanesthetic lidocaine dose. The aim was to assess the quality of anesthesia and the suitability of this protocol for outpatient knee arthroscopy. Methods: Seventy-five outpatients scheduled for knee arthroscopy were randomly assigned to one of three spinal anesthetic protocols: Group L10F25 received 10 mg of lidocaine plus 25 mug fentanyl; Group L10F25E15 received 10 mg of lidocaine plus 25 mug fentanyl plus 15 mug epinephrine; and Group L20F25 received 20 mug lidocaine plus 25 mug fentanyl. Tourniquet pain and surgical pain were assessed using a visual analog scale. If spinal anesthesia was inadequate despite supplementary intravenous analgesia and sedation, the patient was converted to general anesthesia. Recovery times and side-effects in the early postoperative period were recorded. Results: The highest level of sensory block was above the T12 dermatome in all patients. Compared with the other groups, significantly more patients in Group L10F25 converted to general anesthesia. Group L10F25 had a significantly higher mean surgical pain score than the other groups. The mean tourniquet pain score was significantly higher in Group L20F25 than Group L10F25E15. Group L10F25E15 had a significantly shorter time to discharge than the other groups. Post-operative nausea and vomiting and drowsiness were more frequent in Group L10F25 than in the other groups. Conclusion: The combination of 10 mg lidocaine and 25 mug fentanyl plus 15 mug epinephrine provides adequate spinal anesthesia and has favorable recovery characteristics for outpatient knee arthroscopy.	Uludag Univ, Sch Med, Dept Anesthesiol, Bursa, Turkey; Uludag Univ, Sch Med, Dept Orthoped Surg, Bursa, Turkey	Turker, G (reprint author), Uludag Univ Tip Fak, Anesteziyol Reanimasyon Anabilim Dali, TR-16059 Gorukle, Turkey.			TURKER, YUNUS GURKAN/0000-0002-3019-581X			ABOULEISH E, 1993, ANESTH ANALG, V77, P457; Ben-David B, 2000, ANESTH ANALG, V91, P865, DOI 10.1097/00000539-200010000-00018; BONNET F, 1989, BRIT J ANAESTH, V63, P93, DOI 10.1093/bja/63.1.93; CAMANN WR, 1993, ANESTHESIOLOGY, V78, P870, DOI 10.1097/00000542-199305000-00010; CHAMBERS WA, 1981, ANESTH ANALG, V60, P417; CHUNG F, 1995, ANESTH ANALG, V80, P896, DOI 10.1097/00000539-199505000-00008; COLLINS JG, 1984, ANESTHESIOLOGY, V60, P269, DOI 10.1097/00000542-198404000-00001; COLLINS JG, 1981, ANESTH ANALG, V60, P913; CONCEPCION MA, 1988, ANESTH ANALG, V67, P828; CREWS JC, 1994, ANESTHESIOLOGY, V81, P730, DOI 10.1097/00000542-199409000-00027; DAHL JB, 1990, BRIT J ANAESTH, V64, P178, DOI 10.1093/bja/64.2.178; EWART MC, 1987, ANAESTHESIA, V42, P1183, DOI 10.1111/j.1365-2044.1987.tb05225.x; Freedman JM, 1998, ANESTHESIOLOGY, V89, P633, DOI 10.1097/00000542-199809000-00012; GISSEN AJ, 1980, ANESTHESIOLOGY, V53, P467, DOI 10.1097/00000542-198012000-00006; Hodgson PS, 1999, ANESTH ANALG, V88, P797, DOI 10.1097/00000539-199904000-00023; KOZODY R, 1984, CAN ANAESTH SOC J, V31, P503, DOI 10.1007/BF03009534; LEICHT CH, 1986, ANESTH ANALG, V65, P365; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Liu SS, 1997, REGION ANESTH, V22, P500; MACIVER MB, 1992, ANESTHESIOLOGY, V76, P617; MALINOW AM, 1990, ANESTHESIOLOGY, V73, P381, DOI 10.1097/00000542-199009000-00003; MOORE DC, 1987, ANESTHESIOLOGY, V67, P416, DOI 10.1097/00000542-198709000-00024; Morisaki H, 1998, ANESTH ANALG, V86, P1023, DOI 10.1097/00000539-199805000-00022; MULROY MF, 1995, J CLIN ANESTH, V7, P622, DOI 10.1016/0952-8180(95)00144-1; Pavlin DJ, 1998, ANESTH ANALG, V87, P816, DOI 10.1097/00000539-199810000-00014; PAVLIN DJ, 1999, PROBLEMS ANESTHESIA; Pollock JE, 1999, ANESTHESIOLOGY, V90, P445, DOI 10.1097/00000542-199902000-00019; Pollock JE, 1996, ANESTHESIOLOGY, V84, P1361, DOI 10.1097/00000542-199606000-00012; PORTER SS, 1985, ACTA ANAESTH SCAND, V29, P330, DOI 10.1111/j.1399-6576.1985.tb02210.x; REDDY SVR, 1980, J PHARMACOL EXP THER, V213, P525; SPIVEY DL, 1985, ANESTH ANALG, V64, P468; Standl T, 1996, ACTA ANAESTH SCAND, V40, P222, DOI 10.1111/j.1399-6576.1996.tb04423.x; Vaghadia H, 2001, CAN J ANAESTH, V48, P261, DOI 10.1007/BF03019756; Vaghadia H, 2001, CAN J ANAESTH, V48, P256, DOI 10.1007/BF03019755; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; YAKSH TL, 1981, ANESTHESIOLOGY, V54, P451, DOI 10.1097/00000542-198106000-00004	36	7	7	0	0	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2003	47	8					986	992		10.1034/j.1399-6576.2003.00194.x			7	Anesthesiology	Anesthesiology	710BC	WOS:000184660100010	12904191				2020-06-30	J	Grace, RF				Grace, RF			The effect of variable-dose diazepam on dreaming and emergence phenomena in 400 cases of ketamine-fentanyl anaesthesia	ANAESTHESIA			English	Article						Drugs : ketamine, fentanyl, diazepam; Anaesthesia : analgesia, emergence, delirium, rate-pressure product	RATE-PRESSURE PRODUCT	This randomised double-blind field study compared 400 anaesthetics using diazepam (0, 0.025, 0.5, 0.1, 0.175 mg. kg(-1)) with ketamine (1 mg.kg(-1)) and fentanyl (1 mug.kg(-1)) in Melanesian patients. Dreams were very common and generally positive in nature. A minimum of 0.1 mg. kg(-1) of diazepam was needed to significantly reduce dreaming when compared with water (67.5% vs. 94.6%; p<0.0001), and to significantly lower median (95% CI) emergence delirium scores (4 (3-4) vs. 6 (5-7)). Gender and age did not affect the rate of dreaming. Increasing the dose of diazepam did not improve the dream experience. Patient satisfaction scores were similar between groups. Increases in blood pressure and heart rate were greater in dreamers than in non-dreamers. All groups had high rate-pressure products but this was highest when diazepam was not used. Higher diazepam doses significantly reduced the increase in blood pressure and heart rate at 3 and 6 min postketamine. When used with ketamine and fentanyl, 0.1 mg. kg(-1) of diazepam has favourable psychic and cardiovascular effects. Lower diazepam doses generally had little effect whereas larger doses did not enhance the benefits further.	Vila Cent Hosp, Dept Anaesthet, Port Vila, Vanuatu	Grace, RF (reprint author), Vila Cent Hosp, Dept Anaesthet, PMB 013, Port Vila, Vanuatu.	rgrace@vanuatu.gov.vu					Arditti J, 2002, ACTA CLIN BELG, V57, P31, DOI 10.1179/acb.2002.073; CAMPBELL MJ, 1992, [No title captured]; CARTWRIGHT PD, 1984, ANAESTHESIA, V39, P439, DOI 10.1111/j.1365-2044.1984.tb07312.x; COPPEL DL, 1973, ANAESTHESIA, V28, P293, DOI 10.1111/j.1365-2044.1973.tb00449.x; DUNDEE JW, 1970, LANCET, V1, P1370; DUNDEE JW, 1978, ANAESTHESIA, V33, P312, DOI 10.1111/j.1365-2044.1978.tb12413.x; Forjaz CLM, 1998, BRAZ J MED BIOL RES, V31, P1247, DOI 10.1590/S0100-879X1998001000003; FREUCHEN I, 1976, ACTA ANAESTH SCAND, V20, P97, DOI 10.1111/j.1399-6576.1976.tb05015.x; Grace RF, 2001, ANAESTH INTENS CARE, V29, P30, DOI 10.1177/0310057X0102900105; *GRAPHPAD SOFTW, 1990, GRAPHPAD SOFTW V2 04; Hermida RC, 2001, CHRONOBIOL INT, V18, P475, DOI 10.1081/CBI-100103970; Hostetler MA, 2002, AM J EMERG MED, V20, P463, DOI 10.1053/ajem.2002.35496; JEKEL JF, 1996, EPIDEMIOLOGY BIOSTAT, P163; KNOX JWD, 1970, BRIT J ANAESTH, V42, P875, DOI 10.1093/bja/42.10.875; MAGBAGBEOLA JA, 1974, CAN ANAESTH SOC J, V21, P321, DOI 10.1007/BF03005737; MATTILA MAK, 1981, ANAESTHESIST, V30, P500; MATTILA MAK, 1979, ANAESTHESIST, V28, P20; Okamoto G U, 1992, J Clin Pediatr Dent, V16, P253; SKLAR GS, 1981, ANAESTHESIA, V36, P183, DOI 10.1111/j.1365-2044.1981.tb08721.x	19	28	29	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	SEP	2003	58	9					904	910		10.1046/j.1365-2044.2003.03341.x			7	Anesthesiology	Anesthesiology	707QG	WOS:000184520900016	12911367				2020-06-30	J	Teoh, WHL; Sia, ATH				Teoh, WHL; Sia, ATH			Hyperbaric bupivacaine 2.5 mg prolongs analgesia compared with plain bupivacaine when added to intrathecal fentanyl 25 mu g in advanced labor	ANESTHESIA AND ANALGESIA			English	Article							PLUS BUPIVACAINE; SUFENTANIL; EPINEPHRINE	We investigated the effect of sequential administration of intrathecal (IT) hyperbaric bupivacaine (after the initial administration of IT hypobaric fentanyl) on the duration of spinal analgesia. Thirty-seven nulliparous parturients with a cervical dilation 5 cm were randomized to receive either IT fentanyl 25 mug and plain bupivacaine 2.5 mg (group P; n = 19) or IT fentanyl 25 mug and hyperbaric (with 8% glucose) bupivacaine 2.5 mg (group H; n = 18). The two components of the IT injectate were administered sequentially (fentanyl 25 mug diluted in 2 mL of normal saline, immediately followed by 0.5 mL, of 0.5% bupivacaine). Patients were then positioned with their torso elevated at 30degrees for 30 min. Pain scores using 0-100 visual analog scales were collected before combined spinal/epidural analgesia and at 5, 15, and 30 min after the block. Patients in Group H had a longer median duration of analgesia (122 min; range, 80-210 min) than Group P (95 min; range, 75-125 min) (P < 0.01). Group H also had a more limited dermatomal spread (median highest sensory level of T8 versus T4 in group P; P < 0.05). The,side-effect profile was similar. Under these circumstances, hyperbaric bupivacaine conferred an increased duration of IT analgesia compared with plain bupivacaine.	KK Womens & Childrens Hosp, Dept Anesthesia, Singapore 229899, Singapore	Teoh, WHL (reprint author), KK Womens & Childrens Hosp, Dept Anesthesia, 100 Bukit Timah Rd, Singapore 229899, Singapore.			Teoh, Wendy/0000-0001-9594-3009			CAMPBELL DC, 1995, ANESTH ANALG, V81, P305, DOI 10.1097/00000539-199508000-00017; Campbell DC, 1997, ANESTHESIOLOGY, V86, P525, DOI 10.1097/00000542-199703000-00003; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; Gage JC, 1997, ANESTH ANALG, V85, P826, DOI 10.1097/00000539-199710000-00020; Infante NEK, 2000, ANESTHESIOLOGY, V92, P1319, DOI 10.1097/00000542-200005000-00020; Lim EHL, 2002, CAN J ANAESTH, V49, P57, DOI 10.1007/BF03020419; Mardirosoff C, 1999, ANESTH ANALG, V89, P1263; Nelson KE, 1999, ANESTHESIOLOGY, V91, P1293, DOI 10.1097/00000542-199911000-00020; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; Richardson MG, 1997, ANESTH ANALG, V84, P95, DOI 10.1097/00000539-199701000-00018; Sia ATH, 2000, CAN J ANAESTH, V47, P875, DOI 10.1007/BF03019667; Sia ATH, 1999, ANESTH ANALG, V88, P362, DOI 10.1097/00000539-199902000-00026	12	11	12	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	SEP	2003	97	3					873	877		10.1213/01.ANE.0000076388.17223.37			5	Anesthesiology	Anesthesiology	714AN	WOS:000184890300051	12933419				2020-06-30	J	Seo, SA; Khang, G; Rhee, JM; Kim, J; Lee, HB				Seo, SA; Khang, G; Rhee, JM; Kim, J; Lee, HB			Study on in vitro release patterns of fentanyl-loaded PLGA microspheres	JOURNAL OF MICROENCAPSULATION			English	Article						fentanyl; poly(L-lactide-co-glycolide); microspheres; solvent-evaporation method	POLYMER MOLECULAR-WEIGHT; MICROCAPSULE PROPERTIES; GAS-CHROMATOGRAPHY; SUSTAINED-RELEASE; ACID MICROSPHERES; INVITRO RELEASE; LACTIC-ACID; SOLVENT; OVERDOSE; DEATH	In order to study the development of the delivery device of long-acting local anaesthetics for post-operative analgesia and control of chronic pain of cancer patient, fentanyl loaded poly( l -lactide- co -glycolide) (PLGA, molecular weight; 5000, 8000, 20 000, and 33 000 g/mole) microspheres (FMS) were studied. FMS were prepared by an emulsion solvent-evaporation method. The influence of several preparation parameters such as initial drug loading, PLGA concentrations, emulsifier concentrations, oil phase volume and mole ratio and molecular weight has been investigated on the fentanyl release patterns. Generally, the drug showed the biphasic release patterns, with an initial diffusion followed by a lag period before the onset of the degradation phase, but there were no lag times in the device. Fentanyl was slowly released from FMS over 10 days in vitro , with a quasi-zero order property. The release rate increased with increasing drug loading as well as increasing polymer concentration with a relatively small initial burst effect. From the results, FMS may be a good formulation to deliver the anaesthesia for the treatment of chronic pain.	Chonbuk Natl Univ, Dept Polymer Sci & Technol, Chonju 561756, South Korea; Chonbuk Natl Univ, Dept Adv Organ Mat Engn, Chonju 561756, South Korea; Korea Res Inst Chem Technol, Biomat Lab, Taejon 305606, South Korea	Khang, G (reprint author), Chonbuk Natl Univ, Dept Polymer Sci & Technol, 664-14 Dukjin, Chonju 561756, South Korea.		Khang, Gilson/B-2109-2013				Arshady R, 1990, J BIOACT COMPAT POL, V5, P315, DOI 10.1177/088391159000500308; Baselt R. C., 1982, DISPOSITION TOXIC DR; BECK LR, 1985, ADV CONTRACEPT, V1, P19; Birnbaum DT, 2000, J CONTROL RELEASE, V65, P375, DOI 10.1016/S0168-3659(99)00219-9; Cho JC, 2000, POLYM-KOREA, V24, P728; Choi HS, 2002, INT J PHARM, V234, P195, DOI 10.1016/S0378-5173(01)00968-1; Choi HS, 2001, J CHROMATOGR B, V765, P63, DOI 10.1016/S0378-4347(01)00405-4; GARRIOTT JC, 1984, J ANAL TOXICOL, V8, P288, DOI 10.1093/jat/8.6.288; Guyot M, 1998, INT J PHARM, V175, P61, DOI 10.1016/S0378-5173(98)00253-1; HAMMARGREN WR, 1988, J ANAL TOXICOL, V12, P183, DOI 10.1093/jat/12.4.183; Herrmann J, 1995, INT J PHARM, V126, P129, DOI 10.1016/0378-5173(95)04106-0; IKEDA R, 1990, WESTERN J MED, V152, P617; JALIL R, 1990, J MICROENCAPSUL, V7, P297, DOI 10.3109/02652049009021842; JALIL R, 1990, J MICROENCAPSUL, V7, P41, DOI 10.3109/02652049009028422; JALIL R, 1990, J MICROENCAPSUL, V7, P245, DOI 10.3109/02652049009021837; Khang G, 2000, KOREA POLYM J, V8, P253; Khang G, 2000, KOREA POLYM J, V8, P80; Khang G, 1999, BIO-MED MATER ENG, V9, P49; KHANG G, 2001, BIOMEDICAL POLYM; Lee HB, 1999, POLYM PREPRINTS, V40, P288; LEVINE B, 1990, FORENSIC SCI INT, V45, P247, DOI 10.1016/0379-0738(90)90181-W; MARCHALL BE, 1990, PHARM BASIS THERAPEU; MATEJCZYK RJ, 1988, J ANAL TOXICOL, V12, P236, DOI 10.1093/jat/12.4.236; PARE EM, 1987, J ANAL TOXICOL, V11, P272, DOI 10.1093/jat/11.6.272; Sah H, 1997, J CONTROL RELEASE, V47, P233, DOI 10.1016/S0168-3659(97)01647-7; SANDERS LM, 1985, P INT S CONTROL REL, V12, P177; Seo SA, 2002, INT J PHARM, V239, P93, DOI 10.1016/S0378-5173(02)00074-1; Seo SA, 2001, POLYM-KOREA, V25, P884; SEO SA, 2001, BIOMATER RES, V5, P35; Singh M, 1998, ADV DRUG DELIVER REV, V34, P285, DOI 10.1016/S0169-409X(98)00044-1; STURESSON C, 1993, INT J PHARM, V89, P235, DOI 10.1016/0378-5173(93)90249-F; WADA R, 1991, J PHARM PHARMACOL, V43, P605, DOI 10.1111/j.2042-7158.1991.tb03547.x; WAKIYAMA N, 1982, CHEM PHARM BULL, V30, P2621	33	23	24	4	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0265-2048			J MICROENCAPSUL	J. Microencapsul.	SEP-OCT	2003	20	5					569	579		10.1080/0265204031000148013			11	Chemistry, Applied; Engineering, Chemical; Pharmacology & Pharmacy	Chemistry; Engineering; Pharmacology & Pharmacy	710GA	WOS:000184671400002	12909542				2020-06-30	J	Taylor, BK; Basbaum, AI				Taylor, BK; Basbaum, AI			Systemic morphine-induced release of serotonin in the rostroventral medulla is not mimicked by morphine microinjection into the periaqueductal gray	JOURNAL OF NEUROCHEMISTRY			English	Article						analgesia; dependence; dopamine; microdialysis; rat; withdrawal	ROSTRAL VENTROMEDIAL MEDULLA; NUCLEUS RAPHE MAGNUS; FREELY MOVING RATS; NALOXONE-PRECIPITATED WITHDRAWAL; PAIN-MODULATING NEURONS; CENTRAL-NERVOUS-SYSTEM; EXTRACELLULAR SEROTONIN; 5-HT METABOLISM; DORSAL RAPHE; SPINAL-CORD	We used in vivo microdialysis in awake rats to test the hypothesis that intravenous morphine increases serotonin (5-HT) release within the rostral ventromedial medulla (RVM). We also injected morphine into various sites along the rostrocaudal extent of the periaqueductal gray (PAG), and examined the extent of its diffusion to the RVM. Intravenous morphine (3.0 mg/kg) produced thermal antinociception and increased RVM dialysate 5-HT, 5-hydroxyindole acetic acid (5-HIAA), and homovanillic acid (HVA) in a naloxone-reversible manner. As neither PAG microinjection of morphine (5 mug/0.5 muL) nor RVM administration of fentanyl or d-Ala(2),NMePhe(4),Gly-ol(5)]enkephalin (DAMGO) increased RVM 5-HT, we were unable to determine the precise site of action of morphine. Surprisingly, peak morphine levels in the RVM were higher after microinjection into the caudal PAG as compared to either intravenous injection or microinjection into more rostral sites within the PAG. Naloxone-precipitated withdrawal in morphine-tolerant rats not only increased extracellular 5-HT in the RVM, but also dopamine (DA) and HVA. We conclude that substantial amounts of morphine diffuse from the PAG to the RVM, and speculate that opioid receptor interactions at multiple brain sites mediate the analgesic effects of PAG morphine. Further studies will be required to elucidate the contribution of 5-HT and DA release in the RVM to opioid analgesia and opioid withdrawal.	Tulane Univ, Dept Pharmacol, Hlth Sci Ctr, Sch Med, New Orleans, LA 70118 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn, Ctr Integrat Neurosci, San Francisco, CA 94143 USA	Taylor, BK (reprint author), Tulane Univ, Dept Pharmacol, Hlth Sci Ctr, Sch Med, SL83,1430 Tulane Ave, New Orleans, LA 70118 USA.	taylorb@tulane.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA 08973, DA 10356]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 43383, NS 21445]		Adell A, 2002, BRAIN RES REV, V39, P154, DOI 10.1016/S0165-0173(02)00182-0; AIMONE LD, 1986, J NEUROSCI, V6, P1803; ARVIDSSON U, 1995, J NEUROSCI, V15, P1215; BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BEDERSON JB, 1990, SOMATOSENS MOT RES, V7, P185, DOI 10.3109/08990229009144706; BEITZ AJ, 1983, BRAIN RES, V261, P132, DOI 10.1016/0006-8993(83)91292-1; BINEAUTHUROTTE M, 1984, BRAIN RES, V291, P293, DOI 10.1016/0006-8993(84)91261-7; Bodnar RJ, 2000, J BIOMED SCI, V7, P181, DOI 10.1007/BF02255465; Borszcz GS, 1999, BEHAV NEUROSCI, V113, P612; CHAZAL G, 1989, NEUROSCIENCE, V33, P301, DOI 10.1016/0306-4522(89)90210-8; CLARK SL, 1983, BRIT J PHARMACOL, V79, P807, DOI 10.1111/j.1476-5381.1983.tb10019.x; COUCH JR, 1976, LIFE SCI, V19, P761, DOI 10.1016/0024-3205(76)90175-2; DICKENSON AH, 1979, BRAIN RES, V170, P95, DOI 10.1016/0006-8993(79)90943-0; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.neuro.14.1.219; HAIGLER HJ, 1978, J PHARM, V51, P361; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HEINRICHER MM, 1992, NEUROSCIENCE, V48, P533, DOI 10.1016/0306-4522(92)90400-V; Hermann DM, 1997, J CHEM NEUROANAT, V13, P1, DOI 10.1016/S0891-0618(97)00019-7; IWAKIRI H, 1993, NEUROSCI RES, V18, P157, DOI 10.1016/0168-0102(93)90018-L; JAEGER JC, 1965, STUDIES PHYSL, P107; JENSEN TS, 1986, BRAIN RES, V363, P99, DOI 10.1016/0006-8993(86)90662-1; Jolas T, 1997, BRAIN RES, V755, P229, DOI 10.1016/S0006-8993(97)00103-0; KAPLAN H, 1991, J NEUROSCI, V11, P1433; KAY DC, 1981, BRIT J CLIN PHARMACO, V11, P159, DOI 10.1111/j.1365-2125.1981.tb01120.x; KAY DC, 1969, PSYCHOPHARMACOLOGIA, V14, P404, DOI 10.1007/BF00403581; KIEFEL JM, 1992, PHYSIOL BEHAV, V51, P201, DOI 10.1016/0031-9384(92)90224-P; KING C, 1981, SLEEP, V4, P259, DOI 10.1093/sleep/4.3.259; LANDIS CA, 1988, PAIN, V34, P93, DOI 10.1016/0304-3959(88)90186-8; LLEWELYN MB, 1983, BRAIN RES, V258, P59, DOI 10.1016/0006-8993(83)91226-X; LLEWELYN MB, 1984, BRAIN RES, V306, P165, DOI 10.1016/0006-8993(84)90365-2; MARTIN DC, 1991, NEUROPHARMACOLOGY, V30, P323, DOI 10.1016/0028-3908(91)90056-H; Mason P, 2001, ANNU REV NEUROSCI, V24, P737, DOI 10.1146/annurev.neuro.24.1.737; MATES FF, 1995, BRAIN RES, V693, P187, DOI 10.1016/0006-8993(95)00742-9; MATOS FF, 1992, PAIN, V48, P439, DOI 10.1016/0304-3959(92)90097-U; MATOS FF, 1992, J NEUROCHEM, V58, P1773, DOI 10.1111/j.1471-4159.1992.tb10053.x; MATOS FF, 1990, BRAIN RES, V528, P39, DOI 10.1016/0006-8993(90)90192-E; Mitchell JM, 1998, NEUROSCIENCE, V87, P123, DOI 10.1016/S0306-4522(98)00119-5; MORGAN MM, 1992, NEUROSCIENCE, V47, P863, DOI 10.1016/0306-4522(92)90036-2; Mortazavi S, 1999, ANESTHESIOLOGY, V90, P1070, DOI 10.1097/00000542-199904000-00021; Pan ZZ, 1996, NEUROSCIENCE, V74, P855, DOI 10.1016/0306-4522(96)00179-0; PAXINOS G, 1986, [No title captured]; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; POTHOS E, 1991, BRAIN RES, V566, P348, DOI 10.1016/0006-8993(91)91724-F; POTREBIC SB, 1995, J NEUROSCI, V15, P3273; POTREBIC SB, 1994, J NEUROSCI, V14, P1655; PUIG S, 1992, BRAIN RES, V590, P250, DOI 10.1016/0006-8993(92)91102-K; RAFFA RB, 1982, LIFE SCI, V31, P2299, DOI 10.1016/0024-3205(82)90142-4; RAFFA RB, 1982, J CHROMATOGR, V238, P515, DOI 10.1016/S0021-9673(00)81342-4; RIVOT JP, 1989, BRAIN RES, V495, P140, DOI 10.1016/0006-8993(89)91227-4; RIVOT JP, 1988, BRAIN RES, V446, P333, DOI 10.1016/0006-8993(88)90892-X; ROBINSON TE, 1988, BRAIN RES, V450, P209, DOI 10.1016/0006-8993(88)91560-0; Rohde DS, 1998, J NEUROSCI, V18, P4393; Roychowdhury SM, 1997, NEUROSCI LETT, V226, P136, DOI 10.1016/S0304-3940(97)00270-X; Sbrenna S, 2000, BRIT J PHARMACOL, V130, P425, DOI 10.1038/sj.bjp.0703321; STEIN C, 1995, ANN MED, V27, P219, DOI 10.3109/07853899509031962; STEINBUSCH HWM, 1981, NEUROSCIENCE, V6, P557, DOI 10.1016/0306-4522(81)90146-9; TAO R, 1995, NEUROSCIENCE, V68, P553, DOI 10.1016/0306-4522(95)00154-B; Tao R, 2002, J PHARMACOL EXP THER, V303, P549, DOI 10.1124/jpet.102.037861; Tao R, 1998, J PHARMACOL EXP THER, V286, P481; TAO R, 1994, SYNAPSE, V18, P307, DOI 10.1002/syn.890180406; TAYLOR BK, 1995, J NEUROCHEM, V65, P578; URBAN MO, 1994, BRAIN RES, V652, P9, DOI 10.1016/0006-8993(94)90311-5; WALL PD, 1999, TXB PAIN; YAKSH TL, 1978, PAIN, V4, P299, DOI 10.1016/0304-3959(77)90145-2; YEZIERSKI RP, 1982, BRAIN RES, V239, P258, DOI 10.1016/0006-8993(82)90848-4; Yoshida Y, 1999, NEUROSCIENCE, V92, P1357, DOI 10.1016/S0306-4522(99)00046-9	66	23	23	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	SEP	2003	86	5					1129	1141		10.1046/j.1471-4159.2003.01907.x			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	711CX	WOS:000184723000008	12911621				2020-06-30	J	Sleesman, JB; Tobias, JD				Sleesman, JB; Tobias, JD			Anaesthetic implications of the child with Robinow syndrome	PAEDIATRIC ANAESTHESIA			English	Article						Robinow syndrome; fetal face syndrome; mid-face hypoplasia; dwarfism; brachymelia	CONGENITAL HEART-DISEASE; EMPHASIS	Robinow syndrome, originally described in 1969, consists of mesomelic brachymelia, short stature, genital hypoplasia and characteristic facies. Associated organ system involvement may include developmental delay, congenital heart disease, obstructive disorders of the urinary tract and renal cysts. As there is a potential for airway problems related to the facial features, such as midface hypoplasia and micrognathia, perioperative management of these patients is important. The authors present an 8-year-old boy, previously diagnosed with Robinow syndrome, who was admitted for an emergency surgical procedure. The perioperative implications of this disorder are reviewed.	Univ Missouri, Dept Anesthesiol, Columbia, MO 65212 USA; Univ Missouri, Dept Child Hlth, Columbia, MO 65201 USA	Tobias, JD (reprint author), Univ Missouri, Dept Anesthesiol, 3W 1 Hosp Dr, Columbia, MO 65212 USA.						Afzal AR, 2000, HUM GENET, V106, P351, DOI 10.1007/s004390051049; Aksit S, 1997, CLIN GENET, V52, P226; Al-Ata J, 1998, AM J MED GENET, V77, P332, DOI 10.1002/(SICI)1096-8628(19980526)77:4<332::AID-AJMG16>3.0.CO;2-J; Balci S, 1993, Clin Dysmorphol, V2, P199; Balci S, 1998, AM J MED GENET, V79, P27, DOI 10.1002/(SICI)1096-8628(19980827)79:1<27::AID-AJMG7>3.0.CO;2-F; Butler MG, 2000, ANESTH ANALG, V91, P837, DOI 10.1097/00000539-200010000-00014; GuillenNavarro E, 1997, AM J MED GENET, V73, P98, DOI 10.1002/(SICI)1096-8628(19971128)73:1<98::AID-AJMG23>3.0.CO;2-L; LAURITZEN C, 1986, PLAST RECONSTR SURG, V77, P1, DOI 10.1097/00006534-198601000-00001; MACDONALD I, 1995, ANAESTHESIA, V50, P1097, DOI 10.1111/j.1365-2044.1995.tb05973.x; Patton MA, 2002, J MED GENET, V39, P305, DOI 10.1136/jmg.39.5.305; ROBINOW M, 1969, AM J DIS CHILD, V117, P645, DOI 10.1001/archpedi.1969.02100030647005; Robinow M, 1993, Clin Dysmorphol, V2, P189; Soliman AT, 1998, METABOLISM, V47, P1337, DOI 10.1016/S0026-0495(98)90301-8; VENER DF, 1995, ANESTHESIOL CLIN N A, V13, P585; WEBBER SA, 1990, AM J MED GENET, V37, P519, DOI 10.1002/ajmg.1320370418; WIENS L, 1990, CLIN GENET, V37, P482	16	3	3	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	SEP	2003	13	7					629	632		10.1046/j.1460-9592.2003.01132.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	717KB	WOS:000185086700013	12950866				2020-06-30	J	Redwine, KE; Trujillo, KA				Redwine, KE; Trujillo, KA			Effects of NMDA receptor antagonists on acute mu-opioid analgesia in the rat	PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR			English	Article						opioid; analgesia; morphine; fentanyl; glutamate; NMDA	LATE POSTOPERATIVE PAIN; CENTRAL-NERVOUS-SYSTEM; MORPHINE-TOLERANCE; COMPETITIVE ANTAGONIST; GLUTAMATE RECEPTORS; DOUBLE-BLIND; MK-801; DEXTROMETHORPHAN; DEPENDENCE; KETAMINE	Mixed research findings have led to a debate regarding the effect of N-metbyl-D-aspartate (NMDA) receptor antagonists on opiate analgesia. NMDA antagonists have been found in various studies to enhance, to inhibit, or to have no effect on opiate analgesia. The present research used a single protocol to explore the effects of six NMDA receptor antagonists on acute morphine (3.0 mg/kg sc) and fentanyl (0.05 mg/kg sc) analgesia in adult male Sprague-Dawley rats. NMDA receptor antagonists were selected based on their abilities to block various sites on the NMDA receptor complex, including the noncompetitive antagonists MK-801 (0.1 and 0.3 mg/kg ip), dextromethorphan (10.0 and 30.0 mg/kg ip), and memantine (3.0 and 10.0 mg/kg ip), a glycine site antagonist, (+)-HA-966 (10.0 and 30.0 mg/kg ip), a competitive antagonist, LY235959 (1.0 and 3.0 mg/kg ip), and a polyamine site antagonist, ifenprodil (1.0 and 3.0 mg/kg ip). Analgesia was assessed using the tail-flick test. A single dose of each opiate was used. The low doses of the antagonists, which are known to produce significant neural and behavioral actions at NMDA receptors, had no effect on morphine or fentanyl analgesia. At the higher doses, morphine analgesia was significantly enhanced by LY235959 (3.0 mg/kg), and fentanyl analgesia was significantly enhanced by LY235959 (3.0 mg/kg), dextromethorphan (30.0 mg/kg), and (+)-HA-966 (30.0 mg/kg). Enhancement of analgesia occurred without any apparent adverse side effects. None of the NMDA antagonists affected tail-flick responses on their own, except the higher dose of LY235959 (3.0 mg/kg), which produced a mild analgesic effect. Because no consistent effects were observed, the data suggest that NMDA receptors are not involved in acute p-opioid analgesia. The mechanisms underlying the enhancement of opiate analgesia by selected NMDA antagonists, such as LY235959, dextromethorphan, and (+)-HA-966, remain to be determined. (C) 2003 Elsevier Inc. All rights reserved.	Calif State Univ San Marcos, Dept Psychol, San Marcos, CA 92096 USA	Trujillo, KA (reprint author), Calif State Univ San Marcos, Dept Psychol, 333 S Twin Oaks Valley Rd, San Marcos, CA 92096 USA.	keith@csusm.edu			NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 59833]		Ahmedzai S, 1997, EUR J CANCER, V33, pS8, DOI 10.1016/S0959-8049(97)00205-0; Allen RM, 1999, PSYCHOPHARMACOLOGY, V142, P209, DOI 10.1007/s002130050881; Allen RM, 2000, J PHARMACOL EXP THER, V295, P1012; Bell RF, 1999, PAIN, V83, P101, DOI 10.1016/S0304-3959(99)00096-2; Belozertseva IV, 2000, EUR J PHARMACOL, V396, P77, DOI 10.1016/S0014-2999(00)00184-9; BERGE OG, 1981, NEUROPHARMACOLOGY, V20, P653, DOI 10.1016/0028-3908(81)90112-X; Bernardi M, 1996, EUR J PHARMACOL, V298, P51, DOI 10.1016/0014-2999(95)00778-4; Bespalov A, 1998, EUR J PHARMACOL, V351, P299, DOI 10.1016/S0014-2999(98)00324-0; Bespalov AY, 2001, NEUROSCI BIOBEHAV R, V25, P343, DOI 10.1016/S0149-7634(01)00018-5; BESPALOV AY, 2002, IONOTROPIC GLUTAMATE, P301; Bhargava HN, 1997, GEN PHARMACOL, V28, P61, DOI 10.1016/S0306-3623(96)00163-2; Bhargava HN, 1997, BRAIN RES, V747, P246, DOI 10.1016/S0006-8993(96)01270-X; Bilsky EJ, 1996, PAIN, V68, P229, DOI 10.1016/S0304-3959(96)03185-5; Bot G, 1998, J PHARMACOL EXP THER, V285, P1207; BUBSER M, 1992, EUR J PHARMACOL, V229, P75, DOI 10.1016/0014-2999(92)90288-F; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; Carlezon WA, 2000, PSYCHOPHARMACOLOGY, V151, P261, DOI 10.1007/s002130000462; CARTER AJ, 1994, J PHARMACOL EXP THER, V269, P573; Caruso FS, 2000, J PAIN SYMPTOM MANAG, V19, pS31; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Celerier E, 1999, BRAIN RES, V847, P18, DOI 10.1016/S0006-8993(99)01998-8; CHIZH BA, 2002, IONOTROPIC GLUTAMATE, P263; CUDENNEC A, 1994, BRAIN RES, V664, P41, DOI 10.1016/0006-8993(94)91951-8; D'amour FE, 1941, J PHARMACOL EXP THER, V72, P74; DAMBISYA YM, 1994, METHOD FIND EXP CLIN, V16, P179; Danysz W, 1998, PHARMACOL REV, V50, P597; Dewey W.L., 1975, METHODS NARCOTIC RES, P101; Dingledine R, 1999, PHARMACOL REV, V51, P7; Dunbar S, 1996, ANESTHESIOLOGY, V84, P1177, DOI 10.1097/00000542-199605000-00020; DUNN RW, 1992, EUR J PHARMACOL, V214, P207, DOI 10.1016/0014-2999(92)90120-S; ELIOTT K, 1994, PAIN, V59, P361, DOI 10.1016/0304-3959(94)90022-1; ELLIOTT K, 1994, PAIN, V56, P69, DOI 10.1016/0304-3959(94)90151-1; Fairbanks CA, 1997, J PHARMACOL EXP THER, V282, P1408; Fu ES, 1997, ANESTH ANALG, V84, P1086, DOI 10.1097/00000539-199705000-00024; Goldman HV, 2000, POLAR RES, V19, P1; Gonzalez P, 1997, EUR J PHARMACOL, V332, P257, DOI 10.1016/S0014-2999(97)01099-6; GOTTI B, 1988, J PHARMACOL EXP THER, V247, P1211; Grass S, 1996, ACTA PHYSIOL SCAND, V158, P269, DOI 10.1046/j.1365-201X.1996.566309000.x; GUTSTEIN HB, 1993, BRAIN RES, V626, P332, DOI 10.1016/0006-8993(93)90597-G; HERMAN BH, 1995, NEUROPSYCHOPHARMACOL, V13, P269, DOI 10.1016/0893-133X(95)00140-9; Hoffmann O, 1996, NEUROREPORT, V7, P838, DOI 10.1097/00001756-199602290-00037; Ilkjaer S, 2000, PAIN, V86, P19, DOI 10.1016/S0304-3959(99)00305-X; Inturrisi CE, 1997, SEMIN NEUROSCI, V9, P110, DOI 10.1006/smns.1997.0111; Katz NP, 2000, J PAIN SYMPTOM MANAG, V19, pS37; KOLESNIKOV YA, 1993, LIFE SCI, V53, P1489, DOI 10.1016/0024-3205(93)90622-A; Kozela E, 2001, EUR J PHARMACOL, V423, P17, DOI 10.1016/S0014-2999(01)01084-6; Larcher A, 1998, NEUROSCIENCE, V84, P583, DOI 10.1016/S0306-4522(97)00556-3; LIPA SM, 1990, BRAIN RES BULL, V24, P627, DOI 10.1016/0361-9230(90)90169-Z; Lutfy K, 1996, BRAIN RES, V731, P171, DOI 10.1016/S0006-8993(96)00469-6; Lutfy K, 1999, PHARMACOL RES, V40, P435, DOI 10.1006/phrs.1999.0538; LUTFY K, 1995, EUR J PHARMACOL, V273, P187, DOI 10.1016/0014-2999(94)00716-K; LUTFY K, 1993, BRAIN RES, V616, P83, DOI 10.1016/0006-8993(93)90195-S; Manning BH, 1996, PAIN, V67, P79, DOI 10.1016/0304-3959(96)81972-5; Mao JR, 1999, BRAIN RES REV, V30, P289, DOI 10.1016/S0165-0173(99)00020-X; Mao JR, 1996, PAIN, V67, P361, DOI 10.1016/0304-3959(96)03120-X; MAREK P, 1991, BRAIN RES, V547, P77; MazzolaPomietto P, 1996, EUR J PHARMACOL, V308, P329, DOI 10.1016/0014-2999(96)00353-6; Mercadante S, 2000, J PAIN SYMPTOM MANAG, V20, P246, DOI 10.1016/S0885-3924(00)00194-9; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Plesan A, 1999, NEUROSCI LETT, V263, P53, DOI 10.1016/S0304-3940(99)00109-3; Popik P, 1996, PHARMACOL BIOCHEM BE, V53, P791, DOI 10.1016/0091-3057(95)02163-9; Popik P, 1997, J PHARMACOL EXP THER, V280, P854; REISINE T, 1996, [No title captured], P521; TISEO PJ, 1993, J PHARMACOL EXP THER, V264, P1090; TRUJILLO KA, 1991, SCIENCE, V251, P85, DOI 10.1126/science.1824728; TRUJILLO KA, 1991, PHARMACOL BIOCHEM BE, V38, P673, DOI 10.1016/0091-3057(91)90032-W; TRUJILLO KA, 1994, BRAIN RES, V633, P178, DOI 10.1016/0006-8993(94)91538-5; Trujillo KA, 2000, PSYCHOPHARMACOLOGY, V151, P121, DOI 10.1007/s002130000416; TRUJILLO KA, 2001, DRUG ALGOHOL DEPE S1, V63, pS159; TRUJILLO KA, 2003, GLUTAMATE ADDICTION, P295; TRUJILLO KA, 2001, SOC NEUR ABSTR, P27; TRUJILLO KA, 2000, SOC NEUR ABSTR, V26, P672; Tzschentke TM, 1996, EUR J PHARMACOL, V295, P137, DOI 10.1016/0014-2999(95)00667-2; WARMOTH KP, 2002, INT NARC RES C AS CA; WATORSKI K, 2002, THESIS CALIFORNIA ST; Weinbroum AA, 2002, CANCER-AM CANCER SOC, V95, P1164, DOI 10.1002/cncr.10784; Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7; Yamakura T, 1999, PROG NEUROBIOL, V59, P279, DOI 10.1016/S0301-0082(99)00007-6; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zuurmond W W, 2002, Acta Anaesthesiol Belg, V53, P193	82	31	31	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0091-3057			PHARMACOL BIOCHEM BE	Pharmacol. Biochem. Behav.	SEP	2003	76	2					361	372		10.1016/j.pbb.2003.08.009			12	Behavioral Sciences; Neurosciences; Pharmacology & Pharmacy	Behavioral Sciences; Neurosciences & Neurology; Pharmacology & Pharmacy	743AL	WOS:000186550200018	14592689				2020-06-30	J	Brand, JM; Frohn, C; Luhm, J; Kirchner, H; Schmucker, P				Brand, JM; Frohn, C; Luhm, J; Kirchner, H; Schmucker, P			Early alterations in the number of circulating lymphocyte subpopulations and enhanced proinflammatory immune response during opioid-based general anesthesia	SHOCK			English	Article						immunomodulation; fentanyl; propofol; lymphocytes; cytokines	NECROSIS-FACTOR-ALPHA; CYTOKINE PRODUCTION; INDUCED EXPRESSION; CELL SUBSETS; KAPPA-B; PROLACTIN; ENDOCRINE; ENDOTOXIN; PROPOFOL; SURGERY	The balance between proinflammatory and anti-inflammatory processes is of key importance in the reaction of the body to infection, injury, and surgical trauma. Drugs commonly used in anesthesia and intensive care may modulate immunological reactions by influencing intercellular communication through modification of cytokine response and fluctuation of peripheral immune cells such as natural killer (NK) cells, B cells, and T lymphocyte subpopulations (CD4(+) and CD8(+) cells). To examine the effects of general anesthesia with the hypnotic agent propofol and the opioid fentanyl, 30 patients undergoing minor elective orthopedic surgery were studied before and 20 min after application of the anesthetic drugs, but before the start of surgery. We found a significant enhancement of TNF-alpha and IL-1beta release in lipopolysaccharide (LPS)-stimulated whole blood cultures after induction of anesthesia. Similar results were observed with interferon-gamma (IFN-gamma) in cultures stimulated with phytohemagglutinin (PHA). Conversely, synthesis of the anti-inflammatory cytokine interleukin 10 (IL-10) decreased ignificantly in LPS-stimulated cultures. During general anesthesia, we found a decrease of circulating lymphocytes, characterized by a significant increase in the percentage of T lymphocytes in favor of CD4(+) cells, increased B lymphocytes, and a significant decrease of NK cells. These data suggest that anesthesia with propofol and fentanyl promotes proinflammatory immune responses and influences peripheral lymphocyte composition in patients, which may subsequently affect pathophysiological processes during opioid-based anesthesia.	Univ Lubeck, Inst Immunol & Transfus Med, D-23538 Lubeck, Germany; Univ Lubeck, Anesthesiol Clin, D-23538 Lubeck, Germany	Brand, JM (reprint author), Univ Lubeck, Inst Immunol & Transfus Med, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	brand@immu.mu-luebeck.de					Blackwell TS, 1996, BRIT J ANAESTH, V77, P110; Bolke E, 2001, SHOCK, V16, P334, DOI 10.1097/00024382-200116050-00002; Brand JM, 1997, CLIN IMMUNOL IMMUNOP, V83, P190, DOI 10.1006/clin.1997.4351; CROZIER TA, 1994, BRIT J ANAESTH, V72, P280, DOI 10.1093/bja/72.3.280; DELVIN EG, 1994, BRIT J ANAESTH, V73, P315; DeVito WJ, 2000, J CELL BIOCHEM, V77, P455; DEVITO WJ, 1995, J CELL BIOCHEM, V57, P290, DOI 10.1002/jcb.240570213; Fujinaga M, 2002, MOL NEUROBIOL, V25, P167, DOI 10.1385/MN:25:2:167; Galley HF, 1996, BRIT J ANAESTH, V77, P11; Galley HF, 2000, INTENS CARE MED, V26, P267, DOI 10.1007/s001340051149; Hahn RG, 1997, BRIT J ANAESTH, V78, P144; HASHIMOTO T, 1995, ACTA ANAESTH SCAND, V39, P294, DOI 10.1111/j.1399-6576.1995.tb04064.x; HEAGY W, 1990, J EXP MED, V171, P1625, DOI 10.1084/jem.171.5.1625; Hiesmayr MJ, 1999, CLIN EXP IMMUNOL, V115, P315, DOI 10.1046/j.1365-2249.1999.00801.x; HOEHE M, 1988, PSYCHONEUROENDOCRINO, V13, P397, DOI 10.1016/0306-4530(88)90046-7; Knight J., 2001, Current Infectious Disease Reports, V3, P427, DOI 10.1007/BF03160478; Kotani N, 1999, ANESTH ANALG, V89, P1250, DOI 10.1213/00000539-199911000-00032; Larsen B, 1998, ANESTHESIOLOGY, V89, P1218, DOI 10.1097/00000542-199811000-00023; Le Cras AE, 1998, ANESTH ANALG, V87, P1421, DOI 10.1097/00000539-199812000-00041; Liu L, 2001, BRIT J PHARMACOL, V134, P1629, DOI 10.1038/sj.bjp.0704404; Matera L, 2000, ANN NY ACAD SCI, V917, P505; Meli R, 1997, LIFE SCI, V61, P1395, DOI 10.1016/S0024-3205(97)00685-1; Moeniralam HS, 1998, AM J PHYSIOL-ENDOC M, V275, pE440; MORALE MC, 1995, ENDOCRINOLOGY, V136, P3949, DOI 10.1210/en.136.9.3949; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSS J, 1995, ACTA ANAESTH SCAND, V39, P7, DOI 10.1111/j.1399-6576.1995.tb04301.x; Muret J, 2000, SHOCK, V13, P169, DOI 10.1097/00024382-200003000-00001; PETERSON PK, 1993, BIOCHEM PHARMACOL, V46, P343, DOI 10.1016/0006-2952(93)90508-T; PIRTTIKANGAS CO, 1994, ANAESTHESIA, V49, P13, DOI 10.1111/j.1365-2044.1994.tb03304.x; Rolly G, 1984, Eur J Anaesthesiol, V1, P327; Roy S, 1998, BIOCHEM BIOPH RES CO, V245, P392, DOI 10.1006/bbrc.1998.8415; SALO M, 1992, ACTA ANAESTH SCAND, V36, P201, DOI 10.1111/j.1399-6576.1992.tb03452.x; Sobue S, 2001, J GASTROENTEROL, V36, P544, DOI 10.1007/s005350170057; Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0; YuLee LY, 1997, P SOC EXP BIOL MED, V215, P35, DOI 10.3181/00379727-215-44111	35	32	36	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	SEP	2003	20	3					213	217		10.1097/00024382-200309000-00003			5	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	713DQ	WOS:000184841100003	12923491				2020-06-30	J	Hamad, MA; El-Khattary, OAI				Hamad, MA; El-Khattary, OAI			Laparoscopic cholecystectomy under spinal anesthesia with nitrous oxide pneumoperitoneum: A feasibility study	SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES			English	Article						laparoscopy; cholecystectomy; spinal anesthesia	GENERAL-ANESTHESIA; REGIONAL ANESTHESIA; LOCAL-ANESTHESIA; DISEASE; SURGERY	Background: Spinal anesthesia has been successfully used to perform various laparoscopic procedures. However, laparoscopic cholecystectomy under spinal anesthesia has not been reported. Is this feasible? Methods: Ten successive laparoscopic cholecystectomies were performed under spinal anesthesia. The surgical technique was modified using nitrous oxide insufflation, lower levels of intraabdominal pressure, modified trocar sites, and minimal surgical manipulation. We used spinal anesthesia by intrathecal hyperbaric 10-12 mg bupivacaine with 10 mug fentanyl to give an anesthetic level at T8-T6. Results: The mean age was 39.3 years and there were four females. Only one patient was converted to general anesthesia due to intolerable shoulder pain. One patient vomited intraoperatively. Nine patients considered the procedure well tolerated under spinal anesthesia. The mean operative time was 47.4 min. Postoperatively, there were minimal pain and no vomiting. Conclusions: Laparoscopic cholecystectomy can be performed successfully under spinal anesthesia and is well tolerated.	Assiut Univ Hosp, Dept Gen Surg, Assiut 71516, Egypt; Assiut Univ Hosp, Dept Anesthesia, Assiut 71516, Egypt	Hamad, MA (reprint author), Assiut Univ Hosp, Dept Gen Surg, Assiut 71516, Egypt.						Aitola P, 1998, SURG LAPAROSC ENDOSC, V8, P140, DOI 10.1097/00019509-199804000-00013; AJAO OG, 1977, J TROP MED HYG, V80, P126; Collins L M, 2001, Anesthesiol Clin North Am, V19, P43, DOI 10.1016/S0889-8537(05)70210-8; Crabtree JH, 1998, ADV PERIT D, V14, P83; Gramatica L, 2002, SURG ENDOSC, V16, P472, DOI 10.1007/s00464-001-8148-0; Gurmarnik S, 1996, CAN J ANAESTH, V43, P95, DOI 10.1007/BF03015968; HUNTER JG, 1995, SURG ENDOSC-ULTRAS, V9, P501; INOUE H, 1994, SURG ENDOSC-ULTRAS, V8, P714, DOI 10.1007/BF00678574; Johnson A, 1997, LANCET, V349, P631, DOI 10.1016/S0140-6736(96)10032-5; Motamed C, 2000, ANAESTHESIA, V55, P118, DOI 10.1046/j.1365-2044.2000.055002118.x; Ohta J, 1997, INT SURG, V82, P146; Peck E M, 2001, Mo Med, V98, P10; Pursnani KG, 1998, SURG ENDOSC, V12, P1082, DOI 10.1007/s004649900785; RACLE J P, 1986, Annales Francaises d'Anesthesie et de Reanimation, V5, P24, DOI 10.1016/S0750-7658(86)80118-6; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; SHARP JR, 1982, GASTROENTEROLOGY, V82, P453; SOPER NJ, 1992, ARCH SURG-CHICAGO, V127, P917; Spivak H, 1999, SURG ENDOSC-ULTRAS, V13, P1026, DOI 10.1007/s004649901161; Standl T, 1996, ACTA ANAESTH SCAND, V40, P222, DOI 10.1111/j.1399-6576.1996.tb04423.x; Vaghadia H, 2001, CAN J ANAESTH, V48, P273, DOI 10.1007/BF03019758	20	38	42	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0930-2794			SURG ENDOSC	Surg. Endosc.	SEP	2003	17	9					1426	1428		10.1007/s00464-002-8620-5			3	Surgery	Surgery	812OD	WOS:000220847900016	12802665				2020-06-30	J	Paech, MJ; Lim, CB; Banks, SL; Rucklidge, MWM; Doherty, DA				Paech, MJ; Lim, CB; Banks, SL; Rucklidge, MWM; Doherty, DA			A new formulation of nasal fentanyl spray for postoperative analgesia: a pilot study	ANAESTHESIA			English	Article						analgesia, postoperative, intranasal; analgesics, fentanyl	CONTROLLED INTRANASAL ANALGESIA; PAIN MANAGEMENT; ABSORPTION	Twenty-four gynaecological patients receiving postoperative patient-controlled analgesia were enrolled in an open cross-over pilot study evaluating two new formulations of nasal fentanyl spray. The primary outcome was the bioavailability of nasal fentanyl in comparison with intravenous fentanyl. This manuscript describes the clinical outcomes of quality of postoperative analgesia and patient acceptability. There were 21 complete data sets for both sequences of the cross-over design. In randomised order, patients received approximately 50 mug of fentanyl in a single dose by intranasal and intravenous administration, but separated by at least 2 h. Analgesia was of rapid onset (within 5 min) and similar quality. There was no significant difference in side-effects. Four patients experienced mild nasal stinging and although 10 (42%) preferred intravenous administration, seven (29%) preferred intranasal and six (25%) had no preference. We conclude that these formulations of fentanyl, delivered as nasal spray, have potential clinical utility.	King Edward Mem Hosp Women, Dept Anaesthesia & Pain Med, Univ Western Australia, Sch Med & Pharmacol, Subiaco, WA 6008, Australia; Princess Margaret Hosp, Dept Pharm, Women & Childrens Hlth Serv, Subiaco, WA 6008, Australia; Women & Infants Res Fdn, Subiaco, WA 6008, Australia	Paech, MJ (reprint author), King Edward Mem Hosp Women, Dept Anaesthesia & Pain Med, Univ Western Australia, Sch Med & Pharmacol, 374 Bagot Rd, Subiaco, WA 6008, Australia.	michael.paech@health.wa.gov.au		PAECH, MICHAEL/0000-0001-9023-6575			CHIEN YW, 1987, CRC CR REV THER DRUG, V4, P67; Chien YW, 1985, TRANSNASAL SYSTEMIC, P121; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; GIZURARSON S, 1993, ADV DRUG DELIVER REV, V11, P329, DOI 10.1016/0169-409X(93)90015-V; HIRAI S, 1981, INT J PHARM, V7, P317; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; ONeil G, 1997, ANAESTH INTENS CARE, V25, P408, DOI 10.1177/0310057X9702500414; Schwagmeier R, 1996, ANAESTHESIST, V45, P231, DOI 10.1007/s001010050257; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; Striebel H W, 1993, Schmerz, V7, P122, DOI 10.1007/BF02527870; Striebel H W, 1995, Schmerz, V9, P84, DOI 10.1007/BF02528539; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; Striebel HW, 1996, ANESTH ANALG, V83, P548, DOI 10.1097/00000539-199609000-00019; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010; TOISSANT S, 2000, CANADIAN J ANAESTHES, V47, P299; Ward M, 2002, ANAESTHESIA, V57, P48	16	34	36	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	AUG	2003	58	8					740	744		10.1046/j.1365-2044.2003.03286.x			5	Anesthesiology	Anesthesiology	701PE	WOS:000184175300004	12859464				2020-06-30	J	Wong, P; Chadwick, FD; Karovits, J				Wong, P; Chadwick, FD; Karovits, J			Intranasal fentanyl for postoperative analgesia after elective Caesarean section	ANAESTHESIA			English	Letter							PAIN MANAGEMENT; TITRATION		Guys Hosp, London SE1 9RT, England	Wong, P (reprint author), Guys Hosp, London SE1 9RT, England.						Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; STRIEBEL HW, 1992, ANESTHESIOLOGY, V77, P281, DOI 10.1097/00000542-199208000-00010	3	16	17	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	AUG	2003	58	8					818	819		10.1046/j.1365-2044.2003.03295_24.x			2	Anesthesiology	Anesthesiology	701PE	WOS:000184175300041	12859501				2020-06-30	J	Tay, TG; Brake, TJ; Kwan, ASK				Tay, TG; Brake, TJ; Kwan, ASK			Patient-controlled epidural analgesia: A prospective audit of epidural pethidine 4 mg/ml and ropivacaine 0.2% with fentanyl 2 mu g/ml	ANAESTHESIA AND INTENSIVE CARE			English	Article						analgesia : patient controlled, epidural analgesic techniques : epidural, ropivacaine, pethidine, fentanyl	MEPERIDINE; BUPIVACAINE; MORPHINE; SURGERY; EXPERIENCE	A prospective audit of one hundred and forty-seven (147) Acute Pain Service (APS) patients, who received postoperative patient-controlled epidural analgesia (PCEA) using pethidine 4 mg/ml or ropivacaine 0.2% with fentanyl 2 mug/ml in general surgical or orthopaedic wards over a twelve-month period, is presented. Data were collected from APS observation charts over a 48-hour period postoperatively. We found no significant difference in postoperative analgesia or side-effects between pethidine and ropivacaine with fentanyl in orthopaedic or general surgical patients.	United Christian Hosp, Dept Anaesthesia, Pain Management Unit, Kowloon, Hong Kong, Peoples R China	Tay, TG (reprint author), United Christian Hosp, Dept Anesthesiol, Kowloon, Hong Kong, Peoples R China.						Blake DW, 1998, ANAESTH INTENS CARE, V26, P630, DOI 10.1177/0310057X9802600603; Chen PP, 2001, ANAESTHESIA, V56, P1106; Etches RC, 1996, ANESTH ANALG, V83, P81, DOI 10.1097/00000539-199607000-00014; GAMBLING DR, 1990, ANESTH ANALG, V70, P256; Goh JL, 1996, ANAESTH INTENS CARE, V24, P45, DOI 10.1177/0310057X9602400108; GOURLAY GK, 1987, PAIN, V31, P297, DOI 10.1016/0304-3959(87)90159-X; KANEKO M, 1994, ANESTHESIOLOGY, V80, P137, DOI 10.1097/00000542-199401000-00021; Kee WDN, 1997, ANAESTH INTENS CARE, V25, P126, DOI 10.1177/0310057X9702500203; Kee WDN, 1998, ANAESTH INTENS CARE, V26, P247, DOI 10.1177/0310057X9802600303; KEHLET H, 1993, ANESTH ANALG, V77, P1048; LIU SS, 1995, ANESTHESIOLOGY, V83, P757, DOI 10.1097/00000542-199510000-00015; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; OLDROYD GJ, 1994, ANAESTHESIA, V49, P503, DOI 10.1111/j.1365-2044.1994.tb03521.x; PAECH MJ, 1994, ANESTHESIOLOGY, V80, P1268, DOI 10.1097/00000542-199406000-00014; POWER I, 1991, REGION ANESTH, V16, P204; SJOSTROM S, 1988, BRIT J ANAESTH, V60, P358, DOI 10.1093/bja/60.4.358; SLINGER P, 1995, J CARDIOTHOR VASC AN, V9, P128, DOI 10.1016/S1053-0770(05)80182-X; Smith AJ, 1996, ANAESTHESIA, V51, P1013, DOI 10.1111/j.1365-2044.1996.tb14993.x; Wigfull J, 2001, ANAESTHESIA, V56, P70, DOI 10.1046/j.1365-2044.2001.01763-6.x	19	0	0	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	AUG	2003	31	4					412	417		10.1177/0310057X0303100411			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	714LU	WOS:000184916400012	12973966	Bronze			2020-06-30	J	Cravero, JP; Beach, M; Thyr, B; Whalen, K				Cravero, JP; Beach, M; Thyr, B; Whalen, K			The effect of small dose fentanyl on the emergence characteristics of pediatric patients after sevoflurane anesthesia without surgery	ANESTHESIA AND ANALGESIA			English	Article							RECOVERY CHARACTERISTICS; GENERAL-ANESTHESIA; HALOTHANE; CHILDREN; DESFLURANE; AGITATION; PREMEDICATION; MYRINGOTOMY; INDUCTION	We designed this study to measure the effect of a small dose of IV fentanyl on the emergence characteristics of pediatric patients undergoing sevoflurane anesthesia without any surgical intervention. Thirty-two ASA physical status I or II pediatric outpatients receiving sevoflurane anesthesia for magnetic resonance imaging scans were enrolled and assigned in a random and double-blinded manner to receive either placebo (saline) or 1 mug/kg IV fentanyl 10 min before discontinuation of their anesthetic. The primary outcome measure was the percentage of patients with emergence agitation. We also evaluated the duration of agitation and time to meet hospital discharge criteria. Patients who received fentanyl had a decreased incidence of agitation (12% versus 56%) when compared with placebo. There was no significant difference in time to meet hospital discharge criteria. We conclude that the addition of a small dose of fentanyl to inhaled sevoflurane anesthesia decreases the incidence of emergence agitation independent of pain control effects.	Dartmouth Hitchcock Med Ctr, Dept Anesthesiol, Lebanon, NH 03756 USA	Cravero, JP (reprint author), Dartmouth Hitchcock Med Ctr, Dept Anesthesiol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.						Aono J, 1997, ANESTHESIOLOGY, V87, P1298, DOI 10.1097/00000542-199712000-00006; Beskow A, 1999, ACTA ANAESTH SCAND, V43, P536, DOI 10.1034/j.1399-6576.1999.430508.x; Cravero J, 2000, PAEDIATR ANAESTH, V10, P419, DOI 10.1046/j.1460-9592.2000.00560.x; CRAVERO JP, 2000, J CLIN ANESTH, V12, P897; Davis PJ, 1999, ANESTH ANALG, V88, P34, DOI 10.1097/00000539-199901000-00007; ECKENHOFF J, 1961, ANESTHESIOLOGY, V22, P667, DOI 10.1097/00000542-196109000-00002; EPSTEIN RH, 1995, J CLIN ANESTH, V7, P237, DOI 10.1016/0952-8180(95)00007-5; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; GREENSPUN JCF, 1995, J CLIN ANESTH, V7, P398, DOI 10.1016/0952-8180(95)00071-O; JOHANNESSON GP, 1995, ACTA ANAESTH SCAND, V39, P546, DOI 10.1111/j.1399-6576.1995.tb04116.x; Kain ZN, 1999, ANESTHESIOLOGY, V90, P758, DOI 10.1097/00000542-199903000-00018; Kulka PJ, 2001, ANESTH ANALG, V93, P335, DOI 10.1097/00000539-200108000-00019; Lapin SL, 1999, PAEDIATR ANAESTH, V9, P299, DOI 10.1046/j.1460-9592.1999.00351.x; Lerman J, 1996, ANESTHESIOLOGY, V84, P1332, DOI 10.1097/00000542-199606000-00009; LERMAN J, 1994, ANESTHESIOLOGY, V80, P814, DOI 10.1097/00000542-199404000-00014; Murray DJ, 2002, PAEDIATR ANAESTH, V12, P308, DOI 10.1046/j.1460-9592.2002.00789.x; NAITO Y, 1991, BRIT J ANAESTH, V67, P387, DOI 10.1093/bja/67.4.387; NATHANSON MH, 1995, ANESTH ANALG, V81, P1186, DOI 10.1097/00000539-199512000-00012; PATEL SS, 1995, DRUGS, V50, P742, DOI 10.2165/00003495-199550040-00010; SARNER JB, 1995, ANESTHESIOLOGY, V82, P38, DOI 10.1097/00000542-199501000-00006; Sury MRJ, 1996, ANAESTHESIA, V51, P543, DOI 10.1111/j.1365-2044.1996.tb12560.x; VANVLYMEN JM, 2000, ANESTHESIA, P2226; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005	23	95	113	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2003	97	2					364	367		10.1213/01.ANE.0000070227.78670.43			4	Anesthesiology	Anesthesiology	704RW	WOS:000184354600010	12873918				2020-06-30	J	Wajima, Z; Shiga, T; Yoshikawa, T; Ogura, A; Imanaga, K; Inoue, T; Ogawa, R				Wajima, Z; Shiga, T; Yoshikawa, T; Ogura, A; Imanaga, K; Inoue, T; Ogawa, R			Intravenous alprostadil, an analog of prostaglandin E-1, prevents thiamylal-fentanyl-induced bronchoconstriction in humans	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	75th Clinical and Scientific Congress of the International-Anesthesia-Research-Society	MAR 16-20, 2001	FT LAUDERDALE, FLORIDA	Internat Anesthesia Res Soc			MECHANICAL VENTILATION; AIRWAY-RESISTANCE; ENDOTRACHEAL-TUBE; PRESSURE-SUPPORT; SMOOTH-MUSCLE; DOGS; WORK; ANESTHESIA	Prostaglandin (PG) E, relaxes airway smooth muscle in animals. However, no clinical data have been published on the bronchorelaxant effects of IV alprostadil, an analog of PGE(1). We have described experimental thiamylal-fentanyl-induced bronchoconstriction in humans; we now report the effect of IV alprostadil on thiamylal-fentanyl-induced bronchoconstriction. Thirty-two patients were allocated randomly to a control group (n = 16) and alprostadil group (n = 16). Anesthesia was induced with thiamylal 5 mg/kg and vecuronium 0.3 mg/kg and maintained with a continuous infusion of thiamylal 15 mg . kg(-1) . h(-1). The lungs of the patients were ventilated with 50% nitrous oxide in oxygen. Twenty minutes after the induction of anesthesia, patients in the control group were given a continuous infusion of normal saline 20 mL/h, and those in the alprostadil group received a continuous infusion of alprostadil 0.2 mug . kg(-1) . min(-1) (20 mL/h), both for 60 min. Both groups were then given fentanyl 5 mug/kg. Systolic and diastolic arterial blood pressure, heart rate, mean airway resistance (Rawm), expiratory airway resistance (Rawe), and dynamic lung compliance (Cdyn) were measured at the baseline, just before the fentanyl injection (T30), at three consecutive 6-min intervals after fentanyl injection (T36, T42, and T48), and 30 min after fentanyl injection (T60). Baseline Rawm, Rawe, and Cdyn values were comparable between groups. In the control group, both Rawm and Rawe were significantly increased at T36-60, and Cdyn was significantly decreased at T36-60 compared with the baseline. Patients given alprostadil showed no change in Rawm, Rawe, or Cdyn at T36-60. Thus, IV alprostadil seems to have a bronchodilator effect in humans.	Chiba Hokusoh Hosp, Dept Anesthesia, Nippon Med Sch, Inba, Chiba 2701694, Japan; Tama Nagayama Hosp, Dept Anesthesia, Tokyo, Japan; Nippon Med Coll, Dept Anesthesiol, Tokyo 113, Japan; Tokyo Jikeikai Med Sch, Dept Anesthesiol, Tokyo, Japan; Cleveland Clin Fdn, Ctr Anesthesiol Res, Cleveland, OH 44195 USA	Wajima, Z (reprint author), Chiba Hokusoh Hosp, Dept Anesthesia, Nippon Med Sch, 1715 Kamagari, Inba, Chiba 2701694, Japan.			Shiga, Toshiya/0000-0003-0347-7181			BANNER MJ, 1993, CRIT CARE MED, V21, P1333, DOI 10.1097/00003246-199309000-00017; Berry A, 1999, ANESTHESIOLOGY, V90, P395, DOI 10.1097/00000542-199902000-00011; COLEMAN RA, 1994, PROSTAGLANDINS, V47, P151, DOI 10.1016/0090-6980(94)90084-1; GAL TJ, 1994, ANESTH ANALG, V78, P559; GARDINER PJ, 1975, PROSTAGLANDINS, V10, P607, DOI 10.1016/S0090-6980(75)80007-4; Hashimoto Y, 2000, BRIT J ANAESTH, V85, P460, DOI 10.1093/bja/85.3.460; Hashimoto Y, 1999, CRIT CARE MED, V27, P2755, DOI 10.1097/00003246-199912000-00025; HUTAS I, 1981, LUNG, V159, P153, DOI 10.1007/BF02713911; Kondo Shun, 1993, Journal of Smooth Muscle Research, V29, P29; MAIN IHM, 1964, BRIT J PHARM CHEMOTH, V22, P511, DOI 10.1111/j.1476-5381.1964.tb01705.x; MATHE AA, 1977, NEW ENGL J MED, V296, P850, DOI 10.1056/NEJM197704142961505; NATHAN SD, 1993, CHEST, V103, P1215, DOI 10.1378/chest.103.4.1215; PETROS AJ, 1993, ANAESTHESIA, V48, P985; ROBERTS AM, 1985, J APPL PHYSIOL, V58, P1823; ROLLA G, 1995, CHEST, V107, P169, DOI 10.1378/chest.107.1.169; ROSENTHALE ME, 1971, J PHARMACOL EXP THER, V178, P541; Thomas AM, 1997, CHEST, V112, P829, DOI 10.1378/chest.112.3.829; Wajima Z, 2003, CRIT CARE MED, V31, P485, DOI 10.1097/01.CCM.0000049950.58587.84; Wajima Z, 2002, CRIT CARE MED, V30, P820, DOI 10.1097/00003246-200204000-00017; WRIGHT PE, 1989, AM REV RESPIR DIS, V140, P10, DOI 10.1164/ajrccm/140.1.10; Wu RSC, 1996, ANESTH ANALG, V83, P238, DOI 10.1097/00000539-199608000-00007; Yamamura H, 1987, Masui, V36, P527; YAMAZAKI Y, 1994, CHEST, V105, P860, DOI 10.1378/chest.105.3.860; YOSHIMURA M, 1993, ANN CLIN BIOCHEM, V30, P135, DOI 10.1177/000456329303000204	24	3	4	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	AUG	2003	97	2					456	460		10.1213/01.ANE.0000068884.53810.9C			5	Anesthesiology	Anesthesiology	704RW	WOS:000184354600026	12873934				2020-06-30	J	Tao, R; Karnik, M; Ma, ZY; Auerbach, SB				Tao, R; Karnik, M; Ma, ZY; Auerbach, SB			Effect of fentanyl on 5-HT efflux involves both opioid and 5-HT1A receptors	BRITISH JOURNAL OF PHARMACOLOGY			English	Article						dorsal raphe nucleus; serotonin; fentanyl; opioid receptor; 5-HT1A receptor; microdialysis	MORPHINE-INDUCED INCREASES; DORSAL RAPHE NUCLEUS; CENTRAL-NERVOUS-SYSTEM; SEROTONERGIC NEURONS; 5-HYDROXYTRYPTAMINE RELEASE; RAT; INHIBITION; GABA; MICRODIALYSIS; INVOLVEMENT	1 Fentanyl is a mu-opioid analgesic that might disinhibit 5-HT neurons and thus increase 5-HT efflux. However, fentanyl also binds to 5-HT1A receptors, and if it activates 5-HT1A somatodendritic autoreceptors, the resultant inhibition might offset opioid-mediated increases in 5-HT efflux. To test this hypothesis, we used microdialysis to study effects of fentanyl on extracellular 5-HT in the dorsal raphe nucleus (DRN) of unanesthetized rats. 2 Systemic administration of fentanyl (0.01-0.2 mg kg(-1), s.c.) increased 5-HT efflux in the DRN. An intermediate dose of fentanyl (0.05 mg kg(-1)) produced the maximum increase in 5-HT to similar to180% of baseline levels in the DRN. Naltrexone (10 mg kg(-1), s.c.) blocked the increase in response to systemic fentanyl (0.05 mg kg(-1)). 3 In contrast, during infusion into the DRN, fentanyl (10-1000 muM) induced a dose-dependent decrease in 5- HT. Naltrexone and nor-binaltorphimine failed to block the decrease suggesting that mu- and kappa-opioid receptors did not mediate this effect. 4 Systemic (-)-pindolol ( 8 mg kg(-1), s.c.) or infusion of WAY-100635 (100 muM) into the DRN blocked the decrease, and instead 5- HT increased in response to local infusion of fentanyl ( 100 mm). WAY-100635 (0.3 mg kg(-1), s. c.) also potentiated the effect of systemic fentanyl (0.2 mg kg(-1), s.c.). (-)-Pindolol and WAY-100635 block 5HT(1A) receptors, indicating that inhibition of 5-HT neuronal activity resulting from fentanyl binding to somatodendritic autoreceptors attenuated opioid-mediated increases in 5- HT efflux. 5 These results provide novel evidence that besides stimulating mu-opioid receptors, fentanyl is a 5-HT1A receptor agonist. Possibly, this contributes to lethality of fentanyl overdose.	Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; Harvard Univ, Sch Med, Vet Affairs Med Ctr, Dept Psychiat, Brockton, MA 02301 USA	Auerbach, SB (reprint author), Rutgers State Univ, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.	auerbach@biology.rutgers.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [R01 DA014541, DA14541]; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH51080]		Celada P, 2001, J NEUROSCI, V21, P9917, DOI 10.1523/JNEUROSCI.21-24-09917.2001; Chaturvedi K, 2000, MOL BRAIN RES, V76, P64, DOI 10.1016/S0169-328X(99)00332-0; Clarke RW, 2000, PAIN, V85, P239, DOI 10.1016/S0304-3959(99)00272-9; Clifford EM, 1998, BRIT J PHARMACOL, V124, P206, DOI 10.1038/sj.bjp.0701796; DYKSTRA KH, 1992, J NEUROCHEM, V58, P931, DOI 10.1111/j.1471-4159.1992.tb09346.x; ENDOH T, 1992, ARCH INT PHARMACOD T, V316, P30; Fletcher A, 1996, BEHAV BRAIN RES, V73, P337; Fornal CA, 1999, J PHARMACOL EXP THER, V291, P229; Gervasoni D, 2000, J NEUROSCI, V20, P4217; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; JANG Y, 1991, EUR J PHARMACOL, V197, P135; Jolas T, 1997, BRAIN RES, V755, P229, DOI 10.1016/S0006-8993(97)00103-0; Kalyuzhny AE, 1997, NEUROREPORT, V8, P3367, DOI 10.1097/00001756-199710200-00035; LALLEY PM, 1994, J PHYSIOL-LONDON, V476, P117; MAGUIRE P, 1992, EUR J PHARMACOL, V213, P219, DOI 10.1016/0014-2999(92)90685-W; MARTIN DC, 1991, NEUROPHARMACOLOGY, V30, P323, DOI 10.1016/0028-3908(91)90056-H; Megens AAHP, 1998, J PAIN SYMPTOM MANAG, V15, P253, DOI 10.1016/S0885-3924(97)00371-0; MONROE PJ, 1995, EUR J PHARMACOL, V272, P51, DOI 10.1016/0014-2999(94)00623-F; PINNOCK RD, 1992, BRAIN RES, V583, P237, DOI 10.1016/S0006-8993(10)80029-0; Richter DW, 1999, J PHYSIOL-LONDON, V514, P567, DOI 10.1111/j.1469-7793.1999.567ae.x; Sahibzada N, 2000, J PHARMACOL EXP THER, V292, P704; SHARP T, 1989, BRIT J PHARMACOL, V98, P989, DOI 10.1111/j.1476-5381.1989.tb14630.x; Singh VP, 2001, BRAIN RES, V915, P218, DOI 10.1016/S0006-8993(01)02854-2; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TAO R, 1995, NEUROSCIENCE, V68, P553, DOI 10.1016/0306-4522(95)00154-B; Tao R, 2003, BRAIN RES, V961, P109, DOI 10.1016/S0006-8993(02)03851-9; Tao R, 2002, J PHARMACOL EXP THER, V303, P704, DOI 10.1124/jpet.102.038133; Tao R, 2002, J PHARMACOL EXP THER, V303, P549, DOI 10.1124/jpet.102.037861; Tao R, 1996, BRIT J PHARMACOL, V119, P1375, DOI 10.1111/j.1476-5381.1996.tb16049.x; TAO R, 1994, SYNAPSE, V18, P307, DOI 10.1002/syn.890180406; Tao R, 2000, J PSYCHOPHARMACOL, V14, P100, DOI 10.1177/026988110001400201; WANG QP, 1994, BRAIN RES BULL, V34, P575; XU W, 1994, NEUROREPORT, V5, P2665, DOI 10.1097/00001756-199412000-00065	33	22	22	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	AUG	2003	139	8					1498	1504		10.1038/sj.bjp.0705378			7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	712JZ	WOS:000184795700016	12922937	Green Published			2020-06-30	J	Wong, CA; Cariaso, D; Johnson, EC; Leu, D; McCarthy, RJ				Wong, CA; Cariaso, D; Johnson, EC; Leu, D; McCarthy, RJ			Body habitus does not influence spread of sensory blockade after the intrathecal injection of a hypobaric solution in term parturients	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							SPINAL ANALGESIA; 0.5-PERCENT BUPIVACAINE; CEREBROSPINAL-FLUID; PATIENT VARIABLES; ANESTHESIA; OBESITY; LEVEL	Purpose: To determine if the extent of sensory blockade after the intrathecal injection of hypobaric fentanyl (25 mug) and bupicavaine (2.5 mg) in the sitting position in term parturients is influenced by body habitus. Methods: A prospective observational study in 245 term parturients who received intrathecal fentanyl and bupivacaine plus an epidural test dose to initiate labour analgesia at an academic university hospital. The highest sensory blockade to ice and pinprick was determined at 15 and 30 min after the intrathecal injection. Correlations between sensory blockade and parturient height, weight and body mass index (BMI) were determined. Results: There was no association between highest sensory blockade and parturients' height. Increasing weight and BMI were associated with increased cephalad sensory blockade at 15 min, but not at 30 min. The estimated difference in sensory level between women at the extremes of BMI, based on our linear regression model, was less than one dermatome. Conclusion: Height did not influence the extent of sensory analgesia after initiation of intrathecal labour analgesia using a hypobaric solution injected with the parturient in the sitting position. Weight and BMI were associated with a non-clinically significant increase in the cephalic spread of analgesia, suggesting that dose adjustments based on body habitus in this population are not necessary.	Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA	Wong, CA (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, 251 E Huron St,Feinberg 5-704, Chicago, IL 60611 USA.	c-wong2@northwestern.edu	McCarthy, Robert J/J-9113-2018	McCarthy, Robert J/0000-0002-0966-5311; Wong, Cynthia/0000-0002-7144-7008			Abdou WA, 2000, INT J OBSTET ANESTH, V9, P48, DOI 10.1054/ijoa.1999.0342; Bridenbaugh PO, 1998, NEURAL BLOCKADE CLIN, P203; Carpenter RL, 1998, ANESTHESIOLOGY, V89, P24, DOI 10.1097/00000542-199807000-00007; Ekelof NP, 1997, ACTA ANAESTH SCAND, V41, P884, DOI 10.1111/j.1399-6576.1997.tb04804.x; HAMILTON CL, 1995, ANESTHESIOLOGY, V83, P1118, DOI 10.1097/00000542-199511000-00028; HARTWELL BL, 1991, REGION ANESTH, V16, P17; MCCULLOCH WJD, 1986, BRIT J ANAESTH, V58, P610, DOI 10.1093/bja/58.6.610; Moore DC, 1982, REGIONAL ANESTHESIA, V7, P20; NORRIS MC, 1990, ANESTHESIOLOGY, V72, P478, DOI 10.1097/00000542-199003000-00015; Pargger H, 1998, ACTA ANAESTH SCAND, V42, P430, DOI 10.1111/j.1399-6576.1998.tb05137.x; PITKANEN MT, 1987, ANESTH ANALG, V66, P127, DOI 10.1213/00000539-198702000-00005; Richardson MG, 1996, ANESTHESIOLOGY, V85, P326, DOI 10.1097/00000542-199608000-00014; TAIVAINEN T, 1990, BRIT J ANAESTH, V64, P542, DOI 10.1093/bja/64.5.542; Takiguchi T, 1997, ANESTH ANALG, V85, P1097, DOI 10.1097/00000539-199711000-00024	14	8	10	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	AUG-SEP	2003	50	7					689	693		10.1007/BF03018711			5	Anesthesiology	Anesthesiology	720TY	WOS:000185277100012	12944443	Bronze			2020-06-30	J	Takano, Y; Takano, M; Kuno, Y; Sato, E; Sato, I				Takano, Y; Takano, M; Kuno, Y; Sato, E; Sato, I			Lidocaine or fentanyl applied to the surgical wound during spinal surgery produces potent postoperative analgesia	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter							PAIN									Cohen BE, 1997, SPINE, V22, P1892, DOI 10.1097/00007632-199708150-00016; Melzack R, 2001, ANN NY ACAD SCI, V933, P157	2	0	0	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	AUG-SEP	2003	50	7					751	752		10.1007/BF03018724			2	Anesthesiology	Anesthesiology	720TY	WOS:000185277100025	12944456	Bronze			2020-06-30	J	Vansteensel, MJ; Deboer, T; Dahan, A; Meijer, JH				Vansteensel, MJ; Deboer, T; Dahan, A; Meijer, JH			Differential responses of circadian activity onset and offset following GABA-ergic and opioid receptor activation	JOURNAL OF BIOLOGICAL RHYTHMS			English	Article						circadian rhythm; phase shift; opioid; benzodiazepine; nonphotic; multioscillator	HAMSTER SUPRACHIASMATIC NUCLEUS; SHORT-ACTING BENZODIAZEPINE; PHASE-SHIFTS; INTERGENICULATE LEAFLET; ACTIVITY RHYTHMS; CLOCK; ENTRAINMENT; PACEMAKER; MELATONIN; NEURONS	The circadian pacemaker in the mammalian suprachiasmatic nuclei is responsive to photic and nonphotic stimuli. In the present study, the authors have investigated the response of activity onset and offset to application of nonphotic stimuli: the benzodiazepine midazolam and the opioid receptor agonist fentanyl. In correspondence with previous studies, both stimuli induced phase advances of the activity onset when given in the mid- to late subjective day. In contrast, activity offset did not phase advance following these injections. Injections during the early subjective day induced small phase delays of the activity onset, while large phase delays occurred in activity offset. Phase shifts, induced at both circadian time zones, were paralleled by an increase in the length of daily activity (a). The increase in a remained present during several days after the injection. The different kinetics in phase shifting of the activity onset and offset indicate complexity in phase-shifting behavior of the circadian pacemaker in response to nonphotic stimuli. Moreover, the data show responsiveness of the circadian system to GABA-ergic and opioid receptor activation, not only during the mid- to late subjective day but also during the early subjective day. The data implicate that the early subjective day is an interesting phase for analysis of molecular and biochemical processes involved in nonphotic phase shifting.	Leiden Univ, Med Ctr, Dept Neurophysiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Anesthesiol, NL-2300 RC Leiden, Netherlands	Meijer, JH (reprint author), Leiden Univ, Med Ctr, Dept Neurophysiol, Wassenaarseweg 62,POB 9604, NL-2300 RC Leiden, Netherlands.		Dahan, Albert/B-8845-2008; Vansteensel, Mariska/K-8015-2019	Dahan, Albert/0000-0003-3161-3945; Vansteensel, Mariska/0000-0002-9252-5116			Albrecht U, 2001, J BIOL RHYTHM, V16, P100, DOI 10.1177/074873001129001791; Boulos Z, 1996, J BIOL RHYTHM, V11, P216, DOI 10.1177/074873049601100304; Byku M, 2000, BRAIN RES, V873, P189, DOI 10.1016/S0006-8993(00)02304-0; Byku M, 2000, NEUROREPORT, V11, P1449, DOI 10.1097/00001756-200005150-00019; Byku M, 2000, BRAIN RES, V857, P1, DOI 10.1016/S0006-8993(99)02290-8; Daan S, 2001, J BIOL RHYTHM, V16, P105, DOI 10.1177/074873001129001809; ELLIOTT JA, 1994, J COMP PHYSIOL A, V174, P469; Goldman BD, 2001, J BIOL RHYTHM, V16, P283, DOI 10.1177/074873001129001980; Hastings M, 2001, J BIOL RHYTHM, V16, P117, DOI 10.1177/074873001129001818; HONMA K, 1985, JPN J PHYSIOL, V35, P643, DOI 10.2170/jjphysiol.35.643; Horikawa K, 2000, J NEUROSCI, V20, P5867; HUMLOVA M, 1990, NEUROENDOCRINOLOGY, V52, P196, DOI 10.1159/000125573; Jagota A, 2000, NAT NEUROSCI, V3, P372; JOY JE, 1989, EXPERIENTIA, V45, P152, DOI 10.1007/BF01954855; Liu C, 2000, NEURON, V25, P123, DOI 10.1016/S0896-6273(00)80876-4; MEIJER JH, 1995, J BIOL RHYTHM, V10, P4, DOI 10.1177/074873049501000101; Meijer JH, 2000, BRAIN RES, V868, P135, DOI 10.1016/S0006-8993(00)02317-9; MOORE RY, 1993, NEUROSCI LETT, V150, P112, DOI 10.1016/0304-3940(93)90120-A; MORIN LP, 1992, VISUAL NEUROSCI, V8, P219, DOI 10.1017/S095252380000287X; Morin LP, 2001, J COMP NEUROL, V437, P79, DOI 10.1002/cne.1271; MROSOVSKY N, 1993, CHRONOBIOL INT, V10, P271, DOI 10.3109/07420529309059709; MROSOVSKY N, 1989, EXPERIENTIA, V45, P696, DOI 10.1007/BF01974561; Mrugala M, 2000, AM J PHYSIOL-REG I, V278, pR987; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P333, DOI 10.1007/BF01417860; Schwartz WJ, 2001, J BIOL RHYTHM, V16, P302, DOI 10.1177/074873001129002024; Shirakawa T, 2000, EUR J NEUROSCI, V12, P2833, DOI 10.1046/j.1460-9568.2000.00170.x; Sumova A, 1998, AM J PHYSIOL-REG I, V274, pR857; Takahashi J.S., 2001, HDB BEHAV NEUROBIOLO, V12; Tierno A, 2002, BRAIN RES, V937, P66, DOI 10.1016/S0006-8993(02)02468-X; TUREK FW, 1986, NATURE, V321, P167, DOI 10.1038/321167a0; Watanabe K, 2001, J BIOL RHYTHM, V16, P564, DOI 10.1177/074873001129002259; WEE BEF, 1989, PHARMACOL BIOCHEM BE, V32, P901, DOI 10.1016/0091-3057(89)90056-7; Yokota S, 2000, BRIT J PHARMACOL, V131, P1739, DOI 10.1038/sj.bjp.0703735	33	13	13	0	0	SAGE PUBLICATIONS LTD	LONDON	6 BONHILL STREET, LONDON EC2A 4PU, ENGLAND	0748-7304			J BIOL RHYTHM	J. Biol. Rhythms	AUG	2003	18	4					297	306		10.1177/0748730403254283			10	Biology; Physiology	Life Sciences & Biomedicine - Other Topics; Physiology	705TY	WOS:000184412200003	12932082				2020-06-30	J	Bjorkman, S				Bjorkman, S			Reduction and lumping of physiologically based pharmacokinetic models: Prediction of the disposition of fentanyl and pethidine in humans by successively simplified models	JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS			English	Article						pharmacokinetics; whole body physiologically based model; lumping; tissue distribution; opioids	PLASMA PARTITION-COEFFICIENTS; BLOOD-FLOW; DRUG DEVELOPMENT; BODY-COMPOSITION; URINARY PH; IN-VIVO; ALFENTANIL; MEPERIDINE; RAT; PERFORMANCE	Physiologically based pharmacokinetic (PBPK) models can be used to predict drug disposition in humans from animal data and the influence of disease or other changes in physiology on the pharmacokinetics of a drug. The potential usefulness of a PBPK model must however be balanced against the considerable effort needed for its development. Proposed methods to simplify PBPK modeling include predicting the necessary tissue: blood partition coefficients (k(p)) from physicochemical data on the drug instead of determining them in vivo, formal lumping of model compartments, and replacing the various k(p) values of the organs and tissues by only two values, for "fat'' and "lean'' tissues, respectively. The aim of this study was to investigate the effects of simplifying complex PBPK models on their ability to predict drug disposition in humans. Arterial plasma concentration curves of fentanyl and pethidine were simulated by means of a number of successively reduced models. Median absolute prediction errors were used to evaluate the performance of each model, in relation to arterial plasma concentration data from clinical studies, and the Wilcoxon matched pairs test was used for comparison of predictions. An originally diffusion-limited model for fentanyl was simplified to perfusion-limitation, and this model was either lumped, reducing 11 organ/tissue compartments to six, or changed to a model based on only two k(p) values, those of fat (used for fat and lungs) and muscle (used for all other tissues). None of these simplifications appreciably changed the predictions of arterial drug concentrations in the 10 patients. Perfusion-limited models for pethidine were set up using either experimentally determined [Gabrielsson et al. 1986] or theoretically calculated [Davis and Mapleson 1993] k(p) values, and predictions using the former were found to be significantly better. Lumping of the models did not appreciably change the predictions; however, going from a full set of k(p) values to only two ("fat'' and "lean'') had an adverse effect. Using a k(p) for lungs determined either in rats or indirectly in humans [Persson et al. 1988], i.e., a total of three k(p) values, improved these predictions. In conclusion, this study strongly suggested that complex PBPK models for lipophilic basic drugs may be considerably reduced with marginal loss of power to predict standard plasma pharmacokinetics in humans. Determination of only two or three k(p) values instead of a "full'' set can mean an important reduction of experimental work to define a basic model. Organs of particular pharmacological or toxicological interest should of course be investigated separately as needed. This study also suggests and applies a simple method for statistical evaluation of the predictions of PBPK models.	Uppsala Univ, Dept Phamraceut Biosci, Div Pharmacokinet & Drug Therapy, Uppsala, Sweden; Malmo Univ Hosp, Hosp Pharm, Malmo, Sweden	Bjorkman, S (reprint author), Uppsala Univ, Dept Phamraceut Biosci, Div Pharmacokinet & Drug Therapy, Uppsala, Sweden.						BJORKMAN S, 1993, J PHARMACOKINET BIOP, V21, P255, DOI 10.1007/BF01059779; BJORKMAN S, 1994, J PHARMACOKINET BIOP, V22, P381, DOI 10.1007/BF02353862; Bjorkman S, 2000, J PHARM PHARMACOL, V52, P1065, DOI 10.1211/0022357001774985; BJORKMAN S, 1990, ANESTHESIOLOGY, V72, P865, DOI 10.1097/00000542-199005000-00017; Bjorkman S, 1998, ANESTHESIOLOGY, V88, P657, DOI 10.1097/00000542-199803000-00016; Bjorkman S, 2002, J PHARM PHARMACOL, V54, P1237, DOI 10.1211/002235702320402080; Bjorkman S, 2001, J PHARM SCI-US, V90, P1226, DOI 10.1002/jps.1076; BOIS FY, 1991, TOXICOL APPL PHARM, V110, P79, DOI 10.1016/0041-008X(91)90291-L; Boobis A, 2002, EUR J PHARM SCI, V17, P183, DOI 10.1016/S0928-0987(02)00185-9; CHAN K, 1985, METHOD FIND EXP CLIN, V7, P245; Charnick SB, 1995, J PHARMACOKINET BIOP, V23, P217, DOI 10.1007/BF02354273; DAHLSTROM BE, 1979, DRUG METAB DISPOS, V7, P108; DAVIS NR, 1993, BRIT J ANAESTH, V70, P248, DOI 10.1093/bja/70.3.248; EBLING WF, 1994, J PHARMACOKINET BIOP, V22, P259, DOI 10.1007/BF02353622; El-Masri HA, 1998, DRUG METAB DISPOS, V26, P585; GABRIELSSON JL, 1986, J PHARMACOKINET BIOP, V14, P381, DOI 10.1007/BF01059198; HALLYNCK TH, 1981, BRIT J CLIN PHARMACO, V11, P523, DOI 10.1111/j.1365-2125.1981.tb01163.x; HUDSON RJ, 1986, ANESTHESIOLOGY, V64, P334, DOI 10.1097/00000542-198603000-00006; HUG CC, 1985, ANESTHESIOLOGY, V62, P221; KRAMER WG, 1985, J PHARM SCI, V74, P569, DOI 10.1002/jps.2600740517; LEMMENS HJM, 1994, CLIN PHARMACOL THER, V56, P261, DOI 10.1038/clpt.1994.136; MATHER LE, 1978, CLIN PHARMACOKINET, V3, P352, DOI 10.2165/00003088-197803050-00002; NAGATA O, 1990, DRUG METAB DISPOS, V18, P902; Nestorov IA, 1998, J PHARMACOKINET BIOP, V26, P21, DOI 10.1023/A:1023272707390; PERSSON MP, 1988, BRIT J CLIN PHARMACO, V25, P235, DOI 10.1111/j.1365-2125.1988.tb03296.x; Poulin P, 2001, J PHARM SCI-US, V90, P436, DOI 10.1002/1520-6017(200104)90:4<436::AID-JPS1002>3.0.CO;2-P; Poulin P, 2002, J PHARM SCI-US, V91, P1358, DOI 10.1002/jps.10128; Poulin P, 2002, J PHARM SCI-US, V91, P129, DOI 10.1002/jps.10005; PRICE HL, 1960, ANESTHESIOLOGY, V21, P40, DOI 10.1097/00000542-196001000-00008; QIAO GL, 1994, J VET PHARMACOL THER, V17, P127, DOI 10.1111/j.1365-2885.1994.tb00222.x; Ranheim B, 1998, J VET PHARMACOL THER, V21, P491, DOI 10.1046/j.1365-2885.1998.00158.x; REDKE F, 1999, EUR J PHARM SCI, V8, pR19; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHEINER LB, 1981, J PHARMACOKINET BIOP, V9, P503, DOI 10.1007/BF01060893; Shibata N, 2002, J PHARM SCI, V91, P680, DOI 10.1002/jps.10051; Theil FP, 2003, TOXICOL LETT, V138, P29, DOI 10.1016/S0378-4274(02)00374-0; TSUJI A, 1985, DRUG METAB DISPOS, V13, P729; Upton RN, 1997, ANESTHESIOLOGY, V86, P1317, DOI 10.1097/00000542-199706000-00013; UPTON RN, 1991, XENOBIOTICA, V21, P1, DOI 10.3109/00498259109039445; VERBEECK RK, 1981, CLIN PHARMACOL THER, V30, P619, DOI 10.1038/clpt.1981.213; Vermeulen PM, 1997, BRIT J ANAESTH, V79, P488, DOI 10.1093/bja/79.4.488; Wada DR, 1997, ANESTHESIOLOGY, V87, P884, DOI 10.1097/00000542-199710000-00024; WADA DR, 1995, COMPUT METH PROG BIO, V46, P245, DOI 10.1016/0169-2607(95)01624-3; WILLIAMS LR, 1989, CLIN PHYS PHYSIOL M, V10, P187, DOI 10.1088/0143-0815/10/3/001; WU G, 1995, PHARMACOL RES, V31, P393, DOI 10.1016/1043-6618(95)80095-6	46	23	25	0	5	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1567-567X			J PHARMACOKINET PHAR	J. Pharmacokinet. Pharmacodyn.	AUG	2003	30	4					285	307		10.1023/A:1026194618660			23	Pharmacology & Pharmacy	Pharmacology & Pharmacy	733AG	WOS:000185977300003	14650375				2020-06-30	J	Larsson, M; Arvidsson, S; Ekman, C; Bayati, A				Larsson, M; Arvidsson, S; Ekman, C; Bayati, A			A model for chronic quantitative studies of colorectal sensitivity using balloon distension in conscious mice - effects of opioid receptor agonists	NEUROGASTROENTEROLOGY AND MOTILITY			English	Article						colon; colorectal distension; mouse; opioid receptor agonist; visceral sensitivity	IRRITABLE-BOWEL-SYNDROME; MIDBRAIN PERIAQUEDUCTAL GRAY; NOXIOUS VISCERAL STIMULUS; VISCEROSENSITIVE RESPONSE; ATTENUATE RESPONSES; RECTAL DISTENSION; PAIN; RATS; NOCICEPTION; MORPHINE	In the current study, colorectal distension (CRD) was performed in conscious mice, in order to study visceral (colon) sensitivity. Electrodes were chronically implanted into the external oblique muscle to obtain the electromyographic (EMG) response to CRD. CRD was performed using a computerized system, which inflated the balloon with air to the desired pressures. An increasing (10-80 mmHg) and a repeated (12 x 55 mmHg) phasic paradigm with distensions lasting 10 s and with 5-min intervals were used. The EMG recordings were linearly correlated to intracolonic pressures between 10 and 80 mmHg, which are characteristic of the visceromotor response (VMR). Repeated phasic distensions at 55 mmHg resulted in a stable VMR in female mice, but an increasing VMR in male mice. Interestingly, the duration of the VMR was about 5 s, which is shorter than the actual duration of the distension. U-69593 and fentanyl (selective kappa and mu opioid receptor agonists) significantly reduced the VMR at subcutaneous doses of 0.5 and 0.05 mg kg(-1) , respectively. In conclusion, a CRD model for repetitive quantitative studies of colorectal sensitivity and evaluation of pharmacological modulation of visceral sensitivity in conscious mice is presented.	AstraZeneca Molndal, Dept Integrat Pharmacol, Res Area CV&GI, Gastrointestinal Biol,Preclin R&D, S-43183 Molndal, Sweden; AstraZeneca, Dept Biostat, Molndal, Sweden	Larsson, M (reprint author), AstraZeneca Molndal, Dept Integrat Pharmacol, Res Area CV&GI, Gastrointestinal Biol,Preclin R&D, S-43183 Molndal, Sweden.						Abrahamson MH, 2000, GASTROENTEROLOGY, V118, pA379, DOI 10.1016/S0016-5085(00)83624-0; ABRAHAMSON MH, 1999, 9 WORLD C PAIN; ANDERSON RH, 1987, PHYSIOL BEHAV, V41, P635, DOI 10.1016/0031-9384(87)90322-2; Bandler R, 1996, PROG BRAIN RES, V107, P285; BROWN DM, 1962, J PHARM PHARMACOL, V14, P399, DOI 10.1111/j.2042-7158.1962.tb11118.x; Burton MB, 1998, J PHARMACOL EXP THER, V285, P707; DANZEBRINK RM, 1995, PAIN, V63, P39, DOI 10.1016/0304-3959(94)00275-J; Drossman DA, 1999, ALIMENT PHARM THERAP, V13, P3, DOI 10.1046/j.1365-2036.1999.0130s2003.x; Elmer GI, 1998, PAIN, V75, P129, DOI 10.1016/S0304-3959(97)00215-7; GEBHART GF, 1991, CAN J PHYSIOL PHARM, V69, P627, DOI 10.1139/y91-093; Gebhart GF, 2000, ANN NY ACAD SCI, V909, P41; Gebhart GF, 1995, HDB METHODS GASTROIN, V27, P359; HENDERSHOT LC, 1959, J PHARMACOL EXP THER, V125, P237; JULIA V, 1994, GASTROENTEROLOGY, V107, P94, DOI 10.1016/0016-5085(94)90065-5; Kamp EH, 2003, AM J PHYSIOL-GASTR L, V284, pG434, DOI 10.1152/ajpgi.00324.2002; KEAY KA, 1993, NEUROSCI LETT, V154, P23, DOI 10.1016/0304-3940(93)90162-E; KELLY DD, 1986, ANN NY ACAD SCI, V467, P1; LANTERIMINET M, 1993, NEUROSCIENCE, V55, P737, DOI 10.1016/0306-4522(93)90439-M; Martinez V, 1999, PAIN, V81, P179, DOI 10.1016/S0304-3959(99)00008-1; MAYER EA, 1994, GASTROENTEROLOGY, V107, P271, DOI 10.1016/0016-5085(94)90086-8; MERTZ H, 1995, GASTROENTEROLOGY, V109, P40, DOI 10.1016/0016-5085(95)90267-8; Mogil JS, 1996, J PHARMACOL EXP THER, V276, P532; MORTEAU O, 1994, FUND CLIN PHARMACOL, V8, P553, DOI 10.1111/j.1472-8206.1994.tb00837.x; NESS TJ, 1988, BRAIN RES, V450, P153, DOI 10.1016/0006-8993(88)91555-7; NESS TJ, 1991, NEUROSCI LETT, V131, P113, DOI 10.1016/0304-3940(91)90349-X; Plourde V, 1997, AM J PHYSIOL-GASTR L, V273, pG191; RITCHIE J, 1973, GUT, V14, P125, DOI 10.1136/gut.14.2.125; Schmulson M, 2000, AM J GASTROENTEROL, V95, P152; Schmulson MJ, 1999, CURR OPIN GASTROEN, V15, P16, DOI 10.1097/00001574-199901000-00004; Sengupta JN, 1996, GASTROENTEROLOGY, V111, P968, DOI 10.1016/S0016-5085(96)70064-1; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Su X, 1997, J NEUROPHYSIOL, V78, P1003	32	42	47	1	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1350-1925			NEUROGASTROENT MOTIL	Neurogastroenterol. Motil.	AUG	2003	15	4					371	381		10.1046/j.1365-2982.2003.00418.x			11	Gastroenterology & Hepatology; Clinical Neurology; Neurosciences	Gastroenterology & Hepatology; Neurosciences & Neurology	698ZV	WOS:000184032100003	12846725				2020-06-30	J	Manzke, T; Guenther, U; Ponimaskin, EG; Haller, M; Dutschmann, M; Schwarzacher, S; Richter, DW				Manzke, T; Guenther, U; Ponimaskin, EG; Haller, M; Dutschmann, M; Schwarzacher, S; Richter, DW			5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia	SCIENCE			English	Article							5-HYDROXYTRYPTAMINE 4(A) RECEPTOR; ISOLATED RESPIRATORY NETWORK; PREBOTZINGER COMPLEX; RAT-BRAIN; NEURONS; PHARMACOLOGY; SEROTONIN; CLONING; RHYTHM	Opiates are widely used analgesics in anesthesiology, but they have serious adverse effects such as depression of breathing. This is caused by direct inhibition of rhythm-generating respiratory neurons in the Pre-Boetzinger complex (PBC) of the brainstem. We report that serotonin 4(a) [5-HT4(a)] receptors are strongly expressed in respiratory PBC neurons and that their selective activation protects spontaneous respiratory activity. Treatment of rats with a 5-HT4 receptor specific agonist overcame fentanyl-induced respiratory depression and reestablished stable respiratory rhythm without loss of fentanyl's analgesic effect. These findings imply the prospect of a fine-tuned recovery from opioid-induced respiratory depression, through adjustment of intracellular adenosine 3', 5'-monophosphate levels through the convergent signaling pathways in neurons.	Univ Gottingen, Dept Neuro & Sensory Physiol, D-37073 Gottingen, Germany; Univ Gottingen, Ctr Anesthesiol, D-37075 Gottingen, Germany; Dept Anat, D-37075 Gottingen, Germany	Richter, DW (reprint author), Univ Gottingen, Dept Neuro & Sensory Physiol, Humboldtallee 23, D-37073 Gottingen, Germany.			Dutschmann, Mathias/0000-0002-0692-746X; Ponimaskin, evgeni/0000-0002-4570-5130			Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; BOCKAERT J, 1990, MOL PHARMACOL, V37, P408; Claeysen S, 1996, FEBS LETT, V398, P19, DOI 10.1016/S0014-5793(96)01132-5; Compan V, 1996, EUR J NEUROSCI, V8, P2591, DOI 10.1111/j.1460-9568.1996.tb01553.x; DENAVITSAUBIE M, 1978, BRAIN RES, V155, P55, DOI 10.1016/0006-8993(78)90305-0; Dunn EB, 2000, VET HUM TOXICOL, V42, P36; Gray PA, 2001, NAT NEUROSCI, V4, P927, DOI 10.1038/nn0901-927; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; Guyenet PG, 2001, J NEUROPHYSIOL, V86, P438; Heine M, 2002, PFLUG ARCH EUR J PHY, V443, P418, DOI 10.1007/s004240100690; HOYER D, 1994, PHARMACOL REV, V46, P157; Hynie S, 1995, Cesk Fysiol, V44, P135; LI YW, 1997, AM J PHYSIOL, V273, P805; MANZKE T, 2002, FENS FOR ABSTR, V1, P77; MORIN D, 1990, BRAIN RES, V535, P281, DOI 10.1016/0006-8993(90)91611-J; PATON JF, 1996, J NEUROSCI METH, V65, P6; Ponimaskin EG, 2002, J BIOL CHEM, V277, P20812, DOI 10.1074/jbc.M112216200; Ponimaskin EG, 2001, BIOCHEM J, V353, P627, DOI 10.1042/0264-6021:3530627; Richter DW, 1997, RESP PHYSIOL, V110, P113, DOI 10.1016/S0034-5687(97)00077-7; Richter DW, 2000, NEUROSCIENTIST, V6, P181, DOI 10.1177/107385840000600309; SMITH JC, 1992, NEUROSCI LETT, V134, P153, DOI 10.1016/0304-3940(92)90504-Z; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; Vilaro MT, 2002, NEUROPHARMACOLOGY, V42, P60, DOI 10.1016/S0028-3908(01)00154-X; Vilaro MT, 1996, MOL BRAIN RES, V43, P356, DOI 10.1016/S0169-328X(96)00248-3	25	178	190	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 11	2003	301	5630					226	229		10.1126/science.1084674			4	Multidisciplinary Sciences	Science & Technology - Other Topics	699KN	WOS:000184056200047	12855812				2020-06-30	J	Goyagi, T; Tanaka, M; Nishikawa, T				Goyagi, T; Tanaka, M; Nishikawa, T			Fentanyl decreases propofol requirement for laryngeal mask airway insertion	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						fentanyl; laryngeal mask airway; propofol	TRACHEAL INTUBATION; THIOPENTONE; LIGNOCAINE; ANESTHESIA; INDUCTION	Background: Since fentanyl is a potent depressant of the upper airway reflex, preadministration of fentanyl may facilitate insertion of the laryngeal mask airway (LMA(TM)) using propofol. Accordingly, we tested the hypothesis that fentanyl pretreatment would reduce the dose of propofol required for the LMA insertion. Methods: Forty-one healthy patients without sedative premedication were randomly assigned to either fentanyl group, receiving fentanyl 2 mug kg(-1) intravenously, or control group, receiving equal volumes of normal saline. Then, 3 ml of 2% lidocaine was given intravenously to alleviate pain associated with propofol administration. Thirty s after the fentanyl or saline injection, a predetermined dose of 1% propofol was given at a rate of 100 mg min(-1). Insertion of the LMA was attempted 90 s after the completion of the propofol injection. The dose of propofol given to a particular patient was determined by the response of the preceding patient in that group to a higher or lower dose, using the up-and-down method. The first patient in each group received 2.5 mg kg(-1) of propofol, while the step-size was 0.25 mg kg(-1). Patients responses were assessed by a blinded observer. Results: ED50 and ED95 of propofol requirements were significantly less in the fentanyl group (0.82, 1.17 mg kg(-1), respectively) than those in the control group (2.39, 2.62 mg kg(-1), P < 0.001). Conclusion: Our results indicate that preadministration of fentanyl 2 &mu;g kg(-1) decreases the propofol requirement for the LMA insertion.	Akita Univ, Sch Med, Dept Anesthesiol, Akita 0108543, Japan	Goyagi, T (reprint author), Akita Univ, Sch Med, Dept Anesthesiol, Hondo 1-1-1, Akita 0108543, Japan.		Goyagi, Toru/AAI-2885-2020	Goyagi, Toru/0000-0002-3077-4790			BLAKE DW, 1992, ANAESTH INTENS CARE, V20, P479, DOI 10.1177/0310057X9202000415; BRIMACOMBE J, 1993, ANAESTH INTENS CARE, V21, P89, DOI 10.1177/0310057X9302100121; Casati A, 1999, ANESTH ANALG, V88, P917, DOI 10.1097/00000539-199904000-00043; Cook TM, 1996, ANAESTHESIA, V51, P787, DOI 10.1111/j.1365-2044.1996.tb07899.x; Dixon WJ, 1967, STAT ENDOCRINOLOGY, P251; Drage MP, 1996, ANAESTHESIA, V51, P1167, DOI 10.1111/j.1365-2044.1996.tb15062.x; GOODMAN NW, 1987, BRIT J ANAESTH, V59, P1497, DOI 10.1093/bja/59.12.1497; INOMATA S, 1994, ANESTHESIOLOGY, V80, P93, DOI 10.1097/00000542-199401000-00016; Katoh T, 1999, BRIT J ANAESTH, V82, P561; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Kodaka M., 2002, Anesthesia and Analgesia, V94; MATTA BF, 1995, J CLIN ANESTH, V7, P132, DOI 10.1016/0952-8180(94)00027-2; MCKEATING K, 1988, ANAESTHESIA, V43, P638, DOI 10.1111/j.1365-2044.1988.tb04146.x; Nakazawa K, 1999, EUR J ANAESTH, V16, P550, DOI 10.1046/j.1365-2346.1999.00540.x; NEWMAN PTF, 1991, ANAESTHESIA, V46, P235, DOI 10.1111/j.1365-2044.1991.tb09430.x; POULTON TJ, 1979, ANESTHESIOLOGY, V50, P470, DOI 10.1097/00000542-197905000-00018; SCANLON P, 1993, CAN J ANAESTH, V40, P816, DOI 10.1007/BF03009250; Seavell CR, 1996, ANAESTHESIA, V51, P699, DOI 10.1111/j.1365-2044.1996.tb04660.x; STONEHAM MD, 1995, ANAESTHESIA, V50, P464, DOI 10.1111/j.1365-2044.1995.tb06007.x; SUTCLIFFE NP, 1994, BRIT J ANAESTH, V73, P265; Tagaito Y, 1998, ANESTHESIOLOGY, V88, P1459, DOI 10.1097/00000542-199806000-00007; TAGUCHI M, 1994, ANESTHESIOLOGY, V81, P628, DOI 10.1097/00000542-199409000-00016; Taylor IN, 1998, ANAESTHESIA, V53, P222, DOI 10.1046/j.1365-2044.1998.00316.x	23	19	21	0	0	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JUL	2003	47	6					771	774		10.1034/j.1399-6576.2003.00123.x			4	Anesthesiology	Anesthesiology	689WT	WOS:000183516500020	12803598				2020-06-30	J	Beilin, Y; Zahn, J; Abramovitz, S; Bernstein, HH; Hossain, S; Bodian, C				Beilin, Y; Zahn, J; Abramovitz, S; Bernstein, HH; Hossain, S; Bodian, C			Subarachnoid small-dose bupivacaine versus lidocaine for cervical cerclage	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	31st Annual Meeting of the Society-for-Obstetric-Anesthesia-and-Perinatology	MAY 19-22, 1999	DENVER, CO	Soc Obstetr Anesthesia & Perinatol			TRANSIENT NEUROLOGIC SYMPTOMS; CAUDA-EQUINA-SYNDROME; SPINAL-ANESTHESIA; HYPERBARIC LIDOCAINE; AMBULATORY SURGERY; 5-PERCENT; COMPLICATIONS; 0.5-PERCENT; 2-PERCENT; RECOVERY	Cervical cerclage is often performed as an outpatient procedure under subarachnoid anesthesia. Lidocaine was historically the drug of choice for short procedures but has fallen out of favor because of concerns of transient neurologic symptoms (TNS). We performed this study to determine whether small-dose bupivacaine is an acceptable alternative to lidocaine for cervical cerclage. We randomized 59 women to receive either subarachnoid isobaric lidocaine 30 mg or hyperbaric bupivacaine 5.25 mg. Fentanyl 20 mug was added to both local anesthetics, and the total volume was diluted to 3 ml, with 0.9% saline. Onset and highest dermatomal level of sensory block; quality of anesthesia; hypotension; and times until T12 regression, return of lower extremity motor function, ambulation, and micturition were recorded. Symptoms of TNS were evaluated by telephone interview 24 h after surgery. We did not find any significant difference in onset or recovery times between the groups, with the exception of a longer duration until return of lower extremity motor strength in the lidocaine group. Symptoms consistent with TNS that resolved spontaneously within 48 h were reported by two women in the lidocaine group but by none in the bupivacaine group. We conclude that subarachnoid bupivacaine offers a satisfactory alternative to subarachnoid lidocaine for cervical cerclage.	NYU, Mt Sinai Sch Med, Dept Anesthesiol, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Biomath Sci, New York, NY 10029 USA; Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY USA	Beilin, Y (reprint author), NYU, Mt Sinai Sch Med, Dept Anesthesiol, Box 1010,1 Gustave L Levy, New York, NY 10029 USA.	Yaakov.Beilin@mountsinai.org	Zahn, Jeffrey D/AAQ-7195-2020	Zahn, Jeffrey D/0000-0001-8712-752X			Auroy Y, 1997, ANESTHESIOLOGY, V87, P479, DOI 10.1097/00000542-199709000-00005; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BenDavid B, 1996, ANESTH ANALG, V83, P716, DOI 10.1097/00000539-199610000-00009; CONCEPCION M, 1984, DRUGS, V27, P256, DOI 10.2165/00003495-198427030-00005; DEXTER F, 1995, ANESTHESIOLOGY, V82, P94, DOI 10.1097/00000542-199501000-00013; Freedman JM, 1998, ANESTHESIOLOGY, V89, P633, DOI 10.1097/00000542-199809000-00012; Gaiser RR, 2000, J CLIN ANESTH, V12, P476, DOI 10.1016/S0952-8180(00)00186-0; Gentile M, 1997, REGION ANESTH, V22, P511; Gerancher JC, 1997, ANESTHESIOLOGY, V87, P687, DOI 10.1097/00000542-199709000-00031; HAMPL KF, 1995, ANESTH ANALG, V81, P1148, DOI 10.1097/00000539-199512000-00006; Hampl KF, 1996, ANESTH ANALG, V83, P1051, DOI 10.1097/00000539-199611000-00026; Hodgson PS, 1999, ANESTH ANALG, V88, P797, DOI 10.1097/00000539-199904000-00023; Kamphuis ET, 1998, ANESTHESIOLOGY, V88, P310, DOI 10.1097/00000542-199802000-00007; Keld DB, 2000, ACTA ANAESTH SCAND, V44, P285, DOI 10.1034/j.1399-6576.2000.440311.x; LANZ E, 1992, ANAESTHESIST, V41, P231; Loo CC, 1999, ACTA ANAESTH SCAND, V43, P371, DOI 10.1034/j.1399-6576.1999.430402.x; Marshall SI, 1999, ANESTH ANALG, V88, P508, DOI 10.1097/00000539-199903000-00008; Pollock JE, 1999, ANESTHESIOLOGY, V90, P445, DOI 10.1097/00000542-199902000-00019; Pollock JE, 1996, ANESTHESIOLOGY, V84, P1361, DOI 10.1097/00000542-199606000-00012; RAPKIN AJ, 1992, ESSENTIALS OBSTET GY, P436; Runza M, 1998, ANESTH ANALG, V87, P1099; *SAS I INC, 1985, SAS US GUID; Tsen LC, 2001, REGION ANESTH PAIN M, V26, P52, DOI 10.1053/rapm.2001.18185; VANBELLE G, 1993, AM STAT, V47, P165, DOI 10.2307/2684968; WETCHLER BV, 1990, J REPROD MED, V35, P243	25	10	10	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2003	97	1					56	61		10.1213/01.ANE.0000068940.36040.54			6	Anesthesiology	Anesthesiology	695CZ	WOS:000183814700013	12818944				2020-06-30	J	Hess, PE; Vasudevan, A; Snowman, C; Pratt, SD				Hess, PE; Vasudevan, A; Snowman, C; Pratt, SD			Small dose bupivacaine-fentanyl spinal analgesia combined with morphine for labor	ANESTHESIA AND ANALGESIA			English	Article							RESPIRATORY DEPRESSION; INTRATHECAL FENTANYL; EPIDURAL ANALGESIA; RESPONSE RELATIONSHIP; SUFENTANIL; COMBINATION; OPIOIDS; EPINEPHRINE; PAIN	We investigated the duration of labor analgesia produced by a small dose of spinal bupivacaine/fentanyl alone or in combination with a small dose of morphine. Sixty parturients were enrolled in this placebo-controlled, double-blinded, randomized trial. All women received a spinal injection of 12.5 mug of fentanyl with 2 mg of bupivacaine. The morphine group (MBF) also received 125 mug of morphine; the placebo group (BF) received saline. Pain scores were <3 of 10 within 10 min of injection. The median duration of analgesia was similar between groups (89 min versus 84 min; P = not significant), and only 20% of the MBF group experienced prolonged analgesia. During subsequent epidural analgesia, the MBF group had a significantly lesser rate of breakthrough pain (0.15 +/- 0.14 episodes per hour versus 0.26 +/- 0.18 episodes per hour; P = 0.02). Also, during the first 24 h postpartum, the MBF group required significantly fewer medications (3.3 +/- 3.7 doses versus 4.7 +/- 3.5 doses; P = 0.04). Intrathecal injection of this small dose of bupivacaine/fentanyl produced a rapid onset of labor analgesia; the addition of a small dose of morphine did not significantly prolong analgesia, but it improved subsequent pain relief, as measured by the rate of breakthrough pain and postpartum medication requirements. This may provide a clinically useful means of improving intra- and postpartum pain relief.	Beth Israel Deaconess Med Ctr, Dept Anesthesiol & Crit Care, Boston, MA 02215 USA	Hess, PE (reprint author), Beth Israel Deaconess Med Ctr, Dept Anesthesiol & Crit Care, 330 Brookline Ave,St 308, Boston, MA 02215 USA.		Hess, Philip/A-8577-2013	Hess, Philip/0000-0002-1206-0102			Beilin Y, 2002, ANESTH ANALG, V94, P927, DOI 10.1097/00000539-200204000-00029; Birnbach DJ, 1999, ANESTH ANALG, V88, P971, DOI 10.1097/00000539-199905000-00001; BREEN TW, 1993, ANESTH ANALG, V77, P919; Bucklin BA, 2002, REGION ANESTH PAIN M, V27, P23, DOI 10.1053/rapm.2002.29111; CALDWELL LE, 1994, REGION ANESTH, V19, P2; Camann W, 1998, REGION ANESTH PAIN M, V23, P457, DOI 10.1016/S1098-7339(98)90027-X; Celeski D C, 1999, AANA J, V67, P239; Cohen SE, 2000, ANESTHESIOLOGY, V92, P387, DOI 10.1097/00000542-200002000-00019; EISENACH JC, 1991, ANESTHESIOLOGY, V75, P712, DOI 10.1097/00000542-199110000-00040; Fragneto RY, 2000, ANESTH ANALG, V90, P1175, DOI 10.1097/00000539-200005000-00033; FULLER JG, 1990, CAN J ANAESTH, V37, P636, DOI 10.1007/BF03006481; GRIECO WM, 1993, ANESTH ANALG, V77, P1149; HAYS RL, 1994, ANESTHESIOLOGY, V81, P511, DOI 10.1097/00000542-199408000-00032; Hepner DL, 2000, ANESTH ANALG, V91, P1560, DOI 10.1097/00000539-200012000-00051; Herman NL, 1999, ANESTH ANALG, V89, P378, DOI 10.1097/00000539-199908000-00024; Hess PE, 2001, ANESTH ANALG, V93, P414; Katsiris S, 1998, CAN J ANAESTH, V45, P880, DOI 10.1007/BF03012223; Lee BB, 1999, BRIT J ANAESTH, V83, P868, DOI 10.1093/bja/83.6.868; LEIGHTON BL, 1989, ANESTH ANALG, V69, P122; Palmer CM, 1999, ANESTHESIOLOGY, V90, P437, DOI 10.1097/00000542-199902000-00018; Palmer CM, 1998, ANESTHESIOLOGY, V88, P355, DOI 10.1097/00000542-199802000-00014; PALMER CM, 1991, ANESTHESIOLOGY, V74, P1153, DOI 10.1097/00000542-199106000-00029; Stocks GM, 2001, ANESTHESIOLOGY, V94, P593, DOI 10.1097/00000542-200104000-00011; Viscomi CM, 1997, ANESTH ANALG, V84, P1108, DOI 10.1097/00000539-199705000-00028; Yeh HM, 2001, ANESTH ANALG, V92, P665, DOI 10.1097/00000539-200103000-00022	25	20	20	4	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUL	2003	97	1					247	252		10.1213/01.ANE.0000066520.30763.B8			6	Anesthesiology	Anesthesiology	695CZ	WOS:000183814700044	12818975				2020-06-30	J	Eisenach, JC; Hood, DD; Curry, R; Shafer, SL				Eisenach, JC; Hood, DD; Curry, R; Shafer, SL			Cephalad movement of morphine and fentanyl in humans after intrathecal injection	ANESTHESIOLOGY			English	Article							BLOOD-FLOW; PHARMACOKINETICS; BUPIVACAINE; COMBINATION; SUFENTANIL; PULSATIONS; ANALGESIA; NARCOTICS; LUMBAR; SPREAD	Background: Despite decades of use, controversy remains regarding the extent and time course of cephalad spread of opioids in cerebrospinal fluid (CSF) after intrathecal injection. The purpose of this study was to examine differences between two often used opioids, morphine and fentanyl, in distribution in the CSF after intrathecal injection. Methods: Eight healthy volunteers received intrathecal injection of morphine (50 mug) plus fentanyl (50 mug) at a lower lumbar interspace. CSF was sampled through a needle in an upper lumbar interspace for 60-120 min. At the end of this time, a sample was taken from the lower lumbar needle, and both needles were withdrawn. CSF volume was determined by magnetic resonance imaging. Pharmacokinetic modeling was performed with NONMEM. Results: Morphine and fentanyl peaked in CSF at the cephalad needle at similar times (41 +/- 13 min for fentanyl, 57 +/- 12 min for morphine). The ratio of morphine to fentanyl in CSF at the cephalad needle increased with time, surpassing 2:1 by 36 min and 4:1 by 103 min. CSF concentrations did not correlate with weight, height, or lumbosacral CSF volume. The concentrations of morphine and fentanyl at both sampling sites were well described by a simple pharmacokinetic model. The individual model parameters did not correlate with the distance between the needles, CSF volume, patient height, or patient weight. Conclusions. Fentanyl is cleared more rapidly from CSF than morphine, although their initial distribution in the first hour after injection does not differ greatly. The pharmacokinetic model demonstrates that mixing is the primary determinant of early concentrations and is highly variable among individuals.	Wake Forest Univ, Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Ctr Study Pharmacol Plastic Presence Pain, Winston Salem, NC 27157 USA	Eisenach, JC (reprint author), Wake Forest Univ, Sch Med, Dept Anesthesiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Shafer, Steven/0000-0002-0289-7793	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-48085, R01 GM048085]		Baledent O, 2001, INVEST RADIOL, V36, P368, DOI 10.1097/00004424-200107000-00003; Bhadelia RA, 1997, NEURORADIOLOGY, V39, P258, DOI 10.1007/s002340050404; BROMAGE PR, 1982, ANESTHESIOLOGY, V56, P431, DOI 10.1097/00000542-198206000-00004; BROMAGE PR, 1980, PAIN, V9, P145, DOI 10.1016/0304-3959(80)90003-2; Carpenter RL, 1998, ANESTHESIOLOGY, V89, P24, DOI 10.1097/00000542-199807000-00007; COUSINS MJ, 1984, ANESTHESIOLOGY, V61, P276; DANGELO R, 1994, ANESTHESIOLOGY, V80, P1209, DOI 10.1097/00000542-199406000-00007; GOURLAY GK, 1989, PAIN, V38, P253, DOI 10.1016/0304-3959(89)90210-8; Henry-Feugeas MC, 2000, MAGN RESON IMAGING, V18, P387, DOI 10.1016/S0730-725X(99)00142-3; LEIGHTON BL, 1989, ANESTH ANALG, V69, P122; NORRIS MC, 1988, ANESTH ANALG, V67, P555; PALMER CM, 1991, ANESTHESIOLOGY, V74, P1153, DOI 10.1097/00000542-199106000-00029; RIGLER ML, 1991, ANESTHESIOLOGY, V75, P684, DOI 10.1097/00000542-199110000-00021; Shafer SL, 1998, ANESTHESIOLOGY, V89, P1074, DOI 10.1097/00000542-199811000-00007; Tanaka H, 1998, INVEST RADIOL, V33, P141, DOI 10.1097/00004424-199803000-00003; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018	16	25	29	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUL	2003	99	1					166	173		10.1097/00000542-200307000-00027			8	Anesthesiology	Anesthesiology	694PC	WOS:000183782100026	12826857				2020-06-30	J	Maxwell, LK; Thomasy, SM; Slovis, N; Kollias-Baker, C				Maxwell, LK; Thomasy, SM; Slovis, N; Kollias-Baker, C			Pharmacokinetics of fentanyl following intravenous and transdermal administration in horses	EQUINE VETERINARY JOURNAL			English	Article						horse; analgesia; opioids; pharmacokinetics; transdermal; absorption; Loo-Riegelman	ANALGESIA; DISPOSITION; EFFICACY; MORPHINE; PATCHES; PAIN	Reasons for performing study: Although fentanyl has been reported to cause CNS excitation in horses, a transdermal therapeutic system (TTS) containing this mu agonist has recently been used empirically in equine medicine to treat moderate to severe pain. A better understanding of the disposition of fentanyl following transdermal administration would facilitate the clinical use of TTS fentanyl to obtain analgesia in horses. Objectives: To determine the pharmacokinetics of fentanyl following i.v. and TTS patch administration in healthy, mature horses and to evaluate the tolerance of horses to TTS fentanyl administration. Methods: The pharmacokinetics of fentanyl in serum were assessed following a single i.v. dose, a single TTS dose, and multiple TTS doses in 6 healthy horses. Physical examinations, haematology and serum biochemistry analyses during transdermal fentanyl application were then performed to determine tolerance of continuous fentanyl administration. Results: Fentanyl was very rapidly and completely absorbed following a single TTS dose. Mean serum fentanyl concentrations consistent with analgesia in other species were reached by 1 h and maintained until 32 h after patch application. Similar steady state serum concentrations were obtained when multiple doses of TTS fentanyl were administered every 48 or 72 h over 8 or 9 days, with less fluctuation in serum concentrations during the 48 h dosing interval. Three horses exhibited brief (<12 h) episodes of increased body temperature; however, transdermal fentanyl administrations were not associated with other significant changes in haematology and biochemistry panels or physical examination findings. Conclusions and potential relevance: Although the pharmacodynamics of fentanyl have not been investigated fully in horses, transdermally-administered fentanyl exhibited a favourable pharmacokinetic profile without clinically relevant side effects and may be a useful analgesic in equine patients.	Univ Calif Davis, KL Maddy Equine Analyt Chem Lab, Sch Vet Med, Davis, CA 95616 USA; Hagyard Davidson McGee Associates, PSC, Lexington, KY 40511 USA	Maxwell, LK (reprint author), Univ Calif Davis, KL Maddy Equine Analyt Chem Lab, Sch Vet Med, Davis, CA 95616 USA.						BOWER S, 1981, J PHARM PHARMACOL, V33, P507, DOI 10.1111/j.2042-7158.1981.tb13849.x; Carroll GL, 1999, AM J VET RES, V60, P986; COMBIE J, 1979, P 3 INT S EQ MED CON, P311; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; FRINCKE JM, 1980, DRUG METAB DISPOS, V8, P425; Gibaldi M, 1982, PHARMACOKINETICS, P494; GOURLAY GK, 1995, PAIN, V61, P375, DOI 10.1016/0304-3959(94)00204-R; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Harvey-Clark CJ, 2000, LAB ANIM-UK, V34, P386, DOI 10.1258/002367700780387750; HENDERSON GL, 1981, P W PHARMACOL SOC, V24, P137; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; KAMERLING SG, 1985, GEN PHARMACOL, V16, P253, DOI 10.1016/0306-3623(85)90078-3; Kyles AE, 1996, AM J VET RES, V57, P715; Kyles AE, 1998, COMP CONT EDUC PRACT, V20, P721; LAM FC, 1985, J PHARM SCI, V74, P229, DOI 10.1002/jps.2600740229; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; MAMA KR, 1993, CAN J VET RES, V57, P106; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; MATTHEWS NS, 1997, P 6 INT C VET AN THE, P116; MONTEIRORIVIERE NA, 1990, J INVEST DERMATOL, V95, P582, DOI 10.1111/1523-1747.ep12505567; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Papich MG, 1997, SEMIN VET MED SURG, V12, P80, DOI 10.1016/S1096-2867(97)80005-9; Riviere JE, 2001, ADV DRUG DELIVER REV, V50, P175, DOI 10.1016/S0169-409X(01)00157-0; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; Sevarino FB, 1997, J CLIN ANESTH, V9, P173, DOI 10.1016/S0952-8180(97)00043-3; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; WAGNER JG, 1983, J PHARM SCI, V72, P838, DOI 10.1002/jps.2600720738; WECKMAN TJ, 1989, AM J VET RES, V50, P502; Wegner K., 2002, Proceedings of the 48th Annual Convention of the American Association of Equine Practitioners, Orlando, Florida, USA, 4-8 December 2002, P291; YAMAOKA K, 1978, J PHARMACOKINET BIOP, V6, P165, DOI 10.1007/BF01117450	32	41	44	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0425-1644	2042-3306		EQUINE VET J	Equine Vet. J.	JUL	2003	35	5					484	490		10.2746/042516403775600415			7	Veterinary Sciences	Veterinary Sciences	700NZ	WOS:000184119200011	12875327				2020-06-30	J	Jellish, WS; Sheikh, T; Baker, WH; Louie, EK; Slogoff, S				Jellish, WS; Sheikh, T; Baker, WH; Louie, EK; Slogoff, S			Hemodynamic stability, myocardial ischemia, and perioperative outcome after carotid surgery with remifentanil/propofol or isoflurane/fentanyl anesthesia	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						Total Intravenous Anesthesia; inhalational anesthesia; transesophageal echocardiography; carotid endarterectomy	POSTOPERATIVE NAUSEA; ARTERY SURGERY; ENDARTERECTOMY; PREVENTION; COMPLICATIONS; HALOTHANE	This study compares remifentanil/propofol (remi/prop) with isoflurane/fentanyl (iso/fen) anesthesia to determine which provides the greater hemodynamic stability, lesser myocardial ischemia, and morbidity with better postoperative outcomes after carotid endarterectomy. Sixty patients undergoing unilateral carotid endarterectomy were randomized to receive either a remi/prop or iso/fen anesthetic. Hemodynamic variables were recorded during the surgical procedure. In addition, transesophageal echocardiography was used to assess evidence of intraoperative regional wall motion abnormalities suggestive of cardiac ischemia. Emergence and extubation times, recovery from anesthesia, hemodynamic instability, nausea, vomiting, and pain in post anesthesia recovery, discharge delays, ICU admittance, hospital discharge, and preoperative and postoperative troponin levels were compared using appropriate statistical methods with P < 0.05 considered significant. The groups were demographically alike. Hemodynamic variables were similar during intubation and throughout surgery. Twenty-two percent of patients receiving iso/fen developed intraoperative regional wall motion abnormalities suggestive of ischemia, whereas no remi/prop patients had changes (P < 0.05). There was no difference in ST-T wave changes after surgery, and no patient had an elevation in troponin I levels. Postoperative variables were similar except that patients who received iso/fen had lower Stewart recovery scores during the first 15 minutes after post anesthesia care unit admission and a higher incidence of nausea and vomiting the day after surgery, whereas patients receiving remi/prop had discharge delays secondary to hypertension. ICU admittance, time to first void, oral intake, and time to hospital discharge were similar between the groups. At 9 times the cost of an iso/fen anesthesia technique, remi/prop offers little advantage over inhalational anesthesia for carotid endarterectomy.	Loyola Univ, Med Ctr, Dept Anesthesiol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Gen Vasc Surg, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Dept Cardiol, Maywood, IL 60153 USA	Jellish, WS (reprint author), Loyola Univ, Med Ctr, Dept Anesthesiol, 2160 S 1st Ave, Maywood, IL 60153 USA.						ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; ALLEN BT, 1994, J VASC SURG, V19, P834, DOI 10.1016/S0741-5214(94)70008-7; BECQUEMIN JP, 1991, J CARDIOVASC SURG, V32, P592; CORIAT P, 1984, ANESTHESIOLOGY, V61, P193, DOI 10.1097/00000542-198408000-00013; CORSON JD, 1987, ARCH SURG-CHICAGO, V122, P807; DAVIES MJ, 1992, ANAESTH INTENS CARE, V20, P161, DOI 10.1177/0310057X9202000207; DELANGE S, 1982, ANESTHESIOLOGY, V56, P112, DOI 10.1097/00000542-198202000-00006; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; Fiorani P, 1997, EUR J VASC ENDOVASC, V13, P37, DOI 10.1016/S1078-5884(97)80048-2; Gerhardt MA, 1998, J CLIN ANESTH, V10, P249, DOI 10.1016/S0952-8180(98)00017-8; JELLISH WS, 2000, OTOLARYNGOL HEAD NEC, V222, P222; MICHENFELDER JD, 1987, ANESTHESIOLOGY, V67, P336, DOI 10.1097/00000542-198709000-00010; MUCH WA, 1995, CAN J ANAESTH, V42, P577; ROBERTS R, 1994, CIRCULATION, V89, P872, DOI 10.1161/01.CIR.89.2.872; Rusch D, 1999, ANAESTHESIST, V48, P80, DOI 10.1007/s001010050671; SEBEL PS, 1982, ACTA ANAESTH SCAND, V26, P308, DOI 10.1111/j.1399-6576.1982.tb01772.x; Seeberger MD, 1997, ANESTH ANALG, V85, P1252, DOI 10.1097/00000539-199712000-00013; SLOGOFF S, 1989, ANESTHESIOLOGY, V70, P1989; SMITH JS, 1988, ANESTHESIOLOGY, V69, P846, DOI 10.1097/00000542-198812000-00008; STEWARD DJ, 1975, CAN ANAESTH SOC J, V22, P111, DOI 10.1007/BF03004827; Visser K, 2001, ANESTHESIOLOGY, V95, P616, DOI 10.1097/00000542-200109000-00012; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; WEISKOPF RB, 1993, ANESTHESIOLOGY, V79, P1413, DOI 10.1097/00000542-199312000-00033; WILLIE HJ, 1996, J CARDIOTHOR VASC AN, V10, P928	24	12	16	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JUL	2003	15	3					176	184		10.1097/00008506-200307000-00004			9	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	697HF	WOS:000183935900002	12826964				2020-06-30	J	Godambe, SA; Elliot, V; Matheny, D; Pershad, J				Godambe, SA; Elliot, V; Matheny, D; Pershad, J			Comparison of propofol/fentanyl versus ketamine/midazolam for brief orthopedic procedural sedation in a pediatric emergency department	PEDIATRICS			English	Article; Proceedings Paper	Meeting of the American-Academy-of-Pediatrics	OCT 19-25, 2001	SAN FRANCISCO, CALIFORNIA	Amer Acad Pediat		propofol; fentanyl; ketamine; midazolam; procedural sedation	INTENSIVE-CARE UNIT; KETAMINE SEDATION; NON-ANESTHESIOLOGISTS; INTRAVENOUS KETAMINE; PROPOFOL ANESTHESIA; PRACTICE GUIDELINES; CONTROLLED TRIAL; DOUBLE-BLIND; MIDAZOLAM; CHILDREN	Purpose. To compare the effectiveness of 2 medication regimens, propofol/fentanyl (P/F) and ketamine/midazolam (K/M), for brief orthopedic emergency department procedural sedation. This study was powered to compare recovery times (RT) and procedural distress as measured by the Observational Score of Behavioral Distress-revised (OSBD-r; range: 0-23.5 with 23.5 representing maximal distress). Methods. We conducted a prospective, partially-blinded controlled comparative trial comparing intravenous P/F with K/M in a convenience sample of 113 patients aged 3 to 18 years old undergoing orthopedic procedural sedation. All medications were administered by the intermittent intravenous bolus method. An independent sedation nurse recorded total sedation time and RT. Effectiveness was measured using 6 parameters: 1) patient distress as assessed by independent blinded observers after videotape review using the OSBD-r; 2) orthopedic satisfaction score (Likert scale 1-5); 3) sedation nurse satisfaction score (Likert 1-5); 4) parental perception of procedural pain using a 0 to 100 mm Visual Analog Scale with the upper limit being "most pain"; 5) patient recall of the procedure; and 6) 1 to 3 week follow-up. Results. RT and total sedation time were significantly less in the P/F group than in the K/M group (33.4 minutes vs 23.2 minutes). The mean OSBD-r scores during manipulation were 0.084 and 0.278 for the K/M and P/F groups, respectively. Although this difference was statistically significant (95% confidence interval for the mean difference -0.34 to -0.048), both regimens were successful in keeping the scores low. There was no statistical difference between the groups in the other measures of effectiveness. There was a statistically significant difference between the groups in the occurrence of desaturation and late side effects. Conclusions. RT with P/F is shorter than with K/M. P/F is comparable to K/M in reducing procedural distress associated with painful orthopedic procedures in the pediatric emergency department. Although propofol has a greater potential of respiratory depression and airway obstruction as compared with ketamine, it offers some unique advantages including a quicker offset and smoother recovery profile.	Lebonheur Childrens Hosp & Med Ctr, Div Pediat Emergency Med, Memphis, TN USA; Vanderbilt Univ, Child Dev Ctr, Nashville, TN USA; Kosair Childrens Hosp, Div Pediat Emergency Med, Louisville, KY USA	Godambe, SA (reprint author), Univ Louisville, Div Pediat Emergency Med, 571 S Floyd St,Suite 300, Louisville, KY 40202 USA.						BRYSON HM, 1995, DRUGS, V50, P513, DOI 10.2165/00003495-199550030-00008; CLARKSON K, 1993, CHEST, V104, P1029, DOI 10.1378/chest.104.4.1029; Dial S, 2001, PEDIATR EMERG CARE, V17, P414, DOI 10.1097/00006565-200112000-00004; Fatovich DM, 1999, J EMERG MED, V17, P223, DOI 10.1016/S0736-4679(98)00157-7; Glover ML, 1996, J PEDIAT HEMATOL ONC, V18, P377, DOI 10.1097/00043426-199611000-00008; Green SM, 2002, ACAD EMERG MED, V9, P35, DOI 10.1197/aemj.9.1.35; Green SM, 1999, ANN EMERG MED, V34, P492, DOI 10.1016/S0196-0644(99)80051-1; GREEN SM, 1990, ANN EMERG MED, V19, P1024, DOI 10.1016/S0196-0644(05)82568-5; Green SM, 1998, ACAD EMERG MED, V5, P971, DOI 10.1111/j.1553-2712.1998.tb02773.x; GREEN SM, 1990, ANN EMERG MED, V19, P1033, DOI 10.1016/S0196-0644(05)82569-7; Gross JB, 1996, ANESTHESIOLOGY, V84, P459; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; Havel CJ, 1999, ACAD EMERG MED, V6, P989, DOI 10.1111/j.1553-2712.1999.tb01180.x; HERTZOG J, 1999, PEDIATRICS, V103, P1; Hertzog JH, 2000, PEDIATRICS, V106, P742, DOI 10.1542/peds.106.4.742; Hoffman GM, 2002, PEDIATRICS, V109, P236, DOI 10.1542/peds.109.2.236; JAY SM, 1984, J CONSULT CLIN PSYCH, V52, P1106, DOI 10.1037/0022-006X.52.6.1106; JAY SM, 1983, [No title captured], V2, P133, DOI DOI 10.1037/0278-6133.2.2.133; KAIN ZN, 1994, ANESTH ANALG, V79, P1102; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Kennedy RM, 2000, ANN EMERG MED, V35, P297, DOI 10.1016/S0196-0644(00)70085-0; Kennedy RM, 1998, PEDIATRICS, V102, P956, DOI 10.1542/peds.102.4.956; LILBURN JK, 1978, ANAESTHESIA, V33, P307, DOI 10.1111/j.1365-2044.1978.tb12412.x; LOH L, 1972, CAN ANAESTH SOC J, V19, P421, DOI 10.1007/BF03005966; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; Marcus B, 1993, J Am Soc Echocardiogr, V6, P205; MARTIN TM, 1993, ANESTH ANALG, V76, P144; Marx CM, 1997, J CLIN ONCOL, V15, P94, DOI 10.1200/JCO.1997.15.1.94; Miner JR, 2002, ACAD EMERG MED, V9, P275, DOI 10.1197/aemj.9.4.275; OHARA M, 1987, J PEDIATR ORTHOPED, V7, P78, DOI 10.1097/01241398-198701000-00016; PATTERSON KW, 1991, BRIT J ANAESTH, V67, P108, DOI 10.1093/bja/67.1.108; Pepperman ML, 1997, PAEDIATR ANAESTH, V7, P143, DOI 10.1046/j.1460-9592.1997.d01-56.x; Portney LG, 2000, FDN CLIN RES APPL PR, P560; SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304-3959(76)90113-5; Seigler Robert S., 2001, Pediatr Crit Care Med, V2, P20, DOI 10.1097/00130478-200101000-00005; Sherwin TS, 2000, ANN EMERG MED, V35, P229, DOI 10.1016/S0196-0644(00)70073-4; Slonim AD, 1998, CRIT CARE MED, V26, P1900, DOI 10.1097/00003246-199811000-00036; TOBIAS J, 1997, CLIN PEDIATR, V5, P291; Vardi A, 2002, CRIT CARE MED, V30, P1231, DOI 10.1097/00003246-200206000-00010; Wathen JE, 2000, ANN EMERG MED, V36, P579, DOI 10.1067/mem.2000.111131; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007	41	116	120	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUL	2003	112	1					116	123		10.1542/peds.112.1.116			8	Pediatrics	Pediatrics	696WR	WOS:000183911000033	12837876				2020-06-30	J	Kati, I; Demirel, CB; Huseyinoglu, UA; Silay, E; Yagmur, C; Coskuner, I				Kati, I; Demirel, CB; Huseyinoglu, UA; Silay, E; Yagmur, C; Coskuner, I			Comparison of propofol and sevoflurane for laryngeal mask airway insertion	TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						propofol; sevoflurane; laryngeal mask; tidal volume technique	INHALATION INDUCTION; RECOVERY CHARACTERISTICS; OUTPATIENT ANESTHESIA; NITROUS-OXIDE; ADULTS; MAINTENANCE; THIOPENTONE; VENTILATION; ISOFLURANE	In this study, we compared haemodynamic changes, laryngeal mask airway (LMA) insertion time, and complications in patients anesthetized by inhalation of sevoflurane with those of intravenous induction with propofol. One hundred patients, aged between 20-40 years were enrolled in this study. Group I received propofol (2.5 mg/kg IV) and group 2 received sevoflurane (6% + 50% N2O + 50% O-2) by inhalation using the tidal volume technique. LMA insertion time was found to be significantly longer in sevoflurane group than in propofol group. Mean arterial blood pressure was significantly lower within each group after induction in comparison to before induction values. In both groups, the LMA was successfully inserted in all patients. The quality of anaesthesia according to patients was significantly higher in the propofol group (80%) than in sevoflurane group (30%). Odor perception was significantly higher in sevoflurane group (84%) than in propofol group (38%). Apnoea was significantly higher in propofol group (40%) than in sevoflurane group (0%). Sevoflurane is an alternative to propofol for induction of anaesthesia and has a lower incidence of apnoea. Other complication rates are not higher than which propofol but the longer duration of induction time is a disadvantage. (C) 2003 Tohoku University Medical Press.	Yuzuncu Yil Univ, Tip Fak, Anesteziyol Ve Reanimasyon Anabilim Dali, Dept Anesthesiol, TR-65300 Van, Turkey	Kati, I (reprint author), Yuzuncu Yil Univ, Tip Fak, Anesteziyol Ve Reanimasyon Anabilim Dali, Dept Anesthesiol, TR-65300 Van, Turkey.	katiismail@yahoo.com					Bapat P, 1996, CAN J ANAESTH, V43, P564, DOI 10.1007/BF03011767; Fleischmann E, 1999, ANESTH ANALG, V88, P930, DOI 10.1097/00000539-199904000-00046; FREDMAN B, 1995, ANESTH ANALG, V81, P823, DOI 10.1097/00000539-199510000-00028; Hall JE, 1997, ANAESTHESIA, V52, P410, DOI 10.1111/j.1365-2044.1997.091-az0086.x; Jellish WS, 1996, ANESTH ANALG, V82, P479, DOI 10.1097/00000539-199603000-00009; Joo HS, 2000, ANESTH ANALG, V91, P213, DOI 10.1097/00000539-200007000-00040; Keller C, 2001, ANAESTHESIST, V50, P187, DOI 10.1007/s001010050987; Molloy ME, 1999, CAN J ANAESTH, V46, P322, DOI 10.1007/BF03013222; Muzi M, 1996, ANESTHESIOLOGY, V85, P536, DOI 10.1097/00000542-199609000-00012; NATHANSON MH, 1995, ANESTH ANALG, V81, P1186, DOI 10.1097/00000539-199512000-00012; Philip BK, 1999, ANESTH ANALG, V89, P623, DOI 10.1097/00000539-199909000-00014; SCANLON P, 1993, CAN J ANAESTH, V40, P816, DOI 10.1007/BF03009250; Sloan MH, 1996, ANESTH ANALG, V82, P528, DOI 10.1097/00000539-199603000-00018; Smith CE, 2000, J CLIN ANESTH, V12, P392, DOI 10.1016/S0952-8180(00)00177-X; Smith I, 1996, BRIT J ANAESTH, V76, P435; SMITH I, 1992, ANESTH ANALG, V74, P253, DOI 10.1213/00000539-199202000-00015; Smith I, 1999, BRIT J ANAESTH, V83, P564; Thwaites A, 1997, BRIT J ANAESTH, V78, P356; Ti LK, 1999, ANESTH ANALG, V88, P908, DOI 10.1097/00000539-199904000-00041; YURINO M, 1992, ANAESTHESIA, V47, P946, DOI 10.1111/j.1365-2044.1992.tb03195.x; YURINO M, 1993, ANESTH ANALG, V76, P598	21	8	13	0	0	TOHOKU UNIV MEDICAL PRESS	SENDAI	2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN	0040-8727	1349-3329		TOHOKU J EXP MED	Tohoku J. Exp. Med.	JUL	2003	200	3					111	118		10.1620/tjem.200.111			8	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	723TV	WOS:000185448400001	14521253	Bronze			2020-06-30	J	Kornick, CA; Santiago-Palma, J; Schulman, G; O'Brien, PC; Weigand, S; Payne, R; Manfredi, PL				Kornick, CA; Santiago-Palma, J; Schulman, G; O'Brien, PC; Weigand, S; Payne, R; Manfredi, PL			A safe and effective method for converting patients from transdermal to intravenous fentanyl for the treatment of acute cancer-related pain	CANCER			English	Article						pain; fentanyl; transdermal; opioids; patient-controlled analgesia	OPIOID ROTATION; CONTROLLED ANALGESIA; PHARMACOKINETICS; METHADONE; MORPHINE; INFUSION	BACKGROUND. The delayed effects (12-16 hours) of transdermal fentanyl make dose titration difficult during acute exacerbations of cancer pain. Patients at the authors' institution routinely are switched from transdermal to intravenous (IV) fentanyl using a 1:1 (transdermal:IV) conversion during severe episodes of pain. METHODS. The authors evaluated nine consecutive hospitalized patients with cancer who had severe pain for up to 6 days following the conversion from transdermal to IV fentanyl. Pain intensity was rated using an 11-point (0-10) verbal numeric rating scale (NRS). All 9 patients initially reported their pain intensity with movement as greater than or equal to 8 during treatment with transdermal fentanyl. Eight patients initially reported their pain at rest as greater than or equal to 8. In each patient, all transdermal patches were removed, and a continuous infusion (0) delivering IV fentanyl at the same hourly rate was initiated simultaneously. Demand boluses of IV fentanyl equivalent in dosage to 50-100% of the Cl rate remained available by patient-controlled analgesia (PCA). Pain intensity (0-10), sedation (0-3), and hourly fentanyl requirements (micrograms per hour) were assessed and recorded immediately prior to patch removal and at least once daily after the initiation of IV fentanyl. The CI and demand boluses were titrated whenever necessary on the basis of pain intensity and supplemental PCA use. RESULTS. All 9 patients reported mild levels (less than or equal to 4) of pain at rest within 5 days. The median time to achieve mild levels of pain at rest was 1.5 days. Six patients achieved mild levels of pain with movement within 3 days. Three patients never achieved mild levels of pain with movement while receiving IV fentanyl. No serious side effects were reported. CONCLUSIONS. The conversion from transdermal to IV fentanyl can be accomplished safely and effectively using a 1:1 (transdermal:IV) conversion during acute exacerbations of cancer pain. (C) 2003 American Cancer Society.	Mem Sloan Kettering Canc Ctr, Dept Neurol, Pain & Palliat Care Serv, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pharmacol, New York, NY 10021 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA	Kornick, CA (reprint author), Riverside Spine & Pain Phys, P-L,4339 Roosevelt Blvd,Suite 4-5, Jacksonville, FL 32210 USA.				NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA09461-16]		Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Fitzgibbon DR, 1997, PAIN, V73, P259, DOI 10.1016/S0304-3959(97)00118-8; GALER BS, 1992, PAIN, V49, P87, DOI 10.1016/0304-3959(92)90192-E; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; GUPTA SK, 1992, [No title captured], V7, P17; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; KERR IG, 1988, ANN INTERN MED, V108, P554, DOI 10.7326/0003-4819-108-4-554; Kornick CA, 2001, CANCER, V92, P3056, DOI 10.1002/1097-0142(20011215)92:12<3056::AID-CNCR10166>3.0.CO;2-H; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; PAYNE R, 1992, J PAIN SYMPTOM MA S3, V7, P40; Ripamonti C, 1997, Oncology (Williston Park), V11, P373; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008	13	12	12	0	1	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0008-543X			CANCER	Cancer	JUN 15	2003	97	12					3121	3124		10.1002/cncr.11457			4	Oncology	Oncology	686WC	WOS:000183343100026	12784350				2020-06-30	J	Kararmaz, A; Kaya, S; Turhanoglu, S; Ozyilmaz, MA				Kararmaz, A; Kaya, S; Turhanoglu, S; Ozyilmaz, MA			Low-dose bupivacaine-fentanyl spinal anaesthesia for transurethral prostatectomy	ANAESTHESIA			English	Article						anaesthesia : elderly, spinal, fentanyl; surgery : TURP	HYPERBARIC BUPIVACAINE; INTRATHECAL FENTANYL; PROLONGING RECOVERY; ANESTHESIA; HYPOTENSION; BLOCK; LIDOCAINE; DURATION; SURGERY; REPAIR	We evaluated the effect of low-dose bupivacaine plus fentanyl administered intrathecally in elderly patients undergoing transurethral prostatectomy. Patients were randomly assigned to one of two groups. Group F received plain bupivacaine 4 mg with 25 mug of fentanyl and sterile water to a total of 1.5 ml, and Group B received only 0.5% plain bupivacaine 7.5 mg for spinal anaesthesia. Sensory block was adequate for surgery in all patients. The mean level of motor block was higher and the duration of motor block was longer in Group B (p<0.0001). Hypotension and shivering were significantly more common in Group B (p<0.05). The addition of fentanyl 25 mug to plain bupivacaine 4 mg provides adequate analgesia for transurethral prostatectomy with fewer side-effects in elderly patients when compared with the conventional dose of bupivacaine.	Dicle Univ Hosp, Dept Anaesthesiol, TR-21280 Diyarbakir, Turkey	Kararmaz, A (reprint author), Dicle Univ Hosp, Dept Anaesthesiol, TR-21280 Diyarbakir, Turkey.	alper@dicle.edu.tr					BEERS RA, 1994, CAN J ANAESTH, V41, P807, DOI 10.1007/BF03011588; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BIBOULET P, 1993, REGION ANESTH, V18, P170; Boucher C, 2001, CAN J ANAESTH, V48, P466, DOI 10.1007/BF03028310; Chen TY, 2001, ANESTH ANALG, V92, P1020; Chow T C, 1994, Acta Anaesthesiol Sin, V32, P165; COE AJ, 1990, ANAESTHESIA, V45, P241, DOI 10.1111/j.1365-2044.1990.tb14696.x; CRITCHLEY LAH, 1994, BRIT J ANAESTH, V72, P151, DOI 10.1093/bja/72.2.151; Critchley LAH, 1996, ANAESTHESIA, V51, P1139, DOI 10.1111/j.1365-2044.1996.tb15051.x; FernandezGalinski D, 1996, ANESTH ANALG, V83, P537, DOI 10.1097/00000539-199609000-00017; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; Kang F C, 1998, Acta Anaesthesiol Sin, V36, P207; Kuusniemi KS, 2000, ANESTH ANALG, V91, P1452, DOI 10.1097/00000539-200012000-00029; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; MALHOTRA V, 2000, ANESTHESIA, P1949; Martyr JW, 2001, ANAESTH INTENS CARE, V29, P501, DOI 10.1177/0310057X0102900509; Rooke GA, 1997, ANESTH ANALG, V85, P99, DOI 10.1097/00000539-199707000-00018; Sarvela PJ, 1999, ANESTH ANALG, V89, P1257, DOI 10.1213/00000539-199911000-00033; TEJWANI GA, 1992, ANESTH ANALG, V74, P726; Vaghadia H, 1997, ANESTH ANALG, V84, P59, DOI 10.1097/00000539-199701000-00011; VARRASSI G, 1992, ANAESTHESIA, V47, P558, DOI 10.1111/j.1365-2044.1992.tb02323.x; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019	23	44	51	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	JUN	2003	58	6					526	530		10.1046/j.1365-2044.2003.03153.x			5	Anesthesiology	Anesthesiology	681FC	WOS:000183025400004	12846615				2020-06-30	J	Lattermann, R; Wachter, U; Georgieff, M; Goertz, A; Schricker, T				Lattermann, R; Wachter, U; Georgieff, M; Goertz, A; Schricker, T			Catabolic stress response during and after abdominal surgery. Comparison between two anaesthesia procedures	ANAESTHESIST			German	Article						midazolam; fentanyl; isoflurane; glucose; urea	HYPERGLYCEMIC RESPONSE; MIDAZOLAM; GLUCOSE; ISOFLURANE; METABOLISM; ENDOCRINE; ALFENTANIL	Background. The purpose of the study was to investigate the effect of modified neuroleptanesthesia (NLA) with fentanyl/midazolam on the catabolic responses during and after abdominal surgery. Methods. A total of 13 patients undergoing cystoprostatectomy received either modified NLA (n=7) or inhaled anesthesia with isoflurane (ISO, n=6). Glucose and urea production rates were assessed before, during and 1 day after the operation. Plasma concentrations of glucose, urea, lactate, insulin, glucagon and cortisol were also determined. Results. In contrast to isoflurane anesthesia, modified NLA prevented an increase in plasma glucose concentration and glucose production during (P<0.05), but not after surgery. There were no differences in perioperative urea production rates or plasma concentrations of urea, insulin, glucagon and lactate between the two groups. Modified NLA suppressed the intraoperative increase in plasma cortisol concentration as observed in the ISO group (P<0.05). Conclusion. Modified NLA inhibits the increase in plasma glucose concentration and glucose production as seen during isoflurane anesthesia. However, NLA does not influence the catabolic response on the first postoperative day.	McGill Univ, Dept Anesthesia, Montreal, PQ H3A 1A1, Canada; Klinikum Univ Regensburg, Anasthesiol Klin, Regensburg, Germany; Univ Ulm, Anasthesiol Klin, D-89069 Ulm, Germany; St Marien Krankenhaus, Abt Anasthesiol, Ludwigshafen, Germany	Schricker, T (reprint author), McGill Univ, Royal Victoria Hosp, Dept Anesthesia, Room S5-05,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.						ADAMS HA, 1988, ANAESTHESIST, V37, P224; BAGDADE JD, 1974, DIABETES, V23, P9, DOI 10.2337/diab.23.1.9; Chandramouli V, 1997, AM J PHYSIOL-ENDOC M, V273, pE1209; CROZIER TA, 1992, EUR J ANAESTH, V9, P55; CROZIER TA, 1987, ANESTHESIOLOGY, V66, P628, DOI 10.1097/00000542-198705000-00006; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; DESBOROUGH JP, 1991, BRIT J ANAESTH, V67, P390, DOI 10.1093/bja/67.4.390; GIESECKE K, 1988, BRIT J ANAESTH, V61, P575, DOI 10.1093/bja/61.5.575; Gruber EM, 2001, ANESTH ANALG, V92, P882; HORBER FF, 1990, ANESTHESIOLOGY, V73, P82, DOI 10.1097/00000542-199007000-00013; HOSTETTER MK, 1990, DIABETES, V39, P271, DOI 10.2337/diabetes.39.3.271; KEHLET H, 1998, NEURAL BLOCKADE CLIN, P129; Kwoun MO, 1997, JPEN-PARENTER ENTER, V21, P91, DOI 10.1177/014860719702100291; Lattermann R, 2002, ANESTHESIOLOGY, V97, P374, DOI 10.1097/00000542-200208000-00014; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; LUND J, 1986, BRIT J ANAESTH, V58, P851, DOI 10.1093/bja/58.8.851; MOLLER IW, 1985, BRIT J ANAESTH, V57, P591, DOI 10.1093/bja/57.6.591; NILSSON A, 1988, ACTA ANAESTH SCAND, V32, P379, DOI 10.1111/j.1399-6576.1988.tb02749.x; OWEN OE, 1981, J CLIN INVEST, V68, P240, DOI 10.1172/JCI110240; OYAMA T, 1975, CAN ANAESTH SOC J, V22, P696, DOI 10.1007/BF03013318; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; Schricker T, 2000, ANESTH ANALG, V90, P450, DOI 10.1097/00000539-200002000-00039; Schricker T, 1998, CLIN INTENSIVE CARE, V9, P118; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WOLFE RR, 1993, CLIN NUTR PARENTERAL, P113	25	5	6	0	0	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0003-2417			ANAESTHESIST	Anaesthesist	JUN	2003	52	6					500	506		10.1007/s00101-003-0511-1			7	Anesthesiology	Anesthesiology	708TY	WOS:000184586600004	12835870				2020-06-30	J	Recart, A; Issioui, T; White, PF; Klein, K; Watcha, MF; Stool, L; Shah, M				Recart, A; Issioui, T; White, PF; Klein, K; Watcha, MF; Stool, L; Shah, M			The efficacy of celecoxib premedication on postoperative pain and recovery times after ambulatory surgery: A dose-ranging study	ANESTHESIA AND ANALGESIA			English	Article							DOUBLE-BLIND; ROFECOXIB; KETOROLAC; ACETAMINOPHEN; TONSILLECTOMY; PARACETAMOL; COMBINATION; INHIBITORS; MANAGEMENT; ANALGESIA	Recently, the Food and Drug Administration increased the celecoxib dosage recommendation from 200 Ing to 400 mg for acute pain management. No studies have directly compared the analgesic efficacy of different doses of celecoxib for the prevention of postoperative pain. In this prospective, double-blinded, placebo-controlled study, we compared oral celecoxib 200 mg to 400 mg when administered for premedication of outpatients undergoing minor ear-nose-throat surgery. A total of 93 healthy outpatients were assigned to 1 of 3 study groups: control (placebo; n = 30), celecoxib 200 Ing (n = 30), or celecoxib 400 mg (n = 33). The study drug was given orally 3045 min before surgery, and all patients received a standardized general anesthetic technique. During the postoperative period, pain scores (0-10), recovery times, the need for rescue analgesics, quality of recovery (0-100), patient satisfaction with pain management (0-100), and side effects were recorded. Pain was assessed at 30-min intervals using a verbal rating scale, with 0 = no pain to 10 = worst pain imaginable, in the postanesthesia care unit and day surgery unit recovery areas and at 24 h after surgery. Celecoxib 400 Ing was significantly more effective than 200 Ing (and placebo) in reducing postoperative pain. Both celecoxib 200 Ing and 400 Ing were more effective than placebo in reducing the postoperative fentanyl requirement (74 +/- 67 mug and 56 +/- 62 mug versus 120 +/- 86 mug, respectively). The larger dose of celecoxib significantly reduced the percentage of patients with severe pain at discharge (6% versus 37% and 30% in the celecoxib 200 mg and control groups, respectively). The median number of doses of oral analgesic medication after discharge was also significantly reduced in the celecoxib 400 Ing group (0 versus 2 and 2 in the celecoxib 200 Ing and control groups, respectively). However, no differer ces were found among the three study groups with respect to recovery times and secondary outcome variables (e.g., patient satisfaction and quality of recovery). We conclude that oral premedication with celecoxib 400 mg was more effective than 200 Ing in reducing severe postoperative pain and the need for rescue analgesic medication in the postoperative period.	Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA; Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA	White, PF (reprint author), Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	paul.white@utsouthwestern.edu					Anderson B, 2001, ANESTH ANALG, V93, P1626, DOI 10.1097/00000539-200112000-00073; Davies NM, 2000, CLIN PHARMACOKINET, V38, P225, DOI 10.2165/00003088-200038030-00003; Feldman HI, 1997, ANN INTERN MED, V126, P193, DOI 10.7326/0003-4819-126-3-199702010-00003; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Forrest JB, 2002, BRIT J ANAESTH, V88, P227, DOI 10.1093/bja/88.2.227; GUNTER JB, 1995, ANESTH ANALG, V81, P1136, DOI 10.1097/00000539-199512000-00004; Hyllested M, 2002, BRIT J ANAESTH, V88, P199, DOI 10.1093/bja/88.2.199; Issioui T, 2002, ANESTHESIOLOGY, V97, P931, DOI 10.1097/00000542-200210000-00027; Issioui T, 2002, ANESTH ANALG, V94, P1188, DOI 10.1097/00000539-200205000-00025; Malmstrom K, 1999, CLIN THER, V21, P1653, DOI 10.1016/S0149-2918(99)80045-9; Pickering AE, 2002, BRIT J ANAESTH, V88, P72, DOI 10.1093/bja/88.1.72; Reuben SS, 2000, ANESTH ANALG, V91, P1221, DOI 10.1097/00000539-200011000-00032; RUSY LM, 1995, ANESTH ANALG, V80, P226, DOI 10.1097/00000539-199502000-00004; SOUTER AJ, 1994, ANESTH ANALG, V79, P1178; White PF, 2002, ANESTH ANALG, V94, P577, DOI 10.1097/00000539-200203000-00019; Zarate E, 2000, ANESTH ANALG, V90, P1352, DOI 10.1097/00000539-200006000-00017	16	43	48	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2003	96	6					1631	1635		10.1213/01.ANE.0000062526.60681.7B			5	Anesthesiology	Anesthesiology	683LB	WOS:000183148900015	12760986				2020-06-30	J	Iwakiri, H; Nagata, O; Matsukawa, T; Ozaki, M; Sessler, DI				Iwakiri, H; Nagata, O; Matsukawa, T; Ozaki, M; Sessler, DI			Effect-site concentration of propofol for recovery of consciousness is virtually independent of fentanyl effect-site concentration	ANESTHESIA AND ANALGESIA			English	Article							AWAKENING CONCENTRATION; HEMODYNAMIC-RESPONSES; BLOOD-CONCENTRATION; ANESTHESIA; SEVOFLURANE; INFUSION; INCISION	Fentanyl reduces the amount of propofol necessary to prevent responses to surgical stimuli. However, opioids have relatively little effect on consciousness. We, therefore, tested the hypothesis that fentanyl minimally alters the effect-site concentration of propofol associated with awakening. Fifty women having gynecologic laparotomy with propofol anesthesia were randomly allocated into the following target effect-site fentanyl concentrations: 0.8, 1.0, 1.4, 2.0, and 3.0 ng/mL. Fentanyl was continued at the designated rate through the initial postoperative phase. The propofol effect-site concentration associated with eye opening in response to verbal command was regarded as the awakening concentration. The estimated propofol effect-site concentrations at awakening did not differ significantly among the groups and were 1.9 +/- 0.5 mug/mL, with a fentanyl effect-site concentration of 0.8 ng/mL; 1.6 +/- 0.4 mug/mL with 1.0 ng/mL of fentanyl; 1.6 +/- 0.2 mug/mL with 1.4 ng/mL of fentanyl; 1.7 +/- 0.4 mug/mL with 2.0 ng/mL of fentanyl; and 1.6 +/- 0.34 mug/mL with 3.0 ng/mL of fentanyl (mean +/- SD). Seventy percent of the subjects in the 0.8 ng/mL fentanyl group spontaneously complained of pain, whereas none of the patients in the 2 or 3 ng/mL groups did. Five (56%) of 9 women in the 3 ng/mL group had a postoperative respiratory rate <6 breaths/min. Heart rate in one of these women decreased to <40 bpm. These data suggest that the optimal fentanyl effect-site concentration in patients recovering from gynecologic laparoscopy is between 1.4 and 2.0 ng/mL.	Tokyo Womens Med Univ, Dept Anesthesiol, Tokyo 1628666, Japan; Yamanashi Med Univ, Dept Anesthesiol, Yamanashi, Japan; Univ Louisville, Dept Anesthesiol & Pharmacol, OUTCOMES RES Inst, Louisville, KY 40292 USA; Univ Vienna, Ludwig Boltzmann Inst, Vienna, Austria	Ozaki, M (reprint author), Tokyo Womens Med Univ, Dept Anesthesiol, Tokyo 1628666, Japan.		Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077; Ozaki, Makoto/0000-0001-7841-6661	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 58273]		BENETT WRJ, 1976, SCI ENG PROBLEM SOLV; BOWDLE TA, 1989, ANESTHESIOLOGY, V70, P26, DOI 10.1097/00000542-198901000-00007; Doufas AG, 2001, ANESTHESIOLOGY, V94, P585, DOI 10.1097/00000542-200104000-00010; EGER EI, 1971, ANESTHESIOLOGY, V35, P552, DOI 10.1097/00000542-197111000-00023; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; KATOH T, 1993, CAN J ANAESTH, V40, P825, DOI 10.1007/BF03009252; KATOH T, 1994, BRIT J ANAESTH, V73, P322, DOI 10.1093/bja/73.3.322; Kazama T, 1997, ANESTHESIOLOGY, V87, P213, DOI 10.1097/00000542-199708000-00007; LESLIE K, 1995, ANESTH ANALG, V81, P1269, DOI 10.1097/00000539-199512000-00025; Leslie K, 1996, ANESTHESIOLOGY, V84, P52, DOI 10.1097/00000542-199601000-00006; MARSH B, 1991, BRIT J ANAESTH, V67, P41, DOI 10.1093/bja/67.1.41; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; Nagata O, 1998, Masui, V47, P1246; ROIZEN MF, 1981, ANESTHESIOLOGY, V54, P390, DOI 10.1097/00000542-198105000-00008; SHAFER SL, 1990, ANESTHESIOLOGY, V73, P1091, DOI 10.1097/00000542-199012000-00005; SMITH C, 1994, ANESTHESIOLOGY, V81, P820, DOI 10.1097/00000542-199410000-00008; SPLINTER WM, 1989, CAN J ANAESTH, V36, P370, DOI 10.1007/BF03005332; TELFORD RJ, 1992, ANESTH ANALG, V75, P523; Vuyk J, 1997, ANESTHESIOLOGY, V87, P1549, DOI 10.1097/00000542-199712000-00033; Woodhouse A, 2000, REGION ANESTH PAIN M, V25, P259, DOI 10.1016/S1098-7339(00)90008-7	20	16	21	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2003	96	6					1651	1655		10.1213/01.ANE.0000062772.28479.2B			5	Anesthesiology	Anesthesiology	683LB	WOS:000183148900019	12760990				2020-06-30	J	Sakamoto, T; Kawaguchi, M; Kakimoto, M; Inoue, S; Takahashi, M; Furuya, H				Sakamoto, T; Kawaguchi, M; Kakimoto, M; Inoue, S; Takahashi, M; Furuya, H			The effect of hypothermia, on myogenic motor-evoked potentials to electrical stimulation with a single pulse and a train of pulses under propofol/ketamine/fentanyl anesthesia in rabbits	ANESTHESIA AND ANALGESIA			English	Article							SPINAL-CORD HYPOTHERMIA; AORTIC-ANEURYSM REPAIR; NITROUS-OXIDE; KETAMINE/FENTANYL ANESTHESIA; MAGNETIC STIMULATION; BODY-TEMPERATURE; ISOFLURANE; PROPOFOL; RESPONSES; ISCHEMIA	In the present study, we investigated the effect of hypothermia on myogenic motor-evoked potentials (MEPs) in rabbits. The influence of stimulation paradigms to induce MEPs was evaluated. Twelve rabbits anesthetized with ketamine, fentanyl, and propofol were used for the study. Myogenic MEPs in response to electrical stimulation of the motor cortex with a single pulse and a train of three and five pulses were recorded from the soleus muscle. After the control recording of MEPs at 38degreesC of esophageal temperature, the rabbits were cooled by surface cooling. Esophageal temperature was maintained at 35degreesC, 32degreesC, 30degreesC, and 28degreesC, and MEPs were recorded at each point. MEP amplitude to single-pulse stimulation was significantly reduced with a reduction of core temperature to 28degreesC compared with the control value at 38degreesC (0.8 +/- 0.4 mV versus 2.3 +/- 0.3 mV; P < 0.05), whereas MEP amplitude to train-pulse stimulation did not change significantly during the cooling. MEP latency was increased linearly with a reduction of core temperature regardless of stimulation paradigms. In conclusion, these results indicate that a reduction of core temperature to 28degreesC did not influence MEP amplitudes as long as a train of pulses, but not a single pulse, was used for stimulation in rabbits under propofol/ketamine/fentanyl anesthesia.	Nara Med Univ, Dept Anesthesiol, Kashihara, Nara 6348522, Japan	Sakamoto, T (reprint author), Nara Med Univ, Dept Anesthesiol, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.			Takahashi, Masahiro/0000-0002-1556-6600			AESCHBACHER G, 1993, LAB ANIM SCI, V43, P328; de Haan P, 1998, Semin Thorac Cardiovasc Surg, V10, P19; Jacobs MJHM, 1999, J VASC SURG, V29, P48, DOI 10.1016/S0741-5214(99)70349-6; Jou IM, 2000, SPINE, V25, P1878, DOI 10.1097/00007632-200008010-00004; KAKIMOTO M, 2000, BRIT J ANAESTH, V88, P836; Kakinohana M, 1999, ANESTHESIOLOGY, V90, P789, DOI 10.1097/00000542-199903000-00022; KALKMAN CJ, 1992, ANESTHESIOLOGY, V76, P502, DOI 10.1097/00000542-199204000-00003; KALKMAN CJ, 1995, ANESTHESIOLOGY, V83, P270, DOI 10.1097/00000542-199508000-00006; KALKMAN CJ, 1991, ANESTH ANALG, V73, P410; KAWAGUCHI M, 1993, BRIT J ANAESTH, V71, P849, DOI 10.1093/bja/71.6.849; Kawaguchi M, 2000, SPINE, V25, P974, DOI 10.1097/00007632-200004150-00013; Kawaguchi M, 1996, ANESTH ANALG, V82, P593, DOI 10.1097/00000539-199603000-00029; Kawaguchi M, 1998, J NEUROSURG ANESTH, V10, P131, DOI 10.1097/00008506-199807000-00001; Kawaguchi M, 1996, ANESTHESIOLOGY, V85, P1176, DOI 10.1097/00000542-199611000-00027; Ma DQ, 1999, ANESTHESIOLOGY, V91, P1470, DOI 10.1097/00000542-199911000-00041; MARSALA M, 1994, STROKE, V25, P2038, DOI 10.1161/01.STR.25.10.2038; Matsumoto M, 1997, ANESTHESIOLOGY, V86, P1120, DOI 10.1097/00000542-199705000-00016; Meylaerts SA, 1999, J THORAC CARDIOV SUR, V118, P1038, DOI 10.1016/S0022-5223(99)70099-1; ORO J, 1992, SPINE, V17, P498, DOI 10.1097/00007632-199205000-00005; Sakamoto T, 2001, BRIT J ANAESTH, V86, P395, DOI 10.1093/bja/86.3.395; Sueda T, 2000, ANN THORAC SURG, V70, P44, DOI 10.1016/S0003-4975(00)01440-5; TANIGUCHI M, 1993, NEUROSURGERY, V32, P219, DOI 10.1227/00006123-199302000-00011; Ubags LH, 1998, NEUROSURGERY, V43, P90, DOI 10.1097/00006123-199807000-00058; van Dongen EP, 2001, J VASC SURG, V34, P1035, DOI 10.1067/mva.2001.119397; Wan IYP, 2001, EUR J CARDIO-THORAC, V19, P203, DOI 10.1016/S1010-7940(00)00646-1; ZENTNER J, 1989, NEUROSURGERY, V24, P253, DOI 10.1227/00006123-198902000-00016; ZENTNER J, 1992, NEUROSURGERY, V31, P298, DOI 10.1227/00006123-199208000-00015	27	17	18	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2003	96	6					1692	1697		10.1213/01.ANE.0000064202.24119.07			6	Anesthesiology	Anesthesiology	683LB	WOS:000183148900027	12760998				2020-06-30	J	Connelly, NR; Parker, RK; Pedersen, T; Manikantan, T; Lucas, T; Serban, S; El-Mansouri, M; DuBois, S; Delos Santos, E; Rizvi, A; Gibson, C				Connelly, NR; Parker, RK; Pedersen, T; Manikantan, T; Lucas, T; Serban, S; El-Mansouri, M; DuBois, S; Delos Santos, E; Rizvi, A; Gibson, C			Diluent volume for epidural fentanyl and its effect on analgesia in early labor	ANESTHESIA AND ANALGESIA			English	Article							INTRATHECAL SUFENTANIL; CESAREAN-SECTION; PLUS SUFENTANIL; FIRST STAGE; BUPIVACAINE; EPINEPHRINE; LIDOCAINE; ROPIVACAINE; OBSTETRICS; CLONIDINE	Epidural fentanyl after a lidocaine and epinephrine test dose provides adequate analgesia and allows for ambulation during early labor. We designed the current study to determine the influence of the diluent volume of the epidural fentanyl bolus (e.g., whether it has an effect on the onset and duration of analgesia). Sixty laboring primigravid women received a 3-mL epidural test dose of lidocaine with epinephrine and then received a fentanyl 100-mug bolus in either a 2-mL, 10-mL, or 20-ml, volume. Pain scores and side effects were recorded for each patient. The onset of analgesia was similar in all three groups. The mean duration before re-dose was not significantly different in the 2-ml, group (108 +/- 40 min), the 10-ml, group (126 +/- 57 min), or the 20-mL group (126 +/- 41 min). No patient in any group experienced any detectable motor block; one patient (2-ml, group) complained of mild knee weakness and was not allowed to ambulate. In early laboring patients, the volume in which 100 mug of epidural fentanyl (after a lidocaine-epinephrine test dose) is administered does not affect the onset or duration of analgesia, nor does it affect the ability to ambulate.	Baystate Med Ctr, Dept Anesthesiol, Springfield, MA 01199 USA	Connelly, NR (reprint author), Baystate Med Ctr, Dept Anesthesiol, 759 Chestnut St, Springfield, MA 01199 USA.						ASANTILA R, 1993, ACTA ANAESTH SCAND, V37, P764, DOI 10.1111/j.1399-6576.1993.tb03806.x; Birnbach DJ, 1999, ANESTH ANALG, V88, P971, DOI 10.1097/00000539-199905000-00001; BIRNBACH DJ, 1989, ANESTH ANALG, V68, P808; BONNET F, 1984, ACTA ANAESTH SCAND, V28, P147, DOI 10.1111/j.1399-6576.1984.tb02031.x; Breen TW, 1999, INT J OBSTET ANESTH, V8, P226, DOI 10.1016/S0959-289X(99)80101-0; Bromage PR, 1978, EPIDURAL ANALGESIA, P144; Buggy DJ, 1996, BRIT J ANAESTH, V76, P319; Campbell DC, 2000, ANESTH ANALG, V90, P1384, DOI 10.1097/00000539-200006000-00023; Christiaens F, 1998, REGION ANESTH PAIN M, V23, P134, DOI 10.1097/00115550-199823020-00004; Cohen SE, 2000, ANESTHESIOLOGY, V92, P387, DOI 10.1097/00000542-200002000-00019; Connelly NR, 2000, ANESTH ANALG, V91, P374, DOI 10.1097/00000539-200008000-00026; Connelly NR, 2000, INT J OBSTET ANESTH, V9, P94, DOI 10.1054/ijoa.1999.0372; Connelly NR, 2001, ANESTH ANALG, V93, P1001, DOI 10.1097/00000539-200110000-00041; Dunn SM, 1998, ANESTH ANALG, V87, P331, DOI 10.1097/00000539-199808000-00018; Fischer C, 2000, ANESTHESIOLOGY, V92, P1588, DOI 10.1097/00000542-200006000-00015; Kee WDN, 1997, ANESTH ANALG, V85, P380, DOI 10.1097/00000539-199708000-00024; LAVEAUX MMD, 1993, REGION ANESTH, V18, P39; Norris MC, 1999, ANESTH ANALG, V88, P1073, DOI 10.1097/00000539-199905000-00019; Paech M, 1999, ANESTH ANALG, V89, P1590, DOI 10.1097/00000539-199912000-00066; Parker RK, 2002, CAN J ANAESTH, V49, P600, DOI 10.1007/BF03017388; Polley LS, 2000, ANESTHESIOLOGY, V93, P122, DOI 10.1097/00000542-200007000-00022; STEINBERG RB, 1992, REGION ANESTH, V17, P131; STEINBERG RB, 1989, REGION ANESTH, V14, P225	23	9	11	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	JUN	2003	96	6					1799	1804		10.1213/01.ANE.0000061583.77068.0B			6	Anesthesiology	Anesthesiology	683LB	WOS:000183148900044	12761015				2020-06-30	J	Katz, J; Cohen, L; Schmid, R; Chan, VWS; Wowk, A				Katz, J; Cohen, L; Schmid, R; Chan, VWS; Wowk, A			Postoperative morphine use and hyperalgesia are reduced by preoperative but not intraoperative epidural analgesia - Implications for preemptive analgesia and the prevention of central sensitization	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Conference of the Canadian-Pain-Society	MAY 10, 2001	MONTREAL, CANADA	Canadian Pain Soc			ABDOMINAL HYSTERECTOMY; NEURONAL PLASTICITY; FUTURE-DIRECTIONS; IMMUNE FUNCTION; EVENT SCALE; PAIN RELIEF; HEALTHY-MEN; SURGERY; STRESS; NEUROPLASTICITY	Background: The aim of this study was to evaluate the postoperative morphine-sparing effects and reduction in pain and secondary mechanical hyperalgesia after preincisional or postincisional epidural administration of a local anesthetic and an opioid compared with a sham epidural control. Methods: Patients undergoing major gynecologic surgery by laparotomy were randomly assigned to three groups and studied in a double-blinded manner. Group 1 received epidural lidocaine and fentanyl before incision and epidural saline 40 min after incision. Group 2 received epidural saline before incision and epidural lidocaine and fentanyl 40 min after incision. Group 3 received a sham epidural control (with saline injected into a catheter taped to the back) before and 40 min after incision. All patients underwent surgery with general anesthesia. Results: One hundred forty-one patients completed the study (group 1, n = 45; group 2, n = 49; group 3, n = 47). Cumulative patient-controlled analgesia morphine consumption at 48 h was significantly lower (P = 0.04) in group 1 (89.8 +/- 43.3 mg) than group 3 (112.5 +/- 71.5 mg) but not group 2 (95.4 +/- 60.2 mg), although the hourly rate of morphine consumption between 24 and 48 h after surgery was significantly lower (P < 0.0009) in group 1 (1.25 +/- 0.02 mg/h) than group 2 (1.41 +/- 0.02 mg/h). Twenty-four hours after surgery, the visual analog scale pain score on movement was significantly less intense (P = 0.005) in group 1 (4.9 +/- 2.2 cm) than group 3 (6.0 +/- 2.6 cm) but not group 2 (5.3 +/- 2.5 cm), and the von Frey pain threshold near the wound was significantly higher (P = 0.03) in group 1(6.4 +/- 0.6 log mg) than in group 3 (6.1 +/- 0.8 log mg) but not group 2 (6.2 +/- 0.7 log mg). Conclusions: Preincisional administration of epidural lidocaine and fentanyl was associated with a significantly lower rate of morphine use, lower cumulative morphine consumption, and reduced hyperalgesia compared with a sham epidural condition. These results highlight the importance of including a standard treatment control group to avoid the problems of interpretation that arise when two-group studies of preemptive analgesia (preincisional vs. postsurgery) fail to find the anticipated effects.	Toronto Gen Hosp, Dept Anesthesia & Pain Management, Univ Hlth Network, Acute Pain Res Unit, Toronto, ON M5G 2C4, Canada	Katz, J (reprint author), Toronto Gen Hosp, Dept Anesthesia & Pain Management, Univ Hlth Network, Acute Pain Res Unit, EN 3-440,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	jkatz@uhnres.utoronto.ca	Katz, Joel/J-7015-2014	Katz, Joel/0000-0002-8686-447X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35480]		Akural EI, 2002, BRIT J ANAESTH, V88, P803, DOI 10.1093/bja/88.6.803; BROWN B, 1993, [No title captured]; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1993, J PERS SOC PSYCHOL, V65, P375, DOI 10.1037/0022-3514.65.2.375; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Cousins MJ, 2000, REGION ANESTH PAIN M, V25, P6, DOI 10.1016/S1098-7339(00)80005-X; DAHL JB, 1994, DAN MED BULL, V41, P434; DICKENSON AH, 1993, CURRENT OPINION ANAE, V6, P861; GARCIA JBS, 2002, ACUTE PAIN, V4, P23; Glantz S., 1997, PRIMER BIOSTATISTICS, P459; Gottschalk A, 2000, J PAIN, V1, P85, DOI 10.1016/S1526-5900(00)90091-9; Gottschalk A, 1998, JAMA-J AM MED ASSOC, V279, P1076, DOI 10.1001/jama.279.14.1076; HAMMERSLEY JM, 1964, MONTE CARLO METHODS; Haythornthwaite JA, 2000, CLIN J PAIN, V16, pS101, DOI 10.1097/00002508-200006001-00017; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; KATZ J, 1995, EUR J ANAESTH, V12, P8; KATZ J, 1994, PAIN, V59, P395, DOI 10.1016/0304-3959(94)90026-4; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; Katz J, 1999, SURG CLIN N AM, V79, P231, DOI 10.1016/S0039-6109(05)70381-9; Katz J., 2003, CLIN PAIN MANAGEMENT, P113; KISSIN I, 1994, ANESTH ANALG, V79, P809; Kissin I, 1998, ANESTHESIOLOGY, V88, P224, DOI 10.1097/00000542-199801000-00031; Kissin I, 1996, ANESTHESIOLOGY, V84, P1015, DOI 10.1097/00000542-199605000-00001; Kissin I, 2000, ANESTHESIOLOGY, V93, P1138, DOI 10.1097/00000542-200010000-00040; Kundra P, 1997, ANESTH ANALG, V85, P135, DOI 10.1097/00000539-199707000-00024; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Moiniche S, 2002, ANESTHESIOLOGY, V96, P725, DOI 10.1097/00000542-200203000-00032; Nguyen A, 2001, ANESTH ANALG, V93, P1272, DOI 10.1097/00000539-200111000-00048; Niv D, 1999, Minerva Anestesiol, V65, P127; Obata H, 1999, CAN J ANAESTH, V46, P1127, DOI 10.1007/BF03015520; Perkins FM, 2000, ANESTHESIOLOGY, V93, P1123, DOI 10.1097/00000542-200010000-00038; Peters ML, 2000, PAIN, V84, P181, DOI 10.1016/S0304-3959(99)00206-7; RAHE RH, 1978, J HUM STRESS, V4, P3, DOI 10.1080/0097840X.1978.9934972; Reuben SS, 2001, ANESTHESIOLOGY, V95, P390, DOI 10.1097/00000542-200108000-00021; Richards JT, 1998, ANAESTHESIA, V53, P296, DOI 10.1046/j.1365-2044.1998.00288.x; Rockemann MG, 1996, ANESTHESIOLOGY, V84, P1027, DOI 10.1097/00000542-199605000-00003; SCHAEFFER MA, 1984, PSYCHOSOM MED, V46, P227, DOI 10.1097/00006842-198405000-00005; SCHEIER MF, 1985, HEALTH PSYCHOL, V4, P219, DOI 10.1037/0278-6133.4.3.219; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; Taylor BK, 2000, J PAIN, V1, P77, DOI 10.1016/S1526-5900(00)90090-7; WARE JEJ, 1979, HLTH INSURANCE STUDY, V3; WEINSTEIN MC, 1989, MED CARE, V27, P593, DOI 10.1097/00005650-198906000-00003; Wilder-Smith CH, 1998, ACTA ANAESTH SCAND, V42, P299, DOI 10.1111/j.1399-6576.1998.tb04920.x; Wilder-Smith OHG, 1998, ANESTH ANALG, V86, P95, DOI 10.1097/00000539-199801000-00019; WilderSmith OHG, 1996, BRIT J ANAESTH, V76, P816; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Zakowski S G, 1994, Int J Behav Med, V1, P163, DOI 10.1207/s15327558ijbm0102_4; ZAKOWSKI SG, 1992, HEALTH PSYCHOL, V11, P223, DOI 10.1037/0278-6133.11.4.223; ZILBERG NJ, 1982, J CONSULT CLIN PSYCH, V50, P407, DOI 10.1037/0022-006X.50.3.407	51	75	80	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	JUN	2003	98	6					1449	1460		10.1097/00000542-200306000-00023			12	Anesthesiology	Anesthesiology	682DE	WOS:000183075400022	12766657				2020-06-30	J	Allegaert, K; Tibboel, D; Naulaers, G; Tison, D; De Jonge, A; Van Dijk, M; Vanhole, C; Devlieger, H				Allegaert, K; Tibboel, D; Naulaers, G; Tison, D; De Jonge, A; Van Dijk, M; Vanhole, C; Devlieger, H			Systematic evaluation of pain in neonates: effect on the number of intravenous analgesics prescribed	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Article; Proceedings Paper	Annual Meeting of the Belgian-Society-of-Anesthesia-and-Resuscitation	NOV   30, 2002	BRUSSELS, BELGIUM	Belgian Soc Anesthesia & Resuscitat		analgesia; assessment; intensive care units	INFANTS; TRIAL; PHARMACOKINETICS; MANAGEMENT; STRESS	Objective: To document the effect of systematic evaluation of pain in neonates on prescription of intravenous analgesics in a level-III neonatal intensive care unit (NICU) as a marker of increased awareness of treating and preventing pain. Methods: Retrospective analysis of the number of yearly prescribed vials of intravenous analgesics in a level-III NICU during a period before (1996-1999) and after (2000 to August 2002) introduction of a multidimensional pain scale. Correction was carried out by multiple regression analysis for clinical co-variables (admissions, days on parenteral nutrition, days on respiratory support, surgical procedures), which also might explain changes in prescription of analgesics. Postoperative length (hours) of administration of analgesics was calculated in a group of infants (1996-2001) who all received cryotherapy for threshold retinopathy of prematurity (ROP) before (1996-1999) and since (20002001) introduction of pain evaluation. Results: The number of yearly prescribed vials increased from 3140 +/- 619 (mean +/- SD) to 5915 +/- 675 (P < 0.005). There is also a significant increase in the number of surgical interventions (P < 0.05) but not in days on respiratory support, days on parenteral nutrition or in number of admissions. After correction for the number of surgical procedures, the increase in prescribed vials remained significant (P < 0.05). In infants who received cryotherapy, a significant increase in length of postoperative analgesia (65-107 h, P < 0.01) was documented. Even after correction for the increased postoperative length of ventilation, duration of Postoperative analgesia remained significantly (P < 0.05) longer. Conclusions: Systematic evaluation of pain increased awareness of treating and preventing pain in neonates, even after correction for clinical co-variables. This increase was not associated with an increase in potential side-effects (length of respiratory support, length of parenteral nutrition).	Katholieke Univ Leuven Hosp, Dept Paediat, Neonatal Intens Care Unit, B-3000 Louvain, Belgium; Erasmus MC Sophia, Dept Paediat Surg, NL-3015 GJ Rotterdam, Netherlands	Allegaert, K (reprint author), Katholieke Univ Leuven Hosp, Dept Paediat, Neonatal Intens Care Unit, Herestr 49,Gasthuisberg, B-3000 Louvain, Belgium.		van Dijk, Monique/B-6327-2009; Naulaers, Gunnar/AAC-5022-2019; allegaert, karel/C-3611-2016	allegaert, karel/0000-0001-9921-5105; van Dijk, Monique/0000-0002-9856-0318; Naulaers, Gunnar/0000-0003-0735-4808			ALLEGAERT K, 2002, NED TIJDSCHR GENEES, V58, P155; Ambalavanan N, 1999, J PEDIATR-US, V135, P403, DOI 10.1016/S0022-3476(99)70156-3; Anand KJS, 1998, BIOL NEONATE, V73, P1, DOI 10.1159/000013953; Anand KJS, 1999, ARCH PEDIAT ADOL MED, V153, P331; ANAND KJS, 1987, LANCET, V1, P62; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; Anand KJS, 2001, ARCH PEDIAT ADOL MED, V155, P173, DOI 10.1001/archpedi.155.2.173; Anderson BJ, 2002, ANESTHESIOLOGY, V96, P1336, DOI 10.1097/00000542-200206000-00012; AUTRET E, 1993, DEV PHARMACOL THERAP, V20, P129, DOI 10.1159/000457553; Bertolini G, 2002, EUR J CLIN PHARMACOL, V58, P73, DOI 10.1007/s00228-002-0432-y; DAYER P, 1994, DRUGS, V47, P3, DOI 10.2165/00003495-199400471-00003; Kennedy KA, 1999, J PEDIATR-US, V134, P127, DOI 10.1016/S0022-3476(99)70399-9; Lago P, 1998, ARCH DIS CHILD-FETAL, V79, pF194, DOI 10.1136/fn.79.3.F194; McGregor M L, 1998, J AAPOS, V2, P360, DOI 10.1016/S1091-8531(98)90035-0; Phillips DM, 2000, JAMA-J AM MED ASSOC, V284, P428, DOI 10.1001/jama.284.4.428; Stevens B, 1996, CLIN J PAIN, V12, P13, DOI 10.1097/00002508-199603000-00004; van Dijk M, 2002, CLIN PERINATOL, V29, P469, DOI 10.1016/S0095-5108(02)00015-5	17	45	45	0	6	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0031-6970			EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	JUN	2003	59	2					87	90		10.1007/s00228-003-0585-3			4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	701FQ	WOS:000184157900001	12682806				2020-06-30	J	Barrett, AC; Smith, ES; Picker, MJ				Barrett, AC; Smith, ES; Picker, MJ			Use of irreversible antagonists to determine the relative efficacy of mu-opioids in a pigeon drug discrimination procedure: comparison of beta-funaltrexamine and clocinnamox	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							AGONIST EFFICACY; INTRINSIC EFFICACY; APPARENT AFFINITY; RECEPTOR-BINDING; RHESUS-MONKEYS; RAT THALAMUS; MORPHINE; ANTINOCICEPTION; SELECTIVITY; MECHANISMS	The use of irreversible antagonists to assess opioid efficacy has proven fruitful for classifying opioids on the basis of high or low efficacy, but few studies have provided quantitative estimates of efficacy. The purpose of this study was to use beta-funaltrexamine (beta-FNA) and clocinnamox (C-CAM) in a drug discrimination procedure to examine the efficacy of fentanyl, morphine, l-methadone, sufentanil, and etorphine. In pigeons trained to discriminate 0.12 mg/kg fentanyl from water, dose-effect curves were determined for each opioid alone and after pretreatment with beta-FNA and C-CAM. Using quantitative analyses according to an extended model of Black and Leff ( 1983), apparent efficacy (tau) and affinity (K-A) of each opioid was determined, as well as the degree of receptor inactivation (q) produced by each dose of each antagonist. beta-FNA and C-CAM produced dose- and time-dependent, rightward shifts in the dose- effect curves of each opioid, and analyses based on dose-ratios and tau values suggest a rank order of efficacy of etorphine > sufentanil = l-methadone > fentanyl = morphine. Marked differences in the profiles of antagonism produced by beta-FNA and C-CAM were also apparent, as C-CAM, but not beta-FNA, produced insurmountable antagonism. The q values for each antagonist were consistent with these data in indicating that C-CAM and beta-FNA can inactivate nearly 100 and 75% of the receptor population, respectively. In tests conducted in pigeons chronically treated with morphine, doses of beta-FNA that produced parallel, rightward shifts in untreated pigeons flattened the morphine dose-effect curve in morphine-treated pigeons. These results indicate that beta-FNA and C-CAM can differentiate opioids with high relative efficacy and yield comparable estimates of efficacy for various opioids. There are, however, limitations in the proportion of the receptor population that can by eliminated by beta-FNA.	Univ N Carolina, Dept Psychol, Chapel Hill, NC 27599 USA	Barrett, AC (reprint author), Univ N Carolina, Dept Psychol, Davie Hall,CB 3270, Chapel Hill, NC 27599 USA.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA10277, DA15273]		ACETO MD, 1989, ARZNEIMITTEL-FORSCH, V39-1, P570; ADAMS JU, 1990, J PHARMACOL EXP THER, V255, P1027; Bergman J, 2000, PSYCHOPHARMACOLOGY, V153, P67, DOI 10.1007/s002130000567; BLACK JW, 1983, PROC R SOC SER B-BIO, V220, P141, DOI 10.1098/rspb.1983.0093; BURKE TF, 1994, J PHARMACOL EXP THER, V271, P715; COMER SD, 1992, J PHARMACOL EXP THER, V262, P1051; DIRIG DM, 1995, PAIN, V62, P321, DOI 10.1016/0304-3959(95)00006-E; FRANKLIN TG, 1991, BRIT J PHARMACOL, V102, P718, DOI 10.1111/j.1476-5381.1991.tb12239.x; FURCHGOTT RF, 1966, ADV DRUG RES, V3, P21; Holtzman SG, 1997, PHARMACOL BIOCHEM BE, V57, P771, DOI 10.1016/S0091-3057(96)00395-4; KENAKIN TP, 1997, PHARM ANAL DRUG RECE; LIUCHEN LY, 1990, MOL PHARMACOL, V37, P243; LIUCHEN LY, 1987, MOL PHARMACOL, V32, P321; MJANGER E, 1991, J PHARMACOL EXP THER, V258, P544; Morgan D, 1998, PSYCHOPHARMACOLOGY, V140, P20, DOI 10.1007/s002130050734; PICKER MJ, 1993, J PHARMACOL EXP THER, V266, P756; Pitts RC, 1998, J PHARMACOL EXP THER, V285, P1197; PORRECA F, 1983, J PHARMACOL EXP THER, V225, P688; Romero DV, 1999, SYNAPSE, V34, P83, DOI 10.1002/(SICI)1098-2396(199911)34:2<83::AID-SYN1>3.3.CO;2-J; ROTHMAN RB, 1987, PEPTIDES, V8, P1015, DOI 10.1016/0196-9781(87)90130-6; Selley DE, 1997, MOL PHARMACOL, V51, P87; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA; TRAYNOR JR, 1995, MOL PHARMACOL, V47, P848; WALKER EA, 1993, J PHARMACOL EXP THER, V267, P280; Walker EA, 1998, PSYCHOPHARMACOLOGY, V136, P15; Walker EA, 1997, PSYCHOPHARMACOLOGY, V133, P17, DOI 10.1007/s002130050366; Walker EA, 2002, J PHARMACOL EXP THER, V302, P101, DOI 10.1124/jpet.302.1.101; WARD SJ, 1982, J PHARMACOL EXP THER, V220, P494; YOBURN BC, 1995, PHARMACOL BIOCHEM BE, V51, P535, DOI 10.1016/0091-3057(94)00375-S; YOUNG AM, 1984, J PHARMACOL EXP THER, V229, P118; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zernig G, 1996, J PHARMACOL TOXICOL, V35, P223, DOI 10.1016/1056-8719(96)00053-6; ZERNIG G, 1995, LIFE SCI, V57, P2113, DOI 10.1016/0024-3205(95)02204-V; Zernig G, 1997, PSYCHOPHARMACOLOGY, V129, P233, DOI 10.1007/s002130050185; Zernig G, 1996, J PHARMACOL EXP THER, V279, P23; Zhang LG, 2000, PSYCHOPHARMACOLOGY, V148, P136, DOI 10.1007/s002130050035; ZIMMERMAN DM, 1987, J PHARMACOL EXP THER, V241, P374	39	12	15	0	2	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0022-3565			J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JUN	2003	305	3					1061	1070		10.1124/jpet.102.047068			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	680PF	WOS:000182986000032	12649297				2020-06-30	J	Puura, A				Puura, A			Transdermal nicotine increases heart rate after endotracheal intubation	METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY			English	Article						anesthesia; complications; transdermal nicotine	CIGARETTE-SMOKING; DOSE-REQUIREMENTS; PHARMACOKINETICS; ROCURONIUM; PHARMACODYNAMICS; ABSTINENCE; SMOKERS	Transdermal nicotine reduces perioperative withdrawal symptoms when smoking is forbidden. We evaluated the influence of a transdermal nicotine system on cardiovascular response after endotracheal intubation. The study, design was prospective, randomized, double-blind and placebo-controlled. Sixty healthly smokers scheduled for minor surgery under general anesthesia were divided into two groups. The first group received a 21 mg/day transdermal nicotine system while the second group received a placebo transdermal system. After induction with standardized doses of fentanyl, thiopental and atracurium, the patients were intubated immediately, when EMG-response decreased to 10% of the initial control. Heart rate and noninvasive arterial pressures were recorded 1 min and 5 inin after intubation. The transdermal nicotine system significantly increased heart rate compared with the control group without nicotine substitution. Since the transdermal nicotine system increases heart rate it should not be used if tachycardia is potentially dangerous, such as in patients with ischemic heart disease. (C) 2003 Prous Science, All rights reserved.	Valkeakoski Dist Hosp, Dept Anaesthesiol, FIN-36200 Kangasala, Finland	Puura, A (reprint author), Valkeakoski Dist Hosp, Dept Anaesthesiol, Katajatie 19B, FIN-36200 Kangasala, Finland.						Bannon AW, 1998, SCIENCE, V279, P77, DOI 10.1126/science.279.5347.77; BENOWITZ NL, 1982, CLIN PHARMACOL THER, V32, P758, DOI 10.1038/clpt.1982.233; CASPARY S, 1991, INT J CLIN PHARM TH, V29, P92; DUBOIS JP, 1989, METHOD FIND EXP CLIN, V11, P187; ERSKINE RJ, 1994, BRIT J ANAESTH, V73, P298, DOI 10.1093/bja/73.3.298; FERTIG JB, 1986, ADDICT BEHAV, V11, P239, DOI 10.1016/0306-4603(86)90052-3; HICKEY S, 1992, ACTA ANAESTH SCAND, V36, P21, DOI 10.1111/j.1399-6576.1992.tb03416.x; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Latorre F, 1997, ANAESTHESIST, V46, P493, DOI 10.1007/s001010050429; MILLER LG, 1989, CLIN PHARMACOKINET, V17, P90, DOI 10.2165/00003088-198917020-00003; Puhringer FK, 2000, CAN J ANAESTH, V47, P347; Puura AIE, 1998, ANESTH ANALG, V87, P430, DOI 10.1097/00000539-199808000-00037; Rautoma P, 1998, CAN J ANAESTH, V45, P651, DOI 10.1007/BF03012095; ROSENBERG J, 1980, CLIN PHARMACOL THER, V28, P517, DOI 10.1038/clpt.1980.196; Teiria H, 1996, BRIT J ANAESTH, V76, P154; Teiria H, 1997, CAN J ANAESTH, V44, P1269, DOI 10.1007/BF03012774	16	11	12	0	3	PROUS SCIENCE, SA	BARCELONA	PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN	0379-0355			METHOD FIND EXP CLIN	Methods Find. Exp. Clin. Pharmacol.	JUN	2003	25	5					383	385		10.1358/mf.2003.25.5.769661			3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	702VR	WOS:000184245800008	12851662				2020-06-30	J	O'Flaherty, JE; Lin, CX				O'Flaherty, JE; Lin, CX			Does ketamine or magnesium affect posttonsillectomy pain in children?	PAEDIATRIC ANAESTHESIA			English	Article						ketamine; magnesium; tonsillectomy; N-methyl-D-aspartate (NMDA) receptor; postoperative pain	SMALL-DOSE KETAMINE; POSTOPERATIVE ANALGESIC REQUIREMENTS; OBSTRUCTIVE SLEEP-APNEA; ABDOMINAL HYSTERECTOMY; RESPIRATORY COMPROMISE; ORAL DEXTROMETHORPHAN; CENTRAL SENSITIZATION; SURGERY; TONSILLECTOMY; MORPHINE	Background: Many previous studies have suggested a role for the N-methyl-D-aspartate (NMDA) receptor antagonists ketamine and magnesium in decreasing postoperative pain and analgesic requirements in adults, but none has investigated these medications in children. Methods: This randomized, double-blind, placebo-controlled study evaluated the effects of ketamine and magnesium in children undergoing tonsillectomy. Eighty patients, aged 3-12 years, were randomly assigned to four groups. Patients received either ketamine 0.15 mg.kg(-1), magnesium sulphate 30 mg.kg(-1), ketamine 0.15 mg.kg(-1) plus magnesium sulphate 30 mg.kg(-1), or placebo intravenously 5 min prior to the start of surgery. Intraoperative analgesia was standardized, and included fentanyl and dexamethasone. Results: There were no differences among the groups with respect to pain assessment postoperatively. Compared with placebo, the treatment groups did not require less fentanyl in the postanaesthesia recovery room or consume less codeine in the first 24-h postoperatively. There was no evidence of synergism between ketamine and magnesium. There were no differences among the groups in the incidence of nausea, vomiting, sedation, bleeding, or dreaming postoperatively. Conclusion: This study did not demonstrate a decrease in pain or analgesic consumption in children undergoing tonsillectomy when pretreated with a small dose of ketamine and/or magnesium.	Univ Virginia Hlth Syst, Dept Anesthesiol, Charlottesville, VA 22908 USA	O'Flaherty, JE (reprint author), Univ Virginia Hlth Syst, Dept Anesthesiol, POB 800710, Charlottesville, VA 22908 USA.	jeo8m@virginia.edu					Adam F, 1999, ANESTH ANALG, V89, P444, DOI 10.1097/00000539-199908000-00036; ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Chia YY, 1999, ANESTH ANALG, V89, P748, DOI 10.1097/00000539-199909000-00041; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Fu ES, 1997, ANESTH ANALG, V84, P1086, DOI 10.1097/00000539-199705000-00024; HANNALLAH RS, 1987, ANESTHESIOLOGY, V66, P832, DOI 10.1097/00000542-198706000-00023; Henderson DJ, 1999, ANESTH ANALG, V89, P399, DOI 10.1097/00000539-199908000-00028; Kawamata T, 1998, ANESTH ANALG, V86, P594; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Koinig H, 1998, ANESTH ANALG, V87, P206, DOI 10.1097/00000539-199807000-00042; Liu HT, 2001, ANESTH ANALG, V92, P1173; Marcus RJ, 2000, BRIT J ANAESTH, V84, P739; Mathisen LC, 1999, ACTA ANAESTH SCAND, V43, P220, DOI 10.1034/j.1399-6576.1999.430218.x; MCCOLLEY SA, 1992, ARCH OTOLARYNGOL, V118, P940; McConaghy PM, 1998, BRIT J ANAESTH, V81, P731, DOI 10.1093/bja/81.5.731; Menigaux C, 2000, ANESTH ANALG, V90, P129, DOI 10.1097/00000539-200001000-00029; Menigaux C, 2001, ANESTH ANALG, V93, P606, DOI 10.1097/00000539-200109000-00016; Nieminen P, 1997, ACTA OTO-LARYNGOL, P190; Norden J., 1991, ANESTHESIOLOGY, V75, pA934; O'Flaherty JE, 2000, ANESTHESIOLOGY, V93, pU228; Rose JB, 1999, ANESTH ANALG, V88, P749, DOI 10.1097/00000539-199904000-00012; ROSEN GM, 1994, PEDIATRICS, V93, P784; ROYTBLAT L, 1993, ANESTH ANALG, V77, P1161; Smedje H, 1999, ACTA PAEDIATR, V88, P858; Stubhaug A, 1997, ACTA ANAESTH SCAND, V41, P1124, DOI 10.1111/j.1399-6576.1997.tb04854.x; Suzuki M, 1999, ANESTH ANALG, V89, P98, DOI 10.1097/00000539-199907000-00017; Tramer MR, 1996, ANESTHESIOLOGY, V84, P340, DOI 10.1097/00000542-199602000-00011; Wilder-Smith OHG, 1998, ANESTH ANALG, V86, P95, DOI 10.1097/00000539-199801000-00019; WilderSmith CH, 1997, ACTA ANAESTH SCAND, V41, P1023, DOI 10.1111/j.1399-6576.1997.tb04830.x; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026; Wu CT, 2000, WORLD J SURG, V24, P512, DOI 10.1007/s002689910082	32	70	71	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	JUN	2003	13	5					413	421		10.1046/j.1460-9592.2003.01049.x			9	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	687GU	WOS:000183368800008	12791115				2020-06-30	J	Hall, S; Gallagher, RM; Gracely, E; Knowlton, C; Wescules, D				Hall, S; Gallagher, RM; Gracely, E; Knowlton, C; Wescules, D			The terminal cancer patient: Effects of age, gender, and primary tumor site on opioid dose	PAIN MEDICINE			English	Article						opioid analgesics; pain; morphine; oxycodone; fentanyl; palliative care	ORAL MORPHINE; TRANSDERMAL FENTANYL; CHRONIC PAIN; PHARMACOKINETICS; HOSPICE; PLASMA; REQUIREMENTS; DISPOSITION; CONVERSION	Objective. The objective of the current study is to describe correlations between age, gender, and primary cancer site and sustained-release opioid doses prescribed for hospice patients at the end of life. Patients and Setting. This study included all 7,201 hospice patients referred to a North American palliative care specialty pharmacy with the primary diagnosis of cancer and who were prescribed transdermal fentanyl, sustained-release oral morphine, or sustained-release oxycodone. Design. This is a retrospective analysis of the final sustained-release morphine, oxycodone, or transdermal fentanyl doses prescribed to cancer patients, according to pharmacy records. Comparisons between sex and age group were performed with chi-square tests. Mann-Whitney U tests were used to compare mean doses between the sexes. Analyses of covariance (ANCOVA) were used to compare opioid doses between genders and among primary cancer sites while controlling for age. Results. The inverse association between age group and dose was highly significant. For example, final opioid doses less than or equal to120 mg/day oral morphine equivalent were prescribed for only 46.4% of patients between 40 and 49 years of age compared with 86.4% of patients 90 years of age and older. An ANCOVA on the largest non-sex-related diagnoses found primary tumor site and patient age, but not gender, to be associated with sustained-release opioid dose. Conclusion. Both primary tumor site and patient age were associated with final opioid dose. Further investigation is warranted to determine which primary tumor sites are associated with unusually high opioid doses and may highlight the need to optimize adjuvant medication therapy if neuropathic and/or inflammatory pain mechanisms are involved and to refer to pain specialists when appropriate.	PharmD, excelleRx Inst, Philadelphia, PA 19106 USA; Penn Hosp, Coll Med, Pain Med Ctr, Philadelphia, PA 19107 USA; Drexel Univ, Coll Med, Philadelphia, PA 19104 USA; Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19104 USA	Hall, S (reprint author), PharmD, excelleRx Inst, 530 Walnut St,Suite 550, Philadelphia, PA 19106 USA.		Gracely, Ed/Q-6369-2019	Gracely, Ed/0000-0002-8344-3223			Anderson R, 2001, J PAIN SYMPTOM MANAG, V21, P397, DOI 10.1016/S0885-3924(01)00271-8; Ashby M, 1997, J PAIN SYMPTOM MANAG, V14, P157, DOI 10.1016/S0885-3924(97)00020-1; BAILLIE SP, 1989, AGE AGEING, V18, P258, DOI 10.1093/ageing/18.4.258; BELLVILL.JW, 1971, J AMER MED ASSOC, V217, P1835, DOI 10.1001/jama.217.13.1835; BENTLEY JB, 1982, ANESTH ANALG, V61, P968; Bercovitch M, 1999, CANCER-AM CANCER SOC, V86, P871, DOI 10.1002/(SICI)1097-0142(19990901)86:5<871::AID-CNCR25>3.0.CO;2-L; BERKOWITZ BA, 1975, CLIN PHARMACOL THER, V17, P629; Boisvert M, 1995, J PAIN SYMPTOM MANAG, V10, P632, DOI 10.1016/0885-3924(95)00124-7; DAHLSTROM B, 1982, CLIN PHARMACOKINET, V7, P266, DOI 10.2165/00003088-198207030-00006; DHONNEUR G, 1994, ANESTHESIOLOGY, V81, P87, DOI 10.1097/00000542-199407000-00013; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Gammaitoni AR, 2000, PAIN MED, V1, P317, DOI 10.1046/j.1526-4637.2000.00043.x; Gibson SJ, 2001, CLIN GERIATR MED, V17, P433, DOI 10.1016/S0749-0690(05)70079-3; GONG QL, 1991, EUR J PHARMACOL, V193, P47, DOI 10.1016/0014-2999(91)90199-Z; Gordon D B, 1999, J Palliat Med, V2, P209, DOI 10.1089/jpm.1999.2.209; HOLDSWORTH MT, 1994, GERONTOLOGY, V40, P32; KAIKO RF, 1982, MED CLIN N AM, V66, P1079, DOI 10.1016/S0025-7125(16)31383-9; KAIKO RF, 1983, PAIN, V15, P191, DOI 10.1016/0304-3959(83)90018-0; LEMMENS HJM, 1988, ANESTH ANALG, V67, P956; LOESER JD, 2001, BONICAS MANAGEMENT P, P638; MCQUAY HJ, 1990, CLIN PHARMACOL THER, V48, P236, DOI 10.1038/clpt.1990.145; Mercadante S, 2000, SUPPORT CARE CANCER, V8, P123, DOI 10.1007/s005200050026; Mercadante S, 2001, J PAIN SYMPTOM MANAG, V21, P144, DOI 10.1016/S0885-3924(00)00228-1; MOORE AK, 1990, ANESTH ANALG, V70, P316; MORRIS JN, 1986, J CHRON DIS, V39, P27, DOI 10.1016/0021-9681(86)90104-9; OWEN JA, 1983, CLIN PHARMACOL THER, V34, P364, DOI 10.1038/clpt.1983.180; Pereira J, 2001, J PAIN SYMPTOM MANAG, V22, P672, DOI 10.1016/S0885-3924(01)00294-9; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; Rees W D, 1990, Clin Oncol (R Coll Radiol), V2, P79, DOI 10.1016/S0936-6555(05)80792-7; SCHUG SA, 1992, J PAIN SYMPTOM MANAG, V7, P259, DOI 10.1016/0885-3924(92)90059-Q; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; STUBGEN JP, 1995, MUSCLE NERVE, V18, P636, DOI 10.1002/mus.880180611; Vainio A, 1996, J PAIN SYMPTOM MANAG, V12, P3, DOI 10.1016/0885-3924(96)00042-5; Ventaffrida V, 1987, J Pain Symptom Manage, V2, P77, DOI 10.1016/S0885-3924(87)80019-2; Ventafridda V, 1989, J Pain Symptom Manage, V4, P124, DOI 10.1016/0885-3924(89)90005-5; Vigano A, 1998, CANCER-AM CANCER SOC, V83, P1244, DOI 10.1002/(SICI)1097-0142(19980915)83:6<1244::AID-CNCR26>3.3.CO;2-P; WOOLF CJ, 1981, BRAIN RES, V209, P491, DOI 10.1016/0006-8993(81)90176-1; YAKSH TL, 1986, ANESTHESIOLOGY, V64, P590, DOI 10.1097/00000542-198605000-00008	38	48	48	0	2	BLACKWELL PUBLISHING INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	1526-2375			PAIN MED	Pain Med.	JUN	2003	4	2					125	134		10.1046/j.1526-4637.2003.03020.x			10	Anesthesiology; Medicine, General & Internal	Anesthesiology; General & Internal Medicine	687GM	WOS:000183368200004	12873262	Bronze			2020-06-30	J	Schmidt, A; Ryding, E; Akeson, J				Schmidt, A; Ryding, E; Akeson, J			Racemic ketamine does not abolish cerebrovascular autoregulation in the pig	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anesthesia; cerebral autoregulation; cerebral blood flow; fentanyl; intravenous; ketamine; swine; vecuronium; xenon	CEREBRAL BLOOD-FLOW; ANESTHETIZED PIG; INTRACRANIAL-PRESSURE; INDUCED HYPOTENSION; AUTO-REGULATION; PORCINE MODEL; METABOLISM; HEMODYNAMICS; PROPOFOL; VELOCITY	Background: Little is known about the influence of racemic ketamine on autoregulation of cerebral blood flow (CBF), and available reports regarding its influence on cerebral hemodynamics are contradictory. This study was designed to evaluate cerebrovascular responses to changes in the mean arterial pressure (MAP) during ketamine anesthesia. Methods: In eight normoventilated pigs anesthesia was induced with propofol and maintained by i.v. infusion of ketamine (15.0 mg kg(-1) .h(-1) ) during measurements. The intra-arterial xenon clearance technique was used to calculate CBF. Balloon-tipped catheters were introduced in the inferior caval vein and mid-aorta, and increases or decreases by up to 40% in mean arterial pressure (MAP) in random order were achieved by titrated inflation of these balloon catheters. Cerebral blood flow was determined at each MAP level. Regression coefficients of linear pressure-flow curves were calculated in all animals. Results: From the mean baseline level (101 mmHg) MAP was reduced by 20% and 40%, and increased by 26% and 43%. The maximal mean increase and decrease in MAP induced a 12% increase and a 15% decrease, respectively, of CBF from the mean baseline level (52.6 ml.100 g(-1) .min(1) ). The 95% confidence interval (-0.02; 0.38) of the mean regression coefficient of individual pressure-flow curves does not include the regression coefficient (0.64) of a linear correlation between MAP and CBF including origo (correlation coefficient 0.99), which indicates complete lack of cerebrovascular autoregulation. Conclusions: We conclude that autoregulation of CBF is not abolished during continuous ketamine infusion in normoventilated pigs and that previous divergent conclusions are unlikely to be associated with severe impairment of cerebrovascular autoregulation.	Lund Univ, Dept Anesthesia & Intens Care, Lund, Sweden; Lund Univ, Dept Expt Res, Lund, Sweden; Malmo Univ Hosp, Malmo, Sweden; Univ Lund Hosp, Dept Clin Neurophysiol, S-22185 Lund, Sweden	Schmidt, A (reprint author), Hosp Helsingborg, Dept Anesthesia & Intens Care, SE-25187 Helsingborg, Sweden.						AKESON J, 1993, ACTA ANAESTH SCAND, V37, P211, DOI 10.1111/j.1399-6576.1993.tb03703.x; AKESON J, 1992, ACTA ANAESTH SCAND, V36, P419, DOI 10.1111/j.1399-6576.1992.tb03491.x; BJORKMAN S, 1988, J CHROMATOGR-BIOMED, V433, P95, DOI 10.1016/S0378-4347(00)80588-5; CAVAZZUTI M, 1987, J CEREBR BLOOD F MET, V7, P806, DOI 10.1038/jcbfm.1987.138; CHANG T, 1972, ANESTHESIOLOGY, V36, P401, DOI 10.1097/00000542-197204000-00016; DAWSON B, 1971, ANESTH ANAL CURR RES, V50, P443; Engelhard K, 1997, ANASTH INTENSIV NOTF, V32, P721, DOI 10.1055/s-2007-995142; Engelhard K, 2001, CAN J ANAESTH, V48, P1034, DOI 10.1007/BF03016597; Fink H, 2000, BRIT J ANAESTH, V84, P221; GIBBS JM, 1972, BRIT J ANAESTH, V44, P1298, DOI 10.1093/bja/44.12.1298; HERRSCHAFT H, 1973, ANAESTHESIST, V22, P486; HOUGAARD K, 1974, ANESTHESIOLOGY, V41, P562, DOI 10.1097/00000542-197412000-00006; JORCH G, 1987, EUR J PEDIATR, V146, P468, DOI 10.1007/BF00441596; Kreuscher H, 1967, Anaesthesist, V16, P304; Lagerkranser M, 1997, J NEUROSURG ANESTH, V9, P188, DOI 10.1097/00008506-199704000-00015; MAYBERG TS, 1995, ANESTH ANALG, V81, P84, DOI 10.1097/00000539-199507000-00017; NILSSON F, 1995, ACTA ANAESTH SCAND, V39, P827, DOI 10.1111/j.1399-6576.1995.tb04179.x; OREN RE, 1987, STROKE, V18, P441, DOI 10.1161/01.STR.18.2.441; PANERAI RB, 1995, STROKE, V26, P74, DOI 10.1161/01.STR.26.1.74; Sakai K, 2000, ANESTH ANALG, V90, P377, DOI 10.1097/00000539-200002000-00026; SCHWEDLER M, 1982, CAN ANAESTH SOC J, V29, P222, DOI 10.1007/BF03007120; SHAKUNAGA K, 1998, ANESTH ANALG, V86, P1089; STANGE K, 1994, J NEUROSURG ANESTH, V6, P116; STANGE K, 1989, ACTA ANAESTH SCAND, V33, P450, DOI 10.1111/j.1399-6576.1989.tb02944.x; STANGE K, 1991, ANESTH ANALG, V73, P745; TAKESHITA H, 1972, ANESTHESIOLOGY, V36, P69, DOI 10.1097/00000542-197201000-00013; WENDLING WW, 1994, J NEUROSURG ANESTH, V6, P186; WYTE SR, 1972, ANESTHESIOLOGY, V36, P174, DOI 10.1097/00000542-197202000-00021	28	12	13	0	2	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2003	47	5					569	575		10.1034/j.1399-6576.2003.00089.x			7	Anesthesiology	Anesthesiology	668QJ	WOS:000182304400012	12699515	Green Published			2020-06-30	J	Elhakim, M; Khalafallah, Z; El-fattah, HA; Farouk, S; Khattab, A				Elhakim, M; Khalafallah, Z; El-fattah, HA; Farouk, S; Khattab, A			Ketamine reduces swallowing-evoked pain after paediatric tonsillectomy	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anaesthetic : i.m.; ketamine; analgesics : opioid, fentanyl, nonopioid, diclofenac; pain : postoperative; surgery : otolaryngological	SMALL-DOSE KETAMINE; ASPARTATE RECEPTOR BLOCKADE; POSTOPERATIVE PAIN; ORAL DEXTROMETHORPHAN; EPIDURAL MORPHINE; ANALGESIA; CHILDREN; SURGERY; ADENOTONSILLECTOMY; HYPERALGESIA	Background: Ketamine efficacy as an analgesic adjuvant has been studied in several clinical settings with conflicting results. The aim of this study was to investigate the effect of ketamine on spontaneous and swallowing-evoked pain after tonsillectomy. Methods: Fifty children were randomized to receive premedication with either ketamine 0.1 mg kg(-1) i.m. or placebo given 20 min before induction of a standard general anaesthesia. All children received rectal diclofenac 2 mg kg(-1) and fentanyl 1 mug kg(-1) i.v. before surgery. Results: The ketamine group showed significantly lower pain scores both at rest and on swallowing, with less total paracetamol consumption (P < 0.05) during the 24 h after surgery. Significantly more patients required postoperative morphine titration in the control group (P < 0.05). The time to the first oral intake, and duration of i.v. hydration, were significantly shorter and the quality of oral intake was significantly better in the ketamine group (P < 0.05). There were no differences in the incidence of vomiting or dreaming between the groups. Conclusion: Premedication with a small dose of ketamine reduces swallowing-evoked pain after tonsillectomy in children who received an analgesic regimen combining an opioid and a NSAID.	Ain Shams Univ, Fac Med, Dept Anaesthesia, Cairo, Egypt	Elhakim, M (reprint author), Alhorreya Heliopolis, Code 11361,POB 2361, Cairo, Egypt.						Aida S, 2000, ANESTHESIOLOGY, V92, P1624, DOI 10.1097/00000542-200006000-00020; Ambalavanar R, 2002, J NEUROPHYSIOL, V87, P1252, DOI 10.1152/jn.00595.2001; Bespalov AY, 2001, NEUROSCI BIOBEHAV R, V25, P343, DOI 10.1016/S0149-7634(01)00018-5; Dahl V, 2000, ANESTH ANALG, V90, P1419, DOI 10.1097/00000539-200006000-00031; EDWARDS ND, 1993, ANAESTHESIA, V48, P124; Eide PK, 1997, NEUROSURGERY, V41, P505, DOI 10.1097/00006123-199708000-00043; Elhakim M, 1997, ACTA ANAESTH SCAND, V41, P214, DOI 10.1111/j.1399-6576.1997.tb04668.x; Ilkjaer S, 1998, BRIT J ANAESTH, V81, P707, DOI 10.1093/bja/81.5.707; Kawamata T, 1998, ANESTH ANALG, V86, P594; Kohrs R, 1998, ANESTH ANALG, V87, P1186, DOI 10.1097/00000539-199811000-00039; LEACH J, 1993, LARYNGOSCOPE, V103, P619; Marcus RJ, 2000, BRIT J ANAESTH, V84, P739; MAUNUKSELA EL, 1987, CLIN PHARMACOL THER, V42, P137, DOI 10.1038/clpt.1987.123; Menigaux C, 2000, ANESTH ANALG, V90, P129, DOI 10.1097/00000539-200001000-00029; Menigaux C, 2001, ANESTH ANALG, V93, P606, DOI 10.1097/00000539-200109000-00016; Pappas ALS, 1998, ANESTH ANALG, V87, P57, DOI 10.1097/00000539-199807000-00013; Price DD, 1996, PAIN, V68, P119, DOI 10.1016/S0304-3959(96)03183-1; PRICE DD, 1994, PAIN, V59, P165, DOI 10.1016/0304-3959(94)90069-8; Rose JB, 1999, ANESTH ANALG, V88, P749, DOI 10.1097/00000539-199904000-00012; SCHAIBLE HG, 1991, EUR J NEUROSCI, V3, P981, DOI 10.1111/j.1460-9568.1991.tb00034.x; Schmid RL, 1999, PAIN, V82, P111, DOI 10.1016/S0304-3959(99)00044-5; Stubhaug A, 1997, ACTA ANAESTH SCAND, V41, P1124, DOI 10.1111/j.1399-6576.1997.tb04854.x; SUFKA KJ, 1992, PHARMACOL BIOCHEM BE, V41, P349, DOI 10.1016/0091-3057(92)90109-S; Suzuki M, 1999, ANESTH ANALG, V89, P98, DOI 10.1097/00000539-199907000-00017; WEIMERT TA, 1990, ARCH OTOLARYNGOL, V116, P186; Weinbroum AA, 2000, CAN J ANAESTH, V47, P585, DOI 10.1007/BF03018952; Zahn PK, 1998, ANESTHESIOLOGY, V88, P143, DOI 10.1097/00000542-199801000-00022	27	38	39	0	1	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAY	2003	47	5					604	609		10.1034/j.1399-6576.2003.00111.x			6	Anesthesiology	Anesthesiology	668QJ	WOS:000182304400018	12699521				2020-06-30	J	Suresh, S; Lozono, S; Hall, SC				Suresh, S; Lozono, S; Hall, SC			Large-dose intravenous methotrexate-induced cutaneous toxicity: Can oral magnesium oxide reduce pain?	ANESTHESIA AND ANALGESIA			English	Article							MORPHINE; THERAPY		Childrens Mem Hosp, Dept Pediat Anesthesiol, Chicago, IL 60614 USA; Northwestern Univ, Feinberg Sch Med, Dept Anesthesiol, Chicago, IL 60611 USA; Cleveland Clin Fdn, Div Anesthesiol, Cleveland, OH 44195 USA	Suresh, S (reprint author), Childrens Mem Hosp, Dept Pediat Anesthesiol, Box 19,2300 Childrens Plaza, Chicago, IL 60614 USA.						Begon S, 2002, ANESTHESIOLOGY, V96, P627, DOI 10.1097/00000542-200203000-00019; Collins JJ, 1996, J PEDIATR-US, V129, P722, DOI 10.1016/S0022-3476(96)70156-7; Fassoulaki A, 2000, REGION ANESTH PAIN M, V25, P350, DOI 10.1053/rapm.2000.7812; Flombaum CD, 1999, J CLIN ONCOL, V17, P1589, DOI 10.1200/JCO.1999.17.5.1589; FONDEVILA CG, 1989, BRIT J HAEMATOL, V72, P591; Torner O, 1997, CLIN RHEUMATOL, V16, P108, DOI 10.1007/BF02238776; Treon SP, 1996, CLIN CHEM, V42, P1322; Wilson RH, 2002, J CLIN ONCOL, V20, P1767, DOI 10.1200/JCO.2002.07.056; Wong D L, 1988, Pediatr Nurs, V14, P9	9	3	3	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAY	2003	96	5					1413	1414		10.1213/01.ANE.0000057140.33744.65			2	Anesthesiology	Anesthesiology	671GL	WOS:000182456900032	12707144				2020-06-30	J	Golden, S				Golden, S			Surgical stress response in neonates and premature infants	ANESTHESIA AND ANALGESIA			English	Letter							CARDIAC-SURGERY; ANESTHESIA		Loyola Univ, Med Ctr, Ronald McDonald Childrens Hosp, Maywood, IL 60153 USA	Golden, S (reprint author), Loyola Univ, Med Ctr, Ronald McDonald Childrens Hosp, 2160 S 1st Ave, Maywood, IL 60153 USA.						ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1990, CLIN PERINATOL, V17, P207; ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1990, ANESTHESIOLOGY, V73, P661, DOI 10.1097/00000542-199010000-00012; Duncan HP, 2000, BRIT J ANAESTH, V84, P556, DOI 10.1093/bja/84.5.556; Gruber EM, 2001, ANESTH ANALG, V92, P882	6	0	1	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAY	2003	96	5					1526	1526		10.1213/01.ANE.0000048362.63828.8D			1	Anesthesiology	Anesthesiology	671GL	WOS:000182456900049	12707163				2020-06-30	J	Arakawa, M				Arakawa, M			Intrathecal magnesium prolongs fentanyl analgesia	ANESTHESIA AND ANALGESIA			English	Letter							MORPHINE		Toho Univ, Sch Med, Dept Anesthesiol 2, Tokyo, Japan	Arakawa, M (reprint author), Toho Univ, Sch Med, Dept Anesthesiol 2, Tokyo, Japan.						BACIGALUPO G, 1990, J PERINAT MED, V18, P289, DOI 10.1515/jpme.1990.18.4.289; Buvanendran A, 2002, ANESTH ANALG, V95, P661, DOI 10.1097/00000539-200209000-00031; ISERI LT, 1984, AM HEART J, V108, P188, DOI 10.1016/0002-8703(84)90572-6; Kroin JS, 2000, ANESTH ANALG, V90, P913, DOI 10.1213/00000539-200004000-00025; SANTILLAN R, 1994, PAIN, V58, P129, DOI 10.1016/0304-3959(94)90192-9; WONG CH, 1994, ANESTH ANALG, V79, P303	6	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAY	2003	96	5					1533	1533		10.1213/01.ANE.0000058162.70154.BD			1	Anesthesiology	Anesthesiology	671GL	WOS:000182456900064	12707174				2020-06-30	J	Mencke, T; Echternach, M; Kleinschmidt, S; Lux, P; Barth, V; Plinkert, PK; Fuchs-Buder, T				Mencke, T; Echternach, M; Kleinschmidt, S; Lux, P; Barth, V; Plinkert, PK; Fuchs-Buder, T			Laryngeal morbidity and quality of tracheal intubation - A randomized controlled trial	ANESTHESIOLOGY			English	Article; Proceedings Paper	10th Meeting of the European-Society-of-Anesthesiologists/24th European-Academy-of-Anaesthesiology	APR 06-09, 2002	NICE, FRANCE	European Soc Anesthiol, European Acad Anaesthesiol			POSTOPERATIVE SORE THROAT; MUSCLE-RELAXANTS; NEUROMUSCULAR BLOCK; NASOTRACHEAL INTUBATION; AMBULATORY SURGERY; PROPOFOL; ANESTHESIA; ALFENTANIL; REMIFENTANIL; CONSEQUENCES	Background: Vocal cord sequelae and postoperative hoarseness during general anesthesia are a significant source of morbidity for patients and a source of liability for anesthesiologists. Several risk factors leading to laryngeal injury have been identified in the past. However, whether the quality of tracheal intubation affects their incidence or severity is still unclear. Methods. Eighty patients were randomized in two groups (n = 40 for each) to receive a propofol-fentanyl induction regimen with or without atracurium. Intubation conditions were evaluated with the Copenhagen Score; postoperative hoarseness was assessed at 24, 48, and 72 h by a standardized interview; and vocal cords were examined by stroboscopy before and 24 and 72 h after surgery. If postoperative hoarseness or vocal cord sequelae persisted, follow-up examination was performed until complete restitution. Results: Without atracurium, postoperative hoarseness occurred more often (16 vs. 6 patients; P = 0.02). The number of days with postoperative hoarseness was higher when atracurium. was omitted (25 vs. 6 patients; P < 0.001). Similar findings were observed for vocal cord sequelae (incidence of vocal cord sequelae: 15 vs. 3 patients, respectively, P = 0.002; days with vocal cord sequelae: 50 vs. 5 patients, respectively, P < 0.001). Excellent intubating conditions were less frequently associated with postoperative hoarseness compared to good or poor conditions (11, 29, and 57% of patients, respectively; excellent vs. poor: P = 0.008). Similar findings were observed for vocal cord sequelae (11, 22, and 50% of patients, respectively; excellent vs. poor: P = 0.02). Conclusions: The quality of tracheal intubation contributes to laryngeal morbidity, and excellent conditions are less frequently associated with postoperative hoarseness and vocal cord sequelae. Adding atracurium to a propofol-fentanyl induction regimen significantly Improved the quality of tracheal intubation and decreased postoperative hoarseness and vocal cord sequelae.	Univ Saarland, Dept Anesthesia & Crit Care, D-6650 Homburg, Germany; Univ Saarland, Dept Otorhinolaryngol, D-6650 Homburg, Germany	Fuchs-Buder, T (reprint author), CHU Brabois, Dept Anesthesie Reanimat, 4 Rue Morvan, F-54500 Vandoeuvre Les Nancy, France.		Echternach, Matthias/E-3464-2010	Echternach, Matthias/0000-0003-0095-5360			ALCOCK R, 1993, BRIT J ANAESTH, V70, P34, DOI 10.1093/bja/70.1.34; Alexander R, 1999, ANAESTHESIA, V54, P1037, DOI 10.1046/j.1365-2044.1999.00904.x; ANDEL H, 2000, ANESTH ANALG, V90, P458; CHRISTENSEN AM, 1994, BRIT J ANAESTH, V73, P786, DOI 10.1093/bja/73.6.786; COGHLAN SFE, 1993, BRIT J ANAESTH, V70, P89, DOI 10.1093/bja/70.1.89; DEBAENE B, 1995, ANESTH ANALG, V80, P360, DOI 10.1097/00000539-199502000-00026; Domino KB, 1999, ANESTHESIOLOGY, V91, P1703, DOI 10.1097/00000542-199912000-00023; Friedman PG, 1997, ANESTH ANALG, V85, P578, DOI 10.1097/00000539-199709000-00017; GRANGE CS, 1993, EUR J ANAESTH, V10, P9; Grant S, 1998, BRIT J ANAESTH, V81, P540, DOI 10.1093/bja/81.4.540; HARDING CJ, 1987, ANAESTHESIA, V42, P1104, DOI 10.1111/j.1365-2044.1987.tb05179.x; HERLEVSEN P, 1992, ACTA ANAESTH SCAND, V36, P505, DOI 10.1111/j.1399-6576.1992.tb03507.x; Higgins PP, 2002, BRIT J ANAESTH, V88, P582, DOI 10.1093/bja/88.4.582; HUNG OR, 1992, ANESTHESIOLOGY, V77, P237, DOI 10.1097/00000542-199208000-00003; JENSEN PJ, 1982, BRIT J ANAESTH, V54, P453, DOI 10.1093/bja/54.4.453; JONES MW, 1992, ANAESTHESIA, V47, P213, DOI 10.1111/j.1365-2044.1992.tb02121.x; JOORGENSEN LN, 1987, ACTA ANAESTH SCAND, V31, P768; Joshi GP, 1997, ANESTH ANALG, V85, P573, DOI 10.1097/00000539-199709000-00016; KAMBIC V, 1978, BRIT J ANAESTH, V50, P587, DOI 10.1093/bja/50.6.587; KARK AE, 1984, BRIT MED J, V289, P1412, DOI 10.1136/bmj.289.6456.1412; KATZ RL, 1967, ANESTHESIOLOGY, V28, P327, DOI 10.1097/00000542-196703000-00008; Keaveny J P, 1988, Anaesthesia, V43 Suppl, P80, DOI 10.1111/j.1365-2044.1988.tb09079.x; Klemola UM, 2000, ACTA ANAESTH SCAND, V44, P465, DOI 10.1034/j.1399-6576.2000.440419.x; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; McHardy FE, 1999, ANAESTHESIA, V54, P444, DOI 10.1046/j.1365-2044.1999.00780.x; MULHOLLAND D, 1991, ANAESTHESIA, V46, P312, DOI 10.1111/j.1365-2044.1991.tb11506.x; PEPPARD SB, 1983, ANN OTO RHINOL LARYN, V92, P327, DOI 10.1177/000348948309200402; QUICK CA, 1978, ARCH OTOLARYNGOL, V104, P267; SAARNIVAARA L, 1991, ACTA ANAESTH SCAND, V35, P19, DOI 10.1111/j.1399-6576.1991.tb03235.x; SCHELLER MS, 1992, ANESTH ANALG, V75, P788; Schlaich N, 2000, ACTA ANAESTH SCAND, V44, P720, DOI 10.1034/j.1399-6576.2000.440610.x; Smit CF, 2000, CLIN OTOLARYNGOL, V25, P440, DOI 10.1046/j.1365-2273.2000.00418.x; Stevens JB, 1998, ANESTH ANALG, V86, P45, DOI 10.1097/00000539-199801000-00009; STEYN MP, 1994, BRIT J ANAESTH, V72, P403, DOI 10.1093/bja/72.4.403; STOUT DM, 1987, ANESTHESIOLOGY, V67, P419, DOI 10.1097/00000542-198709000-00025; STRIDE PC, 1990, ANAESTHESIA, V45, P968, DOI 10.1111/j.1365-2044.1990.tb14634.x; Tramer MR, 1999, BRIT J ANAESTH, V82, P379, DOI 10.1093/bja/82.3.379; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x; WINKEL E, 1971, ANESTH ANAL CURR RES, V50, P92; WOO P, 1991, J VOICE, V5, P231, DOI 10.1016/S0892-1997(05)80191-2; Wu CL, 2002, ANESTHESIOLOGY, V96, P994, DOI 10.1097/00000542-200204000-00030	42	242	254	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAY	2003	98	5					1049	1056		10.1097/00000542-200305000-00005			8	Anesthesiology	Anesthesiology	672LY	WOS:000182523200004	12717124				2020-06-30	J	Wilder-Smith, OHG; Tassonyi, E; Crul, BJP; Arendt-Nielsen, L				Wilder-Smith, OHG; Tassonyi, E; Crul, BJP; Arendt-Nielsen, L			Quantitative sensory testing and human surgery - Effects of analgesic management on postoperative neuroplasticity	ANESTHESIOLOGY			English	Article							SPINAL SENSITIZATION; HUMAN VOLUNTEERS; ACUTE TOLERANCE; BACK PAIN; STIMULATION; MORPHINE; MECHANISMS; KETAMINE; FENTANYL; HYPERSENSITIVITY	Background: Altered central nervous system sensory processing (neuroplasticity) is a basic mechanism underlying postoperative pain that can be made visible using quantitative sensory testing. Using quantitative sensory testing, the authors investigated how perioperative analgesia affects postoperative neuroplasticity and how this relates to clinical pain measures. Methods: Patients undergoing back surgery received placebo, fentanyl, or ketorolac (n = 15 per group) before isoflurane-nitrous oxide anesthesia. Preoperatively to 5 days postoperatively, we measured thresholds to electrical skin stimulation at the incision site, arm, and leg; pain scores; and morphine patient-controlled analgesia consumption. Results: Decreased pain thresholds versus preoperatively were seen 5 days postoperatively, with decreases greater for ketorolac (-63%; P = 0.00005 vs. preoperatively) than placebo (-45%; P = 0.008 vs. preoperatively) but nonsignificant for fentanyl (-36%; P = 0.9 vs. preoperatively). Mainly nonnociceptive thresholds were increased up to 24 h postoperatively. Postoperative clinical pain measures were similar across drug groups. Postoperative pain tolerance threshold changes did not correlate with preoperative clinical pain measures but were inversely related to preoperative thresholds for placebo and ketorolac but not fentanyl. Conclusions: Without analgesia, neuroplasticity after surgery was inhibitory the first 24 h and followed at 5 days by excitation. Fentanyl efficiently preempted this hyperalgesia, but hyperalgesia was greater with ketorolac than with placebo. Clinical pain measures neither reflected the different effects of ketorolac and fentanyl on postoperative neuroplasticity nor permitted prediction of postoperative neuroplasticity. The information obtained by perioperative quantitative sensory testing is separate from and additional to that from clinical pain measures and may enable more mechanism-based approaches to surgical analgesia management in the future.	Univ Hosp Geneva, Div Anaesthesia, Geneva, Switzerland; Aalborg Univ, Ctr Sensory Motor Interact, Lab Expt Pain Res, Aalborg, Denmark	Wilder-Smith, OHG (reprint author), Radboud Univ Nijmegen Med Ctr, Pain Ctr, Dept Anaesthesiol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	o.wildersmith@anes.umcn.nl	Wilder-Smith, Oliver H.G./E-7541-2012; Arendt-Nielsen, Lars/T-4885-2018	Wilder-Smith, Oliver H.G./0000-0003-4390-2381; Tassonyi, Edomer/0000-0002-7235-1200; Arendt-Nielsen, Lars/0000-0003-0892-1579			BHATTACHARYA SK, 1978, EUR J PHARMACOL, V50, P83, DOI 10.1016/0014-2999(78)90257-1; BOUHASSIRA D, 1995, NEUROSCIENCE, V69, P931, DOI 10.1016/0306-4522(95)00269-O; Bustamante D, 1997, J PHARMACOL EXP THER, V281, P1381; CODERRE TJ, 1993, PAIN, V77, P362; DAHL JB, 1992, BRIT J ANAESTH, V69, P117, DOI 10.1093/bja/69.2.117; Danziger N, 1999, J NEUROSCI, V19, P2394; Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632; GRISEL JE, 1993, PHARMACOL BIOCHEM BE, V45, P161, DOI 10.1016/0091-3057(93)90100-8; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; KEHLET H, 1994, BRIT J ANAESTH, V72, P375, DOI 10.1093/bja/72.4.375; Kissin I, 2000, ANESTH ANALG, V91, P1483, DOI 10.1097/00000539-200012000-00035; Koltzenburg M, 2000, CLIN J PAIN, V16, pS131; Kosek E, 1997, PAIN, V70, P41, DOI 10.1016/S0304-3959(96)03295-2; LAUTENBACHER S, 1993, PAIN, V53, P255, DOI 10.1016/0304-3959(93)90221-A; Liu SS, 1996, ANESTH ANALG, V82, P98, DOI 10.1097/00000539-199601000-00017; LUND C, 1990, BRIT J ANAESTH, V65, P173, DOI 10.1093/bja/65.2.173; Ma WY, 2002, BRAIN RES, V937, P94, DOI 10.1016/S0006-8993(02)02593-3; Maresca M, 1983, J Neurosurg Sci, V27, P83; MCQUAY HJ, 1995, ANN MED, V27, P249, DOI 10.3109/07853899509031967; OCONNOR TC, 1995, ANESTHESIOLOGY, V82, P259, DOI 10.1097/00000542-199501000-00031; PETERS ML, 1992, PAIN, V50, P177, DOI 10.1016/0304-3959(92)90159-9; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; RAJA SN, 1988, ANESTHESIOLOGY, V68, P571, DOI 10.1097/00000542-198804000-00016; RAMSAY DS, 1992, PAIN, V51, P367, DOI 10.1016/0304-3959(92)90222-W; RICE ASC, 1993, J CLIN ANESTH, V5, P459, DOI 10.1016/0952-8180(93)90061-I; RICHMOND CE, 1993, LANCET, V342, P73, DOI 10.1016/0140-6736(93)91284-S; Rivat C, 2002, ANESTHESIOLOGY, V96, P381, DOI 10.1097/00000542-200202000-00025; ROLLMAN GB, 1987, PERCEPT PSYCHOPHYS, V42, P247; Samad TA, 2001, NATURE, V410, P471, DOI 10.1038/35068566; STACHER G, 1986, BRIT J CLIN PHARMACO, V21, P35, DOI 10.1111/j.1365-2125.1986.tb02820.x; TOMI K, 1993, BRIT J ANAESTH, V70, P684, DOI 10.1093/bja/70.6.684; Urban MO, 1999, MED CLIN N AM, V83, P585, DOI 10.1016/S0025-7125(05)70125-5; VANDERBURGHT M, 1994, ACTA ANAESTH SCAND, V38, P161; WALL PD, 1988, PAIN, V33, P289, DOI 10.1016/0304-3959(88)90286-2; Watkins LR, 2001, TRENDS NEUROSCI, V24, P450, DOI 10.1016/S0166-2236(00)01854-3; Wilder-Smith O H, 2000, Prog Brain Res, V129, P505; Wilder-Smith OHG, 1998, ANESTH ANALG, V86, P95, DOI 10.1097/00000539-199801000-00019; Wilder-Smith OHG, 2002, PAIN, V97, P189, DOI 10.1016/S0304-3959(01)00430-4; WilderSmith OHG, 1996, BRIT J ANAESTH, V76, P816; WILLER JC, 1985, ANESTHESIOLOGY, V63, P675; Woolf CJ, 2001, ANESTHESIOLOGY, V95, P241, DOI 10.1097/00000542-200107000-00034; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; WOOLF CJ, 1993, ANESTH ANALG, V77, P362, DOI 10.1213/00000539-199377020-00026	43	73	80	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	MAY	2003	98	5					1214	1222		10.1097/00000542-200305000-00025			9	Anesthesiology	Anesthesiology	672LY	WOS:000182523200024	12717144				2020-06-30	J	Wax, PM; Becker, CE; Curry, SC				Wax, PM; Becker, CE; Curry, SC			Unexpected "gas" casualties in Moscow: A medical toxicology perspective	ANNALS OF EMERGENCY MEDICINE			English	Article							CARFENTANIL CITRATE; FENTANYL; ANESTHESIA; ANALGESIA; IMMOBILIZATION; HYDROCHLORIDE; SUFENTANIL; SAFETY	In October 2002, the Russian military used a mysterious "gas" to incapacitate Chechen rebels at a Moscow theater. Despite increased interest in the potential use of lethal chemical weapons in recent years, the medical community has paid little attention to the development of incapacitating, calmative, and "less than lethal" technologies. In this analysis, we review the events surrounding the use of a calmative "gas" during the Russian military action and discuss what is currently known about fentanyl derivatives, their aerosolization, and the rationale for their use as incapacitating agents. Collectively, the available evidence strongly suggests that a combination of a potent aerosolized fentanyl derivative, such as carfentanil, and an inhalational anesthetic, such as halothane, was used. The paper also assesses potential errors leading to the loss of a substantial number of hostages. Several lessons can be learned from this surprising and novel use of an incapacitating gas.	Good Samaritan Reg Med Ctr, Dept Med Toxicol, Phoenix, AZ 85006 USA	Wax, PM (reprint author), Good Samaritan Reg Med Ctr, Dept Med Toxicol, 925 E McDowell Rd,2nd Floor, Phoenix, AZ 85006 USA.						BAKER JR, 1985, VET REC, V116, P208, DOI 10.1136/vr.116.8.208; CASPI J, 1988, CRIT CARE MED, V16, P238, DOI 10.1097/00003246-198803000-00006; *COMM ASS NONL WEA, 2003, ASS NONL WEAP SCI TE; David Brown, 2002, WASHINGTON POST 1109, VNovember 9, 2002, pA12; Enserink M, 2002, SCIENCE, V298, P1150, DOI 10.1126/science.298.5596.1150; GLENSKI JA, 1988, CAN J ANAESTH, V35, P379, DOI 10.1007/BF03010860; HAIGH JC, 1983, J WILDLIFE DIS, V19, P140, DOI 10.7589/0090-3558-19.2.140; HAIGH JC, 1995, J WILDLIFE DIS, V31, P37, DOI 10.7589/0090-3558-31.1.37; HIGGINS MJ, 1991, ANAESTHESIA, V46, P973, DOI 10.1111/j.1365-2044.1991.tb09862.x; JAFFE AB, 1989, PSYCHOPHARMACOLOGY, V99, P289, DOI 10.1007/BF00445545; Kearns KS, 2000, J ZOO WILDLIFE MED, V31, P185, DOI 10.1638/1042-7260(2000)031[0185:OIOAWD]2.0.CO;2; KREEGER TJ, 1990, J WILDLIFE DIS, V26, P561, DOI 10.7589/0090-3558-26.4.561; LAKOSKI JM, ADV LIMITATIONS CALM; Mama KR, 2000, J AM VET MED ASSOC, V217, P546, DOI 10.2460/javma.2000.217.546; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Miller MW, 1996, J WILDLIFE DIS, V32, P234, DOI 10.7589/0090-3558-32.2.234; Myers Steven Lee, 2002, NY TIMES A      1101, P1; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; ROSOW C, 1993, ANESTHESIOLOGY, V79, P875; RUPPE D, 2002, GLOBAL SECURITY NEWS; SHAW ML, 1995, J AM VET MED ASSOC, V206, P833; TAMMISTO R, 1982, ACT ANAESTH SCAND, V26, P225; VANBEVER WFM, 1976, ARZNEIMITTELFORSCH, V26, P1548; WORSLEY MH, 1990, ANAESTHESIA, V45, P449, DOI 10.1111/j.1365-2044.1990.tb14331.x; 2002, NTI GLOBAL SECU 1108	25	68	72	1	27	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	MAY	2003	41	5					700	705		10.1067/mem.2003.148			6	Emergency Medicine	Emergency Medicine	673ED	WOS:000182566500014	12712038				2020-06-30	J	Rudner, R; Jalowiecki, P; Kawecki, P; Gonciarz, M; Mularczyk, A; Petelenz, M				Rudner, R; Jalowiecki, P; Kawecki, P; Gonciarz, M; Mularczyk, A; Petelenz, M			Conscious analgesia/sedation with remifentanil and propofol versus total intravenous anesthesia with fentanyl, midazolam, and propofol for outpatient colonoscopy	GASTROINTESTINAL ENDOSCOPY			English	Article							NITROUS-OXIDE; SEDATION; PHARMACOKINETICS; PHARMACODYNAMICS; RECOVERY; CARE	Background: This study tested the hypothesis that, for colonoscopy, analgesia/sedation with remifentanil and propofol might be more effective compared with anesthesia by intravenous administration of midazolam, fentanyl, and propofol. Methods: In a prospective, randomized trial, 100 adult patients received either conscious analgesia/sedation (Sedation group) or total intravenous anesthesia (TIVA group). Analgesia/sedation was achieved by infusion of remifentanil (0.20 to 0.25 mug/kg/min) and propofol in titrated doses. TIVA was induced by intravenous administration of fentanyl (2 mug/kg), midazolam (0.05 mg/kg) and propofol (dosage titrated). Cardiorespiratory parameters and bispectral index were monitored and recorded. The quality of the analgesia was assessed with a Numerical Pain Rating Scale (NRS); recovery level and return of psychornotor efficiency were evaluated with, respectively, the Aldrete scale and a Modified Post Anesthesia Discharge Scoring (MPADS) system. Results: Both groups of 50 patients were comparable with respect to demographic data, initial parameters, and duration of colonoscopy. All patients in the TIVA group found the colonoscopy painless (NRS score 0). In the Sedation group, the average pain intensity score was 0.4 (0.8). There was a marked difference between the Sedation and TIVA groups with respect to the time from the end of the procedure until the maximum MPADS score was reached: respectively, -6.9 (4.0) versus 25.7 (8.4) minutes (p < 0.001). In the TIVA group, changes in mean arterial pressure and heart rate and signs of respiratory depression were significant (p < 0.05). Conclusions: Combined administration of remifentanil and propofol for colonoscopy provides sufficient analgesia, satisfactory hemodynamic stability, minor respiratory depression, and rapid recovery, and allows patients to be discharged approximately 15 minutes after the procedure.	Silesian Univ, Sch Med, Dept Anesthesiol & Intens Therapy, Dept Internal Med, Sosnowiec, Poland	Rudner, R (reprint author), Silesian Univ, Sch Med, Dept Anesthesiol & Intens Therapy, Dept Internal Med, Wojewodzki Szpital Specjalistyczny Im Sw Barbary,, Sosnowiec, Poland.						ALDRETE A, 1995, J CLIN ANESTH, V8, P415; Bissonnette B, 1999, CAN J ANAESTH, V46, P154, DOI 10.1007/BF03012550; Burkle H, 1996, ANESTH ANALG, V83, P646, DOI 10.1097/00000539-199609000-00038; CHAPMAN CR, 1985, PAIN, V22, P1, DOI 10.1016/0304-3959(85)90145-9; CHUNG F, 1995, ANESTH ANALG, V80, P896, DOI 10.1097/00000539-199505000-00008; Chung F, 1995, J CLIN MONITOR, V7, P89; Dillon M, 1998, PEDIATRICS, V102, P381, DOI 10.1542/peds.102.2.381; EGAN TD, 1995, CLIN PHARMACOKINET, V29, P80, DOI 10.2165/00003088-199529020-00003; Flaishon R, 1997, ANESTHESIOLOGY, V86, P613, DOI 10.1097/00000542-199703000-00013; Forbes GM, 2000, GASTROINTEST ENDOSC, V51, P271, DOI 10.1016/S0016-5107(00)70354-3; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Greilich PE, 2001, ANESTH ANALG, V92, P80; KEEFFE EB, 1995, GASTROENTEROLOGY, V108, P932, DOI 10.1016/0016-5085(95)90471-9; NotiniGudmarsson AK, 1996, ENDOSCOPY, V28, P283, DOI 10.1055/s-2007-1005454; PITTS M C, 1992, Anesthesiology (Hagerstown), V77, pA101, DOI 10.1097/00000542-199209001-00101; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Reimann FM, 2000, ENDOSCOPY, V32, P239, DOI 10.1055/s-2000-134; SaRego MM, 1997, ANESTH ANALG, V85, P1020, DOI 10.1097/00000539-199711000-00012; SAREGO MM, 1999, ANESTH ANALG, V85, P518; SEBEL PS, 1995, ANESTH ANALG, V80, P990, DOI 10.1097/00000539-199505000-00024; Stermer E, 2000, GASTROINTEST ENDOSC, V51, P278, DOI 10.1016/S0016-5107(00)70355-5; Wong RCK, 2001, GASTROINTEST ENDOSC, V54, P122, DOI 10.1067/mge.2001.116115	23	56	71	1	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0016-5107			GASTROINTEST ENDOSC	Gastrointest. Endosc.	MAY	2003	57	5					657	663		10.1067/mge.2003.207			7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	675AP	WOS:000182671100006	12709693				2020-06-30	J	Radzyminski, S				Radzyminski, S			The effect of ultra low dose epidural analgesia on newborn breastfeeding behaviors	JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING			English	Article						analgesia; anesthesia; breastfeeding; epidural; newborn feeding	NEONATAL BEHAVIOR; BUPIVACAINE; LABOR; RESPONSES; FENTANYL; INFUSION; FETAL; ANESTHESIA; LIDOCAINE; DURATION	Objective: To determine whether a difference in breastfeeding behaviors could be observed between newborns whose mothers received epidural analgesia for labor pain relief and those newborns whose mothers received no pain medication in labor. Design: There were two groups of neonates in this study. One group was born to mothers who received epidural analgesia, and one group was born to mothers who received no pain medication for labor. Both groups were observed for initial breastfeeding behaviors using the Premature Infant Breastfeeding Behavior Scale following birth and at 24 hours. Central nervous system functioning in the newborn was measured with the Neurologic and Adaptive Capacity Score at 2 and 24 hours of age. Setting: A large tertiary hospital in northeast Ohio. Participants: Fifty-six breastfeeding mother-newborn dyads. All mothers were healthy multiparae who gave birth vaginally to normal, full-term, healthy newborns. Main Outcome Measures: Newborns were observed for rooting, latch on, sucking, swallowing, activity state, and neurobehavior. Results: There were no statistically significant differences in breastfeeding behaviors at birth or at 24 hours of age. Conclusion: A possible cause for the lack of significant results may have been the ultra low dose of bupivacaine and fentanyl used in this sample.	Cleveland State Univ, Dept Nursing, Cleveland, OH 44115 USA	Radzyminski, S (reprint author), Cleveland State Univ, Dept Nursing, Rhodes Tower,1983 E 24th St, Cleveland, OH 44115 USA.						ABBOUD TK, 1982, ANESTH ANALG, V61, P638; AMANO K, 1985, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V37, P2291; AMIELTISON C, 1982, ANESTHESIOLOGY, V56, P340, DOI 10.1097/00000542-198205000-00003; BADER AM, 1995, ANESTH ANALG, V81, P829, DOI 10.1097/00000539-199510000-00029; BELSEY EM, 1981, BRIT J OBSTET GYNAEC, V88, P398, DOI 10.1111/j.1471-0528.1981.tb01004.x; BLACKBILL Y, 1974, AM J OBSTET GYNECOL, V118, P377; BONICA J, 1995, OBSTET ANALGESIA ANE; BRAZELTON T, 1961, J PEDIATR-US, V58, P513, DOI 10.1016/S0022-3476(61)80185-6; CARRIE LES, 1981, ANAESTHESIA, V36, P965, DOI 10.1111/j.1365-2044.1981.tb08658.x; CHAPMAN J, 1985, NURS RES, V36, P374; CORKE BC, 1977, ANAESTHESIA, V32, P539, DOI 10.1111/j.1365-2044.1977.tb10001.x; CROWELL MK, 1994, J NURSE-MIDWIFERY, V39, P150, DOI 10.1016/0091-2182(94)90097-3; EDDLESTON JM, 1992, BRIT J ANAESTH, V69, P154, DOI 10.1093/bja/69.2.154; FRANTZ K, 1980, INT C SERIES, V518; Halpern SH, 1999, BIRTH-ISS PERINAT C, V26, P83, DOI 10.1046/j.1523-536x.1999.00083.x; HODGKINSON R, 1982, ANESTHESIOLOGY, V56, P51, DOI 10.1097/00000542-198201000-00012; HODGKINSON R, 1978, CAN ANAESTH SOC J, V25, P405, DOI 10.1007/BF03006570; HOYT M, 1990, ANESTHESIOLOGY, V73, P984; HUGHES R, 1988, PEDIAT NURSING, V11, P271; JOUPPILA R, 1976, ACTA ANAESTH SCAND, V20, P259, DOI 10.1111/j.1399-6576.1976.tb05038.x; KANGASSAARELA T, 1987, ACTA ANAESTH SCAND, V31, P347, DOI 10.1111/j.1399-6576.1987.tb02581.x; KILEFF ME, 1984, ANESTH ANALG, V63, P413; KUHNERT BR, 1985, CLIN PERINATOL, V12, P423; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; LOTHIAN JA, 1995, J NURSE-MIDWIFERY, V40, P328, DOI 10.1016/0091-2182(95)00035-I; MURRAY A, 1981, CHILD DEV, V82, P71; NYGVIST K, 1996, J HUMAN LACTATION, V12, P207; O'Leary-Quinn A., 1997, J OBSTET GYNECOLOGIC, V26, P289; Okutomi T, 2000, REGION ANESTH PAIN M, V25, P228, DOI 10.1016/S1098-7339(00)90003-8; Palm ME, 1999, MYCOLOGIA, V91, P1, DOI 10.2307/3761189; RIGHARD L, 1992, BIRTH-ISS PERINAT C, V19, P185, DOI 10.1111/j.1523-536X.1992.tb00399.x; Riordan J, 2000, J Hum Lact, V16, P7, DOI 10.1177/089033440001600103; ROSEN A, 1994, J U ROCHESTER MED CT, V1, P3; ROSENBLATT DB, 1981, BRIT J OBSTET GYNAEC, V88, P407, DOI 10.1111/j.1471-0528.1981.tb01005.x; SAPKOSKI C, 1992, DEV MED CHILD NEUROL, V34, P1072; SCANLON J, 1976, ANESTHESIOLOGY, V40, P121; SCHERER R, 1995, EUR J OBSTET GYN R B, V59, pS17, DOI 10.1016/0028-2243(95)93909-8; SWANSTROM S, 1981, ACTA PAEDIATR SCAND, V70, P811, DOI 10.1111/j.1651-2227.1981.tb06232.x; TRONICK E, 1976, PEDIATRICS, V58, P94; Vandiver TA, 1997, PSYCHOL REP, V80, P1375, DOI 10.2466/pr0.1997.80.3c.1375; Walker M, 1997, J Hum Lact, V13, P131, DOI 10.1177/089033449701300214; WIENER PC, 1979, ANAESTHESIA, V34, P996, DOI 10.1111/j.1365-2044.1979.tb06247.x; ZADOR G, 1974, [No title captured], V34, P17; ZAKOWSKI M, 1993, ANESTHESIOLOGY, V79, pA1006	44	43	43	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0884-2175			JOGNN	JOGNN	MAY-JUN	2003	32	3					322	331		10.1177/0884217503253440			10	Nursing; Obstetrics & Gynecology	Nursing; Obstetrics & Gynecology	676QY	WOS:000182764600011	12774874				2020-06-30	J	Tallis, GF; Ryan, GM; Lambert, SB; Bowden, DS; McCaw, R; Birch, CJ; Moloney, M; Carnie, JA; Locarnini, SA; Rouch, GJ; Catton, MG				Tallis, GF; Ryan, GM; Lambert, SB; Bowden, DS; McCaw, R; Birch, CJ; Moloney, M; Carnie, JA; Locarnini, SA; Rouch, GJ; Catton, MG			Evidence of patient-to-patient transmission of hepatitis C virus through contaminated intravenous anaesthetic ampoules	JOURNAL OF VIRAL HEPATITIS			English	Article; Proceedings Paper	Conference on Communicable Diseases Control	APR, 2001	CANBERRA, AUSTRALIA			anaesthetic ampoules; arthroscopy; endoscopy; hepatitis C; phylogenetic analysis	INFECTION; ROUTES; GENOTYPES; COHORT; VIALS	Two separate cases of acute hepatitis C virus (HCV) infection following medical procedures, arthroscopy and colonoscopy, are reported. In both episodes, patient risk factors were reviewed, and staff and other patients' sera were tested for HCV antibodies and RNA. HCV RNA positive samples were genotyped, sequenced, and subjected to phylogenetic analysis. No risk factors for HCV infection were identified for either case except for medical procedures. HCV RNA positive patients were identified preceding both cases on the respective theatre lists. HCV infection in a second low risk patient was also identified. Nucleic acid sequencing and phylogenetic analysis of HCV from the two putative source patients and the three recipient patients demonstrated a high degree of relatedness respectively. The results suggest that patient-to-patient transmission occurred in both episodes via contamination of intravenous anaesthetic ampoules with HCV used on multiple patients. Injectable medication ampoules should not be used for more than one patient.	Dept Human Serv Vicotira, Communicable Dis Sect, Melbourne, Vic 3000, Australia; Victorian Infect Dis Reference Lab, Carlton, Vic, Australia	Tallis, GF (reprint author), Dept Human Serv Vicotira, Communicable Dis Sect, Level 17,120 Spencer St, Melbourne, Vic 3000, Australia.		Lambert, Stephen B/B-8348-2008; Lambert, Stephen/N-7819-2019	Lambert, Stephen B/0000-0002-2709-193X; Lambert, Stephen/0000-0002-2709-193X			ALTER MJ, 1983, ANN INTERN MED, V99, P330, DOI 10.7326/0003-4819-99-3-330; Andrews R., 1996, Communicable Diseases Intelligence, V20, P384; Bronowicki JP, 1997, NEW ENGL J MED, V337, P237, DOI 10.1056/NEJM199707243370404; CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CHANT K, 1994, LANCET, V343, P415; Chant K, 1994, NEW S WALES PUBLIC H, V5, P47; CROFTS N, 1993, MED J AUSTRALIA, V159, P237, DOI 10.5694/j.1326-5377.1993.tb137822.x; Druce J, 2001, AUST INFECT CONTROL, V6, P89, DOI 10.1071/HI01089; DRUCE JD, 1995, MED J AUSTRALIA, V162, P513, DOI 10.5694/j.1326-5377.1995.tb138507.x; Elghouzzi MH, 2000, VOX SANG, V79, P138, DOI 10.1159/000031231; FELDENSTEIN J, 1993, PHYLIP PHYLOGENETIC; LUTZ CT, 1984, NEW ENGL J MED, V310, P1335, DOI 10.1056/NEJM198405173102024; MacDonald M, 1996, EPIDEMIOL REV, V18, P137, DOI 10.1093/oxfordjournals.epirev.a017921; Massari M, 2001, J CLIN MICROBIOL, V39, P2860, DOI 10.1128/JCM.39.8.2860-2863.2001; McCaw R, 1997, J VIRAL HEPATITIS, V4, P351, DOI 10.1046/j.1365-2893.1997.00060.x; Merle V, 1999, GASTROEN CLIN BIOL, V23, P439; Mortimer PP, 1999, AIDS, V13, P1779, DOI 10.1097/00002030-199909100-00023; Noguchi S, 1997, SCAND J INFECT DIS, V29, P23, DOI 10.3109/00365549709008659; PARLOW JL, 1989, CAN J ANAESTH, V36, pS61; *PUBL HLTH DIV DEP, 1995, MAN CONTR PREV HEP C, P1; Schvarcz R, 1997, INFECTION, V25, P74, DOI 10.1007/BF02113578; SHIELDS JW, 1994, LANCET, V343, P415; Widell A, 1999, ANN INTERN MED, V130, P130, DOI 10.7326/0003-4819-130-2-199901190-00007	23	58	58	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1352-0504			J VIRAL HEPATITIS	J. Viral Hepatitis	MAY	2003	10	3					234	239		10.1046/j.1365-2893.2003.00424.x			6	Gastroenterology & Hepatology; Infectious Diseases; Virology	Gastroenterology & Hepatology; Infectious Diseases; Virology	672TW	WOS:000182539800013	12753344				2020-06-30	J	Rojas-Perez, E; Castillo-Zamora, C; Nava-Ocampo, AA				Rojas-Perez, E; Castillo-Zamora, C; Nava-Ocampo, AA			A randomized trial of caudal block with bupivacaine 4 mg center dot kg(-1) (1.8 ml center dot kg(-1)) plus morphine (150 mu g center dot kg(-1)) vs general anaesthesia with fentanyl for cardiac surgery	PAEDIATRIC ANAESTHESIA			English	Article						caudal anaesthesia; local anaesthetics; morphine; pain threshold	REGIONAL ANESTHESIA; PEDIATRIC-PATIENTS; IMPORTANT COMPONENT; SURGICAL-PROCEDURES; CHILDREN; TOXICITY; INFUSION; INFANTS	Background: Regional anaesthesia has been used effectively in paediatric patients undergoing cardiac surgery and is thought to be safe. Methods: Thirty patients ASA physical status II-III undergoing scheduled palliative or corrective cardiac surgery, receiving premedication with midazolam and anaesthetic induction with sevoflurane, fentanyl and pancuronium were randomly allocated to two groups. In group 1, patients received bupivacaine 0.22% 4 mg.kg(-1) (1.8 ml.kg(-1)) and morphine 150 mug.kg(-1) by the caudal route. After a 20-min period for the block to take effect, sevoflurane 0.5-1.0% and fentanyl 5 mug.kg(-1) were administered for maintenance of anaesthesia. In group 2, the anaesthetic technique was the same as in group 1, without a caudal block and fentanyl 25 mug.kg(-1) was administered at the moment of surgical incision. Results: Cardiovascular and haemodynamic responses of patients receiving caudal block showed minor variations during the 20-min period between caudal and general anaesthesia. Fentanyl requirements during surgery were lower (P = 0.001) in patients with caudal block than patients with general anaesthesia. Extubation time was shorter (P = 0.034) in the caudal group. Two patients in the general anaesthesia group and one in the caudal group died because of postoperative complications. Conclusions: Caudal block with bupivacaine 0.22% 4 mg.kg(-1) (1.8 ml.kg(-1)) and morphine 150 mug.kg(-1) was safe and effective for paediatric patients undergoing cardiac surgery. However, patients might have a better outcome with a reduction of morphine dosage and administration of a muscle relaxant of shorter duration of action than pancuronium.	Hosp Infantil Mexico Dr Federico Gomez, Dept Anaesthesia & Resp Therapy, Mexico City 06720, DF, Mexico; Inst Nacl Cardiol Ignacio Chavez, Dept Anaesthesia, Mexico City, DF, Mexico; Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada	Castillo-Zamora, C (reprint author), Hosp Infantil Mexico Dr Federico Gomez, Dept Anaesthesia & Resp Therapy, Dr Marquez 162,Col Doctores, Mexico City 06720, DF, Mexico.		Nava-Ocampo, Alejandro/K-3850-2012				AGARWAL R, 1992, ANESTH ANALG, V75, P284; ATTIA J, 1986, ANESTHESIOLOGY, V65, P590, DOI 10.1097/00000542-198612000-00005; Breschan C, 1998, ANAESTHESIST, V47, P290, DOI 10.1007/s001010050559; BROWN DL, 1995, ANESTH ANALG, V81, P321, DOI 10.1097/00000539-199508000-00020; CAIRNS C, 1980, ANAESTHESIA, V35, P806; CAMPBELL MJ, 2000, [No title captured], P36; DALENS B, 1989, ANESTH ANALG, V68, P83, DOI 10.1213/00000539-198902000-00002; Giaufre E, 1996, ANESTH ANALG, V83, P904, DOI 10.1097/00000539-199611000-00003; Giaufre E, 1992, Cah Anesthesiol, V40, P177; Holtby H, 2002, J CARDIOTHOR VASC AN, V16, P379, DOI 10.1053/jcan.2002.125116; MCCLOSKEY JJ, 1992, ANESTH ANALG, V75, P287; Moyao-Garcia D, 2002, PAEDIATR ANAESTH, V12, P404, DOI 10.1046/j.1460-9592.2002.00855.x; Nava-Ocampo A A, 2002, BMC Anesthesiol, V2, P2, DOI 10.1186/1471-2253-2-2; Peterson KL, 2000, ANESTH ANALG, V90, P1014, DOI 10.1097/00000539-200005000-00002; Rosen DA, 2002, J CARDIOTHOR VASC AN, V16, P374, DOI 10.1053/jcan.2002.124152; VED SA, 1993, ANESTHESIOLOGY, V79, P1121, DOI 10.1097/00000542-199311000-00030; Wheatley RG, 2001, BRIT J ANAESTH, V87, P47, DOI 10.1093/bja/87.1.47; YASTER M, 1989, ANESTHESIOLOGY, V70, P324	18	14	14	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	MAY	2003	13	4					311	317		10.1046/j.1460-9592.2003.01063.x			7	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	677AD	WOS:000182784000005	12753443				2020-06-30	J	Kokinsky, E; Nilsson, K; Larsson, LE				Kokinsky, E; Nilsson, K; Larsson, LE			Increased incidence of postoperative nausea and vomiting without additional analgesic effects when a low dose of intravenous fentanyl is combined with a caudal block	PAEDIATRIC ANAESTHESIA			English	Article						children; pain; fentanyl; nausea; postoperative	CHILDREN; SURGERY; PAIN	Background: The use of opioids is known to increase the incidence of postoperative nausea and vomiting (PONV). In spite of this, administration of low doses of an opioid during anaesthesia is common practice, even if a regional anaesthetic technique is used. This study was designed to estimate the effects of intraoperative intravenous administration of fentanyl on PONV in paediatric daycase surgery. Methods: PONV and pain were evaluated in 29 boys during the first 24 h after daycase penile surgery. Anaesthesia was standardized. The patients were allocated to two groups. Fentanyl 1 mug.kg(-1) i.v. or placebo was administered in a randomized, double-blind design. A caudal block with ropivacaine 2 mg.ml(-1), 0.5 ml.kg(-1) was performed preoperatively and topical lidocaine gel 20 mg.ml(-1) was applied over the wound area immediately after surgery. Results: The total incidence of PONV in hospital and at home during the first 24 h was 36% (5/14) when fentanyl was used, whereas no PONV was reported when placebo was given (P < 0.05). The median time to first administration of analgesics after the caudal block was approximately 6 h. It did not differ between groups. Intraoperative fentanyl did not result in any reduction in pain scores nor the incidence of pain. Fentanyl caused apnoea in one-half of the cases and decreased the breathing rates during the first 10 min of surgery. Conclusions: Intraoperative use of i.v. fentanyl 1 &mu;g.kg(-1) combined with a regional anaesthetic block is associated with an increased incidence of PONV without any significant contribution to the postoperative pain relief.	Queen Silvia Childrens Hosp, Dept Anaesthesia & Intens Care, S-41685 Gothenburg, Sweden	Kokinsky, E (reprint author), Queen Silvia Childrens Hosp, Dept Anaesthesia & Intens Care, S-41685 Gothenburg, Sweden.						ANDERSEN R, 1976, CAN ANAESTH SOC J, V23, P366, DOI 10.1007/BF03005916; Andrews PL, 1992, BR J ANAESTH S1, V69, P2; KARLSSON E, 1990, ACTA ANAESTH SCAND, V34, P515, DOI 10.1111/j.1399-6576.1990.tb03136.x; KNIGHT JC, 1994, [No title captured], V4, P45; Kokinsky E, 1999, PAEDIATR ANAESTH, V9, P243; Kotiniemi LH, 1997, ANAESTHESIA, V52, P963, DOI 10.1111/j.1365-2044.1997.203-az0338.x; MENDEL HG, 1995, ANESTH ANALG, V80, P1129, DOI 10.1097/00000539-199506000-00010; Mukherjee K, 2001, ANAESTHESIA, V56, P1193; Romsing J, 2000, ACTA ANAESTH SCAND, V44, P291, DOI 10.1034/j.1399-6576.2000.440312.x; ROWLEY MP, 1982, ANAESTH INTENS CARE, V10, P309, DOI 10.1177/0310057X8201000402; TREETRAKARN T, 1987, ANESTHESIOLOGY, V67, P395, DOI 10.1097/00000542-198709000-00018; WATCHA MF, 1992, ANESTHESIOLOGY, V77, P162, DOI 10.1097/00000542-199207000-00023; Wilson GAM, 1996, ANAESTHESIA, V51, P1005, DOI 10.1111/j.1365-2044.1996.tb14991.x; Wong D L, 1988, Pediatr Nurs, V14, P9	14	7	8	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	MAY	2003	13	4					334	338		10.1046/j.1460-9592.2003.00999.x			5	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	677AD	WOS:000182784000009	12753447				2020-06-30	J	Muller, M; Akinturk, H; Schindler, E; Brau, M; Scholz, S; Valeske, K; Michel-Behnke, I; Thul, J; Schranz, D; Hempelmann, G				Muller, M; Akinturk, H; Schindler, E; Brau, M; Scholz, S; Valeske, K; Michel-Behnke, I; Thul, J; Schranz, D; Hempelmann, G			A combined stage 1 and 2 repair for hypoplastic left heart syndrome: anaesthetic considerations	PAEDIATRIC ANAESTHESIA			English	Article						hypoplastic left heart syndrome; cardiac surgery; Norwood procedure; anaesthesia	INHALED NITRIC-OXIDE; PULMONARY VASCULAR-RESISTANCE; FONTAN OPERATION; CARDIOPULMONARY BYPASS; NORWOOD PROCEDURE; ARTERIAL DUCT; THERAPY; HYPERTENSION; CHILDREN; FAILURE	Therapy of hypoplastic left heart syndrome (HLHS) consists of the staged Norwood procedure or cardiac transplantation. Stenting the ductus arteriosus and subsequent banding of the pulmonary arteries allows the combination of neoaortic reconstruction with the establishment of a bidirectional cavopulmonary connection (combined stage 1 and 2 procedure) in a later session. We report the anaesthetic management in eight infants ranging from 107 to 195 days undergoing a combined stage 1 and 2 procedure. Nonselective pulmonary vasodilators and nitric oxide were needed in all cases to improve oxygen saturation in the postbypass period. Phosphodiesterase inhibitors and epinephrine were required in all patients for inotropic support during and after weaning off cardiopulmonary bypass. The procedure was successful in seven patients. One patient died intraoperatively because of right heart failure. The physiological changes of this new surgical strategy for palliation of HLHS offers a challenge for the anaesthetist primarily in the early postbypass period.	Univ Hosp Giessen, Dept Anaesthesiol Intens Care Pain Therapy, D-35392 Giessen, Germany; Univ Hosp Giessen, Dept Pediat Cardiac Surg, D-35392 Giessen, Germany; Univ Hosp Giessen, Dept Pediat Cardiol, D-35392 Giessen, Germany	Muller, M (reprint author), Univ Hosp Giessen, Dept Anaesthesiol Intens Care Pain Therapy, Rudolf Buchheim Str 7, D-35392 Giessen, Germany.		Mueller, Matthias F/D-8560-2013; Schindler, Ehrenfried/K-2512-2019; Schindler, Ehrenfried/AAQ-4607-2020; Schindler, Ehrenfried/A-1629-2015	Schindler, Ehrenfried/0000-0002-2377-3327; 			Akintuerk H, 2002, CIRCULATION, V105, P1099, DOI 10.1161/hc0902.104709; Boldt J, 1989, J Cardiothorac Anesth, V3, P82, DOI 10.1016/0888-6296(89)90825-9; CELERMAJER DS, 1993, CIRCULATION, V87, P440, DOI 10.1161/01.CIR.87.2.440; Dobyns EL, 1999, J PEDIATR-US, V134, P406, DOI 10.1016/S0022-3476(99)70196-4; Gamillscheg A, 1997, J THORAC CARDIOV SUR, V113, P435, DOI 10.1016/S0022-5223(97)70355-6; GIBBS JL, 1993, BRIT HEART J, V69, P551; Givertz MM, 1996, J AM COLL CARDIOL, V28, P1775, DOI 10.1016/S0735-1097(96)00399-3; Goldman AP, 1996, CIRCULATION, V94, P44; Hehrlein F W, 1998, Ann Thorac Cardiovasc Surg, V4, P125; Ishino K, 1999, J THORAC CARDIOV SUR, V117, P920, DOI 10.1016/S0022-5223(99)70373-9; KATZ AM, 1986, CIRCULATION, V73, P184; Kern JH, 1997, AM J CARDIOL, V80, P170, DOI 10.1016/S0002-9149(97)00313-5; KIRKLIN JW, 1990, EUR J CARDIO-THORAC, V4, P2, DOI 10.1016/1010-7940(90)90232-O; Mahle WT, 2001, ANN THORAC SURG, V71, P61, DOI 10.1016/S0003-4975(00)02324-9; Reddy VM, 1997, J AM COLL CARDIOL, V29, P1365, DOI 10.1016/S0735-1097(97)00068-5; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SCHRANZ D, 1989, Journal of Cardiovascular Pharmacology, V14, pS62; Schulze-Neick I, 2001, J THORAC CARDIOV SUR, V121, P1033, DOI 10.1067/mtc.2001.113747; Thies WR, 1997, Z KARDIOL, V86, P505, DOI 10.1007/s003920050086; WESSEL DL, 1993, CIRCULATION, V88, P2128, DOI 10.1161/01.CIR.88.5.2128	20	7	7	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	MAY	2003	13	4					360	365		10.1046/j.1460-9592.2003.01047.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	677AD	WOS:000182784000015	12753453				2020-06-30	J	Tiippana, E; Nilsson, E; Kalso, E				Tiippana, E; Nilsson, E; Kalso, E			Post-thoracotomy pain after thoracic epidural analgesia: a prospective follow-up study	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						chronic postsurgery pain; post-thoracotomy pain; thoracic epidural analgesia; thoracotomy	TERM POSTTHORACOTOMY PAIN; FENTANYL INFUSION; SURGERY; PATIENT	Background: Pain becomes chronic in 22-67% of patients who undergo a thoracotomy. Thoracic epidural analgesia (TEA) has replaced less invasive methods to manage postoperative pain. We wanted to find out if active use of TEA, combined with extended pain management at home, reduces the incidence of chronic post-thoracotomy pain. Methods: All consecutive thoracotomy patients during a 16-month period were included. On the ward, pain was measured daily by VAS during rest and coughing and the consumption of analgesics was registered. The patients were interviewed one week after discharge by telephone and by a questionnaire after 3 and 6 months to find out how much pain they had. Results: A total of 114 patients were recruited. The data were analysed from 89 patients who had had TEA and 22 who had had other methods. TEA was effective in alleviating pain at rest and during coughing. In the TEA patients the incidence of chronic pain of at least moderate severity was 11% and 12% at 3 and 6 months, respectively. One week after discharge 92% of all patients needed daily pain medication. Conclusions: TEA seems effective in controlling evoked postoperative pain, but technical problems occurred in 24% of the epidural catheters. The incidence of chronic pain was lower compared with previous studies where TEA was not used. The patients had significant pain and needed regular pain medication and instructions during the first week after discharge. Extended postoperative analgesia up to the first week at home is warranted.	Univ Helsinki, Cent Hosp, Dept Anaesthesia & Intens Care Med, Helsinki, Finland	Kalso, E (reprint author), Univ Helsinki Hosp, Dept Anaesthesia & Intens Care Med, Pain Clin, POB 340, FIN-00029 Hus, Finland.						Azad SC, 2000, ANAESTHESIST, V49, P9, DOI 10.1007/s001010050003; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Benedetti F, 1998, J THORAC CARDIOV SUR, V115, P841, DOI 10.1016/S0022-5223(98)70365-4; BENZON HT, 1993, ANESTH ANALG, V76, P316; BONICA JJ, 1990, MANAGEMENT PAIN; Burgess F W, 1994, J Cardiothorac Vasc Anesth, V8, P420, DOI 10.1016/1053-0770(94)90281-X; d'Amours R H, 1998, Chest Surg Clin N Am, V8, P703; Eng J, 1993, J R Coll Surg Edinb, V38, P62; KALSO E, 1992, ACTA ANAESTH SCAND, V36, P96, DOI 10.1111/j.1399-6576.1992.tb03430.x; Katz J, 1996, CLIN J PAIN, V12, P50, DOI 10.1097/00002508-199603000-00009; KAVANAGH BP, 1994, ANESTHESIOLOGY, V81, P737, DOI 10.1097/00000542-199409000-00028; KELLER SM, 1994, J CARDIOVASC SURG, V35, P161; LIU S, 1995, REGION ANESTH, V20, P303; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; LUBENOW TR, 1994, ANN THORAC SURG, V58, P924, DOI 10.1016/0003-4975(94)90435-9; MATSUNAGA M, 1990, PAIN S, V5, P148; O'Connor C J, 1993, J Cardiothorac Vasc Anesth, V7, P595, DOI 10.1016/1053-0770(93)90323-D; PEETERSASDOURIA.C, 1999, [No title captured], V115, P122; Perttunen K, 1999, ACTA ANAESTH SCAND, V43, P563; Richardson J, 1998, ANN THORAC SURG, V65, P300; Richardson J, 2000, ACTA ANAESTH SCAND, V44, P220; Richardson Jonathan, 1994, Pain Clinic, V7, P87; Rogers ML, 2000, EUR J CARDIO-THORAC, V18, P711, DOI 10.1016/S1010-7940(00)00569-8; SABANATHAN S, 1995, ANN ROY COLL SURG, V77, P202; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010; Salzer GM, 1997, ANN THORAC SURG, V63, P1411, DOI 10.1016/S0003-4975(97)00081-7; Sandler A N, 1999, Minerva Anestesiol, V65, P267; Senturk M, 2002, ANESTH ANALG, V94, P11; Slinger PD, 1999, J CARDIOTHOR VASC AN, V13, P350, DOI 10.1016/S1053-0770(99)90276-8	29	71	78	0	0	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2003	47	4					433	438		10.1034/j.1399-6576.2003.00056.x			6	Anesthesiology	Anesthesiology	666MD	WOS:000182180300012	12694143				2020-06-30	J	Niemi, G; Breivik, H				Niemi, G; Breivik, H			The minimally effective concentration of adrenaline in a low-concentration thoracic epidural analgesic infusion of bupivacaine, fentanyl and adrenaline after major surgery - A randomized, double-blind, dose-finding study.	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						alpha(2)-agonist; adrenaline; bupivacaine; dynamic pain; epinephrine; fentanyl; local anaesthetic; opioid; postoperative pain; pruritus; synergistic interaction; thoracic epidural analgesia	CORD BLOOD-FLOW; SPINAL-CORD; INTRATHECAL BUPIVACAINE; LOCAL-ANESTHETICS; ABDOMINAL-SURGERY; CESAREAN-SECTION; EPINEPHRINE; ROPIVACAINE; MORPHINE; DOGS	Background: We have documented that adrenaline 2.0 mug.ml(-1) markedly improves relief of dynamic pain when added to a thoracic epidural analgesic infusion of bupivacaine 1 mg.ml(-1) and fentanyl 2 mug.ml(-1) . Concern about possible adverse effects on spinal cord blood flow, expressed by others, prompted us to find the lowest concentration of adrenaline needed to produce effective and reliable pain relief after major surgery. Methods: A prospective, randomized, double-blind, parallel group study was carried out in 36 patients after major thoracic or upper abdominal surgery. Patients with only mild pain when coughing during titrated thoracic epidural infusion of approximately 9 ml per hour of bupivacaine 1 mg.ml(-1) , fentanyl 2 mug.ml(-1) , and adrenaline 2.0 mug.ml(-1) were included. The study was conducted as a dose-finding study comparing three different adrenaline concentrations in the epidural mixture (0.5, 1.0, and 1.5 mug.ml(-1) ) with each other and with adrenaline 2.0 mug.ml(-1) in our standard epidural mixture. On the 1st postoperative day, the patients were randomly allocated into three equal groups of 12 patients each, and given a double-blind epidural infusion at the same rate, but with different adrenaline concentrations (0.5, 1.0, or 1.5 mug.ml(-1) ). The effects were observed for 4 h or until pain when coughing became unacceptable in spite of rescue analgesia. Rescue analgesia consisted of up to two patient-controlled epidural bolus injections per hour (4 ml) and subsequent i.v. morphine, if necessary. All patients received rectal paracetamol 1 g, every 6th hour. Main outcome measures were pain intensity at rest and when coughing, evaluated by a visual analogue scale and an overall quality of pain relief score. The extent of sensory blockade was evaluated by determining dermatomal hypaesthesia to cold. Results: Pain intensity when coughing increased (P<0.001) and the number of hypaesthetic dermatomal segments decreased (P<0.002) when the concentration of adrenaline was reduced below 1.5 mug.ml(-1) in the triple epidural mixture. This change started within two hours after reducing the concentration of adrenaline below 1.5 mug.ml(-1) . The differences in pain intensities at rest were less pronounced. After 4 h with adrenaline 0.5 or 1.0 mug.ml(-1) pain intensity when coughing was unacceptable in spite of rescue analgesia. After restarting the standard epidural mixture with adrenaline 2.0 mug.ml(-1) , pain intensity was again reduced to mild pain when coughing and the sensory blockade was restored. Occurrence of pruritus increased with a decreasing adrenaline concentration. Conclusion: Adrenaline in a dose-related manner improves the pain-relieving effect and sensory blockade and decreases the occurrence of pruritus of a low-concentration thoracic epidural analgesic infusion of bupivacaine 1 mg . ml(-1) and fentanyl 2 mug.ml(-1) after major thoracic or upper abdominal surgery. The minimally effective concentration of adrenaline, when added to bupivacaine 1 mg.ml(-1) and fentanyl 2 mug.ml(-1) , to maintain relief of dynamic pain is approximately 1.5 mug.ml(-1) . The data clearly document that dynamic, cough-provoked pain is a more sensitive outcome measure for postoperative pain relief than pain at rest.	Univ Oslo, Rikshosp Univ Hosp, Dept Anaesthesiol, N-0027 Oslo, Norway	Niemi, G (reprint author), Univ Oslo, Rikshosp Univ Hosp, Dept Anaesthesiol, N-0027 Oslo, Norway.		Niemi, Geir/O-1308-2017; Breivik, Harald/AAG-2978-2020	Niemi, Geir/0000-0001-5931-1389; Breivik, Harald/0000-0002-1738-9337			AKERMAN B, 1988, ANESTH ANALG, V67, P943; Asokumar B, 1998, ANESTH ANALG, V87, P1309, DOI 10.1097/00000539-199812000-00018; Baron CM, 1996, ANESTH ANALG, V82, P760, DOI 10.1097/00000539-199604000-00015; BREIVIK K, 1995, BAILLIERE CLIN ANAES, V9, P493; Bromage P R, 1965, Acta Anaesthesiol Scand Suppl, V16, P55; BROMAGE PR, 1983, ANESTHESIOLOGY, V58, P257, DOI 10.1097/00000542-198303000-00010; Bromage PR, 1997, ACTA ANAESTH SCAND, V41, P439, DOI 10.1111/j.1399-6576.1997.tb04721.x; BROMAGE PR, 1994, BAILLIERE CLIN ANAES, V7, P793; BURM AGL, 1986, ANESTH ANALG, V65, P1281; CAMANN WR, 1993, ANESTHESIOLOGY, V78, P870, DOI 10.1097/00000542-199305000-00010; Cohen S, 1998, ANESTHESIOLOGY, V89, P1354, DOI 10.1097/00000542-199812000-00012; COHEN S, 1992, ANESTH ANALG, V74, P226, DOI 10.1213/00000539-199202000-00009; DOHI S, 1987, ANESTH ANALG, V66, P599; DOUGLAS MJ, 1986, CAN J ANAESTH, V33, P737, DOI 10.1007/BF03027123; HURLEY RJ, 1991, REGION ANESTH, V16, P303; Iida H, 1999, ANESTHESIOLOGY, V91, P479, DOI 10.1097/00000542-199908000-00023; Kjonniksen I, 2000, ACTA ANAESTH SCAND, V44, P864, DOI 10.1034/j.1399-6576.2000.440713.x; Kokki H, 2002, ACTA ANAESTH SCAND, V46, P647, DOI 10.1034/j.1399-6576.2002.460603.x; KOZODY R, 1984, CAN ANAESTH SOC J, V31, P503, DOI 10.1007/BF03009534; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; Niemi G, 1998, ACTA ANAESTH SCAND, V42, P897, DOI 10.1111/j.1399-6576.1998.tb05348.x; Niemi G, 2002, ANESTH ANALG, V94, P1598, DOI 10.1097/00000539-200206000-00044; Niemi G, 2001, ACTA ANAESTH SCAND, V45, P221, DOI 10.1034/j.1399-6576.2001.450214.x; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P123; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P66; PORTER SS, 1985, ACTA ANAESTH SCAND, V29, P330, DOI 10.1111/j.1399-6576.1985.tb02210.x; ROBERTSON K, 1985, CAN ANAESTH SOC J, V32, P502, DOI 10.1007/BF03010800; Sakaguchi Y, 2000, ANAESTH INTENS CARE, V28, P522, DOI 10.1177/0310057X0002800506; SCOTT DA, 1995, ANESTHESIOLOGY, V83, P727, DOI 10.1097/00000542-199510000-00012; Scott DA, 1999, ANESTH ANALG, V88, P857, DOI 10.1097/00000539-199904000-00033; SOLOMON RE, 1994, ANESTH ANALG, V78, P1164; WANG C, 1993, ANESTHESIOLOGY, V79, P766, DOI 10.1097/00000542-199310000-00019; WELCHEW EA, 1983, ANAESTHESIA, V38, P1037, DOI 10.1111/j.1365-2044.1983.tb12476.x	33	38	42	0	0	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2003	47	4					439	450		10.1034/j.1399-6576.2003.00077.x			12	Anesthesiology	Anesthesiology	666MD	WOS:000182180300013	12694144				2020-06-30	J	Canto, M; Sanchez, MJ; Casas, MA; Bataller, ML				Canto, M; Sanchez, MJ; Casas, MA; Bataller, ML			Bilateral paravertebral blockade for conventional cardiac surgery	ANAESTHESIA			English	Article						surgery, cardiac; anaesthesia, regional, conduction, paravertebral	POSTOPERATIVE ANALGESIA; PAIN RELIEF; BUPIVACAINE; ROPIVACAINE; ANESTHESIA	This prospective observational study aimed to assess the feasibility and efficacy of bilateral continuous paravertebral blockade combined with general anaesthesia in 'on-pump' cardiac surgery. One hundred and eleven elective patients had two paravertebral catheters inserted: one either side of the midline within 2.5 cm of the spinous process of the third or fourth thoracic vertebrae, through which a mixture of ropivacame and fentanyl was infused during and after surgery. In the first 47 patients, haemodynamic and analgesia data were recorded. In all patients, time to tracheal extubation, length of stay in the intensive care unit and the hospital, morbidity and mortality, and any complication attributable to the regional blockade were recorded. The technique was associated with good haemodynamic stability, good postoperative analgesia and short times to tracheal extubation, with few significant complications.	Hosp Gen Alicante, Anesthesiol Serv, Alicante 03010, Spain	Canto, M (reprint author), Hosp Gen Alicante, Anesthesiol Serv, C Pintor Baeza S-N, Alicante 03010, Spain.	m.canto@telefonica.net					BERRISFORD RG, 1993, BRIT J ANAESTH, V70, P201, DOI 10.1093/bja/70.2.201; Canto M, 2002, J CARDIOTHOR VASC AN, V16, P723, DOI 10.1053/jcan.2002.128412; Chaney MA, 1997, ANESTH ANALG, V84, P241, DOI 10.1097/00000539-199702000-00002; CHEEMA SPS, 1995, ANAESTHESIA, V50, P118, DOI 10.1111/j.1365-2044.1995.tb15092.x; Dauphin A, 1997, CAN J ANAESTH, V44, P367, DOI 10.1007/BF03014455; Desai PM, 1999, BRIT J ANAESTH, V82, P149; DICKENSON AH, 1995, BRIT J ANAESTH, V75, P193, DOI 10.1093/bja/75.2.193; EASON MJ, 1979, ANAESTHESIA, V34, P638, DOI 10.1111/j.1365-2044.1979.tb06363.x; Ganapathy S, 1999, J CARDIOTHOR VASC AN, V13, P594, DOI 10.1016/S1053-0770(99)90015-0; GILBERT J, 1989, ACTA ANAESTH SCAND, V33, P142, DOI 10.1111/j.1399-6576.1989.tb02877.x; Joachimsson P O, 1989, J Cardiothorac Anesth, V3, P444, DOI 10.1016/S0888-6296(89)97603-5; Karmakar MK, 1997, PAEDIATR ANAESTH, V7, P469, DOI 10.1046/j.1460-9592.1997.d01-118.x; Mehta Y, 1998, J CARDIOTHOR VASC AN, V12, P162, DOI 10.1016/S1053-0770(98)90324-X; Morrison SG, 2000, ANESTH ANALG, V90, P1308, DOI 10.1097/00000539-200006000-00009; Nair V, 2001, CAN J ANAESTH, V48, P179, DOI 10.1007/BF03019732; Naja Z, 2001, ANAESTHESIA, V56, P1184; Nashef SAM, 1999, EUR J CARDIO-THORAC, V16, P9, DOI 10.1016/S1010-7940(99)00134-7; Ongjoco RRS, 2000, ANESTHESIOLOGY, V92, P968, DOI 10.1097/00000542-200004000-00013; Peterson KL, 2000, ANESTH ANALG, V90, P1014, DOI 10.1097/00000539-200005000-00002; Pettersson N, 1998, REGION ANESTH PAIN M, V23, P189, DOI 10.1097/00115550-199823020-00013; PURCELLJONES G, 1989, ANESTH ANALG, V68, P32; RICHARDSON J, 1995, ANAESTHESIA, V50, P995, DOI 10.1111/j.1365-2044.1995.tb05939.x; ROQUES F, 1995, EUR J CARDIO-THORAC, V9, P433, DOI 10.1016/S1010-7940(05)80078-8; Roques F, 2000, EUR J CARDIO-THORAC, V18, P27, DOI 10.1016/S1010-7940(00)00417-6; Royston D, 1996, ANESTHESIOLOGY, V85, pA83; Saito T, 2001, ACTA ANAESTH SCAND, V45, P30, DOI 10.1034/j.1399-6576.2001.450105.x; SONI AK, 1994, BRIT J ANAESTH, V72, P462, DOI 10.1093/bja/72.4.462	27	31	33	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	APR	2003	58	4					365	370		10.1046/j.1365-2044.2003.03082_2.x			6	Anesthesiology	Anesthesiology	656WR	WOS:000181634500011	12688271				2020-06-30	J	Buyukkocak, U; Ozcan, S; Daphan, C; Apan, A; Koc, C				Buyukkocak, U; Ozcan, S; Daphan, C; Apan, A; Koc, C			A comparison of four intravenous sedation techniques and Bispectral Index monitoring in sinonasal surgery	ANAESTHESIA AND INTENSIVE CARE			English	Article						monitoring : bispectral index surgery : otorhinolaryngological; anaesthetic drugs : midazolam; propofol; opioids : fentanyl, remifentanil; conscious sedation	ENDOSCOPIC SINUS SURGERY; GENERAL-ANESTHESIA; REGIONAL ANESTHESIA; LOCAL-ANESTHESIA; PROPOFOL; REMIFENTANIL; ALFENTANIL; MIDAZOLAM; INDUCTION; FENTANYL	This study was performed to investigate the quality of different intravenous sedation techniques, and the correlation between the Bispectral Index (BIS) values and the Observer's Assessment of Alertness/Sedation (OAA/S) scores. Eighty patients undergoing sinonasal surgery were randomly assigned to one of four groups. Group MF received midazolam and fentanyl, group PF received propofol and fentanyl, group MR received midazolam and remifentanil, and group PR received propofol and remifentanil. Heart rate and mean arterial pressuure values were not different among the groups. SpO(2) decreased only after intravenous medication in groups MF and MR (P<0.017). Emesis was less common with propofol. A positive relationship existed between the BIS values and OAA/S scores during the operation in all groups and the strongest correlation was observed in group PR (r=0.565 and P<0.001). In conclusion, these four intravenous sedation techniques did not change mean arterial pressure, heart rate or SpO(2) clinically and produced a similar level of light sedation. The BIS was useful for monitoring of sedation during sinonasal surgery under local anaesthesia with intravenous sedation.	Kirikkale Univ, Sch Med, Dept Anesthesiol & Reanimat, Kirikkale, Turkey; Kirikkale Univ, Sch Med, Dept Gen Surg, Kirikkale, Turkey; Kirikkale Univ, Sch Med, Dept Otorhinolaryngol & Head & Neck Surg, Kirikkale, Turkey	Buyukkocak, U (reprint author), Kuyuyazisi Cad 23-9, TR-06010 Ankara, Turkey.						Avramov MN, 1996, ANESTHESIOLOGY, V85, P1283, DOI 10.1097/00000542-199612000-00009; Balakrishnan G, 2000, ANESTH ANALG, V91, P163, DOI 10.1097/00000539-200007000-00030; Barr G, 2000, ACTA ANAESTH SCAND, V44, P807, DOI 10.1034/j.1399-6576.2000.440707.x; Billard V, 1997, CLIN PHARMACOL THER, V61, P45, DOI 10.1016/S0009-9236(97)90181-8; Chan MTV, 2000, EUR J ANAESTH, V17, P146, DOI 10.1046/j.1365-2346.2000.00613.x; Fedok FG, 2000, OTOLARYNG HEAD NECK, V122, P560, DOI 10.1016/S0194-5998(00)70101-X; GITTELMAN PD, 1993, ANN OTO RHINOL LARYN, V102, P289, DOI 10.1177/000348949310200408; Guignard B, 2000, ANESTH ANALG, V90, P161, DOI 10.1097/00000539-200001000-00034; Ibrahim AE, 2001, ANESTHESIOLOGY, V95, P1151, DOI 10.1097/00000542-200111000-00019; Iselin-Chaves IA, 2000, ANESTHESIOLOGY, V92, P1300, DOI 10.1097/00000542-200005000-00018; Jellish WS, 2000, OTOLARYNG HEAD NECK, V122, P222, DOI 10.1016/S0194-5998(00)70243-9; Kearse LA, 1998, ANESTHESIOLOGY, V88, P25, DOI 10.1097/00000542-199801000-00007; Lauwers M, 1999, ANESTH ANALG, V88, P134, DOI 10.1097/00000539-199901000-00025; Lee WC, 1997, ANN OTO RHINOL LARYN, V106, P767, DOI 10.1177/000348949710600910; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; Loop T, 2000, ANESTH ANALG, V91, P123, DOI 10.1097/00000539-200007000-00023; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; Mi WD, 1998, CAN J ANAESTH, V45, P19, DOI 10.1007/BF03011986; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; REEVES JG, 2002, CLIN ANAESTHESIOL, P151; Sandler NA, 2000, J ORAL MAXIL SURG, V58, P364, DOI 10.1016/S0278-2391(00)90911-X; SERVIN F, 1999, ANESTH ANALG, V89, P528; SRINIVASAN V, 1995, J LARYNGOL OTOL, V109, P614, DOI 10.1017/S0022215100130853; Strachan AN, 2000, BRIT J ANAESTH, V84, P489	24	4	9	0	1	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	APR	2003	31	2					164	171		10.1177/0310057X0303100204			8	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	668FJ	WOS:000182279400004	12712779	Bronze			2020-06-30	J	Pang, CK; Yap, J; Chen, PP				Pang, CK; Yap, J; Chen, PP			The effect of an alveolar recruitment strategy on oxygenation during laparascopic cholecystectomy	ANAESTHESIA AND INTENSIVE CARE			English	Article; Proceedings Paper	ANZICS 27th Annual Scientific Meeting/8th Australian and New Zealand Paediatric and Neonatal Intensive Care Conference	OCT 17-20, 2002	PERTH, AUSTRALIA			anaesthesia : general; ventilation : strategy, alveolar recruitment surgery : laparoscopic	END-EXPIRATORY PRESSURE; GENERAL-ANESTHESIA; LAPAROSCOPIC CHOLECYSTECTOMY; PULMONARY-FUNCTION; ATELECTASIS; REEXPANSION; VENTILATION; LUNG	This prospective randomized controlled trial examined the effect of an "alveolar recruitment strategy" (ARS) in healthy patients having laparoscopic cholecystectomy. Twenty-four consecutive ASA 1 or 2 patients were randomly allocated to an ARS or control group. All patients were manually ventilated to a maximal airway pressure of 25 to 30 cmH(2)O or a tidal volume of 10 ml/kg during induction of general anaesthesia. After intubation, the control group was ventilated with standardized mechanical ventilation settings. The ARS group was manually ventilated to an airway pressure of 40 cmH(2)O for 10 breaths over one minute, followed by mechanical ventilation with similar standardized settings plus 5 cmH(2)O positive end-expiratory pressure. Blood pressure, heart rate, arterial oxygen and carbon dioxide tension (PaO2 and PaCO2) was measured pre-induction, 20 minutes post induction but before abdominal insufflation, 20 minutes after abdominal insufflation, and 20 minutes after arrival in the recovery room. Demographic and operation data were similar The ARS group pre-insufflation PaO2 [30.16 (9.43)] was higher than the control group [22.19 (9.08)] (P=0.047). There was a significant difference in PaO2 between the ARS [23.94 (4.87)] and control [17.26 (3.93)] groups during the post-insufflation period (P=0.001). There were no significant differences in PaO2 between the groups during baseline and recovery periods. No adverse effects were reported. ARS improved arterial oxygenation intraoperatively in healthy patients having laparoscopic cholecystectomy, without clinical cardiovascular compromise or respiratory complication. We conclude that this alveolar recruitment strategy is a useful method of increasing arterial oxygenation.	Alice Ho Miu Ling Nethersole Hosp, Dept Anaesthesiol Intens Care & Operating Serv, Tai Po, Hong Kong, Peoples R China	Yap, J (reprint author), Alice Ho Miu Ling Nethersole Hosp, Dept Anaesthesiol Intens Care & Operating Serv, Tai Po, Hong Kong, Peoples R China.						AMATO MB, 1995, AM J RESP CRIT CARE, V151, P1835; BENDIXEN HH, 1963, NEW ENGL J MED, V269, P991, DOI 10.1056/NEJM196311072691901; Chumillas MS, 1998, EUR J SURG, V164, P433; Clarke JP, 1998, ANAESTH INTENS CARE, V26, P262, DOI 10.1177/0310057X9802600305; GATTINONI L, 1995, AM J RESP CRIT CARE, V151, P1807, DOI 10.1164/ajrccm.151.6.7767524; GUNNARSSON L, 1995, ACTA ANAESTH SCAND, V39, P302, DOI 10.1111/j.1399-6576.1995.tb04066.x; Joris JL, 1998, BRIT J ANAESTH, V80, P283; Karayiannakis AJ, 1996, BRIT J ANAESTH, V77, P448, DOI 10.1093/bja/77.4.448; LACHMANN B, 1992, INTENS CARE MED, V18, P319, DOI 10.1007/BF01694358; LUMB A, 2000, ANAESTHESIA NUNNS AP, P420; Lumb A.B., 2000, NUNNS APPL RESP PHYS, P163; Medoff BD, 2000, CRIT CARE MED, V28, P1210, DOI 10.1097/00003246-200004000-00051; Milheiro A, 1996, BRIT J SURG, V83, P1059, DOI 10.1002/bjs.1800830808; MOFFA SM, 1993, J TRAUMA, V35, P613, DOI 10.1097/00005373-199310000-00018; Neumann P, 1999, ACTA ANAESTH SCAND, V43, P295, DOI 10.1034/j.1399-6576.1999.430309.x; Rothen HU, 1999, BRIT J ANAESTH, V82, P551; ROTHEN HU, 1995, ANESTHESIOLOGY, V82, P832, DOI 10.1097/00000542-199504000-00004; ROTHEN HU, 1995, ACTA ANAESTH SCAND, V39, P118, DOI 10.1111/j.1399-6576.1995.tb05602.x; Rothen HU, 1998, BRIT J ANAESTH, V81, P681, DOI 10.1093/bja/81.5.681; ROTHEN HU, 1993, BRIT J ANAESTH, V71, P788, DOI 10.1093/bja/71.6.788; Sharma RR, 1999, ANESTHESIOLOGY, V91, P406, DOI 10.1097/00000542-199908000-00014; Tusman G, 1999, BRIT J ANAESTH, V82, P8	22	19	23	0	3	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	APR	2003	31	2					176	180		10.1177/0310057X0303100206			5	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	668FJ	WOS:000182279400006	12712781	Bronze			2020-06-30	J	Chiu, CL; Murugasu, J; Chan, L				Chiu, CL; Murugasu, J; Chan, L			The use of modified VBM laryngeal tube compared to laryngeal mask airway during spontaneous ventilation	ANAESTHESIA AND INTENSIVE CARE			English	Article						airway : laryngeal tube, laryngeal mask airway, spontaneous ventilation	MANAGEMENT; EMERGENCY; RESUSCITATION; PERSONNEL; DEVICE	We have compared the use of the laryngeal mask airway with the new modified laryngeal tube in a prospective randomized controlled study. Sixty ASA 1 or 2 patients, aged 18 to 65 years, scheduled for elective surgery and breathing spontaneously under general anaesthesia, were studied. After preoxygenation, anaesthesia was induced with fentanyl and propofol. The patients were randomized to receive either a laryngeal mask airway or a laryngeal tube. Anaesthesia was maintained with nitrous oxide, oxygen and isoflurane. We recorded the speed and the ease of insertion, the number of attempts needed to successfully secure the airway and intraoperative complications, such as partial airway obstruction needing airway manipulation. The airway devices were removed with the patients fully awake at the end of surgery. Systolic arterial blood pressure, heart rate and end-tidal CO2 were recorded at various time intervals. Postoperative complications were recorded. We found that the incidence of partial airway obstruction needing intraoperative airway manipulation was higher with the laryngeal tube than with the laryngeal mask airway. We conclude that during spontaneous ventilation the modified laryngeal tube is not as reliable in providing a satisfactory airway and we consider it is not a suitable alternative to the laryngeal mask airway.	Univ Malaya, Fac Med, Dept Anaesthesia, Kuala Lumpur 59100, Malaysia	Chiu, CL (reprint author), Univ Malaya, Fac Med, Dept Anaesthesia, Lembah Pantai, Kuala Lumpur 59100, Malaysia.		CHAN, LUCY/B-8887-2010				Agro F, 2001, AM J EMERG MED, V19, P163, DOI 10.1053/ajem.2001.21355; Agro F, 1999, RESUSCITATION, V41, P284; Asai T, 2001, RESUSCITATION, V51, P213, DOI 10.1016/S0300-9572(01)00448-8; Asai T, 2000, ANAESTHESIA, V55, P1099, DOI 10.1046/j.1365-2044.2000.01710.x; CHIU CL, 2001, ASEAN J ANAESTHESIOL, V2, P90; DAVIES PRF, 1990, LANCET, V336, P977, DOI 10.1016/0140-6736(90)92429-L; Dorges V, 2001, RESUSCITATION, V51, P185, DOI 10.1016/S0300-9572(01)00423-3; Dorges V, 2000, ANESTH ANALG, V90, P1220; Dorges V, 2000, CRIT CARE, V4, P369, DOI 10.1186/cc720; Genzwuerker H V, 2000, Prehosp Emerg Care, V4, P168, DOI 10.1080/10903120090941452; Genzwuerker HV, 2002, RESUSCITATION, V52, P221, DOI 10.1016/S0300-9572(01)00472-5; Genzwuerker HV, 2001, RESUSCITATION, V51, P291, DOI 10.1016/S0300-9572(01)00410-5; Miller DM, 2001, EUR J ANAESTH, V18, P593; PENNANT JH, 1992, ANESTH ANALG, V74, P531	14	7	8	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	APR	2003	31	2					187	192		10.1177/0310057X0303100209			6	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	668FJ	WOS:000182279400009	12712784	Bronze			2020-06-30	J	Critchley, LAH; Chan, L				Critchley, LAH; Chan, L			General anaesthesia in a child with Larsen syndrome	ANAESTHESIA AND INTENSIVE CARE			English	Article						anaesthesia : Larsen syndrome		Larsen syndrome is a rare congenital connective tissue disorder which is characterized by multiple dislocations of major joints, typical facial appearance, cervical spine narrowing and instability and respiratory difficulties secondary to laryngotracheomalacia. A case of general anaesthesia for laparoscopic hernia repair in a male child aged 16 months with this syndrome is presented. Anaesthesia was well tolerated though intubation proved difficult. Cervical spine instability and postoperative respiratory complications are potential problems.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China	Critchley, LAH (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anaesthesia & Intens Care, Shatin, Hong Kong, Peoples R China.		Critchley, Lester A H/J-9420-2013				ATKINSON RS, 1987, SYNOPSIS ANAESTHESIA, P429; Becker R, 2000, CLIN GENET, V57, P148, DOI 10.1034/j.1399-0004.2000.570210.x; BONAVENTURE J, 1992, J MED GENET, V29, P465; Caksen H, 2001, GENET COUNSEL, V12, P369; CORMACK RS, 1984, ANAESTHESIA, V39, P1105, DOI 10.1111/j.1365-2044.1984.tb08932.x; GRUNDFAST KM, 1981, ANN OTO RHINOL LARYN, V90, P303, DOI 10.1177/000348948109000401; Johnston CE, 1996, J BONE JOINT SURG AM, V78A, P538, DOI 10.2106/00004623-199604000-00007; KIEL EA, 1983, PEDIATRICS, V71, P942; LARSEN LJ, 1950, J PEDIATR-US, V37, P574, DOI 10.1016/S0022-3476(50)80268-8; LATTA RJ, 1971, J PEDIATR-US, V78, P291, DOI 10.1016/S0022-3476(71)80014-8; Liang CD, 2001, PEDIATR CARDIOL, V22, P245, DOI 10.1007/s002460010213; Michel TC, 2001, ANESTH ANALG, V92, P1266; ROCK MJ, 1988, PEDIATR PULM, V5, P55, DOI 10.1002/ppul.1950050111; STANLEY CS, 1988, CLIN GENET, V33, P395; STEVENSON GW, 1991, ANESTHESIOLOGY, V75, P142, DOI 10.1097/00000542-199107000-00023; STRISCIUGLIO P, 1983, J MED GENET, V20, P422, DOI 10.1136/jmg.20.6.422; Sugarman G I, 1975, Birth Defects Orig Artic Ser, V11, P121; Tobias JD, 1996, J CLIN ANESTH, V8, P255, DOI 10.1016/0952-8180(96)00021-9	18	4	4	0	0	AUSTRALIAN SOC ANAESTHETISTS	EDGECLIFF	P O BOX 600, EDGECLIFF, NSW 2021, AUSTRALIA	0310-057X			ANAESTH INTENS CARE	Anaesth. Intensive Care	APR	2003	31	2					217	220		10.1177/0310057X0303100216			4	Anesthesiology; Critical Care Medicine	Anesthesiology; General & Internal Medicine	668FJ	WOS:000182279400016	12712791	Bronze			2020-06-30	J	Kim, KS; Cheong, MA; Jeon, JW; Lee, JH; Shim, JC				Kim, KS; Cheong, MA; Jeon, JW; Lee, JH; Shim, JC			The dose effect of ephedrine on the onset time of vecuronium	ANESTHESIA AND ANALGESIA			English	Article							CARDIAC-OUTPUT; TRACHEAL INTUBATION; PRIMING PRINCIPLE; ROCURONIUM; PROPOFOL; ANESTHESIA; STIMULATION; COMBINATION; TRAIN-OF-4; RESPONSES	A small dose of ephedrine decreases the onset time of rocuronium and cisatracurium; however, ephedrine might be associated with adverse hemodynamic effects. The appropriate dose of ephedrine has not been determined. We, therefore, studied 120 patients anesthetized with fentanyl 2 mug/kg and propofol 2-2.5 mg/kg who were randomly divided to receive either ephedrine (30,70, or 110 mug/kg) or saline. During propofol anesthesia, the neuromuscular block was monitored by mechanomyography by using submaximal current of train-of-four stimulation every 10 s. To determine cardiac output, a transcutaneous Doppler probe was placed externally at the suprasternal notch. Tracheal intubation was performed by a blinded investigator at 2 min after vecuronium. Neuromuscular block, intubating conditions, and hemodynamic effects were measured during the induction of anesthesia. Both ephedrine 70 and 110 mug/kg improved intubating conditions at 2 min after vecuronium; however, 110 mug/kg was associated with adverse hemodynamic effects. We conclude that ephedrine 70 mug/kg given before the induction of anesthesia improved intubating conditions at 2 min after vecuronium, probably by increased cardiac output without significant adverse hemodynamic effects.	Hanyang Univ Hosp, Dept Anesthesiol, Seoul 133792, South Korea	Kim, KS (reprint author), Hanyang Univ Hosp, Dept Anesthesiol, 17 Haengdang Dong, Seoul 133792, South Korea.	kimks@hanyang.ac.kr		KIM, KYO SANG/0000-0002-2186-3484			Albert F, 2000, Acta Anaesthesiol Belg, V51, P167; BRULL SJ, 1990, ANESTHESIOLOGY, V72, P629, DOI 10.1097/00000542-199004000-00009; CONNELLY NR, 1990, ANESTH ANALG, V70, P650; COOPER R, 1992, BRIT J ANAESTH, V69, P269, DOI 10.1093/bja/69.3.269; DERBYSHIRE DR, 1983, BRIT J ANAESTH, V55, P855, DOI 10.1093/bja/55.9.855; ELBEHEIRY H, 1995, CAN J ANAESTH, V42, P875, DOI 10.1007/BF03011034; FREUND PR, 1987, AM J SURG, V153, P490, DOI 10.1016/0002-9610(87)90800-2; Gamlin F, 1999, ANAESTH INTENS CARE, V27, P477, DOI 10.1177/0310057X9902700507; Gamlin F, 1996, ANAESTHESIA, V51, P488, DOI 10.1111/j.1365-2044.1996.tb07799.x; Horak J, 2000, CRIT CARE CLIN, V16, P411, DOI 10.1016/S0749-0704(05)70120-2; JONES RM, 1989, BRIT J ANAESTH, V63, P1, DOI 10.1093/bja/63.1.1; MAGORIAN T, 1993, ANESTHESIOLOGY, V79, P913, DOI 10.1097/00000542-199311000-00007; Munoz HR, 1997, ANESTH ANALG, V85, P437, DOI 10.1097/00000539-199708000-00034; NAGUIB M, 1994, CAN J ANAESTH, V41, P902, DOI 10.1007/BF03010932; PARK WK, 1992, ANESTH ANALG, V74, P395; PERRINO AC, 1990, ANESTH ANALG, V71, P651; PERRINO AC, 1991, ANESTH ANALG, V73, P705; RORVIK K, 1988, BRIT J ANAESTH, V61, P180, DOI 10.1093/bja/61.2.180; SCHMID ER, 1993, ANESTH ANALG, V77, P971; SCHWARZ S, 1985, ANESTHESIOLOGY, V62, P388, DOI 10.1097/00000542-198504000-00004; SILVERMAN DG, 1992, ANESTHESIOLOGY, V76, P34, DOI 10.1097/00000542-199201000-00005; Szmuk P, 2000, ANESTH ANALG, V90, P1217, DOI 10.1097/00000539-200005000-00041; Tsen LC, 2000, J CLIN ANESTH, V12, P378, DOI 10.1016/S0952-8180(00)00176-8; TULLOCK WC, 1990, ANESTH ANALG, V70, P86; Upton RN, 1999, ANESTH ANALG, V89, P545, DOI 10.1097/00000539-199909000-00002	25	12	15	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2003	96	4					1042	1046		10.1213/01.ANE.0000034551.93647.3A			5	Anesthesiology	Anesthesiology	659ZB	WOS:000181808300024	12651656				2020-06-30	J	Multz, AS				Multz, AS			Prolonged dexmedetomidine infusion as an adjunct in treating sedation-induced withdrawal	ANESTHESIA AND ANALGESIA			English	Article							ANALGESIC PROPERTIES; INTENSIVE-CARE; AGONISTS; RATS; ANESTHESIA; COCAINE; ALPHA-2		Long Isl Jewish Med Ctr, Med ICU, New Hyde Pk, NY 11040 USA	Multz, AS (reprint author), Long Isl Jewish Med Ctr, Med ICU, 270-05 76th Ave, New Hyde Pk, NY 11040 USA.	amultz@lij.edu					Aley KO, 1997, J NEUROSCI, V17, P3907; ASHTON H, 1987, BRIT J ADDICT, V82, P665; COUPAR IM, 1992, N-S ARCH PHARMACOL, V345, P553; GHIGNONE M, 1986, ANESTHESIOLOGY, V64, P36, DOI 10.1097/00000542-198601000-00007; Glass MJ, 2002, SYNAPSE, V43, P208, DOI 10.1002/syn.10036; Hall JE, 2000, ANESTH ANALG, V90, P699, DOI 10.1097/00000539-200003000-00035; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; KERSTEN JR, 1995, ANESTH ANALG, V80, P114, DOI 10.1097/00000539-199501000-00020; Khan ZP, 1999, ANAESTHESIA, V54, P146, DOI 10.1046/j.1365-2044.1999.00659.x; LIDBRINK P, 1974, BRAIN RES, V74, P19, DOI 10.1016/0006-8993(74)90109-7; MAZE M, 1991, ANESTH ANALG, V73, P204; Maze M, 1988, J Clin Anesth, V1, P146, DOI 10.1016/0952-8180(88)90034-7; MEERT TF, 1994, ANESTHESIOLOGY, V81, P677, DOI 10.1097/00000542-199409000-00022; MILNE B, 1991, CAN J ANAESTH, V38, P809, DOI 10.1007/BF03036952; RIKER RR, 1908, ANESTHESIOLOGY, V95, pA383; Shafer A, 1998, CRIT CARE MED, V26, P947, DOI 10.1097/00003246-199805000-00034; TELLA SR, 1992, J PHARMACOL EXP THER, V262, P936; Venn RM, 2000, CRIT CARE, V4, P302, DOI 10.1186/cc712; VENN RM, IN PRESS INTENSIVE C	19	39	39	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2003	96	4					1054	1055		10.1213/01.ANE.0000050773.70232.08			2	Anesthesiology	Anesthesiology	659ZB	WOS:000181808300027	12651659				2020-06-30	J	Mathews, DM; Kumaran, KR; Neuman, GG				Mathews, DM; Kumaran, KR; Neuman, GG			Bispectral index-derived facial electromyography-guided fentanyl titration in the opiate-exposed patient	ANESTHESIA AND ANALGESIA			English	Article							ANESTHESIA; EMG		St Vincents Catholic Med Ctr St Vincents Manhatta, Dept Anesthesiol, New York, NY USA	Mathews, DM (reprint author), 153 W 11th St,NR 408, New York, NY 10011 USA.	dmathews@saintvincentsnyc.org					CHANG TL, 1988, ANESTH ANALG, V67, P521; DUTTON RC, 1997, J CLIN MONITOR, V14, P5; EDMONDS H L JR, 1986, International Journal of Clinical Monitoring and Computing, V3, P135, DOI 10.1007/BF01880767; Edmonds H L Jr, 1985, Int J Clin Monit Comput, V1, P201, DOI 10.1007/BF01720184; Harmel M H, 1978, Acta Anaesthesiol Scand Suppl, V70, P97; Lysakowski C, 2001, BRIT J ANAESTH, V86, P523, DOI 10.1093/bja/86.4.523; Paloheimo M, 1990, Acta Anaesthesiol Scand Suppl, V93, P1; PALOHEIMO M, 1989, EUR J ANAESTH, V6, P111; PRKACHIN KM, 1992, PAIN, V51, P297, DOI 10.1016/0304-3959(92)90213-U; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; Shander A, 2001, J CLIN ANESTH, V13, P78; Song DJ, 1997, ANESTHESIOLOGY, V87, P842, DOI 10.1097/00000542-199710000-00018; YLIHANKALA A, 1994, BRIT J ANAESTH, V73, P174, DOI 10.1093/bja/73.2.174	13	12	15	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2003	96	4					1062	1064		10.1213/01.ANE.0000050770.60636.09			3	Anesthesiology	Anesthesiology	659ZB	WOS:000181808300029	12651661				2020-06-30	J	Ueta, K; Takeda, K; Ohsumi, H; Haruna, J; Shibuya, H; Mashimo, T				Ueta, K; Takeda, K; Ohsumi, H; Haruna, J; Shibuya, H; Mashimo, T			A small Preoperative test dose of intravenous fentanyl can predict subsequent analgesic efficacy and incidence of side effects in patients due to receive epidural fentanyl	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 14-18, 2000	SAN FRANCISCO, CALIFORNIA	Amer Soc Anesthesiologists			POSTOPERATIVE NAUSEA; OPIATE-RECEPTOR; BUPIVACAINE; INTUBATION; EXPRESSION; RESPONSES; PAIN	Because individual variation is a likely factor affecting both the incidence and severity of side effects and the analgesic efficacy of epidural opioids, assessment of individual variation could be useful in deciding optimal dosage. By evaluating the response to a small test dose of IV fentanyl, we designed this study to predict the degree of pain relief and the incidence of side effects in patients who would be receiving postoperative epidural fentanyl. Before the induction of anesthesia, 50 mug of fentanyl was administered IV, and 2 min after fentanyl, the patient response was evaluated. Twenty-three patients, who reported nausea, sleepiness, dizziness, sensation of warmth, and other symptoms, were categorized as responders (Group R); the remaining 20 patients were categorized as non-responders (Group NR). At the completion of surgery, infusion of epidural fentanyl was administered (0.3 mg/d in 0.25% bupivacaine) for 96 h. At postoperative Hours 6 and 24, Group R had significantly lower visual analog scale scores for postoperative pain intensity and required fewer analgesics than Group NR. The incidence of side effects, however, was 74% for Group R and 10% for Group NR (P < 0.05), and side effects were more serious in Group R. This study demonstrates that preoperative administration of a small dose of fentanyl during the induction of anesthesia enables prediction of the analgesic efficacy of postoperative epidural fentanyl and the incidence and severity of side effects.	Osaka Univ, Dept Anesthesiol, Sch Med, Osaka 5650871, Japan; Osaka Natl Hosp, Dept Anesthesia, Osaka, Japan; Fujita Hlth Univ, Dept Anesthesiol, Aichi, Japan	Ueta, K (reprint author), Osaka Univ, Dept Anesthesiol, Sch Med, 2-2 Yamadaoka, Osaka 5650871, Japan.	kueta@anes.med.osaka-u.ac.jp	Takeda, Kiyoshi/C-9331-2009				ANANTHANARAYAN C, 1990, ANAESTHESIA, V45, P595, DOI 10.1111/j.1365-2044.1990.tb14852.x; BILLARD V, 1994, ANESTHESIOLOGY, V81, P1384, DOI 10.1097/00000542-199412000-00013; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; COHEN S, 1992, ANESTH ANALG, V74, P226, DOI 10.1213/00000539-199202000-00009; Eberhart LHJ, 2000, ACTA ANAESTH SCAND, V44, P480, DOI 10.1034/j.1399-6576.2000.440422.x; Eberhart LHJ, 1999, EUR J ANAESTH, V16, P290, DOI 10.1046/j.1365-2346.1999.00480.x; Gedney JA, 1998, ANAESTHESIA, V53, P1148, DOI 10.1046/j.1365-2044.1998.00636.x; Ko SH, 1998, ANESTH ANALG, V86, P658, DOI 10.1097/00000539-199803000-00041; Korttila K, 1998, ACTA ANAESTH SCAND, V42, P493, DOI 10.1111/j.1399-6576.1998.tb05156.x; Larkin M, 1999, LANCET, V354, P310, DOI 10.1016/S0140-6736(05)75217-X; Parlow JL, 1999, CAN J ANAESTH, V46, P719, DOI 10.1007/BF03013905; Uhl GR, 1999, P NATL ACAD SCI USA, V96, P7752, DOI 10.1073/pnas.96.14.7752; Woodhouse A, 1999, PAIN, V80, P545, DOI 10.1016/S0304-3959(98)00247-4; YASUI M, 1998, RINSHOUMASUI, V21, P1701	14	4	4	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2003	96	4					1079	1082		10.1213/01.ANE.0000055364.39576.FF			4	Anesthesiology	Anesthesiology	659ZB	WOS:000181808300032	12651664				2020-06-30	J	Capogna, G; Camorcia, M; Columb, MO				Capogna, G; Camorcia, M; Columb, MO			Minimum analgesic doses of fentanyl and sufentanil for epidural analgesia in the first stage of labor	ANESTHESIA AND ANALGESIA			English	Article							BUPIVACAINE; DELIVERY; LIDOCAINE	In this study, we sought to determine the minimum analgesic doses and relative potencies of fentanyl and sufentanil when they are used as the sole epidural analgesic during the first stage of labor. Nulliparous parturients (n = 66) in spontaneous labor at term gestation and requesting epidural analgesia were enrolled into this prospective, double-blinded, randomized, sequential-allocation study. Each woman received fentanyl or sufentanil diluted with 0.9% wt/vol saline to a volume of 10 mL. The initial dose was arbitrarily chosen to be 125 mug for fentanyl and 25 mug for sufentanil, with subsequent doses being determined by the response of the previous patient (testing interval, 5 mug for fentanyl and 1 mug for sufentanil). Efficacy was accepted if the visual analog score decreased to less than or equal to10 mm on a 100-mm scale within 30 min. The minimum analgesic dose or median effective dose was 21.1 mug (95% confidence interval [CI], 20.2-21.9 mug) for sufentanil and 124.2 mug (95% CI, 118.1-130.6 mug) for fentanyl (P < 0.0001). The sufentanil/fentanyl potency ratio was 5.9 (95% CI, 5.6-6.3). In conclusion, we have established the equivalent doses and relative potencies of fentanyl and sufentanil for epidural analgesia in the first stage of labor.	Citta Roma Hosp, Dept Anesthesia, I-00152 Rome, Italy; Univ S Manchester Hosp, Dept Anaesthesia & Intens Care, Manchester M20 8LR, Lancs, England	Capogna, G (reprint author), Citta Roma Hosp, Dept Anesthesia, Casa Cura Citta Roma,V Maidalchini 20, I-00152 Rome, Italy.	g.capogna@pronet.it	Columb, Malachy/F-9588-2016	Columb, Malachy/0000-0001-7837-4262			BIRNBACH DJ, 1989, ANESTH ANALG, V68, P808; BROWNRIDGE P, 1991, CURR ANAESTH CRIT CA, V2, P92; Capogna G, 1998, BRIT J ANAESTH, V80, P11; Capogna G, 2001, ANESTHESIOLOGY, V94, P740, DOI 10.1097/00000542-200105000-00009; CARRIE LES, 1981, ANAESTHESIA, V36, P965, DOI 10.1111/j.1365-2044.1981.tb08658.x; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; COHEN S, 1993, ANESTHESIOLOGY, V78, P486, DOI 10.1097/00000542-199303000-00012; Cohen S, 1996, CAN J ANAESTH, V43, P341, DOI 10.1007/BF03011711; Cohen SE, 2000, ANESTHESIOLOGY, V92, P387, DOI 10.1097/00000542-200002000-00019; COLUMB MO, 1995, ANESTH ANALG, V81, P833, DOI 10.1097/00000539-199510000-00030; Connelly NR, 2000, ANESTH ANALG, V91, P374, DOI 10.1097/00000539-200008000-00026; Grass JA, 1997, ANESTH ANALG, V85, P365, DOI 10.1097/00000539-199708000-00022; Herman NL, 1998, J CLIN ANESTH, V10, P670, DOI 10.1016/S0952-8180(98)00113-5; JUSTINS DM, 1982, BRIT J ANAESTH, V54, P409, DOI 10.1093/bja/54.4.409; KENNETH N, 2002, ANESTHESIOLOGY, V96, P1070; ROSEN CE, 1984, PHARMACOTHERAPY, V4, P11; ROSS BK, 1987, CLIN OBSTET GYNECOL, V30, P552, DOI 10.1097/00003081-198709000-00010; STEINBERG RB, 1992, REGION ANESTH, V17, P131; STEINBERG RB, 1989, REGION ANESTH, V14, P225; VANDEWALLE J, 1976, ACTA ANAESTH BELG, V27, P129	20	28	50	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	APR	2003	96	4					1178	1182		10.1213/01.ANE.0000054003.03645.CF			5	Anesthesiology	Anesthesiology	659ZB	WOS:000181808300048	12651680				2020-06-30	J	Ibrahim, AE; Feldman, J; Karim, A; Kharasch, ED				Ibrahim, AE; Feldman, J; Karim, A; Kharasch, ED			Simultaneous assessment of drug interactions with low- and high-extraction - Opioids application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil	ANESTHESIOLOGY			English	Article							CHROMATOGRAPHY-MASS-SPECTROMETRY; HEPATIC CYTOCHROME-P450 3A4; HUMAN-LIVER-MICROSOMES; INTERINDIVIDUAL VARIABILITY; GAS-CHROMATOGRAPHY; HEALTHY-VOLUNTEERS; NONINVASIVE PROBE; CYP3A4 ACTIVITY; HALF-LIFE; DISPOSITION	Background: Parecoxib is a parenteral cyclooxygenase-2 (COX-2) inhibitor intended for perioperative analgesia. It is an inactive prodrug hydrolyzed in vivo to the active inhibitor valdecoxib, a substrate for hepatic cytochrome P450 3A4 (CYP3A4); hence, a potential exists for metabolic interactions with other CYP3A substrates. This study determined the effects of parecoxib on the pharmacokinetics and pharmacodynamics of the CYP3A substrates fentanyl and alfentanil compared with the CYP3A inhibitor troleandomycin. Alfentanil is a low-extraction drug with a clearance that is highly susceptible to drug interactions; fentanyl is a high-extraction drug and, thus, is theoretically less vulnerable. We therefore also tested the hypothesis that the extraction ratio influences the consequence of altered hepatic metabolism of these opioids. Methods. After Institutional Review Board-approved, written, informed consent was obtained, 12 22- to 40-yr-old healthy volunteers were enrolled in the study. The protocol was a randomized, double-blinded, balanced, placebo-controlled, three-session (placebo, parecoxib, or troleandomycin pretreatment) crossover. Subjects received both alfentanil (15 mug/kg) and fentanyl (5 mug/kg; 15-min intravenous Infusion) 1 h after placebo, parecoxib (40 mg intravenously every 12 h), or troleandomycin (every 6 h). Study sessions were separated by 7 or more days. Opioid concentrations in venous blood were determined by liquid chromatography-mass spectrometry. Pharmacokinetic parameters were determined by noncompartmental analysis. Opioid effects were determined by pupillometry, respiratory rate, and Visual Analog Scale scores. Results. There were no significant differences between the placebo and parecoxib treatments in alfentanil or fentanyl plasma concentration, maximum observed plasma concentration, area under the plasma time-concentration time curve, clearance, elimination half-life, or volume of distribution. However, disposition of alfentanil, and to a lesser extent fentanyl, was significantly altered by troleandomycin. Clearances were reduced to 12% (0.64 +/- 0.25 ml . kg(-1) . min(-1)) and 61% (9.35 +/- 3.07) of control (5.53 +/- 2.16 and 15.3 +/- 5.0) for alfentanil and fentanyl (P < 0.001). Pupil diameter versus time curves were similar between placebo and parecoxib treatments but were significantly different after troleandomycin. Conclusions: Single-dose parecoxib does not alter fentanyl or alfentanil disposition or clinical effects and does not appear to cause significant CYP3A drug interactions. CYP3A inhibition decreases alfentanil clearance more than fentanyl clearance, confirming that the extraction ratio influences the consequence of altered hepatic drug metabolism. Modified cassette, or "cocktail," dosing is useful for assessing drug interactions in humans.	Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA	Kharasch, ED (reprint author), Univ Washington, Dept Anesthesiol, Box 356540,1959 NE Pacific St,RR-442, Seattle, WA 98195 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR00037]; NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [K24DA00417]; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM63674]		Ahonen J, 1996, ANESTHESIOLOGY, V85, P1246, DOI 10.1097/00000542-199612000-00004; BARTKOWSKI RR, 1989, CLIN PHARMACOL THER, V46, P99, DOI 10.1038/clpt.1989.112; BARTKOWSKI RR, 1993, ANESTHESIOLOGY, V78, P260, DOI 10.1097/00000542-199302000-00008; BOWER S, 1982, BRIT J ANAESTH, V54, P871, DOI 10.1093/bja/54.8.871; Caraco Y, 1996, J PHARMACOL EXP THER, V278, P1165; Dresser GK, 2000, CLIN PHARMACOKINET, V38, P41, DOI 10.2165/00003088-200038010-00003; Dyer KR, 1999, CLIN PHARMACOL THER, V65, P685, DOI 10.1016/S0009-9236(99)90090-5; Fleishaker JC, 1996, J PHARMACOL EXP THER, V277, P991; FLEISHAKER JC, 1993, J CLIN PHARMACOL, V33, P171; GOROMARU T, 1984, ANESTHESIOLOGY, V61, P73, DOI 10.1097/00000542-198461010-00013; HENTHORN TK, 1989, ANESTHESIOLOGY, V71, P635, DOI 10.1097/00000542-198911000-00002; Ibrahim A, 2002, ANESTH ANALG, V95, P667, DOI 10.1097/00000539-200209000-00032; Ito K, 1998, PHARMACOL REV, V50, P387; Jain KK, 2000, EXPERT OPIN INV DRUG, V9, P2717, DOI 10.1517/13543784.9.11.2717; Kharasch ED, 1997, ANESTHESIOLOGY, V87, P26, DOI 10.1097/00000542-199707000-00005; Kharasch ED, 1999, J CLIN PHARMACOL, V39, P664, DOI 10.1177/00912709922008290; Kharasch ED, 1997, ANESTHESIOLOGY, V87, P36, DOI 10.1097/00000542-199707000-00006; Labroo RB, 1997, DRUG METAB DISPOS, V25, P1072; LABROO RB, 1995, DRUG METAB DISPOS, V23, P490; LAVRIJSEN KLM, 1988, ANESTHESIOLOGY, V69, P535, DOI 10.1097/00000542-198810000-00013; Li AP, 1995, TOXICOLOGY, V104, P1, DOI 10.1016/0300-483X(95)03155-9; Lin JH, 2001, ANNU REV PHARMACOL, V41, P535, DOI 10.1146/annurev.pharmtox.41.1.535; Lotsch J, 2001, ANESTHESIOLOGY, V95, P1329; Mather LE, 1998, BRIT J CLIN PHARMACO, V46, P37, DOI 10.1046/j.1365-2125.1998.00035.x; Mertens MJ, 2001, ANESTHESIOLOGY, V94, P949, DOI 10.1097/00000542-200106000-00006; Mildh LH, 2001, ANESTH ANALG, V93, P939, DOI 10.1097/00000539-200110000-00028; OLKKOLA KT, 1993, CLIN PHARMACOL THER, V53, P298, DOI 10.1038/clpt.1993.25; Olkkola KT, 1996, ANESTH ANALG, V82, P511, DOI 10.1097/00000539-199603000-00015; Olkkola KT, 1999, ANESTHESIOLOGY, V91, P681, DOI 10.1097/00000542-199909000-00020; Palkama VJ, 1998, ANESTH ANALG, V87, P190, DOI 10.1097/00000539-199807000-00039; Palkama VJ, 1998, BRIT J ANAESTH, V81, P598, DOI 10.1093/bja/81.4.598; Phimmasone S, 2001, CLIN PHARMACOL THER, V70, P505, DOI 10.1067/mcp.2001.119994; RaucoulesAime M, 1997, ANESTH ANALG, V84, P1019, DOI 10.1097/00000539-199705000-00012; RAVNBORG M, 1987, ANESTH ANALG, V66, P847; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; Streetman DS, 2000, CLIN PHARMACOL THER, V68, P375, DOI 10.1067/mcp.2000.109519; Talley JJ, 2000, J MED CHEM, V43, P1661, DOI 10.1021/jm000069h; Tateishi T, 1996, ANESTH ANALG, V82, P167; TEMPELHOFF R, 1990, CAN J ANAESTH, V37, P327, DOI 10.1007/BF03005584; Thummel KE, 1998, ANNU REV PHARMACOL, V38, P389, DOI 10.1146/annurev.pharmtox.38.1.389; VANROOY HH, 1981, J CHROMATOGR, V223, P85, DOI 10.1016/S0378-4347(00)80070-5; WESTERLING D, 1995, THER DRUG MONIT, V17, P287, DOI 10.1097/00007691-199506000-00013; White RE, 2001, DRUG METAB DISPOS, V29, P957; Wienkers LC, 1996, J PHARMACOL EXP THER, V277, P982	44	46	47	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	APR	2003	98	4					853	861		10.1097/00000542-200304000-00011			9	Anesthesiology	Anesthesiology	660ZG	WOS:000181865500010	12657846				2020-06-30	J	Dominguez, KD; Lomako, DM; Katz, RW; Kelly, HW				Dominguez, KD; Lomako, DM; Katz, RW; Kelly, HW			Opioid withdrawal in critically ill neonates	ANNALS OF PHARMACOTHERAPY			English	Article; Proceedings Paper	30th International Educational and Scientific Symposium of the Society-for-Critical-Care-Medicine	FEB 11-14, 2001	SAN FRANCISCO, CALIFORNIA	Soc Crit Care Med		fentanyl; neonates; opioid withdrawal	FENTANYL; TOLERANCE; CHILDREN; DEPENDENCE; SEDATION; INFANTS	OBJECTIVE: To determine the occurrence of and risk factors for opioid withdrawal in critically ill neonates receiving continuous infusions of fentanyl. DESIGN: A prospective interventional cohort study was conducted in a university hospital neonatal intensive care unit with 19 neonates who received a minimum of 24 hours of fentanyl by continuous infusion. MEASUREMENTS: Fentanyl total dose, duration of infusion, and peak infusion rate were recorded. Patients were evaluated for withdrawal using the Neonatal Abstinence Scoring System of Finnegan. Patients with a score 8 were considered to have opioid withdrawal. MAIN RESULTS: Withdrawal was observed in 10 (53%) of 19 neonates. The fentanyl total dose (median 525 vs. 168 pg/kg, respectively; p = 0.03) and infusion duration (median 10 vs. 7 d, respectively; p = 0.04) were significantly greater in neonates with withdrawal compared to those without withdrawal. A fentanyl total dose greater than or equal to415 pg/kg predicted Withdrawal with 70% sensitivity and 78% specificity. A fentanyl infusion duration greater than or equal to8 days predicted withdrawal with 90% sensitivity and 67% specificity. The most frequent symptoms of withdrawal were sleeping <3 hours after feeding (81%) and increased muscle tone (55%). In all neonates with withdrawal, onset occurred within 24 hours of fentanyl discontinuation. CONCLUSIONS: Opioid withdrawal occurs frequently in critically ill neonates who receive continuous infusions of fentanyl. Longer infusion duration and higher total dose were associated with withdrawal symptoms.	Univ New Mexico, Hlth Sci Ctr, Coll Pharm, Albuquerque, NM 87131 USA; Univ New Mexico, Univ Hosp, Hlth Sci Ctr, Dept Pharm, Albuquerque, NM 87131 USA; Univ New Mexico, Hlth Sci Ctr, Dept Pediat, Albuquerque, NM 87131 USA	Dominguez, KD (reprint author), Univ New Mexico, Hlth Sci Ctr, Coll Pharm, 2502 Marble NE, Albuquerque, NM 87131 USA.				NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00997]		ANAND KJS, 1994, CRIT CARE MED, V22, P334, DOI 10.1097/00003246-199402000-00027; ARNOLD JH, 1990, ANESTHESIOLOGY, V73, P1136, DOI 10.1097/00000542-199012000-00011; Arnold SM, 1999, CYTOTHERAPY, V1, P119, DOI 10.1080/0032472031000141249; Buck ML, 1996, J PEDIAT PHARM PRACT, V1, P155; FINNEGAN LP, 1975, [No title captured], P139; Franck L S, 1998, Am J Crit Care, V7, P364; French J P, 1994, J Pediatr Nurs, V9, P107; HYNYNEN M, 1987, ACTA ANAESTH SCAND, V31, P706, DOI 10.1111/j.1399-6576.1987.tb02649.x; KATZ R, 1994, CRIT CARE MED, V22, P763, DOI 10.1097/00003246-199405000-00009; KOREN G, 1984, EUR J CLIN PHARMACOL, V27, P51; MARX CM, 1993, PEDIATRICS, V91, P369; Orsini AJ, 1996, J PEDIATR-US, V129, P140, DOI 10.1016/S0022-3476(96)70201-9; Santeiro M L, 1997, J Perinatol, V17, P135; Suresh S, 1998, SEMIN PERINATOL, V22, P425, DOI 10.1016/S0146-0005(98)80058-X; Tobias JD, 2000, CRIT CARE MED, V28, P2122, DOI 10.1097/00003246-200006000-00079	15	35	36	0	1	HARVEY WHITNEY BOOKS CO	CINCINNATI	PO BOX 42696, CINCINNATI, OH 45242 USA	1060-0280			ANN PHARMACOTHER	Ann. Pharmacother.	APR	2003	37	4					473	477		10.1345/aph.1C324			5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	661AP	WOS:000181869300001	12659598				2020-06-30	J	Eichenberger, U; Giani, C; Petersen-Felix, S; Graven-Nielsen, T; Arendt-Neilsen, L; Curatolo, M				Eichenberger, U; Giani, C; Petersen-Felix, S; Graven-Nielsen, T; Arendt-Neilsen, L; Curatolo, M			Lumbar epidural fentanyl: segmental spread and effect on temporal summation and muscle pain	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesic techniques, epidural; analgesics opioid, fentanyl; pain, threshold	DOUBLE-BLIND; ADMINISTERED MORPHINE; ANALGESIA; SUFENTANIL; HUMANS; ALFENTANIL; ANESTHESIA; KETAMINE; QUANTIFICATION; BUPIVACAINE	Background. Despite extensive use, different aspects of the pharmacological action of epidural fentanyl have not been clarified. We applied a multi-modal sensory test procedure to investigate the effect of epidural fentanyl on segmental spread, temporal summation (as a measure for short-lasting central hyperexcitability) and muscle pain. Methods. Thirty patients received either placebo, 50 or 100 mug single dose of fentanyl epidurally (L2-3), in a randomized, double-blind fashion. Heat pain tolerance thresholds at eight dermatomes from S1 to fifth cranial nerve (assessment of segmental spread), pain threshold to transcutaneous repeated electrical stimulation of the sural nerve (assessment of temporal summation) and pain intensity after injection of hypertonic saline into the tibialis anterior muscle (assessment of muscle pain) were recorded. Results. Fentanyl 100 mug, but not 50 mug, produced analgesia to heat stimulation only at L2. Surprisingly, no effect at S1 was detected. Both fentanyl doses significantly increased temporal summation threshold and decreased muscle pain intensity. Conclusions. The findings suggest that a single lumbar epidural dose of fentanyl should be injected at the spinal interspace corresponding to the dermatomal site of pain. Increased effect on L2 compared with S1 suggests that drug effect on spinal nerve roots and binding to opioid receptors on the dorsal root ganglia may be more important than traditionally believed for the segmental effect of epidurally injected fentanyl. Epidural fentanyl increases temporal summation threshold and could therefore contribute to prevention and treatment of central hypersensitivity states. I.M. injection of hypertonic saline is a sensitive technique for detecting the analgesic action of epidural opioids.	Univ Bern, Inselspital, Dept Anaesthesiol, Div Pain Therapy, CH-3010 Bern, Switzerland; Univ Aalborg, Ctr Sensory Motor Interact, Lab Expt Pain Res, Aalborg, Denmark	Eichenberger, U (reprint author), Univ Bern, Inselspital, Dept Anaesthesiol, Div Pain Therapy, CH-3010 Bern, Switzerland.		Curatolo, Michele/A-5859-2011	Curatolo, Michele/0000-0003-4130-6826; Graven-Nielsen, Thomas/0000-0002-7787-4860; Arendt-Nielsen, Lars/0000-0003-0892-1579			Aida S, 2000, ANESTHESIOLOGY, V92, P1624, DOI 10.1097/00000542-200006000-00020; Angst MS, 2000, ANESTHESIOLOGY, V92, P312, DOI 10.1097/00000542-200002000-00011; ARENDTNIELSEN L, 1991, ACTA ANAESTH SCAND, V35, P430, DOI 10.1111/j.1399-6576.1991.tb03323.x; ARENDTNIELSEN L, 1995, ANESTH ANALG, V81, P63, DOI 10.1097/00000539-199507000-00013; ARENDTNIELSEN L, 1994, EUR J APPL PHYSIOL O, V68, P266, DOI 10.1007/BF00376776; ARENDTNIELSEN L, 1991, ACTA ANAESTH SCAND, V35, P24, DOI 10.1111/j.1399-6576.1991.tb03236.x; BLANCO J, 1987, EUR J ANAESTH, V4, P395; BRENNUM J, 1993, PAIN, V52, P75, DOI 10.1016/0304-3959(93)90117-8; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; CURATOLO M, 1995, BRIT J ANAESTH, V75, P634, DOI 10.1093/bja/75.5.634; Curatolo M, 1997, BRIT J ANAESTH, V78, P88; Curatolo M, 1997, ANESTHESIOLOGY, V87, P785, DOI 10.1097/00000542-199710000-00011; Curatolo M, 1998, ACTA ANAESTH SCAND, V42, P910, DOI 10.1111/j.1399-6576.1998.tb05349.x; Curatolo M, 2001, CLIN J PAIN, V17, P306, DOI 10.1097/00002508-200112000-00004; Curatolo M, 2000, BRIT J ANAESTH, V85, P529, DOI 10.1093/bja/85.4.529; Curatolo M, 2000, ANESTHESIOLOGY, V93, P1517, DOI 10.1097/00000542-200012000-00025; FIELDS HL, 1980, NATURE, V284, P351, DOI 10.1038/284351a0; GISSEN AJ, 1987, ANESTH ANALG, V66, P1272; Grass JA, 1997, ANESTH ANALG, V85, P365, DOI 10.1097/00000539-199708000-00022; Graven-Nielsen T, 2000, PAIN, V85, P483, DOI 10.1016/S0304-3959(99)00308-5; GravenNielsen T, 1997, PAIN, V69, P111, DOI 10.1016/S0304-3959(96)03243-5; Hogan Q, 1996, ANESTHESIOLOGY, V85, P37, DOI 10.1097/00000542-199607000-00006; Liu SS, 1996, ANESTH ANALG, V82, P98, DOI 10.1097/00000539-199601000-00017; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; Luginbuhl M, 2001, ANESTHESIOLOGY, V95, P22, DOI 10.1097/00000542-200107000-00009; Pocock SJ, 1983, CLIN TRIALS PRACTICA, P80; POWER I, 1991, REGION ANESTH, V16, P204; PRICE DD, 1972, EXP NEUROL, V37, P371, DOI 10.1016/0014-4886(72)90081-7; PRICE DD, 1992, PAIN, V49, P163, DOI 10.1016/0304-3959(92)90139-3; Render CA, 1996, ANAESTHESIA, V51, P1070, DOI 10.1111/j.1365-2044.1996.tb15009.x; SCOTT DA, 1995, ANESTHESIOLOGY, V83, P727, DOI 10.1097/00000542-199510000-00012; STEIN C, 1995, NEW ENGL J MED, V332, P1685, DOI 10.1056/NEJM199506223322506; Ummenhofer WC, 2000, ANESTHESIOLOGY, V92, P739, DOI 10.1097/00000542-200003000-00018; VANDERBURGHT M, 1994, ACTA ANAESTH SCAND, V38, P161; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	35	20	21	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	APR	2003	90	4					467	473		10.1093/bja/aeg100			7	Anesthesiology	Anesthesiology	664TX	WOS:000182078500010	12644419	Green Published, Bronze			2020-06-30	J	Nitahara, K; Matsunaga, M; Katori, K; Yotsui, H; Higuchi, H; Higa, K				Nitahara, K; Matsunaga, M; Katori, K; Yotsui, H; Higuchi, H; Higa, K			Effect of continuous low-dose intravenous diltiazem on epidural fentanyl analgesia after lower abdominal surgery	BRITISH JOURNAL OF ANAESTHESIA			English	Article						analgesic techniques, epidural; analgesics opioid, fentanyl; heart, antiarrhythmics, diltiazem; heart block, calcium channel blockers; pain, postoperative	MORPHINE	Background. The postoperative opioid-sparing effects of systemic L-type calcium channel blockers are controversial. We investigated whether the postoperative analgesic effect of epidural fentanyl was enhanced by i.v. infusion of diltiazem at a rate that would minimize any cardiovascular depressant effect. Methods. After elective lower abdominal gynaecological surgery, 30 patients were randomized to receive continuous i.v. diltiazem 1 mug kg(-1) min(-1) (diltiazem group) or the same volume of saline (control group) for 24 h. Cumulative postoperative epidural fentanyl consumption, visual analogue scale (VAS) scores and verbal rating scores (VRS) at rest and during mobilization, sedation scores, incidence of side-effects and overall patient satisfaction were assessed. Results. There was no significant difference in cumulative epidural fentanyl consumption between the groups at any period. Although there were no statistically significant differences in VAS, scores, VRS, sedation scores, incidence of side-effects and overall patient satisfaction, there was a trend to an increased incidence of nausea in the diltiazem group. Conclusions. Continuous i.v. infusion of diltiazem did not reduce epidural fentanyl consumption when administered at dosages having minimal haemodynamic depressant effects.	Fukuoka Univ, Sch Med, Dept Anesthesiol, Jonan Ku, Fukuoka 8140180, Japan	Nitahara, K (reprint author), Fukuoka Univ, Sch Med, Dept Anesthesiol, Jonan Ku, 7-45-1 Nanakuma, Fukuoka 8140180, Japan.						ALLEN GS, 1983, NEW ENGL J MED, V308, P24; Cohen S, 1998, ANESTHESIOLOGY, V89, P1354, DOI 10.1097/00000542-199812000-00012; Cohen S, 2002, ANESTH ANALG, V94, P674, DOI 10.1097/00000539-200203000-00036; FUKUHARA S, 1989, J CLIN PHARMACOL, V29, P102, DOI 10.1002/j.1552-4604.1989.tb03294.x; JOYAL M, 1986, AM HEART J, V111, P54, DOI 10.1016/0002-8703(86)90553-3; Katori K, 1997, Masui, V46, P835; KOH JY, 1992, BRAIN RES, V587, P233, DOI 10.1016/0006-8993(92)91002-V; NAITO K, 1986, ARZNEIMITTEL-FORSCH, V36-1, P25; OMOTE K, 1993, ANESTHESIOLOGY, V79, P746, DOI 10.1097/00000542-199310000-00017; SANTILLAN R, 1994, PAIN, V58, P129, DOI 10.1016/0304-3959(94)90192-9	10	1	1	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	APR	2003	90	4					507	509		10.1093/bja/aeg095			3	Anesthesiology	Anesthesiology	664TX	WOS:000182078500017	12644426	Bronze			2020-06-30	J	Feld, JM; Laurito, CE; Beckerman, M; Vincent, J; Hoffman, WE				Feld, JM; Laurito, CE; Beckerman, M; Vincent, J; Hoffman, WE			Non-opioid analgesia improves pain relief and decreases sedation after gastric bypass surgery	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							SMALL-DOSE KETAMINE; POSTOPERATIVE PAIN; DOUBLE-BLIND; INTRAVENOUS LIDOCAINE; AMBULATORY SURGERY; EPIDURAL ANALGESIA; MORPHINE; ANESTHESIA; PREMEDICATION; CLONIDINE	Purpose: Several non-opioid drugs have been shown to provide analgesia during and after surgery. We compared sevoflurane anesthesia with fentanyl analgesia to sevoflurane and non-opioid drug treatment for gastric bypass surgery and recovery. : Thirty obese patients (body mass index > 50 kg(.)m(-2)) undergoing gastric bypass were randomized to receive sevoflurane anesthesia with either fentanyl or a non-opioid regimen including ketorolac, clonidine, lidocaine, ketamine, magnesium sulfate, and methylprednisolone. Morphine use by patient-controlled analgesia (BCA) pump and pain score measured by visual analogue scale were determined in the postanesthesia care unit (PACU) and for the first 16 hr after surgery. Sedation was evaluated in the PACU. Investigators assessing patient outcomes were blinded to the study group. Results: Fentanyl treated patients were more sedated in the PACU compared to the non-opioid group. Non-opioid treated patients required 5.2 +/- 2.6 mg(.)hr(-1) morphine by PCA during their stay in the PACU while patients anesthetized with fentanyl used 7.8 +/- 3.3 mg(.)hr(-1) (P < 0.05). Fentanyl and non-opioid treated patients showed no difference in pain score one or 16 hr after surgery. Conclusion: Our results show that non-opioid analgesia produced pain relief and less sedation during recovery from gastric bypass surgery compared to fentanyl.	Univ Illinois, Dept Anesthesiol, Chicago, IL 60612 USA	Hoffman, WE (reprint author), Univ Illinois, Dept Anesthesiol, 1740 W Taylor St,MC 515, Chicago, IL 60612 USA.						Aasboe V, 1998, ANESTH ANALG, V87, P319, DOI 10.1097/00000539-199808000-00015; Adams JP, 2000, BRIT J ANAESTH, V85, P91, DOI 10.1093/bja/85.1.91; Adriaenssens G, 1999, BRIT J ANAESTH, V83, P393; Andersen G, 2000, ACTA ANAESTH SCAND, V44, P296, DOI 10.1034/j.1399-6576.2000.440313.x; Biring MS, 1999, AM J MED SCI, V318, P293, DOI 10.1097/00000441-199911000-00002; Casati A, 2000, ANESTH ANALG, V91, P388, DOI 10.1097/00000539-200008000-00029; CASSUTO J, 1985, ANESTH ANALG, V64, P971; Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; Chow GK, 2001, J ENDOUROL, V15, P171, DOI 10.1089/089277901750134502; DECLIVELOWE SG, 1958, ANAESTHESIA, V13, P139; DING YF, 1992, ANESTH ANALG, V75, P566; GLASSER RS, 1993, J NEUROSURG, V78, P383, DOI 10.3171/jns.1993.78.3.0383; Groudine SB, 1998, ANESTH ANALG, V86, P235, DOI 10.1097/00000539-199802000-00003; Handa F, 2000, J CLIN ANESTH, V12, P19, DOI 10.1016/S0952-8180(99)00131-2; HIMES RS, 1977, ANESTHESIOLOGY, V47, P437, DOI 10.1097/00000542-197711000-00010; HIROTA K, 1995, ACTA ANAESTH SCAND, V39, P174, DOI 10.1111/j.1399-6576.1995.tb04038.x; Hollmann MW, 2000, ANESTHESIOLOGY, V93, P858, DOI 10.1097/00000542-200009000-00038; Kamibayashi T, 2000, ANESTHESIOLOGY, V93, P1345, DOI 10.1097/00000542-200011000-00030; Katz J, 2001, CAN J ANAESTH, V48, P105, DOI 10.1007/BF03019721; Kehlet H, 2002, AM J SURG, V183, P630, DOI 10.1016/S0002-9610(02)00866-8; Ko SH, 2001, ANESTHESIOLOGY, V95, P640, DOI 10.1097/00000542-200109000-00016; Laulin JP, 2002, ANESTH ANALG, V94, P1263, DOI 10.1097/00000539-200205000-00040; LEVANEN J, 1995, ANESTHESIOLOGY, V82, P1117, DOI 10.1097/00000542-199505000-00005; Liu HT, 2001, ANESTH ANALG, V92, P1173; MAUNUKSELA EL, 1992, CLIN PHARMACOL THER, V52, P436, DOI 10.1038/clpt.1992.167; MCCAFFERTY DM, 1994, AM J PHYSIOL, V266, pG560; Menigaux C, 2000, ANESTH ANALG, V90, P129, DOI 10.1097/00000539-200001000-00029; Mortero RF, 2001, ANESTH ANALG, V92, P1465; Nellgard P, 1996, ACTA ANAESTH SCAND, V40, P287, DOI 10.1111/j.1399-6576.1996.tb04435.x; OHLMS LA, 1995, ARCH OTOLARYNGOL, V121, P737; PELOSI P, 1998, ANESTH ANALG, V87, P645; RAWAL N, 1984, ANESTH ANALG, V63, P583; Schulz-Stubner S, 2001, EUR J ANAESTH, V18, P723, DOI 10.1046/j.1365-2346.2001.00921.x; SCHULZE S, 1990, ACTA CHIR SCAND, V156, P203; Taittonen MT, 1998, ANESTH ANALG, V87, P161, DOI 10.1097/00000539-199807000-00034; Taniguchi T, 2000, CRIT CARE MED, V28, P755, DOI 10.1097/00003246-200003000-00025; VANDERCAR DH, 1991, ANESTHESIOLOGY, V74, P623, DOI 10.1097/00000542-199103000-00036; WATCHA MF, 1992, ANESTHESIOLOGY, V76, P368, DOI 10.1097/00000542-199203000-00008; White PF, 2002, ANESTH ANALG, V94, P577, DOI 10.1097/00000539-200203000-00019; WHITE PF, 1982, ANESTHESIOLOGY, V56, P119, DOI 10.1097/00000542-198202000-00007; Wilder-Smith O H, 2000, Prog Brain Res, V129, P505; Wu CL, 2002, ANESTHESIOLOGY, V96, P841, DOI 10.1097/00000542-200204000-00010	42	47	48	0	2	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	APR	2003	50	4					336	341		10.1007/BF03021029			6	Anesthesiology	Anesthesiology	669HY	WOS:000182346900005	12670809	Bronze			2020-06-30	J	Gadalla, F; Lee, SHR; Choi, KC; Fong, J; Gomillion, MC; Leighton, BL				Gadalla, F; Lee, SHR; Choi, KC; Fong, J; Gomillion, MC; Leighton, BL			Injecting saline through the epidural needle decreases the iv epidural catheter placement during combined spinal-epidural rate labour analgesia	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							OBSTETRIC PATIENTS; TOP-UP; ANESTHESIA; MECHANISM; INSERTION; PUNCTURE; RISK	Purpose: To determine if injecting 10 mL saline before epidural catheter threading (pre-cannulation epidural fluid injection) can decrease the incidence of iv epidural catheter placement during combined spinal-epidural (CSE) labour analgesia. Methods: One hundred healthy women requesting CSE labour analgesia with either fentanyl 20 mug or sufentanil 10 mug were prospectively randomized to receive either no epidural injection (dry group, n = 50) or epidural 10 mL-saline injection (saline group, n = 50) before epidural catheter placement. A nylon multiport catheter was then threaded 3-5 cm into the epidural space and the needle was removed. We diagnosed iv catheter placement if blood was freely aspirated, if the mother became tachycarclic after injection of epinephrine 15 mug, or if intracardiac air was heard (using ultrasound) after injection,of air 1.5 mL. Results: Intravenous epidural catheter placement occurred in one saline and ten dry group patients (P < 0.01). No complications of excessive cephalad intrathecal opioid spread (i.e., difficulty swallowing, hypoxemia, or respiratory arrest) occurred. Conclusions: Injecting 10 mL or saline through the epidural needle after intrathecal opioid injection and before threading the catheter significantly decreased accidental venous catheter placement without any apparent. increase in complications from excessive cephalad intrathecal opioid spread.	Cornell Univ, Weill Med Coll, Dept Anesthesiol, New York, NY 10021 USA; Women & Infants Hosp Rhode Isl, Providence, RI USA	Gadalla, F (reprint author), Cornell Univ, Weill Med Coll, Dept Anesthesiol, 525 E 68th St, New York, NY 10021 USA.	fgadafla@med.cornell.edu					Albright GA, 1999, REGION ANESTH PAIN M, V24, P117, DOI 10.1016/S1098-7339(99)90071-8; ANGLE PJ, 2001, ANESTHESIOLOGY, V95, pA1070; BLUMGART CH, 1992, BRIT J ANAESTH, V69, P457, DOI 10.1093/bja/69.5.457; Dickson MAS, 1997, BRIT J ANAESTH, V79, P297, DOI 10.1093/bja/79.3.297; Ferouz F, 1997, ANESTH ANALG, V85, P1088; GRAYZEL J, 1989, ANESTHESIOLOGY, V71, P320, DOI 10.1097/00000542-198908000-00034; HOLMSTROM B, 1995, ANESTH ANALG, V80, P747, DOI 10.1097/00000539-199504000-00017; Jaime F, 2000, J CLIN ANESTH, V12, P89, DOI 10.1016/S0952-8180(00)00116-1; LEIGHTON BL, 1987, ANESTHESIOLOGY, V66, P688, DOI 10.1097/00000542-198705000-00017; Leighton BL, 2000, ANESTHESIOLOGY, V92, P1840, DOI 10.1097/00000542-200006000-00049; Leighton BL, 2000, ANESTHESIOLOGY, V92, P1617, DOI 10.1097/00000542-200006000-00018; MANNION D, 1991, ANAESTHESIA, V46, P585, DOI 10.1111/j.1365-2044.1991.tb09665.x; Norris MC, 1998, ANESTHESIOLOGY, V88, P1495, DOI 10.1097/00000542-199806000-00012; ROLBIN SH, 1990, CAN J ANAESTH, V37, P337, DOI 10.1007/BF03005586; SCOTT DA, 1993, ANAESTH INTENS CARE, V21, P284, DOI 10.1177/0310057X9302100304; Stienstra R, 1999, ANESTH ANALG, V88, P810, DOI 10.1097/00000539-199904000-00024; Stienstra R, 1996, ANESTH ANALG, V83, P382, DOI 10.1097/00000539-199608000-00031; Takiguchi T, 1997, ANESTH ANALG, V85, P1097, DOI 10.1097/00000539-199711000-00024; VERNIQUET AJW, 1980, ANAESTHESIA, V35, P660, DOI 10.1111/j.1365-2044.1980.tb03880.x	19	24	26	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	APR	2003	50	4					382	385		10.1007/BF03021036			4	Anesthesiology	Anesthesiology	669HY	WOS:000182346900012	12670816	Bronze			2020-06-30	J	Schumann, R; Rafique, MB				Schumann, R; Rafique, MB			Low-dose epidural anesthesia for cervical cerclage	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter							SPINAL-ANESTHESIA; TRANSIENT					Rafique, Muhammad/AAJ-5600-2020				BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Freedman JM, 1998, ANESTHESIOLOGY, V89, P633, DOI 10.1097/00000542-199809000-00012; Pollock JE, 1996, ANESTHESIOLOGY, V84, P1361, DOI 10.1097/00000542-199606000-00012; RICHARDSON M, 1998, ANESTHESIOLOGY SA, V88, pA32; ZAHN J, 1999, ANESTHESIOLOGY SA, V90, pA24	5	4	4	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	APR	2003	50	4					424	425		10.1007/BF03021047			2	Anesthesiology	Anesthesiology	669HY	WOS:000182346900023	12670827	Bronze			2020-06-30	J	Statler, KD; Alexander, HL; Vagni, VA; Nemoto, EM; Tofovic, SP; Dixon, CE; Jenkins, LW; Marion, DW; Kochanek, PM				Statler, KD; Alexander, HL; Vagni, VA; Nemoto, EM; Tofovic, SP; Dixon, CE; Jenkins, LW; Marion, DW; Kochanek, PM			Moderate hypothermia may be detrimental after traumatic brain injury in fentanyl-anesthetized rats	CRITICAL CARE MEDICINE			English	Article						brain injury; sedation; analgesia; narcotics; excitotoxicity	CONTROLLED CORTICAL IMPACT; CEREBRAL BLOOD-FLOW; LOW INTRACRANIAL-PRESSURE; TOXICITY IN-VIVO; SPIN-LABELED MRI; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; GLUCOSE-METABOLISM; GLUTAMATE RELEASE; GLOBAL-ISCHEMIA	Objectives: To determine whether transient, moderate hypothermia is beneficial after traumatic brain injury in fentanyl-anesthetized rats. Design: Prospective, randomized study. Setting: University-based animal research facility. Subjects: Adult male Sprague-Dawley rats. Interventions: All rats were intubated, mechanically ventilated, and anesthetized with fentanyl (10 mug/kg intravenous bolus and then 50 mug.kg(-1).hr(-1) infusion). Controlled cortical impact was performed to the left parietal cortex, followed immediately by 1 hr of either normothermia (brain temperature 37+/-0.5degreesC) or hypothermia (brain temperature 32+/-0.5degreesC). Hypothermic rats were rewarmed gradually over 1 hr. Fentanyl anesthesia and mechanical ventilation were continued in both groups until the end of rewarming (2 hrs after traumatic brain injury). Measurements and Main Results: Histologic assessment performed 72 hrs after traumatic brain injury was the primary outcome variable. Secondary outcome variables were physiologic variables monitored during the first 2 hrs after traumatic brain injury and plasma catecholamine and serum fentanyl concentrations measured at the end of both hypothermia and rewarming (1 and 2 hrs after traumatic brain injury). Contusion volume was larger in hypothermic vs. normothermic rats (44.3+/-4.2 vs. 28.6+/-4.0 mm, p<.05), but hippocampal neuronal survival did not differ between groups. Physiologic variables did not differ between groups. Plasma dopamine and norepinephrine concentrations were increased at the end of hypothermia in hypothermic (vs. normothermic) rats (p<.05), indicating that hypothermia augmented the systemic stress response. Similarly, serum fentanyl concentrations were higher in hypothermic (vs. normothermic) rats at the end of both hypothermia and rewarming (p<.05), demonstrating that hypothermia reduced the clearance and/or metabolism of fentanyl. Conclusions: Moderate hypothermia was detrimental after experimental traumatic brain injury in fentanyl-anesthetized rats. Since treatment with hypothermia has provided reliable benefit in experimental traumatic brain injury with inhalational anesthetics, these results indicate that the choice of anesthesia/analgesia after traumatic brain injury may dramatically influence response to other therapeutic interventions, such as hypothermia. Given that narcotics commonly are administered to patients after severe traumatic brain injury, this study may have clinical implications.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15260 USA	Kochanek, PM (reprint author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40686]		ALCARAZ C, 1989, CLIN EXP PHARMACOL P, V16, P367, DOI 10.1111/j.1440-1681.1989.tb01573.x; Beaumont A, 2001, J NEUROTRAUM, V18, P1359, DOI 10.1089/08977150152725650; Beaumont A, 2000, ACT NEUR S, V76, P147; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; Eilers H, 1996, ANESTHESIOLOGY, V85, P600, DOI 10.1097/00000542-199609000-00020; Frank SM, 1997, AM J PHYSIOL-REG I, V272, pR557; Fujisawa H, 1999, J NEUROTRAUM, V16, P1083, DOI 10.1089/neu.1999.16.1083; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GREEN EJ, 1995, BRAIN RES, V702, P145, DOI 10.1016/0006-8993(95)01034-1; HANSEN TD, 1989, BRIT J ANAESTH, V63, P290, DOI 10.1093/bja/63.3.290; Harada H, 1999, ANESTH ANALG, V89, P1442, DOI 10.1097/00000539-199912000-00022; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; KEARSE LA, 1993, ELECTROEN CLIN NEURO, V87, P374, DOI 10.1016/0013-4694(93)90150-T; Kimbro JR, 2000, ANESTHESIOLOGY, V92, P806, DOI 10.1097/00000542-200003000-00024; KISSIN I, 1983, CAN ANAESTH SOC J, V30, P623, DOI 10.1007/BF03015233; KOREN G, 1987, EUR J CLIN PHARMACOL, V32, P373, DOI 10.1007/BF00543972; Lenz C, 1999, ANESTHESIOLOGY, V91, P1720, DOI 10.1097/00000542-199912000-00025; MACHENSEN GB, 1999, ANESTHESIOLOGY, V90, P1; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Markgraf CG, 2001, J NEUROTRAUM, V18, P175, DOI 10.1089/08977150150502604; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Miura Y, 1999, ANESTH ANALG, V88, P787, DOI 10.1097/00000539-199904000-00020; Miura Y, 1998, ANESTHESIOLOGY, V89, P391, DOI 10.1097/00000542-199808000-00016; Mori K, 1999, NEUROL RES, V21, P585, DOI 10.1080/01616412.1999.11740981; Mueller E, 2000, ACTA NEUROCHIR SUPPL, V76, P551; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; Nemoto EM, 1996, ANESTH ANALG, V83, P1262, DOI 10.1097/00000539-199612000-00023; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Popovic R, 2000, ANESTHESIOLOGY, V92, P1343, DOI 10.1097/00000542-200005000-00024; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SAFO Y, 1985, ACTA ANAESTH SCAND, V29, P594, DOI 10.1111/j.1399-6576.1985.tb02261.x; Schmid-Elsaesser R, 1999, STROKE, V30, P1891, DOI 10.1161/01.STR.30.9.1891; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Soonthon-Brant V, 1999, ANESTH ANALG, V88, P49, DOI 10.1097/00000539-199901000-00010; Statler KD, 2000, CRIT CARE MED, V28, pA210; Statler KD, 2000, CRIT CARE MED, V28, pA53; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Suehiro E, 1999, J NEUROTRAUM, V16, P285, DOI 10.1089/neu.1999.16.285; TEMPELHOFF R, 1992, J NEUROSURG, V77, P201, DOI 10.3171/jns.1992.77.2.0201; Tofovic SP, 1996, J CARDIOVASC PHARM, V28, P302, DOI 10.1097/00005344-199608000-00018; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510	62	17	17	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2003	31	4					1134	1139		10.1097/01.CCM.0000054864.43122.52			6	Critical Care Medicine	General & Internal Medicine	670MF	WOS:000182411900022	12682484				2020-06-30	J	Madenoglu, H; Yildiz, K; Dogru, K; Kurtsoy, T; Guler, G; Boyaci, A				Madenoglu, H; Yildiz, K; Dogru, K; Kurtsoy, T; Guler, G; Boyaci, A			Randomized, double-blinded comparison of tropisetron and placebo for prevention of postoperative nausea and vomiting after supratentorial craniotomy	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						supratentorial craniotomy; postoperative nausea and vomiting; tropisetron	LAPAROSCOPIC CHOLECYSTECTOMY; GYNECOLOGIC SURGERY; ELECTIVE CRANIOTOMY; ONDANSETRON; DROPERIDOL; METOCLOPRAMIDE; CHILDREN; WOMEN	This prospective, randomized, placebo-controlled, double-blinded study was designed to evaluate the efficacy of tropisetron in preventing postoperative nausea and vomiting after elective supratentorial craniotomy in adult patients. We studied 65 ASA physical status I-III patients aged 18 to 76 years who were undergoing elective craniotomy for resection of various supratentorial tumors. Patients were divided into two groups and received either 2 mg of tropisetron (group T) or saline placebo (group P) intravenously at the time of dural closure. A standard general anesthetic technique was used. Episodes of nausea and vomiting and the need for rescue antiemetic medication were recorded during 24 hours postoperatively. Demographic data, duration of surgery and anesthesia, and sedation scores were comparable in both groups. Nausea occurred in 30% of group T patients and in 46.7% of group P patients (P > .05). The incidence of emetic episodes was 26.7% and 56.7% in the two groups (P < .05). Rescue antiemetic medication was needed in 26.7% and 60% of the patients (P < .05). Administration of a single dose of tropisetron (2 mg intravenously) given at the time of dural closure was effective in reducing postoperative nausea and vomiting after elective craniotomy for supratentorial tumor resection in adult patients.	Erciyes Univ, Sch Med, Dept Anesthesiol, Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Neurosurg, Kayseri, Turkey	Madenoglu, H (reprint author), Yildirim Beyazit Mah, Sivas Cad, Ozkar Sitesi 192-3, TR-38030 Kayseri, Turkey.						AliMelkkila T, 1996, ANAESTHESIA, V51, P232, DOI 10.1111/j.1365-2044.1996.tb13639.x; ALLEN JC, 1985, J CLIN ONCOL, V3, P1136, DOI 10.1200/JCO.1985.3.8.1136; Alon E, 1996, ANESTH ANALG, V82, P338, DOI 10.1097/00000539-199602000-00022; Alon E, 1998, ANESTH ANALG, V86, P617, DOI 10.1097/00000539-199803000-00034; Boogaerts JG, 2000, J CLIN ANESTH, V12, P402, DOI 10.1016/S0952-8180(00)00182-3; Capouet V, 1996, BRIT J ANAESTH, V76, P54; Dunbar PJ, 1999, ANESTH ANALG, V88, P335, DOI 10.1097/00000539-199902000-00021; DUPRE LJ, 1980, BRIT J ANAESTH, V52, P831; Fabling JM, 1997, J NEUROSURG ANESTH, V9, P308, DOI 10.1097/00008506-199710000-00003; Fabling JM, 2000, ANESTH ANALG, V91, P358, DOI 10.1097/00000539-200008000-00023; Furst SR, 1996, ANESTH ANALG, V83, P325, DOI 10.1097/00000539-199608000-00021; Jokela R, 1999, ACTA ANAESTH SCAND, V43, P645, DOI 10.1034/j.1399-6576.1999.430609.x; Jokela R, 2002, ACTA ANAESTH SCAND, V46, P519, DOI 10.1034/j.1399-6576.2002.460508.x; Kathirvel S, 2001, J NEUROSURG ANESTH, V13, P207, DOI 10.1097/00008506-200107000-00005; KAUFMANN MA, 1994, ANESTH ANALG, V78, P988; Kovac AL, 2000, DRUGS, V59, P213, DOI 10.2165/00003495-200059020-00005; LEE CR, 1993, DRUGS, V46, P925, DOI 10.2165/00003495-199346050-00009; MCKENZIE R, 1994, ANESTH ANALG, V79, P961; MELNICK B, 1989, ANESTH ANALG, V69, P748; Naguib M, 1996, CAN J ANAESTH, V43, P226, DOI 10.1007/BF03011739; Purhonen S, 1997, ANESTH ANALG, V84, P662, DOI 10.1097/00000539-199703000-00036; Tasch Mark D, 2002, Curr Opin Anaesthesiol, V15, P377, DOI 10.1097/00001503-200206000-00017; ZOMERS PJW, 1993, BRIT J ANAESTH, V71, P677, DOI 10.1093/bja/71.5.677	23	19	21	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	APR	2003	15	2					82	86		10.1097/00008506-200304000-00003			5	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	660ZL	WOS:000181865900002	12657991				2020-06-30	J	Gil, AG; Illera, JC; Silvan, G; Illera, M				Gil, AG; Illera, JC; Silvan, G; Illera, M			Effects of the anaesthetic/tranquillizer treatments on selected plasma biochemical parameters in NZW rabbits	LABORATORY ANIMALS			English	Article						rabbit; sedation; anaesthesia; fentanyl; droperidol; ketamine; xylazine; diazepam; ALT; AST; ALP; GGT; BUN; creatinine; potassium; phosphate	RENAL-FUNCTION; ANESTHESIA; KETAMINE	In order to assess the response of plasma biochemical parameters to anaesthesia, 40 New Zealand White (NZW) rabbits were assigned to four treatment groups (n = 10): control (1 ml i.v. saline solution), fentanyl-droperidol (FD) (0.4 ml/kg s.c. of 'thalamonal' solution; 2.5 mg/ml droperidol, 0.05 mg/ml fentanyl), ketamine (K) (10 mg/kg i.v.) with either xylazine (X) (3 mg/kg i.v.) or diazepam (D) (2 mg/kg i.v.). Blood samples were obtained from the central car artery at six time points: before injection, and at 10, 30, 60, 120 min and 24 h after injection of the anaesthetics/saline. Plasma ALT, AST, ALP, GGT, BUN, creatinine, phosphate and potassium levels were measured by the Hitachi 747 autoanalyser. The administration of K-X increased (P < 0.05) plasma ALT (from 11.4 +/- 0.9 to 20.2 +/- 1.7 IU/l, at 10 min), AST (from 10.5 +/- 3.3 to 34 +/- 2.1 IU/l, at 120 min), BUN (from 17.2 +/- 0.9 to 25.8 +/- 1.8 mg/dl, at 60 min) and creatinine concentrations (from 1 +/- 0.1 to 1.6 +/- 0.2 mg/dl, at 10 min). After K-D administration, we observed an increase (P < 0.05) in plasma ALT (from 11.4 +/- 0.9 to 20.2 +/- 1.1 IU/l, at 10 min), AST (from 11.4 +/- 1.6 to 28 +/- 3.7 IU/l, at 10 min), BUN (from 15.8 +/- 0.8 to 30 +/- 1.5 mg/dl, at 10 min) and creatinine levels (from 1 +/- 0.08 to 2.2 +/- 0.2 mg/dl, at 120 min). No significant changes were seen in the FD group. We conclude that K-X and K-D may affect plasma concentration of select serum enzymes and biochemical parameters. These results should be taken into account when blood samples are evaluated in treated rabbits.	Univ Complutense Madrid, Fac Vet, Dept Fisiol Anim, E-28040 Madrid, Spain	Gil, AG (reprint author), Univ Complutense Madrid, Fac Vet, Dept Fisiol Anim, E-28040 Madrid, Spain.	alfredo_gonzalez_gil@yahoo.es		GONZALEZ GIL, ALFREDO/0000-0002-5802-8028			BORKOWSKI GL, 1990, LAB ANIM SCI, V40, P270; BURCHARDI H, 1994, EUR J ANAESTH, V11, P163; BUSH BM, 1991, INTERPRETATION LAB R, P221; DUNNETT CW, 1955, J AM STAT ASSOC, V50, P1096; Flecknell P., 1998, ANESTESIA ANIMALES L; FOX RR, 1989, CLIN CHEM LAB ANIMAL, P41; GVOZDENOVIC LV, 1993, HUM EXP TOXICOL, V12, P279, DOI 10.1177/096032719301200404; HIRASAWA H, 1975, ANAESTHESIST, V24, P349; HOBBS BA, 1991, AM J VET RES, V52, P669; Hoffmann W. E., 1989, CLIN CHEM LAB ANIMAL, P237; ILLERA JC, 1992, REV ESP FISIOL, V48, P7; ILLERA JC, 1990, REV EXPT ANIMAL, V1, P53; Kozma C., 1974, The biology of the laboratory rabbit,, P49; LOEB WF, 1989, CLIN CHEM LAB ANIMAL, P415; MERCATELLO A, 1990, ANN FR ANESTH, V9, P507, DOI 10.1016/S0750-7658(05)80223-0; Oh K.-s., 1984, Korean Journal of Veterinary Research, V24, P127; RILEY JH, 1989, CLIN CHEM LAB ANIMAL, P345; Spiegel H U, 1992, J Invest Surg, V5, P315, DOI 10.3109/08941939209012449; STEFFEY E. P, 1995, VET PHARM THERAPEUTI, P149; STROMBECK DR, 1991, SMALL ANIMAL GASTROE, P574; WYATT JD, 1989, LAB ANIM SCI, V39, P411; Zahir F. I., 1995, Assiut Veterinary Medical Journal, V34, P1	22	13	13	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0023-6772	1758-1117		LAB ANIM-UK	Lab. Anim.	APR	2003	37	2					155	161		10.1258/00236770360563804			7	Veterinary Sciences; Zoology	Veterinary Sciences; Zoology	667QY	WOS:000182245300010	12689427				2020-06-30	J	Korhonen, AM; Valanne, JV; Jokela, RM; Ravaska, P; Korttila, K				Korhonen, AM; Valanne, JV; Jokela, RM; Ravaska, P; Korttila, K			Intrathecal hyperbaric bupivacaine 3 mg plus fentanyl 10 mu g for outpatient knee arthroscopy with tourniquet	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						discharge after spinal anesthesia; low-dose hyberbaric bupivacaine; motor and sensory block; outpatient; PACU time; spinal anesthesia; unilateral	MINIDOSE LIDOCAINE-FENTANYL; SPINAL-ANESTHESIA; PROLONGING RECOVERY; 0.5-PERCENT; SYMPTOMS; DURATION; SURGERY; EXTENT	Background: Combination of local anesthetic and opioid enables the use of less spinal anesthetic and increases the success of anesthesia. Intrathecal opioid does not prolong motor recovery and thus should not delay discharge home. We hypothesized that 3 mg of hyperbaric bupivacaine with 10 mug of fentanyl permits fast-tracking or shorter stay in post anesthesia care unit (PACU), and earlier discharge home, compared with 4 mg of hyperbaric bupivacaine. Methods: In this double-blind study, 100 outpatients undergoing knee arthroscopy received randomly either 4 mg of bupivacaine (B4) or 3 mg of bupivacaine + 10 mug fentanyl (B3F) intrathecally. The volume of 0.8 ml was injected at the L2/3 interspace over a 2-min period. A lateral decubitus position was maintained for 10 min. The sensory block was recorded by using thermal stimuli, and motor block was assessed according to a modified Bromage scale. Fast-tracking criteria were complete recovery of motor block, sensory block Th12 or lower and stable vital signs. Results: One block (1%) failed. Motor recovery was faster in the B3F group: 60% of the patients recovered in 80 min or less compared with 28% in group B4 (P=0.002). The PACU-time was shorter: 36 (10-103) vs. 55 (10-140) min, respectively (P=0.005). Seventeen (B3F) vs. nine patients (B4) could bypass PACU (NS). Time to discharge home was similar in both groups. In the B3F group, 75% of the patients developed pruritus. Conclusion: Both solutions produced reliable spinal anesthesia for outpatient knee arthroscopy. The PACU-time was shorter in the bupivacaine-fentanyl group, but both groups reached home-readiness equally.	Lapland Cent Hosp, Dept Anesthesia, FIN-96400 Rovaniemi, Finland; Univ Helsinki, Dept Anesthesia & Intens Care, Helsinki, Finland	Korhonen, AM (reprint author), Lapland Cent Hosp, Dept Anesthesia, Ounasrinteentie 22, FIN-96400 Rovaniemi, Finland.	anna-maija.korhonen@hus.fi	Jokela, Ritva/E-1286-2013				Ben-David B, 2000, ANESTH ANALG, V91, P865, DOI 10.1097/00000539-200010000-00018; Ben-David B, 2001, ANESTH ANALG, V93, P319, DOI 10.1097/00000539-200108000-00016; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BenDavid B, 1996, ANESTH ANALG, V83, P716, DOI 10.1097/00000539-199610000-00009; Enk D, 1998, Curr Opin Anaesthesiol, V11, P511, DOI 10.1097/00001503-199810000-00011; Hamber EA, 1999, REGION ANESTH PAIN M, V24, P255; Hiller A, 1997, BRIT J ANAESTH, V79, P301, DOI 10.1093/bja/79.3.301; Infante NEK, 2000, ANESTHESIOLOGY, V92, P1319, DOI 10.1097/00000542-200005000-00020; Keld DB, 2000, ACTA ANAESTH SCAND, V44, P285, DOI 10.1034/j.1399-6576.2000.440311.x; KORTTILA K, 1995, ANAESTHESIA, V50, P22, DOI 10.1111/j.1365-2044.1995.tb06186.x; Kuusniemi KS, 1997, REGION ANESTH, V22, P534; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Liu SS, 2001, ANESTHESIOLOGY, V94, P888, DOI 10.1097/00000542-200105000-00030; Mulroy MF, 2000, ANESTH ANALG, V91, P860, DOI 10.1097/00000539-200010000-00017; Ostgaard G, 2000, ACTA ANAESTH SCAND, V44, P436, DOI 10.1034/j.1399-6576.2000.440413.x; Patterson L, 2001, CAN J ANAESTH, V48, P768, DOI 10.1007/BF03016692; Salmela L, 1998, ACTA ANAESTH SCAND, V42, P765, DOI 10.1111/j.1399-6576.1998.tb05319.x; Urmey WF, 1997, ANESTH ANALG, V84, P337, DOI 10.1097/00000539-199702000-00017; Valanne JV, 2001, ANESTH ANALG, V93, P1377, DOI 10.1097/00000539-200112000-00005	19	51	52	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	MAR	2003	47	3					342	346		10.1034/j.1399-6576.2003.00092.x			5	Anesthesiology	Anesthesiology	658RA	WOS:000181733200014	12648202				2020-06-30	J	Ramachandran, K; Srirangadarshan; Kapoor, V				Ramachandran, K; Srirangadarshan; Kapoor, V			Treating ECG changes during Caesarean section: is it worth the headache?	ANAESTHESIA			English	Letter									N Manchester Grp Hosp, Manchester M8 5RB, Lancs, England	Ramachandran, K (reprint author), N Manchester Grp Hosp, Manchester M8 5RB, Lancs, England.						MATHEW JP, 1992, ANESTHESIOLOGY, V77, P635, DOI 10.1097/00000542-199210000-00004; Moran C, 2001, ANAESTHESIA, V56, P1051, DOI 10.1046/j.1365-2044.2001.02271.x; PALMER CM, 1990, ANESTH ANALG, V70, P36; Spence A, 2002, ANAESTHESIA, V57, P722, DOI 10.1046/j.1365-2044.2002.270920.x	4	0	0	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0003-2409	1365-2044		ANAESTHESIA	Anaesthesia	MAR	2003	58	3					293	294		10.1046/j.1365-2044.2003.306822.x			2	Anesthesiology	Anesthesiology	656QZ	WOS:000181619600035	12603478				2020-06-30	J	Birmingham, PK; Wheeler, M; Suresh, S; Dsida, RM; Rae, BR; Obrecht, J; Andreoni, VA; Hall, SC; Cote, CJ				Birmingham, PK; Wheeler, M; Suresh, S; Dsida, RM; Rae, BR; Obrecht, J; Andreoni, VA; Hall, SC; Cote, CJ			Patient-controlled epidural analgesia in children: Can they do it?	ANESTHESIA AND ANALGESIA			English	Article							PEDIATRIC REGIONAL ANESTHESIA; POSTOPERATIVE ANALGESIA; ABDOMINAL-SURGERY; PAIN RELIEF; LUMBAR; INFUSION; MORPHINE; FENTANYL; INFANTS; THORACOTOMY	Extensive clinical experience and many studies support the use of IV patient-controlled analgesia (IV PCA) and regional anesthesia techniques for the treatment of postoperative pain in children. In contrast, little has been reported about the ability of children to use patient-controlled epidural analgesia (PCEA) or about the efficacy of this technique. We report a descriptive analysis of prospectively recorded data in 128 children (132 procedures) in whom PCEA was used for acute postoperative pain control. Satisfactory analgesia was obtained in 119 patients (90.1%) for up to 103 h with no episodes of desaturation and without clinical evidence of toxicity or serious adverse effects. Analgesia was satisfactory with the initial settings in 89 patients; in 38 others, this was achieved with changes in PCEA settings or solution. Five patients were switched to IV PCA because of inadequate analgesia. Eight patients with satisfactory analgesia were converted to IV PCA because of adverse effects. Children as young as 5 yr had the cognitive ability to understand and the willingness to use PCEA, consistent with reported use of IV PCA. Careful attention should be paid to the total hourly local anesthetic dose to avoid exceeding the recommended limits. Our prospectively collected data demonstrate that PCEA provides satisfactory analgesia with a small incidence of adverse side effects in children and should be considered along with other strategies in pediatric postoperative pain management.	Northwestern Univ, Childrens Mem Hosp, Dept Anesthesiol, Chicago, IL 60614 USA; Northwestern Univ, Childrens Mem Hosp, Dept Nursing, Chicago, IL 60614 USA; Northwestern Univ, Childrens Mem Hosp, Dept Pediat, Chicago, IL 60614 USA	Birmingham, PK (reprint author), Childrens Mem Hosp, Dept Pediat Anesthesiol 19, 2300 Childrens Plaza, Chicago, IL 60614 USA.						ANTOK E, 2001, ANESTHESIOLOGY, V95, pA1239; BERDE CB, 1991, J PEDIATR-US, V118, P460, DOI 10.1016/S0022-3476(05)82169-9; BERDE CB, 1992, ANESTH ANALG, V75, P164; Blanco D, 1996, ANESTHESIOLOGY, V84, P1312, DOI 10.1097/00000542-199606000-00006; BOSENBERG AT, 1988, ANESTHESIOLOGY, V69, P265; BOUCHARD F, 1995, REGION ANESTH, V20, P385; BOUDREAULT D, 1991, ANESTH ANALG, V73, P132; Brodner G, 1997, ANAESTHESIST, V46, pS165, DOI 10.1007/PL00002487; CAUDLE CL, 1993, J PEDIATR SURG, V28, P554, DOI 10.1016/0022-3468(93)90615-R; DESPARMET J, 1987, ANESTHESIOLOGY, V67, P108, DOI 10.1097/00000542-198707000-00021; DOYLE E, 1994, BRIT J ANAESTH, V72, P160, DOI 10.1093/bja/72.2.160; ECOFFEY C, 1986, ANESTHESIOLOGY, V65, P87, DOI 10.1097/00000542-198607000-00017; GAUKROGER PB, 1989, ANAESTH INTENS CARE, V17, P264, DOI 10.1177/0310057X8901700304; Gaukroger PB, 1993, PAIN INFANTS CHILDRE, P203; GILLESPIE JA, 1992, [No title captured], V2, P51; GUNTER JB, 1992, ANESTHESIOLOGY, V76, P935, DOI 10.1097/00000542-199206000-00010; Kost-Byerly S, 1998, ANESTH ANALG, V86, P712, DOI 10.1097/00000539-199804000-00007; Krane EJ, 1998, REGION ANESTH PAIN M, V23, P433, DOI 10.1016/S1098-7339(98)90023-2; LIN YC, 2001, ANESTHESIOLOGY, V95, pA1241; Monitto CL, 2000, ANESTH ANALG, V91, P573, DOI 10.1213/00000539-200009000-00014; Mulroy MF, 1996, REGION ANESTH, V21, P100; MURAT I, 1987, BRIT J ANAESTH, V59, P1441, DOI 10.1093/bja/59.11.1441; RODGERS BM, 1988, J PEDIATR SURG, V23, P259, DOI 10.1016/S0022-3468(88)80735-8; RUSY LM, 1997, AM J ANESTH, V24, P212; SLADE JM, 1994, BRIT J ANAESTH, V73, P634, DOI 10.1093/bja/73.5.634; STRAFFORD MA, 1995, ANESTH ANALG, V80, P234, DOI 10.1097/00000539-199502000-00006; SURESH S, 1994, ANESTH ANALG, V78, P605, DOI 10.1213/00000539-199403000-00040; Suresh Santhanam, 2002, Anesthesiol Clin North Am, V20, P83, DOI 10.1016/S0889-8537(03)00056-7; SWENSON JD, 1994, ANESTH ANALG, V78, P215, DOI 10.1213/00000539-199402000-00004; Van Boerum DH, 2000, SPINE, V25, P2355, DOI 10.1097/00007632-200009150-00014; WELDON BC, 1993, CLIN J PAIN, V9, P26, DOI 10.1097/00002508-199303000-00004; YASTER M, 1989, ANESTHESIOLOGY, V70, P324	32	23	24	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2003	96	3					686	691		10.1213/01.ANE.0000047209.18191.9E			6	Anesthesiology	Anesthesiology	648VY	WOS:000181172600009	12598244				2020-06-30	J	Meininger, D; Byhahn, C; Kessler, P; Nordmeyer, J; Alparslan, Y; Hall, BA; Bremerich, DH				Meininger, D; Byhahn, C; Kessler, P; Nordmeyer, J; Alparslan, Y; Hall, BA; Bremerich, DH			Intrathecal fentanyl, sufentanil, or placebo combined with hyperbaric mepivacaine 2% for parturients undergoing elective cesarean delivery	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	75th Clinical and Scientific Congress of the International-Anesthesia-Research-Society	MAR 16-20, 2001	FT LAUDERDALE, FL	Internat Anesthesia Res Soc			TRANSIENT RADICULAR IRRITATION; SPINAL-ANESTHESIA; NEUROLOGIC SYMPTOMS; SECTION; BUPIVACAINE; LIDOCAINE; ANALGESIA; HYPOTENSION; PREVENTION; EFFICACY	Worldwide, long-acting bupivacaine is the most popular local anesthetic for spinal anesthesia in parturients undergoing elective cesarean delivery. With advances in surgical techniques, e.g., the Misgav Ladach method, and shorter duration of surgery, the local anesthetic mepivacaine, with an intermediate duration of action, may be a reasonable alternative. Our aim in the present study was to evaluate the effects of 2% hyperbaric mepivacaine alone, or combined with either intrathecal fentanyl (5 and 10 mug), or sufentanil (2.5 and 5 mug), on sensory, motor, and analgesic block characteristics, hemodynamic variables, and neonatal outcome in a randomized, prospective, and double-blinded study (n = 100, 20 parturients per group, singleton pregnancy, >37 wk of gestation). No parturient experienced intraoperative pain. The average duration of motor block Bromage 3 in all groups was 68 min, and resolution time to Bromage 0 was 118 min. Maximal cephalad sensory block level was T3-6 and could be established within 6 min. Complete analgesia was significantly prolonged in all groups receiving intrathecal opioids, yet, with sufentanil 5 mug, even the duration of effective analgesia was significantly extended. Neonatal outcome was not affected by intrathecal opioid administration. In conclusion, 2% hyperbaric mepivacaine is a feasible local anesthetic for spinal anesthesia in parturients undergoing elective cesarean delivery, particularly with short duration of surgery.	Univ Clin, Dept Anesthesiol Intens Care Med & Pain Therapy, D-60590 Frankfurt, Germany; Mayo Clin, Dept Anesthesiol, Rochester, MN USA	Bremerich, DH (reprint author), Univ Clin, Dept Anesthesiol Intens Care Med & Pain Therapy, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	bremerich@em.uni-frankfurt.de					ABBOUND TK, 1987, REGION ANESTH, V12, P76; Aouad MT, 2001, ANESTH ANALG, V92, P401, DOI 10.1213/00000539-200102000-00023; BELZARENA SD, 1992, ANESTH ANALG, V74, P653; Ben-David B, 2000, REGION ANESTH PAIN M, V25, P235, DOI 10.1016/S1098-7339(00)90004-X; Bowdle TA, 1998, DRUG SAFETY, V19, P173, DOI 10.2165/00002018-199819030-00002; BROMAGE PR, 1964, BRIT J ANAESTH, V36, P342, DOI 10.1093/bja/36.6.342; BROWN WU, 1976, OBSTET GYNECOL, V48, P27; Burns SM, 2001, ANAESTHESIA, V56, P794; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; CLARK RB, 1975, BRIT J ANAESTH, V47, P1283, DOI 10.1093/bja/47.12.1283; Dahl JB, 1999, ANESTHESIOLOGY, V91, P1919, DOI 10.1097/00000542-199912000-00045; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; ESCARMENT J, 1989, ANN FR ANESTH, V8, P636, DOI 10.1016/S0750-7658(89)80181-9; Federici D, 1997, INT J GYNECOL OBSTET, V57, P273, DOI 10.1016/S0020-7292(97)00069-6; Herman NL, 1999, ANESTH ANALG, V89, P378, DOI 10.1097/00000539-199908000-00024; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Liguori GA, 1998, ANESTHESIOLOGY, V88, P619, DOI 10.1097/00000542-199803000-00010; LIPTON E, 1966, AM J OBSTET GYNECOL, V96, P333, DOI 10.1016/0002-9378(66)90235-3; Lynch J, 1997, ANESTH ANALG, V85, P872, DOI 10.1097/00000539-199710000-00030; Meuser T, 1998, ANAESTHESIST, V47, P557, DOI 10.1007/s001010050596; MORISHIMA HO, 1966, ANESTHESIOLOGY, V27, P147, DOI 10.1097/00000542-196603000-00006; MUELLER H, 1985, Regional-Anaesthesie, V8, P43; Norris MC, 1998, REGION ANESTH PAIN M, V23, P252, DOI 10.1016/S1098-7339(98)90050-5; RILEY ET, 1995, ANESTH ANALG, V81, P838, DOI 10.1097/00000539-199510000-00031; Runza M, 1998, ANESTH ANALG, V87, P1099; Salmela L, 1998, ACTA ANAESTH SCAND, V42, P765, DOI 10.1111/j.1399-6576.1998.tb05319.x; SCANLON JW, 1974, ANESTHESIOLOGY, V40, P121, DOI 10.1097/00000542-197402000-00005; Tarkkila P, 1996, REGION ANESTH, V21, P26	29	25	27	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	MAR	2003	96	3					852	858		10.1213/01.ANE.0000049685.38809.7E			7	Anesthesiology	Anesthesiology	648VY	WOS:000181172600038	12598273				2020-06-30	J	Carter, AC; Nicholas, JJ				Carter, AC; Nicholas, JJ			The importance of the complete history in the discovery of a potential suicide: A case report	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						geriatrics; medical history taking; rehabilitation; suicide		Suicidal ideation and completed suicides are an increasing problem among the elderly. In 1992, the elderly accounted for 13% of the population but represented 20% of all completed suicides. There are recognized risk factors for suicides in elderly patients, which include depression, deteriorating physical health, and loss of independent functioning. A complete history enables the examiner to establish a relationship with the patient and to formulate a diagnosis. Unfortunately, histories are often incomplete. Many factors can account for this, including financial pressures, patient volume, and overspecialization. The physiatric history is the integration of many parts. It incorporates not only the physiatrist's evaluation but those of other disciplines as well, for example, physical and occupational therapy. The physiatric history is a sensitive tool for assessing the state of being of the whole patient. We describe a case in which a careful and complete physiatric history and physical examination revealed an elderly patient with suicidal ideation and a plan.	Temple Univ Hosp & Med Sch, Dept Phys Med & Rehabil, Philadelphia, PA 19140 USA	Carter, AC (reprint author), 701 Summit Ave,Apt D-117, Philadelphia, PA 19128 USA.						BATES B, 1995, PHYSICAL EXAMINATION, P95; BATES B, 1995, PHYSICAL EXAMINATION, P1; BLUMENTHAL SJ, 1988, MED CLIN N AM, V72, P937, DOI 10.1016/S0025-7125(16)30754-4; *CDC, 1996, MMWR-MORBID MORTAL W, V45, P3; Conwell Y, 1997, PSYCHIAT CLIN N AM, V20, P667, DOI 10.1016/S0193-953X(05)70336-1; Conwell Y, 2000, J AM GERIATR SOC, V48, P23, DOI 10.1111/j.1532-5415.2000.tb03024.x; ERICKSON RP, 1998, REHABILITATION MED P, P61; MCPEAK LA, 2000, PHYSICAL MED REHABIL, P3; Vastag B, 2001, JAMA-J AM MED ASSOC, V285, P2701, DOI 10.1001/jama.285.21.2701	9	2	2	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2003	84	3					460	461		10.1053/apmr.2003.50000			2	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	653KL	WOS:000181434300022	12638118				2020-06-30	J	Chiarella, AB; Jolly, DT; Huston, CM; Clanachan, AS				Chiarella, AB; Jolly, DT; Huston, CM; Clanachan, AS			Comparison of four strategies to reduce the pain associated with intravenous administration of rocuronium	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetics, rocuronium; injection, pain; osmolality; pH	INJECTION; LIDOCAINE; BROMIDE	Background. I.V. rocuronium produces intense discomfort at the site of injection in conscious patients. Four strategies to reduce or prevent this discomfort were studied. Methods. Two hundred and fifty adult patients, ASA I-III, were randomized into five groups of 50 patients in a blinded, prospective study. The control group received rocuronium 10 mg alone. For the remaining four groups, rocuronium 10 mg was mixed with sodium bicarbonate 8.4% 2 ml, fentanyl 100 mug, lidocaine 2% or normal saline. The pH and osmolality of all mixtures were measured. Patient data were analysed using ordinal logistic regression. Osmolality and pH data were analysed using the Kruskal-Wallis test with Dunn's multiple comparison test. Results. When compared with rocuronium alone, only the addition of saline failed to significantly reduce the pain reported by patients. The addition of fentanyl reduced the complaint of pain by 1.9 times (P<0.049) and the addition of lidocaine 2% reduced it by 3.6 times (P<0.0001). Sodium bicarbonate 8.4% reduced the reporting of pain by 18.4 times (P<0.0001). Conclusions. Sodium bicarbonate 8.4%, when added to rocuronium, markedly reduces the experience of pain during the i.v. administration of a small dose of rocuronium.	Univ Alberta Hosp, Dept Anesthesiol & Pain Med, Walter C Mackenzie Hlth Sci Ctr 3B2 32, Edmonton, AB T6G 2B7, Canada; Univ Alberta, Fac Pharm & Pharmaceut Sci, Dent Pharm Ctr 3118, Edmonton, AB T6G 2N8, Canada	Chiarella, AB (reprint author), Univ Alberta Hosp, Dept Anesthesiol & Pain Med, Walter C Mackenzie Hlth Sci Ctr 3B2 32, 8440-112 St, Edmonton, AB T6G 2B7, Canada.		Huston, Carolyn/G-4429-2012				Borgeat A, 1997, BRIT J ANAESTH, V79, P382, DOI 10.1093/bja/79.3.382; Borgeat A, 1997, J CLIN ANESTH, V9, P650, DOI 10.1016/S0952-8180(97)00192-X; Cheong KF, 2000, BRIT J ANAESTH, V84, P106; Dalgleish DJ, 2000, ANAESTHESIA, V55, P828, DOI 10.1046/j.1365-2044.2000.01629-34.x; Joshi GP, 1997, ANESTH ANALG, V84, P228, DOI 10.1097/00000539-199701000-00044; KLEMENT W, 1991, BRIT J ANAESTH, V66, P189, DOI 10.1093/bja/66.2.189; LOCKEY D, 1995, ANAESTHESIA, V50, P474, DOI 10.1111/j.1365-2044.1995.tb06019.x; Martin R, 1998, CAN J ANAESTH, V45, P521, DOI 10.1007/BF03012701; Shevchenko Y, 1999, ANESTH ANALG, V88, P746, DOI 10.1097/00000539-199904000-00011	9	14	14	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	MAR	2003	90	3								10.1093/bja/aeg054			3	Anesthesiology	Anesthesiology	652ZG	WOS:000181410300020		Bronze			2020-06-30	J	Agarwal, A; Azim, A; Ambesh, S; Bose, N; Dhiraj, S; Sahu, D; Singh, U				Agarwal, A; Azim, A; Ambesh, S; Bose, N; Dhiraj, S; Sahu, D; Singh, U			Salbutamol, beclomethasone or sodium chromoglycate suppress coughing induced by iv fentanyl	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							ANESTHESIA; BOLUS; RELEASE	Purpose: Fentanyl, a synthetic opioid, is a popular choice amongst anesthesiologists in the operating room. Preinduction iv fentanyl bolus is associated with coughing in 28-45% of patients. Coughing due to fentanyl is not always benign and at times may be explosive requiring immediate intervention. We have studied the role of aerosol inhalation of salbutamol, beclomethasone and sodium chromoglycate in preventing fentanyl induced coughing and have compared their efficacy. Methods: Two hundred patients aged 18-60 yr, undergoing elective laparoscopic cholecystectomy were randomized into four groups of 50 each. Group I served as control, while Groups II, III and IV received an aerosol inhalation of salbutamol, beclomethasone or sodium chromoglycate 15 min prior to entering the operating room. Following iv fentanyl (2 mug.kg(-1)) the incidence of cough was recorded and graded as mild (1-2), moderate (3-5) and severe (> 5) depending on the number of coughs observed. Results were analyzed using 'z' and Fischer's Exact test. A P value of less than or equal to 0.05 was considered significant. Results: The incidence of cough was 28% in the control group, 6%, 0% and 4% in the salbutamol, beclomethasone and sodium chromoglycate groups respectively. Occurrence of cough was significantly low (P greater than or equal to 0.05) in the treatment groups, however the difference amongst the groups was not significant (P ! 0.05). Conclusion: The use of salbutamol, beclomethasone or sodium chromoglycate aerosol 15 min prior to iv fentanyl administration minimizes fentanyl-induced coughing.	SGPGIMS, Dept Anesthesia, Lucknow 226014, Uttar Pradesh, India; SGPGIMS, Dept Biostat, Lucknow 226014, Uttar Pradesh, India	Agarwal, A (reprint author), SGPGIMS, Dept Anesthesia, Type 4-48, Lucknow 226014, Uttar Pradesh, India.						Bailey P.L., 2000, ANESTHESIA, P273; BOHRER H, 1990, ANAESTHESIA, V45, P18, DOI 10.1111/j.1365-2044.1990.tb14496.x; BOVILL JG, 1984, ANESTHESIOLOGY, V61, P731; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; FLACKE JW, 1987, ANESTH ANALG, V66, P723; GRELL FL, 1970, ANESTH ANAL CURR RES, V49, P523; Lui PW, 1996, CAN J ANAESTH, V43, P1216; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; PHUA WT, 1991, CAN J ANAESTH, V38, P330, DOI 10.1007/BF03007623; REITAN JA, 1978, ANESTH ANALG, V57, P31; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; Tweed WA, 2001, ANESTH ANALG, V92, P1442; YASUDA I, 1978, ANESTHESIOLOGY, V49, P117, DOI 10.1097/00000542-197808000-00012	13	60	93	0	1	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	MAR	2003	50	3					297	300		10.1007/BF03017801			4	Anesthesiology	Anesthesiology	655TE	WOS:000181568100016	12620955	Bronze			2020-06-30	J	Meissner, W; Dohrn, B; Reinhart, K				Meissner, W; Dohrn, B; Reinhart, K			Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia	CRITICAL CARE MEDICINE			English	Article						gastrointestinal motility; intensive care unit; gastroesophageal reflux; analgesics, opioid; enteral nutrition; aspiration; fentanyl	ILL PATIENTS; ORAL NALOXONE; INDUCED DELAY; CONSTIPATION; SHOCK; ABSORPTION; MOTILITY; MORPHINE; REVERSAL	Objective: Opioid analgesia impairs gastrointestinal motility. Enteral administration of naloxone theoretically allows selective blocking of intestinal opioid receptors caused by extensive pre-systemic metabolism. Therefore, we studied the effect of enteral naloxone on the amount of gastric tube reflux, the frequency of pneumonia, and the time until first defecation in mechanically ventilated patients with fentanyl analgesia. Design: Prospective, randomized, double-blinded study. Setting: University hospital intensive care unit. Patients: Eighty-four mechanically ventilated, fentanyl-treated patients without gastrointestinal surgery or diseases. Interventions: Patients were assigned to receive 8 mg naloxone or placebo four times daily via a gastric tube during fentanyl administration. Measurements and Main Results: Thirty-eight patients received naloxone and 43 placebo; three patients were excluded because of protocol violation. Median gastric tube reflux volume (54 vs. 129 mL, p = .03) and frequency of pneumonia (34% vs. 56%, p = .04) were significantly lower in the naloxone group. In both groups, time until first defecation, ventilation time, and length of intensive care unit stay did not differ. There was no difference in fentanyl requirements between the naloxone and the placebo group (7 vs. 6.5 mug/kg/hr, p = .15). Conclusions: Our results provide evidence that the administration of enteral opioid antagonists in ventilated patients with opioid analgesia might be a simple-and possibly preventive-treatment of increased gastric tube reflux and reduces frequency of pneumonia.	Univ Jena, Dept Anesthesiol & Intens Care, D-07740 Jena, Germany	Meissner, W (reprint author), Univ Jena, Dept Anesthesiol & Intens Care, D-07740 Jena, Germany.						Berger MM, 2000, CRIT CARE MED, V28, P2217, DOI 10.1097/00003246-200007000-00006; Chapman MJ, 2000, CRIT CARE MED, V28, P2334, DOI 10.1097/00003246-200007000-00026; CULPEPPERMORGAN JA, 1992, CLIN PHARMACOL THER, V52, P90, DOI 10.1038/clpt.1992.106; Davies AR, 2002, CRIT CARE MED, V30, P586, DOI 10.1097/00003246-200203000-00016; Drakulovic MB, 1999, LANCET, V354, P1851, DOI 10.1016/S0140-6736(98)12251-1; DZIKI AJ, 1993, CIRC SHOCK, V39, P29; FISHMAN J, 1973, J PHARMACOL EXP THER, V187, P575; Heyland DK, 1996, INTENS CARE MED, V22, P1339, DOI 10.1007/s001340050261; INGLIS TJJ, 1993, LANCET, V341, P911, DOI 10.1016/0140-6736(93)91208-4; Jooste CA, 1999, INTENS CARE MED, V25, P464, DOI 10.1007/s001340050881; KREEK MJ, 1983, LANCET, V1, P261, DOI 10.1016/S0140-6736(83)91684-7; KUEPPERS PM, 1993, ANN SURG, V217, P286, DOI 10.1097/00000658-199303000-00011; Meissner W, 2000, PAIN, V84, P105, DOI 10.1016/S0304-3959(99)00185-2; MITTAL RK, 1986, DIGEST DIS SCI, V31, P936, DOI 10.1007/BF01303214; Murphy DB, 1997, ANESTHESIOLOGY, V87, P765, DOI 10.1097/00000542-199710000-00008; Napolitano LM, 2000, CRIT CARE MED, V28, P887, DOI 10.1097/00003246-200003000-00050; NIMMO WS, 1979, BRIT MED J, V2, P1189, DOI 10.1136/bmj.2.6199.1189; REYNOLDS JC, 1984, AM J PHYSIOL, V246, pG130; ROBERTS DE, 1988, LANCET, V2, P699; Roy S, 1998, MOL BRAIN RES, V56, P281, DOI 10.1016/S0169-328X(98)00051-5; SYKES NP, 1991, LANCET, V337, P1475, DOI 10.1016/0140-6736(91)93162-3; Taguchi A, 2001, NEW ENGL J MED, V345, P935, DOI 10.1056/NEJMoa010564; VOLLMER KO, 1996, ACTA PHARM TOXICOL S, V5; Wilmer A, 1999, GASTROENTEROLOGY, V116, P1293, DOI 10.1016/S0016-5085(99)70492-0; Yuan CS, 2000, JAMA-J AM MED ASSOC, V283, P367, DOI 10.1001/jama.283.3.367	25	66	69	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2003	31	3					776	780		10.1097/01.CCM.0000053652.80849.9F			5	Critical Care Medicine	General & Internal Medicine	660RP	WOS:000181846800017	12626983				2020-06-30	J	Holtzman, SG				Holtzman, SG			Discrimination of a single dose of morphine followed by naltrexone: Substitution of other agonists for morphine and other antagonists for naltrexone in a rat model of acute dependence	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							MU-OPIOID RECEPTOR; OPIATE WITHDRAWAL; PRECIPITATED WITHDRAWAL; PHYSICAL-DEPENDENCE; NARCOTIC DEPENDENCE; INTRINSIC EFFICACY; IN-VIVO; TOLERANCE; STIMULUS; PRETREATMENT	Rats were trained to discriminate 4-h pretreatment with 10 mg/kg morphine and 15-min pretreatment with 0.3 mg/kg naltrexone (morphine-->naltrexone) from pretreatment with saline and 0.3 mg/kg naltrexone (saline-->naltrexone). The discrimination seems to derive from interoceptive stimuli from antagonist-precipitated withdrawal from acute morphine dependence. The purpose of this study was to extend pharmacological characterization of the discrimination by testing opioid agonists other than morphine and antagonists other than naltrexone. Of seven mu-opioid agonists tested in place of morphine, only two (heroin and levorphanol) substituted completely for it; trials completed on the morphine-->naltrexone-appropriate lever increased as a function of agonist and naltrexone dose. Agonists with intrinsic efficacy higher (etorphine, fentanyl, and methadone) or lower (buprenorphine and meperidine) than that of morphine substituted only partially. However, when naltrexone was administered during continuous infusion of fentanyl or methadone via s.c. osmotic pump, rats responded as if they had received morphine-->naltrexone; discriminative responding correlated with global withdrawal scores. Rats responded primarily on the saline-->naltrexone-appropriate lever when naltrexone was administered after pretreatment with dextrorphan, the dextrorotatory isomer of levorphanol, or mu-opioid agonists (5-alpha,7-alpha,8-alphabeta)-(+)-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro(4,5)dec-8-yl]-benzeneacetamide (U69,593) and spiradoline. Antagonists with no intrinsic efficacy at mu-opioid receptors (naloxone and diprenorphine) substituted completely for naltrexone, whereas those with some efficacy (nalorphine and levallorphan) substituted partially. Thus, morphine-->naltrexone-like stimulus control of behavior by drugs administered acutely requires pretreatment with certain mu-opioid agonists and a pure antagonist, is independent of agonist efficacy, and is stereoselective. Interoceptive stimuli from naltrexone-precipitated opioid withdrawal are more similar across morphine-like agonists during chronic dependence than they are during acute dependence.	Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	Holtzman, SG (reprint author), Emory Univ, Sch Med, Dept Pharmacol, 1510 Clifton Rd, Atlanta, GA 30322 USA.	sholtzm@emory.edu			NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA00541, K05 DA00008]		ADAMS JU, 1990, J PHARMACOL EXP THER, V253, P483; ADAMS JU, 1991, EUR J PHARMACOL, V193, P67, DOI 10.1016/0014-2999(91)90201-Z; BICKEL WK, 1988, J PHARMACOL EXP THER, V244, P126; BLASIG J, 1973, PSYCHOPHARMACOLOGIA, V33, P19; Chavkin C, 2001, MOL PHARMACOL, V60, P20; Easterling KW, 1997, J PHARMACOL EXP THER, V281, P188; Easterling KW, 1999, J PHARMACOL EXP THER, V288, P1269; EISENBERG RM, 1979, J PHARMACOL EXP THER, V211, P364; Eissenberg T, 1996, J PHARMACOL EXP THER, V276, P449; Emmerson PJ, 1996, J PHARMACOL EXP THER, V278, P1121; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; GELLERT VF, 1978, J PHARMACOL EXP THER, V205, P536; GELLERT VF, 1979, J PHARMACOL EXP THER, V211, P596; Greenwald MK, 1996, J PHARMACOL EXP THER, V277, P1228; Holtzman SG, 1997, PHARMACOL BIOCHEM BE, V57, P771, DOI 10.1016/S0091-3057(96)00395-4; Holtzman SG, 2000, PHARMACOL BIOCHEM BE, V66, P517, DOI 10.1016/S0091-3057(00)00172-6; HOLTZMAN SG, 1990, TESTING EVALUATION D, P195; Lee KO, 1999, EUR J PHARMACOL, V378, P323, DOI 10.1016/S0014-2999(99)00460-4; MALDONADO R, 1992, J PHARMACOL EXP THER, V261, P669; MEYER DR, 1977, LIFE SCI, V21, P1087, DOI 10.1016/0024-3205(77)90106-0; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; SCHULTEIS G, 1994, J PHARMACOL EXP THER, V271, P1391; Schulteis G, 1999, BEHAV PHARMACOL, V10, P235, DOI 10.1097/00008877-199905000-00001; Selley DE, 1998, J PHARMACOL EXP THER, V285, P496; SHANNON HE, 1977, J PHARMACOL EXP THER, V201, P55; SHANNON HE, 1976, J PHARMACOL EXP THER, V198, P54; SHARMA SK, 1975, P NATL ACAD SCI USA, V72, P3092, DOI 10.1073/pnas.72.8.3092; Shippenberg TS, 2000, PSYCHOPHARMACOLOGY, V151, P351, DOI 10.1007/s002130000475; SMITH MA, 1995, BEHAV PHARMACOL, V6, P703; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; WALKER EA, 1994, J PHARMACOL EXP THER, V271, P959; Wang DX, 2001, J NEUROCHEM, V77, P1590, DOI 10.1046/j.1471-4159.2001.00362.x; WANG Z, 1994, LIFE SCI, V54, pPL339, DOI 10.1016/0024-3205(94)90022-1; WAY EL, 1969, J PHARMACOL EXP THER, V167, P1; WAY EL, 1967, FED PROC, V26, P1115; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; White DA, 2001, J PHARMACOL EXP THER, V298, P156; WRIGHT C, 1991, DRUG ALCOHOL DEPEN, V27, P139, DOI 10.1016/0376-8716(91)90033-U; YOUNG AM, 1986, PSYCHOPHARMACOLOGY, V88, P201, DOI 10.1007/BF00652241; YOUNG AM, 1991, J PHARMACOL EXP THER, V257, P795	40	9	9	0	0	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	MAR	2003	304	3					1033	1041		10.1124/jpet.102.044875			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	648XP	WOS:000181176900017	12604679	Green Published			2020-06-30	J	Okutomi, T; Mochizuki, J; Amano, K; Datta, S				Okutomi, T; Mochizuki, J; Amano, K; Datta, S			The effect of intrathecal epinephrine on epidural infused analgesics during labor	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 10-20, 2001	NEW ORLEANS, LA	Amer Soc Anesthesiologists		epinephrine; epidural analgesia; bupivacaine; fentanyl; labor analgesia	HEART-RATE CHANGES; SUFENTANIL; BUPIVACAINE; CLONIDINE; FENTANYL; ADRENALINE; SECTION	Background and Objectives: In order to prolong labor analgesia, one may add intrathecal epinephrine to the combination of bupivacaine and fentanyl. In this study, we tested the hypothesis that the addition of intrathecal epinephrine would lessen the requirement for a rescue dose of epidural analgesia during labor. Methods: one hundred-eight parturients randomly received intrathecal bupivacaine 2.5 mg and fentanyl 25 mug, with epinephrine 100 mug (Group BFE) or without (Group BF). Analgesia was assessed by visual analogue pain score (VAPS) 15 and 30 minutes after drug administration. Then, epidural analgesia (0.1% bupivacaine with 0.0002% fentanyl and 1:250,000 epinephrine at 10 mL/h) was initiated. if the patient requested additional analgesia and VAPS was over 30 mm, we added 8 mL epidural bupivacaine 0.125%. The requirement for additional analgesia, the incidence of motor block assessed by a modified Bromage score, hypotension, nausea, and pruritus was noted. Results: Except for 3 parturients in Group BF, satisfactory analgesia was achieved in all parturients 30 minutes after intrathecal drug administration. Following 30 minutes of intrathecal drug administration, VAPSs (mean +/- SD) were 0 +/- 4 mm in Group BFE and 4 +/- 11 mm in Group BF. The number of patients who required additional labor analgesia in Group BFE (11 patients, 20%) was significantly less than in Group BF (26 patients, 48%) (P =.003). The incidence of motor block 30 minutes after spinal analgesia in Group BFE (12 patients, 22%) was significantly higher than in Group BF (3 patients, 6%) (P =.024). Nausea and pruritus were similar in both groups. Conclusion: The addition of epinephrine to intrathecal bupivacaine-fentanyl lessened the requirement for additional epidural analgesia without increasing hypotension, nausea, or pruritus. However, the incidence of motor block may be increased without labor prolongation. Reg Anesth Pain Med 2003,-28:108-112.	Kitasato Univ, Dept Anesthesiol, Sch Med, Sagamihara, Kanagawa 2288555, Japan; Kitasato Univ, Sch Med, Dept Obstet & Gynecol, Sagamihara, Kanagawa 2288555, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesia, Boston, MA 02115 USA	Okutomi, T (reprint author), Kitasato Univ, Dept Anesthesiol, Sch Med, 1-15-1 Kitasato, Sagamihara, Kanagawa 2288555, Japan.	toshiyukiokutomi@hotmail.com					Acalovschi I, 1997, ANESTH ANALG, V84, P1333, DOI 10.1097/00000539-199706000-00029; Albright GA, 1997, REGION ANESTH, V22, P400, DOI 10.1016/S1098-7339(97)80025-9; BROMAGE PR, 1983, ANESTHESIOLOGY, V58, P257, DOI 10.1097/00000542-198303000-00010; CAMANN WR, 1993, ANESTHESIOLOGY, V78, P870, DOI 10.1097/00000542-199305000-00010; Campbell DC, 1997, ANESTHESIOLOGY, V86, P525, DOI 10.1097/00000542-199703000-00003; Cascio M, 1997, CAN J ANAESTH, V44, P605, DOI 10.1007/BF03015443; COLLINS JG, 1983, ANESTH ANALG, V62, P253; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; D'Angelo R, 1999, ANESTH ANALG, V88, P573, DOI 10.1097/00000539-199903000-00020; D'Angelo R, 2001, ANESTHESIOLOGY, V94, pU14; Dounas M, 1996, EUR J ANAESTH, V13, P594, DOI 10.1046/j.1365-2346.1996.00053.x; Gambling DR, 1998, ANESTHESIOLOGY, V89, P1336, DOI 10.1097/00000542-199812000-00010; Gautier PE, 1997, REGION ANESTH, V22, P143, DOI 10.1016/S1098-7339(06)80033-7; GRIECO WM, 1993, ANESTH ANALG, V77, P1149; Nielsen PE, 1996, ANESTH ANALG, V83, P742, DOI 10.1097/00000539-199610000-00014; Palmer CM, 1999, ANESTH ANALG, V88, P577, DOI 10.1097/00000539-199903000-00021; RANDALLS B, 1991, BRIT J ANAESTH, V66, P314, DOI 10.1093/bja/66.3.314; ROBERTSON K, 1985, CAN ANAESTH SOC J, V32, P502, DOI 10.1007/BF03010800; Sia ATH, 2000, CAN J ANAESTH, V47, P875, DOI 10.1007/BF03019667; STACEY RGW, 1993, BRIT J ANAESTH, V71, P499, DOI 10.1093/bja/71.4.499; Vercauteren MP, 2001, REGION ANESTH PAIN M, V26, P473, DOI 10.1053/rapm.2001.24406; VERCAUTEREN MP, 1994, ANAESTHESIA, V49, P767	23	12	12	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	MAR-APR	2003	28	2					108	112		10.1053/rapm.2003.50026			5	Anesthesiology	Anesthesiology	664GF	WOS:000182052800007	12677620				2020-06-30	J	Theodoridis, T; Waap, I; Schwalen, S; Kramer, J				Theodoridis, T; Waap, I; Schwalen, S; Kramer, J			Fentanyl-TTS in the treatment of pain caused by arthrosis	ZEITSCHRIFT FUR ORTHOPADIE UND IHRE GRENZGEBIETE			German	Article						fentanyl-TTS; opioids; pain; gonarthrosis; coxarthrosis	PLACEBO-CONTROLLED TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CONTROLLED-RELEASE OXYCODONE; DOUBLE-BLIND; TRANSDERMAL FENTANYL; OSTEOARTHRITIS PAIN; JOINT PAIN; CODEINE; EFFICACY; TRAMADOL	Aim: Efficacy and tolerability of analgesic treatment with fentanyl-TTS (Durogesic(R)) for pain caused by arthrosis was investigated. Method: Treatment with fentanyl-TTS was started for the first time in patients with severe pain caused by coxarthrosis and/or gonarthrosis and was prospectively documented for 30 days. Pain was assessed by the patient with an 11-step numerical analogue scale and by the physician with 5 questions (5-step scale) adapted from the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Results: A total of 243 patients (166 women, 77 men) with a mean age of 67 years (range 28-94) was treated. In the patient's rating, pain at rest as well as in motion decreased significantly from 6.4 +/- 2.1 to 2.9 +/- 2.0 and from 8.1 +/- 1.5 to 4.2 +/- 21, respectively (p < 0.001 for both comparisons). The sum score for the 5 questions with a detailed pain assessment by the physician decreased from 18.8 +/- 3.2 to 11.2 42 (p < 0.001). A significant pain reduction was also observed for each of the 5 single questions. At the end of observation the proportions of patients with no pain or impairment under different conditions were 5% (climbing stairs), 14% (walking), 26% (standing), 33% (lying/sitting), and 44% (sleeping). The most common adverse events were nausea, vomiting, obstipation, and dizziness. Treatment with fentanyl-TTS was usually well-tolerated. Conclusion: Severe pain caused by arthrosis can be well treated with fentanyl-TTS with a favourable safety profile.	Ruhr Univ Bochum, St Josef Hosp, Orthopad Klin, D-44791 Bochum, Germany; Janssen Cilag GmbH, Neuss, Germany	Theodoridis, T (reprint author), Ruhr Univ Bochum, St Josef Hosp, Orthopad Klin, Gudrunstr 56, D-44791 Bochum, Germany.						*ARZN DTSCH ARZT, 2001, EMP THER DEG GEL ARZ; BELLAMY N, 1995, J RHEUMATOL, V22, P49; BOISSIER C, 1992, J CLIN PHARMACOL, V32, P990, DOI 10.1002/j.1552-4604.1992.tb03800.x; Caldwell JR, 1999, J RHEUMATOL, V26, P862; Cheville A, 2001, J BONE JOINT SURG AM, V83A, P572, DOI 10.2106/00004623-200104000-00013; Fleischmann RM, 2001, CURR THER RES CLIN E, V62, P113, DOI 10.1016/S0011-393X(01)80021-7; *GASTR NEB NICHT S, 1999, ARZNEIMITTELBRIEF, V33, P1; Geba GP, 2002, JAMA-J AM MED ASSOC, V287, P64, DOI 10.1001/jama.287.1.64; GRAMAS DA, 1995, TREATMENT RHEUMATIC, P286; Hosie J, 1996, BRIT J RHEUMATOL, V35, P39; JENSEN EM, 1994, DRUG INVEST, V8, P211, DOI 10.1007/BF03258480; KJAERSGAARDANDERSEN P, 1990, PAIN, V43, P309, DOI 10.1016/0304-3959(90)90028-C; Kraus VB, 1997, MED CLIN N AM, V81, P85, DOI 10.1016/S0025-7125(05)70506-X; LAWRENCE JS, 1966, ANN RHEUM DIS, V25, P1; LICHTENSTEIN DR, 1995, ARTHRITIS RHEUM, V38, P5, DOI 10.1002/art.1780380103; LLOYD RS, 1992, CURR MED RES OPIN, V13, P37, DOI 10.1185/03007999209115221; Muijsers RBR, 2001, DRUGS, V61, P2289, DOI 10.2165/00003495-200161150-00014; Palmer BF, 1995, J INVEST MED, V43, P516; Peloso PM, 2001, J RHEUMATOL, V28, P6; Peloso PM, 2000, J RHEUMATOL, V27, P764; Perrot S, 1999, REV RHUM, V66, P571; QUIDING H, 1992, PAIN, V50, P303, DOI 10.1016/0304-3959(92)90035-A; Roth SH, 1998, J RHEUMATOL, V25, P1358; Roth SH, 2000, ARCH INTERN MED, V160, P853, DOI 10.1001/archinte.160.6.853; Schnitzer TJ, 1999, ARTHRITIS RHEUM-US, V42, P1370, DOI 10.1002/1529-0131(199907)42:7<1370::AID-ANR10>3.0.CO;2-T; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; VANCAUWENBERGE H, 1992, INT J CLIN PHARM RES, V12, P1; Ytterberg SR, 1998, ARTHRITIS RHEUM, V41, P1603, DOI 10.1002/1529-0131(199809)41:9<1603::AID-ART10>3.0.CO;2-U	28	3	4	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0044-3220			Z ORTHOP GRENZGEB	Z. Orthop. Grenzg.	MAR-APR	2003	141	2					217	222		10.1055/s-2003-38651			6	Orthopedics	Orthopedics	676UM	WOS:000182771000013	12695960				2020-06-30	J	Choi, WY; Irwin, MG; Hui, TWC; Lim, HH; Chan, KL				Choi, WY; Irwin, MG; Hui, TWC; Lim, HH; Chan, KL			EMLA (R) cream versus dorsal penile nerve block for postcircumcision analgesia in children	ANESTHESIA AND ANALGESIA			English	Article							POST-CIRCUMCISION ANALGESIA; POSTOPERATIVE ANALGESIA; NEONATAL CIRCUMCISION; RING BLOCK; PAIN; PRILOCAINE; ANESTHESIA; LIDOCAINE	We conducted a prospective, randomized, double-blinded trial comparing preoperative application of EMLA(R) cream and sodium chloride solution dorsal penile block (n = 31) with placebo cream and bupivacaine dorsal penile nerve block (n = 32) for postcircumcision analgesia. Pain was assessed using modified Children's Hospital of Eastern Ontario Pain Scale and the duration of block by the time to requirement of first dose of postoperative analgesic. There was no difference in Children's Hospital of Eastern Ontario Pain Scale between the two groups, but bupivacaine dorsal penile nerve block resulted in longer analgesia (P = 0.003). There were no local or systemic complications related to either technique, and there was a very small incidence of vomiting. We conclude that preoperative application of EMLA(R) cream is an effective and simple method to produce postcircumcision analgesia with a very small incidence of adverse effects.	Pamela Youde Nethersole Eastern Hosp, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; Queen Mary Hosp, Dept Anesthesiol, Hong Kong, Hong Kong, Peoples R China	Choi, WY (reprint author), Pamela Youde Nethersole Eastern Hosp, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China.	reginachoi@hotmail.com	Irwin, Michael/C-4286-2009	Irwin, Michael/0000-0001-5801-274X			CHAMBERS FA, 1994, BRIT J ANAESTH, V73, P437, DOI 10.1093/bja/73.4.437; Finley GA, 1996, PAIN, V64, P83; HOWARD CR, 1994, PEDIATRICS, V93, P641; Howard CR, 1999, AM J OBSTET GYNECOL, V181, P1506, DOI 10.1016/S0002-9378(99)70397-2; Irwin MG, 1996, ANAESTH INTENS CARE, V24, P365, DOI 10.1177/0310057X9602400311; Lander J, 1997, JAMA-J AM MED ASSOC, V278, P2157, DOI 10.1001/jama.278.24.2157; LEE JJ, 1992, ANAESTHESIA, V47, P1081, DOI 10.1111/j.1365-2044.1992.tb04211.x; MARTIN LVH, 1982, BRIT J ANAESTH, V54, P1263, DOI 10.1093/bja/54.12.1263; McGowan PR, 1998, PAEDIATR ANAESTH, V8, P403; SARA CA, 1985, ANAESTH INTENS CARE, V13, P79, DOI 10.1177/0310057X8501300111; SEROUR F, 1994, ANESTH ANALG, V79, P129; SEROUR F, 1995, J UROLOGY, V153, P474, DOI 10.1097/00005392-199502000-00062; Serour F, 1996, CAN J ANAESTH, V43, P954, DOI 10.1007/BF03011810; Taddio A, 1997, NEW ENGL J MED, V336, P1197, DOI 10.1056/NEJM199704243361701	14	27	29	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2003	96	2					396	399		10.1097/00000539-200302000-00018			4	Anesthesiology	Anesthesiology	638YV	WOS:000180601400016	12538184				2020-06-30	J	Brookes, ZLS; Brown, NJ; Reilly, CS				Brookes, ZLS; Brown, NJ; Reilly, CS			The dose-dependent effects of fentanyl on rat skeletal muscle microcirculation in vivo	ANESTHESIA AND ANALGESIA			English	Article							CEREBRAL-CIRCULATION; OPIOID RECEPTOR; OPIATE RECEPTOR; SUFENTANIL; ALFENTANIL; METABOLISM; AGONISTS	Determining the effects of analgesia on the microcirculation is difficult because the surgery needed to allow in vivo observation often requires anesthesia. In this study, we used the dorsal microcirculatory chamber (DMC) to determine the effects of large (1,17) and small (SF) dose IV fentanyl on the microcirculation compared with a conscious control. Male Wistar rats (130 g, n = 5) were implanted with the DMC to enclose a single layer of striated muscle. Animals were allowed 3 wk to recover from surgery and then, over the following 2 wk (1 infusion/wk) using intravital microscopy, the microcirculation was viewed in conscious animals (t = 0-30 min), followed by an induction bolus dose (t = 40-45 min), then a "step-up" maintenance infusion of one of the following, LF (40-90 mug . kg(-1) . h(-1)), SF (10-60 mug . kg(-1) . h(-1)), or saline (5-10 mug . kg(-1) . h(-1)) (t = 45-105 min). Small arterioles (<30 mu m) dilated (23.6% +/- 7.1%) after induction with LF, but constricted (-21.3% +/- 7.1%) with SF (P < 0.05). During maintenance, constriction increased with increasing dose of LF (-21.9% +/- 4.0%) and SF (-16.7% +/- 9.1%) (t = 105 min, P < 0.05). Similar patterns were observed in all arterioles (10-120 mu m) and venules (15-250 mu m). We conclude that the DMC provides an excellent technique for observing microcirculatory responses to fentanyl, and in rat skeletal muscle in vivo, an IV infusion of fentanyl produces significant constriction of arterioles.	Univ Sheffield, Royal Hallamshire Hosp, Div Clin Sci, Sect Surg & Anesthet Sci, Sheffield S10 2JF, S Yorkshire, England	Reilly, CS (reprint author), Univ Sheffield, Royal Hallamshire Hosp, Div Clin Sci, Sect Surg & Anesthet Sci, Sheffield S10 2JF, S Yorkshire, England.	c.s.reilly@sheffield.ac.uk		Brookes, Zoe/0000-0002-8096-6256; Brown, Nicola/0000-0002-2100-1905			Albrecht E, 1997, PHARMACOL BIOCHEM BE, V58, P189, DOI 10.1016/S0091-3057(96)00480-7; BACHELARD H, 1995, BRIT J PHARMACOL, V115, P613, DOI 10.1111/j.1476-5381.1995.tb14976.x; Brookes ZLS, 2000, BRIT J ANAESTH, V85, P901, DOI 10.1093/bja/85.6.901; Brookes ZLS, 2002, BRIT J ANAESTH, V88, P255, DOI 10.1093/bja/88.2.255; Cadet P, 2000, ENDOTHELIUM-NEW YORK, V7, P185, DOI 10.3109/10623320009165316; CARLSSON C, 1982, ANESTHESIOLOGY, V57, P375, DOI 10.1097/00000542-198211000-00005; FEUERSTEIN G, 1985, PEPTIDES, V6, P11, DOI 10.1016/0196-9781(85)90005-1; HUTCHINS PM, 1988, HYPERTENSION, V12, P74, DOI 10.1161/01.HYP.12.1.74; HUTCHINS PM, 1973, MICROVASC RES, V5, P131, DOI 10.1016/0026-2862(73)90064-2; LANG RM, 1992, J APPL PHYSIOL, V73, P143; MARSHALL JM, 1982, J PHYSIOL-LONDON, V332, P169, DOI 10.1113/jphysiol.1982.sp014408; MAY CN, 1991, BRIT J PHARMACOL, V102, P639, DOI 10.1111/j.1476-5381.1991.tb12226.x; MEDVEDEV OS, 1988, OPIOID PEPTIDES BLOO, P159; MILDE LN, 1990, ANESTH ANALG, V70, P138; MILLER FN, 1982, MICROVASC RES, V24, P56, DOI 10.1016/0026-2862(82)90042-5; MONITTO CL, 1993, ANESTH ANALG, V76, P985; NUSSMEIER NA, 1991, ANESTH ANALG, V72, P221, DOI 10.1213/00000539-199102000-00015; PARRA L, 1995, EUR J PHARMACOL, V277, P99, DOI 10.1016/0014-2999(95)00067-U; SMITH TL, 1985, MICROVASC RES, V29, P360, DOI 10.1016/0026-2862(85)90025-1; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; TAMMISTO T, 1970, BRIT J ANAESTH, V42, P317, DOI 10.1093/bja/42.4.317; TODA N, 1977, ANESTHESIOLOGY, V46, P411, DOI 10.1097/00000542-197706000-00007; Ward ME, 1996, J APPL PHYSIOL, V80, P802; WHITE DA, 1990, ANESTH ANALG, V71, P29; YASTER M, 1987, ANESTHESIOLOGY, V66, P524, DOI 10.1097/00000542-198704000-00013	25	12	13	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	FEB	2003	96	2					456	462		10.1097/00000539-200302000-00030			7	Anesthesiology	Anesthesiology	638YV	WOS:000180601400028	12538196				2020-06-30	J	Petersen, KD; Landsfeldt, U; Cold, GE; Petersen, CB; Mau, S; Hauerberg, J; Holst, P; Olsen, KS				Petersen, KD; Landsfeldt, U; Cold, GE; Petersen, CB; Mau, S; Hauerberg, J; Holst, P; Olsen, KS			Intracranial pressure and cerebral hemodynamic in patients with cerebral tumors - A randomized prospective study of patients subjected to craniotomy in propofol-fentanyl, isoflurane-fentanyl, or sevoflurane-fentanyl anesthesia	ANESTHESIOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 14-18, 2000	SAN FRANCISCO, CALIFORNIA	Amer Soc Anesthesiologists			CEREBROSPINAL-FLUID PRESSURE; BLOOD-FLOW; SUBDURAL PRESSURE; TRANSSPHENOIDAL HYPOPHYSECTOMY; NEUROSURGICAL PATIENTS; NORMOCAPNIC PATIENTS; TACTILE ESTIMATION; OXYGEN-SATURATION; METABOLIC-RATE; DOSE-RESPONSE	Background: A critical point during craniotomy is opening of dura, where a high intracranial pressure (ICP) results in swelling of cerebral tissue. Controlled studies concerning ICP, degree of dural tension, and degree of cerebral swelling are therefore warranted. Methods: In an open-label study, 117 patients with supratentorial cerebral tumors were randomized to propofol-fentanyl (group 1), isoflurane-fentanyl (group 2), or sevoflurane-fentanyl anesthesia (group 3). Normo- to moderate hypocapnia was applied, with a target level of arterial carbon dioxid tension of 30-40 mmHg. Mean arterial blood pressure was stabilized with intravenous ephedrine (2.5-5 mg) if necessary. Subdural ICP, mean arterial blood pressure, cerebral perfusion pressure (CPP), arteriovenous oxygen difference (AVDo(2)), internal jugular vein oxygen saturation were monitored before and after a 10-min period of hyperventilation, and the carbon dioxide reactivity was calculated. Furthermore, the tension of dura before and during hyperventilation and the degree of cerebral swelling during hyperventilation and after opening of the dura were estimated by the neurosurgeon. Results. No differences were found between groups with regard to demographics, neuroradiologic examination, positioning of the head, and time to ICP measurement. Before and during hyperventilation, ICP was significantly lower and mean arterial blood pressure and CPP significantly higher in group 1 compared with groups 2 and 3 (P < 0.05). The tension of dura before and during hyperventilation was significantly lower in group 1 compared with group2 (P < 0.05), but not significantly different from group 3. In group 1, cerebral swelling after opening of dura was significantly lower compared with groups 2 and 3 (P < 0.05). Furthermore, AVDo(2) was significantly higher and jugular vein oxygen saturation and carbon dioxide reactivity were significantly lower in group 1 compared with groups 2 and 3 (P < 0.05). No significant differences with regard to ICP, CPP, AVDo(2), carbon dioxide reactivity, and jugular vein oxygen saturation were found between patients anesthetized with isoflurane and sevoflurane. Conclusions: The study indicates that before as well as during hyperventilation, subdural ICP and AVDo(2) are lower and CPP higher in propofol-anesthetized patients compared with patients anesthetized with isoflurane or sevoflurane. These findings were associated with less tendency for cerebral swelling after opening of dura in the propofol group. The carbon dioxide reactivity in patients anesthetized with isoflurane and sevoflurane was significantly higher than in the propofol group. The differences in subdural ICP between the groups are presumed to be caused by differences in the degree of vasoconstriction elicited by the anesthetic agents, but autoregulatory mechanisms caused by differences in CPP cannot be excluded.	Aarhus Univ Hosp, Dept Neuroanesthesia, DK-8000 Aarhus C, Denmark	Cold, GE (reprint author), Aarhus Univ Hosp, Dept Neuroanesthesia, DK-8000 Aarhus C, Denmark.						ADAMS RW, 1981, ANESTHESIOLOGY, V54, P97, DOI 10.1097/00000542-198102000-00001; ALGOTSSON L, 1988, ACTA ANAESTH SCAND, V32, P15, DOI 10.1111/j.1399-6576.1988.tb02678.x; ALKIRE MT, 1995, ANESTHESIOLOGY, V82, P393, DOI 10.1097/00000542-199502000-00010; ARTRU AA, 1984, ANESTHESIOLOGY, V61, P529, DOI 10.1097/00000542-198411000-00009; ARTRU AA, 1993, J NEUROSURG ANESTH, V5, P250; Artru AA, 1997, ANESTH ANALG, V85, P587, DOI 10.1097/00000539-199709000-00019; Artru AA, 2000, J NEUROSURG ANESTH, V12, P37, DOI 10.1097/00008506-200001000-00008; Bundgaard H, 1998, ACTA ANAESTH SCAND, V42, P621, DOI 10.1111/j.1399-6576.1998.tb05292.x; Bundgaard H, 1998, ACT NEUR S, V71, P276; Bundgaard H, 2000, BRIT J NEUROSURG, V14, P229; Cenic A, 2000, ANESTH ANALG, V90, P1376, DOI 10.1097/00000539-200006000-00021; Cho S, 1996, ANESTHESIOLOGY, V85, P755, DOI 10.1097/00000542-199610000-00010; Cold GE, 1996, BRIT J NEUROSURG, V10, P69; ENDO H, 1977, J NEUROSURG, V46, P271, DOI 10.3171/jns.1977.46.3.0271; FORTUNE JB, 1995, J TRAUMA, V39, P463; Gopinath SP, 1996, ANESTH ANALG, V83, P1014, DOI 10.1097/00000539-199611000-00020; GORDON E, 1988, ACTA ANAESTH SCAND, V32, P108, DOI 10.1111/j.1399-6576.1988.tb02696.x; Harrison JM, 1999, BRIT J ANAESTH, V83, P839, DOI 10.1093/bja/83.6.839; Hauerberg J, 2001, J NEUROSURG ANESTH, V13, P213, DOI 10.1097/00008506-200107000-00006; HEISS WD, 1978, EUR NEUROL, V17, P135, DOI 10.1159/000115017; Inada T, 1996, CAN J ANAESTH, V43, P1019, DOI 10.1007/BF03011903; Jansen GFA, 1999, ANESTH ANALG, V89, P358, DOI 10.1097/00000539-199908000-00021; Jorgensen HA, 1999, BRIT J NEUROSURG, V13, P449; Kanaya N, 2002, ANESTH ANALG, V94, P1207, DOI 10.1097/00000539-200205000-00029; Kuroda Y, 1996, ANESTHESIOLOGY, V84, P555, DOI 10.1097/00000542-199603000-00010; Lorenz IH, 2001, J NEUROSURG ANESTH, V13, P288, DOI 10.1097/00008506-200110000-00002; MADSEN JB, 1987, ANESTHESIOLOGY, V66, P332, DOI 10.1097/00000542-198703000-00012; MADSEN JB, 1987, BRIT J ANAESTH, V59, P1204, DOI 10.1093/bja/59.10.1204; MADSEN JB, 1991, FOCUS INFUSION, P162; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; Mielck F, 1999, ANESTH ANALG, V89, P364, DOI 10.1097/00000539-199908000-00022; MOSS E, 1990, BRIT J ANAESTH, V65, P823, DOI 10.1093/bja/65.6.823; MOSS E, 1995, BRIT J ANAESTH, V75, P527, DOI 10.1093/bja/75.5.527; Nandate K, 2000, BRIT J ANAESTH, V84, P631, DOI 10.1093/bja/84.5.631; OLSEN KS, 1994, BRIT J ANAESTH, V72, P66, DOI 10.1093/bja/72.1.66; Oshima T, 2002, ACTA ANAESTH SCAND, V46, P831, DOI 10.1034/j.1399-6576.2002.460713.x; PINAUD M, 1990, ANESTHESIOLOGY, V73, P404, DOI 10.1097/00000542-199009000-00007; RAMANI R, 1992, J NEUROSURG ANESTH, V4, P110, DOI 10.1097/00008506-199204000-00006; RAVUSSIN P, 1991, J NEUROSURG ANESTH, V3, P85, DOI 10.1097/00008506-199106000-00002; SCHELLER MS, 1988, ANESTHESIOLOGY, V68, P548, DOI 10.1097/00000542-198804000-00012; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; Summors AC, 1999, ANESTH ANALG, V88, P341, DOI 10.1097/00000539-199902000-00022; Talke P, 1999, ANESTHESIOLOGY, V91, P127, DOI 10.1097/00000542-199907000-00020; Talke P, 1996, ANESTHESIOLOGY, V85, P999, DOI 10.1097/00000542-199611000-00006; Todd MM, 1996, J NEUROSURG ANESTH, V8, P296, DOI 10.1097/00008506-199610000-00007; TODD MM, 1993, ANESTHESIOLOGY, V78, P1005, DOI 10.1097/00000542-199306000-00002	46	111	118	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	FEB	2003	98	2					329	336		10.1097/00000542-200302000-00010			8	Anesthesiology	Anesthesiology	640LW	WOS:000180691200008	12552189				2020-06-30	J	Sarang, A; Dinsmore, J				Sarang, A; Dinsmore, J			Anaesthesia for awake craniotomy - evolution of a technique that facilitates awake neurological testing	BRITISH JOURNAL OF ANAESTHESIA			English	Article						anaesthetic techniques; complications; surgery, craniotomy	LARYNGEAL MASK; PROPOFOL; PATIENT; TUMOR; BRAIN; REMIFENTANIL; RESECTION; SEDATION	Background. There is an increasing trend towards performing craniotomy awake. The challenge for the anaesthetist is to provide adequate analgesia and sedation, haemodynamic stability, and a safe airway, with an awake, cooperative patient for neurological testing. Methods. The records of all patients who had awake craniotomy at our institution were reviewed. Patients were divided into three groups according to anaesthetic technique. Patients in Group I were sedated throughout the procedure. Patients in Groups 2 and 3 had an asleep-awake-asleep technique. Those in Group 2 were anaesthetized with a propofol infusion and fentanyl, and breathed spontaneously through a laryngeal mask airway (LMAdagger). Patients in Group 3 had total i.v. anaesthesia with propofol and remifentanil, and ventilation was controlled using an LMA. We noted the incidence of complications in each group. Results. There were 99 procedures carried out between 1989 and 2002. Group 3 had the fewest complications. No patients in Group 3 developed hypercapnia (E'(CO2) >6 kPa), compared with all of the patients in Group 2. Patients in Group I had no E, (CO2) monitoring, but 7% developed airway obstruction. No patients in Group 3 required additional analgesia for pain, compared with 70% of patients in Group 2. Conclusions. We have developed a technique for craniotomy, which facilitates awake neurological testing, is safe, and has good patient satisfaction.	Atkinson Morleys Hosp, Dept Anaesthesia, London SW20 0NE, England	Dinsmore, J (reprint author), Atkinson Morleys Hosp, Dept Anaesthesia, Copse Hill, London SW20 0NE, England.						ARCHER DP, 1988, CAN J ANAESTH, V35, P338, DOI 10.1007/BF03010852; Blanshard HJ, 2001, ANESTH ANALG, V92, P89; Danks RA, 1998, NEUROSURGERY, V42, P28, DOI 10.1097/00006123-199801000-00006; Fukaya C, 2001, J CLIN NEUROSCI, V8, P253, DOI 10.1054/jocn.2000.0866; Hans P, 2000, ANAESTHESIA, V55, P255, DOI 10.1046/j.1365-2044.2000.01277.x; Herrick IA, 1997, ANESTH ANALG, V84, P1285, DOI 10.1097/00000539-199706000-00021; Huncke K, 1998, NEUROSURGERY, V42, P1312, DOI 10.1097/00006123-199806000-00069; Johnson KB, 1998, J NEUROSURG ANESTH, V10, P25, DOI 10.1097/00008506-199801000-00006; Meyer RB, 2001, MAYO CLIN PROC, V76, P677, DOI 10.4065/76.7.677; Sahjpaul RL, 2000, CAN J NEUROL SCI, V27, pS55, DOI 10.1017/S0317167100000676; Sidaras G, 2001, BRIT J ANAESTH, V86, P749, DOI 10.1093/bja/86.6.749; Taylor MD, 1999, J NEUROSURG, V90, P35, DOI 10.3171/jns.1999.90.1.0035; Tongier WK, 2000, J CLIN ANESTH, V12, P592, DOI 10.1016/S0952-8180(00)00211-7	13	108	121	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912			BRIT J ANAESTH	Br. J. Anaesth.	FEB	2003	90	2					161	165		10.1093/bja/aeg037			5	Anesthesiology	Anesthesiology	644AN	WOS:000180895900009	12538371	Bronze			2020-06-30	J	Kevin, LG				Kevin, LG			Propofol and myocardial lipid peroxidation	BRITISH JOURNAL OF ANAESTHESIA			English	Letter													Unal, Necmettin/0000-0002-9440-7893				0	1	1	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	FEB	2003	90	2					253	253		10.1093/bja/aeg512			1	Anesthesiology	Anesthesiology	644AN	WOS:000180895900031	12538389	Bronze			2020-06-30	J	Sayin, MM; Ozatamer, O; Unal, N				Sayin, MM; Ozatamer, O; Unal, N			Propofol and myocardial lipid peroxidation	BRITISH JOURNAL OF ANAESTHESIA			English	Letter							FREE-RADICALS; CARDIOPROTECTION; PROTECTION; TRIGGER; BYPASS						Unal, Necmettin/0000-0002-9440-7893			Almaas R, 2000, ANESTHESIOLOGY, V92, P764, DOI 10.1097/00000542-200003000-00020; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Belhomme D, 1999, CIRCULATION, V100, P340; Cohen MV, 2001, CIRC RES, V89, P273, DOI 10.1161/hh1501.094266; De Hert SG, 2002, ANESTHESIOLOGY, V97, P42, DOI 10.1097/00000542-200207000-00007; Kaeffer N, 1997, CIRCULATION, V96, P2311; Mullenheim J, 2002, ANESTHESIOLOGY, V96, P934; Patel HH, 2001, J MOL CELL CARDIOL, V33, P1455, DOI 10.1006/jmcc.2001.1408; Pouzet B, 2002, ANN THORAC SURG, V73, P843, DOI 10.1016/S0003-4975(01)03454-3; Sayin MM, 2002, BRIT J ANAESTH, V89, P242, DOI 10.1093/bja/aef173; SMITH DS, 1980, ACTA PHYSIOL SCAND, P129; Sommerschild HT, 2002, ACTA ANAESTH SCAND, V46, P123, DOI 10.1034/j.1399-6576.2002.460202.x; Wu ZK, 2001, CARDIOVASC SURG, V9, P362, DOI 10.1016/S0967-2109(00)00146-0; Wu ZK, 2001, CHEST, V119, P1061, DOI 10.1378/chest.119.4.1061; Zhang HY, 2002, J PHARMACOL EXP THER, V301, P1012, DOI 10.1124/jpet.301.3.1012	15	0	0	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	FEB	2003	90	2					253	254		10.1093/bja/aeg512			2	Anesthesiology	Anesthesiology	644AN	WOS:000180895900032		Bronze			2020-06-30	J	Jabbour-Khoury, SI; Dabbous, AS; Rizk, LB; Jalad, NMA; Bartelmaos, TE; El-Khatib, MF; Baraka, AS				Jabbour-Khoury, SI; Dabbous, AS; Rizk, LB; Jalad, NMA; Bartelmaos, TE; El-Khatib, MF; Baraka, AS			A combination of alfentanil-lidocaine-propofol provides better intubating conditions than fentanyl-lidocaine-propofol in the absence of muscle relaxants	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							TRACHEAL INTUBATION; INDUCED RIGIDITY; ANESTHESIA; THIOPENTONE; INDUCTION; ADULTS	Purpose: To compare the ease of tracheal intubation without the use of muscle relaxants following an alfentanil-lidocaine-propofol sequence vs a fentanyl-lidocaine-propofol sequence. Clinical features: In 80 ASA I and II adult patients undergoing elective laparoscopic surgery, we compared the intubating conditions following alfentanil 20 mug.kg(-1), lidocaine 1.5 mg.kg(-1), propofol 3 mg.kg(-1) (Group I; n = 40) vs fentanyl 2 mug.kg(-1), lidocaine 1.5 mg.kg(-1), propofol 3 mg.kg(-1) (Group II; n = 40). The intubating conditions were scored by jaw relaxation, vocal cord position and response to intubation, as well as by blood pressure and heart rate changes. The intubating conditions were good or excellent in 95% of patients in Group I vs 62.5% of patients in Group II (P < 0.05). Blood pressure decreased from a preinduction value of 86 +/- 13 mmHg to 72 +/- 28 mmHg and 74 +/- 19 mmHg in Group I, and from 85 +/- 12 mmHg to 78 +/- 15 mmHg and 78 +/- 12 mmHg in Group II, one and five minutes following intubation (P < 0.05). This drop in blood pressure was not different between the two groups. Conclusion: An alfentanil-lidocaine-propofol sequence offers significantly better intubating conditions than a fentanyl- lidocaine-propofol sequence in healthy adult patients.	Amer Univ Beirut, Dept Anesthesiol, Med Ctr, Beirut, Lebanon	Baraka, AS (reprint author), Amer Univ Beirut, Dept Anesthesiol, Med Ctr, POB 11-0236, Beirut, Lebanon.						BARKER P, 1992, BRIT J ANAESTH, V69, P23, DOI 10.1093/bja/69.1.23; BENTHUYSEN JL, 1986, ANESTHESIOLOGY, V64, P440, DOI 10.1097/00000542-198604000-00005; CAMU F, 1982, ANESTH ANALG, V61, P657; HOVORKA J, 1991, ACTA ANAESTH SCAND, V35, P326, DOI 10.1111/j.1399-6576.1991.tb03298.x; Iamaroon A, 2001, ANESTH ANALG, V92, P523, DOI 10.1213/00000539-200102000-00045; MCDONNELL TE, 1984, ANESTHESIOLOGY, V60, P136, DOI 10.1097/00000542-198402000-00010; MCKEATING K, 1988, ANAESTHESIA, V43, P638, DOI 10.1111/j.1365-2044.1988.tb04146.x; MORGAN GE, 2002, AIRWAY MANAGEMENT CL, P59; REVES J.G., 2000, ANESTHESIA, P228; SCHELLER MS, 1992, ANESTH ANALG, V75, P788; SCOTT JC, 1985, ANESTHESIOLOGY, V62, P234, DOI 10.1097/00000542-198503000-00005; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P629, DOI 10.1097/00000542-199304000-00003	12	15	17	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	FEB	2003	50	2					116	120		10.1007/BF03017841			5	Anesthesiology	Anesthesiology	649DQ	WOS:000181192000004	12560299	Bronze			2020-06-30	J	Gao, C; Chen, LW; Chen, J; Xu, XJ; Chi, ZQ				Gao, C; Chen, LW; Chen, J; Xu, XJ; Chi, ZQ			Ohmefentanyl stereoisomers induce changes of CREB phosphorylation in hippocampus of mice in conditioned place preference paradigm	CELL RESEARCH			English	Article						cAMP-response element binding protein (CREB); ohmefentanyl stereo isomers; opiates; hippocampus; conditioned place preference (CPP)	ELEMENT-BINDING PROTEIN; KINASE-II; CHRONIC MORPHINE; RAT HIPPOCAMPUS; MOLECULAR-BASIS; DRUG-ADDICTION; DEPENDENCE; PLASTICITY; SENSITIZATION; TRANSCRIPTION	The present study was designed to determine the changes of phosphorylation of cAMP- response element binding protein (CREB) in hippocampus induced by ohmefentanyl stereoisomers (F9202 and F9204) in conditioned place preference (CPP) paradigm. The results showed that mice receiving F9202 and P9204 displayed obvious CPP. They could all significantly stimulate CREB phosphorylation and maintained for a long time without affecting total CREB protein levels. The effect of F9204 was similar to morphine which effect was more potent and longer than F9202. We also examined the effects of ketamine, a noncompetitive N-mthyl-D-aspartate receptor (NR) antagonist, on morphine-, F9202- and F9204- induced CPP and phosphorylation of CREB in hippocampus. Ketamine could suppress not only the place preference but also the phosphorylation of CREB produced by morphine, F9202 and F9204. These findings suggest that alterations in the phosphorylation of CREB be relevant to opiates signaling and the development of opiates dependence. NR antagonists may interfere with opiates dependence and may have potential therapeutic implications.	Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, Dept Pharmacol 2, Shanghai 200031, Peoples R China; Xuzhou Med Coll, Res Ctr Biochem & Mol Biol, Xuzhou 221002, Jiangsu, Peoples R China	Chi, ZQ (reprint author), Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Mat Med, Dept Pharmacol 2, 294 Taiyuan Rd, Shanghai 200031, Peoples R China.	zqchi@mail.shcnc.ac.cn					Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Bisaga A, 2000, DRUG ALCOHOL DEPEN, V59, P1, DOI 10.1016/S0376-8716(99)00107-6; Brine GA, 1997, CURR MED CHEM, V4, P247; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; Fan GH, 1999, MOL PHARMACOL, V56, P39; GUITART X, 1992, J NEUROCHEM, V58, P1168, DOI 10.1111/j.1471-4159.1992.tb09377.x; Guo GW, 2000, LIFE SCI, V67, P113, DOI 10.1016/S0024-3205(00)00617-2; Hyman SE, 1996, SCIENCE, V273, P611, DOI 10.1126/science.273.5275.611; LaneLadd SB, 1997, J NEUROSCI, V17, P7890; LAYER RT, 1993, PHARMACOL BIOCHEM BE, V44, P245, DOI 10.1016/0091-3057(93)90306-E; Lou LG, 1999, MOL PHARMACOL, V55, P557; Lu L, 2000, NEUROSCI LETT, V291, P191, DOI 10.1016/S0304-3940(00)01352-5; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nestler EJ, 2001, SCIENCE, V292, P2266, DOI 10.1126/science.1063024; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Robbins TW, 1999, NATURE, V398, P567, DOI 10.1038/19208; Scheggi S, 2002, NEUROSCIENCE, V109, P267, DOI 10.1016/S0306-4522(01)00483-3; Shaw-Lutchman TZ, 2002, J NEUROSCI, V22, P3663; SUZUKI T, 1993, BRAIN RES, V602, P45, DOI 10.1016/0006-8993(93)90239-J; Suzuki T, 2000, LIFE SCI, V67, P383, DOI 10.1016/S0024-3205(00)00639-1; TZSCHENTKE TM, 1995, NEUROSCI LETT, V193, P37, DOI 10.1016/0304-3940(95)11662-G; Vanderschuren LJMJ, 2001, EUR J NEUROSCI, V14, P1533, DOI 10.1046/j.0953-816x.2001.01775.x; Walters CL, 2001, J NEUROSCI, V21, P9438, DOI 10.1523/JNEUROSCI.21-23-09438.2001; WANG ZX, 1995, J MED CHEM, V38, P3652, DOI 10.1021/jm00018a026; Wei Q, 2000, CELL RES, V10, P93, DOI 10.1038/sj.cr.7290039; Wickelgren I, 1998, SCIENCE, V280, P2045, DOI 10.1126/science.280.5372.2045; Wise RA, 1998, DRUG ALCOHOL DEPEN, V51, P13, DOI 10.1016/S0376-8716(98)00063-5; Xu J, 2002, CELL RES, V12, P177, DOI 10.1038/sj.cr.7290124	28	13	17	3	8	INST BIOCHEMISTRY & CELL BIOLOGY	SHANGHAI	SIBS, CAS, 319 YUEYANG ROAD, SHANGHAI, 200031, PEOPLES R CHINA	1001-0602	1748-7838		CELL RES	Cell Res.	FEB	2003	13	1					29	34		10.1038/sj.cr.7290148			6	Cell Biology	Cell Biology	673UB	WOS:000182597600004	12643347	Bronze			2020-06-30	J	Hatzidakis, AA; Charonitakis, E; Athanasiou, A; Tsetis, D; Chlouverakis, G; Papamastorakis, G; Roussopoulou, G; Gourtsoyiannis, NC				Hatzidakis, AA; Charonitakis, E; Athanasiou, A; Tsetis, D; Chlouverakis, G; Papamastorakis, G; Roussopoulou, G; Gourtsoyiannis, NC			Sedations and analgesia in patients undergoing percutaneous transhepatic biliary drainage	CLINICAL RADIOLOGY			English	Article						interventional radiology; sedation; analgesia; iliary drainage; nursing care	INTERVENTIONAL RADIOLOGY; CONSCIOUS SEDATION; MIDAZOLAM; ANESTHESIA; PAIN; PERCEPTION; FENTANYL; PROPOFOL	AIM: To present our experience using intravenous sedoanalgesia for percutaneous biliary drainage. MATERIALS AND METHODS: This study comprised 100 patients, all of whom were continuously monitored [electrocardiogram (ECG), blood pressure, pulse oxymetry] and received an initial dose of 2 mg midazolam followed by 0.02 mg fentanyl. Before every anticipated painful procedure, a maintenance dose of 0.01 mg fentanyl was administered. If the procedure continued and the patient became aware, another 1 mg midazolam was given. This was repeated if patients felt pain. A total dose of 0.08 mg fentanyl and 7 mg midazolam was never exceeded. Immediately after the procedure, the nurse was asked to evaluate patients' pain score. The patients were asked 3 h later to complete a visual 10-degree pain score scale. RESULTS: The average dose of fentanyl and midazolam was 0.042 mg (0.03-0.08 mg) and 4.28 mg (2-7 mg), respectively. Only one patient recorded the procedure as painful. The scores given by the attending nurse (1-7 points, mean 2.9) correlated well with those given by the patients (1-6 points, mean 2.72). No complications were noted. CONCLUSION: According to our experience, interventional radiologists practising biliary procedures can administer low doses of midazolam and minimize the doses of fentanyl, without loss of adequate sedation and analgesia. (C) 2003 The Royal College of Radiologists. Published by Elsevier Science Ltd. All rights reserved.	Univ Hosp Heraklion, Dept Radiol, Med Sch Crete, Iraklion, Greece; Univ Crete, Sch Educ, Rethimnon, Greece	Hatzidakis, AA (reprint author), Em Kastrinaki 7, Iraklion 71306, Crete, Greece.						Arepally A, 2001, CARDIOVASC INTER RAD, V24, P185, DOI 10.1007/s002700002549; CRAGG AH, 1991, AM J ROENTGENOL, V157, P173, DOI 10.2214/ajr.157.1.2048514; Gross JB, 1996, ANESTHESIOLOGY, V84, P459; HARSHFIELD DL, 1993, AM J ROENTGENOL, V161, P1057, DOI 10.2214/ajr.161.5.7903843; Haslam PJ, 2000, CARDIOVASC INTER RAD, V23, P256, DOI 10.1007/s002700010065; Hiew C Y, 1995, Australas Radiol, V39, P128, DOI 10.1111/j.1440-1673.1995.tb00256.x; HOLZMAN RS, 1994, J CLIN ANESTH, V6, P265, DOI 10.1016/0952-8180(94)90072-8; Kraft M, 1999, SEMIN INTERVENT RAD, V16, P89, DOI 10.1055/s-0028-1082194; Lang EV, 1997, ACAD RADIOL, V4, P753, DOI 10.1016/S1076-6332(97)80079-7; LANG EV, 1996, 21 ANN M SCVIR, P81; Manninen PH, 1997, CAN J ANAESTH, V44, P26, DOI 10.1007/BF03014320; MCDERMOTT VGM, 1993, BRIT J RADIOL, V66, P667, DOI 10.1259/0007-1285-66-788-667; MILLER DL, 1987, RADIOLOGY, V162, P195, DOI 10.1148/radiology.162.1.3786761; Mueller PR, 1997, RADIOLOGY, V202, P339, DOI 10.1148/radiology.202.2.9015053; Mueller PR, 2000, RADIOLOGY, V215, P684, DOI 10.1148/radiology.215.3.r00jn33684; MURRAY AW, 1990, GUT, V31, P270, DOI 10.1136/gut.31.3.270; Oran NT, 2000, CANCER NURS, V23, P128, DOI 10.1097/00002820-200004000-00009; Razzaq R, 2000, CLIN RADIOL, V55, P131, DOI 10.1053/crad.1999.0325; REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017; Savader S J, 1993, J Vasc Interv Radiol, V4, P539, DOI 10.1016/S1051-0443(93)71917-X; Skehan SJ, 2000, RADIOLOGY, V216, P653, DOI 10.1148/radiology.216.3.r00se09653; Trotteur G, 2000, JBR-BTR, V83, P111; Wagner HJ, 1996, J VASC INTERV RADIOL, V7, P673, DOI 10.1016/S1051-0443(96)70827-8	23	8	9	0	1	W B SAUNDERS CO LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0009-9260			CLIN RADIOL	Clin. Radiol.	FEB	2003	58	2					121	127		10.1053/crad.2002.1128			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	650AY	WOS:000181241200005	12623040				2020-06-30	J	Wajima, Z; Yoshikawa, T; Ogura, A; Imanaga, K; Shiga, T; Inoue, T; Ogawa, R				Wajima, Z; Yoshikawa, T; Ogura, A; Imanaga, K; Shiga, T; Inoue, T; Ogawa, R			Intravenous nicorandil prevents thiamylal-fentanyl-induced bronchoconstriction in humans	CRITICAL CARE MEDICINE			English	Article						induced bronchoconstriction; bronchorelaxant; nicorandil; thiamylal; fentanyl	BRONCHIAL HYPERRESPONSIVENESS; MECHANICAL VENTILATION; TRACHEAL INTUBATION; AIRWAY-RESISTANCE; ENDOTRACHEAL-TUBE; PRESSURE-SUPPORT; ANGINA-PECTORIS; WORK; BRONCHODILATATION; ANESTHESIA	Objective: Nicorandil has a hybrid property between nitrates and potassium channel openers and has been reported to cause a concentration-dependent relaxation of isolated guinea pig trachealis. Experimental asthma in a guinea pig model was also inhibited by nicorandil. However, no clinical data on the bronchorelaxant effects of this drug have been published. The aim of this study was to investigate whether intravenous nicorandil prevents thiamylal-fentanyl-induced bronchoconstriction. Design: Double-blind, prospective, placebo-controlled, randomized study. Patients: A total of 36 patients were randomly allocated to two groups: a control group (n = 18) and a nicorandil group (n = 18). Interventions: Intravenous administration of nicorandil or a placebo (normal saline). Measurements and Main Results: Anesthesia was induced with 5 mg/kg thiamylal and 0.3 mg/kg vecuronium. A continuous infusion of 15 mg.kg(-1).hr(-1) thiamylal was then used to maintain the anesthesia. Controlled ventilation was maintained, delivering 50% nitrous oxide in oxygen. At 20 mins after the induction of anesthesia, the control group patients were given a 6 mL/hr continuous infusion of normal saline and the nicorandil group patients were given a 6 mg.hr(-1) (6 mL/hr) continuous infusion of nicorandil for 60 mins. At 30 mins after the start of the study, both groups received a 5-mug/kg dose of fentanyl. Systolic and diastolic arterial pressure, heart rate, mean airway resistance, expiratory airway resistance, and dynamic lung compliance were measured for the baseline condition, just before the administration of fentanyl (T30), at three consecutive 6-min intervals after the fentanyl injection (T36, T42, and T48) and 30 mins after the fentanyl injection (T60). Both groups had comparable baseline values for mean airway resistance, expiratory airway resistance, and dynamic lung compliance. In the control group, both mean airway resistance and expiratory airway resistance increased significantly at T36-60, compared with the baseline values, and dynamic lung compliance decreased significantly at T36-60, compared with the baseline value. In the nicorandil group, no changes in mean airway resistance, expiratory airway resistance, or dynamic lung compliance occurred at T36-60. Conclusions: Our observations suggest that the intravenous administration of nicorandil has a bronchodilator effect in humans.	Chiba Hokusoh Hosp, Nippon Med Sch, Dept Anesthesia, Inba, Chiba 2701694, Japan; Hakujikai Mem Hosp, Dept Anesthesia, Tokyo, Japan; Tokyo Jikeikai Med Sch, Dept Anesthesiol, Tokyo, Japan; Yale Univ, Sch Med, Dept Anesthesiol, New Haven, CT 06520 USA; Nippon Med Coll, Dept Anesthesiol, Tokyo 113, Japan	Wajima, Z (reprint author), Chiba Hokusoh Hosp, Nippon Med Sch, Dept Anesthesia, 1715 Kamagari, Inba, Chiba 2701694, Japan.			Shiga, Toshiya/0000-0003-0347-7181			ALLEN SL, 1986, BRIT J PHARMACOL, V87, P117, DOI 10.1111/j.1476-5381.1986.tb10163.x; ARNOLD JMO, 1994, INT J CARDIOL, V44, P203, DOI 10.1016/0167-5273(94)90284-4; BANNER MJ, 1993, CRIT CARE MED, V21, P1333, DOI 10.1097/00003246-199309000-00017; Berry A, 1999, ANESTHESIOLOGY, V90, P395, DOI 10.1097/00000542-199902000-00011; BUCKLE DR, 1993, PULM PHARMACOL, V6, P161, DOI 10.1006/pulp.1993.1022; CAMM AJ, 1989, AM J CARDIOL, V63, pJ61, DOI 10.1016/0002-9149(89)90207-5; GAL TJ, 1994, ANESTH ANALG, V78, P559; HOFMANN F, 1994, AIRWAYS SMOOTH MUSCL, P253; ICHINOSE M, 1990, J PHARMACOL EXP THER, V252, P1207; KAMEI K, 1994, BRIT J PHARMACOL, V113, P889, DOI 10.1111/j.1476-5381.1994.tb17076.x; KATO K, 1993, EUR HEART J, V14, P40, DOI 10.1093/eurheartj/14.suppl_B.40; KINOSHITA M, 1986, AM J CARDIOL, V58, P733, DOI 10.1016/0002-9149(86)90347-4; Markham A, 2000, DRUGS, V60, P955, DOI 10.2165/00003495-200060040-00007; MCNEIL JJ, 1997, AVERYS DRUG TREATMEN, P809; NAGAI H, 1991, JPN J PHARMACOL, V56, P13, DOI 10.1254/jjp.56.13; NAKAE I, 1994, CARDIOVASC DRUG THER, V8, P137, DOI 10.1007/BF00877102; NATHAN SD, 1993, CHEST, V103, P1215, DOI 10.1378/chest.103.4.1215; NIJKAMP FP, 1995, ARCH INT PHARMACOD T, V329, P81; PETROS AJ, 1993, ANAESTHESIA, V48, P985; Rolla G, 1995, PULM PHARMACOL THER, V8, P137, DOI 10.1006/pulp.1995.1017; ROLLA G, 1995, CHEST, V107, P169, DOI 10.1378/chest.107.1.169; Thomas AM, 1997, CHEST, V112, P829, DOI 10.1378/chest.112.3.829; Wajima Z, 2002, CRIT CARE MED, V30, P820, DOI 10.1097/00003246-200204000-00017; WILLIAMS AJ, 1990, LANCET, V336, P334, DOI 10.1016/0140-6736(90)91877-D; WRIGHT PE, 1989, AM REV RESPIR DIS, V140, P10, DOI 10.1164/ajrccm/140.1.10; Wu RSC, 1996, ANESTH ANALG, V83, P238, DOI 10.1097/00000539-199608000-00007; Wu RSC, 1996, BRIT J ANAESTH, V77, P735; YAMAZAKI Y, 1994, CHEST, V105, P860, DOI 10.1378/chest.105.3.860	28	6	7	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	FEB	2003	31	2					485	490		10.1097/01.CCM.0000049950.58587.84			6	Critical Care Medicine	General & Internal Medicine	644LQ	WOS:000180919700021	12576956				2020-06-30	J	Hansen, LN; Ravn, JB; Yndgaard, S				Hansen, LN; Ravn, JB; Yndgaard, S			Early extubation after single-lung transplantation: Analysis of the first 106 cases	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						lung transplantation; anesthesia; extubation		Objective: To determine if a modern anesthetic approach permits extubation immediately after surgery for single-lung transplantation. Design: A retrospective study of all patients undergoing single-lung transplantation from June 1993 to December 1999 in Denmark. Setting: Rigshospitalet, Copenhagen University hospital. Participants: One hundred six consecutive patients scheduled for single-lung transplantation. Interventions: From July 1997, the anesthetic approach was changed to facilitate early extubation. The changes included epidural analgesia and short-acting anesthetic drugs. Measurements and Main Results: One hundred six patients were anesthetized for single-lung transplantation. The first 33 patients were moved to the intensive care unit for postoperative mechanical ventilation. After the change of anesthesia technique, 53 of 73 patients were extubated in the operating room. Eleven patients needed reintubation within the first 24 hours because of respiratory insufficiency, pulmonary edema, hemorrhage, or pneumothorax. The need for reintubation increased the length of stay in the intensive care unit by 1 day from 2 to 3 days (NS). The possibility of early extubation or the need for reintubation was not related to age, weight, sex, preoperative condition, mode of transport of the graft, duration of graft ischemia, or side of transplantation. Conclusion: This study has shown that it is possible to extubate patients in the operating room immediately after single-lung transplantation in the majority of cases. Copyright 2003, Elsevier Science (USA). All rights reserved.	Copenhagen Univ Hosp, Rigshosp, Dept Cardiothorac Anesthesia, Copenhagen, Denmark; Copenhagen Univ Hosp, Rigshosp, Dept Cardiothorac Surg, Copenhagen, Denmark	Hansen, LN (reprint author), Hostrups Have 7,3th, DK-1954 Frederiksberg, Denmark.	norrekjaer@dadlnet.dk					Christie JD, 1998, CHEST, V114, P51, DOI 10.1378/chest.114.1.51; DAVIS RD, 1994, ANN THORAC SURG, V58, P1327, DOI 10.1016/0003-4975(94)91907-0; ESMORE DS, 1994, J CARDIAC SURG, V9, P1, DOI 10.1111/j.1540-8191.1994.tb00818.x; Fiser SM, 2001, J HEART LUNG TRANSPL, V20, P631, DOI 10.1016/S1053-2498(01)00249-2; HAYDOCK DA, 1992, J THORAC CARDIOV SUR, V103, P329; Kollef MH, 1999, INTENS CARE MED, V25, P553, DOI 10.1007/s001340050902; Lee KH, 1996, CHEST, V110, P1014, DOI 10.1378/chest.110.4.1014; LOW DE, 1992, J THORAC CARDIOV SUR, V103, P1119; Montes FR, 2000, ANESTH ANALG, V91, P776, DOI 10.1097/00000539-200010000-00003; Myles PS, 1998, SEMIN CARDIOTHORAC V, V2, P140; RAMSAY KJ, 1998, ANESTH ANALG, V86, pS306; Rello J, 1999, AM J RESP CRIT CARE, V159, P1742, DOI 10.1164/ajrccm.159.6.9808030; Westerlind A, 1999, J CARDIOTHOR VASC AN, V13, P249, DOI 10.1016/S1053-0770(99)90258-6	13	16	17	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	FEB	2003	17	1					36	39		10.1053/jcan.2003.7			4	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	653WZ	WOS:000181461200007	12635058				2020-06-30	J	Chakravarthy, M; Jawali, V; Patil, TA; Srinivasan, KN; Jayaprakash, K; Mahajan, V; Manohar, M; Das, JK; Khan, J				Chakravarthy, M; Jawali, V; Patil, TA; Srinivasan, KN; Jayaprakash, K; Mahajan, V; Manohar, M; Das, JK; Khan, J			High thoracic epidural Anesthesia as the sole anesthetic for redo off-pump coronary artery bypass surgery	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						high thoracic epidural anesthesia; awake patient; off-pump coronary artery bypass surgery	CONSCIOUS PATIENT; EXTUBATION; RESPONSES		Wockhardt Heart Inst, Bangalore 560052, Karnataka, India	Chakravarthy, M (reprint author), Wockhardt Heart Inst, 14 Cunningham Rd, Bangalore 560052, Karnataka, India.						Anderson MB, 2001, EUR J CARDIO-THORAC, V20, P415, DOI 10.1016/S1010-7940(01)00831-4; BLOMBERG S, 1990, ANESTHESIOLOGY, V73, P840, DOI 10.1097/00000542-199011000-00008; DAVID A, 2000, ANN THORAC SURG, V70, P96; Ho AMH, 2000, CHEST, V117, P551, DOI 10.1378/chest.117.2.551; Karagoz HY, 2000, ANN THORAC SURG, V70, P91, DOI 10.1016/S0003-4975(00)01271-6; Kritzinger M, 1999, BR J ANESTH, V82, P18; Lansing A M, 2000, J Ky Med Assoc, V98, P406; Liem TH, 1998, J CARDIOTHOR VASC AN, V12, P668, DOI 10.1016/S1053-0770(98)90240-3; Mehta Y, 1998, J CARDIOTHOR VASC AN, V12, P162, DOI 10.1016/S1053-0770(98)90324-X; Mikawa K, 1997, ANESTH ANALG, V85, P1005, DOI 10.1097/00000539-199711000-00009; O'Connor CJ, 2001, ANESTH ANALG, V93, P523, DOI 10.1097/00000539-200109000-00001; PAULISSIAN R, 1991, ANESTH ANALG, V73, P10; VANDERMEULEN EP, 1994, ANESTH ANALG, V79, P1165; Vanek T, 2001, EUR J CARDIO-THORAC, V20, P858, DOI 10.1016/S1010-7940(01)00924-1	14	4	4	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	FEB	2003	17	1					84	86		10.1053/jcan.2003.16			3	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	653WZ	WOS:000181461200017	12635068				2020-06-30	J	Basar, H; Yilmaz, E; Ozcan, S; Buyukkocak, U; Sari, F; Apan, A; Batislam, E				Basar, H; Yilmaz, E; Ozcan, S; Buyukkocak, U; Sari, F; Apan, A; Batislam, E			Four analgesic techniques for shockwave lithotripsy: Eutectic mixture local anesthetic is a good alternative	JOURNAL OF ENDOUROLOGY			English	Article							PATIENT-CONTROLLED ANALGESIA; WAVE LITHOTRIPSY; EMLA CREAM; PAIN; DICLOFENAC; TRAMADOL; REQUIREMENT; EFFICACY; SURGERY	Background and Purpose: Various sedative and analgesic medication has been used for shockwave lithotripsy (SWL). The aim of this study was to evaluate the efficacy of different anesthesia modalities in these patients. Patients and Methods: One hundred patients were randomly divided into four groups. The first (Group F) received fentanyl 1 mug/kg intravenously (IV), the second (Group D) received diclofenac sodium 1 mg/kg-intramuscularly (IM), the third (Group T) received tramadol 1.5 mg/kg IM, and the fourth (Group E) was given 15 g of eutectic mixture local anesthetic (EMLA) cream containing lidocaine and prilocaine. After routine preoperative evaluation, all patients received midazolam 2 mg IV 5 minutes before lithotripsy for sedative premedication. In all groups, a supplemental 25-mug bolus of fentanyl was administered IV when patients complained of pain, moved, or grimaced in response to the shockwaves. Pain intensity was evaluated on a 0- to 100-mm visual analog scale (VAS). The level of sedation was determined using the Observer's Assessment of Alertness/Sedation (OAS/S). Side effects such as bradypnea, oxygen desaturation, bradycardia, pruritus, and nausea and vomiting were recorded. Results: There were no statistically significant differences among the four groups with regard to VAS, OAS/S scores, or side effects. In Group F, the mean arterial pressure was decreased significantly at 10 and 20 minutes. The patients in this group also manifested a decrease of oxygen saturation at the first, tenth, and twentieth minutes and the end of SWL. Conclusion: Application of EMLA cream was as safe and effective as fentanyl, diclofenac, and tramadol,. and reduction of the fentanyl dose during SWL was possible.	Kirikkale Univ, Dept Anesthesiol, TR-71100 Kirikkale, Turkey; Kirikkale Univ, Intens Care Unit, TR-71100 Kirikkale, Turkey; Kirikkale Univ, Dept Urol, TR-71100 Kirikkale, Turkey	Yilmaz, E (reprint author), Kirikkale Univ, Tip Fak, Urol ABD, TR-71100 Kirikkale, Turkey.	erdaly69@mynet.com	Batislam, Ertan/E-2892-2016	Batislam, Ertan/0000-0002-7493-4573			ARENDTNIELSEN L, 1990, ACTA DERM-VENEREOL, V70, P314; BIERKENS AF, 1991, J UROLOGY, V146, P287, DOI 10.1016/S0022-5347(17)37772-8; BJERRING P, 1990, BRIT J ANAESTH, V64, P173, DOI 10.1093/bja/64.2.173; Broome IJ, 1999, ANAESTHESIA, V54, P289; CHAUSSY CG, 1989, J UROLOGY, V141, P782, DOI 10.1016/S0022-5347(17)41010-X; Cohen E, 1998, EUR J CLIN PHARMACOL, V54, P455, DOI 10.1007/s002280050492; EHRETH JT, 1994, J UROLOGY, V152, P1379, DOI 10.1016/S0022-5347(17)32425-4; Gesztesi Z, 2000, ANESTH ANALG, V90, P567, DOI 10.1097/00000539-200003000-00013; Issa MM, 1999, UROLOGY, V54, P625, DOI 10.1016/S0090-4295(99)00231-9; MCDONALD PF, 1992, BRIT J ANAESTH, V69, P399, DOI 10.1093/bja/69.4.399; MONK TG, 1991, ANESTH ANALG, V72, P616; MONK TG, 1994, ANESTH ANALG, V79, P506; POWER I, 1990, ANAESTHESIA, V45, P916, DOI 10.1111/j.1365-2044.1990.tb14618.x; Rego MMS, 1999, ANESTH ANALG, V88, P723; Schelling G, 1996, J UROLOGY, V155, P43, DOI 10.1016/S0022-5347(01)66534-0; Schmidt A, 2001, ACTA ANAESTH SCAND, V45, P48, DOI 10.1034/j.1399-6576.2001.450108.x; Silvasti M, 1999, EUR J ANAESTH, V16, P834, DOI 10.1046/j.1365-2346.1999.00597.x; VICKERS MD, 1992, ANAESTHESIA, V47, P291, DOI 10.1111/j.1365-2044.1992.tb02166.x; Vickers MD, 1991, SYSTEMIC ANALGESICS, P162	19	33	33	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0892-7790	1557-900X		J ENDOUROL	J. Endourol.	FEB	2003	17	1					3	6		10.1089/089277903321196706			4	Urology & Nephrology	Urology & Nephrology	650XX	WOS:000181290500002	12639353				2020-06-30	J	Kokki, H; Nikanne, E; Aho, M; Virtaniemi, J				Kokki, H; Nikanne, E; Aho, M; Virtaniemi, J			Pain intensity after laseruvulopalatoplasty and tonsillectomy	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PLATELET-FUNCTION; SLEEP-APNEA; KETOPROFEN; VOLUNTEERS; UVULOPALATOPHARYNGOPLASTY; UVULOPALATOPLASTY; DICLOFENAC; KETOROLAC	OBJECTIVE: The first objective of this study was to evaluate pain intensity and opioid consumption during the first 24 hours after uvulopalatoplasty and tonsillectomy in the hospital, and the second was to evaluate pain intensity and its progression during the first 2 weeks after surgery at home. STUDY DESIGN AND SETTINGS: In a prospective parallel group study, 51 patients with uvulopalatoplasty or tonsillectomy were studied. Ketoprofen, a nonsteroidal antiinflammatory drug, and fentanyl citrate, an opioid, were used as analgesics. RESULTS: Despite ketoprofen,infusion and free access to a patient-controlled pump with fentanyl citrate for rescue analgesia, inadequate pain relief was common both after uvulopalatoplasty (35%) and after tonsillectomy (28%) during the first 24 hours after surgery. The consumption of fentanyl citrate was similar after both operations. At home, pain intensity was highest in the mornings during the first 5 days, and 10 patients had some pain still after 2 weeks. Also at home, high pain scores were reported commonly in both groups. CONCLUSION: Significant pain after uvulopalatoplasty and tonsillectomy lasted for several days. Ketoprofen in the commercial capsule form proved to be too short acting for overnight pain relief. SIGNIFICANCE: Pain treatment in patients with uvulopalatoplasty and tonsillectomy should be improved to allow patients a peaceful recovery after surgery.	Kuopio Univ Hosp, Dept Anesthesiol & Intens Care, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Otorhinolaryngol, FIN-70211 Kuopio, Finland; Cent Hosp Jyvaskyla, Dept Otorhinolaryngol, Jyvaskyla, Finland	Kokki, H (reprint author), Kuopio Univ Hosp, Dept Anesthesiol & Intens Care, POB 1777, FIN-70211 Kuopio, Finland.	hannu.kokki@kuh.fi					Boushra NN, 1996, CAN J ANAESTH, V43, P599, DOI 10.1007/BF03011774; CARENFELT C, 1991, ANN OTO RHINOL LARYN, V100, P451, DOI 10.1177/000348949110000604; COLMAN MF, 1987, SNORING OBSTRUCTIVE, P171; DAHL JB, 1991, BRIT J ANAESTH, V66, P703, DOI 10.1093/bja/66.6.703; de Meijer A, 1999, CLIN PHARMACOL THER, V66, P425, DOI 10.1053/cp.1999.v66.a101063; Dickson RI, 1996, J OTOLARYNGOL, V25, P155; HENDOLIN H, 1994, ACTA ANAESTH SCAND, V38, P694, DOI 10.1111/j.1399-6576.1994.tb03979.x; Kostamovaara PA, 1998, BRIT J ANAESTH, V81, P369, DOI 10.1093/bja/81.3.369; Moren J, 1997, ANESTH ANALG, V85, P400, DOI 10.1097/00000539-199708000-00028; Niemi TT, 1997, ACTA ANAESTH SCAND, V41, P1353, DOI 10.1111/j.1399-6576.1997.tb04657.x; Smith I, 1999, J LARYNGOL OTOL, V113, P28, DOI 10.1017/S0022215100143087; Vane JR, 1998, AM J MED, V104, p2S, DOI DOI 10.1016/S0002-9343(97)00203-9; Virtaniemi J, 1999, LARYNGOSCOPE, V109, P1950, DOI 10.1097/00005537-199912000-00010; Warnock FF, 1998, PAIN, V75, P37, DOI 10.1016/S0304-3959(97)00202-9; WHO Collaborating Centre for Drug Statistics Methodology, GUID ATC CLASS DDD A; *WORLD MED ASS, 2000, ETH PRINC MED RES IN	16	7	8	0	0	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0194-5998	1097-6817		OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	FEB	2003	128	2					273	279		10.1067/mhn.2003.82			7	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	651GJ	WOS:000181311900018	12601326				2020-06-30	J	Friesen, RH; Veit, AS; Archibald, DJ; Campanini, RS				Friesen, RH; Veit, AS; Archibald, DJ; Campanini, RS			A comparison of remifentanil and fentanyl for fast track paediatric cardiac anaesthesia	PAEDIATRIC ANAESTHESIA			English	Article						anaesthesia; cardiac; anaesthetics; intravenous; remifentanil; fentanyl; fast track	BYPASS GRAFT-SURGERY; EARLY EXTUBATION; HEART-SURGERY; TOLERANCE; EFFICACY	Background : Fast track anaesthetic protocols for cardiac surgical patients have been developed to facilitate early tracheal extubation. We compared anaesthetics based on either remifentanil or fentanyl for fast track paediatric cardiac anaesthesia. Methods : Fifty patients with atrial septal defect or simple ventricular septal defect who were deemed suitable for fast track anaesthetic management were randomly assigned to group R (remifentanil) or group F (fentanyl). After sevoflurane induction, patients received either R infusion or F bolus. Following intubation, isoflurane 0.5 MAC was administered to all patients. Blood pressure (BP) and heart rate (HR) were recorded at baseline and pre- and postinduction, intubation, skin incision and sternotomy. Other parameters measured included time to extubation, reintubation rate and requirements for postoperative analgesia, ondansetron, and nitroprusside in the paediatric intensive care unit. Results : BP decreased similarly from baseline in both groups. Decreases in HR over time were significantly greater in group R. Haemodynamic response to incision/sternotomy was low and similar in both groups. There were no significant differences in extubation time, reintubation incidence, postoperative narcotic requirements, postoperative hypertension or postoperative nausea/vomiting. Conclusions : The remifentanil based anaesthetic was associated with a significantly slower HR than the fentanyl based anaesthetic. The clinical implications of the slower HR during remifentanil anaesthesia could be important and should be investigated.	Univ Colorado, Dept Anesthesiol, Childrens Hosp, Sch Med, Denver, CO 80218 USA	Friesen, RH (reprint author), Univ Colorado, Dept Anesthesiol, Childrens Hosp, Sch Med, 1056 E 19th Ave, Denver, CO 80218 USA.						BARASH PG, 1980, ANN THORAC SURG, V29, P228, DOI 10.1016/S0003-4975(10)61872-3; BURROWS FA, 1992, CAN J ANAESTH, V39, P1041, DOI 10.1007/BF03008372; Cheng DCH, 2001, ANESTH ANALG, V92, P1094; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; Davis PJ, 2000, ANESTH ANALG, V90, P863, DOI 10.1213/00000539-200004000-00017; Elliott P, 2000, ANESTH ANALG, V91, P58, DOI 10.1097/00000539-200007000-00011; Engoren M, 2001, ANESTH ANALG, V93, P859, DOI 10.1097/00000539-200110000-00011; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; Lake CL, 2000, PAEDIATR ANAESTH, V10, P231, DOI 10.1046/j.1460-9592.2000.00521.x; Mollhoff T, 2001, BRIT J ANAESTH, V87, P718, DOI 10.1093/bja/87.5.718; NAIK S K, 1991, Perfusion (London), V6, P41, DOI 10.1177/026765919100600106; SCHULLER JL, 1984, BRIT J ANAESTH, V56, P1101, DOI 10.1093/bja/56.10.1101; TURLEY K, 1994, ANN THORAC SURG, V58, P57, DOI 10.1016/0003-4975(94)91072-3	13	26	30	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	FEB	2003	13	2					122	125		10.1046/j.1460-9592.2003.00978.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	642JU	WOS:000180801000006	12562484				2020-06-30	J	Baris, S; Karakaya, D; Kelsaka, E; Guldogus, F; Ariturk, E; Tur, A				Baris, S; Karakaya, D; Kelsaka, E; Guldogus, F; Ariturk, E; Tur, A			Comparison of fentanyl-bupivacaine or midazolam-bupivacaine mixtures with plain bupivacaine for caudal anaesthesia in children	PAEDIATRIC ANAESTHESIA			English	Article						caudal block; opioid; fentanyl; benzodiazepine; midazolam; local anaesthetic; bupivacaine	INTRATHECAL MIDAZOLAM; ANALGESIA; RABBIT; NEUROTOXICITY; ANESTHESIA; RECOVERY; MORPHINE; BLOCK	Background : The aim of this study was to evaluate the intensity and effectiveness of 0.75 ml.kg(-1) bupivacaine 0.25% with the addition of fentanyl or midazolam for caudal block in children undergoing inguinal herniorrhaphy. Methods : Seventy-five children were allocated randomly to three groups to receive a caudal block with either 0.25% bupivacaine with fentanyl 1 mug.kg (-1) (group BF) or with midazolam 50 mug.kg(-1) (group BM) or bupivacaine alone (group B) after induction of anaesthesia. Haemodynamic parameters, degree of pain, additional analgesic requirements and side-effects were evaluated. Results : The mean systolic arterial pressure at 10, 20, 30 min after caudal block was higher in group B compared with groups BF and BM. Mean intraoperative heart rate was lower in group BF than the other groups. Adequate analgesia was obtained in all patients (100%) in group BF, 23 patients (92%) in group BM and 21 patients (84%) in group B (P > 0.05). The time to recovery to an Aldrete score of 10 was significantly shorter in group B than group BM (P < 0.05). Although not significant, it was also shorter in group B than group BF. There was no difference in additional analgesic requirements between the groups in the first 24 h. Sedation score was higher in the midazolam group at 60 and 90 min postoperatively than the other groups. Conclusions : Caudal block with 0.75 ml.kg(-1) 0.25% bupivacaine and 50 mug.kg(-1) midazolam or 1 mug.kg(-1) fentanyl provides no further analgesic advantages to bupivacaine alone when administered immediately after induction of anaesthesia in children undergoing unilateral inguinal herniorrhaphy.	Ondokuz Mayis Univ, Fac Med, Dept Anaesthesiol, TR-55139 Kurupelit, Samsun, Turkey; Ondokuz Mayis Univ, Fac Med, Dept Paediat Surg, TR-55139 Kurupelit, Samsun, Turkey	Baris, S (reprint author), Ondokuz Mayis Univ, Fac Med, Dept Anaesthesiol, TR-55139 Kurupelit, Samsun, Turkey.	sbaris@omu.edu.tr					ALDRETE JA, 1970, ANESTH ANAL CURR RES, V49, P924; Bahar M, 1998, EUR J ANAESTH, V15, P695, DOI 10.1097/00003643-199811000-00011; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BONICA JJ, 1990, MANAGEMENT PAIN, P461; BOSKOVSKI N, 1981, ANAESTHESIA, V36, P67, DOI 10.1111/j.1365-2044.1981.tb08610.x; Bozkurt P, 1997, PAEDIATR ANAESTH, V7, P385, DOI 10.1046/j.1460-9592.1997.d01-107.x; CAMPBELL FA, 1992, CAN J ANAESTH, V39, P661, DOI 10.1007/BF03008226; Constant I, 1998, BRIT J ANAESTH, V80, P294; Dalens BJ, 1995, REGIONAL ANESTHESIA, P171; EDWARDS M, 1990, ANESTHESIOLOGY, V73, P273, DOI 10.1097/00000542-199008000-00015; Erdine S, 1999, PAIN, V80, P419, DOI 10.1016/S0304-3959(98)00240-1; FORTUNA A, 1967, BRIT J ANAESTH, V39, P165, DOI 10.1093/bja/39.2.165; GOODCHILD CS, 1987, BRIT J CLIN PHARMACO, V23, P279, DOI 10.1111/j.1365-2125.1987.tb03046.x; Gulec S, 1998, EUR J ANAESTH, V15, P161, DOI 10.1046/j.1365-2346.1998.00262.x; GUNTER JB, 1991, ANESTHESIOLOGY, V75, P57, DOI 10.1097/00000542-199107000-00010; HANNALLAH RS, 1999, PROBLEMS ANESTH, V11, P95; JENSEN BH, 1981, ACTA ANAESTH SCAND, V25, P373, DOI 10.1111/j.1399-6576.1981.tb01668.x; Joshi W, 1999, PAEDIATR ANAESTH, V9, P317, DOI 10.1046/j.1460-9592.1999.00368.x; MALINOVSKY JM, 1991, ANESTHESIOLOGY, V75, P91, DOI 10.1097/00000542-199107000-00015; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; NAGUIB M, 1995, CAN J ANAESTH, V42, P758, DOI 10.1007/BF03011172; Nishiyama T, 1991, Masui, V40, P1353; NISHIYAMA T, 1992, Japanese Journal of Anesthesiology, V41, P49; Nishiyama T, 1999, ANESTH ANALG, V89, P717; Rowney DA, 1998, ANAESTHESIA, V53, P980, DOI 10.1046/j.1365-2044.1998.00527.x; SWENSSON BA, 1995, REGION ANESTH, V20, P426	26	23	23	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	FEB	2003	13	2					126	131		10.1046/j.1460-9592.2003.00979.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	642JU	WOS:000180801000007	12562485				2020-06-30	J	Baker, A; Meert, T				Baker, A; Meert, T			Morphine and d-amphetamine nullify each others' hypothermic effects in mice	PHARMACOLOGY & TOXICOLOGY			English	Article							RECEPTOR AGONISTS; BODY-TEMPERATURE; OPIOID AGONISTS; DOPAMINE; RAT; THERMOREGULATION; HYPERTHERMIA; INVOLVEMENT; MOUSE; D-1	We have examined the effects of the psychostimulant d-amphetamine and the neuroleptic haloperidol on hypothermia induced by intraperitoneal injection of the centrally penetrating opioids morphine, fentanyl and sufentanil and the peripherally acting opioid loperamide. Measuring rectal body temperatures, dose-response relationships were established for all compounds. Morphine and sufentanil produced hyperthermia at low doses and dose-related hypothermia at higher doses. Fentanyl and loperamide produced dose-related hypothermia. Fixed doses of each opioid producing significant hypothermia were selected for interaction studies. The psychostimulant d-amphetamine was found to produce biphasic effects with low doses inducing hypothermia and higher doses inducing hyperthemia. Haloperidol produced dose-related hypothermia. The selected doses of the opioids were then injected followed after 15 min. by injection of hypothermia producing doses of d-amphetamine or haloperidol. Hypothermia induced by morphine, fentanyl and sufentanil was reversed by d-amphetamine whereas loperamide-induced hypothermia was unaffected. Rebound hyperthermia was also measured with fentanyl and sufentanil. Haloperidol increased the hypothermic effects of morphine, fentanyl and sufentanil but not of loperamide. In conclusion, the central stimulating effects of opioids and amphetamine may combine resulting in thermogenesis and reversal of hypothermia. Central mechanisms of opioid-induced hypothermia in mice are influenced by drugs which alter the dopamine system, whereas peripheral mechanisms are unaffected. A possible clinical implication for this dopaminergic interaction may be toxicity associated with hyperpyrexia caused by psychostimulant misuse, which is increasingly occurring concomitantly with abuse of opioids.	Janssen Res Fdn, CNS Dis Res, B-2340 Beerse, Belgium	Baker, A (reprint author), Care Of Meert T, Janssen Res Fdn, CNS Dis Res, Turnhoutseweg, B-2340 Beerse, Belgium.	ABAKER5@janbe.jnj.com					ADLER MW, 1998, ANN REV PHARM TOXICO, V28, P429; BAKER AK, 2002, J PHARMACOL EXP THER, V302, P1; BLIGH J, 1979, NEUROSCIENCE, V4, P1213, DOI 10.1016/0306-4522(79)90153-2; BOSCHI G, 1985, NEUROPHARMACOLOGY, V24, P117, DOI 10.1016/0028-3908(85)90170-4; Bowyer JF, 2000, TOXICOL SCI, V55, P133, DOI 10.1093/toxsci/55.1.133; COLBOC O, 1980, J PHARM PHARMACOL, V32, P624, DOI 10.1111/j.2042-7158.1980.tb13018.x; COX B, 1975, J PHARM PHARMACOL, V27, P242, DOI 10.1111/j.2042-7158.1975.tb10693.x; COX B, 1979, J PHARM PHARMACOL, V31, P352, DOI 10.1111/j.2042-7158.1979.tb13521.x; COX B, 1976, EUR J PHARMACOL, V36, P33, DOI 10.1016/0014-2999(76)90253-3; KHACHATURIAN H, 1982, BRAIN RES BULL, V9, P441, DOI 10.1016/0361-9230(82)90154-X; LECCI A, 1991, J NEURAL TRANSM-GEN, V83, P67, DOI 10.1007/BF01244453; LONGONI R, 1987, PSYCHOPHARMACOLOGY, V93, P401, DOI 10.1007/BF00187265; MARTIN JR, 1985, EUR J PHARMACOL, V119, P75, DOI 10.1016/0014-2999(85)90324-3; MCBRIDE DC, 1992, J PSYCHOACTIVE DRUGS, V24, P411, DOI 10.1080/02791072.1992.10471665; Meert TF, 1996, PHARM WORLD SCI, V18, P1, DOI 10.1007/BF00449683; ROSOW CE, 1980, J PHARMACOL EXP THER, V213, P273; SANCHEZ C, 1989, EUR J PHARMACOL, V171, P201, DOI 10.1016/0014-2999(89)90108-8; Siegel S, 1956, NONPARAMETRIC STAT B; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; SPENCER RL, 1990, J PHARMACOL EXP THER, V252, P696; Steentoft A, 2001, FORENSIC SCI INT, V123, P63, DOI 10.1016/S0379-0738(01)00524-2; Tor-Agbidye J, 2001, TOXICOL SCI, V60, P103, DOI 10.1093/toxsci/60.1.103; TRULSON ME, 1985, EUR J PHARMACOL, V114, P105, DOI 10.1016/0014-2999(85)90530-8; URWYLER S, 1981, LIFE SCI, V28, P2277, DOI 10.1016/0024-3205(81)90580-4; VANNUETEN JM, 1979, BIOCHEM PHARMACOL, V28, P1433, DOI 10.1016/0006-2952(79)90450-7; Wallace M E, 2000, J Am Board Fam Pract, V13, P302; WOOD PL, 1982, NEUROPHARMACOLOGY, V21, P1305, DOI 10.1016/0028-3908(82)90138-1; Xin L, 1997, J PHARMACOL EXP THER, V281, P499; YEHUDA S, 1981, INT J NEUROSCI, V13, P117, DOI 10.3109/00207458109043310; YEHUDA S, 1981, INT J NEUROSCI, V12, P147, DOI 10.3109/00207458108985797; YEHUDA S, 1980, PEPTIDES, V1, P179, DOI 10.1016/0196-9781(80)90084-4; YEHUDA S, 1982, PEPTIDES, V3, P105, DOI 10.1016/0196-9781(82)90036-5; Yuan CS, 1999, NEUROPHARMACOLOGY, V38, P425, DOI 10.1016/S0028-3908(98)00192-0; ZARRINDAST MR, 1992, PSYCHOPHARMACOLOGY, V107, P341, DOI 10.1007/BF02245159; ZARRINDAST MR, 1992, GEN PHARMACOL, V23, P1221, DOI 10.1016/0306-3623(92)90315-B; ZARRINDAST MR, 1994, J PSYCHOPHARMACOL, V8, P222, DOI 10.1177/026988119400800405	36	8	8	0	1	BLACKWELL MUNKSGAARD	FREDERIKSBERG C	1 ROSENORNS ALLE, DK-1970 FREDERIKSBERG C, DENMARK	0901-9928			PHARMACOL TOXICOL	Pharmacol. Toxicol.	FEB	2003	92	2					64	70		10.1034/j.1600-0773.2003.t01-1-920202.x			7	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	653JP	WOS:000181432300002	12747575				2020-06-30	J	Carter, KA				Carter, KA			Heat-associated increase in transdermal fentanyl absorption	AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY			English	Article							OVERDOSE; PATCH		Drug Store Bi Lo, Kannapolis, NC 28081 USA	Carter, KA (reprint author), 83 McCurdy St, Concord, NC 28027 USA.						Frolich M, 2001, ANESTH ANALG, V93, P647; *JANSS PHARM, 2001, DUR PACK INS; LACY CF, 2001, DRUG INFORMATION HDB, P495; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029	5	16	16	0	1	AMER SOC HEALTH-SYSTEM PHARMACISTS	BETHESDA	7272 WISCONSIN AVE, BETHESDA, MD 20814 USA	1079-2082			AM J HEALTH-SYST PH	Am. J. Health-Syst. Pharm.	JAN 15	2003	60	2					191	192		10.1093/ajhp/60.2.191			2	Pharmacology & Pharmacy	Pharmacology & Pharmacy	640AU	WOS:000180664200013	12561665				2020-06-30	J	Gupta, A; Axelsson, K; Thorn, SE; Matthiessen, P; Larsson, LG; Holmstrom, B; Wattwil, M				Gupta, A; Axelsson, K; Thorn, SE; Matthiessen, P; Larsson, LG; Holmstrom, B; Wattwil, M			Low-dose bupivacaine plus fentanyl for spinal anesthesia during ambulatory inguinal herniorrhaphy: a comparison between 6 mg and 7.5 mg of bupivacaine	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anesthesia : spinal; drugs : bupivacaine, fentanyl; surgery : ambulatory, inguinal herniorrhaphy	OUTPATIENT KNEE ARTHROSCOPY; INTRATHECAL FENTANYL; PROLONGING RECOVERY; URINARY RETENTION; LOCAL-ANESTHESIA; HOME-READINESS; LIDOCAINE; SURGERY	Background: Inguinal herniorrhaphy is commonly performed as an outpatient procedure. Spinal anesthesia offers some advantages over general anesthesia in this setting. Methods: Forty patients were randomly divided into two groups according to a double-blind protocol: Group L had spinal anesthesia with bupivacaine 6.0 mg and Group H with bupivacaine 7.5 mg; in both groups, fentanyl 25 mug was added to the spinal anesthetic. The sensory block was measured by 'pin-prick' and the motor block was evaluated by a modified Bromage scale. Results: No differences were seen in the spread, duration and regression of sensory block between the groups on the operated side. A greater number of patients required analgesics during the operation in Group L (6) compared with Group H (1) (P< 0.05). The return of the modified Bromage scale to grade 0 was earlier in Group L than in Group H (P< 0.05) but the time to mobilization and discharge was similar. Seven patients (17%) needed to be catheterized and two had the catheter retained overnight. Times to home discharge (median) were 350 and 445 min, respectively, in Groups L and H. Postoperatively and during the first week, visual analog pain scores, analgesic requirements and side-effects were similar between the groups. In Group H, 95% of the patients and in Group L 85% would have the same anesthetic again if operated upon for a similar procedure. Conclusions: Spinal anesthesia with bupivacaine 7.5 mg and fentanyl offers an alternative to general or local anesthesia for ambulatory inguinal herniorrhaphy. However, the long discharge times and risk for urinary retention restrict its routine use in all patients.	Univ Hosp, Dept Anesthesiol & Intens Care, Orebro, Sweden; Univ Hosp, Dept Surg, Orebro, Sweden; Univ Hosp, Div Ambulatory Surg, Orebro, Sweden	Gupta, A (reprint author), Johns Hopkins Med Inst, Dept Anesthesiol & Crit Care Med, 600 N Wolfe St,Carnegie 280, Baltimore, MD 21287 USA.			Thorn, Sven-Egron/0000-0001-7010-6757			AXELSSON K, 1985, ACTA ANAESTH SCAND, V29, P79, DOI 10.1111/j.1399-6576.1985.tb02163.x; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; BenDavid B, 1996, ANESTH ANALG, V83, P716, DOI 10.1097/00000539-199610000-00009; Callesen T, 1998, BRIT J SURG, V85, P1412; Callesen T, 2001, ANESTH ANALG, V93, P1373, DOI 10.1097/00000539-200112000-00004; Chilvers CR, 1997, ANESTH ANALG, V84, P65, DOI 10.1097/00000539-199701000-00012; CHUNG F, 1995, J CLIN ANESTH, V7, P500, DOI 10.1016/0952-8180(95)00130-A; Fanelli G, 2000, CAN J ANAESTH, V47, P746, DOI 10.1007/BF03019476; FINLEY RK, 1991, AM SURGEON, V57, P486; Hampl K, 1999, ACTA ANAESTH SCAND, V43, P359; Kehlet H, 2001, ANESTH ANALG, V93, P1367; Kuusniemi KS, 1997, REGION ANESTH, V22, P534; Lau H, 2001, Hernia, V5, P17, DOI 10.1007/BF01576159; Liguori GA, 1998, ANESTHESIOLOGY, V88, P619, DOI 10.1097/00000542-199803000-00010; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Mulroy MF, 2001, REGION ANESTH PAIN M, V26, P252, DOI 10.1053/rapm.2001.22997; NOLTE H, 1977, ANAESTHESIST, V26, P33; PETROS JG, 1990, AM J SURG, V159, P374, DOI 10.1016/S0002-9610(05)81274-7; PITTONI G, 1995, ANESTH ANALG, V81, P73, DOI 10.1097/00000539-199507000-00015; Pollock JE, 1999, ANESTHESIOLOGY, V90, P445, DOI 10.1097/00000542-199902000-00019; Roussel J R, 1999, AANA J, V67, P337; Song DJ, 2000, ANESTH ANALG, V91, P876, DOI 10.1097/00000539-200010000-00020; Tarkkila P, 1997, ANAESTHESIA, V52, P1157, DOI 10.1111/j.1365-2044.1997.223-az0358.x; TVERSKOY M, 1990, ANESTH ANALG, V70, P29, DOI 10.1213/00000539-199001000-00006; Valanne JV, 2001, ANESTH ANALG, V93, P1377, DOI 10.1097/00000539-200112000-00005	25	57	61	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2003	47	1					13	19		10.1034/j.1399-6576.2003.470103.x			7	Anesthesiology	Anesthesiology	627RL	WOS:000179948400003	12492791				2020-06-30	J	Turker, G; Uckunkaya, N; Yavascaoglu, B; Yilmazlar, A; Ozcelik, S				Turker, G; Uckunkaya, N; Yavascaoglu, B; Yilmazlar, A; Ozcelik, S			Comparison of the catheter-technique psoas compartment block and the epidural block for analgesia in partial hip replacement surgery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						anesthetic technique; epidural block; hip surgery; psoas compartment block; regional	REGIONAL ANESTHESIA; GENERAL-ANESTHESIA; LUMBAR PLEXUS; COMPLICATIONS	Background: The aim of this study was to compare the intra- and postoperative analgesia provided by the catheter-technique psoas compartment block and the epidural block in hip-fractured patients. We also compared hemodynamic stability, motor blockade, ease of performing the technique, and complications. Methods: Thirty patients who underwent partial hip replacement surgery were included in this prospective single-blind study. Subjects were randomly assigned to Group E (n=15; general anesthesia plus epidural block with 15 ml of 0.5% bupivacaine) or Group P (n=15; general anesthesia plus psoas compartment block with 30 ml of 0.5% bupivacaine). Hemodynamic parameters were recorded at 10-min intervals intraoperatively. Regional anesthesia procedure time, number of attempts at block, intraoperative blood loss, and need for supplemental fentanyl and/or ephedrine were noted. Postoperatively, a patient-controlled analgesia device delivered an infusion and boluses of bupivacaine/fentanyl. Pain, motor blockade, ambulation time, patient satisfaction with analgesia, and complications were recorded postsurgery. Results: The epidural required significantly more attempts than the psoas block, thus procedure time was longer in this group. Group E also showed significantly greater drops in mean arterial blood pressure from baseline at 30, 40 and 50 min after the start of general anesthesia. Significantly more Group E patients required epinephrine supplementation. The groups were similar regarding pain scores (at rest and on movement) and patient satisfaction, but Group E had higher motor blockade scores, longer ambulation time, and significantly more complications. Conclusion: The continuous psoas compartment block provides excellent intraoperative and postoperative analgesia with a low incidence of complications for partial hip replacement surgery.	Uludag Univ, Fac Med, Dept Anesthesiol & Reanimat, Bursa, Turkey	Turker, G (reprint author), Uludag Univ, Tip Fak, Anesteziyol & Reanimasyon Anabilim Dali, TR-16059 Gorukle, Turkey.	gturker@uludag.edu.tr		TURKER, YUNUS GURKAN/0000-0002-3019-581X			Auroy Y, 1997, ANESTHESIOLOGY, V87, P479, DOI 10.1097/00000542-199709000-00005; BENDAVID B, 1990, ANESTH ANALG, V71, P298; CHAYEN D, 1976, ANESTHESIOLOGY, V45, P95, DOI 10.1097/00000542-197607000-00019; COOKE ED, 1977, LANCET, V2, P797; COVERT CR, 1989, CAN J ANAESTH, V36, P311, DOI 10.1007/BF03010771; DAHLGREN N, 1995, ACTA ANAESTH SCAND, V39, P872, DOI 10.1111/j.1399-6576.1995.tb04190.x; DALENS B, 1988, ANESTH ANALG, V67, P750; GERMANN PAS, 1979, ANAESTH INTENS CARE, V7, P229, DOI 10.1177/0310057X7900700304; Horlocker TT, 1998, REGION ANESTH PAIN M, V23, P237, DOI 10.1016/S1098-7339(98)90047-5; Hynson JM, 1996, ANESTH ANALG, V82, P1072, DOI 10.1097/00000539-199605000-00035; MODIG J, 1983, ANESTH ANALG, V62, P174; MODIG J, 1989, REGION ANESTH, V11, P72; MURAVCHICK S, 1976, ANESTH ANALG, V55, P350; NANCARROW C, 1986, BRIT J ANAESTH, V58, P29, DOI 10.1093/bja/58.1.29; PARKINSON SK, 1989, ANESTH ANALG, V68, P243; STEPHEN GW, 1969, BRIT J ANAESTH, V41, P933, DOI 10.1093/bja/41.11.933; STERNLO JE, 1995, ACTA ANAESTH SCAND, V39, P557, DOI 10.1111/j.1399-6576.1995.tb04119.x; Tokat O, 2002, J INT MED RES, V30, P161, DOI 10.1177/147323000203000208; VAGHADIA H, 1992, CAN J ANAESTH, V39, P75, DOI 10.1007/BF03008678; WHITE BL, 1987, J BONE JOINT SURG AM, V69A, P1335; WINNIE AP, 1974, [No title captured], V1, P11	21	49	55	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2003	47	1					30	36		10.1034/j.1399-6576.2003.470106.x			7	Anesthesiology	Anesthesiology	627RL	WOS:000179948400006	12492794				2020-06-30	J	Earl, DS; Grimes, S; Kinsella, SM				Earl, DS; Grimes, S; Kinsella, SM			Pain control in day-case surgery	ANAESTHESIA			English	Letter							MANAGEMENT		Bristol Royal Infirm & Gen Hosp, Bristol, Avon, England	Earl, DS (reprint author), Bristol Royal Infirm & Gen Hosp, Bristol, Avon, England.						Claxton AR, 1997, ANESTH ANALG, V84, P509, DOI 10.1097/00000539-199703000-00008; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; MCHUGH, 2002, ANAESTHESIA, V57, P270; MONTGOMERY, 2002, ANAESTHESIA, V57, P727; Paech MJ, 1998, ANAESTH INTENS CARE, V26, P152, DOI 10.1177/0310057X9802600204	5	1	1	0	0	BLACKWELL PUBLISHING LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	JAN	2003	58	1					100	101		10.1046/j.1365-2044.2003.296822.x			2	Anesthesiology	Anesthesiology	627JC	WOS:000179929200040	12492691				2020-06-30	J	Adams, HA; Meyer, P; Stoppa, A; Muller-Goch, A; Bayer, P; Hecker, H				Adams, HA; Meyer, P; Stoppa, A; Muller-Goch, A; Bayer, P; Hecker, H			Anaesthesia for caesarean section. Comparison of two general anaesthetic regimens and spinal anaesthesia	ANAESTHESIST			German	Article						caesarean section; anaesthesia; endocrine stress response; esketamine; sevoflurane	ELECTIVE CESAREAN-SECTION; ANESTHETIC INDUCTION; GERMAN SURVEY; KETAMINE; AWARENESS; DELIVERY; THIOPENTONE; ISOFLURANE	Objectives. The study was undertaken to compare different anaesthetic techniques for scheduled or urgent caesarean section with respect to maternal circulatory parameters, maternal and fetal endocrine stress response, fetal vitality parameters and further clinical parameters such as recovery and analgesic demand. Methods. After ethical approval, patients scheduled for general anaesthesia were randomly allocated to the esketamine group (n=21; induction with 0.5 mg/kg BW esketamine and 1.5 mg/kg BW methohexitone, ventilation until cord cuting with FiO(2) 1.0) and the sevoflurane-group (n=21; induction with 1.5-2.0 mg/kg BW methohexitone, ventilation until uterotomia with N2O/O-2 [FiO(2) 0,5] and endtidal sevoflurane concentrations about 1.0 vol%). After fetal development, all patients received 2.5 mug/kg BW fentanyl and sevoflurane (about 1.0 vol% endtidal) during ventilation with N2O/O-2 (FiO(2) 0.33). As a further control, a group with spinal anaesthesia (n=22; 2.6-3.0 ml isobaric bupivacaine 0.5 %) was investigated. Maternal circulatory and endocrine plasmatic stress parameters were investigated at five time points and fetal parameters once after development. alphaless than or equal to0.05 was considered significant. Results. Biometric data were comparable in all groups. Systolic arterial pressure was higher in the esketamine group (p=0.008), whereas the heart rate was lower during spinal anaesthesia (p<0.001). Plasma noradrenaline decreased in all collectives (p<0.001) and mean group levels of noradrenaline (p=0.04) and adrenaline (p<0.001) were lower during spinal anaesthesia. In all groups, antidiuretic hormone (ADH) remained within the normal range or was slightly increased. Adrenocorticotropic hormone (ACTH) initially increased in all groups and decreased in later time course (p<0.001). Cortisol increased in all groups (p<0.001) but group levels were lower during spinal anaesthesia (p<0.001). In the groups with general anaesthesia, no significant differences in recovery times were obvious, and neither recall nor dream reactions were observed. Postoperative hypoxic incidents (psaO(2) <90%) were comparable between the groups. After spinal anaesthesia, first analgesic demand was later than in the controls (p=0.001), and the total amount of piritramide was lower (p=0.02). Nausea and vomiting were more frequent during spinal anaesthesia (p=0.03). All patients were content with their regimen. Apgar scores, pH-values and adrenaline, noradrenaline and cortisol in plasma were comparable in all groups of children (69 children, 5 gemini). The fetal concentration of esketamine (251 ng/ml) was lower than the corresponding maternal values (493 ng/ml). Conclusions When compared with methohexitone, sevoflurane and N2O for caesarean section, initial total intravenous anaesthesia with esketamine and methohexitone mediated specific antinociception without negative maternal or fetal effects and not taking invasion kinetics or elimination between uterotomia and cord cutting into consideration. Avoidance of N2O allows optimal oxygenation of the fetomaternal unit. Stress protection and hemodynamic responses were well balanced, and intraoperative recall or negative dream reactions were lacking. Superior postoperative pain protection was advantageous after spinal anaesthesia, but in contrast, nausea and vomiting were more frequent in this group.	Klinikum Hannover Oststadt, Med Hsch Hannover, Abt Anasthesiol 2, D-30659 Hannover, Germany; Stadt Klinikum Braunschweig, Abt Anasthesiol, Braunschweig, Germany; Stadt Klinikum Braunschweig, Frauenklin, Braunschweig, Germany; Hannover Med Sch, Frauenklin Geburtshilfe Pranatalmed & Allgemeine, Hannover, Germany; Hannover Med Sch, Inst Biometrie, Hannover, Germany	Adams, HA (reprint author), Klinikum Hannover Oststadt, Med Hsch Hannover, Abt Anasthesiol 2, Podbielskistr 380, D-30659 Hannover, Germany.	adams.ha@mh-hannover.de	Meyer, Peter/A-3726-2010				Adams H A, 1991, Anasthesiol Intensivmed Notfallmed Schmerzther, V26, P294, DOI 10.1055/s-2007-1000588; ADAMS H A, 1989, Regional-Anaesthesie, V12, P87; ADAMS HA, 1992, ANAESTHESIST, V41, P588; ADAMS HA, 1992, ANAESTHESIST, V41, P619; Adams HA, 1997, ANAESTHESIST, V46, P1026, DOI 10.1007/s001010050503; BARAKA A, 1989, BRIT J ANAESTH, V62, P645, DOI 10.1093/bja/62.6.645; BARAKA A, 1990, CAN J ANAESTH, V37, P641, DOI 10.1007/BF03006482; CROZIER TA, 1993, BRIT J ANAESTH, V70, P47, DOI 10.1093/bja/70.1.47; Desborough JP, 2000, BRIT J ANAESTH, V85, P109, DOI 10.1093/bja/85.1.109; DICK W, 1976, ANAESTHESIST, V25, P83; GAITINI L, 1995, CAN J ANAESTH, V42, P377, DOI 10.1007/BF03015480; GAMBLING DR, 1995, ANESTH ANALG, V81, P90, DOI 10.1097/00000539-199507000-00018; HAGNEVIK K, 1988, ACTA ANAESTH SCAND, V32, P234; Haimeur CT, 1997, CAH ANESTHESIOL, V45, P9; Hawkins JL, 1997, ANESTHESIOLOGY, V86, P277, DOI 10.1097/00000542-199702000-00002; Joura EA, 2000, GYNAKOLOGE, V33, P298, DOI 10.1007/s001290050549; Kee WDN, 1997, ANESTH ANALG, V85, P1294, DOI 10.1097/00000539-199712000-00021; Khaw KS, 2002, BRIT J ANAESTH, V88, P18, DOI 10.1093/bja/88.1.18; KRISSEL J, 1994, EUR J ANAESTH, V11, P115; MARX GF, 1977, CLIN USE KETAMINE OB, P1; Navarro EM, 2000, ANASTH INTENSIV NOTF, V35, P232, DOI 10.1055/s-2000-11988; Olthoff D, 1998, ANAESTHESIST, V47, pS63, DOI 10.1007/PL00002501; Panchal S, 2001, ANESTH ANALG, V93, P134; PLOTZ EJ, 1981, GYNAKOLOGIE GEBURTSH; POHJAVUORI M, 1985, EUR J OBSTET GYN R B, V19, P67, DOI 10.1016/0028-2243(85)90021-8; RAMIN SM, 1991, J CLIN ENDOCR METAB, V73, P182, DOI 10.1210/jcem-73-1-182; Schneck H, 1999, ANESTH ANALG, V88, P63, DOI 10.1097/00000539-199901000-00012; SCHULTETUS RR, 1985, CAN ANAESTH SOC J, V32, P592, DOI 10.1007/BF03011404; Stamer UM, 1998, ACTA ANAESTH SCAND, V42, P678	29	8	8	0	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	JAN	2003	52	1					23	32		10.1007/s00101-002-0440-4			10	Anesthesiology	Anesthesiology	652BV	WOS:000181360400004	12577162				2020-06-30	J	Knuttgen, D; Zeidler, D; Doehn, M				Knuttgen, D; Zeidler, D; Doehn, M			Secondary lung surgery following contralateral pneumonectomy. Anaesthesiological considerations	ANAESTHESIST			German	Article						thoracic surgery; pneumonectomy; high frequency jet ventilation; anaesthesia	FREQUENCY JET VENTILATION; BRONCHOGENIC-CARCINOMA; PULMONARY RESECTION; RESIDUAL LUNG; PROPOFOL; SURVIVAL; CANCERS	Although there have been an increasing number of reports on secondary lung surgery following contralateral pneumonectomy in recent years, little information is available about the anaesthesiological management of these patients. We therefore report on a 58-year-old patient who had already undergone a left-sided pneumonectomy and now required a right-sided thoracotomy to remove a recurrent tumour in the right upper lobe. The patient received a total intravenous anaesthesia (propofol,fentanyl) combined with atracurium for muscle relaxation. Following the orotracheal intubation with a Woodbridge tube, the patient was ventilated with the high frequency jet ventilation technique. The jet stream was administered via a catheter placed in the tube. The arterial O-2 saturation during ventilation was always 100%,and arterial CO2 partial pressure was also normal. No complications occurred during tumour resection from the right upper lobe, and the patient was transferred to the ICU with stable pulmonary and haemodynamic conditions. After 2 h of ventilation, the patient was extubated with a completely expanded lung. The postoperative recovery was uneventful. This case report shows that, presupposing a sufficient pulmonary capacity, secondary lung surgery in previously pneumonectomised patients is feasible without complications given an appropriate anaesthesiological management.	Krankenhaus Merheim, Kliniken Stadt Koln, Abt Anasthesiol, D-51109 Cologne, Germany; Krankenhaus Merheim, Kliniken Stadt Koln, Lungenklin, D-51109 Cologne, Germany	Knuttgen, D (reprint author), Krankenhaus Merheim, Kliniken Stadt Koln, Abt Anasthesiol, D-51109 Cologne, Germany.						BARKER JA, 1990, CHEST, V97, P248, DOI 10.1378/chest.97.1.248; BOLLIGER CT, 1995, CHEST, V108, P341, DOI 10.1378/chest.108.2.341; Cheng EY, 1996, ANESTH ANALG, V83, P162, DOI 10.1097/00000539-199607000-00028; CONACHER ID, 1990, BRIT J ANAESTH, V65, P806, DOI 10.1093/bja/65.6.806; CONTI G, 1993, ACTA ANAESTH SCAND, V37, P105, DOI 10.1111/j.1399-6576.1993.tb03609.x; DESCHAMPS C, 1990, J THORAC CARDIOV SUR, V99, P769; Dikmen Y, 1997, EUR J ANAESTH, V14, P239, DOI 10.1046/j.1365-2346.1997.00005.x; HUGHES RK, 1961, J THORAC CARDIOV SUR, V41, P421; JENSIK RJ, 1981, J THORAC CARDIOV SUR, V82, P658; JUDD DR, 1985, ANN THORAC SURG, V40, P623, DOI 10.1016/S0003-4975(10)60364-5; KITTLE CF, 1985, ANN THORAC SURG, V40, P294, DOI 10.1016/S0003-4975(10)60045-8; Knuttgen D, 2001, ANAESTHESIST, V50, P585, DOI 10.1007/s001010100185; LEVASSEUR P, 1991, EUR J CARDIO-THORAC, V6, P639; MARKOS J, 1989, AM REV RESPIR DIS, V139, P902, DOI 10.1164/ajrccm/139.4.902; MARTINI N, 1975, J THORAC CARDIOV SUR, V70, P606; MASSARD G, 1995, J THORAC CARDIOV SUR, V109, P597, DOI 10.1016/S0022-5223(95)70300-4; Motsch J, 2001, ANASTH INTENSIVMED, V42, P237; MOUSSET X, 1989, ANN CHIR, V43, P658; NEPTUNE WB, 1966, J THORAC CARDIOV SUR, V52, P342, DOI 10.1016/S0022-5223(19)43414-4; PARK WK, 1992, ANESTHESIOLOGY, V77, P956, DOI 10.1097/00000542-199211000-00019; ROESLIN N, 1987, ANN CHIR THORAC CARD, V43, P125; SALERNO TA, 1978, ANN THORAC SURG, V27, P3; SHIELDS TW, 1964, J THORAC CARDIOV SUR, V48, P401, DOI 10.1016/S0022-5223(19)33537-8; Spaggiari L, 1996, ANN THORAC SURG, V62, P1598, DOI 10.1016/S0003-4975(96)00608-X; STRUVECHRISTENS.E, 1970, J THORAC CARDIOVASC, V61, P501; Terzi A, 1997, THORAC CARDIOV SURG, V45, P273, DOI 10.1055/s-2007-1013748; VETTERMANN J, 1988, ANESTHESIOLOGY, V69, P688, DOI 10.1097/00000542-198811000-00009; WESTERMANN CJJ, 1993, J THORAC CARDIOV SUR, V106, P868; ZOLLINGER A, 1995, ANAESTHESIOLOGIE, P668; Zwissler B, 2000, ANAESTHESIST, V49, P788, DOI 10.1007/s001010070052	30	0	0	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0003-2417			ANAESTHESIST	Anaesthesist	JAN	2003	52	1					42	46		10.1007/s00101-002-0415-5			5	Anesthesiology	Anesthesiology	652BV	WOS:000181360400006	12577164				2020-06-30	J	McDowell, TS				McDowell, TS			Fentanyl decreases Ca2+ currents in a population of capsaicin-responsive sensory neurons	ANESTHESIOLOGY			English	Article							ROOT GANGLION NEURONS; CALCIUM-CHANNEL CURRENTS; OPIOID RECEPTORS; HIGH-THRESHOLD; CONDUCTION-VELOCITY; AFFERENT-FIBERS; EVOKED RELEASE; IN-VITRO; RAT SKIN; INHIBITION	Background: Neuraxial opioids produce analgesia in part by decreasing excitatory neurotransmitter release from primary nociceptive neurons, an effect that may be due to inhibition of presynaptic voltage-activated Ca2+ channels. The purpose of this study was to determine whether opioids decrease Ca2+ currents (I-Ca.) in primary nociceptive neurons, identified by their response to the algogenic agent capsaicin. Methods: I-Ca was recorded from acutely isolated rat dorsal root ganglion neurons using the whole cell patch clamp technique before, during, and after application of the mu-opioid agonist fentanyl (0.01-1 muM). Capsaicin was applied to each cell at the end of the experiment. Results. Fentanyl reduced I-Ca in a greater proportion of capsaicin-responsive cells (62 of 106, 58%) than capsaicin-unresponsive cells (2 of 15, 13%; P < 0.05). Among capsaicin-responsive cells, the decrease in I-Ca was 38 +/- 3% (n = 36, 1 muM) in fentanyl-sensitive cells versus just 7 +/- 1% (n = 15, 1 muM; P < 0.05) in fentanyl-insensitive cells. Among capsaicin-responsive cells, I-Ca inactivated more rapidly in fentanyl-sensitive cells (tau(h), 52 +/- 4 ms, n = 22) than In fentanyl-insensitive cells (93 +/- 14 ms, n = 24; P < 0.05). This was not due to differences in the types of Ca2+ channels expressed as the magnitudes of W-conotoxin GVIA-sensitive (N-type), nifedipine-sensitive (L-type), and GVIA-nifedipine-resistant (primarily P-/Q-type) components of I-Ca. were similar. Conclusions. The results show that opioid-sensitive Ca2+ channels are expressed by very few capsaicin-unresponsive neurons but by more than half of capsaicin-responsive neurons. The identity of the remaining capsaicin-responsive (and therefore presumed nociceptive) neurons that express opioid-insensitive Ca2+ channels is unknown but may represent a potential target of future non-opioid-based therapies for acute pain.	Univ Wisconsin, Sch Med, Ctr Clin Sci, Dept Anesthesiol, Madison, WI 53792 USA	McDowell, TS (reprint author), Univ Wisconsin, Sch Med, Ctr Clin Sci, Dept Anesthesiol, B6-319,600 Highland Ave, Madison, WI 53792 USA.						Abdulla FA, 1998, J NEUROSCI, V18, P9685; AIMONE LD, 1989, PEPTIDES, V10, P1127, DOI 10.1016/0196-9781(89)90003-X; BAUMANN TK, 1991, J NEUROPHYSIOL, V66, P212; Beland B, 2001, PAIN, V90, P143, DOI 10.1016/S0304-3959(00)00397-3; Borgland SL, 2001, J PHYSIOL-LONDON, V536, P35, DOI 10.1111/j.1469-7793.2001.t01-1-00035.x; BRENNUM J, 1993, PAIN, V52, P75, DOI 10.1016/0304-3959(93)90117-8; BROMAGE PR, 1982, ANESTH ANALG, V61, P490; CARDENAS CG, 1995, J NEUROPHYSIOL, V74, P1870; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; DelMar LP, 1996, J NEUROPHYSIOL, V76, P2192; Gold MS, 1996, NEUROSCIENCE, V71, P265, DOI 10.1016/0306-4522(95)00433-5; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARPER AA, 1985, J PHYSIOL-LONDON, V359, P31, DOI 10.1113/jphysiol.1985.sp015573; JESSELL TM, 1977, NATURE, V268, P549, DOI 10.1038/268549a0; LEE KH, 1986, J COMP NEUROL, V243, P335, DOI 10.1002/cne.902430305; LIGHT AR, 1979, J COMP NEUROL, V186, P133, DOI 10.1002/cne.901860203; LIGHT AR, 1992, PAIN HEADACHE, P10; Liu NJ, 1995, J PHARMACOL EXP THER, V275, P1293; LYNN B, 1982, BRAIN RES, V238, P29, DOI 10.1016/0006-8993(82)90768-5; MACDONALD RL, 1978, SCIENCE, V199, P1449, DOI 10.1126/science.204015; McDonough SI, 1996, J NEUROSCI, V16, P2612; MOISES HC, 1994, J NEUROSCI, V14, P5903; NOMURA K, 1994, J PHARMACOL EXP THER, V270, P466; PETERSEN M, 1991, BRAIN RES, V561, P20, DOI 10.1016/0006-8993(91)90744-G; RUSIN KI, 1995, J NEUROSCI, V15, P4315; SCHROEDER JE, 1991, NEURON, V6, P13, DOI 10.1016/0896-6273(91)90117-I; SCHROEDER JE, 1993, J NEUROSCI, V13, P867; SCROGGS RS, 1992, J PHYSIOL-LONDON, V445, P639, DOI 10.1113/jphysiol.1992.sp018944; SENO N, 1993, NEUROSCIENCE, V55, P563, DOI 10.1016/0306-4522(93)90524-J; Stucky CL, 1998, NEUROSCIENCE, V84, P1257, DOI 10.1016/S0306-4522(97)00572-1; Stucky CL, 1999, J NEUROSCI, V19, P6497; SZOLCSANYI J, 1988, BRAIN RES, V446, P262, DOI 10.1016/0006-8993(88)90885-2; SZOLCSANYI J, 1993, [No title captured], P1; TADDESE A, 1995, SCIENCE, V270, P1366, DOI 10.1126/science.270.5240.1366; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; UEDA M, 1995, NEUROPHARMACOLOGY, V34, P303, DOI 10.1016/0028-3908(94)00160-T; Vyklicky L, 1998, J NEUROPHYSIOL, V79, P670; Yaksh TL, 1997, ACTA ANAESTH SCAND, V41, P94, DOI 10.1111/j.1399-6576.1997.tb04623.x	39	8	10	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	JAN	2003	98	1					223	231		10.1097/00000542-200301000-00034			9	Anesthesiology	Anesthesiology	632CZ	WOS:000180207300032	12503001				2020-06-30	J	Harrison, CM; Goddard, JM; Rittey, CD				Harrison, CM; Goddard, JM; Rittey, CD			The use of regional anaesthetic blockade in a child with recurrent erythromelalgia	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article								Primary erythromelalgia is a rare condition, which is characterised by redness, burning pain, and increased temperature of the extremities. We describe a 6 year old boy with symptoms of erythromelalgia and the difficulty surrounding treatment of this condition. Severe pain responded to the use of regional anaesthetic blocks.	Sheffield Childrens Hosp, Dept Anaesthesia, Sheffield, S Yorkshire, England; Ryegate Childrens Ctr, Sheffield, S Yorkshire, England	Harrison, CM (reprint author), Jessop Wing Neonatal Intens Care Unit, Tree Root Walk, Sheffield S10 2SF, S Yorkshire, England.			Harrison, Cath/0000-0003-4268-4562			Brown GE, 1932, AM J MED SCI, V183, P468, DOI 10.1097/00000441-193204000-00005; DANGELO R, 1992, ANESTH ANALG, V74, P142; Davis MDP, 2000, ARCH DERMATOL, V136, P330, DOI 10.1001/archderm.136.3.330; JORGENSEN HP, 1978, ARCH DERMATOL, V114, P112, DOI 10.1001/archderm.114.1.112; LEVINE AM, 1987, ARCH PHYS MED REHAB, V68, P119; MARTIN JC, 1994, ANN DERMATOL VENER, V121, P309; MITCHELL SW, 1878, [No title captured], V76, P17; Mufson I, 1937, AM HEART J, V13, P483, DOI 10.1016/S0002-8703(37)90863-9; STROZIK K, 1992, CLIN PEDIATR, V31, P378, DOI 10.1177/000992289203100614; THOMPSON GH, 1979, CLIN ORTHOP RELAT R, P249; UNO H, 1983, ARCH DERMATOL, V119, P65, DOI 10.1001/archderm.119.1.65	11	8	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	JAN	2003	88	1					65	66		10.1136/adc.88.1.65			2	Pediatrics	Pediatrics	632PG	WOS:000180231400021	12495966	Green Published, Bronze			2020-06-30	J	Bpharm, SR; Fortier, LP				Bpharm, SR; Fortier, LP			Fentanyl-induced rigidity during emergence from general anesthesia potentiated by venlafexine	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							OPIOID-INDUCED RIGIDITY; PROPOFOL; DESFLURANE; INDUCTION; VENTILATION; MYOCLONUS; DIFFICULT; SEIZURES; CLOSURE	Purpose: To present and discuss a case of opioid-induced rigidity with low-dose fentanyl during recovery from anesthesia. Clinical features: A 41-yr-old woman underwent laparotomy for total abdominal hysterectomy and bilateral salpingo- oophorectomy under general anesthesia. She received a total of 500 mug of fentanyl by iv intermittent boluses during the three-hour anesthetic. During emergence from anesthesia, while intubated, the patient presented with rigidity. No changes in ventilatory parameters were measured during the episode. The only notable predisposing factor was treatment with venlafexine, an antidepressant that modifies serotonin and norepinephrine levels. She was successfully treated with iv naloxone 20 mug. The rest of the postoperative period was uneventful. Conclusion: We observed an atypical case of opioid-induced rigidity in contrast to the classical syndrome, which presents at induction with high-dose opioids. This syndrome has many clinical presentations with neurologic and ventilatory signs of varying intensity. Early recognition of the syndrome and adequate treatment is crucial. If treated adequately, opioid-induced rigidity is self-limited with few complications.	Univ Montreal, Dept Anesthesiol, Montreal, PQ, Canada	Fortier, LP (reprint author), Hop Maison Neuve Rosemont, Dept Anesthesiol, 5415 Boul Assompt, Montreal, PQ H1T 2M4, Canada.	hmranest@odyssee.net					Abrams JT, 1996, ANESTH ANALG, V83, P629, DOI 10.1097/00000539-199609000-00034; Bennett JA, 1997, ANESTHESIOLOGY, V87, P1070, DOI 10.1097/00000542-199711000-00010; BONNET F, 1986, EUR J ANAESTH, V3, P413; BOWDLE TA, 1994, ANESTH ANALG, V78, P783; Cohen IT, 2001, ANESTH ANALG, V93, P88; COMSTOCK MK, 1981, ANESTH ANALG, V60, P362; FINLEY GA, 1993, CAN J ANAESTH, V40, P863, DOI 10.1007/BF03009258; Fortier LP, 2002, PRATICIEN ANESTHESIE, V6, P17; Grundman U, 1998, ACTA ANAESTH SCAND, V42, P845, DOI 10.1111/j.1399-6576.1998.tb05332.x; HAMILTON WK, 1953, ANESTHESIOLOGY, V14, P550, DOI 10.1097/00000542-195311000-00002; HUGHES NJ, 1995, CAN J ANAESTH, V42, P744, DOI 10.1007/BF03012676; Islander G, 2000, ACTA ANAESTH SCAND, V44, P144, DOI 10.1034/j.1399-6576.2000.440203.x; KLAUSNER JM, 1988, ARCH SURG-CHICAGO, V123, P66; MCCULLOCH PR, 1990, CAN J ANAESTH, V37, P739, DOI 10.1007/BF03006531; POKELA ML, 1992, ANESTH ANALG, V75, P252; RIES CR, 1994, CAN J ANAESTH, V41, P414, DOI 10.1007/BF03009864; SCAMMAN FL, 1983, ANESTH ANALG, V62, P332; SMITH NT, 1989, ANESTHESIOLOGY, V71, P852; Viscomi CM, 1997, OBSTET GYNECOL, V89, P822, DOI 10.1016/S0029-7844(97)81423-8; Welborn LG, 1996, ANESTH ANALG, V83, P917, DOI 10.1097/00000539-199611000-00005	20	30	33	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	JAN	2003	50	1					32	35		10.1007/BF03020183			4	Anesthesiology	Anesthesiology	637PX	WOS:000180522500008	12514147	Bronze			2020-06-30	J	van Seventer, R; Smit, JM; Schipper, RM; Wicks, MA; Zuurmond, WWA				van Seventer, R; Smit, JM; Schipper, RM; Wicks, MA; Zuurmond, WWA			Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						cancer pain; constipation; opioid naive; sustained-release morphine; transdermal fentanyl	LONG-TERM TREATMENT; TRANSDERMAL FENTANYL; CANCER PAIN; PHARMACOKINETICS; EFFICACY; TRIAL	Objective: This randomised, multicentre, direct open comparative trial evaluated the efficacy, treatment convenience, tolerability and safety aspects of transdermal therapeutic system (TTS)-fentanyl and sustained-release oral morphine (SRM) in both opioid-nave patients with moderate-to-severe cancer-related pain and in patients who had already been using opioids for mild-to-moderate pain. The two treatment groups were run in parallel. Special attention was paid to constipation, nausea/vomiting, drowsiness and respiratory depression. Patients and methods: The 131 enrolled patients started the 4-week treatment at low doses of opioid (25 mug/h TTS-fentanyl for 3 days or 30 mg SRM every 12 h) and were individually titrated. Tolerability, efficacy and safety were assessed throughout the study period. Frequency of constipation was the primary study variable and accordingly the study was powered for this. Both patients and investigators made a global treatment evaluation. Results: TTS-fentanyl and SFM were shown to be equally effective. Pain control and sleep quality improved with both treatments. None of the patients developed respiratory depression. Statistically significantly more patients in the SRM treatment group discontinued the trial prematurely (59% vs 27%; p < 0.001), particularly due to adverse events (36% vs 4%; p < 0.001). Fewer patients in the TTS-fentanyl than in the SRM treatment group reported constipation during the trial. This finding was statistically significant after 1 week of treatment (27% vs 57%; p = 0.003). The favourable tolerability profile of TTS-fentanyl was also reflected in both the patient and the investigator global evaluation of the treatment. Patient assessment favoured TTS-fentanyl treatment in terms of a significantly lower rate of troublesome side-effects ('quite a bit' to,very much' troublesome side-effects in 14% vs 36% of patients; p = 0.003) and less interruption of daily activities (absence of any interruption of daily activities in 88% vs 63% of patients; p = 0.012). Investigators scored TTS-fentanyl as significantly better with respect to 'side-effects' (p = 0.039) and ,overall impression' (p = 0.013). Sub-analyses of opioid-ndive users gave similar results. Conclusion: These data indicate that TTS-fentanyl, when used as an opioid of first choice in the treatment of cancer-related pain, is as effective as, but better tolerated than, SRM, including in opioid-naive patients.	Vrije Univ Amsterdam Med Ctr, Dept Anaesthesiol, NL-1007 MB Amsterdam, Netherlands; Amphia Hosp, Dept Anaesthesiol, Breda, Netherlands; Gelre Hosp, Dept Internal Med, Apeldoorn, Netherlands; Catharina Hosp, Dept Pulm & TB, Eindhoven, Netherlands; St Jansdal Hosp, Dept Anaesthesiol, Harderwijk, Netherlands	Zuurmond, WWA (reprint author), Vrije Univ Amsterdam Med Ctr, Dept Anaesthesiol, POB 7057, NL-1007 MB Amsterdam, Netherlands.	wwa.zuurmond@vumc.nl					Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Cleary J F, 2000, Cancer Control, V7, P120; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; DONNER B, 1995, ANTI-CANCER DRUG, V6, P39, DOI 10.1097/00001813-199504003-00007; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; JACOBS LM, 1994, ADV TRAUM CRIT CARE, V9, P1; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; Makin MK, 2001, J ROY SOC MED, V94, P17, DOI 10.1177/014107680109400105; Menten J, 2002, CURR MED RES OPIN, V18, P488, DOI 10.1185/030079902125001272; Mercadante S, 1999, ONCOLOGY-NY, V13, P215; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; TURK DC, 1987, PAIN, V30, P177, DOI 10.1016/0304-3959(87)91073-6; VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; Yeo W, 1997, PALLIATIVE MED, V11, P233, DOI 10.1177/026921639701100308; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9	24	56	61	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0300-7995	1473-4877		CURR MED RES OPIN	Curr. Med. Res. Opin.		2003	19	6					457	469		10.1185/030079903125002045			13	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	725TZ	WOS:000185559600001	14594516				2020-06-30	J	Kornick, CA; Santiago-Palma, J; Moryl, N; Payne, R; Obbens, EAMT				Kornick, CA; Santiago-Palma, J; Moryl, N; Payne, R; Obbens, EAMT			Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain	DRUG SAFETY			English	Review							CHRONIC NONCANCER PAIN; QUALITY-OF-LIFE; CHRONIC NONMALIGNANT PAIN; RELEASE ORAL MORPHINE; ACUTE TOXIC DELIRIUM; CANCER-RELATED PAIN; LONG-TERM TREATMENT; TO-DAY TITRATION; POSTOPERATIVE PAIN; CLINICAL PHARMACOKINETICS	Transdermal fentanyl is effective and well tolerated for the treatment of chronic pain caused by malignancy and non-malignant conditions when administered according to the manufacturer's recommendations. Compared with oral opioids, the advantages of transdermal fentanyl include a lower incidence and impact of adverse effects (constipation, nausea and vomiting, and daytime drowsiness), a higher degree of patient satisfaction, improved quality of life, improved convenience and compliance resulting from administration every 72 hours, and decreased use of rescue medication. Transdermal fentanyl is a useful analgesic for cancer patients who are unable to swallow or have gastrointestinal problems. Transdermal fentanyl forms a depot within the upper skin layers before entering the microcirculation. Therapeutic blood levels are attained 12-16 hours after patch application and decrease slowly with a half-life of 16-22 hours following removal. Patients with chronic pain should be titrated to adequate relief with short-acting oral or parenteral opioids prior to the initiation of transdermal fentanyl in order to prevent exacerbations of pain or opioid-related adverse effects. Transdermal fentanyl can then be initiated based on the 24-hour opioid requirement once adequate analgesia has been achieved. The prolonged elimination of transdermal fentanyl can become problematic if patients develop opioid-related adverse effects, especially hypoventilation. Adverse effects do not improve immediately after patch removal and may take many hours to resolve. Patients who experience opioid-related toxicity associated with respiratory depression should be treated immediately with an opioid antagonist such as naloxone and closely monitored for at least 24 hours. Because of the short half-life of naloxone, sequential doses or a continuous infusion of the opioid antagonist may be necessary. Transdermal fentanyl should be administered cautiously to patients with pre-existing conditions such as emphysema that may predispose them to the development of hypoventilation. Transdermal fentanyl is indicated only for patients who require continuous opioid administration for the treatment of chronic pain that cannot be managed with other medications. It is contraindicated in the management of acute and postoperative pain, as pain may decrease more rapidly in these circumstances than fentanyl blood levels can be adjusted, leading to the development of life-threatening hypoventilation. Cognitive and physical impairments such as confusion and abnormal co-ordination can occur with transdermal fentanyl. Therefore, patients should be instructed to refrain from driving or operating machinery immediately following the initiation of transdermal fentanyl, or after any dosage increase. Patients may resume such activities once the absence of these potential adverse effects is documented.	Mem Sloan Kettering Canc Ctr, Pain & Palliat Care Serv, Dept Neurol, New York, NY USA	Kornick, CA (reprint author), Riverside Spine & Pain Phys, PL Suite 4-5,4339 Roosevelt Blvd, Jacksonville, FL 32210 USA.	kornick@riversidespine.com	Lin, Zhao/C-8319-2011	Lin, Zhao/0000-0002-6131-9723	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32-CA09461]		*AC PAIN MAG GUID, 1992, AHCPR PUBL; AHMEDZAI S, 1994, J DRUG DEV, V6, P93; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Allan L, 2001, BRIT MED J, V322, P1154, DOI 10.1136/bmj.322.7295.1154; Alsahaf MH, 2000, J PAIN SYMPTOM MANAG, V20, P210, DOI 10.1016/S0885-3924(00)00173-1; ASHBURN MA, 1993, ANESTH ANALG, V76, P402; Bannwarth B, 1999, DRUG SAFETY, V21, P283, DOI 10.2165/00002018-199921040-00004; Barkin RL, 2001, SOUTH MED J, V94, P756; Barkin RL, 1996, DM-DIS MON, V42, P389; BERNSTEIN KJ, 1994, J ORAL MAXIL SURG, V52, P896, DOI 10.1016/0278-2391(94)90277-1; BERNSTEIN KJ, 1994, DIS COLON RECTUM, V37, P1339, DOI 10.1007/BF02257808; BOVILL JG, 1987, DRUGS, V33, P520, DOI 10.2165/00003495-198733050-00006; Breitbart W, 2000, ONCOLOGY-NY, V14, P695; BRENA SF, 1991, CLIN J PAIN, V7, P342, DOI 10.1097/00002508-199112000-00015; BROOKS D, 1995, SUPPORT CARE CANCER, V3, P210, DOI 10.1007/BF00368895; BROOME IJ, 1995, ANAESTHESIA, V50, P300, DOI 10.1111/j.1365-2044.1995.tb04603.x; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; BULOW HH, 1995, ACTA ANAESTH SCAND, V39, P835; BURCHMAN SL, 1995, J PAIN SYMPTOM MANAG, V10, P556, DOI 10.1016/0885-3924(95)00085-D; CALIS KA, 1992, CLIN PHARMACY, V11, P22; Collins JJ, 1999, J PEDIATR-US, V134, P319, DOI 10.1016/S0022-3476(99)70457-9; Coyle N, 1990, J Pain Symptom Manage, V5, P83; Davies AN, 1996, PALLIATIVE MED, V10, P348; Dellemijn PLI, 1998, J PAIN SYMPTOM MANAG, V16, P220, DOI 10.1016/S0885-3924(98)00070-0; DESIO JM, 1993, ANESTHESIOLOGY, V79, P1139, DOI 10.1097/00000542-199311000-00036; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; DUTHIE DJR, 1988, BRIT J ANAESTH, V60, P614, DOI 10.1093/bja/60.6.614; Edinboro LE, 1997, J FORENSIC SCI, V42, P741; Elsner F, 1999, SCHMERZ, V13, P273, DOI 10.1007/s004820050210; ESTEVE M, 1991, ANESTHESIOLOGY, V75, pA705; *FDA, 1990, JAMA-J AM MED ASSOC, V264, P1802; FERRELL BR, 1994, J PAIN SYMPTOM MANAG, V9, P221, DOI 10.1016/0885-3924(94)90099-X; Flannagan LM, 1996, J FORENSIC SCI, V41, P320; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; Frolich M, 2001, ANESTH ANALG, V93, P647; Fudin J, 1997, AM J HEALTH-SYST PH, V54, P87, DOI 10.1093/ajhp/54.1.87; GALER BS, 1992, PAIN, V49, P87, DOI 10.1016/0304-3959(92)90192-E; GOURLAY GK, 1989, PAIN, V37, P193, DOI 10.1016/0304-3959(89)90130-9; GOURLAY GK, 1990, PAIN, V40, P21, DOI 10.1016/0304-3959(90)91046-L; Grond S, 1997, PAIN, V69, P191, DOI 10.1016/S0304-3959(96)03254-X; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 1992, J PAIN SYMPTOM MANAG, V7, pS17, DOI 10.1016/0885-3924(92)90049-N; Hammack JE, 1996, J PAIN SYMPTOM MANAG, V12, P234, DOI 10.1016/0885-3924(96)00191-1; Han PKJ, 2002, J PAIN SYMPTOM MANAG, V23, P66, DOI 10.1016/S0885-3924(01)00370-0; Hanks GW, 2001, BRIT J CANCER, V84, P587, DOI 10.1054/bjoc.2001.1680; Hardwick WE, 1997, SOUTH MED J, V90, P962, DOI 10.1097/00007611-199709000-00023; HERBST LH, 1992, J PAIN SYMPTOM MANAG, V7, pS54, DOI 10.1016/0885-3924(92)90056-N; HIGGS CMB, 1995, J PAIN SYMPTOM MANAG, V10, P4, DOI 10.1016/0885-3924(94)00060-X; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; JACOX A, 1994, [No title captured]; *JANSS PHARM PROD, 2001, DUR FENT TRANSD SYST; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; KlockgetherRadke A, 1997, ANAESTHESIST, V46, P428, DOI 10.1007/s001010050420; Kornick CA, 2003, CANCER, V97, P3121, DOI 10.1002/cncr.11457; Kornick CA, 2001, J PAIN S1, V2, pS35; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; Kramer Christopher, 1998, Journal of the American Osteopathic Association, V98, P385; KUZMA PJ, 1995, ANESTHESIOLOGY, V83, P869; Lawlor P, 1997, PAIN, V72, P79, DOI 10.1016/S0304-3959(97)00018-3; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.3.CO;2-8; LEHMANN KA, 1992, J PAIN SYMPTOM MANAG, V7, pS8, DOI 10.1016/0885-3924(92)90048-M; Mantovani G, 1999, ANTICANCER RES, V19, P3495; MARQUARDT KA, 1994, J TOXICOL-CLIN TOXIC, V32, P75, DOI 10.3109/15563659409000433; MARQUARDT KA, 1995, ANN PHARMACOTHER, V29, P969, DOI 10.1177/106002809502901001; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; MAVES TJ, 1992, J PAIN SYMPTOM MANAG, V7, pS58, DOI 10.1016/0885-3924(92)90057-O; McCarberg B H, 2001, Am J Ther, V8, P181, DOI 10.1097/00045391-200105000-00006; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Milligan K, 2001, J PAIN, V2, P197, DOI 10.1054/jpai.2001.25352; MISER AW, 1989, PAIN, V37, P15, DOI 10.1016/0304-3959(89)90148-6; Moulin DE, 1996, LANCET, V347, P143, DOI 10.1016/S0140-6736(96)90339-6; Neighbors DM, 2001, J PAIN SYMPTOM MANAG, V21, P129, DOI 10.1016/S0885-3924(00)00247-5; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; Payne R, 1998, SEMIN ONCOL, V25, P47; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; PAYNE R, 1995, ANTI-CANCER DRUG, V6, P50, DOI 10.1097/00001813-199504003-00009; PAYNE R, 1992, J PAIN SYMPTOM MANAG, V7, pS40, DOI 10.1016/0885-3924(92)90052-J; PLEZIA PM, 1989, PHARMACOTHERAPY, V9, P2; Portenoy R.K., 1990, J PAIN SYMPTOM MANAG, V5, P46; PORTENOY RK, 1986, PAIN, V25, P171, DOI 10.1016/0304-3959(86)90091-6; Portenoy RK, 1996, J PAIN SYMPTOM MANAG, V11, P203, DOI 10.1016/0885-3924(95)00187-5; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; REISINE T, 1996, GOODMAN GILMANS PHAR, P543; Roberge RJ, 2000, J EMERG MED, V18, P147, DOI 10.1016/S0736-4679(99)00185-7; ROSE PG, 1993, ANESTH ANALG, V77, P390, DOI 10.1213/00000539-199377020-00029; ROY SD, 1990, PHARMACEUT RES, V7, P842, DOI 10.1023/A:1015912932416; RUNG GW, 1993, ANESTH ANALG, V76, pS363; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; SCHOFFERMAN J, 1993, J PAIN SYMPTOM MANAG, V8, P279, DOI 10.1016/0885-3924(93)90156-P; Scholz J, 1996, CLIN PHARMACOKINET, V31, P275, DOI 10.2165/00003088-199631040-00004; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SIMMONDS MA, 1992, J PAIN SYMPTOM MANAG, V7, pS36, DOI 10.1016/0885-3924(92)90051-I; SIMMONDS MA, 1989, P AN M AM SOC CLIN, V8, P324; Simpson RK, 1997, J PAIN SYMPTOM MANAG, V14, P218, DOI 10.1016/S0885-3924(97)00183-8; SLAPPENDEL R, 1994, ANN ONCOL S8, V5, P200; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; SLOVER R, 1992, J PAIN SYMPTOM MANAG, V7, pS45, DOI 10.1016/0885-3924(92)90053-K; SONG CW, 1989, INT J RADIAT ONCOL, V17, P1041, DOI 10.1016/0360-3016(89)90153-3; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; STEINBERG RB, 1992, ANESTH ANALG, V75, P1014; Strupp C, 2000, ONCOL REP, V7, P659; Thompson JP, 1998, BRIT J ANAESTH, V81, P152; Turk DC, 1996, J PAIN SYMPTOM MANAG, V11, P218, DOI 10.1016/0885-3924(95)00188-3; *US DEP HHS, 2001 DAWN REP NARC A; VANBASTELAERE M, 1993, BRIT J ANAESTH, V70, P75; VARVEL JR, 1989, ANESTHESIOLOGY, V70, P928, DOI 10.1097/00000542-198906000-00008; VECCHIONE A, 1995, HOSP PHARM REPORT, V12, P11; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; VONBORMANN B, 1991, TRANSDERMAL FENTANYL, P119; Wong J O, 1997, Acta Anaesthesiol Sin, V35, P25; Woodroffe MA, 1997, CAN FAM PHYSICIAN, V43, P268; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9; ZENZ M, 1994, J PAIN SYMPTOM MANAG, V9, P54, DOI 10.1016/0885-3924(94)90149-X; 1993, PERSXX TIMES    1115, pB4	118	65	67	1	13	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0114-5916	1179-1942		DRUG SAFETY	Drug Saf.		2003	26	13					951	973		10.2165/00002018-200326130-00004			23	Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology	Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology	736QQ	WOS:000186185000004	14583070				2020-06-30	J	Kaiser, GM; Fruhauf, NR; Zhang, HW; Westermann, S; Bolle, I; Oldhafer, KJ; Broelsch, CE				Kaiser, Gernot M.; Fruehauf, Nils R.; Zhang, Hongwei; Westermann, Stephanie; Bolle, Ines; Oldhafer, Karl J.; Broelsch, Christoph E.			Intravenous Infusion Anesthesis with Propofol-Midazolam-Fentanyl for Experimental Surgery in Swine	JOURNAL OF INVESTIGATIVE SURGERY			English	Article						experimental surgery; intravenous anesthesia; swine		There is a need for prolonged anesthesia procedures in experimental surgery. Animals in this study received fentanyl, Midazolam, and Propofol administered by continuous intravenous infusion for anesthesia along with controlled ventilation. Time of anesthesia was 413 +/- 95 min. Animals could be extubated 20 +/- 12 min after operation. Animals recovered completely from anesthesia by day 1 after surgery with almost normal physical activity. This study clearly shows that intravenous infusion anesthesia is safe and easy to handle in prolonged anesthesia for experimental surgery in swine. This anesthetic protocol can also be used for intraoperative transportation.	[Kaiser, Gernot M.; Fruehauf, Nils R.; Zhang, Hongwei; Westermann, Stephanie; Oldhafer, Karl J.; Broelsch, Christoph E.] Univ Hosp, Dept Gen Surg & Transplantat, Essen, Germany; [Bolle, Ines] Univ Hosp, Anim Lab, Essen, Germany	Kaiser, GM (reprint author), Univ Essen Gesamthsch, Dept Gen & Transplantat Surg, Hufelandstr 55, D-45147 Essen, Germany.	gernot.kaiser@uni-essen.de					Blobner M, 1999, ANASTH INTENSIV NOTF, V34, P94; Cruz JI, 1999, TRANSPLANT P, V31, P2404, DOI 10.1016/S0041-1345(99)00402-9; DAVIDSON JAH, 1993, BRIT J ANAESTH, V70, P163, DOI 10.1093/bja/70.2.163; DEGROOD PMRM, 1985, POSTGRAD MED J, V61, P65; FRAMSTAD T, 1994, LAB ANIMAL, V30, P209; Goldmann C, 1999, RES EXP MED, V199, P35, DOI 10.1007/s004330050131; GRONERT GA, 1976, ANESTHESIOLOGY, V44, P36, DOI 10.1097/00000542-197601000-00008; Lin HC, 1997, VET SURG, V26, P247, DOI 10.1111/j.1532-950X.1997.tb01494.x; OLDHAFER KJ, 1997, J INVEST SURG, V10, P53; REVES JG, 1985, ANESTHESIOLOGY, V62, P310, DOI 10.1097/00000542-198503000-00017; SEBEL PS, 1989, ANESTHESIOLOGY, V71, P260, DOI 10.1097/00000542-198908000-00015; SMITH AC, 1991, LAB ANIM SCI, V41, P157; Stevens JB, 1998, ANESTH ANALG, V86, P45, DOI 10.1097/00000539-199801000-00009; Svendsen P, 1998, SCAND J LAB ANIM SCI, V25, P31; Swindle M M, 1988, J Invest Surg, V1, P65, DOI 10.3109/08941938809141077; SWINDLE MM, 1986, LAB ANIM SCI, V36, P357; Swindle MM, 1998, SCAND J LAB ANIM SCI, V25, P11; WHITE PF, 1989, ANESTH ANALG, V68, P161, DOI 10.1213/00000539-198902000-00017	18	15	15	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	0894-1939			J INVEST SURG	J. Invest. Surg.		2003	16	6					353	357		10.1080/08941930390250223			5	Surgery	Surgery	V13AR	WOS:000207640200005	14708548				2020-06-30	J	Hung, CJ; Liu, FY; Shaiu, YC; Kao, A; Lin, CC; Lee, CC				Hung, CJ; Liu, FY; Shaiu, YC; Kao, A; Lin, CC; Lee, CC			Assessing transient pulmonary injury induced by volatile anesthetics by increased lung uptake of technetium-99m hexamethylpropylene amine oxime	LUNG			English	Article						volatile anesthetics; technetium-99m hexamethylpropylene amine oxime	ISOFLURANE	Volatile anesthetics such as halothane and isoflurane have long been thought to affect pulmonary function. The purpose of this study was to examine whether volatile anesthetics (halothane and isoflurane) can induce pulmonary vascular endothelium damage. Before surgery, 1 h after surgery, and 1 week after surgery, the degree of pulmonary vascular endothelium damage was represented as increased lung/liver uptake ratios (L/L ratio) and measured on technetium-99m hexamethylpropylene amine oxime (Tc-99m HMPAO) lung scan in 3 groups of the patients. Group 1 included 20 patients undergoing surgery and receiving volatile anesthesia with 1% halothane. Group 2 included 20 patients undergoing surgery and receiving volatile anesthesia with 1.5% isoflurane. Group 3 included 20 patients undergoing surgery with intravenous anesthesia drugs. No significant change of L/L ratio was found from before surgery, 1 h after surgery, to 1 week after surgery in group 3 patients. In groups 1 and 2 patients, significantly transient increased L/L ratio was found 1 h after surgery. We conclude that volatile anesthesia (halothane and isoflurane) can induce transient pulmonary vascular endothelium damage, represented as transiently increased L/L ratios on Tc-99m HMPAO lung scan.	China Med Coll Hosp, Dept Nucl Med, Taichung 404, Taiwan; China Med Coll Hosp, Dept Med Res, Taichung 404, Taiwan; China Med Coll Hosp, Dept Anesthesia Pain Clin, Taichung, Taiwan; China Med Coll Hosp, Dept Crit Care Med, Taichung, Taiwan; Far Eastern Mem Hosp, Dept Nucl Med, Taipei, Taiwan	Kao, A (reprint author), China Med Coll Hosp, Dept Nucl Med, 2 Yuh Der Rd, Taichung 404, Taiwan.			Liu, Feng-Yuan/0000-0001-5520-3268			DUECK R, 1980, ANESTHESIOLOGY, V52, P113; Gunaydin B, 1997, RESP MED, V91, P351, DOI 10.1016/S0954-6111(97)90062-7; Shih CM, 2002, RESPIRATION, V69, P143, DOI 10.1159/000056317; SUGA K, 1994, J NUCL MED, V35, P1520; Sun SS, 2000, LUNG, V178, P129, DOI 10.1007/s004080000016; TOCINO M, 1990, LUNG RHEUMATIC DIS, P81; TOUYA JJ, 1985, J NUCL MED, V26, P1302	7	9	10	0	0	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0341-2040			LUNG	Lung	JAN-FEB	2003	181	1					1	7		10.1007/s00408-002-0109-4			7	Respiratory System	Respiratory System	674ZC	WOS:000182667100001	12879335				2020-06-30	J	Regnard, C; Pelham, A				Regnard, C; Pelham, A			Severe respiratory depression and sedation with transdermal fentanyl: four case studies	PALLIATIVE MEDICINE			English	Article						adverse effects; fentanyl; respiratory depression; sedation; transdermal administration	CLINICAL PHARMACOKINETICS; DOUBLE-BLIND; PAIN; PATIENT; PLACEBO; PATCH; TRIAL		Newcastle City Hosp NHS Trust, St Oswalds Hospice, Newcastle Upon Tyne, Tyne & Wear, England; Prudhoe NHS Trust, Newcastle Upon Tyne, Tyne & Wear, England; Univ Newcastle Upon Tyne, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Pelham, A (reprint author), St Oswalds Hospice, Registrar Palliat Med, Regent Ave, Newcastle Upon Tyne NE3 1EE, Tyne & Wear, England.						BECKER LD, 1976, ANESTHESIOLOGY, V44, P291, DOI 10.1097/00000542-197604000-00003; Bleeker CP, 2001, EUR J PAIN-LONDON, V5, P325, DOI 10.1053/eujp.2000.0220; BULOW HH, 1995, ACTA ANAESTH SCAND, V39, P835; Frolich M, 2001, ANESTH ANALG, V93, P647; Grond S, 2000, CLIN PHARMACOKINET, V38, P59, DOI 10.2165/00003088-200038010-00004; GUPTA SK, 1992, [No title captured], V7, P17; Latasch L, 1989, Acta Anaesthesiol Belg, V40, P113; MATHER LE, 1983, CLIN PHARMACOKINET, V8, P422, DOI 10.2165/00003088-198308050-00004; McLoughlin R, 1997, PALLIATIVE MED, V11, P419; Newshan G, 1998, J PAIN SYMPTOM MANAG, V16, P277; Nugent M, 2001, J PAIN SYMPTOM MANAG, V21, P385, DOI 10.1016/S0885-3924(01)00257-3; Radbruch L, 2001, PALLIATIVE MED, V15, P309, DOI 10.1191/026921601678320296; SANDLER AN, 1994, ANESTHESIOLOGY, V81, P1169, DOI 10.1097/00000542-199411000-00010; VANBASTELAERE M, 1995, J CLIN ANESTH, V7, P26, DOI 10.1016/0952-8180(94)00000-T	14	26	26	1	3	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.		2003	17	8					714	716		10.1191/0269216303pm838cr			3	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	751LQ	WOS:000187068900010	14694924				2020-06-30	J	Janczewski, WA; Onimaru, H; Homma, I; Feldman, JL				Janczewski, WA; Onimaru, H; Homma, I; Feldman, JL			Opioid-resistant respiratory pathway from the preinspiratory neurones to abdominal muscles: in vivo and in vitro study in the newborn rat	JOURNAL OF PHYSIOLOGY-LONDON			English	Article							STEM-SPINAL-CORD; BETA-ENDORPHIN IMMUNOREACTIVITY; MEDULLARY EXPIRATORY NEURONS; RHYTHM-GENERATING NEURONS; NEONATAL RAT; CARBON-DIOXIDE; MOTONEURONS; NETWORK; CAT; DEPRESSION	We report that after spontaneous breathing movements are stopped by administration of opioids (opioid-induced apnoea) in neonatal rats, abdominal muscles continue to contract at a rate similar to that observed during periods of ventilation. Correspondingly, in vitro bath application of a mu opioid receptor agonist suppresses the activity of the fourth cervical root (C4) supplying the diaphragm, but not the rhythmic activity of the first lumbar root (L1) innervating the abdominal muscles. This indicates the existence of opioid-resistant rhythmogenic neurones and a neuronal pathway transmitting their activity to the abdominal motoneurones. We have investigated this pathway by using a brainstem-spinal cord preparation of the neonatal rat. We identified bulbospinal neurones with a firing pattern identical to that of the L1 root. These neurones were located caudal to the obex in the vicinity of the nucleus retroambiguus. Resting potentials ranged from -49 to -40 mV (mean +/- S.D. -44.0 +/- 4.3 mV). The mean input resistance was 315.5 +/- 54.8 MOmega. The mean antidromic latency from the L1 level was 42.8 +/- 4.4 ms. Axons crossed the midline at the level of the cell body. The activity pattern of the bulbospinal neurones and the L1 root consisted of two bursts per respiratory cycle with a silent period during inspiration. This pattern is characteristic of preinspiratory neurones. We found that 11% of the preinspiratory neurones projected to the area where the bulbospinal neurones were located. These preinspiratory neurones were found in the rostral ventrolateral medulla close (200-350 mum) to the ventral surface at the level of the rostral half of the nucleus retrofacialis. Our data suggest the operation of a disynaptic pathway from the preinspiratory neurones to the L1 motoneurones in the in vitro preparation. We propose that the same pathway is responsible for rhythmic activation of the abdominal muscles during opioid-induced apnoea in the newborn rat.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; Showa Univ, Sch Med, Dept Physiol, Shinagawa Ku, Tokyo 1428555, Japan	Janczewski, WA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Box 951763,10833 Conte Ave, Los Angeles, CA 90095 USA.			Feldman, Jack/0000-0003-3692-9412	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL 40959, R01 HL040959]		ARITA H, 1987, BRAIN RES, V401, P258, DOI 10.1016/0006-8993(87)91410-7; BAINTON CR, 1979, J PHYSIOL-LONDON, V296, P291, DOI 10.1113/jphysiol.1979.sp013006; BAINTON CR, 1978, J PHYSIOL-LONDON, V280, P249, DOI 10.1113/jphysiol.1978.sp012383; Ballanyi K, 1999, PROG NEUROBIOL, V59, P583, DOI 10.1016/S0301-0082(99)00009-X; Ballanyi K, 1997, J PHYSIOL-LONDON, V504, P127, DOI 10.1111/j.1469-7793.1997.127bf.x; BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Billig I, 2000, J NEUROSCI, V20, P7446; BOERS J, 1999, SOC NEUR ABSTR; Bonner G, 2000, EUR J PHARMACOL, V403, P37, DOI 10.1016/S0014-2999(00)00578-1; BRAGG P, 1995, J APPL PHYSIOL, V79, P1519; Brockhaus J, 1998, EUR J NEUROSCI, V10, P3823, DOI 10.1046/j.1460-9568.1998.00396.x; Colman AS, 2001, RESP PHYSIOL, V127, P157, DOI 10.1016/S0034-5687(01)00240-7; DAVIS PJ, 1986, CLIN PHARMACOKINET, V11, P18, DOI 10.2165/00003088-198611010-00002; De Troyer A, 1986, HDB PHYSL 3, V3, P443; FREGOSI RF, 1992, RESP PHYSIOL, V89, P179, DOI 10.1016/0034-5687(92)90049-3; Gray PA, 1999, SCIENCE, V286, P1566, DOI 10.1126/science.286.5444.1566; GREER JJ, 1995, J PHYSIOL-LONDON, V485, P845, DOI 10.1113/jphysiol.1995.sp020774; HOLSTEGE G, 1982, PROG BRAIN RES, V57, P145, DOI 10.1016/S0079-6123(08)64128-X; HOLSTEGE JC, 1987, NEUROSCIENCE, V23, P809, DOI 10.1016/0306-4522(87)90160-6; HOWARD RS, 1991, J PHYSIOL-LONDON, V437, P181, DOI 10.1113/jphysiol.1991.sp018590; Iizuka M, 1999, J PHYSIOL-LONDON, V520, P293, DOI 10.1111/j.1469-7793.1999.00293.x; Iscoe S, 1998, PROG NEUROBIOL, V56, P433, DOI 10.1016/S0301-0082(98)00046-X; Janczewski WA, 1999, NEUROSCI RES, V23, P276; JANSEN AH, 1991, J APPL PHYSIOL, V70, P1431; JANSEN AH, 1983, PHYSIOL REV, V63, P437; MEUCCI E, 1989, EUR J PHARMACOL, V171, P167, DOI 10.1016/0014-2999(89)90105-2; MILLER AD, 1985, J NEUROPHYSIOL, V54, P155; MYER EC, 1987, J PEDIATR-US, V111, P660, DOI 10.1016/S0022-3476(87)80239-1; ONIMARU H, 1992, PFLUG ARCH EUR J PHY, V420, P399, DOI 10.1007/BF00374476; ONIMARU H, 1988, BRAIN RES, V445, P314, DOI 10.1016/0006-8993(88)91194-8; ONIMARU H, 1995, EXP BRAIN RES, V106, P57; ONIMARU H, 1990, PFLUG ARCH EUR J PHY, V417, P425, DOI 10.1007/BF00370663; Onimaru H, 1997, JPN J PHYSIOL, V47, P385, DOI 10.2170/jjphysiol.47.385; ONIMARU H, 1987, NEUROSCI LETT, V78, P151, DOI 10.1016/0304-3940(87)90624-0; ONIMARU H, 1989, EXP BRAIN RES, V76, P530, DOI 10.1007/BF00248909; PAXINOS G, 1999, CHEMOARCHITECTONIC A; Sahibzada N, 2000, J PHARMACOL EXP THER, V292, P704; SASAKI SI, 1994, BRAIN RES, V648, P229, DOI 10.1016/0006-8993(94)91122-3; SHOOK JE, 1990, AM REV RESPIR DIS, V142, P895, DOI 10.1164/ajrccm/142.4.895; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149; SOUTHALL DP, 1985, LANCET, V2, P571; STORM H, 1994, EUR J PEDIATR, V153, P675, DOI 10.1007/BF02190691; SUZUE T, 1984, J PHYSIOL-LONDON, V354, P173, DOI 10.1113/jphysiol.1984.sp015370; Takeda S, 2001, ANESTHESIOLOGY, V95, P740, DOI 10.1097/00000542-200109000-00029; VanderHorst VGJM, 2000, J COMP NEUROL, V424, P233, DOI 10.1002/1096-9861(20000821)424:2<233::AID-CNE4>3.0.CO;2-C; Wang WG, 1996, J PHYSIOL-LONDON, V490, P277, DOI 10.1113/jphysiol.1996.sp021143; WINDH RT, 1995, J PHARMACOL EXP THER, V273, P1353; WIXSON SK, 1997, AM COLL LAB, P165	48	129	130	0	2	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4221 USA	0022-3751			J PHYSIOL-LONDON	J. Physiol.-London	DEC 15	2002	545	3					1017	1026		10.1113/jphysiol.2002.023408			10	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	631QK	WOS:000180178300024	12482904	Green Published			2020-06-30	J	Kampe, S; Nori, H; Kasper, SM; Diefenbach, C				Kampe, S; Nori, H; Kasper, SM; Diefenbach, C			Cesarian section and local anaesthesia: insufficient spread of spinal anaesthesia with hyperbaric bupivacaine 0.5%/5% glucose compared to hyperbaric bupivacaine 0.5%/8% glucose?	ANAESTHESIST			German	Article						cesarian section; density local anaesthetics; bupivacaine; fentanyl	ANESTHESIA; FENTANYL; DENSITY	In our hospital hyperbaric Carbostesin 0.5%(R) (AstraZeneca) had been substituted by hyperbaric Bucain 0.5%(R) fentanyl (Curasan) and both drugs were believed to be identical in their actions. However, both local anaesthetics differ in the amount of glucose they contain. We report about three patients who underwent cesarian section under spinal anaesthesia. In two patients we observed an insufficient spread of spinal anaesthesia after administration of hyperbaric Bucain 0.5%(R) The third patient received the normally used combination of hyperbaric Carbostesin 0.5%(R) and fentanyl and the subarachnoid block proceeded completely uneventfully. According to the literature the clinical efficacy of hyperbaric Carbostesin 0.5%(R) and hyperbaric Bucain 0.5%(R) should be identical and therefore a critical dilution of the Bucain should not have occurred because of the addition of fentanyl.	Univ Cologne, Klin Anasthesiol & Operat Intensivmed, D-50931 Cologne, Germany	Kampe, S (reprint author), Univ Cologne, Klin Anasthesiol & Operat Intensivmed, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.	Sandra.Kampe@medizin.uni-koeln.de					BANNISTER J, 1990, BRIT J ANAESTH, V64, P232, DOI 10.1093/bja/64.2.232; BARASH PG, 1997, CLIN ANESTH, P654; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; CHAMBERS WA, 1981, BRIT J ANAESTH, V53, P279, DOI 10.1093/bja/53.3.279; Hare GMT, 1998, CAN J ANAESTH, V45, P341, DOI 10.1007/BF03012026; Hempel V, 2001, ANASTH INTENSIVMED, V42, P619; Lui ACP, 1998, CAN J ANAESTH, V45, P297, DOI 10.1007/BF03012018; Parlow JL, 1999, CAN J ANAESTH, V46, P66, DOI 10.1007/BF03012518	9	0	0	0	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	DEC	2002	51	12					993	995		10.1007/s00101-002-0406-6			3	Anesthesiology	Anesthesiology	629HV	WOS:000180045000008	12486588				2020-06-30	J	Ben-David, B; DeMeo, PJ; Lucyk, C; Solosko, D				Ben-David, B; DeMeo, PJ; Lucyk, C; Solosko, D			Minidose lidocaine-fentanyl spinal anesthesia in ambulatory surgery: Prophylactic nalbuphine versus nalbuphine plus droperidol	ANESTHESIA AND ANALGESIA			English	Article							MORPHINE-INDUCED PRURITUS; EPIDURAL MORPHINE; OUTPATIENT LAPAROSCOPY; INFUSION; INHIBITION; NALOXONE; PREVENTION; OPIOIDS; NAUSEA	Minidose lidocaine-fentanyl spinal anesthesia (SAB(MLF)) is a safe, effective, and efficient anesthetic for ambulatory surgery. Unfortunately, it has a frequent incidence of pruritus and a substantial incidence of nausea and vomiting. Nalbuphine is effective in treating or preventing pruritus after intrathecal or epidural morphine but may or may not have a beneficial effect on nausea and vomiting. Droperidol has demonstrated antiemetic efficacy with neuraxial opiates. In this study, we examined the prophylactic use of nalbuphine alone compared with nalbuphine with droperidol after SAB(MLF). One-hundred-twenty-four patients having outpatient knee arthroscopy under SAB(MLF) with 20 mg of lidocaine 0.5% and 20 mug of fentanyl were randomized to receive W at the end of surgery either 4 mg of nalbuphine (Group N) or droperidol 0.625 mg plus nalbuphine 4 mg (Group ND). The incidences of early (before discharge) and late onset nausea were, respectively, 18% versus 5% and 32% versus 13%. The postoperative incidences of pruritus were 61% versus 40%, whereas 19% of patients in Group N compared with 2% of patients in Group ND requested treatment for this. Group ND had lower pain scores and had a longer delay until first use of analgesic. There were no differences in average times to discharge. The only side effect of the medications was an increased drowsiness in Group ND. In conclusion, as prophylactic medication for use in conjunction with SAB(MLF), the addition of droperidol 0.625 mg to nalbuphine 4 mg was superior to nalbuphine alone. The combination provided for reduced postoperative nausea, pruritus, and pain-benefits that persisted after discharge home. The combination also avoided isolated cases of extreme delay in discharge.	Allegheny Gen Hosp, Dept Anesthesiol, Pittsburgh, PA 15212 USA; Allegheny Gen Hosp, Dept Orthoped Surg, Pittsburgh, PA 15212 USA	Ben-David, B (reprint author), Allegheny Gen Hosp, Dept Anesthesia, 320 E N Ave, Pittsburgh, PA 15212 USA.	b.bendavid@verizon.net	DeMeo, Patrick/P-3232-2019				ALDRETE JA, 1995, J PAIN SYMPTOM MANAG, V10, P544, DOI 10.1016/0885-3924(95)00104-7; BACH V, 1986, ANAESTHESIA, V41, P1116, DOI 10.1111/j.1365-2044.1986.tb12959.x; Ben-David B, 2000, ANESTH ANALG, V91, P865, DOI 10.1097/00000539-200010000-00018; Ben-David B, 2001, ANESTH ANALG, V93, P319, DOI 10.1097/00000539-200108000-00016; BenDavid B, 1997, ANESTH ANALG, V85, P560, DOI 10.1097/00000539-199709000-00014; Charuluxananan S, 2001, ANESTH ANALG, V93, P162; COHEN SE, 1992, ANESTH ANALG, V75, P747; Henzi I, 2000, CAN J ANAESTH, V47, P537, DOI 10.1007/BF03018945; HORTA ML, 1993, REGION ANESTH, V18, P118; Horta ML, 1996, REGION ANESTH, V21, P312; Horta ML, 2000, ANESTH ANALG, V90, P638, DOI 10.1097/00000539-200003000-00025; Kendrick WD, 1996, ANESTH ANALG, V82, P641, DOI 10.1097/00000539-199603000-00037; Kjellberg F, 2001, EUR J ANAESTH, V18, P346, DOI 10.1046/j.0265-0215.2000.00826.x; Kotake Y, 2000, J CLIN ANESTH, V12, P9, DOI 10.1016/S0952-8180(99)00113-0; LIU S, 1995, ANESTH ANALG, V80, P730, DOI 10.1097/00000539-199504000-00014; Macario A, 1999, ANESTH ANALG, V89, P652, DOI 10.1097/00000539-199909000-00022; MORGAN PJ, 1991, REGION ANESTH, V16, P84; Mulroy MF, 2001, REGION ANESTH PAIN M, V26, P252, DOI 10.1053/rapm.2001.22997; Sanansilp V, 1998, ANESTH ANALG, V86, P532, DOI 10.1097/00000539-199803000-00016; Somrat C, 1999, J Obstet Gynaecol Res, V25, P209; Vaghadia H, 1997, ANESTH ANALG, V84, P59, DOI 10.1097/00000539-199701000-00011; Vaghadia H, 2001, CAN J ANAESTH, V48, P256, DOI 10.1007/BF03019755; Wang JJ, 1996, REGION ANESTH, V21, P214; Wang JJ, 1998, REGION ANESTH PAIN M, V23, P479, DOI 10.1016/S1098-7339(98)90031-1	24	16	19	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2002	95	6					1596	1600		10.1097/00000539-200212000-00023			5	Anesthesiology	Anesthesiology	622KK	WOS:000179646100023	12456423				2020-06-30	J	Chen, XG; Tang, J; White, PF; Wender, RH; Ma, H; Sloninsky, A; Kariger, R				Chen, XG; Tang, J; White, PF; Wender, RH; Ma, H; Sloninsky, A; Kariger, R			A comparison of patient state index and bispectral index values during the perioperative period	ANESTHESIA AND ANALGESIA			English	Article							SPECTRAL EDGE FREQUENCY; PROPOFOL; RECOVERY; CONSCIOUSNESS; ALFENTANIL; ANESTHESIA; MIDAZOLAM; DEPTH	The patient state index (PSI), a quantitative electroencephalographic index, has been recently introduced into clinical practice as a monitor for assessing consciousness during sedation and general anesthesia. We designed this observational study to compare the sensitivity and specificity of the PSI with that of the bispectral index (BIS) with respect to their ability to predict the loss of consciousness and emergence from anesthesia, as well as to assess changes in IV (propofol) and inhaled (desflurane) anesthetics during the maintenance period. Twenty consenting patients scheduled for elective laparoscopic surgical procedures were enrolled in this prospective clinical study. Anesthesia was induced with propofol 2 mg/kg IV and fentanyl 1 mug/kg IV, and tracheal intubation was facilitated with cisatracurium 0.3 mg/kg IV. Desflurane 4% in combination with nitrous oxide 60% in oxygen was administered for the maintenance of anesthesia. Comparative PSI and BIS values were obtained at specific time intervals during the induction, maintenance, and emergence periods. The changes in these indices were recorded after the administration of propofol (20 mg IV) or with 2% increases or decreases in the inspired concentration of desflurane during the maintenance period. With logistic regression models, both the BIS and PSI were found to be effective as predictors of unconsciousness (i.e., failed to respond to verbal stimuli) (P < 0.01). The PSI also correlated with the BIS during both the induction of (r = 0.78) and emergence from (r = 0.73) general anesthesia. However, the area under the receiver operating characteristic curve for detection of consciousness indicated a better performance with the PSI (0.95 +/- 0.04) than the BIS (0.79 +/- 0.04). During the maintenance period, the PSI values were comparable to the BIS in response to changes in propofol and desflurane but displayed greater interpatient variability. Finally, the PSI (versus BIS) values were less interfered with by the electrocautery unit during surgery (16% versus 65%, respectively). In conclusion, the PSI may prove to be a viable alternative to the BIS for evaluating consciousness during the induction of and emergence from general anesthesia, as well as for titrating the administration of propofol and desflurane during the maintenance period. However, further studies with the PSA device are needed to determine its role in anesthesia.	Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Dallas, TX 75390 USA; Cedars Sinai Med Ctr, Dept Anesthesiol, Los Angeles, CA 90048 USA	White, PF (reprint author), Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, 5323 Harry Hines Blvd,F2-208, Dallas, TX 75390 USA.	paul.white@utsouthwestern.edu					Chabot RJ, 1997, CLIN ELECTROENCEPHAL, V28, P98, DOI 10.1177/155005949702800207; DUTTON RC, 1987, CONSCIOUSNESS AWAREN, P72; Flaishon R, 1997, ANESTHESIOLOGY, V86, P613, DOI 10.1097/00000542-199703000-00013; Gan TJ, 1997, ANESTHESIOLOGY, V87, P808, DOI 10.1097/00000542-199710000-00014; GHOURI AF, 1993, J CLIN MONITOR, V9, P176, DOI 10.1007/BF01617025; Glass PS, 1997, ANESTHESIOLOGY, V86, P836, DOI 10.1097/00000542-199704000-00014; Gugino LA, 2001, BRIT J ANAESTH, V87, P421, DOI 10.1093/bja/87.3.421; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Heier T, 1996, ACTA ANAESTH SCAND, V40, P1087, DOI 10.1111/j.1399-6576.1996.tb05570.x; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; LEVY WJ, 1980, ANESTHESIOLOGY, V53, P223, DOI 10.1097/00000542-198009000-00009; Liu J, 1996, ANESTHESIOLOGY, V84, P64, DOI 10.1097/00000542-199601000-00007; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; PIERCE ET, 2001, ANESTHESIOLOGY, V95, pA283; PRICHEP LS, 2000, MEMORY AWARENESS ANE, V4, P97; RAMPIL IJ, 1987, ANESTHESIOLOGY, V67, P139, DOI 10.1097/00000542-198707000-00033; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Sebel PS, 1997, ANESTH ANALG, V84, P891, DOI 10.1097/00000539-199704000-00035; Song DJ, 1997, ANESTHESIOLOGY, V87, P842, DOI 10.1097/00000542-199710000-00018; STANSKI DR, 1986, ANESTHESIA, P1001; TINKER JH, 1977, ANESTHESIOLOGY, V46, P252, DOI 10.1097/00000542-197704000-00005; WHITE PF, 1989, ANESTH ANALG, V68, P177, DOI 10.1213/00000539-198902000-00020	22	40	42	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	DEC	2002	95	6					1669	1674		10.1097/00000539-200212000-00036			6	Anesthesiology	Anesthesiology	622KK	WOS:000179646100036	12456436				2020-06-30	J	Kang, YJ; Vincler, M; Li, XH; Conklin, D; Eisenach, JC				Kang, YJ; Vincler, M; Li, XH; Conklin, D; Eisenach, JC			Intrathecal ketorolac reverses hypersensitivity following acute fentanyl exposure	ANESTHESIOLOGY			English	Article							SPINAL PROSTAGLANDIN E-2; OPIOID TOLERANCE; HYPERALGESIA; RAT; CYCLOOXYGENASE; MORPHINE; REMIFENTANIL; INHIBITION; PAIN; WITHDRAWAL		Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Study Pharmacol Plast Presence Pain, Winston Salem, NC 27157 USA	Eisenach, JC (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 48085]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 41386]		Celerier E, 2000, ANESTHESIOLOGY, V92, P465, DOI 10.1097/00000542-200002000-00029; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; Chia YT, 1999, CAN J ANAESTH, V46, P872, DOI 10.1007/BF03012978; DECONNO F, 1991, PAIN, V47, P337, DOI 10.1016/0304-3959(91)90225-M; Dunbar SA, 1998, J PHARMACOL EXP THER, V284, P678; Dunbar SA, 2000, ANESTH ANALG, V91, P417, DOI 10.1097/00000539-200008000-00035; Eisenach JC, 2000, ANESTHESIOLOGY, V92, P308, DOI 10.1097/00000542-200002000-00009; Guhring H, 2000, J NEUROSCI, V20, P6714, DOI 10.1523/JNEUROSCI.20-17-06714.2000; Guignard B, 2000, ANESTHESIOLOGY, V93, P409, DOI 10.1097/00000542-200008000-00019; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Lashbrook JM, 1999, PAIN, V82, P65, DOI 10.1016/S0304-3959(99)00031-7; Laulin JP, 1999, NEUROSCIENCE, V89, P631, DOI 10.1016/S0306-4522(98)00652-6; MALMBERG AB, 1992, J PHARMACOL EXP THER, V263, P136; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; MISER AW, 1986, AM J DIS CHILD, V140, P603, DOI 10.1001/archpedi.1986.02140200113039; Petersen KL, 2001, ANESTHESIOLOGY, V94, P15, DOI 10.1097/00000542-200101000-00008; Powell KJ, 1999, BRIT J PHARMACOL, V127, P631, DOI 10.1038/sj.bjp.0702587; Schwab JM, 2000, J NEUROIMMUNOL, V111, P122, DOI 10.1016/S0165-5728(00)00372-6; SJOGREN P, 1993, PAIN, V55, P93, DOI 10.1016/0304-3959(93)90188-U; Versteeg HH, 1999, FEBS LETT, V445, P1, DOI 10.1016/S0014-5793(99)00105-2; Vinik HR, 1998, ANESTH ANALG, V86, P1307, DOI 10.1097/00000539-199806000-00033; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Willingale HL, 1997, BRIT J PHARMACOL, V122, P1593, DOI 10.1038/sj.bjp.0701548; Yaksh TL, 2001, J NEUROSCI, V21, P5847; Yaksh TL, 1976, PHYSIOL BEHAV, V7, P1032	26	5	8	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	DEC	2002	97	6					1641	1644		10.1097/00000542-200212000-00046			4	Anesthesiology	Anesthesiology	621LN	WOS:000179590500045	12459700				2020-06-30	J	Abdallah, C; Karsli, C; Bissonnette, B				Abdallah, C; Karsli, C; Bissonnette, B			Fentanyl is more effective than remifentanil at preventing increases in cerebral blood flow velocity during intubation in children	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 13-17, 2001	NEW ORLEANS, LOUISIANA	Amer Soc Anesthesiologists			TRANSCRANIAL DOPPLER; HEMODYNAMIC-RESPONSE; CARBON-DIOXIDE; PHARMACOKINETICS; SEVOFLURANE; SUFENTANIL; GI87084B; PRESSURE; HUMANS; PHARMACODYNAMICS	Purpose: Controlling the cerebral and systemic hemodynamic responses to laryngoscopy and tracheal intubation may play a role in determining clinical outcome in pediatric neurosurgical patients. This study compared the effects of remifentanil and fentanyl on cerebral blood flow velocity (CBFV) and hemodynamic profile during laryngoscopy and tracheal intubation in children under sevoflurane anesthesia. Methods: Sixty healthy children aged two to six years undergoing dental surgery under general anesthesia were enrolled. Each child was randomly assigned to receive a remifentanil or fentanyl infusion, at a rate of 0.75, 1.0, or 1.5 mug(.)kg(-1.)min(-1) after induction of anesthesia with 2% sevoflurane. Middle cerebral artery blood flow velocity was measured by transcranial Doppler (TCD) sonography. Once a baseline set of hemodynamic variables and TCD measurements were recorded, the opioid infusion was started. Measurements were taken at two-minute intervals, starting four minutes prior to laryngoscopy until four minutes following naso-tracheal intubation. Results: Remifentanil caused a more significant decrease in mean arterial pressure and CBFV prior to tracheal intubation than did fentanyl (P < 0.001). During laryngoscopy and for two minutes following tracheal intubation, CBFV increased in all remifentanil groups (P < 0.05), whereas it remained stable in all fentanyl groups. Conclusion: This study suggests that fentanyl was more effective than remifentanil at preventing increases in CBFV during and immediately following laryngoscopy and tracheal intubation in children undergoing sevoflurane anesthesia. Fentanyl also seemed to provide a more stable hemodynamic profile prior to laryngoscopy and tracheal intubation when compared to remifentanil.	Hosp Sick Children, Dept Anesthesia, Toronto, ON M5G 1X8, Canada; Univ Toronto, Toronto, ON, Canada	Bissonnette, B (reprint author), Hosp Sick Children, Dept Anesthesia, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.						Alexander R, 1999, ANAESTHESIA, V54, P1037, DOI 10.1046/j.1365-2044.1999.00904.x; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; Bissonnette B, 1998, CAN J ANAESTH, V45, P199, DOI 10.1007/BF03012902; Cho S, 1996, ANESTHESIOLOGY, V85, P755, DOI 10.1097/00000542-199610000-00010; DAHLGREN N, 1981, ANAESTHESIA, V36, P1022, DOI 10.1111/j.1365-2044.1981.tb08676.x; EGAN TD, 1993, ANESTHESIOLOGY, V79, P881, DOI 10.1097/00000542-199311000-00004; EGAN TD, 2000, CLIN APPL SHORT ACTI; FAIRGRIEVE R, 2000, ANESTHESIOLOGY, V93, pA1305; GILLER CA, 1993, NEUROSURGERY, V32, P737, DOI 10.1227/00006123-199305000-00006; Glass PSA, 1999, ANESTHESIOLOGY, V90, P1556, DOI 10.1097/00000542-199906000-00010; GLASS PSA, 1993, ANESTH ANALG, V77, P1031; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Gupta S, 1997, BRIT J ANAESTH, V79, P469, DOI 10.1093/bja/79.4.469; Hanel F, 1997, J NEUROSURG ANESTH, V9, P223; Huber P, 1967, Invest Radiol, V2, P17, DOI 10.1097/00004424-196701000-00016; Jhaveri R, 1997, ANESTHESIOLOGY, V87, P253, DOI 10.1097/00000542-199708000-00011; Kolbitsch C, 1997, J NEUROSURG ANESTH, V9, P313, DOI 10.1097/00008506-199710000-00004; Kovac AL, 1996, J CLIN ANESTH, V8, P63, DOI 10.1016/0952-8180(95)00147-6; Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019; MAYER N, 1990, ANESTHESIOLOGY, V73, P240, DOI 10.1097/00000542-199008000-00009; MILLAR C, 1994, CAN J ANAESTH, V41, P281, DOI 10.1007/BF03009904; NEWELL DW, 1994, STROKE, V25, P793, DOI 10.1161/01.STR.25.4.793; Ostapkovich ND, 1998, ANESTHESIOLOGY, V89, P358, DOI 10.1097/00000542-199808000-00011; PILATO MA, 1991, CAN J ANAESTH, V38, P37, DOI 10.1007/BF03009161; Rosow CE, 1999, ANESTH ANALG, V89, pS1; SANDOR P, 1986, BRAIN RES, V386, P122, DOI 10.1016/0006-8993(86)90148-4; STEPHAN H, 1991, ANAESTHESIST, V40, P153; Thompson JP, 1998, BRIT J ANAESTH, V80, P467, DOI 10.1093/bja/80.4.467; THOMSON IR, 1989, CAN J ANAESTH, V36, P367, DOI 10.1007/BF03005331; WERNER C, 1991, ANESTH ANALG, V72, P177, DOI 10.1213/00000539-199102000-00006; WESTMORELAND CL, 1993, ANESTHESIOLOGY, V79, P893, DOI 10.1097/00000542-199311000-00005	31	16	16	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	DEC	2002	49	10					1070	1075		10.1007/BF03017905			6	Anesthesiology	Anesthesiology	633DH	WOS:000180263600013	12477681	Bronze			2020-06-30	J	Nakayama, M; Hayashi, M; Kanaya, N; Namiki, A				Nakayama, M; Hayashi, M; Kanaya, N; Namiki, A			Fentanyl abolishes the hyperdynamic response to isoflurane without affecting the change in bispectral index	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Letter							RAPID INCREASE									EBERT TJ, 1993, ANESTHESIOLOGY, V79, P444, DOI 10.1097/00000542-199309000-00006; Nakayama M, 2001, CAN J ANAESTH, V48, P958, DOI 10.1007/BF03016584; RANDELL T, 1991, ACTA ANAESTH SCAND, V35, P600, DOI 10.1111/j.1399-6576.1991.tb03356.x; TANAKA S, 1994, ANESTHESIOLOGY, V81, P1341, DOI 10.1097/00000542-199412000-00007; YLIHANKALA A, 1993, ANESTHESIOLOGY, V78, P266, DOI 10.1097/00000542-199302000-00009	5	2	2	0	0	CANADIAN ANESTHESIOLOGISTS SOC	TORONTO	1 EGLINTON AVE EAST, SUITE 208, TORONTO, ONTARIO M4P 3A1, CANADA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	DEC	2002	49	10					1100	1101		10.1007/BF03017915			2	Anesthesiology	Anesthesiology	633DH	WOS:000180263600023	12477690	Bronze			2020-06-30	J	Bowler, I; Djaiani, G; Abel, R; Pugh, S; Dunne, J; Hall, J				Bowler, I; Djaiani, G; Abel, R; Pugh, S; Dunne, J; Hall, J			A combination of intrathecal morphine and remifentanil anesthesia for fast-track cardiac anesthesia and surgery	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article						fast-track cardiac anesthesia (FTCA); cardiac surgery; remifentanil; intrathecal morphine; early extubation; pulmonary function tests	THORACIC EPIDURAL ANALGESIA; BYPASS GRAFT-SURGERY; EARLY EXTUBATION; TRACHEAL EXTUBATION; CORONARY; PROPOFOL; FENTANYL; TRIAL; CARE; UNIT	Objective: To determine if the combined remifentanil and intrathecal morphine (RITM) anesthetic technique facilitates early extubation in patients undergoing coronary artery bypass graft (CABG) surgery. Design: Prospective, randomized, controlled clinical trial. Setting: Referral center for cardiothoracic surgery at a university hospital. Participants: Patients (n = 24) undergoing first-time elective CABG surgery. Interventions: Two groups represented RITM (n = 12) and fentanyl-based (controls, n = 12) anesthesia. Premedication was standardized to temazepam, 0.4 mg/kg, and anesthesia was induced with etomidate, 0.3 mg/kg, in both groups. The RITM group received remifentanil, 1 mug/kg bolus followed by 0.25 to 1 mug/kg/min infusion, and intrathecal morphine, 2 mg. The control group received fentanyl, 12 mug/kg in 3 divided doses. Anesthesia was maintained with isoflurane and pancuronium in both groups. After completion of surgery, the remifentanil infusion was stopped. Complete reversal of muscle relaxation was ensured with a nerve stimulator, and a propofol infusion, 0.5 to 3 mg/kg/h, was started in both groups. All patients were transferred to the intensive care unit (ICU) to receive standardized postoperative care. Intensivists and ICU nurses were blinded to the group assignment. Propofol infusion was stopped, and the tracheal extubation was accomplished when extubation criteria were fulfilled. Measurements and Main Results: Both groups were similar with respect to demographic data and surgical characteristics. Extubation times were 156 +/- 82 minutes and 258 +/- 91 minutes in the RITM and control groups (p = 0.012). Patients in the RITM group exhibited lower visual analog scale pain scores during the first 2 hours after extubation (p < 0.04). Morphine requirements during the 24 hours after extubation were 2.5 +/- 3 mg in the RITM group and 16 +/- 11 mg in the control group (p = 0.0018). Sedation scores were lower in the RITM group during the first 3 hours after extubation (p < 0.03). Pulmonary function tests as assessed by spirometry were better in the RITM group at 6 and 12 hours after extubation (p < 0.04). There were no significant differences in PaO2 and PaCO2 after extubation between the 2 groups. None of the patients had episodes of apnea during the immediate 24-hour postextubation period. Two patients from the RITM group required reintubation on the second and sixth postoperative days. There were no differences in ICU and hospital length of stay between the 2 groups. Conclusion: Implementation of the RITM technique provided earlier tracheal extubation, decreased level of sedation, excellent analgesia, and improved spirometry in the early postoperative period. The impact of RITM on ICU and hospital length of stay and potential cost benefits require further evaluation. Copyright 2002 Elsevier Science (USA). All rights reserved.	Univ Toronto, Toronto Gen Hosp, Div Cardiac Anesthesia & Intens Care, Toronto, ON M5G 2C4, Canada; Univ Wales Hosp, Dept Anesthesia, Cardiff, S Glam, Wales	Djaiani, G (reprint author), Univ Toronto, Toronto Gen Hosp, Div Cardiac Anesthesia & Intens Care, Eaton N 3-410,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	george.djaiani@uhn.on.ca					Ahonen J, 2000, ANESTH ANALG, V90, P1269, DOI 10.1097/00000539-200006000-00003; AUN C, 1985, EUR J ANAESTH, V2, P419; Chaney MA, 1999, J CARDIOTHOR VASC AN, V13, P574, DOI 10.1016/S1053-0770(99)90010-1; Chaney MA, 1997, ANESTH ANALG, V84, P241, DOI 10.1097/00000539-199702000-00002; Chaney MA, 1996, ANESTH ANALG, V83, P215, DOI 10.1097/00000539-199608000-00003; CHANEY MA, 1995, CAN J ANAESTH, V42, P891, DOI 10.1007/BF03011037; Cheng DCH, 1996, J THORAC CARDIOV SUR, V112, P755, DOI 10.1016/S0022-5223(96)70062-4; Cheng DCH, 1996, ANESTHESIOLOGY, V85, P1300, DOI 10.1097/00000542-199612000-00011; Cheng DCH, 1998, ANESTHESIOLOGY, V88, P1429, DOI 10.1097/00000542-199806000-00002; Cheng DCH, 2001, ANESTH ANALG, V92, P1094; Djaiani GN, 2001, J CARDIOTHOR VASC AN, V15, P152, DOI 10.1053/jcan.2001.21936; Fawcett WJ, 1997, ANAESTHESIA, V52, P294, DOI 10.1111/j.1365-2044.1997.80-az0088.x; FITZPATRICK GJ, 1998, BRIT J ANAESTH, V60, P639; GALL SA, 1988, J THORAC CARDIOV SUR, V95, P819; Goldstein S, 2001, J CARDIOTHOR VASC AN, V15, P158, DOI 10.1053/jcan.2001.21937; Hadjinikolaou L, 2000, ANN ROY COLL SURG, V82, P53; HICKEY RF, 1995, J CARDIAC SURG, V10, P340, DOI 10.1111/j.1540-8191.1995.tb00621.x; Howie MB, 2001, ANESTH ANALG, V92, P1084; Liem T H, 1992, J Cardiothorac Vasc Anesth, V6, P156; Liem T H, 1992, J Cardiothorac Vasc Anesth, V6, P162; MANGANO DT, 1992, ANESTHESIOLOGY, V76, P342, DOI 10.1097/00000542-199203000-00004; MATHEWS ET, 1980, LANCET, V2, P543; MOORE CM, 1995, BRIT J ANAESTH, V75, P387, DOI 10.1093/bja/75.4.387; Olivier P, 2000, J CARDIOTHOR VASC AN, V14, P29, DOI 10.1016/S1053-0770(00)90052-1; Shroff A, 1997, J CLIN ANESTH, V9, P415, DOI 10.1016/S0952-8180(97)00081-0; STENSETH R, 1994, ACTA ANAESTH SCAND, V38, P834, DOI 10.1111/j.1399-6576.1994.tb04014.x; Stenseth R, 1996, EUR J CARDIO-THORAC, V10, P859, DOI 10.1016/S1010-7940(96)80311-3; Taylor A, 1996, J CARDIOTHOR VASC AN, V10, P225, DOI 10.1016/S1053-0770(96)80242-4; VANSTRUM GS, 1988, ANESTH ANALG, V67, P261; Zarate E, 2000, ANESTH ANALG, V91, P283	30	36	40	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1053-0770	1532-8422		J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	DEC	2002	16	6					709	714		10.1053/jcan.2002.128414			6	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	626CY	WOS:000179855800008	12486651				2020-06-30	J	Paradis, C; Dufresne, C; Bolon, M; Boulieu, R				Paradis, C; Dufresne, C; Bolon, M; Boulieu, R			Solid-phase microextraction of human plasma samples for determination of sufentanil by gas chromatography-mass spectrometry	THERAPEUTIC DRUG MONITORING			English	Article						sufentanil; morphinomimetics; solid-phase microextraction; biological samples; gas chromatography; mass spectrometry	BIOLOGICAL SAMPLES; MICRO-EXTRACTION; ASSAY; ALFENTANIL; RADIOIMMUNOASSAY; CLOZAPINE	A solid-phase microextraction (SPME) method has been developed for the quantitative analysis of sufentanil from human plasma by gas chromatography-mass spectrometry (GC-MS). The immersion SPME sampling technique was optimized for the extraction of sufentanil from plasma. The influence of the pH and the ionic strength of the sample on the extraction of the analytes by the SPME fiber were investigated. Sufentanil and fentanyl (internal standard) were extracted from plasma with a 65-mum polydimethylsiloxane-divinylbenzene (PDMS-DVB) fiber for 30 minutes using salting out agents in basic conditions. The calibration curve was linear over a concentration range of 6-50 ng/mL. Intraday and interday relative standard deviations were 3.6% and 10.6%, respectively. The limit of quantification was 6 ng/mL for a plasma volume of 1 mL. With regard to selectivity, simplicity, and low cost, the SPME method described should be useful for a rapid extraction of sufentanil from human plasma.	Univ Lyon 1, ISPB, Dept Pharm Clin Pharmacocinet & Evaluat Medicamen, F-69373 Lyon 08, France; Hop NeuroCardiol, Lab Pharmacocinet Clin, Lyon, France	Boulieu, R (reprint author), Univ Lyon 1, ISPB, Dept Pharm Clin Pharmacocinet & Evaluat Medicamen, 8 Ave Rockefeller, F-69373 Lyon 08, France.						ARTHUR CL, 1990, ANAL CHEM, V62, P2145, DOI 10.1021/ac00218a019; BANSAL R, 1995, J LIQ CHROMATOGR, V18, P339, DOI 10.1080/10826079508009243; Dufresne C, 2001, CLIN CHEM, V47, P600; Eisert R, 1997, CRIT REV ANAL CHEM, V27, P103, DOI 10.1080/10408349708050585; Krogh M, 1997, J CHROMATOGR B, V689, P357, DOI 10.1016/S0378-4347(96)00352-0; KROGH M, 1995, J CHROMATOGR B, V673, P299, DOI 10.1016/0378-4347(95)00273-8; Kruggel S, 1999, FRESEN J ANAL CHEM, V364, P654, DOI 10.1007/s002160051407; Kruggel S, 2000, THER DRUG MONIT, V22, P723, DOI 10.1097/00007691-200012000-00012; LEMMENS HJM, 1995, ANAESTH PHARM REV, V3, P67; MICHIELS M, 1983, J PHARM PHARMACOL, V35, P86, DOI 10.1111/j.2042-7158.1983.tb04275.x; Pawliszyn J., 1999, APPL SOLID PHASE MIC; Pawliszyn J., 1997, SOLID PHASE MICROEXT; Reubsaet KJ, 1998, J PHARMACEUT BIOMED, V18, P667; Rossi SS, 1996, CLIN CHIM ACTA, V244, P103, DOI 10.1016/0009-8981(95)06195-9; Rovio S, 1997, J LIQ CHROMATOGR R T, V20, P1311, DOI 10.1080/10826079708010978; Scheppers Wercinski S.A., 1999, SOLID PHASE MICROEXT; Snow NH, 2000, J CHROMATOGR A, V885, P445, DOI 10.1016/S0021-9673(00)00192-8; Theodoridis G, 2000, J CHROMATOGR B, V745, P49, DOI 10.1016/S0378-4347(00)00203-6; Ulrich S, 1999, J CHROMATOGR B, V731, P231, DOI 10.1016/S0378-4347(99)00230-3; WOESTENBORGHS R, 1981, J CHROMATOGR, V224, P122, DOI 10.1016/S0378-4347(00)80145-0; WOESTENBORGHS RJH, 1994, ANESTHESIOLOGY, V80, P666, DOI 10.1097/00000542-199403000-00025	21	22	22	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0163-4356			THER DRUG MONIT	Ther. Drug Monit.	DEC	2002	24	6					768	774		10.1097/00007691-200212000-00014			7	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	617GL	WOS:000179353700014	12451295				2020-06-30	J	Enserink, M; Stone, R				Enserink, M; Stone, R			Toxicology - Questions swirl over knockout gas used in hostage crisis	SCIENCE			English	News Item																	0	9	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 8	2002	298	5596					1150	1151		10.1126/science.298.5596.1150			2	Multidisciplinary Sciences	Science & Technology - Other Topics	612MQ	WOS:000179080400002	12424343				2020-06-30	J	Schiermeier, Q				Schiermeier, Q			Hostage deaths put gas weapons in spotlight	NATURE			English	News Item																	0	15	15	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 7	2002	420	6911					7	7		10.1038/420007a			1	Multidisciplinary Sciences	Science & Technology - Other Topics	612HJ	WOS:000179068100011	12422177	Bronze			2020-06-30	J	Okutomi, T; Hoshino, Y; Amano, K; Okamoto, H; Hoka, S				Okutomi, T; Hoshino, Y; Amano, K; Okamoto, H; Hoka, S			Intrathecal fentanyl/meperidine combined with low-dose epidural bupivacaine for Cesarean section in a patient with advanced Krukenberg tumors	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						cesarean section; intrathecal opioids; Krukenberg tumor; malignant ascites	PREGNANCY; MEPERIDINE; CANCER; LABOR; BLOCK	This case report demonstrates the anesthetic management of a 41-year-old primiparous parturient with massive ascites due to advanced Krukenberg tumors, undergoing Cesarean section. We chose a combined intrathecal-epidural technique, using intrathecal hypobaric fentanyl and hyperbaric meperidine, and a low dose of epidural bupivacaine in order to avoid hemodynamic instability in this critically ill patient. Surgery was carried out without difficulty under adequate regional anesthesia. The blood pressure was maintained with low doses of phenylephrine and dopamine. Opioid-related complications such as nausea-vomiting, pruritus, drowsiness, and respiratory depression were not observed in this patient. Therefore, intrathecal opioids combined with a low dose of epidural local anesthetics for Cesarean section is suitable for critically ill patients with malignant abdominal tumors, such as a Krukenberg tumor, complicated by massive ascites.	Kitasato Univ, Dept Anesthesiol, Sch Med, Kanagawa 2288555, Japan; Kitasato Univ, Dept Obstet & Gynecol, Sch Med, Kanagawa 2288555, Japan	Okutomi, T (reprint author), Kitasato Univ, Dept Anesthesiol, Sch Med, 1-15-1 Kitasato, Kanagawa 2288555, Japan.						Booth JV, 2000, ANESTHESIOLOGY, V93, P418, DOI 10.1097/00000542-200008000-00020; Chan YM, 1999, J REPROD MED, V44, P986; CHEUN J K, 1989, Journal of Korean Medical Science, V4, P135; Gaiser RR, 1998, J CLIN ANESTH, V10, P488, DOI 10.1016/S0952-8180(98)00076-2; Hagen A, 1998, EUR J OBSTET GYN R B, V80, P273, DOI 10.1016/S0301-2115(98)00102-X; KAFLE SK, 1993, CAN J ANAESTH, V40, P718, DOI 10.1007/BF03009767; Kodama Issei, 1997, Kurume Medical Journal, V44, P179; Lee A, 2002, ANESTH ANALG, V94, P920, DOI 10.1097/00000539-200204000-00028; RAWAL N, 1988, ACTA ANAESTH SCAND, V32, P61, DOI 10.1111/j.1399-6576.1988.tb02689.x; REDDY SVR, 1980, BRAIN RES, V189, P391; Sandmeier D, 2000, EUR J GYNAECOL ONCOL, V21, P58; Stienstra R, 1999, ANESTH ANALG, V88, P810, DOI 10.1097/00000539-199904000-00024; THOREN T, 1994, ANESTH ANALG, V78, P1087; UEO H, 1991, WORLD J SURG, V15, P293, DOI 10.1007/BF01659068; YAKUSHIJI M, 1987, Acta Obstetrica et Gynaecologica Japonica (Japanese Edition), V39, P479	15	5	5	0	0	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	NOV	2002	46	10					1272	1275		10.1034/j.1399-6576.2002.461016.x			4	Anesthesiology	Anesthesiology	612AK	WOS:000179050800016	12421201				2020-06-30	J	Weinbroum, AA; Glick, A; Copperman, Y; Yashar, T; Rudick, V; Flaishon, R				Weinbroum, AA; Glick, A; Copperman, Y; Yashar, T; Rudick, V; Flaishon, R			Halothane, isoflurane, and fentanyl increase the minimally effective defibrillation threshold of an implantable cardioverter defibrillator: First report in humans	ANESTHESIA AND ANALGESIA			English	Article							HIGH-RISK; PROPOFOL; SEDATION; ANESTHETICS; PHARMACOKINETICS; PHARMACODYNAMICS; ENFLURANE; RECOVERY	Placing an implantable cardioverter defibrillator (ICD) involves the induction of ventricular fibrillation, whereupon the minimally effective defibrillation energy threshold (DFT) is determined. We evaluated the effects of 0.7% halothane, 1% isoflurane, or 1.5 mug/kg of IV fentanyl during N2O/oxygen-based general anesthesia (GA) or those of subcutaneous 1.5% lidocaine plus IV 0.35 mg/kg of propofol on the DFT during ICD implantation in humans (n = 20 per group). Thirty minutes after the first set of DFT measurements under such conditions, the inhaled anesthetics were withdrawn, and all three GA groups received fentanyl I mug/kg TV (second set). A third set was taken 30 min later, before the GA patients awakened and when only NC/oxygen was delivered for GA. The lidocaine plus propofol patients were given the same rV propofol bolus 1 min before each fibrillation/ defibrillation trial and at the same time points as the three GA groups. The first DFTs were 16.1 +/- 2.2 J (halothane), 17.7 +/- 2.7 J (isoflurane), 16.4 +/- 2.9 J (fentanyl), and 12.9 +/- 3.81J (lidocaine plus propofol) (P = 0.01). The second set of DFTs were significantly lower than the first sets for the halothane (P = 0.01) and isoflurane (P = 0.02), but not the fentanyl or lidocaine plus propofol, regimens. The third DFTs were significantly (P < 0.01) lower than the first ones for the three GA groups, but not for the lidocaine plus propofol patients. Thus, halothane, isoflurane, and fentanyl increased DFT values during ICD implantation in humans, whereas lidocaine plus intermittent small-dose IV propofol minimized these thresholds.	Tel Aviv Sourasky Med Ctr, Post Anesthesia Care Unit, IL-64239 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Anesthesiol & Crit Care, IL-64239 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Cardiol, IL-64239 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Weinbroum, AA (reprint author), Tel Aviv Sourasky Med Ctr, Post Anesthesia Care Unit, 6 Weizman St, IL-64239 Tel Aviv, Israel.	draviw@tasmc.health.gov.il					ATLEE JL, 1986, ANESTHESIOLOGY, V64, P703, DOI 10.1097/00000542-198606000-00005; Bigger JT, 1997, NEW ENGL J MED, V337, P1569, DOI 10.1056/NEJM199711273372201; Buxton AE, 1999, NEW ENGL J MED, V341, P1882, DOI 10.1056/NEJM199912163412503; Canessa R, 1991, J Cardiothorac Vasc Anesth, V5, P566, DOI 10.1016/1053-0770(91)90007-G; Cohen TJ, 2000, J INVASIVE CARDIOL, V12, P121; Doenicke AW, 1997, ANESTH ANALG, V85, P1399, DOI 10.1097/00000539-199712000-00040; EBLING WF, 1990, ANESTHESIOLOGY, V72, P650, DOI 10.1097/00000542-199004000-00013; FITZPATRICK AP, 1994, CIRCULATION, V89, P2503, DOI 10.1161/01.CIR.89.6.2503; GILL RM, 1993, PACE, V16, P708, DOI 10.1111/j.1540-8159.1993.tb01649.x; HUG CC, 1981, ANESTHESIOLOGY, V55, P369, DOI 10.1097/00000542-198110000-00006; HUNT GB, 1988, CIRCULATION, V78, P221, DOI 10.1161/01.CIR.78.1.221; JARVIS AS, 1994, PACE, V17, P280, DOI 10.1111/j.1540-8159.1994.tb01389.x; KARATASSAS A, 1993, AUST NZ J SURG, V63, P266, DOI 10.1111/j.1445-2197.1993.tb00380.x; KODAMA I, 1994, AM J PHYSIOL, V267, pH248; LASZLO A, 1991, ANESTHESIOLOGY, V75, P98, DOI 10.1097/00000542-199107000-00016; Lehmann A, 2001, J CARDIOTHOR VASC AN, V15, P445, DOI 10.1053/jcan.2001.24979; Lipscomb KJ, 1998, HEART, V79, P253, DOI 10.1136/hrt.79.3.253; Michaloudis D, 1999, EUR J ANAESTH, V16, P842, DOI 10.1046/j.1365-2346.1999.00599.x; MOFFITT EA, 1984, ANESTH ANALG, V63, P1071; Pacifico A, 1997, CIRCULATION, V95, P946; Pinosky ML, 1996, J CARDIOTHOR VASC AN, V10, P764, DOI 10.1016/S1053-0770(96)80202-3; Roden D. M., 1996, GOODMAN GILMANS PHAR, P839; Stadnicka A, 2000, ANESTH ANALG, V90, P824, DOI 10.1213/00000539-200004000-00010; STEINBECK G, 1994, AM HEART J, V127, P1064, DOI 10.1016/0002-8703(94)90088-4; Wahr JA, 1996, ANESTHESIOLOGY, V84, P1350, DOI 10.1097/00000542-199606000-00011; Weinbroum AA, 1997, INTENS CARE MED, V23, P1258, DOI 10.1007/s001340050495; WRAY DL, 1992, CLIN ANESTH, P1021; YOUNGS EJ, 1994, ANESTHESIOLOGY, V81, P833, DOI 10.1097/00000542-199410000-00010	28	17	17	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2002	95	5					1147	1153		10.1097/00000539-200211000-00004			7	Anesthesiology	Anesthesiology	609NV	WOS:000178912600004	12401582				2020-06-30	J	Laird, TH; Stayer, SA; Rivenes, SM; Lewin, MB; McKenzie, ED; Fraser, CD; Andropoulos, DB				Laird, TH; Stayer, SA; Rivenes, SM; Lewin, MB; McKenzie, ED; Fraser, CD; Andropoulos, DB			Pulmonary-to-systemic blood flow ratio effects of sevoflurane, isoflurane, halothane, and fentanyl/midazolam with 100% oxygen in children with congenital heart disease	ANESTHESIA AND ANALGESIA			English	Article; Proceedings Paper	22nd Annual Meeting of the Society-of-Cardiovascular-Anesthesiologists	MAY 08-09, 2000	ORLANDO, FL	Soc Cardiovasc Anesthesiologists			COMPARATIVE HEMODYNAMIC DEPRESSION; MYOCARDIAL-CONTRACTILITY; FENTANYL; INFANTS; PHARMACOKINETICS; MIDAZOLAM; ECHOCARDIOGRAPHY; INDUCTION; DOPPLER; AGE	The cardiovascular effects of volatile anesthetics in children with congenital heart disease have been studied, but there are limited data on the effects of anesthetics on pulmonary-to-systemic blood flow ratio (Qp:Qs) in patients with intracardiac shunting. In this study, we compared the effects of halothane, isoflurane, sevoflurane, and fentanyl/midazolam on Qp:Qs and myocardial contractility in patients with atrial (ASD) or ventricular (VSD) septal defects. Forty patients younger than 14 yr old scheduled to undergo repair of ASD or VSD were randomized to receive halothane, sevoflurane, isoflurane, or fentanyl/midazolam. Cardiovascular and echocardiographic data were recorded at baseline, randomly ordered 1 and 1.5 mean alveolar anesthetic	Texas Childrens Hosp, Div Pediat Cardiovasc Anesthesiol, Houston, TX 77030 USA; Texas Childrens Hosp, Div Pediat Cardiol, Houston, TX 77030 USA; Texas Childrens Hosp, Div Congenital Heart Surg, Houston, TX 77030 USA; Baylor Coll Med, Houston, TX 77030 USA; Childrens Hosp & Reg Med Ctr, Div Pediat Cardiol, Seattle, WA USA; Univ Washington, Sch Med, Seattle, WA USA	Andropoulos, DB (reprint author), Texas Childrens Hosp, Div Pediat Cardiovasc Anesthesiol, 6621 Fannin,WT 19345H, Houston, TX 77030 USA.	dra@bcm.tmc.edu					CAMERON CB, 1984, ANESTH ANALG, V63, P418; Charpie JR, 2001, AM J CARDIOL, V87, P198, DOI 10.1016/S0002-9149(00)01316-3; COOK DR, 1996, SMITHS ANESTHESIA IN, P159; EGER EI, 2000, ANESTHESIA, P74; Friesen RH, 2000, PAEDIATR ANAESTH, V10, P267, DOI 10.1046/j.1460-9592.2000.00495.x; Glenski J A, 1988, J Cardiothorac Anesth, V2, P147, DOI 10.1016/0888-6296(88)90264-5; GOLDBERG SJ, 1982, AM J CARDIOL, V50, P1394, DOI 10.1016/0002-9149(82)90481-7; GREELEY WJ, 1996, SMITHS ANESTHESIA IN, P520; GREGORY GA, 1969, ANESTHESIOLOGY, V30, P488, DOI 10.1097/00000542-196905000-00003; HICKEY PR, 1985, ANESTH ANALG, V64, P483; Holzman RS, 1996, ANESTHESIOLOGY, V85, P1260, DOI 10.1097/00000542-199612000-00006; JONES RDM, 1993, BRIT J ANAESTH, V70, P286, DOI 10.1093/bja/70.3.286; KOREN G, 1984, ANESTH ANALG, V63, P577; LERMAN J, 1995, ANESTH ANALG, V81, pS4, DOI 10.1097/00000539-199512001-00002; LOCK JE, 1982, PEDIATR CARDIOL, V3, P41, DOI 10.1007/BF02082331; MERCIER JC, 1982, CIRCULATION, V65, P962, DOI 10.1161/01.CIR.65.5.962; MURRAY D, 1987, ANESTHESIOLOGY, V67, P211, DOI 10.1097/00000542-198708000-00010; MURRAY DJ, 1992, ANESTH ANALG, V74, P329; PAYNE K, 1989, EUR J CLIN PHARMACOL, V37, P267, DOI 10.1007/BF00679782; Rivenes SM, 2001, ANESTHESIOLOGY, V94, P223, DOI 10.1097/00000542-200102000-00010; SALONEN M, 1987, ANESTH ANALG, V66, P625; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SINGLETON MA, 1987, CAN J ANAESTH, V34, P152, DOI 10.1007/BF03015333; Wodey E, 1997, ANESTHESIOLOGY, V87, P795, DOI 10.1097/00000542-199710000-00012	24	40	43	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2002	95	5					1200	1206		10.1097/00000539-200211000-00016			7	Anesthesiology	Anesthesiology	609NV	WOS:000178912600016	12401594				2020-06-30	J	Pirat, A; Akpek, E; Arslan, G				Pirat, A; Akpek, E; Arslan, G			Intrathecal versus IV fentanyl in pediatric cardiac anesthesia	ANESTHESIA AND ANALGESIA			English	Article							REGIONAL ANESTHESIA; STRESS RESPONSES; PHARMACOKINETICS; SUFENTANIL; CHILDREN; SURGERY; INFANTS; BYPASS	Systemic large-dose opioids are widely used in pediatric cardiac anesthesia, but there are no randomized, prospective studies regarding the use of intrathecal (IT) opioids for these procedures. In this randomized, prospective study, we compared cardiovascular and neurohumoral responses during IT or IV fentanyl anesthesia for pediatric cardiac surgery. Thirty children aged 6 mo to 6 yr were anesthetized with an IV fentanyl bolus of 10 ug/kg. This was followed by a fentanyl infusion of 10 mug (.) kg(-1) (.) h(-1) (Group IV; n = 10), 2 mug/kg of IT fentanyl (Group IT; n = 10), or combined IV and IT protocols (Group IV + IT; n = 10). Heart rate, mean arterial blood pressure, additional fentanyl doses, time to first analgesic requirement, COMFORT and Children's Hospital of Eastern Ontario Pain Scale scores, and extubation time were recorded. Blood cortisol, insulin, glucose, and lactate levels were measured presurgery, poststernotomy, during the rewarming phase of cardiopulmonary bypass (CPB), and 6 and 24 h after surgery. The patients' urinary cortisol excretion rates were also measured during the first postoperative day. The findings in all three groups were statistically similar, except for higher blood glucose levels during CPB in Group IT compared with Group IV (P < 0.004). Group IV + IT was the only group in which the increases in heart rate and mean arterial blood pressure from presurgery to poststernotomy were not significant. The 24-h urinary cortisol excretion rates (mug (.) kg(-1) (.) d(-1)) were 61.51 +/- 39, 92.54 +/- 67.55, and 40.15 +/- 29.69 for Groups IV, IT, and IV + IT, respectively (P > 0.05). A single IT injection of fentanyl 2 mug/kg offers no advantage over systemic fentanyl (10 mug/kg bolus and 10 mug (.) kg(-1) (.) d(-1)) with regard to hemodynamic stability or suppression of stress response. The combination of these two regimens may provide better hemodynamic stability during the pre-CPB period and may be associated with a decreased 24-h urinary cortisol excretion rate.	Baskent Univ, Hastanesi Anesteziyol Anabilim Dali, Fac Med, Dept Anesthesiol, TR-06490 Ankara, Turkey	Pirat, A (reprint author), Baskent Univ, Hastanesi Anesteziyol Anabilim Dali, Fac Med, Dept Anesthesiol, 10 Sok 45, TR-06490 Ankara, Turkey.	arashpirat@hotmail.com					ALLEN PD, 1986, ANESTH ANALG, V65, P165; AMBUEL B, 1992, J PEDIATR PSYCHOL, V17, P95, DOI 10.1093/jpepsy/17.1.95; ANAND KJS, 1992, NEW ENGL J MED, V326, P1, DOI 10.1056/NEJM199201023260101; ANAND KJS, 1990, ANESTHESIOLOGY, V73, P661, DOI 10.1097/00000542-199010000-00012; Barankay A, 1992, J Cardiothorac Vasc Anesth, V6, P185, DOI 10.1016/1053-0770(92)90195-D; BOVILL JG, 1980, BRIT J ANAESTH, V52, P795, DOI 10.1093/bja/52.8.795; CARR D, 1998, NEURAL BLOCKADE CLIN, P115; COUSINS MJ, 1979, LANCET, V1, P1141; Duncan HP, 2000, BRIT J ANAESTH, V84, P556, DOI 10.1093/bja/84.5.556; Gruber EM, 2001, ANESTH ANALG, V92, P882; Hammer GB, 2000, ANESTH ANALG, V90, P1020, DOI 10.1097/00000539-200005000-00004; HOLLEY FO, 1982, CLIN PHARMACOKINET, V7, P234, DOI 10.2165/00003088-198207030-00004; LAUSSEN PC, 1998, PEDIAT CARDIAC INTEN, P85; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; Mychaskiw G, 2000, ANESTH ANALG, V91, P1562, DOI 10.1097/00000539-200012000-00056; Peterson KL, 2000, ANESTH ANALG, V90, P1014, DOI 10.1097/00000539-200005000-00002; Rosen D A, 1990, J Cardiothorac Anesth, V4, P332, DOI 10.1016/0888-6296(90)90041-D; TORDA TA, 1982, BRIT J ANAESTH, V54, P291, DOI 10.1093/bja/54.3.291; VANDERMEULEN EP, 1994, ANESTH ANALG, V79, P1165; WILLENS JS, 1993, HEART LUNG, V22, P239; WOLFE MJ, 1980, BRIT J ANAESTH, V52, P357, DOI 10.1093/bja/52.3.357-a; YASTER M, 1987, ANESTHESIOLOGY, V66, P433, DOI 10.1097/00000542-198703000-00035	22	22	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2002	95	5					1207	1214		10.1097/00000539-200211000-00017			8	Anesthesiology	Anesthesiology	609NV	WOS:000178912600017	12401595				2020-06-30	J	Buckenmaier, CC; Nielsen, KC; Pietrobon, R; Klein, SM; Martin, AH; Greengrass, RA; Steele, SM				Buckenmaier, CC; Nielsen, KC; Pietrobon, R; Klein, SM; Martin, AH; Greengrass, RA; Steele, SM			Small-dose intrathecal lidocaine versus ropivacaine for anorectal surgery in an ambulatory setting	ANESTHESIA AND ANALGESIA			English	Article							TRANSIENT NEUROLOGIC SYMPTOMS; SPINAL-ANESTHESIA; RADICULAR IRRITATION; NEUROTOXICITY	Spinal anesthesia with the local anesthetic lidocaine has come under scrutiny because it is associated with transient neurologic symptoms (TNS). We designed this study to prospectively compare the efficacy of ropivacaine as an alternative to lidocaine in patientsundergoing elective outpatient anorectal procedures. Seventy two patients were randomized to receive either hyperbaric lidocaine 25 mg with fentanyl 20 mug (n = 37) or hyperbaric ropivacame 4 mg with fentanyl 20 mug (n = 35) . Patients were examined for motor block, sensory block, and block duration. Patients were contacted at 24,48, 72, and 168 h and questioned about their perceptions of pain after the spinal with specific questions designed to diagnose TNS. There were no patients with TNS in either group. There was no significant difference between the lidocaine and ropivacaine groups in any of the outcomes studied. In conclusion, intrathecal hyperbaric small-dose ropivacaine with fentanyl is an acceptable anesthetic for anorectal surgery.	Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Buckenmaier, CC (reprint author), Duke Univ, Med Ctr, Dept Anesthesiol, Box 3094, Durham, NC 27710 USA.	bucke001@mc.duke.edu		Pietrobon, Ricardo/0000-0003-2996-2193			Aouad MT, 2001, ANESTH ANALG, V92, P401, DOI 10.1213/00000539-200102000-00023; Ben-David B, 2000, ANESTH ANALG, V91, P865, DOI 10.1097/00000539-200010000-00018; Freedman JM, 1998, ANESTHESIOLOGY, V89, P633, DOI 10.1097/00000542-199809000-00012; HAMPL KF, 1995, ANESTH ANALG, V81, P1148, DOI 10.1097/00000539-199512000-00006; Hampl KF, 1998, ANESTHESIOLOGY, V88, P629, DOI 10.1097/00000542-199803000-00012; Hampl KF, 1996, ANESTH ANALG, V83, P1051, DOI 10.1097/00000539-199611000-00026; Hodgson PS, 2000, REGION ANESTH PAIN M, V25, P218, DOI 10.1016/S1098-7339(00)90001-4; Hodgson PS, 1999, ANESTH ANALG, V88, P797, DOI 10.1097/00000539-199904000-00023; Horlocker T T, 2000, Anesthesiol Clin North Am, V18, P461, DOI 10.1016/S0889-8537(05)70172-3; Johnson ME, 2000, MAYO CLIN PROC, V75, P921, DOI 10.4065/75.9.921; Li ST, 2000, ANESTHESIOLOGY, V93, P1225, DOI 10.1097/00000542-200011000-00015; Liu SS, 2001, ANESTHESIOLOGY, V94, P888, DOI 10.1097/00000542-200105000-00030; Lynch J, 1997, ANESTH ANALG, V85, P872, DOI 10.1097/00000539-199710000-00030; Moore DC, 1998, REGION ANESTH PAIN M, V23, P605, DOI 10.1016/S1098-7339(98)90089-X; Morisaki H, 1998, ANESTH ANALG, V86, P1023, DOI 10.1097/00000539-199805000-00022; Philip J, 2001, ANESTH ANALG, V92, P405, DOI 10.1213/00000539-200102000-00024; Pollock JE, 1999, ANESTHESIOLOGY, V90, P445, DOI 10.1097/00000542-199902000-00019; Pollock JE, 1996, ANESTHESIOLOGY, V84, P1361, DOI 10.1097/00000542-199606000-00012; Rowlingson JC, 2000, REGION ANESTH PAIN M, V25, P215; SCHNEIDER M, 1993, ANESTH ANALG, V76, P1154; Sumi M, 1996, ANESTH ANALG, V82, P1076, DOI 10.1097/00000539-199605000-00036	21	30	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2002	95	5					1253	1257		10.1097/00000539-200211000-00028			5	Anesthesiology	Anesthesiology	609NV	WOS:000178912600028	12401606				2020-06-30	J	Turan, A; Emet, S; Karamanlioglu, B; Memis, D; Turan, N; Pamukcu, Z				Turan, A; Emet, S; Karamanlioglu, B; Memis, D; Turan, N; Pamukcu, Z			Analgesic effects of rofecoxib in ear-nose-throat surgery	ANESTHESIA AND ANALGESIA			English	Article							DENTAL PAIN; CELECOXIB; COX-2	In this study we evaluated the analgesic efficacy and the opioid-sparing effect of rofecoxib in ear-nose-throat surgery patients. Patients undergoing nasal septal or sinus surgery were randomized to receive either oral placebo or rofecoxib 50 mg 1 h before surgery. All patients received propofol 0.8 mg/kg, fentanyl 1 mug/kg, and local anesthesia at the operative site. Sedation was maintained by a continuous infusion of propofol adjusted to maintain sedation at a 2-3 level on the Ramsey scale. Additional fentanyl 0.5-1 mug/kg was administered at the patient's request or if the verbal rating scale score was >4. Patient sedation and pain scores were obtained at 5, 15, 30 45, and 60 min during surgery and 30 min and 2, 4, 6, 12, and 24 h after completion of the procedure. During the postoperative period, diclofenac 75 mg IM was administered for analgesia at the patient's request or if the visual analog scale (VAS) rating for pain was more than 4. VAS pain scores, intraoperative fentanyl, and postoperative diclofenac requirements were significantly smaller in the rofecoxib group compared with the placebo group (P < 0.001). The times to first analgesic request were also significantly less in the rofecoxib group. We conclude that the preoperative administration of oral rofecoxib provided a significant analgesic benefit and decreased the need for opioids in patients undergoing nasal septal and nasal sinus surgery.	Trakya Univ, Fac Med, Dept Anaesthesiol, TR-22030 Edirne, Turkey; Trakya Univ, Fac Med, Dept Biostat, TR-22030 Edirne, Turkey	Turan, A (reprint author), Trakya Univ, Fac Med, Dept Anesthesiol & Reanimat, TR-22030 Edirne, Turkey.	alparslanturan@yahoo.com					Bekker A., 2002, Anesthesia and Analgesia, V94; Blakeley KR, 1998, ANESTH ANALG, V87, P827, DOI 10.1097/00000539-199810000-00015; Ehrich EW, 1999, CLIN PHARMACOL THER, V65, P336, DOI 10.1016/S0009-9236(99)70113-X; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Huang JJ, 2001, J CLIN ANESTH, V13, P94, DOI 10.1016/S0952-8180(01)00219-7; Issioui T, 2002, ANESTH ANALG, V94, P1188, DOI 10.1097/00000539-200205000-00025; ISSIOUI T, 2000, ANESTH ANALG, V94, pS4; ISSIOUI T, 2001, ANESTHESIOLOGY, V94, pA35; Malmstrom K, 1999, CLIN THER, V21, P1653, DOI 10.1016/S0149-2918(99)80045-9; Michaloliakou C, 1996, ANESTH ANALG, V82, P44, DOI 10.1097/00000539-199601000-00009; Rawal N, 2001, BRIT J ANAESTH, V87, P73, DOI 10.1093/bja/87.1.73; Reicin A, 2001, Am J Orthop (Belle Mead NJ), V30, P40; Reuben SS, 2000, ANESTH ANALG, V91, P1221, DOI 10.1097/00000539-200011000-00032; SHEN Q, 2001, ANESTHESIOLOGY, V95, pA961; Van Hecken A, 2000, J CLIN PHARMACOL, V40, P1109; White PF, 2002, ANESTH ANALG, V94, P577, DOI 10.1097/00000539-200203000-00019	16	38	40	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2002	95	5					1308	1311		10.1097/00000539-200211000-00039			4	Anesthesiology	Anesthesiology	609NV	WOS:000178912600039	12401617				2020-06-30	J	Macias, A; Monedero, P; Adame, M; Torre, W; Fidalgo, I; Hidalgo, F				Macias, A; Monedero, P; Adame, M; Torre, W; Fidalgo, I; Hidalgo, F			A randomized, double-blinded comparison of thoracic epidural ropivacaine, ropivacaine/fentanyl, or bupivacaine/fentanyl for postthoracotomy analgesia	ANESTHESIA AND ANALGESIA			English	Article							POSTOPERATIVE PAIN; MU-G/ML; FENTANYL; SUFENTANIL; INFUSION; SURGERY; LABOR; THORACOTOMY; COMBINATION	Epidural ropivacaine has not been compared with bupivacaine for postthoracotomy analgesia. Eighty patients undergoing elective lung surgery were randomized in a double-blinded manner to receive one of three solutions for high thoracic epidural analgesia. A continuous epidural infusion of 0.1 mL(.)kg(-1.)h(-1) of either 0.2% ropivacaine, 0.15% ropivacaine/fentanyl 5 mug/mL, or 0.1% bupivacame/fentanyl 5 mug/mL was started at admission to the intensive care unit. We assessed pain scores (rest and spirometry), IV morphine consumption, spirometry, hand grip strength, Paco(2), heart rate, blood pressure, respiratory rate, and side effects (sedation, nausea, vomiting, and pruritus) for 48 h. Thoracic epidural ropivacame/fentanyl provided adequate pain relief similar to bupivacaine/fentanyl during the first 2 postoperative days after posterolateral thoracotomy. The use of plain 0.2% ropivacaine was associated with worse pain control during spirometry, larger consumption of IV morphine, and increased incidence of postoperative nausea and vomiting. Morphine requirements were larger in the ropivacaine group, with no differences between bupivacaine/fentanyl and ropivacaine/fentanyl groups. Patients in the ropivacaine group experienced more pain and performed worse in spirometry than patients who received epidural fentanyl. There was no significant difference in motor block. We conclude that epidural ropivacaine/fentanyl offers no clinical advantage compared with bupivacaine/fentanyl for postthoracotomy analgesia.	Univ Navarra, Dept Anesthesia & Crit Care, Clin Univ, Pamplona, Spain; Univ Navarra, Thorac Surg Serv, Clin Univ, Pamplona, Spain	Monedero, P (reprint author), Univ Navarra, Dept Anesthesia & Crit Care, Clin Univ, Pio XII,36, Pamplona, Spain.	pmonedero@unav.es	Monedero, Pablo/M-6100-2019; Monedero, Pablo/A-1696-2008	Monedero, Pablo/0000-0002-1596-5644; Monedero, Pablo/0000-0002-1596-5644			Azad S C, 2001, Curr Opin Anaesthesiol, V14, P87; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; Berti M, 2000, CAN J ANAESTH, V47, P27, DOI 10.1007/BF03020727; Fischer C, 2000, ANESTHESIOLOGY, V92, P1588, DOI 10.1097/00000542-200006000-00015; Gautier P, 1999, ANESTHESIOLOGY, V90, P772, DOI 10.1097/00000542-199903000-00020; Gruber EM, 2001, ANESTH ANALG, V92, P1015; Hodgson PS, 2001, ANESTH ANALG, V92, P1024; Jorgensen H, 2000, BRIT J ANAESTH, V84, P144; KAVANAGH BP, 1994, ANESTHESIOLOGY, V81, P737, DOI 10.1097/00000542-199409000-00028; Knudsen K, 1997, BRIT J ANAESTH, V78, P507; Liu N, 2001, ANESTH ANALG, V92, P31; Liu SS, 1999, ANESTHESIOLOGY, V90, P727, DOI 10.1097/00000542-199903000-00014; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; MATHIOWETZ V, 1985, ARCH PHYS MED REHAB, V66, P69; McClellan KJ, 2000, DRUGS, V60, P1065, DOI 10.2165/00003495-200060050-00007; Muldoon T, 1998, BRIT J ANAESTH, V80, P680; Polley LS, 1999, ANESTHESIOLOGY, V90, P944, DOI 10.1097/00000542-199904000-00003; Scawn NDA, 2001, ANESTH ANALG, V93, P260, DOI 10.1097/00000539-200108000-00004; Scott DA, 1999, ANESTH ANALG, V88, P857, DOI 10.1097/00000539-199904000-00033; THOMSON CA, 1995, ANESTH ANALG, V81, P973, DOI 10.1097/00000539-199511000-00014; Warner DO, 1996, ANESTHESIOLOGY, V85, P761, DOI 10.1097/00000542-199610000-00011; Whiteside R, 2000, BRIT J ANAESTH, V84, P720	22	25	29	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2002	95	5					1344	1350		10.1097/00000539-200211000-00046			7	Anesthesiology	Anesthesiology	609NV	WOS:000178912600046	12401624				2020-06-30	J	Paech, MJ; Banks, SL; Gurrin, LC; Yeo, ST; Pavy, TJG				Paech, MJ; Banks, SL; Gurrin, LC; Yeo, ST; Pavy, TJG			A randomized, double-blinded trial of subarachnoid bupivacaine and fentanyl, with or without clonidine, for combined spinal/epidural analgesia during labor	ANESTHESIA AND ANALGESIA			English	Article							CONTROLLED EPIDURAL ANALGESIA; INTRATHECAL CLONIDINE; SPINAL CLONIDINE; SUFENTANIL; AGONISTS	Subarachnoid clonidine may increase the duration of spinal opioid and local anesthetic analgesia during labor, but it may also increase hypotension and sedation, and the therapeutic range is unclear. We studied 110 term parturients of mixed parity having combined spinal/epidural analgesia during labor in this randomized, double-blinded trial. All received subarachnoid fentanyl 20 mug and bupivacaine 2.5 mg, plus either saline or clonidine (15, 30, or 45 mug). Of 101 per-protocol parturients (n = 25,24, 26, and 26 in Groups C0, C15, C30, and C45, respectively), 22 delivered before the cessation of spinal analgesia. Group demographics and pain scores from Time 0 to 120 min were similar. There was no significant difference among groups in the duration of spinal analgesia (P = 0.09) or in the duration of clonidine groups combined compared with control (median, 120 min [interquartile range, 96-139 min] versus 98 min [80-120 min]; P = 0.07). Systolic blood pressure was significantly lower in all clonidine groups between 40 and 90 min (P = 0.001). Hypotension (P = 0.05) and the requirement for ephedrine (P = 0.02) were dose dependent, but groups had a similar incidence of hypotension. The addition of clonidine 15-45 mug to subarachnoid fentanyl and bupivacaine reduced blood pressure and did not significantly increase the duration of spinal analgesia.	King Edward Mem Hosp Women, Dept Anesthesia & Pain Med, Subiaco, WA 6008, Australia; Womans & Infants Res Fdn, Perth, WA, Australia	Paech, MJ (reprint author), King Edward Mem Hosp Women, Dept Anesthesia & Pain Med, 374 Bagot Rd, Subiaco, WA 6008, Australia.	michael.paech@health.wa.gov.au		Gurrin, Lyle/0000-0001-7052-1969; PAECH, MICHAEL/0000-0001-9023-6575			ABOULEISH A, 1994, CAN J ANAESTH, V41, P575, DOI 10.1007/BF03009995; CAIN DJ, 2000, ANESTHESIOLOGY, P93; Campbell DC, 1997, ANESTHESIOLOGY, V86, P525, DOI 10.1097/00000542-199703000-00003; CAPOGNA G, 1993, BRIT J ANAESTH, V71, P294, DOI 10.1093/bja/71.2.294; CASTRO MI, 1989, ANESTHESIOLOGY, V71, P418, DOI 10.1097/00000542-198909000-00018; Chiari A, 1999, ANESTHESIOLOGY, V91, P388, DOI 10.1097/00000542-199908000-00012; Collis RE, 1999, BRIT J ANAESTH, V82, P233, DOI 10.1093/bja/82.2.233; D'Angelo R, 2000, REGION ANESTH PAIN M, V25, P3, DOI 10.1016/S1098-7339(00)80003-6; D'Angelo R, 1999, ANESTH ANALG, V88, P573, DOI 10.1097/00000539-199903000-00020; EISENACH JC, 1990, ANESTHESIOLOGY, V72, P663, DOI 10.1097/00000542-199004000-00015; Eisenach JC, 1996, ANESTHESIOLOGY, V85, P655, DOI 10.1097/00000542-199609000-00026; Eisenach JC, 2000, PAIN, V84, P57, DOI 10.1016/S0304-3959(99)00181-5; Gautier PE, 1998, ANESTHESIOLOGY, V88, P651, DOI 10.1097/00000542-199803000-00015; Mandell GL, 1996, REGION ANESTH, V21, P103; Mercier FJ, 1998, ANESTHESIOLOGY, V89, P594, DOI 10.1097/00000542-199809000-00007; Nelson K, 2000, ANESTHESIOLOGY, V93, pU216; Nickells JS, 2000, ANAESTHESIA, V55, P17, DOI 10.1046/j.1365-2044.2000.01071.x; Owen MD, 2000, ANESTHESIOLOGY, V92, P361, DOI 10.1097/00000542-200002000-00016; Paech MJ, 2000, REGION ANESTH PAIN M, V25, P34, DOI 10.1016/S1098-7339(00)80008-5; Palmer CM, 1999, ANESTHESIOLOGY, V91, P84, DOI 10.1097/00000542-199907000-00015; Russell R, 1999, INT J OBSTET ANESTH, V8, P56, DOI 10.1016/S0959-289X(99)80153-8; Sia ATH, 2000, CAN J ANAESTH, V47, P875, DOI 10.1007/BF03019667; YAKSH TL, 1981, ANESTHESIOLOGY, V54, P451, DOI 10.1097/00000542-198106000-00004	23	26	28	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	NOV	2002	95	5					1396	1401		10.1097/00000539-200211000-00054			6	Anesthesiology	Anesthesiology	609NV	WOS:000178912600054	12401632				2020-06-30	J	Slavov, V; Motamed, C; Massou, N; Rebufat, Y; Duvaldestin, P				Slavov, V; Motamed, C; Massou, N; Rebufat, Y; Duvaldestin, P			Systolic blood pressure, not BIS, is associated with movement during laryngoscopy and intubation	CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE			English	Article							NITROUS-OXIDE ANESTHESIA; BISPECTRAL INDEX; HEMODYNAMIC-RESPONSES; SKIN INCISION; DEPTH; ELECTROENCEPHALOGRAM; PREDICTION; AWARENESS; RECALL	Objective: To compare bispectral index (BIS) values to hemodynamic variations, in order to evaluate adequacy of anesthesia during orotracheal intubation with muscle relaxants. Methods: Forty-one patients ASA I-II, scheduled for elective peripheral surgery under general anesthesia with tracheal intubation were enrolled in the study. Fentanyl/thiopental followed by vecuronium were used for induction. Onset of relaxation was monitored at the orbicularis occuli (OO) muscle using train-of-four stimulation. Intubation was performed when no response at the OO was detected visually. Intubating conditions were noted. The "isolated forearm" technique was used to detect movement during aryngoscopy/intubation. BIS values, pulse rate (PR), and systolic pressure were recorded before induction, during laryngoscopy/intubation and 60 sec after intubation. Results: Although intubating conditions were clinically adequate for all patients, ten out of 41 had movement of the isolated arm during laryngoscopy/intubation. BIS values were not significantly different for these patients: 67 (55-83) compared to those who had no movement: 60 (35-80), P = 0.6. During laryngoscopy, PR increased for all patients while systolic pressure increased significantly only in patients who moved: 125 (100-136) mmHg vs those who did not: 108 (67-140), P < 0.05. Conclusion: Systolic pressure elevations were associated with inadequate anesthesia as evaluated by the "isolated forearm" technique, during laryngoscopy/intubation. BIS values were not different between groups, suggesting that systolic blood pressure may be a better predictor of inadequate anesthesia under the circumstances described.	Hop Henri Mondor, AP HP, Serv Anesthesie Reanimat, F-94010 Creteil, France; Univ Paris 12, F-94010 Creteil, France	Motamed, C (reprint author), Hop Henri Mondor, AP HP, Serv Anesthesie Reanimat, 51 Ave Marechal De Lattre Tassigny, F-94010 Creteil, France.	cyrus.motamed@hmn.ap-hop-paris.fr					BILLARD V, 1997, C ACT 39 C NAT AN RE, P17; BOGOD DG, 1990, ANAESTHESIA, V45, P279, DOI 10.1111/j.1365-2044.1990.tb14732.x; Bruhn J, 2000, ANESTHESIOLOGY, V92, P1485, DOI 10.1097/00000542-200005000-00042; Drummond JC, 2000, ANESTHESIOLOGY, V93, P876, DOI 10.1097/00000542-200009000-00039; GLASS PSA, 1994, ANESTHESIA, P389; Guignard B, 2000, ANESTH ANALG, V90, P161, DOI 10.1097/00000539-200001000-00034; Hastings RH, 1996, ANESTH ANALG, V82, P462, DOI 10.1097/00000539-199603000-00005; KEARSE LA, 1994, ELECTROEN CLIN NEURO, V90, P194, DOI 10.1016/0013-4694(94)90091-4; KEARSE LA, 1994, ANESTHESIOLOGY, V81, P1365, DOI 10.1097/00000542-199412000-00010; Leslie K, 1996, ANESTHESIOLOGY, V84, P52, DOI 10.1097/00000542-199601000-00006; Liu J, 1997, ANESTH ANALG, V84, P185, DOI 10.1097/00000539-199701000-00033; Mollestad KE, 1998, ACTA ANAESTH SCAND, V42, P1184, DOI 10.1111/j.1399-6576.1998.tb05274.x; Schwender D, 1997, ACTA ANAESTH SCAND, V41, P313; Sleigh JW, 1999, ANESTH ANALG, V88, P659, DOI 10.1097/00000539-199903000-00035; TUNSTALL ME, 1977, BRIT MED J, V1, P1321, DOI 10.1136/bmj.1.6072.1321-a; VERNON JM, 1995, ANESTH ANALG, V80, P780, DOI 10.1097/00000539-199504000-00023; VibyMogensen J, 1996, ACTA ANAESTH SCAND, V40, P59, DOI 10.1111/j.1399-6576.1996.tb04389.x	17	10	14	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0832-610X			CAN J ANAESTH	Can. J. Anaesth.-J. Can. Anesth.	NOV	2002	49	9					918	921		10.1007/BF03016874			4	Anesthesiology	Anesthesiology	618TB	WOS:000179432400005	12419716	Bronze			2020-06-30	J	Rolfseng, OK; Skogvoll, E; Borchgrevink, PC				Rolfseng, OK; Skogvoll, E; Borchgrevink, PC			Epidural bupivacaine with sufentanil or fentanyl during labour: a randomized, double-blind study	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article						anaesthetics, local, bupivacaine; analgesia, epidural; analgesics, opioid, sufentanil, fentanyl; pregnancy, labour	CESAREAN-SECTION; PAIN RELIEF; 0.125-PERCENT BUPIVACAINE; POSTOPERATIVE ANALGESIA; INTRATHECAL MORPHINE; AMBULATION; ADRENALINE; OBSTETRICS; DELIVERY; OPIOIDS	Background and objective: Epidural analgesia with bupivacaine plus either sufentanil or fentanyl is widely used during labour, but it is not clear which opiold is to be preferred. The study compared these opioids at equianalgesic doses in terms of analgesia, onset time and side-effects. Methods: Ninety females in active labour were entered into the randomized, double-blind trial. A test dose of bupivacaine was given into the epidural space. Parturients in Group S received sufentanil 8 mL as a bolus dose, followed by an infusion at a rate of 5 mL h(-1) of a mixture containing sufentanil 1 mug mL(-1) and bupivacaine 1 mg mL(-1). Patients in Group F received fentanyl 8 mL as a bolus, followed by an infusion at 5 mL h(-1) of a solution containing fentanyl 3.5 mug mL(-1) and bupivacalne 1 mg mL(-1). Additional boluses of 5 mL were of the relevant solution were given if necessary. Results: In a ratio of 1.0 : 3.5 (sufentanil 1 mug versus fentanyl 3.5 mug), both groups reported the same analgesia with the same onset time. The onset time to obtain 50% of the initial visual analogue score was 10 and 11 min for Groups S and F, respectively. Mean visual analogue scores in Groups S and F respectively declined from 77 and 82 before epidural blockade, to 29 and 27 during the first stage of labour, and to 69 and 59 respectively during the second stage. Overall satisfaction among parturients was high (98 and 906), particularly during the first stage (98 and 98%), and also to a large degree during the second stage of labour (74 and 79%). Furthermore, only a few extra bolus doses were required (mean 0.9 and 1.2, Groups S and F, respectively). All the females could stand on their own, and almost all (81%, Group S; 79% Group F) could walk 20 to without help. There were no serious adverse effects. Moderate side-effects occurred equally often with the possible exception of less nausea and vomiting in the fentanyl group. Conclusions: Epidural analgesia for ambulatory parturients with bupivacalne plus either sufentanil or fentanyl (ratio 1-0 : 3.5) provides good analgesia with a low frequency of modest side-effects. No clinical differences were found between the opioids.	Univ Trondheim Hosp, Dept Anaesthesiol, N-7006 Trondheim, Norway; Univ Trondheim Hosp, Unit Appl Clin Res, N-7006 Trondheim, Norway	Rolfseng, OK (reprint author), Univ Trondheim Hosp, Dept Anaesthesiol, N-7006 Trondheim, Norway.						AKERMAN B, 1988, ANESTH ANALG, V67, P943; CAPOGNA G, 1989, REGION ANESTH, V14, P282; CODA BA, 1994, ANESTHESIOLOGY, V81, P1149, DOI 10.1097/00000542-199411000-00008; COHEN S, 1993, ANESTHESIOLOGY, V78, P486, DOI 10.1097/00000542-199303000-00012; Cohen S, 1996, CAN J ANAESTH, V43, P341, DOI 10.1007/BF03011711; COHEN SE, 1987, ANESTHESIOLOGY, V67, P403, DOI 10.1097/00000542-198709000-00020; DONADONI R, 1985, ANAESTHESIA, V40, P634, DOI 10.1111/j.1365-2044.1985.tb10939.x; ETCHES RC, 1989, CAN J ANAESTH, V36, P165, DOI 10.1007/BF03011441; FISCHER RL, 1988, ANESTH ANALG, V67, P559; FLYNN AM, 1978, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.6137.591; GELLER E, 1993, ANESTH ANALG, V76, P1243, DOI 10.1213/00000539-199376060-00011; GRASS JA, 1992, J PAIN SYMPTOM MANAG, V7, P271, DOI 10.1016/0885-3924(92)90061-L; Herman NL, 1998, J CLIN ANESTH, V10, P670, DOI 10.1016/S0952-8180(98)00113-5; LIRZIN JD, 1989, BRIT J ANAESTH, V62, P641, DOI 10.1093/bja/62.6.641; LOFTUS JR, 1995, ANESTHESIOLOGY, V83, P300, DOI 10.1097/00000542-199508000-00010; MADEJ TH, 1987, ANAESTHESIA, V42, P1156, DOI 10.1111/j.1365-2044.1987.tb05220.x; MURPHY JD, 1991, BRIT MED J, V302, P564, DOI 10.1136/bmj.302.6776.564; Olofsson C, 1998, ACTA ANAESTH SCAND, V42, P284, DOI 10.1111/j.1399-6576.1998.tb04918.x; PENNING JP, 1992, ANESTHESIOLOGY, V77, P1186, DOI 10.1097/00000542-199212000-00021; PHILLIPS GH, 1988, ANESTH ANALG, V67, P835; PRINCE G, 1986, ANAESTHESIA, V41, P1240, DOI 10.1111/j.1365-2044.1986.tb13011.x; RAWAL N, 1984, ANESTH ANALG, V63, P583; ROSEN MA, 1988, ANESTHESIOLOGY, V68, P448, DOI 10.1097/00000542-198803000-00024; RUSSELL R, 1993, ANAESTHESIA, V48, P856, DOI 10.1111/j.1365-2044.1993.tb07413.x; RUTTER DV, 1981, BRIT J ANAESTH, V53, P915, DOI 10.1093/bja/53.9.915; STEINBERG RB, 1992, REGION ANESTH, V17, P131; TEJWANI GA, 1992, ANESTH ANALG, V74, P726; THOREN T, 1994, P EUR SOC REG AN, P228; VERBORGH C, 1986, EUR J ANAESTH, V3, P313; VERTOMMEN JD, 1994, ANAESTHESIA, V49, P678, DOI 10.1111/j.1365-2044.1994.tb04396.x; VERTOMMEN JD, 1991, ANESTHESIOLOGY, V74, P809, DOI 10.1097/00000542-199105000-00002; WELCHEW EA, 1983, ANAESTHESIA, V38, P1037, DOI 10.1111/j.1365-2044.1983.tb12476.x; WESTMORE MD, 1990, ANAESTH INTENS CARE, V18, P292, DOI 10.1177/0310057X9001800303; WHITING WC, 1988, ANESTHESIOLOGY, V69, P36, DOI 10.1097/00000542-198807000-00006	34	6	11	0	0	GREENWICH MEDICAL MEDIA LTD	LONDON	137 EUSTON RD, 4TH FLOOR, LONDON NW1 2AA, ENGLAND	0265-0215			EUR J ANAESTH	Eur. J. Anaesth.	NOV	2002	19	11					812	818		10.1017/S026502150200131X			7	Anesthesiology	Anesthesiology	617TQ	WOS:000179377300007	12442931				2020-06-30	J	Duncan, A				Duncan, A			The use of fentanyl and alfentanil sprays for episodic pain	PALLIATIVE MEDICINE			English	Letter									Gloucestershire Royal Hosp NHS Trust, Gloucester, England	Duncan, A (reprint author), Gloucestershire Royal Hosp NHS Trust, Great Western Rd, Gloucester, England.						LARIJANI GE, 1987, CLIN PHARMACY, V6, P275; WEINBERG DS, 1988, CLIN PHARMACOL THER, V44, P335, DOI 10.1038/clpt.1988.159; Zeppetella G, 2000, PALLIATIVE MED, V14, P57, DOI 10.1191/026921600668793500	3	5	5	0	0	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.	NOV	2002	16	6					550	550		10.1191/0269216302pm610xx			1	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	621YV	WOS:000179619500019	12465709				2020-06-30	J	Chung, CJ; Yun, SH; Hwang, GB; Park, JS; Chin, YJ				Chung, CJ; Yun, SH; Hwang, GB; Park, JS; Chin, YJ			Intrathecal fentanyl added to hyperbaric ropivacaine for cesarean delivery	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Article						cesarean delivery; fentanyl; ropivacaine; spinal anesthesia	SPINAL-ANESTHESIA; BUPIVACAINE; SECTION; SUFENTANIL; ANALGESIA; SURGERY	Background and objectives: Hyperbaric ropivacaine produces adequate spinal anesthesia for cesarean delivery. Addition of opioid to local anesthetics improves spinal anesthesia. We assessed the effect of fentanyl added to hyperbaric ropivacaine for spinal anesthesia for cesarean delivery. Methods: Fifty-nine healthy, full-term parturients scheduled for elective cesarean delivery under spinal anesthesia were randomly assigned in a double-blind fashion to receive either fentanyl 10 mug or normal saline 0.2 mL added to 0.5% hyperbaric ropivacaine 18 mg. Characteristics of spinal block, intraoperative quality of spinal anesthesia, side effects, complete analgesia (time to first feeling of pain), and effective analgesia (time to first request of analgesics) were assessed. Results: Duration of sensory block was prolonged in the fentanyl group (P < .05). Duration of motor block was similar in both groups. The quality of intraoperative analgesia was better in the fentanyl group (P < .05). Incidence of side effects did not differ between groups. Duration of complete analgesia (143.2 +/- 34.2 minutes v 101.4 +/- 21.4 minutes; P < .001) and effective analgesia (207.2 +/- 32.2 minutes v 136.3 +/- 14.1 minutes; P < .001) were prolonged in the fentanyl group. Conclusions: Adding fentanyl 10 mug to hyperbaric ropivacaine 18 mg for spinal anesthesia for cesarean delivery improves intraoperative anesthesia and increases the analgesia in the early postoperative period.	Dong A Univ Hosp, Dept Anesthesiol, Coll Med, Seo Gu, Pusan 602715, South Korea; Maryknoll Gen Hosp, Dept Obstet & Gynecol, Pusan, South Korea	Chung, CJ (reprint author), Dong A Univ Hosp, Dept Anesthesiol, Coll Med, Seo Gu, Dongdesindong, Pusan 602715, South Korea.	cjchung@daunet.donga.ac.kr					BELZARENA SD, 1992, ANESTH ANALG, V74, P653; Choi DH, 2000, REGION ANESTH PAIN M, V25, P240, DOI 10.1016/S1098-7339(00)90005-1; Chu C C, 1995, Acta Anaesthesiol Sin, V33, P149; Chung CJ, 2001, ANESTH ANALG, V93, P157; Dahlgren G, 1997, ANESTH ANALG, V85, P1288, DOI 10.1097/00000539-199712000-00020; Gautier PE, 1999, ANESTHESIOLOGY, V91, P1239, DOI 10.1097/00000542-199911000-00013; HUNT CO, 1989, ANESTHESIOLOGY, V71, P535, DOI 10.1097/00000542-198910000-00009; Khaw KS, 2002, ANESTH ANALG, V94, P680, DOI 10.1097/00000539-200203000-00037; Khaw KS, 2001, ANESTHESIOLOGY, V95, P1346, DOI 10.1097/00000542-200112000-00011; Malinovsky JM, 2000, ANESTH ANALG, V91, P1457, DOI 10.1097/00000539-200012000-00030; PALMER CM, 1995, REGION ANESTH, V20, P389; Shende D, 1998, ANAESTHESIA, V53, P706, DOI 10.1046/j.1365-2044.1998.329-az0482.x; Soni AK, 2001, CAN J ANAESTH, V48, P677, DOI 10.1007/BF03016202; VANKLEEF JW, 1994, ANESTH ANALG, V78, P1125; Whiteside JB, 2001, BRIT J ANAESTH, V86, P241, DOI 10.1093/bja/86.2.241	15	22	25	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1098-7339	1532-8651		REGION ANESTH PAIN M	Region. Anesth. Pain Med.	NOV-DEC	2002	27	6					600	603		10.1053/rapm.2002.36455			4	Anesthesiology	Anesthesiology	618YQ	WOS:000179446100011	12430112				2020-06-30	J	Heid, F; Jage, J				Heid, F; Jage, J			Background infusion during intravenous patient-controlled analgesia: The new routine analgesia?	ANESTHESIOLOGY			English	Letter							ABDOMINAL AORTIC-SURGERY; PAIN MANAGEMENT; SAFETY		Univ Mainz, Anesthesiol Clin, D-6500 Mainz, Germany	Heid, F (reprint author), Univ Mainz, Anesthesiol Clin, D-6500 Mainz, Germany.						Boylan JF, 1998, ANESTHESIOLOGY, V89, P585, DOI 10.1097/00000542-199809000-00006; Brodner G, 2000, EUR J ANAESTH, V17, P566, DOI 10.1046/j.1365-2346.2000.00738.x; Macintyre PE, 2001, BRIT J ANAESTH, V87, P36, DOI 10.1093/bja/87.1.36; Norris EJ, 2001, ANESTHESIOLOGY, V95, P1054, DOI 10.1097/00000542-200111000-00006; RosenbergAdamsen S, 1996, BRIT J ANAESTH, V76, P552; SALOMAKI TE, 1991, ANESTHESIOLOGY, V75, P790, DOI 10.1097/00000542-199111000-00010; SCHUG SA, 1993, PAIN, V55, P387, DOI 10.1016/0304-3959(93)90016-I	7	0	0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022			ANESTHESIOLOGY	Anesthesiology	OCT	2002	97	4					1028	1028		10.1097/00000542-200210000-00049			1	Anesthesiology	Anesthesiology	600UH	WOS:000178409800048	12357183				2020-06-30	J	McCrory, C; Diviney, D; Moriarty, J; Luke, D; Fitzgerald, D				McCrory, C; Diviney, D; Moriarty, J; Luke, D; Fitzgerald, D			Comparison between repeat bolus intrathecal morphine and an epidurally delivered bupivacaine and fentanyl combination in the management of post-thoracotomy pain with or without cyclooxygenase inhibition	JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA			English	Article; Proceedings Paper	Post Graduate Assembly in Anesthesiology	DEC   12, 1999	NEW YORK, NEW YORK			thoracotomy; analgesia; epidural; intrathecal; nonsteroidal anti-inflammatory drugs (NSAIDs)	TERM POSTTHORACOTOMY PAIN; THORACIC-SURGERY; ANALGESIA	Objective: To compare the analgesic efficacy of a traditional-epidurally delivered bupivacaine/fentanyl combination with a repeat bolus intrathecal morphine technique in the management of post-thoracotomy pain and to assess further the effect of cyclooxygenase (COX) inhibition on both modalities. Design: Prospective, randomized, blinded study. Setting: University teaching hospital. Participants: Patients having thoracic surgery. Interventions: Epidural and intrathecal catheters were inserted. Blood and urine samples were collected for analysis. COX-1 and COX-2 inhibition with ibuprofen and nimesulide (COX-2 selective) was instituted. Measurements and Main Results: Pain was assessed at rest and coughing by visual analog scale. Peak expiratory flow rate, patient satisfaction rating, sedation score, analgesic requirements, and preoperative and postoperative urinary creatinine levels were measured. The spinal and nimesulide combination showed the lowest pain scores (p < 0.001), least reduction in peak expiratory flow rate (p < 0.001), and highest patient satisfaction rating (p = 0.02). COX inhibition did not affect analgesic requirements in the epidural group or increase urinary creatinine in any group. Conclusion: The intrathecal morphine and nimesulide combination offered significantly better analgesia than any other combination studied. The efficacious interaction between opioids and nonsteroidal anti-inflammatory drugs may be COX-2 mediated. Copyright 2002, Elsevier Science (USA). All rights reserved.	St James Hosp, Dept Anesthesia, Dublin 8, Ireland; St James Hosp, Dept Intens Care, Dublin 8, Ireland; St James Hosp, Dept Thorac Surg, Dublin 8, Ireland; Royal Coll Surgeons Ireland, Dept Clin Pharmacol, Dublin 2, Ireland	McCrory, C (reprint author), St James Hosp, Dept Anesthesia, Dublin 8, Ireland.			mccrory, connail/0000-0003-2993-6622			Amer S., 1993, PAIN DIGEST, V3, P15; BIEBUYCK JF, 1994, ANESTHESIOLOGY, V81, P737; DAJCZMAN E, 1991, CHEST, V99, P270, DOI 10.1378/chest.99.2.270; Ebersberger A, 1999, NEUROSCIENCE, V93, P775, DOI 10.1016/S0306-4522(99)00164-5; Gwirtz KH, 1999, ANESTH ANALG, V88, P599, DOI 10.1097/00000539-199903000-00026; Katz J, 1996, CLIN J PAIN, V12, P50, DOI 10.1097/00002508-199603000-00009; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Lashbrook JM, 1999, PAIN, V82, P65, DOI 10.1016/S0304-3959(99)00031-7; Mahon SV, 1999, ANAESTHESIA, V54, P641, DOI 10.1046/j.1365-2044.1999.00856.x; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MERSKEY H, 1994, [No title captured], P222; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Panara MR, 1998, CLIN PHARMACOL THER, V63, P672, DOI 10.1016/S0009-9236(98)90091-1; PATRIGNANI P, 1994, J PHARMACOL EXP THER, V271, P1705; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; Peeters-Asdourian C, 1999, CHEST, V115, p122S, DOI 10.1378/chest.115.suppl_2.122S; Perttunen K, 1999, ACTA ANAESTH SCAND, V43, P563; Richardson J, 1999, BRIT J ANAESTH, V83, P387; Sandler A N, 1999, Minerva Anestesiol, V65, P267; THOMSON CA, 1995, ANESTH ANALG, V81, P973, DOI 10.1097/00000539-199511000-00014	20	20	20	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1053-0770			J CARDIOTHOR VASC AN	J. Cardiothorac. Vasc. Anesth.	OCT	2002	16	5					607	611		10.1053/jcan.2002.126957			5	Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System; Peripheral Vascular Disease	Anesthesiology; Cardiovascular System & Cardiology; Respiratory System	603JQ	WOS:000178556200015	12407615				2020-06-30	J	Becker, R; Schmidt, W; Viehl, H; Rupp, D				Becker, R; Schmidt, W; Viehl, H; Rupp, D			Drugs for supplementation in cataract surgery with a laryngeal mask	OPHTHALMOLOGE			German	Article						cataract surgery; laryngeal mask; supplementation; intraocular pressure	INTRAOCULAR-PRESSURE CHANGES; TRACHEAL TUBE; OPHTHALMIC SURGERY; AIRWAY; ANESTHESIA; INSERTION	Background. We compared intraocular pressure (IOP), vitreous pressure and several anaesthesiological parameters for patients who underwent cataract surgery with propofol anaesthesia, laryngeal mask and different supplementations with reference to the effect of S-ketamin in particular. Patients and methods. In 4 groups with 15 patients cataract surgery (phacoemulsification) was carried out using anaesthesia with propofol, laryngeal masks and spontaneous breathing if possible, supplementation with propofol (0.6 mg/kg, group 1), S-ketamin (0.3 mg/kg, group 2), ketamin (0.6 mg/kg, group 3) or fentanyl (0.5 mug/kg, group 4); IOP measurement with tonopen XL and scoring vitreous pressure at different times during anaesthesia (score 0-3). Results. For IOP and vitreous pressure, none of the different supplementations showed a significant difference. Insertion of the laryngeal mask did not cause a rise in intraocular pressure. The number of patients with spontaneous breathing during the operation in group 4 was significantly lower than in groups 1-3. No significant differences were observed between the different anaesthesiological parameters. Conclusion. S-Ketamin had no significant effect on IOP and vitreous pressure during phacoemulsification. It offers a safe "handling" of patients because of a high spontaneous breathing rate and lower concentration compared to Ketamin.	Univ Giessen, Zentrum Augenheilkunde, D-35385 Giessen, Germany; Univ Giessen, Abt Anaesthesiol & Operat Intens Med, D-35385 Giessen, Germany	Becker, R (reprint author), Univ Giessen, Zentrum Augenheilkunde, Friedrichstr 18, D-35385 Giessen, Germany.						Adams HA, 1997, ANAESTHESIST, V46, P1026, DOI 10.1007/s001010050503; ADAMS HA, 1998, ANAESTHESIOL REANIMA, V23; AKHTAR TM, 1992, ANAESTHESIA, V47, P668, DOI 10.1111/j.1365-2044.1992.tb02387.x; Ates Y, 1998, ACTA ANAESTH SCAND, V42, P1180, DOI 10.1111/j.1399-6576.1998.tb05273.x; BARCLAY K, 1994, ANAESTHESIA, V49, P159, DOI 10.1111/j.1365-2044.1994.tb03378.x; Blancard N, 1996, ANN FR ANESTH, V15, P1008, DOI 10.1016/S0750-7658(96)89469-X; BRAIN AIJ, 1983, BRIT J ANAESTH, V55, P801, DOI 10.1093/bja/55.8.801; COOK JH, 1981, ANAESTHESIA, V36, P359, DOI 10.1111/j.1365-2044.1981.tb10238.x; Dick HB, 2000, OPHTHALMOLOGE, V97, P792, DOI 10.1007/s003470070031; DODEN W, 1983, KLIN MONATSBL AUGENH, V182, P246, DOI 10.1055/s-2008-1054757; HESSEMER V, 1988, KLIN MONATSBL AUGENH, V193, P420, DOI 10.1055/s-2008-1050280; Himmelseher S, 1998, ANASTH INTENSIV NOTF, V33, P764, DOI 10.1055/s-2007-994851; Jacobi PC, 2000, ARCH OPHTHALMOL-CHIC, V118, P1037, DOI 10.1001/archopht.118.8.1037; KRETZ FJ, 1996, ANASTHESIE INTENSIVM; Langenstein H, 1997, ANAESTHESIST, V46, P389, DOI 10.1007/s001010050415; MYINT Y, 1995, ANAESTHESIA, V50, P126, DOI 10.1111/j.1365-2044.1995.tb15094.x; PETERSEN KU, 2000, DT ARZTEBL, V97, pA3089; Poloch A, 1996, Klin Oczna, V98, P45; Strong M, 1999, FOOD DRUG LAW J, V54, P463; Tucker GT, 2000, LANCET, V355, P1085, DOI 10.1016/S0140-6736(00)02047-X; Whitford AM, 1997, ANAESTHESIA, V52, P794, DOI 10.1111/j.1365-2044.1997.186-az0317.x	21	2	2	0	0	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0941-293X			OPHTHALMOLOGE	Ophthalmologe	OCT	2002	99	10					752	+		10.1007/s00347-002-0655-4			4	Ophthalmology	Ophthalmology	610WW	WOS:000178985800004	12376849				2020-06-30	J	Bauman, LA; Cannon, ML; McCloskey, J; Allen, S; James, RL; Tobin, JR; Politis, GD				Bauman, LA; Cannon, ML; McCloskey, J; Allen, S; James, RL; Tobin, JR; Politis, GD			Unconscious sedation in children: a prospective multi-arm clinical trial	PAEDIATRIC ANAESTHESIA			English	Article						analgesia; fentanyl; methohexital; paediatric; propofol; remifentanil; sedation	REMIFENTANIL	Background: We report the evaluation of six sedative-hypnotic and analgesic combinations administered to children undergoing brief periods of unconscious (or deep) sedation for painful procedures. Methods: In a prospective, open-label, randomized, controlled study of six groups of 27-30 children each, patients were randomly assigned to receive propofol or methohexital for sedation-hypnosis, and one of three incremental doses of fentanyl or remifentanil, respectively. Results: An infusion of methohexital (10 mg.ml(-1)) combined with remifentanil (6.67 mug.ml(-1)) provided significantly shorter geometric mean times to initial emergence, to eye-opening and to discharge, and required airway interventions that were not significantly more frequent than all groups sedated with propofol and fentanyl. Conclusions: The combination of methohexital and remifentanil appears to be a satisfactory method for unconcious sedation for short painful procedures in children.	Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Sect Pediat Anesthesiol & Crit Care Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Nursing, Sect Pediat Anesthesiol & Crit Care Med, Winston Salem, NC 27157 USA	Bauman, LA (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Dept Anesthesiol, Sect Pediat Anesthesiol & Crit Care Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.						Bauman LA, 1999, AM J EMERG MED, V17, P1, DOI 10.1016/S0735-6757(99)90001-3; Glass PSA, 1999, ANESTH ANALG, V89, pS7; Rosow CE, 1999, ANESTH ANALG, V89, pS1	3	12	15	0	0	BLACKWELL PUBLISHING LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	OCT	2002	12	8					674	679		10.1046/j.1460-9592.2002.00947.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	624DL	WOS:000179745000003	12472702				2020-06-30	J	Holth, LST; Friesen, R; Green, C; Krahn, J				Holth, LST; Friesen, R; Green, C; Krahn, J			A simple method for quantifying fentanyl, sufentanil, or morphine in discard syringes from anesthesia procedures	THERAPEUTIC DRUG MONITORING			English	Article						fentanyl; sufentanil; morphine; quantify; discard syringe		Fentanyl, sufentanil, and morphine are commonly used in the conduct of anesthesia. Medical staff working with these drugs are at high risk of addiction. To detect and prevent diversion, a method was developed to quantify these drugs in discard syringes using the BioRad REMEDi HS(TM) Drug Profiling System. For fentanyl, the lowest concentration detected is 0.1 mug/mL, and the assay is linear to 5.0 mug/mL; the within-run coefficient of variation (CV) is 0.9% (n = 5), and between-run CV is 2.5% (n = 20). For sufentanil, the lowest concentration detected is 0.5 mug/mL, and the assay is linear to 11.0 mug/mL; the within-run CV is 2.0% (n = 5), and the between-run CV is 2.4% (n = 20). For morphine, the lowest concentration detected is 0.5 mug/mL, and the assay is linear to 10.0 mug/mL; the within-run CV is 11.6% (n = 5), and between-run CV is 11.3% (n = 20). Other drugs commonly used in the operating room were checked for cross-reactivity on the REMEDi HS(TM), none cross-reacted. The REMEDi HS(TM) can be used for rapid, accurate quantification of fentanyl, sufentanil, and morphine in discard syringes from anesthesia procedures or related medical applications.	Dynacare Kasper Med Labs, Edmonton, AB T5V 1B4, Canada; St Boniface Gen Hosp, Dept Anesthesiol, Winnipeg, MB R2H 2A6, Canada; St Boniface Gen Hosp, Dept Biochem, Winnipeg, MB R2H 2A6, Canada	Holth, LST (reprint author), Dynacare Kasper Med Labs, 14940 123rd Ave, Edmonton, AB T5V 1B4, Canada.	laurel.holth@dkml.com					Alexander BH, 2000, ANESTHESIOLOGY, V93, P922, DOI 10.1097/00000542-200010000-00008; *BIOR DIAGN GROUP, 1997, REMEDI HS DRUG PROF; DEWELL WM, 1993, AM J HOSP PHARM, V50, P2374, DOI 10.1093/ajhp/50.11.2374; RUBINO M, 1995, ASHP ANN M, V52; *TASK FORC CLIN DE, MOD CURR DRUG AB ADD	5	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0163-4356	1536-3694		THER DRUG MONIT	Ther. Drug Monit.	OCT	2002	24	5					665	669		10.1097/00007691-200210000-00014			5	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	Medical Laboratory Technology; Pharmacology & Pharmacy; Toxicology	598CB	WOS:000178256600013	12352940				2020-06-30	J	Boyev, KP; Liberman, MC; Brown, MC				Boyev, KP; Liberman, MC; Brown, MC			Effects of anesthesia on efferent-mediated adaptation of the DPOAE	JARO			English	Article; Proceedings Paper	Midwinter Meeting of the Association-for-Research-in-Otolaryngology	FEB 20-24, 2000	ST PETERSBURG, FLORIDA	Assoc Res Otolarynol		olivocochlear reflex; otoacoustic emission; sodium pentobarbital; superior olivary complex; cochlea	PRODUCT OTOACOUSTIC EMISSION; SINGLE OLIVOCOCHLEAR NEURONS; COCHLEAR MICROMECHANICAL PROPERTIES; COMPOUND ACTION-POTENTIALS; GUINEA-PIG COCHLEA; 2 DISCRETE SOURCES; INFERIOR COLLICULUS; CONTRALATERAL SOUND; RESPONSE PROPERTIES; ACOUSTIC STIMULATION	Distortion product otoacoustic emissions (DPOAE) adapt after primary tone onset, with an similar to100 ms time constant, due to feedback effects of medial olivo-cochlear (MOC) activity elicited by the primary tones. We tracked DPOAE postonset adaptation as a metric of MOC reflex strength, before during and after induction of anesthesia in guinea pigs. Reflex strength was significantly diminished by the barbiturate/neuroleptic anesthesia most commonly used in this species. The MOC reflex recovered more slowly than toe-pinch or startle reflexes, correlating better with recovery of general mobility. When individual anesthetic agents were assessed, the barbiturate (pentobarbital) significantly diminished MOC reflex strength, whereas fentanyl. or droperidol did not. These results suggest that previous studies using anesthetized preparations may have underestimated the magnitude of sound-evoked responses in the OC pathway.	Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA; Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02138 USA	Brown, MC (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.				NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [T32 DC00020, 5 R01 DC00188, R01 DC01089, P30 DC005209]		Avan P, 1996, EXP BRAIN RES, V109, P9, DOI 10.1007/BF00228621; BORG E, 1975, ACTA PHYSIOL SCAND, V94, P327, DOI 10.1111/j.1748-1716.1975.tb05893.x; BROWN AM, 1987, HEARING RES, V31, P25, DOI 10.1016/0378-5955(87)90211-5; Brown MC, 1998, J NEUROPHYSIOL, V79, P3088; BROWN MC, 1989, HEARING RES, V40, P93, DOI 10.1016/0378-5955(89)90103-2; Brown MC, 2001, J NEUROPHYSIOL, V86, P2381; Brown MC, 1998, J NEUROPHYSIOL, V79, P3077; CARMEL PW, 1963, J NEUROPHYSIOL, V26, P598; DEVENECIA RK, 2001, ABSTR ASS RES OTOLAR, V23, P46; EVANS EF, 1979, ARCH OTOLARYNGOL, V105, P185; FAYELUND H, 1986, ANAT EMBRYOL, V175, P35, DOI 10.1007/BF00315454; FEX J, 1965, ACTA PHYSIOL SCAND, V64, P43, DOI 10.1111/j.1748-1716.1965.tb04152.x; FEX J, 1962, ACTA PHYSIOL SCAND, V55, P1; FROEHLICH P, 1993, HEARING RES, V66, P1, DOI 10.1016/0378-5955(93)90254-X; Giraud AL, 1995, BRAIN RES, V705, P15, DOI 10.1016/0006-8993(95)01091-2; GODFREY DA, 1975, J COMP NEUROL, V162, P247, DOI 10.1002/cne.901620206; Guinan J. J., 1996, COCHLEA, P435; GUMMER M, 1988, HEARING RES, V36, P41, DOI 10.1016/0378-5955(88)90136-0; Kalluri R, 2001, J ACOUST SOC AM, V109, P622, DOI 10.1121/1.1334597; KAWASE T, 1993, J NEUROPHYSIOL, V70, P2519; Khalfa S, 2001, NEUROSCIENCE, V104, P347, DOI 10.1016/S0306-4522(01)00072-0; KIANG NY, 1961, SCIENCE, V133, P1927, DOI 10.1126/science.133.3468.1927; KIM DO, 1980, J ACOUST SOC AM, V67, P1704, DOI 10.1121/1.384297; Kujawa SG, 2001, JARO, V2, P268, DOI 10.1007/s101620010047; KUWADA S, 1989, J NEUROPHYSIOL, V61, P269; Liberman MC, 1996, J ACOUST SOC AM, V99, P3572, DOI 10.1121/1.414956; LIBERMAN MC, 1989, HEARING RES, V38, P47, DOI 10.1016/0378-5955(89)90127-5; LIBERMAN MC, 1988, J NEUROPHYSIOL, V60, P1779; LIBERMAN MC, 1986, HEARING RES, V24, P17, DOI 10.1016/0378-5955(86)90003-1; Maison SF, 2000, J NEUROSCI, V20, P4701, DOI 10.1523/JNEUROSCI.20-12-04701.2000; Morand N, 1998, HEARING RES, V121, P71, DOI 10.1016/S0378-5955(98)00068-9; MOTT JB, 1989, HEARING RES, V38, P229, DOI 10.1016/0378-5955(89)90068-3; Mulders WHA, 2000, HEARING RES, V149, P11, DOI 10.1016/S0378-5955(00)00157-X; Mulders WHAM, 2000, HEARING RES, V144, P65, DOI 10.1016/S0378-5955(00)00046-0; NUTTALL AL, 1974, J ACOUST SOC AM, V56, P1231, DOI 10.1121/1.1903413; PANG XD, 1986, PERIPHERAL AUDITORY, P36; PUEL JL, 1990, J ACOUST SOC AM, V87, P1630, DOI 10.1121/1.399410; RELKIN EM, 2001, ABSTR ASS RES OT, V24, P6; ROBERTSON D, 1985, HEARING RES, V20, P63, DOI 10.1016/0378-5955(85)90059-0; ROBERTSON D, 1988, BRAIN RES, V462, P47, DOI 10.1016/0006-8993(88)90583-5; SIEGEL JH, 1982, HEARING RES, V6, P171, DOI 10.1016/0378-5955(82)90052-1; SMITH DW, 1994, BRAIN RES, V652, P243, DOI 10.1016/0006-8993(94)90233-X; Smith DW, 2000, J ACOUST SOC AM, V107, P933, DOI 10.1121/1.428274; Sun XM, 1999, J ACOUST SOC AM, V105, P3399, DOI 10.1121/1.424668; THOMPSON AM, 1993, J COMP NEUROL, V335, P402, DOI 10.1002/cne.903350309; THOMPSON AM, 1991, J COMP NEUROL, V303, P267, DOI 10.1002/cne.903030209; VER IL, 1975, J ACOUST SOC AM, V58, P392, DOI 10.1121/1.380682; VETTER DE, 1993, HEARING RES, V70, P173, DOI 10.1016/0378-5955(93)90156-U; VEUILLET E, 1991, J NEUROPHYSIOL, V65, P724; WARR WB, 1992, MAMMALIAN AUDITORY P, P410; WARREN EH, 1989, HEARING RES, V37, P105, DOI 10.1016/0378-5955(89)90033-6; WHITEHEAD ML, 1992, J ACOUST SOC AM, V92, P2662, DOI 10.1121/1.404382; WHITEHEAD ML, 1992, J ACOUST SOC AM, V91, P1587, DOI 10.1121/1.402440; WIEDERHOLD ML, 1970, J ACOUST SOC AM, V48, P950, DOI 10.1121/1.1912234; Ye Y, 2000, J COMP NEUROL, V420, P127	55	40	43	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	1525-3961			JARO	JARO	SEP	2002	3	3					362	373		10.1007/s101620020044			12	Neurosciences; Otorhinolaryngology	Neurosciences & Neurology; Otorhinolaryngology	600NR	WOS:000178397700011	12382109	Green Published			2020-06-30	J	Wheeler, M; Birmingham, PK; Dsida, RM; Wang, Z; Cote, CJ; Avram, MJ				Wheeler, M; Birmingham, PK; Dsida, RM; Wang, Z; Cote, CJ; Avram, MJ			Uptake pharmacokinetics of the Fentanyl Oralet((R)) in children scheduled for central venous access removal: implications for the timing of initiating painful procedures	PAEDIATRIC ANAESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 17-21, 1998	ORLANDO, FLORIDA	Amer Soc Anesthesiol		anaesthesia; fentanyl; premedication; analgesia; fentanyl Oralet (R)	PREANESTHETIC MEDICATION; SURGERY PATIENTS; CITRATE; PREMEDICATION; ANALGESIA; ADULTS	Background : The Fentanyl Oralet((R)) (Abbott Laboratories, Abbott Park, IL, USA) is an oral transmucosal drug delivery system. We previously examined pharmacokinetic parameters of children who had completed consumption of the Fentanyl Oralet((R)) . The present study was designed to clarify pharmacokinetic parameters during the consumption phase to determine if there is an optimal administration time before painful procedures. Methods : Patients, aged 3-10 years, who were scheduled for elective removal of central venous access devices under general anaesthesia, received a Fentanyl Oralet((R)) (fentanyl 10-15 mug.kg(-1) ). Plasma fentanyl concentrations were measured by radioimmunoassay. Data from blood samples obtained during and after consumption of the Fentanyl Oralet((R)) from 17 patients in the present study were combined with data from our previous study to better characterize both the consumption and postconsumption concentration versus time profiles. Results : Estimated fentanyl bioavailability (mean +/- SD) was low (36.1 +/- 0.4%), as were peak plasma concentrations (1.03 +/- 0.31 ng.ml(-1) ), suggesting that many children swallowed a large fraction of the dose. This led to a relatively late and variable peak concentration time of 53 +/- 40 min. In addition, because of the apparently large degree of gastrointestinal absorption, concentration versus time curves were wide and flat. Conclusions : The wide and flat concentration versus time profile may allow flexibility in the timing of a painful procedure following Fentanyl Oralet((R)) administration. However, the variability of the time to peak concentration makes it difficult to suggest a minimum interval between Fentanyl Oralet((R)) consumption and the start of a painful procedure.	Childrens Mem Hosp, Dept Pediat Anesthesiol, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Dept Anesthesiol, Chicago, IL USA; Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60611 USA	Wheeler, M (reprint author), Childrens Mem Hosp, Dept Pediat Anesthesiol, Chicago, IL 60614 USA.		Avram, Michael/M-7681-2019				AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; COTE CJ, 1991, ANESTHESIOLOGY, V74, P980, DOI 10.1097/00000542-199106000-00003; Dsida RM, 1998, ANESTH ANALG, V86, P66, DOI 10.1097/00000539-199801000-00013; Epstein RH, 1996, ANESTH ANALG, V83, P1200, DOI 10.1097/00000539-199612000-00012; Foster DM, 1998, ADV EXP MED BIOL, V445, P59; FRIESEN RH, 1995, PAEDIATR ANAESTH, V5, P29, DOI 10.1111/j.1460-9592.1995.tb00236.x; FRIESEN RH, 1992, ANESTHESIOLOGY, V76, P46, DOI 10.1097/00000542-199201000-00007; Ginsberg B, 1996, ANESTHESIOLOGY, V85, P1268, DOI 10.1097/00000542-199612000-00007; Ginsberg B, 1998, PAEDIATR ANAESTH, V8, P413; MCCLAIN DA, 1980, CLIN PHARMACOL THER, V28, P106, DOI 10.1038/clpt.1980.138; MICHIELS M, 1977, EUR J CLIN PHARMACOL, V12, P153, DOI 10.1007/BF00645137; Peng PWH, 1999, ANESTHESIOLOGY, V90, P576, DOI 10.1097/00000542-199902000-00034; PRESTON RA, 1993, ANESTHESIOLOGY, V79, pA370; *SAAM I, 1997, SAAM 2 US GUID VERS; SCHECHTER NL, 1995, PEDIATRICS, V95, P335; SCHECHTER NL, 1989, PEDIATR CLIN N AM, V36, P781; Schechter NL, 1997, PEDIATRICS, V99, P890, DOI 10.1542/peds.99.6.890; STREISAND JB, 1989, ANESTH ANALG, V69, P28; STREISAND JB, 1991, ANESTHESIOLOGY, V75, P223, DOI 10.1097/00000542-199108000-00009; STREISAND JB, 1993, ANESTHESIOLOGY, V78, P629, DOI 10.1097/00000542-199304000-00003; Weisman SJ, 1998, ARCH PEDIAT ADOL MED, V152, P147	21	26	28	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	SEP	2002	12	7					594	599		10.1046/j.1460-9592.2002.00949.x			6	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	599PG	WOS:000178343800006	12358654				2020-06-30	J	Freeman, KO; Connelly, NR; Schwartz, D; Jacobs, BR; Schreibstein, JM; Gibson, C				Freeman, KO; Connelly, NR; Schwartz, D; Jacobs, BR; Schreibstein, JM; Gibson, C			Analgesia for paediatric tonsillectomy and adenoidectomy with intramuscular clonidine	PAEDIATRIC ANAESTHESIA			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 07-22, 1999	Dallas, TX	Amer Soc Anesthesiologists		surgery : tonsillectomy and adenoidectomy; alpha(2)-receptor agonist : clonidine	CHILDREN; PAIN	Background : After undergoing tonsillectomy and adenoidectomy (T&A), children may experience significant pain. Clonidine, an alpha(2) agonist, exhibits significant analgesic properties. The current investigation sought to determine whether intramuscular (I.M.) clonidine would decrease pain in paediatric patients undergoing T&A. Methods : Thirty-nine children undergoing elective T&A were studied. Following inhalational anaesthetic induction, fentanyl (2 mug.kg(-1) ) was given intravenously, acetaminophen (paracetamol) (30 mg.kg(-1) ) was given rectally and the children then randomly received an i.m. injection of either normal saline or clonidine (2mug.kg(-1) ). Perioperative analgesic requirements in the postanaesthesia care unit and at home following hospital discharge were evaluated. Results : There were no significant demographic, analgesic consumption, haemodynamic or pain score differences between the groups. Conclusions : We do not recommend adding i.m. clonidine (2 mug.kg(-1) ) to the analgesic regimen of children undergoing tonsillectomy and adenoidectomy.	Baystate Med Ctr, Dept Anesthesiol, Springfield, MA 01199 USA; Baystate Med Ctr, Dept Surg, Springfield, MA 01199 USA	Connelly, NR (reprint author), Baystate Med Ctr, Dept Anesthesiol, 759 Chestnut St, Springfield, MA 01199 USA.	neil.roy.connelly@bhs.org					BeanLijewski JD, 1997, ANESTH ANALG, V84, P1232, DOI 10.1097/00000539-199706000-00011; Bergendahl HTG, 1997, ACTA ANAESTH SCAND, V41, P381, DOI 10.1111/j.1399-6576.1997.tb04703.x; HALL MJ, 1998, [No title captured], V300; Lavy JA, 1997, INT J PEDIATR OTORHI, V42, P11, DOI 10.1016/S0165-5876(97)00107-9; Mikawa K, 1996, ANESTH ANALG, V82, P225, DOI 10.1097/00000539-199602000-00001; Reimer EJ, 1998, CAN J ANAESTH, V45, P1162, DOI 10.1007/BF03012457; Splinter WM, 1996, CAN J ANAESTH, V43, P560, DOI 10.1007/BF03011766	7	4	5	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1155-5645			PAEDIATR ANAESTH	Paediatr. Anaesth.	SEP	2002	12	7					617	620		10.1046/j.1460-9592.2002.00914.x			4	Anesthesiology; Pediatrics	Anesthesiology; Pediatrics	599PG	WOS:000178343800010	12358658				2020-06-30	J	McNamara, P				McNamara, P			Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care	PALLIATIVE MEDICINE			English	Article						cognitive function; morphine; opioid switching; palliative care; toxicity; transdermal fentanyl	CANCER PAIN; ORAL MORPHINE; HEALTHY-VOLUNTEERS; TERMINAL CANCER; MENTAL STATUS; ROTATION; PSYCHOMOTOR; METHADONE; EFFICACY	The study objective was to determine whether switching patients from morphine to transdermal fentanyl resulted in a reduction of morphine-associated side effects, and an improvement in cognitive function and patients' well being while maintaining adequate pain and symptom control. Nineteen patients aged 42-86 with terminal cancer, maintained on morphine for pain and distressed as a result of morphine toxicity, were given the dose of fentanyl corresponding to their current morphine dose. Pain control was then maintained (mostly fentanyl 50-100 mug/h) over the 14-day study period. Throughout the study, patients' global assessment of well being (primary efficacy variable) was statistically significantly improved. Sleepiness and drowsiness were significantly less of a problem. There was a trend towards improvement in attention span/concentration, and in the power and quality of concentration. Cognitive function tests also revealed a significant improvement in working (short term) and speed of memory although not in secondary (long term) memory. Patients did not experience hallucinations or delusions and there was no change in levels of anxiety or depression (Hospital Anxiety Depression Scale). The incidence of dizziness was significantly reduced, and there was a nonsignificant decrease in number of patients who suffered myoclonus and in the severity of this condition over the 14 days. The investigator's overall impression of treatment with transdermal fentanyl was 'fair', which was not in agreement with the positive impression expressed by patients (score 74, range: 0 worst, 100 best). Further work is required to determine if the improvement in patients' well being and cognitive function is achieved in larger study populations.	St Oswalds Hospice, Newcastle Upon Tyne NE3 1EE, Tyne & Wear, England	McNamara, P (reprint author), St Oswalds Hospice, Regent Ave, Newcastle Upon Tyne NE3 1EE, Tyne & Wear, England.						AHMEDZAI S, 1994, J DRUG DEV, V6, P93; Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; BRUERA E, 1992, PAIN, V48, P397, DOI 10.1016/0304-3959(92)90090-X; Bruera E, 1996, CANCER, V78, P852, DOI 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P192, DOI 10.1016/0885-3924(92)90074-R; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P287, DOI 10.1016/0885-3924(95)00005-J; Clemons M, 1996, CANCER TREAT REV, V22, P451, DOI 10.1016/S0305-7372(96)90026-2; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; Donner B, 1996, PAIN, V64, P527, DOI 10.1016/0304-3959(95)00180-8; FISHBAIN DA, 1992, CLIN J PAIN, V8, P77, DOI 10.1097/00002508-199206000-00003; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; HANKS G, 1999, OXFORD TXB PALLIATIV, P331; HANKS GW, 1995, EUR J CLIN PHARMACOL, V48, P455; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Korte W, 1996, J PAIN SYMPTOM MANAG, V11, P139, DOI 10.1016/0885-3924(95)00162-X; LEIPZIG RM, 1987, PHARMACOLOGY, V35, P47, DOI 10.1159/000138294; Maddocks I, 1996, J PAIN SYMPTOM MANAG, V12, P182, DOI 10.1016/0885-3924(96)00050-4; Mercadante, 1999, Cancer Control, V6, P191; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; MISER AW, 1989, PAIN, V37, P15, DOI 10.1016/0304-3959(89)90148-6; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; REGNARD CFB, 1998, GUIDE SYMPTOM RELIEF, P97; SCHOLES C, CME B PALLIATIVE MED, V1, P13; STIEFEL F, 1992, J PAIN SYMPTOM MANAG, V7, P94, DOI 10.1016/0885-3924(92)90120-7; Vigano A, 1996, PAIN, V67, P115, DOI 10.1016/0304-3959(96)03112-0; World Health Organization, 1990, CANC PAIN REL PALL C; ZACNY JP, 1994, J PHARMACOL EXP THER, V268, P1; ZACNY JP, 1994, J PHARMACOL EXP THER, V270, P579; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9	31	27	28	0	1	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0269-2163			PALLIATIVE MED	Palliat. Med.	SEP	2002	16	5					425	434		10.1191/0269216302pm536oa			10	Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal	Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine	600AJ	WOS:000178368200009	12380661				2020-06-30	J	Henry, A; Tetzlaff, JE; Steckner, K				Henry, A; Tetzlaff, JE; Steckner, K			Ondansetron is effective in treatment of pruritus after intrathecal fentanyl	REGIONAL ANESTHESIA AND PAIN MEDICINE			English	Letter							SEROTONIN; RECEPTORS; ANTAGONISTS; MORPHINE; MICE		Cleveland Clin Fdn, Dept Gen Anesthesiol, Div Anesthesiol & Crit Care Med, Cleveland, OH 44195 USA	Henry, A (reprint author), Cleveland Clin Fdn, Dept Gen Anesthesiol, Div Anesthesiol & Crit Care Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.						Arai L, 1996, PAEDIATR ANAESTH, V6, P337, DOI 10.1111/j.1460-9592.1996.tb00460.x; Balaskas EV, 1998, NEPHRON, V78, P395, DOI 10.1159/000044967; Borgeat A, 1999, ANESTHESIOLOGY, V90, P432, DOI 10.1097/00000542-199902000-00017; Hamel E, 1999, CAN J NEUROL SCI, V26, pS2; Kuraishi Y, 2000, J BIOMED SCI, V7, P248, DOI 10.1159/000025455; Kyriakides K, 1999, BRIT J ANAESTH, V82, P439, DOI 10.1093/bja/82.3.439; MILLER R, 2000, ANESTHESIA, P293; Muller C, 1998, EUR J GASTROEN HEPAT, V10, P865; SCHWORER H, 1995, PAIN, V61, P33, DOI 10.1016/0304-3959(94)00145-5; Yamaguchi T, 1999, NEUROSCI RES, V35, P77, DOI 10.1016/S0168-0102(99)00070-X	10	4	4	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	1098-7339			REGION ANESTH PAIN M	Region. Anesth. Pain Med.	SEP-OCT	2002	27	5					538	540		10.1053/rapm.2002.35165			3	Anesthesiology	Anesthesiology	603YK	WOS:000178588700028	12373716				2020-06-30	J	Gellasch, KL; Kruse-Elliott, KT; Osmond, CS; Shih, ANC; Bjorling, DE				Gellasch, KL; Kruse-Elliott, KT; Osmond, CS; Shih, ANC; Bjorling, DE			Comparison of transdermal administration of fentanyl versus intramuscular administration of butorphanol for analgesia after onychectomy in cats	JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION			English	Article							POSTOPERATIVE PAIN	Objective-To compare postoperative discomfort assessed by subjective pain score and plasma cortisol concentrations in cats undergoing onychectomy that received analgesia by use of transdermal fentanyl (TDF) patches or an IM injection of butorphanol. Design-Randomized prospective clinical trial. Animals-22 client-owned cats weighing 2.2 to 5 kg (4.84 to 11 lb) undergoing onychectomy. Procedure-Researchers were blinded to which cats received a TDF patch (25 mug/h) 18 to 24 hours prior to surgery or an IM injection of butorphanol (0.2 mg/kg [0.09 mg/lb]) at the time of sedation, immediately following extubation, and at 4-hour intervals thereafter for 12 hours. Clinical variables, plasma cortisol concentration, and pain scores were evaluated and recorded 24 hours prior to surgery, at extubation, and 2, 4, 8, 12, 24, 36, and 48 hours after surgery. Results-The TDF group had a lower pain score than the butorphanol group only at 8 hours after surgery. Both groups had significantly lower mean plasma cortisol concentrations 0, 24, 36, and 48 hours after surgery, compared with mean plasma cortisol concentrations prior to surgery. No significant differences in appetite or response to handling the feet were observed between the 2 groups. Conclusions and Clinical Relevance-Our data did not reveal a difference in pain relief between administration of TDF and butorphanol. Plasma cortisol concentrations were not different between groups. Fentanyl appeared to provide equivalent analgesia to butorphanol in cats undergoing onychectomy. The primary advantage of using a TDF patch is that repeated injections are not required.	Univ Wisconsin, Sch Vet Med, Dept Surg Sci, Madison, WI 53706 USA	Kruse-Elliott, KT (reprint author), Univ Wisconsin, Sch Vet Med, Dept Surg Sci, Madison, WI 53706 USA.						BENEDETTI C, 1984, ADV PAIN RES THER, V7, P373; BENSON GJ, 1991, VET SURG, V20, P222, DOI 10.1111/j.1532-950X.1991.tb00340.x; Briggs SL, 1998, VET SURG, V27, P466, DOI 10.1111/j.1532-950X.1998.tb00158.x; Cambridge AJ, 2000, J AM VET MED ASSOC, V217, P685, DOI 10.2460/javma.2000.217.685; Carroll GL, 1998, J AM VET MED ASSOC, V213, P246; FOSSUM TW, 1997, SMALL ANIMAL SURG, P145; Franks JN, 2000, J AM VET MED ASSOC, V217, P1013, DOI 10.2460/javma.2000.217.1013; Fryirsa B, 1997, J CHROMATOGR B, V688, P79, DOI 10.1016/S0378-4347(97)88058-9; GOURLAY GK, 1988, ANESTH ANALG, V67, P329; HOLLEY FO, 1988, BRIT J ANAESTH, V60, P608, DOI 10.1093/bja/60.6.608; Lee DD, 2000, AM J VET RES, V61, P672, DOI 10.2460/ajvr.2000.61.672; LEHMANN K A, 1988, Acta Anaesthesiologica Belgica, V39, P11; MELZACK R, 1990, SCI AM, V262, P27, DOI 10.1038/scientificamerican0290-27; RIJNBERK A, 1988, VET REC, V122, P178, DOI 10.1136/vr.122.8.178; Robinson TM, 1999, J AM ANIM HOSP ASSOC, V35, P95, DOI 10.5326/15473317-35-2-95; ScherkNixon M, 1996, J AM ANIM HOSP ASSOC, V32, P19, DOI 10.5326/15473317-32-1-19; Slingsby LS, 1998, VET REC, V143, P185, DOI 10.1136/vr.143.7.185; Smith JD, 1996, AM J VET RES, V57, P1674; Winkler KP, 1997, J AM ANIM HOSP ASSOC, V33, P346, DOI 10.5326/15473317-33-4-346	19	49	51	0	7	AMER VETERINARY MEDICAL ASSOC	SCHAUMBURG	1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA	0003-1488			J AM VET MED ASSOC	J. Am. Vet. Med. Assoc.	APR 1	2002	220	7					1020	1024		10.2460/javma.2002.220.1020			5	Veterinary Sciences	Veterinary Sciences	537CA	WOS:000174738600026	12420780				2020-06-30	J	Menten, J; Desmedt, M; Lossignol, D; Mullie, A				Menten, J; Desmedt, M; Lossignol, D; Mullie, A			Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: Results of a compassionate-use study with special focus on elderly patients	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						cancer pain; constipation; elderly patient; tolerability; transdermal fentanyl	QUALITY-OF-LIFE; TRANSDERMAL FENTANYL; ORAL MORPHINE; EFFICACY; MANAGEMENT	Goals of the work: This open compassionate-use prospective registration study evaluated the tolerability, ease of use and applied doses of transdermal (TTS) fentanyl in adult patients with cancer-related pain requiring strong opioid analgesia. Elderly patients were particularly focussed on. Patients and methods: Previous pain medication was converted to an appropriate dose of TTS-fentanyl. I m mediate-release morphine rescue medication was allowed as needed for breakthrough pain. Dose adjustments of ITS-fentanyl, rescue morphine requirements, the ease of use and side-effects were assessed monthly, with special emphasis paid to the severity of constipation and the use of laxatives. Main results: A total of 663 patients with cancer-related pain, including 8% opioid-naive patients, were enrolled; 661 patients used at least 1 patch of TTS-fentanyl. Of these, 455 subjects were assessed at baseline and at 1 post-baseline visit at least. Individual treatment ranged from a few days to 21/2 years; TTS-fentanyl doses ranged from 25 to. 950 mug/h. The major reason for study termination was non-drug-related death (61%). Approximately 40% of patients reported constipation. The frequency of constipation depended on the rescue morphine dose used, but no dose-relationship was found for TTS-fentanyl. Patient acceptance of the patches was high; around 85% of patents rated convenience as good to excellent. The ease of use and tolerability of TTS-fentanyl in the elderly patents were comparable to that in the total population, except for a slight increase of non-serious adverse events. Conclusions: TTS-fentanyl can be applied as long-term therapy to patients with cancer-related pain, including the elderly.	Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Clin Univ St Luc, B-1200 Brussels, Belgium; Inst Jules Bordet, B-1000 Brussels, Belgium; Algemeen Ziekenhuis St Jan, B-8000 Brugge, Belgium	Menten, J (reprint author), Univ Hosp Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium.						Ahmedzai S, 1997, J PAIN SYMPTOM MANAG, V13, P254, DOI 10.1016/S0885-3924(97)00082-1; Breitbart W, 2000, ONCOLOGY-NY, V14, P695; Cleary J F, 2000, Cancer Control, V7, P120; Donner B, 1998, J PAIN SYMPTOM MANAG, V15, P168, DOI 10.1016/S0885-3924(97)00361-8; Hunt R, 1999, J PAIN SYMPTOM MANAG, V18, P111, DOI 10.1016/S0885-3924(99)00051-2; Iconomou G, 2000, ANTICANCER RES, V20, P4821; Jacox A, 1994, MANAGEMENT CANC PAIN; Jakobsson M, 1999, ANTICANCER RES, V19, P4441; Jeal W, 1997, DRUGS, V53, P109, DOI 10.2165/00003495-199753010-00011; Payne R, 1998, SEMIN ONCOL, V25, P47; Payne R, 1998, J CLIN ONCOL, V16, P1588, DOI 10.1200/JCO.1998.16.4.1588; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Radbruch L, 2000, PALLIATIVE MED, V14, P111, DOI 10.1191/026921600671594561; SIMMONDS MA, 1992, J PAIN SYMPTOM MANAG, V7, pS36, DOI 10.1016/0885-3924(92)90051-I; Sloan PA, 1998, J PAIN SYMPTOM MANAG, V16, P102, DOI 10.1016/S0885-3924(98)00044-X; SOUTHAM MA, 1995, ANTI-CANCER DRUG, V6, P29, DOI 10.1097/00001813-199504003-00005; Vielvoye-Kerkmeer APE, 2000, J PAIN SYMPTOM MANAG, V19, P185, DOI 10.1016/S0885-3924(99)00152-9; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9	18	29	31	1	2	LIBRAPHARM	NEWBURY	C/O DR. PETER L CLARKE, GEMINI HOUSE, 162 CRAVEN RD, NEWBURY RG14 5NR, BERKSHIRE, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.		2002	18	8					488	498		10.1185/030079902125001272			11	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	640TF	WOS:000180703500007	12564660				2020-06-30	J	FOLDES, FF; TORIDA, TAG				FOLDES, FF; TORIDA, TAG			COMPARATIVE STUDIES WITH NARCOTICS AND NARCOTIC ANTAGONISTS IN MAN	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article																DAVIDSON GM, 1963, ANESTHESIOLOGY, V24, P129; DRILL VA, 1958, PHARMACOLOGY MEDICIN, P231; DRIPPS RD, 1947, AM J PHYSIOL, V149, P43; FOLDES F, 1964, ANESTHESIOLOGY, V25, P95, DOI 10.1097/00000542-196401000-00024; FOLDES FF, 1963, AM J MED SCI, V245, P23; FOLDES FF, 1958, JAMA-J AM MED ASSOC, V166, P325, DOI 10.1001/jama.1958.02990040011003; FOLDES FF, 1957, AM J MED SCI, V233, P1, DOI 10.1097/00000441-195701000-00001; FOLDES FF, 1957, AM J MED SCI, V233, P153, DOI 10.1097/00000441-195702000-00006; FOLDES FF, 1964, MED CLIN N AM, V48, P421, DOI 10.1016/S0025-7125(16)33474-5; FOLDES FF, 1957, ANAESTHESIST, V9, P95; SADOVE MS, 1963, JAMA-J AM MED ASSOC, V183, P666; WAY EL, 1962, B WHO, P39; WOODS LA, 1957, J PHARMACOL EXP THER, V120, P58	13	29	29	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.		1965	9	2					121	&		10.1111/j.1399-6576.1965.tb00499.x			0	Anesthesiology	Anesthesiology	66755	WOS:A19656675500006	14319086				2020-06-30	J	KREUSCHER, H				KREUSCHER, H			DIE NEUROLEPTANALGESIE	DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT			English	Review																ADRIANI J, 1955, SELECTION ANESTHESIA; ALDER A, 1961, Anaesthesist, V10, P321; BERGMANN H, 1962, Anaesthesist, V11, P109; BERISOW, 1928, ARCH KLIN CHIR, V149, P571; BERISOW, 1927, ARCH KLIN CHIR, V144, P222; BOGER P, 1965, 2 BREM NEUR S; BROWN A S, 1962, Anaesthesist, V11, P22; BUHR G, 1965, 2 BREM NEUR; CHASSIN, 1928, ARCH KLIN CHIR, V153, P344; CORSSEN G, 1964, ANESTH ANALG, V43, P748; DE CASTRO J, 1962, Anaesthesist, V11, P10; DECASTRO J, 1959, 10 C FRANC AN LYON; DOENICKE A, 1965, 2 BREM NEUR; EMMERSON, 1937, ANESTH ANALG CURR RE, V16, P85; FREY R, 1962, 1 EUR K AN S NEUR WI; GEMPERLE M, 1964, Anaesthesist, V13, P6; GOTT A, PERSONAL COMMUNICATI; JANSSEN P, 1962, Anaesthesist, V11, P1; JANSSEN PAJ, 1957, J PHARM PHARMACOL, V9, P381, DOI 10.1111/j.2042-7158.1957.tb12290.x; JANSSEN PAJ, 1962, BRIT J ANAESTH, V34, P260, DOI 10.1093/bja/34.4.260; JANSSEN PAJ, 1956, EXPERIENTIA, V12, P293, DOI 10.1007/BF02159614; KAPFERER J M, 1961, Anaesthesist, V10, P101; KREUSCHER H, 1964, 8 SCAND AN K TURK; KUCHER R, 1953, Anaesthesist, V2, P196; LABORIT H, 1951, PRESSE MED, V59, P1329; MUNCHEN J, 1965, 2 BREM NEUR; NILSSON E, 1963, ANESTHESIOLOGY, V24, P267, DOI 10.1097/00000542-196305000-00001; NILSSON E, 1962, ANAESTHESIST, V11, P7; RITTMEYER P, 1965, 2 BREM NEUR; SABATHIE M, 1962, Anaesthesist, V11, P20; SABATHIE M, 1960, Anesth Analg (Paris), V17, P434; SABATHIE M, 1960, Anesth Analg (Paris), V17, P186; SCHAUMANN O, 1956, BRIT MED J, V2, P1091, DOI 10.1136/bmj.2.5001.1091; SCHAUMANN O, 1957, HANDB EXP PHARMAKOL, V12; SCHORER R, 1965, 2 BREM NEUR; SCHWEDER N, 1963, GEMEINSAME TAGUNG OS; ZADECK P, 1965, 2 BREM NEUR S HEIDL; ZINDLER M, 1964, 3 INT AN SAO PAULO	38	6	6	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0012-0472	1439-4413		DEUT MED WOCHENSCHR	Dtsch. Med. Wochenschr.		1965	90	16					721	+		10.1055/s-0028-1111409			1	Medicine, General & Internal	General & Internal Medicine	63543	WOS:A19656354300011	14282227				2020-06-30	